WO2001098454A2 - Human dna sequences - Google Patents

Abstract

Novel human cDNA sequence of a clones, the encoded protein sequence of a clones, antibodies and variants thereof, are provided. The disclosed sequence of a clones find application in a number of ways, including use in profiling assays. In this regard, various assemblages of nucleic acids or proteins are provided that are useful in providing large arrays of human material for implementing large-scale screening strategies. The disclosed sequence of a clones may also be used in formulating medicaments, treating various disorders and in certain diagnostic applications.

Description

HUMANDNA SEQUENCES

Background ofthe Invention

Current methods for testing pharmacological substances rely on a three-stage testing approach to drug development. Firsti candidate compounds are typically screened in some sort of in vitro system! like inhibition of cancer cell growth- Candidates are then tested in an animal model! as a first approximation of systemic effects! including efficacy and toxicity. Compounds that still show promise after these initial in vivo screensi finally are tested in humans- Againi human testing typically occurs in three phases: toxicity^1* preliminary efficacyi and efficacy. The entire process can take more than a decade and cost hundreds of millions of dollars- Aside from the monetary costs and protracted time scale! moreover! current testing regimes waste the lives of countless laboratory animals and needlessly endanger the lives of human subjects-

A need exists! therefore! for more sophisticated drug screening techniques that can be done rapidly in vi tro- These screening techniques ideally will be reflective of systemic and/or organ-specific responses! so that they provide a reliable indicator of action in a human body- Current techniques! however! tend to utilize only a single or limited number of markers! thus answering only very simple questions that are of questionable medical import- For example! a typical in vitro assay may ask whether a lead compound binds a particular receptor! which has been implicated in a certain disorder- It is presumed that such binding is indicative of therapeutic usefulness! but it does not even purport to address systemic effects.

Not only are screening techniques for efficacy inadequate! the available toxicity screens likewise are inadequate- Toxicity! on a first leveli is usually measured by animal testing- Aside from the complications related to in vivo versus in vitro testingi such screens are insufficient because of differences in metabolism! uptake! etc-! relative to humans- Thus improved methods would be not only be in vitro-basedi they would also be more "human-¹¹

With the increasing miniaturization of screening assays and the growing availability of targets for pharmaceutical intervention! there is increasing interest in developing arrays containing large numbers of these targets that can be assayed simultaneously- If such an array contains a large enough population of targets! it can be used to essentially mimic the systemic response- In other words! the array becomes an in vitro surrogate for the human body- The more refined the arrays the more accurate the predictive capability- In theory! an array could be constructed that can detect all of the known human expression products simultaneously! therebyi providing a very reliable indicator of the human response to a given compound- These arrays offer advantages over the present in vitro screening systems in that they can assay large numbers of responses simultaneously. They are superior to animal testing because they are more "human" andi thus! more predictive of human responses- In order to construct such arrays! however! the field is in need of further human targets- Advantageously! such targets will be provided with additional physiologically relevant information! such as whether the target is expressed in a particular tissue and whether it is related to a known functional class of targets- In this wayi the artisan can focus as neededi for examplei on tissue-specific effects or target class-specific effectsi thereby providing information useful in evaluating efficacy and/or toxicity-

In addition to a need for pharmacological screening targets! there is a need for further pharmacological substances- These substances can be used in the formulation of medicinal compositions and in treating a wide variety of disorders-

The present invention responds to the aforementioned and other needs in the field by providing a population of novel targets usefuli inter alia-i in the profiling and medicinal contexts described above-

Summary of the Invention It is an object of the invention! thereforei to provide a set of human cDNA clones- Further to this object! the invention provides sequences of human cDNA clones that were isolated from libraries generated from different human tissues- It is another object of the invention to provide assemblages of targets useful in profiling matrices for screening pharmacological test compounds- According to this object! assemblages comprising different populations of human nucleic acidsi proteins and antibodies are provided- In different embodiments! cDNA library-specific assemblages and target-family- specific targets are provided- It is a further object of the invention to provide a database of human nucleotide and protein sequences- Further to this objecti novel human nucleotide and protein sequences are provided in electronic form- In one embodiment! one or more of these sequences is provided in a searchable database-

It is still another object of the invention to provide biologically active target molecules useful in treating or detecting human disorders- Further to this objecti the invention provides nucleic acid and protein molecules that have the capacity to affect disease etiology or symptoms or correlate with known disease states- Also further to this object! a database is provided which comprises the disclosed molecules in electronic form ■

Detailed Description

The invention results from a need in the art for new human nucleic acids and proteins- This need arises in several contexts- Firsti there is a need to identify targets for therapeutic intervention- Secondi there is a need to identify molecules that may be adversely affected in a therapeutic contexti thereby resulting in toxicity. Knowledge of these molecules will aid in the design of new medicaments with enhanced efficacy and decreased toxicity. Finallyi the need encompasses human nucleic acids and proteins that have medicinal applicability in their own right- In view of these needsi the present inventors set out to isolate and sequence human cDNAs from tissue-specific libraries- In this wayi they represent subsets of molecules likely to be targets for therapeutic intervention or for avoiding toxicity- In addition! the inventors divided the molecules into various sub- categoriesi based on suspected functionality! structural similarity etc! which are of interest from a pharmacological perspective-

GENERAL DESCRIPTION OF THE INVENTIVE MOLECULES

The present invention provides novel polynucleotide molecules thati in some instances! have similarities with known molecules- The inventive DNAs were cloned from five different human cDNA libraries- In addition to these DNA molecules! the invention provides their protein translations and antibodies derived from them- The inventive DNA and protein sequences are show individually in the Description of the Sequences- The inventive nucleic acids also include the complements of the DNA sequences provided in the Description of the Sequences as well as their RNA counterparts- Methods of producing the molecules also are provided- Further! the invention provides methods for detecting all or part of the molecules and of detecting polynucleotides encoding all or part of the molecules-

The inventive molecules derive from five cDNA libraries: human fetal braini human fetal kidneyi human melanomai human testisi and human amygdala- For convenience! each sequence bears a designation that indicates from which library it is derived- In particular! these designations are : "hfpbr¹¹ for human fetal braini hfkd" for human fetal kidneyi "hmel" for human melanomai htes" for human testisi and "hamy¹¹ for human amygdala- The individual libraries were constructed and screened as described below in the examples- The protein and DNA molecules of the invention are variously described herein as "target" molecules or "inventive" molecules- The sequences and other information pertinent to the nucleic acid and protein molecules of the invention are shown below in the Description of the Sequences-

Description of the Sequences

Key to the Description of the Sequences The desctiptions below provide the coding sequences of the inventive cDNAsi as well as the protein sequences and other useful information! as set out herein-

Grouping

The clones were assigned to the following sixteen functional and/or tissue-derived groups:

I- Amygdala derived Ξ- Cell Cycle

3- Cell Structure and Motility "4- Differentiation/Development 5- Intracellular Transport and Trafficking b- Melanoma derived 7- Metabolism fl- Nucleic Acid Management

-^*-). Signal Transduction

ID- Transmembrane Protein

II- Transcription Factors 1Ξ- Brain derived

13- Kidney derived m - Mammary Carcinoma derived IS- Testes derived lb- Uterus derived

Description of Clone Files

The individual clone files are structured in the same pattern- The Sections are separated by paragraphs- 1. Clone Name

The clone names are deciphered with reference to the following example:

DKFZphfkdΞ_3klι wherein the code represents:

• producer of library ("DKFZ") (for convenience! this reference may be eliminated)

• a "p" for "plasmid cDNA library" (for convenience! this reference may be eliminated)

• library name (e-g- hfbr = human fetal braini hfkd = human fetal kidneyi h el = human melanomai htes = human testisi hamy = human amygdala)

• an underscore ("_") to separate library information from plate information

• plate number (e-g- "3")

• plate coordinates (letter firsti e-g- "kl5")

Group 3. Introduction short review of the similarities! function of the protein and possible applications

4. Short Information specifications about the cDNA (who sequencedi completeness of the cDNAi similarity! who sequencedi chromosomal localisation! length of cDNAi localisation of poly A tail and polyadenylation signal)

5. cDNA-Sequence

6. BLASTn Results search results of blasting the cDNA sequence against all public databases

7. Medline Entries information about genes/proteins similar to the novel cDNA (if available)

8. Putative Encoded Protein Information specifications about the encoded protein (ORF: length and localisation of the reading frame)

9. Protein Sequence

10. BLASTp Results search results of blasting the protein sequence against all public databases

11. Pedant Information output of fully automated annotation: summarises peptide information! homologiesi patterns as follows:

ELengthJ - length of the protein = number of amino acid residues

EMU]]

- molecular weight of the protein CpIH - isoelectric point EH0M0LJ

- shows protein with closest similarity to the cDNA- encoded protein EFUNCATJ

- functional information according to a catalogue developed by Munich Information center for Protein Sequences (MIPS)

EBLOCKSJ - Blocks are multiply aligned ungapped segments corresponding to the most highly conserved regions of proteins- The blocks for the Blocks Database are made automatically by looking for the most highly conserved regions in groups of proteins documented in the Prosite Database- The Prosite pattern for a protein group is not used in any way to make the Blocks Database and the pattern may or may not be contained in one of the blocks representing a group- These blocks are then calibrated against the SUISS-PROT database to obtain a measure of the chance distribution of matches- It is these calibrated blocks that make up the Blocks Database- The LJULJ versions of the Prosite and SUISS-PROT Databases that are used on this server are located at the ExPASy Uorld Uide Ueb (UUU) Molecular Biology Server of the Geneva University Hospital and the University of Geneva- Uorld Uide Ueb URL http : //blocks- fhere- org/blocks/about_blocks ■ html/ is the entry point to the database-

- here Blocks segments found in the analysed protein sequences are displayed ESC0P3

Nearly all proteins have structural similarities with other proteins andi in some of these casesi share a common evolutionary origin- The scop database provides a detailed and comprehensive description of the structural and evolutionary relationships between all proteins whose structure is knowni including all entries in Brookhaven National Laboratory's Protein Data Bank (PDB). It is available as a set of tightly linked hypertext documents which make the large database comprehensible and accessible- In addition! the hypertext pages offer a panoply of representations of proteinsi including links to PDB entriesi sequences! references! images and interactive display systems- Uorld Uide Ueb URL http : //scop -mrc- lmb-cam-ac.uk/scop/ is the entry point to the database- Existing automatic sequence and structure comparison tools cannot identify all structural and evolutionary relationships between proteins- The scop classification of proteins has been constructed manually by visual inspection and comparison of structures! but with the assistance of tools to make the task manageable and help provide generality- Proteins are classified to reflect both structural and evolutionary relatedness. Many levels exist in the hierarchy! but the principal levels are familyi superfamily and fold- The exact position of boundaries between these levels are to some degree subjective- Scop evolutionary classification is generally conservative: where any doubt about relatedness existsi we made new divisions at the family and superfamily levels- - - here SCOPE segments found in the analysed protein sequences are displayed EEC! ENZYME is a repository of information relative to the nomenclature of enzymes- It is primarily based on the recommendations of the Nomenclature Committee of the

International Union of Biochemistry and Molecular Biology (IUBMB) and it describes each type of characterized enzyme for which an EC (Enzyme Commission) number has been provided- Uorld Uide Ueb URL http://www-expasy.ch/enzyme/ is the entry point to the database-

- here EC-number and name of enzymes with similarity to the analysed protein sequences are displayed

EPIRKUJ

- functional information according to the Protein Information Resource (PIR) database catalogue developed by Munich Information Center for Protein Sequences (MIPS)ι the National Biomedical Research Foundation (NBRF) and the International Protein Information Database in Japan (JIPID). ESUPFAMID - information according to the Protein Information Resource (PIR) database catalogue of protein superfamilies developed by Munich Information Center for Protein Sequences (MIPS)ι the National Biomedical Research Foundation (NBRF) and the International Protein Information Database in Japan (JIPID) - EPR0SITE3 please refer to 1Ξ- PROSITE Motifs EPFAMID please refer to 13- PFAM Motifs

EKU3

- overall Ξdimensional folding information

- 3D indicates that the proteins is similar to a protein of which a 3 dimensional structure is known - overall structural information

11

The last PEDANT-block depicts information about the folding structure of the protein generated by PREDATOR- PREDATOR is a secondary structure prediction program- It takes as input a single protein sequence to be predicted and can optimally use a set of unaligned sequences as additional information to predict the query sequence- The mean prediction accuracy of PREDATOR is

for a single sequence and 7_\V. for a set of related sequences- PREDATOR does not use multiple sequence alignment- Insteadi it relies on careful pairwise local alignments of the sequences in the set with the query sequence to be predicted-

Uorld Uide Ueb URL http://www.embl- heidelberg.de/argos/predator/predator_info.html is the entry point to the database-

- H = helixi E = extended or sheeti _ = coili T = transmembranei B = beta

- x indicates a low-complexity region with repeat-like structure which is omitted in all BLAST searches

12. PROSITE Motifs PROSITE is a database of protein families and domains- It consists of biologically significant sitesi patterns and profiles that help to reliably identify to which known protein family (if any) a new sequence belongs- Uorld Uide Ueb URL http://www-expasy -ch/prosite/ is the entry point to the database- A description of the prosite consensus patterns is provided hereini after the description of the individual sequences-

13. PFAM Motifs PFAM (protein families) is a large collection of multiple sequence alignments and hidden Markov models covering many common protein domains- Uorld Uide Ueb URL http : //www- sanger • ac- uk/Pfam/ is the entry point to the database-

In the charts belowi the groups of sequences are listedi and the description of the individual clones follows-

Group Amygdala derived

Group Brain derived

r-

Group cell cycle

I

Group Cell structure and motility

I

Group Differentiation/Development

I π

Group Intracellular Transport and Trafficking

en i

Group Melanoma derived

-~J

Group Metabolism

0 I

Group Nucleic acid management

<£>

Group Signal transduction

IV) o

Group Testis derived

Group Transmembrane proteins

ro ΓSD i

Group Transcription factors

I o

»KFZphamyS_lDhl7

group: signal transduction DKFZphamyΞ_lDhl7 encodes a novel IflD amino acid protein which shows weak similarity to murine had-

The novel protein contains a Zinc finger motif of the C3HC4 type (RING finger)- The RING-finger domain is involved in mediating protein-protein interactions- Proteins containing a RING-finger are '- mammalian V(D)J recombination activating protein (RAGl)τ mouse rpt-li human rf p -i human SΞ Kd Ro/SS-A protein and others- The family of RING finger proteins contains a number of oncogenes- For example PHL-I a probable transcription factor-i BRCAlπ the mammalian cbl- and bmi-1 proto-oncogenes-

The new protein can find application in modulating protein- protein-interaction and in studying the expression profile of amygdala-specific genes-

weak similarity to hacl (Mus musculus)

Sequenced by LMU

Locus: unknown

Insert length: A35 bp

Poly A stretch at pos- 751π polyadenylation signal at pos- 7Ξ^C1

1 CACAGAGATC ATTGTCAACC AGGCCTGTGG GGGGGACATG CCTGCCTTGG

51 AAGGGGCACC CCATACCCCG CCACTGCCAC GGCGGCCCCG TAAGGGAAGC

1D1 TCGGAGCTGG GCTTTCCCCG CGTGGCCCCA GAGGATGAGG TCATTGTGAA 151 TCAGTACGTG ATTCGGCCTG GCCCCTCGGC CTCGGCGGCT TCTTCGGCGG

ΞD1 CGGCAGGCGA GCCCCTGGAG TGCCCCACCT GTGGGCACTC CTACAATGTC

ESI ACCCAGCGGA GGCCCCGCGT GCTGTCCTGC CTGCACTCTG TGTGTGAGCA

3D1 GTGCCTGCAG ATTCTCTACG AGTCCTGCCC CAAGTACAAG TTCATCTCCT

3S1 GCCCCACCTG CCGCCGTGAG ACTGTGCTCT TCACCGACTA CGGCCTGGCC 4D1 GCGCTGGCTG TCAACACGTC CATCCTGAGC CGCCTGCCGC CTGAGGCGCT

451 GACGGCCCCA TCCGGGGGTC AGTGGGGGGC TGAGCCCGAG GGCAGCTGCT

5D1 ACCAGACCTT CCGGCAGTAC TGTGGGGCCG CGTGCACCTG CCACGTGCGG

551 AACCCACTGT CCGCCTGCTC CATCATGTAG TAGCGCCTGC CTGCCCGCCA bDl CTGCCCGCTG AGCCTCGCTC GCTGCTTCTT CAGGGACCCG GCCCTGCCCT b51 GCCGCCCGCT GACCCTTCCT TCCCCACCAT GGCTTCCGGC CCCACCCCGA

7D1 GTGGCATTGT CGCTGCAGCC AACTTTGCCA TTAAAACTCT TTGCCAAAGT

751 TAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA flDl AAAAAAAAAA AAAAGAAAAA AAAAAAAAAA AAAAG

BLAST Results No BLAST result

Medline entries

No Hedline entry

Peptide information for frame Ξ

ORF from 3fl bp to 577 bpi peptide length: IflD Category: similarity to unknown protein

Classification: Cellular transport and traffic Prosite motifs: PRENYLATION (177-lflD) ZINC FINGER C3HC4 (fll-IO)

1 MPALEGAPHT PPLPRRPRKG SSELGFPRVA PEDEVIVNflY VIRPGPSASA

51 ASSAAAGEPL ECPTCGHSYN VTflRRPRVLS CLHSVCEύCL (3ILYESCP Y

IDl KFISCPTCRR ETVLFTDYGL AALAVNTSIL SRLPPEALTA PSGGώϋlGAEP 151 EGSCYflTFRώ YCGAACTCHV RNPLSACSIM

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphamyΞ_lDhl7-, frame Ξ No Alert BLASTP hits found

Pedant information for DKFZphamyΞ_lDhl7-ι frame Ξ

Report for DKFZphamyΞ_lDhl7-Ξ

CLENGTHJ IflD

CpIH 7-^5 EHOMOLHI TREIBL : ACDD77E7_7 gene: "FflK7-7^πi Arabidopsis thaliana chromosome 1 BAC FAK7 sequence! complete sequence- 3e-Dtι

[[BLOCKS! BLDDflSTC

[BLOCKS! PFD14bEA EBL0CKS3 PRDD7t,3H

CBL0CKS3 BLDD51A Zinc finger-, C3HC4 type-, proteins

[PROSITE! PRENYLATION 1

EPR0SITE3 ZINC_FINGER_C3HC4 1

EPFAII]] Zinc finger-. C3HC4 type (RING finger) EKLπ Alpha_Beta

[KliO LOϋJ COMPLEXITY S-5L '/. SE<3 MPALEGAPHTPPLPRRPRKGSSELGFPRVAPEDEVIVNώYVIRPGPSASAASSAAAGEPL

SEG xxxxxxxxxx- - - -

PRD cccccccccccccccccccccccccccccccceeeeeeeeeeecccccchhhhhhhcccc SE(2 ECPTCGHSYNVT(2RRPRVLSCLHSVCE(2CL(2ILYESCPKYKFISCPTCRRETVLFTDYGL

SEG

PRD cccccccccccccccceeeecchhhhhhhhhhhhhccccceeeecccccceeeeeccccc

SE<2 AALAVNTSILSRLPPEALTAPSGG(3lGAEPEGSCY(3TFRd3YCGAACTCHVRNPLSACSII1 SEG

PRD cchhhhhhhhhcccccccccccccccccccccccchhhhhhhcceeeecccccceeeccc

Prosite for DKFZphamyE_lDhl7-E

PSQDΞT 177->lfll PRENYLATION PD0CDD2t,tι

PSDDSlfl fll->^c.l ZINC FINGER C3HC4 PD0CDD44T

Pfam for DKFZphamyΞ_lDhl7 -5

HMH_NAHE Zinc finger-, C3HC4 type (RING finger)

HΠΠ

*CPICFcTF<31 DyPI PFdePml 1 PCgHsFCypCIrrlιl C

CP C Y+ +P+ L C+HS C+ C+ ++ C

(Query __E CPTC GHSYNVT(3RRPRVLSCLHSVCE(3CL-

(3ILYESCPKYKFISC IDS

HUM PmC* P C ώuery IDt, PTC IDA

DKFZphamyΞ_10p7

group: signal transduction

DKFZphamyΞ__10p7 encodes a novel lbl5 amino acid protein with similarity to Na+/CaΞ+ exchange proteins- The Transport of CaΞ+ from the sarcoplasm into the sarcoplasmic reticulum is an essential process in the initiation of muscle relaxation-

In addition-, the novel protein contains a PROSITE multicopper oxidase signature- Multicopper oxidases are enzymes that possess three spectroscopically different copper centers-

The new protein can find application in modulation of NA+/Ca5+- exchange and voltage-dependend processes-

similarity to Na+/CaΞ+ exchange proteins

ATG in frame 3 is first in clone- Sequenced by LHU

Locus: unknown

Insert length "■ 5Ξ3fc> bp Poly A stretch at pos- SΞlfc.-, no polyadenylation signal found

1 CGGACGCGTG GGCGGACGCG TGGGCCCTGT ATACCTGTGC CACTTTGTGC

SI CTTAAGGAAC AAGCTTGCTC AGCGTTTTCA TTTTTCAGTG CTTCTGAGGG IDl TCCCCAGTGT TTCTGGATGA CATCATGGAT CAGCCCAGCT GTCAACAATT

151 CAGACTTCTG GACCTACAGG AAAAACATGA CCAGGGTAGC ATCTCTTTTT

2D1 AGTGGTCAGG CTGTGGCTGG GAGTGACTAT GAGCCTGTGA CAAGGCAATG

SSI GGCCATAATG CAGGAAGGTG ATGAATTCGC AAATCTCACA GTGTCTATTC

3D1 TTCCTGATGA TTTCCCAGAG ATGGATGAGA GTTTTCTAAT TTCTCTCCTT 3S1 GAAGTTCACC TCATGAACAT TTCAGCCAGT TTGAAAAATC A6CCAACCAT

4D1 AGGACAGCCA AATATTTCTA CAGTTGTCAT AGCACTAAAT GGTGATGCCT

451 TTGGAGTGTT TGTGATCTAC AGTATTAGTC CCAATACTTC CGAAGATGGC

5D1 TTATTTGTTG AAGTTCAGGA GCAGCCCCAA ACCTTGGTGG AGCT6ATGAT

551 ACACAGGACA GGGGGCAGCT TA6GTCAAGT GGCAGTCGAA TGGCGTGTTG bDl TTGGTGGAAC AGCTACTGAA GGTTTAGATT TTATAGGTGC TGGAGAGATT b51 CTGACCTTTG CTGAAGGTGA AACCAAAAAG ACAGTCATTT TAACCATCTT

7D1 GGATGACTCT GAACCAGAGG ATGACGAAAG TATCATAGTT AGTTTGGTGT

7S1 ACACTGAAGG TGGAAGTAGA ATTTTGCCAA GCTCCGACAC TGTTAGAGTG

AD1 AACATTTTGG CCAATGACAA TGTGGCAGGA ATTGTTAGCT TTCAGACAGC SSI TTCCAGATCT GTCATAGGTC ATGAAGGAGA AATTTTACAA TTCCATGTGA

IDl TAAGAACTTT CCCTGGTCGA GGAAATGTTA CTGTTAACTG GAAAATTATT

TSI GGGCAAAATC TAGAACTCAA TTTTGCTAAC TTTAGCGGAC AACTTTTCTT

1DD1 TCCTGAGGGG TCGTTGAATA CAACATTGTT TGTGCATTTG TTGGATGACA

1DS1 ACATTCCTGA GGAGAAAGAA GTATACCAAG TCATTCTGTA TGATGTCAGG 11D1 ACACAAGGAG TTCCACCAGC CGGAATCGCC CTGCTTGATG CTCAAGGATA

1151 TGCAGCTGTC CTCACAGTAG AAGCCAGTGA TGAACCACAT GGAGTTTTAA

1ΞD1 ATTTTGCTCT TTCATCAAGA TTTGTGTTAC TACAAGAGGC TAACATAACA

1Ξ51 ATTCAGCTTT TCATCAACAG A6AATTTGGA TCTCTAGGAG CTATCAATGT 13D1 CACATATACC ACGGTTCCTG GAATGCTGAG TCTGAAGAAC CAAACAGTAG

1351 GAAACCTAGC AGAGCCAGAA GTTGATTTTG TCCCTATCAT TGGCTTTCTG

14D1 ATTTTAGAAG AAGGGGAAAC AGCAGCAGCC ATCAACATTA CCATTCTTGA

1451 GGATGATGTA CCAGAGCTAG AAGAATATTT CCTGGTGAAT TTAACTTACG 15D1 TTGGACTTAC CATGGCTGCT TCAACTTCAT TTCCTCCCAG ACTAGATTCA

1S51 GAAGGTTTGA CTGCACAAGT TATTATTGAT GCCAATGATG GGGCCCGAGG

ItDl TGTAATTGAA TGGCAACAAA GCAGGTTTGA AGTAAATGAA ACCCATGGAA lbSl GTTTAACATT GGTAGCCCAG AGGAGCAGAG AACCTCTTGG CCATGTTTCC

17D1 TTATTTGTGT ATGCTCAGAA TTTGGAAGCA CAAGTGGGGC TGGATTATAT 1751 CTTCACCCCA ATGATTCTTC ATTTTGCTGA TGGAGAAA6G TATAAAAATG

1AD1 TCAATATCAT GATTCTTGAT GATGACATTC CAGAAGGAGA TGAAAAATTT lflSl CAGCTGATTT TAACAAATCC TTCTCCTGGA CTAGAGCTAG GGAAAAATAC

ΠDI AATAGCCTTA ATTATTGTCC TTGCTAATGA TGACGGCCCT GGAGTTCTAT

1T51 CATTTAACAA CAGTGAGCAC TTTTTCCTAA GAGAGCCAAC AGCTCTCTAC 2D01 GTCCAGGAGA GTGTTGCAGT ATTGTACATT GTTCGGGAAC CTGCACAAGG

ΞDS1 ATTGTTTGGA ACAGTGACAG TTCAGTTCAT TGTGACAGAA GTGAATTCCT

Ξ1D1 CAAATGAATC TAAAGATCTG ACTCCTTCCA AAGGCTATAT TGTTTTAGAA

Ξ1S1 GAAGGTGTTC GATTCAAGGC CCTACAAATA TCTGCCATAT TAGACACGGA

2201 ACCAGAAATG GATGAGTATT TTGTTTGCAC CTTGTTTAAT CCAACTGGAG ΞΞ51 GTGCTAGACT AGGGGTGCAT GTTCAAACCC TGATAACAGT TTTGCAAAAC

Ξ3D1 CAGGCCCCTT TGGGGCTATT CAGTATCTCT GCAGTTGAAA ATAGAGCCAC

2351 CTCCATAGAC ATCGAAGAAG CCAATAGGAC CGTGTATTTA AATGTATCTC

H4D1 GAACTAATGG CATTGATTTG GCTGTGAGTG TGCAGTGGGA GACAGTATCT

24S1 GAAACAGCCT TTGGCATGA6 GGGAATGGAT GTTGTGTTTT CCGTATTTCA 2501 AAGTTTTTTG GATGAATCAG CTTCTGGCTG GTGTTTCTTT ACTTTGGAAA

2551 ATTTAATATA TGGTATAATG TTAAGAAAAT CATCTGTTAC TGTTTACCGA

2bDl TGGCAGGGGA TTTTTATTCC AGTTGAGGAT TTAAATATAG AAAATCCTAA

2b51 AACTTGTGAG GCCTTTAATA TTGGTTTTTC TCCCTACTTT GTGATTACTC

27D1 ATGAAGAAAG AAATGAAGAA AAGCCTTCTC TTAACAGTGT GTTTACATTC 2751 ACATCTGGAT TTAAATTATT CCTGGTACAA ACAATCATTA TTCTGGAAAG

2AD1 TTCTCAAGTA A6ATATTTTA CTTCAGACAG CCAAGATTAT TTAATCATTG

2AS1 CAAGTCAAAG AGATGATTCC GAATTAACTC AGGTCTTCAG GTGGAATGGA

2^C.01 GGAAGCTTCG TGTTGCATCA AAAACTCCCT GTCCGAGGTG TGCTGACCGT

STSl GGCCTTGTTC AACAAGGGAG GCTCTGTGTT CTTAGCCATT TCCCAGGCTA 3DD1 ATGCCAGGCT AAACTCCCTT TTATTCAGAT GGTCTGGCAG TGGGTTTATT

3D51 AACTTTCAAG AGGTGCCTGT CAGTGGGACA ACAGAAGTTG AGGCTTTGTC

31D1 TTCAGCCAAT GATATTTACC TAATATTTGC CAAAAATGTC TTTCTAGGAG

3151 ATCAGAATTC AATTGATATT TTCATCTGGG AGATGGGACA GTCTTCCTTC

32D1 AGGTATTTTC AGTCTGTAGA TTTTGCTGCT GTTAACAGAA TCCACTCCTT 3251 CACACCAGCC TCAGGAATAG CCCACATACT TCTTATTGGC CAAGATATGT

33D1 CTGCTCTTTA CTGCTGGAAT TCGGAGCGTA ATCAATTCTC TTTTGTTCTG

3351 GAAGTACCTT CTGCTTATGA TGTGGCTTCT GTTACAGTAA AGTCCCTTAA

34D1 TTCAAGCAAG AATTTAATAG CTCTAGTGGG AGCTCATTCA CATATATATG

3451 AGCTAGCCTA CATTTCCAGC CATTCTGACT TTATTCCTAG TTCAGGTGAA 35D1 CTGATATTTG AACCTGGTGA GAGAGAAGCT ACAATAGCAG TAAATATCCT

35S1 TGATGATACA GTTCCAGAAA AAGAAGAATC CTTCAAAGTT CAACTTAAAA

3b01 ATCCCAAAGG AGGAGCAGAG ATTGGCATTA ATGATTCTGT AACAATAACC

3b51 ATTCTGTCTA ATGATGATGC CTATGGAATT GTTGCATTTG CTCAGAATTC

37D1 ATTATATAAG CAAGTGGAAG AAATGGAGCA AGATAGCCTA GTAACCTTGA 3751 ACGTTGAACG CTTAAAAGGA ACATATGGCC GTATAACCAT AGCATGGGAA

3AD1 GCTGATGGAA GTATTAGTGA TATATTTCCT ACCTCAGGAG TGATTTTATT

3fl51 TACTGAAGGC CAGGTACTGT CAACAATCAC TCTAACTATT CTTGCTGATA

3=101 ATATACCAGA GTTATCAGAG GTTGTGATTG TAACCCTCAC CCGTATCACC

3151 ACAGAAGGGG TTGAGGACTC ATACAAAGGT GCTACTATTG ATCAGGACAG 40D1 AAGCAAGTCT GTTATAACAA CTTTGCCCAA TGACTCACCT TTTGGCTTGG

4DS1 TGGGCTGGCG TGCTGCGTCT GTCTTCATTA GAGTAGCA6A GCCTAAAGAA

41D1 AACACCACCA CTCTTCAGTT ACAAATAGCT CGAGATAAAG GACTACTTGG

4151 GGATATTGCC ATTCACTTGA GAGCTCAACC CAATTTCTTA CTGCATGTCG 42D1 ATAATCAAGC TACTGAGAAT GAAGATTATG TATTGCAAGA AACAATAATA

4251 ATAATGAAAG AAAACATAAA AGAAGCTCAT GCCGAAGTTT CCATTTTGCC

43D1 GGAT6ACCTT CCTGAATTGG AGGAAGGATT TATTGTCACT ATCACTGAGG

4351 TGAACCTGGT GAACTCTGAC TTCTCTACAG GACAGCCAAG TGTGCGGAGG 44D1 CCCGGAATGG AAATAGCTGA GATAATGATA GAAGAAAATG ACGATCCCAG

44S1 AGGAATTTTT ATGTTTCATG TTACTAGAGG CGCTGGGGAA GTTATTACTG

4501 CCTATGAGGT GCCTCCACCC TTGAACGTTC TTCAAGTTCC TGTAGTCCGG

4S51 CTGGCTGGAA GCTTTGGGGC AGTAAATGTT TATTGGAAAG CATCACCAGA

4b01 CAGTGCTGGC CTGGAAGACT TTAAACCATC TCATGGGATT CTTGAATTTG 4b51 CAGATAAACA GGTTACTGCA ATGATAGAAA TCACCATAAT TGATGATGCT

47D1 GAATTTGAAT TGACAGAGAC GTTCAATATT TCCTTGATCA GTGTTGCTGG

4751 AGGTGGCAGA CTTGGTGATG ATGTTGTGGT AACTGTTGTT ATTCCACAAA

4AD1 ATGATTCTCC ATTT6GAGTA TTTGGATTTG AAGAAAAGAC TGTAAGTTAA

4A51 ACATATCAGG GGAAAGCCTT GTTTCAGGCT AGCGTTTCAT GTAATTTTGA 4101 GTAGAAAGTG TCTCACATTT TTGTTTT6GA AGTCTTGGCC AGGCATGGTG

4151 GCTCATGCCA GTAATCCCAG CACTTTGGGA GGCCGCAGCG GGCAGATCAC

SDD1 GAGGTCAGGA GATTGACACC ATCCTGGCCA ATATGGTTGA ATTCCCGTCT

SD51 CTACTGAAAG TACAAAAATT AGCTGGGCGT GGTG6CACAT GCCTGTATTC

S101 CCAGATACTT GGGAGGCTGA GGCAGGAGAC TCGCTTGAAC CCAGGAGGCA 5151 GAGGTTGCAG TGAGCTGAGA TCACGCCATT GCACTCCAGC CTGGCGACAT

52D1 AGAGAGACTC CATCTCAAAA AAAAAAAAAA AAAAAG

BLAST Results

No BLAST result

riedline entries

No Nedline entry

Peptide information for frame 3

ORF from 0 bp to 4fl47 bpi peptide length: l__ll_ Category: putative protein

Classification: Cell signaling/communication Prosite motifs: MULTIC0PPER_0XIDASE1 (151-171)

1 DAϋJADAUALY TCATLCLKEώ ACSAFSFFSA SEGP<2CFIiJfT SUISPAVNNS

51 DFITYRKNIT RVASLFSGώA VAGSDYEPVT R<3bIAir.i2EGD EFANLTVSIL

101 PDDFPEMDES FLISLLEVHL MNISASLKNfl PTIGflPNIST VVIALNGDAF

151 GVFVIYSISP NTSEDGLFVE Vι3E<3P<2TLVE LMIHRTGGSL GflVAVEURVV 201 GGTATEGLDF IGAGEILTFA EGETKKTVIL TILDDSEPED DESIIVSLVY

251 TEGGSRILPS SDTVRVNILA NDNVAGIVSF (3TASRSVIGH EGEILώFHVI

301 RTFPGRGNVT VNUKIIGώNL ELNFANFSG(3 LFFPEGSLNT TLFVHLLDDN

351 IPEEKEVYώV ILYDVRTώGV PPAGIALLDA (3GYAAVLTVE ASDEPHGVLN

401 FALSSRFVLL <2EANITI<2LF INREFGSLGA INVTYTTVPG MLSLKNώTVG 4S1 NLAEPEVDFV PIIGFLILEE GETAAAINIT ILEDDVPELE EYFLVNLTYV

501 GLTHAASTSF PPRLDSEGLT AflVIIDANDG ARGVIEU(3(3S RFEVNETHGS

5S1 LTLVAC3RSRE PLGHVSLFVY AfiNLEAώVGL DYIFTPNILH FADGERYKNV tαi NIHILDDDIP EGDEKFOLIL TNPSPGLELG KNTIALIIVL ANDDGPGVLS b51 FNNSEHFFLR EPTALYVflES VAVLYIVREP AώGLFGTVTV (2FIVTEVNSS

701 NESKDLTPSK GYIVLEEGVR FKAL(3ISAIL DTEPEMDEYF VCTLFNPTGG

751 ARLGVHVflTL ITVL(2N(3APL GLFSISAVEN RATSIDIEEA NRTVYLNVSR

A01 TNGIDLAVSV <2tJETVSETAF GMRGMDVVFS VFtfSFLDESA SGIilCFFTLEN fiSl LIYGIMLRKS SVTVYRUOGI FIPVEDLNIE NPKTCEAFNI GFSPYFVITH

IDl EERNEEKPSL NSVFTFTSGF KLFLVfiTIII LESSώVRYFT SDSflDYLIIA

ISI SβRDDSELTfl VFRINGGSFV LHώKLPVRGV LTVALFNKGG SVFLAISώAN

10D1 ARLNSLLFRϋJ SGSGFINFώE VPVS6TTEVE ALSSANDIYL IFAKNVFLGD

1DS1 (3NSIDIFIUJE MG(2SSFRYF(3 SVDFAAVNRI HSFTPASGIA HILLIGύDNS 1101 ALYCUNSERN (3FSFVLEVPS AYDVASVTVK SLNSSKNLIA LVGAHSHIYE

1151 LAYISSHSDF IPSSGELIFE PGEREATIAV NILDDTVPEK EESFKVGΪLKN

1201 PKGGAEIGIN DSVTITILSN DDAYGIVAFA <3NSLYK(3VEE MEUDSLVTLN

1251 VERLKGTYGR ITIAUEADGS ISDIFPTSGV ILFTEG(2VLS TITLTILADN

13D1 IPELSEVVIV TLTRITTEGV EDSYKGATID (3DRSKSVITT LPNDSPFGLV 13S1 GURAASVFIR VAEPKENTTT L(2L(2IARDKG LLGDIAIHLR AflPNFLLHVD

1401 NflATENEDYV LflETIIIMKE NIKEAHAEVS ILPDDLPELE EGFIVTITEV

14S1 NLVNSDFSTG (3PSVRRPGME IAEIMIEEND DPRGIFMFHV TRGAGEVITA

1501 YEVPPPLNVL (3VPVVRLAGS FGAVNVYQIKA SPDSAGLEDF KPSHGILEFA

1551 DKώVTAIIEI TIIDDAEFEL TETFNISLIS VAGGGRLGDD VVVTVVIPiJN IbOl DSPFGVFGFE EKTVS

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_10p7τ frame 3 TREMBL:AF0550fl4_l gene: "VLGRl"τ product: "very large G-protein coupled receptor-l^πi Homo sapiens very large G-protein coupled receptor- 1 (VLGR1) mRNA-, complete eds--, N = 3-, Score = 2A4-, P = l-2e-33

T EPlBL:»riAF1fl17--_l gene: "Calx"i product: "CALX"ή Drosophila melanogaster 3Na ( + )-lCa (2+) exchanger (Calx) mRNA-. complete eds--. N = 1-. Score = 17A-, P = S-Se-OI

>TREMBL:AF0SS0fl4_l gene: "VLGRl^πi product: "very large G-protein coupled receptor-l"ή Homo sapiens very large G-protein coupled receptor-1 (VLGR1) mRNAi complete eds-

Length = lilt.?

HSPs

Score = 2A4 (42-b bits)-, Expect = LΞe-33-ι Sum P(3) = l - Se-33 Identities = l.2/73fl (2k, )-, Positives = 314/73A (42*) fluery- b7 SG(3AVAGSDYEPVTR(2UAIM(3EGDEFANLTVSILPDDFPEnDESFLISLLEVHLnNISAS 12b

S + G DY + a G + + +SI+ D+ E +E +E+

L + Sb ct : 1D2 SSASPGGVDYI-LHGSTVTF(2HG(2NLSFINISIIDDNESEFEEP

IEILLTGATGG 155 fiuery- 127 LKN(3PTIG(3PNISTVVIALNGDAFGVFVIYSISPNTSEDGLFVEV(3E(3P(3TLV-ELriIHR 1A5

+G+ +S ++IA + FGV N S+ + +

T++ L++ R

Sbjct : ISb A VLGRHLVSRIIIAKSDSPFGVIRFL NώSK

ISIANPNSTNILSLVLER 2D3 ώuery : lAb TGGSLGώVAVEIilRVVGGTATEGL DFIG-AGEILTFAEGETK-

KTVILTXXXXXXX 23A

TGG LG + + V Id VG + E L D + F EGE

+T+ILT Sbjct : 204

TGGLLGEI(3VNIα⁾ETVGPNS<2EALLP(3NRDIADPVSGLFYFGEGEGGVRTIILTIYPHEEI 2b3 ώuery : 231 XXXXXXXXXLVYTEGGSRILPSSDTVRVNILANDNVAGIVSF—

(3TASRSVIGH EG 212 L +G +++ + V + I + G+V F +T S+

EG

Sb jct : 2b4 EVEETFIIKLHLVKGEAKLDSRAKDVTLTI(2EFGDPNGVV<2FAPETLSKKTYSEPLALEG 323 ώuery : 213 EIL(2FHVIRTFPGR-GNVTVNlιlKIIG(2-

NLELNFANFSGώLFFPEGSLNTTLFVHLLDDN 350

+L +R G G + M U + + + ++ +F + SG +G +

VHLL D

Sb j ct : 324 PLLITFFVRRVKGTFGEIMVYhlELSSEFDITEDFLSTSGFFTIADGESEASFDVHLLPDE 3A3

(3uery : 3S1

IPEEKEVY(3VILYDVRT(3GVPPAGIALLDAι3GYAAVLTVEASDEPHGVLNFAL-SSRFVL 401 +PE +E Y + L V G A LD + +V A+D+PHGV FAL S R +

Sb jct : 3A4 VPEIEEDYVIώLVSVE GGAELDLEKSITUFSVYANDDPHGV--

FALYSDRfiSI 434 fluery : 410 LflEANI— TI(3LFINREFGSLGAINVTYTTVPG!1LSLKNι3T- VGNLAEPEVDFVPIIGFL 4bb

L N+ +1(3+ I R G+ G + V K (3 V AE +

L

Sbjct: 435 LIG(2NLIRSId3INITRLAGTFGDVAVGLRISSDH---KE(3PIVTENAER(3— L 4A2 ώuery: 4b7

ILEEGETAAAINITILEDDVPELEEYFLVNLTYVGLTMAASTSFPPRLDSEGLTAflVIID 52b ++++G T + 1 L F + L V L P L E

+ A V + Sbj ct : 4A3 VVKDGATYKVDVVPIKN(3VFLSLGSNFTL(3LVTVI1LVGGRFYGI1PTIL(2-

EAKSA-VLPV 540 ώuery : S27 ANDGARGVIEU<3⁽2SRFEV-NETHGSLTLVA⁽2RSREPLGHVSLFV

YAfiNLEAώVGLDY SA2 + A + ++ + F++ N T G+ ++ R R G +S+ YA

LE +

Sb jct : S41 SEKAANS(2VGFESTAF(2LMNITAGTSHVI1ISR- RGTYGALSVA ITTGYAPGLEIPEFIVV S11 ώuery: Sfl3 -IFTPMI-- LHFADGERYKNVNIMILDDDIPEGDEKF(2LILTNPSPGLELGKNTIALIIV b31

TP + L F+ GE+ K V + P E F L L+ G + IV

Sb jct : bOO GNNTPTLGSLSFSHGEflRKGVFLUTFPS-- PGϋJPEAFVLHL^'SGV(3SSAPGGA(3LRSGFIV bS7

(Juery : b40 LANDDGPGVLSFN- NSEHFFLREPTALYV(3ESVAVLYIVREPA(2GLFGTVTV(3FIVTEVN blA

A + GV F+ . + S + + E T + ++ L+ G +

T

Sbjct: b5A -AEIEPMGVFdFSTSSRNIIVSEDTflM-IRLHVβRL

GFHSDLIKVSY(3TTAG 70S

(3uery: bll SSNESKDLTP-SKGYIVLEEGVRFKALώlSAILDTEPEIIDEYFVCTL FNP 747

S+ +D P G + ++ +1+ I D E++E+F L

F+ Sbjct: 701

SAKPLEDFEPV(2NGELFF(3KF(2TEVDFEITIIND(QLSEIEEFFYINLTSVEIRGL(3KFDV 7bfl βuery: 74A TGGARLGVHV(2T-LITVL(2N(3APLGLFSISAVENR-ATSIDIE

EANRTVYLNVSRT A01 RL + +IT+L N G+ IS E A ++D E

YL+ S+T

Sbjct: 7b1 NUSPRLNLDFSVAVITILDNDDLAGH- DISFPETTVAVAVDTTLIPVETESTTYLSTSKT A27 fluery: A02 NGI fl04

I

Sbjct: fl2A TTI A30

Score = 2bb (31-1 bits)-, Expect = 4-0e-2Sι Sum P(3) = 4-0e-25 Identities = 17S/70A (24 )-, Positives = 30b/70A (43V.) ώuery : 131

PTIG(3PNISTVVIALNGDAFGVFVIYSISPNTSEDGLFVEV(3E(3P(2TLVELriIHRTGGSL 110 P IG +1 ++I N +A G+ P + EV+E L+ + + R G +

Sbjct : 31 PEIGNISIVRIIIHKNDNAEGII EFDPKYTA FEVEEDVG-

LIMIPVVRLHGTY 10

Ouery : 111 GfiVAVEURVVGGTATEG- LDFIGAGEILTFAEGETKKTVILTXXXXXXXXXXXXXXXXLV 241

C V ++ +A+ G +D+I G +TF G+ + ++

L

Sbjct : 11

GYVTADFIS(3SSSASPGGVDYILHGSTVTF(3HG(3NLSFINISIIDDNESEFEEPIEILLT 15D ώuery : 2S0 YTEGGSRILPSSDTVRVNILANDNVAGIVSF(3TASRSVIGHEGE —

ILώFHVIRTFPGRG 3D7

GG+ +L R+ I +D+ G++ F S+ I + IL +

RT G Sb jct : 151 GATGGA-

VLGRHLVSRIIIAKSDSPFGVIRFLNώSKISIANPNSTIIILSLVLERTGGLLG 2D1 2uery: 30A NVTVNUKIIGfiN LELN--FAN-FSG(2LFFPEGSLNT-

TLFVHLLDDNIPEEKEVY 35δ

+ VNIι)+ +G N L N A+ SG +F EG T+ + +

E +E + Sbjct: 21D

EI(2VNUETVGPNS(3EALLP(3NRDIADPVSGLFYFGEGEGGVRTIILTIYPHEEIEVEETF 2b1

(3uery: 3S1 (3VILYDVRT(3GVPPAGIALLDA(3GYAAVLTVEASDEPHGVLNFA — - LSSRFV---LL(3E 412 + L+ V+ G A LD++ LT++ +P+GV+ FA LS +

L E

Sbjct: 270 IIKLHLVK

GEAKLDSRAKDVTLTI(3EFGDPNGVV(3FAPETLSKKTYSEPLALE 322 (Query: 413

ANITIfiLFINREFGSLGAINVTYTTVPGNLSLKNtQTVGNLAEPEVDFVPIIGFLILEEGE 472

+ I F+ R G+ G I V + L ++ ++ E DF+

GF + +GE

Sbjct: 323 GPLLITFFVRRVKGTFGEIdVYϋ) ELSSEF--DITE--- DFLSTSGFFTIADGE 37D

(Query: 473

TAAAINITILEDDVPELEEYFLVNLTYVGLTNAASTSFPPRLDSEGLTAflVIIDANDGAR 532 + A+ ++ +L D+VPE+EE +++ L S LD E + AND

Sbjct: 371 SEASFDVHLLPDEVPEIEEDYVIώLV

SVEGGAELDLEKSITUFSVYANDDPH 422

(Query: 533 GVIEIι)(Q(2SRFEV---NETHGSLTLVAlQRSREPLGHVS-- LFVYAώNLEAfiVGLDYIFTPri 5A7

GV R + S+ + R G + L + + + E +

Sbjct: 423 GVFALYSDR(3SILIG(QNLIRSI(QINITRLAGTFGDVAVGLRISSDHKE(QPIVTENAER(QL 4 2

(Query: 5flA ILHFADGERYKNVNIMILDDDI--PEGDE-KF(QLILTNPSPGLELGKNTI-- -ALIIVLA b41

++ DG YK V +++ + + + G (3L+ G G TI

A VL Sbjcf- 4fl3 VVK — DGATYK-

VDVVPIKN(3VFLSLGSNFTL(3LVTVriLVGGRFYGriPTIL(3EAKSAVLP 531

Query: b42

NDDGPGVLSFNNSEHFFLREPTALYV(3ESVAVLYIVREPA(3GLFGTVTV(3FIV TE bib + NS+ F E TA + A ' V +G +G ++V +

E

Sbjct: 540 VSEKAA NS(3VGF--

ESTAFtJLtlNITAGTSHVrilSRRGTYGALSVAldTTGYAPGLE 512 (Query: b17

VNSSNESKDLTPSKGYIVLEEGVRFKALOISAILDTEPEMDEYFVCTLFNPTGGARLGVH 75b + ++TP+ G + G + K + + P E FV L

A G

Sbjct: 513 IPEFIVVGNI1TPTLGSLSFSHGE(3RKGVFLI TF-- PSPGlilPEAFVLHLSGVflSSAPGGAfl bSO fluery: 7S7 VflTLITVLflNώAPLGLFSISAVENRATSIDIEEANRTVYLNVSRTNGI-- DLAVSV(3 )ET A14 +++ V + + P+G+F S +R +1 + E + + L+V R G DL + V + + T

Sbjct: bSl LRSGFIVAEIE-PHGVFiQFST-SSR — NHVSEDTflHIRLHVtQRLFGFHSDL-IKVSYtQT 705

(Query: 515 VSETAFGHRGMDVVFS VFfQSFLDE A3A

+ +A + + V + F(Q F E

Sbjct: 7Db TAGSAKPLEDFEPV(QNGELFF(QKF(QTE 732 Score = 24b (3b-1 bits)-, Expect = 4-le-32-, Sum P(3) = 4-le-32 Identities = 12/33A (27*)-, Positives = 1S7/33A (4b*)

(Query: Sll PPRLDSEGLTAtQVIIDANDGARGVIEU-- <QtQSRFEVNETHGSLTLVA(QRSREPLGHVSLF SbA PP + + + ++II ND A G+IE+ + + FEV E G + + R

G + V +

Sbjct: 3A PPEIGNISIV-

RIIIMKNDNAEGIIEFDPKYTAFEVEEDVGLimPVVRLHGTYGYVTAD lb (Query: Sb VYA(QNLEA(QVG-

LDYIFTPMILHFADGERYKNVNirilLDDDIPEGDEKFlQLILTNPSPGL b27

+(Q+ A G +DYI + F G+ +NI I+DD+ E +E

+++LT + G

Sbjct: 17 FIS(QSSSASPGGVDYILHGSTVTF(QHG(QNLSFINISIIDDNESEFEEPIEILLTGATGGA ISb

(Query: b2A

ELGKNTIALIIVLANDDGPGVLSFNNSEHFFLREPTALYV(3ESVAVLYIVREPA(QGLFGT bA7 LG++ ++ 11+ +D GV+ F N + P S +L +V E GL G

Sbjct: 157 VLGRHLVSRIIIAKSDSPFGVIRFLNiQSKISIANP

STMILSLVLERTGGLLGE 21D

(Query: bAA VTVώFIVTEVNSSN ESKDLT-PSKGYIVLEEGVR- FKALώlSAILDTEPEMDEYFV 741

+ V + NS +++D+ P G EG + + ++ E

E++E F+

Sbjcf- 211

IiQVNUETVGPNSiQEALLPiQNRDIADPVSGLFYFGEGEGGVRTIILTIYPHEEIEVEETFI 27D

(Query: 742 CTLFNPTGGARLGVHV(2TL-ITVL(QN<QAPLGL--FSISAVENRATSIDIE-

EANRTVYLN 717

L G A+L + + +T+ + P G+ F+ + + S + E

+ Sbjct: 271

IKLHLVKGEAKLDSRAKDVTLTIfQEFGDPNGVVtQFAPETLSKKTYSEPLALEGPLLITFF 330

(Query: 71fi VSRTNGIDLAVSViQUETVSETAFGMRGIIDVVFSVFiQSFLDESASGhJCFFTL A4A V R G + V tilE SE F + + FL S SG FFT +

Sbjct: 331 VRRVKGTFGEIMVYIαJELSSE FDITEDFL — TSG — FFTI

3bb

Score = 24b (3b-1 bits)-, Expect = l-le-11-, Sum P(3) = l-le-11 Identities = A7/303 (2A*)-, Positives = 13A/3D3 (45*)

(Query: Hb2 PSSGELIFEPGEREA-TIAVNILDDTVPEKEESFKVtQLKNPKGGAEIGIN- DSVTITILS 1211 P SG F GE TI + I E EE+F ++L KG A++ VT+TI

Sbjct: 23b

PVSGLFYFGEGEGGVRTIILTIYPHEEIEVEETFIIKLHLVKGEAKLDSRAKDVTLTIiQE 215

(Query : 1220 NDDAYGIVAFAtQNSL

YKlQVEEMEiQDSLVTLNVERLKGTYGRITIAϋJEADGSIS--- 1272

D G+V F A +L Y + +E L+T V R+KGT+G I + UE

Sbjct : 21b FGDPNGVViQFAPETLSKKTYSEPLALEGPLLITFFVRRVKGTFGEiriVYldELSSEFDITE 355

(Query : 1273

DIFPTSGVILFTEGiQVLSTITLTILADNIPELSEVVIVTLTRITTEGVEDSYKGATIDtQD 1332 D TSG +G+ ++ + +L D +PE+ E ++ L ++ EG GA +D +

Sbjct : 35b DFLSTSGFFTIADGESEASFDVHLLPDEVPEIEEDYVK3L— SVEG

-GAELDLE 407

(Query: 1333 RSKSVITTLPNDSPFGLVGlι)RAASVFIRVAEPKENTTTL(QL(QIARDKGLLGDIAIHLRA(Q 1312

+S + + ND P G+ + I + + ++(Q+ I R G

GD+A+ LR

Sbj cf- 40fi KSITh)FSVYANDDPHGVFALYSDRι2SILIG(Q--

NLIRSIlQINITRLAGTFGDVAVGLRIS 4b5

(Query : 1313 PNFLLHVDNlQ-

ATENEDYVLiQETIIIMKENIKEAHAEVSILPDDLPELEEGFIVTITEVN 1451

+ H + TEN E +++K+ I L F

+ + V Sbjct: 4bb SD HKEβPIVTENA

ER(3LVVKDGATYKVDVVPIKN(3VFLSLGSNFTL(QLVTVπ 517

(Query: 1452 LVNSDFSTGiQPSV 14b4 LV F G P++ Sbjct: Slfl LVGGRFY-GMPTI 521

Score = 24b (3b-1 bits)-, Expect = l-le-11-. Sum P(3) = l-le-11 Identities = A1/334 (2b*)-, Positives = 150/334 (44*) ώuery: 1151

DFIPSSGELIFEPGEREATIAVNILDDTVPEKEESFKVlQLKNPKGGAEIGINDSVTITIL 121A D+I + F+ G+ + 1 ++I+DD E EE ++ L GGA +G +

I I

Sbjct: 110 DYILHGSTVTF(QHG(QNLSFINISIIDDNESEFEEPIEILLTGATGGAVLGRHLVSRIIIA Ibl

(Query: 1211

SNDDAYGIVAFA(3NSLYK(QVEEHE(QDSLVTLNVERLKGTYGRITIAIilEADGSIS 1272

+D +G++ F S + +++L +ER G G I + LIE G S

Sbjct: 17D KSDSPFGVIRFLNlQSKIS- IANPNSTMILSLVLERTGGLLGEIiQVNIilETVGPNSlQEALLP 22A

(Query: 1273 DIF-PTSGVILFTEG(QV- LSTITLTILADNIPELSE VIVTLTRITTEGVEDSYKGA 1327

DI P SG+ F EG+ + TI LTI E+ E 1+ L + E DS Sb jct : 221 (QNRDIADPVSGLFYFGE6EGGVRTIILTIYPHEEIEVEETFIIKLHLVKGEAKLDS 2fl4

(Query : 132fl TIDiQDRSKSVITTLPN-DSPFGLVGURAASVFIRV-AEPK-- ENTTTLiQLtJIARDKGLLG 13A3

R+K V T+ P G+V + ++ + +EP E +

R KG G

Sb jct : 2AS

RAKDVTLTIiQEFGDPNGVVlQFAPETLSKKTYSEPLALEGPLLITFFVRRVKGTFG 331

(Query : 13A4 DIAIHLRA(QPNFLLHVDN<QATENEDYVL<QETIIiriKENIKEAHAEVSILPDDLPELEEGF 1443

+1 ++ F + ED++ + + EA +V

+LPD++PE+EE + Sb jct : 340 EIMVYIilELSSEFDI

TEDFLSTSGFFTIADGESEASFDVHLLPDEVPEIEEDY 311

(Query : 1444 IVTITEVNLVNSDFSTGiQPSVRRPGriEIAEirilEENDDPRGIFriFHVTR 1412 ++ + V + + + I + NDDP G+F + R

Sbj ct : 312 VIiQLVSVE GGAELDLEK SITUFSVYANDDPHGVFALYSDR

431

Score = 237 (35-b bits)-, Expect = 1-4e-34-, Sum P(3) = 1-4e-34 Identities = lDl/3b7 (27*)-, Positives = Ib5/3b7 (44*)

(Query- __f

SGiQAVAGSDYEPVTRiQliiAIIIlQEGDEFANLTVSILPDDFPEriDESFLISLLEVHLMNISAS 12b S + G Y + a G + + +SI+ D+ E +E +E+ L +

Sbjct : 102 SSASPGGVDYI-LHGSTVTF(3HG(3NLSFINISIIDDNESEFEEP

IEILLTGATGG 155 fluery : 127 LKN(QPTIG(QPNISTVVIALNGDAFGVFVIYSISPNTSEDGLFVEV<QE(QP(QTLVEL!1IHRT lAb

+G+ +S ++IA + F6V N S+ +

++ L++ RT

Sb jct : 15b A VLGRHLVSRIIIAKSDSPFGVIRFL NlQSKISI — -

ANPNSTMILSLVLERT 204

(Query : 1A7 GGSLGlQVAVEURVVGGTATEGL DFIG-AGEILTFAEGETK-

KTVILTXXXXXXXX 231

GG LG++ V h) VG + E L D + F EGE +T+ILT

Sbjct : 2D5 GGLLGEI(QVNIι⁾ETVGPNS(2EALLPi3NRDIADPVSGLFYFGEGEGGVRTIILTIYPHEEIE 2b4

(Query : 24D XXXXXXXXLVYTEGGSRILPSSDTVRVNILANDNVAGIVSF--

(QTASRSVIGH EGE 213

L +G +++ + V + I + G+V F +T S+ EG

Sb jct : 2bS VEETFIIKLHLVKGEAKLDSRAKDVTLTI(^QEFGDPNGVV(QFAPETLSKKTYSEPLALEGP 324

(Query : 214 IL(2FHVIRTFPGR-GNVTVNh)KIIG(3- NLELNFANFSGiQLFFPEGSLNTTLFVHLLDDNI 351

+ L +R G G + J lιl++ + ++ +F + SG +G +

VHLL D + Sbjct: 325 LLITFFVRRVKGTFGEIMVYIαJELSSEFDITEDFLSTSGFFTIADGESEASFDVHLLPDEV 3A4

(Query: 352 PEEKEVY(QVILYDVRT(QGVPPAGIALLDA(QGYAAVLTVEASDEPHGVLNFAL-SSRFVLL 41D

PE +E Y + L V G A LD + +V A+D+PHGV FAL

S R +L

Sbjct: 3fl5 PEIEEDYVIfQLVSVE GGAELDLEKSITUFSVYANDDPHGV —

FALYSDRiQSIL 435

(Query: 411 (QEANI--TI(2LFINREFGSLGAINV 433

N+ +I(Q+ I R G+ G + V Sbjct: 43b IG(QNLIRSI(QINITRLAGTFGDVAV 4b0 Score = 230 (34-5 bits)-, Expect = 2-3e-14-, Sum P(3) = 2-3e-14 Identities = 1A/3bA (2b*)-, Positives = lb4/3bA (44*)

(Query: 1240 EME(QD-

SLVTLNVERLKGTYGRITIAUEADGSISDIFPTSGVILFTEGfQVLSTITLTILA 121A E+E+D L+ + V RL GTYG +T + + S + P GV G

ST + T

Sbjct: 71 EVEEDVGLIMIPVVRLHGTYGYVTADFISC2SSSAS--P-GGVDYILHG —

STVTFiQH-G 123 (Query: 1211 DNIPELSE VIVTLTRITTEGVEDSYKGATIDiQDRSKSVITTL---

PNDSPFGLVGURAA 1355

N+ ++ +1 E +E GAT + +++ +

+DSPFG++ +

Sbjct: 124 (^QNLSFINISIIDDNESEFEEPIEILLTGATGGAVLGRHLVSRIIIAKSDSPFGVIRFLNiQ 1S3

(Query: 135b SVFIRVAEPKENTTTL(QL(QIARDKGLLGDIAIHLRA(Q- PNFLLHVDN(QATENEDYVL(QET 1414

S I +A P +T L L + R GLLG+I ++ PN + Q. + D V

Sbjct: 1A4 SK-ISIANPN- STI ILSLVLERTGGLLGEI(QVNIjJETVGPNS(3EALLP(QNRDIADPV--SG 231 fiuery: 1415 IIIMKENIKEAHAEV- SILPDDLPELEEGFIVTITEVNLVNSDFSTGlQPSVRRPGriEIAE 1473

+ E + +1 P + E+EE FI+ +++LV G+ +

+ +

Sbjct: 24D LFYFGEGEGGVRTIILTIYPHEEIEVEETFII---KLHLVK

GEAKLDSRAKDVT- 210

(Query: 1474

IMIEENDDPRGIFHFHVTRGAGEVITAYEXXXXXXXXXXXXXXXAGSFGAVNVYUKASPD 1S33 + I+E DP G+ F + + + G+FG +

VYU+ S + Sbjct: 211

LTI(3EFGDPNGVVι3FAPETLSKKTYSEPLALEGPLLITFFVRRVKGTFGEiriVYlι)ELSSE 3S0

(Query: 1534

SAGLEDFKPSHGILEFADKflVTAMIEITIIDDAEFELTETFNISLISVAGGGRLGDDV V 1513 EDF + G AD + A ++ ++ D E+ E + I L+SV GG

L + + Sbjct: 351 FDITEDFLSTSGFFTIADGESEASFDVHLLPDEVPEIEEDYVIi^QLVSVEGGAELDLEKSI 41D (Query: 1514 T-VVIP<QNDSPFGVF lb07

T + ND P GVF Sbjct: 411 TϋJFSVYANDDPHGVF 425

Score = 11D (2A-5 bits)-, Expect = 7-Se-ll-. Sum P⁽3) = 7-5e-ll Identities = 13b/511 (23*) •, Positives = 247/511 (41*)

(Query: b7 SGtQAVAGSDYEPVTRtQ lAirKQEGDEFANLTVSILPDDFPENDESFLISLLEVHLriNISAS 12b

+ G A D + EPV <Q+ + + + I+ D E + + E F I+L V

+ +

Sbjct: 707

AGSAKPLEDFEPV(3NGELFF(QKF(3TEVDFEITIIND(QLSEIEEFFYINLTSVEIRGL(QKF 7bb

(Query: 127 LKN-(QPTIG(QP-NISTVVIALNGDAFGVFVIY-

SISPNTSEDGLFVEVlQEώPlQTLVELMI 1S3

N P + +++ + I G+ + + + + D + V+ +

T L Sbjct: 7b7

DVNUSPRLNLDFSVAVITILDNDDLAGI1DISFPETTVAVAVDTTLIPVETESTTY — LST A24

(Query: 1A4 HRTGGSLGiQVAVEI RVVGGTATEGLDFIGAGEILTF-- AEGETKKTVILTXXXXXXXXXX 241 +T L V +V T G+ I + + + T + + K + T

Sbjct: A2S SKTTTIL(3PTNVV-AIV — TEATGVSAIPE- KLVTLH6TPAVSEKPDVATVTANVSIHGT AAD

(Query: 242 XXXXXXLVYTEGGSRILPSSDTVRVNILANDNVAGIVSF-- (QTASRSVIGHEGEILiQFHV 211

+VY E + + +T V I G VS +T E

L F

Sbjct: AA1 FSLGPSIVYIEEEMKN-

GTFNTAEVLIRRTGGFTGNVSITVKTFGERCAfQNEPNALPF-- 137

(Query: 300

IRTFPGRGNVTVNUKIIGiQNLELNFANFSGlQLFFPEGSLNTTLFVHLLPDNIPEEKEVYiQ 3S1 R G N + T Id + E +F + L F +G + V +LDD +

PE +E + Sbjct: 13A -RGIYGISNLT--UAVE

EEDFEE(QTLTLIFLDGERERKVSV(QILDDDEPEG(QEFFY 110

(Query: 3b0 VILYDVRT(2GVPPAGIALLDA(Q---GYAA-- VLTVEASDEPHGVLNFALSSRFVL-LiQEA 413 V L + P G +++ + G+AA ++ + SD +G++ F+ S+

L L + E

Sbjct: HI VFLTN

P(QGGA(QIVEGKDDTGFAAFANVIITGSDLHNGIIGFSEES(QSGLELREG 1D44 (Query: 414 NITIiQLFI NREFGSLGAI-

NVTYTTVPGI LSLKNiQTVGNLAEPEVDFVPIIGFL 4bb

+ +L + NR F + VT ++ L+ V NL E E+

V G

Sbjct: 1045 AVMRRLHLIVTR(QPNRAFEDVKVFIdRVTLNKT--VVVL(QKDGV-NLI1E- EL(3SVS--GTT 101A

(Query: 4b7 ILEEGETAAAINITILEDDVPELEEYFLVNL — TYVGLTMAASTSFPPRLDSEGLTAiQVI 524 G+T I+I + + VP++E YF V L G + S F

E +0 + Sbjct: 1011

TCTHG<QTKCFISIELKPEKVP(QVEVYFFVELYEATAGAAINNSARFA(QIKILESDESι2SL 115A

(Query: 525 IDANDGARGVIEld(Q(QSRF— EVNETHGS- LTLVA(QRSREPLGHVSLFVYA(QNLEA(3VGL SAO

+ + G+R + +++ +V G+ L + S + L

A G Sbjct: 1151

VYFSVGSRLAVAHKKATLISLfQVARDSGTGLMMSVNFSTlQELRSAETIGRTIISPAISGK 121A

(Query: SA1 DYIFTPMILHFADGERYKNVNIMILDD-- DIPEGDEKFfiLILTNPSPGLELGKNTIALII b3B D + + T L F G + R + + + + + + + + + F(Q + + L +P G +

K I

Sbjct: 1211 DFVITEGTLVFEPG(QRSTVLDVILTPETGSLNSFPKRF(QIVLFDPKGGARIDKVYGTANI 127A (Query: b31 VLAND-DGPGVLSFNNSEH bSb

L +D D + + H

Sbjct: 1271 TLVSDADS(QAIldGLAD(3LH 1217

Score = 1AA (2A-2 bits)-. Expect = l-2e-33-. Sum P(3) = l-2e-33 Identities = A4/321 (25*)-, Positives = 14b/321 (44*)

(Query: H2 SVTVKSLNS

SKNLIALVGAHSHIYELAYISSHSDFIPSSGELIFEPGEREATIAV HAD

S+TVK+ N + G + I L + DF + LIF GERE ++V

Sbjct: 117 SITVKTFGERCAiQMEPNALPFRGIYG- ISNLTldAVEEEDFEEiQTLTLIFLDGERERKVSV 175

(Query: 11A1 NILDDTVPEKEESFKViQLKNPKGGAEI — GINDS VTITILSNDDAY- GIVAFAtQNS 1233

ILDD PE +E F V L NP+GGA+I G +D+ + I++ D +

GI+ F++ S

Sbjct: 17b

(^QILDDDEPEG(QEFFYVFLTNP(QGGA(^QIVEGKDDTGFAAFAI1VIITGSDLHNGIIGFSEES 1035

(Query: 1234 LYK(QVEEME(QDSLVT---LNVERLKG-TYGRITIAIdEAD-

GSISDIFPTSGVILFTEGiQV 12AA

+ E+ + + + + L V R + + + ld + GV

L E (Q Sbjcf- 103b —

(^QSGLELREGAVriRRLHLIVTR(2PNRAFEDVKVFURVTLNKTVVVL(QKDGVNLI1EEL(QS 1013

(Query: 12A1 LSTITLTILADNIPELS-EVVIVTLTRITTEGVEDSYK- — GATIDiQDRSKSVITTLPND 1344 +S T + +S E+ + ++ + Y+ GA 1+ +

I L +D Sbjct: 1014 VSGTTTCTMGfiTKCFISIELKPEKVPl^QVEVYFFVELYEATAGAAINNSARFAiQIKILESD 1153 (^Query: 1345 SPFGLVGIdRAASVFIRVAEPKENTTTL(^QLι3IARDKG--LLGDIAI

HLRAiQPNFLLHV 1311

LV + S R + A + T + L(Q + ARD G L+ + LR +

+ Sbjct: 1154 EStQSLVYFSVGS

RLAVAHKKATLISL(3VARDSGTGLM1 SVNFST(QELRSAETIGRTI IBID

(Query: 140D DN(QATENEDYVL(3ETIIIMKENIKEAHAEVSILPD 1434

+ A +D+V+ E ++ + + +V + P+

Sbjct: 1211 ISPAISGKDFVITEGTLVFEPGtQRSTVLDVILTPE 124S

Score = __&__ (27-1 bits)-, Expect = 2-5e-13-, Sum P(3) = 2-5e-13 Identities = 7S/242 (3D*)-, Positives = 113/242 (4b*)

(Query: 120b EIGINDSVTITILSNDDAYGIVAFAiQNSLYKiQVEEMEiQDSLVTLNVERLKGTYGRITIAId 12b5

EIG V I 1+ ND+A GI+ F + Y E E L+ + V RL

GTYG +T + Sbjct: 40 EIGNISIVRIIIMKNDNAEGIIEF--

DPKYTAFEVEEDVGLIMIPVVRLHGTYGYVTADF 17

(2uery: 12bb EADGSIS

DIFPTSGVILFTEGtQVLSTITLTILADNIPELSEVVIVTLTRITTEGV 1320 + S + D + F Ga LS I ++I+ DN E E + +

LT T G Sbjct: Ifi

IS(QSSSASPGGVDYILHGSTVTF(QHG(QNLSFINISIIDDNESEFEEPIEILLTGAT--G- 154 (Query: 1321

EDSYKGATID(QDRSKSVITTLPNDSPFGLVGIdRAASVFIRVAEPKENTTTL(QL(QIARDKG 13A0

GA + + +1 +DSPFG++ + S I +A P +T L

L + R G

Sbjct: 15S GAVLGRHLVSRIIIA-KSDSPFGVIRFLN(QSK-ISIANPN- STMILSLVLERTGG 20b

(Query- 13A1 LLGDIAIHLRA(Q-PNFLLHVDN(2ATENEDYVL<3ETIIIMKENIKEAHAEV- SILPDDLPE 143A

LLG+I ++ PN + lQ + D V + E + +1 P + E

Sbjct: 207 LLGEI(QVNIdETVGPNS(QEALLP(QNRDIADPV-- SGLFYFGEGEGGVRTIILTIYPHEEIE 2b4

(Query: 1431 LEEGFIVTI 1447 +EE FI+ +

Sbjct: 2bS VEETFIIKL 273

Score = 171 (2b-1 bits)-, Expect = 1-4e-34-, Sum P(3) = 1-4e-34 Identities = bS/244 (2b*)-, Positives = 114/244 (4b*)

(Query: 5fll DYIFTPMILHFADGERYKNVNIMILDDDIPEGDEKFiQLILTNPSPGLEL-- GKN T b33

D+ + L F DGER + V++ ILDDD PEG E F + LTNP G ++

GK + Sbjct: 154

DFEE(^QTLTLIFLDGERERKVSV^(QILDDDEPEG⁽QEFFYVFLTNP^(QGGA(QIVEGKDDTGFAA 1013

(^Query: b34 IALIIVLANDDGPGVLSFNNSEHFFLREPTALYViQESVAVLYIVREPAiQG-- LFGTV bAA A++I+ +D G++ F+ L ++ L + R+P +

+F V

Sbjct: 1D14 FAMVIITGSDLHNGIIGFSEESi^QSGLELREGAVflRR-- LHLIVTRlQPNRAFEDVKVFIdRV 1071 Query: bAI TV(Q— FIVTEVNSSNESKDLTPSKGYIVLEEGVRFKAL(QISAILDTEPEriDEYFVCTLFN 74b

T+ +V + + N ++L G G + I + P+++ YF L+

Sbjct: 1072 TLNKTVVVL(QKDGVNLHEEL(QSVSGTTTCTHGι2TKCFISIELKPEKVP(QVEVYFFVELYE 1131

(Query: 747 PTGGARLGVHVώ- TLITVLiQNiQAPLGLFSISAVENRATSIDIEEANRTVYLNVSRTNGID ADS

T GA + + I +L++ L S V +R ++ ++A + L

V + R +G

Sbjct: 1132 ATAGAAINNSARFA(QIKILESDES(QSLVYFS-VGSRL-AVAHKKAT-

LISLiQVARDSGTG 11AA

(Query: AOb LAVSViQldET A14 L +SV + T

Sbjct: HA1 LMMSVNFST 1117 Score = 174 (2b-l bits)-, Expect = 4-le-32-, Sum P(3) = 4-le-32 Identities = SA/20D (21*)-, Positives = 102/20D (51*)

(Query: HS1

DFIPSSGELIFEPGEREATIAVNILDDTVPEKEESFKV(QLKNPKGGAEIGINDSVT-ITI 1217 DF+ +SG GE EA+ V ++L D VPE EE + +(QL + +GGAE+ +

S+T + + Sbjct: 35b DFLSTSGFFTIADGESEASFDVHLLPDEVPEIEEDYVIβLVSVEGGAELDLEKSITldFSV 415 (Query: I21fl LSNDDAYGIVAFA(QNSLYK(3VEE!1EιQDSL —

VTLNVERLKGTYGRITIAIdEADGSISDIF 1275

+ NDD +G+ A + +(Q + (Q+ + + +N+ RL GT + G + +

SD

Sbjct: 41b YANDDPHGVFALYSD RlQSILIGtQNLIRSIiQINITRLAGTFGDVAVGLRIS SDHK 4b1

(Query- 127b PTSGVILFTEGtQVLSTITLTILADNIPELSE VI

VTLTRITTEGVEDSYKGA-TI 1321

V E (Q + + T D +P + + V + TL +T V + G TI

Sbjct: 47D E(QPIVTENAER(QLVVKDGATYKVDVVPIKN(3VFLSLGSNFTL(3LVTVr.LVG6RFYGr.PTI 521

(Query: 133D DiQDRSKSVITTLPNDSPFGLVGldRAAS 135b (Q+ +KS + + + VG+ + +

Sbjct: S3D L(QE-AKSAVLPVSEKAANS(QVGFESTA 5SS

Score = 14S (21-fl bits)-, Expect = 4-3e-24-, Sum P(3) = 4-3e-24 Identities = 104/31b (2b*)-, Positives = 17D/31b (42*)

(Query: AA

EGDEFANLTVSILPDDFPEMDESFLISLLEVHLMNISASLKNtQPTIGtQPNIST VIALNG 147

+G+ A+ V +LPD+ PE++E ++I L+ V A L + +1 +

+ N Sbjct: 3bA DGESEASFDVHLLPDEVPEIEEDYVI<^QLVSVEG---GAELDLEKSI

TldFSVYAND 411 (Query: 14A

DAFGVFVIYSISPNTSEDGLFVEV(QE(QP(QTLVELMIHRTGGSLG(QVAVEldRVVGGTATEG 207 D GVF +YS D + + + +++ I R G+ G VAV R+

+ Sbjct: 420 DPHGVFALYS

DRiQSILIGiQNLIRSIfllNITRLAGTFGDVAVGLRISSDHKEiQP 472

(Query: 20fi LDFIGAGEILTFAEGETKKTVILTXXXXXXXXXXXXXXXXLVYTE-GGSRI- -LPSS-DT 2b3 + A L +G T K ++ LV G R

+P+

Sbjct: 473 IVTENAER(QLVVKDGATYKVDVVPIKN(QVFLSLGSNFTL(QLVTVΓ1LVGGRFYGΓ1PTIL(QE 532 (Query: _>__ VRVNIL-ANDNVAGI-VSFiQTASRSVIGHEGEILiQFHVIRTFPGR-

GNVTVNldKI-IGiQN 311

+ +L ++ A V F++ + ++ HV+ + G G ++V

Id

Sbjct: 533 AKSAVLPVSEKAANS(QVGFESTAF(QLf1NITAGTS-- HVrilSRRGTYGALSVAIdTTGYAPG 510

(Query: 32D LEL

NFANFSG(QLFFPEGSLNTTLFVHLLDDNIPEEKEVY(QVILYDVRT(QGVPP 372

LE+ N G L F G +F+ E + + L V++ P

Sbjct: 511 LEIPEFIVVGNflTPTLGSLSFSHGEiQRKGVFLIdTFPS — PGIdPEAFVLHLSGViQSSA-- P b4b ώuery: 373 AGIALLDA(QGYAAVLTVEASDEPHGVLNFALSSRFVLL(QEANITIιQLFINREFG-SLGAI 431

G L G+ + A EP GV F+ SSR +++ E I+L + R

FG I

Sbjct: b47 GGAiQL—RSGF

IVAEIEPMGVF(QFSTSSRNIIVSEDT(QMIRLHV<QRLFGFHSDLI bll

(Query: 432 NVTYTTVPGNLS-LKN-(QTV--GNLA EPEVDF-

VPIIGFLILEEGETAAAINITIL 4A2

V+Y T G L++ + V G L + EVDF + 11 L E E

IN+T + Sbjct: 700 KVSY(QTTAGSAKPLEDFEPV(QNGELFF(QKF(QTEVDFEITIIND(2-

LSEIEEFFYINLTSV 7SA

(Query: 463 E 4A3 E Sbjct: 751 E 751

Score = 142 (21-3 bits)-, Expect = 5-be-OS-, Sum P(3) = S-be-OS Identities = 54/17S (30*)-, Positives = 7b/175 (43*) (Query: 143S

DLPELEEGFIVTITEVNLVNSDFSTGflPSVRRPGMEIAEINIEENDDPRGIFNFHVTRGA 1414 DL + G+ TI E N + D (QP + 1 I+I +ND+ GI

F

Sbjct: lb DLYDFGRGYDFTI(3E-NGL(QID (QPP- EIGNISIVRIIiriKNDNAEGIIEFDPK — - bb

(Query: 1415 GEVITAYEXXXXXXXXXXXXXXXAGSFGAVNVYld-- KASPDSAGLEDFKPSHGILEFADK 1552 TA+E G++G V + ++S S G D+

+ F

Sbjct: b?

YTAFEVEEDVGLIHIPVVRLHGTYGYVTADFISiQSSSASPGGVDYILHGSTVTFiQHG 123

(Query: 15S3 (QVTAriIEITIIDDAEFELTETFNISLISVAGGGRLGDDVVVTVVIP(QNDSPFGVF6F lbOI

(2 + 1 I + IIDD E E E I L GG LG +V + + I

++DSPFGV F Sbjct: 124

(QNLSFINISIIDDNESEFEEPIEILLTGATGGAVLGRHLVSRIIIAKSDSPF6VIRF IAD

Score = 125 (1A-A bits)-, Expect = 4-0e-25-, Sum P(3) = 4-0e-2S Identities = 77/3DA (25*)-, Positives = 134/30A (43*)

(Query: 1141 LVGAHSHIYELAYISSHS DFIP-

SSGELIFEPGEREATIAVNILDDTVPEKEES 1113

L G HS + +++Y ++ DF P +GEL F+ + E + I++D

+ E EE Sbjct: bll

LFGFHSDLIKVSY(QTTAGSAKPLEDFEPV(QNGELFF(QKF(QTEVDFEITIINDlQLSEIEEF 750

(Query: 1114 FKViQLKNP--

KGGAEIGINDSVTITILSNDDAYGIVAFA(QNSLYK(QVEEI E(QDSLVTLNV 1251 F + L + +G + +N S + + D + ++ N

D L + + +

Sbjct: 751 FYINLTSVEIRGLiQKFDVNIdSPRLNL-- -DFSVAVITILDN

DDLAGMDI 71b (Query: 1252

ERLKGTYGRITIAIdEADGSISDIFPTSGVILFTEG(QVLSTITLTILADNIPELSEVVIVT 1311

+ + T + A D ++ + S L T + + + T + + E

+ V +

Sbjct: 717 SFPETTVAVAVDTTLIPVETESTTYLSTS- KTTTILtQPTNVVAIVTEATGVSAIP A5D

(Query: 1312

LTRITTEGVEDSYKGATID(QDRSKSVITTLPNDSPFGLVGldRAASVFIRVAEPKENT-TT 1370

+ T G T V T N S G + V + I E K T T

SBJCT: AS1 EKLVTLHG TPAVSEKPDVATVTANVSIHGTFSLGPSIVYIE-

EEΓIKNGTFNT 101

(Query: 1371 L(QL(QIARDKGLLGDIAIHLRA (QPNFL LHVDNlQ-- ATENEDYVLiQETI 1415

++ I R G G+++I ++ +PN L + N A E

ED+ (Q

Sbjct: 1D2

AEVLIRRTGGFTGNVSITVKTFGERCA(2riEPNALPFRGIYGISNLTldAVEEEDFEE(^QTLT Ibl

(Query- 141b IIMKENIKEAHAEVSILPDDLPELEEGFIVTIT 144A +1 + +E V IL DD PE +E F V +T

Sbjcf- 1b2 LIFLDGERERKVSViQILDDDEPEGlQEFFYVFLT 114 Score = 123 (1A-5 bits)-, Expect = b-0e-2fi-, Sum P(3) = b-Oe-EA Identities = 11/372 (24*)-, Positives = ISO/372 (4D*) (Query : 3Ab VLTVEASDEPHGVLNFALSSRFVLL<3EA--NITI

(QLFINREFGSLGAINVTYTTV-- 43A

V TV A+ HG F+L V ++E N T ++ I R G G

+ ++T T Sb jct : AbA VATVTANVSIHGT—

FSLGPSIVYIEEENKNGTFNTAEVLIRRTGGFTGNVSITVKTFGE 125

(Query : 431 PGMLSLKN-tQTVGNL--

AEPEVDFVPHGFLILEEGETAAAINITILEDDVPEL 4A1 P L + + NL A E DF LI +GE + + +

IL+DD PE Sbjct : 12b RCA(QMEPNALPFRGIYGISNLTldAVEEEDFEE(QTLTLIFLDGERERKVSV(QILDDDEPEG 1A5 (Query : 410 EEYFLVNLTYVGLTMAASTSFPPRLDSE6LTA--(QVIIDANDGARGVI~-

Elι)(Q(QSRFEV 544

+E+F V LT D G A VII +D G+I E

(QS E +

Sbjct : 1Ab (QEFFYVFLT NPiQGGAiQIVEGKDDTGFAAFAMVIITGSDLHNGIIGFSEESlQSGLEL 1D41

(Query : 545 NE--THGSLTLVA(QRS-REPLGHVSLF — VYA(QNLEA(3VGLDYIFTPHILHFADGERYKN 511

E L L+ R V +F V + D + L G

Sbjct: 1042 REGAVMRRLHLIVTR(QPNRAFEDVKVFIdRVTLNKTVVVL(QKDGVNLr.EELflSVSGTTTCT 1101

(Query: bOO VNIMILDDDIPEGDEKFiQLILTNPSPGLELGKNT- IALIIVLANDDGPGVLSF bSl

++I + + +P+ + F + L + G + + A I +L

+D+ ++ F

Sbjct: 1102

MG<QTKCFISIELKPEKVP(QVEVYFFVELYEATAGAAINNSARFA(QIKILESDES(QSLVYF llbl

(Query: b52 NNSEHFFLREPTALYV(QESVAVLYIVREPA(QGLFGTVTV<3FIVTEVNSSNE-

-SKDLTPS 701

+ + A + L + R+ GL ++V F E+ S+

++P+ Sbjct: Hb SVGSRLAVAHKKATLIS L(QVARDSGTGLM—

MSVNFSTiQELRSAETIGRTIISPA 1214

(Query: 710 -—KGYIVLEEGVRFKAL(QISAILD 731

K +++ E + F+ (3 S +LD Sbjct: 1215 ISGKDFVITEGTLVFEPG(3RSTVLD 1231

Score = 120 (1A-0 bits)-, Expect = l-Ae-22-, Sum P(3) = l-Ae-22 Identities = 77/31b (24*)-, Positives = 127/31b (40*) (3uery: 1255 KGTYGRITIAldE—-ADGS

ISDIFPTSGVILFTEG(3VLSTITLTILADNIPEL 1304

+GTYG +++Ald A G + ++ PT G + F+ G+ + L

P

Sbjct : 573 RGTYGALSVAUTTGYAPGLEIPEFIVVGNriTPTLGSLSFSHGElQRKGVFLIilTFPS— PGld b3D

(Query : 1305 SEVVIVTLTRITTEGVEDSYKGATID(3DRSKSVITTLPNDSPFGLVGIιJRAASVFIRVAEP 13b4 E ++ L+ GV+ S G (Q RS ++ + P G+ + +S

I V + E

Sbjct : b31 PEAFVLHLS GV(QSSAPGGA--(3LRSGFIVAEI —

EPHGVFiQFSTSSRNIIVSE- b71

(Query : 13b5 KENTTTL(QL(QIARDKGLLGDIAIHLRA<QPNFLLHVDN(QATENEDYV- LώETIIinKENIK 1423

+ T + + L + R G D+ I + (Q A ED+ +(Q

+ + + Sbj ct : bδO --DT(QHIRLHV(3RLFGFHSDL-IKVSY(QTTA

GSAKPLEDFEPV(QNGELFF(QKF(3T 731

(Query : 1424 EAHAEVSILPDDLPELEEGFIVTITEVNLVN- SDFSTG(3PSVRRPGI EIAEI(1IEENDDP 14 A2 E E++I+ D L E+EE F + +T V + F +A I

I +NDD

Sb jct : 732 EVDFEITIIND(QLSEIEEFFYINLTSVEIRGL(QKFDVNIdSPRLNLDFSVAVITILDNDDL 711 (Query : 14A3 RGI-FMFHVTRGAGEVITAY---

EXXXXXXXXXXXXXXXAGSFGAVNVYldKASPDSAGLE 1S3A

G+ F T A V T E V +

+A+ SA E

Sb j ct : 712 AGMDISFPETTVAVAVDTTLIPVETESTTYLSTSKTTTILiQPTNVVAIVTEATGVSAIPE A51

(Query : 1S31 DFKPSHGILEFADKlQVTAI IEITIIDDAEFEL 157D

HG ++K A + + ' F L

Sb j ct : AS2 KLVTLHGTP AVSEKPDVATVT ANVSIHGTFSL AA3

Score = 113 (17-0 bits)-, Expect = 1-4e-34-, Sum P(3) = 1-4e-34 Identities = 2A/A7 (32*) Positives = 50/A7 (57*)

(Query: H5b SHSDFIPSSGELIFEPGEREATIAVNILDDT-- VPEKEESFKViQLKNPKGGAEIG-INDS 1212

S DF+ + G L+FEPG+R + V + +T + + F++ L +PKGGA

I + +

Sbjct: 121b

SGKDFVITEGTLVFEPG(QRSTVLDVILTPETGSLNSFPKRF(QIVLFDPKGGARIDKVYGT 127S

(Query: 1213 VTITILSNDDAYGIVAFAiQNSLYKlQVEE 1240

IT++S+ D+ I A + L++ V +

Sbjct: 127b ANITLVSDADSiQAIUGLA-DiQLHlQPVND 1302 Score = 13 (14-0 bits)-, Expect = 4-le-32-, Sum P(3) = 4-le-32 Identities = 57/222 (25*)-, Positives = 10/222 (40*)

(Query: 1404 TENEDYVL--(2ETIIiriKENIKEAHAE VSILPDDLPEL

EEGFIVTITEVN 1451 TE+ Y+ + T 1+ N+ E VS +P+ L L E+

+ T+T

Sbjct: Alb TESTTYLSTSKTTTILOPTNVVAIVTEATGVSAIPEKLVTLHGTPAVSEKPDVATVTANV A7S (Query: 14S2 LVNSDFSTGfQPSVRRPGHEIAEirHEENDDPRGIFHFHVTRGAGEV- ITAYEXXXXXXXX 1510

++ FS G PS+ + I E M + + + G V IT Sbjct: A7b SIHGTFSLG-PSI

VYIEEEHKNGTFNTAEVLIRRTGGFTGNVSITVKTFGERCAiQri 130

(Query: 1511 XXXXXXXAGSFGAVNVYldKASPDSAGLEDFKPSHGILEFADKtQVTANIEITIIDDAEFEL 157D

G +G N+ Id EDF+ L F D + + +

I+DD E E

Sbjct: 131 EPNALPFRGIYGISNLTldAVEE

EDFEE(QTLTLIFLDGERERKVSV(QILDDDEPEG 1A5

(Query: 1571 TETFNISLISVAGGGRL--GDD VVVTVVIPώNDSPFGVFGFEEKTVS

IblS

E F + L + GG ++ G D V+I +D G+ GF E++ S

Sbjct: Ifib (QEFFYVFLTNPι3GGAι3IVEGKDDTGFAAFAriVIITGSDLHNGIIGFSEES(3S 1037

Score = 13 (14-D bits)-, Expect = l-Oe-18-, Sum P(3) = 1-De-lfl Identities = 51/236 (21*)-, Positives = 107/236 (44*) (Query: bOD VNIMILDDDIPEGDEKFiQLILTNPSPGLELGKNT-

IALIIVLANDDGPGVLSFNNSEHFF b5δ

++I + + +p+ + F + L + G + + A I +L +D+ ++

F +

Sbjct: HO ISIELKPEKVP(3VEVYFFVELYEATAGAAINNSARFA(QIKILESDES(QSLVYFSVGSRLA llbδ

(Query: bS LREPTALYV(3ESVAVLYIVREPA(3GLFGTVTV<3FIVTEVNSSNE-- SKDLTPS- — GYI 713

+ A + L + R+ GL ++V F E+ S+ ++P+ K ++

Sbjct: llbl VAHKKATLIS LfQVARDSGTGLM — riSVNFSTtQELRSAETIGRTIISPAISGKDFV 1221

(Query: 714 VLEEGVRFKAL<QISAILDT--EPE MDEY FVCTLFNPTGGARLG- VHViQTLITVL 7b4

+ E + F+ (3 S +LD PE ++ + F LF+P GGAR+ V +

IT + +

Sbjct: 1222

ITEGTLVFEPG(QRSTVLDVILTPETGSLNSFPKRF3IVLFDPKGGARIDKVYGTANITLV 12A1

(Query: ?b5 (QNiQAPLGLFSISAVENRATSIDI-

EEANRTVYLNVSRTNGIDLAVSVlQldETVSETAFGIIR 623

+ ++ ++ ++ + DI T+ + V+ T D +S +

+ Sbjct: 12A2 SDADS(QAIldGLAD(QLH(QPVNDDILNRVLHTISMKVA-

TENTDE(QLSAf1MHLIEKIT--TE 133A

(Query- 624 GMD VFSV A31 G FSV Sbjct: 1331 GKItQAFSV 134b

Score = 12 (13-A bits)-, Expect = l-Se-25-, Sum P(3) = l-Se-25 Identities = 44/177 (24*)-, Positives = 62/177 (4b*) (Query: bδO

PA(3GLFGTVTV(QFIVTEVNSSNESKDLTPSKGYIVLEEGVRFKAL^(QISAILDTEPEI1DEY 731

P +G++G + + V E + E + LT ++ +G R + + + + D

EPE E + Sbjct: 13b PFRGIYGISNLTIdAVEEEDF — EEiQTLT

LIFLDGERERKVSV(QILDDDEPE6(QEF 166

(Query: 740 FVCTLFNPTGGARL

GVHV(QTLITVL(QN(3APLGLFSISAVENRATSIDIEEAN- 711

F L NP GGA++ G ++ + + G+ S

+ + + E

Sbjct: Ifil FYVFLTNP(QGGA(QIVEGKDDTGFAAFAriVIITGSDLHNGIIGFS- EESIQSGLELREGAV lD4b

(Query: 712 -RTVYLNVSRT-NGIDLAVSViQldE-TVSETAF

GNRGNDVVFSVFiQSFLDESASGtd 643

R ++L V+R N V V Id T + ++T G+ M+ + SV +

Sbjct: 1047 MRRLHLIVTR(QPNRAFEDVKVFIdRVTLNKTVVVLιQKDGVNLriEEL(QSVSGTTTCTriG(QTK 110b

(Query: 644 CFFTLE 641

CF ++E Sbjct: 1107 CFISIE 1112

Score = 11 (13-7 bits)-, Expect = b-be-32-, Sum P(3) = b-be-32 Identities = 41/153 (32*) n Positives = 70/153 (45*)

(Query: I4bb RPGNEIAEIMIEENDDPRGIFMFHVTRGAGEVITAYEXXXXXXXXXXXXXXXAGSFGAVN 152S

R G +AEI +P G+F F + + +1 + + + +

Sbjct: bS2 RSGFIVAEI EPHGVFlQFSTS--

SRNIIVSEDT(QriIRLHV(QRLFGFHSD---LIK 70D

(Query: lS2b VYIdKASPDSAG-LEDFKP-

SHGILEFADKlQVTAI IEITIIDDAEFELTETFNISLISVAG 1563

V ++ + SA LEDF + P +6 L F (Q EITII + D E+ E F

I + L SV Sbjct: 701

VSY(3TTAGSAKPLEDFEPVlQNGELFF(QKF(QTEVDFEITIIND(QLSEIEEFFYINLTSVEI 7b0

(Query: 1564 GG RLGDDVVVTVV-IPtQNDSPFGV-FGFEEKTVS IblS

G RL D V V+ I ND G+ F E TV+ Sbjct: 7bl RGL(QKFDVNldSPRLNLDFSVAVITILDNDDLAGI DISFPETTVA 604

Score = bS (1-6 bits)-, Expect = 6-6e-21-, Sum P(3) = 6-δe-21 Identities = 2b/11 (2b*)-, Positives = 50/11 (50*) (Query: 1232 NSLYK(3VEEI1E(3DSLVTLNVERLKGTYGRITIAIdEADGS ISDIF —

PTSGVILFTE 1265

NS K+ + + D ++++ GT IT+ +AD ++D P

+ IL

Sbjct: 1250 NSFPKRFOIVLFDPKGGARIDKVYGT- ANITLVSDADS(3AIIdGLAD(3LH(3PVNDDIL — - 13DS

Query: I2δb GiQVLSTITLTILADNIPELSEVVIVTLTRITTEGVEDSYKGAT 1326

+VL TI++ + +N E ++ + +ITTEG ++ A+

Sbjct: 130b NRVLHTISHKVATENTDE(QLSAIiriHLIEKITTEGKI(QAFSVAS 1346

Score = 46 (7-2 bits)-, Expect = l-le-27-, Sum P(3) = l-le-27 Identities = 23/115 (20*)-, Positives = 44/115 (36*) (Query : 1411 TAYEXXXXXXXXXXXXXXXAGSFGAVNVYIdKAS

PDSAGLEDFKPSHGILEFAD 1551

TA + + G + + GA++V Id P+ + + P +

G L F + Sbjct : 5S4

TAFlQLMNITAGTSHVMISRRGTYGALSVAldTTGYAPGLEIPEFIVVGNMTPTLGSLSFSH bl3

Query : 1SS2 KώVTAHIEITIIDDAEFELTETFNISLI-- SVAGGGRLGDDVVVTVVIP(QNDSPFGVFGF IbOI + + + + ++S + S GG +L +V +

P GVF F

Sb jct : bl 4 GE(3RKGVFLIdTFPSPGIdPEAFVLHLSGV(3SSAPGGA(3LRSGFIVAEI

EPNGVFtQF bbβ

Pedant information for DKFZphamy2__10p7-> frame 3

Report for DKFZphamy2_lDp7-3

[LENGTH! lblS

[Mid! 177b00 - Sδ

[pi! 4 - 37

[HOriOL! TREMBL:AF0550δ4_l gene: "VLGRl"ή product: very large G-protein coupled receptor-l"i Homo sapiens very large G- protein coupled receptoi—1 (VLGR1) mRNA-, complete eds- 5e-24 [BLOCKS! BPD1413A [BLOCKS! BL00713B Sodium : dicarboxylate symporter family proteins

[BLOCKS! PR01D03A

[BLOCKS! PR00412C

[BLOCKS! BL00624E [PIRKId! heart le-Dδ [PIRKId! ion transport le-Oδ

[PIRKId! transmembrane protein 3e-06 [PIRKId! phosphoprotein 2e-0δ [PIRKId! membrane protein le-06

[PROSITE! IULTIC0PPER_0XIDASE1 1 EKld! All_Beta

[Kid! LOld COMPLEXITY 2-b0 *

SE(3 DAIdADAIdALYTCATLCLKE(3ACSAFSFFSASEGP(3CFUriTSωiSPAVNNSDFIdTYRKNπT SEG xxxxxxxxxxx

PRD ccchhhhhhhhchhhhhhhhhhheeeeeecccccceeeeeeeccccccccceeeecccee

SE(3 RVASLFSGfiAVAGSDYEPVTRflldAIMiQEGDEFANLTVSILPDDFPEMDESFLISLLEVHL

SEG PRD eeeeeccccccccccceeeceeeeeeccccceeeeeeeeccccccchhhhhhhhhhhhhh

SE(Q MNISASLKN<QPTIG<^QPNISTVVIALNGDAFGVFVIYSISPNTSEDGLFVEV(QE(QP(QTLVE

SEG

PRD hccccccccccccccccceeeeeeecccceeeeeeeeecccccccceeeeeeecccceee

SE(Q LMIHRTGGSLGώVAVEldRVVGGTATEGLDFIGAGEILTFAEGETKKTVILTILDDSEPED

SEG xxxxxxxxx

PRD eeeeecccccceeeeeeecccccccccccccccceeeeeccccceeeeeeeeeccccccc SE(Q DESIIVSLVYTEGGSRILPSSDTVRVNILANDNVAGIVSFiQTASRSVIGHEGEILiQFHVI

SEG xxxxxxx

PRD ccceeeeeeeccccccccccccceeeeeeccccceeeeeeeccceeeeccccceeeeeee

SE(Q RTFPGRGNVTVNIdKIIG(3NLELNFANFSG(QLFFPEGSLNTTLFVHLLDDNIPEEKEVY(3V

SEG

PRD eccccccceeeeeeeecccccccccccccceeecccceeeeeeeeeecccccccccceee SE(Q ILYDVRT(QGVPPAGIALLDA(QGYAAVLTVEASDEPHGVLNFALSSRFVLL(QEANITI(QLF

SEG

PRD eeccceeeeccchhhhhhhhccccceeeeeecccccceeeeeeceeeeeecccccceeee

SE(Q INREFGSLGAINVTYTTVPGHLSLKNiQTVGNLAEPEVDFVPIIGFLILEEGETAAAINIT SEG

PRD cccccccceeeeeeecccccccccccccccccccccceeeeeeeeeeeccccccccceee

SE(3 ILEDDVPELEEYFLVNLTYVGLTMAASTSFPPRLDSEGLTAiQVIIDANDGARGVIEIdlQiQS

SEG PRD eccccchhhhhheeeeeeeecceeecccccccccccccceeeeeeeccccceeeeeeccc

SE(Q RFEVNETHGSLTLVA(QRSREPLGHVSLFVYA(QNLEA(QVGLDYIFTPπiLHFADGERYKNV

SEG

PRD eeeecccccceeeeeeccccccceeeeeeeeccccccccccccccceeeecccccceeee

SE(Q NIMILDDDIPEGDEKFiQLILTNPSPGLELGKNTIALIIVLANDDGPGVLSFNNSEHFFLR

SEG

PRD eeeeeccccccccceeeeeeeccccccccccceeeeeeeecccccceeeeeeccceeeee SE(Q EPTALYV(QESVAVLYIVREPA(QGLFGTVTV(QFIVTEVNSSNESKDLTPSKGYIVLEEGVR

SEG

PRD ccceeeeccchhhhhhhhhcccccceeeeeeeeeeeccccccccccccccceeeeeccce

SE(Q FKAL(QISAILDTEPEMDEYFVCTLFNPTGGARLGVHV(3TLITVL(3N(QAPLGLFSISAVEN SEG

PRD eeeeeeeeecccchhhhhhheeeeecccccceeehhhhhhhhhhhhhcccceeeeeecch

SE(Q RATSIDIEEANRTVYLNVSRTNGIDLAVSV(QldETVSETAFGf1RGHDVVFSVF(QSFLDESA

SEG PRD hhhhhccccccceeeeeeeccccchhhhheeeeeccceeeeccccceeeeeeeecccccc

SElQ SGldCFFTLENLIYGiriLRKSSVTVYRldlQGIFIPVEDLNIENPKTCEAFNIGFSPYFVITH

SEG

PRD cceeeeeccccccceeecccceeeecccceeeccceeeeccccccceeecccccceeeee

SE(^Q EERNEEKPSLNSVFTFTSGFKLFLV(QTIIILESS(^QVRYFTSDS(QDYLIIAS(QRDDSELT(Q

SEG

PRD hhhhhcccceeeeeeecccceeeeeceeecccccceeeeccccceeeeeeecccccceee SE(Q VFRIdNGGSFVLH(3KLPVRGVLTVALFNKGGSVFLAIS(QANARLNSLLFRIdSGSGFINF(QE

SEG

PRD eeeeccceeeeeeccccceeeeeeeeccccceeeeeeehhhhhheeeeeecccccceeee

SE(Q VPVSGTTEVEALSSANDIYLIFAKNVFLGD⁽3NSIDIFIldEriG(QSSFRYF(QSVDFAAVNRI SEG

PRD eeccccceeeeccccceeeeeeeeeeeecccceeeeeeeeccccceeeeeeccceeeece

SE(Q HSFTPASGIAHILLIG(QDMSALYCIdNSERN^(QFSFVLEVPSAYDVASVTVKSLNSSKNLIA SEG

PRD eecccccceeeeeeeccccceeeeecccccceeeeeeeccccceeeeeeeccccccceee

SE(3 LVGAHSHIYELAYISSHSDFIPSSGELIFEPGEREATIAVNILDDTVPEKEESFKV(3LKN SEG

PRD eeccceeeeeeeeeeccccccccceeeeecccchhhhheeeeeccccccccceeeeeeec

SEG PKGGAEIGINDSVTITILSNDDAYGIVAFAflNSLYKtQVEEMEtQDSLVTLNVERLKGTYGR

SEG PRD ccccceeecccceeeeeecccccchhhhhhccchhhhhhhhhhhhhhhhhhhccccceee

SE(Q ITIAldEADGSISDIFPTSGVILFTEGlQVLSTITLTILADNIPELSEVVIVTLTRITTEGV

SEG

PRD eeeeeeeccceeeeeccccceeeeccccccceeeeeecccceeeeeeeeeeeeeeceeee

SE(Q EDSYKGATID(3DRSKSVITTLPNDSPFGLVGldRAASVFIRVAEPKENTTTL(QL(QIARDKG

SEG

PRD cceeeeeeeecccceeeeeecccccccceeehhhhhheeeeeccccccccceeeeccccc SE(Q LLGDIAIHLRA(QPNFLLHVDN<QATENEDYVL(QETIIIHKENIKEAHAEVSILPDDLPELE

SEG

PRD ccccccceeecccceeeeeccccccccceeeeeeeeeecccchhhhheeeeccccccccc

SEβ EGFIVTITEVNLVNSDFSTGIQPSVRRPGΓIEIAEII IEENDDPRGIFΓIFHVTRGAGEVITA SEG

PRD cceeeeeeeeeeccccccccccccccccchhhhhhhhcccccceeeeeeeeccccceeee

SE(Q YEVPPPLNVL(QVPVVRLAGSFGAVNVYldKASPDSAGLEDFKPSHGILEFADK(QVTAI1IEI

SEG - - xxxxxxxxxxxxxxx PRD eeccccceeeeeeeeeecccccceeeeeeccccccccccccccceeeeecccceeeecce

SE(Q TIIDDAEFELTETFNISLISVAGGGRLGDDVVVTVVIPiQNDSPFGVFGFEEKTVS

SEG

PRD eeechhhhhhhhcceeeeeeecccccccceeeeeeeecccccccceeeecccccc

Prosi te f or DKFZphamy2_lDp7 - 3 PS0D071 151->172 I ULTIC0PPER_0XIDASE1 PD0C00D7b

( No Pf am data ava i l abl e f or DKFZphamy2_10p7 - 3 )

DKFZphamy2_lld2

group: transmembrane protein

DKFZphamy2_lld2 encodes a novel S52 amino acid protein without similarity to known proteins- The novel protein contains 2 transmembrane regions-

No informative Blast resultsi no predictive prosite-, pfam or scope motife-

The new protein can find application in studying the expression profile of amygdala-specific genes and as a new marker for amygdala cells-

unknown protein

Pedant: TRANSMEMBRANE 2

Sequenced by EMBL Locus: /map="lbpl3 ■ 3"

Insert length: 2131 bp

Poly A stretch at pos- 212D-, polyadenylation signal at pos- 26b1

1 GGCGGGTGAG AGGCCGCGGC GGCAGGTCCA CCTGGGCTTG CGAAGGCACA

SI GATTCCCCGT CCACAGCTCA CGACCAGATG CACCAGCAGG AGTCCACATC

101 GAGGACGTCC TCCGGGCACT CCCACGACCA GTGACCAGGA GTTAAACTTT

151 GGGATGTGCC CGTGATGTTG GACCACAAGG ACTTAGAGGC CGAAATCCAC 201 CCCTTGAAAA ATGAAGAAAG AAAATCGCAG GAAAATCTGG GAAATCCATC

251 AAAAAATGAG GATAACGTGA AAAGCGCGCC TCCACAGTCC CGGCTCTCCC

301 GGTGCCGAGC GGCGGCGTTT TTTCTTTCAT TGTTTCTCTG CCTTTTTGTG

351 GTGTTCGTCG TCTCATTCGT CATCCCGTGT CCAGACCGGC CGGCGTCACA

401 GCGAATGTGG AGGATAGACT ACAGTGCCGC TGTTATCTAT GACTTTCTGG 451 CTGTGGATGA TATAAACGGG GACAG6ATCC AAGATGTTCT TTTTCTTTAT

501 AAAAACACCA ACAGCAGCAA CAATTTCAGC CGATCCTGTG TGGACGAAGG

5S1 CTTTTCCTCT CCCTGCACCT TTGCAGCTGC TGTGTCGGGG GCCAACGGCA bOl GCACGCTCTG GGAGAGACCT GTGGCCCAAG ACGTGGCCCT CGTGGAGTGT b51 GCTGTGCCCC AGCCAAGAGG CAGTGAGGCA CCTTCTGCCT GCATCCTGGT 701 GGGCAGACCC AGTTCTTTCA TTGCAGTCAA CTTGTTCACA GGGGAAACCC

7S1 TGTGGAACCA CAGCAGCAGC TTCAGCGGGA ATGCGTCCAT CCTGAGCCCT δOl CTGCTGCAGG TGCCTGATGT GGACGGCGAT GGGGCCCCAG ACCTGCTGGT

651 TCTCACCCAG GAGCGGGAGG AGGTTAGTGG CCACCTCTAC TCCGGCAGCA

101 CCGGGCACCA GATTGGCCTC AGAGGCAGCC TTGGTGTGGA CGGGGAAAGT 151 GGCTTCCTCC TTCACGTCAC CAGGACAGGT GCCCACTACA TCCTCTTTCC

1001 CTGCGCAAGC TCCCTCTGCG GCTGCTCTGT GAAGGGTCTC TACGAGAAGG

1DS1 TGACCGGGAG CGGCGGCCCG TTCAAGAGTG ACCCGCACTG GGAGAGCATG

1101 CTCAATGCCA CCACCCGCAG GATGCTTTCC CACAGCTCTG GAGCAGTGCG

1151 CTACCTGATG CATGTCCCAG GGAACGCCGG TGCAGATGTG CTTCTTGTGG 12D1 GCTCAGAGGC CTTCGTGCTG CTGGACGGGC AGGAGCTGAC GCCTCGCTGG

12S1 ACACCCAAGG CAGCCCATGT CCTGAGAAAA CCCATCTTCG GCCGCTACAA

13D1 ACCAGACACC TTGGCTGTAG CCGTTGAAAA CGGAACTGGC ACCGACAGAC

1351 AGATCCTGTT TCTGGACCTT GGCACTGGAG CCGTCCT6TG TAGCCTAGCC 1401 CTCCCGAGCC TCCCTGGGGG TCCACTGTCC GCCAGCCTGC CGACCGCAGA

1451 CCACCGCTCA GCCTTCTTCT TCTGGGGCCT CCACGAGCTG GGGAGCACCA

1501 GCGAGACGGA GACCGGGGAG GCCCGGCkCk GCCTGTACAT GTTCCACCCC

15S1 ACCCT6CCGC GCGTGCTGCT GGAGCTGGCC AATGTCTCTA CCCACATTGT

IbOl CGCCTTTGAC GCCGTCCTGT TTGAGCCAAG CCGCCACGCC GCCTACATCC

IbSl TTCTGACAGG CCCGGCAGAC TCAGAGGCAC CCGGCCTGGT CTCTGTGATC

1701 AAGCACAAGG TGCGGGACCT TGTCCCAAGC AGCAGGGTGG TCCGCCTGGG

17S1 TGAGGGTGGG CCAGACAGTG ACCAAGCCAT CAGGGACCGG TTCTCCCGGC

1601 TGCGGTACCA GAGTGAGGCG TAGAGGCACG CCAGCCAGAG CCTGTGGAGA

1A51 GACTCCGCCT GCTGACACTA AACGTCCTGG GAAGTGGGCC CTTCCCTGGG

1101 TCTCTGCACT GACTCCCCCA CTCCTGACCC TGGTGAT6GT CGCCACTGGG

11S1 CAGCAGCAGC CTTACCAGTC CTCCATGATC ACACCCAGGG ACCTGCATGG

2001 GTGAGGGGAC ACCCTGGGCC TCTCTCCCGC CCAGCATCCT CCCTGAGTCC

2051 CCACACAGGG CCTCACTCTG CACCCCACCA GGGTCCCGCT CACACCAGGC

2101 AGCCTTCATA GTGGTCTCCC TGGCCACCTT GGGCAGAGCT GGGTCATGCA

2151 GCACCCCATC CTTACCCGGT GCCCTCTCCT TGCCAGCTTC TCCCCAGGCC

2201 AGAGCGGCCA TCGCGTAGAA AGAACCAGGG TGTCCCCGGG ACAGGCCGTC

2251 CCCCACCCCA TCCTGTAGAG TCCATTCCCC TTTTCCCTCC TGTGCTCTGT

2301 CCCCCAAGGA GTCATGGAAC TCAGGGTACT GGGCCTCAAC GGGAACCTGA

2351 GACAGCTTCC AGCTTCGCAG CCCTTCCCGG AGCTACAGGG GGATCCTCTA

2401 GCATGGGGGG TGTGACTTGG T.TCCTTTGAC CAGGTCCTGT GAGGAAGCCT

2451 GGAGCAAGGG TCTCCCCCAG CAGGATGGGT GGGGCCTGCT CTGGAGCTGA

2501 GCCCGTGGCC GCTCACAGGT GTCCTTAGTG GTGTTGCAGC TGTCTACTGG

2SS1 CTGCATGTGC TGTGAATATC CCAAGGAACT GGCTGTGGAA TGCGTGTTTG

2b01 GGTCAGTCTG TGCCCTCTCA GTAGACACTG GAGCTGCTCT GTCCCTGAAG

2b51 AGGCCCCGTG CCCCAGGCAT GGCAAGCGCC TGCCTCTCCC CTTCCGGTGC

2701 TCACACGCCC ACGCCGTGCC ACCCGATGCA GGACTCACCT CTGTGCCTTG

2751 CTGCTCCTGA GGCCCAAGGG CAGCCATGGT GCTCTGTACT GCTCGGGCCG

2601 CCCAGGTCAC AGAGCCTGAG CTTCGTAGCC AAAGCAGCCT GATGACCCAC

2651 CCACCAAGGA AGAAAGCAGA ATAAACATTT TTGCACTGCC TGAAAAACCC

2101 CGGTGGTCAG GCGTGAGCCT AAAAAAAAAA AAAAAAAAA

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 2

ORF from 2555 bp to 2631 bp=, peptide length: 15 Category: questionable ORF Classification: unclassified

1 MCCEYPKELA VECVFGSVCA LSVDTGAALS LKRPRAPGMA SACLSPSGAH 51 TPTPCHPMlQD SPLCLAAPEA ι3G(QPldCSVLL GPPRSβSLSF VAKAA BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_lld2-, frame 2

TREMBL:MMIGCF_2 Mouse ig gamma2a-b (c57bl/b allele) c gene and secreted tail--, N = l-i Score = 73-, P = 0-1

>TREMBL:MMIGCF_2 Mouse ig gamma2a-b (cS7bl/b allele) c gene and secreted tail - Length = 334

HSPs:

Score = 73 (11-D bits)-, Expect = l-le-01-, P = l-De-01 Identities = lb/41 (32*)-, Positives = 27/41 (55*)

(Query: 44 LSPSGAHTPTPCHPM(3DSPLCLAAPEA(3G(3PldCSVLLGPPRS(QSLSFVA 12

+ P T PC P+++ P C AAP+ G P SV + PP+ + + ++ Sbjct: It, IEPRVPIT(QNPCPPLKECPPC-AAPDLLGGP--SVFIFPPKIKDVLMIS 141

Peptide information for frame 3

ORF from lb5 bp to 1620 bpi peptide length: 552

Category: putative protein

Classification: Transmembrane proteins unclassified

1 MLDHKDLEAE IHPLKNEERK S(3ENLGNPSK NEDNVKSAPP (3SRLSRCRAA

51 AFFLSLFLCL FVVFVVSFVI PCPDRPAS(3R MldRIDYSAAV IYDFLAVDDI

101 NGDRIC3DVLF LYKNTNSSNN FSRSCVDEGF SSPCTFAAAV SGANGSTLldE

151 RPVAiSDVALV ECAVPlQPRGS EAPSACILVG RPSSFIAVNL FTGETLIdNHS 201 SSFSGNASIL SPLLtQVPDVD GDGAPDLLVL TlQEREEVSGH LYSGSTGHώl

251 6LRGSLGVDG ESGFLLHVTR TGAHYILFPC ASSLCGCSVK GLYEKVTGSG

301 GPFKSDPHldE SMLNATTRRM LSHSSGAVRY LMHVPGNAGA DVLLVGSEAF

351 VLLDGlQELTP RldTPKAAHVL RKPIFGRYKP DTLAVAVENG TGTDRiQILFL

401 DLGTGAVLCS LALPSLPGGP LSASLPTADH RSAFFFIdGLH ELGSTSETET 451 GEARHSLYMF HPTLPRVLLE LANVSTHIVA FDAVLFEPSR HAAYILLTGP

501 ADSEAPGLVS VIKHKVRDLV PSSRVVRLGE GGPDSDiQAIR DRFSRLRYflS

5S1 EA

BLASTP hits

No BLASTP hits available Alert BLASTP hits for DKFZphamy2_lld2-, frame 3

No Alert BLASTP hits found Pedant information for DKFZphamy2_lld2ι frame 2

Report for DKFZphamy2_lld2-2

[LENGTH! 15

[MU! 1757-36

[pi! b-bδ [BLOCKS! PR00521E

[Kid! Alpha_Beta

SE(3 MCCEYPKELAVECVFGSVCALSVDTGAALSLKRPRAPGMASACLSPSGAHTPTPCHPM(3D PRD cccchhhhhhhhhccceeeeeecccchhhhhccccccccccccccccccccccccccccc

SE(3 SPLCLAAPEA(QG(2PldCSVLLGPPRS(QSLSFVAKAA PRD ccccccccccccccceeeeccccccchhhhhhccc

(No Prosite data available for DKFZphamy2_lld2-2)

(No Pfam data available for DKFZphamy2_lld2-2)

Pedant information for DKFZphamy2_lld2π frame 3

Report for DKFZphamy2_lld2- 3

[LENGTH! 552

[Mid! 51bS1-b6

[pi! 5-84 [BLOCKS! PRD0211G

[BLOCKS! BL002βδC Tissue inhibitors of metalloproteinases proteins

[BLOCKS! PR0043bA

[Kid! TRANSMEMBRANE 2 [Kid! LOld_C MPLEXITY 6 - 15 *

SE(Q MLDHKDLEAEIHPLKNEERKSiQENLGNPSKNEDNVKSAPPiQSRLSRCRAAAFFLSLFLCL

SEG xxxxxxxxx PRD ccchhhhhhhcccccccccccccccccccccccccccccccchhhhhhhhhhhhhhhhhh

MEM MMMMMMM

SEfQ FVVFVVSFVIPCPDRPASl^QRMIdRIDYSAAVIYDFLAVDDINGDRIiQDVLFLYKNTNSSNN

SEG xxxxxxxxx PRD hhhhhhhccccccccccchhhhhhhchhhhhhhhhccccccccchhhhhhhccccccccc

MEM MMMMMMMMMM

SE(Q FSRSCVDEGFSSPCTFAAAVSGANGSTLIdERPVA(^QDVALVECAVP(^QPRGSEAPSACILVG

SEG PRD ccccccccccccccccccccccccccccccccccchhhhhhhccccccccccceeeeeec

MEM

SE(3 RPSSFIAVNLFTGETLDNHSSSFSGNASILSPLLi^QVPDVDGDGAPDLLVLTiQEREEVSGH SEG

PRD cccceeeeeccccccccccccccccceeeecceeecccccccccccchhhhhhhhhhhcc

MEM SE(Q LYSGSTGHiQIGLRGSLGVDGESGFLLHVTRTGAHYILFPCASSLCGCSVKGLYEKVTGSG

SEG

PRD cccccccccccccccccccccceeeeeeecccceeeeeccccccccccceeeeccccccc

MEM SE(Q GPFKSDPHIdESMLNATTRRMLSHSSGAVRYLMHVPGNAGADVLLVGSEAFVLLDGiQELTP

SEG

PRD ccccccccccccchhhhhhhhhcccccceeeccccccccceeeeeccceeeeeccccccc

MEM SE(Q RldTPKAAHVLRKPIFGRYKPDTLAVAVENGTGTDRlQILFLDLGTGAVLCSLALPSLPGGP

SEG xxxxxxxxxxx

PRD ccchhhhhhcccccccccccceeeeeeccccccceeeeeeeccccceeeeeeeccccccc

MEM MMMMMMMMMMMMMMMMM SE(Q LSASLPTADHRSAFFFIdGLHELGSTSETETGEARHSLYMFHPTLPRVLLELANVSTHIVA

SEG xxxxxx xxxxxxxxxx

PRD ccccccccccccceeeccccccccccccccccccccceeeccccccccccccccceeeee

MEM SE(Q FDAVLFEPSRHAAYILLTGPADSEAPGLVSVIKHKVRDLVPSSRVVRLGEGGPDSD(3AIR

SEG

PRD eeeeeeccccceeeeeecccccccccceeeeeecccccccccceeeeecccccccchhhh

MEM SE(2 DRFSRLRY(3SEA

SEG

PRD hhhhhhhhhccc

MEM

(No Prosite data available for DKFZphamy2_lld2 -3) (No Pfam data available for DKFZphamy2_lld2-3)

DKFZphamy2_lln4

group: nucleic acid management

DKFZphamy2_lln4 encodes a novel 1011 amino acid protein with similarity to RAD16 of Schizosaccharomyces pombe and YLR3A3w of Saccharomyees cerevisia-

The novel protein contains a ATP/GTP-binding site motif A (P- loop)- It has similarity to RAD16 acts in a DNA repair pathway for removal of UV-induced DNA damage- YLR3δ3w of Saccharomyees cerevisiae is a recombination repair protein-

The new protein can find application in modulation of DNA-repair and a as a new tool for manipulation of nucleic acids- similarity to RAD16 (Schizosaccharomyces pombe) comment on P53b12:

FUNCTION: ACTS IN A DNA REPAIR PATHWAY FOR REMOVAL OF UV-INDUCED DNA DAMAGE THAT IS DISTINCT FROM CLASSICAL NUCLEOTIDE EXCISION REPAIR AND IN REPAIR OF IONIZING RADIATION DAMAGE-

Sequenced by EMBL

Locus: /map="2" Insert length: 3b71 bp

Poly A stretch at pos- 3b4b-> polyadenylation signal at pos- 3b20

1 ACCGCGGTGG GCGCCGGGGC TCCCGGGAAT CTACCTTCTC CTGCGGCCGG SI CACGCGGTTC CCAGGGGGCC AGCGGCGGTC AGCCGAGGTC GAGACGCCCG

101 CAGGGTGGCC TTAGCGGCCG GTCGTACCAC GGCAGCCCCG CCGATCAGGT

151 TCCTTTGGGA GACTTCGACT T6TTGGCGAA ATGAACCGGA GAAGAATCCC

201 AATTGGGAAT TGCGGAAAAC AGGACTCTAG GGTAGAGAAA GGTTGTAGAA

251 CCAATAGGGT TTGAGACCTG ATGGCCAAAA GAAAGGAAGA AAATTTTTCC 301 TCTCCTAAAA ATGCCAAAAG GCCAAGACAA GAAGAATTGG AGGATTTTGA

351 TAAAGATGGT GACGAAGACG AATGTAAAGG TACTACTTTG ACTGCAGCAG

401 AAGTTGGAAT AATTGAGAGT ATTCACCTAA AAAACTTCAT GTGTCATTCA

451 ATGCTTGGAC CTTTTAAGTT TGGTTCTAAT GTCAACTTTG TTGTTGGCAA

SD1 CAATGGAAGT GGGAAGAGTG CAGTACTCAC AGCTCTCATA GTCGGTCTTG S51 GTGGAAGAGC AGTTGCTACT AATAGAGGAT CCTCTTTAAA AGGTTTTGTG bOl AAAGATGGAC AGAACTCTGC AGATATCTCA ATAACATTGA GGAACAGAGG b51 AGATGATGCC TTTAAAGCCA GTGTGTATGG TAACTCTATA CTTATACAGC

701 AACACATCAG CATAGATGGA AGTCGATCTT ATAAACTTAA AAGTGCAACA

751 GGCTCCGTGG TTTCCACGAG GAAAGAAGAG CTGATTGCAA TTCTTGATCA 8D1 TTTTAACATC CAGGTGGATA ATCCAGTTTC TGTTTTAACA CAAGAAATGA

651 GCAAGCAGTT CTTACAGTCT AAAAATGAAG GAGACAAATA CAAATTCTTC

IDl ATGAAAGCAA CGCAACTTGA ACAGATGAAG GAAGATTATT CATACATTAT

151 GGAAACGAAA GAAAGAACAA AGGAGCAGAT ACATCAAGGA GAAGAGCGGC

1D01 TTACTGAACT AAAGCGCCAG TGTGTAGAGA AAGAGGAACG TTTTCAAAGT 1D51 ATTGCTGGTT TAAGTACAAT GAAGACTAAT TTAGAGTCCT TGAAACATGA

1101 AATGGCTTGG GCAGTGGTCA ATGAAATTGA AAAACAATTG AATGCCATCA

1151 GAGATAATAT CAAAATTGGA GAAGATCGTG CTGCTAGACT TGACAGGAAA

1201 ATGGAAGAAC AGCAGGTCAG ACTTAATGAG GCAGAACAAA AGTACAAGGA 1251 TATTCAAGAC AAACTAGAAA AGATTAGTGA AGAGACAAAT GCACGAGCAC

1301 CAGAATGTAT GGCATTGAAA GCAGATGTTG TTGCTAAGAA AAGGGCCTAT

1351 AATGAAGCTG AGGTTTTATA TAACCGATCC TTAAACGAAT ATAAAGCATT

1401 AAAGAAAGAT GATGAGCAGC TTTGTAAACG AATTGAAGAG CTGAAAAAAA 1451 GTACTGACCA ATCTTTGGAA CCTGAACGGT TGGAAAGACA AAAAAAAATA

1S01 TCTTGGTTAA AAGAGAGAGT AAAGGCCTTT CAAAATCAAG AAAATTCAGT

15S1 CAATCAAGAG ATCGAACAGT TTCAGCAAGC CATAGAAAAG GACAAAGAAG

IbOl AACATGGCAA AATTAAGAGA GAAGAATTAG ATGTGAAGCA TGCACTGAGC lb51 TACAATCAGA GGCAACTGAA AGAATTGAAA GATAGTAAAA CTGATCGACT 1701 CAAAAGATTT GGCCCTAATG TTCCAGCTCT TCTTGAAGCC ATAGATGATG

1751 CTTATAGACA AGGACATTTT ACCTATAAAC CTGTAGGCCC TTTAGGAGCT

1601 TGCATTCATC TTCGGGACCC AGAACTTGCT TTGGCTATTG AATCTTGCTT

1651 AAAAGGGCTT CTGCAGGCCT ATTGTTGCCA TAATCATGCT GATGAAAGGG

1101 TCCTTCAGGC ACTCATGAAA AGGTTTTATT TACCAGGGAC CTCACGGCCA 1151 CCGATAATAG TTTCTGAGTT TCGGAATGAG ATATATGATG TAAGACACAG

2001 AGCTGCTTAT CATCCAGACT TTCCAACAGT TCTGACAGCT TTAGAAATAG

2051 ATAATGCGGT TGTGGCAAAT AGCCTAATTG ACATGAGAGG CATAGAGACA

2101 GTGCTACTAA TCAAAAATAA TTCTGTAGCT CGT6CAGTAA TGCAGTCCCA

2151 AAAGCCACCC AAAAATTGTA GAGAAGCTTT TACTGCTGAT GGTGATCAAG 2201 TTTTTGCAGG ACGTTATTAT TCATCTGAAA ATACAAGACC TAAGTTCCTA

2251 AGCAGAGATG TGGATTCTGA AATAAGTGAC TTGGAGAATG AGGTTGAAAA

2301 TAAGACGGCC CAGATATTAA ATCTTCAGCA ACATTTATCT GCCCTTGAAA

2351 AAGATATTAA ACACAATGAG GAACTTCTTA AAAGGTGCCA ACTACATTAT

2401 AAAGAACTAA AGATGAAAAT AAGAAAAAAT ATTTCTGAAA TTCGGGAACT 24S1 TGAGAACATA GAAGAACACC AGTCTGTAGA TATTGCAACT TTGGAAGATG

2501 AAGCTCAGGA AAATAAAAGC AAAATGAAAA TGGTTGAGGA ACATATGGAG

25S1 CAACAAAAAG AAAATATGGA GCATCTTAAA AGTCTGAAAA TAGAAGCAGA

2b01 AAATAAGTAT GATGCAATTA AATTCAAAAT TAATCAACTA TCGGAGCTAG

2bSl CAGACCCACT TAAGGATGAA TTAAACCTTG CTGATTCTGA AGTGGATAAC 27D1 CAAAAACGAG GGAAACGACA TTATGAAGAA AAACAAAAAG AACACTTGGA

2751 TACCTTAAAT AAAAAGAAAC GAGAACTGGA TAT6AAAGAG AAAGAACTAG

2601 AGGAGAAAAT GTCACAAGCA AGACAAATCT GCCCAGAGCG TATAGAAGTA

2δ51 GAAAAATCTG CATCAATTCT GGACAAAGAA ATTAATCGAT TAAGGCAGAA

2101 GATACAGGCA GAACATGCTA GTCATGGAGA TCGAGAGGAA ATAATGAGGC 2151 AGTACCAAGA AGCAAGAGAG ACCTATCTTG ATCTGGATAG TAAAGTGAGG

30D1 ACTTTAAAAA AGTTTATTAA ATTACTGGGA GAAATCATGG AGCACAGATT

3051 CAAGACATAT CAACAATTTA GAAGGTGTTT GACTTTACGA TGCAAATTAT

3101 ACTTTGACAA CTTACTATCT CAGCGGGCCT ATTGTGGAAA AATGAATTTT

3151 GACCACAAGA ATGAAACTCT AAGTATATCA GTTCAGCCTG GAGAAGGAAA 3201 TAAAGCTGCT TTCAATGACA TGAGAGCCTT GTCTGGAGGT GAACGTTCTT

3251 TCTCCACAGT GTGTTTTATT CTTTCCCTGT GGTCCATCGC AGAATCTCCT

3301 TTCAGATGCC TGGATGAATT TGATGTCTAC ATGGATATGG TTAATAGGAG

3351 AATTGCCATG GACTTGATAC TGAAGATGGC AGATTCCCAG CGTTTTAGAC

3401 AGTTTATCTT GCTCACACCT CAAAGCATGA GTTCACTTCC ATCCAGTAAA 34S1 CTGATAAGAA TTCTCCGAAT GTCTGATCCT GAAAGAGGAC AAACTACATT

3501 GCCTTTCAGA CCTGTGACTC AAGAAGAAGA TGATGACCAA AGGTGATTTG

3551 TAACTTAACA TGCCTTGTCC TGATGTTGAA GGATTTGTGA AGGGAAAAAA

3b01 AATTCTGGAC TCTTTGATAT AATAAAATGA GACTGGAGGC ATTCTGAAAA

3b51 AAAAAAAAAA AAAAAAAAAA AAAAAAAAA

BLAST Results

o BLAST result

Medline entries 1b0b1417:

Lehmann AR-, Idalicka M-, Griffiths DJ-, Murray JM-, Idatts FZ-, McCready S-,

Carr AM-"-, The radlδ gene of Schizosaccharomyces pombe defines a new subgroup of the SMC superfamily involved in DNA repair- Mol Cell Biol 1115 DecilS (12) :70b7-60 113601b7:

Mengiste T-, Revenkova E-, Bechtold N-. Paszkowski J - --, An SMC-like protein is required for efficient homologous recombination in Arabidopsis- EMBO J 1111 Aug Ibilδ (lb) : 4505-12

Peptide information for frame 1

ORF from 271 bp to 3543 bpi peptide length 1011 Category: similarity to known protein Classification: Nucleic acid management Prosite motifs: RGD (12b-12β) ATP GTP A (7b-63)

1 MAKRKEENFS SPKNAKRPRlQ EELEDFDKDG DEDECKGTTL TAAEVGIIES 51 IHLKNFMCHS MLGPFKFGSN VNFVVGNNGS GKSAVLTALI VGLG6RAVAT

IDl NRGSSLKGFV KDGiQNSADIS ITLRNRGDDA FKASVYGNSI LI<Q(QHISIDG

151 SRSYKLKSAT GSVVSTRKEE LIAILDHFNI (QVDNPVSVLT (3EMSK(QFL(QS

2D1 KNEGDKYKFF MKAT(QLE(QMK EDYSYIMETK ERTKE(QIH(3G EERLTELKRβ

251 CVEKEERFtQS IAGLSTMKTN LESLKHEMAld AVVNEIEKiQL NAIRDNIKIG 301 EDRAARLDRK MEE(3(3VRLNE AE(QKYKDI(3D KLEKISEETN ARAPECMALK

351 ADVVAKKRAY NEAEVLYNRS LNEYKALKKD DEiQLCKRIEE LKKSTD(QSLE

401 PERLERlQKKI SldLKERVKAF (QN(QENSVN(QE IE(QF<Q(QAIEK DKEEHGKIKR

451 EELDVKHALS YNlQRlQLKELK DSKTDRLKRF GPNVPALLEA IDDAYRlQGHF

501 TYKPVGPLGA CIHLRDPELA LAIESCLKGL LiQAYCCHNHA DERVLiQALMK 551 RFYLPGTSRP PIIVSEFRNE IYDVRHRAAY HPDFPTVLTA LEIDNAVVAN bOl SLIDMRGIET VLLIKNNSVA RAVM(3S(3KPP KNCREAFTAD GDlQVFAGRYY b51 SSENTRPKFL SRDVDSEISD LENEVENKTA (QILNL(Q(QHLS ALEKDIKHNE

701 ELLKRCiQLHY KELKMKIRKN ISEIRELENI EEHtQSVDIAT LEDEAfiENKS

7S1 KMKMVEEHME (QiQKENMEHLK SLKIEAENKY DAIKFKINlQL SELADPLKDE 801 LNLADSEVDN (QKRGKRHYEE KiQKEHLDTLN KKKRELDMKE KELEEKMSiQA

651 RlQICPERIEV EKSASILDKE INRLRtQKIiQA EHASHGDREE IMRIQYIQEARE

101 TYLDLDSKVR TLKKFIKLLG EIMEHRFKTY (QflFRRCLTLR CKLYFDNLLS

151 (QRAYCGKMNF DHKNETLSIS ViQPGEGNKAA FNDMRALSGG ERSFSTVCFI

10D1 LSLIdSIAESP FRCLDEFDVY MDMVNRRIAM DLILKMADSiQ RFRlQFILLTP 1051 (QSMSSLPSSK LIRILRMSDP ERGώTTLPFR PVT(QEEDDD(Q R

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_lln4-, frame 1 SUISSPR0T:RAlβ_SCHP0 DNA REPAIR PROTEIN RADlδ--, N = 1 -, Score = 1D21-, P = S-2e-lD3

PIR:S5147D hypothetical protein YLR363w - yeast (Saccharomyees cerevisiae)τ N = 1-, Score = 623-, P = Se-δ2

>SldISSPR0T:RAlδ_SCHP0 DNA REPAIR PROTEIN RADlβ-

Length = 1-.140

HSPs: Score = 1021 (153-2 bits)-, Expect = 5-2e-103-, P = S-2e-103 Identities = 315/1D11 (2δ*)-, Positives = S40/1011 (41*)

(Query: 2 AKRKEENFSSPKNAKRPRfQEELEDF— KDGDEDECKGTTLTAAE

VGIIESIHLKN 55 A R ++N ++ + +E ++DG+ D T T +

VG+IE IHL N Sbjct: 45 ASRN(QDNRPER(QSRL(QRSSSLIE(3VRGNEDGENDVLN(3TRETNSNFDNRVGVIECIHLVN 1D4 βuery: 5b

FMCHSMLGPXXXXXXXXXXXXXXXXXXXAVLTALIVGLGGRAVATNRGSSLKGFVKDGiQN US FMCH L A+LT L + LG +A TNR ++K

VK G+N

Sbjct: IDS FMCHDSL- KINFGPRINFVIGHNGSGKSAILTGLTICLGAKASNTNRAPNMKSLVKiQGKN lb3

(Query : lib

SADISITLRNRGDDAFKASVYGNSILI(Q(QHISIDGSRSYKLKSATGSVVSTRKEELIAIL 17S A IS+T+ NRG +A++ +YG SI I++ I +GS Y+L+S G+V+ST+++EL I Sbj ct : lb4 YARISVTISNRGFEAYώPEIYGKSITIERTIRREGSSEYRLRSFNGTVISTKRDELDNIC 223

(Query- 17b DHFNI(QVDNPVSVLT(2EMSK<QFL(QSKNEGDKYKFFMKATι2LE(QMKEDYSYIMETKERTKE 235

DH +(Q + DNP + + + LT(Q+ + + (QFL + + +KY+ FMK (QL + (Q + + E + YS I

+ + TK

Sb jct : 224

DHMGL(3IDNPMNILT(3DTAR(3FLGNSSPKEKY(3LFMKGI(3LK(3LEENYSLIE(QSLINTKN 263

(Query : 23b

(QIH(QGEERLTELKR(QCVEKEERF^(QSIAGLSTMKTNLESLKHEMAI AVVNEIEK(QLNAIRD 215 + + ++ L ++ E + ++ + LE K EM UJA V

E+EK+L Sb jct : 264

VLGNKKTGVSYLAKKEEEYKLLIdE(QSRETENLHNLLE(QKKGEMVIdA(QVVEVEKEL 336

(Query : 21b NIKIGEDRAARLDRKMEE(^{Q (Q}VRLNEAE(^QKYKDI(QDKLEKISEETNARAP- ECMALKADVV 354 + E + K+ E + L DI K+ EE RA E

K +

Sbjct : 331 --LLAEKEF(QHAEVKLSEAKENLESIVTN(QSDIDGKISS- KEEVIGRAKGETDTTKSKFE 315 ώuery: 355

AKKRAYNEAEVLYNRSLNEYKALKKDDE(QLCKRIEELKKSTD(QSLEPERLER(QKKISIdLK 414

+ ++ Y +N+ K+D + I K D E ER ++ +

Sbj ct : 31b DIVKTFDG YRSEMNDVDI(QKRDI(QN — -

SINAAKSCLDVYRElQLNTERARENNLGG 448

Query : 415 ERVKAF(QN(QENSVN(QEIE(QF-(Qf3AIEKDKE EHG KIKREELDVKHALS 4bD

+++ N+ N++ +EI +Q +E + + E G + ++

+ + +S

Sbj ct : 441

S(3IEKRANESNNL(3REIADLSE(3IVELESKRNDLHSALLEMGGNLTSLLTKKDSIANKIS 508

(Query : 4bl

YN(3R(3LKELKDSKTDRLKRFGPNVPALLEAIDDAYR(3GHFTYKPVGPLGACIHLRDPELA 520

LK L+D + D++ FG N+P LL+ I R+ F + P GP+G +

+++ + Sb jct : 501 D(QSEHLKVLEDV(QRDKVSAFGKNMPι3LLKLIT--- RETRF(QHPPKGPMGKYMTVKE(QKIdH 5bS

(Query: 521

LAIESCLKGLLiQAYCCHNHADERVLiQALMKRFYLPGTSRPPIIVSEFRNEIYDVRHRAAY 58D L IE L ++ + +H D+ +L+ LM++ T ++V +

YD ++

Sbjct: Sbb LIIERILGNVINGFIVRSHHD(QLILKELMR(QSNCHAT VVVGK

YDPFDYSSG bib (Query: 581 HPD—

FPTVLTALEIDNAVVANSLIDMRGIETVLLIKNNSVARAVM(QS(QKPPKNCREAFT b3δ

PD +PTVL ++ D+ V ++LI+ GIE +LLI++ A A M+ +

N + +

Sbjct : bl7 EPDSώYPTVLKIIKFDDDEVLHTLINHLGIEKMLLIEDRREAEAYMK— RGIANVTlQCYA b74

(Query : b31 ADG-DlQVFAGRYYSSENTR— PKFLSRDVDSEI — SDLENEVENKTA(QILNL(Q(QHLSAL b12

D ++ + R S++ + K + I S E E K L Q + ++

Sbjct : b75 LDPRNRGYGFRIVST(QRSSGISKVTPldNRPPRIGFSSSTSIEAEKKILDDLKK(3YNFASN 734

(Query : b13 E-KDIKHNEELLKRC(QLHYKELKMKIRKNIS-EIRELENIEEH(Q-SV-D--- IATLEDEA 745

+ + K + KR + E I+K I + RE+ + + E + SV D

I TLE

Sbjct : 735

<QLNEAKIE(QAKFKRDE(2LLVEKIEGIKKRILLKRREVNSLES(QELSVLDTEKI(3TLERRI 714

(Query : 74b (QENKSKMKMVEEHME(Q(QKENMEH-

LKSLKIEAENKYDAIKFKINfQLSELADPLKDELN-L 603

E + +++ ++ K N EH ++ + + + Kl ++

L+ EL+ L Sbjcf- 715 SETEKELESYAG(2L(QDAK-

NEEHRIRDN(QRPVIEEIRIYREKI(QTET(QRLSSL(3TELSRL 653 Query : 804

ADSEVDN(QKRGKRHYEEK(QKEHLDTLNXXXXXXXXXXXXXXXXXS(QAR(QICPERIEVEKS 8b3 D + +++ +RH + + + L ++A C

ER+ V+ S Sbjct : 654 RDEKRNSEVDIERH-R(QTVESCTNILREKEAKKV(QCA(QVVADYTAKANTRC- ERVPVlQLS 111

(Query : 6b 4 ASILDKEINRLRiQKIiQAEHASHG- DREEIMR(3Y(3EARETYLDLDSKVRTLKKFIKLLGEI 122 + LD El RL+ +1 G E+ Y A+E + V L +

+ + L E

Sbjct : 112 PAELDNEIERL(3M(3IAEIdRNRTGVSVE(QAAEDYLNAKEKHD(QAKVLVARLT(3LL(3ALEET 171 (Query: 123

MEHRFKTY(3(3FRRCLTLRCKLYFDNLLS(3RAYCGKMNFDHKNETLSISV(QPGEGNKA-AF 161 + R + + +FR+ +TLR K F+ LSiQR + GK+ H+ E L V P

N A A

Sbjct: 172 LRRRNEMIdTKFRKLITLRTKELFELYLS(QRNFTGKLVIKH(3EEFLEPRVYPANRNLATAH 1031

(Query : 162 N

DMRALSGGERSFSTVCFILSLldSIAESPFRCLDEFDVYMDMVNRRIAMDLIL 1034

N ++ LSGGE+SF+T+C +LS+U P RCLDEFDV+MD VNR +++ +++

Sb j ct : 1032 NRHEKSKVSVlQGLSGGEKSFATICMLLSIIdEAMSCPLRCLDEFDVFMDAVNRLVSIKMMV 1011

(Query : 1035 KMADS(QRFR(QFILLTP(QSMSSLPSSKLIRILRMSDPERG(QTTLP 1076 A +(QFI +TP(Q M + K + + R+SDP + LP

Sbj ct : 1012 DSAKDSSDK(3FIFITP(3DMG(3IGLDKDVVVFRLSDPVVSSSALP 1135

Pedant information for DKFZphamy2_lln4-. frame 1

Report for DKFZphamy2_lln4-l

[LENGTH! 1011

[Mid! 12b32b-13

[pi! b-57

[HOMOL! SldISSPROT:RAlβ_SCHPO DNA REPAIR PROTEIN RADlβ- le-

1D1 [FUNCAT! 03-11 recombination and dna repair [S- cerevisiae-i

YLR383w! le-68

[FUNCAT! 08- D7 vesicular transport (golgi network-, etc) [S- cerevisiae-, YDLOSflw! 3e-lb

[FUNCAT! 30-03 organization of cytoplasm [S- cerevisiae-, YDLOSSw! 3e-lb

[FUNCAT! D1-13 biogenesis of chromosome structure [S- cerevisiae-, YLROδbw! 2e-14

[FUNCAT! 1 genome replication-, transcription-, recombination and repair [M- jannaschii-, MJlb43! 3e-14 [FUNCAT! 3D-04 organization of cytoskeleton [S- cerevisiae-,

YIL141c! le-12

[FUNCAT! D3-22 cell cycle control and mitosis [S- cerevisiae-,

YDR35bw! 8e-12 [FUNCAT! 01-10 nuclear biogenesis [S- cerevisiae-, YDR35bw! βe-12

[FUNCAT! 30-10 nuclear organization [S- cerevisiae-. YFLDOβw!

3e-ll [FUNCAT! 11-04 dna repair (direct repair-, base excision repair and nucleotide excision repair) [S- cerevisiae-. YKROISw! 2e-D1

[FUNCAT! 11 unclassified proteins [S- cerevisiae-, Y0R21bc!

5e-D1

[FUNCAT! 03-25 cytokinesis [S- cerevisiae-, YHR023ω MY01 - myosin-1 isoform! 8e-08

[FUNCAT! D3-D4 budding-, cell polarity and filament formation [S- cerevisiae-. YHRD23w MY01 - myosin-1 isoform! δe-08

[FUNCAT! Dδ-22 cytoskeleton-dependent transport [S- cerevisiae-.

YHR023W MY01 - myosin-1 isoform! 6e-0β [FUNCAT! 0b-D7 protein modification (glycolsylationπ acylation-, myristylation-, palmitylationi farnesylation and processing) [S- cerevisiae-, YKL201c! 2e-D7

[FUNCAT! 03-13 meiosis [S- cerevisiae-, YDR2δ5w! 4e-07

[FUNCAT! 30-13 organization of chromosome structure [S- cerevisiae-. YDR265w! 4e-07

[FUNCAT! 16 classification not yet clear-cut [S- cerevisiae-.

YJR134c! 7e-D7

[FUNCAT! Ob-10 assembly of protein complexes [S- cerevisiae-.

YPR141c! 7e-07 [FUNCAT! 30-05 organization of centrosome [S- cerevisiae-.

YPR141c! 7e-07

[FUNCAT! 11-01 stress response [S- cerevisiae-. YPR141c! 7e-D7

[FUNCAT! 03-D7 pheromone response! mating-type determination-, sex-specific proteins [S- cerevisiae-, YPR141c! 7e-D7 [FUNCAT! r general function prediction [H- influenzae-,

HI075b! le-Db

[FUNCAT! 10-D5-11 other pheromone response activities [S- cerevisiae-, YHR15βc! 2e-Db

[FUNCAT! 05-D4 translation (initiation! elongation and termination) [S- cerevisiae-, YALD35w! 3e-D4

[FUNCAT! 30-02 organization of plasma membrane [S- cerevisiae-.

YERDOβc! 4e-04

[FUNCAT! 08-lb extracellular transport [S- cerevisiae-.

YERDOSc! 4e-04 [FUNCAT! 01-04 biogenesis of cytoskeleton [S- cerevisiae-.

YKL171c! 7e-04

[FUNCAT! 03-22-01 cell cycle check point proteins [S- cerevisiae-. YGLOδbw! 7e-04

[FUNCAT! 06- DI nuclear transport [S- cerevisiae-. YDL207w! D-0D1 [FUNCAT! 04-07 rna transport [S- cerevisiae-, YDL207w! 0-001

[BLOCKS! BL0032bC Tropomyosins proteins

[BLOCKS! PR01004B

[BLOCKS! BLDD121A Colipase proteins

[BLOCKS! PF0DS60A [SCOP! d2tmab_ 1-10S-4.1-1 Tropomyosin [rabbit

(Oryctolagus cuniculus) 3e-0b

[EC! 3- b-1- 32 Myosin ATPase 1e-2D

[PIRKId! phosphotransferase le-lb

[PIRKId! nucleus 2e-10 [PIRKId! blocked amino end 2e-07

[PIRKId! citrulline 2e-10

[PIRKId! tandem repeat 1e-2D

[PIRKId! heterodimer 3e-ll [PIRKId! endocytosis 2e-13

[PIRKId! heart 1e-2D

[PIRKId! polymorphism le-10

[PIRKId! serine/threonine-specific protein kinase 1e-lb [PIRKIil! transmembrane protein 8e-15

CPIRKld! zinc finger 2e-13

[PIRKId! metal binding 2e-13

[PIRKId! DNA binding 2e-0b

[PIRKId! muscle contraction 1e-20 [PIRKId! acetylated amino end 3e-13

[PIRKId! actin binding 1e-2D

[PIRKId! mitosis βe-10

[PIRKId! icrotubule binding 3e-01

[PIRKId! chromosomal protein 3e-ll [PIRKId! ATP 1e-20

[PIRKId! receptor 2e-0b

[PIRKId! thick filament 1e-20

[PIRKId! phosphoprotein 2e-14

[PIRKId! glycoprotein le-10 [PIRKId! skeletal muscle le-lδ

[PIRKId! calcium binding 2e-10

[PIRKId! alternative splicing 3e-12

[PIRKId! DNA condensation 3e-ll

[PIRKId! P-loop 1e-2D [PIRKId! coiled coil 1e-20

[PIRKId! heptad repeat le-10

[PIRKId! methylated amino acid 1e-20

[PIRKId! basement membrane le-lD

[PIRKId! immunoglobulin receptor 4e-01 [PIRKId! peripheral membrane protein 2e-13

[PIRKId! cardiac muscle 1e-2D

[PIRKId! extracellular matrix le-10

[PIRKId! hydrolase 1e-20

[PIRKId! microtubule 2e-lD [PIRKId! muscle 2e-14

[PIRKId! membrane protein le-10

[PIRKId! EF hand 2e-10

[PIRKId! cell division βe-10

[PIRKId! cytoskeleton le-13 [PIRKId! hair 2e-10

[PIRKId! calmodulin binding 2e-13

[PIRKId! Golgi apparatus be-Dδ

[PIRKId! smooth muscle 2e-07

[SUPFAM! conserved hypothetical P115 protein 4e-2b [SUPFAM! myosin heavy chain 1e-20

[SUPFAM! unassigned Ser/Thr or Tyr-specific protein , kinases 1e- lb

[SUPFAM! centromere protein E 3e-01

[SUPFAM! calmodulin repeat homology 2e-10 [SUPFAM! alpha-actinin actin-binding domain homology 7e-D7

[SUPFAM! myosin motor domain homology 1e-20

[SUPFAM! tropomyosin Se-06

[SUPFAM! plectin 7e-07

[SUPFAM! pleckstrin repeat homology 3e-01 [SUPFAM! trichohyalin 2e-10

[SUPFAM! hypothetical protein MJ1322 2e-0b

[SUPFAM! ribosomal protein SID homology 7e-D7

[SUPFAM! protein kinase C zinc-binding repeat homology 3e-D1 [SUPFAM! giantin 1e-12

[SUPFAM! protein kinase homology le-lb

[SUPFAM! kinesin motor domain homology 3e-D1

[SUPFAM! human early endosome antigen 1 2e-13 [SUPFAM! MS protein 4e-01

[SUPFAM! cytoskeletal keratin βe-Ob

[PROSITE! ATP_GTP_A 1

[PROSITE! RGD 1

[Kid! All_Alpha [Kid! LOld_COMPLEXITY 3-30 *

[Kid! COILED COIL 15-12 *

SE(Q MAKRKEENFSSPKNAKRPRtQEELEDFDKDGDEDECKGTTLTAAEVGIIESIHLKNFMCHS SEG

PRD ccchhhhhcccccccccchhhhhhcccccccccccccccccccccceeeeehhhhhhccc COILS

SE(Q MLGPFKFGSNVNFVVGNNGSGKSAVLTALIVGLGGRAVATNRGSSLKGFVKDG(QNSADIS SEG - - • -xxxxxxxxxxxxxxxxxxx

PRD ccccccccceeeeeeccccccchhhhhhhhhhcccccccccccccceeeecccccceeee COILS

SE(Q ITLRNRGDDAFKASVYGNSILI(Q(3HISIDGSRSYKLKSATGSVVSTRKEELIAILDHFNI

SEG

PRD eeeecccccccccccccccccchhhhhccccceeeeccccchhhhhhhhhhhhhhhhhhh

COILS

SE(3 (QVDNPVSVLT(QEMSK(QFLι3SKNEGDKYKFFMKAT(QLE(QMKEDYSYIMETKERTKE(QIH(QG SEG

PRD cccchhhhhhhhhhhhhhhhhhcchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS

SE(Q EERLTELKR(QCVEKEERF(QSIAGLSTMKTNLESLKHEMAIdAVVNEIEK(QLNAIRDNIKIG

SEG PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS CCCCCCCCCCCCCCCC

SEiQ EDRAARLDRKMEE(Q(QVRLNEAE(QKYKDI(QDKLEKISEETNARAPECMALKADVVAKKRAY SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS

CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC SE(Q NEAEVLYNRSLNEYKALKKDDE(2LCKRIEELKKSTD(3SLEPERLER(3KKISIdLKERVKAF SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS

SE(Q (QN(3ENSVN(QEIE(QF(3(^QAIEKDKEEHGKIKREELDVKHALSYN(3R(3LKELKDSKTDRLKRF

SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS

SE(Q GPNVPALLEAIDDAYR(QGHFTYKPVGPLGACIHLRDPELALAIESCLKGLL(3AYCCHNHA SEG

PRD hhhhhhhhhhhhhhhhhtihhhcccccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS

SE(3 DERVL(3ALMKRFYLPGTSRPPIIVSEFRNEIYDVRHRAAYHPDFPTVLTALEIDNAVVAN SEG ■

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhcccccchhhhhhhhhhhhhhhh COILS

SE<3 SLIDMRGIETVLLIKNNSVARAVM(3S(3KPPKNCREAFTADGD(QVFAGRYYSSENTRPKFL SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhchhhhhhhhhhhhhhhhhhh COILS

SE(Q SRDVDSEISDLENEVENKTA(3ILNL(Q(QHLSALEKDIKHNEELLKRC(QLHYKELKMKIRKN SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC

SE(Q ISEIRELENIEEH(3SVDIATLEDEA(3ENKSKMKMVEEHME<3(3KENMEHLKSLKIEAENKY SEG PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC

SE(Q DAIKFKIN(QLSELADPLKDELNLADSEVDN(QKRGKRHYEEK(QKEHLDTLNKKKRELDMKE SEG xxxxxxxxxx

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS

CCCCCCCCCCCC CCCCCCCCCCCCCCCCCCCCC SE(Q KELEEKMS(QAR(3ICPERIEVEKSASILDKEINRLR(QKI(QAEHASHGDREEIMR(QY(QEARE

SEG xxxxxxx

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhcchhhhhhhhhhhhh COILS

CCCCCCCCCCCCCC

SE(Q TYLDLDSKVRTLKKFIKLLGEIMEHRFKTYι3(3FRRCLTLRCKLYFDNLLS(QRAYCGKMNF SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhcccceee COILS

SE(3 DHKNETLSISVώPGEGNKAAFNDMRALSGGERSFSTVCFILSLIdSIAESPFRCLDEFDVY SEG

PRD eccccccceeeeccccchhhhhhcccccccchhhhhhhhhhhhhhhhccccchhhhhhhh COILS

SE(Q MDMVNRRIAMDLILKMADS(^QRFR(^QFILLTP(^QSMSSLPSSKLIRILRMSDPERG(3TTLPFR SEG

PRD hhhhhhhhhhhhhhhhhhhhhhceeeeeeccccccccccceeeeeecccccccccccccc COILS

SE(3 PVT(3EEDDD(3R

SEG

PRD chhhhhhhccc

COILS

Prosite for DKFZphamy2_lln4 - 1 PSOOOlb 12b->121 RGD PDOCODOlb

PSD0D17 7b->64 ATP GTP A PD0CDD017

(No Pfam data available for DKFZphamy2_lln4 - 1)

DKFZphamy2_121fl1

group: cell structure and motility

DKFZphamy2_121f11 encodes a novel 251 amino acid protein with high similarity to a Rat ankyrin binding glycoprotein-1 related mRNA-

Ankyrin binding glycoproteins play a role in neural cell adhesion and in prosate tumor cell transformation- DKFZphamy2_121f11 ■ p3 is expressed in brain-, uterus and prostate above average- The new protein can find application modulation of cyto skeleton- membrane interactions-

similarity to ankyrin binding glycoprotein-1 related mRNA (Rattus norvegicus)

Sequenced by DKFZ

Locus: /map="l"

Insert length: 1416 bp

Poly A stretch at pos- 1471-. polyadenylation signal at pos- 14bD

1 CGGCACCTTC GCCGGCGCCC TCGCCCACCC CAGCCCCGCC CCAGAAGGAG

SI CAGCCCCCCG CGGAGACCCC TACAGACGCT GCTGTCTTGA CCTCACCCCC

101 AGCCCCTGCT CCCCCGGTGA CCCCTAGCAA ACCAATGGCC GGCACCACAG

ISI ACCGAGAAGA AGCCACTCGG CTCTTGGCTG AGAAGCGGCG CCAGGCCCGG

201 GAGCAGCGGG AGCGCGAGGA GCAGGAGCGG AGGCTGCAGG CAGAAAGGGA 251 CAAGCGAATG CGAGAGGAGC AGCTGGCACG GGAGGCCGAG GCCCGGGCGG

3D1 AGCGGGAGGC GGAGGCCCGG AGGCGGGAGG AGCAGGAGGC ACGAGAGAAG

351 GCGCAGGCCG AGCAGGAGGA GCAGGAGCGG CTGCAGAAGC AGAAAGAGGA

401 GGCCGAAGCT CGGTCGCGGG AAGAGGCGGA GCGGCAGCGT CTGGAGCGGG

4S1 AAAAGCACTT CCAGCAGCAG GAGCAAGAGC GGCAAGAGCG CAGAAAGCGT SD1 CTGGAGGAGA TCATGAAGAG GACTCGGAAG TCAGAAGTTT CTGAAACCAA

S51 GAAGCAGGAC AGCAAGGAGG CCAACGCCAA CGGTTCCAGC CCAGAGCCTG bOl TGAAAGCTGT GGAGGCTCGG TCCCCAGGGC TGCAGAAGGA GGCTGTGCAG bSl AAAGAGGAGC CCATCCCACA GGAGCCTCAG TGGAGTCTCC CAAGCAAGGA

7D1 GTTGCCAGCG TCCCTGGTGA ATGGCCTGCA GCCTCTCCCA GCACACCAGG 751 AGAATGGCTT CTCCACCAAC GGACCCTCTG GGGACAAGAG TCTGAGCCGA

801 ACACCAGAGA CACTCCTGCC CTTTGCAGAG GCAGAAGCCT TCCTCAAGAA

851 AGCTGTGGTG CAGTCCCCGC AGGTCACAGA AGTCCTTTAA GAGGGTTTGC

IDl CTTGGATCCG GGCACAGTTG TGAGGGCTCC TCTGCATCAC CTACCAGGAT

151 GTCTGGAGGA GAAAAAGACA GAACAAAGAT GGAAGTGGCC TGGGCCCCTG 1D01 GGGGTGGGTC CTCTCTGTTG TTTTTAATCT GCACCTTATA GACTGATGTC

1051 TCTTTGGCCG GAGCCAGATC TGCCCCTCAG TGCATTCGTG TGCTCGCACG

1101 CGCAGACATC CCTTCTCCCC CATACACACA TATACACTCA CAGCCTCTCT

1151 GGCCTCTTCC CTTGGGGAGG GGCCACCTGT AGTATTTGCC TTGATTTGGT

12D1 GGGGTACAGT GGATGTGAAT ACTGTAAATA GCTTGTGCTC AGACTCCTCT 12S1 GCGTGGAGAG GGTGGGTGCA GGAGGCAGAC CCTCCCCCCA AAGCCCCCTG

1301 GGGAGATCTT CCTCTCTCTA TTTAACTGTA ACTGAGGGGG ATCCCAGGTC

1351 TGGGGATGGG GGACACCTTG GGCCACAGGA TACTGGTTGC TTCAGGGGTA

14D1 CCCATGCCCC CTGCCCTCGC CTGGAATCAG TGTTACTGCA TCTGATTAAA 14S1 TGTCTCCAGA AATAAAGAAT AATTCTGCCA AAAAAAAAAA AAAAAAAA

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 3

ORF from 13S bp to 687 bpi peptide length: 251 Category: putative protein Classification: Cell signaling/communication

1 MAGTTDREEA TRLLAEKRR(3 ARE(3REREE(Q ERRLtQAERDK RMREEiQLARE 51 AEARAEREAE ARRREElQEAR EKA(QAE(QEE(Q ERL(QK(QKEEA EARSREEAER

101 (SRLEREKHFiQ (Q(QE(3ER(3ERR KRLEEIMKRT RKSEVSETKK (QDSKEANANG

ISI SSPEPVKAVE ARSPGLiQKEA V(3KEEPIP(3E PfQldSLPSKEL PASLVNGLtQP

201 LPAHώENGFS TNGPSGDKSL SRTPETLLPF AEAEAFLKKA VV(3SP(QVTEV

251 L

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_121f11-, frame 3

No Alert BLASTP hits found

Pedant information for DKFZphamy2_121f11-, frame 3

Report for DKFZphamy2_121f11- 3

[LENGTH! 215

[Mid! 33517- lb

[pi! S-bl [HOMOL! TREMBLNEld:AB033013_l gene: "KIAA1167"i product

"KIAA1167 protein"^:. Homo sapiens mRNA for KIAA1167 protein-, partial eds- le-b4

[BLOCKS! PFD1140D

[BLOCKS! BL00412D Neuromodulin (GAP-43) proteins [BLOCKS! BL0D82bC

[BLOCKS! BL0D422C Granins proteins

[BLOCKS! PRDDlb7C

[BLOCKS! PFDD112A [BLOCKS! BL00224B Cl athr i n l i ght ccha in protei ns

[BLOCKS! PR00041D

[BLOCKS! PR00110A

[KU! A l l A l pha

[Kid! L ld_C MPLEXITY 51 - 11 *

[KU! COILED COIL 10 - 51 *

SE<Q APSPAPSPTPAPP(QKE(QPPAETPTDAAVLTSPPAPAPPVTPSKPMAGTTDREEATRLLAE SEG xxxxxxxxxxxxxxxxxxxxxx - ■ xxxxxxxxxxxxxxxxxxxxx - XX

PRD cccccccccccccccccccccccccceeeeccccccccccccccccccchhhhhhhhhhh COILS

SEfQ KRR(QARE(QREREE(QERRL(QAERDKRMREE(3LAREAEARAEREAEARRREEι3EAREKA(3AE

SEG XXXXXXXXXXXXXXXXXXXXX- • ■ ■ XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS CCCCCCCCCCCCC

SE<2 (QEE(QERL(3K(QKEEAEARSREEAER(3RLEREKHF(3(3(QE(QER(QERRKRLEEIMKRTRKSEVS

SEG XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhccccc COILS CCCCCCCCCCCCCCCCCC

SE(Q ETKKώDSKEANANGSSPEPVKAVEARSPGL(QKEAV(QKEEPIP(QEP(QldSLPSKELPASLVN SEG

PRD chhhhhhhhhccccccccceeeeccccccchhhhhhhhcccccccccccccccccceeee COILS

SE(Q GL(QPLPAH(QENGFSTNGPSGDKSLSRTPETLLPFAEAEAFLKKAVV(3SP(QVTEVL

SEG PRD ecccccccccccccccccccccccccccchhhhhhhhhhhhhhhhhccccccccc COILS

(No Prosite data available for DKFZphamy2_121f11 - 3) (No Pfam data available for DKFZphamy2_121f11.3)

DKFZphamy2_121m2

group: cell cycle

DKFZphamy2_121m2 encodes a novel 4δ0 amino acid protein with similarity to human PA2b-T2 protein- PA2b-T2 is a pS3 responsive gene- The protein is predominantly expressed in brain-, breast and kidney and may represent a potential novel regulator of cellular growth- Isoforms are differentially induced by genotoxic stress (UV-, gamma-irradiation and cytotoxic drugs)in a p53-dependent manner-

The new protein can find application in modulating cell division and apoptosis pathways-

similarity to PA2b nuclear protein isoforms (Homo sapiens) probably differential polyadenylation Sequenced by DKFZ Locus-" unknown

Insert length: 3327 bp

Poly A stretch at pos. 33Dbι polyadenylation signal at pos. 3271

1 TCCAGCACCA AAGCGGCCGT TCTCGGATTC CGGAGCGTTC TGGAGCCCCG

51 AGAGACGCCC CGGGGTTCTA GAAGCTCCCC GGCGGCGCCC AGTCCCGGCT

101 TCATTCGGGC GTCCCTCCGA AACCCACTCG GGTGCACGGG TCGTCGGCGA 151 GCCGCGACCG GGTCCTGGCG CGCACCATGA TCGTGGCGGA CTCCGAGTGC

201 CGCGCAGAGC TCAAGGACTA CCTGCGGTTC GCCCCGGGCG GCGTCGGCGA

2S1 CTCGGGCCCC GGAGAGGAGC AGAGGGAGAG CCGGGCTCGG CGAGGCCCTC

301 GAGGGCCCAG CGCCTTCATC CCCGTGGAGG AGGTCCTTCG GGAGGGGGCT

351 GAGAGCCTCG AGCAGCACCT GGGGCTGGAG GCACTGATGT CCTCTGGGCG 4D1 AGTAGACAAC CTGGCAGTGG TGATGGGCCT GCACCCTGAC TACTTTACCA

4S1 GCTTCTGGCG CCTGCACTAC CTGCTGCTGC ACACGGATGG TCCCTT6GCC

SD1 AGCTCCTGGC GCCACTACAT TGCCATCATG GCTGCCGCCC GCCATCAGT6

SSI TTCTTACCTG GTAGGCTCCC ACATGGCCGA GTTTCTGCAG ACTGGTGGTG bOl ACCCTGAGTG GCTGCTGGGC CTCCACCGGG CCCCCGAGAA GCTGCGCAAA bSl CTCAGCGAGA TCAACAAGTT GCTGGCGCAT CGGCCATGGC TCATCACCAA

701 GGAACACATC CAGGCCTTGC TGAAGACCGG CGAGCACACT TGGTCCCTGG

751 CCGAGCTCAT TCAGGCTCTG GTCCTGCTCA CCCACTGCCA CTCGCTCTCC δOl TCCTTCGTGT TTGGCTGTGG CATCCTCCCT GAGGGGGATG CAGATGGCAG

651 CCCTGCCCCC CAGGCACCTA CACCCCCTAG TGAACAGAGC AGCCCCCCAA 101 GCAGGGACCC GTTGAACAAC TCTGGGGGCT TTGAGTCTGC CCGCGACGTG

151 GAGGCGCTGA TGGAGCGCAT GCAGCAGCTG CAGGAGAGCC TGCTGCGGGA

10D1 TGAGGGGACG TCCCAGGAGG AGATGGAGAG CCGCTTTGAG CTGGAGAAGT

1051 CAGAGAGCCT GCTGGTGACC CCCTCAGCTG ACATCCTGGA GCCCTCTCCA

1101 CACCCAGACA TGCTGTGCTT TGTGGAAGAC CCTACTTTCG GATATGAGGA 1151 CTTCACTCGG AGAGGGGCTC AGGCACCCCC TACCTTCCGG GCCCAGGATT

12D1 ATACCTGGGA AGACCATGGC TACTCGCTGA TCCAGCGGCT TTACCCTGAG

1251 GGTGGGCAGC TGCTGGATGA GAAGTTCCAG GCAGCCTATA GCCTCACCTA

1301 CAATACCATC GCCATGCACA GTGGTGTGGA CACCTCCGTG CTCCGCAGGG 1351 CCATCTGGAA CTATATCCAC TGCGTCTTTG GCATCAGATA TGATGACTAT

1401 GATTATGGGG AGGTGAACCA GCTCCTGGAG CGGAACCTCA AGGTCTATAT

1451 CAAGACAGTG GCCTGCTACC CAGAGAAGAC CACCCGAAGA ATGTACAACC

1501 TCTTCTGGAG GCACTTCCGC CACTCAGAGA AGGTCCACGT GAACTTGCT6

1551 CTCCTGGAGG CGCGCATGCA AGCCGCTCTG CTGTACGCCC TCCGTGCCAT

IbOl CACCCGCTAC ATGACCTGAC TCCTGAGCAG GACCTGGGCC CGGTTCAGCT

IbSl CCCCACAAGG ACTTCTCTGT CTGGAGACAG CCCCAGACCC TTTTGTGTCC

1701 CATGCCCACC CTCCCCACGC TGCAGTGGGC TTGTGTGTGA TGTGCAGTCC

17S1 CGAAGCCACA CCCTCCCTTT TCCTCACTGG AATGGACAGT TCATTGCACT

1801 GACTCTGGGA TCTCAGCCCT GCTCCTGGGA GCTGGAAGAG CACTTGGAGA

1651 TCCTAAGGGA CCACACCCTT CCTCCTTCCC CTGCCCACAG AGGCAGAGGG

1101 CACAGGAAAG AAGCCGGGCC AAGCTCGGAA TTAATGTGCC ACAAGTGTTG

1151 TGGCCTTCCT GAACTGGGAA GTCCCTGGCT GGCCCCCGGG GGAGAGGGGC

2001 AAATGCCTCC GGGACTGACA CTCCAGGCAG CTTTGCCTTC TCTCCCCTGT

2051 CATTTCCAGA TTTCATTACC TCCTACTTGC CATTCACCCA TCAATGTGAA

2101 AGTCAGGGTC ACAGCTGGTC TGTGTGTCCA GTTCCCTAAA AGCCTGTTCT

2151 GTTGGGCAGC CTGAGGCTGT TGCCCGAATC CTAGTTCAGT TTTTTGACTT

2201 CCTTTGCCCT TTTTCCCTTT TCTCCATGCT TAATGGTGTG AGGCGTCAGG

2251 AGAGAGGCCA AGTACATAAA AAAAAAAAAA AGCAGATTAT CTCTAGAGAG

2301 TTTGAGCCTT TGCTGGTCAC ATTGCCTTCT GAAGAGGAGG GAGTATTAGA

2351 TTATAAATCC TCTTTATTTT GGTCCTTTAT GCTTGAGGTT CCAACCTGGA

2401 GCCACAGTGT GTGAGAGGAG GAGGAGAGGG AGAATTCTGT TCTCCCAGAG

2451 CTGCACCTGC CTCGCAGAGG CCAGCACCCC ACTCTCCTGC CTCCAGTGGC

2501 CCTGCCGCAG ATGTCTCCCA AAAAGTTGAG CCTTTCTAGA TGGCTTAGGT

25S1 GGCACCATGG CTCAGCAGGA GGGGCGGGkG GCACCAGGGT TCTTGTTTGG

2bDl ACCCTGCCCC TGGGCCATGG CCAGGTGACC ATGGCTACAT TGCCAAACCT

2bSl CTGACTGCCA CAGCTGCAGA CTGAGAGGGT GGGTCTGAGT CCCCACAATG

27D1 TCTGAAGCTG CCCCTGGGAT TCTCAGGCCA ACCTGCCAAC AGCAAGCGGA

2751 TTTTCTTGCA AGATCAGGGA CCCCATTTCT GCAGCCAGTG TCTCCTGGGT

2601 GCCTTCTGAG GACTCCCACC CCCATCCCAG TATCTCATCT GTCCCCTCTC

2δ51 CTGGGGCTTA AGTGGGTTGC TTCCAGGCAG AAGCAGCCAA GGACCGATTC

2101 CAGGCACTTT CTGTAGCAAA TGACTGTGAA TTACGACTTC TCTTGCCCTT

2151 CTTCTAGCAG TCTGTGCCTC CTCTCTGACC AGTTTGGAGG GCACTGAAGA

3001 AAGGCAAGGG CCGTGCTGCT GCTGGGCGGG GCAGGAGAGG AGCCTGGCCA

3051 GTGTGCCACA TTAAATACCC GTGCAGGCGC GGAGAAGCAA CCGGCACCCC

3101 CTTCCGGCCT GAAAGCCCTC CCTGCAAGAA GGTGTGCAGG AGAGAAGAGG

3151 CCCCGGCATG GGGATCTGGG TTCTAGAGGG CATGTGATGA CTGTAAATGT

3201 TCACTGGGTG GGTAGGGAGT GGTATCCAGT GTTCAAGTGC AGAAATCTTT

3251 GGCTTTGCTA CCAGTTCCAT ATGATGAGAA ATAAACGTTC GCTGAGGTTT

3301 TGTTTCATAA AAAAAAAAAA AAAAAAA

BLAST Results

No BLAST result

Medline entries

15024170: Buckbinder L ■ -> Talbott R-n Seizinger B-R--, Kley N-=. Gene regulation by temperature-sensitive p53 mutants ' identification of p53 response genes- Proc Natl- Acad- Sci- U-S A- 11⁽22) :lDb40-lDb44(1114) -

1124117: Velasco-Miguel S-, Buckbinder L-, Jean P-. Gelbert L-, Talbott R-,

Laidlaw

Ji Seizinger Bi Kley N ■ ϊ PA2bι a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes. Oncogene

1111

Jan 7-^16(1) :127-37

Peptide information for frame 3

ORF from 177 bp to Iblb bpi peptide length: 480 Category: strong similarity to known protein Classification: Cell division

1 MIVADSECRA ELKDYLRFAP GGVGDSGPGE EtQRESRARRG PRGPSAFIPV 51 EEVLREGAES LEOHLGLEAL MSSGRVDNLA VVMGLHPDYF TSFIdRLHYLL

101 LHTDGPLASS IdRHYIAIMAA ARHiQCSYLVG SHMAEFLώTG GDPEldLLGLH

151 RAPEKLRKLS EINKLLAHRP ldLITKEHI(QA LLKTGEHTldS LAELIiQALVL

201 LTHCHSLSSF VFGCGILPEG DADGSPAPiQA PTPPSEβSSP PSRDPLNNSG

251 GFESARDVEA LMERM(3(3L(QE SLLRDEGTS(Q EEMESRFELE KSESLLVTPS 301 ADILEPSPHP DMLCFVEDPT FGYEDFTRRG A(QAPPTFRA(Q DYTUEDHGYS

351 LI(3RLYPEGG (QLLDEKFfiAA YSLTYNTIAM HSGVDTSVLR RAIldNYIHCV

401 FGIRYDDYDY GEVNlQLLERN LKVYIKTVAC YPEKTTRRMY NLFldRHFRHS

451 EKVHVNLLLL EARMlQAALLY ALRAITRYMT

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_121m2ι frame 3

TREMBL:AF033120_1 gene: "PA2b"ή product: ^πpS3 regulated PA2b-T2 nuclear protein"i Homo sapiens p53 regulated PA2b-T2 nuclear protein (PA2b) mR A! complete eds-! N = li Score = 1377ι P = 1-7e-141

TREMBL:AF033122_1 gene: "PA2b"i product: "non-pS3 regulated PA2b- Tl nuclear protein"i Homo sapiens non-p53 regulated PA2b-Tl nuclear protein (PA2b) mRNAi complete eds-! N = li Score = 13b3ι P = 3e- 131 TREMBL:AF033121_1 gene: "PA2b"i product: "pS3 regulated PA2b-T3 nuclear protein"i Homo sapiens p53 regulated PA2b-T3 nuclear protein (PA2b) mRNAi complete eds-! N = l -ι Score = 130?! P = 2-Se-133

>TREMBL:AF03312D_1 gene: "PA2b^π! product: "p53 regulated PA2b-T2 nuclear protein"! Homo sapiens p53 regulated PA2b-T2 nuclear protein (PA2b) mRNA! complete eds-

Length = 412

HSPs:

Score = 1377 (20b-b bits)! Expect = 1.7e-141τ P = 1-7e-141 Identities = 277/471 (5δ*)τ Positives = 334/471 (70*)

Query : 22 GVGDSGPGEEiQRESRARRGPR GPSAFIPVEEVLREGAESLE(QH-

LGLEALMSSGRV 7b

G G G +(Q E R PR GPS FIP +E+L+ G+E + H L ++ + GR+ Sbjct: 22

GCK(QCGGGRD(QDEELGIRIPRPLG(QGPSRFIPEKEILιQVGSEDA(QMHALFADSFAALGRL 61

(Query : 77

DNLAVVMGLHPDYFTSFURLHYLLLHTDGPLASSURHYIAIMAAARHiQCSYLVGSHMAEF 13b DN+ +VM HP Y SF + + LL DGPL +RHYI

IMAAARHiQCSYLV H+ +F Sb j ct : 62

DNITLVMVFHP(QYLESFLKT(QHYLL(QMDGPLPLHYRHYIGIMAAARH(QCSYLVNLHVNDF 141 (Query : 137

L(QTGGDPEldLLGLHRAPEKLRKLSEINKLLAHRPldLITKEHI(QALLKTGEHTIdSLAELI(Q lib L GGDP + ldL GL AP + KL+ L E + NK + LAHRPULITKEHI+ LLK

EH+USLAEL+

Sb j ct : 142 LHVGGDPKldLNGLENAP(QKL(3NLGELNKVLAHRPldLITKEHIEGLLKAEEHSIιlSLAELVH 2D1

Query : H? ALVLLTHCHSLSSFVFGCGILPEGDADGXXXXXXXXXX

XXXXXXXXRDPLNNS 241

A+VLLTH HSL+SF FGCGI PE DG P+N++

Sb jct : 2D2 AVVLLTHYHSLASFTFGCGISPEIHCDGGHTFRPPSVSNYCICDITNGNHSVDEMPVNSA 2bl

(Query : 250 GGF ESARDVEALMERM(Q(QL(3ESLLRDEG- TSiQEEMESRFELEKSESLLVTPSADILE 30S

+ S +VEALME + M + (QL(QE RDE SiQEEM SRFE + EK ES+ V

S + D E

Sb j ct : 2h2 ENVSVSDSFFEVEALMEKMR(3L(3EC--

RDEEEASiQEEMASRFEIEKRESMFVF-SSDDEE 316

(Query : 30b

PSPHPDMLCFVEDPTFGYEDFTRRGA(QAPPTFRA(QDYTldEDHGYSLI(QRLYPEGG(QLLDE 3b5 + P + ED + + GY + DF + R G P TFR (QDY UEDHGYSL +

RLYP+ G(QL + DE Sbjct : 311 VTPARAVSRHFEDTSYGYKDFSRHGMHVP-

TFRViQDYCUEDHGYSLVNRLYPDVGlQLIDE 377

(Query : 3bb

KFtQAAYSLTYNTIAMHSGVDTSVLRRAIIdNYIHCVFGIRYDDYDYGEVNiQLLERNLKVYI 425 KF AY+LTYNT+AMH

VDTS + LRRAIldNYIHC + FGIRYDDYDYGE + N(QLL + R+ KVYI Sb j ct : 376 KFHIAYNLTYNTMAMHKDVDTSMLRRAIldNYIHCMFGIRYDDYDYGEINiQLLDRSFKVYI 437 (Query: 42b

KTVACYPEKTTRRMYNLFURHFRHSEKVHVNLLLLEARM(3AALLYALRAITRYMT 480 KTV C PEK T+RMY+ FldR F+HSEKVHVNLLL+EARM(QA LLYALRAITRYMT Sbjct: 436 KTVVCTPEKVTKRMYDSFIdR(QFKHSEKVHVNLLLIEARM(3AELLYALRAITRYMT 412

Pedant information for DKFZphamy2_121m2! frame 3

Report for DKFZphamy2_121m2 ■ 3

[LENGTH! 460

[Mid! 54413-12

[pi! 5-57

[HOMOL! TREMBL:AF033120_1 gene: "PA2bⁿ! product: "pS3 regulated PA2b-T2 nuclear protein"i Homo sapiens p53 regulated

PA2b-T2 nuclear protein (PA2b) mRNAi complete eds- le-151

[BLOCKS! PR00D41D

[KU! All_Alpha

[KU! LOId_COMPLEXITY 3-75 *

SE<3 MIVADSECRAELKDYLRFAPGGVGDSGPGEEiQRESRARRGPRGPSAFIPVEEVLREGAES

SEG

PRD cccchhhhhhhhhhhhhccccccccccccchhhhhhhccccccccccccchhhhhhhhhh

SEl^Q LEfQHLGLEALMSSGRVDNLAVVMGLHPDYFTSFldRLHYLLLHTDGPLASSIdRHYIAIMAA

SEG

PRD hhhhhhhhhhhhhccccccceeeeccccchhhhhhhhhhhhhcccccchhhhhhhhhhhh SE(Q ARH(3CSYLVGSHMAEFL(QTGGDPEULLGLHRAPEKLRKLSEINKLLAHRPIdLITKEHI(QA SEG

PRD hhhhhheeeccccceeeecccccccccccccchhhhhhhhhhhhhhhhccceeehhhhhh

SE(Q LLKTGEHTUSLAELI(3ALVLLTHCHSLSSFVFGCGILPEGDADGSPAP(QAPTPPSE(QSSP SEG xxxxxxxxxxxxxxxx

PRD hhhhhcchhhhhhhhhhhhhhhhccccccccccccccccccccccccccccccccccccc

SE(Q PSRDPLNNSGGFESARDVEALMERM(Q(QL(QESLLRDEGTS(QEEMESRFELEKSESLLVTPS SEG xx PRD cccccccccccchhhhhhhhhhhhhhhhhhhhhhhhccchhhhhhhhhhhhhheeeeccc

SE(Q ADILEPSPHPDMLCFVEDPTFGYEDFTRRGA(^QAPPTFRA(QDYTUEDHGYSLI(QRLYPEGG

SEG

PRD ccccccccccceeeeccccccccccccccccccccceeeeeeccccccceeeeecccccc

SE(Q ⁽3LLDEKF(^QAAYSLTYNTIAMHSGVDTSVLRRAIIdNYIHCVFGIRYDDYDYGEVN(QLLERN

SEG

PRD hhhhhhhhhhhhhcccceeecccccchhhhhhhhhhhhhhccccccccccchhhhhhhhh SEl^Q LKVYIKTVACYPEKTTRRMYNLFIdRHFRHSEKVHVNLLLLEARM(3AALLYALRAITRYMT SEG

PRD hheeeeeeeecccchhhhhhhhhhhhhhccchhhhhhhhhhhhhhhhhhhhhhhhhhccc (No Prosite data available for DKFZphamy2_121m2-3) (No Pfam data available for DKFZphamy2_121m2- 3)

DKFZphamy2_121ol7

group: transmembrane protein

DKFZphamy2_121ol7 encodes a novel 212 amino acid protein without similarity to known proteins- The novel protein contains 1 transmembrane region- No informative BLAST results No predictive prosite! pfam or SCOP motife-

The new protein can find application in studying the expression profile of amygdala-specific genes and as a new marker for amygdala cells-

unknown protein

Pedant: TRANSMEMBRANE 1

Sequenced by DKFZ Locus-" /map="16b-b cR from top of Chr22 linkage group"

Insert length: 2b10 bp

Poly A stretch at pos- bbl! polyadenylation signal at pos- 2b34

1 TGCTGGGAAA AGTGACTGCG ATTCTGAAGA ACCGCTGCCT TGCAAGGTCA

SI AGGACATTCA GTGGTT6CTG 6GGTCCGCAG ACTACTGCCA CCCACTCACC

101 ATCAACTCTG TTAGCCCAAT TGCCCTGCTG AACAACTGCC TGAATACAGG

151 CTTTAGGTTC CCCTGGACTC CAGCCAAGGC TGTTCAGGTG GGACCATGGT 201 GCTCTTTAAG CGTGATCGGA GGGAAGACAC ACAGCAGGGC CACCATTCCA

251 TGAATGGGAG GTGTACAGAT CACTTTCTCT TTGTGCTCAG TTCTCTTCTG

301 TCTCCAGCAG CTATATTGGT AAGACTAGTA CCTGCCAGGG AGAGGTGCCC

351 CCAAGTGAAG GGGTACAGTG GCACCTGGGA AAAGGCACCT GGAAGGTTTC

401 CATGTGGCCC AGCCCAGCAT GGAAGCAGGG TGGGAACTCT GCTGTGTCGC 451 CAGCCCTCAC TCTACTCAAG TGGCTTTTTG AGAGCCCTGC CATGTCTGTG

501 TCAGGCCTGT GCTGCTTCAC ACCCTACAGC TGCCTGGGAA AGGCCGGCCA

5S1 CGCTCCCTGT CCACACACTC CCTGTCCACA CACTCCCTGT CCACAACTGC bOl AGCCGGGCCC TCTGCCTATG GGCACCCAAT CCAAGCAGCT GCTCCACCTT b51 TGTTTGGCAT GGTGATTTGT GTTTTTTCTC TTGGTGCTTA TGTGTGTGGG 701 CTTGGGACGA GTGCTGGTAT GCACTTAGGA CCTTCTTGAT AGCTCCCTGC

751 ACTTTGGAAC ACGGA6CAGA TGAGAGAGGG TCAGGGGCTT GCCCTCCACC

801 TTGGACTTGG AAGAAGCCCA CATTGGAGAG GTGAGGACCC CATGGTGGCT

8S1 CTAGTGGAAG ATACGTTAGT CTCCAGCTAA GGAGGATGAG GCGCAGCCCC

101 AGAGGGAGAC CTCAGTGATA GGGGATCAGG CTACGAAAGT GGGGGkkGGG 151 AGATGCTTTG TACATATTTT GGGGTTATAA TTTCTCTAAA TTTTAGGAGA

1001 ACGGGTATTG ATTGATAAAA GGGACAGGCA GTA6TGTTCA ACAGTGCATG

1D51 TGAAGGAAAG TTCTGTTTTC CATGGTTTT6 ACATTCTTTG GACTGTATTG

1101 TGACTGCTGT CTGGTCCACA TGGTACCCTT TTGGTAAGTA GGCTTCAGTG

1151 CATACCAGGG TATCACTGGA GATGGGAGTT AGTGAAGGGG TGACTCCCTG 1201 GCCTAGTATA GTGTGACCCT GGGACAACTT AATGTCCTAA AGCATTTTGG

1251 TGACTTCTA6 G6AATAGCAA AGACCTATTT CATTGTCCCC AG6TAAGTAT

13D1 GTGATGAGCA ATGAGGAGGA GTGGAAAACA AAACCCAGAA AGTGCGGCAG

1351 GACCAGCCTG ACGCACACGC TCCTGTTGTC ATGGCAGACA GCCGCCTTGG 1401 GTGGGCACCA CCCTGGCAGT TCCAGCCTGT AGGGGAGTGA AGGGACATGG

14S1 CTGAGCTGGG CATGTGCTGA GGTTGACTTA GGGAACAAGC CCTGGGATTG

1501 GACAAAAGGG CCCATGCTGC AGCCACTGAC TGGGGGCAGA GCTCTGGGTG

1S51 GAAGAGGGAA GAGATCCTAA TGGAGGCGCC TCCATCTGCA ACCACAGTTG IbDl TAAGGCTCAT GGCACCTCTG CTTGGAAAGC ACTGGTTTAG GGACTTAGAG

IbSl AGGTAGGCAC AAGGTGGGTC TCCTGGGTAA GGGAAGCAAG AGCAGACTGT

17D1 TGGGCCAACA GGAGAAGCTC CCCAGAGTAG GGGAGAAGGT TGGGGTGTAG

1751 GGCCTTCCAC GTGGAACAGA CAGCCCCTGT GTCTCTGTCT CTTGGGGACC

1801 TGAGTTTGGG TGGGGTGGCA GTTGGCACAG CGCAGATGCG GTAGAGATGG 16S1 GAGGAAACCC AGCTCCTCAC TTCCGTGTGC CTCATGCCTT TGCATACACA

1101 AGCACCAAAC CTACTAGGTC TTCTCATTAC CCATGTAAAC CACATGTTAG

1151 ATAAATTTTT GCAAGTAGAG GAAAGAAGGA AATAAAACAT CACATTTTGG

20D1 TGTCTCTCAG GCTTTCCCCC CCAACTATGG TTTCTTTGCT TTTTGTTTTA

2DS1 ACATAGTTTT GTTGCTGTCT TCTGTAATGA TACAGTTTTG TGCAGCTGTT 2101 TTCACTTAGC ATATCGTGGG CATCTCCCCT TATGATTACT AAATATTTTA

2151 TTTTGGAGTG GCTGTGTACT CTCCCATTGA CTAGATGGAC CATTGTGCCA

2201 GTTGCCAATC ACTAATGCTG TTACTAACTT TTCAGTTATA AATTGATGAA

2251 TATCTTTGTG CACAGGCTGT TTCCCAATGT CAAGTTATTA GGGTAGACTC

2301 CAGGAGGTGG GATTCTTCAA CTAAAGAATA TGAAAACCTT TGAGGCTTTT 23S1 ACTACATATT GACAAAATGG TTTCCGGAAA TATTTGTATC CCCTTACACT

24D1 GCCACCAGCA AGGATAAACA TGTCCATCTT GCCCGTATTG GGAATTATCA

2451 TCTGGCTAAA TATTTGCTAA TTTGATAATG AAAAAATAGC ATCGTGTTTC

2501 AGTTGGCATT TCACTGACTT CTAGCACGGT TGAACATCTT TCATGTGGAG

2551 CGATTGTATT TCCTCCTTTG TGGATTGTCA GTGTCCTTTG CTCTATCTTC 2b01 TGGGGTCAGA TAAATTTGTA TGAGCTCGGT ATATATTAAA GATATTAACC

2b51 TGGTGTGTGT CAAAAAAAAA AAAAAAAAAA AAAAAAAAAA

BLAST Results

Entry HS1033E1S from database EMBL:

Human DNA sequence from clone 1D33E15 on chromosome 22ql3 -1-13- 2 ■ Contains part of a novel gene! ESTs and a GSS- Score = 5111! P = 5-le-2b2! identities = 1187/1115

Entry HSN128A12 from database EMBL:

Human DNA sequence from cosmid N128A12 on chromosome 22ql2-qter contains ESTsi CpG island- Score = 5036! P = D-Oe+OO! identities = 1014/1011

Entry HSb1034b from database EMBL: human STS UI-14034- Score = 1800! P = l-4e-7bτ identities = 312/417

Medline entries

No Medline entry

Peptide information for frame 1

ORF from lib bp to 631 bp=. peptide length: 212 Category: putative protein Classification: no clue

1 MVLFKRDRRE DT(Q(QGHHSMN GRCTDHFLFV LSSLLSPAAI LVRLVPARER

51 CPlQVKGYSGT UEKAPGRFPC GPAώHGSRVG TLLCROPSLY SSGFLRALPC

IDl LC(3ACAASHP TAAldERPATL PVHTLPVHTL PVHNCSRALC LUAPNPSSCS

151 TFVIdHGDLCF FSIdCLCVUAU DECIdYALRTF LIAPCTLEHG ADERGSGACP

201 PPldTUKKPTL ER

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_121ol7! frame 1 No Alert BLASTP hits found Pedant information for DKFZphamy2_121ol7! frame 1

Report for DKFZphamy2_121ol7 - 1

[LENGTH! 212

[Mid! 23727 - 55

[pi! 6 - 73

[Kid! TRANSMEMBRANE

SE(3 MVLFKRDRREDT(3(QGHHSMNGRCTDHFLFVLSSLLSPAAILVRLVPARERCP(QVKGYSGT

PRD ccchhhhhcccccccccccccccccchhhhhhhhccccceeeeecccccccccccccccc

MEM MMMMMMMMMMMMMMMMM

SElQ lιlEKAPGRFPCGPA(QHGSRVGTLLCR(QPSLYSSGFLRALPCLC(QACAASHPTAAldERPATL

PRD ccccccccccccccccccceeeeeccccccccccccccccchhhhhhccccccccccccc

MEM SEO PVHTLPVHTLPVHNCSRALCLUAPNPSSCSTFVIdHGDLCFFSIdCLCVIdAldDECIdYALRTF

PRD ccccccccccccccccceeeeecccccccceeeecccceeecccceeeeccchhhhhhhe

MEM

SE(3 LIAPCTLEHGADERGSGACPPPUTIdKKPTLER PRD eeeccccccccccccccccccccccccccccc

MEM

(No Prosite data available for DKFZphamy2_121ol7-l) (No Pfam data available for DKFZphamy2_121ol7 -1) DKFZphamy2_12d7

group: signal transduction

DKFZphamy2__12d7 encodes a novel 552 amino acid proteini which is a so far unknown alternative spliced form of disks large homolog DLG2.

It seems to be predominantly expressed in the retinai germ cells and brain- It contains a SH3-domain and a guanylate kinase domain. These conserved regions are shared among members of the discs-large family of proteins that include human p55ι a membrane protein expressed in erythrocytesi rat PSD-15/SAPIDι a synapse protein expressed in brain Drosophila dlg-A! a septate junction protein expressed in various epithelia! and human and mouse ZO-1 and canine Z0-2ι two tight junction proteins- The Homologue of Drosophilai dlg-Ai acts as a tumor suppressor- All members of this family may be involved in signal transduction-

The new protein can find application in modulating/blocking intracellular signal transduction pathways-

similarity to disks large homolog DLG2 (Homo sapiens) alternative splicing: see DLG2 complete eds- frame shift: around position 1437 one C too many

Sequenced by EMBL

Locus: /map="33β-b cR from top of Chrl7 linkage group"

Insert length: 4220 bp

Poly A stretch at pos- 418Dι polyadenylation signal at pos- 41bS

1 CCCGGCTGCG CTGGAGCCGC CCGGAGCTAG GGGCTTCCCG GGGCGCAGGA

51 GAGACGTTTC AGAGCCCTTG CCTCCTTCAC CATGCCGGTT GCCGCCACCA

101 ACTCTGAAAC TGCCATGCAG CAAGTCCTGG ACAACTTGGG ATCCCTCCCC

151 AGTGCCACGG GGGCTGCAGA GCTGGACCTG ATCTTCCTTC GAGGCATTAT

201 GGAAAGTCCC ATAGTAAGAT CCCTGGCCAA GGCCCATGAG AGGCTGGAGG 251 AGACGAAGCT GGAGGCCGTG AGAGACAACA ACCTGGAGCT GGTGCAGGAG

301 ATCCTGCGGG ACCTGGCGCA GCTGGCTGAG CAGAGCAGCA CAGCCGCCGA

351 GCTGGCCCAC ATCCTCCAGG AGCCCCACTT CCAGTCCCTC CTGGAGACGC

4D1 ACGACTCTGT GGCCTCAAAG ACCTATGAGA CACCACCCCC CAGCCCTGGC

4S1 CTGGACCCTA CGTTCAGCAA CCAGCCTGTA CCTCCCGATG CTGTGCGCAT 501 GGTGGGCATC C6CAAGACAG CCGGAGAACA TCTGGGTGTA ACGTTCCGCG

5S1 TGGAGGGCGG CGAGCTGGTG ATCGCGCGCA TTCTGCATGG GGGCATGGTG bOl GCTCAGCAAG GCCTGCTGCA TGTGGGTGAC ATCATCAAGG AGGTGAACGG b51 GCAGCCAGTG GGCAGTGACC CCCGCGCACT GCAGGAGCTC CTGCGCAATG

701 CCAGTGGCAG TGTCATCCTC AAGATCCTGC CCAGCTACCA GGAGCCCCAT 7S1 CTGCCCCGCC AGGTATTTGT GAAATGTCAC TTTGACTATG ACCCGGCCCG

801 AGACAGCCTC ATCCCCTGCA AGGAAGCAGG CCTGCGCTTC AACGCCGGGG

851 ACTTGCTCCA GATCGTAAAC CAGGATGATG CCAACTGGTG GCAGGCATGC

IDl CATGTCGAAG GGGGCAGTGC TGGGCTCATT CCCAGCCAGC TGCTGGAGGA 151 GAAGCGGAAA GCATTTGTCA AGAGGGACCT GGAGCTGACA CCAAACTCAG

1001 GGACCCTATG CGGCAGCCTT TCAGGAAAGA AAAAGAAGCG AATGATGTAT

1051 TTGACCACCA AGAATGCAGA GTTTGACCGT CATGAGCTGC TCATTTATGA

1101 GGAGGTGGCC CGCATGCCCC CGTTCCGCCG GAAAACCCTG GTACTGATTG 1151 GGGCTCAGGG CGTGGGACGG CGCAGCCTGA AGAACAAGCT CATCATGTGG

12D1 GATCCAGATC GCTATGGCAC CACGGTGCCC TACACCTCCC GGCGGCCGAA

1251 AGACTCAGAG CGGGAAGGTC AGGGTTACAG CTTTGTGTCC CGTGGGGAGA

1301 TGGAGGCTGA CGTCCGTGCT GGGCGCTACC TGGAGCATGG CGAATACGAG

1351 GGCAACCTGT ATGGCACACG TATTGACTCC ATCCGGGGCG TGGTCGCTGC 1401 TGGGAAGGTG TGCGTGCTGG ATGTCAACCC CCAGGCCGGT GAAGGTGCTA

1451 CGAACGGCCG AGTTTGTCCC TTACGTGGTG TTCATCGAGG CCCCAGACTT

1SD1 CGAGACCCTG CGGGCCATGA ACAGGGCTGC GCTGGAGAGT GGAATATCCA

1S51 CCAAGCAGCT CACGGAGGCG GACCTGAGAC GGACAGTGGA GGAGAGCAGC

IbOl CGCATCCAGC GGGGCTACGG GCACTACTTT GACCTCTGCC TGGTCAATAG IbSl CAACCTGGAG AGGACCTTCC GCGAGCTCCA GACAGCCATG GAGAAGCTAC

1701 GGACAGAGCC CCAGTGGGTG CCTGTCAGCT GGGTGTACTG AGCCTGTTCA

1751 CCTGGTCCTT GGCTCACTCT GTGTTGAAAC CCAGAACCTG AATCCATCCC

1801 CCTCCTGACC TGTGACCCCC TGCCACAATC CTTAGCCCCC ATATCTGGCT

18S1 GTCCTTGGGT AACAGCTCCC AGCAGGCCCT AAGTCTGGCT TCAGCACAGA 1101 GGCGTGCACT GCCAGGGAGG TGGGCATTCA TGGGGTACCT TGTGCCCAG.G

1151 TGCTGCCCAC TCCTGATGCC CATTGGTCAC CAGATATCTC TGAGGGCCAA

20D1 GCTATGCCCA GGAATGTGTC AGAGTCACCT CCATAATGGT CAGTACAGAG

20S1 AAGAGAAAAG CTGCTTTGGG ACCACATGGT CAGTAGGCAC ACTGCCCCTG

21D1 CCACCCCTCC CCAGTCACCA GTTCTCCTCT GGACTGGCCA CACCCACCCC 2151 ATTCCTGGAC TCCTCCCACC TCTCACCCCT GTGTCGGAGG AACAGGCCTT

2201 GGGCTGTTTC CGTGTGACCA GGGGAATGTG TGGCCCGCTG GCAGCCAGGC

2251 AGGCCCGGGT GGTGGTGCCA GCCTGGTGCC ATCTTGAAGG CTGGAGGAGT

2301 CAGAGTGAGA GCCAGTGGCC ACAGCTGCAG AGCACTGCAG CTCCCAGCTC

2351 CTTTGGAAAG GGACAGGGTC GCAGGGCAGA TGCTGCTCGG TCCTTCCCTC 24D1 ATCCACAGCT TCTCACTGCC GAAGTTTCTC CAGATTTCTC CAATGTGTCC

24S1 TGACAGGTCA GCCCTGCTCC CCACAGGGCC AGGCTGGCAG GGGCCATTGG

2501 GCTCAGCCCA GGTAGGGGCA GGATGGAGGG CTGAGCCCTG TGACAACCTG

2S51 CTGTTACCAA CTGAAGAGCC CCAAGCTCTC CATGGCCCAC AGCAGGCACA

2b01 GGTCTGAGCT CTATGTCCTT GACCTTGGTC CATTTGGTTT TCTGTCTAGC 2bSl CAGGTCCAGG TAGCCCACTT GCATCAGGGC TGCTGGGTTG GAGGGGCTAA

2701 GGAGGAGTGC AGAGGGGACC TTGGGAGCCT GGGCTTGAAG GACAGTTGCC

2751 CTCCAGGAGG TTCCTCACAC ACAACTCCAG AGGCGCCATT TACACTGTAG

2801 TCTGTACAAC CTGTGGTTCC ACGTGCATGT TCGGCACCTG TCTGTGCCTC

2651 TGGCACCAGG TTGTGTGTGT GTGCGTGTGC ACGTGCGTGT GTGTGTGTGT 21D1 GTGTCAGGTT TAGTTTGGGG AGGAAGCAAA GGGTTTTGTT TTGGAGGTCA

2151 CTCTTTGGGG CCCCTTTCTG GGGGTTCCCC ATCAGCCCTC ATTTCTTATA

30D1 ATACCCTGAT CCCAGACTCC AAAGCCCTGG TCCTTTCCTG ATGTCTCCTC

3D51 CCTTGTCTTA TTGTCCCCCT ACCCTAAATG CCCCCCTGCC ATAACTTGGG

3101 GAGGGCAGTT TTGTAAAATA GGAGACTCCC TTTAAGAAAG AATGCTGTCC 3151 TAGATGTACT TGGGCATCTC ATCCTTCATT ATTCTCTGCA TTCCTTCCGG

32D1 GGGGAGCCTG TCCTCAGAGG GGACAACCTG TGACACCCTG AGTCCAAACC

3251 CTTGTGCCTC CCAGTTCTTC CAAGTGTCTA ACTAGTCTTC GCTGCAGCGT

3301 CAGCCAAAGC TGGCCCCTGA ACCACTGTGT GCCCATTTCC TAGGGAAGGG

3351 GAAGGAGAAT AAACAGAATA TTTATTACAA ATGTTAGAAT ATATTTCTTA 3401 TACTAGGAAT CTCATTTGCA TTTGCATAGA CTATACACAT GGGGTGGAAA

34S1 GGCCAGGCCT GCCCCCATCT CGTTGGTGTG GCTCTGCGTA TACTACACAC

35D1 TCATTCTCCT GCTCCTCTTT TCCCTTAGTC AGTGTCCTTT CATCCTGATT

3551 CAGCTCTGCC TTGCATCACC CTCAGCCTAA GGGAGTGGGA AGGAAATGGG

3b01 GTGTTTTCTT GCTGACCTGA GGCTATAGGG TCACTTGCCA TTTCCTACCT 3b51 TCTCTGGGGG ATTTGAGGGT AGAGGCAGGG GAAGATCTGT TGTTGCAGTT

37D1 GCTTCTGCCC CCTTGATCCA AATGACCATC ATCTCTGATG GAGATGGGTT

3751 GGGTACCTGG CCTTCATGGC ACCTTCACTG CTAGGGATGC TCAAGGGGCA

3801 GGCCTGGGGC CCTTCCCTCC TGTCTCTTCT CGGTCTTTCC TCTCTGAGCA 3651 GCCTCCTACC TCCCCTGCCT GAGCCCTCAC TCCACAGCCC TCCCAGGTAC

3101 CTAGCAGAGG CTGTCAGTCC TTGGCTCACC TGGAACAGGG CTGGGGCTGG

3151 GTTGGAACAG GTGTGTGCCC CCACCACAGC TCTATGACTC TGTTCTCCCT

4001 CCCTGCCATT GTGGACTCTT GTATTTGAGG GACCTCAAGA GAGTGAGGAC

4051 CCTACCATCC ACTGTCCATA TTCAGTCCCA GCCCCAGTGC GCTTCCTCTG

4101 TTCCCTCCCT CAGCCATCCA ATTCTTGAGT TTTCTCACTG ATTGGTTTTC

4151 TTTCTTTTTC CTTGGATTAA ATGTGAAAGC AAAGAAAAAA AAAAAAAAAA

42D1 AAAAAAAAAA AAAAAAAAAA

BLAST Results

No BLAST result

Medline entries

1b070428:

Mazoyer Si Gayther SAi Nagai MAi Smith SAi Dunning Ai van

Rensburg EJi

Albertsen Hi Idhite Ri

Ponder BA-ϊ A gene (DLG2) located at 17ql2-q21 encodes a new homologue of the Drosophila tumor suppressor dlg-A- Genomics 1115 Jul lήEfi(l) :2S-31

Peptide information for frame 1

ORF from 62 bp to 1437 bpi peptide length: 452 Category: strong similarity to known protein Classification: Cell signaling/communication Prosite motifs: GUANYLATE KINASE 1 (38S-4D2)

1 MPVAATNSET AMlQiQVLDNLG SLPSATGAAE LDLIFLRGIM ESPIVRSLAK

51 AHERLEETKL EAVRDNNLEL V(QEILRDLA(Q LAEiQSSTAAE LAHILώEPHF

IDl (3SLLETHDSV ASKTYETPPP SPGLDPTFSN (QPVPPDAVRM VGIRKTAGEH 151 LGVTFRVEGG ELVIARILHG GMVA(Q(QGLLH VGDIIKEVNG (3PVGSDPRAL

201 (3ELLRNASGS VILKILPSYώ EPHLPRϊQVFV KCHFDYDPAR DSLIPCKEAG

251 LRFNAGDLLO IVNtQDDANUId (QACHVEGGSA GLIPSOLLEE KRKAFVKRDL

301 ELTPNSGTLC GSLSGKKKKR MMYLTTKNAE FDRHELLIYE EVARMPPFRR

351 KTLVLIGAtQG VGRRSLKNKL IMldDPDRYGT TVPYTSRRPK DSEREGiQGYS 401 FVSRGEMEAD VRAGRYLEHG EYEGNLYGTR IDSIRGVVAA GKVCVLDVNP

451 Qk

BLASTP hits

No BLASTP hits available Alert BLASTP hits for DKFZphamy2_12d7ι frame 1 No Alert BLASTP hits found

Peptide information for frame 2

ORF from 1431 bp to 1736 bpi peptide length: loo Category: strong similarity to known protein Classification: Cell signaling/communication Prosite motifs: LEUCINE ZIPPER (bb-87)

1 VKVLRTAEFV PYVVFIEAPD FETLRAMNRA ALESGISTKlQ LTEADLRRTV 51 EESSRIiQRGY GHYFDLCLVN SNLERTFREL (QTAMEKLRTE PlQldVPVSUVY

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_12d7ι frame 2 No Alert BLASTP hits found

Pedant information for DKFZphamy2_12d7ι frame 1

Report for ^' DKFZphamy2_12d7.1

[LENGTH! 51b

[MU! 5b45β. 3b

[pi! b-21

[HOMOL! PIR:A57bS3 disks large homolog DLG2 - human 0-0

[FUNCAT! 01-03 ■11 other nucleotide-metabolism activities [S. cerevisiaei YDR4S4c! 7e-lS

[FUNCAT! f nucleotide metabolism and transport [H- influenzaei

HI1743! 3e-D7

[BLOCKS! PRD08 34F

[BLOCKS! BLDD65bC

[BLOCKS! BLD08 SbB Guanylate kinase proteins

[BLOCKS! BLD085bA Guanylate kinase proteins

[SCOP! dlgky 3.21-1-1-1 Guanylate kinase [baker's yeast (Saccharomyce 8e-45

[SCOP! dlkwab_ 2-2b.l.l-2 Cask/Lin-2 [Human (Homo sapiens) 4e-34

[EC! 2.7-4 ■6 Guanylate kinase βe-17

[PIRKId! blocked amino end 8e-17

[PIRKU! phosphotransferase 8e-17

[PIRKId! monomer 6e-17

[PIRKU! duplication 5e-21

[PIRKId! signal transduction 3e-24

[PIRKU! alternative splicing Se-21

[PIRKId! P-loop 8e-17

[PIRKU! acetylated amino end le-lb [PIRKU! membrane protein 1e-74

[PIRKId! magnesium 6e-17

[PIRKU! ATP fle-17

[SUPFAM! SH3 homology 1e-74 [SUPFAM! discs-large tumor suppressor 3e-24

[SUPFAM! unassigned Ser/Thr or Tyr-specific protein kinases Sell

[SUPFAM! protein kinase homology 5e-ll

[SUPFAM! GLGF domain homology 1e-74 [SUPFAM! guanylate kinase fle-17

[SUPFAM! guanylate kinase homology 1e-74

[PROSITE! GUANYLATE_KINASE_1 1

[PFAM! Src homology domain 3

[Kid! Irregular [Kid! 3D

SE(3 MPVAATNSETAMiQiQVLDNLGSLPSATGAAELDLIFLRGIMESPIVRSLAKAHERLEETKL Igky-

SE(Q EAVRDNNLELV(QEILRDLA(3LAE(3SSTAAELAHIL(3EPHF<3SLLETHDSVASKTYETPPP Igky-

SE(3 SPGLDPTFSN(3PVPPDAVRMVGIRKTAGEHLGVTFRVEGGELVIARILHGGMVA(3(3GLLH Igky-

SElQ VGDIIKEVNG(QPVGSDPRAL(QELLRNASGSVILKILPSY(QEPHLPR(QVFVKCHFDYDPAR lgky-

SE(Q DSLIPCKEAGLRFNAGDLL(QIVN(QDDANUU(QACHVEGGSAGLIPS(3LLEEKRKAFVKRDL Igky-

SE(3 ELTPNSGTLCGSLSGKKKKRMMYLTTKNAEFDRHELLIYEEVARMPPFRRKTLVLIGAiQG Igky- CCEEEECTTT

SElQ VGRRSLKNKLIMUDPDRYGTTVPYTSRRPKDSEREGlQGYSFVSRGEMEADVRAGRYLEHG Igky-

TCHHHHHHHHHHHTTTTEEECCEEECCCCTTTTTTTTTTEECCHHHHHHHHHHCCEEEEE

SE(3 EYEGNLYGTRIDSIRGVVAAGKVCVLDVNPlQAGEGATNGRVCPLRGVHRGPRLRDPAGHE Igky-

EETTEEEEEEHHHHHHHHHHCCEEEEECCHH SElQ (QGCAGEUNIH(QAAHGGGPETDSGGE(QPHPAGLRALL lgky-

Prosite for DKFZphamy2_12d7.1

PSDOfiSb 385->403 GUANYLATE_KINASE_1 PD0C00b70 Pfam for DKFZphamy2_12d7-l

HMM_NAME Src homology domain 3

HMM

*pyVIALYDYqAqd pDELSFkEGDIIillEdsDD . UldrgRnnn +V+ +DY++ + + L F GD ++I++++D+ UU +

(Query 228

VFVKCHFDYDPARDSLIPCKEAGLRFNAGDLL(3IVN(3DDANUU(3ACHVE 27b

HMM TNGiQEGUIPSNYVEPi* ++ G+IPS +E+

Query 277 GG-SAGLIPS(3LLEEK 211

Pedant information for DKFZphamy2_12d7ι frame 2

Report for DKFZphamy2_12d7- 2

[LENGTH! 175

[Mid! 11721- ID

[pi! 1-bl

[HOMOL! PIR:A57b53 disks large homolog DLG2 - human 7e-S3 [PIRKU! membrane protein le-13

[SUPFAM! SH3 homology le-13

[SUPFAM! GLGF domain homology le-13

[SUPFAM! guanylate kinase homology le-13

[PROSITE! LEUCINE_ZIPPER 1 [Kid! Alpha_Beta

SE(Q MAPRCPTPPGGRKTiQSGKVRVTALCPVGRURLTSVLGATUSMANTRATCMAHVLTPSGAU

PRD ccccccccccccccccceeeeeeeccccccceeeeeccccccchhhhhhhhhhccccccc

SE(^Q SLLGRCACUMSTPRPVKVLRTAEFVPYVVFIEAPDFETLRAMNRAALESGISTK(3LTEAD

PRD ccccceeeeecccchhhhhhhhhcceeeeeeeccchhhhhhhhhhhhhccccchhhhhhh

SE(3 LRRTVEESSRI(3RGYGHYFDLCLVNSNLERTFREL(3TAMEKLRTEP(QUVPVSUVY PRD hhhhhhhhhhhhhhhhhheeeeeecccchhhhhhhhhhhhhhhhccccccccccc

Pros i te f or DKFZphamy2_12d7 . 2 PS00D21 141->lb3 LEUCINE_ZIPPER PD0C00021

( No Pf am data ava i l abl e f or DKFZphamy2_12d7 - 2 ) DKFZphamy2_12g7

group: amygdala derived

DKFZphamy2_12g7 encodes a novel 254 amino acid protein without similarity to known proteins- No informative BLAST resultsi No predictive prositei pfam or SCOP motife.

The new protein can find application in studying the expression profile of amygdala-specific genes-

putative protein

Sequenced by EMBL

Locus: unknown

Insert length"- 1257 bp

No poly A stretch foundi no polyadenylation signal found

1 CTCCAAGACT TCCTTGCTGT GAGGCTCGTG TGGACCCCAG AGCATGCACA

51 GGCTGTTTAC TCCACAGAGT GGCTTTGAGA ATCAGATGAG ACTGTGCTGG

101 CGAAGGCCCT GTGGGAATGA GGAACGCTGT AGTGTTTGCT GGTCCCTGTT 151 TCTGCCCCCA GGAAAGCAGC TGTGTGAGGA GGAGCGCCGG GCCATGCAGG

201 CTGCCCTGGA CTCCGTCGTC TGCCACACGC CCCTCAACAA CCTTGGCTTT

2S1 TCCCGGAAGG GCAGCGCGCT CACCTTCAGT GTGGCCTTCC AGGCTCTGAG

3D1 GACGGGGCTC TTCGAGCTAA GCCAGCACAT GAAACTGAAG CTGCAGTTCA

351 CCGCCAGCGT GTCCCACCCT CCACCCGAGG CCCGGCCCCT CTCCCGCAAG 401 AGCAGCCCCA GAAGCCCTGC TGTCCGGGAC TTGGTGGAGA GGCATCAGGC

451 TAGCCTGGGC CGCTCCCAGT CCTTCTCCCA CCAGCAGCCT TCCCGAAGCC

501 ACCTCATGAG GTCGGGCAGT GTGATGGAGC GCAGAGCATC ACGCCCCCTG

S51 TGGCCTCTCC TGTTGGCCGC CCCCTCTACC TGCCCCCGGA CAAGGCTGTG bOl TTGTCTCTGG ACAAGATTGC CAAGCGCGAG TGCAAGGTCC TGGTGGTGGA bSl ACCCGTCAAG TAGCACCGTG CCAGCTCTGT TCCCTCTTAC ACTCCAGAGA

701 CCCAACGCCC CCAGAGGGTA TCCTTGCTCC CGGGCTGTGC CTCCCCTGGG

751 ATGCCTCCCA GACGGGGGTG AAGAGGCCTG GCAGAGCTGC CTGTCTTGTG

601 TCTGCTGATG AGGGATGGGG GAAGAAGCTG TGAAGTGGGC GGGCATGGCT

651 GGGACTAAGC CACCAGTATT CCCCGACGTT CCTGTGGGGG GGGCTGGCCC 101 ACCCCTAGGC CAGGGCAAGG GTTCCCAGAG CTCCCTTGTC CCCGGCCCTT

151 TACCCTGGTT CTGAGTTTAC AAAGTCTCTT CCTCATTCCC GTTGAGTTCT

10D1 TTCCCACCTC TGACATTCCC TCCCTCCCTC CCGCAGGCTG AGATTAGAGG

1051 GTGGTGATGG CTAAGGGCCC CTGACAGTGA CCTTCCTGTC TCAGGGGTTG

1101 GGGACAGGGC CAGGTAGCCT CCTGCCCCTT ATGTTTACGT TTGCAGCCTG 1151 AAGCACTTTA ATTTTTTTTT TTTTTGGTCT GTCCCTGTAA CTAATTTTCC

12D1 AACTATTGCT TCCAACTGAA ATAAGACTAT TAAATGCCTG TTCAGAGGGA

1251 AAAAAAA

BLAST Results

No BLAST result Medline entries

No Medline entry

Peptide information for frame 2

ORF from 44 bp to 8D5 bpi peptide length 2S4 Category: putative protein Classification: no clue

1 MHRLFTPiQSG FENlQMRLCUR RPCGNEERCS VCUSLFLPPG KiQLCEEERRA

51 MiQAALDSVVC HTPLNNLGFS RKGSALTFSV AF<3ALRTGLF ELSOHMKLKL

IDl (3FTASVSHPP PEARPLSRKS SPRSPAVRDL VERHiQASLGR SiQSFSHlQlQPS

151 RSHLMRSGSV MERRASRPLU PLLLAAPSTC PRTRLCCLUT RLPSASARSld

201 UUNPSSSTVP ALFPLTLiQRP NAPRGYPCSR AVPPLGCLPD GGEEAUiQSCL 251 SCVC

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_12g7ι frame 2 No Alert BLASTP hits found

Pedant information for DKFZphamy2_12g7ι frame 2

Report for DKFZphamy2_12g7 ■ 2

[LENGTH! 254

[Mid! 28471-11

[pi! 10-00

[BLOCKS! BL01D13C Oxystero l -b i nd i ng prote in f ami l y prote i ns

[KU! A l pha_Beta [KU! LOU COMPLEXITY 4 - 72 *

SE(Q MHRLFTP(QSGFEN(QMRLCURRPCGNEERCSVCUSLFLPPGK(QLCEEERRAM(QAALDSVVC

SEG PRD ccccccccccccchhhhhhcccccccceeeeeeeeeccccccchhhhhhhhhhhhhheee

SElQ HTPLNNLGFSRKGSALTFSVAFlQALRTGLFELSlQHMKLKLi^QFTASVSHPPPEARPLSRKS

SEG xxxxxxx

PRD cccccccccccccceeeehhhhhhhhhhhhhhhhhhhhhhhhhhhccccccccccccccc

SE(3 SPRSPAVRDLVERH(3ASLGRS(3SFSH(3(3PSRSHLMRSGSVMERRASRPLUPLLLAAPSTC

SEG xxxxx

PRD ccccchhhhhhhhhhhhcccccccccccccceeeecccchhhhhhccccccccccccccc SE(3 PRTRLCCLUTRLPSASARSUUUNPSSSTVPALFPLTL(3RPNAPRGYPCSRAVPPLGCLPD SEG

PRD cccceeeeeccccccccceeeccccccccccccccccccccccccccccccccccccccc

SE(3 GGEEAUlSSCLSCVC SEG

PRD cchhhhhhhhhccc

(No Prosite data available for DKFZphamy2_12g7 - 2) (No Pfam data available for DKFZphamy2_12g7-2)

DKFZphamy2_lΞil

group: amygdala derived

DKFZphamy2__12il encodes a novel 263 amino acid protein with weak similarity to F41Eb-3 of Caenorhabditis elegans- No informative BLAST resultsi No predictive prositei pfam or SCOP motife.

The new protein can find application in studying the expression profile of amygdala-specific genes-

putative protein

Sequenced by EMBL

Locus: /map="3"

Insert length: 2528 bp

Poly A stretch at pos- 2515ι polyadenylation signal at pos- 2411

1 ATATAGTTGG ATCAAACAAA AACAACACAA TTTGTCCCGA TAATTATCAA

51 ACAGCACAGC TACTTGCCTT AATTTTAGAG TTACTCACAT TTTGTGTGGA

101 ACATCACACA TATCACATAA AAAACTATAT TATGAACAAG GACTTGCTAA ISI GAAGAGTCTT GGTCTTGATG AATTCAAAGC ACACTTTTCT GGCCTTGTGT

2D1 GCCCTTCGCT TTATGAGGCG GATAATTGGA CTTAAAGATG AATTTTATAA

251 TCGTTACATC ACCAAGGGAA ATCTTTTTGA GCCAGTTATA AATGCACTTC

301 TGGATAATGG AACTCGGTAT AATCTGTTGA ATTCAGCTGT TATTGAGTTG

351 TTTGAATTTA TAAGAGTGGA AGATATCAAG TCTCTTACTG CCCATATAGT 4D1 TGAAAACTTT TATAAAGCAC TTGAATCGAT TGAATATGTT CAGACATTCA

451 AAGGATTGAA GACTAAATAT GAGCAAGAAA AAGACAGACA AAATCAGAAA

501 CTGAACAGTG TACCATCTAT ATTGCGTAGT AACAGATTTC GCAGAGATGC

5S1 AAAAGCCTTG GAAGAGGATG AAGAAATGTG GTTTAATGAA GATGAAGAAG bOl AGGAAGGAAA AGCAGTTGTG GCACCAGTGG AAAAACCTAA GCCAGAAGAT b51 GATTTTCCAG ATAATTATGA AAAGTTTATG GAGACTAAAA AAGCAAAAGA

7D1 AAGTGAAGAC AAGGΑAAACC TTCCCAAAAG GACATCTCCT GGTGGCTTCA

7S1 AATTTACTTT CTCCCACTCT GCCAGTGCTG CTAATGGAAC AAACAGTAAA

601 TCTGTAGTGG CTCAGATACC ACCAGCAACT TCTAATGGAT CCTCTTCCAA

851 AACCACAAAC TTGCCTACGT CAGTAACAGC CACCAAGGGA AGTTTGGTTG IDl GCTTAGTGGA TTATCCAGAT GATGAAGAGG AAGATGAAGA AGAAGAATCG

ISI TCCCCCAGGA AAAGACCTCG TCTTGGCTCA TAAAATATTT ATTAGGGGAC

1001 CCTCAACATG TGGTCTTACA ATGCTGCAAC TGTTCAGTGA GCTGAAAATC

1051 TGAATCAGAA AGCTTTCTCA ATTGAACTTA TAAAATATAC AAGGAGTAGC

1101 AAAAGACAGT ATATCAGCTA AGAGAGTTTA GTTCTAATAA AAATCAGGCT 1151 TCCCAGGAAC TTGATTGCTT GCTAGTAATT AAGGGGTTTG CCTTTTAGGC

1201 TGTCAAAACA AACATTAGTA ACCAGAACCT GGGAGATAGC TTCTCAGCAA

1251 GGAAAAGTCA CAGGTTTGGG GACGGTTTAG GGGAGGGGAA AAGGTTGATA

1301 TAATAATGCA GGGTTGCTCC TCGGGGTGTC GATCTAGAAA CAATTTTACA

1351 GAACTTCAGT TGTAAACTCA ATAACATTAC TTGTATAATG GTGCTGGCCA 1401 TGTTGTTGTT TTAATCAGTT GCCTCTTTTT AAAAGAAATT TTTATGGAAA

1451 ACACATTCAA CTATCATTAA AAAAATGAAG TTAAGCTGTT GGGACCATTT

1501 CTTTAAGATT TAACAAAAGT TCAGCCTTTT AGGTAGTTGA AGGGAAGTAC

15S1 ACCCCGTATT CAGCACATGT TGAGTTTTCT ACACCAGGAA TTTTCAATAT IbOl GTATATTGAT GAAAACAAGC TCAATTCAAA CTGGACAGTT TTAAGATAAT lbSl GTTAAAATCA GCACTTTTAG AGACAACGAA GGCCAAGAAT CAGTACAGTA 1701 GTATTCCAAA ATGATTTTCT CTAGAAATTT GAAAGTAGAT CGAACAGAAT 1751 GTTGTCAACC GCCTACCAGT ACAATCTTTT GTGGAAGATA CTTTGAAATC 1601 ACTTTCTACT TTGTTAGTAA AGTTCTGTCT TTCCAGAGCT GCAAGTTTTA 1651 AAGTGTTACT TATACAGACC AACCAAGAAT AGTGCTGAAT TAAGTGGCAT 1101 TTAGTATCTA GAAGCCATTT TGATCCAAGA AGCTACTTAA GTGTCAAAGT 1151 CAGCATGCAG CACATGTAGC TTTTCTGTAA ACAAGGGTGT GATATGAAAG 20D1 CTGCT AAGAAGAGTA AAAGCACATT CCATATACGT AAGTGAATTT 2051 TAAAA ATAAA TTGAGGCAAA CAGTTAAGTT TTATTTTTAG AGCAACAAGT 21D1 TAACTGTAAA TATTTTAATG TTAGTTTGCT CATCTATGAT CTGAGATCAT 2151 GCCGAAGTGA GAAAAATCTC CCCAAAATAC AATTTAATGC ATTGGGAAAA 2201 AAAAACTTTA ACAGTAATTC CAGCCACAAT CTTTAGATCA CCCTTGTAAT 22S1 GTGTTACGGG TCCATTTTTC CTGGAATCGT TTAATCTAAA GCAGTTTCCC 2301 CTGTTTTGGA GATTTTGTAG TTAATTTTAA TTTTGGCTAT TGTTTGGAAA 2351 AGATGAGCTG TCTGTGTAGA TATGAAGTAT AGTTTTTTCC ATAAAACAGA 24D1 TGTTTATTTT GTATTAAAAA ATACCACTGT ACTTGTTTTA CACCATTTGT 24S1 ATACATGTGG TGATATTAAT GCTAAACTGT AAAATTCAGG AATTAAAATG 2501 TGACCCTGTA ATTCCAAAAA AAAAAAAA

BLAST Results

Entry AF01b448_8 from database TREMBL: gene: "F41Eb-3"i Caenorhabditis elegans cosmid F41Eb- Score = 310ι P = S-De-32ι identities = 73/164ι positives 118/lS4ι frame +3

Entry HS21125b from database EMBL: human STS SHGC-1S844- Score = 177ι P = 5-Se-38i identities = 111/202

Medline entries

No Medline entry

Peptide information for frame 3

ORF from 132 bp to 18D bpi peptide length: 263 Category: putative protein Classification: no clue

1 MNKDLLRRVL VLMNSKHTFL ALCALRFMRR IIGLKDEFYN RYITKGNLFE

51 PVINALLDNG TRYNLLNSAV IELFEFIRVE DIKSLTAHIV ENFYKALESI

IDl EYVOTFKGLK TKYE<3EKDR<3 N(3KLNSVPSI LRSNRFRRDA KALEEDEEMU

ISI FNEDEEEEGK AVVAPVEKPK PEDDFPDNYE KFMETKKAKE SEDKENLPKR 2D1 TSPGGFKFTF SHSASAANGT NSKSVVA(3IP PATSNGSSSK TTNLPTSVTA

251 TKGSLVGLVD YPDDEEEDEE EESSPRKRPR LGS BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_12ilι frame 3 No Alert BLASTP hits found Pedant information for DKFZphamy2_12ilι frame 3

Report for DKFZphamy2_12il-3

[LENGTH! 32b

[MU! 372bl-10

[pi! S-bD

[H0M0L! TREMBL:AF01b448_8 gene: "F41Eb-3"i Caenorhabditis elegans cosmid F41Eb- le-3b

[FUNCAT! 01-05-04 regulation of carbohydrate utilization [S- cerevisiaei YNL201c! 2e-D8

[BLOCKS! BL0D357 Histone H2B proteins

[BLOCKS! BP02232B [BLOCKS! PR01D73C

[BLOCKS! BPD3050C

[BLOCKS! BP03560F

[BLOCKS! PR00613F

[KU! All_Alpha [KU! LOU COMPLEXITY 10-43 *

SElQ IVGSNKNNTICPDNYfQTAώLLALILELLTFCVEHHTYHIKNYIMNKDLLRRVLVLMNSKH

SEG xxxxxxxxx

PRD cccccccccccccchhhhhhhhhhhhhhhhhhcccchhhhhhhhhhhhhhhhhhhhccch

SElQ TFLALCALRFMRRIIGLKDEFYNRYITKGNLFEPVINALLDNGTRYNLLNSAVIELFEFI

SEG

PRD hhhhhhhhhhhhhhhhccchhhhhccccccchhhhhhhhhcccccccccchhhhhhhhhh

SElQ RVEDIKSLTAHIVENFYKALESIEYVIQTFKGLKTKYEIQEKDRIQNIQKLNSVPSILRSNRFR

SEG

PRD hheeehhhhhhhhhhhhhhhhhhhhhhhhccchhhhhhhhhcccccccccccccccchhh

SElQ RDAKALEEDEEMUFNEDEEEEGKAVVAPVEKPKPEDDFPDNYEKFMETKKAKESEDKENL

SEG xxxxxxxxxxxxxxx

PRD hhhhhhhhhhhhhhhccccccceeeeeeeccccccccccccchhhhhhhhhhhhcccccc

SElQ PKRTSPGGFKFTFSHSASAANGTNSKSVVAlQIPPATSNGSSSKTTNLPTSVTATKGSLVG

SEG

PRD ccccccccceeeeccccccccccccceeeeecccccccccccccccccccccccccccee

SElQ LVDYPDDEEEDEEEESSPRKRPRLGS

SEG xxxxxxxxxx

PRD eeccccccchhhhhcccccccccccc

(No Prosite data available for DKFZphamy2_12il .3) (No Pfam data available for DKFZphamy2_12il -3)

DKFZphamy2_13gl1

group: amygdala derived

DKFZphamy2_13gl1 encodes a novel 281 amino acid protein without similarity to known proteins- The novel protein contains a PROSITE ASP_PR0TEASE motif and seem to be expressed Ubiquitously-

No informative BLAST resultsi No predictive prositei pfam or SCOP motife.

The new protein can find application in studying the expression profile of amygdala-specific genes-

unknown protein perhaps complete eds- Pedant: SIGNAL_PEPTIDE Sequenced by EMBL

Locus: /chromosome="12pl3-3"

Insert length: 2754 bp Poly A stretch at pos- 2743ι polyadenylation signal at pos- 2724

1 GCAATCTCGG GAAATTGGAG ACTGACGCGG CTGCTCCTGC ATGTTATTTA

51 TTTTTCCTCT TTCCCTCCCG TGGAGACCCT CCTGTTGGAA AGAGAGCTGC 101 AGCACGGGAC AGAGACAGGC AGGAAGAAGC AGAGAGGACT CGGTGACGCC

151 CCCACCGAGC AGCCCCTGGC CCACTCCTCC AGCAGGGGCC ATGAGCACCA

2D1 AGCAGGAGGC CAGGAGAGAT GAGGGAGAAG CCAGGACGAG GGGGCAGGAG

251 GCACAGCTTC GAGACCGAGC CCACCTGAGC CAGCAGCGCC GGCTCAAACA

301 GGCCACCCAG TTCCTGCACA AGGACTCGGC CGACCTGCTC CCGCTGGACA 351 GCCTCAAGAG GCTCGGCACC TCCAAGGACT TGCAGCCGCG CAGTGTGATC

401 CAAAGACGCC TGGTGGAGGG AAACCCGAAT TGGCTTCAGG GGGAGCCTCC

451 CCGGATGCAG GACCTGATTC ATGGCCAGGA GAGCAGGAGG AAGACCAGCA

501 GGACAGAGAT TCCAGCTCTT CTGGTCAACT GCAAGTGCCA GGACCAGCTG

S51 CTTAGAGTGG CCGTTGACAC AGGCACCCAA TACAATCGGA TCTCTGCTGG bDl ATGTCTCAGC CGCCTGGGGT TAGAGAAAAG GGTCCTAAAA GCCTCAGCTG bSl GGGACCTGGC CCCTGGGCCC CCAACCCAGG TGGAGCAGTT GGAGCTACAG

701 CTGGGGCAGG AGACTGTGGT GTGCTCGGCA CAGGTGGTGG ATGCTGAGAG

751 TCCTGAATTC TGCCTGGGCC TGCAGACTCT GCTTTCTCTC AAGTGCTGCA

801 TCGACCTGGA GCACGGAGTG CTGCGGCTGA AAGCCCCGTT CTCAGAGCTA 8S1 CCCTTCCTGC CTTTGTACCA AGAGCCTGGC CAGTGACTGC TGTCTCAGTC

101 AGTCCCCAGA GGGAAAGACC TTGCCTTAGA AGAAGAGGCG TGTGGGGAAC

151 GGGGGCTCTT GAAGCCAGGT AGCTGGGGAC TATGGTGTCT GCCCTTCCAA

1001 TCACCTCCCT GACCCCTGCT GTCCCATTTT CCCCAGCTGG CCGCATTCCT

1051 CTCTGCTTCT CAGCAGCTGT CCTACTCCCC AGGACGAGTT TTCACTAGAG 1101 GGCCCACGAT GCCAGGATTC TGATTCATCT TCCTCCCAAG AAAAGCAAAG

1151 CCAAATCAAG ACCACAGATA GGAACCTAAG CACAATGGGG TGCCTGCTTG

1201 GGCTGGGTCG AAGGCTCTGC TGACTGCTGT CCTTGTCCAT CACCCAATAC

1251 CACCCCAAAC ACAACTCAAC TTCCCACACC ACCATGTCTC TCACCACACC 1301 TTCTGGGCCT CATTATCTCC CACAACTAGA CCGCCATGCC TCACCAACCT

1351 ATGTCCCTGG ACCTCCTGGT GTCTGCCTCT CGGAGTCTGT GCACATCTGC

1401 TCACAGTTGA GTGGGGGAAG AAACAGCCAG AATTCAATAC AACAAAGAGC

1451 GGGAGTTAGT ATAGGAATGT CCATCTCATA AGGCTGAGAG CTATTTTTTC 1501 CTGTGGCTGC AAATGTCTGA AGCCAGTTAG TTTGATTACC CTGTGCAAAA

1SS1 CCTTGGACAT ACTTCTGCTA TTAACGCTAT AGGTATTTAT CCGTTTCCAC

IbOl TGGCTTTTTG TACCCACCGA GCCCCTGAGC CTTGCGTGTG TGTGTGTGGA lb51 AGAGCCTTGT AGAGAACTGC TCCTGTGAGG CAGACAGGAC AGTGAGGTTG

1701 TCACCACTCA GACTTCACCT ATTCAGCATT CTTTCTGATT TCTAGAACTA 17S1 TCCACCTCAT TAGGCCTTCT TCCTATCCCC ATCTCTGGCC TCTTGAGCTT

1601 AAGCTTGTAT TGTCCTGGAA TCAGTGGCTT TCTAACCCCC TGCCAGGCTT

1851 TGCCAAAGCA AAAAGACAGA GGCTTTTTTT TTTTTTTTAA AGTTTGGGGT

11D1 CTGTCAGGAG ACAGAGGCTT TTTTGAATTC ACTGTGAAGA GAAGAACCCG

1151 AACCTTAAGA CGCCAGATCC CTGAGAGTCT TTCTGGCTGG TTTGAGTCTC 2D01 TCAAATCATG GATTAGGAGT AAAGAAAGAG GCAGGCGCAA TGGCTCATGC

2D51 CTGTAATCCC AGCACTTTGG GAGGCTGAGG TGGGTGGATC ACTTGAGGTC

2101 AGGAGTTTGA GACCAGCCTG GGTAATATGG CAAAACCCCA TCTCTACTAA

21S1 AAAATACAAA AATTAGCCAG GTATGGTGGT GAACACCTGT AATCCCAGCT

2201 ACTTGGAAGG CTGAGGCATA GGAGTTGCTT GAACCTGGGA GATGGGGGTT 2251 GTAGTGAGCC AAGTTCGTGC CATCGGACTC CAGCCTGGGT GAAGGAGTGA

23D1 GACCCTGTCT CCAAAAACAA ACAAAAAAGG AGCAGAGAAA GACAGTGGTA

23S1 CAGCTAACCT GAACAAGGGA ACTGGGACCG TTGGGCTGAA ACAGTCTTGA

2401 GCCTGGGGTT GACTGGGTTA GAGAAGAACC GGGATGCAAG GAGCTGCCTG

2451 TGACACCTGG CCTGCCCTTT CTCAGCTGCC TCCCCTGCCC TTTCTCAGCT 25D1 GCCTCCCCTG CCCTCAGAAG GAAAGGAGAG GGCTCACTTA TCACTTGTGC

2S51 CATAGCACCT GGTCTCAAAA TCCTAAAAGC TTTCCTCGCC CTCACTGCCT

2b01 TGCTCCACAA GGTCCACTTT CCTGGGTCTT GTGCTGTGCC TTTCCTTGTC

2bSl TGCCTCCTGC TGCTTCTGTA ACTGCAGACC CCA6GCCCAA TTGCAAGCCC

27D1 TCGGCTCAGC TGCTTCTCCA TTGGAATAAA CTCTTGTTTC TCTAAAAAAA 2751 AAAA

BLAST Resul ts

No BLAST resu l t

Medl i ne entri es

No Med l i ne entry

Pepti de i nf ormati on f or f rame 2

ORF f rom 41 bp to 683 bp i pept i de length : 281 Category : putat i ve prote i n Cl ass i f i cati on : no c lue Pros i te moti f s : ASP PROTEASE ( 173-184 )

1 MLFIFPLSLP URPSCUKESC STG(QR(QAGRS REDSVTPPPS SPUPTPPAGA

51 MSTKiQEARRD EGEARTRGiQE AlQLRDRAHLS (Q(QRRLKιQAT(Q FLHKDSADLL

101 PLDSLKRLGT SKDLlQPRSVI (QRRLVEGNPN ULlQGEPPRMiQ DLIHGlQESRR

ISI KTSRTEIPAL LVN CKCIQD IQ L LRVAVDTGT(3 YNRISAGCLS RLGLEKRVLK 2D1 ASAGDLAPGP PTiQVElQLELiQ LGlQETVVCSA (QVVDAESPEF CLGLiQTLLSL 251 KCCIDLEHGV LRLKAPFSEL PFLPLYώEPG (Q

BLASTP h its

No BLASTP hits available Alert BLASTP hits for DKFZphamy2_13gl1ι frame 2

PIR:S50b4b hypothetical protein YER143w - yeast (Saccharomyees cerevisiae)ι N = li Score = 10ι P = D-2b TREMBL:RNDObO_l product: "DNA (cytosine-S- ) -methyltransferase"i Rattus norvegicus mRNA for DNA (cytosine-5-) -methyltransferase! partial eds • i N = li Score = 61ι P = D-61

>PIR:S50b4b hypothetical protein YER143w - yeast (Saccharomyees cerevisiae)

Length = 426

HSPs:

Score = 10 (13-5 bits)ι Expect = 3-De-Olι P = 2-be-Dl Identities = 28/112 (2S*)ι Positives = 46/112 (42*)

(Query: 155 TEIPALLVNCKClQDtQLLRVAVDTGTlQYNRISAGCLSRLGLEKRVLKASAGD- --LAPGPP 211

T++P L +N + + ++ VDTG Q +S + GL + + K G+ + G Sbjct: 111

T(QVPMLYINIEINNYPVKAFVDTGA(QTTIMSTRLAKKTGLSRMIDKRFIGEARGVGTGKI 256

(Query: 212 XXXXXXXXXXXXXXXX- CSA(QVVDAESPEFCLGL(QTLLSLKCCIDLEHGVLRL 2b3 CS V+D + + +GL L C+DL+

VLR+

Sbjct: 251 IGRIHIQAIQVKIETIQYIPCSFTVLDTDI- DVLIGLDMLKRHLACVDLKENVLRI 310

Pedant information for DKFZphamy2_13gl1ι frame 2

Report for DKFZphamy2_13gl1- 2

[LENGTH! 281

[MU! 31330-17

[pi! 6-75 [BLOCKS! PR00041D

[BLOCKS! BP01121G

[PROSITE! ASP_PROTEASE

[KU! All_Alpha [KU! SIGNAL_PEPTIDE 17

[KU! LOU COMPLEXITY L ib *

SElQ MLFIFPLSLPURPSCUKESCSTG(QR(QAGRSREDSVTPPPSSPUPTPPAGAMSTK(QEARRD

SEG xxxxxxxxxxxx

PRD ccccccccccccccceeeccccccccccccceeecccccccccccccccchhhhhhhhhh

SElQ EGEARTRG(QEA(QLRDRAHLSιQ(3RRLK(QAT(QFLHKDSADLLPLDSLKRLGTSKDL(QPRSVI SEG

PRD ccccccchhhhhhhhhhhhhhhhhhhhhhhhhhccccccccccccccccccccccchhhh

SE(Q <QRRLVEGNPNUL(QGEPPRM<QDLIHG(QESRRKTSRTEIPALLVNCKC(QD(QLLRVAVDTGTιQ

SEG PRD hhhhhccccccccccccccccccccccccccccccccchhhhhhhchhhhhhhhhhccce

SE(Q YNRISAGCLSRLGLEKRVLKASAGDLAPGPPT(QVE(QLEL(QLG(QETVVCSA(QVVDAESPEF

SEG xxxxxxxxxxxxxxxx

PRD eeecccchhhhhhhhhhhhhhhccccccccccchhhhhhhhccceeeeccceeecccccc

SE(3 CLGL(3TLLSLKCCIDLEHGVLRLKAPFSELPFLPLY<3EPG(3 SEG

PRD cccchhhhhhhhhhcchhhhhhhcccccccccccccccccc

Prosite for DKFZphamy2_13gl1 • 2

PS0D141 173->185 ASP PROTEASE PD0C0D128

(No Pfam data available for DKFZphamy2_13gl1 -2)

DKFZphamy2_14b5

group: intracellular transport and trafficing

DKFZphamy2_14bS encodes a novel 771 amino acid protein which shows bl* identity to the human TYL protein and 48* identity to the human Tic protein-

Both proteins show similarity to Sec7 of Saccharomyees cerevisiaei which takes function in vesicular traficking. The new protein shows also significant similarity to human ARN03ι which is involved in the control of Golgi structure and function- DKFZphamy2_14b5 is predominantly expressed in the ens and germ cells-

The new protein can find application in diagnosis/therapy of diseases related to vesicular traficking e-g- in synapses of the central nervous system and in studying expression profiles.

similarity to TYL protein (Homo sapiens)

Sequenced by EMBL

Locus: /map="44S-7 cR from top of Chr5 linkage group" Insert length: 4528 bp

Poly A stretch at pos- 4511ι polyadenylation signal at pos- 4481

1 CTCGCTCAGC CTCTCCACAT CGCGGCTCCG GCACCTGAAG GGACGCGGGC SI GGGCGCGGGC AGCTCCGACC GGCGGCGGCG GGGCGGGACA GGCAGCCCGG

101 CGGCCTCCGA TGGCCCCGCC GTGAGAGGCC GGACCCGCGG CGGGGACCAG

ISI CAGCGGTCTA GAGGAGTCCC AGGAGCAGCC AGGACAGGCG GAAGCAGTGG

2D1 CTGCCATGGA GGAGGACAAG CTCTTATCTG CAGTGCCTGA GGAAGGCGAT

251 GCCACCCGTG ACCCCGGTCC AGAGCCTGAA GAGGAGCCAG GGGTCCGGAA 301 TGGGATGGCC AGTGAGGGCC TGAACAGCAG CCTCTGCAGC CCAGGGCACG

351 AGCGAAGGGG CACCCCAGCG GACACTGAGG AACCCACGAA GGACCCAGAT

4D1 GTGGCCTTCC ATGGCCTCAG CCTTGGCCTC TCTCTCACCA ATGGCCTAGC

4S1 CCTGGGGCCA GACTTGAACA TTCTGGAAGA TTCAGCGGAG TCCAGGCCCT

501 GGAGGGCTGG CGTGCTGGCA GAGGGGGACA ATGCTTCCAG GAGCCTCTAC 551 CCAGATGCTG AGGACCCTCA GCTGGGGTTG GATGGTCCCG GGGAGCCAGA bOl TGTGCGGGAT GGCTTCAGCG CCACGTTTGA GAAGATTCTG GAGTCAGAGC bSl TGCTGCGGGG CACCCAGTAC AGCAGCCTCG ACTCCCTAGA CGGGCTGAGC

7D1 CTCACGGATG AGAGCGACAG CTGCGTCAGC TTCGAGGCCC CCCTCACACC

751 CCTCATCCAG CAGCGGGCCC GTGACAGCCC TGAGCCAGGG GCTGGGTTGG 801 GCATTGGGGA CATGGCGTTT GAGGGGGACA TGGGGGCAGC TGGTGGTGAT

851 GGGGAGCTGG GCAGCCCCCT GCGGCGCTCC ATCTCCAGCA GCCGCTCTGA

101 GAATGTCCTG AGCCGCCTGT CTCTCATGGC CATGCCCAAT GGATTCCATG

ISI AAGATGGCCC TCAGGGCCCA GGGGGGGATG AGGATGATGA TGAGGAGGAC

1001 ACGGACAAGT TGCTGAACTC AGCCAGTGAC CCCAGCCTGA AGGATGGCCT 1051 GTCAGACTCA GACTCTGAGC TCAGCAGCTC GGAGGGGTTG GAGCCTGGTA

1101 GTGCAGACCC TCTGGCCAAC GGGTGCCAGG GGGTCAGTGA AGCTGCTCAT

1151 CGGCTGGCAC GCCGTCTCTA CCACCTCGAG GGCTTCCAGC GCTGTGATGT

12D1 GGCCCGGCAG CTGGGCAAGA ACAACGAGTT TAGCAGGCTG GTGGCCGGGG 12S1 AGTACCTCAG TTTCTTCGAC TTCTCGGGCT TGACTCTGGA CGGAGCACTC

1301 AGAACATTCT TGAAGGCCTT CCCGCTGATG GGGGAGACAC AAGAGCGTGA

1351 GCGGGTCCTC ACACACTTCT CCCGCCGGTA CTGCCAGTGC AACCCTGATG

1401 ACAGCACTTC GGAAGATGGG ATCCACACGC TCACCTGTGC CCTGATGCTG 1451 CTCAACACGG ACCTGCACGG CCACAACATT GGCAAAAAGA TGTCCTGTCA

1501 GCAATTCATT GCCAACTTGG ACCAGCTGAA TGATGGCCAA GACTTTGCCA

1551 AAGACCTGCT GAAGACCCTT TACAACTCCA TCAAGAATGA AAAGCTGGAA

IbOl TGGGCCATTG ATGAGGATGA GCTGAGGAAA TCCCTGTCTG AGCTGGTGGA

IbSl TGACAAGTTC GGGACAGGCA CGAAGAAGGT GACGCGAATC CTGGATGGTG 1701 GCAACCCCTT CCTGGATGTC CCACAGGCGC TCAGTGCCAC CACCTACAAG

17S1 CACGGCGTCC TGACCCGGAA GACTCACGCT GACATGGATG GCAAGAGGAC

1801 GCCCCGTGGG AGGCGTGGCT GGAAGAAATT CTACGCAGTG CTCAAAGGGA

1851 CCATCCTGTA CCTGCAGAAG GATGAGTACA GGCCTGACAA AGCTCTATCG

1101 GAGGGTGACC TGAAGAACGC CATTCGCGTG CATCACGCTC TGGCCACCAG 1151 GGCCTCTGAC TACAGCAAGA AGTCCAACGT GCTGAAGCTT AAGACAGCCG

20D1 ACTGGAGGGT ATTCCTCTTC CAGGCACCGA GCAAGGAAGA AATGCTGTCC

2051 TGGATCCTCA GGATCAACCT GGTGGCAGCC ATCTTCTCTG CCCCGGCCTT

21D1 CCCAGCCGCT GTCAGCTCCA TGAAGAAGTT CTGTCGGCCC CTGCTGCCCT

2151 CCTGCACCAC CCGCCTCTGC CAGGAGGAGC AACTGCGGTC TCATGAGAAT 2201 AAGTTGAGGC AGCTGACTGC GGAGCTGGCC GAACACAGGT GTCACCCAGT

2251 CGAGAGGGGC ATCAAGTCCA AGGAGGCCGA GGAGTACCGG TTGAAGGAGC

23D1 ACTATCTCAC CTTCGAGAAA AGCCGTTATG AGACCTATAT CCACCTCCTG

2351 GCTATGAAAA TCAAAGTGGG CTCAGATGAT CTGGAGCGGA TTGAGGCCCG

2401 GCTGGCCACT CTGGAAGGGG ATGACCCTTC TCTCCGGAAG ACACATTCAA 24S1 GCCCTGCCCT CAGCCAGGGC CATGTGACTG GCAGCAAAAC CACAAAGGAT

2501 GCCACTGGGC CTGATACTTA GCTGACATGG ATTTGCAGAC CCCAGGGTGG

2S51 GCAGATGTCT CCAGTGGGGT CAGTGAGCAC AATTCCAGCC AGGGGCCACT

2b01 TGGACCAAGC TCCAGTCAGT TGATGGGCAG CTAGAGGGGT GCAGAAAGCC

2bSl TGTGGGCCCA GGAGATGGAG ATGCCGTTTG TGGCGTTGAT CTCCTTGCGT 2701 CCTTGGGCAT CTCCGGGCAT CAGACCCTCT CCCTGGCCCT TGTTTTCCTC

2751 TCCACCATGG AGCCTCATTT TGTAGGCCAG TTGTGTGCAT GCTCTAGACA

28D1 CCACCTCGCT GGAGAAGCTG GAAGGGCTGT TGTCTTCCCA GGTCTTTCTC

2851 TTCTCATCAA GCTCCTCTCC TCATCTTTTT TGTGTGTGAG GGCAGGTCTT

21D1 GACTCTAGGT CTCAGCTGGA ACCCCACCCT TTCTCCTCCT CCTTCCTCTG 2151 AGTTGACCAG CAGCAGGTCT GCCGACCACC AGCACCATCC TCTCCTCCCA

30D1 GCAGCCTCCA GAACCATGCC CAGGTCTCCT GCCTCACATC ACAATAATCT

3051 GGGACCCAGG CTTGTGCCCT TTCAGTGTAA AGCTGACTCC ATCACATGTG

3101 CATCCACTTC TTTTCATCCA TTGAGATCAC ACTGCCTCCT TTTTATACAG

3151 ACACAAATAT ACATCTATAA GAATAATATA TACATAAGGA ACCCCTGAAA 32D1 GATGGTTTTG GAACTGGAAT CAGTTAGAGG ATGAAATCAG ATAAAGGAAA

32S1 AGCCTATTTT GGAGCTTCCC CTGTTAG6AA GGATGGCTGC ACCTGGCCCC

3301 CTGGCATTCC TGACGCTCTA GGAGGGAAGG GGGAGGCAGT GCTGGCCTCC

3351 CTTGCCCTGT TTTTCCCTCT TCCAGCTGAC CTGTGACTTA TACTGCTCTT

34D1 ACCGATGATA CTTTTGGAAA AAATAGAGCG TGTATGCACC GCCCCGTTTG 3451 TCCCATGGAT ATCCTGGGGT GTGAGTCGGA TGGGACCACG GCCCTGTTTA

3SD1 TATTTGGGTC TTTATGTTGG TGCTGCCAGG TCTCTGAGCT CCAGAGGTGG

3S51 CCTCTTGGAC AGATCTACTG CTATAGGAAT AAAAGACACT CTGTCTCGCA

3b01 AATGGCTGCT TGTCAACAAG CCCAAAGATG CTTGTCGGAG GACGGTTATG

3bSl GAAGCCCTTA ATTCTTGGTT GTGGGAAAAG GTGGAATGAC AAGTTATTGA 37D1 TTGTTTTTCT GTCGCTATTT CTTTCATTTG TCTAGTGAAT CAGAAAGGCT

3751 TAGCCAAGGC CACATCTGGG AAGAGTGGAG AAATTTGCCA CTTGACGATC

3601 ACGGATTAGC TAGCACCTTT AAGCCCTGCA TTTCTCCAAC TGACAAGTGG

3851 GTGGGGGTGA TGGCACATTC AGTGTGGCTA TGAAGAGCGA ATCCTCTCTA

3101 TTGTTTAAAT AGATTACTGT AGTTTGGCCA GGAATTTGGC GTCAGTGGTA 3151 ACACACTTAG TTAATAAAAT AAGCCAGGCT TGCAACTAAG TATCTAACTT

4D01 TACAGGCCCA CTCACATTTG AGGCAAGGGG CTATTGAGTA TGTGGAGAGA

4D51 TGTAGTGATT TAAATTCAGA TTATTTAAGT TGGATCAGCT GAAGTGTGTT

4101 TTAGACCCAA ACCATCTGGC CCCTTCGTTT TGCTCAGAGG AAGTAAATGT 41S1 TCACTTAAAT GAAATTGAAA ACGCCATGTG GCACCACAAA AGAGCTCTCT

42D1 GTACTTTCCC CATGCTGCCT CAAAAGTTCT GTGAGTTTCG GGGTCAGTGT

4251 CCCACCCTTC ACTTCCCGAG GGCGGGTGAG TGGAGAGCAG AGCCAGGAGC

4301 TCTGGCAGCT GTGGACAGAT GTGCTTCCTG AGCATGGGTT GTGCCTCCCA

4351 TCAGTAAAAA AATGTTTAGT TCACTTCCTT AATTGTATAA TTATTTATTT

44D1 GTAAATTATA TACATGTACT ACTGTACTAA AATATTATGT ACATTATAAA

44S1 ACATACACAA AAATAGAAAT TTAAAAAAGA TGAGATGAAA ATAAATCTAA

4501 GTCAAAGTTC CAAAAAAAAA AAAAAAAA

BLAST Results

No BLAST result

Medline entries

18D8b482:

Perletti Li Talarico Di Trecca Di Ronchetti Di Fracchiolla NSi

Maiolo ATi Neri A-i Identification of a novel gene-, PSDi adjacent to

NFKB2/lyt-10ι which contains See? and pleckstrin-homology domains.

Genomics 4b : 251-251 (1117)

Peptide information for frame 2

ORF from 20b bp to 2518 bpi peptide length: 771 Category: similarity to known protein

Classification: Cell signaling/communication

1 MEEDKLLSAV PEEGDATRDP GPEPEEEPGV RNGMASEGLN SSLCSPGHER

51 RGTPADTEEP TKDPDVAFHG LSLGLSLTNG LALGPDLNIL EDSAESRPUR 101 AGVLAEGDNA SRSLYPDAED PiQLGLDGPGE PDVRDGFSAT FEKILESELL

151 RGTtQYSSLDS LDGLSLTDES DSCVSFEAPL TPLIlQiQRARD SPEPGAGLGI

2D1 GDMAFEGDMG AAGGDGELGS PLRRSISSSR SENVLSRLSL MAMPNGFHED

251 GPiQGPGGDED DDEEDTDKLL NSASDPSLKD GLSDSDSELS SSEGLEPGSA

301 DPLANGCiQGV SEAAHRLARR LYHLEGFlQRC DVARiQLGKNN EFSRLVAGEY 351 LSFFDFSGLT LDGALRTFLK AFPLMGETύE RERVLTHFSR RYCiQCNPDDS

4D1 TSEDGIHTLT CALMLLNTDL HGHNIGKKMS CIQIQFIANLDIQ LNDGflDFAKD

451 LLKTLYNSIK NEKLEUAIDE DELRKSLSEL VDDKFGTGTK KVTRILDGGN

501 PFLDVPI3ALS ATTYKHGVLT RKTHADMDGK RTPRGRRGUK KFYAVLKGTI

S51 LYLiQKDEYRP DKALSEGDLK NAIRVHHALA TRASDYSKKS NVLKLKTADU bOl RVFLFiQAPSK EEMLSUILRI NLVAAIFSAP AFPAAVSSMK KFCRPLLPSC bSl TTRLClQEElQL RSHENKLR(3L TAELAEHRCH PVERGIKSKE AEEYRLKEHY

701 LTFEKSRYET YIHLLAMKIK VGSDDLERIE ARLATLEGDD PSLRKTHSSP 751 ALS(3GHVTGS KTTKDATGPD T

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_14bSι frame 2 PIR:GD1205 TYL protein - humani N = 2τ Score = 1421ι P = 8-be-lSD

TREMBL:AB023151_1 gene: "KIAAD142"i product: "KIAA0142 protein"i Homo sapiens mRNA for KIAAD142 proteini partial cds-i N = li Score = 1251ι P

= 2.3e-127

TREMBL:Ub3127_l gene: "TIC"i product: "Tic"i Human SEC7 homolog Tic (TIC) mRNAi complete cds-i N = li Score = 105Dι P = 4-be-lOb

>PIR."GD120S TYL protein - human Length = b45

HSPs:

Score = 1421 (213-2 bits)ι Expect = 6-be-lSOι Sum P(2) = 8-be- 150 Identities = 260/452 (bl*)ι Positives = 33b/452 (74*) ώuery: 3D1

DPLANGC(QGVSEAAHRLARRLYHLEGF(QRCDVAR(QLGKNNEFSRLVAGEYLSFFDFSGLT 3b0 D L+NG + EAA RLA+RLY L+GF++ DVAR LGKNN+FS+LVAGEYL FF F+G+T

Sbjct: Ibb DTLSNGIQKADLEAAIQRLAKRLYRLDGFRKADVARHLGKNNDFSKLVAGEYLKFFVFTGMT 22S

(Query: 3bl LDGALRTFLKAFPLMGETIQERERVLTHFSRRYCIQCNPDDSTSEDGIHTLTCALMLLNTDL 42D

LD ALR FLK LMGETiQERERVL HFS + RY (QCNP+ +SEDG

HTLTCALMLLNTDL

Sbjct: 22b

LDIQALRVFLKELALMGETIQERERVLAHFSIQRYFIQCNPEALSSEDGAHTLTCALMLLNTDL 285

(Query: 421

HGHNIGKKMSC(Q(3FIANLD(QLNDGιQDFAKDLLKTLYNSIKNEKLEUAIDEDELRKSLSEL 460 HGHNIGK+M+C FI NL+ LNDG DF ++LLK

LY+SIKNEKL+UAIDE+ELR+SLSEL Sbjct: 28b

HGHNIGKRMTCGDFIGNLEGLNDGGDFPRELLKALYSSIKNEKLiQUAIDEEELRRSLSEL 34S

(Query: 461 VDDKFGTGTKKVTRIL

DGGNPFLDVPiQALSATTYKHGVLTRKTHADMDGKRTPRGR 53b D K + RI G +PFLD+ A YKHG L RK HAD D

++TPRG+

Sbjct: 34b ADPN

PKVIKRISGGSGSGSSPFLDLTPEPGAAVYKHGALVRKVHADPDCRKTPRGK 4D1 (Query: 537

RGUKKFYAVLKGTILYLiSKDEYRPDKALSEGDLKNAIRVHHALATRASDYSKKSNVLKLK 51b

RGUK F+ +LKG ILYLiQK+EY+P KALSE +LKNAI +HHALATRASDYSK+ +V L+ Sbjct : 402 RGUKSFHGILKGMILYL(QKEEYKPGKALSETELKNAISIHHALATRASDYSKRPHVFYLR 4bl

(Query : 517 TADURVFLFlQAPSKEEMLSUILRINLXXXXXXXXXXXXXXXSMKKFCRPLLPSCTTRLCiQ bSb

TADURVFLFlQAPS E + M SUI RIN+ S KKF

RPLLPS TRL (Q Sbjct : 4b2 TADURVFLF(QAPSLEιQM(QSUITRINVVAAMFSAPPFPAAVSS(QKKFSRPLLPSAATRLS(Q S21

(Query : b57 EElQLRSHENKLRiQLTAELAEHRCHPVERGIKSKEAEEYRLKEHYLTFEKSRYETYIHLLA 71b

EE(Q + R + HE KL+ + +EL EHR + + + KEAEE R KE YL FEKSRY TY LL Sbj ct : S22

EE(Q^'VRTHEAKLKAMASELREHRAAι3LGKKGRGKEAEEιQR(QKEAYLEFEKSRYSTYAALLR 561

(Query : 717 MKIKVGSDDLERIEARLATLEGDDPSLRKTHSSPAL 752 +K+K GS++L+ +EA LA + L +HSSP+L Sb jct : 582 VKLKAGSEELDAVEAALA(QAGSTEDGLPPSHSSPSL bl7

Score = b3 ( 1 - 5 bits ) ι Expect = β - be-lSD i Sum P ( 2 ) = 6 - be-lSD Ident i ties = 11/b4 ( 21* ) ι Posi t i ves = 23/b4 ( 35* ) (Query : 132 DVRDGFSATFEKILESELLRGTlQYXXXXXXXXXXXXXXXXX- CVSFEAPLTPLIlQlQRARD 110

D D FS FE ILES +GT Y +FE P P

+

Sbjct : 18 DGPDSFSCVFEAILESHRAKGTSYTSLASLEALASPGPTiQSPFFTFELPPiQPPAPRPDPP 77

(Query: 111 SPEP 114

+P P Sbjct: 78 APAP 81

Pedant information for DKFZphamy2_14bSι frame 2

Report for DKFZphamy2_14b5-2

[LENGTH! 771

[MU! 64bbD.S5 [pi! 5-04

[HOMOL! PIR:GD1205 TYL protein - human le-158

[FUNCAT! 3D- 01 organization of intracellular transport vesicles

[S. cerevisiaei YDR17Dc! 5e-22

[FUNCAT! 30-08 organization of golgi [S- cerevisiaei YDR170c! Se-22

[FUNCAT! 3D-03 organization of cytoplasm [S- cerevisiaei

YDR170c! 5e-22

[FUNCAT! D6-D7 vesicular transport (golgi networki etc) [S- cerevisiaei YDR170c! Se-22 [FUNCAT! 11 unclassified proteins [S- cerevisiaei YPRDISc!

4e-04

[BLOCKS! BL01277B

[BLOCKS! BP02373F [BLOCKS! PRD0b55C

[BLOCKS! PRD1088F

[BLOCKS! PR0D221B

[BLOCKS! BP02b4bD [BLOCKS! PRD0311A

[BLOCKS! DM013S4M

[BLOCKS! PF013b1B

[BLOCKS! PF013b1A

[SCOP! dlbtn 2.41-1-1-2 beta-spectrin [mouse (Mus musculus) brain le-31

[PIRKU! transmembrane protein le-2D

[SUPFAM! Caenorhabditis elegans K0bH7-4 protein 7e-24

[SUPFAM! pleckstrin repeat homology 7e-24

[PFAM! PH (pleckstrin homology) domain [KU! Irregular

[KU! 3D

[KU! LOU COMPLEXITY 18-42 *

SElQ MEEDKLLSAVPEEGDATRDPGPEPEEEPGVRNGMASEGLNSSLCSPGHERRGTPADTEEP SEG xxxxxxxxxx lbtn-

SE(Q TKDPDVAFHGLSLGLSLTNGLALGPDLNILEDSAESRPURAGVLAEGDNASRSLYPDAED SEG xxxxxxxxxxxxxxx lbtn-

SElQ P(QLGLDGPGEPDVRDGFSATFEKILESELLRGT(QYSSLDSLDGLSLTDESDSCVSFEAPL

SEG xxxxxxxxxxxxxxxxx

Ibtn-

SE(Q TPLIiQiQRARDSPEPGAGLGIGDMAFEGDMGAAGGDGELGSPLRRSISSSRSENVLSRLSL SEG xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

Ibtn-

SElQ MAMPNGFHEDGPώGPGGDEDDDEEDTDKLLNSASDPSLKDGLSDSDSELSSSEGLEPGSA SEG xxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxx.

Ibtn-

SElQ DPLANGClQGVSEAAHRLARRLYHLEGFiQRCDVARiQLGKNNEFSRLVAGEYLSFFDFSGLT SEG

Ibtn-

SElQ LDGALRTFLKAFPLMGETiQERERVLTHFSRRYClQCNPDDSTSEDGIHTLTCALMLLNTDL SEG

Ibtn-

SElQ HGHNIGKKMSC(Q(QFIANLD(QLNDG(3DFAKDLLKTLYNSIKNEKLEUAIDEDELRKSLSEL SEG

Ibtn- SElQ VDDKFGTGTKKVTRILDGGNPFLDVPlQALSATTYKHGVLTRKTHADMDGKRTPRGRRGUK

SEG

Ibtn- EEEEEEEEEETTTEET— TTTCEE

SElQ KFYAVLKGTILYLiQKDEYRPDKALSEGDLKNAIRVHHALATRASDYSKKSNVLKLKTADU SEG

Ibtn- EEEEEEETTEEEEECCHHHHHHCCBTTT- TCCEETTTTEEEETTTTTCTTTEEEEETTTT

SElQ RVFLFlQAPSKEEMLSUILRINLVAAIFSAPAFPAAVSSMKKFCRPLLPSCTTRLCiQEEiQL

SEG xxxxxxxxxxxxxxx

Ibtn- CEEEEECCCHHHHHHHHHHHH

SElQ RSHENKLRlQLTAELAEHRCHPVERGIKSKEAEEYRLKEHYLTFEKSRYETYIHLLAMKIK SEG

Ibtn-

SElQ VGSDDLERIEARLATLEGDDPSLRKTHSSPALSlQGHVTGSKTTKDATGPDT

SEG

Ibtn-

(No Prosite data available for DKFZphamy2_14bS .2)

Pfam for DKFZphamy2_14bS- 2

HMM_NAME PH (pleckstrin homology) domain HMM

*dvIREGUMyKUgswrkstg nUqrRUFvLrndpnrLiYYkddk

+ ++G + +++ + ++ U++ ++VL++ + L++

KD+

(Query 512 TTYKHGVLTRKTHADMDGKRTPRGRRGUKKFYAVLKG-- TILYLtQKDE- 5S7

HMM dekPr YMlIdld . cUrMidVEidUmmdndHCFilUtrq . rtYYF

+P+ ++++ + ++D ++ +++ +++T + R+++F

(Query 5S8 -YRPDKALSEGDLKNAIRVHHALATRASDYSKK-

SNVLKLKTADURVFLF b05

HMM (QAeNeEEMmeUMsalrRalw* (QA+++EEM +U+ 1+ + +

(Query bOb (QAPSKEEMLSUILRINLVAA b2S DKFZphamy2_14mlb

group: transcription factors

DKFZphamy2_14mlb.pl encodes a novel 252 amino acid protein with similarity to the homeotic protein emx2 of mani mouse and zebra fish as well as to the gene "empty spiracles" of Drosophila melanogaster-

Homoeobox genes are known to play important roles in developmental processes- In zebrafish emx2 mRNAs are found in the dorsal telencephaloni parts of the diencephalon and the otocyst- The human homologue Emx2 appears to be already expressed in 8-5 day embryos- It is also expressed in the presumptive cerebral cortexi olfactory bulbsi in some neuroectodermal areas in embryonic head including olfactory placodes in earlier stages and olfactory epithelia later in development- Mutants of the D- melanogaster gene "mempty spiracles" display spiracles devoid of filzkorperi no antenna and an open head-

The new protein can find application in modulating the expression of genes controlled by this transcription factor and modulation of neuronal development. strong similarity to homeotic protein emx2 (Homo sapiens) perhaps differential splicing

Sequenced by EMBL

Locus: /chromosome="lD" Insert length: 241b bp

Poly A stretch at pos- 2316ι polyadenylation signal at pos- 2373

1 GAAAAAAAAA GAAAAAAAAA GAAAAAAAAT TACCCCAATC CACGCCTGCA SI AATTCTTCTG GAAGGATTTT CCCCCCTCTC TTCAGGTTGG GCGCGTTTGG

IDl TGCAAGATTC TCGGGATCCT CGGCTTTGCC TCTCCCTCTC CCTCCCCCCT

151 CCTTTCCTTT TTCCTTTCCT TTCCTTTCTT TCTTCCTTTC CTTCCCCCCA

2D1 CCCCCACCCC CACCCCAAAC AAACGAGTCC CCAATTCTCG TCCGTCCTCG

251 CCGCGGGCAG CGGGCGGCGG AGGCAGCGTG CGGCGGTCGC CAGGAGCTGG 301 GAGCCCAGGG CGCCCGCTCC TCGGCGCAGC ATGTTCCAGC CGGCGCCCAA

351 GCGCTGCTTC ACCATCGAGT CGCTGGTGGC CAAGGACAGT CCCCTGCCCG

401 CCTCGCGCTC CGAGGACCCC ATCCGTCCCG CGGCACTCAG CTACGCTAAC

451 TCCAGCCCCA TAAATCCGTT CCTCAACGGC TTCCACTCGG CCGCCGCCGC

501 CGCCGCCGGT AGGGGCGTCT ACTCCAACCC GGACTTGGTG TTCGCCGAGG S51 CGGTCTCGCA CCCGCCCAAC CCCGCCGTGC CAGTGCACCC GGTGCCGCCG bOl CCGCACGCCC TGGCCGCCCA CCCCCTACCC TCCTCGCACT CGCCACACCC bSl CCTATTCGCC TCGCAGCAGC GGGATCCGTC CACCTTCTAC CCCTGGCTCA

7D1 TCCACCGCTA CCGATATCTG GGTCATCGCT TCCAAGGGAA CGACACTAGC

751 CCCGAGAGTT TCCTTTTGCA CAACGCGCTG GCCCGAAAGC CCAAGCGGAT 601 CCGAACCGCC TTCTCCCCGT CCCAGCTTCT AAGGCTGGAA CACGCCTTTG

651 AGAAGAATCA CTACGTGGTG GGCGCCGAAA GGAAGCAGCT GGCACACAGC

IDl CTCAGCCTCA CGGAAACTCA GGTAAAAGTA TGGTTTCAGA ACCGAAGAAC

ISI AAAGTTCAAA AGGCAGAAGC TGGAGGAAGA AGGCTCAGAT TCGCAACAAA 1DD1 AGAAAAAAGG GACGCACCAT ATTAACCGGT GGAGAATCGC CACCAAGCAG

1DS1 GCGAGTCCGG AGGAAATAGA CGTGACCTCA GATGATTAAA AACATAAACC

11D1 TAACCCCACA GAAACGGACA ACATGGAGCA AAAGAGACAG GGAGAGGTGG

1151 AGAAGGAAAA AACCCTACAA AACAAAAACA AACCGCATAC ACGTTCACCG 12D1 AGAAAGGGAG AGGGAATCGG AGGGAGCAGC GGAATGCGGC GAAGACTCTG

1251 GACAGCGAGG GCACAGGGTC CCAAACCGAG GCCGCGCCAA GATGGCAGAG

1301 GATGGAGGCT CCTTCATCAA CAAGCGACCC TCGTCTAAAG AGGCAGCTGA

13S1 GTGAGAGACA CAGAGAGAAG GAGAAAGAGG GAGGGAGAGA GAGAAAGAGA

1401 GAGAAAGAGA GAGAGAGAGA GAGAGAAAGC TGAACGTGCA CTCTGACAAG 1451 GGGAGCTGTC AATCAAACAC CAAACCGGGG AGACAAGATG ATTGGCAGGT

1501 ATTCCGTTTA TCACAGTCCA CTTAAAAAAT GATGATGATG ATAAAAACCA

15S1 CGACCCAACC AGGCACAGGA CTTTTTTGTT TTTTGCACTT CGCTGTGTTT

IbOl CCCCCCCATC TTTAAAAATA ATTAGTAATA AAAAACAAAA ATTCCATATC lb51 TAGCCCCATC CCACACCTGT TTCAAATCCT TGAAATGCAT GTAGCAGTTG 1701 TTGGGCGAAT GGTGTTTAAA GACCGAAAAT GAATTGTAAT TTTCTTTTCC

17S1 TTTTAAAGAC AGGTTCTGTG TGCTTTTTAT TTTGATTTTT TTTCCCAAGA

1601 AATGTGCAGT CTGTAAACAC TTTTTGATAC CTTCTGATGT CAAAGTGATT

1651 GTGCAAGCTA AATGAAGTAG GCTCAGCGAT AGTGGTCCTC TTACAGAGAA

1101 ACGGGGAGCA GGACGACGGG GGGGCTGGGG GTGGCGGGGG AGGGTGCCCA 1151 CAAAAAGAAT CAGGACTTGT ACTGGGAAAA AAACCCCTAA ATTAATTATA

20D1 TTTCTTGGAC ATTCCCTTTC CTAACATCCT GAGGCTTAAA ACCCTGATGC

2051 AAACTTCTCC TTTCAGTGGT TGGAGAAATT GGCCGAGTTC AACCATTCAC

2101 TGCAATGCCT ATTCCAAACT TTAAATCTAT CTATTGCAAA ACCTGAAGGA

21S1 CTGTAGTTAG CGGGGATGAT GTTAAGTGTG GCCAAGCGCA CGGCGGCAAG 22D1 TTTTCAAGCA CTGAGTTTCT ATTCCAAGAT CATAGACTTA CTAAAGAGAG

2251 TGACAAATGC TTCCTTAATG TCTTCTATAC CAGAATGTAA ATATTTTTGT

2301 GTTTTGTGTT AATTTGTTAG AATTCTAACA CACTATATAC TTCCAAGAAG

2351 TATGTCAATG TCAATATTTT GTCAATAAAG ATTTATCAAT ATGCCCTCAC

2401 AAAAAAAAAA AAAAAA

BLAST alert EMBL/EMBLNEU

EMBLNEU:AL1333S3 Human DNA sequence *** SEQUENCING IN PROGRESS *** from clone RP11-483F1U N = 2ι Score = 3108ι P = 5-3e-134

EMBL:HSEMX2 H. sapiens EMX2 mRNAi N = li Score = 236Sι P = 5-le- IDl

Medline entries

12331b0b:

Simeone Ai Gulisano Mi Acampora Di Stornaiuolo Ai Rambaldi Mi

Boncinelli E- i

Two vertebrate homeobox genes related to the Drosophila empty spiracles gene are expressed in the embryonic cerebral cortex EMBO J

1112 Julill(7) :2541-50

Peptide information for frame 1 ORF from 331 bp to 106b bpi peptide length: 252

Category: questionable ORF

Classification: unset

Prosite motifs: HOMEOBOX 1 (167-210)

1 MFώPAPKRCF TIESLVAKDS PLPASRSEDP IRPAALSYAN SSPINPFLNG

51 FHSAAAAAAG RGVYSNPDLV FAEAVSHPPN PAVPVHPVPP PHALAAHPLP

IDl SSHSPHPLFA S(Q(QRDPSTFY PULIHRYRYL GHRFlQGNDTS PESFLLHNAL ISI ARKPKRIRTA FSPSlQLLRLE HAFEKNHYVV GAERKiQLAHS LSLTETlQVKV

2D1 UFiQNRRTKFK RiQKLEEEGSD S(Q(QKKKGTHH INRURIATKlQ ASPEEIDVTS

251 DD

Alert BLASTP hits for DKFZphamy2_14mlbι frame 1

PIR:I51737 homeotic protein emx2 - zebra fishi N = 2ι Score = 7S3ι P = le-105

PIR:S22722 homeotic protein emx2 - human (fragment)i N = li Score 7b3ι P = l-3e-7S TREMBL:0LA1324D3_1 gene: "emx2"i product: "Emx2 protein"i Oryzias latipes mRNA for Emx2 proteini partiali N = 2ι Score = 513ι P = 4-Se-72

>PIR:S22722 homeotic protein emx2 - human (fragment) Length = 158

HSPs:

Score = 7b3 (114-5 bits)ι Expect = l-3e-7Sι P = l-3e-7S Identities = 144/144 (100*)ι Positives = 144/144 (1DD*)

(Query: 101 FAS(Q(QRDPSTFYPULIHRYRYLGHRF(3GNDTSPESFLLHNALARKPKRIRTAFSPSfQLLR lb8

FAS(Q(QRDPSTFYPULIHRYRYLGHRF(3GNDTSPESFLLHNALARKPKRIRTAFSPS(QLLR Sbjct: IS FAS(3(QRDPSTFYPULIHRYRYLGHRF(QGNDTSPESFLLHNALARKPKRIRTAFSPS(QLLR 74

(Query: ibl LEHAFEKNHYVVGAERK(QLAHSLSLTET(QVKVUF(QNRRTKFKR(QKLEEEGSDS(Q(QKKKGT 226

LEHAFEKNHYVVGAERK(QLAHSLSLTET(QVKVUF(^QNRRTKFKR(QKLEEEGSDS(QιQKKKGT Sbjct: 75

LEHAFEKNHYVVGAERK(QLAHSLSLTET(QVKVUF(QNRRTKFKR(QKLEEEGSDS(Q(QKKKGT 134

(Query: 221 HHINRURIATKiQASPEEIDVTSDD 2S2 HHINRURIATKiQASPEEIDVTSDD Sbjct: 135 HHINRURIATKiQASPEEIDVTSDD 158

Pedant information for DKFZphamy2_14mlbι frame 1 Report for DKFZphamy2_14mlb .1

[LENGTH! 3b2

[MU! 40741-26

[pi! 10- SI

[H0M0L! PIR:IS1737 homeotic protein emx2 - zebra fish le-

113 [FUNCAT! 3D-10 nuclear organization [S cerevisiae-

YMLD27w! Se-DS

[FUNCAT! 04-11 other transcription activities [S cerevisiae i YMLO 27w! 5e- D5

[FUNCAT! 03- D7 pheromone re isponse i mating-type determinationi sex-specifie protei .ns [S - cerevisiae i YCRO 17w! Se- 04

[FUNCAT! 04.05-01 -04 transcriptional control [S- cerevisiae i YDL1 Obc! 7e- D4

[FUNCAT! 01-04-04 regulation of phosphate utilization [S. cerevisiaei YDLlObc! 7e-04

[FUNCAT! DI.03-13 regulation of nucleotide metabolism

[S. cerevisiaei YDLlObc! 7e-04

[BLOCKS! PR0D041D

[BLOCKS! PRD01D1H [BLOCKS! PR0D467F

[BLOCKS! PR0D71bG

[BLOCKS! BL0DD35C

[BLOCKS! BL0D027 'Homeobox' domain proteins

[BLOCKS! PRD0D2bA [BLOCKS! BL0D032C

[BLOCKS! BL0D032B 'Homeobox ' antennapedia-type protein

[SCOP! dlau7bl 1-4.1-l.b Pit-1 POU homeodomain Pit-1

Pit-1 [Rat (Rattu Se-lb

[SCOP! dlyrna_ 1-4-1.1-2 mating type protein Al Homeodomain mat alpha 2e -IS

[SCOP! dlenh 1-4- 1-1-1 engrailed Homeodomain

[(Drosophila mel anogaster 2e-13

[PIRKU! nucleus le-b7

[PIRKU! heart 3e -10 [PIRKU! DNA binding le-b7

[PIRKU! leukemia 3e-lS

[PIRKU! alternative splicing le-10

[PIRKU! proto-oncogene 3e- 15

[PIRKU! transcri ption factor be-11 [PIRKU! embryo 1e-12

[PIRKU! transcription regulation le-b7

[PIRKU! homeobox le-b7

[SUPFAM! homeobox homology le-b7

[SUPFAM! homeotic protein Hox AS 7e-10 [SUPFAM! homeotic protein Hox B3 3e-lD

[SUPFAM! homeotic protein Hox B2 3e-ll

[SUPFAM! homeotic protein Hox Bl 7e-ll

[SUPFAM! unassigned homeobox proteins le-b7

[SUPFAM! homeotic protein goosecoid 4e-10 [SUPFAM! homeotic protein Hox D4 1e-12

[PROSITE! HOMEOBOX. _1 1

[PFAM! Homeobox domain

[KU! Irregular [KU! 3D

[KU! LOU_COMPLEXITY 25 . bl *

SElQ

EKKRKKKKKNYPNPRLiQILLEGFSPLSSGUARLVlQDSRDPRLCLSLSLPPPFLFPFLSFL SEG

• xxxxxxxx xxxxxxxxxxxxxxxxx

If jlA

SElQ

SSFPSPHPHPHPK(QTSP(QFSSVLAAGSGRRR(3RAAVARSUEPRAPAPRRSMF(QPAPKRCF SEG xxxxxxxxxxxx xxxxxxxxxxxxxxxx

If jlA

SE(Q TIESLVAKDSPLPASRSEDPIRPAALSYANSSPINPFLNGFHSAAAAAAGRGVYSNPDLV SEG xxxxxx

If jlA

SE(Q

FAEAVSHPPNPAVPVHPVPPPHALAAHPLPSSHSPHPLFASiQiQRDPSTFYPULIHRYRYL

SEG

. • • • xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx IfjlA

SElQ

GHRFIQGNDTSPESFLLHNALARKPKRIRTAFSPSIQLLRLEHAFEKNHYVVGAERKIQLAHS SEG

If jlA CCCCCCCCCCHHHHHHHHHHHHHTTTTCHHHHHHHHHH SElQ

LSLTET(QVKVUF(QNRRTKFKR(QKLEEEGSDS(3<QKKKGTHHINRURIATK<QASPEEIDVTS SEG

If j lA HCCCHHHHHHHHHHHHHHHHHH

SElQ DD

SEG I f j l A

Prosite for DKFZphamy2_14mlb- 1 PSD0D27 217->321 H0ME0B0X_1 PD0C0D027

Pfam for DKFZphamy2_14mlb ■ 1 HMM_NAME Homeobox domai n

HMM *RRRpRTtFTre<QLdELEREFHf NrYPTRqRREELA(QmLNLTER(QVKIUF

+ R RT+F+ +IQL ++LE +F+ N + Y+ ++R + LA + + L+LTE + (QVK + UF (Query 2b4

PKRIRT AFSPS(QLLRLEHAFEKNHYVVGAERK(JLAHSLSLTET(QVKVUF 312

HMM iQNRRMKUKRMH*

IQNRR + K KR + (Query 313 (QNRRTKFKRiQK 323

DKFZphamy2_lbel4

group: amygdala derived

DKFZphamy2__lbel4 -p3 encodes a novel 328 amino acid proteini similar to carbonic anhydrase-related proteins-

A similar cDNA encoding a protein of the same length was identified in sheep- This protein shows a strong signal sequence! which indicates that it is a secreted protein- The new protein belongs to a protein familyi which was designated carbonic anhydrase-related protein XI (CA-RP XI)τ encoded by CA11 (human) and Carll (mousei rat). Despite potentially inactivating changes in the active-site residues! CA-RP XI is evolving very slowly in mammalsi a property indicative of an important function! which has also been observed in the two other "acatalytic" CA isoformsi CA-RP VIII and CA-RP X-

No informative BLAST resultsi No predictive prositei pfam or SCOP motife.

The new protein can find application in studying the expression profile of amygdala-specific genes-

similarity to carbonic anhydrase-related protein (Homo sapiens) ESTs ending at appr- 18DD have polyA-signal Sequenced by EMBL Locus: /map="17q24i 5-13cR from GATA41CDS" Insert length: 22b? bp

Poly A stretch at pos- 2252ι polyadenylation signal at pos- 2231

1 GGATGGAAAT AGTCTGGGAG GTGCTTTTTC TTCTTCAAGC CAATTTCATC SI GTCTGCATAT CAGCTCAACA GAATTCACCA AAAATCCATG AAGGCTGGTG

101 GGCATACAAG GAGGTGGTCC AGGGAAGCTT TGTTCCAGTT CCTTCTTTCT

151 GGGGATTGGT GAACTCAGCT TGGAATCTTT GCTCTGTGGG GAAACGGCAG

201 TCGCCAGTCA ACATAGAGAC CAGTCACATG ATCTTCGACC CCTTTCTGAC

251 ACCTCTTCGC ATCAACACGG GGGGCAGGAA GGTCAGTGGG ACCATGTACA 301 ACACTGGAAG ACACGTATCC CTTCGCCTGG ACAAGGAGCA CTTGGTCAAC

351 ATATCTGGAG GGCCCATGAC ATACAGCCAC CGGCTGGAGG AGATCCGACT

401 ACACTTTGGG AGTGAGGACA GCCAAGGGTC GGAGCACCTC CTCAATGGAC

451 AGGCCTTCTC TGGGGAGGTG CAGCTCATCC ACTATAACCA TGAGCTATAT

S01 ACGAATGTCA CAGAAGCTGC AAAGAGTCCA AATGGATTGG TGGTAGTTTC SSI TATATTTATA AAAGTTTCTG ATTCATCAAA CCCATTTCTT AATCGAATGC bOl TCAACAGAGA TACTATCACA AGAATAACAT ATAAAAATGA TGCATATTTA bSl CTACAGGGGC TTAATATAGA GGAACTATAT CCAGAGACCT CTAGTTTCAT

701 CACTTATGAT GGGTCGATGA CTATCCCACC CTGCTATGAG ACAGCAAGTT

751 GGATCATAAT GAACAAACCT GTCTATATAA CCAGGATGCA GATGCATTCC 801 TTGCGCCTGC TCAGCCAGAA CCAGCCATCT CAGATCTTTC TGAGCATGAG

651 TGACAACTTC AGGCCTGTCC AGCCACTCAA CAACCGCTGC ATCCGCACCA

101 ATATCAACTT CAGTTTACAG GGGAAGGACT GTCCAAACAA CCGAGCCCAG

151 AAGCTTCAGT ATAGAGTAAA TGAATGGCTC CTCAAGTAGG GAACAAAGCC 10D1 AAGAAGAATC CCACCTCAGT GAAATGCTAC AACTGTGAAT TGACGTAACC

1051 TAGAATGTCC CCCTTCTTGC TTCTCTCTCC TTCTTTCCCC CAAGCCTCAT

11D1 TCATTCTTGG GATTGGCCCT TTCTTCATGA AAAGTGTCTG CAAAACCATG

1151 GCAGAGGAAT ACATCTCTCA CACATACTCA CAAACACACA CACAAGCACT 1201 TGCACATACA TACAAACACA TGCAAACATA CCTACACACA CACACACTCT

1251 TACAACCTCC ATCATGGGAA GTCAAGTTTC AGAAACAAAA GTCTCATTCA

1301 TAAGAGGTCT TAGAAGAAAA TAACCAGTTA ACCTGATTTC AATTTTGATA

1351 CCGTTTTCCT GAACTAATAA ATCTACCCAA TGAGACTTTT CAGCCTTTGT

14D1 ACATACAAAA TTCTTCCAAA AGAGAGAGGA GAAAATACAG CTCTGATGGC 1451 ATCAAACGGA CTTTGCATCA AGTAATTTCA GATAGTGTCC TAGGATCCTT

1501 TGAGGGTGCT GGTAGCAGGT GAGCAGGACA AAGTTGACCA AGGACACTTA

15S1 TTTCTAGATT ATGATTCTTC TGTTTACTCA ACAATTTACA AAGAAAAAAA

IbOl GGACAGACAT TGAAGAGCTA CACATTGTAT ATATATCACC ACAGACTATA

IbSl AGGAAATGGA ATTATTTCCC TCTTTGTCAC ATATCTGTAG TAGGATTTGC 1701 CAAGATCAGA AATGATCCAT TTGCTGTTTC TTGTTTTCCA AAGGTCATAC

1751 ATTGTGTTTG GTTATTGTTA CCAGCTCAAT AAATGTGTTT AACGAGTTAA

1601 TTTCATTTTT CTGGCTTTGG TCTGTTCTCC TTCCTTACAG GCTAAGCCCT

1651 GGCTCCATGC AACTGCATTC TTTGATTTCA CTTGTTCCTT CATCTACATG

1101 TTTTGTTCAT TTGCAGCCAG TTTTTACTGA GTTTGTGGCA ATCAGGAATG 1151 CATTTGCTAA GCAAGTATGA CTTTAATTCC ACTCCATGGC TCAATCATTC

20D1 ACATGAGGTG AGCTTCAGCC TGAGATAGCA GGCGACAGAC TTCTTGCGTT

2051 TCAAAACTGC CATGCCCCCC TGTGATGCTC CCGTGAAGGA ATGCACTTTG

2101 CCTTGTAAGT TCCTGGGAAA GGGGTATGTT TTCTCTCCAG GTGCAGCCAG

21S1 ATCTCACAAA GTACAAAACG AATGCCTTTC TTTTCTTGTT TATAATGGTC 22D1 ACTCACTGTG TTTGGTTACT GTCAAGAAAT CAATAAATGT GTTTAACAAG

2251 TCAAAAAAAA AAAAAAA

BLAST alert EMBL/EMBLNEU

EMBL:AF0b4654 Homo sapiens map 17q24i 5-13cR from GATA41C05 repeat regioni complete sequence- i N = 2ι Score = 6764ι P = D

EMBLNEU:AC005683 Homo sapiens chromosome 17 clone RP11-158E11 map

17ι

UORKING DRAFT SEiQUENCEi 2 ordered pieces- i N = 3ι Score = b2b0ι P

= 0

Medline entries

1017341: Lovejoy DAi Hewett-Emmett Di Porter CAi Cepoi Di Sheffield Ai

Tashian RE-i Evolutionarily conserved! "acatalytic" carbonic anhydrase-related protein XI contains a sequence motif present in the neuropeptide sauvagine: the human

CA-RP XI gene (CA11) is embedded between the secretor gene cluster and the DBP gene at 11ql3-3. Genomics 1118 Dec 15iS4 (3) : 484-1 Peptide information for frame 3

ORF from 0 bp to 18b bpi peptide length: 321 Category: similarity to known protein Classification: unclassified

1 MEIVUEVLFL LiQANFIVCIS A(3(QNSPKIHE GUUAYKE VlQ GSFVPVPSFU 51 GLVNSAUNLC SVGKRiQSPVN IETSHMIFDP FLTPLRINTG GRKVSGTMYN

IDl TGRHVSLRLD KEHLVNISGG PMTYSHRLEE IRLHFGSEDS (QGSEHLLNGiQ

151 AFSGEVlQLIH YNHELYTNVT EAAKSPNGLV VVSIFIKVSD SSNPFLNRML

2D1 NRDTITRITY KNDAYLLtQGL NIEELYPETS SFITYDGSMT IPPCYETASU

251 IIMNKPVYIT RMiQMHSLRLL S(QN(QPS(QIFL SMSDNFRPViQ PLNNRCIRTN 301 INFSLtQGKDC PNNRAtQKLiQY RVNEULLK

Alert BLASTP hits for DKFZphamy2_lbel4ι frame 3 PIR:JED375 carbonic anhydrase-related protein - humani N = li Score = 137ι P = 4-be-14

SUISSNEU:CAHB_SHEEP CARBONIC ANHYDRASE-RELATED PROTEIN 2 PRECURSOR

(CARP 2) (CA-RP II) (CA-XD-i N = li Score = 13Sι P = 7-5e-14

>PIR:JE037S carbonic anhydrase-related protein - human Length = 328

HSPs:

Score = 137 (140-b bits)ι Expect = 4-be-14ι P = 4-be-14 Identities = lbl/267 (5β*)ι Positives = 223/287 (77*) fluery: 3D

EGUUAYKEVViQGSFVPVPSFUGLVNSAUNLCSVGKRtQSPVNIETSHMIFDPFLTPLRINT 81 E UU+YK+ +IQG+FVP P FUGLVN+AU+LC+VGKR(QSPV++E +++DPFL PLR++T Sbjct: 32 EDUUSYKDNLlQGNFVPGPPFUGLVNAAUSLCAVGKRlQSPVDVEVKRVLYDPFLPPLRLST 11 fluery: ID GGRKVSGTMYNTGRHVSLRLDKEHLVNISGGPMTYSHRLEEIRLHFGSEDSiQGSEHLLNG 141

GG K+ GT+YNTGRHVS +VN+SGGP+ YSHRL E+RL FG+ D

GSEH +N

Sbjct: 12

GGEKLRGTLYNTGRHVSFLPAPRPVVNVSGGPLLYSHRLSELRLLFGARDGAGSEHtQINH ISI

(Query: 150

(QAFSGEVώLIHYNHELYTNVTEAAKSPNGLVVVSIFIKVSDSSNPFLNRMLNRDTITRIT 201 Q FS EV<QLIH + N ELY N + A + + PNGL + + S+F+ V +

+SNPFL+R+LNRDTITRI+ Sb j ct : 152

(QGFSAEViQLIHFNiQELYGNFSAASRGPNGLAILSLFVNVASTSNPFLSRLLNRDTITRIS 211 (Query : 21D

YKNDAYLL(QGLNIEELYPETSSFITYDGSMTIPPCYETASUIIMNKPVYITRM(3MHSLRL 2b1 YKNDAY Lfl L++E L+PE+ FITY GS++ PPC ET +UI++++ + IT + (QMHSLRL Sb j ct : 212

YKNDAYFLlQDLSLELLFPESFGFITYiQGSLSTPPCSETVTUILIDRALNITSLlQMHSLRL 271

(Query : 270 LS(QN(QPS(QIFLSMSDNFRPV(3PLNNRCIRTNINFSL(3GKDC-- PNNR 314 LSlQN PSlQIF S + S N RP + (QPL +R +R N + + C PN R Sb jct : 272 LS(QNPPS(3IF(QSLSGNSRPL(QPLAHRALRGNRDPRHPERRCRGPNYR 316

Pedant inf ormati on f or DKFZphamy2_lbel4 ι f rame 3

Report f or DKFZphamy2_lbel4 - 3

[LENGTH! 328

[MU! 375b3 . 11 [pi! 8 - 22

[HOMOL! PIR : J E037S carboni c anhydrase-rel ated prote i n - human le-lDl

[BLOCKS! DM011D1B

[BLOCKS! BL0Dlb2F [BLOCKS! BL0Dlb2E

[BLOCKS! BL0Dlb2D

[BLOCKS! BL0Dlb2C Eukaryotic-type carbonic anhydrases proteins

[BLOCKS! BL001b2A Eukaryotic-type carbonic anhydrases proteins

[SCOP! dlznca_ 2.5b-l.l-3 Carbonic anhydrase [human

(Homo sapiens le-103

[SCOP! d2cba 2-Sb.l.l.2 Carbonic anhydrase [human

(Homo sapiens 1e-17 [EC! 4.2-1-1 Carbonate dehydratase le-3b

[EC! 3-1.3-46 Protein-tyrosine-phosphatase 2e-2D

[PIRKU! blocked amino end 8e-21

[PIRKU! carbon-oxygen lyase le-3b

[PIRKU! zinc le-3b [PIRKU! polymorphism 2e-20

[PIRKU! hydro-lyase le-3b

[PIRKU! transmembrane protein 3e-23

[PIRKU! tyrosine-specific phosphatase 2e-2D

[PIRKU! brain be-lb [PIRKU! acetylated amino end le-3b

[PIRKU! phosphatidylinositol linkage 2e-11

[PIRKU! receptor 2e-20

[PIRKU! liver 3e-21

[PIRKU! phosphoprotein 2e-2D [PIRKU! saliva 2e-21

[PIRKU! glycoprotein 2e-22

[PIRKU! mitochondrion le-32

[PIRKU! monomer 3e-32

[PIRKU! alternative splicing be-lb [PIRKU! lipoprotein 2e-11

[PIRKU! pyroglutamic acid 2e-21

[PIRKU! metalloprotein be-35

[PIRKU! muscle 4e-31 [PIRKU! membrane protein 2e-11

[PIRKU! phosphoric monoester hydrolase 2e-20

[PIRKU! homodimer 3e-23

[SUPFAM! fibronectin type III repeat homology 2e-2D

[SUPFAM! carbonic anhydrase homology le-3b

[SUPFAM! protein-tyrosine-phosphatasei receptor type zeta be-lb

[SUPFAM! carbonate dehydratase le-3b

[SUPFAM! protein-tyrosine-phosphatasei receptor type gamma

2e-20

[SUPFAM! protein-tyrosine-phosphatase homology 2e-2D

[SUPFAM! leukocyte common antigen cytosolic domain homology 2e-2D

[PFAM! Eukaryotic-type carbonic anhydrases

[KU! All_Beta

[KU! 3D

[KU! SIGNAL_PEPTIDE 22

SElQ

MEIVUEVLFLL(3ANFIVCISA<Q(QNSPKIHEGUUAYKEVV(QGSFVPVPSFUGLVNSAUNLC lugc-

SElQ

SVGKRiQSPVNIETSHMIFDPFLTPLRINTGGRKVSGTMYNTGRHVSLRLDKEHLVNISGG luge- - . TTTTCCCEETTTTTEETTTTCEEEEETT- TTCEEEEEETTTTEEEEECTTTTTEEEEE SElQ

PMTYSHRLEEIRLHFGSEDSiQGSEHLLNGlQAFSGEVlQLIHYNHELYTNVTEAAKSPNGLV luge- TTCCCEEEEEEEEEETTTTTTCTTTEETTBCCCEEEEEEEEEGG- GTTHHHHHCTTTTEE SElQ

VVSIFIKVSDSSNPFLNRMLNRDTITRITYKNDAYLLiQGLNIEELYPETSSFITYDGSMT luge- EEEEEEEEC-CCCGGGHHHH-- HHGGGCCTTTEEEETTTTCGGGGCCCCCCEEEEEECCC SElQ

IPPCYETASUIIMNKPVYITRM(QMHSLRLLS(QN(QPS(QIFLSMSDNFRPV(QPLNNRCIRTN lugc-

TTTTCCCEEEEEECCCEEECHHHHHHHHCCBCCTTTTCCCBTTTTCCCCCCTTTTCCEEC SElQ INFSLiQGKDCPNNRAlQKLiQYRVNEULLK luge-

(No Prosite data available for DKFZphamy2_lbel4 -3)

Pfam for DKFZphamy2_lbel4 -3

HMM NAME Eukaryotic-type carbonic anhydrases

HMM

*UCYgeHUGPEHH UHkhYPIAU. GDR(QSPINI(QUkearYDPS U Y E + U +++ + + G R(QSP + NI + +

+ DP

(Query 33

UAYKEVViQGSFVPVPSFUGLVNSAUNLCSVGKRiQSPVNIETSHMIFDPF 61

HMM LKPUrv - SYYpaUCrEUelUNNGHSFiQVeFDDSMDMSVLsGGPLPgHPYR

L P+R+ ++ ++++ ++ N+G+ + +D +SGGP++

+ + R (Query 62 LTPLRINTGGRKVSG — TMYNTGRHVSLRLDK-

EHLVNISGGPMTY-SHR 127

HMM

Lk(QFHFHUGGASsNDUGSEHTVDGmkYPMELHLVHUNStKYnNYdEA(Qdq L + ++H G S++ +GSEH ++G +++ E+ L+H+N +Y N+

EA + +

(Query 126 LEEIRLHFG--

SEDS(QGSEHLLNG(QAFSGEV(QLIHYNHELYTNVTEAAKS 175 HMM

PDGLAVIGVFMKVGNYqENPyLiQKVv. - DALdnlKYKGKratMTNFDPsC

P+GL V+ +F+KV NP L++ + D + I YK + +++++

(Query 17b PNGLVVVSIFIKVS- DSSNPFLNRMLNRDTITRITYKNDAYLLiQGLNIEE 224

HMM LLPpPnCRDYUTYPGSLTTPPChECVTUIVCKEPIsISsE(QMUKFRsLLF

L P+ + TY GS+T+PPC+E UI+ P+ I + (QM +R L

(Query 225 LYPE--

TSSFITYDGSMTIPPCYETASUIIMNKPVYITRM(QMHSLRLLS(Q 272

HMM NhEGEeeVpMVDNURPPiQPLKhRvVRASF* N +M DN+RP (QPL++R +R +

(Query 273 N(QPS(QIFLSMSDNFRPV(QPLNNRCIRTNI 3D1

DKFZphamy2_lcl2

group: nucleic acid management

DKFZphamy2_lcl2 encodes a novel 422 amino acid protein with partial identity to I-kappa-B-related protein and to BRCAl- I-kappa-B-related protein interacts with transcription factors and BRCAl has a function in DNA damage response- I-kappa-B-alpha mutations contribute to constitutive NF-kappaB activity in cultured and primary HRS (Hodgkin/Reed-Sternberg) cells and are therefore involved in the pathogenesis of Hodgkin's disease (HD) patients.

The new protein can find application in modulating DNA repair and mutagenesis and also in expression profiling in HD related syndro s-

similarity to I-kappa-B-related protein

Sequenced by MediGenomix

Locus: unknown

Insert length: lb4S bp

Poly A stretch at pos- lb2bι polyadenylation signal at pos. IbOS

1 GGATTTTCCT TGGTCTTAAG ATGGGTAGAA ATGTGATGCG ACACATGTCT

SI GATGACTTAG GAAGTTATGT TTCTCTTTCG TGTGATGACT TTTCTTCACA

IDl GGAATTAGAG ATTTTCATTT GCTCCTTTTC CTCCTCCTGG CTTCAAATGT ISI TTGTTGCAGA GGCAGTCTTT AAAAAGTTGT GTCTACAGAG CTCTGGCAGT

201 GTTTCTTCTG AGCCACTCTC TCTTCAGAAA ATGGTATATT CCTATTTACC

251 AGCCTTGGGG AAAACTGGTG TGCTTGGGTC TGGAAAGATT CAGGTGTCAA

301 AGAAAATAGG ACAGCGGCCT TGTTTTGACT CTCAGAGAAC CTTACTAATG

351 CTGAATGGTA CTAAACAAAA ACAAGTCGAA GGGCTGCCAG AGTTACTAGA 401 CCTGAACCTT GCTAAATGTT CCTCATCATT AAAAAAATTG AAAAAGAAGT

451 CAGAAGGAGA ATTGTCATGT TCCAAGGAGA ATTGCCCCTC TGTAGTTAAA

SD1 AAGATGAATT TTCACAAGAC TAATCTAAAA GGAGAAACAG CCCTGCATAG

551 AGCTTGCATA AATAACCAAG TGGAGAAATT GATTCTTCTT CTCTCTTTGC bOl CAGGAATAGA CATCAATGTT AAAGACAATG CTGGCTGGAC GCCTTTGCAT b51 GAAGCCTGTA ACTATGGCAA CACAGTGTGT GTCCAGGAAA TTTTGCAACG

7D1 TTGTCCAGAG GTAGATCTGC TCACTCAAGT GGACGGGGTG ACTCCTTTGC

7S1 ATGATGCACT GTCAAACGGA CATGTAGAAA TTGGCAAGCT GCTACTACAG

801 CATGGGGGCC CAGTGCTTTT ACAACAGAGG AATGCTAAGG GAGAATTGCC

851 CTTGGATTAT GTGGTTTCAC CTCAAATCAA AGAAGAACTG TTTGCTATTA 101 CAAAAATAGA AGATACAGTG GAGAACTTTC ATGCACAAGC AGAGAAACAT

151 TTTCATTACC AGCAACTTGA ATTTGGCTCC TTTTTACTTA GTAGGATGTT

10D1 GCTAAATTTT TGTTCAATTT TTGATTTATC TTCAGAGTTC ATTTTAGCTT

1051 CCAAAGGGTT AACTCATCTA AATGAACTGC TTATGGCTTG TAAAAGTCAT

1101 AAAGAAACCA CCAGTGTTCA TACTGACTGG TTACTGGATC TTTATGCTGG 1151 AAATATAAAG ACATTGCAGA AACTCCCACA CATTCTTAAG GAACTGCCTG

1201 AGAATTTGAA AGTGTGTCCT GGGGTACACA CTGAGGCCTT GATGATAACA

1251 TTGGAAATGA TGTGTCGGTC AGTCATGGAG TTTTCATGAT GATGCTAGAA

13D1 AGTATGGATT GACTTTCTAA ATCTGTTCAG TTTGCATTGG TACTTACTGT 1351 GGACTTCATA GCTTACTGAC AGATAGTAAT TTGATTTATT TATTGACAGA

1401 CTTTGCAGCC TTGCTAAATT TTAAAAGCAT TTTTAAAAAA ACTTCTACAA

1451 AACTCTAGTA TGGGCTTCTG ACTTTTTCCA GGGTGTAGAA TTTGACTCAA

1S01 AAGTAAAAAT AATTTTGTTT TAGTATATTC TACTTTCATT AATGTTTTTT

15S1 TGTTCTGAAA GTGATATTAT ATTGTACATG TAAAATTAAT TTAAATATTT

IbOl TTTCAAATAA AAATGTAATG TCCTGTAAAA AAAAAAAAAA AAAAA

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 3

ORF from 21 bp to 126b bpi peptide length: 422 Category: similarity to known protein Classification: Cell signaling/communication

1 MGRNVMRHMS DDLGSYVSLS CDDFSSOELE IFICSFSSSU LώMFVAEAVF 51 KKLCLiQSSGS VSSEPLSLfQK MVYSYLPALG KTGVLGSGKI (QVSKKIGlQRP

101 CFDSlQRTLLM LNGTK<QK(QVE GLPELLDLNL AKCSSSLKKL KKKSEGELSC

151 SKENCPSVVK KMNFHKTNLK GETALHRACI NNiQVEKLILL LSLPGIDINV

201 KDNAGUTPLH EACNYGNTVC VώEILiQRCPE VDLLTlQVDGV TPLHDALSNG

251 HVEIGKLLLtQ HGGPVLL(Q(QR NAKGELPLDY VVSPώlKEEL FAITKIEDTV 301 ENFHAlQAEKH FHY(Q(QLEFGS FLLSRMLLNF CSIFDLSSEF ILASKGLTHL

351 NELLMACKSH KETTSVHTDU LLDLYAGNIK TLtQKLPHILK ELPENLKVCP

401 GVHTEALMIT LEMMCRSVME FS

BLASTP hits

No BLASTP hits available Alert BLASTP hits for DKFZphamy2_lcl2ι frame 3

PIR:ASb421 I-kappa-B-related protein - humani N = li Score = 242ι

P =

4-be-lδ

TREMBLNEU:AF036D42_1 gene: "BARDl"i product: "BRCAl-associated

RING domain protein"i Homo sapiens BRCAl-associated RING domain protein (BARD1) gene-, exons 10ι 11 and complete cds-i N = li Score = 23bι

P = b-le-17 >PIR:A5b421 I-kappa-B-related protein - human Length = 481 HSPs:

Score = 242 (3b-3 bits)τ Expect = 4-be-lδι P = 4-be-lδ Identities = 52/116 (44*)ι Positives = 71/llδ (b0*) (Query: 15b

PSVVKKMNFHKTNLKGETALHRACINNiQVEKLILLLSLPGIDINVKDNAGUTPLHEACNY 215 P K + + + N GET LHRACI (Q+ ++ L+ G +N +D

GUTPLHEACNY

Sbjct: 354 PGAAKGSKUNRRNDMGETLLHRACIEG(QLRRV(QDLVR- (QGHPLNPRDYCGUTPLHEACNY 412

(Query: 21b GNTVCVIQEILIQRCPEVDLL-- T(QVDGVTPLHDALSNGHVEIGKLLL(QHGGPVLL(Q(QRNA 272

G+ V+ +L VD +G+TPLHDAL+ GH E+ +LLL+ G V L+ R A

Sbjct: 413 GHLEIVRFLLDHGAAVDDPGGώGCEGITPLHDALNCGHFEVAELLLERGASVTLRTRKA 471

Pedant information for DKFZphamy2_lcl2ι frame 3

Report for DKFZphamy2_lcl2-3

[LENGTH! 422

[MU! 47071-16

[pi! b-57

[HOMOL! PIR:A5b421 I-kappa-B-related protein - human 3e-11

[FUNCAT! 11 unclassified proteins [S- cerevisiaei YIL112w!

3e-ll

[FUNCAT! Ob-13-01 cytoplasmic degradation [S- cerevisiaei

YGR232w! 4e-0b [FUNCAT! 30-1D nuclear organization [S- cerevisiaei YIR033w!

2e-D4

[FUNCAT! 04-D5-01-D7 chromatin modification [S- cerevisiae!

YIR033w! 2e-D4

[SCOP! dlawcb_ 1-11-3-1-2 GA binding protein (GABP) alpha GA bindini be-24

[EC! 3-1-3-53 Myosin-light-chain-phosphatase 1e-Db

[PIRKU! phosphotransferase 3e-D7

[PIRKU! tandem repeat le-Ob

[PIRKU! transmembrane protein 7e-10 [PIRKU! serine/threonine-specific protein kinase 3e-07

[PIRKU! phosphoprotein 3e-lD

[PIRKU! integrin binding 3e-07

[PIRKU! alternative splicing 3e-ll

[PIRKU! peripheral membrane protein 2e-01 [PIRKU! transcription regulation 3e-0b

[PIRKU! phosphoric monoester hydrolase le-Ob

[PIRKU! cytoskeleton 4e-10

[PIRKU! smooth muscle le-Ob [SUPFAM! ankyrin 3e-ll

[SUPFAM! ankyrin repeat homology 3e-ll

[SUPFAM! unassigned ankyrin repeat proteins 7e-10

[PFAM! Ank repeat

[KU! Irregular

[KU! 3D

[KU! LOU COMPLEXITY 6-53 *

SElQ MGRNVMRHMSDDLGSYVSLSCDDFSSlQELEIFICSFSSSULlQMFVAEAVFKKLCLiQSSGS SEG xxxxxx lawcB

SElQ VSSEPLSLlQKMVYSYLPALGKTGVLGSGKIiQVSKKIGiQRPCFDSlQRTLLMLNGTKiQKlQVE SEG xxxxxxxx lawcB

SElQ GLPELLDLNLAKCSSSLKKLKKKSEGELSCSKENCPSVVKKMNFHKTNLKGETALHRACI SEG xxxxxxxxxxxxxxxxxxxxxx lawcB

SE(Q NN(QVEKLILLLSLPGIDINVKDNAGUTPLHEACNYGNTVCV(QEIL3RCPEVDLLT(QVDGV

SEG lawcB TTTTCCHHHHHHHHCCHHHHHHHHHCCCTTTTCTTTTC- SEύ TPLHDALSNGHVEIGKLLL(QHGGPVLL(Q(QRNAKGELPLDYVVSP(QIKEELFAITKIEDTV

SEG lawcB

CHHHHHHHHTTHHHHHHHHHCCCTT SElQ ENFHAIQAEKHFHYIQIQLEFGSFLLSRMLLNFCSIFDLSSEFILASKGLTHLNELLMACKSH SEG lawcB

SElQ KETTSVHTDULLDLYAGNIKTLIQKLPHILKELPENLKVCPGVHTEALMITLEMMCRSVME SEG lawcB

SEiQ FS SEG lawcB

(No Prosite data available for DKFZphamy2_lcl2 -3)

Pfam for DKFZphamy2_lcl2 - 3

HMM_NAME Ank repeat

HMM *GyTPLHIAARyNNvEMVrlLL(QH-GADIN* G+T+LH A+++N+VE LLL+ G DIN

(Query 171 GETALHRACINNlQVEKLILLLSLPGIDIN 111

34-46 (bits) f: 20S t: 232 Target: dkfzphamy2_lcl2- 3 similarity to I-kappa-B-related protein

Alignment to HMM consensus: (Query *GyTPLHIAARyNNvEMVrlLL(3HGADIN*

G+TPLH A+ Y+N+ +V+ L(Q+ + ++ dkfzphamy2 205 GUTPLHEACNYGNTVCV(QEIL(QRCPEVD 232

(Query f: 231 t: 2bb Target: dkfzphamy2_lcl2-3 similarity to I-kappa-B-related protein Alignment to HMM consensus:

HMM *GyTPLHIAARyNNvEMVrlLL(QHGADIN* G TPLH A +++VE+ +LLL(QHG +

(Query 231 GVTPLHDALSNGHVEIGKLLLlQHGGPVL 2bb DKFZphamy2_lil

group: nucleic acid management

DKFZphamy2_lil encodes a novel b21 amino acidprotein with similarity to the murine hemin-sensitive initiation factor 2-

The hemin-sensitive initiation factor 2 is expressed predominantly in liveri spleeni colon and uterus and contains 2 protein kinase motifs- The mouse homologue inhibits protein synthesis in stress conditions by phosphorylation of eif-2-alpha. Four different eIF2alpha kinases have been identified in mammalian cellsi the he e-regulated inhibitor (HRI)ι the interferon-inducible RNA-dependent kinase (PKR)ι the endoplasmic reticulum-resident kinase (PERK) and MGCN2- The new protein represents a new member of this family

The new protein can find application in modulating/blocking of translation •

similarity to hemin-sensitive initiation factor 2 (Mus musculus)ι complete eds. alpha kinase complete eds- probably complete in genomic clone DJ0042MD2

Sequenced by MediGenomix

Locus: /map="37.H cR from top of Chr7 linkage group"

Insert length: 26b3 bp

Poly A stretch at pos- 2844ι polyadenylation signal at pos- 2824

1 GCAGTGCTGG GCTGGCCGGC GGGCTGGGCT GCGGCCCGCG CGCGGCCGGC

SI GATGCAGGGG GGCAACTCCG GGGTCCGCAA GCGCGAAGAG GAGGGCGACG

101 GGGCTGGGGC TGTGGCTGCG CCGCCGGCCA TCGACTTTCC CGCCGAGGGC

151 CCGGACCCCG AATATGACGA ATCTGATGTT CCAGCAGAAA TCCAGGTGTT 2D1 AAAAGAACCC CTACAACAGC CAACCTTCCC TTTTGCAGTT GCAAACCAAC

251 TCTTGCTGGT TTCTTTGCTG GAGCACTTGA GCCACGTGCA TGAACCAAAC

301 CCACTTCGTT CAAGACAGGT GTTTAAGCTA CTTTGCCAGA CGTTTATCAA

351 AATGGGGCTG CTGTCTTCTT TCACTTGTAG TGACGAGTTT AGCTCATTGA 4D1 GACTACATCA CAACAGAGCT ATTACTCACT TAATGAGGTC TGCTAAAGAG

451 AGAGTTCGTC AGGATCCTTG TGAGGATATT TCTCGTATCC AGAAAATCAG

SOI ATCAAGGGAA GTAGCCTTGG AAGCACAAAC TTCACGTTAC TTAAATGAAT

551 TTGAAGAACT TGCCATCTTA GGAAAAGGTG GATACGGAAG AGTATACAAG bOl GTCAGGAATA AATTAGATGG TCAGTATTAT GCAATAAAAA AAATCCTGAT b51 TAAGGGTGCA ACTAAAACAG TTTGCATGAA GGTCCTACGG GAAGTGAAGG

701 TGCTGGCAGG TCTTCAGCAC CCCAATATTG TTGGCTATCA CACCGCGTGG

751 ATAGAACATG TTCATGTGAT TCAGCCACGA GACAGAGCTG CCATTGAGTT

601 GCCATCTCTG GAAGTGCTCT CCGACCAGGA AGAGGACAGA GAGCAATGTG

651 GTGTTAAAAA TGATGAAAGT AGCAGCTCAT CCATTATCTT TGCTGAGCCC 101 ACCCCAGAAA AAGAAAAACG CTTTGGAGAA TCTGACACTG AAAATCAGAA

151 TAACAAGTCG GTGAAGTACA CCACCAATTT AGTCATAAGA GAATCTGGTG

1D01 AACTTGAGTC GACCCTGGAG CTCCAGGAAA ATGGCTTGGC TGGTTTGTCT

1051 GCCAGTTCAA TTGTGGAACA GCAGCTGCCA CTCAGGCGTA ATTCCCACCT

1101 AGAGGAGAGT TTCACATCCA CCGAAGAATC TTCCGAAGAA AATGTCAACT 1151 TTTTGGGTCA GACAGAGGCA CAGTACCACC TGATGCTGCA CATCCAGATG

1201 CAGCTGTGTG AGCTCTCGCT GTGGGATTGG ATAGTCGAGA GAAACAAGCG

12S1 GGGCCGGGAG TATGTGGACG AGTCTGCCTG TCCTTATGTT ATGGCCAATG

13D1 TTGCAACAAA AATTTTTCAA GAATTGGTAG AAGGTGTGTT TTACATACAT

1351 AACATGGGAA TTGTGCACCG AGATCTGAAG CCAAGAAATA TTTTTCTTCA 1401 TGGCCCTGAT CAGCAAGTAA AAATAGGAGA CTTTGGTCTG GCCTGCACAG

1451 ACATCCTACA GAAGAACACA GACTGGACCA ACAGAAACGG GAAGAGAACA

1501 CCAACACATA CGTCCAGAGT GGGTACTTGT CTGTACGCTT CACCCGAACA

15S1 GTTGGAAGGA TCTGAGTATG ATGCCAAGTC AGATATGTAC AGCTTGGGTG

IbOl TGGTCCTGCT AGAGCTCTTT CAGCCGTTTG GAACAGAAAT GGAGCGAGCA IbSl GAAGTTCTAA CAGGTTTAAG AACTGGTCAG TTGCCGGAAT CCCTCCGTAA

17D1 AAGGTGTCCA GTGCAAGCCA AGTATATCCA GCACTTAACG AGAAGGAACT

17S1 CATCGCAGAG ACCATCTGCC ATTCAGCTGC TGCAGAGTGA ACTTTTCCAA

1601 AATTCTGGAA ATGTTAACCT CACCCTACAG ATGAAGATAA TAGAGCAAGA

1651 AAAAGAAATT GCAGAACTAA AGAAGCAGCT AAACCTCCTT TCTCAAGACA 1101 AAGGGGTGAG GGATGACGGA AAGGATGGGG GCGTGGGATG AAAGTGGACT

1151 TAACTTTTAA GGTAGTTAAC TGGAATGTAA ATTTTTAATC TTTATTAGGG

20D1 TATAGTTGGT ACAATGCTTC GTTGTATTTA GTAAGCCTTT ACAAGACTTG

2D51 TTAAAGATGT CAGAGTGCCC CAAGCTGCCG TTCCTTCCCT TCCTGCCCCA

2101 CAAGCTCCTT TTCCTGAATT TCCTACCTAA ATATTAACCA TATGCCTAGT 21S1 CTCTGAAACT AAAAACTTGG ACCTCATCCT CAATTATTTT CTCCTTTCAA

22D1 CTCTGTTGAC CCTCTGTCTG GTCTTCCTCT AGAAGGTTCT ACCGCAGAAA

2251 TTGATGTGTG CTCCCTGCCC TCGTCACTGC CCAAGCCCGG GCCTGCACAT

2301 ACTCACTGGA CTGTTCCAGT TTTGACAGCT GCCAGTCTTC CTGCCCCTTT

2351 CACACTGCAG CTGAAGTTCA TTACCTGAAG GACGCCTCAT CATTTCATTC 2401 CTTGGCTCCA AACCTTCTGC TGCCTCTAAG ATAAAAGCTC AACTTCTTAA

2451 CAGTGTACAG TGTGCAACTT CCAACCTTTT TATCTGTTCT CTCCACCTTC

2S01 AGTTTAGCGT CATTCCAAAA CCACACCCTT GCAAAGCTTT GTACTCCGCA

2551 CCCCAGATGA TCTCCAGGCA GCTCAGATCT CTTTCCTGCC TTTGCCCTGC

2b01 ACTGTTCCCC GGTACTTCCT CCTTTATTGT AGCACTCAGC TCCCCAGCCA 2b51 ATCTGTACAT CCCTCAGAGG CAGCGATCTG ATGAATTGGT TTTTGAATCC

2701 CAGAAAGGGT CTGCCATGGA GTTGGCAGTC ATCACGGTAG ATGGCGTATG

27S1 ATTTTGCTGA ATTTTAAATA AAATGAAAAC CATAAATTAC ATGATGCTTT

2601 TATTGACACT TGACAACTGG CCTAAATAAA AAGACTCTGA CTCCAAAAAA

2651 AAAAAAAAAA AAA

BLAST Results Entry AF0266D6 from database EMBL:

Mus musculus hemin-sensitive initiation factor 2 alpha kinase mRNAi complete eds.

Score = bbflδi P = 2-7e-21bι identities = 1122/2S34

Entry AC005115 from database EMBL:

Homo sapiens clone DJ0D42M02ι UORKING DRAFT SEiQUENCEi 13 unordered pieces • Score = 511bι P = D-Oe+OOi identities = 1010/1146

Medline entries

11042001: Berlanga J-J-i Herrero S-i de Haro C-i Characterization of the hemin-sensitive eukaryotic initiation factor 2alpha kinase from mouse nonerythroid cellsi J- Biol- Chem- 273 (4δ) : 3234D-3234b (1116) .

Peptide information for frame 1

ORF from 52 bp to 1136 bpi peptide length: b21

Category: similarity to known protein

Classification: Protein management

Prosite motifs: PR0TEIN_KINASE_ATP (173-llb)

PR0TEIN_KINASE_ATP (173-117)

PROTEIN KINASE_ST (437-441)

1 MiQGGNSGVRK REEEGDGAGA VAAPPAIDFP AEGPDPEYDE SDVPAEItQVL 51 KEPL(Q(3PTFP FAVAN-2LLLV SLLEHLSHVH EPNPLRSRiQV FKLLClQTFIK

101 MGLLSSFTCS DEFSSLRLHH NRAITHLMRS AKERVRiQDPC EDISRIlQKIR

ISI SREVALEAiQT SRYLNEFEEL AILGKGGYGR VYKVRNKLDG (QYYAIKKILI

2D1 KGATKTVCMK VLREVKVLAG LtQHPNIVGYH TAUIEHVHVI (QPRDRAAIEL

251 PSLEVLSDiQE EDREiQCGVKN DESSSSSIIF AEPTPEKEKR FGESDTENiQN 301 NKSVKYTTNL VIRESGELES TLELlQENGLA GLSASSIVElQ (QLPLRRNSHL

3S1 EESFTSTEES SEENVNFLGiQ TEAiQYHLMLH I(QM(QLCELSL UDUIVERNKR

4D1 GREYVDESAC PYVMANVATK IFiQELVEGVF YIHNMGIVHR DLKPRNIFLH

451 GPDlQiQVKIGD FGLACTDILiQ KNTDUTNRN6 KRTPTHTSRV GTCLYASPEiQ

501 LEGSEYDAKS DMYSLGVVLL ELFlQPFGTEM ERAEVLTGLR TGiQLPESLRK 551 RCPV(3AKYI(Q HLTRRNSSiQR PSAIIQLLIQSE LFiQNSGNVNL TLiQMKIIElQE bOl KEIAELKKiQL NLLSlQDKGVR DDGKDGGVG

BLASTP hits

No BLASTP hits available Alert BLASTP hits for DKFZphamy2_lilι frame 1

No Alert BLASTP hits found Pedant information for DKFZphamy2_lilι frame 1

Report for DKFZphamy2_lil -1

[LENGTH! b4b

[MU! 72736.76^"

[pi! 5.60

[H0M0L! SUISSNEU:HRI_MOUSE HEME-REGULATED EUKARYOTIC INITIATION FACTOR EIF-2-ALPHA KINASE (EC 2.7-1.-) (HEME-REGULATED INHIBITOR) (HRI) (HEME-CONTROLLED REPRESSOR) (HCR) (HEMIN- SENSITIVE INITIATION FACTOR-2 ALPHA KINASE). D-D

[FUNCAT! D5.D7 translational control ES. cerevisiaei YDR283c! 2e-43 EFUNCAT! 30-03 organization of cytoplasm ES- cerevisiaei YDR263c! 2e-43

EFUNCAT! .10.02-11 key kinases ES- cerevisiaei Y0R231w! 8e-14 EFUNCAT! 03- D4 buddingi cell polarity and filament formation ES- cerevisiaei Y0R231w! δe-14 EFUNCAT! 03-01 cell growth ES- cerevisiaei Y0R231w! δe-14

EFUNCAT! 11-01 stress response ES- cerevisiaei Y0R231w! δe-14 EFUNCAT! 03-22 cell cycle control and mitosis ES- cerevisiaei Y0R231w! fle-lM EFUNCAT! 30-10 nuclear organization ES- cerevisiaei YKLlOlw! δe-12

EFUNCAT! 11 unclassified proteins ES- cerevisiaei YPLlSDw! βe-12

EFUNCAT! D3-13 meiosis ES- cerevisiaei YDR523c! Ξe-11

EFUNCAT! D3-10 sporulation and germination ES- cerevisiaei YDR523c! Ξe-11

EFUNCAT! D1-01 biogenesis of cell wall ES- cerevisiaei YPL14Dc! 4e-ll

EFUNCAT! 10-D3.11 key kinases ES- cerevisiaei YCR073c! 1e-ll EFUNCAT! 16 classification not yet clear-cut ES- cerevisiaei YHRD62c! le-10

EFUNCAT! 03-07 pheromone response! mating-type determination! sex-specific proteins ES- cerevisiaei YLR3b2w! 2e-lD EFUNCAT! 10.05-11 key kinases ES- cerevisiaei YLR3b2w! Ξe-ID EFUNCAT! 10-04-11 key kinases ES- cerevisiaei YLR3b2w! Ξe-ID EFUNCAT! 10-11 other signal-transduction activities ES- cerevisiaei YDLlOlc! 3e-lD

EFUNCAT! 11-04 dna repair (direct repairi base excision repair and nucleotide excision repair) ES- cerevisiaei YDLlOlc! 3e-10 EFUNCAT! 03-25 cytokinesis ES- cerevisiaei YDR507c! 3e-10 EFUNCAT! 04-0S.01.D1 general transcription activities ES. cerevisiaei YDLlOβw! le-01

EFUNCAT! 03- lb dna synthesis and replication ES- cerevisiaei YBRlbOw! le-01 EFUNCAT! 01-05.04 regulation of carbohydrate utilization ES. cerevisiaei YLR113w! 4e-01

[FUNCAT! 02-11 metabolism of energy reserves (glycogeni trehalose) [S. cerevisiaei YPL031c! le-06 [FUNCAT! 04.05.01-04 transcriptional control [S- cerevisiaei

YPLD31c! le-08

[FUNCAT! 01-04-04 regulation of phosphate utilization [S- cerevisiaei YPL031c! le-06 [FUNCAT! c energy conversion EM- genitaliunrii MG101! 2e-08

EFUNCAT! 03-11 recombination and dna repair ES- cerevisiaei

Y0R351c! le-07

EFUNCAT! 03-22-01 cell cycle check point proteins ES- cerevisiaei YPL153c! le-07 EFUNCAT! 10-05-01 regulation of g-protein activity ES- cerevisiaei YBLOlbw! 7e-07

EFUNCAT! 04-03-11 other trna-transcription activities ES- cerevisiaei YIL03Sc! le-Ob

EFUNCAT! 08-13 vacuolar transport ES- cerevisiaei YGLlδOw! le-Ob

EFUNCAT! Ob- 13-04 lysosomal and vacuolar degradation ES- cerevisiaei YGLlβOw! le-Ob

EFUNCAT! 04-11 other transcription activities ES- cerevisiaei

YER121w! 2e-0b EFUNCAT! 30-02 organization of plasma membrane ES- cerevisiaei

YDR122w! 2e-0b

EFUNCAT! 30-07 organization of endoplasmatic reticulum ES- cerevisiaei YHR071c! 3e-Db

EFUNCAT! Ol-Ob-10 regulation of lipidi fatty-acid and sterol biosynthesis ES- cerevisiaei YHR071c! 3e-0b

EFUNCAT! 06-11 other intracellular-transport activities ES- cerevisiaei YKLllβc! le-05

EFUNCAT! 10-04-11 other nutritional-response activities ES- cerevisiaei YKLllδc! le-OS EFUNCAT! D1-04 biogenesis of cytoskeleton ES. cerevisiaei

YNL020c! le-05

EFUNCAT! Ob- 07 protein modification (glycolsylationi acylationi myristylationi palmitylationi farnesylation and processing) ES- cerevisiaei YFL033c! 4e-04 EFUNCAT! 01-02-04 regulation of nitrogen and sulphur utilization ES- cerevisiaei YNL163c! 7e-04

[BLOCKS! BL00107A Protein kinases ATP-binding region proteins

[SCOP! dlir3a_ S-l-l-2-b insulin receptor Complex

(transf erase/substrate) le-22 [SCOP! dlfgkb_ 5.1.1.2-5 Fibroblast growth factor receptor 1 [human (Horn 1e-27

[SCOP! dlphk 5.1-1-l.b gamma-subunit of glycogen phosphorylase kinas 2e-23

[SCOP! dlabo 5.1.1-1.14 Protein kiase CK2ι alpha subunit [Maize (Ze le-23

[SCOP! d31ck 5 ■ 1.1 • E ■ Ξ Lymphocyte kinase (lck⁾ [Human

(Homo sapiens) 3e-22

ESCOP! d2erk 5.1.1.1.11 MAP kinase Erk2 [rat (Rattus norvegicus) 7e-20 ESCOP! dlcdkb_ 5-1.1.1.2 cAMP-dependent PKi catalytic subunit Comple be-11

[SCOP! dlhcl 5-1.1.1-1 Cyclin-dependent PK [Human

(Homo sapiens) 5e-21

[EC! 2-7.1-112 Protein-tyrosine kinase le-08 [EC! 2-7-l-12b beta-Adrenergic-receptor kinase 2e-08

[EC! 2-7-1-117 Myosin-light-chain kinase le-01

[EC! 2-7.1-37 Protein kinase Se-12 EEC! 2-7-1-123 Ca2+/calmodulin-dependent protein kinase 4e-

01

EPIRKU! phosphotransferase 0-0

EPIRKU! nucleus le-01 EPIRKU! RNA binding 2e-21

EPIRKU! duplication βe-10

EPIRKU! tandem repeat 4e-01

EPIRKU! zinc Se-12

[PIRKU! cell cycle control 2e-01 [PIRKU! serine/threonine-specific protein kinase 0-0

[PIRKU! transmembrane protein 2e-01

[PIRKU! zinc finger 8e-10

[PIRKU! oncogene be-12

[PIRKU! autophosphorylation 0-0 [PIRKU! coat protein le-11

[PIRKU! magnesium le-01

[PIRKU! ATP 0-0

[PIRKU! polyprotein be-12

[PIRKU! receptor le-01 [PIRKU! phosphoprotein D-D

[PIRKU! sporulation 2e-01

[PIRKU! glycoprotein le-01

[PIRKU! growth factor receptor le-11

[PIRKU! signal transduction 2e-12 [PIRKU! serine/threonine/tyrosine-specific protein kinase

8e-10

[PIRKU! protein kinase δe-10

[PIRKU! transforming protein 2e-12

[PIRKU! heme binding 0-0 [PIRKU! purine nucleotide binding 2e-10

[PIRKU! calcium binding 4e-01

[PIRKU! meiosis le-08

[PIRKU! alternative splicing le-11

[PIRKU! P-loop 2e-10 [PIRKU! proto-oncogene 2e-12

[PIRKU! segmentation 4e-10

[PIRKU! stress-induced protein le-DI

[PIRKU! EF hand 4e-01

[PIRKU! cell division le-01 [PIRKU! calmodulin binding 4e-01

[SUPFAM! LIM protein kinase 8e-10

[SUPFAM! calcium-dependent protein kinase 4e-01

[SUPFAM! rat protein kinase raf 5e-12

[SUPFAM! AMP-activated protein kinase 2e-0δ [SUPFAM! protein kinase byr2 Se-01

[SUPFAM! SH2 homology le-06

[SUPFAM! unassigned Ser/Thr or Tyr-specific protein kinases 0-0

[SUPFAM! leucine-rich alpha-2-glycoprotein repeat homology le-01 [SUPFAM! double-stranded RNA-binding repeat homology 2e-21

[SUPFAM! histidine--tRNA ligase homology be-42

[SUPFAM! SAM homology 5e-01

[SUPFAM! avian retrovirus IC10 gag-Rmil-env polyprotein le-11

[SUPFAM! LIM metal-binding repeat homology βe-10 [SUPFAM! GCN2 protein be-42

[SUPFAM! protein kinase homology 0-0

[SUPFAM! protein kinase C zinc-binding repeat homology 2e-12

[SUPFAM! Ca2+/calmodulin-dependent protein kinase II 4e-0β [SUPFAM! beta-adrenergic-receptor kinase 2e-0δ

ESUPFAM! kinase-related transforming protein be-12

[SUPFAM! protein kinase A-raf 2e-12

[SUPFAM! SH3 homology le-06 [SUPFAM! Ca2+/calmodulin-dependent protein kinase 4e-01

[SUPFAM! protein kinase Xa21 le-01

[SUPFAM! calmodulin repeat homology 4e-01

ESUPFAM! protein kinase DUN1 le-01

ESUPFAM! pleckstrin repeat homology le-01 ESUPFAM! protein kinase TIK Ξe-Ξl

ESUPFAM! protein-tyrosine kinase tec le-06

ESUPFAM! kinase interaction domain homology le-01

EPROSITE! PROTEIN_KINASE_ATP 2

EPROSITE! PROTEIN_KINASE_ST 1 EPFAM! Eukaryotic protein kinase domain

EKU! Irregular

EKU! 3D

EKU! L0U_C0MPLEXITY 10-11 *

EKU! COILED COIL 5-2b *

SE(Q AVLGUPAGUAAARARPAMiQGGNSGVRKREEEGDGAGAVAAPPAIDFPAEGPDPEYDESDV SEG ---xxxxxxxxxxxxxx xxxxxxxxxxxxxxx

COILS

1jstA

SElQ PAEI(QVLKEPL(Q(QPTFPFAVAN(QLLLVSLLEHLSHVHEPNPLRSR(QVFKLLC<QTFIKMGL SEG xxxxxxxxxxxxxxx

COILS

1 j stA

SElQ LSSFTCSDEFSSLRLHHNRAITHLMRSAKERVRϊQDPCEDISRIiQKIRSREVALEAiQTSRY SEG -

COILS I j stA

SElQ LNEFEELAILGKGGYGRVYKVRNKLDG(QYYAIKKILIKGATKTVCMKVLREVKVLAGL(3H SEG COILS

IjstA

TTTEEEEEECCCBTTBCEEEEEETTTTCEEEEEEECCTTTTTTTTHHHHHHHHHHHTTTB SE(Q PNIVGYHTAUIEHVHVI(^QPRDRAAIELPSLEVLSD(^QEEDRE(QCGVKNDESSSSSIIFAEP SEG

COILS

I j stA TTBC

SElQ TPEKEKRFGESDTEN(QNNKSVKYTTNLVIRESGELESTLEL<^QENGLAGLSASSIVE(Q(QLP SEG COILS

IjstA

SElQ LRRNSHLEESFTSTEESSEENVNFLG(QTEA(QYHLMLHI(QM(QLCELSLUDUIVERNKRGRE SEG xxxxxxxxxxxxx

COILS IjstA

SElQ YVDESACPYVMANVATKIF(QELVEGVFYIHNMGIVHRDLKPRNIFLHGPD(Q(QVKIGDFGL SEG COILS

IjstA

SElQ ACTDILIQKNTDUTNRNGKRTPTHTSRVGTCLYASPEIQLEGSEYDAKSDMYSLGVVLLELF SEG

COILS

IjstA

SElQ (QPFGTEMERAEVLTGLRTG(QLPESLRKRCPV(QAKYI(QHLTRRNSS(2RPSAI(3LL(QSELF(Q SEG ,

COILS

IjstA

SElQ NSGNVNLTL(QMKIIE(QEKEIAELKK(QLNLLS(QDKGVRDDGKDGGVG SEG xxxxxxxxxxxxxx

COILS - -CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC ■

IjstA

Prosite for DKFZphamy2_lil- 1

PS00107 110->214 PROTEIN_KINASE_ATP PD0C00100

PS00107 110->21S PROTEIN_KINASE_ATP PD0C00100 PS00106 454->4b7 PROTEIN KINASE ST PD0C00100

Pfam for DKFZphamy2_lil ■ 1

HMM_NAME Eukaryotic protein kinase domain

HMM *YeigRiIGeGsFGtVYkCiUr-TGeIVAIKIIk-krsms F1REI

+E + I+G+G++G+VYK++++ +G+ +AIK+I K ++ +LRE+ (Query 164

FEELAILGKGGYGRVYKVRNKLDG(QYYAIKKILIKGATKTVCMKVLREV 232

HMM qlMRrLnHPNIIRFYDwFedddDHI* ++++ L+HPNI+ + +++ ++ H+

(Query 233 KVLAGL(QHPNIVGYHTAUI-EHVHV 25b

HMM

*IYMIMEYMeGGDLFDYIrrng pMsEwelrfIMyύlL +++ M+++E +L+D+I++++ ++ + + +1+

+++

(Query 31b LHIlQMώLCEL-

SLUDUIVERNKRGREYVDESACPYVMANVATKIFiQELV 443 HMM rGMeYLHSMgllHRDLKPENILIDeN.gqIKIcDFGLARqMn

+ G+ Y + H + MGI + HRDLKP + NI + + + (Q + KI + DFGLA +

(Query 444

EGVFYIHNMGIVHRDLKPRNIFLHGPD(Q(3VKIGDFGLACTDIL(QKNTDUT 413

HMM nYerMttfCGTPUYMMAPEVIImgnyYttkVDMUSFGCILUEMMT

+ T+++GT Y +PE ++G++Y+ K+DM+S+G++L

E++ (Query 414 NRNGKRTPTHTSRVGTCLYA-SPEiQ-

LEGSEYDAKSDMYSLGVVLLELF- 540

HMM

GepPFyd-.dnMemlmrliqr.frrpfUpnCSeElyDFMrwCUnyDPekR +PF ++ E + ++ + ++ ++ +C+ +++ + + +++

++R

(Query 541 — (QPFGTEMERAEVLTGLRTG(QLPESLRKRCPV(QAKYI(Q-

HLTRRNSSiQR 567 HMM PTFriQILnHPUF*

P + + (Q + L + + F (Query 566 PSAIIQLLIQSELF 511

DKFZphamy2_lil4

group: transmembrane proteins

DKFZphamy2_lil4 encodes a novel bl7 amino acid protein with similarity to the human l(3)mbt protein homolog. Mutations of the Drosophila l(3)mbt gene lead to malignant brain tumors- The novel protein contains 1 transmembrane domain- No informative BLAST resultsi No predictive prositei pfam or SCOP motife The new protein can find application in studying the expression profile of oncogenes and amgydala-specif ic genes and as a new marker for amygdala cells-

similarity to Human l(3)mbt protein homolog mRNA

> 14 exons (HS7SbG23 (EMBLNEU)) Pedant: TRANSMEMBRANE 1 Sequenced by MediGeno ix

Locus: /map="22ql3-31-13-33"

Insert length: 3071 bp Poly A stretch at pos- 3052ι no polyadenylation signal found

1 GGCAGGCCAA TATGGCTTCC TGCACCT6GT GACGCTTGGC GAAACTGAGG

SI TCTCATGGAG AAGCCCCGGA GTATTGAGGA GACCCCATCT TCAGAACCAA

101 TGGAGGAAGA GGAAGATGAC GACTTGGAGC TGTTTGGTGG CTATGATAGT

ISI TTCCGGAGTT ATAACAGCAG TGTGGGCAGT GAGAGCAGCT CCTATCTGGA

201 GGAGTCAAGT GAAGCAGAAA ATGAGGATCG GGAAGCAGGG GAACTGCCGA

251 CCTCCCCGCT GCATTTGCTC AGCCCTGGGA CTCCTCGCTC CTTGGATGGC

301 AGTGGTTCTG AGCCAGCTGT CTGTGAGATG TGTGGTATCG TGGGTACAAG

351 GGAAGCCTTC TTCTCCAAGA CCAAGAGGTT CTGCAGCGTC TCCTGCTCCA

401 GGAGCTACTC CTCCAACTCC AAGAAAGCCA GTATCTTGGC TAGATTACAG

451 GGAAAACCAC CGACCAAAAA AGCCAAAGTC CTGCACAAGG CTGCCTGGTC

501 TGCCAAAATT GGAGCCTTCC TCCACTCTCA AGGGACAGGA CAGCTGGCAG

S51 ATGGGACACC AACAGGACAA GACGCTCTGG TCTTGGGCTT CGACTGGGGG bOl AAGTTCCTGA AGGATCACAG TTACAAGGCT GCTCCCGTCA GCTGTTTCAA bSl GCACGTCCCA CTCTATGACC AGTGGGAGGA TGTGATGAAA GGGATGAAGG

701 TGGAGGTGCT CAACAGTGAT GCTGTGCTCC CCAGCCGGGT GTACTGGATC

751 GCCTCTGTCA TCCAGACAGC AGGGTATCGG GTGCTGCTTC GGTATGAAGG

601 CTTTGAAAAT GACGCCAGCC ATGACTTCTG GTGCAACCTG GGAACAGTGG

6S1 ATGTCCACCC CATTGGCTGG TGTGCCATCA ACAGCAAGAT CCTAGTGCCC

101 CCACGGACCA TCCATGCCAA GTTCACCGAC TGGAAGGGCT ACCTCATGAA

151 ACGGCTGGTG GGCTCCAGGA CGCTTCCCGT GGATTTCCAC ATCAAGATGG

1001 TGGAGAGCAT GAAGTACCCC TTTAGGCAGG GCATGCGGCT GGAAGTGGTG

1051 GACAAGTCCC AGGTGTCACG CACTCGCATG GCTGTGGTGG ACACAGTAAT

1101 CGGGGGTCGC CTACGGCTCC TCTACGAGGA TGGTGACAGT GACGACGACT

1151 TCTGGTGCCA CATGTGGAGC CCCCTGATCC ACCCAGTGGG TTGGTCACGA

1201 CGTGTGGGCC ACGGCATCAA GATGTCAGAG AGGCGAAGTG ACATGGCCCA

1251 TCACCCCACC TTCCGGAAGA TCTACTGTGA TGCCGTTCCT TACCTCTTCA 1301 AGAAGGTACG AGCAGTCTAC ACAGAAGGCG GTTGGTTTGA GGAAGGGATG

1351 AAGCTGGAGG CCATTGACCC CCTGAATCTG GGCAACATCT GCGTGGCAAC

1401 TGTCTGTAAG GTTCTCCTGG ATGGATACCT GATGATCTGT GTGGACGGGG

1451 GGCCCTCCAC AGATGGCTTG GACTGGTTCT GCTACCATGC CTCTTCCCAC

15D1 GCCATCTTCC CGGCCACCTT CTGTCAGAAG AATGACATTG AGCTCACACC

1551 GCCAAAAGGT TATGAGGCAC AGACTTTCAA CTGGGAGAAC TACTTGGAGA

IbOl AGACCAAGTC GAAAGCCGCT CCATCGAGAC TCTTTAACAT GGATTGCCCA lb51 AACCATGGCT TCAAGGTGGG CATGAAGCTG GAGGCCGTGG ACCTGATGGA

1701 GCCCCGGCTC ATCTGTGTGG CCACGGTGAA ACGAGTGGTG CATCGGCTCC

1751 TCAGCATCCA CTTTGACGGC TGGGACAGCG AGTACGACCA GTGGGTGGAC

1601 TGCGAGTCCC CAGACATCTA CCCCGTCGGC TGGTGTGAGC TCACCGGCTA

16S1 CCAGCTCCAG CCTCCTGTGG CCGCAGGTGT GGGCTCTCGT GGCCCTAAGA

1101 GGCTCTGACT TTCTTTCCTC TTCTTTTTTC CTTCTTCCCC CGCCCCTGTG

1151 CCCATCTCCG TTCTTTGGCA TGAGGTGGAG ATGTCTCATG GACCACTTTA

2001 AGTAGAGAGT GAGCCCCGTC ACCCAGCCCC TGCTCCTGAC TTCTCTGTCT

2051 CCCTTTCCCT CTGGCCTGCA GAGCTCCTTC CTTCATCTTG CCCACTCTGT

2101 CATATGTTCG TGCCCTTGTG CACCCAGGTA AACTACCCAG GTCCCTCTGA

21S1 GCAGCCCTGG TAACAAGGGT GGGAAGAAGG GACAGCTGTT CTCCGGCCCC

2201 TCCTCCAGCC CCGCCCTCTC CTCATTGCCC AGGTTTGGCT TCCTGTCTTG

2251 GGGTGTCTCG TGTGGGAGGG TGGATGGGGT CTCGGGATGC GCCTGTGCCC

2301 TGTGTCCTCC CAGGGACCCT CTTCTCATCT CTTTCACCCT TGTCTTTCAA

2351 CAACAGAACC GGCCACACCG CTGAAGGCCA AAGAGGCCAC AAAGAAGAAA

2401 AAGAAACAGT TTGGGAAGAA AAGGAAAAGA ATCCCGCCCA CTAAGACGCG

2451 ACCCCTCAGA CAGGGGTCCA AGAAGCCCCT GCTGGAGGAC GACCCTCAGG

2501 GTGCCAGGAA GATCTCGTCG GAGCCTGTTC CTGGCGAGAT CATTGCTGTG

25S1 CGTGTGAAGG AAGAGCATCT AGACGTGGCC TCGCCCGACA AGGCTTCAAG

2b01 TCCAGAGCTG CCTGTCTCCG TCGAGAACAT CAAGCAGGAA ACAGACGACT

2b51 GAGCCTTCCT GCCTCCAGCC TGGCTTCTAG CTGGAAGCCA GCCCAGCGTT

2701 TCTCTACCAC CACCACCATG CCTCCACCTG ACTTTGGCTT GGAGACTGAT

27S1 CCTCTCTGTG TAAATTCTGC CCGGTGCTGT GAAGGCTGGA CGGTGGAGGA

2δ01 CCTGCTGGGG TCTCCTGGGA CCCGCCTGTT GCTTCTGCCC TCCCCTGTGG

2651 AAAGGTCTAT ATGACGGGCC GCCTGAGGCC CCAGAACTCG TCTGTGAACC

2101 ACCTTTTCCA GCCAGAGTTC CCAAAGCTGG AACGCTAGCT GCCTGCTCTT

21S1 CCTTAAGATG GCCTCCCCCC GACCCGCCAC GGCCCTCAGT TGCCAGGGAT

3001 GGGGCCACCA CTGTCACACT GTGGAATACA AGACAGTGAA CTCTGTCTGC

3051 CTAAAAAAAA AAAAAAAAAA A

BLAST Results

Entry HS7SbG23 from database EMBLNEU:

Human DNA sequence from clone 75bG23 on chromosome 22ql3-31-13 - 33

Score = 3131ι P = O-Oe+OOi identities = 67S/154

Entry Uδ135β_l from database TREMBL: product: "l(3)mbt protein homolog"i Human l(3)mbt protein homolog mRNAi complete eds- Score = SOSi P = 7-2e-45ι identities = 123/320ι positives = 170/320ι frame +1

Entry AB014S61_1 from database TREMBL: gene: "KIAAObδl"i product: "KIAAObβl protein"i Homo sapiens mRNA for KIAAObβl proteini partial eds- Score = SD3ι P = l-4e-4bι identities = 122/3D7ι positives = lb3/307ι frame +1

Medline entries

No Medline entry

Peptide information for frame 1

ORF from 55 bp to 1105 bpi peptide length: bl7 Category: similarity to known protein Classification: unclassified

1 MEKPRSIEET PSSEPMEEEE DDDLELFGGY DSFRSYNSSV GSESSSYLEE

51 SSEAENEDRE AGELPTSPLH LLSPGTPRSL DGSGSEPAVC EMCGIVGTRE

101 AFFSKTKRFC SVSCSRSYSS NSKKASILAR LiQGKPPTKKA KVLHKAAUSA

151 KIGAFLHSlQG TGlQLADGTPT GiQDALVLGFD UGKFLKDHSY KAAPVSCFKH 201 VPLYDώUEDV MKGMKVEVLN SDAVLPSRVY UIASVIiQTAG YRVLLRYEGF

2S1 ENDASHDFUC NLGTVDVHPI GUCAINSKIL VPPRTIHAKF TDUKGYLMKR

301 LVGSRTLPVD FHIKMVESMK YPFRtQGMRLE VDKSlQVSRT RMAVVDTVIG

351 GRLRLLYEDG DSDDDFUCHM USPLIHPVGU SRRVGHGIKM SERRSDMAHH

401 PTFRKIYCDA VPYLFKKVRA VYTEGGUFEE GMKLEAIDPL NLGNICVATV 451 CKVLLDGYLM ICVDGGPSTD GLDUFCYHAS SHAIFPATFC (QKNDIELTPP

501 KGYEAώTFNU ENYLEKTKSK AAPSRLFNMD CPNHGFKVGM KLEAVDLMEP

SSI RLICVATVKR VVHRLLSIHF DGUDSEYDiQU VDCESPDIYP VGUCELTGYlQ bOl LlQPPVAAGVG SRGPKRL

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_lil4 i frame 1

TREMBL:ABD14Sβl_l gene: "KIAAObδl"i product: "KIAAObδl protein"i Homo sapiens mRNA for KIAAObδl proteini partial cds-i N = li Score = S03ι P = 3-1e-4δ

TREMBL:U8135δ_l product: "l(3)mbt protein homolog"i Human l(3)mbt protein homolog mRNAi complete cds-i N = li Score = SOSi P = b-2e-48

>TREMBL:U6135δ_l product: "l(3)mbt protein homolog"i Human l(3)mbt protein homolog mRNAi complete eds- Length = 772 HSPs:

Score = S05 (75. A bits)ι Expect = b-2e-4δι P = b-2e-4β Identities = 123/313 (31*)ι Positives = 170/313 (54*)

(Query: 213 UKGYLMKRLVGSRTLPVDFH-- IKMVESMKYPFR(QGMRLEVVDKS(QVSRTRMAVVDTVIG 350

U+ YL ++ + T PV + V K F+ GM+LE +D S + V V G

Sbjct: 206 UESYLEEiQK — AITAPVSLF(QDS(3AVTHNKNGFKLGMKLEGIDP(QHPSMYFILTVAEVCG 2b5

(Query: 351 GRLRLLYEDGDSD-DDFUCHMUSPLIHPVGUSRRVGHGIKMSE — RRSDMAHHPTFRKIY 407

RLRL + DG S+ DFU + SP IHP GU + GH +++ + + + + Sbjct: 2bb YRLRLHF- DGYSECHDFUVNANSPDIHPAGUFEKTGHKLIQLPKGYKEEEFSUSIQYMCSTR 324 (Query: 4DΘ CDAVP-

YLFKKVRAVYTEGGUFEEGMKLEAIDPLNLGNICVATVCKVLLDGYLMICVDGG 4bb

A P ++F G F+ GMKLEA+D +N +CVA+V V+ D

++ D

Sbjct: 325 A(QAAPKHMFVS(QSHSPPPLG-F(QVGMKLEAVDRMNPSLVCVASVTDVV- DSRFLVHFDNU 3δ2

(Query: 4b7 PSTDGLDUFCYHASSHAIFPATFClQKNDIELTPPKGY- EAfQTFNUENYLEKTKSKAAPSR 52S

T D + + C SS I P +C(QK LTPP+ Y + F UE YLE + T + A P+

Sbjct: 363 DDT--YDYUC- DPSSPYIHPVGUC(QK(QGKPLTPP(QDYPDPDNFCUEKYLEETGASAVPTU 431

(Query: 52b LFNMDCPNHGFKVGMKLEAVDLMEPRLICVATVKRVVHRLLSIHFDGUDSEYDiQUVDCES S65

F + P H F V MKLEAVD P LI VA+V+ V + IHFDGU

YD U+D +

Sbjct: 440 AFKVR-

PPHSFLVNMKLEAVDRRNPALIRVASVEDVEDHRIKIHFDGUSHGYDFUIDADH 416

(Query: Sβb PDIYPVGUCELTGY(QL(QPPV b05 PDI+P GUC TG+ L(QPP+

Sbjct: 411 PDIHPAGUCSKTGHPLiQPPL Slβ Score = 333 (50-0 bits)ι Expect = 4-le-27ι P = 4-le-27 Identities = 103/324 (31*)ι Positives = 151/324 (4b*)

(Query: 171 FDUGKFLKDHSYKAAPVSCFKHVPLYDώUEDVMK- GMKVEVLNSDAVLPSRVYUIASVIiQ 237 + U +L++ APVS F+ ++ K GMK+E + D PS

+Y+I +V +

Sbjct: 20b USUESYLEE(QKAITAPVSLF(QDS(QAVTHNKNGFKLGMKLEGI—DP(QHPS- MYFILTVAE 2bΞ (Query: 236

TAGYRVLLRYEGFENDASHDFUCNLGTVDVHPIGUCAINSKILVPPRTIHAKFTDUKGYL 217

GYR+ L ++G+ HDFU N + D+HP GU L P+ + U Y+ Sbjct: 2b3 VCGYRLRLHFDGYSE-- CHDFUVNANSPDIHPAGUFEKTGHKLώLPKGYKEEEFSUSiQYM 320

(Query: 216 MKRLVGSRTLPVDFHIKMVESMKYP

FR(QGMRLEVVDKS(QVSRTRMAVVDTVIGGRLR 354

+R H+ + +S P F+ GM+LE VD+ S +A V

V+ R

Sbjct: 321 CS

TRA(QAAPKHMFVS(QSHSPPPLGF(3VGMKLEAVDRMNPSLVCVASVTDVVDSRFL 37b

(Query: 3SS LLYEDGDSDDDFUCHMUSPLIHPVGUSRRVGHGIKMSERRSD

MAHHPTFRKIYCDAV 411

+ +++ D D+UC SP IHPVGU ++ G + + D + AV Sbjct: 377

VHFDNUDDTYDYUCDPSSPYIHPVGUCiQKfQGKPLTPPlQDYPDPDNFCUEKYLEETGASAV 43b

(Query: 412

PYLFKKVRAVYTEGGUFEEGMKLEAIDPLNLGNICVATVCKVLLDGYLMICVDGGPSTDG 471 P KVR ++ F MKLEA + D N I VA + V V D + I

DG + G

Sbjct: 437 PTUAFKVRPPHS FLVNMKLEAVDRRNPALIRVASVEDVE-

DHRIKIHFDGU--SHG 461 (Query: 472 LDUFCYHASSHAIFPATFClQKNDIELTPPKG 502

D F A I PA +C K L PP G

Sbjct: 410 YD-FUIDADHPDIHPAGUCSKTGHPL(QPPLG 511

Score = 23b (35-4 bits)ι Expect = 2-5e-lbι P = 2-Se-lb Identities = 47/110 (42*)ι Positives = bb/110 (bO*)

(Query: 411 PPKGYEAiQTFNUENYLEKTKSKAAPSRLF-NMDCPNH- — GFKVGMKLEAVDLMEPRLIC 5S4

P G + + ++UE+YLE+ K+ AP LF + H GFK+GMKLE +D P +

Sbjct: 117 PATGEKKECUSUESYLEEIQKAITAPVSLFIQDSIQAVTHNKNGFKLGMKLEGIDPIQHPSMYF 25b

(Query: 555 VATVKRVVHRLLSIHFDGUDSEYDtQUVDCESPDIYPVGUCELTGYiQLiQPP b04

+ TV V L +HFDG+ +D UV+ SPDI + P GU E TG + + L(Q P

Sbjct: 257 ILTVAEVCGYRLRLHFDGYSECHDFUVNANSPDIHPAGUFEKTGHKLiQLP

3Db

Pedant information for DKFZphamy2_lil4ι frame 1

Report for DKFZphamy2_lil -1

ELENGTH! bl7 EMU! b12b4.11 Epl! b.OS EHOMOL! TREMBL :U6135δ_l product: "l(3)mbt protein homolog"i Human l(3)mbt protein homolog mRNAi complete eds- le-47

EBLOCKS! BL0120bA Amiloride-sensitive sodium channels proteins EKU! TRANSMEMBRANE 1

EKU! LOU COMPLEXITY 1-40 *

S E lQ MEKPRSIEETPSSEPMEEEEDDDLELFGGYDSFRSYNSSVGSESSSYLEESSEAENEDRE

SEG xxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxx

PRD ccccceeeeccccccccccccccccccccccccccccccccccccccccccccccccccc

MEM

S ElQ AGELPTSPLHLLSPGTPRSLDGSGSEPAVCEMCGIVGTREAFFSKTKRFCSVSCSRSYSS

SEG xxxxxxxxxx

PRD ccccccccccccccccccccccccccceeeeeecccccccccccccccceeeeccccccc

MEM

S E lQ NSKKASILARL(QGKPPTKKAKVLHKAAUSAKIGAFLHS(QGTG(QLADGTPTG(QDALVLGFD

SEG xxxxxx

PRD ccchhhhhhhhhcccccccchhhhhhhhhhhhhhhcccccccccccccccccceeeeecc

MEM

SE lQ UGKFLKDHSYKAAPVSCFKHVPLYDIQUEDVMKGMKVEVLNSDAVLPSRVYUIASVIIQTAG

SEG

PRD chhhhhhccccccccccccccccccccchhhhhheeeeeccccccceeeehhhhhhhhhc

MEM

SE lQ YRVLLRYEGFENDASHDFUCNLGTVDVHPIGUCAINSKILVPPRTIHAKFTDUKGYLMKR

SEG

PRD ceeeeeeccccccccceeeeccccccccccccccccceeeccccccccccccchhhhhhh

MEM

S E lQ LVGSRTLPVDFHIKMVESMKYPFRώGMRLEVVDKSfQVSRTRMAVVDTVIGGRLRLLYEDG

SEG

PRD hccccccccccccccccccccccccccceeeecccccceeeeeeeeeccccceeeeeccc

MEM

S E lQ DSDDDFUCHMUSPLIHPVGUSRRVGHGIKMSERRSDMAHHPTFRKIYCDAVPYLFKKVRA

SEG

PRD cccceeeeeccccccccccccccccccccccccccccccchhhhhhcccccccccccccc

MEM

S E lQ VYTEGGUFEEGMKLEAIDPLNLGNICVATVCKVLLDGYLMICVDGGPSTDGLDUFCYHAS

SEG

PRD ccccccchhhhheeeeccccccceeeeeeehhhhhcceeeeeeccccccccceeeeeecc

MEM MMMMMMMMMMMMMMMMM

S E lQ SHAIFPATFC(QKNDIELTPPKGYEA(QTFNUENYLEKTKSKAAPSRLFNMDCPNHGFKVGM

SEG

PRD cccccccccccccccccccccccccchhhhhhhhhhhhccccccccccccccchhhhhhe

MEM

S E lQ KLEAVDLMEPRLICVATVKRVVHRLLSIHFDGUDSEYDiQUVDCESPDIYPVGUCELTGYlQ

SEG

PRD eeecccccccceeeeeehhhhhhhheeeeeccccccccccccccccccccceeeeccccc

MEM

S ElQ LiQPPVAAGVGSRGPKRL

SEG

PRD ccccccccccccccccc

MEM (No Prosite data available for DKFZphamy2_lil4 ■ 1) (No Pfam data available for DKFZphamy2_lil4.1)

DKFZphamy2_li24

group: differentiation/development

DKFZphamy2_li24 encodes a novel 835 amino acid protein without partial similarity to rattus norvegicus Notch2 protein- Notch family molecules are thought to be negative regulators of neuronal differentiation in early brain development. Notch2 is expressed not only by neuronal cells in the embryonic braini but also by glial cells in the postnatal brain- The new protein represents a new member of this family and may be involved in specific differentation or developmental pathways of the nervous system -

The new protein can find application in modulating development and differentiation of amygdala cells-

putative protein probably complete eds-

Sequenced by MediGenomix

Locus: unknown Insert length: 27bδ bp

Poly A stretch at pos- 2714ι polyadenylation signal at pos- 2b17

1 AGAAATCTTC AGCCAAACAG CTGCAGGAAG TAGAGAAGGT TAAACCCCAG 51 AGTGAGAAAG TTCATCAGAC TCTGATTCTG GACCCAGCAC AGAGGAAGAG

101 ACTCCAGCAG CAGATGCAGC AGCACGTTCA GCTCTTGACC CAAATCCACC

151 TTCTTGCCAC CTGCAACCCC AACCTCAATC CGGAGGCCAC TACCACCAGG

201 ATATTTCTTA AAGAGCTGGG AACCTTTGCT CAAAGCTCCA TCGCCCTTCA

251 CCATCAGTAC AACCCCAAGT TTCAGACCCT GTTCCAACCC TGTAACTTGA 301 TGGGAGCTAT GCAGCTGATT GAAGACTTCA GCACACATGT CAGCATTGAC

3S1 TGCAGCCCTC ATAAAACTGT CAAGAAGACT GCGAATGAAT TTCCCTGTTT

401 GCCAAAGCAA GTGGCTTGGA TTCTGGCCAC AAGCAAGGTT TTCATGTATC

451 CAGAGTTACT TCCAGTGTGT TCCCTGAAGG CAAAGAATCC CCAGGATAAG

501 ATCGTCTTCA CCAAGGCTGA GGACAATTTG TTAGCTTTAG GACTGAAGCA 551 TTTTGAAGGA ACTGAGTTTC CTAATCCTCT AATCAGCAAG TACCTTCTAA bOl CCTGCAAAAC TGCCCACCAA CTGACAGTGA GAATCAAGAA CCTCAACATG bSl AACAGAGCTC CTGACAACAT CATTAAATTT TATAAGAAGA CCAAACAGCT

7D1 GCCAGTCCTA GGAAAATGCT GTGAAGAGAT CCAGCCACAT CAGTGGAAGC

7S1 CACCTATAGA GAGAGAAGAA CACCGGCTCC CATTCTGGTT AAAGGCCAGT 601 CTGCCATCCA TCCAGGAAGA ACTGCGGCAC ATGGCTGATG GTGCTAGAGA

651 GGTAGGAAAT ATGACTGGAA CCACTGAGAT CAACTCAGAT CGAAGCCTAG

101 AAAAAGACAA TTTGGAGTTG GGGAGTGAAT CTCGGTACCC ACTGCTATTG

ISI CCTAAGGGTG TAGTCCTGAA ACTGAAGCCA GTTGCCACCC GTTTCCCCAG

1001 GAAGGCTTGG AGACAGAAGC GTTCATCAGT CCTGAAGCCC CTCCTTATCC 1051 AACCCAGCCC CTCTCTCCAG CCCAGCTTCA ACCCTGGGAA AACACCAGCC

1101 CGATCAACTC ATTCAGAAGC CCCTCCGAGC AAAATGGTGC TCCGGATTCC

1151 TCACCCAATA CAGCCAGCCA CTGTTTTACA GACAGTTCCA GGTGTCCCTC

1201 CACTGGGGGT CAGTGGAGGT GAGAGTTTTG AGTCTCCTGC AGCACTGCCT 1251 GCTGTGCCCC CTGAGGCCAG GACAAGCTTC CCTCTGTCTG AGTCCCAGAC

1301 TTTGCTCTCT TCTGCCCCTG TGCCCAAGGT AATGCTGCCC TCCCTTGCCC

1351 CTTCTAAGTT TCGAAAGCCA TATGTGAGAC GGAGACCCTC AAAGAGAAGA

1401 GGAGTCAAGG CCTCTCCCTG TATGAAACCT GCCCCTGTTA TCCACCACCC 1451 TGCATCTGTT ATCTTCACTG TTCCTGCTAC CACTGTGAAG ATTGTGAGCC

1S01 TTGGCGGTGG CTGTAACATG ATCCAGCCTG TCAATGCGGC TGTGGCCCAG

15S1 AGTCCCCAGA CTATTCCCAT CACTACCCTC TTGGTTAACC CTACTTCCTT

IbOl CCCCTGTCCA TTGAACCAGT CCCTTGTGGC CTCCTCTGTC TCACCCTTAA

IbSl TTGTTTCTGG CAATTCTGTG AATCTTCCTA TACCATCCAC CCCTGAAGAT 1701 AAGGCCCACG TGAATGTGGA CATTGCTTGT GCTGTGGCTG ATGGGGAAAA

17S1 TGCCTTTCAG GGCCTAGAAC CCAAATTAGA GCCCCAGGAA CTATCTCCTC

1801 TCTCTGCTAC TGTTTTCCCG AAAGTGGAAC ATAGCCCAGG GCCTCCACTA

1851 GCAGATGCAG AGTGCCAAGA AGGATTGTCA GAGAATAGTG CCTGTCGCTG

1101 GACCGTTGTG AAAACAGAGG AGGGGAGGCA AGCTCTGGAG CCGCTCCCTC 1151 AGGGCATCCA GGAGTCTCTA AACAACCCTA CCCCTGGGGA TTTAGAGGAA

2001 ATTGTCAAGA TGGAACCTGA AGAAGCTAGA GAGGAAATCA GTGGATCCCC

2051 TGAGCGTGAT ATTTGTGATG ACATCAAAGT GGAACATGCT GTGGAATTGG

2101 ACACTGGTGC CCCAAGCGAG GAGTTGAGCA GTGCTGGAGA AGTAACGAAA

2151 CAGACAGTCT TACAGAAGGA AGAGGAGAGG AGTCAGCCAA CTAAAACCCC 2201 TTCATCTTCT CAAGAGCCCC CTGATGAAGG AACCTCAGGG ACAGATGTGA

2251 ACAAAGGATC ATCAAAGAAT GCTTTGTCCT CAATGGATCC TGAAGTGAGG

2301 CTTAGTAGCC CCCCAGGGAA GCCAGAAGAT TCATCCAGTG TTGATGGTCA

23S1 GTCAGTGGGG ACTCCAGTTG GGCCAGAAAC TGGAGGAGAG AAGAATGGGC

2401 CAGAAGAAGA GGAAGAAGAG GACTTTGATG ACCTCACCCA AGATGAGGAA 2451 GATGAAATGT CATCAGCTTC TGAGGAATCT GTGCTTTCTG TCCCAGAACT

2SD1 CCAGGTGAGA GCTGGAGAAT ATTCTCAAGT ATTTCGTGGA CTCAGTAATA

25S1 TGTATCACTT ATTGATATGC CACCTGCTTG CTTGCTGCAC TATGGATAGT

2b01 CCTAAAATCA TTTGTATTTG ATTTGTGAAT GCATTATGGG ACATGATTGT

2bSl GGAGTTGAGG TGAAATGAGA TGGAAAGGAT GAAATTTTAC TTATTATATT 2701 AAACTCGTTT ACACATTAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAGA

27S1 AAAAAAAAAA AAAAAAAA

BLAST Results

Entry RNNOTCHX from database EMBL: Rat notch 2 mRNA- Score = 818ι P = l-be-2bι identities = 21b/277

Medline entries

No Medline entry

Peptide information for frame 3

ORF from 114 bp to 2blδ bpi peptide length: δ35 Category: putative protein Classification: Differentiation/Development

1 Mι3(3HV(QLLT(Q IHLLATCNPN LNPEATTTRI FLKELGTFAiQ SSIALHHiQYN 51 PKF(QTLF(QPC NLMGAMώLIE DFSTHVSIDC SPHKTVKKTA NEFPCLPKiQV 101 AUILATSKVF MYPELLPVCS LKAKNPlQDKI VFTKAEDNLL ALGLKHFEGT

151 EFPNPLISKY LLTCKTAHiQL TVRIKNLNMN RAPDNIIKFY KKTKiQLPVLG

201 KCCEEI(QPH(Q UKPPIEREEH RLPFULKASL PSIiQEELRHM ADGAREVGNM

251 TGTTEINSDR SLEKDNLELG SESRYPLLLP KGVVLKLKPV ATRFPRKAUR

301 (QKRSSVLKPL LI(QPSPSL(2P SFNPGKTPAR STHSEAPPSK MVLRIPHPIlQ

351 PATVLiQTVPG VPPLGVSGGE SFESPAALPA VPPEARTSFP LSESiQTLLSS

401 APVPKVMLPS LAPSKFRKPY VRRRPSKRRG VKASPCMKPA PVIHHPASVI

4S1 FTVPATTVKI VSLGGGCNMI (QPVNAAVAlQS PiQTIPITTLL VNPTSFPCPL

501 NiQSLVASSVS PLIVSGNSVN LPIPSTPEDK AHVNVDIACA VADGENAFlQG

SSI LEPKLEPtQEL SPLSATVFPK VEHSPGPPLA DAEClQEGLSE NSACRUTVVK bOl TEEGRlQALEP LPώGIiQESLN NPTPGDLEEI VKMEPEEARE EISGSPERDI bSl CDDIKVEHAV ELDTGAPSEE LSSAGEVTKtQ TVLiQKEEERS (QPTKTPSSSlQ

701 EPPDEGTSGT DVNKGSSKNA LSSMDPEVRL SSPPGKPEDS SSVDGύSVGT

751 PVGPETGGEK NGPEEEEEED FDDLTiQDEED EMSSASEESV LSVPELiQVRA

601 GEYSlQVFRGL SNMYHLLICH LLACCTMDSP KIICI

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_li24ι frame 3 No Alert BLASTP hits found

Pedant information for DKFZphamy2_li24 ι frame 3

Report for DKFZphamy2_li24 ■ 3

ELENGTH! 672

EMU! 153bb-21

Epl! 5.67

EHOMOL! PIR:S4δ47β glucan li 4-alpha-glucosidase (EC

3.2-L3) - yeast (Saccharomyees cerevisiae) 5e-0b

EFUNCAT! 30-01 organization of cell wall ES- cerevisiaei

YIROllc! 2e-07

EFUNCAT! 3D-10 extracellular/secretion proteins ES- cerevisiae-

YIROllc! 2e-07

EFUNCAT! 01-05-01 carbohydrate utilization ES- cerevisiaei

YIROllc! 2e-07

EFUNCAT! 02-10 tricarboxylic-acid pathway ES- cerevisiaei

YDR14δc! Se-04

EFUNCAT! 30-lb mitochondrial organization ES- cerevisiaei

YDR14δc! 5e-04

EKU! Alpha_Beta

EKU! LOU COMPLEXITY 1-40 *

SEl^Q KSSAK(^QLι^QEVEKVKP⁽QSEKVHιQTLILDPAι3RKRL(Q(Q(QM(Q(QHV(QLLT(QIHLLATCNPNLNP

SEG xxxxxxxxxxxxxx

PRD ccchhhhhhhhhhhccccchhhhhcccchhhhhhhhhhhhhhhhhhhhhhhhcccccccc

SEl^Q EATTTRIFLKELGTFA(QSSIALHH(QYNPKF(3TLF(QPCNLMGAM(QLIEDFSTHVSIDCSPH

SEG

PRD cchhhhhhhhhhhhhhhhhhhhhcccccceeeeecccchhhhhhhhhhceeeeeeccccc SElQ KTVKKTANEFPCLPKlQVAUILATSKVFMYPELLPVCSLKAKNPlQDKIVFTKAEDNLLALG

SEG

PRD eeeeeccccccccchhhhhhhccceeeecccccccccccccccceeeeeeeccchhhhhh

SElQ LKHFEGTEFPNPLISKYLLTCKTAHlQLTVRIKNLNMNRAPDNIIKFYKKTKlQLPVLGKCC

SEG

PRD hheeecccccccceeeeeeeehhhhhhhhheeeccccccccceeeeeeccccccccceee SElQ EEI(QPH(QUKPPIEREEHRLPFULKASLPSI(QEELRHMADGAREVGNMTGTTEINSDRSLE

SEG

PRD eeecccccccccchhhhhcceeeecchhhhhhhhhhhhhhhhhhhcccccccccccceee

SElQ KDNLELGSESRYPLLLPKGVVLKLKPVATRFPRKAURlQKRSSVLKPLLIlQPSPSLiQPSFN SEG xxxxxxxxxxxxxxx xxxxxxxxxxxxxxx. ■

PRD ecccccccccccccccccceeeeeeeeeeeccchhhhhhccccccccccccccccccccc

SElQ PGKTPARSTHSEAPPSKMVLRIPHPIiQPATVLlQTVPGVPPLGVSGGESFESPAALPAVPP

SEG xxxxxxxxxxxx PRD cccccccccccccccccceeecccccceeeeeeccccccccccccccccccccccccccc

SElQ EARTSFPLSESiQTLLSSAPVPKVMLPSLAPSKFRKPYVRRRPSKRRGVKASPCMKPAPVI

SEG

PRD cccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc

SElQ HHPASVIFTVPATTVKIVSLGGGCNMI(QPVNAAVA(QSP(QTIPITTLLVNPTSFPCPLN(QS

SEG

PRD ccccceeecccccceeeeeccccccccccccccccccccccccceeeccccccccccccc SElQ LVASSVSPLIVSGNSVNLPIPSTPEDKAHVNVDIACAVADGENAFiQGLEPKLEPiQELSPL

SEG

PRD ccccccccccccccccccccccccccccccccccceeecccccccccccccccccccccc

SElQ SATVFPKVEHSPGPPLADAEC(QEGLSENSACRUTVVKTEEGR(QALEPLP(QGIfQESLNNPT SEG

PRD ccccccccccccccccccccccccccccccceeeeeecccccccccccccceeeeccccc

SElQ PGDLEEIVKMEPEEAREEISGSPERDICDDIKVEHAVELDTGAPSEELSSAGEVTKiQTVL

SEG PRD ccccccccccccccceeeccccccccccccccccccccccccccccccccccccccchhh

SElQ (QKEEERSlQPTKTPSSSiQEPPDEGTSGTDVNKGSSKNALSSMDPEVRLSSPPGKPEDSSSV

SEG

PRD hhhhhhcccccccccccccccccccccccccccccccccccccccccccccccccccccc

SElQ DGώSVGTPVGPETGGEKNGPEEEEEEDFDDLTiQDEEDEMSSASEESVLSVPELiQVRAGEY

SEG xxxxxxxxxxxxxxxxxxxxxxxxxx

PRD cccccccccccccccccccchhhhhhhcccchhhhhhhhhhcccccccccceeeeecccc SEA SiQVFRGLSNMYHLLICHLLACCTMDSPKIICI

SEG

PRD eeeeeehhhhhhhhhhhhhhhhcccccccccc

(No Prosite data available for DKFZphamy2_li24 • 3) (No Pfam data available for DKFZphamy2_li24 -3) DKFZphamy2_ljl1

group: differentiation/development DKFZphamy2_ljll encodes a novel ISO amino acid protein with high similarity to the allograft inflammatory factor-1 of Cyprinus carpio-

Allograft inflammatory factor-1 (AIF-11 is a protein involved in allograft rejection- In experimental autoimmune encephalomyelitis (EAE)ι neuritis(EAN) and uveitis (EAU) it is produced by macrophages and microglia cells-

The new protein can find clinical application in the development of tools to enhance the compatibility of transplanted tissues as well as in expression profiling of autoimmune diseases and infections.

strong similarity to allograft inflammatory factor-1 (Cyprinus carpio) identical to DKFZphamy2_lnl Sequenced by MediGenomix

Locus: /map="504-1 cR from top of Chrl linkage group"

Insert length: 3361 bp Poly A stretch at pos- 33b2ι polyadenylation signal at pos- 3344

1 GCCGGAGCCC GGACCAGGCG CCTGTGCCTC CTCCTCGTCC CTCGCCGCGT

SI CCGCGAAGCC TGGAGCCGGC GGGAGCCCCG CGCTCGCCAT GTCGGGCGAG 101 CTCAGCAACA GGTTCCAAGG AGGGAAGGCG TTCGGCTTGC TCAAAGCCCG

ISI GCAGGAGAGG AGGCTGGCCG AGATCAACCG GGAGTTTCTG TGTGACCAGA

201 AGTACAGTGA TGAAGAGAAC CTTCCAGAAA AGCTCACAGC CTTCAAAGAG

251 AAGTACATGG AGTTTGACCT GAACAATGAA GGCGAGATTG ACCTGATGTC

301 TTTAAAGAGG ATGATGGAGA AGCTTGGTGT CCCCAAGACC CACCTGGAGA 351 TGAAGAAGAT GATCTCAGAG GTGACAGGAG GGGTCAGTGA CACTATATCC

401 TACCGAGACT TTGTGAACAT GATGCTGGGG AAACGGTCGG CTGTCCTCAA

4S1 GTTAGTCATG ATGTTTGAAG GAAAAGCCAA CGAGAGCAGC CCCAAGCCAG

501 TTGGCCCCCC TCCAGAGAGA GACATTGCTA GCCTGCCCTG AGGACCCCGC

5S1 CTGGACTCCC CAGCCTTCCC ACCCCATACC TCCCTCCCGA TCTTGCTGCC bOl CTTCTTGACA CACTGTGATC TCTCTCTCTC TCATTTGTTT GGTCATTGAG bSl GGTTTGTTTG TGTTTTCATC AATGTCTTTG TAAAGCACAA ATTATCTGCC

701 TTAAAGGGGC TCTGGGTCGG GGAATCCTGA GCCTTGGGTC CCCTCCCTCT

751 CTTCTTCCCT CCTTCCCCGC TCCCTGTGCA GAAGGGCTGA TATCAAACCA δOl AAAACTAGAG GGGGCAGGGC CAGGGCAG6G AGGCTTCCAG CCTGTGTTCC 651 CCTCACTTGG AGGAACCAGC ACTCTCCATC CTTTCAGAAA 6TCTCCAAGC

101 CAAGTTCAGG CTCACTGACC TGGCTCTGAC GAGGACCCCA GGCCACTCTG

151 AGAAGACCTT GGAGTAGGGA CAAGGCTGCA GGGCCTCTTT CGGGTTTCCT

1001 TGGACAGTGC CATGGTTCCA GTGCTCTGGT GTCACCCAGG ACACAGCCAC 10S1 TCGGGGCCCC GCTGCCCCAG CTGATCCCCA CTCATTCCAC ACCTCTTCTC

1101 ATCCTCAGTG ATGTGAAGGT GGGAAGGAAA GGAGCTTGGC ATTGGGAGCC

1151 CTTCAAGAAG GTACCAGAAG GAACCCTCCA GTCCTGCTCT CTGGCCACAC

1201 CTGTGCAGGC AGCTGAGAGG CAGCGTGCAG CCCTACTGTC CCTTACTGGG 1251 GCAGCAGAGG GCTTCGGAGG CAGAAGTGAG GCCTGGGGTT TGGGGGGAAA

1301 GGTCAGCTCA GTGCTGTTCC ACCTTTTAGG GAGGATACTG AGGGGACCAG

13S1 GATGGGAGAA TGAGGAGTAA AATGCTCACG GCAAAGTCAG CAGCACTGGT

1401 AAGCCAAGAC TGAGAAATAC AAGGTTGCTT GTCTGACCCC AATCTGCTTG

1451 AAACCTGACT CTGCTTCTCT CATTTGTCTT CCTACCCTAC TCACATAATT 1S01 CACTCATTGA CTCACTCATT CACCAGATAT TTATTGACCT GCTATTATAA

15S1 GCTTTACATC CTCCCATGTT GTCCTGGCAT GTGCAGTATA CACGGTCTAA

IbOl CTCATCTCTC CCCAGATCTC TCAGAACCTT GAGCTTGGGA ATTGAACTGG lb51 GGTCACCTGT GTCCTTTCTT ATGGACTCGC AGGATTTTAG AACCCTAATG

1701 CACCCTGGAG GGTAGCTGGG CCAGACTTCT CATTTCACAG GTGAGGAGAC 17S1 TGGTGCCCCA CAGGGATTAA GTGCCTTGCC CAAGGTCAGG CTTATCTCCA

1601 GAGGGAGGTG CCCTGGACTG GGGCCCAGAT GTTCAGGGAC CCTGCCTACA

IδSl CCTCATTTCC AGTGTGGGCT GCCTTAGTTA GTTATGAGAA CAGGGAAGGG

1101 CTGGGAAGAG ACAGCCTCCA AGGTCAACAC TTGGAGAGGG TTTCACTTGC

11S1 TCTGAAGACC CTGGTCCAGG ATTCGCCCTC TCCCATGCCT TCAAGTCAGC 2001 ATCAGGCTTA GGGCAAAGAC CAGGCCTCTG AAGCTGCCTC TTGTAATTCA

2051 TGCAGGAAGA TGTCAAAGTC AGCCCCATCT TGGCTGATCA GGGTGTTCAG

2101 CCTTAACCCC ACCTGTGTTC TGAAGTCTCT TACCCTACCT GCTCAGGACT

2151 GAGACAGTTA TTCACTGAAC ATATTTATTA AGCACTTGCT GTAGGCCAAC

2201 AGTTAAGAAT CCAATAATGA AATGGACAGA TTCATGGAAC TTAGAGTCCA 2251 ATAGGAAAGT GAGACCCAGA CAATGACAAT GAGATAAATG TTAGGAAGGG

2301 GGAGGTATGG GGTGACTTCC CTGCAGTCCT GGGGGCCTAC ATGGGCCCAA

2351 GACTGGGTGA GAGTCTTGGC AGAGCCTTTG CAACACCTTA AGTGGACAGG

2401 ACTGGGAGGT CTTGGTGGTT GGAGCCAACG TGGGTTCCCT GCGGCTCCTT

2451 AGTCACCTCT GATAGCAGAT TGAGGGAGGA AAACAGGTAA GGCATGAGGA 2S01 AATGGCCAGG TTGGGTTAAC CCACTGGTTT CAACCAGTTC AGGAATGAGG

25S1 TTATTTGGCC ATGACT6GCT GATCTTGAGC TCAAGGATCT GCTTCAAATG

2b01 CACACAGGCC TAGTTGAAGT TTAAACCCCA GCAAAACATT CCTCCCTGTA

2b51 AATGGAAAAT CCTACTTCTA CCCCCACCCT GCCCTGTTTT TTGTTTTTTT

2701 TTTCCCCAAG ATCATTAGAT GTCCTCACCC CTCCTCACTG CCTCTCCTCT 27S1 CTGGGACAGG CTGGGACCTT TGAGGAAGAT AAAGCCTTCC TTGACTACCC

2801 ATCATATTCA GTGTCCCTGT TCCTCACTCA GAGAGGAAGG CAGAACCAGT

2851 CAGGCTTATT TCAGTAAGTT CCACAGTTCT ACAAGACTGC AGGAATTCTC

2101 CTTAAGGGAG GAGAGCAAGC AGGTGTGGCC CCAGCTTCTG GAAATGGCAG

2151 AAGAGAGGGT TTTCTCATTG AATGGGGGTG GGGGCTCGTG TGTCCTGGGA 30D1 AACCCCATCA GTCCCTTCAT TTCTTGAGAC TCAACTCCTG GGAGGAGAGG

3051 GTCTCAAGAG TTGTCCCTGG AAGGAGGGCG GGGGCAGTCT GCATCTATTT

3101 CAGGTTGTGG CTCTTGGTTC TAGGACTCTT ACTTCTCTGG CTAAGGGCTC

3151 AGCTTCTTGG GACTTCAACC ATCTTCTTTC TGAAAGACCA AATCTAATGT

3201 AACCAGTAAC GTGAGGACTG CCAAGTATGG CTTTGTCCCT ATGACTCAGA 3251 GGAGGGTTTG TCGGGCAAAT TCAGGTGGAT GAAGTATGTG TGTGCGTGTG

3301 CATGGGAGTG TGCGTGGACT GGGATATCAT CTCTACAGCC TGCAAATAAA

33S1 CCAGACAAAC TTAAAAAAAA AAAAAAAAAA A

BLAST Results

Entry AB012301_1 from database TREMBL: product: "allograft inflammatory factor-l"i Cyprinus carpio mRNA for allograft inflammatory factor-li complete eds-

Score = 57Sι P = 3-7e-S4ι identities = 113/14bι positives =

126/14bι frame +2

Medline entries

No Medline entry

Peptide information for frame 2

ORF from 81 bp to 538 bpi peptide length: 150 Category: strong similarity to known protein Classification: unclassified

1 MSGELSNRF(Q GGKAFGLLKA RiQERRLAEIN REFLCDlQKYS DEENLPEKLT SI AFKEKYMEFD LNNEGEIDLM SLKRMMEKLG VPKTHLEMKK MISEVTGGVS

101 DTISYRDFVN MMLGKRSAVL KLVMMFEGKA NESSPKPVGP PPERDIASLP

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_ljlli frame 2 No Alert BLASTP hits found

Pedant information for DKFZphamy2__ljlli frame 2

Report for DKFZphamy2_ljll ■ 2

ELENGTH! 15D

EMU! 170b7-8b

E Eppll!! bb--bb33

EH0M0L! TREMBL AB0123D1_1 product: "allograft inflammatory factor-l"i Cyprinus carpio mRNA for allograft inflammatory factor-li complete eds- 2e-S1 EFUNCAT! 30-04 organization of cytoskeleton ES- cerevisiaei

YBRlOlc! 5e-04

EFUNCAT! 03-07 pheromone response! mating-type determination! sex-specific proteins ES- cerevisiaei YBRlOlc! Se-04

EFUNCAT! Oδ-11 cellular import ES- cerevisiaei YBRlOlc! 5e-04 EFUNCAT! 10-02-11 other morphogenetic activities ES- cerevisiaei YBRlOlc! Se-04

EFUNCAT! 03-22 cell cycle control and mitosis ES. cerevisiaei

YBRlOlc! Se-04

EFUNCAT! 03-04 buddingi cell polarity and filament formation ES- cerevisiaei YBRlOlc! Se-04

EFUNCAT! 03-01 cell growth ES- cerevisiaei YBRlOlc! Se-04

EFUNCAT! 30-05 organization of centrosome ES- cerevisiaei

YBRlOlc! 5e-04 ESCOP! d2mysb_ 1-37-1-5-15 Myosin Essential Chain Myosin

Regulatory Chai 5e-2D

ESCOP! dlwdcb_ 1-37-1-S-14 Myosin Essential Chain Myosin

Regulatory Chai 3e-05 ESCOP! dlosa 1-37-1.5-13 Calmodulin E(Paramecium tetraurelia) 3e-lb

ESCOP! dlauib_ 1-37-1.5.11 Calcineurin regulatory subunit

(B-chain 2e-lb •

EPIRKU! duplication 7e-0b EPIRKU! mitosis 7e-0b

EPIRKU! calcium binding 7e-0b

[PIRKU! EF hand 7e-0b

[PIRKU! cell division 7e-0b

[SUPFAM! unassigned calmodulin-related proteins 3e-47 [SUPFAM! calmodulin 7e-0b

[SUPFAM! calmodulin repeat homology 3e-47

[KU! All_Alpha

[KU! 3D

SElQ MSGELSNRFlQGGKAFGLLKARlQERRLAEINREFLCDlQKYSDEENLPEKLTAFKEKYMEFD lctr- HHHHHHHHHHHHHT SEl^Q LNNEGEIDLMSLKRMMEKLGVPKTHLEMKKMISEVTGGVSDTISYRDFVNMMLGKRSAVL lctr-

TTTTTCBCHHHHHHHHHHTTTCCCHHHHHHHHHHCTTTTCCCBCHHHHHHHHCCTTTHHH

SElQ KLVMMFEGKANESSPKPVGPPPERDIASLP lctr- HHHHHHTTTTC

(No Prosite data available for DKFZphamy2_ljll ■ 2) (No Pfam data available for DKFZphamy2_ljll .2)

DKFZphamy2_24b4

group: cell cyle

DKFZphamy2_24b4 encodes a novel blδ amino acid protein with similarity to human STIML The stromal interaction molecular 1 gene (STIMl) encodes a type I trans-membrane protein of unknown functioni which induces growth arrest and degeneration of the human tumor cell lines G401 and RD but not HBL100 and CaLu-bi suggesting a role in the pathogenesis of rhabdomyosarcomas and rhabdoid tumors- There is also strong similarity to a Mus musculus stromal cell proteini which selectively increases interleukin 7-dependent proliferation of pre-B cells- The novel protein contains 1 transmembrane domain-

The new protein can find application in modulation of tumour growth-

similarity to STIMl (Homo sapiens) probably differential polyadenylation: _cf- EST-BLAST file- perhaps complete eds- Pedant: SIGNAL PEPTIDE and TRANSMEMBRANE 1

Sequenced by GBF

Locus: /map="131-2 cR from top of Chr4 linkage group'

Insert length: 3305 bp

Poly A stretch at pos- 3274ι polyadenylation signal at pos- 32b0 ^' I

1 GGCGCCTTCA TCCCGCCTCG ACTCCTGGCC CAGCGTGGGG CTGGCTGCTG

51 CGGCGGCGGC GCTGGGCTGC GTTGCTGGTG CTCGGGCTGC TGGTACCCGG

101 AGCGGCGGAC GGATGCGAGC TTGTGCCCCG GCACCTCCGC GGGCGGCGGG ISI CGACTGGCTC TGCCGCAACT GCCGCCTCCT CTCCCGCCGC GGCGGCCGGC

201 GATAGCCCGG CGCTCATGAC AGATCCCTGC ATGTCACTGA GTCCACCATG

251 CTTTACAGAA GAAGACAGAT TTAGTCTGGA AGCTCTTCAA ACAATACATA

301 AACAAATGGA TGATGACAAA GATGGTGGAA TTGAAGTAGA GGAAAGTGAT

351 GAATTCATCA GAGAAGATAT GAAATATAAA GATGCTACTA ATAAACACAG 401 CCATCTGCAC AGAGAAGATA AACATATAAC GATTGAGGAT TTATGGAAAC

451 GATGGAAAAC ATCAGAAGTT CATAATTGGA CCCTTGAAGA CACTCTTCAG

SOI TGGTTGATAG AGTTTGTTGA ACTACCCCAA TATGAGAAGA ATTTTAGAGA

SSI CAACAATGTC AAAGGAACGA CACTTCCCAG GATAGCAGTG CACGAACCTT bOl CATTTATGAT CTCCCAGTTG AAAATCAGTG ACCGGAGTCA CAGACAAAAA bSl CTTCAGCTCA AGGCATTGGA TGTGGTTTTG TTTGGACCTC TAACACGCCC

7D1 ACCTCATAAC TGGATGAAAG ATTTTATCCT CACAGTTTCT ATAGTAATTG

751 GTGTTGGAGG CTGCTGGTTT GCTTATACGC AGAATAAGAC ATCAAAAGAA

601 CATGTTGCAA AAATGATGAA AGATTTAGAG AGCTTACAAA CTGCAGAGCA

651 AAGTCTAATG GACTTACAAG AGAGGCTTGA AAAGGCACAG GAAGAAAACA 101 GAAATGTTGC TGTAGAAAAG CAAAATTTAG AGCGCAAAAT GATGGATGAA

151 ATCAATTATG CAAAGGAGGA GGCTTGTCGG CTGAGAGAGC TAAGGGAGGG

1001 AGCTGAATGT GAATTGAGTA GACGTCAGTA TGCAGAACAG GAATTGGAAC

10S1 AGGTTCGCAT GGCTCTGAAA AAGGCCGAAA AAGAATTTGA ACTGAGAAGC 1101 AGTTGGTCTG TTCCAGATGC ACTTCAGAAA TGGCTTCAGT TAACACATGA

1151 AGTAGAAGTG CAATACTACA ATATTAAAAG ACAAAACGCT GAAATGCAGC

1201 TAGCTATTGC TAAAGATGAG GCAGAAAAAA TTAAAAAGAA GAGAAGCACA

1251 GTCTTTGGGA CTCTGCACGT TGCACACAGC TCCTCCCTAG ATGAGGTAGA 1301 CCACAAAATT CTGGAAGCAA AGAAAGCTCT CTCTGAGTTG ACAACTTGTT

13S1 TACGAGAACG ACTTTTTCGC TGGCAACAAA TTGAGAAGAT CTGTGGCTTT

1401 CAGATAGCCC ATAACTCAGG ACTCCCCAGC CTGACCTCTT CCCTTTATTC

1451 TGATCACAGC TGGGTGGTGA TGCCCAGAGT CTCCATTCCA CCCTATCCAA

1S01 TTGCTGGAGG AGTTGATGAC TTAGATGAAG ACACACCCCC AATAGTGTCA 15S1 CAATTTCCCG GGACCATGGC TAAACCTCCT GGATCATTAG CCAGAAGCAG

IbOl CAGCCTGTGC CGTTCACGCC GCAGCATTGT GCCGTCCTCG CCTCAGCCTC

IbSl AGCGAGCTCA GCTTGCTCCA CACGCCCCCC ACCCGTCACA CCCTCGGCAC

1701 CCTCACCACC CGCAACACAC ACCACACTCC TTGCCTTCCC CTGATCCAGA

1751 TATCCTCTCA GTGTCAAGTT GCCCTGCGCT TTATCGAAAT GAAGAGGAGG IδOl AAGAGGCCAT TTACTTCTCT GCTGAAAAGC AATGGGAAGT GCCAGACACA

1651 GCTTCAGAAT GTGACTCCTT AAATTCTTCC ATTGGAAGGA AACAGTCTCC

1101 TCCTTTAAGC CTCGAGATAT ACCAAACATT ATCTCCGCGA AAGATATCAA

1151 GAGATGAGGT GTCCCTAGAG GATTCCTCCC GAGGGGATTC GCCTGTAACT

2001 GTGGATGTGT CTTGGGGTTC TCCCGACTGT GTAGGTCTGA CAGAAACTAA 20S1 GAGTATGATC TTCAGTCCTG CAAGCAAAGT GTACAATGGC ATTTTGGAGA

2101 AATCCTGTAG CATGAACCAG CTTTCCAGTG GCATCCCGGT GCCTAAACCT

2151 CGCCACACAT CATGTTCCTC AGCTGGCAAC GACAGTAAAC CAGTTCAGGA

2201 AGCCCCAAGT GTTGCCAGAA TAAGCAGCAT CCCACATGAC CTTTGTCATA

22S1 ATGGAGAGAA AAGCAAAAAG CCATCAAAAA TCAAAAGCCT TTTTAAGAAG 2301 AAATCTAAGT GAACTGGCTG ACTTGATGGA ATCATGTTCA AGTGGCATCT

2351 GTAAACTATT ATCCCCCACC CTCCACTCCC CACCTTTTTT TTGGTTTAAT

2401 TTTAGGAATG TAACTCCATT GGGGCTTTCC AGGCCGGATG CCATAGTGGA

2451 ACATCCAGAA GGGCAACTGT CTACTGTCTG CTTATTTAAG TGACTATATA

2S01 TAATCAATTC ATCAAGCCAG TTATTACTGA AAAATCATTG AAATGAGACA 2SS1 GTTTACAGTC ATTTCTGCCT ATTTATTTCT GCTTTGTTCT CAGTGATGTA

2b01 TATGCAACAT TTTGTTGAAA GCCACGATGG ACTTACAAGC TTTAATGGAC

2b51 TCGTAAGCCA GCATGGGCTT GCAAAAATTT CTTGTTTACC AGAGCATCTT

2701 CTTATCTTTC CACAGAGCTA TTTACATCCT GGACTATATA ACTTAAAAGA

2751 AGTAAAACGT AATTGCACTA CTGTTTTCCA GACTGGAAAA AAAAAAAAAT 2601 CTCTGCAAGT GAAACTGTAT AGAGTTTATA AAATGACTAT GGATAGGGGA

2651 CTGTTTTCAC TTTTAGATCA AAATGGGTTT TTAAGTAGAA CCTAGGGTTT

2101 CTAATTGACT TGATTTCTGG AAATGAAAAC CCGCGCTTTT ATTATGGGAA

2151 GCTTCTTGAA CTGCATTTAC TATTGTGAAG TTTCAAGTCC CGCTGTAAAG

3001 ATCATGTTGT TTTGTTTTCC CCAGGGCTTT CACTGTGATT TACTGCATTG 3051 CAGGCTGTAT GATAAAACAC ACATAATTTA AAGAGAGAAG GCTCTTGATT

3101 CCTTATGCAA GTGGAAGAGT TGAAACTTGA TTGAAGGACT TAAAACATTC

31S1 ACAACCTTAA GCCGAGGTGG GGGGATATGG GGATTCAGGC AGTTGTTTAC

3201 ACACTTTGAA TAACTGCAAA GGATTTACGG TTTGTGAAAA ATGTGTACTG

3251 TGGAAAAGAT AATAAATTGA AGACATTAAA AAAAAGAAAA AAAAAAAAAA 3301 AAAAA

BLAST Results

Entry HSS242blO_l from database TREMBL: gene: "STIMl"i product: "GOK"i Homo sapiens GOK (STIMl) mRNAi complete eds- Score = 1317ι P = 4-2e-142ι identities = 275/447ι positives =

33b/447ι frame +3 Entry MMU47323_1 from database TREMBL: product: "stromal cell protein"i Mus musculus stromal cell protein mRNAi complete eds- Score = 1314ι P = 6-6e-142i identities = 274/447ι positives = 33b/447ι frame +3

Entry HS117341 from database EMBL: human STS ESTlb7471-

Score = 1310ι P = 1.1e-57ι identities = 264/267

Medline entries

17071b12:

Parker NJi Begley CGi Smith PJi Fox RM-i Molecular cloning of a novel human gene (DllS461bE) at chromosomal region llplS-S- Genomics 111b Oct 15i37 (2) :253-b

1b32bbβ0: Oritani Ki Kincade PU-i Identification of stromal cell products that interact with pre-B cells- J Cell Biol 111b Augil34 (3) : 771-62

Peptide information for frame 3

ORF from 21b bp to 2301 bpi peptide length: blβ Category: similarity to known protein Classification: Cell signaling/communication Prosite motifs: RGD (561-511)

1 MTDPCMSLSP PCFTEEDRFS LEALiQTIHKiQ MDDDKDGGIE VEESDEFIRE

51 DMKYKDATNK HSHLHREDKH ITIEDLUKRU KTSEVHNUTL EDTLlQULIEF

101 VELPlQYEKNF RDNNVKGTTL PRIAVHEPSF MISώLKISDR SHR(QKL(QLKA ISI LDVVLFGPLT RPPHNUMKDF ILTVSIVIGV GGCUFAYTlQN KTSKEHVAKM

201 MKDLESLiQTA EtQSLMDLiQER LEKAiQEENRN VAVEKlQNLER KMMDEINYAK

251 EEACRLRELR EGAECELSRR (QYAEiQELEiQV RMALKKAEKE FELRSSUSVP

301 DALlQKULlQLT HEVEVcQYYNI KRlQNAEMlQLA IAKDEAEKIK KKRSTVFGTL

3S1 HVAHSSSLDE VDHKILEAKK ALSELTTCLR ERLFRUiQlQIE KICGFiQIAHN 401 SGLPSLTSSL YSDHSUVVMP RVSIPPYPIA GGVDDLDEDT PPIVSlQFPGT

451 MAKPPGSLAR SSSLCRSRRS IVPSSPcQPiQR AlQLAPHAPHP SHPRHPHHPiQ

501 HTPHSLPSPD PDILSVSSCP ALYRNEEEEE AIYFSAEKlQU EVPDTASECD

SSI SLNSSIGRKiQ SPPLSLEIYfi TLSPRKISRD EVSLEDSSRG DSPVTVDVSU bOl GSPDCVGLTE TKSMIFSPAS KVYNGILEKS CSMNiQLSSGI PVPKPRHTSC bSl SSAGNDSKPV (QEAPSVARIS SIPHDLCHNG EKSKKPSKIK SLFKKKSK BLASTP hits No BLASTP hits available Alert BLASTP hits for DKFZphamy2_24b4ι frame 3

No Alert BLASTP hits found

Pedant information for DKFZphamy2_24b4ι frame 3

Report f or DKFZphamy2_24b4 - 3

[LENGTH! 7b1

[MU! 6bb73 - 41

[pi! b - bl

[H0M0L! TREMBL:HS5242blO_l gene: "STIMl"i product: "G0K"i

Homo sapiens GOK (STIMl) mRNAi complete eds. le-154 [BLOCKS! BLOOδβbC Dihydroxy-acid and b-phosphogluconate dehydratases proteins

[BLOCKS! PR00021D

[BLOCKS! PR010S3F

[BLOCKS! BL0072bB AP endonucleases family 1 proteins [PROSITE! RGD 1

[KU! SIGNAL_PEPTIDE 3δ

[KU! TRANSMEMBRANE 1

[KU! L0U_C0MPLEXITY 15-δb *

[KU! COILED COIL 6-45 *

SElQ RLHPASTPGPAUGULLRRRRUAALLVLGLLVPGAADGCELVPRHLRGRRATGSAATAASS

SEG xxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxx

PRD cccccccccccchhhhhhhhhhhhhhhhhcccccccccccchhhhhhhcccccccccccc COILS

MEM

SElQ PAAAAGDSPALMTDPCMSLSPPCFTEEDRFSLEALiQTIHKiQMDDDKDGGIEVEESDEFIR SEG xxxxxxxxxx

PRD ccccccccccccccccccccccccchhhhhhhhhhhhhhhhhhcccccceeeecchhhhh COILS

MEM

SElQ EDMKYKDATNKHSHLHREDKHITIEDLUKRUKTSEVHNUTLEDTLlQULIEFVELPiQYEKN SEG

PRD hhcccccccccccccccccceeeehhhhhhhhhhccccchhhhhhhhhhhhhhcccchhh COILS

MEM

SElQ FRDNNVKGTTLPRIAVHEPSFMISlQLKISDRSHRlQKLiQLKALDVVLFGPLTRPPHNUMKD SEG PRD hhhhhccccccceeeeecccceeeeeecccchhhhhhhhhhheeeecccccccccccchh COILS

MEM SElQ FILTVSIVIGVGGCUFAYT(QNKTSKEHVAKMMKDLESL(QTAE(QSLMDL(QERLEKA(QEENR

SEG

PRD hhheeeeeeccccceeeecccccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhcc COILS CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC

MEM MMMMMMMMMMMMMMMMM

SElQ NVAVEKiQNLERKMMDEINYAKEEACRLRELREGAECELSRRiQYAElQELEiQVRMALKKAEK SEG

PRD ceeeehhhhhhhhhhhhhhhhhhhhhhhhhhhhcchhhhhhhhhhhhhhhhhhhhhhhhh COILS

CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC

MEM

SElQ EFELRSSUSVPDAL(QKUL(QLTHEVEV(QYYNIKR(QNAEM(QLAIAKDEAEKIKKKRSTVFGT SEG xxxxxxxxxxxxx

PRD hhhhhccccccchhhhhhhhhhhheeeeccchhhhhhhhhhhhhhhhhhhhhhhhhccce COILS

MEM

SElQ LHVAHSSSLDEVDHKILEAKKALSELTTCLRERLFRUiQiQIEKICGFlQIAHNSGLPSLTSS SEG PRD eeeeeccccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhcceeeeccccccceee COILS

MEM SElQ LYSDHSUVVMPRVSIPPYPIAGGVDDLDEDTPPIVSiQFPGTMAKPPGSLARSSSLCRSRR

SEG xxxxxxxxxxxxx

PRD cccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc COILS MEM

SElQ SIVPSSPIQPIQRAIQLAPHAPHPSHPRHPHHPIQHTPHSLPSPDPDILSVSSCPALYRNEEEE

SEG x xxxxxxxxxxxxxxxxxxxxxxxxx xxxx

PRD eeecccccccccccccccccccccccccccccccccccccccceeeeeecccchhhhhhh COILS

MEM

SElQ EAIYFSAEKIQUEVPDTASECDSLNSSIGRKIQSPPLSLEIYIQTLSPRKISRDEVSLEDSSR SEG x

PRD hhhhhhhhhhcccccccccccccccccccccccceeeeeeeecccccccccccccccccc COILS

MEM

SElQ GDSPVTVDVSUGSPDCVGLTETKSMIFSPASKVYNGILEKSCSMNiQLSSGIPVPKPRHTS SEG

PRD cccceeeeeccccccccceeeccccccccccceeeeeeeccccccccccccccccccccc COILS

MEM

SElQ CSSAGNDSKPViQEAPSVARISSIPHDLCHNGEKSKKPSKIKSLFKKKSK SEG xxxxxxxxxxxxxxxxx

PRD ccccccccceeeecceeeeeccccccccccccccccccceeeeeecccc

COILS

MEM

Prosite for DKFZphamy2_24b4 -3 PSOOOlb bb0->bb3 RGD PDOCOOOlb

(No Pfam data available for DKFZphamy2_24b4.3)

DKFZphamy2_24cδ

group: transmembrane protein

DKFZphamy2_24cδ encodes a novel 454 amino acid protein without similarity to known proteins- The novel protein contains 1 transmembrane region- No informative BLAST resultsi No predictive prositei pfam or SCOP motife-

The new protein can find application in studying the expression profile of amygdala-specific genes and as a new marker for amygdala cells-

putative protein

EST of GEN-42bH07 is 141 Bp longer at S'-end perhaps complete eds- Pedant: TRANSMEMBRANE 1

Sequenced by GBF

Locus". /map="b01.7 cR from top of Chr3 linkage group" Insert length: 3200 bp

Poly A stretch at pos- 3177ι polyadenylation signal at pos. 315b

1 CCTGTCCACA GGGCCCGCTC CAGCAGCCAT GGCAACCACA TCCTCCAAGC 51 CAGAGGGCCG CCCTCGAGGG CAGGCTGCCC CCACCATCCT GCTGACAAAG

101 CCACCGGGGG CCACCAGCCG CCCCACCACA GCGCCCCCCC GCACTACCAC

151 ACGCAGGCCC CCCAGGCCCC CAGGCTCTTC CCGAAAAGGG GCTGGTAATT

201 CATCACGCCC TGTCCCGCCT GCACCTGGTG GCCACTCCAG GAGTAAAGAA

251 GGACAGCGAG GACGAAATCC AAGCTCCACA CCTCTGGGGC AGAAGCGGCC 301 CCTGGGGAAA ATCTTTCAGA TCTACAAGGG CAACTTCACA GGGTCTGTGG

351 AACCGGAGCC CTCTACCCTC ACCCCCAGGA CCCCACTCTG GGGCTACTCC

401 TCTTCACCAC AGCCCCAGAC AGTGGCTGCG ACCACAGTGC CCAGCAATAC

451 CTCATGGGCA CCCACCACCA CCTCCCTGGG GCCTGCAAAG GACAAGCCAG

501 GCCTTCGCAG AGCAGCCCAG GGGGGTGGTT CTACCTTCAC CAGCCAAGGA S51 GGGACACCAG ATGCCACAGC AGCCTCAGGT GCCCCTGTCA GTCCACAAGC bOl TGCCCCAGTG CCTTCTCAGC GCCCCCACCA CGGTGACCCA CAGGATGGCC bSl CCAGCCATAG TGACTCTTGG CTTACTGTTA CCCCTGGCAC CAGCAGACCT

701 CTGTCTACCA GCTCTGGGGT CTTCACGGCT GCCACGGGGC CCACCCCAGC

751 TGCCTTCGAT ACCAGTGTCT CAGCCCCTTC CCAGGGGATT CCTCAGGGAG 601 CATCCACAAC CCCACAAGCT CCAACCCATC CCTCCAGGGT CTCAGAAAGC

651 ACTATTTCTG GAGCCAAGGA GGAGACTGTG GCCACCCTCA CCATGACCGA

101 CCGGGTGCCC AGTCCTCTCT CCACAGTGGT ATCCACA6CC ACAGGCAATT

151 TCCTCAACCG CCTGGTCCCC GCCGGGACCT GGAAGCCTGG GACAGCAGGG

1001 AACATCTCCC ATGTGGCCGA GGGGGkCkkk CCGCAGCACA GAGCCACCAT 1051 CTGCCTGAGC AAGATGGATA TCGCCTGGGT GATCCTGGCC ATCAGCGTGC

1101 CCATCTCCTC CTGCTCTGTC CTGCTGACGG TGTGCTGCAT GAAGAGGAAG

1151 AAGAAGACCG CCAACCCGGA GAACAACCTG AGCTACTGGA ACAACACCAT

1201 CACCATGGAC TACTTCAACA GGCATGCTGT GGAGCTGCCC AGGGAGATCC 12S1 AGTCCCTTGA AACCTCTGAG GACCAGCTCT CAGAGCCCCG CTCCCCAGCC

1301 AATGGCGACT ATAGAGACAC TGGGATGGTC CTTGTTAACC CCTTCTGTCA

1351 AGAAACACTG TTTGTGGGAA ACGATCAAGT ATCTGAGATC TAACTACAGC

1401 AGGCATCACT TTGCCATTCC GTATTTTTCG TCTCTAAATT ATAAATATAC 1451 AAATATATAT ATTATAAATA TAACCTTTGT GTAACCCTGA CTTAATGAGA

1501 AACATTTTCA GCTTTTTTTC CTATGAATTG TCAACATCTT TTTTACAAGT

1SS1 GTGGTTTAAA AAAAAAAAAA CTTTACAGAA TGATCTGTGG CTTTATAAAA

IbOl TAAAGGTATT TCTAAGCAAA GCAGTTGCAT TGATTGCTTC TCTTAATAAC

IbSl TATTCTTGAG CACCTGGGGA TCCCAGGAAC CCTGGTCAGG TGAGGTAAGA 1701 GACTGACCTC CTGTAGAAGC TGAATGTTAC AGTGGTCAAG CGCACGATTC

17S1 TTTGAGTGAT TCTTAAAGCT CTGGTTCCTC TTGATTTGGT GTGACCCCAT

IflDl TTCCTCCCTT CTCATACGCA CACCTGTAAA GGGAACTGGA CCGCCTCAGG

IδSl GGAAGACGGC AGACTCATGC ACAGAGAAGG AAAAGGGAAC ATCTCATCAC

,. , 1.101 CTCTGAGGAT GAGTACCCTG GAGCCTTATG ACGGCACCAT TGGATGTCAT 1151 GTTTAATTCC ATCCAAGTTG TGGATGGCAG GCAGGAGCAT GGAGCCCTCA

2001 GGAATCCATG GAGGACATCA AGGCATCCCA AGGCCATATT CCCCTAACAT

2051 TACTTCCACT GCTAACAACA GGACTGCCTT TCCCTGGTGG GAAAATGCTC

2101 CCTTTATGCC CATTCCTGTA TCCCCTCCAA CACCCACATC TGCATTAAAC

2151 ACCCGTGCCT TTCTCTTGGA GAGGGTTTAG ATGCAGATCC CGGCCCTGGA 2201 GCTTTAAAAT GCTTGCCCTT CCTTCTTCAA GGATCAAATG TTTATTGGGG

2251 TTCAGCTTTG TTTTCTCAAA AGGCCATGGT ATCGTGCCCC TGAGGAACAT

2301 GTTTATCTAA GAAGCTTTGA GGTAGTAGAG CGATAATTTT TGAAACCTTC

2351 CTCCTGCAAT CTTTAAAAAA GkkkkkkkkG ATTGCCCAAA CAAATCATTT

2401 GGGAGAAGAC ATCATTATAC TCCTACTTGG CACTGCAAAC CTGCTCGCAG 2451 CACCAGCCGG TGGACTTGCC ATCCAGCTCT CAGCTTCCAC TGCTCCCCTT

2501 GTTCCCGGCC GGCTGGCTGC CTCCCCGTGC TGTGTCCAGC ACGGCCAACA

25S1 ACGTCAGACC CTCAGAGACG CCCAAGGGGC TTCCAGAGGT GGCCGCTTCT

2b01 CTATTTTTTC CTGATTGTGG CTGAGAGAGA TGATTACTGC TTTGACACTT

2b51 CCTTTCTCTA AAAGAAAAAT AGTTTGATAG TATATTTTGA ATATAGATGC 2701 TCTTATAGTC AGATTGGGAA TTGAACTTGA ATATTGGGTC ATATGTTTGT

27S1 GTTGTTGCTG TAGTCTATCA TGACTTTTTT CTTTCTGCAT TTTCCTTAAA

2601 AAAAAAAAAA AGATGGCCTT CAAAAGTGTG TTCTCAATGT TGTATGAACC

2851 TCCTTCACAT GAGTTCGGTT GTTGTCTCTC TTCAAAGACT CTTCAACCCA

2101 CAAAGAAGCA ACTAAATGTT TCTCTAAGTT TAATTTTCTA GCGTGTTGTT 21S1 GTCTTACCTT TTTAACCTTA CCATAATATT TCTGTTAACT GTTACATTTA

3001 ATATACCAAT GTGTGTAAGT ATACAGAGAA AAATCTGTTT GTAAAGTAAA

3051 ATTTATATAT AATATATGTA ATCAAAGATA CATATGTTAT ATATACATAT

3101 GTGGATGTAT GACTTATTTT TCCTTATCCA CAGATTTCAG CTACCATGTA

31S1 TATATAAATA AACTTATTTT ATTAGCCAGA GAAAAAAAAA AAAAAAAAAA

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 2

ORF from 21 bp to 1310 bpi peptide length: 151 Category: putative protein

Classification: Transmembrane proteins unclassified

1 MATTSSKPEG RPRGiQAAPTI LLTKPPGATS RPTTAPPRTT TRRPPRPPGS 51 SRKGAGNSSR PVPPAPGGHS RSKEGlQRGRN PSSTPLGiQKR PLGKIFlQIYK

101 GNFTGSVEPE PSTLTPRTPL UGYSSSPIQPIQ TVAATTVPSN TSUAPTTTSL

151 GPAKDKPGLR RAAiQGGGSTF TSlQGGTPDAT AASGAPVSPlQ AAPVPSiQRPH

201 HGDPlQDGPSH SDSULTVTPG TSRPLSTSSG VFTAATGPTP AAFDTSVSAP

251 SiQGIPlQGAST TPlQAPTHPSR VSESTISGAK EETVATLTMT DRVPSPLSTV 301 VSTATGNFLN RLVPAGTUKP GTAGNISHVA EGDKPiQHRAT ICLSKMDIAU

3S1 VILAISVPIS SCSVLLTVCC MKRKKKTANP ENNLSYUNNT ITMDYFNRHA

401 VELPREIiQSL ETSEDiQLSEP RSPANGDYRD TGMVLVNPFC (QETLFVGNDfl

451 VSEI

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_24cβι frame 2

No Alert BLASTP hits found Pedant information for DKFZphamy2_24cβι frame 2

Report for DKFZphamy2_24cβ .2

[LENGTH! 4b3

[MU! 48277-64

[pi! 1-60

[FUNCAT! 18 classification not yet clear-cut [S- cerevisiaei YJRlSlc! 2e-04

[BLOCKS! PR00112F

[BLOCKS! BP03b1bF

[KU! TRANSMEMBRANE 1

[KU! L0U_C0MPLEXITY 15-55 *

SElQ LSTGPAPAAMATTSSKPEGRPRGiQAAPTILLTKPPGATSRPTTAPPRTTTRRPPRPPGSS

SEG xxxxxxxxxxxxxxxxxxxxxxxxxxx

PRD ccccchhhhhhhhcccccccccccccceeeeccccccccccccccccccccccccccccc MEM

SElQ RKGAGNSSRPVPPAPGGHSRSKEGIQRGRNPSSTPLGIQKRPLGKIFIQIYKGNFTGSVEPEP

SEG x

PRD cccccccccccccccccccccccccccccccccccccccccceeeeeecccccccccccc MEM

SElQ STLTPRTPLUGYSSSPlQPlQTVAATTVPSNTSUAPTTTSLGPAKDKPGLRRAAiQGGGSTFT

SEG xxxxxxxx

PRD ccccccccccccccccccceeeeeecccccccccccccccccccccccceeecccccccc MEM

SElQ S(QGGTPDATAASGAPVSP(QAAPVPS(QRPHHGDP(^QDGPSHSDSULTVTPGTSRPLSTSSGV S EG X XX X X - - - - X X X X X X X XX X X X X X X XX -. PRD ccccccccccccccccccccccccccccccccccccccccceeeeeccccccccccccce

MEM

SElQ FTAATGPTPAAFDTSVSAPSlQGIPiQGASTTPfiAPTHPSRVSESTISGAKEETVATLTMTD SEG xxxxxxxxxxxxxx

PRD eeeeccccccccccccccccccccccccccccccccccceeeeeecccchhhhhhhcccc

MEM

SElQ RVPSPLSTVVSTATGNFLNRLVPAGTUKPGTAGNISHVAEGDKPiQHRATICLSKMDIAUV SEG

PRD ccccccceeeeeccccccccccccccccccccccceeecccccccceeeccccchhhhhh

MEM M

SE(Q ILAISVPISSCSVLLTVCCMKRKKKTANPENNLSYUNNTITMDYFNRHAVELPREIlQSLE SEG

PRD hhhhccccccccceeeehhhhhhccccccccccccccccccccccccccccccchhhhhc

MEM MMMMMMMMMMMMMMMM

SElQ TSEDiQLSEPRSPANGDYRDTGMVLVNPFCiQETLFVGNDlQVSEI SEG

PRD cccccccccccccccccccceeeeecccccceeeeeccccccc

MEM

(No Prosite data available for DKFZphamy2_24c6- 2) (No Pfam data available for DKFZphamy2_24cβ - 2)

DKFZphamy2_24kl5

group: amygdala derived

DKFZphamy2_24kl5 encodes a novel 271 amino acid protein with weak similarity to pecanex of Drosophila melanogaster- Pecanex is a maternal-effect neurogenic genei involved in differentiation processes in the developing central nervous system- DKFZphamy2_24kl5-p3 seems to be expressed ubiquitiously-

The new protein can find application in studying the expression profile of amygdala-specific genes and as a new marker for amygdala cells-

similarity to pecanex (Drosophila melanogaster) probably complete eds-

Sequenced by GBF Locus: unknown

Insert length: I4b4 bp

Poly A stretch at pos. 1445ι polyadenylation signal at pos- 1421

1 AAGGAAAACA AGAGGACATG CCATATATTC CTCTCATGGA GTTCAGTTGT

SI TCACATTCTC ACTTAGTATG CTTACCCGCA GAGTGGAGGA CTAGCTGTAT

101 GCCCAGTTCC AAAATGAAGG AGATGAGCTC GTTATTTCCA GAAGACTGGT

151 ACCAATTTGT TCTAAGGCAG TTGGAATGTT ATCATTCAGA AGAGAAGGCC 201 TCAAATGTAC TGGAAGAAAT TGCCAAGGAC AAAGTTTTAA AAGACTTTTA

251 TGTTCATACA GTAATGACTT GTTATTTTAG TTTATTTGGA ATAGACAATA

301 TGGCTCCTAG TCCTGGTCAT ATATTGAGAG TTTACGGTGG TGTTTTGCCT

351 TGGTCTGTTG CTTTGGACTG GCTCACAGAA AAGCCAGAAC TGTTTCAACT

401 AGCACTGAAA GCATTCAGGT ATACTCTGAA ACTAATGATT GATAAAGCAA 451 GTTTAGGTCC AATAGAAGAC TTTAGAGAAC TGATTAAGTA CCTTGAAGAA

501 TATGAACGTG ACTGGTACAT TGGTTTGGTA TCTGATGAAA AGTGGAAGGA

551 AGCAATTTTA CAAGAAAAGC CATACTTGTT TTCTCTGGGG TATGATTCTA bOl ATATGGGAAT TTACACTGGG AGAGTGCTTA GCCTTCAAGA ATTATTGATC b51 CAAGTGGGAA AGTTAAATCC TGAAGCTGTT AGAGGTCAGT GGGCCAATCT 701 TTCATGGGAA TTACTTTATG CCACAAACGA TGATGAAGAA CGTTATAGTA

751 TACAAGCTCA TCCACTACTT TTAAGAAATC TTACGGTACA AGCAGCAGAA

601 CCTCCCCTGG GATATCCGAT TTATTCTTCA AAACCTCTCC ACATACATTT

651 GTATTAGAGC TCATTTTGAC TGTAATGTCA TCAAATGCAA TGTTTTTATT

101 TTTTCATCCT AAAAAAGTAA CTGTGATTCT TGTAACTTGA GGACTTCTCC 151 ACACCCCCAT TCAGATGCCT GAGAACAGCT AAGCTCCGTA AAGTTGGTTC

1001 TCTTAGCCAT CTTAATGGTT CTAAAAAACA GCAAAAACAT CTTTATGTCT

1051 AAGATAAAAG AACTATTTGG CCAATATTTG TGCCCTCTGG ACTTTAGTAG

1101 GCTTTGGTAA ATGTGAGAAA ACTTTTGTAG AATTATCATA TAATGAATTT

1151 TGTAATGCTT TCTTAAATGT GTTATAGGTG AATTGCCATA CAAAGTTAAC 1201 AGCTATGTAA TTTTTACATA CTTAAGAGAT AAACATATCA GTGTTCTAAG

12S1 TAGTGATAAT GGATCCTGTT GAAGGTTAAC ATAATGTGTA TATATTTGTT

1301 TGAAATATAA TTTATAGTAT TTTCAAATGT GCTGATTTAT TTTGACATCT

1351 AATATCTGAA TGTTTTTGTA TCAAGTAGTT TGTTTTCATA GACTTCAATT 1401 CATAAACTTT AAAAAACTTT TAATAAAATA TTTTCCTTCC TTTTCAAAAA 1451 AAAAAAAAAA AAAA

BLAST Results

Entry AC007131 from database EMBLNEU:

Homo sapiens clone 422_H_5ι UORKING DRAFT SEiQUENCEi 5 unordered pieces-

Score = 411bι P = 0-Oe+OOι identities = 640/856 3 exons

Medline entries

No Medline entry

Peptide information for frame 3

ORF from 18 bp to 8S4 bpi peptide length: 271 Category: similarity to known protein Classification: unclassified 1 MPYIPLMEFS CSHSHLVCLP AEURTSCMPS SKMKEMSSLF PEDUYώFVLR

51 (QLECYHSEEK ASNVLEEIAK DKVLKDFYVH TVMTCYFSLF GIDNMAPSPG

101 HILRVYGGVL PUSVALDULT EKPELFiQLAL KAFRYTLKLM IDKASLGPIE

151 DFRELIKYLE EYERDUYIGL VSDEKUKEAI LiQEKPYLFSL GYDSNMGIYT

201 GRVLSLiQELL IlQVGKLNPEA VRGώUANLSU ELLYATNDDE ERYSIlQAHPL 2S1 LLRNLTViQAA EPPLGYPIYS SKPLHIHLY

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_24kl5ι frame 3 No Alert BLASTP hits found

Pedant information for DKFZphamy2_24klSι frame 3

Report for DKFZphamy2_24kl5-3

[LENGTH! 264 [MU! 330bb-31 [pi! 5.17

[HOMOL! TREMBL:AF0b7b08_ll gene: "B0S11.12"i, Caenorhabditis elegans cosmid B0511. 2e-13 [KU! Alpha_Beta SElQ GKIQEDMPYIPLMEFSCSHSHLVCLPAEURTSCMPSSKMKEMSSLFPEDUYIQFVLRIQLECY

PRD ccccccccccceeeecccceeeeecccccccccccccccccccccccchhhhhhhhhhhh

SElQ HSEEKASNVLEEIAKDKVLKDFYVHTVMTCYFSLFGIDNMAPSPGHILRVYGGVLPUSVA

PRD hhhhhhhhhhhhhhhhhhhhhhheeeeeeeeeeeecccccccccceeeeeeccccccccc

SElQ LDULTEKPELFlQLALKAFRYTLKLMIDKASLGPIEDFRELIKYLEEYERDUYIGLVSDEK PRD cchhhhhchhhhhhhhhhhhhhhhhhhhhcccccchhhhhhhhhhhhhhheeeeeccccc

SElQ UKEAIL<QEKPYLFSLGYDSNMGIYTGRVLSL(QELLI(QVGKLNPEAVRG(QUANLSUELLYA

PRD hhhhhhhhcchhhhhhhhcccccchhhhhhhhhhhhheeeeechhhhhhhhhhhhheeee SE(Q TNDDEERYSI(QAHPLLLRNLTV(QAAEPPLGYPIYSSKPLHIHLY

PRD cccccccccccchhhhhhhhhhhccccccccccccccccccccc

(No Prosite data available for DKFZphamy2_24kl5-3) (No Pfam data available for DKFZphamy2_24klS-3)

DKFZphamy2_2al3

group: amygdala derived

DKFZphamy2_2al3 encodes a novel 440 amino acid protein without similarity to known proteins- No informative BLAST resultsi No predictive prositei pfam or SCOP motife ■

The new protein can find application in studying the expression profile of amygdala-specific genes-

putative protein perhaps complete cds-

Sequenced by MediGenomix

Locus: /map="lbpl3-3" Insert length: 2584 bp

Poly A stretch at pos- 25b2ι polyadenylation signal at pos- 2545

1 GTTCCTGAGG ACGTGCTACG GGGGCAGCTT CCTGGTACAC GAGTCGTTCC 51 TCTACAAGCG GGAGAAGGCT GTCGGGGACA AGGTGTATTG GACCTGCCGG

101 GACCACGCGC TGCACGGCTG CCGGAGCCGG GCCATCACCC AGGGACAGCG

151 GGTGACTGTG ATGCGTGGGC ACTGCCACCA GCCCGATATG GAGGGCCTGG

201 AAGCCCGGCG GCAGCAGGAG AAGGCCGTGG AGACGCTGCA GGCTGG6CAG

2S1 GACGGCCCTG GGAGCCAAGT GGACACGCTG CTCCGAGGCG TGGATAGTTT 301 GCTCTACCGC AGGGGTCCGG GTCCCCTGAC TCTCACCAGG CCTCGGCCCA

351 GAAAGCGAGC AAAGGTCGAA GACCAGGAGC TGCCAACCCA GCCCGAGGCC

401 CCAGACGAGC ACCAGGACAT GGACGCAGAC CCGGGAGGCC CTGAGTTCCT

451 GAAGACGCCC CTGGGGGGCA GCTTCCTGGT GTACGAGTCC TTCCTCTACC

SOI GGCGGGAGAA GGCGGCTGGG GAGAAGGTGT ATTGGACCTG CCGGGACCAG S51 GCCCGCATGG GCTGCCGCAG CCGCGCCATC ACCCAGGGCC GACGGGTGAC bOl TGTCATGCGT GGTCACTGCC ACCCGCCCGA CCTGGGAGGC CTGGAGGCCC bSl TGAGGCAGCG GGAGAAACGC CCCAACACGG CGCAGCGGGG GAGCCCAGGC

701 GCTGGCCTCT CTTTCCAGTG GCTCTTCCGG ATCCTGCAGC TTTTGGGTCA

751 TGCTCCTGTG CTGCTGTGCC CCTCAGGGTC CTCCTGCCTC CCGAGCCTCC 801 CTGCTCCACA TGGCCCCTGC CCAGCCCTCT CCATCCCTCT TGAAGGAGGC

651 CCCGAGTTCC TGAAGACGCC CCTGGGGGGC AGCTTCCTGG TGTACGAGTC

101 CTTCCTCTAC CGGCGGGAGA AGGCGGCCGG GGAGAAGGTG TATTGGACCT

151 GCCGGGACCA GGCCCGCATG GGCTGCCGCA GCCGCGCCAT CACCCAGGGC

1001 CGGCGGGTCA TGGTCATGCG CAGGCACTGC CACCCACCGG ACCTGGGCGG 1051 CCTGGAGGCC CTGCGGCAGC GGGAGCACTT CCCCAACCTG GCGCAGTGGG

1101 ACAGCCCAGA TCCTCTCCGG CCCCTGGAGT TCCTGAGGAC TTCCCTGGGG

1151 GGCAGGTTCC TGGTGCACGA GTCCTTCCTC TACAGGAAGG AGAAGGCGGC

1201 TGGGGAGAAG GTGTACTGGA TGTGCCGGGA CCAGGCTCGG CTGGGCTGCC

1251 GCAGCCGCGC CATAACCCAG GGCCACCGCA TCATGGTCAT GCGCAGCCAC 1301 TGCCATCAGC CTGACCTGGC AGGCCTGGAG GCCTTGAGGC AACGGGAGCG

1351 GCTCCCCACC ACGGCCCAGC AGGAGGACCC AGAAAAGATT CAAGTTCAGC

1401 TGTGCTTCAA GACGTGTTCT CCTGAAAGCC AGCAGATTTA TGGGGACATC

1451 AAAGACGTCA GACTGGATGG CGAGTCCCAG TGAGGCGATG TGGGCAGAGG 1501 AGCTCCGAGC CGCCCACCCA AGGTGGCTTC ACATCCACAC AGGCACTTCC

15S1 CATCCACCTA GGTTTGGCTT AGCAGAAACT TCTTTTCATT CTTCCAAAGC

IbOl ATCGATGGTC TTCGCGTCTC CTCAGGAGGT CTCCCAGGAG GAATTCTTGG lb51 ATGGTGTCCT CATGTCGGCG GAGAACAGTG CTCAGAGCTG GCGCTTGCAG 1701 ACGCAGCTGT CGTGGGGCAG GGCGGTGGCG CCTTCCTGAC CTTTGGAAGA

1751 CATGACAAAG CTGCCTGGAC ACGGACGCCC CTGCTGTACG GCCACAGCAC

1801 CCCTGGGTTT GCAGAGCACG CAGCCTTCCT AGGGCTTTCC ACCTGGCGAG

1651 GCCCCGCTCT GCTCAGCACG GTGCAAAGTG AATGCTGCTG TCTTGGAGCC

1101 TGGGCACGTT TGGGGAAGTT CCTGCTTCAA ACTGAGCTGC CCCGCATAGG 1151 CCAGGTCAAC CCACACCAAT CTTTTCTGGA CAGGTGCTGG GTAGGCCTTC

2001 CTGGTCTCTG GCCGCCTGCT GCCAGGGTGT GGCCATCCCC AGCAACCGGA

2051 GCCGGCCAAA CCAGAGGCCT CGCTCCGCAC TCCACACTTT CCTTTCTGTG

2101 CTCCTTCCAA GTTAAATTAA ACCCCCTCTC CACGATTCCC ACGGCAGGCG

2151 TCATTCCCGA GATGGGAGCC AGTCCAGGGG TCAGCAGGAG CCAGCGCTGG 2201 GCACACGTGC CCTGGCTGAG GCCAGCGGCA TCCTGGGTGG CCCAGGTCCA

2251 TCCTGGGCAG CAAAGGCGTG TCCCCTTCTG TCAGACAGCT TCACAGAGTG

2301 TGGCTTCACC AGTCAGAGGG AGCAGTCCGG AGAGGCAAGA TGACCCCACC

2351 GGGACTGCAG AGCCTCCTCC TTACTAACAA GGACCTGTCC GCAGCCGCGA

2401 GGTCCTTCAC TCCCACCCTG TAATTGTGGG GGGAGTGCCA GCAACAGGCC 2451 TGTCCCCTGG CAAGTTGGCC ACGGAACCCA CCATGCACTG CAAGGCTGTG

2501 ACAGCCTGGG CACCCCTGCT TCTCCTCTGC TTGTACGGTT CCCCCAATAA

2S51 ATCCTATTTT CCATCAAAAA AAAAAAAAAA AAAA

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 2

ORF from Ibl bp to 1480 bpi peptide length: 440

Category: putative protein

Classification: no clue 1 MRGHCHlQPDM EGLEARRIQIQE KAVETL(QAG(Q DGPGSiQVDTL LRGVDSLLYR

SI RGPGPLTLTR PRPRKRAKVE D(QELPT(QPEA PDEHiQDMDAD PGGPEFLKTP

101 LGGSFLVYES FLYRREKAAG EKVYUTCRDiQ ARMGCRSRAI TlQGRRVTVMR

151 GHCHPPDLGG LEALRiQREKR PNTAiQRGSPG AGLSFώULFR ILlQLLGHAPV

201 LLCPSGSSCL PSLPAPHGPC PALSIPLEGG PEFLKTPLGG SFLVYESFLY 251 RREKAAGEKV YUTCRDlQARM GCRSRAITlQG RRVMVMRRHC HPPDLGGLEA

301 LRlQREHFPNL AiQUDSPDPLR PLEFLRTSLG GRFLVHESFL YRKEKAAGEK

351 VYUMCRDlQAR LGCRSRAITlQ GHRIMVMRSH CHlQPDLAGLE ALRώRERLPT

401 TA(Q(QEDPEKI (QVώLCFKTCS PES(Q(QIYGDI KDVRLDGESώ

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_2al3ι frame 2 No Alert BLASTP hits found

Pedant information for DKFZphamy2_2al3ι frame 2

Report for DKFZphamy2_2al3 - 2

[LENGTH! 413

[MU! 55840-13

[pi! 1-33

[KU! Alpha_Beta

[KU! LOU COMPLEXITY b-21 *

SE(Q FLRTCYGGSFLVHESFLYKREKAVGDKVYUTCRDHALHGCRSRAITlQGlQRVTVMRGHCHfQ

SEG

PRD ccccccccceeeccchhhhhhhhhccceeeeecccccccccceeeeccceeeeeeccccc

SElQ PDMEGLEARRIQIQEKAVETLIQAGIQDGPGSIQVDTLLRGVDSLLYRRGPGPLTLTRPRPRKRA SEG xxxxxxxxxxxxxxx- - -

PRD cccchhhhhhhhhhhhhhhhhcccccccccccccccccceeeeecccceeecccccchhh

SElQ KVED(QELPT(QPEAPDEH(QDMDADPGGPEFLKTPLGGSFLVYESFLYRREKAAGEKVYUTC

SEG PRD hhhhhcccccccccccccccccccccccccccccccceeeehhhhhhhhhhhccceeeec

SElQ RD(QARMGCRSRAIT<QGRRVTVMRGHCHPPDLGGLEALR(QREKRPNTA(QRGSPGAGLSF(QU

SEG

PRD cchhhhhccceeecccceeeeeecccccccccchhhhhhhhhccccccccccccchhhhh

SElQ LFRILiQLLGHAPVLLCPSGSSCLPSLPAPHGPCPALSIPLEGGPEFLKTPLGGSFLVYES

SEG xxxxxxxxxxxxxxxx

PRD hhhhhhhhhccceeeccccccccccccccccccccccccccccccccccccccceeeehh SElQ FLYRREKAAGEKVYUTCRD(QARMGCRSRAIT(QGRRVMVMRRHCHPPDLGGLEALR(QREHF

SEG

PRD hhhhhhhhhccceeeeccchhhhhccceeecccceeeeeecccccccccchhhhhhhhhc

SElQ PNLAIQUDSPDPLRPLEFLRTSLGGRFLVHESFLYRKEKAAGEKVYUMCRDIQARLGCRSRA SEG

PRD ccccccccccccchhhhhhhcccceeeeecchhhhhhhhccceeeecchhhhhhhccccc

SElQ IT(3GHRIMVMRSHCH(QPDLAGLEALR<QRERLPTTA(Qι3EDPEKI(QV(QLCFKTCSPES(Q(QIY

SEG PRD ccccceeeeeeccccccccchhhhhhhhhhhhhccccccccceeehhhhhcccccccccc

SElQ GDIKDVRLDGESiQ

SEG

PRD ccccccccccccc

(No Prosite data available for DKFZphamy2_2al3- 2) (No Pfam data available for DKFZphamy2_2al3-2)

DKFZphamy2_2bl1

group: differentiation/development

DKFZphamy2_2bl1 encodes a novel 761 amino acid protein which originates from TXBP151 mRNA by alternative splicing-

It is ubiquitously expressed- The mRNA is also subject to alternative polyadenylation. Overexpression of TXBPISI in NIH3T3 cells causes inhibition of apoptosis induced by tumour necrosis factor (TNF). It binds to A20ι which is also an inhibitor of cell death by a yet unknown mechanism-

The new protein can find application in modifying/blocking apoptosic pathways and therefore serve as a tool in diagnosis of cancer predisposition and as a tool in cell culture-

TXBPlSli differentially spliced differential splicing differential polyadenylation

Sequenced by MediGenomix Locus: /map="7plS"

Insert length: 3028 bp

Poly A stretch at pos- 2865ι polyadenylation signal at pos- 28bS

1 GAAGAGGTTC GGCGGCTGAT GGCGGATCAG GATCGGAAGC CTGCGTAACT

SI TTCTCCCTTG ATCCGG6AGT CTTTCCACTG GATTCACAAT GACATCCTTT

101 CAAGAAGTCC CATTGCAGAC TTCCAACTTT GCCCATGTCA TCTTTCAAAA

151 TGTGGCCAAG AGTTACCTTC CTAATGCACA CCTGGAATGT CATTACACCT 201 TAACTCCATA TATTCATCCA CATCCAAAAG ATTGGGTTGG TATATTCAAG

251 GTTGGATGGA GTACTGCTCG TGATTATTAC ACGTTTTTAT GGTCCCCTAT

301 GCCTGAACAT TATGTGGAAG GATCAACAGT CAATTGTGTA CTAGCATTCC

351 AAGGATATTA CCTTCCAAAT GATGATGGAG AATTTTATCA GTTCTGTTAC

401 GTTACCCATA AGGGTGAAAT TCGTGGAGCA AGTACACCTT TCCAGTTTCG 4S1 AGCTTCTTCT CCAGTTGAAG AGCTGCTTAC TATGGAAGAT GAAGGAAATT

501 CTGACATGTT AGTGGTGACC ACAAAAGCAG GCCTTCTTGA GTTGAAAATT

SSI GAGAAAACCA TGAAAGAAAA AGAAGAACTG TTAAAGTTAA TTGCCGTTCT bOl GGAAAAAGAA ACAGCACAAC TTCGAGAACA AGTTGGGAGA ATGGAAAGAG bSl AACTTAACCA TGAGAAAGAA AGATGTGACC AACTGCAAGC AGAACAAAAG 701 GGTCTTACTG AAGTAACACA AAGCTTAAAA ATGGAAAATG AAGAGTTTAA

751 GAAGAGGTTC AGTGATGCTA CATCCAAAGC CCATCAGCTT GAGGAAGATA

801 TTGTGTCAGT AACACATAAA GCAATTGAAA AAGAAACCGA ATTAGACAGT

851 TTAAAGGACA AACTCAAGAA GGCACAACAT GAAAGAGAAC AACTTGAATG

101 TCAGTTGAAG ACAGAGAAGG ATGAAAAGGA ACTTTATAAG GTACATTTGA 151 AGAATACAGA AATAGAAAAT ACCAAGCTTA TGTCAGAGGT CCAGACTTTA

1001 AAAAATTTAG ATGGGAACAA AGAAAGCGTG ATTACTCATT TCAAAGAAGA

10S1 GATTGGCAGG CTGCAGTTAT GTTTGGCTGA AAAGGAAAAT CTGCAAAGAA

1101 CTTTCCTGCT TACAACCTCA AGTAAAGAAG ATACTTGTTT TTTAAAGGAG 1151 CAACTTCGTA AAGCAGAGGA ACAGGTTCAG GCAACTCGGC AAGAAGTTGT

1201 CTTTCTGGCT AAAGAACTCA GTGATGCTGT CAACGTACGA GACAGAACGA

1251 TGGCAGACCT GCATACTGCA CGCTTGGAAA ACGAGAAAGT GAAAAAGCAG

1301 TTAGCTGATG CAGTGGCAGA ACTTAAACTA AATGCTATGA AAAAAGATCA 1351 GGACAAGACT GATACACTGG AACACGAACT AAGAAGAGAA GTTGAAGATC

1401 TGAAACTCCG TCTTCAGATG GCTGCAGACC ATTATAAAGA AAAATTTAAG

1451 GAATGCCAAA GGCTCCAAAA ACAAATAAAC AAACTTTCAG ATCAATCAGC

1501 TAATAATAAT AATGTCTTCA CAAAGAAAAC GGGGAATCAG CAGAAAGTGA

15S1 ATGATGCTTC AGTAAACACA GACCCAGCCA CTTCTGCCTC TACTGTAGAT IbOl GTAAAGCCAT CACCTTCTGC AGCAGAGGCA GATTTTGACA TAGTAACAAA

IbSl GGGGCAAGTC TGTGAAATGA CCAAAGAAAT TGCTGACAAA ACAGAAAAGT

1701 ATAATAAATG TAAACAACTC TTGCAGGATG AGAAAGCAAA ATGCAATAAA

17S1 TATGCTGATG AACTTGCAAA AATGGAGCTG AAATGGAAAG AACAAGTGAA

1601 AATTGCTGAA AATGTAAAAC TTGAACTAGC TGAAGTACAG GACAATTATA 1851 AAGAACTTAA AAGGAGTCTA GAAAATCCAG CAGAAAGGAA AATGGAAGGT

1101 CAGAATTCCC AGAGTCCTCA ATGTTTCAAA ACATGCTCAG AGCAAAATGG

1151 TTATGTTCTC ACATTGTCAA ATGCACAACC AGTTCTGCAA TATGGTAATC

2001 CTTATGCATC TCAGGAAACA AGAGATGGAG CAGATGGTGC TTTTTACCCA

2051 GATGAAATAC AAAGGCCACC TGTCAGAGTC CCCTCTTGGG GACTGGAAGA 2101 CAATGTTGTC TGCAGCCAGC CTGCTCGAAA CTTTAGTCGG CCTGATGGCT

21S1 TAGAGGACTC TGAGGATAGC AAAGAAGATG AGAATGTGCC TACTGCTCCT

2201 GATCCTCCAA GTCAACATTT ACGTGGGCAT GGGACAGGCT TTTGCTTTGA

2251 TTCCAGCTTT GATGTTCACA AGAAGTGTCC CCTCTGTGAG TTAATGTTTC

2301 CTCCTAACTA TGATCAGAGC AAATTTGAAG AACATGTTGA AAGTCACTGG 2351 AAGGTGTGCC CGATGTGCAG CGAGCAGTTC CCTCCTGACT ATGACCAGCA

2401 GGTGTTTGAA AGGCATGTGC AGACCCATTT TGATCAGAAT GTTCTAAATT

2451 TTGACTAGTT ACTTTTTATT ATGAGTTAAT ATAGTTTAGC AGTAAAAAAA

2S01 AAAAAAAAAA ACCACACCTA AAATAGACCA CTGAGGAGAC CATAGAGCGG

2551 ATGCTTTCAT GCACCCTTTA CTGCACTTTC TGACCAGGAG CTACTTTGAG 2b01 TTTGGTGTTA CTAGGATCAG GGTCAGTCTT TGGCTTATCA ATAAATTTTA

2b51 ATCTCTGTTA ATCTTACCTG CTTTAAAAAA AAGTTCTTGT GTGTTCGTAT

2701 CTTTATTTAT TCCCTAGTTT GCAGAACTGT CTGAATAAAG GATACAAGGA

27S1 TTATTTCAAT GTTACTGCAC TGAAAAACGT GTATGTATTA GTGTGCTAGA

2801 TTATTTAGCA GAATATTCAC AAGTTTCTGT TGACCTTGTT GATTGAGCAT 2651 GACTACTAAA TATTATGTAA TAAAAAGCAT TTGTCATAAC AAAAAAAAAA

2101 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA

21S1 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA

3001 AAAAAAAAAA AAAAAAAAAA AAAAAAAA

BLAST Results

No BLAST result

Medline entries

113bl184."

De Valck Di Jin DYi Heyninck Ki Van de Craen Mi Contreras Ri

Fiers Ui

Jeang KTi Beyaert R-i The zinc finger protein A20 interacts with a novel anti-apoptotic protein which is cleaved by specific caspases-

Oncogene

1111 Jul 22il8(21) :41β2-10 Peptide information for frame 2

ORF from 81 bp to 245S bpi peptide length: 761 Category: known protein Classification: Cell division

1 MTSFlQEVPLiQ TSNFAHVIFlQ NVAKSYLPNA HLECHYTLTP YIHPHPKDUV

51 GIFKVGUSTA RDYYTFLUSP MPEHYVEGST VNCVLAFiQGY YLPNDDGEFY

101 (QFCYVTHKGE IRGASTPFlQF RASSPVEELL TMEDEGNSDM LVVTTKAGLL ISI ELKIEKTMKE KEELLKLIAV LEKETAOLRE (QVGRMERELN HEKERCDIQLIQ

201 AEiQKGLTEVT (QSLKMENEEF KKRFSDATSK AHlQLEEDIVS VTHKAIEKET

251 ELDSLKDKLK KAlQHERElQLE CύLKTEKDEK ELYKVHLKNT EIENTKLMSE

301 VlQTLKNLDGN KESVITHFKE EIGRLlQLCLA EKENLώRTFL LTTSSKEDTC

3S1 FLKEiQLRKAE EIQVIQATRIQEV VFLAKELSDA VNVRDRTMAD LHTARLENEK 401 VKKiQLADAVA ELKLNAMKKD (QDKTDTLEHE LRREVEDLKL RLiQMAADHYK

451 EKFKEC(QRL(Q KiQINKLSDώS ANNNNVFTKK TGNiQlQKVNDA SVNTDPATSA

SOI STVDVKPSPS AAEADFDIVT KGlQVCEMTKE IADKTEKYNK CKIQLLIQDEKA

5S1 KCNKYADELA KMELKUKElQV KIAENVKLEL AEViQDNYKEL KRSLENPAER bOl KMEGlQNSlQSP (QCFKTCSEiQN GYVLTLSNAlQ PVLiQYGNPYA SiQETRDGADG bSl AFYPDEIlQRP PVRVPSUGLE DNVVCSlQPAR NFSRPDGLED SEDSKEDENV

701 PTAPDPPSiQH LRGHGTGFCF DSSFDVHKKC PLCELMFPPN YDlQSKFEEHV 7S1 ESHUKVCPMC SElQFPPDYDiQ (QVFERHViQTH FDiQNVLNFD

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_2bl1ι frame 2

TREMBL:HS336211_1 product: "taxi-binding protein TXBP151"i Homo sapiens taxi-binding protein TXBPISI mRNAi complete cds-i N = 2ι

Score

= 2148ι P = 0

>TREMBL:HS338211_1 product: "taxi-binding protein TXBP151"i Homo sapiens taxi-binding protein TXBP151 mRNAi complete eds-

Length = 747

HSPs: Score = 2148 (442-3 bits)ι Expect = 0-Oe+OOι Sum P(2) = O-Oe+00 Identities = 57S/b03 (15*)ι Positives = S7b/bD3 (15*)

(Query: 1 MTSF(QEVPL(QTSNFAHVIF(QNVAKSYLPNAHLECHYTLTPYIHPHPKDUVGIFKVGUSTA bO

MTSF(QEVPL(QTSNFAHVIF(QNVAKSYLPNAHLECHYTLTPYIHPHPKDUVGIFKVGUSTA Sbjct: 1 MTSF(QEVPL(QTSNFAHVIF(QNVAKSYLPNAHLECHYTLTPYIHPHPKDUVGIFKVGUSTA bO (Query: bl RDYYTFLUSPMPEHYVEGSTVNCVLAF(QGYYLPNDDGEFY(QFCYVTHKGEIRGASTPF(QF 120 RDYYTFLUSPMPEHYVEGSTVNCVLAF(QGYYLPNDDGEFY(QFCYVTHKGEIRGASTPF(QF Sbjct: bl RDYYTFLUSPMPEHYVE6STVNCVLAF(QGYYLPNDDGEFY(QFCYVTHKGEIRGASTPF(QF 120

(Query: 121 RASSPVEELLTMEDEGNSDMLVVTTKAGXXXXXXXXXXXXXXXXXXXXXXXXXXTAiQLRE 180

RASSPVEELLTMEDEGNSDMLVVTTKAG

TAiQLRE

Sbjct: 121

RASSPVEELLTMEDEGNSDMLVVTTKAGLLELKIEKTMKEKEELLKLIAVLEKETAiQLRE 180

(Query: 181

(QVGRMERELNHEKERCD(QL(QAE(QKGLTEVT(QSLKMENEEFKKRFSDATSKAH(QLEEDIVS 240 IQVGRMERELNHEKERCDIQLIQAEIQKGLTEVTIQSLKMENEEFKKRFSDATSKAH

+EEDIVS Sbjct: 181

(QVGRMERELNHEKERCD(QL(QAE(QKGLTEVT(QSLKMENEEFKKRFSDATSKAHHVEEDIVS 240

(Query: 241 VTHKAIEKETELDSLKDKLKKA(QHERE(QLEC(QLKTEKDEKELYKVHLKNTEIENTKLMSE 300

VTHKAIEKETELDSLKDKLKKA(QHERE(QLECιQLKTEKDEKELYKVHLKNTEIENTKLMSE Sbjct: 241 VTHKAIEKETELDSLKDKLKKAlQHERElQLEClQLKTEKDEKELYKVHLKNTEIENTKLMSE 300 Ouery : 301

ViQTLKNLDGNKESVITHFKEEIGRLlQLCLAEKENLlQRTFLLTTSSKEDTCFLKEiQLRKAE 3b0

V(QTLKNLDGNKESVITHFKEEIGRL(QLCLAEKENL(3RTFLLTTSSKEDTCFLKE(QLRKAE Sb j ct : 301 V(QTLKNLDGNKESVITHFKEEIGRL(QLCLAEKENL(QRTFLLTTSSKEDTCFLKE(QLRKAE 3b0

(Query : 3bl E(QV(QATR(QEVVFLAKELSDAVNVRDRTMADLHTARLENEKVKK(QLADAVAELKLNAMKKD 420 E(QV(QATR(QEVVFLAKELSDAVNVRDRTMADLHTARLENEKVKK(QLADAVAELKLNAMKKD Sb jct : 3bl E(QV(QATRtQEVVFLAKELSDAVNVRDRTMADLHTARLENEKVKK(QLADAVAELKLNAMKKD 420

(Query : 421 (QDKTDTLEHELRREVEDLKLRL(QMAADHYKEKFKEC(QRL(QK(QINKLSD(QSANNNNVFTKK 480

(QDKTDTLEHELRREVEDLKLRL(QMAADHYKEKFKEC(QRL(QK(QINKLSD(QSANNNNVFTKK Sb jct : 421 (3DKTDTLEHELRREVEDLKLRL(QMAADHYKEKFKEC(QRL(QK(QINKLSD(QSANNNNVFTKK 480

(Query: 481 TGN(Q(QKVNDASVNTDPATSASTVDVKPSPSAAEADFDIVTKG(QVCEMTKEIADKTEKYNK 540

TGNtQiQKVNDASVNTDPATSASTVDVKPSPSAAEADFDIVTKGlQVCEMTKEIADKTEKYNK Sbjct: 461

TGNlQiQKVNDASVNTDPATSASTVDVKPSPSAAEADFDIVTKGiQVCEMTKEIADKTEKYNK 540 (Query: S41 CK(QLLιQDEKAKCNKYADELAKMELKUKE(QVKIAENVKLELAEVι3DNYKELKRSLENPAER bOO

CKlQLLlQDEKAKCNKYADELAKMELKUKElQVKIAENVKLELAEViQDNYKELKRSLENPAER Sbjct: 541

CKiQLLlQDEKAKCNKYADELAKMELKUKEiQVKIAENVKLELAEVlQDNYKELKRSLENPAER bOO

(Query: bDl KME b03 KME Sbjct: bOl KME b03

Score = 631 (124-7 bits)ι Expect = 0-Oe+OOι Sum P(2) = O-Oe+00 Identities = 147/153 (1b*)ι Positives = 141/153 (17*) (Query: b37

NPYASIQETRDGADGAFYPDEIIQRPPVRVPSUGLEDNVVCSIQPARNFSRPDGLEDSEDSKE bib NP A ++

DGADGAFYPDEIiQRPPVRVPSUGLEDNVVCSiQPARNFSRPDGLEDSEDSKE

Sbjct: Sib NP- AERKMEDGADGAFYPDEIlQRPPVRVPSUGLEDNVVCSlQPARNFSRPDGLEDSEDSKE bS4

(Query: b17 DENVPTAPDPPSIQHLRGHGTGFCFDSSFDVHKKCPLCELMFPPNYDIQSKFEEHVESHUKV 75b DENVPTAPDPPSlQHLRGHGTGFCFDSSFDVHKKCPLCELMFPPNYDiQSKFEEHVESHUKV Sbjct: b5S DE VPTAPDPPSlQHLRGHGTGFCFDSSFDVHKKCPLCELMFPPNYDlQSKFEEHVESHUKV 714

(Query: 757 CPMCSEiQFPPDYDiQiQVFERHViQTHFDiQNVLNFD 761 CPMCSElQFPPDYDiQiQVFERHVlQTHFDiQNVLNFD

Sbjct: 715 CPMCSE(QFPPDYD(QiQVFERHV(QTHFD(QNVLNFD 747

Score = 104 (15. t bits)ι Expect = 1-2e-02ι Sum P(2) = 6 - 6e-02 Identities = 60/351 (22*)ι Positives = 1S7/3S1 (44*)

(Query : 177 <QLR---E(QVGRMERELNH- EKERCD(QL(QAE(3KGLTEVT(QSLKMENEEFKKRFSDATSKAH 232

(QLR E(QV +E+ KE D + + + ++ + + + ENE+ KK+

+ DA Sb j ct : 355 (QLRKAEE(QV(QATR(QEVVFLAKELSDAVNVRDRTMADL- HTARLENEKVKKiQLADA 406

(Query : 233 (QLEEDIVSVTHKAIEKETE- LDSLKDKLKKAlQHERElQLECiQLKTEKDEKELYKVHLKNTE 211 + + A++K+ + D+L+ +L++ E E L+ +L+ D

YK K +

Sb j ct : 401 VAELKLNAMKKD(QDKTDTLEHELRR---EVEDLKLRL(QMAADH- —

YKEKFKEClQ 457 (Query : 212

IENTKLMSEV(QTLKNLDGNKESVITHFKEEIGRL(QLCLAEKENL(QRTFLLTTSSKEDTCF 351

+L ++ L + N +V T ++ G Q N T

T + + S D

Sb j ct : 456 RL(QK(QINKLSD(QSANNNNVFT KKTGN(Q(QKVNDASVN TDPATSASTVD 504

(Query : 3S2 LKElQLRKAEEiQVlQ- ATRiQEVVFLAKELSDAVNVRDRTMADLHTARLENEKVKKiQLADAVA 410 +K AE T+ +V + KE++D ++ L + + K +LA

Sbjct: S05

VKPSPSAAEADFDIVTKG(QVCEMTKEIADKTEKYNKCK(QLL(QDEKAKCNKYADELAKMEL Sb4

(Query: 411 ELKLNAMKKDiQDKTDTLE HELRREVED-LKLRLiQMAAD—

HYKEKFKEC(Q-RL(QK 4bl

+ K + K + E EL+R +E+ + +++ AD Y ++ + R+ Sbjct: 5bS

KUKE(QVKIAENVKLELAEV(QDNYKELKRSLENPAERKMEDGADGAFYPDEI(QRPPVRVPS b24

(Query: 4b2 -—(QINKLSDiQSANNNNVFTKKTG—- N(Q(QKVNDASVNTDPATSASTVDVKPSPSAAEAD 515 + N + (Q A N F++ G ++ D +V T P + +

+ ++

Sbjct: b25 UGLEDNVVCSώPARN

FSRPDGLEDSEDSKEDENVPTAPDPPSlQHLRGHGTGFCFDSS bβl (Query: Sib FDIVTKGώVCEM S27

FD+ K +CE+ Sbjct: b62 FDVHKKCPLCEL b13

Pedant information for DKFZphamy2_2bl1ι frame 2

Report for DKFZphamy2_2bl1 -2

[LENGTH! 761

[MU! 10877-47

[pi! 5-30

[HOMOL! TREMBL:HS338211_1 product: "taxi-binding protein TXBP151"i Homo sapiens taxi-binding protein TXBPISI mRNAi complete eds- 0-0

[FUNCAT! 11 unclassified proteins [S- cerevisiaei Y0R21bc!

3e-14

[FUNCAT! 06-07 vesicular transport (golgi network-, etc-) ES- cerevisiaei YDLOSβw! 2e-13

[FUNCAT! 30-03 organization of cytoplasm [S- cerevisiaei

YDLOSδw! 2e-13

[FUNCAT! 01-10 nuclear biogenesis [S- cerevisiaei YDR3Sbw!

4e-13 [FUNCAT! 30-04 organization of cytoskeleton [S- cerevisiaei

YDR35bw! 4e-13

[FUNCAT! 03-22 cell cycle control and mitosis [S- cerevisiaei

YDR3Sbw! 4e-13

[FUNCAT! 11-04 dna repair (direct repairi base excision repair and nucleotide excision repair) [S- cerevisiaei YKR015w! 7e-12

[FUNCAT! 3D-10 nuclear organization [S- cerevisiaei YKROISw!

7e-12

[FUNCAT! 03-25 cytokinesis [S- cerevisiaei YHR023w MY01 - myosin-1 isoform! be-11 [FUNCAT! 08-22 cytoskeleton-dependent transport [S- cerevisiaei

YHR023w MY01 - myosin-1 isoform! be-11

[FUNCAT! 03-04 buddingi cell polarity and filament formation

[S- cerevisiaei YHR023w MY01 - myosin-1 isoform! be-11 [FUNCAT! 1 genome replication! transcriptioni recombination and repair [M- jannaschiii MJ1322! 3e-0δ

[FUNCAT! 16 classification not yet clear-cut [S- cerevisiaei

YJR134c! 4e-06 [FUNCAT! 03-11 recombination and dna repair [S- cerevisiaei

YNL2S0w! 2e-07

[FUNCAT! 03.13 meiosis CS- cerevisiaei YNL250w! 2e-D7

[FUNCAT! 03-01 cell growth [S- cerevisiaei YNL071c! 2e-0b

[FUNCAT! 03-07 pheromone response! mating-type determination! sex-specific proteins [S- cerevisiaei YNLD71c! 2e-0b

[FUNCAT! 08-11 other intracellular-transport activities [S- cerevisiaei YNL071c! 2e-0b

[FUNCAT! 01-13 biogenesis of chromosome structure [S- cerevisiaei YLROδbw! 5e-0b [FUNCAT! 11-01 stress response CS. cerevisiaei YPR141c! 2e-05

[FUNCAT! Ob-10 assembly of protein complexes [S- cerevisiaei

YPR141c! 2e-0S

[FUNCAT! 03.22-01 cell cycle check point proteins [S- cerevisiaei YGLOδbw! 2e-05 [FUNCAT! 30-05 organization of centrosome [S- cerevisiaei

YPR141c! 2e-0S

[FUNCAT! 06-lb extracellular transport [S- cerevisiaei

Y0R32bw! le-04

[FUNCAT! 01-2S vacuolar and lysosomal biogenesis [S- cerevisiaei Y0R32bw! le-04

EFUNCAT! 30- lb mitochondrial organization [S- cerevisiaei

YALOllw! 2e-04

[FUNCAT! Ob-07 protein modification (glycolsylationi acylationi myristylationi palmitylationi farnesylation and processing) CS. cerevisiaei YKL201c! 2e-D4

[FUNCAT! e amino acid metabolism and transport [M- genitaliumi

MG042! 4e-04

[FUNCAT! 30-13 organization of chromosome structure [S- cerevisiaei YDR265w! 7e-04 [FUNCAT! n secretion and adhesion EM- jannaschiii MJ0211!

0-001

EFUNCAT! 05-04 translation (initiation! elongation and termination) ES- cerevisiaei YAL035w! 0-001

EBL0CKS! BL0032bD Tropomyosins proteins EBL0CKS! PR00545E

EBL0CKS! PR00041F

ESCOP! d2tmab_ 1-10S-4-1-1 Tropomyosin Erabbit

(Oryctolagus cuniculus) 5e-0S

EEC! 3- b- 1-32 Myosin ATPase 5e-lb EPIRKU! nucleus 2e-3S

EPIRKU! phosphotransferase 5e-10

EPIRKU! duplication 2e-01

EPIRKU! citrulline 7e-01

EPIRKU! tandem repeat 2e-13 EPIRKU! heterodimer 2e-0β

EPIRKU! heart 2e-ll

EPIRKU! endocytosis 3e-10

[PIRKU! polymorphism le-01

[PIRKU! transmembrane protein be-12 [PIRKU! serine/threonine-specific protein kinase Se-10

[PIRKU! cell wall 7e-01

[PIRKU! zinc finger 3e-10

[PIRKU! surface antigen be-06 [PIRKU! DNA binding be-12

[PIRKU! metal binding 3e-10

[PIRKU! muscle contraction 2e-13

[PIRKU! brain δe-06 [PIRKU! acetylated amino end 4e-01

[PIRKU! actin binding 5e-lb

[PIRKU! endoplasmic reticulum 4e-01

EPIRKU! mitosis 3e-15

[PIRKU! microtubule binding 3e-15 [PIRKU! ATP Se-lb

[PIRKU! chromosomal protein 2e-06

[PIRKU! receptor 4e-10

[PIRKU! thick filament 2e-13

[PIRKU! phosphoprotein 5e-lb [PIRKU! glycoprotein 4e-10

[PIRKU! skeletal muscle 7e-ll

[PIRKU! calcium binding 7e-01

[PIRKU! alternative splicing 3e-13

[PIRKU! DNA condensation 2e-08 [PIRKU! coiled coil Se-lb

[PIRKU! P-loop Se-lb

[PIRKU! heptad repeat 3e-13

[PIRKU! methylated amino acid 2e-13

[PIRKU! basement membrane le-01 [PIRKU! immunoglobulin receptor 2e-01

[PIRKU! peripheral membrane protein 3e-10

[PIRKU! cardiac muscle 2e-ll

[PIRKU! extracellular matrix le-01

[PIRKU! hydrolase 5e-lb [PIRKU! microtubule le-11

[PIRKU! muscle le-01

[PIRKU! membrane protein le-01

[PIRKU! EF hand 7e-01

[PIRKU! protein biosynthesis 4e-01 [PIRKU! cytoskeleton 3e-13

[PIRKU! hair 7e-01

[PIRKU! Golgi apparatus le-11

[PIRKU! calmodulin binding 3e-10

[SUPFAM! myosin heavy chain Se-lb [SUPFAM! conserved hypothetical P115 protein 4e-10

[SUPFAM! IgA Fc receptor 7e-01

[SUPFAM! centromere protein E 3e-lS

[SUPFAM! unassigned Ser/Thr or Tyr-specific protein kinases Se- 10 [SUPFAM! calmodulin repeat homology 7e-01

ESUPFAM! myosin motor domain homology Se-lb

[SUPFAM! alpha-actinin actin-binding domain homology 5e-10

[SUPFAM! hypothetical protein MJ0114 4e-08

[SUPFAM! tropomyosin be-01 [SUPFAM! plectin Se-10

[SUPFAM! trichohyalin 7e-01

[SUPFAM! pleckstrin repeat homology le-08

[SUPFAM! ribosomal protein S10 homology 5e-10

[SUPFAM! giantin 4e-13 [SUPFAM! protein kinase homology 5e-10

[SUPFAM! protein kinase C zinc-binding repeat homology le-06

[SUPFAM! kinesin motor domain homology 3e-15

[SUPFAM! human early endosome antigen 1 3e-10 [SUPFAM! myosin MY02 δe-Oδ

[SUPFAM! unassigned kinesin-related proteins le-10

[SUPFAM! MS protein 3e-10

[SUPFAM! cytoskeletal keratin 4e-07

[KU! All_Alpha

[KU! L0U_C0MPLEXITY 3 - 3D *

[KU! COILED COIL 22 - 16 *

SElQ MTSFiQEVPLiQTSNFAHVIFiQNVAKSYLPNAHLECHYTLTPYIHPHPKDUVGIFKVGUSTA SEG

PRD ccceeeeeccccceeeeeccccccccccccceeeeeccccccccccccceeeeeeecccc COILS

SElQ RDYYTFLUSPMPEHYVEGSTVNCVLAFiQGYYLPNDDGEFYlQFCYVTHKGEIRGASTPFiQF SEG

PRD eeeeeeeecccccccccccccceeeecccccccccccceeeeeeeccccccccccccccc COILS

SElQ RASSPVEELLTMEDEGNSDMLVVTTKAGLLELKIEKTMKEKEELLKLIAVLEKETAlQLRE

SEG xxxxxxxxxxxxxxxxxxxxxxxxxx

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC

SElQ (QVGRMERELNHEKERCD(QL(QAE(QKGLTEVT(QSLKMENEEFKKRFSDATSKAH(QLEEDIVS SEG PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS

CCCCCCCCCCCCCCCCCCC CCCCCCCC

SElQ VTHKAIEKETELDSLKDKLKKAIQHEREIQLECIQLKTEKDEKELYKVHLKNTEIENTKLMSE SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS

CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC SElQ V(QTLKNLDGNKESVITHFKEEIGRL(QLCLAEKENL(QRTFLLTTSSKEDTCFLKE(QLRKAE SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS ccccccccccc

SElQ ElQVlQATRiQEVVFLAKELSDAVNVRDRTMADLHTARLENEKVKKlQLADAVAELKLNAMKKD

SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh

COILS CCCCCCCCCCCCCCCCCCCCCCC

SElQ <QDKTDTLEHELRREVEDLKLRL(QMAADHYKEKFKEC(QRL(QK(QINKLSD(QSANNNNVFTKK SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS

SElQ TGNiQiQKVNDASVNTDPATSASTVDVKPSPSAAEADFDIVTKGlQVCEMTKEIADKTEKYNK SEG

PRD hhhhhhhhhhhhhchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS

SElQ CK(QLL(QDEKAKCNKYADELAKMELKUKE(QVKIAENVKLELAEV(QDNYKELKRSLENPAER

SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS CCCCCCCCCCCCCCCCCCCCCCCCCCCC

SEύ KMEG(QNSι3SP(QCFKTCSE<QNGYVLTLSNA(QPVL(QYGNPYASfQETRDGADGAFYPDEI(2RP SEG

PRD hhhhhhcccchhhhhhhhhhheeeeccccceeeecccccccccccccccccccccccccc COILS

SElQ PVRVPSUGLEDN VCSiQPARNFSRPDGLEDSEDSKEDENVPTAPDPPSfQHLRGHGTGFCF SEG PRD ccccccccccceeeeccccccccccccccccccccccccccccccccccccccccccccc COILS

SE(Q DSSFDVHKKCPLCELMFPPNYD(QSKFEEHVESHUKVCPMCSE(QFPPDYD(Q(QVFERHV(QTH SEG

PRD ccccccccccccccccccccccchhhhhhhhhhhhccccccccccccchhhhhhhhhhhh COILS

SElQ FDlQNVLNFD

SEG

PRD hcceeeccc COILS

(No Prosite data available for DKFZphamy2_2bl1 - 2)

(No Pfam data available for DKFZphamy2_2bl1-2)

DKFZphamy2_2c22

group: metabolism

DKFZphamy2_2c22 encodes a novel 3b4 amino acid protein with similarity to the l-acyl-glycerol-3-phosphate acyltransferase of Zea mais-

It contains one leucine zipper- The protein is belived to play a role in fatty acid metabolism- It is ubiqitous expressed! with a slight predominance in uterus-, placenta and foreskin- The new protein can find application in modulation of fatty acid metabolism and as a new enzyme for biotechnological production processes-

weak similarity to l-acyl-glycerol-3-phosphate acyltransferase (Zea mais) perhaps complete eds-

Sequenced by MediGenomix

Locus: /map="6" Insert length: 3403 bp

Poly A stretch at pos- 3373ι polyadenylation signal at pos- 3351

1 AGATGCTGCT GTCCCTGGTG CTCCACACGT ACTCCATGCG CTACCTGCTG 51 CCCAGCGTCG TGCTCCTGGG CACGGCGCCC ACCTACGTGT TGGCCTGGGG

101 GGTCTGGCGG CTGCTCTCCG CCTTCCTGCC CGCCCGCTTC TACCAAGCGC

151 TGGACGACCG GCTCTACTGC GTCTACCAGA GCATGGTGCT CTTCTTCTTC

201 GAGAATTACA CCGGGGTCCA GATATTGCTA TATGGAGATT TGCCAAAAAA

251 TAAAGAAAAT ATAATATATT TAGCAAATCA TCAAAGCACA GTTGACTGGA 301 TTGTTGCTGA CATCTTGGCC ATCAGGCAGA ATGCGCTAGG ACATGTGCGC

351 TACGTGCTGA AAGAAGGGTT AAAATGGCTG CCATTGTATG GGTGTTACTT

401 TGCTCAGCAT GGAGGAATCT ATGTAAAGCG CAGTGCCAAA TTTAACGAGA

451 AAGAGATGCG AAACAAGTTG CAGAGCTACG TGGACGCAGG AACTCCAATG

501 TATCTTGTGA TTTTTCCAGA AGGTACAAGG TATAATCCAG AGCAAACAAA 551 AGTCCTTTCA GCTAGTCAGG CATTTGCTGC CCAACGTGGC CTTGCAGTAT bOl TAAAACATGT GCTAACACCA CGAATAAAGG CAACTCACGT TGCTTTTGAT b51 TGCATGAAGA ATTATTTAGA TGCAATTTAT GATGTTACGG TGGTTTATGA

701 AGGGAAAGAC GATGGAGGGC AGCGAAGAGA GTCACCGACC ATGACGGAAT

7S1 TTCTCTGCAA AGAATGTCCA AAAATTCATA TTCACATTGA TCGTATCGAC 601 AAAAAAGATG TCCCAGAAGA ACAAGAACAT ATGAGAAGAT GGCTGCATGA

651 ACGTTTCGAA ATCAAAGATA AGATGCTTAT AGAATTTTAT GAGTCACCAG

101 ATCCAGAAAG AAGAAAAAGA TTTCCTGGGA AAAGTGTTAA TTCCAAATTA

151 AGTATCAAGA AGACTTTACC ATCAATGTTG ATCTTAAGTG GTTTGACTGC

1001 AGGCATGCTT ATGACCGATG CTGGAAGGAA GCTGTATGTG AACACCTGGA 10S1 TATATGGAAC CCTACTTGGC TGCCTGTGGG TTACTATTAA AGCATAGACA

1101 AGTAGCTGTC TCCAGACAGT GGGATGTGCT ACATTGTCTA TTTTTGGCGG

1151 CTGCACATGA CATCAAATTG TTTCCTGAAT TTATTAAGGA GTGTAAATAA

1201 AGCCTTGTTG ATTGAAGATT GGATAATAGA ATTTGTGACG AAAGCTGATA 1251 TGCAATGGTC TTGGGCAAAC ATACCTGGTT GTACAACTTT AGCATCGGGG

1301 CTGCTGGAAG GGTAAAAGCT AAATGGAGTT TCTCCTGCTC TGTCCATTTC

1351 CTATGAACTA ATGACAACTT GAGAAGGCTG GGAGGATTGT GTATTTTGCA

1401 AGTCAGATGG CTGCATTTTT GAGCATTAAT TTGCAGCGTA TTTCACTTTT 1451 TCTGTTATTT TCAATTTATT ACAACTTGAC AGCTCCAAGC TCTTATTACT

1S01 AAAGTATTTA GTATCTTGCA GCTAGTTAAT ATTTCATCTT TTGCTTATTT

15S1 CTACAAGTCA GTGAAATAAA TTGTATTTAG GAAGTGTCAG GATGTTCAAA

IbOl GGAAAGGGTA AAAAGTGTTC ATGGGGAAAA AGCTCTGTTT AGCACATGAT

IbSl TTTATTGTAT TGCGTTATTA GCTGATTTTA CTCATTTTAT ATTTGCAAAA 1701 TAAATTTCTA ATATTTATTG AAATTGCTTA ATTTGCACAC CCTGTACACA

17S1 CAGAAAATGG TATAAAATAT GAGAACGAAG TTTAAAATTG TGACTCTGAT

1601 TCATTATAGC AGAACTTTAA ATTTCCCAGC TTTTTGAAGA TTTAAGCTAC

1651 GCTATTAGTA CTTCCCTTTG TCTGTGCCAT AAGTGCTTGA AAACGTTAAG

1101 GTTTTCTGTT TTGTTTTGTT TTTTTAATAT CAAAAGAGTC GGTGTGAACC 1151 TTGGTTGGAC CCCAAGTTCA CAAGATTTTT AAGGTGATGA GAGCCTGCAG

2D01 ACATTCTGCC TAGATTTACT AGCGTGTGCC TTTTGCCTGC TTCTCTTTGA

2051 TTTCACAGAA TATTCATTCA GAAGTCGCGT TTCTGTAGTG TGGTGGATTC

2101 CCACTGGGCT CTGGTCCTTC CCTTGGATCC CGTCAGTGGT GCTGCTCAGC

21S1 GGCTTGCACG CAGACTTGCT AGGAAGAAAT GCAGAGCCAG CCTGTGCTGC 2201 CCACTTTCAG AGTTGAACTC TTTAAGCCCT TGTGAGTGGG CTTCACCAGC

2251 TACTGCAGAG GCATTTTGCA TTTGTCTGTG TCAAGAAGTT CACCTTCTCA

2301 AGCCAGTGAA ATACAGACTT AATTTGTCAT GACTGAACGA ATTTGTTTAT

2351 TTCCCATTAG GTTTAGTGGA GCTACACATT AATATGTATC GCCTTAGAGC

2401 AAGAGCTGTG TTCCAGGAAC CAGATCACGA TTTTTAGCCA TGGAACAATA 2451 TATCCCATGG GAGAAGACCT TTCAGTGTGA ACTGTTCTAT TTTTGTGTTA

2501 TAATTTAAAC TTCGATTTCC TCATAGTCCT TTAAGTTGAC ATTTCTGCTT

2551 ACTGCTACTG GATTTTTGCT GCAGAAATAT ATCAGTGGCC CACATTAAAC

2b01 ATACCAGTTG GATCATGATA AGCAAAATGA AAGAAATAAT GATTAAGGGA

2b51 AAATTAAGTG ACTGTGTTAC ACTGCTTCTC CCATGCCAGA GAATAAACTC 2701 TTTCAAGCAT CATCTTTGAA GAGTCGTGTG GTGTGAATTG GTTTGTGTAC

27S1 ATTAGAATGT ATGCACACAT CCATGGACAC TCAGGATATA GTTGGCCTAA

2601 TAATCGGGGC ATGGGTAAAA CTTATGAAAA TTTCCTCATG CTGAATTGTA

2651 ATTTTCTCTT ACCTGTAAAG TAAAATTTAG ATCAATTCCA TGTCTTTGTT

2101 AAGTACAGGG ATTTAATATA TTTTGAATAT AATGGGTATG TTCTAAATTT 21S1 GAACTTTGAG AGGCAATACT GTTGGAATTA TGTGGATTCT AACTCATTTT

30D1 AACAAGGTAG CCTGACCTGC ATAAGATCAC TTGAATGTTA GGTTTCATAG

3051 AACTATACTA ATCTTCTCAC AAAAGGTCTA TAAAATACAG TCGTTGAAAA

3101 AAATTTTGTA TCAAAATGTT TGGAAAATTA GAAGCTTCTC CTTAACCTGT

3151 ATTGATACTG ACTTGAATTA TTTTCTAAAA TTAAGAGCCG TATACCTACC 3201 TGTAAGTCTT TTCACATATC ATTTAAACTT TTGTTTGTAT TATTACTGAT

3251 TTACAGCTTA GTTATTAATT TTTCTTTATA AGAATGCCGT CGATGTGCAT

3301 GCTTTTATGT TTTTCAGAAA AGGGTGTGTT TGGATGAAAG TAAAAAAAAA

3351 AAATAAAATC TTTCACTGTC TCTAAAAAAA AAAGAAAAAA AAAAAAAAAA 3401 AAA

BLAST Results

o BLAST result

Medline entries

o Medline entry Peptide information for frame 3

ORF from 3 bp to 1014 bpi peptide length: 3b4 Category: similarity to known protein Classification: Metabolism Prosite motifs: LEUCINE ZIPPER (105-12b)

1 MLLSLVLHTY SMRYLLPSVV LLGTAPTYVL AUGVURLLSA FLPARFYlQAL

SI DDRLYCVYlQS MVLFFFENYT GVlQILLYGDL PKNKENIIYL ANHlQSTVDUI

101 VADILAIRiQN ALGHVRYVLK EGLKULPLYG CYFAώHGGIY VKRSAKFNEK

151 EMRNKLG2SYV DAGTPMYLVI FPEGTRYNPE (QTKVLSASiQA FAAlQRGLAVL 201 KHVLTPRIKA THVAFDCMKN YLDAIYDVTV VYEGKDDGGiQ RRESPTMTEF

251 LCKECPKIHI HIDRIDKKDV PEElQEHMRRU LHERFEIKDK MLIEFYESPD

301 PERRKRFPGK SVNSKLSIKK TLPSMLILSG LTAGMLMTDA GRKLYVNTUI

351 YGTLLGCLUV TIKA

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_2c22ι frame 3

No Alert BLASTP hits found Pedant information for DKFZphamy2_2c22ι frame 3

Report for DKFZphamy2_2c2 ■ 3

[LENGTH! 3b4 [MU! 42072-47

[pi! 1-lβ

[HOMOL! TREMBL:CEAF313b_l gene: "F26B3-5"i Caenorhabditis elegans cosmid F2δB3- 2e-3b

[FUNCAT! 11 unclassified proteins [S- cerevisiaei YDROlδc!

7e-13

[FUNCAT! Ol-Ob-01 lipidi fatty-acid and sterol biosynthesis

[S- cerevisiaei YDLD52c! 4e-05 [FUNCAT! 30-11 other cellular organization [S- cerevisiaei

YDL0S2c! 4e-05

[BLOCKS! BL012b3A

[BLOCKS! BPOOIδlA

[PIRKU! transmembrane protein 2e-ll [SUPFAM! probable membrane protein YBR042c 2e-ll

[PROSITE! LEUCINE_ZIPPER 1

[KU! Alpha_Beta

[KU! LOU COMPLEXITY 3-57 *

SElQ MLLSLVLHTYSMRYLLPSVVLLGTAPTYVLAUGVURLLSAFLPARFYlQALDDRLYCVYiQS SEG

PRD ccchhhhhhhhhccccccceeecccceeeccchhhhhhhhhhhhhhhhhhhhhhhhhhhh SElQ MVLFFFENYTGViQILLYGDLPKNKENIIYLANHiQSTVDUIVADILAIRlQNALGHVRYVLK

SEG

PRD hhhhhhhceeeeeeeeeccccccccceeeeecccchhhhhhhhhhhhhccccchhhhhhh

SElQ EGLKULPLYGCYFAiQHGGIYVKRSAKFNEKEMRNKLiQSYVDAGTPMYLVIFPEGTRYNPE

SEG

PRD hhhccccccceeeccceeeeeeccccccchhhhhhhhhhhccccceeeeeecccccchhh SElQ (QTKVLSASiQAFAAlQRGLAVLKHVLTPRIKATHVAFDCMKNYLDAIYDVTVVYEGKDDGGiQ

SEG

PRD hhhhhhhhhhhhhhhcccccceeeecccchhhhhhhhhhhcceeeceeeeeecccccccc

SElQ RRESPTMTEFLCKECPKIHIHIDRIDKKDVPEEiQEHMRRULHERFEIKDKMLIEFYESPD SEG xxxxxxxxxxxxx

PRD cccccchhhhhccccceeeeeecccccccccccchhhhhhhhhhhhhhhhhhhhhhhccc

SE(Q PERRKRFPGKSVNSKLSIKKTLPSMLILSGLTAGMLMTDAGRKLYVNTUIYGTLLGCLUV

SEG PRD cccccccccccchhhhhhhhchhhhhchhhhhhhhhhccccceeeeeeeechhhhhhhhh

SE(Q TIKA

SEG • • • ■

PRD hccc

Prosite for DKFZphamy2_2c22 ■ 3 PS00021 10S->127 LEUCINE ZIPPER PD0CD0021

(No Pfam data available for DKFZphamy2_2c22 ■ 3)

DKFZphamy2_2flδ

group: signal transduction

DKFZphamy2_2f16 encodes a novel 215 amino acid protein with similarity to sodium channel protein betal of Rattus norvegicus. The sodium channel protein beta 1 of Rattus norvegicus is crucial in the assembly! expression! and functional modulation of the heterotrimeric complex of the rat brain sodium channel. The expression of the new protein seems to be restricted to braini all matching ESTs isolated so far-, derive from there-

The new protein can find application in modulating the sodium channel beta li studying the expression profile in neurodegenerative diseases and of amygdala -specific genes-

similarity to sodium channel protein betal (Rattus norvegicus)

Pedant: SIGNAL_PEPTIDE

Sequenced by MediGenomix

Locus: unknown

Insert length: 4D52 bp

Poly A stretch at pos- 403Sι no polyadenylation signal found

1 CAGGGCTGAC AGCACACACG GCCTGGGGGC CTAGAGAAGG ATTGCTGATC 51 ACCTGCCACC CAGGGTCGGG GCCCCGCACC ATCCGGGGGC GAGCTCCCGG

101 GAAGGGGCTC CCCCTCTACA CCCACCCCCC AACCTCTGAC ATCGCCGGCC

151 GAACGGGAGC TGCCGCTTCC TTCCCGGCCC CGCTGCACCT CCCCAGGGAG

201 CCGAGGGCGG GCGTGGACGG GACCGACGTG GAACGCATTC TGTAGCCCAG

251 ACGGGCGGCC CCGGCGGCTT CGGGAGTGGG GTCACGCCCA GCTGGAGAAG 301 CAGTTAGGGC GGACGAAGCA GGAGCCGCGG GGCTGGGAGG ATTCCAGTCG

3S1 GAACGCAACC GATCCTGGGG AGGCGAGAGG TGAATCAACC TGGACCCTTC

401 CACAGCCTGG CTGCTAGGCC AGCAGTGCGA CTCCCTTCCG AGCTGAGCTT

451 ACCCTGGGCG CAAACGAGCG AGGCAGGGGC GCGAGTGGAA GCTGGAGTTC

S01 CGGGGTGGGC GGGGAGGCGA CTGTCCGTGG TGCTGAGCGC CGGCGAGAGC 5S1 GGGCGCGGAG CGGCTGATCA GCTCCCTCGA ACTGGGGAGG TCCAGTGGGG bOl TCGCTTAGGG CCCAAAGCCC CCGCCCGGCT CCAAAAGCTC CCAGGGCCTC bSl CCCAGGCACC GGTGCTCGGC CCTTCCTTCG GTCAGAAAGT CGCCCCCTGG

701 GGGCAGTTCG TCCCAAAGGG TTTCCTCGAA AGAATCTGAG AGGGCGCAGT

7S1 CCTTGACCGA GGGAATCTCT CTGTGTAGCC TTGGAAGCCG CCAGCCCCAG 601 AAGATGCCTG CCTTCAATAG ATTGTTTCCC CTGGCTTCTC TCGTGCTTAT δSl CTACTGGGTC AGTGTCTGCT TCCCTGTGTG TGTGGAAGTG CCCTCGGAGA

IDl CGGAGGCCGT GCAGGGCAAC CCCATGAAGC TGCGCTGCAT CTCCTGCATG

ISI AAGAGAGAGG AGGTGGAGGC CACCACGGTG GTGGAATGGT TCTACAGGCC

10D1 CGAGGGCGGT AAAGATTTCC TTATTTACGA GTATCGGAAT GGCCACCAGG 1051 AGGTGGAGAG CCCCTTTCAG GGGCGCCTGC AGTGGAATGG CAGCAAGGAC

1101 CTGCAGGACG TGTCCATCAC TGTGCTCAAC GTCACTCTGA ACGACTCTGG

1151 CCTCTACACC TGCAATGTGT CCCGGGAGTT TGAGTTTGAG GCGCATCGGC

1201 CCTTTGTGAA GACGACGCGG CTGATCCCCC TAAGAGTCAC CGAGGAGGCT 12S1 GGAGAGGACT TCACCTCTGT GGTCTCAGAA ATCATGATGT ACATCCTTCT

1301 GGTCTTCCTC ACCTTGTGGC TGCTCATCGA GATGATATAT TGCTACAGAA

1351 AGGTCTCAAA AGCCGAAGAG GCAGCCCAAG AAAACGCGTC TGACTACCTT

1401 GCCATCCCAT CTGAGAACAA GGAGAACTCT GCGGTACCAG TGGAGGAATA 1451 GAACAGGAGC AGTGTGACAT GAGGTGGCCT GAACACCTGA GGGACTGGAC

1501 ATCCCATGTT CAGCAATGTC AATGGCATCA GGAGGGCGCC CCAAGGGCCC

1SS1 CATCGCTTCC CTTCATGCAT CCATTGTTCT GTTCATTCAT TCATCCATAC

IbOl ATCCACCTGC CTCTGAGCTT TCACCTCTGA CTCCCTAACT CCATCAGACC

IbSl TCTACGCACC ATAAGACTCT GCCAGAACTG AGAAGCCAAC ATTTCTACAT 1701 AGACTCAACC TCACCCTCTC CTAGTTTTCC AACAAGACAC TCCAAAGCCA

17S1 ACTGGATTTC TCCCCTGTGC TCCAAATGAC TTTGTACAAG TGCTGGAGTT

1801 AGCACCTCCC TCTGCCCTTA ACTGGCTGGA ACTGGTTCAT TCTCCATTAC

1851 TGCAAGAGAA TGGAAGTCTT AATAGAAGGA AGCAGGAGTG ATTAGTTCGG

1101 GTTAAAGCAA AAGTGTGTCA TGAACTTGGA TTCCCTGAAG TCAGTTTTGT 1151 CAGGTTCATG GCCCACTTTG CTACAGCATC AGAGTGAAGC ACGCCTGTCT

2001 AGGTTCTCCA GTGACAGAAA GATCCTGAAG CATGGACTAA CATGCTCTCT

2051 GGAGCTTAGT ACTCCAGAGC TAGATCCTGA TGGGTCTCTA AGGTTCCCTC

2101 CAAGAAGACA AGGACAGGAG ACTTGGGAAG GACCAATGGT AATTTAAGTG

2151 GCTCTTAAAA AGTCATGCAA CATGTTTCTG GACACGTTCC TGATCCTATT 2201 GCGATAATGT ATGTGTGCCC TCCCTGTGGG CACACCACCT GGGCATTAGG

22S1 ACTGAAATTC CTGAGTTCTT CCTCTCAAAA TTTCTGTGCA CCAGTATTAT

2301 TCCTCATTTT ACATACAGGA GGCAACTAAG ACTCATACAG GGCTCAACTG

2351 AATAAGAGGC TTAAGAGGAT AAACTGGAGC AGAAATAAGC CTTAGGTGCT

2401 GCCCAGTTTA CACTTCCTGG GATGGATGTT TTTGTTTGTT TTGTTTTTTG 2451 TTTTTTTTGT TTGAGATGGA GTCTCACTCT GTCACCTAGG CTAGAGTGCA

2501 GTGGTGTGAT CTCGGCTCAC TGCAACCTCT GCCTCTTGGG TTCAAGCAAT

25S1 TCTCATGCCT CGGCCTCTCC AGTAGCTGGG ATTACAGGTG TGCACCACCA

2b01 CGCCTGGCTA AATTTTGTAT TTTTAGTACA GACAGGGTTT GACTATGTTG

2b51 GCCAGGCTAG TCTTGAACTC CTGACCTCAA ATGACCCACC CACCTCAGCC 27D1 TCCCAAAGTG CT6AGATTAC AGGCGTGAGG CACTGCGCCC GGTGGATAAC

27S1 TTTGTTTCTG AAAAGACTGA CATTGAACTT GTCTATGGCA ATGCTTCTTT

2601 CACAAGCACG GACTGGGCTG AGGTCAACTC TGATAGATTC AGATGACTAG

2651 AAATTGGCCA AAAAAGCAGG GAGAAGAACA TGAGGTAGAC TTAAAGAACT

2101 TCCTTTATGT AAAGATCTGT GACTCTGAAA TATCCTCCAA AAGGAGAGTG 2151 CATCTGAGAC TGATATTTAA ACTAAGAAAA ATGTTTAGTC TGAGATGGAT

3001 CATAAGTAAA TGAGCAGTGT GAGAGGGGAG GGATGGGTAG GTGCTTTCCA

3051 AATACTTCGC CTATGAATGC ATAATTTTCA GATTTTTTTC CCCTAGATTT

3101 TGAGGGAGCA GAGAAACTGG AAAAAACTTT AGTCAATATC TCGTGTTTCA

3151 TTTTAATTAA GTGACAGGTC CAAGTGTGAC ATCCTTCAGC ACCCAGGGAC 3201 AAGAGAGGGG AAAGATGCTT TATGGAATGT AAGAAGATGA AGGTGACTGG

3251 GATTCAGCGA GAGAGAGGTC CCTCAGACCT GGGACCTCCC TTTATAGGGA

3301 AAGACCATAT TCCATAGGTT TAGGGCTTTA CCTTAAAAGC TCATTTTTTT

33S1 CATTCTTCCA TCCCTAGGAA AGTACTTAAA ACCAGACTTT TAAATTTTTA

3401 TTTATTTATT ATTATTTTTT TGAGACAGAT TCTCACTCTG TCTCCCAGGC 3451 TAGAGTGCAG TGGTGCAATC TCAGCTCACT GCAGCCTCAA CTGCCCCAGG

3S01 TTTAAGCAAT CCTCCCACCT CAGCCCCCAG GTAACTGGGA CTACAGGCAT

35S1 GCACCACCAT GCCTGGCTAA TTTTTGTATT TTATGTAGAG ACAGGGGTCT

3b01 TGCCATGTCG CCCAGGCTGA TCTTGAACTC CTGGGCTCAA GCAATCTGCC

3b51 AGCCTCAGCC TCTCAAAGTG CTGGGATTAC AGGCCTGAGC AACTGTGCCT 3701 GGCCCAAAAC CAGACCGTTA ACACATTAAA GAGTCTGATT TTGTTGAAGA

37S1 AAATATTTGC AATAAATTCA AGACTCTTCT TATTGGTAAT TTTCCACACA

3601 ATCCCTCTGA AATAAGGGAG AGGATATAGA CCTTTTTAAC TTTATAGTTA

3651 GAAAAATTGG CCTCAGTGTG AAATTTTTCC AGTCCCATAG CTCATGGATG

3101 CCACCAGCTT GCGGTAGTAG CAAGATGCTT ACTACCACAC CGTTTTCCTC 3151 GGTGGCCCAA TAGCTCGTGT ATCTAAGTTG AACCCGGCAG TATGCATGAT

4001 TGCCTTTTTC TCTTCTTTTT AAAAAAACCC AACTCAAAAA AAAAAAAAAA 4051 AA BLAST Results

No BLAST result

Medline entries

12271207:

Isom LLi De Jongh KSi Patton DEi Reber BFi Offord Ji Charbonneau

Ualsh Ki Goldin ALi Catterall

UA-i Primary structure and functional expression of the beta 1 subunit of the rat brain sodium channel- Science 1112 May 8i2Sb (5056) : 631-42 1b2351Sl:

Belcher SMi Howe JR-i Cloning of the cDNA encoding the sodium channel beta 1 subunit from rabbit- Gene 111b May 6il70(2) :265-b 1335774b:

McClatchey AIi Cannon SCi Slaugenhaupt SAi Gusella JF-i The cloning and expression of a sodium channel beta

1-subunit cDNA from human brain- Hum Mol Genet 1113 Juni (b) :745- 1

Peptide information for frame 3

ORF from 804 bp to 1446 bpi peptide length: 215 Category: similarity to known protein Classification-" Transmembrane proteins unclassified

1 MPAFNRLFPL ASLVLIYUVS VCFPVCVEVP SETEAViQGNP MKLRCISCMK

51 REEVEATTVV EUFYRPEGGK DFLIYEYRNG H(QEVESPF(QG RLiQUNGSKDL

101 (QDVSITVLNV TLNDSGLYTC NVSREFEFEA HRPFVKTTRL IPLRVTEEAG 151 EDFTSVVSEI MMYILLVFLT LULLIEMIYC YRKVSKAEEA AώENASDYLA

201 IPSENKENSA VPVEE

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_2flδι frame 3

PIR:JC4788 sodium channel protein betal chain - rabbiti N = li

Score =

434ι P = β.3e-41 PIR:AS5734 sodium channeli voltage-gatedi beta-1 chain precursor human! N = li Score = 42βι P = 3-be-40

PIR:A42737 sodium channel beta 1 subunit - rati N = li Score =

421ι P =

2.8e-40

>PIR:JC4768 sodium channel protein betal chain - rabbit Length ^~= 218

HSPs:

Score = 434 (bS-1 bits)ι Expect = 8.3e-41ι P = δ-3e-41 Identities = 100/214 (4b*)ι Positives = 121/214 (bO*)

(Query: ID LASLVLIYUVSVCFPVCVEVPSETEAVlQGNPMKLRCISCMKREEVEATTVVEUFYRPEGG bl

LA +V VS + CVEV SETEAV G K+ CISC +R E A T

EU +R +G

Sbjct: 5

LAF VGAALVSSAUGGCVEVDSETEAVYGMTFKILCISCKRRSETTAETFTEUTFRώKGT b4

(Query : 70 KDFL-IYEYRNGHtQEVESP--F(QGRL(QUNGS

KDL(QDVSITVLNVTLNDSGLYTCNVS 123

+ + F+ I Y N + + E F + GR+ UNGS KDLiQD + SI + NVT N

SG Y C+V Sb jct : bS

EEFVKILRYENEVLlQLEEDERFEGRVVUNGSRGTKDLlQDLSIFITNVTYNHSGDYiQCHVY 124

(Query: 124

REFEFEAHRPFVKTTRLIPLRVTEEAGEDFTSVVSEIMMYIXXXXXXXXXXIEMIYCYRK 183 R FE + + I L V ++A D S+VSEIMMY+

EM+YCY+K Sbjct: 125 RLLSFENYEHNTSVVKKIHLEVVDKANRDMASIVSEIMMYVLIVVLTIULVAEMVYCYKK 184 (Query: 184 VSKAEEAA-iQENASDYLAIPSENKEN-SAVPVEE 21S

++ A EAA (QENAS+YLAI SE+KEN + V V E Sbjct: 185 IAAATEAAAiQENASEYLAITSESKENCTGViQVAE 216

Pedant information for DKFZphamy2_2flβι frame 3

Report for DKFZphamy2_2f16 ■ 3

[LENGTH! 21S [MU! 24702-40

[pi! 4-bl

[HOMOL! PIR:JC47δδ sodium channel protein betal chain rabbit 3e-41

[BLOCKS! BL00401D Prokaryotic sulfate-binding proteins [BLOCKS! BP00S70 ESCOP! dlneu 2-1-1-1-1 Myelin membrane adhesion molecule P0 Era 2e-43

EPIRKU! Schwann cell 2e-07

EPIRKU! transmembrane protein le-40 EPIRKU! myelin 2e-07

EPIRKU! phosphoprotein 5e-D7

EPIRKU! glycoprotein le-40

[PIRKU! structural protein 2e-07

[PIRKU! muscle le-40 [PIRKU! membrane protein Se-07

[SUPFAM! immunoglobulin homology 2e-07

[SUPFAM! myelin P0 protein 2e-07

[PFAM! IG (immunoglobulin) superfamily

[KU! All_Beta [KU! 3D

[KU! SIGNAL_PEPTIDE 23

[KU! LOU COMPLEXITY 4 - b5 *

SElQ MPAFNRLFPLASLVLIYUVSVCFPVCVEVPSETEAVlQGNPMKLRCISCMKREEVEATTVV

SEG

Ineu- CEEEECCEEEETTTbCEEECE-

EEECCCCCCCCCEE SElQ EUFYRPEGGKDFLIYEYRNGH(QEVESPF(QGRL(QUNGSKDL(QDVSITVLNVTLNDSGLYTC SEG

Ineu-

EEEEEETTTCCCEEEEEETTEEEETTTTTTTEEECCBGGGCBCCEEECCbTTTTTEEEEE SEώ NVSREFEFEAHRPFVKTTRLIPLRVTEEAGEDFTSVVSEIMMYILLVFLTLULLIEMIYC

SEG xxxxxxxxxx

Ineu-

EE SE(Q YRKVSKAEEAAOENASDYLAIPSENKENSAVPVEE

SEG

Ineu-

(No Prosite data available for DKFZphamy2_2flδ ■ )

Pfam for DKFZphamy2_2flδ-3

HMM_NAME IG (immunoglobulin) superfamily

HMM yrNgqp ipssegyUytRweqqgRYs i s i f qLtl i sUepeDsGtYUCmV* YRNG ++ E+ ++ R++++G ++ +++T+ +++ +DSG

Y+C+V

(Query 77 YRNGHiQEV--

ESPFiQGRLlQUNGSKDLlQDVSITVLNVTLNDSGLYTCNV 122 DKFZphamy2_2f22

group: nucleic acid management

DKFZphamy2_2f22 encodes a novel 471 amino acid protein with similarity to YDL153c of Saccharomyees cerevisia- The novel protein is ubiquitously expressed- YDLlS3c is involved in transcriptional silencing-

The new protein can find application in modulation of transcriptioni e-g- transcriptional silencing-

putative protein probably complete eds- perhaps differential polyadenylation

YDL153c is involved in transcriptional silencing

Sequenced by MediGenomix Locus: /map="4"

Insert length: 2011 bp

Poly A stretch at pos- 20D0ι polyadenylation signal at pos- 1161

1 GGAGTCTGCA AACTCCGGTG GTAGGGGAGC GCGCTGCTGT TTAGAGCCAC

SI GAGTTACCGG AGCGCCTGAT TCCTGCGCCG AAGTCAGTGG TGGCCGAAAG

IDl TCCGGAGTCG CTGTAAAACC TGAGATTGTG AGCCATGGTG GGGAGATCCC

151 GGCGGCGCGG AGCAGCTAAG TGGGCAGCTG TGCGAGCCAA GGCAGGTCCC 2D1 ACGCTCACCG ACGAAAATGG AGATGATTTA GGATTGCCAC CCTCACCAGG

251 GGACACCAGC TACTACCAAG ATCAGGTAGA TGACTTTCAT GAGGCACGAT

301 CCCGGGCCGC CTTAGCTAAG GGCTGGAATG AAGTACAGAG TGGAGACGAG

351 GAGGATGGCG AGGAGGAGGA GGAGGAGGTG CTAGCCCTAG ATATGGACGA

401 TGAGGACGAC GAAGATGGAG GGAATGCGGG GGAGGAGGAG GAGGAGGAGA 4S1 ATGCCGATGA TGATGGTGGG AGCTCCGTGC AAAGTGAAGC TGAGGCCTCT

501 GTGGATCCCA GTTTGTCGTG GGGTCAGAGG AAAAAACTTT ACTATGACAC

5S1 GGACTATGGT TCCAAGTCCC GAGGCCGGCA GAGTCAACAG GAGGCAGAGG bOl AGGAGGAAAG AGAGGAGGAG GAGGAGGCAC AGATCATTCA GCGGCGCCTA b51 GCCCAAGCGC TGCAAGAGGA TGATTTTGGT GTCGCCTGGG TTGAGGCCTT 7D1 TGCAAAACCA GTGCCTCAGG TAGATGAGGC TGAGACACGG GTCGTGAAGG

7S1 ATTTGGCTAA AGTTTCAGTG AAAGAGAAGC TGAAAATGTT GCGAAAGGAA

601 TCACCAGAAC TCTTGGAGCT GATAGAAGAC CTGAAAGTCA AGTTGACAGA

651 GGTTAAGGAT GAGCTGGAGC CATTGTTAGA GTTGGTGGAA CAAGGGATCA

IDl TTCCACCCGG AAAAGGAAGC CAATACTTGA GGACCAAGTA CAACCTCTAC 151 TTGAATTATT GCTCGAACAT CAGTTTTTAT TTGATCCTGA AAGCTAGGAG

1001 AGTCCCAGCA CATGGACATC CTGTCATAGA AAGGCTTGTT ACCTACCGAA

1051 ATTTGATCAA CAAGCTGTCC GTTGTGGATC AGAAGCTGTC CTCAGAAATT

1101 CGTCATCTGT TGACACTTAA GGATGATGCT GTAAAGAAAG AACTGATTCC

1151 AAAAGCAAAA TCCACCAAGC CCAAACCAAA GTCTGTTTCA AAGACTTCTG 1201 CTGCTGCCTG TGCTGTTACA GATCTTTCTG ATGATTCTGA TTTTGATGAA

1251 AAAGCAAAAC TGAAGTACTA TAAAGAAATA GAAGACAGGC AAAAGCTAAA

1301 GAGAAAGAAA GAAGAAAATA GCACTGAAGA ACAGGCTCTT GAAGATCAAA

1351 ATGCAAAGAG AGCTATTACC TATCAAATTG CTAAAAATAG GGGACTTACT 1401 CCTAGGAGAA AGAAGATTGA TCGCAATCCC AGAGTGAAAC ACAGAGAGAA

14S1 GTTCAGAAGA GCCAAAATTA GAAGAAGAGG CCAGGTTCGT GAAGTTCGTA

15D1 AAGAAGAGCA ACGTTATAGT GGTGAATTAT CTGGCATTCG TGCAGGAGTT

1551 AAAAAGAGCA TTAAGCTTAA ATGAAGTTTT TGCTTAGCAT AAGGTTTTTG IbOl GCAGTTTTGG ATCAATAAAT TTTTACTTTT AACTAAAGTC ATTGTATTAA lb51 TATATAATAC TTTAAATTTT AAAAATTCTT GTCCACAAGG AAATTTGTCT

17D1 GGGTTATTGG ACAATTTATA AGAACTATGG GAGCAATATG AAGGTGCTTG

17S1 AGAAAAGAGA TGATGTTGAA GTTTTCCAAT ATTCTGTTGA AGTTTTCCAA

1801 TATTAAGTAT TAGCTTAGGG AAATTTCACA GTTCATTGTG GAGTGTTAAA 1851 CTTAGAACAT GTGTAACTTT TCACATAAAG AGAATGCATC TTTGACAGTT

1101 ATCTTATTTG TAAGGCAGCC TATAAAATAG TTCTGAAGTA TTTTATTTAC

1151 CTAACTATAA TTATTGGGCC AGATACTTGT TAATAAATGG GCTTAATGTC 2001 AAAAAAAAAA AAAAAAAAA

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 3

ORF from 135 bp to 1571 bpi peptide length 471 Category: similarity to unknown protein Classification: Nucleic acid management

1 MVGRSRRRGA AKUAAVRAKA GPTLTDENGD DLGLPPSPGD TSYYIQDIQVDD

51 FHEARSRAAL AKGUNEViQSG DEEDGEEEEE EVLALDMDDE DDEDGGNAGE

101 EEEEENADDD GGSSVύSEAE ASVDPSLSUG (QRKKLYYDTD YGSKSRGROS

151 (QiQEAEEEERE EEEEA(QII(QR RLA(QAL(QEDD FGVAUVEAFA KPVPiQVDEAE 201 TRVVKDLAKV SVKEKLKMLR KESPELLELI EDLKVKLTEV KDELEPLLEL

251 VElQGIIPPGK GSfQYLRTKYN LYLNYCSNIS FYLILKARRV PAHGHPVIER

301 LVTYRNLINK LSVVDiQKLSS EIRHLLTLKD DAVKKELIPK AKSTKPKPKS

351 VSKTSAAACA VTDLSDDSDF DEKAKLKYYK EIEDRώKLKR KKEENSTEElQ

401 ALEDώNAKRA ITYlQIAKNRG LTPRRKKIDR NPRVKHREKF RRAKIRRRGlQ 4S1 VREVRKEEiQR YSGELSGIRA GVKKSIKLK

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_2f22ι frame 3

PIR:Sb77Dl hypothetical protein YDL153c - yeast (Saccharomyees cerevisiae)ι N = 4ι Score = 134ι P = l-8e-08 PIR:T08b14 hypothetical protein DKFZpSb40012 • 1 - human

(fragment)ι l\l = li Score = 141ι P = S.8e-D7

TREMBL :SPBC3B8_1 gene: "SPBC3B6 • 01"i product: "hypothetical protein"i

S. pombe chromosome II cosmid c3B8-ι N = 2ι Score = lb4ι P = b-2e-

13

>TREMBL:SPBC3B8_1 gene: "SPBC3B8 - 01"i product: "hypothetical protein"i

S-pombe chromosome II cosmid c3B6- Length = 517

HSPs:

Score = lb4 (24. bits)ι Expect = b-2e-13ι Sum P(2) = b-2e-13 Identities = 44/12b (34*)ι Positives = bδ/12b (53*)

(Query: 3b7 DSDFDEKAKLKYYKEIEDR(QKLKRK-KEEN STEEiQALE-

DIQNAKRAITYIQ 414

D + +++ L YY+ ++ + K+ +K ++EN S + +E +

KR IT Sbjct: 472

DREVEDlQDDLDYYESLDKKSKMAKKLRKENHDLERDLIRASRHPELIELGEGDKRGITLD 531

(Query: 415 IAKNRGLTPRRKKIDRNPRVKHXXXXXXXXXXXXG(QVREVRKEE(QR- YSGELSGIRAGVK 473 IAKNRGLTPRR K +RNPR+K + + Q Y+GE

+GI+AG+ Sbjct: 532 IAKNRGLTPRRPKENRNPRLKKRMRYEKAKKKLASKKAIYKGAPOGGYAGEiQTGIKAGLV 511 (Query: 474 KSIKLK 471

KSIKL+ Sbjct: S12 KSIKLlQ 517

Score = 60 (12-D bits)ι Expect = b-2e-13ι Sum P(2) = b-2e-13 Identities = 21/121 (22*)ι Positives = bb/121 (51*)

(Query: H7 DEAETRVVK-DLAKVSVKEKLKMLRKESP--ELLELIE

DLKVKLTEVKDELEPLLE 241

D ++ + +K D + +++E ++ + + P ELL+++E + ++ L E+ ++L+P L

Sb j ct : 173 DNSDLKSIK(QDSSAAAIEELV(Q(QISPDLPRTELLKILEAKHPEF(QLFLDEL- N(QLKP(QLN 231

(Query : 2S0 LVEiQGIIPPGKGSiQYLRTKYNLYLNYCSNISFYL- ILKARRVPAHGHPVIERLVTYRNLI 3D6

+ + + + S(Q L+ + Y S + + FY +LK HP++

LV +

Sbjct: 232 EIKEKL- KTYPSS(QLL(QA(QCTALSTYISFLTFYFALLKDGEEDLKNHPIMVDLVRCK(QTU 210

(Query: 301 NKLSVVDtQKLS 311

+D+ L+ Sbjct: 211 ESYCGLDEVLT 301 Score = SI (6-1 bits)ι Expect = 1.2e-llι Sum P(2) = 1. Ξe-11 Identities = lδ/51 (30*)ι Positives = 35/51 (51*) (Query: lib VDEAETRVVKDLAKVSVKEKLKMLRKESPEL

LELIEDLKVKLTEVKDELE—PLLEL 2SD

++E ++ DL + E LK+L + PE L+ + LK +L E+K++L+ P +L

Sbjct: 161 IEELV(Q(QISPDLPRT ELLKILEAKHPEF(QLFLDELN(QLKP(QLNEIKEKLKTYPSS<QL 245

(Query: 251 VE 252

++ Sbjct: 24b LiQ 247

Score = 57 (β-b bits)ι Expect = 3-Oe-Dlι Sum P(2) = 2-be-Ol Identities = 13/56 (22*)ι Positives = 2b/Sδ (44*)

(Query : 3b7 DSDFDEKAKLKYYKEIEDRiQKLKRK-- KEENSTEE(QALED(QNAKRAITY(QIAKNRGLT 422

D + +++ L YY+ ++ + K+ +K KE + E + I

RG + T

Sb jct : 472 DREVEDiQDDLDYYESLDKKSKMAKKLRKENHDLERDLIRASRHPELIELGEGDKRGIT 521

Score = 42 (b-3 bits)ι Expect = 5-2e-D1ι Sum P(2) = S-2e-01 Identities = 13/51 (25*) i Positives = 21/51 (5b*)

(Query: m AETRVVKDLAKVSVKEKLKMLRKESPE-- LLELIEDLKVKLTEVKDELEPLLE 241

+ET + D+++ + LK ++++S + EL++ + L + EL +LE

Sbjct: ibO SETDAIDDIS(QUADNSDLKSIKώDSSAAAIEELV(Q(QISPDLP— RTELLKILE 210

Score = 31 (5-1 bits)ι Expect = 1-le-Dδι Sum P(2) = 1. le-06 Identities = δ/lβ (44*)ι Positives = 11/18 (bl*)

(Query: 43 YYflDlQVDDFHEARSRAAL bO +Y +I3+D RSRA L

Sbjct: 402 FYANlQIDlQKAAKRSRAVL 411

Pedant information for DKFZphamy2_2f22ι frame 3

Report for DKFZphamy2_2f22-3

[LENGTH! 471

[MU! 54558-00

Epl! 5-50

[HOMOL! TREMBL:SPBC3Bδ_1 gene: "SPBC3B6 ■ D1"i product:

"hypothetical protein"i S-pombe chromosome II cosmid c3Bδ- le-lD [FUNCAT! 04-05.01.04 transcriptional control [S- cerevisiaei

YDLlS3c! le-06

[BLOCKS! PRD0526D

[BLOCKS! BL003bDC Ribosomal protein SI proteins [BLOCKS! BL001b4A Syndecans proteins

[BLOCKS! PRDDb24G

[BLOCKS! PR00626H

[BLOCKS! BL00624B Elongation factor 1 beta/beta ' /delta chain proteins

EKU! All_Alpha

EKU! L0U_C0MPLEXITY 24-b3 *

EKU! COILED COIL 7-10 *

SElQ MVGRSRRRGAAKUAAVRAKAGPTLTDENGDDLGLPPSPGDTSYYlQDiQVDDFHEARSRAAL SEG xxxxxxxxxxxxxxxx

PRD cccccchhhhhhhhhhhhhccccccccccccccccccccccccccchhhhhhhhhhhhhh COILS

SElQ AKGUNEVIQSGDEEDGEEEEEEVLALDMDDEDDEDGGNAGEEEEEENADDDGGSSVIQSEAE

SEG xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

PRD hhcccccccccccchhhhhhhhhhhhhhccccccccchhhhhhhhhhccccccchhhhhh COILS

SElQ ASVDPSLSUG(QRKKLYYDTDYGSKSRGR(QS(Q<QEAEEEEREEEEEA(QII(QRRLA(QAL<QEDD SEG xxxxxxxxxxxxxxxxxxxxxxxxxxx PRD hcccccccccccceeeecccccccccccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhcc COILS

SElQ FGVAUVEAFAKPVPtQVDEAETRVVKDLAKVSVKEKLKMLRKESPELLELIEDLKVKLTEV SEG

PRD chhhhhhhhhhccchhhhhhhhhhhhhhhhhhhhhhhhhhhcchhhhhhhhhhhhhhhhh COILS CCCCCCCCCCCCCCCCCCCCCCCCCCCCC SElQ KDELEPLLELVElQGIIPPGKGSlQYLRTKYNLYLNYCSNISFYLILKARRVPAHGHPVIER SEG

PRD hhhhhhhhhhhhhhhcccccchhhhhhhhhhhhhhhhhhhhhhhhhhhcccccccccccc COILS ccccc

SElQ LVTYRNLINKLSVVDlQKLSSEIRHLLTLKDDAVKKELIPKAKSTKPKPKSVSKTSAAACA SEG xxxxxxxxxxxxxxxxxxxx- ■

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhcchhhhhhhhhhhhcccccccchhhhhhhhh COILS

SElQ VTDLSDDSDFDEKAKLKYYKEIEDRlQKLKRKKEENSTEEiQALEDlQNAKRAITYlQIAKNRG SEG

PRD hhhhcccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhc COILS

SElQ LTPRRKKIDRNPRVKHREKFRRAKIRRRGlQVREVRKEEiQRYSGELSGIRAGVKKSIKLK SEG xxxxxxxxxxxx PRD cccccccccccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhcccccchhhhhhhhccc COILS (No Prosite data available for DKFZphamy2_2f 2- 3) (No Pfam data available for DKFZphamy2_2f22 -3)

DKFZphamy2_2gl2

group: nucleic acid management

DKFZphamy2_2gl2 encodes a novel 111 amino acid protein with similarity to NVL-2 of Rattus norvegicus- The novel protein contains 3 EF-hand calcium-binding domains- The related human VILIP Ca-dependend protein specifically binds the 3'-untranslated region of the neurotrophin receptori trkBi an mRNA localized to hippoca pal dendrites in an activity-dependent manner- The new protein exhibists elevated expression in brain and testis-

The new protein can find application in studying the expression profile of brain-specific genes and as a new marker for neuronal cells-

strong similarity to NVL-2 (Rattus norvegicus)

Comment for P35332: FUNCTION: MAY BE INVOLVED IN THE CALCIUM-DEPENDENT REGULATION OF

RHODOPSIN PHOSPHORYLATION.

TISSUE SPECIFICITY: NEURON-SPECIFIC IN THE CENTRAL AND PERIPHERAL

NERVOUS SYSTEM-

MISCELLANEOUS: PROBABLY BINDS TUO OR THREE CALCIUM IONS (BY SIMILARITY)

SIMILARITY: TO OTHER EF-HAND CALCIUM BINDING PROTEINSi BELONGS TO

THE

RECOVERIN SUBFAMILY- Sequenced by MediGenomix

Locus: /chromosome="l"

Insert length: 4265 bp Poly A stretch at pos- 4256ι polyadenylation signal at pos- 4247

1 GGCGGCTCCG GCGCAGACCT TGGAGAGCAC AGCTGCCGGC CCGCGAGCCA

51 GCCTCGGTTC CCGCGGCCCG CCGAGGCTCG GAGCCATCCA GCGACCCGGC 101 GACCGGCCTC AGGCCCCGCC ATGGGGAAGA CCAACAGCAA GCTGGCCCCC

151 GAGGTGCTGG AGGACCTTGT TCAGAACACT GAGTTCAGCG AGCAGGAGCT

201 GAAGCAGTGG TACAAGGGCT TCCTGAAGGA CTGCCCCAGC GGCATCCTCA

251 ACCTGGAGGA GTTTCAGCAG CTCTACATCA AGTTCTTCCC CTACGGCGAC

3D1 GCCTCCAAGT TCGCGCAGCA CGCTTTCCGC ACCTTCGACA AGAACGGCGA 3S1 CGGCACCATC GACTTCCGGG AGTTCATCTG CGCCCTGTCG GTCACCTCCC

401 GCGGCAGCTT CGAGCAGAAG CTCAACTGGG CCTTTGAGAT GTACGACCTG

451 GACGGCGACG GGCGAATCAC GCGCCTGGAG ATGCTGGAGA TCATCGAGGC

501 AATCTACAAG ATGGTGGGCA CCGTGATCAT GATGCGCATG AACCAGGACG

SSI GGCTCACGCC CCAGCAGCGT GTGGACAAGA TCTTCAAGAA GATGGACCAG bDl GATAAGGACG ACCAGATTAC ATTGGAGGAG TTCAAGGAGG CAGCCAAGAG bSl TGACCCATCC ATTGTGTTGC TGCTGCAGTG TGACATGCAG AAGTAGAAGC

701 TGGTGAGGGG CAGGGTCCCT GGCCAGAAGG GGCATGGCCA CCTCCCAACC

751 TGATGACCTC TCTGGCTGGC CTCCCAGGAG GAGGGACACT CCAGCCCCCC δOl TCTCTGGCCC ACCCAGTCCT CTGCCCAAGC CCTTCCTCCC CTCCATCAAG δSl ATCTTTGAGG GACCACCTCA CCCTGCAAAA GAGACAGGTC CTCCAGTACC

101 CT6TCTTCTA GCCCCACCTC CCACTTGGCC AGAACCAATG TCCATTGGGC

151 ATAGGGGAGT TGGCTTTTGC CCCAGGAGGT GAGGTTAAGG AGTTGGGGGC 1001 CTGGGGTTCT GGTTAGGAAT TCTCTTGATC CTGGGATTAT GCTTTATAGG

1051 ATGTGGTCCC ACAGGCCTGT CACAGGGCCA AATTGGGTCT GTCCATTCCT

1101 GAGGCTCCAG ATCCCATAAA GGGGGTCTCT TCCCCATCCC TTCTACTCTA

1151 CCTGGCCCTT CCAGCCCCAG CCTTTGGAGC GTTCATTCAG TCCTTTCTTC

1201 AGCTAATGAT TACTGAGCAC CTGTTTGGTG CTAAGGATAT GGTCATTTAC 1251 AAGACACATC TTGTGCCCTC TGGAAGCTCA TAGGGTTGTG AGGCAAACTT

1301 CCAGCCGTCA GGGTCTCAGC TAAGCAGAAG GTGCTGGAAG GCTGGTTAGT

1351 CTGGGAGGAG CTATTTCATC TTCCAGCTCA GCTCCACACA AAGCTGCAGA

1401 AGGACGAAAT GAAAAGCATT TGGAAGTTTA GGAGCCACGT GAGTGAAAGT

1451 TTTAAGAAAA ATGAAATTTA TGTCATACTT ATTTTTTTAG TACCCTTTAA 1501 AGGAGCTACA GTCATTTTAT TATTTCAGGA GGTTAAAATA TACTCTATAT

15S1 TACTTGGTTT ATTATAAAAT GATTAAATGA ATAGAGAAAA TATTAATTTT

IbOl CAAGGGGAAA AAACCTGAGA AGAAAGGGAG AAAAGACCAT GAAATTTACC

11.51 AGATAACACT TTTTAAGACT AAGTCCTGAG CTGCCACTCT CAGCAGTTTT

1701 TGCTGCTTCA GCTCTTCCTT TTTATTACCT TTTTCAATTC AACAAGCAAC 1751 TTTCTGCTAC ATACTTACTC CGGTTGGGTG CTGACTTCAG GGACAGGAAA

1601 AAGCAAGGTT TGCAAAGAGT GAAACTAGTG TATATTCCGT ATCTTGGTAG

1651 TTCGTTTCTG GATTGGGTTT AGTTTCAGAA CTGGACTTGT TCCTTCACTG

1101 CCACAGAATC AGAAAGAGCT AGAAGAAAAG GCTCACCTGG CCACTGTTTA

1151 GGCACCCAGA CATAATTTAT GGACGAAATG CCTAAAAATG TGCCAGGCAT 2001 GCTCTGTTTG AGAGGCTTTT TCTAACCCCA AATCTTAGAT CTGCCAGGTA

2DS1 GTTCAACATC TTCCAAGTGT GCTGGTTCTG CTTTCCAATG CCTGCTTCCC

2101 AATTTTGGAT CCATGAGCTA TACAGCTGCA TGCTTTGACT GCCGGAAAAA

21S1 TTAATCTTGC TTCTTCATCA GGTCTTTCTC CTGTACTTGT GATCAGAAAT

2201 TACCTTTGAC GTGCAGTGAC AGTTGATTTC CTCTTGAACT GCCGGTGAAA 2251 ACAGTCTAGT ACACAGGTGC TGTCAGCCCA GGGTGGGAGC AGGAAATGAT

23D1 TGCTGAGCCC GGGGCAGGGG AATTGCATCT GCAGGAAAGA GATGCAGCAT

2351 GCTCCTCACT CCTGAGTGCC CACCTGTCCT GCTTCTCTGC AGGTGAAAAC

2401 TCTGGGGGAT GCTGATCAAT AGAGCTTGGT CCCAAGCTCT ACTGGGCCCT

2451 TGGAGGTAGC AAGGCCACTG GGTTGCTATC CTCTTGATGG GGATAGCAAC 2501 CACTGGTTTG CAACCACTGG GTTGCTATCC TTTTGCTATC CTCTTGCTCA

25S1 TGACCAGCCA TATGGTGAGG CTGGGGAGTT CACATCCTCA GGCAGGAACT

2b01 AGCAGTTGTT TATCCAGCAA TGCCTCAAGG ATGTTGCATT GCTCCCAGGA

2b51 GCTGGCTATT AGGTATGTCT TGTGCGGTCA GTCAGCATCA CAGACACATA

27D1 GATGCTCACC AGCCTGGCTT AGCTGGGACC TAAATCTTCT GGTGAAAAGC 27S1 TTTTCACTAA GTGAGGTTCC TTCCCTGCAA ATGCTGAATC TAGCCTAATT

2601 CGCAACCACA CAGAATTTCA TGGCTTTCAA AGGCTTGCCA TGTGCCCCAT

2651 CTCATTCTAT ACTCACATCC CATGGAGGTG AGGATTTTCA CTTCTTTTCT

21D1 CTAGACTTGG AAGCTGAGAT TCAGAGAGGA AGCATCCCTT GTGCAAGATC

2151 ACATAGTCAG GAGGTGACAC AGGGCTAAGA CTTGAACCAA GGCTCTAAGA 3001 GGATTTCTTC TTTTCAGAGT CTCTTCCCTG TCCATTTCTG TGACTAAGCT

3D51 GTGCAGAGGT TGACAGCAGG GCAAGTTACA TTGATATTCA TCCTTTATAG

31D1 GCTTCCTGCT AAAAAGCTTC TGAGATTGTG GTCTTCCAAA AAAAATAGGA

3151 GCTTGGTTGA AGTCCCCACA TTTTCAAGCA CTCAGTGTTC TGCCTCTGGC

3201 AGCTGTGCTA ACAGCTCAGT GCTGTCCTGG GAGTCCTCTG ACTCAGAACC 3251 CTCGAAGCAT CCTGCATTGT CTTTACCCAC CATCATCGTC ACTAAGAGAA

33D1 ACATGCCTAC CCATGAAGGC GTGTTTGATT ACTCCAGGCT TCTGGACACA

33S1 CATACCCATG GGTGATTTTT GCTCCTCAGG CCCAATATTC TCAGACAGCC

3401 CAGCAGTGTG AACACACAAT GCCAGGCCAG GAACTGGGAC CACCATCTTG

3451 CTGATGGAAG GAACAACAGG TGGCCCAGGA CATGCTCCTG CATACTCCTG 3S01 GGTGTCCCAG GGACTGTGTG CTCAGGAGCA CTGTGGTAGA GCACTGGCCC

35S1 TGCCTTGAGA AGAGACACAG GTCTCCCGTC CCTGCACCAG CTGAGAGAGA

3b01 CTTGCCACAA AGCACAAGGC TGGCAGAGAT TTATGTATGA CTTGCACAGA

3b51 CACAAAAATA TACAGACAAT CAAAACATTG ATATATTCAA ACTCTCCTTT 3701 AAATTCCAAT CTTATTGCAA CAACTCTGTG AATTGCAAGG TCCCAGAATC

3751 TGCCTTCTCA CATACTCTAC CCTCATTCAT CCTTTTGGGC TAATTGATGA

36D1 GCATCTTATT TCTTATCTCT AAAAATTATC AGCAAAGGCT ACTTCAGATG

3651 GCCACTTTAG TCCTTTCAGC TGTAGTCAGG ATTATTTAAC TTACCTGTAT

3101 ATCAAAAGTG AAGAAAAAGT TAGTTCATAA GTAAAGGCAC TAAATCCTTT

3151 CCTGACAATG GCAGAGTCTC TAGAGGTAGA AATTTGCCTT GCTGCAGAGA

40D1 GAGAAGGAAT GGCGTGGGAT GGGGGAAAGA AAAGAAAGAG AAGAAGAGAA

4051 GAAGCTGGGG TCTCCAGGCA GGGTAGTAAG CTGACACTAA ATATTTTTTA

4101 CACAAAAATG TATTGAAGCA ACAAATATTT CCTGAAGATC CACCCTGGGT

41S1 GAGGCTTTGA GCTGACTTTA GAGATCACTG TGGGGTCAAG AATGTCTTAC

4201 ATGTTTTATT CATCATTCTT GAAAAAAGAA ATAATTCAAA CCTTGGAATT

4251 AAAAAGTCAG AAAAACAAAA AAAAAAAAAA AAAAA

BLAST Results

No BLAST result

Medline entries

133b7470:

Kajimoto Yi Shirai Yi Mukai Hi Kuno Ti Tanaka C-i Molecular cloning of two additional members of the neural visinin-like Ca (2+)-binding protein gene family- J Neurochem 1113

Sepibl(3):1011-b

1b071121:

Polymeropoulos M-H-i Ide S-i Soares M-B-i Lennon G-G-i Sequence characterization and genetic mapping of the human VSNLl genei a homologue of the rat visinin-like peptide RNVP1- Genomics 21(1) :273-275(1115) -

Peptide information for frame 1

ORF from 121 bp to b13 bpi peptide length: m Category: strong similarity to known protein Classification: Protein management Prosite motifs: EF_HAND (73-65) EF_HAND (101-121) EF HAND (151-171)

1 MGKTNSKLAP EVLEDLViQNT EFSE(QELK(QU YKGFLKDCPS GILNLEEF(Q(Q

SI LYIKFFPYGD ASKFAlQHAFR TFDKNGDGTI DFREFICALS VTSRGSFEiQK

101 LNUAFEMYDL DGDGRITRLE MLEIIEAIYK MVGTVIMMRM N(QDGLTP(Q(QR

151 VDKIFKKMDiQ DKDDiQITLEE FKEAAKSDPS IVLLLIQCDMIQ K

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_2gl2ι frame 1 No Alert BLASTP hits found

Pedant information for DKFZphamy2_2gl2ι frame 1

Report for DKFZphamy2_2gl2-l

ELENGTH! 231 EMU! 2b277-12

Epl! 5.2b

EHOMOL! PIR:JH061S neural visinin-like Ca2+-binding protein-type 2 - rat Ie-1D7

EFUNCAT! 16 classification not yet clear-cut ES- cerevisiaei YDR373w! 3e-52

EFUNCAT! 03-01 cell growth ES. cerevisiaei YKLllOw! 3e-16

EFUNCAT! 03.07 pheromone responsei mating-type determination! sex-specific proteins ES- cerevisiaei YKLllOw! 3e-lβ

EFUNCAT! 13-04 homeostasis of other ions ES- cerevisiaei YKLllOw! 3e-lδ

EFUNCAT! 04-05-01-04 transcriptional control ES- cerevisiaei

YKLllOw! 3e-lβ

EFUNCAT! 30-03 organization of cytoplasm ES- cerevisiaei

YKLllOw! 3e-lβ EFUNCAT! 11-01 stress response ES- cerevisiaei YGRlOOw! 7e-04

EBLOCKS! BL00303B S-100/ICaBP type calcium binding protein

EBLOCKS! BL00016

EBLOCKS! PR00450G

EBLOCKS! PR004S0F EBLOCKS! PR0045DE

EBLOCKS! PR004SDD

EBLOCKS! PR0045DC

EBLOCKS! PR004S0B

EBLOCKS! PR00450A ESCOP! dlosa 1-37.1-5.13 Calmodulin E(Paramecium tetraurelia) 6e-25

ESCOP! dlrec 1.37.1.5-21 Recoverin Ebovine (Bos taurus) le-72

ESCOP! dla4pa_ 1-37-1-2-5 Calcyclin (S100) [Human (Homo sapiens)ι PI 7e-0S

[SCOP! dlrro 1-37.1-4-1 Oncomodulin [rat (Rattus norvegicus) 2e-17

[SCOP! dlsyma_ 1-37-1-2-2 Calcyclin (S100) [rat (Rattus norvegicus) 1e-14 [SCOP! d4icb 1.37-1.1-1 Calbindin D1K [bovine (Bos taurus) 2e-lδ

[SCOP! dlauib_ 1-37-1-5-11 Calcineurin regulatory subunit

(B-chain le-45

[PIRKU! blocked amino end le-11 [PIRKU! phosphotransferase 3e-D6

[PIRKU! duplication 7e-17

[PIRKU! tandem repeat 7e-0b

[PIRKU! heterodimer 7e-17 [PIRKU! heart 7e-Db

[PIRKU! serine/threonine-specific protein kinase 7e-0b

[PIRKU! acetylated amino end 7e-0b

[PIRKU! ATP 7e-0b [PIRKU! skeletal muscle 7e-0b

[PIRKU! signal transduction 4e-b1

[PIRKU! protein kinase 3e-0β

[PIRKU! calcium binding le-11

[PIRKU! alternative splicing le-13 [PIRKU! lipoprotein le-11

[PIRKU! cardiac muscle 7e-0b

[PIRKU! muscle 7e-0b

[PIRKU! myristylation le-11

[PIRKU! EF hand le-11 [PIRKU! retina le-4b

[SUPFAM! calcium-dependent protein kinase 3e-06

[SUPFAM! unassigned calmodulin-related proteins 2e-34

[SUPFAM! protein kinase homology 3e-0β

[SUPFAM! calmodulin le-11 [SUPFAM! calmodulin repeat homology le-11

[PROSITE! EF_HAND 3

[PFAM! EF hand

[KU! All_Alpha

[KU! 3D

SE(Q GGSGADLGEHSCRPASiQPRFPRPAEARSHPATRRPASGPAMGKTNSKLAPEVLEDLViQNT Irec- HHHHHHHHHTTTT

SElQ EFSE(QELK(QUYKGFLKDCPSGILNLEEF(Q(QLYIKFFPYGDASKFA(QHAFRTFDKNGDGTI Irec- CCCHHHHHHHHHHHHHHTTTTEEEHHHHHHHHHHHTTTTCHHHHHHHHHHHH---

--CEE SElQ DFREFICALSVTSRGSFElQKLNUAFEMYDLDGDGRITRLEMLEIIEAIYKMVGTVIMMRM Irec-

EHHHHHHHHHHHHCCCGGGHHHHHHHHHTTTTCCCEEHHHHHHHHHHHHHCCTTTTGGGC

SElQ N(QDGLTP(Q(QRVDKIFKKMD(QDKDD(QITLEEFKEAAKSDPSIVLLL(QCDMιQK lrec- TTTTTCHHHHHHHHHHHHCCTTTTEECHHHHHHHHHHCHHHHHHHCCCHHH

Prosite for DKFZphamy2_2gl2-l

PSDDOlβ 113->12b EF_HAND PD0C0D016

PS00018 141->lb2 EF_HAND PDOCOOOlδ

PS00016 111->212 EF HAND PD0C00016

Pfam for DKFZphamy2_2gl2-l

HMM NAME EF hand

HMM *EIqEMFrmMDkDGDGyIDFEEFmeMMkem* (Q +FR +DK+GDG+IDF EF+ +++ (Query 104 FAiQHAFRTFDKNGDGTIDFREFICALSVT 132

27-15 140 Ibβ 1 21 dkfzphamy2_2gl2 - 1 strong similarity to NVL-2 (Rattus norvegicus) Alignment to HMM consensus:

(Query *EIqEMFrmMDkDGDGyIDFEEFmeMMkem*

++++F+M+D DGDG+I+ E++E++ ++ dkfzphamy2 140 KLNUAFEMYDLDGDGRITRLEMLEIIEAI Ibδ (Query 216 1 ^' 21 dkfzphamy2_2gl2-l strong similarity to NVL-2 (Rattus norvegicus)

Alignment to HMM consensus: HMM *EIqEMFrmMDkDGDGyIDFEEFmeMMkem*

++++F++MD+D+D +1+ EEF+E+ K+ (Query 110 RVDKIFKKMDlQDKDDiQITLEEFKEAAKSD 216

DKFZphamy2_2il7

group: amygdala derived

DKFZphamy2_2il7 encodes a novel 4b2 amino acid protein without similarity to known proteins. Most ESTs are derived from brain and pancreas- No informative BLAST resultsi No predictive prositei pfam or SCOP motife ■

The new protein can find application in studying the expression profile of amygdala-specific genes-

unknown protein perhaps complete eds-

Sequenced by MediGenomix Locus: unknown

Insert length: 3473 bp

Poly A stretch at pos- 3454ι polyadenylation signal at pos- 343b

1 GATATCCCAA TCTTTGGACT GCATCCTGGT TGCCTCTACT GTGGTCACCT

SI TTGGGAAGAA ATGTCTTCTG TAAAAAGAAG TCTGAAGCAA GAAATAGTTA

101 CTCAGTTTCA CTGTTCAGCT GCTGAAGGAG ATATTGCCAA GTTAACAGGA

ISI ATACTCA6TC ATTCTCCATC TCTTCTCAAT GAAACTTCTG AAAATGGCTG

201 GACTGCTTTA ATGTATGCGG CAAGGAATGG GCACCCAGAG ATAGTCCAAT 251 TTCTGCTTGA GAAAGGGTGT GACAGATCAA TTGTCAATAA ATCAAGGCAG

301 ACTGCACTGG ATATTGCTGT ATTTTGGGGT TATAAGCATA TAGCTAATTT

351 ACTAGCTACT GCTAAAGGTG GGAAGAAGCC TTGGTTCCTA ACGAATGAAG

401 TGGAAGAATG TGAAAATTAT TTTAGCAAAA CACTACTGGA CCGGAAAAGT

4S1 GAAAAGAGGA ATAATTCTGA CTGGCTGCTA GCTAAAGAAA GCCATCCAGC 501 CACAGTTTTT ATTCTTTTCT CAGATTTAAA TCCCTTGGTT ACTCTAGGTG

S51 GCAATAAAGA AAGTTTCCAA CAGCCAGAAG TTAGGCTTTG TCAGCTGAAC bOl TACACAGATA TAAAGGATTA TTTGGCCCAG CCTGAGAAGA TCACCTTGAT b51 TTTTCTTGGA GTAGAACTTG AAATAAAAGA CAAACTACTT AATTATGCTG

701 GTGAAGTCCC GAGAGAGGAG GAAGATGGAT TGGTTGCCTG GTTTGCTCTA 751 GGTATAGATC CTATTGCTGC TGAAGAATTC AAGCAAAGAC ATGAAAATTG

601 TTACTTTCTT CATCCTCCTA TGCCAGCCCT TCTGCAATTG AAAGAAAAAG

ΘS1 AAGCTGGGGT TGTAGCTCAA GCAAGATCTG TTCTTGCCT6 GCACAGTCGA

101 TACAAGTTTT GCCCAACCTG TGGAAATGCA ACTAAAATTG AAGAAGGTGG

151 CTATAAGAGA CTATGTTTAA AAGAAGACTG TCCTAGTCTC AATGGCGTCC 1001 ATAATACCTC ATACCCAAGA GTTGATCCAG TAGTAATCAT GCAAGTTATT

1051 CATCCAGATG GGACCAAATG CCTTTTAGGC AGGCAGAAAA GATTTCCCCC

1101 AGGCATGTTT ACTTGCCTTG CTGGATTTAT TGAGCCTGGA GAGACAATAG

1151 AAGATGCTGT TAGGAGAGAA GTAGAAGAGG AAAGTGGAGT CAAAGTTGGC

1201 CATGTTCAGT ATGTTGCTTG TCAACCATGG CCAATGCCTT CCTCCTTAAT 12S1 GATTGGTTGC TTAGCTCTAG CAGTGTCTAC AGAAATTAAA GTTGACAAGA

1301 ATGAAATAGA GGATGCCCGC TGGTTCACTA GAGAACAGGT CCTGGATGTT

1351 CTGACCAAAG GGAAGCAGCA GGCATTCTTT GTGCCACCAA GCCGAGCTAT

1401 TGCACATCAA TTAATCAAAC ACTGGATTAG AATAAATCCT AATCTCTAAA 1451 TCTAAGAACT AAGCTTTGAG TATTATTTAA TAATTTCTAA TAACACTCAT

1S01 TCCTCAAGTG ATATTAGAGA TTATTCAGTA CTCTTGAGAG TGTCACAACA

1551 CAAAATACGA TGTTGGGTTT TCGAAATATT TTCAAAGTGT TCTGTCTTAA

IbOl TCACAAATTC ATATTTTTAC ACATTTTTAC AATATTGCCT CAGATTATGT lb51 TAAATTTGGG TCAGTCTTCT CTGAACTTTT TCTCTCTCGG TTTCTTTTCT

1701 TCCTTCACAG TTTTATCTCA CAAAACCATT TTTCTAATAA GAGACATCAT

17S1 GTTGGAAAGA TGTTGTAGAA ATGTGCATAA ATTTCAGTGC CTCTTGTAAG

1601 CATTAAACTG ATGATGAAGA AAGTTCCTGA TTTGAGAAAT GAATCAAAGT

1651 AATTTTAATG AATTTTTAGC TTGTATTAGC TTGAGTTAGC TGGCATTGAT 1101 TTTTTAGTCC TTTTGTTACC TTTAAGTTGT CAATATATGG TTTTTGTTCA

1151 TCTCCCCATT GTAGTCCCAC TTGCTCTTTC CTGGGGGTTC CATTGTTCTA

2001 GCAGTGGAGG TGTTACAGTG TCGCCACTCG TCTAATTTGA CCAGTGTTAA

2051 GAATTTTCTA ATTTAATAAT TTAATAGTGA TCTCAATACC ACACCCTCAT

2101 GGAAGGAGAA AAGCATACTA TTATATCTGG GACCTCTCTT TTAGACCTAA 2151 AATTAATTAA CATATCTACT TATATGTTAC TTATACCTAA AGCTGTTATT

2201 AAGACAAACC AAGATTCTCT GCTTTTGCAC TGAAATTAAA CTTGAAAGGA

2251 ATTCTCCTCA AAGGTCGGAT ATTAAATAAG TCCCAGGCAG ATTTACATAT

2301 TTAATTTAAA ACATTGGCTT TATTTCATTT TGTGATGAGT GATGTATCTG

2351 TGTTAACAAA AAATTGTATA ATCATTACCA ATACTATTTA TTATGCTCAA 2401 ATATATCTTG GCTTTGACCT TATTTCAACA CATTCTAAGA AGCCTTGACA

24S1 AAGTAAGTAT ATTTTAGAGC TGAATCAGTA AGATTCTAGA GAAAGCAAAA

2501 CATAGTAGTT CACAATTTTG CAACATAGAA AGTCACATTT TGAAAGGCTA

2551 TTTTGAAATT GATTTAATAG CTATTATAGT TTATGAATAT CAAAATTTGT

2b01 ATAATTTGCA TCTTTACTAA TGTATGCTAG AGCTACAAGA GACCTTAAGG 2b51 ATAATATATG AAATTAGCTT TCCTTATTTT ATAGATAAGG AAAAAGAAAT

2701 TGTGAAAGGT GAATTTACCT AATTAGTGAA AGTTACATAA CTAATTACAA

2751 CAGTCTGTAC TATATAATGC AGAGGACGAT TCTCCCTGTA AAAGGAACTA

2601 GAAGCTATTA CTAAAAATAT ATATAGACAA AATTAAAAGA AGGAATGATA

2651 AGAATAAATT TAATTTACCA AATATTGTTA ATTAAAATTT TAGATACTTA 2101 ACATTTATTT AACTTAAATA AAAGATAACT GTCAGATAAA ACTTTATTTT

2151 ACTAATGAGC AGTGATTTTC TTAGGAATTG ATGAAGGCTT ATTGGTATCA

3001 AGAATTTAAA CCAAATTAAA ACTGACAGAG GACATTTAGA TACATAATAA

3051 AATTCGAGCT ACATAAGTAT ATGGAAAATA ATGTACCTTG ATTATTATGA

3101 AATAGAGCAT CTTGAAATTC AGTTTTACTC TAAATGTACT TTTAATACTT 3151 GCAGATTCTA AGATTACATT GTGAAATTCC AGGTTTTCAT AATGTTAAAA

3201 TAGGAAAGTA GAATATAAAG TATCAACAAG TGTAGTTATA CATTTTGTTT

3251 TGGATATTTA ATCCTTACTT GGGAAAAAAT CAGCATCTAG GTAAATTATT

3301 ATTTTAATAA GAACTCTTAA ATTGCCAACC TCTGAGAGGT GAAAAGCTAT

33S1 GTAAATAGAA GGAATGGCCA GTTCAAAAGA ATAGTAGAAG TGATAGTGCC 3401 GTGAATGTAT TCTACTGGAA ATGAATGTAA TAATACATTA AATTTTTAAA

3451 ATCGAAAAAA AAAAAAAAAA AAA

BLAST Results

o BLAST result

Medline entries

o Medline entry

Peptide information for frame 1 ORF from bl bp to 144b bpi peptide length 4b2 Category: putative protein Classification: unclassified Prosite motifs: MUTT (355-374)

1 MSSVKRSLKlQ EIVTlQFHCSA AEGDIAKLTG ILSHSPSLLN ETSENGUTAL 51 MYAARNGHPE IViQFLLEKGC DRSIVNKSRiQ TALDIAVFUG YKHIANLLAT 101 AKGGKKPUFL TNEVEECENY FSKTLLDRKS EKRNNSDULL AKESHPATVF 151 ILFSDLNPLV TLGGNKESFlQ (QPEVRLCiQLN YTDIKDYLAiQ PEKITLIFLG 201 VELEIKDKLL NYAGEVPREE EDGLVAUFAL GIDPIAAEEF KiQRHENCYFL 2S1 HPPMPALL(QL KEKEAGVVAώ ARSVLAUHSR YKFCPTCGNA TKIEEGGYKR 301 LCLKEDCPSL NGVHNTSYPR VDPVVIMiQVI HPDGTKCLLG RiQKRFPPGMF 351 TCLAGFIEPG ETIEDAVRRE VEEESGVKVG HVlQYVACtQPU PMPSSLMIGC 401 LALAVSTEIK VDKNEIEDAR UFTRElQVLDV LTKGKIQIQAFF VPPSRAIAHiQ 451 LIKHUIRINP NL

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_2il7ι frame 1 No Alert BLASTP hits found

Pedant information for DKFZphamy2_2il7ι frame 1

Report for DKFZphamy2_2il7 -1

ELENGTH! 4b2

EMU! 5207b-25

Epl! b-36

EHOMOL! TREMBL:SPBC1778_3 gene: "SPBC1778 - 03c"i product:

"conserved hypothetical protein"i S. pombe chromosome II cosmid cl778. le-45

EFUNCAT! 11 unclassified proteins ES. cerevisiaei YGL0b7w!

4e-34

EFUNCAT! r general function prediction [H- influenzaei

HI0432 pyrophosphohydrolase! 4e-24 [FUNCAT! 1 genome replication! transcriptioni recombination and repair EM- jannaschiii MJ1141 nucleotide pyrophosphohydrolase! le-04

EBLOCKS! BL00211F Anion exchangers family proteins

[BLOCKS! BL01213B [BLOCKS! DM01101

[BLOCKS! PF00D23A

[BLOCKS! BL0D813 mutT domain proteins _/

[SCOP! dlawcb_ 1-11.3.1.2 GA binding protein (GABP) alpha

GA bindini 2e-35 [SUPFAM! hypothetical protein HI0432 le-22

[PROSITE! MUTT 1

[PFAM! Bacterial utT protein

[PFAM! Ank repeat [KU! Irregular

[KU! 3D

SElQ MSSVKRSLKlQEIVTiQFHCSAAEGDIAKLTGILSHSPSLLNETSENGUTALMYAARNGHPE lawcB .CCCTTTTCTTTCCHHHHHHHHTTHHHHHHHHHCCCTT-

TTEETTTEEHHHHHHHHCCHH

SElQ IVlQFLLEKGCDRSIVNKSRiQTALDIAVFUGYKHIANLLATAKGGKKPUFLTNEVEECENY lawcB

HHHHHHHHCCTTTTCBTTTBCHHHHHHHHCCHHHHHHH

SElQ FSKTLLDRKSEKRNNSDULLAKESHPATVFILFSDLNPLVTLGGNKESFiQiQPEVRLCiQLN lawcB

SElQ YTDIKDYLAiQPEKITLIFLGVELEIKDKLLNYAGEVPREEEDGLVAUFALGIDPIAAEEF lawcB

SElQ KiQRHENCYFLHPPMPALLlQLKEKEAGVVAlQARSVLAUHSRYKFCPTCGNATKIEEGGYKR lawcB

SElQ LCLKEDCPSLNGVHNTSYPRVDPVVIMlQVIHPDGTKCLLGRlQKRFPPGMFTCLAGFIEPG lawcB

SElQ ETIEDAVRREVEEESGVKVGHVlQYVACiQPUPMPSSLMIGCLALAVSTEIKVDKNEIEDAR lawcB

SE(Q UFTREIQVLDVLTKGKIQIQAFFVPPSRAIAHIQLIKHUIRINPNL lawcB

Prosite for DKFZphamy2_2il7-l PS0Oδ13 355->37S MUTT PDOCOOblS

Pfam for DKFZphamy2_2il7.1

HMM_NAME Ank repeat

HMM *GyTPLHIAARyNNvEMVrlLL(QHGADIN* G+T+L++AAR+++ E+V++LL++G D

(Query 4b GUTALMYAARNGHPEIVlQFLLEKGCDRS 73

HMM_NAME Bacterial mutT protein

HMM *ILMiqRedppnHYdtHhgdUIFPGGkIEeGETPE(QCarREIUEETGI* L++++++ +++ + ++G+IE+GET+E+++RRE++EE+G+

(Query 337 CLLGRlQKRF—PPG

MFTCLAGFIEPGETIEDAVRREVEEESGV 377

DKFZphamy2_2ol3

group: intracellular transport and trafficing

DKFZphamy2_2ol3 encodes a novel 510 amino acid protein with high similarity to murine synaptotagmin 3- The novel protein contains two C2 domains- The C2 domain is thought to be involved in calcium-dependent phospholipid binding. Synaptotagmins are essential for Ca (2+) -regulated exocytosis of neurosecretory vesicles- The new protein can find application in modulating/blocking synaptic activity-

similarity to synaptotagmin 3 (Mus musculus)

Sequenced by MediGenomix

Locus: unknown Insert length: 2131 bp

Poly A stretch at pos- 2112ι polyadenylation signal at pos- 2664

1 ACTCTATGTC TCCTCTCGTT GGATTGTGAC ACCGGGAGGT CAGGGAACTC SI CAGGACCTTG TTCTCTGCTG GATTCGCAGC AACCAGCACA GCACGTAGGG

101 CGTAGTTGGT GCTGGATGGA TGTTTGTTGA ATGAATGAAT GATGAATGGC

ISI TGGCACCTTG TCTGCTCATC CCTAACTCCT GTTCCTTCAT CTGTGCAGCC

201 CTAATCTTTG TTTCCTCATC TGTCCATCCC TTTATTTGTG CATCCTCATT

251 CTTAGCCCCT TCACTGCCCT TCTCCATCTC TTCCTCCTTG TTCATTTGTC 301 CCTGTTCTCT GTCCTCTACT CCACTCATGC CCATCTCTGT CCCCTTGACT

3S1 TACCCAGTCC CTGCTACTAT CTCCATCCCT AATTTCTGCC CTCTTGTCTG

4D1 TCTACTCCTA ATTCCTTTTC CTTGTCCATC CCTAATACCT GTCACCTTGT

451 CCTTCTTCCT CGAATCTCCA TCCCTAATCC ATCTGCCCCT AATCTCTGTC

501 CCCTTTGCCC ATCCTTCCTT TTCTCGGTGT CTCTTTCCAC CCTTATCTCC 5S1 ACACCTGCCC ACCCTGCACT CCCATTCTGT TTCCCATCTG CACCCTTGCC bDl CCATCCCTCC CACACACAGG ACCAGACGGC CACCATGTCA GGAGACTACG b51 AGGATGACCT CTGCCGGCGG GCACTCATCC TGGTCTCGGA CCTCTGTGCG

701 CGGGTCCGAG ATGCTGACAC CAACGACAGG TGCCAGGAGT TCAATGACCG

7S1 AATCCGAGGC TATCCCCGGG GTCCAGATGC AGACATCTCC GTGAGCCTGC 601 TGTCGGTCAT CGTGACATTC TGTGGCATTG TCCTTCTGGG TGTCTCTCTC

651 TTCGTGTCCT GGAAGTTGTG CTGGGTGCCC TGGCGGGACA AGGGAGGCTC

101 GGCAGTGGGC GGTGGCCCCC TGCGCAAAGA CCTAGGCCCT GGTGTCGGGC

ISI TGGCAGGCCT GGTAGGCGGA GGCGGGCACC ACCTGGCGGC TGGCCTGGGT

1001 GGCCATCCTC TGCTGGGCGG CCCACACCAC CATGCCCATG CCGCCCACCA 1051 TCCACCCTTT GCTGAGCTGC TGGAGCCAGG CAGCCTGGGG GGTTCTGACA

1101 CCCCTGAGCC CTCCTACTTG GACATGGACT CGTATCCAGA GGCTGCAGCA

1151 GCAGCAGTGG CCGCTGGGGT CAAACCGAGC CAAACATCCC CTGAGCTGCC

1201 CTCTGAGGGG GGAGCAGGCT CTGGGTTGCT CCTGCTGCCC CCCAGTGGTG

1251 GGGGCTTGCC CAGTGCCCAG TCACATCAGC AGGTCACAAG CCTGGCACCC 1301 ACTACCAGGT ACCCAGCCCT GCCCCGACCC CTCACCCAGC AGACTCTGAC

13S1 CTCCCAGCCG GACCCCAGCA GTGAGGAGCG CCCACCTGCC CTGCCCTTAC

1401 CCCTGCCTGG AGGCGAGGAA AAAGCCAAAC TCATTGGGCA GATTAAGCCA

1451 GAGCTGTACC AGGGGACTGG CCCTGGTGGC CGGCGGAGCG GTGGGGGCCC 1501 AGGCTCTGGA GAGGCAGGCA CAGGGGCACC CTGTGGCCGT ATCAGCTTCG

15S1 CCCTGCGGTA CCTCTATGGC TCGGACCAGC TGGTGGTGAG GATCCTGCAG lbDl GCCCTGGACC TCCCTGCCAA GGACTCCAAC GGCTTCTCAG ACCCCTACGT

IbSl CAAGATCTAC CTGCTGCCTG ACCGCAAGAA AAAGTTTCAG ACCAAGGTGC

1701 ACAGGAAGAC CCTGAACCCC GTCTTCAATG AGACGTTTCA ATTCTCGGTG

17S1 CCCCTGGCCG AGCTGGCCCA ACGCAAACTG CACTTCAGCG TCTATGACTT

1601 TGACCGCTTC TCGCGGCACG ACCTCATCGG CCAGGTGGTG CTGGACAACC

1651 TCCTGGAGCT GGCCGAGCAG CCCCCTGACC GCCCGCTCTG GAGGGACATC

1101 GTGGAGGGCG GCTCGGAAAA AGCAGATCTT GGGGAGCTCA ACTTCTCACT

1151 CTGCTACCTC CCCACGGCCG GGCGCCTCAC CGTGACCATC ATCAAAGCCT

2001 CTAACCTCAA AGCGATGGAC CTCACTGGCT TCTCAGACCC CTACGTGAAG

20S1 GCCTCCCTGA TCAGCGAGGG GCGGCGTCTG AAGAAGCGGA AAACCTCCAT

2101 CAAGAAGAAC ACGCTGAACC CCACCTATAA TGAGGCGCTG GTGTTCGACG

2151 TGGCCCCCGA GAGCGTGGAG AACGTGGGGC TCAGCATCGC CGTGGTGGAC

2201 TACGACTGCA TCGGGCACAA CGAGGTGATC GGCGTGTGCC GTGTGGGCCC

2251 CGACGCTGCC GACCCGCACG GCCGCGAGCA CTGGGCAGAG ATGCTGGCCA

2301 ATCCCCGCAA GCCCGTGGAG CACTGGCATC AGCTAGTGGA GGAAAAGACT

23S1 GTGACCAGCT TCACAAAAGG CAGCAAAGGA CTATCAGAGA AAGAGAACTC

2401 CGAGTGAGGG GTCTGGCCTA GGCCCGGGAT CGGACCAGGC TCCCTCAGGA

2451 CCCCATCCTT TCCTGCCCGG ACCGTGAATT CATCTCCTTG AAGCCATAAC

2S01 GTCCGAGCTG CTGGTGCGGG GCAGCCCTGG CCCTAGGCTT CCTAACCCTG

25S1 GAAGCGAGAG GATGAGAGGA GGCCGGCCCA GCTCCTTCTT TCAGGGTGGG

2b01 GGTCATTCAG CCTCCACTGT GTCTGTCTTT TCTTCCCTGG GGCTCCCCCT

2b51 CGAGGCGAGG GGCCATGCAT GTCTGGGGGA CCCCTGCCCC CCAAAACCCT

2701 CTGTCTGTCT CTGTCTCTTT GCTGTTTGTC CAAGACTCAG TGTCCCGACC

2751 CTTGTTCTCG CCGTGAATGT CAATGGGCCA ATCCTCTCTG TCCTTTCAGA

2801 CACACACACA CCTGTGTCCA CCCCTTCTGT TCGCCACACC CTGCGTCTGG

2651 CCGGTCCCCC CACTGCTGCT GCTATCAACG CCAGAATAAA CACACTCTGT

2101 GGGTCTCACT CCAAAAAAAA AAAAAAAAAA A

BLAST Results

Entry MMAB813_1 from database TREMBL: product: "synaptotagmin 3"i Mus musculus mRNA for synaptotagmin

3ι complete eds-

Score = 1614ι P = S-7e-231ι identities = 3b2/450ι positives = 3b1/4S0ι frame +2

Medline entries

1b0b4733:

Fukuda Mi Kojima Ti Aruga Ji Niinobe Mi Mikoshiba K-i Functional diversity of C2 domains of synaptotagmin family-

Mutational analysis of inositol high polyphosphate binding domain- J

Biol Chem 1115 Nov 3i270 (44) :2bS23-7

Peptide information for frame 2 ORF from b3S bp to 2404 bpi peptide length: 510 Category: strong similarity to known protein Classification: Cell signaling/communication Prosite motifs: C2_D0MAIN_1 (323-336) C2_D0MAIN_1 (455-470)

1 MSGDYEDDLC RRALILVSDL CARVRDADTN DRCiQEFNDRI RGYPRGPDAD

51 ISVSLLSVIV TFCGIVLLGV SLFVSUKLCU VPURDKGGSA VGGGPLRKDL

101 GPGVGLAGLV GGGGHHLAAG LGGHPLLGGP HHHAHAAHHP PFAELLEPGS

ISI LGGSDTPEPS YLDMDSYPEA AAAAVAAGVK PSlQTSPELPS EGGAGSGLLL

201 LPPSGGGLPS AlQSHiQiQVTSL APTTRYPALP RPLTlQlQTLTS (QPDPSSEERP 251 PALPLPLPGG EEKAKLIGiQI KPELYiQGTGP GGRRSGGGPG SGEAGTGAPC

301 GRISFALRYL YGSDlQLVVRI LlQALDLPAKD SNGFSDPYVK IYLLPDRKKK

351 FlQTKVHRKTL NPVFNETFiQF SVPLAELAlQR KLHFSVYDFD RFSRHDLIGiQ

401 VVLDNLLELA ElQPPDRPLUR DIVEGGSEKA DLGELNFSLC YLPTAGRLTV

451 TIIKASNLKA MDLTGFSDPY VKASLISEGR RLKKRKTSIK KNTLNPTYNE 501 ALVFDVAPES VENVGLSIAV VDYDCIGHNE VIGVCRVGPD AADPHGREHU

SSI AEMLANPRKP VEHUHώLVEE KTVTSFTKGS KGLSEKENSE

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_2ol3ι frame 2

TREMBL:MMAB613_1 product: "synaptotagmin 3"i Mus musculus mRNA for synaptotagmin 3ι complete cds-i N = 2ι Score = 1814ι P = l-le-231

>TREMBL:MMAB613_1 product: "synaptotagmin 3"i Mus musculus mRNA for synaptotagmin 3ι complete eds- Length = Sδ7

HSPs

Score = 1614 (272-2 bits)ι Expect = l-le-231ι Sum P(2) = l-le- 231 Identities = 3b2/441 (60*)ι Positives = 3b1/441 (62*)

(Query: 142 FAELLEPGSLGGSDTPEPSYLDMDSYPEXXXXXX- XXGVKPSiQTXXXXXXXXXXXXXXXX 200

FAELLEPG LGGS+ PEPSYLDMDSYPE GVKPSiQT Sbjct: 143

FAELLEPGGLGGSELPEPSYLDMDSYPEAAVASVVAAGVKPSlQTSPELPSEGGTGSGLLL 202

(Query : 201

XXXXXXXXXXX(QSH(Q(QVTSLAPTTRYPALPRPLT(Q(QTLTS(QPDXXXXXXXXXXXXXXXXX 2b0 (QSH(QιQVTSLAPTTRYPALPRPLT(Q(QTLT+ιQ D

Sb j ct : 203 LPPSGGGLPSA(QSH(Q(QVTSLAPTTRYPALPRPLT(Q(QTLTT(QADPSTEERPPALPLPLPGG 2b2 (Query: 2bl XXKAKLIG(QIKPELY(QXXXXXXXXXXXXXXXXXXXXXXPCGRISFALRYLYGSD(QLVVRI 320

KAKLIG(QIKPELY(Q PCGRISFALRYLYGSDlQLVVRI

Sbjct: 2b3 EEKAKLIGIQIKPELYIQGTGPGGRRGGGSGEAGA

PCGRISFALRYLYGSDlQLVVRI 317

(Query: 321 LIQALDLPAKDSNGFSDPYVKIYLLPDRKKKFIQTKVHRKTLNPVFNETFIQFSVPLAELAIQR 360

LlQALDLPAKDSNGFSDPYVKIYLLPDRKKKFiQTKVHRKTLNP + FNETFlQFSVPLAELAiQR Sbjct: 316 LiQALDLPAKDSNGFSDPYVKIYLLPDRKKKFlQTKVHRKTLNPIFNETFiQFSVPLAELAiQR 377 (Query: 361

KLHFSVYDFDRFSRHDLIGiQVVLDNLLELAEiQPPDRPLURDIVEGGSEKADLGELNFSLC 440

KLHFSVYDFDRFSRHDLIGiQVVLDNLLELAEiQPPDRPLURDI+EGGSEKADLGELNFSLC Sbjct: 376 KLHFSVYDFDRFSRHDLIGUVVLDNLLELAEiQPPDRPLURDILEGGSEKADLGELNFSLC 437

(Query: 441 YLPTAGRLTVTIIKASNLKAMDLTGFSDPYVKASLISEGRRLKKRKTSIKKNTLNPTYNE 500 YLPTAGRLTVTIIKASNLKAMDLTGFSDPYVKASLISEGRRLKKRKTSIKKNTLNPTYNE Sbjct: 436 YLPTAGRLTVTIIKASNLKAMDLTGFSDPYVKASLISEGRRLKKRKTSIKKNTLNPTYNE 417

(Query: 501 ALVFDVAPESVENVGLSIAVVDYDCIGHNEVIGVCRVGPDAADPHGREHUAEMLANPRKP SbO

ALVFDVAPESVENVGLSIAVVDYDCIGHNEVIGVCRVGP+AADPHGREHUAEMLANPRKP Sbjct: 416

ALVFDVAPESVENVGLSIAVVDYDCIGHNEVIGVCRVGPEAADPHGREHUAEMLANPRKP 557

(Query: 5bl VEHUHύLVEEKTVTSFTKGSKGLSEKENSE 510

VEHUH(QLVEEKT++SFTKG KGLSEKENSE Sbjct: 5S6 VEHUHlQLVEEKTLSSFTKGGKGLSEKENSE 567 Score = S20 (78-0 bits)ι Expect = l-le-231ι Sum P(2) = l-le-231 Identities = 18/100 (18*)ι Positives = 11/100 (11*)

(Query: 1 MSGDYEDDLCRRALILVSDLCARVRDADTNDRCiQEFND- RIRGYPRGPDADISVSLLSVI 51 MSGDYEDDLCRRALILVSDLCARVRDADTNDRC(QEFN+

RIRGYPRGPDADISVSLLSVI Sbjct: 1 MSGDYEDDLCRRALILVSDLCARVRDADTNDRCiQEFNELRIRGYPRGPDADISVSLLSVI bO (Query: t,0 VTFCGIVLLGVSLFVSUKLCUVPURDKGGSAVGGGPLRKD 11

VTFCGIVLLGVSLFVSUKLCUVPURDKGGSAVGGGPLRKD Sbjct: bl VTFCGIVLLGVSLFVSUKLCUVPURDKGGSAVGGGPLRKD 100

Pedant information for DKFZphamy2_2ol3ι frame 2

Report for DKFZphamy2_2ol3-2 [LENGTH! S10

EMU! b3304-02 [pi! __ _ ____

[HOMOL! TREMBL:MMAB813_1 product: "synaptotagmin 3"i Mus musculus mRNA for synaptotagmin 3ι complete eds- 0-0

[FUNCAT! 11 unclassified proteins [S- cerevisiaei YML072c! be-10 [FUNCAT! 01-Ob-Ol lipidi fatty-acid and sterol biosynthesis

[S- cerevisiaei YGR170w! 7e-0b

[FUNCAT! 30-08 organization of golgi [S- cerevisiaei YGR170w!

7e-0b

[BLOCKS! BL01224A N-acetyl-gamma-glutamyl-phosphate reductase proteins

[BLOCKS! BL01013B Oxysterol-binding protein family proteins

[BLOCKS! PF013b8B

[SCOP! dla25a_ 2-b-l-2-2 C2 domain from protein kinase c

(beta) [Ra 2e-27 [SCOP! dlrsy 2-b-1.2.1 Synaptogamin IT first C2 domain

[Rat (Rattu 4e-43

ESCOP! dlrlw Ξ-b.1.1-2 A domain from cytosolic phospholipase A2 EHuma Se-12

ESCOP! dlqasb2 2-b-l-l.l Phosphoinositide-specific phospholipase C 4e-27

EPIRKU! phosphotransferase 7e-15

EPIRKU! duplication be-7b

EPIRKU! synaptic vesicle le-lb7

EPIRKU! phorbol ester binding 2e-14 EPIRKU! zinc 2e-14

EPIRKU! transmembrane protein 0-0

EPIRKU! serine/threonine-specific protein kinase 7e-lS

EPIRKU! membrane trafficking 0-0

EPIRKU! phospholipid binding be-7b EPIRKU! autophosphorylation 7e-15

EPIRKU! ATP 7e-15

EPIRKU! phosphoprotein 7e-15

EPIRKU! glycoprotein le-lb7

EPIRKU! calcium binding Se-34 EPIRKU! alternative splicing le-10

EPIRKU! dimer le-7S

EPIRKU! membrane protein le-lb7

EPIRKU! calmodulin binding 2e-74

ESUPFAM! ras-specific GAP catalytic domain homology le-08 ESUPFAM! protein kinase C zinc-binding repeat homology 7e-lS

ESUPFAM! protein kinase homology 7e-15

ESUPFAM! protein kinase C alpha 7e-lS

ESUPFAM! HsC2 phosphatidylinositol 3-kinase le-01

ESUPFAM! synaptotagmin 0-0 ESUPFAM! PX domain homology le-01

ESUPFAM! pleckstrin repeat homology le-08

ESUPFAM! protein kinase C C2 region homology 0.0

EPROSITE! C2_D0MAIN_1 2

EPFAM! C2 domain EKU! Irregular

EKU! 3D

EKU! L0U_C0MPLEXITY 20-00 * SE(Q MSGDYEDDLCRRALILVSDLCARVRDADTNDRCiQEFNDRIRGYPRGPDADISVSLLSVIV

SEG

Irsy-

SElQ TFCGIVLLGVSLFVSUKLCUVPURDKGGSAVGGGPLRKDLGPGVGLAGLVGGGGHHLAAG

SEG xxxxxxxxxxxxxxxxxxxxx

Irsy-

SElQ LGGHPLLGGPHHHAHAAHHPPFAELLEPGSLGGSDTPEPSYLDMDSYPEAAAAAVAAGVK

SEG xxxxxxxxxxxxxxxxxxxxx xxxxxxxx- ■ ■

Irsy-

SElQ PSlQTSPELPSEGGAGSGLLLLPPSGGGLPSAiQSHiQlQVTSLAPTTRYPALPRPLTiQiQTLTS

SEG - • ■ ■ xxxxxxxxxxxxxxxxxxxxxxxxxxx

Irsy-

SElQ (QPDPSSEERPPALPLPLPGGEEKAKLIGfllKPELYiQGTGPGGRRSGGGPGSGEAGTGAPC

SEG ■ ■ ■ xxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxx ■ ■

Irsy-

SElQ GRISFALRYLYGSDiQLVVRILiQALDLPAKDSNGFSDPYVKIYLLPDRKKKFiQTKVHRKTL SEG

Irsy- CEEEEEEEEETTTTEEEEEEEEEECCCCCBTTTBBCEEEEEEEETTTTTTEECCCTTTBT

SElQ NPVFNETF<QFSVPLAELAlQRKLHFSVYDFDRFSRHDLIG(QVVLDNLLELAE<QPPDRPLUR SEG

Irsy- TTEEEEEEEECCCHHHHHCCEEEEEEEECTTTTCCEEEEE

SElQ DIVEGGSEKADLGELNFSLCYLPTAGRLTVTIIKASNLKAMDLTGFSDPYVKASLISEGR

SEG

Irsy-

SE(Q RLKKRKTSIKKNTLNPTYNEALVFDVAPESVENVGLSIAVVDYDCIGHNEVIGVCRVGPD

SEG

Irsy-

SElQ AADPHGREHUAEMLANPRKPVEHUHiQLVEEKTVTSFTKGSKGLSEKENSE

SEG lrsy- ■

Prosite for DKFZphamy2_2ol3-2

PS00411 323->331 C2_D0MAIN_1 PD0C00360 PS00411 455->471 C2_D0MAIN_1 PD0C00380 Pf am f or DKFZphamy2_2ol3 - 2

HMM_NAME C2 doma i n

HMM *LtVrIIeARNLUkMDMnGfSDPYVKVdMdPdpkDtkKUKTkTi UNNGLN

L+VRI++A +L+++D+NGFSDPYVK++++PD+K KK++TK+++++ LN

(Query 31b LVVRILiQALDLPAKDSNGFSDPYVKIYLLPDRK —

KKFiQTKVHRKT-LN 3bl

HMM PVUNEEeFvF edlPyPd l qrkMLRFaVUDUDRFSRBDFIGHC i * PV+N E+F+F +P+ +L+ + L+F+V+D+DRFSR+D+IG+++ ώuery 3b2 PVFN-ETFiQFS-VPLAELA(QRKLHFSVYDFDRFSRHDLIG(QVV 402

HMM *LtVrIIeARNLUkMDMnGf SDPYVKVdMdPdpkDtkKUKTkT iUNNGLN

LTV+II+A NL++MD +GFSDPYVK +++ + +++KK+KT++++N+ LN (Query 446

LTVTIIKASNLKAMDLTGFSDPYVKASLISEGRRLKKRKTSIKKNT-LN 415

HMM PVUNEEeFvFedlPyPdlqrkMLRFaVUDUDRFSRBDFIGHCi*

P++N E +VF+ ++ ++ +++ L +AV D+D+++++++IG+C+ (Query 41b PTYN-EALVFD-VAPESVENVGLSIAVVDYDCIGHNEVIGVCR

53b

DKFZphamy2_7 j S

group: differentiation/development

DKFZphamy2_7 S encodes a novel b13 amino acid protein with similarity to Tspyll testis-specific Y-encoded-like protein of Mus musculus- TSPY genes are arranged in clusters on the Y chromosome of many mammalian species- TSPY is believed to function in early spermatogenesis and is a candidate for GBYi the putative gonadoblastoma-inducing gene on the Y- The TSPY family forms part of a superfamilyi TTSNi with autosomal representatives! highly conserved in mammals and beyond-

The new protein can find application in studying the expression profile of testis- and brain-specific genes and diagnosis/therapy of malfunctioning male fertility-

HRIHFB221b similarity to Y-linked Gene of Mus musculus

Sequenced by BMFZ

Locus: unknown Insert length: 2611 bp

Poly A stretch at pos- 2800ι polyadenylation signal at pos- 2771

1 AGGAGAGCTG GTTGCGTGAG TCTCCTCAGC TCTGCTTACC GGTGCGACTA 51 GCGGCkGCGk CGCGGCTAAA AGCGAAGGGG CGAGTGCGAG TCCCCTGAGC

IDl TGTACGAACG CGGTCGCCAT GGACCGCCCA GATGAGGGGC CTCCGGCCAA

151 GACCCGCCGC CTGAGCAGCT CCGAGTCTCC ACAGCGCGAC CCGCCCCCGC

2D1 CGCCGCCGCC GCCGCCGCTC CTCCGACTGC CGCTGCCTCC ACCCCAGCAG

2S1 CGCCCGAGGC TCCAGGAGGA AACGGAGGCG GCACAGGTGC TGGCCGATAT 3D1 GAGGGGGGTG GGACTGGGCC CCGCGCTGCC CCCGCCGCCT CCCTATGTCA

351 TTCTCGAGGA GGGGGGGATC CGCGCATACT TCACGCTCGG TGCTGAGTGT

401 CCCGGCTGGG ATTCTACCAT CGAGTCGGGG TATGGGGAGG CGCCCCCGCC

451 CACGGAGAGC CTGGAAGCAC TCCCCACTCC TGAGGCCTCG GGGGGGAGCC

S01 TGGAAATCGA TTTTCAGGTT GTACAGTCGA GCAGTTTTGG TGGAGAGGGG S51 GCCCTAGAAA CCTGTAGCGC AGTGGGGTGG GCGCCCCAGA GGTTAGTTGA bOl CCCGAAGAGC AAGGAAGAGG CGATCATCAT AGTGGAGGAT GAGGATGAGG bSl ATGAGCGGGA GAGTATGAGG AGCAGCAGGA GGCGGCGGCG GCGGCGGAGG

7D1 AGGAAGCAGA GGAAGGTGAA GAGGGAAAGC AGAGAGAGAA ATGCCGAGAG

7S1 GATGGAGAGC ATCCTGCAGG CACTGGAGGA TATTCAGCTG GATCTGGAGG 801 CAGTGAACAT CAAGGCAGGC AAAGCCTTCC TGCGTCTCAA GCGCAAGTTC

8S1 ATCCAGATGC GAAGACCCTT CCTGGAGCGC AGAGACCTCA TCATCCAGCA

IDl TATCCCAGGC TTCTGGGTCA AAGCATTCCT CAACCACCCC AGAATTTCAA

151 TTTTGATCAA CCGACGTGAT GAAGACATTT TCCGCTACTT GACCAATCTG

10D1 CAGGTACAGG ATCTCAGACA TATCTCCATG GGCTACAAAA TGAAGCTGTA 1051 CTTCCAGACT AACCCCTACT TCACAAACAT GGTGATTGTC AAGGAGTTCC

11D1 AGCGCAACCG CTCAGGCCGG CTGGTGTCTC ACTCAACCCC AATCCGCTGG

11S1 CACCGGGGCC AGGAACCCCA GGCCCGTCGT CACGGGAACC AGGATGCGAG

1201 CCACAGCTTT TTCAGCTGGT TCTCAAACCA TAGCCTCCCA GAGGCTGACA 1251 GGATTGCTGA GATTATCAAG AATGATCTGT GGGTTAACCC TCTACGCTAC

1301 TACCTGAGAG AAAGGGGCTC CAGGATAAAG AGAAAGAAGC AAGAAATGAA

13S1 GAAACGTAAA ACCAGGGGCA GATGTGAGGT GGTGATCATG GAAGACGCCC

1401 CTGACTATTA TGCAGTGGAA GACATTTTCA GCGAGATCTC AGACATTGAT 1451 GAGACAATTC ATGACATCAA GATCTCTGAC TTCATGGAGA CCACCGACTA

1501 CTTCGAGACC ACTGACAATG AGATAACTGA CATCAATGAG AACATCTGCG

15S1 ACAGCGAGAA TCCTGACCAC AATGAGGTCC CCAACAACGA GACCACTGAT

IbOl AACAACGAGA GTGCTGATGA CCACGAAACC ACTGACAACA ATGAGAGTGC lb51 AGATGACAAC AACGAGAATC CTGAAGACAA TAACAAGAAC ACTGATGACA 1701 ACGAAGAGAA CCCTAACAAC AACGAGAACA CTTACGGCAA CAACTTCTTC

17S1 AAAGGTGGCT TCTGGGGCAG CCATGGCAAC AACCAGGACA GCAGCGACAG

1601 TGACAATGAA GCAGATGAGG CCAGTGATGA TGAAGATAAT GATGGCAACG

1851 AAGGTGACAA TGAGGGCAGT GATGATGATG GCAATGAAGG TGACAATGAA

1101 GGCAGCGATG ATGACGACAG AGACATTGAG TACTATGAGA AAGTTATTGA 11S1 AGACTTTGAC AAGGATCAGG CTGACTACGA GGACGTGATA GAGATCATCT

2001 CAGACGAATC AGTGGAAGAA GAGGGCATTG AGGAAGGCAT CCAGCAAGAT

2051 GAGGACATCT ATGAGGAAGG AAACTATGAG GAGGAAGGAA GTGAAGATGT

2101 CTGGGAAGAA GGGGAAGATT CGGACGACTC TGACCTAGAG GATGTGCTTC

2151 AGGTCCCAAA CGGTTGGGCC AATCCGGGGA AGAGGGGGAA AACCGGATAA 2201 GGGTTTTCCC CTTTTGGGGA TCACCTCTCT GTATCCCCCA CCCACTATCC

22S1 CATTTGCCCT CCTCCTCAGC TAGGGCCACG CGGCCCCACA TTGCACTTCT

23D1 GGGGGGTGAC CGACTTCGTA CACGGGTTTA AAGTTTATTT TTATGGTTTA

2351 GTCATTGCAG AGTTCTTATT TTGGGGGGAG GGAAAGGGGG CTAGTCCCCT

2401 TCTTTTGGCC CTCCGCCCCC GCAGGCTTCT GTGTGCTGCT AACTGTATTT 2451 ATTGTGATGC CTTGGTCAGG GCCCCTCTAC CCACTTCTCC CAGTCAGTTG

2SD1 TGGCCCCAGC CCCTCTCCCT GTGCTGTGTG GAGTGGACAC CCTGACCCCC

25S1 GAAGCGGGGA GGGCCGCTGT GGCCTTCGTC ACAGCCGCGC AGTGCCCATG

2b01 GAGGCGCTGC TGCCACCTTC CTCTCCCAAG TTCTTTCTCC ATCCCTCTCC

2b51 TCTTCCCGCC GCGCCGCTAG CCCGCCTCGG TGTCTATGCA AGGCCGCTTC 2701 GCCATTGCGG TATTCTTTGC GGTATTCTTG TCCCCGTCCC CCAGAAGGCT

27S1 CGCCTCTCCC CGTGGACCCT GTTAATCCCA ATAAAATTCT GAGCAAGTTT

2801 AAAAAAAAAA AAAAAAAAA

BLAST Results

No BLAST result

Medline entries

163118b4: Vogel Ti Dittrich Oi Mehraein Yi Dechend Fi Schnieders Fi Schmidtke

J-iMurine and human TSPYL genes: novel members of the TSPY-SET-NAPILI family. Cytogenet Cell Genet lllδiδl (3-4 ) : 2bS-70

Peptide information for frame 2

ORF from 111 bp to 2117 bpi peptide length: b13 Category: similarity to known protein Classification: unclassified 1 MDRPDEGPPA KTRRLSSSES PiQRDPPPPPP PPPLLRLPLP PP(Q(QRPRL(QE

SI ETEAAώVLAD MRGVGLGPAL PPPPPYVILE EGGIRAYFTL GAECPGUDST

101 IESGYGEAPP PTESLEALPT PEASGGSLEI DF(QVV(QSSSF GGEGALETCS

151 AVGUAPiQRLV DPKSKEEAII IVEDEDEDER ESMRSSRRRR RRRRRKiQRKV

201 KRESRERNAE RMESILiQALE DIlQLDLEAVN IKAGKAFLRL KRKFIώMRRP

2S1 FLERRDLIIiQ HIPGFUVKAF LNHPRISILI NRRDEDIFRY LTNLlQViQDLR

301 HISMGYKMKL YF(QTNPYFTN MVIVKEFlQRN RSGRLVSHST PIRUHRGlQEP

351 (QARRHGNώDA SHSFFSUFSN HSLPEADRIA EIIKNDLUVN PLRYYLRERG

401 SRIKRKKiQEM KKRKTRGRCE VVIMEDAPDY YAVEDIFSEI SDIDETIHDI

4S1 KISDFMETTD YFETTDNEIT DINENICDSE NPDHNEVPNN ETTDNNESAD

501 DHETTDNNES ADDNNENPED NNKNTDDNEE NPNNNENTYG NNFFKGGFUG

551 SHGNNiQDSSD SDNEADEASD DEDNDGNEGD NEGSDDDGNE GDNEGSDDDD bDl RDIEYYEKVI EDFDKDiQADY EDVIEIISDE SVEEEGIEEG IlQiQDEDIYEE b51 GNYEEEGSED VUEEGEDSDD SDLEDVLlQVP NGUANPGKRG KTG

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphamy2_7jSi frame 2 TREMBL:AB01S345_1 gene: "HRIHFB221b" i Homo sapiens HRIHFB221b mRNAi partial cds-i N = 4ι Score = 1313ι P = 2-le-lbS

TREMBL:HSDJ4βbI3_2 gene: "dJ4δbI3-2"i product: "dJ4δbI3-2 (KIAAD721

(NAP (Nucleosome Assembly Protein) domain containg protein))"i Human

DNA sequence from clone 46bI3 on chromosome bq22-l-22-3. Contains the part of a gene for a novel proteini the gene for KIAAD721 (NAP

(Nucleosome Assembly Protein) domain containg protein)ι the TSPYL gene for TSPY-like (testis specific proteini Y-linked like)ι and an

RPS5 (4DS Ribosomal Protein SS) pseudogene- Contains ESTsi STSsi GSSs and two putative CpG islands-i N = li Score = S70ι P = 3-4e-5S

>TREMBL:AB01534S_1 gene: "HRIHFB221b"i Homo sapiens HRIHFB221b mRNAi partial cds-

Length = 4δb HSPs:

Score = 1313 (201-0 bits)ι Expect = 2-le-lbSι Sum P(4) = 2-le- lb5 Identities = 2b6/21S (10*)ι Positives = 2bδ/21S (ID*)

(Query : 206 NAERMESILiQALEDIiQLDLEAVNIKAGKAFLRLKRKFIiQMRRPFLERRDLIIlQHIPGFUV 2b7 NAERMESILlQALEDIlQLDLEAVNIKAGKAFLRLKRKFIiQMRRPFLERRDLIIlQHIPGFUV Sbjct: 1

NAERMESILlQALEDIiQLDLEAVNIKAGKAFLRLKRKFIiQMRRPFLERRDLIIiQHIPGFUV bO

(Query: Ebβ KAFLNHPRISILINRRDEDIFRYLTNL(QV(QDLRHISMGYKMKLYF(QTNPYFTNMVIVKEF 327

KAFLNHPRISILINRRDEDIFRYLTNL(QV(QDLRHISMGYKMKLYF(QTNPYFTNMVIVKEF Sbjct: bl

KAFLNHPRISILINRRDEDIFRYLTNLiQVlQDLRHISMGYKMKLYFiQTNPYFTNMVIVKEF 120

(Query: 328

(QRNRSGRLVSHSTPIRUHRGiQEPiQARRHGNlQDAXXXXXXXXXXXXLPEADRIAEIIKNDL 367 (QRNRSGRLVSHSTPIRUHRGiQEPiQARRHGNlQDA

LPEADRIAEIIKNDL Sbjct: 121 (QRNRSGRLVSHSTPIRUHRGlQEPiQARRHGNlQDASHSFFSUFSNHSLPEADRIAEIIKNDL 160 (Query: 366

UVNPLRYYLRERGSXXXXXXXXXXXXXXXGRCEVVIMEDAPDYYAVEDIFSEISDIDETI 447 UVNPLRYYLRERGS

GRCEVVIMEDAPDYYAVEDIFSEISDIDETI

Sbjct: 161 UVNPLRYYLRERGSRIKRKKlQEMKKRKTRGRCEVVIMEDAPDYYAVEDIFSEISDIDETI 240

(Query: 446 HDIKISDFMETTDYFETTDNEITDINENICDSENPDHNEVPNNETTDNNESADDH 502 HDIKISDFMETTDYFETTDNEITDINENICDSENPDHNEVPNNETTDNNESADDH Sbjct: Ξ41 HDIKISDFMETTDYFETTDNEITDINENICDSENPDHNEVPNNETTDNNESADDH 215

Score = 117 (17-b bits)ι Expect = 1-Oe-llι Sum P(4) = 1-Oe-ll Identities = 32/77 (41*)ι Positives = 44/77 (S7*)

(Query: 42b

DAPDYYAVEDIFSEISDIDETIHDIKISDFMETTDYFETTDNEITDINENICDSENPDHN 465 + DY+ D +EI+DI+E I D E D+ E +NE TD NE+ D E D+N

Sbjct: 2S0 ETTDYFETTD—NEITDINENICD

SENPDHNEVPNNETTDNNESADDHETTDNN 301

(Query: 4βb EVP--NNETT-DNNESADDH 502 E NNE DNN++ DD+

Sbjct: 302 ESADDNNENPEDNNKNTDDN 321

Score = 14 (14-1 bits)ι Expect = 2-le-lb5ι Sum P(4) = 2-le-lbS Identities = lb/lb (lDO*)ι Positives = lb/lb (100*)

(Query: b7β (QVPNGUANPGKRGKTG b13

(QVPNGUANPGKRGKTG Sbjct: 471 (QVPNGUANPGKRGKTG 4δb Score = 10 (13-5 bits)ι Expect = 1-le-lbι Sum P(4) = 1-le-lb Identities = 34/65 (40*)ι Positives = 45/65 (52*) (Query: 42b DAPDYYAVEDIFSEISDIDETIHDIKISDFME TTDYFETTDN-

EITDINENICDS 471

+ DY+ D +EI+DI+E I D + D E TTD E+ D+ E TD NE+ D+ Sbjct: 25D ETTDYFETTD—

NEITDINENICDSENPDHNEVPNNETTDNNESADDHETTDNNESADDN 307

(Query: 460 -ENPDHN EVPNN-ETTDNN 41b

ENP+ N E PNN E T N Sbjct: 306 NENPEDNNKNTDDNEENPNNNENTYGN 334

Score = 87 (13-1 bits)ι Expect = 2-le-lbSι Sum P(4) = 2-le-lbS Identities = 14/14 (100*)ι Positives = 14/14 (100*) (Query: 543 FFKGGFUGSHGNNiQ 55b

FFKGGFUGSHGNNiQ Sbjct: 33b FFKGGFUGSHGNNiQ 341

Score = 85 (12-6 bits)ι Expect = 2-le-lbSι Sum P(4) = 2-le-lbS Identities = lb/16 (86*) i Positives = 17/16 (14*)

(Query: bOl RDIEYYEKVIEDFDKDiQA blδ

RDIEYYEK IEDFD+D<QA Sbjct: 314 RDIEYYEKGIEDFDRDlQA 411

Score = bO (1-0 bits)ι Expect = S-3e-D3ι Sum P(4) = 5-3e-03 Identities = 21/bb (31*)ι Positives = 33/bb (SD*)

(Query : 42b DAPDYYAVEDIFSEISDIDETIHD-IKIS- DFMETTDYFETTDNEITDINENICDSENPD 463

D DY V +1 S+ S +E I + 1+ D E +Y E ++ + E+

D S+ D

Sb jct : 4D1

DiQADYEDVIEIISDESVEEEGIEEGIlQlQDEDIYEEGNYEEEGSEDVUEEGEDSDDSDLED 4bδ

(Query : 484 HNEVPN 4δ1

+ VPN

Sbjct: 4b1 VLlQVPN 474 Score = 41 (7-4 bits)ι Expect = l-4e-0bι Sum P(4) = l-4e-Db Identities = 12/35 (34*)ι Positives = 21/3S (bO*)

(Query: 4b3 ETTDNEITDINENICDSENPDHNEVPNNETTDNNE 417 E +D+E D NE + + D NE +NE +D+++ Sbjct: 3b0 EASDDEDNDGNEGDNEGSDDDGNE-GDNEGSDDDD 313

Score = 42 (b-3 bits)ι Expect = 7-2e-0bι Sum P(4) = 7-2e-Db Identities = 11/37 (21*)ι Positives = lδ/37 (4δ*) (Query: 4b5 TDNEITDINENICDSENPDHNEVPNNETTDNNESADD SOI

+DNE + + D E+ D NE N + D+ D+ Sbjct: 354 SDNEADEAS DDEDNDGNEGDNEGSDDDGNEGDN 3δb

Pedant information for DKFZphamy2_7jSi frame 2

Report for DKFZphamy2_7jS-2 ELENGTH! b13

EMU! 71435-07 Epl! 4-45

EHOMOL! TREMBL:AB015345_1 gene: "HRIHFB221b" i Homo sapiens

HRIHFB221b mRNAi partial eds- le-171

EFUNCAT! Ob-ID assembly of protein complexes ES- cerevisiaei

YKRD4βc! 4e-0S EFUNCAT! 03-22 cell cycle control and mitosis ES- cerevisiaei

YKR048c! 4e-05

EFUNCAT! 03-04 buddingi cell polarity and filament formation

ES- cerevisiaei YKR04βc! 4e-DS

EFUNCAT! 01-13 biogenesis of chromosome structure ES- cerevisiaei YKR048c! 4e-D5

EFUNCAT! 30-10 nuclear organization ES- cerevisiaei YKRD46c!

4e-D5

EBLOCKS! BP02b4bH

EBLOCKS! BP02b4bE EBLOCKS! PF00424A

EBLOCKS! BL00415N Synapsins proteins

EBLOCKS! BP02711E

EBLOCKS! BL00046 Protamine PI proteins

EBLOCKS! PR00D41D EBLOCKS! PFOOISbD

[BLOCKS! PF0015bC

[BLOCKS! PFOOISbB

[PIRKU! nucleus 8e-33

[PIRKU! phosphoprotein 8e-33 [PIRKU! alternative splicing δe-33

[KU! Alpha_Beta

[KU! LOU COMPLEXITY 35-35 *

SElQ MDRPDEGPPAKTRRLSSSESPiQRDPPPPPPPPPLLRLPLPPPiQlQRPRLlQEETEAAiQVLAD

SEG xxxxxxxxxxxxxxxxxxxxxxxxxxxxx

PRD ccccccccccccccccccccccccccccccccccccccccccchhhhhhhhhhhhhhhhh

SElQ MRGVGLGPALPPPPPYVILEEGGIRAYFTLGAECPGUDSTIESGYGEAPPPTESLEALPT SEG - - ■ -xxxxxxxxxxx

PRD ccccceeeeccccccccccccccceeeeccccccccccceeecccccccccchhhhhhhh

SElQ PEASGGSLEIDFlQVViQSSSFGGEGALETCSAVGUAPlQRLVDPKSKEEAIIIVEDEDEDER

SEG xxxxxxxx PRD hcccccccccceeeeecccccchhhhhhhhccccccccccccchhhhhhhhhhhhhhhhh

SElQ ESMRSSRRRRRRRRRKiQRKVKRESRERNAERMESILiQALEDIlQLDLEAVNIKAGKAFLRL

SEG xxxxxxxxxxxxxxxxxxxxxxxxxxx

PRD hhhhhhhhhhhhhhhhhhhhhhhhhccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh

SElQ KRKFIlQMRRPFLERRDLIIiQHIPGFUVKAFLNHPRISILINRRDEDIFRYLTNLiQVlQDLR

SEG

PRD hhhhhhhhhhhhhhhhhhhhhccccceeeccccccchhhhhccchhhhhhhhhhhhhhhc SElQ HISMGYKMKLYF(QTNPYFTNMVIVKEF(QRNRSGRLVSHSTPIRUHRG<QEP(QARRHGN(QDA

SEG

PRD cccccceeeeeeccccccchhhhhhhcccccccceeeccccccccccccccccccccccc SElQ SHSFFSUFSNHSLPEADRIAEIIKNDLUVNPLRYYLRERGSRIKRKKlQEMKKRKTRGRCE

SEG xxxxxxxxxxxx ■. xxxxxxxxxxxxxxx- ■ ■ •

PRD cccceeeccccccccchhhhhhhhhhhhcccchhhhhhhhhhhhhhhcceeeeecccccc SElQ VVIMEDAPDYYAVEDIFSEISDIDETIHDIKISDFMETTDYFETTDNEITDINENICDSE

SEG

PRD eeeccccccceeehhhhhhhhhhccccccceeeeeccccccccccchhhhhhhhcccccc

SElQ NPDHNEVPNNETTDNNESADDHETTDNNESADDNNENPEDNNKNTDDNEENPNNNENTYG SEG xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

PRD ccccccceeeecccccccccccccccccchhhhhcccccceeeeeccccccccccccccc

SElQ NNFFKGGFUGSHGNNlQDSSDSDNEADEASDDEDNDGNEGDNEGSDDDGNEGDNEGSDDDD

SEG XX xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx PRD cccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc

SElQ RDIEYYEKVIEDFDKDlQADYEDVIEIISDESVEEEGIEEGIiQiQDEDIYEEGNYEEEGSED

SEG xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

PRD cchhhhhhhhhhhcccccchhhhheeeecccccccccccccccccceeecccccccccce

SElQ VUEEGEDSDDSDLEDVLiQVPNGUANPGKRGKTG SEG xxxxxxxxxxxxxxxxx

PRD eeecccccccccceeeeeccccccccccccccc

(No Prosite data available for DKFZphamy2_7 jS - 2) (No Pfam data available for DKFZphamy2_7jS - 2)

Pedant information for DKFZphamy2_7 jSi frame 3

Report for DKFZphamy2_7 jS-3

[LENGTH! ISO

[MU! IbδlD-bl

[pi! 12-88

[BLOCKS! PR00308A

[KU! All_Alpha

[KU! LOU COMPLEXITY bl-33 *

SElQ MRTSATARILTTMRSPTTRPLITTRVLMTTKPLTTMRViQMTTTRILKTITRTLMTTKRTL

SEG xxxxxxxxxxxxxxxxxxxxx

PRD ccchhhhhhhhhhcccccccccceeeeccccccchhhhhhhhhhhhhhhhhhhccccccc

SElQ TTTRTLTATTSSKVASGAAMATTRTAATVTMKiQMRPVMMKIMMATKVTMRAVMMMAMKVT SEG xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxx

PRD ccccceeecccccccchhhhhhhhhhhhhhhhhchhhhhhhhhhhhhhhhhhhhhhhhhh

SElQ MKAAMMTTETLSTMRKLLKTLTRIRLTTRT

SEG xxxxxxxx- xxxxxxxxxxxxxxxxxxxxx PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhccc

(No Prosite data available for DKFZphamy2_7 S- 3) (No Pfam data available for DKFZphamy2_7j5- 3) DKFZphfbr2_7δcl2

group: nucleic acid management DKFZphfbr2_7δcl2 encodes a novel 52δ amino acid protein with high csimilarity to glutamyl-tRNA (Gin) amidotransferase subunit A of the hyperthermophilic bacterium Aquifex aeolicus-

The novel protein contains one ATP/GTP-binding site motif A (P- loop). This loop interacts with one of the phosphate groups of a A or G nucleotide. It is found in numerous ATP- or GTP-binding proteinsi such as ATP synthase alpha and beta subunitsi Myosin heavy chainsi Kinesin heavy chains and kinesin-like proteinsi Dynamins and dynamin-like proteinsi several kinasesi DNA and RNA helicasesi GTP-binding elongation factors and the Ras family of GTP-binding proteins. The protein seems to be expressed ubiquitously.

The new protein can find application in the modulation of translational pathways-

similarity to glutamyl-tRNA (Gin) amidotransferase subunit A

(Aquifex aeolicus)

Sequenced by MediGenomix

Locus-" /map="bδb-3 cR from top of Chrb linkage group'

Insert length: 3244 bp

Poly A stretch at pos- 3222ι polyadenylation signal at pos- 32D4

1 AGTGACAATT AAAGATGGCT GCGCCCATGT AACATCACTA GCGACCGGTG

51 ACCTCTTTTT CCCCCTTGCC TGGCTCCTGT GGTGGCAGGC TGGGCACGAG

101 GACCATGCTG GGCCGGAGCC TCCGAGAAGT TTCTGCGGCA CTGAAACAAG

151 GCCAAATTAC ACCAACAGAG CTCTGTCAAA AATGTCTCTC TCTTATCAAG

2D1 AAGGCCAAGT TTCTAAATGC CTACATTACT GTGTCAGAAG AGGTGGCCTT 2S1 AAAACAAGCT GAAGAATCAG AAAAGAGATA TAAGAATGGA CAGTCACTTG

301 GGGATTTAGA TGGAATTCCT ATTGCAGTAA AAGACAATTT CAGCACTTCT

351 GGCATTGAGA CAACATGTGC ATCAAATATG CTGAAAGGTT ATATACCACC

401 TTATAATGCT ACAGTAGTTC AGAAGTTGTT GGATCAGGGA GCTCTACTAA

451 TGGGAAAAAC AAATTTAGAT GAGTTTGCTA TGGGATCTGG GAGCACAGAT SD1 GGTGTATTTG GACCAGTTAA AAACCCCTGG AGTTATTCAA AACGATATAG

5S1 AGAAAAGAGG AAGCAGAATC CCCACAGCGA GAATGAAGAT TCAGACTGGC bOl TGATAACTGG AGGAAGCCCA GGTGGGAGTG CAGCTGCTGT ATCGGCGTTC bSl ACATGCTACG CGGCTTTAGG ATCAGATACA GGAGGATCGA CCAGAAATCC

7D1 TGCTGCCCAC TGTGGGCTTG TTGGTTTCAA ACCAAGCTAT GGCTTAGTTT 7S1 CCCGTCATGG TCTCATTCCC CTGGTGAATT CGATGGATGT GCCAGGAATC

601 TTAACCAGAT GTGTGGATGA TGCAGCAATT GTGTTGGGTG CACTGGCCGG

651 ACCTGACCCC AGGGACTCTA CCACAGTACA TGAACCTATT AATAAACCAT

101 TCATGCTTCC CAGTTTGGCA GATGTGAGCA AACTATGTAT AGGAATTCCA ISI AAGGAATATC TTGTACCGGA ATTATCAAGT GAAGTACAGT CTCTTTGGTC

1D01 CAAAGCTGCT GACCTCTTTG AGTCTGAGGG GGCCAAAGTA ATTGAAGTAT

1051 CCCTTCCTCA CACCAGTTAT TCAATTGTCT GCTACCATGT ATTGTGCACA

1101 TCAGAAGTGG CATCGAATAT GGCAAGATTT GATGGGCTAC AATATGGTCA 1151 CAGATGTGAC ATTGATGTGT CCACTGAAGC CATGTATGCT GCAACCAGAC

12D1 GAGAAGGATT TAATGATGTG GTGAGAGGAA GAATTCTCTC AGGAAACTTT

12S1 TTCTTATTAA AAGAAAACTA TGAAAATTAT TTTGTCAAAG CACAGAAAGT

1301 GAGACGCCTC ATTGCTAATG ACTTTGTAAA TGCTTTTAAC TCTGGAGTAG

1351 ATGTCTTGCT AACTCCCACC ACCTTGAGTG AGGCAGTACC ATACTTGGAG 1401 TTCATCAAAG AGGACAACAG AACCCGAAGT GCCCAGGATG ATATTTTTAC

1451 ACAAGCTGTA AATATGGCAG GATTGCCAGC AGTGAGTATC CCTGTTGCAC

15D1 TCTCAAACCA AGGGTTGCCA ATAGGACTGC AGTTTATTGG ACGTGCGTTT

1S51 TGTGACCAGC AGCTTCTTAC AGTAGCCAAA TGGTTTGAAA AACAAGTACA

IbOl GTTTCCTGTT ATTCAACTTC AAGAACTCAT GGATGATTGT TCAGCAGTCC IbSl TTGAAAATGA AAAGTTAGCC TCTGTCTCTC TAAAACAGTA AACATATCTT

17D1 ACAAATTAAA ATGACTTTTA GGCTGGGTGC AGTGGCTCAC ACCTGTAATC

1751 CCAGCACTTT GGGAGGCCAA GGCGAGCGGA TCATGAGGTC AGAAGATCTA

1601 GAACAGCCTG GTCAACATGG TGAAACCCCG TCTCTACTAA AAATACAAAA

16S1 ATTAGCCAGG CTTAGTGGCG GGCATCTGTA GTCCCAGCTA CTCAGGAGGC 1101 TGAGGCAGGA GAATCACTTG AACCCTGGAG GTGGAGGTTG CAGTGAGCCG

1151 AGATCATGCC ACTGCACTGC ACTCCAGCCT GGGTGACAAA GCAAGACTGT

2DD1 GTCTCAAAAT AAATAAATAA AATAAAATAA AATGACGTAC AGAGATTCTA

2051 TATTCTAGAG AGTCAAATGG TCTTGCTCAA TTCTTGTAAT TAGGTTCTTG

21D1 TTAATACAGT CATTCCATGG AATTACTTTT TAAAATTCCT GTGACAATTA 21S1 ATAATAAATA ACGTGTCAGC ATTTAGTAAG CATCCACTAA GTGTACAATA

2201 CTTCTACAAT AACACAAGAT ACCTGTTCCT CAAAGACAAT GCATTCTGCC

2251 ATAATGTTCA TTAAAGAGTT TACAGTAAAA ATAAGATTAG GGATAAACTT

2301 CTCAAAAATT GTACATCTGT GTAACTAAAG CACTAACAAA AACATGAATA

2351 GTCCTTCTAG AGGTAACTTG GATAGCCTAG GCAGGCAACT TATCATGTGG 2401 TGAAGGCCGC CTCAGGGGTT GTTAAAAATG CACAGAAACA ATTGAGTGCG

24S1 ATTATTGGCT TCTGAGCGCT GAGCAGAGCA GGTGGAAGAG GAACTTTGAG

25D1 CACAGGAGGA AATGCAACCA GTCAGGGCCC AGAATCATGC AAATCTCAGG

2SS1 GGTATGCCTC TCTGGGGAGG AGCTCCACTT GCAGGGACTC CTTTTATTTC

2b01 CCTAAGAAAG AGCTGAAATG ACTGAGAACT TTCCTTTCCT CCTTAGAGTT 2b51 ACAATTTTAC TTCTGCTATT CCGGAGCCCA TGCCTAGAAG CCAGAACAAC

27D1 TCCATGTTAC ACTGAGTTCA TGCTCCTATT TACTGATCAC AAATGAGCTC

2751 ATTAATGTCA TCGAAACATT TATTGTAACC TAACAGACCA TCACAGATTG

2601 GAAACTTGGT AGATAGCAGA GCATGGTATT AGTGAAAAAG GTTCAAAATA

2651 CACAAGTAAC ATACACTCTG AAAAACATGC AGATAATTTG CTGATGAAGC 2101 AGAAGAGGGG ATGCGCATGG CAAGAACTTG CCTTACCCCA GATTCTCTAT

2151 ATCTCATGGT TTCCTTTTCC TCTTGACTGT CTTTACGAGT GTTTTTTATT

3D01 TGGGACCCTC GAGCCCAGAG ATATTAATGG ATATCTGTAT TCAATATTTG

3DS1 ACAAAATCTA ATGGAAACCA TCCATTTACT CATGATAAGG CTTCATCACT

31D1 GGATTTCTGT GTCTTCACTA GAACACCATT GTCATCTCAT ATTGATCAGG 3151 TATTTTAATC TAGCACTTAC ATATTGTTGA TAAATGAAAG CTGAATTGTT

3201 ACTTAATAAA TTCACTTTGT TTAGCAAAAA AAAAAAAAAA AAAA

BLAST Results

o BLAST result

Medline entries

o Medline entry Peptide information for frame 3

ORF from 1D5 bp to lb88 bpi peptide length^; 528

Category: similarity to known protein

Classification: Protein management

Prosite motifs: ATP GTP A (112-111)

1 MLGRS LREVS AALKiQGlQITP TELCiQKCLSL IKKAKFLNAY ITVSEEVALK 51 (QAEESEKRYK NGlQSLGDLDG IPIAVKDNFS TSGIETTCAS NMLKGYIPPY 101 NATVV(QKLLD (QGALLMGKTN LDEFAMGSGS TDGVFGPVKN PUSYSKRYRE 151 KRKlQNPHSEN EDSDULITGG SPGGSAAAVS AFTCYAALGS DTGGSTRNPA 201 AHCGLVGFKP SYGLVSRHGL IPLVNSMDVP GILTRCVDDA AIVLGALAGP 251 DPRDSTTVHE PINKPFMLPS LADVSKLCIG IPKEYLVPEL SSEViQSLUSK 301 AADLFESEGA KVIEVSLPHT SYSIVCYHVL CTSEVASNMA RFDGLlQYGHR 351 CDIDVSTEAM YAATRREGFN DVVRGRILSG NFFLLKENYE NYFVKAiQKVR 4D1 RLIANDFVNA FNSGVDVLLT PTTLSEAVPY LEFIKEDNRT RSA(QDDIFT(Q 451 AVNMAGLPAV SIPVALSNώG LPIGLlQFIGR AFCDIQIQLLTV AKUFEKiQViQF 501 PVIiQL(3ELMD DCSAVLENEK LASVSLKiQ

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphfbr2_78cl2ι frame 3

PIR:F70322 glutamyl-tRNA (Gin) amidotransferase subunit A -

Aquifex aeolicusi N = 2ι Score = b20ι P = 4-3e-81

>PIR:F7D322 glutamyl-tRNA (Gin) amidotransferase subunit A - Aquifex aeolicus

Length = 478

HSPs: Score = b20 (13-D bits)ι Expect = 4-3e-61ι Sum P(2) = 4-3e-81 Identities = 13S/311 (42*)ι Positives = 115/311 (bl*)

(Query : 187

ALGSDTGGSTRNPAAHCGLVGFKPSYGLVSRHGLIPLVNSMDVPGILTRCVDDAAIVLGA 24b +LGSDTGGS R PA+ CG++G KP+YG VSR+GL+ +S+D G+ R

+D A+VL Sb jct : lb3 SLGSDTGGSIRiQPASFCGVIGIKPTYGRVSRYGLVAFASSLDlQIGVFGRRTEDVALVLEV 222 (Query: 247

LAGPDPRDSTTVHEPINKPFMLPSLADVSKLCIGIPKEYLVPELSSEViQSLUSKAADLFE 30b

++G D +DST+ P+ + + +V L IG+PKE+ EL +V+ + E Sbjct: 223 ISGUDEKDSTSAKVPVPE- USEEVKKEVKGLKIGLPKEFFEYELύPiQVKEAFENFIKELE 261

(Query- 307 SEGAKVIEVSLPHTSYSIVCYHVLCTSEVASNMARFDGLiQYGHRCDIDVSTEAMYAATRR 3bb

EG ++ EVSLPH YSI Y+++ SE +SN+AR+DG++YG+R MYA TR

Sbjct: 2δ2 KEGFEIKEVSLPHVKYSIPTYYIIAPSEASSNLARYDGVRYGYRAKEYKDIFEMYARTRD 341

(Query: 3b7 EGFNDVVRGRILSGNFFLLKENYENYFVKAώKVRRLIANDFVNAFNSGVDVLLTPTTLSE 42b

EGF V+ RI+ G F L Y+ Y++KA(QKVRRLI NDF+ AF VDV+ +PTT Sbjct: 342 EGFGPEVKRRIMLGTFALSAGYYDAYYLKAlQKVRRLITNDFLKAFEE- VDVIASPTT—P 316

(Query: 427

AVPYLEFIKEDNRTRSA(QDDIFT(QAVNMAGLPAVSIPVALSN(QGLPIGLιQFIGRAFCDιQ(Q 48b +P+ + +N DI T N + AGLPA+SIP+A + GLP+G (Q

IG+ + +

Sbjct: 311 TLPFKFGERLENPIEMYLSDILTVPANLAGLPAISIPIAUKD- GLPVGGlQLIGKHUDETT 457 (Query: 487 LLTVAK-UFEK(QV(QFPVI(QL 505

LL ++ U +K + I L Sbjct: 456 LLiQISYLUEiQKFKHYEKIPL 477

Score = 261 (43-4 bits)ι Expect = 4-3e-81ι Sum P(2) = 4-3e-61 Identities = b4/143 (44*)ι Positives = 10/143 (b2*)

(Query: 4 RSLREVSAALKIQGIQITPTELCIQKCLSLIKKAKF-

LNAYITVSEEVALKiQAEESEKRYKNG b2

+ SL E+ LK + G+ + + P E+ + + + + AYIT ALKiQAE + + R

Sbjct: 5 KSLSELRELLKRGEVSPKEVVESFYDRYN(QTEEKVKAYITPLYGKALK(QAESLKER bO ώuery: b3 (QSLGDLDGIPIAVKDNFSTSGIETTCASNMLKGYIPPYNATVVlQKLLDiQGALLMGKTNLD 122

L L GIPIAVKDN G +TTCAS +L+ ++ PY+ATV+++L

GAL++GKTNLD Sbjct: bl -EL-

PLFGIPIAVKDNILVEGEKTTCASKILENFVAPYDATVIERLKKAGALIVGKTNLD 118

(Query: 123 EFAMGSGSTDGVFGPVKNPUSYSK 14b

EFAMGS + F P KNPU +

Sbjct: 111 EFAMGSSTEYSAFFPTKNPUDLER 142

Pedant information for DKFZphf br2_78cl2ι frame 3

Report for DKFZphf br2_78cl2-3

[LENGTH! 526 [MU! 574bδ-76 [pi! S-57

[H0M0L! PIR:E7172S glutamyl-tRNA amidotransferase chain A

(gatA) RP1S2 - Rickettsia prowazekii 2e-13

[FUNCAT! r general function prediction [M- jannaschiii MJllbO! δe-bl tFUNCAT! DI- 02-01 nitrogen and sulphur utilization ES- cerevisiaei YMR213c! le-S5

[FUNCAT! c energy conversion [M- genitaliumi MG011! 4e-41

[FUNCAT! 01.01-10 amino-acid degradation [S- cerevisiaei YBR20δc! 2e-31

[FUNCAT! 01-03-01 purine-ribonucleotide metabolism [S- cerevisiaei YBR20βc! 2e-31

[BLOCKS! BLD0S71

[EC! b-3-4-b Urea carboxylase 5e-3D [EC! 3-5.1-4 Amidase 3e-31

[EC! 3-5-2-12 b-Aminohexanoate-cyclic-dimer hydrolase le-17

[PIRKU! ligase Se-3D

[PIRKU! transmembrane protein 5e-30

[PIRKU! ATP Se-3D [PIRKU! crown gall tumor le-21

[PIRKU! mitochondrion 2e-13

[PIRKU! purine nucleotide binding 5e-30

[PIRKU! P-loop Se-30

[PIRKU! hydrolase 3e-31 [PIRKU! biotin 5e-30

ESUPFAM! amidase 3e-31

ESUPFAM! biotin carboxylase homology Se-3D

ESUPFAM! indoleacetamide hydrolase 7e-12

ESUPFAM! lipoyl/biotin-binding homology 5e-30 EPROSITE! ATP_GTP_A 1

EKU! Alpha_Beta

EKU! LOU COMPLEXITY 2-4b *

SElQ MLGRSLREVSAALKlQGlQITPTELClQKCLSLIKKAKFLNAYITVSEEVALKlQAEESEKRYK

SEG

PRD ccchhhhhhhhhhhhhcccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh

SElQ NGlQSLGDLDGIPIAVKDNFSTSGIETTCASNMLKGYIPPYNATVViQKLLDlQGALLMGKTN SEG

PRD hccccccccccceeeecccccccccccchhhhhhhcccccchhhhhhhhhccceeeeccc

SElQ LDEFAMGSGSTDGVFGPVKNPUSYSKRYREKRKlQNPHSENEDSDULITGGSPGGSAAAVS

SEG xxxxxxxxxxxx PRD ccccccccccccccccccccccccceeecccccccccccccccccccccccccccccchh

SElQ AFTCYAALGSDTGGSTRNPAAHCGLVGFKPSYGLVSRHGLIPLVNSMDVPGILTRCVDDA

SEG x

PRD hhhheeeecccccccccccccceeeecccccceeeeccceeeeecccccccccchhhhhh

SElQ AIVLGALAGPDPRDSTTVHEPINKPFMLPSLADVSKLCIGIPKEYLVPELSSEViQSLUSK

SEG

PRD hhhhhhhccccccccccccccccccccccccccccceeeecccccccccchhhhhhhhhh SElQ AADLFESEGAKVIEVSLPHTSYSIVCYHVLCTSEVASNMARFDGLl^QYGHRCDIDVSTEAM

SEG

PRD hhhhhhhhcceeeeeeccccceeeeeeeeehhhhhhhhhhhhhcccceeeccchhhhhhh SElQ YAATRREGFNDVVRGRILSGNFFLLKENYENYFVKAlQKVRRLIANDFVNAFNSGVDVLLT

SEG

PRD hhhhhhcccchhhhhhhhhhheeeccccchhhhhhhhhhhhhhhhhhhhhhhhheeeeee SElQ PTTLSEAVPYLEFIKEDNRTRSAlQDDIFTlQAVNMAGLPAVSIPVALSNiQGLPIGLlQFIGR

SEG

PRD cccccccccccccccccccccccccceeeeccccccccccccccccccccccceeeeeec

SElQ AFCDlQiQLLTVAKUFEKlQVlQFPVIiQLlQELMDDCSAVLENEKLASVSLKiQ SEG

PRD cccchhhhhhhhhhhhhhhhhheeehhhhhhheeeeccccceeeeccc

Pros i te f or DKFZphf br2_7βcl2 - 3

PSOOD17 112->120 ATP_GTP_A PD0C00D17

( No Pf am data ava i l abl e f or DKFZphf br2_76cl2 . 3 ) DKFZphf br2_7βdlδ

group: brain derived

DKFZphfbr2_7βdlδ encodes a novel S35 amino acid protein with weak similarity to a human putative mitogen-activated protein kinase kinase kinase-

No informative BLAST resultsi No predictive prositei pfam or SCOP motife. The new protein can find application in studying the expression profile of brain-specific genes. similarity to putative mitogen-activated protein kinase kinase kinase (Homo sapiens)

Sequenced by MediGenomix

Locus: unknown

Insert length: 2156 bp

Poly A stretch at pos- 2136ι polyadenylation signal at pos. 2117

1 ATCCGGGGCC CCGGAACCCG AGCTGGAGCT GAAGCGCAGG CTGCGGGGCG

51 CGGAGTCGGG AGTGCAGGCC TGAGTGTTCC TTCCAGCATG TCGGAGGGGG

101 AGTCCCAGAC AGTACTTAGC AGTGGCTCAG ACCCAAAGGT AGAATCCTCA

151 TCTTCAGCCC CTGGCCTGAC ATCAGTGTCA CCTCCTGTGA CCTCCACAAC

201 CTCAGCTGCT TCCCCAGAGG AAGAAGAAGA AAGTGAAGAT GAGTCTGAGA 251 TTTTGGAAGA GTCGCCCTGT GGGCGCTGGC AGAAGAGGCG AGAAGAGGTG

301 AATCAACGGA ATGTACCAGG TATTGACAGT GCATACCTGG CCATGGATAC

351 AGAGGAAGGT GTAGAGGTTG TGTGGAATGA GGTACAGTTC TCTGAACGCA

401 AGAACTACAA GCTGCAGGAG GAAAAGGTTC GTGCTGTGTT TGATAATCTG 451 ATTCAATTGG AGCATCTTAA CATTGTTAAG TTTCACAAAT ATTGGGCTGA

501 CATTAAAGAG AACAAGGCCA GGGTCATTTT TATCACAGAA TACATGTCAT

S51 CTGGGAGTCT GAAGCAATTT CTGAAGAAGA CCAAAAAGAA CCACAAGACG bOl ATGAATGAAA AGGCATGGAA GCGTTGGTGC ACACAAATCC TCTCTGCCCT b51 AAGCTACCTG CACTCCTGTG ACCCCCCCAT CATCCATGGG AACCTGACCT

701 GTGACACCAT CTTCATCCAG CACAACGGAC TCATCAAGAT TGGCTCTGTG

751 GCTCCTGACA CTATCAACAA TCATGTGAAG ACTTGTCGAG AAGAGCAGAA

601 GAATCTACAC TTCTTTGCAC CAGAGTATGG AGAAGTCACT AATGTGACAA

651 CAGCAGTGGA CATCTACTCC TTTGGCATGT GTGCACTGGA GATGGCAGTG 101 CTGGAGATTC AGGGCAATGG AGAGTCCTCA TATGTGCCAC AGGAAGCCAT

151 CAGCAGTGCC ATCCAGCTTC TAGAAGACCC ATTACAGAGG GAGTTCATTC

1D01 AAAAGTGCCT GCAGTCTGAG CCTGCTCGCA GACCAACAGC CAGAGAACTC

1DS1 CTGTTCCACC CAGCATTGTT TGAAGTGCCC TCGCTCAAAC TCCTTGCGGC

1101 CCACTGCATT GTGGGACACC AACACATGAT CCCAGAGAAC GCTCTAGAGG 1151 AGATCACCAA AAACATGGAT ACTAGTGCCG TACTGGCTGA AATCCCTGCA

1201 GGACCAGGAA GAGAACCAGT TCAGACTTTG TACTCTCAGT CACCAGCTCT

1251 GGAATTAGAT AAATTCCTTG AAGATGTCAG GAATGGGATC TATCCTCTGA

13D1 CAGCCTTTGG GCTGCCTCGG CCCCAGCAGC CACAGCAGGA GGAGGTGACA

13S1 TCACCTGTCG TGCCCCCCTC TGTCAAGACT CCGACACCTG AACCAGCTGA 1401 GGTGGAGACT CGCAAGGTGG TGCTGATGCA GTGCAACATT GAGTCGGTGG

1451 AGGAGGGAGT CAAACACCAC CTGACACTTC TGCTGAAGTT GGAGGACAAA

1SD1 CTGAACCGGC ACCTGAGCTG TGACCTGATG CCAAATGAGA ATATCCCCGA

1S51 GTTGGCGGCT GAGCTGGTGC AGCTGGGCTT CATTAGTGAG GCTGACCAGA

IbOl GCCGGTTGAC TTCTCTGCTA GAAGAGACCT TGAACAAGTT CAATTTTGCC IbSl AGGAACAGTA CCCTCAACTC AGCCGCTGTC ACCGTCTCCT CTTAGAGCTC

17D1 ACTCGGGCCA GGCCCTGATC TGCGCTGTGG CTGTCCCTGG ACGTGCTGCA

1751 GCCCTCCTGT CCCTTCCCCC CAGTCAGTAT TACCCTGTGA AGCCCCTTCC

16D1 CTCCTTTATT ATTCAGGAGG GCTGGGGGGG CTCCCTGGTT CTGAGCATCA

1651 TCCTTTCCCC TCCCCTCTCT TCCTCCCCTC TGCACTTTGT TTACTTGTTT 1101 TGCACAGACG TGGGCCTGGG CCTTCTCAGC AGCCGCCTTC TAGTTGGGGG

1151 CTAGTCGCTG ATCTGCCGGC TCCCGCCCAG CCTGTGTGGA AAGGAGGCCC

2D01 ACGGGCACTA GGGGAGCCGA ATTCTACAAT CCCGCTGGGG CGGCCGGGGC

2051 GGGAGAGAAA GGTGGTGCTG CAGTGGTGGC CCTGGGGGGC CATTCGATTC

2101 GCCTCAGTTG CTGCTGTAAT AAAAGTCTAC TTTTTGCCAA AAAAAAAAAA 2151 AAAAAAAA

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 1

ORF from 66 bp to lb12 bpi peptide length: 535 Category: similarity to unknown protein Classification: Protein management

1 MSEGESiQTVL SSGSDPKVES SSSAPGLTSV SPPVTSTTSA ASPEEEEESE 51 DESEILEESP CGRUlQKRREE VNlQRNVPGID SAYLAMDTEE GVEWUNEViQ

101 FSERKNYKLiQ EEKVRAVFDN LIlQLEHLNIV KFHKYUADIK ENKARVIFIT

151 EYMSSGSLKlQ FLKKTKKNHK TMNEKAUKRU CTiQILSALSY LHSCDPPIIH

201 GNLTCDTIFI (QHNGLIKIGS VAPDTINNHV KTCREElQKNL HFFAPEY6EV 251 TNVTTAVDIY SFGMCALEMA VLEIlQGNGES SYVPώEAISS AIIQLLEDPLIQ

3D1 REFIlQKCLiQS EPARRPTARE LLFHPALFEV PSLKLLAAHC IVGHiQHMIPE

351 NALEEITKNM DTSAVLAEIP AGPGREPVlQT LYSiQSPALEL DKFLEDVRNG

401 IYPLTAFGLP RP(Q<QPι2<QEEV TSPVVPPSVK TPTPEPAEVE TRKVVLMiQCN

451 IESVEEGVKH HLTLLLKLED KLNRHLSCDL MPNENIPELA AELVlQLGFIS 501 EADiQSRLTSL LEETLNKFNF ARNSTLNSAA VTVSS

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphfbr2_78dlβι frame 1

TREMBL".ACDD14b5_14 gene: "T1J14.14"i product: "putative mitogen activated protein kinase kinase"i Arabidopsis thaliana chromosome III

BAC T1J14 genomic sequence! complete sequence- i N = li Score =

372ι P = l-le-33

TREMBL:AF14Sb1D_l gene: "BcDNA - LD28bS7"i product:

"BcDNA-LD2δb57"i

Drosophila melanogaster clone LD2δbS7 BcDNA - LD2βbS7

(BcDNA-LD2βb57) mRNAi complete cds-i N = li Score = 114Dι P = l-3e-115

PIR:T02151 probable mitogen activated protein kinase - rice-, N =

Score = 311ι P = l-4e-3S

>TREMBL:AF145b1D_l gene: "BcDNA - LD2δbS7"i product: "BcDNA-LD2βbS7"i Drosophila melanogaster clone LD28b57 BcDNA -LD2βbS7 (BcDNA-LD2δbS7) mRNAi complete eds-

Length = b37 HSPs:

Score = 1140 (171. D bits)ι Expect = 1.3e-115ι P = 1.3e-llS Identities = 230/4b5 (41*)ι Positives = 3D4/4bS (b5*) (Query : bl

CGRU⁽QKRREEVN<^QRNVPGIDSAYLAMDTEEGVEVVUNEV(^QFSERKNYKL^(QEEKVRAVFDN 120 CGRU KRREEV + (QR + VPGID +LAMDTEEGVEVVUNEV(Q + + + K

(QEEK + R VFDN

Sbjct : 1D2 CGRULKRREEVD(QRDVPGIDCVHLAMDTEEGVEVVUNEV(QYASL(QELKS(^QEEKMR(QVFDN Ibl

(Query : 121 LIiQLEHLNIVKFHKYUADIKE- NKARVIFITEYMSSGSLKlQFLKKTKKNHKTMNEKAUKR 171 L + (QL + H NIVKFH + YU D ++ + RV + FITEYMSSGSLK(QFLK + TK + N K + ++U+R Sbjct: lb2

LL(QLDH(QNIVKFHRYUTDT(Q(QAERPRVVFITEYMSSGSLK<QFLKRTKRNAKRLPLESURR 221

(Query: 160 UCT(QILSALSYLHSCDPPIIHGNLTCDTIFI(QHNGLIKIGSVAPDTINNHVKTCREE(QKN 231

UCTlQILSALSYLHSC PPIIHGNLTCD + IFIiQHNGL + KIGSV PD ++ V + RE + + Sbjct: 222

UCTiQILSALSYLHSCSPPIIHGNLTCDSIFIlQHNGLVKIGSVVPDAVHYSVRRGRERERE 261

(Query: 240 LHFF-APEYGEVTNVTTAVDIYSFGMCALEMAVLEI(Q-

GNGESSYVPiQEAISSAIiQ 213 H + F APEYG +T A + DIY + FGMCALEMA LEIiQ N ES+ +

+ E I I Sbjct: 262 RERGAHYFιQAPEYGAAD(QLTAALDIYAFGMCALEMAALEI(3PSNSESTAINEETI(QRTIF 341 (Query: 214 LLEDPL(QREFI(QKCLιQSEPARRPTARELLFHPALFEVPSLKLLAAHCIV

GHiQHMIPE 350

LE+ LιQR+ I + KCL +P RP + A +LLFHP LFEV SLKLL AHC + V

+ + M E

Sbjct: 342 SLENDL(QRDLIRKCLNP(QP(QDRPSANDLLFHPLLFEVHSLKLLTAHCLVFSPANRTMFSE 401

(Query: 351 NALEEITKNM- DTSAVLAEIPAGPGREPV(QTLYS(QSPALELDKFLEDVRNGIYPLTAFGL 4D1

A + + + V+A++ G+E L S A +L+KF+EDV+ G+YPL +

Sbjct: 402 TAFDGLM(QRYY(QPDVVMA(QLRLAGG<QER(QYRLADVSGADKLEKFVEDVKYGVYPLITYS- 4b0 fluery: 410 PRXXXXXXXXXXXXXXXXXXXXXXXXXAEVETRKVVLMiQCNIESVEEGVXXXXXXXXXXX 4b1

+ + E+R++V M C+++ E+

Sbjct: 4bl GKKPPNFRSRAASPERADSVKSATPEPVDTESRRIVNMMCSVKIKEDSNDITMTILLRMD 520 (Query: 470 XXXXXXXSCDLMPNENIPELAAELVIQLGFISEADIQSRLTSLLEETL SIS

+ C + N+ +L +ELV + LGF+ DiQ ++ LLEETL Sbjct: S21 DKMNRIQLTCIQVNENDTAADLTSELVRLGFVHLDDIQDKIIQVLLEETL 5bb

Pedant information for DKFZphf br2_7βdlδι frame 1

Report for DKFZphf br2_7δdlβ ■ 1

ELENGTH! Sb4 EMU! b24b4-87

Epl! 5-10

EHOMOL! TREMBL:AF14Sb10_l gene: "BcDNA - LD2βb57"i product: "BcDNA- LD28b57"i Drosophila melanogaster clone LD28b57

BcDNA. LD28b57 (BcDNA - LD2βbS7 ) mRNAi complete eds- le-123 EFUNCAT! D3-22 cell cycle control and mitosis ES. cerevisiaei

YJLOISw! be-15 EFUNCAT! 3D- 03 organization of cytoplasm ES- cerevisiaei

YJLDISw! be-15

EFUNCAT! 11-01 stress response ES- cerevisiaei YJLDISw! be-lS

EFUNCAT! 03-01 cell growth ES- cerevisiaei YJLDISw! be-15 EFUNCAT! ID.02-11 key kinases ES- cerevisiaei YJLD15w! be-lS

EFUNCAT! 03-D4 buddingi cell polarity and filament formation ES- cerevisiaei YJL015w! be-15

EFUNCAT! 18 classification not yet clear-cut ES- cerevisiaei

YLRDIbw! 2e-01 EFUNCAT! 3D-02 organization of plasma membrane ES- cerevisiaei

YLRDIbw! 2e-D1

EFUNCAT! ID.03.11 key kinases ES. cerevisiaei YNR031c! 3e-D1

EFUNCAT! 01. DI biogenesis of cell wall ES- cerevisiaei

YNR031c! 3e-01 EFUNCAT! 03-D7 pheromone responsei mating-type determination! sex-specific proteins ES- cerevisiaei YLR3b2w! 4e-0β

EFUNCAT! ID- 05- 11 key kinases ES- cerevisiaei YLR3b2w! 4e-06

EFUNCAT! ID- 04-11 key kinases ES- cerevisiaei YLR3b2w! 4e-0δ

EFUNCAT! 11-04 dna repair (direct repairi base excision repair and nucleotide excision repair) ES- cerevisiaei YPL153c! le-D7

EFUNCAT! 03-11 recombination and dna repair ES- cerevisiaei

YPL153c! le-07

EFUNCAT! 03-22-01 cell cycle check point proteins ES- cerevisiaei YPL153c! le-07 EFUNCAT! 3D-10 nuclear organization ES- cerevisiaei YPL153c! le-D7

EFUNCAT! 03-25 cytokinesis ES- cerevisiaei YDR5D7c! le-07

EFUNCAT! 10-11 other signal-transduction activities ES- cerevisiaei YPLlS3c! le-07 EFUNCAT! 03-13 meiosis ES- cerevisiaei YDR523c! 3e-07

EFUNCAT! D3-1D sporulation and germination ES- cerevisiaei

YDRS23c! 3e-D7

EFUNCAT! 03-lb dna synthesis and replication ES- cerevisiaei

YMRDOlc! 2e-0b EFUNCAT! 11 unclassified proteins ES- cerevisiaei YDR410c!

3e-05

EFUNCAT! 05-07 translational control ES- cerevisiaei YDR2δ3c! le-04

EFUNCAT! 01.05-04 regulation of carbohydrate utilization ES- cerevisiaei YDR477w! le-04

EBLOCKS! PF00b37A

EBLOCKS! BP03111J

EBLOCKS! PF01317B

ESCOP! dlir3a_ 5-1-1-2-b insulin receptor Complex (transferase/substrate) 2e-S3

ESCOP! dlphk S-l-l-l-b gamma-subunit of glycogen phosphorylase kinas 3e-bβ

ESCOP! dlfgkb_ 5.1-1.2.5 Fibroblast growth factor receptor 1 [human (Horn le-55 [SCOP! dlabo 5-1.1.1.14 Protein kiase CK2ι alpha subunit [Maize (Ze 2e-55

[SCOP! d31ck 5-1.1-2-2 Lymphocyte kinase (lck) [Human

(Homo sapiens) 7e-S4

[SCOP! d2erk 5.1.1.1-11 MAP kinase Erk2 [rat (Rattus norvegicus) 1e-71

[SCOP! dlcdkb_ 5-1.1.1-2 cAMP-dependent PKi catalytic subunit Comple le-55 [SCOP! dlhcl 5-1-1-1-1 Cyclin-dependent PK [Human

(Homo sapiens) 4e-b7

[EC! 2-7-1-112 Protein-tyrosine kinase 4e-0b

[EC! 2-7.1-37 Protein kinase 3e-D1 EPIRKU! phosphotransferase 2e-2δ

[PIRKU! nucleus 3e-0b

[PIRKU! RNA binding 3e-10

[PIRKU! tandem repeat 4e-07

[PIRKU! cell cycle control 3e-0b [PIRKU! serine/threonine-specific protein kinase 2e-13

[PIRKU! transmembrane protein 4e-07

[PIRKU! autophosphorylation 3e-10

[PIRKU! tyrosine-specific protein kinase 4e-Db

[PIRKU! magnesium 4e-D7 [PIRKU! ATP 2e-13

[PIRKU! receptor 4e-07

[PIRKU! phosphoprotein 2e-13

[PIRKU! apoptosis 3e-0b

[PIRKU! glycoprotein 4e-07 [PIRKU! protein kinase 2e-2δ

EPIRKU! signal transduction 2e-0β

EPIRKU! cell division le-11

EPIRKU! calmodulin binding 3e-0b

ESUPFAM! protein kinase byr2 le-Ob ESUPFAM! unassigned Ser/Thr or Tyr-specific protein kinases 2e-

13

ESUPFAM! leucine-rich alpha-2-glycoprotein repeat homology 4e-D7

ESUPFAM! double-stranded RNA-binding repeat homology 3e-10 ESUPFAM! SAM homology le-Ob

ESUPFAM! death-associated protein kinase 3e-0b

ESUPFAM! ankyrin repeat homology 3e-0b

ESUPFAM! protein kinase homology 2e-2δ

ESUPFAM! kinase-related transforming protein 2e-0b ESUPFAM! protein kinase SPK1 3e-0b

ESUPFAM! protein kinase Xa21 4e-07

ESUPFAM! protein kinase TIK 3e-lD

ESUPFAM! kinase interaction domain homology 3e-Db

EPFAM! Eukaryotic protein kinase domain EKU! All_Alpha

EKU! 3D

EKU! LOU COMPLEXITY lb-41 *

SElQ IRGPGTRAGAEAiQAAGRGVGSAGLSVPSSMSEGESlQTVLSSGSDPKVESSSSAPGLTSVS SEG - - - ■ xxxxxxxxxxxxxxxx xxxxx

IkobA

SElQ PPVTSTTSAASPEEEEESEDESEILEESPCGRUiQKRREEVNiQRNVPGIDSAYLAMDTEEG SEG xxxxxxxxxxxxxxxxxxxxxxxxxxxxx

IkobA

SE(Q VEVVUNEViQFSERKNYKLiQEEKVRAVFDNLIlQLEHLNIVKFHKYUADIKENKARVIFITE SEG

IkobA CHHHHHHHHHHHHHHHTTTBTTBCCEE

EEEETTTEEEEEEC SElQ YMSSGSLK(QFLKKTKKNHKTMNEKAUKRUCT(QILSALSYLHSCDPPIIHGNLTCDTIFI(Q SEG

IkobA CCCCEEH--HHHHCTTTTC-CCHHHHHHHHHHHHHHHHHHH-- HHCEETTTTTTTTEETT

SElQ HNGLIKIGSVAPDTINNHVKTCREEiQKNLHFFAPEYGEVTNVTTAVDIYSFGMCALEMAV SEG

IkobA TTCCEEECCTTTTEECTTTTEEEEETTTGGGCCHHHHHCCCBCHHHHHHHHHHHHHHHHC

SElQ LEIlQGNGESSYVPiQEAISSAIiQLLEDPLlQREFIlQKCLiQSEPARRPTARELLFHPALFEVP SEG

IkobA CCTTTTCCCHHHHHHHHHHCCCCTTTHHHHHHHHHTTTTTGGGCCCHHHHHHTTTT

SElQ SLKLLAAHCIVGH(QHMIPENALEEITKNMDTSAVLAEIPAGPGREPV(2TLYS(QSPALELD SEG

IkobA

SElQ KFLEDVRNGIYPLTAFGLPRPIQIQPIQIQEEVTSPVVPPSVKTPTPEPAEVETRKVVLMIQCNI SEG xxxxxxxxxxxxxxxxxxxxxxxxx

IkobA

SElQ ESVEEGVKHHLTLLLKLEDKLNRHLSCDLMPNENIPELAAELVIQLGFISEADIQSRLTSLL SEG xxxxxxxxxxxxxxxxxx

IkobA

SElQ EETLNKFNFARNSTLNSAAVTVSS

SEG

IkobA

(No Prosite data available for DKFZphfbr2_76dlβ -1)

Pfam for DKFZphfbr2_7δdlβ-l

HMM_NAME Eukaryotic protein kinase domain HMM

*rLnHPNIIRFYDwFed- - - ddDHIYMIMEYMeGGDLFDYIrrng p

+L H NI++F ++ D + ++ +I+EYM G+L +++++ +

(Query 1S2

(QLEHLNIVKFHKYUADIKENKARVIFITEYMSSGSLKlQFLKKTKKNHKT 2D0

HMM

MsEwelrflMyiQILrGMeYLHSMg- - IIHRDLKPENILIDeNgqIKIcDF

M+E+ +++ +IQIL++++YLHS IIH L + I+I +NG

IKI+ (Query 2D1

MNEKAUKRUCTiQILSALSYLHSCDPPIIHGNLTCDTIFIiQHNGLIKIGSV 250 HMM GLARqMnnYerMttfCGTPUYMMAPEVIImgnyYttkVDMUSFGCILUEM

++ N+ + + + APE + ++ TT+VD++SFG+

EM (Query 251 APDTINNHVKTCREE<QKNLHFF-APEY-

GEVTNVTTAVDIYSFGMCALEM 216

HMM

MTGepPFyddnMemlmrliqrfrrpfUpnCSeElyDFMrwCUnyDPekRP + ++ + N E + ++ + ++ + + ++F+ +C++

P++RP

(Query 211 A~ VLEIfl-

GNGESSYVP(QEAISSAI(QLLEDPL(QREFI(QKCL(QSEPARRP 345 HMM TFriQILnHPUF*

T+R++L HP + (Query 34b TARELLFHPAL 35b

DKFZphfbr2_7θd4

group: transmembrane protein

DKFZphfbr2_7βd4 encodes a novel Iδδ amino acid protein without similarity to known proteins.

The novel protein contains 1 transmembrane region and a Cytochrome c family heme-binding site- No informative BLAST resultsi No predictive prositei pfam or SCOP motife ■

The new protein can find application in studying the expression profile of brain-specific genes and as a new marker for amygdala cells-

weak similarity to hypothetical protein of Arabidopsis thaliana perhaps complete eds- Pedant: TRANSMEMBRANE 1

Sequenced by MediGenomix

Locus: unknown

Insert length: 1547 bp

Poly A stretch at pos- 1527ι polyadenylation signal at pos- 15Dδ

1 TTGCCGCCGC CGCCACCCCC GCCCAGGATG GCGGAAGTGG AGGCGCCGAC

51 GGCGGCCGAG ACGGACATGA AGCAATATCA AGGCTCCGGC GGCGTCGCCA

101 TGGATGTGGA ACGGAGTCGC TTCCCCTACT GCGTGGTGTG GACGCCCATC 151 CCGGTGCTCA CGTGGTTTTT CCCCATCATC GGCCACATGG GCATCTGCAC

201 ATCCACAGGA GTCATTCGGG ACTTCGCGGG CCCCTACTTT GTCTCAGAGG

251 ACAACATGGC CTTTGGAAAG CCTGCCAAGT ACTGGAAGTT GGACCCTGCT

3D1 CAGGTCTATG CTAGCGGGCC CAACGCATGG GACACGGCTG TGCACGACGC

3S1 CTCTGAGGAG TACAAGCACC GCATGCACAA TCTCTGCTGT GACAACTGCC 401 ACTCGCACGT GGCATTGGCC CTGAATCTGA TGCGCTACAA CAACAGCACC

451 AACTGGAATA TGGTGACGCT CTGCTTCTTC TGCCTGCTCT ACGGGAAGTA

501 CGTCAGCGTT GGGGCCTTCG TGAAGACCTG GCTGCCCTTC ATCCTTCTCC

5S1 TGGGCATCAT CCTCACCGTC AGCCTGGTCT TTAACCTCCG GTGATGGCTG bOl CTCGGTGGCC CCACACCCAC CAGGGTCCCG AGGAAACAGC CGCCATCCCT bSl TTTGGTTCCA GATTTTTTTC TCCTCACCCC AAAAGGCAGG GTTGGGCCTG

7D1 CTGTTGTGGA CCGGGGGTCG GGGCTGGCAG GATGGAAGGA CTGAGGACCA

751 GCATGAAGTG GGGGTTTGTT GTCTCCCTGC CTCTCAGAAG CACCCTGTCC

601 CCTCCTCCCC AGGCCTGTGA CTCCGGCCCT GGAAGCCCCT TTGTTCTTCT

651 GTTGAAAGGC TTTGGCTTCC CTCTGTAGAG CTGCTCCCGC CACCACCTGC 101 TGGGGTCCTG CCTCAGCCCA GTGCCCAGTA TGGGGAGAGG AGGACATTTG

151 GGCTCACCTG TCAAGGTGGC CCTGGGACCA GAGCTGGTCC CAGCATGGGG

10D1 TGCACCGGGT ACACTTAACG TGTCTCTATA AGCCAAGTTG CTTCAGGACC

1051 TTCACCACTG GCCTCTAGAA TGGTCCAGAG GGGCTGGCTG GGTCCCTTTG

11D1 TCAGACTCCT GCCGGCAGCT GCCCTGGGGG ACATGTGTGC CCATCTGGCA 1151 TCCTCCAGCC CGTGCAGTCC GCTCTTCACT GTTCCACGGC CTCCCAGTGC

1201 CTCCCAGCAT TGGACCCATC TCCCCCTGCA GTTTGAGGCC AGAGAGGTGA

1251 GTGGACCTGA CAAGTGCCAG AGTAACCGTG TAGACAGAGC AGTGTAGACA

13D1 GCGCTCAGCC CCAGCCCCAG GTGTGGACCT CATGCTGGTG ATGGCTCCCC 13S1 TGGGTGGCCT GCCAGCACAG CCAGTGCCAT CAGGGAGCTG AAGGGGCTGT

1401 CCCCCACCTA ACTCCAGCTC CCCCTTCACG TTGTCACCAA GGCCCTGTGC

1451 CGCCCGCCTC GCCCCCCTGC TCTGTGGATT CCTTTGGGAA GGGCTCCCTG

1501 GGCAGGACAA TAAAGAGTTT TGACTCCAAA AAAAAAAAAA AAAAAAA

BLAST Results

Entry TD2blb from database PIR:' hypothetical protein T11L16-12 - Arabidopsis thaliana Score = 221ι P = l-3e-17ι identities = 57/lblι positives 76/lblι frame +1

Medline entries

No Medline entry

Peptide information for frame 1

ORF from 26 bp to S11 bpi peptide length 166 Category: similarity to unknown protein Classification: no clue Prosite motifs: CYTOCHROME C (121-111)

1 MAEVEAPTAA ETDMKiQYiQGS GGVAMDVERS RFPYCVVUTP IPVLTUFFPI 51 IGHMGICTST GVIRDFAGPY FVSEDNMAFG KPAKYUKLDP AlQVYASGPNA

101 UDTAVHDASE EYKHRMHNLC CDNCHSHVAL ALNLMRYNNS TNUNMVTLCF

151 FCLLYGKYVS VGAFVKTULP FILLLGIILT VSLVFNLR

BLASTP hits

No BLASTP hits available Alert BLASTP hits for DKFZphfbr2_7δd4 ■, frame 1

PIR:T02blb hypothetical protein T11L18-12 - Arabidopsis thalianai

N =

2ι Score = 22bι P = 4-Se-21

>PIR:TD2blb hypothetical protein T11L18-12 - Arabidopsis thaliana Length = 2b7 HSPs:

Score = 22b (33-1 bits)ι Expect = 4-5e-21ι Sum P(2) = 4-Se-21 Identities = 52/132 (31*)ι Positives = 71/132 (53*) (Query: 25 MDVERSRFPYCVVUTPIPVLTUFFPIIGHMGICTSTGVIRDFAGPYFVSEDNMAFGKPAK 64

+D ++S+FP C+VUTP+PV++U P IGH+G+C GVI DFAG F++ D+ AFG PA+

Sbjct: bl IDTKKSKFPCCIVUTPLPVVSULAPFIGHIGLCREDGVILDFAGSNFINVDDFAFGPPAR 12D

(Query: 65 YUKLDPAlQVYASGPNAUDTAVHDASEEYKHRMHNLC-- CDNCHSHVALALNLMRYNNST- 141

Y +LD + PN H +KH DN S +

YN T

Sbjct: 121 YLlQLDRTKCCLP-PNMGG---

HTCKYGFKHTDFGTARTUDNALSSSTRSFEHKTYNIFTC 17b

(Query: 142 NUN-MVTLCFFCLLYG ISb N + V C L YG

Sbjct: 177 NCHSFVANCLNRLCYG 112 Score = 157 (23-b bits)ι Expect = l.fle-13ι Sum P(2) = l-δe-13 Identities = 27/61 (33*)ι Positives = 50/61 (bl*)

(Query: 101

UDTAVHDASEEYKHRMHNLCCDNCHSHVALALNLMRYNNSTNUNMVTLCFFCLLYGKYVS IbO UD A+ ++ ++H+ +N+ NCHS VA LN + Y S UNMV +

++ GK+++ Sbjct: 155 UDNALSSSTRSFEHKTYNIFTCNCHSFVANCLNRLCYGGSMEUNMVNVAILLMIKGKUIN 214 (Query: ibl VGAFVKTULPFILL--LGIIL 171

+ V+++LP ++ LG++L Sbjct: 215 GSSVVRSFLPCAVVTSLGVVL 235

Score = 3b (5-4 bits)ι Expect = 4-Se-21ι Sum P(2) = 4-Se-21 Identities = 7/21 (33*)ι Positives = 14/21 (bb*)

(Query: ID AETDMKIQYIQGSGGVAMDVERS 3D

++ ++K +G G MD++RS Sbjct: 12 SDRNLKMSRGRGVPMMDLKRS 32

Pedant information for DKFZphfbr2_7δd4 i frame 1

Report for DKFZphfbr2_7δd4.1

ELENGTH! 166 EMU! 21176. bb Epl! b-27

EHOMOL! PIR:TD2blb hypothetical protein T11L18-12 - Arabidopsis thaliana 7e-32 EPROSITE! CYT0CHR0ME_C 1 EKU! TRANSMEMBRANE 1

SElQ MAEVEAPTAAETDMK(QY(QGSGGVAMDVERSRFPYCVVUTPIPVLTUFFPIIGHMGICTST PRD cccccchhhhhhhhhhccccccccccccccccccceeeccceeeeeeeeecccceeecce M EM

SElQ GVIRDFAGPYFVSEDNMAFGKPAKYUKLDPAiQVYASGPNAUDTAVHDASEEYKHRMHNLC

PRD eeeeccccccccccccccccccceeeeccccceeeccccccccccccccchhhhhhhhee MEM

SElQ CDNCHSHVALALNLMRYNNSTNUNMVTLCFFCLLYGKYVSVGAFVKTULPFILLLGIILT

PRD ecccchhhhhhhhhhhccccccchhhhhhhhhhhccceeeeeeeeeeeccceeeeceeec

MEM MMMMMMMMMMMM

SElQ VSLVFNLR PRD ceeeeccc MEM MMMMM...

Prosite for DKFZphfbr2_78d4-l PSD011D 121->127 CYTOCHROME_C PDOCODlbl

(No Pfam data available for DKFZphfbr2_7βd4.1)

DKFZphfbr2_7δelβ

group: brain derived

DKFZphfbr2_76elδ encodes a novel 3D7 amino acid protein without similarity to known proteins- The mRNA is differentially polyadenylated.

No informative BLAST resultsi No predictive prositei pfam or SCOP motife •

The new protein can find application in studying the expression profile of brain-specific genes-

similarity to hypothetical protein of Arabidopsis thaliana differential polyadenylation > 7 exons complete on human genomic clone 451B21ap- perhaps complete eds- Sequenced by MediGenomix

Locus: /map="144 -50 cR from top of Chrb linkage group"

Insert length: 301b bp Poly A stretch at pos- 3075ι polyadenylation signal at pos- 3047

1 TGGTGAGTTC GGAGTAGAGA TGGCCGCGCT TGCACCGCTG CCCCCGCTCC

51 CCGCACAGCT CAAGAGCATA CAGCATCATC TGAGGACGGC TCAGGAGCAT 101 GACAAGCGAG ACCCTGTGGT GGCTTATTAC TGTCGTTTAT ACGCAATGCA

ISI GACTGGAATG AAGATCGATA GTAAAACTCC TGAATGTCGC AAATTTTTAT

2D1 CAAAGTTAAT GGATCAGTTA GAAGCTCTAA AGAAGCAGTT GGGTGATAAT

251 GAAGCTATTA CTCAAGAAAT AGTGGGCTGT GCCCATTTGG AGAATTATGC

301 TTTGAAAATG TTTTTGTATG CAGACAATGA AGATCGTGCT GGACGATTTC 351 ACAAAAACAT GATCAAGTCC TTCTATACTG CAAGTCTTTT GATAGATGTC

4D1 ATAACAGTAT TTGGAGAACT CACTGATGAA AATGTGAAAC ACAGGAAGTA

451 TGCCAGATGG AAGGCAACAT ACATCCATAA TTGTTTAAAG AATGGGGAGA

501 CTCCTCAAGC AGGCCCTGTT GGAATTGAAG AAGATAATGA TATTGAAGAA

5S1 AATGAAGATG CTGGAGCAGC CTCTCTGCCC ACTCAGCCAA CTCAGCCATC bOl ATCATCTTCA ACTTATGACC CAAGCAACAT GCCATCAGGC AACTATACTG bSl GAATACAGAT TCCTCCGGGT GCACACGCTC CAGCTAATAC ACCAGCAGAA

701 GTGCCTCACA GCACAGGTGT AGCAAGTAAT ACTATCCAAC CTACTCCACA

7S1 GACTATACCT GCCATTGATC CCGCACTTTT CAATACAATT TCCCAGGGGG

601 ATGTTCGTCT AACCCCAGAA GACTTTGCTA GAGCTCAGAA GTACTGCAAA 651 TATGCTGGCA GTGCTTTGCA GTATGAAGAT GTAAGCACTG CTGTCCAGAA

101 TCTACAAAAG GCTCTCAAGT TACTGACGAC AGGCAGAGAA TGAAGCCTTT

151 GTATGACAGA CCCATGTATT TTTGGCATGA GGAACTAACA GTCCATTACT

1D01 CTATCTTCAG CCTATCAGGA TCACAGTTTT AAGGAAGACT TGGTTTTGTT

1051 GAATATGACA ATGAAATCTG TGTGTATCAG ATTTTTATTG AAGCATTCAT 1101 CAGCAGCCTC AACCAGTTTT CATTGTCCAT TTACTAGATT CAATCGTCTC

1151 TGAGTATATA GGGCTGATGT TAGCAAGACC CTAAAAATGT CCATTGAACC

12D1 CTGCTTCAAA AAATGAAAAC ACACCTCTAT AAAATGTGTA CTGGGAATAA

1251 GCTTTGTATT TACATACATT AGGGGAATTT TTTAAAATCT GTAATGTTTG 13D1 GACAAACAGA TGATATTACT TTGCTATAAA ATTATAAATG TAACTTTTAA

1351 TAAAGATAGC CAGAATATTC TAAATTAGAA ATTACGTTTT TGTTTCCCTC

1401 AAGACATAAA ACAAATATAA ACATTCTAAA CTGCTGGATG AATCTGAAAA

1451 GACATTAAGT TCAAATTTTA ATTTATTCTC ATATTAAATA TAACTCCATT 1501 AAAAGTTTAA AATTTCATGG GAGAAAATAT AATAAGGTAA AGAGGTAGAA

1S51 TCACTTTCAG ACTTAAGAAT AATGTTGATT TCCCAAGTGC TTTACCTTAT

IbOl CTGTTAAAGC GTAAGATGAA TTGGTATTTG CTTCATAGGC AGTTTGACTG

IbSl CATGTATTAG AGAAT6AAAA GAAGATATTT GTAGTAATGC CTGGAAACTT

1701 GGTGCTTTAA ATTAAGGTAC TCCTCTGCTG CTGTAGAATG GATTCCACAC 1751 AGTGGATAGC TATGGGTGAT TCAGAATATT ATGTTTAGAT TCCCATTTGT

IδOl TAAGTTTATA AGTTTTGTGG GGAATTATGA ACTTACTGTG TACTACCTGC

18S1 ATTTGTGCTG TGTGAAAAAT AAATACAAGG ATTCGTTTAG CTAATTCAAC

1101 TTACTACAAA GACAAATGTC TGTTTTTATT TGCCTGCTAG GATTGTCTTT

1151 TTTAAAAGTC ATTTTTATTT ATAGGAATAT GGGTGTTTCT ATAGGAAGAA 20D1 ACAGGTTTTT TGTTTTTTGT TTTTTAAGAT AAATTTGACA AAGTTAACTG

2DS1 AAATTTATCT GGTCCATTTT ATTCATGCTA CTAAGATGGG AATCTTTAAA

21D1 CACAAGGGTC AGCAAGCTTT GGCCCATGGA TTGGCCACCT GTTACGTAAA

2151 TAAAGTTTCT TTGAAACAAG CCTACACTCA TTCATTTATG TTTTGTCTGT

2201 GGTTGCTTTC CACAACTGCA GAGTTGTATG GCTTGCAAGT CTAAAAACAT 2251 TTACTATTTG GCCCTCTAAG AAAAAGTTAA GACACCTAGT CTAATGGCCT

23D1 TTTGGGAAAA AACAAATCAC TAACTCATAA TCATTTATAT CCATTATTTT

23S1 CTGCATAAAT GTAATGCTAT TGTACAGGGT TTGGTAGAAT AAATATTCA6

2401 ACTGACTAAA CTGTTCTAAA TTCTCACAAA AAAGTCCCCA AACAACATGC

2451 CTCCTAAAAA ACATTTTCCT ATCTTTTACA AGAGGTATGA ACATTTGTAG 2S01 GGTTCCACAT TTGCATCTAG AAATCCAATG CTCTTTAGAA TGTTATTACG

2SS1 AATAGAAAGA TGGCCAGGAT GACCTTTAGT GTTACATGAT GTTCAGCAAA

2b01 TTTTAATTCA AACCTTGATA TGCCTGGACA CTGAAAAGTA AACGCATCAC

2b51 CTCCTATTTT ATACCCTACC TTCTGGTTCC CAATTGGGAG AGCACATAGA

27D1 GGGAAGGAGA CAATATAGAA ACTACGGAGT CCGCTGGTAG TGGGCTGCAT 27S1 GGTGTGACAG AGCCCTTCTC TGTAAAAT66 AAATGACACC ACTAGCCATC

2601 TCAATAGTTA CAAGAATTAA AAGAGATACA GTACCTGAAG TGCTTAGCGC

2651 ATGGTAGCAT TTCATAAATG TTTAGTGTCA ATACTAATGC TCTAATAATG

2101 TAAATTGTTA ATAATTTATT TCCCTAATAT CAGGAAATCC CAGTTGTCTA

2151 TGTGGCCCAG TGCTTAAAAA CGCCTTCTTG CATGAGGGGA TTGAACTATA 3001 CAATGTTTGT TAACTTTGTA TTTGTATTTT TTCCTATAAA ATCTTAAAAT

3051 AAAATTAGGA GATGTGTTCT GATGTAAAAA AAAAAAAAAA AAAAAA

BLAST Results

Entry HS451B21 from database EMBL:

Human DNA sequence *** SEQUENCING IN PROGRESS *** from clone 4S1B21 Score = 11211ι P = 0-Oe+DOι identities = 2267/2343

Medline entries

No Medline entry

Peptide information for frame 2 ORF from 2D bp to 140 bpi peptide length: 307 Category: similarity to unknown protein Classification: no clue 1 MAALAPLPPL PA(QLKSI(QHH LRTA(QEHDKR DPVVAYYCRL YAMiQTGMKID

51 SKTPECRKFL SKLMDiQLEAL KKiQLGDNEAI TiQEIVGCAHL ENYALKMFLY

101 ADNEDRAGRF HKNMIKSFYT ASLLIDVITV FGELTDENVK HRKYARUKAT

151 YIHNCLKNGE TPώAGPVGIE EDNDIEENED AGAASLPTiQP TlQPSSSSTYD

2D1 PSNMPSGNYT GIiQIPPGAHA PANTPAEVPH STGVASNTKQ PTPiQTIPAID 251 PALFNTISiQG DVRLTPEDFA RAώKYCKYAG SALfQYEDVST AV(QNL(QKALK

301 LLTTGRE

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphfbr2_7βelβι frame 2

No Alert BLASTP hits found

Pedant information for DKFZphfbr2_7βelβι frame 2

Report for DKFZphfbr2_7δelδ -2

ELENGTH! 313 EMU! 344b3-15

Epl! S-b4

EHOMOL! PIR:TD471δ hypothetical protein F10M23-1D -

Arabidopsis thaliana 3e-22

EKU! All_Alpha EKU! LOU COMPLEXITY Ib-bl *

SElQ GEFGVEMAALAPLPPLPAiQLKSIlQHHLRTAiQEHDKRDPVVAYYCRLYAMlQTGMKIDSKTP

SEG xxxxxxxxxxxxx PRD ccchhhhhheeecccccchhhhhhhhhhhhhhhhcccceeehhhhhhhhhhccccccccc

SElQ ECRKFLSKLMD(QLEALKK<QLGDNEAIT(2EIVGCAHLENYALKMFLYADNEDRAGRFHKNM

SEG

PRD chhhhhhhhhhhhhhhhhhhcccccccchhhhhhhhhhhhhhhhhhhccccccccccchh

SElQ IKSFYTASLLIDVITVFGELTDENVKHRKYARUKATYIHNCLKNGETPiQAGPVGIEEDND

SEG xxxxxxx

PRD hhhhhhhhhhhhhhhcccccccchhhhhhhhhhhhhhhhhhhhccccccccccccccccc SEA IEENEDAGAASLPTiQPTlQPSSSSTYDPSNMPSGNYTGIlQIPPGAHAPANTPAEVPHSTGV

SEG xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

PRD cccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc

SElQ ASNTIiQPTPlQTIPAIDPALFNTISiQGDVRLTPEDFARAiQKYCKYAGSALiQYEDVSTAVlQN SEG

PRD cccccccccccccccccccccccccccccccchhhhhhhhhhhhhcceeeecchhhhhhh

SElQ LlQKALKLLTTGRE SEG

PRD hhhhhhhhccccc

(No Prosite data available for DKFZphfbr2_7δelδ -2) (No Pfam data available for DKFZphfbr2_7δelβ - 2)

DKFZphfbr2_76i21

group: metabolism

DKFZphfbr2_78i21 encodes a novel 477 amino acid protein with similarity to beta-aspartate methyltransferases - The L-isoaspartyl methyltransferase (Pimt)ι as an examplei is a highly conserved enzyme utilising S-adenosylmethionine (AdoMet) to methylate aspartate residues of proteins damaged by age- related isomerisation and deamidation- The new protein can find application in diagnosis/modulation of protein damage and age-related degenerative processes-

unknown protein weak similarity to beta-aspartate methyltransferase pimT of Mycobacterium leprae perhaps complete eds- Sequenced by MediGenomix

Locus: unknown

Insert length: 1642 bp Poly A stretch at pos- 1811ι polyadenylation signal at pos- 1602

1 CCTTCGCGAA ACACTATGCT AATGGCATGG TGCCGCGGTC CTGTCTTGCT

51 GTGCCTGCGG CAGGGGCTCG GAACCAATTC ATTCCTGCAC GGCCTGGGGC 101 AGGAGCCCTT CGAGGGAGCT CGGTCACTGT GTTGCAGGTC CTCGCCTAGA

ISI GACCTGCGAG ATGGAGAAAG AGAGCACGAG GCGGCACAAA GGAAAGCCCC

2D1 AGGAGCAGAG TCTTGCCCAT CTCTCCCTCT GAGCATCTCG GACATTGGGA

251 CTGGATGTCT TTCGTCACTG GAAAACCTCA GACTGCCGAC GCTGCGGGAA

301 GAGTCATCCC CTCGAGAGCT CGAGGACTCG AGCGGAGACC AGGGCCGGTG 3S1 CGGTCCCACA CACCAGGGAT CCGAGGATCC TTCGATGCTC TCGCAGGCCC

401 AGTCCGCTAC CGAGGTCGAA GAGCGTCACG TCTCCCCTTC TTGTTCAACT

451 TCCAGAGAGA GACCCTTTCA GGCTGGGGAA CTGATTTTAG CTGAGACTGG

501 GGAGGGAGAA ACAAAATTTA AGAAATTATT TAGGTTGAAC AACTTCGGAC

551 TCTTAAATAG TAACTGGGGG GCAGTCCCGT TCGGCAAGAT CGTGGGGAAG bOl TTCCCCGGCC AGATACTGAG GAGTTCCTTC GGTAAGCAGT ACATGCTGAG b51 GAGGCCAGCC TTGGAAGACT ATGTAGTATT GATGAAAAGA GGGACTGCCA

701 TAACATTCCC AAAGGATATT AATATGATTC TCTCAATGAT GGATATCAAC

751 CCAGGTGATA CTGTTTTGGA AGCTGGCTCA GGCTCTGGTG GAATGAGCTT

801 ATTTTTATCC AAA6CAGTTG GATCACAAGG ACGAGTCATA AGTTTTGAGG 851 TACGAAAAGA CCACCATGAT CTGGCTAAGA AGAATTACAA ACACTGGCGT

101 GATTCATGGA AATTAAGTCA TGTAGAAGAG TGGCCAGACA ATGTGGATTT

151 TATTCATAAG GACATTTCAG GAGCAACCGA AGACATAAAA TCTTTAACAT

1D01 TTGACGCAGT AGCTTTGGAT ATGTTAAATC CTCATGTTAC TTTGCCTGTT

1DS1 TTTTACCCAC ATCTTAAGCA TGGTGGTGTA TGTGCTGTAT ATGTAGTAAA 11D1 CATCACACAG GTTATTGAAC TTTTAGATGG AATTCGCACC TGTGAACTTG

1151 CTCTTTCATG TGAAAAGATA AGCGAGGTCA TTGTCAGAGA TTGGTTGGTT

12D1 TGCCTTGCAA AACAGAAAAA TGGAATTTTA GCTCAAAAAG TAGAATCTAA

1251 AATCAACACA GATGTACAAC TAGATTCTCA AGAGAAAATT GGAGTTAAAG 1301 GTGAGCTGTT TCAAGAGGAT GACCATGAAG AATCGCATTC TGATTTTCCA

1351 TATGGATCAT TTCCCTATGT TGCTAGACCA GTACACTGGC AACCTGGTCA

1401 TACAGCTTTT CTTGTCAAGT TGAGGAAGGT CAAACCACAA CTTAACTGAG

1451 TACTCCAGAT GACAGTAACT GACTTGAAGA TGGAAAAATA TCAAAATAGA

1501 ACTTTATATT GAAAATCACT GCTTCCATAG ATTGGCATTT TTAGCTATTA

1551 CTATGACTTA TATAACTTAT ACATATAATT TTGAAAATAA CAACTAAAAG

IbOl ATGTATAACA TAGCAAAACT GCTTAAACAT CCCATTTTGA CACTTGTCTT lb51 GCAGTTAGTT TGACATTTTG TAGTTAATGA TTCCAAATTG GTTTAGTTGG

1701 GCCATCTCAT TCTTCACTTC CTGTAAACCA CTCCATAGAT TTGTCTTTCT

1751 TCAAGAAATT AGTTTTCTTT CCTTTATTTG ATTGATGGTC ATTGACTACT

1801 GAAATAAAAT ATGCATTTTA AGAAAAAAAA AAAAAAAAAA AA

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 1

ORF from lb bp to 144b bpi peptide length: 477 Category: putative protein Classification: no clue

1 MLMAUCRGPV LLCLRiQGLGT NSFLHGLGiQE PFEGARSLCC RSSPRDLRDG 51 EREHEAAiQRK APGAESCPSL PLSISDIGTG CLSSLENLRL PTLREESSPR

101 ELEDSSGDlQG RCGPTHlQGSE DPSMLSiQAlQS ATEVEERHVS PSCSTSRERP

151 FlQAGELILAE TGEGETKFKK LFRLNNFGLL NSNUGAVPFG KIVGKFPGlQI

2D1 LRSSFGKiQYM LRRPALEDYV VLMKRGTAIT FPKDINMILS MMDINPGDTV

251 LEAGSGSGGM SLFLSKAVGS (QGRVISFEVR KDHHDLAKKN YKHURDSUKL 301 SHVEEUPDNV DFIHKDISGA TEDIKSLTFD AVALDMLNPH VTLPVFYPHL

351 KHGGVCAVYV VNITlQVIELL DGIRTCELAL SCEKISEVIV RDULVCLAKlQ

4D1 KNGILAiQKVE SKINTDVlQLD SlQEKIGVKGE LFiQEDDHEES HSDFPYGSFP

451 YVARPVHUlQP GHTAFLVKLR KVKPlQLN

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphfbr2_78i21ι frame 1

No Alert BLASTP hits found Pedant information for DKFZphfbr2_7βi21ι frame 1

Report for DKFZphfbr2_76i21 - 1 ELENGTH! 462

EMU! 53521-2D Epl! b-26

EHOMOL! TREMBL:AFD6660D_2 product: "unknown"i Rhodococcus erythropolis ARC (arc) genei complete cdsi and unknown genes- 2e-

23

EFUNCAT! r general function prediction EM- jannaschiii MJ0134! be-10

EFUNCAT! 05-07 translational control ES- cerevisiaei YJL125c! be-04

EBLOCKS! BL00601E

EBLOCKS! BL01271A EKU! Alpha_Beta

EKU! LOU COMPLEXITY 2-41 *

SElQ PSRNTMLMAUCRGPVLLCLRIQGLGTNSFLHGLGIQEPFEGARSLCCRSSPRDLRDGEREHE SEG

PRD cccceeeeeecccccchhhhhccccceeeeeccccceeeceeeeccccccccccchhhhh

SElQ AAiQRKAPGAESCPSLPLSISDIGTGCLSSLENLRLPTLREESSPRELEDSSGDiQGRCGPT

SEG PRD hhhhhccccccccccceeeeeecccccccceeeccccccccccccccccccccccccccc

SElQ HiQGSEDPSMLSlQAiQSATEVEERHVSPSCSTSRERPFiQAGELILAETGEGETKFKKLFRLN

SEG

PRD cccccccchhhhhhhhhhhhhccccccccccccccccccceeeecccccccceeeeeecc

SElQ NFGLLNSNUGAVPFGKIVGKFPGlQILRSSFGKiQYMLRRPALEDYVVLMKRGTAITFPKDI

SEG

PRD ccccccccccccccceeeccccceeeeecccceeeeccchhhhhhhhhhccceeeecccc SElQ NMILSMMDINPGDTVLEAGSGSGGMSLFLSKAVGSlQGRVISFEVRKDHHDLAKKNYKHUR

SEG xxxxxxxxxxxx

PRD cceeecccccccceeeeeccccchhhhhhhhhccccceeeeeehhhhhhhhhhhhhhhhh

SElQ DSUKLSHVEEUPDNVDFIHKDISGATEDIKSLTFDAVALDMLNPHVTLPVFYPHLKHGGV SEG

PRD hccccccccccccceeeeecccccccccccccccceeeecccccccchhhhhhhcccccc

SElQ CAVY VNITlQVIELLDGIRTCELALSCEKISEVIVRDULVCLAKiQKNGILAlQKVESKINT

SEG PRD eeeeeechhhhhhhhhhhhhhhhhhhhccceeeeeehhhhhhhhhhccceeeeccccccc

SElQ DV(QLDS(QEKIGVKGELF(QEDDHEESHSDFPYGSFPYVARPVHU(3PGHTAFLVKLRKVKPιQ

SEG

PRD cccccccccccccccccccccccccccccccccccccccccccccccceeeeeccccccc

SElQ LN SEG - . PRD cc

⁽No Prosite data available for DKFZphfbr2_7δi21.1) (No Pfam data available for DKFZphfbr2_7βi21 ■ 1) DKFZphmel2_12jl

group: melanoma derived

DKFZphmel2_12jl encodes a novel 105 amino acid proteini which has similarity to integrin I of Saccharomyees cerevisiae.

The novel protein contains a leucin zipper-

No informative BLAST resultsi No predictive prositei pfam or SCOP motife - The new protein can find application in studying the expression profile of melanoma-specific genes-

weak similarity to integrin I (Saccharomyees cerevisiae)

Sequenced by EMBL

Locus: unknown Insert length: 2142 bp

Poly A stretch at pos- 212bι no polyadenylation signal found

1 CGAAAGCTAA AGGCCGGCGC ACGCTGGGCG GTGGTGGTCC CTAAGCCGGG 51 CCGCGGCCGG TGCAATGGAC TCCACTGCCT GCTTGAAGTC CTTGCTCCTG

IDl ACTGTCAGTC AGTACAAAGC CGTGAAGTCA GAGGCGAACG CCACTCAGCT

151 TTTGCGGCAC TTGGAGGTAA TTTCTGGACA GAAACTCACA CGACTATTTA

201 CATCAAATCA GATATTAACA AGTGAATGCT TGAGTTGCCT TGTAGAGCTA

251 CTTGAAGACC CCAACATAAG TGCTTCACTG ATCTTAAGTA TTATCGGTTT 301 GCTGTCTCAA CTAGCAGTAG ACATTGAAAC CAGAGATTGT CTTCAGAATA

351 CATATAATCT GAATAGTGTG CTGGCGGGAG TGGTTTGTCG GAGCAGCCAC

401 ACTGATTCGG TGTTTTTGCA GTGCATTCAA CTTCTACAGA AGTTAACATA

451 TAATGTCAAA ATTTTCTATT CTGGTGCCAA TATAGATGAA TTAATTACGT

SD1 TCCTGATAGA TCACATTCAA TCTTCTGAAG ATGAGTTAAA AATGCCTTGT 551 CTAGGATTAT TGGCAAATCT TTGTCGGCAC AATCTTTCTG TTCAAACGCA bOl CATAAAGACA TTGAGTAATG TGAAATCTTT TTATCGAACT CTTATCACCT b51 TGTTGGCCCA TAGTAGTTTA ACTGTGGTTG TGTTTGCACT TTCAATATTA

7D1 TCCAGTTTGA CATTAAATGA AGAGGTGGGG GAAAAGCTAT TCCATGCTCG

751 AAACATTCAT CAGACTTTTC AACTAATATT TAATATTCTC ATAAACGGTG 601 ATGGCACTCT AACTAGAAAG TATTCAGTTG ACCTACTGAT GGATCTCCTT

651 AAGAATCCTA AAATTGCTGA TTATCTCACC AGATATGAGC ACTTTTCTTC

101 ATGTCTTCAC CAAGTATTAG GTCTTCTTAA TGGAAAGGAT CCTGATTCCT

151 CTTCAAAGGT TTTAGAATTA CTTCTTGCCT TCTGTTCAGT GACTCAGCTG

10D1 CGCCATATGC TCACTCAGAT GATGTTTGAA CAGTCTCCAC CTGGCAGCGC 1051 CACTCTGGGA AGCCATACTA AATGTTTAGA ACCTACTGTG GCTCTACTGC

1101 GCTGGTTAAG CCAACCTTTG GACGGATCAG AAAACTGTTC TGTTTTAGCA

1151 TTGGAGTTGT TCAAGGAAAT ATTTGAGGAT GTCATAGATG CTGCTAACTG

12D1 TTCCTCGGCT GATCGTTTTG TGACCCTTCT GCTGCCTACA ATCCTTGATC

1251 AACTTCAGTT CACAGAACAA AATCTAGATG AGGCTTTAAC AAGAAAAAAT 1301 GTGAAAGGGA TTGCCAAGGC CATTGAAGTT TTGTTAACTC TCTGTGGAGA

1351 TGATACACTA AAAATGCATA TTGCAAAAAT CTTGACAACT GTCAAGTGTA

14D1 CCACTCTTAT AGAACAACAA TTTACATATG GCAAGATTGA CCTGGGATTT

1451 GGAACAAAGG TTGCAGATTC TGAATTATGC AAACTTGCTG CTGATGTAAT 1501 TTTGAAAACT CTTGATTTGA TTAACAAACT TAAACCATTG GTTCCTGGTA

1551 TGGAAGTAAG CTTCTACAAA ATACTTCAGG ACCCACGTTT GATTACTCCT

IbOl TTGGCTTTTG CTTTAACGTC AGATAATAGA GAACAAGTAC AGTCTGGACT lb51 GAGAATATTA TTGGAGGCTG CTCCACTGCC AGATTTTCCT GCTTTAGTAC 17D1 TTGGAGAAAG TATAGCAGCA AACAATGCCT ATAGACAACA GGAAACAGAA

1751 CATATACCCA GAAAAATGCC CTGGCAATCA TCAAATCACA GTTTTCCAAC

IβOl ATCAATAAAG TGTTTAACTC CTCATTTGAA AGATGGTGTT CCTGGATTGA

1651 ATATTGAAGA ATTAATAGAG AAACTTCAGT CTGGAATGGT GGTAAAGGAT

1101 CAGATTTGTG ATGTGAGAAT ATCTGACATA ATGGATGTAT ATGAAATGAA 1151 ACTATCCACA TTAGCTTCCA AAGAAAGCAG GCTACAAGAT CTTTTGGAAA

20D1 CAAAAGCTCT AGCCCTTGCA CAGGCTGATA GACTGATTGC TCAGCATCGC

2051 TGTCAAAGAA CTCAAGCTGA AACAGAGGCA CGGACACTTG CTAGTATGTT

21D1 GAGAGAAGTT GAGAGAAAAA ATGAAGAGCT TAGTGTGTTG CTGAAGGCGC

2151 AGCAAGTTGA ATCAGAAAGA GCGCAGAGTG ATATTGAGCA TCTCTTTCAA 2201 CATAATAGGA AGTTAGAGTC TGTGGCTGAA GAACATGAAA TACTGACAAA

2251 ATCCTACATG GAACTTCTTC AGAGAAATGA AAGTACTGAA AAGAAGAATA

2301 AAGATTTACA GATCACATGT GATTCTCTGA ATAAACAAAT TGAGACAGTG

2351 AAAAAGTTGA ATGAGTCACT CAAGGAACAA AATGAAAAAA GTATTGCCCA

2401 ATTAATAGAG AAAGAAGAAC AGAGAAAAGA AGTACAGAAT CAGCTAGTAG 2451 ACAGAGAACA TAAGCTAGCA AATTTGCATC AAAAAACAAA AGTACAAGAA

25D1 GAAAAGATTA AAACCTTACA AAAGGAAAGG GAAGATAAGG AAGAAACCAT

2551 TGATATCCTT AGAAAAGAAT TAAGCAGAAC AGAACAGATA AGAAAAGAGT

2b01 TGAGCATTAA GGCTTCCTCC CTAGAGGTTC AAAAGGCACA ATTAGAAGGT

2b51 CGTTTGGAAG AGAAAGAGTC CTTGGTGAAA CTTCAGCAAG AGGAATTGAA 27D1 CAAACACTCC CACATGATAG CAATGATCCA CAGTTTAAGT GGTGGAAAAA

2751 TAAATCCAGA AACTGTGAAT CTCAGTATAT AGACATTATG GCATTTTGGA

2601 ATTTGTAATC TCATGATATT TTTGATGTAT TTATCTATTG GAGGGGGGGT

2651 GGGTAGGGGA GTTAATTTGT GACTTCGTAA CAATAAGAAG TTATTATCTA

2101 ATTTAGTAAA GACCCTGATC TGTTGCAAAA AAAAAAAAAA AA

BLAST Results

No BLAST result

Medline entries

1b031111:

Hostetter MKi Tao NJi Gale Ci Herman DJi McClellan Mi Sharp RLi

Kendrick KE-i Antigenic and functional conservation of an integrin

I-domain in

Saccharomyees cerevisiae- Biochem Mol Med 1115 Augi55(2) :122-30

11456454:

Berton Gi Lowell CA-i Integrin signalling in neutrophils and macrophages. Cell Signal 1111 Sepill (1) : b21-35

Peptide information for frame Ξ

ORF from b5 bp to 2771 bpi peptide length: 105 Category: putative protein

Classification: Cellular transport and traffic

Prosite motifs: LEUCINE ZIPPER (331-352)

1 MDSTACLKSL LLTVSiQYKAV KSEANATlQLL RHLEVISGiQK LTRLFTSNiQI

51 LTSECLSCLV ELLEDPNISA SLILSIIGLL SiQLAVDIETR DCLώNTYNLN

101 SVLAGVVCRS SHTDSVFLiQC IiQLLlQKLTYN VKIFYSGANI DELITFLIDH

151 IiQSSEDELKM PCLGLLANLC RHNLSViQTHI KTLSNVKSFY RTLITLLAHS 2D1 SLTVVVFALS ILSSLTLNEE VGEKLFHARN IHiQTFiQLIFN ILINGDGTLT

251 RKYSVDLLMD LLKNPKIADY LTRYEHFSSC LHiQVLGLLNG KDPDSSSKVL

301 ELLLAFCSVT (QLRHMLTiQMM FElQSPPGSAT LGSHTKCLEP TVALLRULSiQ

351 PLDGSENCSV LALELFKEIF EDVIDAANCS SADRFVTLLL PTILD(QL(QFT

401 ElQNLDEALTR KNVKGIAKAI EVLLTLCGDD TLKMHIAKIL TTVKCTTLIE 451 (QiQFTYGKIDL GFGTKVADSE LCKLAADVIL KTLDLINKLK PLVPGMEVSF

5D1 YKILiQDPRLI TPLAFALTSD NREIQVIQSGLR ILLEAAPLPD FPALVLGESI

551 AANNAYRlQlQE TEHIPRKMPU (QSSNHSFPTS IKCLTPHLKD GVPGLNIEEL bOl IEKLlQSGMVV KDiQICDVRIS DIMDVYEMKL STLASKESRL (QDLLETKALA b51 LAiQADRLIAlQ HRCIQRTIQAET EARTLASMLR EVERKNEELS VLLKAIQIQVES 7D1 ERAiQSDIEHL FlQHNRKLESV AEEHEILTKS YMELLiQRNES TEKKNKDLlQI

751 TCDSLNKiQIE TVKKLNESLK EiQNEKSIAlQL IEKEElQRKEV (QNiQLVDREHK

801 LANLHύKTKV (QEEKIKTLώK EREDKEETID ILRKELSRTE (QIRKELSIKA

651 SSLEVlQKAlQL EGRLEEKESL VKLiQlQEELNK HSHMIAMIHS LSGGKINPET IDl VNLSI

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphmel2_12 li frame 2

TREMBL :SCINTANA_1 Saccharomyees cerevisiae integrin analogue genei complete cds-i N = li Score = 21bι P = l-3e-13

>TREMBL :SCINTANA_1 Saccharomyees cerevisiae integrin analogue genei complete eds-

Length = liOlS

HSPs :

Score = 21b ( 32 - 4 bi ts ) ι Expect = l - 3e-13 ι P = l - 3e-13 Ident i t ies = 6D/302 ( 2b* ) ι Posit i ves = 155/3D2 ( 51* )

(Query : 517 IEELIEKLiQSGMVVKDlQICDVRISDIM — DVYEMKLSTLASKESRLiQDLLETKALALAiQ b53

I L EKL++ D+ + +IS++ + E +L+ + ++ L+

LET AL +

Sb jct : 275 ISLLKEKLETATTANDENVN- KISELTKTREELEAELAAYKNLKNELETKLETSEKALKE 333

(Query : b54 A---DRLIA(QHRCtQRT<QAETEAR TLASMLREVERKNEELSVLLKA-

(QiQVESERAtQ 704 + + + + IQ + TE + +L + L +E +++E + L+ LK

+ Q+ ++ iQ Sbjct : 334

VKENEEHLKEEKIlQLEKEATETKiQlQLNSLRANLESLEKEHEDLAAiQLKKYEElQIANKERiQ 313

(Query : 7D5 SDIEHLFlQHNRKLESVAEEHEILTKSYMEL LlQRNESTEKKNKDLlQIT-

CDSLNKiQIE 7b0

+ E + <Q N ++ S +E + E + K EL ++ +ST ++ +L+ + D + LN <QI + Sb jct : 314 YN-

EEISiQLNDEITSTlQlQENESIKKKNDELEGEVKAMKSTSEElQSNLKKSEIDALNLlQIK 452

(Query : 7bl

TVKKLNESLKE(QNEKSIA(QLIEKEE(QRKEV(QN(QLVDREHKLANLH(QKTKV(QEEKIKT 817 +KK NE+ + +SI + + + KE + IQ + + +E +++ L K K

E + K

Sb j ct : 453 ELKKKNETNEASLLESIKSIESETVKIKELlQDECNFKEKEVSELEDKLKASEDKNSKYLE 512 (Query : 616 LiQKEREDKEETIDI LRKELSRTElQIRKELSIKASSLE-

V(QKA(QLEGRLEEKESLVK 672

LiQKE E +E +D L+ +L + + K S L + + K E R

+ E L K

Sb j ct : 513 LiQKESEKIKEELDAKTTELKIlQLEKVTNLSKAKEKSESELSRLKKTSSEERKNAEEfQLEK 572

(Query : 673 L(Q(QE 67b L+ E

Sb j ct : 573 LKNE 57b

Score = 18b (27-1 bits)ι Expect = 2-De-lOι P = 2-Oe-lO Identities = 62/301 (27*)ι Positives = 155/301 (51*)

(Query: 516 EELIEKLiQSGMVVKDlQICDVRISDIMDVYEMKLSTLASKESR LlQD- LLETKALALAώ b53

+ELI +L(Q+ +K + D S++ V L K++ LiQD +L

K

Sbjct: bll DELI-

RLiQNENELKAKEIDNTRSELEKVSLSNDELLEEKlQNTIKSLiQDEILSYKDKITRN bbl

(Query: b54

ADRLIA(QHRC(QRT(QAETEARTLASMLREVERKNEELSVLLKA(Q(QVESERAιQSDIEHLF 3H 713 + + L + + R + E+ L LR + ++ LK + ES +

++++E + Sb j ct : b70 DEKLLSIERDSKRDLES

LKElQLRAAlQESKAKVEEGLKKLEEESSKEKAELEKSKEM 725

(Query : 714 NRKLESVAEEHEILTKSYMELLiQRN-ESTEKKNKDLlQITCDSL- NKiQIETVKKLNESLKE 771 +KLES E +E KS ME ++++ E E+ K + +L +++ + +

++NES K+ Sb j ct : 72b MKKLESTIESNETELKSSMETIRKSDEKLEiQSKKSAEEDIKNLiQHEKSDLISRINESEKD 785 (Query : 772 (QNE-KSIA<QLIEKEE<QRKE-V(QN<QLVDREHKL- ANLHlQKTKViQEEKIKTLiQKEREDKEET 826

E KS ++ K E V+ +L + + K+ N + T V + K++

+++E +DK+ Sbjct: 78b IEELKSKLRIEAKSSSELETVKlQELNNAiQEKIRVNAEENT- VLKSKLEDIERELKDKiQAE 844

(Query: 821 IDILR — KEL — SRTEiQIRKEL SIKASSLEVlQKAiQLE-

GRLEEKESLVKLiQ 674

I + KEL SR + + + +EL S + S EV + K <Q + E

+L+EK L++ + Sbjct: 645 IKSNIQEEKELLTSRLKELEIQELDSTIQIQKAIQKSEEESRAEVRKFIQVEKSIQLDEKAMLLETK 104

(Query: 675 (QEEL-NK 680

+ L NK Sbjct: IDS YNDLVNK 111 Score = 173 (2b.0 bits)ι Expect = 5-7e-D1ι P = 5-7e-01 Identities = 77/267 (2b*)ι Positives = 14b/267 (50*)

(Query: bOl IEKLiQSGMVVKDiQICDVRISDIMDVYEMKLSTLASKES — RL(QDLLETKALALA(QADRLI b5β + + K + + K + + + IS + D E+ ST ES + D LE +

A +

Sbjct: 38D LKKYEE(QIANKER(QYNEEIS(QLND~EIT- ST(Q(QENESIKKKNDELEGEVKAMKST 432 (Query: b51 A(QHRC(QRT(QAETEARTLASMLREVERKNE--

ELSVLLKAιQιQVESERAιQSDIEHLF(QH-NR 715

++ + ++E +A L ++E+++KNE E S+L + +ESE + 1+

L N

Sbjct: 433 SEE<QSNLKKSEIDALNL--(QIKELKKKNETNEASLLESIKSIESETVK-- IKELiQDECNF 468

(Query: 71b KLESVAEEHEILTKSY — - MELLtQRNESTEKKNKDLiQITCDSLNKiQIETVKKLNESLKElQ 772

K + V + E + L S + L+ + +EK + + L L (Q + E V L+++ KE+

Sbjct: 481 KEKEVSELEDKLKASEDKNSKYLEL(QKESEKIKEELDAKTTELKI<QLEKVTNLSKA-KEK 547

(Query: 773 NEKSIA(QLIE-KEE(QRKEV(QN(QL--VDREHKLAN-- LHlQKTKViQEEKIKTLlQKEREDKEE 827

+ E + + + L + E + RK + (QL + E ++ N ++ K+ E T +

+ E +K

Sbjct: 548

SESELSRLKKTSSEERKNAEE(QLEKLKNEI(^QIKN(QAFEKERKLLNEGSSTIT(QEYSEKIN b07

(Query: 828 TI-

DILRKELSRTE(QIRKELSIKASSLEV(QKA(QLEGRLEEKESLVKL(Q(QEELNKHSHMI 665

T+ D L + + E KE+ S LE + LEEK + + +K (Q + E +

+ I Sbjct: b08

TLEDELIRLiQNENELKAKEIDNTRSELEKVSLSNDELLEEKlQNTIKSLi^QDEILSYKDKI bbb

Score = 171 (25-7 bits)ι Expect = 1-3e-01ι P = 1-3e-D1 Identities = 7b/311 (24*)ι Positives = 152/311 (48*)

(Query: 51b NIEELIEKL(QSGMVVKD(Q

ICDVRISDIMDVYEMKLSTLASKESRLiQDLLETKA b46 N EE +EKL++ + +K+Q + + S I Y K++TL +

RL(Q+ E KA Sbjct: Sb5

NAEE(QLEKLKNEI(QIKN(^QAFEKERKLLNEGSSTIT(QEYSEKINTLEDELIRL(QNENELKA b24

(Query: b41 LALAOADRLIAiQHRCtQRTiQA-ETEARTLASMLREVERKNEELSVL- LKAlQiQVESERAiQSD 70b

+ + + + E + T+ S+ E+ ++++ K

+E + ++ D Sbjct: b25

KEIDNTRSELEKVSLSNDELLEEKiQNTIKSL(QDEILSYKDKITRNDEKLLSIERD-SKRD b83

(Query: 7D7 IEHLFIQHNRKL-ESVAEEHEILTKSYMELLIQRNESTEKKN---

KDLiQITCDS LNKlQ 758 +E L + R ES A+ E L K E + EK K L+ T +S

L

Sbjct: b84 LESLKElQLRAAiQESKAKVEEGLKKLEEESSKEKAELEKSKEMMKKLESTIESNETELKSS 743 (Query: 751 IETVKKLNESLKEIQNEKSIAIQLIEK-

EEIQRKEVIQNIQLVDREHKLANLHIQKTKVIQEE K 614

+ ET + + K +E L E(Q + + KS + 1+ + ++ ++ + + + + E + L K + + + + +

Sbjct: 744 METIRKSDEKL- ElQSKKSAEEDIKNLiQHEKSDLISRINESEKDIEELKSKLRIEAKSSSE 802

(Query: 615 IKTLlQKEREDKEETIDILRKE LSRTElQIRKELSIKASSL---

EVIQKAIQLEGRLEEK 6b7

++T+++E + +E I + +E S+ E I +EL K + + + +K L RL+E

Sbjct: 603 LETVKIQELNNAIQEKIRVNAEENTVLKSKLEDIERELKDKIQAEIKSNIQEEKELLTSRLKEL 8b2

(Query: 6b8 ESLVKLiQlQEELNK 880 E + (Q + + K

Sbjct: 6b3 E(QELDST(Q(QKA(QK 875

Score = lb5 (24-8 bits)ι Expect = 4-le-08ι P = 4-le-Dβ Identities = b5/28b (22*)ι Positives = 141/28b (52*)

(Query: 515 LNIEELIEKLlQSGMVVKDlQICDVR-ISDIMDVYEMKLSTLASKESRL- (QDLLETKALALA b52

+N ++ + L+ + K I +++ I++ ++ +++ + L+ ++ + ++L+E K+ Sbjct: 114 VNHlQKETKSLKEDIAAK--

ITEIKAINENLEKMKI(QCNNLSKEKEHISKELVEYKS-RF(Q 170

(Query: b53 (QADRLIA(QHRClQRT(QAETEARTLASMLREVERKNEELSVLLKA(Q(QVESE

-RAiQSDIE 7D8 D L+A+ T+ + ++LA+ ++++ +NE L ++ + ES

(Q+ 1 +

Sbjct: 171 SHDNLVAK LTE

KLKSLANNYKDMlQAENESLIKAVEESKNESSIiQLSNLiQNKID 223 (Query: 7D1 HLF(QH--NRKLE—

SVAEEHEILTKSYMELL(QRNESTEKKNKDL(QITCDSLNK(QIETVKK 7b4

+ Q N ++E S+ + E L K+ +L (Q E K+ + D Ql +K+ Sbjct: 224 SMSIQEKENFIQIERGSIEKNIEIQLKKTISDLEIQTKEEIISKSDSSK

DEYESiQISLLKE 26D

(Query: 7b5 LNESLKE(QNEKSIA(QLIEKEE(QRKEV(QN(QLVDREHKLANLH(QKTKV(QEEKIKTLι3KERED 824

E+ N++++ ++ E + R+E++ +L ++ L K + E+ +K

+ + + E

Sbict: Pfll

KLETATTANDENVNKISELTKTREELEAELAAYKNLKNELETKLETSEKALKEVKENEEH 340

(Query: 825 - KEETIDILRKELSRTE(QIRKELSIKASSLEV(QKA(QLEGRLEEKESLVKL<Q(QEELNK 880

KEE I L KE + T + iQ L SLE + L +L + + E + + +

+ N + Sbjct: 341 LKEEKIiQ-

LEKEATETK(Q(QLNSLRANLESLEKEHEDLAA(QLKKYEEiQIANKER(QYNE 31b

Score = 158 (23-7 bits)ι Expect = l-1e-07ι P = 1. le-07 Identities = 74/2bδ (27*)ι Positives = 13b/2b8 (50*)

(Query: 516 EELIEKL(QSGMVVKD(QICDVRISDIMDVYEM--KL- STLASKESRL(QDLLET--KALALA b52

+E -K++ G+ ++ +++ EM KL ST+ S E+ L+ +ET

K + Sbjct: b15

(QESKAKVEEGLKKLEEESSKEKAELEKSKEMMKKLESTIESNETELKSSMETIRKSDEKL 754

(Query: b53

(QADRLIA(QHRC(QRT(QAETEARTLASMLREVERKNEELSVLLKAιQ(QVESERA(QSDIEHLF(Q 712 + + A+ + IQ E L S + E E+ EEL L+ + S

+ + + L

Sbjct: 755 EiQSKKSAEEDIKNLώHEKS — DLISRINESEKDIEELKSKLRIEAKSSSELETVKlQELNN 612 (Query: 713 HNRKLESVAEEHEILTKSYMELL(QRNESTEKKNKDL(QITCDSLNKtQIET--

VKKLNESLK 77D

K+ AEE+ +L KS +E ++R E K+K +1 + K++ T

+K+L + L

Sbjct: δl3 AiQEKIRVNAEENTVL-KSKLEDIER ELKDK3AEIKSN(QEEKELLTSRLKELE(QELD 6b7

(Query: 771 E(QNEKSIA(QLIEKEE(QRKEV(QNιQLVDR~- EHKLANLHlQKTKViQEEKIKTLiQKEREDKEE δ27

+ K AiQ E EE R EV+ V + + + K L K K + +++ + ++

Sbjct: δbδ ST(Q(QK--A(QKSE- EESRAEVRKFiQVEKSiQLDEKAMLLETKYNDLVNKElQAUKRDEDTVKK 124

(Query: 626 TIDILRKELSRTEιQIRKEL-SIKASSLEV(QKA(QLEGRLE 8b5 T D R+E+ E++ KEL ++KA + ++++A E R E

Sbjct: 125 TTDSiQRiQEI- — EKLAKELDNLKAENSKLKEAN-EDRSE 151

Score = 155 (23-3 bits)ι Expect = 3-1e-07ι P = 3-1e-07 Identities = 73/2b1 (27*)ι Positives = 133/2b1 (41*)

(^Query: b24 DVYEMKLSTLASKESRL^(QD-LLETKALALA^(QADRLIA^(QHRC^(QRT(QAET- — EARTLASML b71 ++ E K +T+ S LflD +L K ++L++ R + E+ +

R

Sbjct: b43 ELLEEKlQNTIKS

LlQDEILSYKDKITRNDEKLLSIERDSKRDLESLKEiQLRAAiQESK blδ

(Query: bβO REVE — RKNEELSVLLKAlQiQVESERAiQSDIEHLFiQHNRKLESVAEEHEILTKSYMELLlQ 73b

+VE +K EE S KA+ +S+ +E + N + E +

KS +L Q Sbjct: bll AKVEEGLKKLEEESSKEKAELEKSKEMMKKLESTIESNET-- ELKSSMETIRKSDEKLEiQ 75b

(Query: 737 RNESTEKKNKDLiQITCDSLNKiQIETVKKLNESLKElQ--- NEKSIAiQLIEKEEiQRKEVlQNlQ 713 +S E+ K + L(Q L +1 +K E LK + KS + + L

+ + + Q +

Sbjct: 757 SKKSAEEDIKNLlQHEKSDLISRINESEKDIEELKSKLRIEAKSSSELETVKlQELNNAlQEK 61b (Query: 714 L-VDREH

KLANLHlQKTKVlQEEKIKTLiQKEREDKEETIDILRKELSRTEiQIRKEL 64b

+ V+ E KL ++ ++ K ++ +IK+ (Q + E+E + L +EL

T + (Q + +

Sbjct: 817 IRVNAEENTVLKSKLEDIERELKDK(QAEIKSN(QEEKELLTSRLKELE(QELDST<Q(Q-KA<QK 875

(Query: 847 SIKASSLEV(QKA(QLE-GRLEEKESLVKL<Q(QEEL-NK 860

S + S EV + K (Q + E +L + EK L + + + +L NK Sbjct: 87b SEEESRAEVRKFlQVEKSlQLDEKAMLLETKYNDLVNK 111

Score = 14b (21-1 bits)ι Expect = 3-Se-Dbι P = 3.5e-0b Identities = 73/311 (23*)ι Positives = 152/311 (46*)

(Query: 520 DNREώViQSGLRIL LEAAPLPDFPALV-- LGESIAANNAYRIQIQETEHIPRK-MPUIQ 571

+++ +V+ GL+ L E A L ++ L +1 +N + E I

Sbjct: bib ESKAKVEEGLKKLEEESSKEKAELEKSKEMMKKLESTIESNETELKSSMETIRKSDEKLE 755

(Query: 572 SSNHSFPTSIKCLTPHLKDGVPGLNIEEL- IEKLlQSGMVVKDlQICDVRISDIMDVYEMKL b30

S S IK L D + +N E IE+L+S + + + + S

+ + + +L Sbjct: 75b (QSKKSAEEDIKNLlQHEKSDLISRINESEKDIEELKSKLRI

EAKSSSELETVKlQEL 61D

(Query: b31 STLASK— -

ESRLIQDLLETKALALAIQADRLIAIQHRCIQRTIQAETEARTLASMLREVERKNE b87 + K + +L + + K L +R + + + + E L S

L+E+E++ +

Sbjct: 811 NNAlQEKIRVNAEENTVLKSK--- LEDIERELKDK(3AEIKSN(QEEKELLTSRLKELE(QELD 6b7 (Query: bδ8

ELSVLLKAiQlQVESERAlQSDIEHLFi^QHNRKLESVAEEHEILTKSYMELLi^QRNESTEKKNKD 747

S KAtQ+ E E + + + + + F<Q + + E+ +L Y +L+ +

+ + + + Sbjct: 6bβ — STIQIQKAIQKSEEE-SRAEVRK-FIQVEKS — ^(QLDEKAMLLETKYNDLVNKEl^QAUKRDEDT 121

(Query: 748 L(QITCDSLNK(QIETVKKLNESLKE(QNEKSIA(QLIEKEE(QRKEV(QN(QLV--- DREHKLANL 804

++ T DS ++IE + K ++LK +N K L E E R E+ + ++ D

+ K N

Sbjct: 122 VKKTTDSIQRIQEIEKLAKELDNLKAENSK

LKEANEDRSEIDDLMLLVTDLDEK— NA 175

(Query: 605 H(QKTKV(QEEKIKTL(QKEREDKEETID 830

++K+++ ++ E +D+EE D

Sbjct: 17b KYRSKLKDLGVEISSDEEDDEEEEDD 1001 Score = 14b (21-1 bits)ι Expect = 4-be-Dbι P = 4-be-Ob Identities = 82/313 (2b*)ι Positives = 145/313 (4b*)

(Query: 518

EELIEKLlQSGMVVKDiQICDVRISDIMDVYEMKLSTLASKESRLiQDLLETKALALAlQADRL b57 EEL +L + +K + + + + + E+K + KE + + <Q LE +A

Sbjct: 304 EELEAELAAYKNLKNELETKLETSEKALKEVKENEEHLKEEKIlQ — LEKEATETKlQiQ 358 (Query: b58 IA(QHRC(QRT(QAETEARTLASMLREVERK NEELSVL

LKA(Q(QVESERA(QSD 70b

+ R E E LA+ L + + E + NEE+S L + + (Q

E + E +

Sbjct: 351 LNSLRANLESLEKEHEDLAA(QLKKYEE(QIANKER(QYNEEIS(QLNDEITST(Q(QENESIKKK 416

(Query: 707 IEHLFiQHNRKLESVAEEHEILTKSYMELLlQRN- ESTEKKNKDL(QITCDSLNK(QIET-VKK 7b4

+ L + ++S +EE L KS ++ L + +KKN+ + + K IE+ K

Sbjct: 411 NDELEGEVKAMKSTSEE(2SNLKKSEIDALNL(QIKELKKKNETNEASLLESIKSIESETVK 476

(Query: 7b5 LNESLKE(QN--EKSIA(QLIEK---EE(QRKEV<QN(QLVDREHKLAN-LH(QKT-- -KVlQEEKI 615

+ E E N EK +++L +K E + +L K+ L KT

K + (Q EK +

Sbjct: 471

IKEL(QDECNFKEKEVSELEDKLKASEDKNSKYLEL(QKESEKIKEELDAKTTELKIiQLEKV 536

(Query: δlb

KTLlQKEREDKEETIDILRKELSRTEiQIRKELSIKASSLEViQKAlQLEGRLEEKESLVKLiQlQ δ75

L K +E E ELSR + + K S + + E iQ +L+ ++ K

+ + + Sbjct: 531 TNLSKAKEKSES ELSR—-

LKKTSSEERKNAEElQLEKLKNEIlQIKNiQAFEKER 5βδ

(Query: 67b EELNKHSHMIAMIHSLSGGKINPETVNL 103 + LN+ S I +S + E + L Sbjct: 561 KLLNEGSSTITlQEYSEKINTLEDELIRL bib

Score = 145 (21-8 bits)ι Expect = 5-le-Obι P = 5-le-Ob Identities = 51/24b (23*)ι Positives = 115/24b (4b*) (Query: t,34 ASKESRLiQ- DLLETKALALAIQADRLIAIQHRCIQRTIQAETEARTLASMLREVERKNEELSVL b12

+ ES +(Q L+ K + + + (Q + +R E L + + + E + EE + +

Sbjct: 2D7 SKNESSIIQLSNLIQNKIDSMSIQEKE

NF(QIERGSIEKNIE(QLKKTISDLE(QTKEE--II 2bl

(Query: b13 LKA(Q(QVESERA(QSDIEHLF(QHNRKLESVAEEHEI LTKSYMELLlQRNESTEKKNKD 747

K+ + E +S I L + + + A + + LTK+ EL

+ + +

Sbjct: 2b2 SKSDSSKDEY-ESiQIS-

LLKEKLETATTANDENVNKISELTKTREELEAELAAYKNLKNE 311

(Query: 746

L(QITCDSLNK(QIETVKKLNESLKE(^QNEKSIA(QLIEKEE(QRKEV(QN<QLVDREHKLANLH(QK 807 L+ ++ K ++ VK+ E LKE+ + + E ++(Q ++ L E

+ +L + Sbjct: 320

LETKLETSEKALKEVKENEEHLKEEKI(QLEKEATETK(Q(QLNSLRANLESLEKEHEDLAA(Q 371

(Query: 608

TKV(QEEKIKTLιQKEREDKEETIDILRKELSRTE(QIRKELSIKASSLEV(QKA(QLEGRLEEK Sb7 K EE + I KER+ EE I L E + + T + (Q + + K LE +

+ + EE +

Sbjct: 380 LKKYEEiQIAN — KERiQYNEE- ISiQLNDEITSTiQlQENESIKKKNDELEGEVKAMKSTSEEiQ 43b (Query: 8b6 ESLVKLiQiQEELN 871

+L K + + LN Sbjct: 437 SNLKKSEIDALN 448

Score = 137 (20. b bits)ι Expect = 4.2e-05ι P = 4-2e-DS Identities = 61/312 (25*)ι Positives = 140/312 (44*)

(Query: 516 EELIEKLiQSGMVVKDiQICDVRISDIMDVYEMKLSTLASK-ESRLlQDLLET- KALALAiQAD b55

+EL ++++ ++ +++ S+I D +++ L K E+ LLE+ K + +

Sbjct". 420 DELEGEVKAMKSTSEElQSNLKKSEI- DALNLlQIKELKKKNETNEASLLESIKSIESETVK 478

(Query: b5b RLIA(QHRC(QRT(QAETEARTLASMLREVERKNEELSVLLKA(Q(QVESERA(QSDIEHLF(QHNR 715

<Q C E E L L+ E KN + L K + E +

L

Sbjct: 471 IKELlQDECNFK--

EKEVSELEDKLKASEDKNSKYLELlQKESEKIKEELDAKTTELKIiQLE 53b

(Query: 71b

KLESVAEEHEILTKSYMELL(QRNESTEKKNKDL(2ITCDSLNK(QIETVKKLNESLKE(QNEK 775 K+ + + + + E + + S + L + + S E + KN + (Q+ (QI+ + +

K NE Sbjct: 537 KVTNLSKAKE-KSESELSRLKKTSSEERKNAEEl^QLEKLKNEIiQIKN-

(QAFEKERKLLNEG 514 (Query: 77b SIA<QLIEKEEιQRKEV<QNιQLV--DREHKL-ANLHι3KTKV(QEEKIKTL(QKER- EDKEETIDI 631

S E E+ ++++L+ E++L A T+ + EK+ E

E+K+ TI Sbjct: 515

SSTITiQEYSEKINTLEDELIRLiQNENELKAKEIDNTRSELEKVSLSNDELLEEKlQNTIKS bS4

(Query: 632 LRKE-LSRTE(QI RKELSIKASS LEVώKAiQLEGRLEEK

ESLVKL(Q(QE 87b L+ E LS + + I K LSI+ S LE K (QL E K E L

KL + + E

Sbjct: b55 L(QDEILSYKDKITRNDEKLLSIERDSKRDLESLKE(QLRAA(QESKAKVEEGLKKLEEESSK 714 (Query: 877 ELNKHSHMIAMIHS 81D

EL K M+ + S Sbjct: 715 EKAELEKSKEMMKKLES 731

Score = 126 (11-2 bits)ι Expect = 3-1e-04ι P = 3-1e-04 Identities = 60/35b (22*)ι Positives = 148/35b (41*)

(Query: 54b LGESIAANNAYR(Q(QETEHIPRKMPU(QSSNHSFPTSIKCLTPHL

KDGVPGLN-I 517

L E + ++ E+ + ++S+ H SIK L L K G+N +

Sbjct: 25

LDEMT(QLRDVLETKDKEN(QTALLEYKSTIHK(QEDSIKTLEKELETILS(QKKKAEDGINKM 84

(Query: 518 EELIEKLlQSGMVVKDiQICD-- VRISDIMDVYEMKLSTLASKESRLiQDLLETKALALAiQAD b55

+ + L M ++ C + D +V K T + KE + E

KA+ +

Sbjct: 65 GKDLFALSREM(QAVEENCKNL(QKEKDKSNVNH(QK-

ETKSLKEDIAAKITEIKAIN-ENLE 142

(Query: b5b

RLIA(QHRC(QRT(QAETEARTLASMLREVERKNEELSVLLKA<Q(QVESERA(QSDIEHLF(QHNR 715 + + (Q C E E ++ L E + + + L+ + + + +

+ + N Sbjct: 143 KMKI(Q--CNNLSKEKEH--

ISKELVEYKSRFIQSHDNLVAKLTEKLKSLANNYKDMIQAENE 116

(Query: 71b KLESVAEEHEILTKSYMELLiQRN- ESTEKKNKDLlQITCDSLNKiQIETVKKLNESLKEiQNE 774 L EE + + + L(Q +S ++ ++ iQI S+ K IE +KK

L + + E

Sbjct: 111 SLIKAVEESKNESSI(QLSNL(QNKIDSMS<QEKENFιQIERGSIEKNIE(QLKKTISDLE(QTKE 256 (Query: 775

KSIA(QLIEKEEιQRKEV(QN(QLVDREHKLANLH(QKTKV<QEEKIKTL(QKEREDKEETI 621

+ I + + + + E + + IQ+ + KL Kl L K RE+ E

+

Sbjct: 251 EIISK — - SDSSKDEYESiQISLLKEKLETATTANDENVNKISELTKTREELEAELAAYKN 315

(Query: 830 --DILRKELSRTEIQIRKELSIKASSLEVIQKAIQLEGRLEE-KESLVKLIQIQ — EELNK-HSH 683 + L +L +E+ KE+ L+ +K (QLE E K+ L L+ E L K H

Sbjct: 31b

LKNELETKLETSEKALKEVKENEEHLKEEKIiQLEKEATETKiQiQLNSLRANLESLEKEHED 375

(Query: 664 MIAMI 868

+ A + Sbjct: 37b LAAiQL 380 Score = 117 (17-b bits)ι Expect = 3.8e-03ι P = 3-8e-D3 Identities = 50/240 (20*)ι Positives = 111/24D (4b*)

(Query: b34

ASKESRL(QDLLETKALALA(QADRLIA(QHRC(QRT(QAETEARTLASMLREVERKNEELSVLL b13 A E L+ L E + A+ ++ + + E+ L S + + +

+E+L

Sbjct: bll AKVEEGLKKLEEESSKEKAELEKSKEMMKKLESTIESNETELKSSMETIRKSDEKLEiQSK 758 (Query: b14 KA(Q(QVESERA(Q---SD-

IEHLFlQHNRKLESVAEEHEILTKSYMELLlQRNESTEKKNKDLlQ 741

K+ + + + Q SD I + + + +E + + I KS EL +

+ + +

Sbjct: 751 KSAEEDIKNLlQHEKSDLISRINESEKDIEELKSKLRIEAKSSSELETVKiQELNNAiQEKIR 618

(Query: 750

ITCDSLNK(QIETVKKLNESLKE(QNEKSIA(QLIEKEE(QRKEV(QN(QLVDREHKLANLH(QKTK 801 + + N +++ KL + +E +K A++ +E+++ + ++L + E +L + <QK +

Sbjct: 611 VNAEE-NTVLKS--KLEDIERELKDK(Q- AEIKSN(QEEKELLTSRLKELE(QELDST(Q<QKA(Q 874

(Query: 810 ViQEEK IKTL(QKEREDKEETIDILRKELSRTE(QIRKELSIKASSLEV3KA(QLEGRLE 8b5

EE+ ++ Q E+ +E +L E + + KE + K V+K

+ + +

Sbjct: 875 KSEEESRAEVRKFiQVEKSiQLDEKAMLL-- ETKYNDLVNKEIQAUKRDEDTVKKTT-DSIQRIQ 131

(Query: 8bb EKESLVK 872

E E L K Sbjct: 132 EIEKLAK 136 Score = 101 (lb-4 bits)ι Expect = 2-be-D2ι P = 2-5e-02 Identities = b4/264 (22*)ι Positives = 135/284 (47*)

(Query: 518

EELIEKL(^QSGMVVKD(^QICDVRISDIMDVYEMKLSTLASKESRL(QDLLETKALALA Qk bS4 +E + + + KL + S + + + 1 E + S E + + + L K +

+ + + +

Sbjct: 723 KEMMKKLESTIESNETELKSSMETIRKSDEKLEl^QSKKSAEEDIKNLiQHEKSDLISRINES 782 (Query: b55 DRLIAIQHRCIQ-

RT(QAETEARTLASMLREVERKNEELSVLLKA^(Qι^QVESERA(QSDIEH-LFιQ 712

++ I + + + R +A++ + L ++ +E+ E++ V + V + +

DIE L Sbjct: 783 EKDIEELKSKLRIEAKSSSE-LETVKiQELNNAiQEKIRVNAEENTVLKSKLE- DIERELKD 640

(Query: 713 HNRKLESVAEEHEILTKSYMELL(QRNESTEKK-NKDL(QITCDSLNK- (QIETVKKLNES-- 7bβ

+++S EE E+LT EL Q +ST++K K + + + K (Q+E +L+E

Sbjct: 641 KiQAEIKSNiQEEKELLTSRLKELEiQELDSTlQlQKAlQKSEEESRAEVRKFiQVEK- SiQLDEKAM 611

(Query: 7b1 LKElQNEKSIA- — (QLIEKEEiQ-- RKEV(QN(QLVDREHKLANLH(QKTKV(QEEKIKTLiQKERE 623

L E + (Q + + + E +K +<Q + E KLA K +

K+K ++R Sbjct: 1DD LLETKYNDLVNKEIQAUKRDEDTVKKTTDSIQRIQEIE- KLAKELDNLKAENSKLKEANEDRS 158

(Query: 624 DKEETI DILRKELSRTEiQIRKELSIKASSLEVlQKAlQLEGRLEEKE

8b8 + ++ + D+ K ++ K+L ++ SS E + E E+ E

Sbjct: 151 EIDDLMLLVTDLDEKNAKYRSKL-KDLGVEISSDEEDDEEEEDDEEDDE 100b

Score = lb (14-4 bits)ι Expect = 1-le+ODι P = b-be-01 Identities = 40/21D (11*)ι Positives = 101/210 (46*)

(Query: fc,81 EVERKN-- EELSVLLKAiQlQVESERAlQSDIEHLFlQHNRKLESVAEEHEILTKSYMELLlQRN 738

E E KN + L + + + V + + + L ++ + + + L K +L +

Sbjct: IS

ETELKNVRDSLDEMTlQLRDVLETKDKENiQTALLEYKSTIHKiQEDSIKTLEKELETILSiQK 74

(Query: 731 ESTE KKNKDLιQITCDSLNK(QIETVKKLNESLKE(QNEKSIA(QLIEKEE(QRKEV(QN(QL 714

+ E K KDL +L+++++ V++ ++L+++ +KS + +++

K ++ +

Sbjct: 75 KKAEDGINKMGKDLF ALSREMiQAVEENCKNLlQKEKDKSN

VNHiQKETKSLKEDI 127

(Query: 715 VDREHKLANLH(QKTKV(QEEKIKTL(QKERED-

KEETIDILRKELSRTEfQIRKELSIKASSL 853

+ ++ +++ + + + L KE+E +E ++ + S + K

L+ K SL Sbjct: 128 AAKITEIKAINENLEKMKIi^QCNNLSKEKEHISKELVEYKSRFOSHDNLVAK-

LTEKLKSL 16b

(Query: 654 EVlQKAiQLEGRLEEKESLVKLlQiQEELNKHSHMIAMIHS 610

++ E ESL+K +E N+ S ++ + + Sbjct: 167 ANNYKDMiQA ENESLIKAVEESKNESSIIQLSNLIQN 22D

Score = 52 (7-6 bits)ι Expect = 2-Oe-lDι P = 2-Oe-lD Identities = 31/lb7 (23*⁾ι Positives = 74/lb7 (44*⁾ (^Query: 11 LNSVLAGVVCRSSHTDSVFLι3CI(QLL(QKLTYNVKIFYSGANIDEL-

ITFLIDHIiQSSEDE 157

LN + + ++ ++ L+ 1+ ++ T +K N E ++ L D

+++SED+ Sbjct : 447 LNL(QIKELKKKNETNEASLLESIKSIESETVKIKEL(QDECNFKEKEVSELEDKLKASEDK 50b

(Query : 156 - LKMPCLGLLANLCRHNLSVlQTHIKTLSNVKSFYRTLITLLAHSSLTVVVFALSILSSLT 21b

K L + + L +T T ++ T ++ S + +

S

Sb jct : 507 NSKYLELiQKESEKIKEELDAKT — TELKIώLEKVTNLSKAKEKSESELSRLKKTSSEER Sb3

(Query : 217 LN-EEVGEKLFHARNI-H(QTF(QLIFNILINGDGTLTRKYS--VDLLMDLL 2b2

N EE EKL + I +<Q F+ +L G T+T+ + YS ++ L D L

Sb j ct : 5b4 KNAEEiQLEKLKNEIlQIKNiQAFEKERKLLNEGSSTITiQEYSEKINTLEDEL bl3

Pedant information for DKFZphmel2_12jli frame 2

Report for DKFZphmel2_12jl .2

[LENGTH! 105 EMU! 102Db7-61

Epl! 5- 65

EHOMOL! TREMBL:SCINTANA_1 Saccharomyees cerevisiae integrin analogue genei complete eds- le-14

EFUNCAT! 06. D7 vesicular transport (golgi networki etc-) ES. cerevisiaei YDL058w! 5e-lb

EFUNCAT! 3D-03 organization of cytoplasm ES- cerevisiaei

YDLD58w! 5e-lb

EFUNCAT! 1 genome replication! transcriptioni recombination and repair EM- jannaschiii MJ1322! le-10 EFUNCAT! OLID nuclear biogenesis [S- cerevisiaei YDR35bw!

2e-10

[FUNCAT! 3D-04 organization of cytoskeleton [S- cerevisiaei

YDR35bw! 2e-lD

[FUNCAT! D3-22 cell cycle control and mitosis [S- cerevisiaei YDR35bw! 2e-lD

EFUNCAT! 30- ID nuclear organization ES- cerevisiaei YKR015w! le-01

EFUNCAT! 11-04 dna repair (direct repairi base excision repair and nucleotide excision repair) ES- cerevisiaei YKR015w! le-DI EFUNCAT! 08-22 cytoskeleton-dependent transport ES- cerevisiaei

YHR023w MY01 - myosin-1 isoform! 4e-01

EFUNCAT! D3-04 buddingi cell polarity and filament formation

ES- cerevisiaei YHRD23w MY01 - myosin-1 isoform! 4e-01

EFUNCAT! 03-25 cytokinesis ES. cerevisiaei YHR023w MY01 - myosin-1 isoform! 4e-01

EFUNCAT! 11 unclassified proteins ES- cerevisiaei YNLOIlw!

3e-08

EFUNCAT! 01-25 vacuolar and lysosomal biogenesis ES- cerevisiaei Y0R32bw! be-06 EFUNCAT! OS-lb extracellular transport ES- cerevisiaei

Y0R32bw! be-08

EFUNCAT! 01-13 biogenesis of chromosome structure ES- cerevisiaei YLROSbw! fie-OS EFUNCAT! 16 classification not yet clear-cut ES. cerevisiaei YJR134c! le-07

EFUNCAT! 0b-D7 protein modification (glycolsylationi acylationi myristylationi palmitylationi farnesylation and processing) ES- cerevisiaei YKL201c! 4e-D7

EFUNCAT! 30-05 organization of centrosome ES- cerevisiaei YIL144w! 4e-0b

EFUNCAT! D3-07 pheromone responsei mating-type determination! sex-specific proteins ES- cerevisiaei YNLD71c! 5e-0b [FUNCAT! D3-01 cell growth [S- cerevisiaei YNLD71c! 5e-0b

[FUNCAT! 06-11 other intracellular-transport activities [S- cerevisiaei YNL071c! 5e-0b

EFUNCAT! D1-04 biogenesis of cytoskeleton [S- cerevisiaei

YKL171c! be-Db

E[FFUUNNCCAATT!! 3300.-0022 organization of plasma membrane [S- cerevisiaei

YERODβc! δe-Ob

EFUNCAT! 03.11 recombination and dna repair [S- cerevisiaei

YNL250w! le-05

EFUNCAT! 03-13 meiosis [S- cerevisiaei YDR265w! le-05

E[FFUUNNCCAATT!! 3300--1133 organization of chromosome structure ES- cerevisiaei YDR285w! le-05

EFUNCAT! 11- DI stress response ES. cerevisiaei YPR141c! 2e-05

EFUNCAT! Db-10 assembly of protein complexes ES- cerevisiaei

YPR141c! 2e-D5 EFUNCAT! Ob-Dl protein folding and stabilization ES- cerevisiaei YNL227c! le-05

[FUNCAT! 05-D4 translation (initiation! elongation and termination) [S- cerevisiaei YALD35w! le-04

[FUNCAT! 10.05-11 other pheromone response activities [S- cerevisiaei YHR158c! le-04

[FUNCAT! o chaperones EM- genitaliumi MG355! 2e-D4

[FUNCAT! 03-22-01 cell cycle check point proteins [S- cerevisiaei YGLOβbw! 2e-04

[FUNCAT! 03-1D sporulation and germination [S- cerevisiaei YNL225c! 3e-04

[FUNCAT! r general function prediction [M- jannaschiii

MJ1254! 4e-D4

[FUNCAT! Oβ-Dl nuclear transport [S- cerevisiaei YPL174c! 4e-04

[FUNCAT! 04-05-D1.01 general transcription activities [S- cerevisiaei YMR227c TAFb7 - TFIID subunit! be-D4

[BLOCKS! PR01D02E

[BLOCKS! BLDllbOB Kinesin light chain repeat proteins

[BLOCKS! BLD032bD Tropomyosins proteins

[SCOP! d2tmab_ 1-1D5-4-1.1 Tropomyosin [rabbit (Oryctolagus cuniculus) 3e-23

[EC! 3. -1- 32 Myosin ATPase 4e-10

[PIRKU! nucleus Se-DI

[PIRKU! phosphotransferase 2e-07

[PIRKU! blocked amino end le-Ob [PIRKU! duplication 2e-07

[PIRKU! citrulline 3e-D6

[PIRKU! tandem repeat 4e-10

[PIRKU! heterodimer le-07

[PIRKU! heart 4e-06 [PIRKU! endocytosis 7e-D8

[PIRKU! transmembrane protein le-14

[PIRKU! serine/threonine-specific protein kinase 2e-07

[PIRKU! cell wall 2e-0b EPIRKU! zinc finger 7e-08

EPIRKU! DNA binding 3e-D1

EPIRKU! metal binding 7e-06

EPIRKU! muscle contraction 4e-10 EPIRKU! brain 2e-0b

EPIRKU! acetylated amino end 2e-D7

EPIRKU! heterotetramer 5e-07

EPIRKU! actin binding 4e-lD

EPIRKU! mitosis le-08 EPIRKU! microtubule binding le-Dδ

EPIRKU! ATP 4e-10

EPIRKU! chromosomal protein le-D7

EPIRKU! thick filament le-10

EPIRKU! phosphoprotein le-01 EPIRKU! skeletal muscle le-08

EPIRKU! calcium binding 3e-06

EPIRKU! alternative splicing le-10

EPIRKU! DNA condensation le-D7

EPIRKU! coiled coil le-14 EPIRKU! P-loop 2e-10

EPIRKU! heptad repeat 5e-01

EPIRKU! methylated amino acid 4e-10

EPIRKU! immunoglobulin receptor 2e-D7

EPIRKU! peripheral membrane protein 7e-0β EPIRKU! cardiac muscle 4e-08

EPIRKU! hydrolase 4e-lD

EPIRKU! microtubule 5e-01

EPIRKU! muscle 4e-08

EPIRKU! membrane protein 5e-01 EPIRKU! EF hand 3e-08

EPIRKU! cell division le-Ob

EPIRKU! cytoskeleton be-01

EPIRKU! hair 3e-08

EPIRKU! calmodulin binding 7e-08 EPIRKU! Golgi apparatus 2e-07

ESUPFAM! hypothetical protein YJL074c 5e-01

ESUPFAM! unassigned Ser/Thr or Tyr-specific protein kinases 2e-

07

ESUPFAM! myosin motor domain homology 2e-10 ESUPFAM! alpha-actinin actin-binding domain homology be-01

ESUPFAM! tropomyosin 2e-0δ

ESUPFAM! kinesin heavy chain 5e-07

ESUPFAM! plectin be-01

ESUPFAM! SAM homology le-Ob ESUPFAM! trichohyalin 3e-08

ESUPFAM! ribosomal protein S10 homology be-01

ESUPFAM! protein kinase C zinc-binding repeat homology Se-01

ESUPFAM! giantin 7e-0δ

ESUPFAM! protein kinase homology 2e-07 ESUPFAM! protein 4-1 membrane-binding domain homology le-06

ESUPFAM! human early endoso e antigen 1 7e-0δ

ESUPFAM! myosin MY02 2e-0b

ESUPFAM! MS protein 3e-01

ESUPFAM! Mycoplasma genitalium hypothetical protein MG216 5e-01 ESUPFAM! myosin heavy chain 2e-10

ESUPFAM! conserved hypothetical PUS protein 3e-01

ESUPFAM! centromere protein E le-06

ESUPFAM! calmodulin repeat homology 3e-06 ESUPFAM! hypothetical protein MJ0114 2e-07

ESUPFAM! hypothetical protein MJ1322 3e-01

ESUPFAM! pleckstrin repeat homology 5e-01

ESUPFAM! kinesin motor domain homology le-06

ESUPFAM! ezrin"1e-^*H3.8

EPROSITE! LEUCINE_ZIPPER 1

EKU! TRANSMEMBRANE 2

EKU! L0U_C0MPLEXITY 3-01 *

EKU! COILED COIL 18-34 *

SElQ MDSTACLKSLLLTVS(QYKAVKSEANAT(QLLRHLEVISG(QKLTRLFTSN<QILTSECLSCLV SEG xxxxxxxxxx

PRD ccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhccccceeeeeecceeeeeehhhhhh COILS

MEM

SE(Q ELLEDPNISASLILSIIGLLSiQLAVDIETRDCLiQNTYNLNSVLAGVVCRSSHTDSVFLlQC SEG xxxx- • - xxxxxxxxxxxxxx

PRD hhhhccccchhhhhhhhchhhhhhhhhhcccccccccceeeeeeeeeeeccccccchhhh COILS

MEM MMMMMMMMMMMMMMMMM_'

SElQ IlQLLlQKLTYNVKIFYSGANIDELITFLIDHIiQSSEDELKMPCLGLLANLCRHNLSViQTHI SEG

PRD hhhhhhhcceeeeeecccchhhhhhhhhhhhhhhhhhhccccceeeeeeeecceeeeeee COILS

MEM

SElQ KTLSNVKSFYRTLITLLAHSSLTVVVFALSILSSLTLNEEVGEKLFHARNIHiQTFlQLIFN SEG PRD eeeehhhhhhhhhhhhhhcccccccceeehhhhhhchhhhhhhhhhhhhhhhhhhhhhhh COILS

MEM MMMMMMMMMMMMMMMMM SElQ ILINGDGTLTRKYSVDLLMDLLKNPKIADYLTRYEHFSSCLHlQVLGLLNGKDPDSSSKVL SEG

PRD hhcccccceeeehhhhhhhhhhccccchhhhhheeeeehhhhhhhhcccccccccchhhh COILS MEM

SElQ ELLLAFCSVTIQLRHMLTIQMMFEIQSPPGSATLGSHTKCLEPTVALLRULSIQPLDGSENCSV SEG i

PRD hhhhhchhhhhhhhhhhhhhhhccccccccccccceeehhhhhhhhhhhcccccccchhh COILS

MEM

SElQ LALELFKEIFEDVIDAANCSSADRFVTLLLPTILDiQLlQFTEiQNLDEALTRKNVKGIAKAI SEG

PRD hhhhhhhhhhhhhhhhcccccchhhhhheeehhhhhhhhhhhhhhhhhhhhhchhhhhhh COILS MEM

SElQ EVLLTLCGDDTLKMHIAKILTTVKCTTLIEiQlQFTYGKIDLGFGTKVADSELCKLAADVIL SEG

PRD hhhhhhccccchhhhhhhhhhhheeeeeeeeeeecccccccccceeehhhhhhhhhhhhh COILS

MEM SElQ KTLDLINKLKPLVPGMEVSFYKILIQDPRLITPLAFALTSDNREIQVIQSGLRILLEAAPLPD SEG

PRD hhhhhhhhcccccccccccceeeccccccchhhhhhhccccchhhhhhhhhhhhhccccc COILS MEM

SElQ FPALVLGESIAANNAYRiQiQETEHIPRKMPUiQSSNHSFPTSIKCLTPHLKDGVPGLNIEEL SEG

PRD cceeeeehhhhhhhhhhhhhhhhhhhhhhhhcccccccchhhhhhhhhhhhhhhhhhhhh COILS

MEM

SElQ IEKLiQSGMVVKDfQICDVRISDIMDVYEMKLSTLASKESRLiQDLLETKALALAiQADRLIAiQ SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS

MEM

SElQ HRCiQRTiQAETEARTLASMLREVERKNEELSVLLKAlQlQVESERAlQSDIEHLFlQHNRKLESV

SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC

MEM

SElQ AEEHEILTKSYMELLiQRNESTEKKNKDLlQITCDSLNKlQIETVKKLNESLKElQNEKSIAiQL

SEG PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC

MEM SElQ IEKEEiQRKEViQNlQLVDREHKLANLHiQKTKVlQEEKIKTLlQKEREDKEETIDILRKELSRTE

SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC MEM

SElQ IQIRKELSIKASSLEVIQKAIQLEGRLEEKESLVKLIQIQEELNKHSHMIAMIHSLSGGKINPET

SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhcccc COILS

CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC

MEM SElQ VNLSI

SEG

PRD ccccc

COILS

MEM

Prosite for DKFZphmel2_12 l.2

PS00021 331->353 LEUCINE ZIPPER PD0C00021

(No Pfam data available for DKFZphmel2_lΞ l ■ 2)

DKFZphmel2_7gl4

group: intracellular transport and trafficing

DKFZphmel2_7gl4 encodes a novel 173 amino acid protein with similarity to the dor (deep orange) protein of drosophila melanogaster.

The novel protein is also similar to the vakuolar membrane protein pep3 of Saccharomyees cerevisiaei which is involved in protein sorting mechanisms- The expression profile is ubiquitous and a role in protein transport/targeting is likely-

The new protein can find application in modulation of the sorting of proteins into different compartments-

similarity to DEEP ORANGE (Drosophila melanogaster) perhaps complete eds- and full length Sequenced by MediGeno ix Locus: unknown

Insert length: 3151 bp

Poly A stretch at pos- 3813ι polyadenylation signal at pos- 3874

1 GCCCGCGTCA CGGGGGCGGG AGTCAGCTGA GCTGCCGGGG CGAGGTTGGG

SI ATCACCTGGC ACCGGCTGAA GGGAGCCTGT GATTTTTTTG TAGCGGGGGC

101 GGGGAGTAAG GTGCAAGACT GCGCCAGATT CAAGGACGAG GGCTGCCCGA 151 TTATCTCGCT GCATAAGGCA AGAGCAAGAG GATCCTCAGG ATTTTAAAGA

201 GGAGGCGACG GCTGCAGGTT CCCAGGATCT GTCAGAGGCT GGGGAGTTAC

251 AGCTTCCATT CTGGGGCGAC GGGGACCCCG GGGGGGTAGC CCTTTTGTAA

301 TCCCCAGGCC CCGGACAAAG AGCCCAGAGG CCGGGCACCA TGGCGTCCAT

351 CCTGGATGAG TACGAGAACT CGCTGTCCCG CTCGGCCGTC TTGCAGCCCG 401 GCTGCCCTAG CGTGGGCATC CCCCACTCGG GGTATGTGAA TGCCCAGCTG

4S1 GAGAAGGAAG TGCCCATCTT CACAAAGCAG CGCATTGACT TCACCCCTTC

501 CGAGCGCATT ACCAGTCTTG TCGTCTCCAG CAATCAGCTG TGCATGAGCC

5S1 TGGGCAAGGA TACACTGCTC CGCATTGACT TGGGCAAGGC AAATGAGCCC bOl AACCACGTGG AGCTGGGACG TAAGGATGAC GCAAAAGTTC ACAAGATGTT b51 CCTTGACCAT ACTGGCTCTC ACCTGCTGAT TGCCCTGAGC AGCACGGAGG

701 TCCTCTACGT GAACCGAAAT GGACAGAAGG TACGGCCACT AGCACGCTGG

7S1 AAGGGGCAGC TGGTGGAGAG TGTGGGTTGG AACAAGGCAC TGGGCACGGA

801 GAGCAGCACA GGCCCCATCC TGGTCGGGAC TGCCCAAGGC CACATCTTTG

851 AAGCAGAGCT CTCAGCCAGC GAAGGTGGGC TTTTCGGCCC TGCTCCGGAT 101 CTCTACTTCC GCCCATTGTA CGTGCTAAAT GAAGAAGGGG GTCCAGCACC

ISI TGTGTGCTCC CTTGAGGCCG AGCGGGGCCC TGATGGGCGT AGCTTTGTTA

1001 TTGCCACCAC TCGGCAGCGC CTCTTCCAGT TCATAGGCCG AGCAGCAGAG

1051 GGGGCTGAGG CCCAGGGTTT CTCAGGGCTC TTTGCAGCTT ACACGGACCA

1101 CCCACCCCCA TTCCGTGAGT TTCCCAGCAA CCTGGGCTAC AGTGAGTTGG 1151 CCTTCTACAC CCCCAAGCTG CGCTCCGCAC CCCGGGCCTT CGCCTGGATG

1201 ATGGGGGATG GTGTGTTGTA TGGGGCATTG GACTGTGGGC GCCCTGACTC

1251 TCTGCTGAGC GAGGAGCGAG TCTGGGAGTA CCCAGAGGGG GTAGGGCCTG

1301 GGGCCAGCCC ACCCCTAGCC ATCGTCTTGA CCCAGTTCCA CTTCCTGCTG 1351 CTACTGGCAG ACCGGGTGGA GGCAGTGTGC ACACTGACCG GGCAGGTGGT

1401 GCTGCGGGAT CACTTCCTGG AGAAATTTGG GCCGCTGAAG CACATGGTGA

1451 AGGACTCCTC CACAGGCCAG CTGTGGGCCT ACACTGAGCG GGCTGTCTTC

1SD1 CGCTACCACG TGCAACGGGA GGCCCGAGAT GTCTGGCGCA CCTATCTGGA 15S1 CATGAACCGC TTCGATCTGG CCAAAGAGTA TTGTCGAGAG CGGCCCGACT

IbOl GCCTGGACAC GGTCCTGGCC CGGGAGGCCG ATTTCTGCTT TCGCCAGCGT lb51 CGCTACCTGG AGAGCGCACG CTGCTATGCC CTGACCCAGA GCTACTTTGA

1701 GGAGATTGCC CTCAAGTTCC TGGAGGCCCG ACAGGAGGAG GCTCTGGCTG

17S1 AGTTCCTGCA GCGAAAACTG GCCAGTTTGA AGCCAGCCGA ACGTACCCAG 18D1 GCCACACTGC TGACCACCTG GCTGACAGAG CTCTACCTGA GCCGGCTTGG

1851 GGCTCTGCAG GGCGACCCAG AGGCCCTGAC TCTCTACCGA GAAACCAAGG

1101 AATGCTTTCG AACCTTCCTC AGCAGCCCCC GCCACAAAGA GTGGCTCTTT

1151 GCCAGCCGGG CCTCTATCCA TGAGCTGCTC GCCAGTCATG GGGACACAGA

2001 ACACATGGTG TACTTTGCAG TGATCATGCA GGACTATGAG CGGGTGGTGG 2051 CTTACCACTG TCAGCACGAG GCCTACGAGG AGGCCCTGGC CGTGCTCGCC

2101 CGCCACCGTG ACCCCCAGCT CTTCTACAAG TTCTCACCCA TCCTCATCCG

21S1 TCACATCCCC CGCCAGCTTG TAGATGCCTG GATTGAGATG GGCAGCCGGC

2201 TGGATGCTCG TCAGCTCATT CCTGCCCTGG TGAACTACAG CCAGGGTGGT

2251 GAGGTCCAGC AGGTGAGCCA GGCCATCCGC TACATGGAGT TCTGCGTGAA 2301 CGTGCTGGGG GAGACTGAGC AGGCCATCCA CAACTACCTG CTGTCACTGT

2351 ATGCCCGTGG CCGGCCGGAC TCACTACTGG CCTATCTGGA GCAGGCTGGG

2401 GCCAGCCCCC ACCGGGTGCA TTACGACCTC AAGTATGCGC TGCGGCTCTG

2451 CGCCGAGCAT GGCCACCACC GCGCTTGTGT CCATGTCTAC AAGGTCCTAG

2501 AGCTGTATGA GGAGGCCGTG GACCTGGCCC TGCAGGTGGA TGTGGACCTG 25S1 GCCAAGCAGT GTGCAGACCT GCCTGAGGAG GATGAGGAAT TGCGCAAGAA

2bDl GCTGTGGCTG AAGATCGCAC GGCACGTGGT GCAGGAAGAG GAAGATGTAC

2b51 AGACAGCCAT GGCTTGCCTG GCTAGCTGCC CCTTGCTCAA GATTGAGGAT

2701 GTGCTGCCCT TCTTTCCTGA TTTCGTCACC ATCGACCACT TCAAGGAGGC

27S1 GATCTGCAGC TCACTTAAGG CCTACAACCA CCACATCCAG GAGCTGCAGC 2801 GGGAGATGGA AGAGGCTACA GCCAGTGCCC AGCGCATCCG GCGAGACCTG

2851 CAGGAGCTGC GGGGCCGCTA CGGCACTGTG GAGCCCCAGG ACAAATGTGC

2101 CACCTGCGAC TTCCCCCTGC TCAACCGCCC TTTTTACCTC TTCCTCTGTG

2151 GCCATATGTT CCATGCTGAC TGCCTGCTGC AGGCTGTGCG ACCTGGCCTG

3001 CCAGCCTACA AGCAGGCCCG GCTGGAGGAG CTGCAGAGGA AGCTGGGGGC 3051 TGCTCCACCC CCAGCCAAGG GCTCTGCCCG GGCCAAGGAG GCCGAGGGTG

3101 GGGCTGCCAC GGCAGGGCCC AGCCGGGAAC AGCTCAAGGC TGACCTGGAT

3151 GAGTTGGTGG CCGCTGAGTG TGTGTACTGT GGGGAGCTGA TGATCCGCTC

3201 TATCGACCGG CCGTTCATCG ACCCCCAGCG CTACGAGGAG GAGCAGCTCA

3251 GTTGGCTGTA GGAGGGTGTC ACCTTTGATG GGGGTGGGCA ATGGGGAGCA 3301 GTGGCTTGAA CCCACTTGAG AAGGCTGCCT CCTAGGCTCT GCTCAGTCAT

3351 CTTGCAATTG CCACACTGTG ACCACGTTGA CGGGAGTAGA GTAGCGCTGT

3401 TGGCCAGGAG GTGTCAGGTG TGAGTGTATT CTGCCAGCTT TTCATGCTGT

3451 TCTTCAGAGC TGCAGTTATG CCAGACCATC AGCCTGCCTC CCAGTAGAGG

3501 CCCTTCACCT GGAGAAGTCA GAAATCTGAC CCAATTCCAC CCCCTGCCTC 35S1 TAGCACCTCT TCTGTCCCTG TCATTCCCCA CACACGTCCT GTTCACCTCG

3b01 AGAGAGAGAG AGAGAGAGCA CCTTTCTTCC GTCTGTTCAC TCTGCGGCCT

3b51 CTGGAATCCC AGCTCTTCTC TCTCAGAAGA AGCCTTCTCT TCCTCCTGCC

3701 TGTAGGTGTC CCAGAAGTGA GAAGGCAGCC TTCGAAGTCC TGGGCATTGG

3751 GTGAGAAAGT GATGCTAGTT GGGGCATGCT TTTGTGCACA CTCTCTGGGG 3601 CTCCAGTGTG AAGGGTGCCC TGGGGCTGAG GGCCTTGTGG AGGATGGTCG

3651 GTGGTGGTGA TGGAGGTGGA GAGCATTAAA CTGTCTGCAC TGCAAAAAAA

3101 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAGAAAAAA AAAAAAAAAA

3151 A

BLAST Results No BLAST result

Medline entries

17216037:

Shestopal SAi Makunin IVi Belyaeva ESi Ashburner Mi Zhimulev

IF-iMol

Gen Genet 1117 Feb 20i253 (5) : b42-8

1204130b:

Robinson JSi Graham TRi Emr SD-i A putative zinc finger proteini Saccharomyees cerevisiae Vpslδpi affects late Golgi functions required for vacuolar protein sorting and efficient alpha-factor prohormone maturation. Mol Cell Biol 1111 Decill (12) :5δl3-24

12041305: Preston RAi Manolson MFi Becherer Ki Ueidenhammer Ei Kirkpatriek

Uright Ri

Jones EU-i Isolation and characterization of PEP3ι a gene required for vacuolar biogenesis in Saccharomyees cerevisiae. Mol Cell

Biol 1111

Decill(12) :S601-12

Peptide information for frame 1

ORF from 340 bp to 3256 bpi peptide length: 173 Category: similarity to known protein

Classification: Cellular transport and traffic

1 MASILDEYEN SLSRSAVLώP GCPSVGIPHS GYVNAiQLEKE VPIFTKiQRID 51 FTPSERITSL VVSSNlQLCMS LGKDTLLRID LGKANEPNHV ELGRKDDAKV

101 HKMFLDHTGS HLLIALSSTE VLYVNRNGiQK VRPLARUKGtQ LVESVGUNKA

151 LGTESSTGPI LVGTAiQGHIF EAELSASEGG LFGPAPDLYF RPLYVLNEEG

201 GPAPVCSLEA ERGPDGRSFV IATTRiQRLFlQ FIGRAAEGAE AlQGFSGLFAA

251 YTDHPPPFRE FPSNLGYSEL AFYTPKLRSA PRAFAUMMGD GVLYGALDCG 301 RPDSLLSEER VUEYPEGVGP GASPPLAIVL TlQFHFLLLLA DRVEAVCTLT

351 GώVVLRDHFL EKFGPLKHMV KDSSTGiQLUA YTERAVFRYH ViQREARDVUR

401 TYLDMNRFDL AKEYCRERPD CLDTVLAREA DFCFRiQRRYL ESARCYALTiQ

451 SYFEEIALKF LEARiQEEALA EFLiQRKLASL KPAERTiQATL LTTULTELYL

501 SRLGALiQGDP EALTLYRETK ECFRTFLSSP RHKEULFASR ASIHELLASH 551 GDTEHMVYFA VIMiQDYERVV AYHCiQHEAYE EALAVLARHR DPiQLFYKFSP bOl ILIRHIPRiQL VDAUIEMGSR LDARlQLIPAL VNYSiQGGEVlQ (QVSiQAIRYME b51 FCVNVLGETE (QAIHNYLLSL YARGRPDSLL AYLEiQAGASP HRVHYDLKYA

701 LRLCAEHGHH RACVHVYKVL ELYEEAVDLA LiQVDVDLAKlQ CADLPEEDEE

751 LRKKLULKIA RHVVlQEEEDV (QTAMACLASC PLLKIEDVLP FFPDFVTIDH 801 FKEAICSSLK AYNHHIiQELlQ REMEEATASA (QRIRRDLlQEL RGRYGTVEPlQ

651 DKCATCDFPL LNRPFYLFLC GHMFHADCLL (QAVRPGLPAY KiQARLEELiQR

101 KLGAAPPPAK GSARAKEAEG GAATAGPSRE iQLKADLDELV AAECVYCGEL 151 MIRSIDRPFI DPIQRYEEEIQL SUL BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphmel2_7gl i frame 1 SUISSPR0T:D0R_DR0ME DEEP ORANGE PROTEIN- i N = li Score = 1271ι P

2-4e-130

PIR:A41143 vacuolar membrane protein PEP3 - yeast (Saccharomyees cerevisiae)ι N = 3ι Score = 2bbι P = 5-le-27

>SUISSPR0T:D0R_DR0ME DEEP ORANGE PROTEIN Length = lι002

HSPs:

Score = 1271 (111-1 bits)ι Expect = 2-4e-130ι P = 2-4e-130 Identities = 303/647 (35*)ι Positives = 4b3/647 (54*)

(Query: 130

KVRPLARUKG(QLVESVGUNKALGTESSTGPILVGTA(QGHIFEAELSASEGGLFGPAPDLY 181 KVR + ++K + +V +N G ESSTGPIL+GT++G IFE EL+ + G

+ Sb j ct : 155 KVRRIEKFKDHEITAVAFNPYHGNESSTGPILLGTSRGLIFETELNPAADG- HV(Q 208

(Query : HO FRPLYVLNEEGGPA-PVCSLEAERGPDG- RSFVIATTR(QRLF(QFIGRAAEGAEA(QGFSGL 247 + LY L G P P+ L+ R P+ R ++ T+ + ++ F +

AE + +

Sb jct : 201 RKiQLYDLGL-GRPKYPITGLKLLRVPNSSRYIIVVTSPECIYTF — (QETLKAEERSLiQAI 2b5 (Query: 248 FAAYTD--

HPPPFREFPSNLGYSELAFYTPKLRSAPRAFAUMMGDGVLYGAL--DCGRPD 303

FA Y P E ++L +S+L F+ P P+ +AU+ G+G+ G L

+

Sb jct : 2bb FAGYVSGV(QEPHCEERKTDLTFS(QLRFFAPPNSKYPK(QUAULCGEGIRVGELSIEANSAA 325

(Query : 304 SLLSEERV---UEYPEGVGPGA--- S PPL A IVLT IQF H FLLLL A D RVEA VCT L T GIQVVLRD 357

+L+ + +E + G + P A VLT++H +LL AD V A+C L + V + +

Sbj ct : 32b TLIGNTLINLDFEKTMHLSYGERRLNTPKAFVLTEYHAVLLYADHVRAICLLN(QE(QVY(QE 385

(Query : 358 HFLE- KFGPLKHMVKDSSTGlQLUAYTERAVFRYHViQREARDVURTYLDMNRFDLAKEYCR 41b

F E + G + +D TG ++ YT + VF V RE R+VUR YLD

+++LA + Sb j ct : 38b AFDEARVGKPLSIERDELTGSIYVYTVKTVFNLRVTREERNVURIYLDKGiQYELATAHAA 445

(Query : 417 ERPDCLDTVLAREADFCFR(QRRYLESARCYALT(QSYFEEIALKFLEAR(QEEALAEFL(QRK 47b

E P+ L VL + AD F Y +A YA T FEE+ LKF+ +

+ + + + + +

Sb jct : 44 b

EDPEHL(QLVLC(QRADAAFADGSY(QVAADYYAETDKSFEEVCLKFMVLPDKRPIINYVKKR 505

(Query : 477 LASL--KPAERXXXXXXXXXXXXXXXSRLGAL(Q

GDPEALTLYRETKEC-FRTFLSS 521

L+ + KP E L L P+ +R + +

+ F + Sbjct : 50b

LSRVTTKPMETDELDEDKMNIIKALVIULIDLYLIiQINMPDKDEEURSSUlQTEYDEFMME 5b5

(Query : 530

PRHKEULFASRASIHELLASHGDTEHMVYFAVIMlQDYERVVAYHCiQHEAYEEALAVLARH 561 +R ++ +L + A H D +M FA+ + DY+ WA + E Y

EAL L

Sb jct : 5bb AHVLSCTR(QNRETVR(QLIAEHADPRNMA(QFAIAIGDYDEVVA<QιQLKAECYAEAL<QTLIN(Q b25 (Query: 510

RDP(QLFYKFSPILIRHIPR(QLVDAUIEMGSRLDAR(QLIPALVNYS(QGGEV(Q(QVS(QAIRYM b41 R+P+LFYK++P LI +P+ VDA + GSRL+ +L+P L+ + E ++

+(Q RY+

Sbjct: b2b RNPELFYKYAPELITRLPKPTVDALMAlQGSRLEVEKLVPTLI- IMENRE(QRE(QT(Q--RYL b82 βuery : b50

EFCVNVLGETElQAIHNYLLSLYARGRPDSLLAYLEiQAGASPHRVHYDLKYALRLCAEHGH 701 EF + L T AIHN+LL LYA P L+ YLE G VHYD+ YA ++C +

Sbjct : b83 EFAIYKLNTTNDAIHNFLLHLYAEHEPKLLMKYLEIiQGRDESLVHYDIYYAHKVCTDLDV 742

(Query : 710 HRACVHVYKVLELYEEAVDLAL(QVDVDLAK(QCADLPEEDEELRKKLULKIARHVV(QEEED 7b1

A V + +L + AVDLAL D+ LAK+ A P D ++R+KLUL+IA

H ++ D

Sbjct: 743 KEARVFLECMLRKUISAVDLALTFDMKLAKETASRPS-

DSKIRRKLULRIAYHDIKGTND 601

(Query: 770

VlQTAMACLASCPLLKIEDVLPFFPDFVTIDHFKEAICSSLKAYNHHIlQELiQREMEEATAS 621 V+ A+ L C LL+IED+LPFF DF ID+FKEAIC +L+ YN

IiQELlQREM E T Sb j ct : 802

VKKALNLLKECDLLRIEDLLPFFADFEKIDNFKEAICDALRDYNiQRIlQELiQREMAETTElQ βbl

(Query : 830

A(QRIRRDLιQELRGRYGTVEP(QDKCATCDFPLLNRPFYLFLCGHMFHADCLL(QAVRPGLPA 881 R +L(Q + LR TVE (QD C C+ LL +PF + + F + CGH FH + DCL +

V P L

Sbj ct : 8b2 TDRATAEL(Q(QLR(QHSLTVES(QDTCEICEMMLLVKPFFIFICGHKFHSDCLEKHVVPLLTK 121 (Query: 610

YKlQARLEELlQRKLGAAPPPXXXXXXXXXXXXXXXXXXPSRElQLKADLDELVAAECVYCGE 141 + RL L+++L A R LK ++++++AA+C++CG Sbjct: 122 EiQCRRLGTLKlQiQLEAEVflTlQAiQPlQSGALSKiQiQAMELiQRKRAALKTEIEDILAADCLFCG- 160

(Query: 150 LMIRSIDRPFIDP(QRYEEE(QLSU 172 L+I +ID+PF+D +E+ + U

Sbjct: 161 LLISTIDiQPFVDD — UElQVNVEU 1001

Score = 2b8 (40-2 bits)ι Expect = 3-be-llι P = 3-be-ll Identities = 11/281 (32*)ι Positives = 14b/281 (51*)

(Query: 3b <QLEKEVPIFTK(QRIDF-TPSE- — RITSLVVSSNlQLCMSLG---

KDTLLRIDLGKANEPN 88

+ ++E IF++ ++ PS + L VS N L LG + TLLR

L +A P Sbjct: 37

ETDEEDEIFSRHKMVLRVPSNCTGDLMHLAVSRNULVCLLGTPERTTLLRFFLPRAIPPG lb

(Query: 81 HVELGRK- — DDAKVHKMFLDHTGSHLLIAL- — SST EVLYVN —

RNGiQ KV 131 L + K+ +MFLD TG H++IAL S+T + LY++ +

Q KV

Sbjct: 17 EAVLEKYLSGSGYKITRMFLDPTGHHIIIALVPKSATAGVSPDFLYIHCLESP(QA(Q(QLKV ISb (Query: 132

RPLARUKGlQLVESVGUNKALGTESSTGPILVGTAiQGHIFEAELSASEGGLFGPAPDLYFR 111

R + ++K + +V +N G ESSTGPIL+GT++G IFE EL+ + G + +

Sbjct: 157 RRIEKFKDHEITAVAFNPYHGNESSTGPILLGTSRGLIFETELNPAADG-— ---HViQRK 210

(Query: 112 PLYVLNEEGGPA-PVCSLEAERGPDG- RSFVIATTR(QRLF(QFIGRAAEGAEA(QGFSGLFA 241

LY L G P P+ L+ R P+ R ++ T+ + ++ F + AE + +FA

Sbjct: 211 (QLYDLGL-GRPKYPITGLKLLRVPNSSRYIIVVTSPECIYTF — (QETLKAEERSLiQAIFA 2b7

(^Query: 250 AYTD--HPPPFREFPSNLGYSELAFYTPKLRSAPRAFAUMMGDGVLYGAL 217

Y P E ++L +S+L F+ P P+ +AU+ G+G+ G L

Sbjct: 2b6 GYVSGVIQEPHCEERKTDLTFSIQLRFFAPPNSKYPKIQUAULCGEGIRVGEL

317

Pedant information for DKFZphmel2_7gl4ι frame 1

Report for DKFZphmel2_7gl4 -1

ELENGTH! 173 EMU! 11018b.01 Epl! 5-72

EHOMOL! SUISSPR0T:D0R_DR0ME DEEP ORANGE PROTEIN^, le-145

EFUNCAT! 30-25 vacuolar and lysosomal organization ES- cerevisiaei YLR148w! 5e-41 EFUNCAT! 0b-D4 protein targetingi sorting and translocation ES- cerevisiaei YLR146w! Se-41

EFUNCAT! 06-07 vesicular transport (golgi networki etc) ES. cerevisiaei YLR148w! 5e-41

EBLOCKS! BLOOlObF Galactokinase proteins EBLOCKS! PR01014B

EBLOCKS! BP0330bB

EBLOCKS! PFOObOOB

EPIRKU! yeast vacuole le-31

EPIRKU! transmembrane protein le-31 EKU! Alpha_Beta

EKU! L0U_C0MPLEXITY 3-31 *

EKU! COILED COIL 4-83 *

SElQ MASILDEYENSLSRSAVLlQPGCPSVGIPHSGYVNAiQLEKEVPIFTKiQRIDFTPSERITSL SEG

PRD ccceeeccccccceeeeecccccceeeecccchhhhhhhhhhhhhhhhhhcccccceeee COILS

SElQ VVSSNiQLCMSLGKDTLLRIDLGKANEPNHVELGRKDDAKVHKMFLDHTGSHLLIALSSTE

SEG

PRD eeccceeeeecccccceeeccccccccceeeeehhhhhhhheeecccccceeeeeeccce

COILS

SElQ VLYVNRNGiQKVRPLARUKGlQLVESVGUNKALGTESSTGPILVGTAlQGHIFEAELSASEGG SEG

PRD eeeeecccccchhhhhcccceeeeeecccccccccccceeeeecccchhhhhhhhhhccc COILS

SElQ LFGPAPDLYFRPLYVLNEEGGPAPVCSLEAERGPDGRSFVIATTRiQRLFlQFIGRAAEGAE SEG PRD ccccccccccceeeeecccccccceeecccccccccceeeeeehhhhhhhhhhcchhhhh COILS

SElQ AlQGFSGLFAAYTDHPPPFREFPSNLGYSELAFYTPKLRSAPRAFAUMMGDGVLYGALDCG SEG

PRD hhhchhhhhhhhccccccccccccccccceeeecccccchhhhhhhhcccceeeeeeccc COILS

SElQ RPDSLLSEERVUEYPEGVGPGASPPLAIVLTi^QFHFLLLLADRVEAVCTLTGiQVVLRDHFL SEG

PRD cccccchhhhhhccccccccccccchhhhhhhhhhhhhhhhheeeecccchhhhhhhhhh COILS

SElQ EKF GPL KH M VK D SS T GIQLUA YTE RA VFRY H V IQ RE A R D VUR T YL DM NRFD L AKEYCR E RP D

SEG

PRD hcccccccccccccccceeeehhhhhhhhhhhhhhhhhhhhhhccchhhhhhhhhhhccc COILS

SElQ CLDTVLAREADFCFRiQRRYLESARCYALTiQSYFEEIALKFLEARiQEEALAEFLlQRKLASL SEG

PRD cchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhc COILS

SElQ KPAERTIQATLLTTULTELYLSRLGALIQGDPEALTLYRETKECFRTFLSSPRHKEULFASR SEG xxxxxxxxxxxxxxx

PRD ccchhhhhhhhhhhhhhhhhhhhhcccccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS

SElQ ASIHELLASHGDTEHMVYFAVIMlQDYERVVAYHClQHEAYEEALAVLARHRDPlQLFYKFSP SEG

PRD hhhhhhhhhccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhccchhhhhcce COILS

SElQ ILIRHIPRlQLVDAUIEMGSRLDARl^QLIPALVNYSl^QGGEViQiQVSlQAIRYMEFCVNVLGETE SEG

PRD eeeeccccchhhhhhhhccccccccccchhhhhccccchhhhhhhhhhhhhhhhccccch COILS

SElQ (QAIHNYLLSLYARGRPDSLLAYLEl^QAGASPHRVHYDLKYALRLCAEHGHHRACVHVYKVL SEG PRD hhhhhhhhhhhhhcccchhhhhhhhcccccccccchhhhhhhhhhhhcccccceeehhhh COILS

SElQ ELYEEAVDLALlQVDVDLAKl^QCADLPEEDEELRKKLULKIARHVVlQEEEDViQTAMACLASC SEG

PRD hhhhhhhhhhhhhchhhhhhhhhccccchhhhhhhhhhhhhhhhhhcchhhhhhhhhhhc COILS

SElQ PLLKIEDVLPFFPDFVTIDHFKEAICSSLKAYNHHIi^QELiQREMEEATASAlQRIRRDLlQEL

SEG

PRD ccchhhhhhcccccceeechhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh

COILS CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC

SElQ RGRYGTVEPlQDKCATCDFPLLNRPFYLFLCGHMFHADCLLiQAVRPGLPAYKlQARLEELώR

SEG

PRD hhhheeeeccccccccccccccceeeeeeeccchhhhhhhhhhhccchhhhhhhhhhhhh

COILS CCCCCCCC

SElQ KLGAAPPPAKGSARAKEAEGGAATAGPSREl^QLKADLDELVAAECVYCGELMIRSIDRPFI SEG xxxxxxxxxxxxxxxxxx

PRD hhhhhcchhhhhhhhhhhcccchhhhhhhhhhhhhhhhhhhhhhhccccceeeecccccc COILS

SElQ DPiQRYEEElQLSUL SEG

PRD chhhhhhhhhccc COILS

(No Prosite data available for DKFZphmel2_7gl4 - 1)

(No Pfam data available for DKFZphmel2_7gl4 -1)

DKFZphmel2_7kl1

group: melanoma derived

DKFZphmel2_7kl1 encodes a novel 234 amino acid protein without similarity to known proteins- Transcpripts can be found in almost any tissuei but are most abundant in kidney and retina- No informative BLAST resultsi No predictive prositei pfam or SCOP motife ■ The new protein can find application in studying the expression profile of melanoma-specific genes-

unknown protein first ATG in frame 1

Sequenced by MediGenomix Locus: /map="3"

Insert length: 238b bp

Poly A stretch at pos- 2343ι polyadenylation signal at pos- 2323

1 GGCAAAAGTC CAGGAATTAT CTTCATCCCT GGCTATCTTT CTTATATGAA

SI TGGTACAAAA GCGTTGGCGA TTGAGGAGTT TTGCAAATCT CTAGGTCACG

101 CCTGCATAAG GTTTGATTAC TCAGGAGTTG GAAGTTCAGA TGGTAACTCA

151 GAGGAAAGCA CACTGGGGAA ATGGAGAAAA GATGTTCTTT CTATAATTGA 201 TGACTTAGCT GATGGGCCAC AGATTCTTGT TGGATCTAGC CTTGGAGGGT

2S1 GGCTTATGCT TCATGCTGCA ATTGCACGAC CAGAGAAGGT TGTGGCTCTT

301 ATTGGTGTAG CTACAGCTGC AGATACCTTA GTGACAAAGT TTAATCAGCT

351 TCCTGTTGAG CTAAAAAAGG AAGTAGAGAT GAAAGGTGTG TGGAGCATGC

401 CATCAAAATA CTCTGAAGAA GGAGTTTATA ACGTTCAGTA CAGTTTCATT 451 AAAGAAGCTG AACATCACTG CTTGTTACAT AGCCCAATTC CTGTGAACTG

501 CCCCATAAGA TTGCTCCATG GCATGAAGGA TGACATTGTA CCTTGGCATA

551 CATCAATGCA GGTTGCCGAT CGAGTACTCA GCACAGATGT GGATGTCATC bOl CTCCGAAAAC ACAGTGATCA CCGAATGAGG GAAAAAGCAG ACATTCAACT bSl TCTTGTTTAC ACTATTGATG ACTTAATTGA TAAGCTCTCA ACTATAGTTA 701 ACTAGTATCA CATGTTTAGT TGGTATGTAA ACTAATGTAT CCAGAAGATT

751 GGAAGAGGGA TAAGAAATGA AAGATCCTGA TACTTTAGGT TTTTCCCTTT

801 CCTCTATTTT GTAAATATAA GATGAGTATT ATTTAATGAT GTATTTGCAT

851 AAGTAATGCA AATTGTGAAG AAGGACCAGC TGCTGTTTAG AAAATTTTCT

101 CCTTCCTTCT GTCCTTGATT TTTTTTCATT AAAGTATTTC CTTTTTTTAA 151 TTCAAGAAAA GTTTACCTTT CTTATGCTTA TGTTAGCTAT GCCAGCTCTT

1001 AATTGCATCC TTTTCTAATT AGGATTATTA ATAAAGCGTG AATATTTTGT

1051 TTTTTATTAT AGACAGAAAT TTGTAACATT ACTTCTGATT TGAAAATGCA

1101 ATTCACAAAA TATAGGGAAA TTTTTATTGA AGTAAATTTG AAATGATGGA

1151 GAAATTTCAG AAGCATAATA AAGTTCACAA TAAGGATAAT ACTTTATATA 1201 ATGTATAAAG TATATATAAT ATAATATATA TGTTATATAA ACTGCACATT

1251 ATATTCAAAC TTAAAATTGA GCTTTTTTTT TAAAGGCCCA AAATTGTACA

1301 GTGATACAAG GAGCTATTTC TAAAATTTGG CTTATGTATA ATATATTTAA

1351 ATGGGGAATT TCATCTAAAA CAATGATGTA GTATTTTTAA TATTCTGATT 1401 GGTAAAATTA AAGAGGAAAT TAATCTTTAT ATATTATTTC TTGCAGAAAC

1451 ATTCATTATT TTATTAATAT TGCCCTAAGT ACAACTAGGC AAGTGATTGC

1501 CACCTAAATC AGAAGACGTT CTAAAGTCAG TAAGAAAGTG TGAAATGCTA

1551 GTATAAAGGT TATTTTTTTT CTTTCCTAAA TAACTAAAGT GAGGTGTAGA

IbOl TTGAGCCTTG ATATTATTTA GTTAATGTTT TTTATTAATT AATTTTGGCT lb51 GGACTTTATT TAGCTTGATT AGGTTATTAT CTGTCAAACC TTTTAAGTTG

1701 ACAACATGAC TCATATATAT ACATGTGTAT AAGATGAGCA TGTGTCGAAG

1751 ACTTATTCGA CTCATTAATG AGGAAACCAG CAGATAGTAA ACCTGGTTCA

1801 AAGTACAATT CAAGAAACTG AGTATTTATG GGCATTGAAG AAAAAATGTT

1651 GAGATAAAAT TGCTGTGCAG AAAAAAGTGT TAATGAAGCC GACCTGACTA

1101 CTTAACCTTA GAGACCTGCT TTACAAGGTT GGCCCTTGAT TGGCATCTGG

1151 GAACTTGGAG TTCAGGGGGC TTCCACCATT CCCAGAACTG ATCAAAGTAG

2001 CTTACTATAT CTAAACTGTA AAACAATATA GTTTCTCCTG AACACCTGCT

2051 TTCCTTCTGG GAGTCTGGAA TTTTGGTATG TGCCAGGCAG AGACTACCTT

2101 TGTGACCAGC TCCCAGTAAA AACCCCAGGC ACTCAGTCTC TAACAAGCTT

2151 TTCTGGTTGA CAGTGTTTCA CAAGTGCTGT TACAACTGGT TGCTGGGAGA

2201 ATTAAGCTCA TCCTCTGTGA TTCCACTGGC GGAGGATTCT TGGAAGCTTG

2251 CACTTAGTTT CCCCTGACTT CACCCCATGT GTCTTTTTTC CTTTGCTGAT

2301 TTTGTTTTGT ATCCTTTCAC TGTAATAAAT CATGGCCGTG AGCAGAAAAA

2351 AAAAAAAAAA AAAAAAAAAT AAAAAAAAAA AAAAAA

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 1

ORF from 4b bp to 702 bpi peptide length 211 Category: similarity to unknown protein Classification: unclassified

1 MNGTKALAIE EFCKSLGHAC IRFDYSGVGS SDGNSEESTL GKURKDVLSI

51 IDDLADGPlQI LVGSSLGGUL MLHAAIARPE KVVALIGVAT AADTLVTKFN

101 (QLPVELKKEV EMKGVUSMPS KYSEEGVYNV (QYSFIKEAEH HCLLHSPIPV

151 NCPIRLLHGM KDDIVPUHTS MiQVADRVLST DVDVILRKHS DHRMREKADI

201 (QLLVYTIDDL IDKLSTIVN

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphmel2_7kl1ι frame 1 No Alert BLASTP hits found Pedant information for DKFZphmel2_7kl1ι frame 1

Report for DKFZphmel2_7kl1-l

ELENGTH! 211

EMU! 24301-18

Epl! 5-bl [H0M0L! PIR:A71b11 hypothetical protein RP343 - Rickettsia prowazekii 3e-21

[BLOCKS! BP04352K

[BLOCKS! PR00826E

[KU! Alpha_Beta

SElQ MNGTKALAIEEFCKSLGHACIRFDYSGVGSSDGNSEESTLGKURKDVLSIIDDLADGPiQI PRD ccchhhhhhhhhhhhccceeeeeeccccccccccccccccchhhhhhhhhhhhhccccee SElQ LVGSSLGGULMLHAAIARPEKVVALIGVATAADTLVTKFNiQLPVELKKEVEMKGVUSMPS PRD eeecccchhhhhhhhhhccceeeeeeeeeehhhhhhcccccchhhhhhhhhhhheeeccc

SElQ KYSEEGVYNVlQYSFIKEAEHHCLLHSPIPVNCPIRLLHGMKDDIVPUHTSMiQVADRVLST PRD ccccccceeeehhhhhhhhhhhhhhhccccccceeecccccccccccchhhhhhhhhhhh

SElQ DVDVILRKHSDHRMREKADIiQLLVYTIDDLIDKLSTIVN PRD hheeeeeccccchhhhhhhheeeeehhhhhhhhcccccc

(No Prosite data available for DKFZphmel2_7kl1- 1) (No Pfam data available for DKFZphmel2_7kl1-l)

DKFZphtes3_10ilb

group: nucleic acid management

DKFZphtes3_10ilb encodes a novel 742 amino acid protein with similarity to human ZK1-

The ZK1 gene is one of early response genes by exposure to ionizing radiationi and plays a role in radiation-induced apoptotic cell death on hematopoietic cells- The novel protein contains 18 zinc finger domainsi a RGD cell attachment and a ATP GTP A domain- The new protein can find application in diagnosis/therapy in leukemia predisposition/disease in the modulation of DNA repair-

similarity to ZK1 (Homo sapiens)ι complete eds-

Sequenced by (Qiagen

Locus: unknown Insert length: 2684 bp

Poly A stretch at pos- 28blι polyadenylation signal at pos- 2835

1 CGGAAATGGA GGGGGTCGCT TTCCTCACCT TCCTCGCTGC GCGGGCGGCG

51 GTTGGTAACC GGTCAGACCA GCCCGAGAGG GACCTGGTGC CTGTACCCAG

101 GCTTCTGTCG CTCTGTCGCC TGCGCTATGC CCTGCTGTAG TCACAGGAGC

151 TGTAGAGAGG ACCCCGGTAC ATCTGAAAGC CGGGAAATGG ACCCAGTGGC 201 CTTTGAGGAT GTGGCTGTGA ACTTCACCCA GGAAGAGTGG ACATTGCTGG

251 ATATTTCCCA GAAGAATCTC TTCAGGGAAG TGATGCTGGA AACTTTCAGG

301 AACCTGACCT CTATAGGAAA AAAATGGAGT GACCAGAACA TTGAATATGA

351 GTACCAAAAC CCCAGAAGAA GCTTCAGGAG TCTCATAGAA GAGAAAGTCA

401 ATGAAATTAA AGAAGACAGT CATTGTGGAG AAACTTTTAC CCAGGTTCCA 451 GATGACAGAC TGAACTTCCA GGAGAAGAAA GCTTCTCCTG AAGTAAAATC

501 ATGTGACAGC TTTGTGTGTG CAGAAGTTGG CATAGGTAAC TCATCTTTTA

551 ATATGAGCAT CAGAGGTGAC ACTGGACACA AGGCATATGA GTATCAGGAA bOl TATGGACCAA AGCCATATAA GTGTCAACAA CCTAAAAATA AGAAAGCCTT b51 CAGGTATCGC CCATCCATTA GAACACAAGA AAGGGATCAC ACTGGAGAGA 701 AACCCTATGC TTGTAAAGTC TGTGGAAAAA CCTTTATTTT CCATTCAAGC

751 ATTCGAAGAC ACATGGTAAT GCACAGTGGG GATGGAACTT ATAAATGTAA

801 ATTTTGTGGG AAAGCCTTCC ATTCTTTCAG TTTATATCTT ATCCATGAAA

651 GAACTCACAC TGGAGAGAAA CCATATGAAT GTAAACAATG TGGTAAATCC

101 TTTACTTATT CTGCTACCCT TCAAATACAT GAAAGAACTC ACACTGGGGA 151 GAAGCCCTAT GAATGTAGCA AATGTGATAA AGCATTTCAT AGTTCTAGTT

1001 CCTATCATAG ACATGAAAGA AGTCACATGG GAGAGAAGCC TTATCAATGC

1051 AAAGAATGTG GAAAAGCATT TGCATATACC AGTTCTCTTC GTAGACATGA

1101 AAGGACCCAC TCTGGGAAAA AACCGTATGA ATGTAAGCAA TATGGGGAAG

1151 GCTTATCCTA TCTTATAAGT TTTCAAACAC ACATAAGAAT GAACTCTGGA 1201 GAAAGACCTT ATAAATGTAA GATATGTGGG AAAGGCTTTT ATTCTGCCAA

1251 GTCATTTCAA ACACATGAAA AAACTCACAC TGGAGAGAAA CGCTATAAAT

1301 GCAAGCAATG TGGTAAAGCC TTCAATCTTT CCAGTTCCTT TCGATATCAT

1351 GAAAGGATTC ACACTGGAGA GAAACCCTAT GAGTGTAAGC AGTGTGGGAA

1401 AGCCTTCAGA TCTGCCTCAC AGCTTCGAGT GCACGGTGGG ACTCACACTG 1451 GAGAGAAACC CTATGAATGT AAGGAATGTG GGAAAGCCTT CAGATCTACC

1501 TCACACCTTC GAGTGCATGG TAGGACTCAT ACTGGAGAGA AACCCTATGA

1551 ATGTAAGGAA TGTGGGAAAG CCTTCAGATA TGTGAAGCAC CTTCAAATTC

IbOl ATGAAAGGAC AGAAAAACAC ATAAGAATGC CCTCTGGAGA AAGACCTTAT

IbSl AAATGTAGTA TATGTGAGAA AGGCTTTTAT TCTGCCAAGT CATTTCAAAC 1701 ACATGAAAAA ACTCACACTG GAGAGAAACC CTATGAATGC AACCAATGTG

1751 GTAAAGCCTT CAGATGTTGC AATTCCCTTC GATATCATGA AAGGACTCAC

1601 ACTGGAGAGA AACCCTATGA GTGTAAGCAA TGTGGGAAAG CCTTCAGATC

1851 TGCCTCACAC CTTCGAATGC ATGAAAGGAC TCACACTGGA GAGAAACCCT

1101 ATGAGTGTAA GCAATGTGGG AAAGCCTTCA GTTGTGCCTC AAACCTTCGA 1151 AAGCATGGTA GGACTCACAC TGGAGAGAAA CCCTATGAGT GTAAGCAATG

2001 TGGGAAAGCC TTCAGATCTG CCTCAAACCT TCAGATGCAT GAAAGGACTC

2051 ACACTGGAGA GAAACCCTAT GAATGTAAGG AATGCGAAAA AGCATTCTGT

2101 AAATTCTCTT CTTTTCAAAT ACATGAAAGG AAGCACAGAG GAGAGAAGCC

2151 CTATGAATGT AAGCATTGTG GGAATGGATT CACATCTGCC AAGATTCTTC 2201 AAATACATGC AAGAACACAC ATTGGAGAGA AACACTATGA ATGTAAGGAA

2251 TGCGGAAAAG CATTCAATTA TTTTTCTTCC TTGCATATAC ACGCAAGGAC

2301 TCATATGGGA GAGAAGCCAT ATGAATGTAA GGATTGTGGG AAAGCATTCA

2351 GCTAGCCTGG TTCCTTTTAT GGACATGAAT AGACTCACAC TGGAAGGAAG

2401 CACTATGAAT GCAAGCAATG TGGCAAAACT TTCACATTTT CCAGTTCTTT 2451 TCGATATCAT GAAAGGACTC ACACTGGGGA GAAACCCTAT CAATGTAAGC

2501 AGTGTGGGAA AGCCTTCATT CCTTTTACTT CTTTTCAATG TCATGAAAGG

2551 ACTCACACGG GAGAGAAACC CTATGAGTGT ATTCTAGTTC CGTTTGATAT

2b01 CATGAAAGGA CTTACACTGG AGTGAAACCC TATGAATGTA AGCAATGTGG 2b51 GAAAGCCTTC AGATGTGCCT CGCACCTTCA ACGGCATGGA AGGGTTCACA

27D1 CTTGGGAGAA ACTCTATGAA TGTAAGCAGT ATGGGAAAGC CTTCAGATCT

2751 GCCAAGATTC TTTGAATACA GATAATTAAT GTAAACAATT ATCATAAGTA

2801 TACTAACATG TTATTCTTTT TAAATAAGAA GGTATAATAA AATATCCCAT

2651 TGGTTTTATG TATTAAAAAA AAAAAAAAAA AAAA

BLAST Results

No BLAST result

Medline entries

16401134:

Katoh Oi Oguri Ti Takahashi Ti Takai Si Fujiwara Yi Uatanabe H-i novel Kruppel-type zinc finger genei is induced following exposure to ionizing radiation and enhances apoptotic cell death on hematopoietic cells- Biochem Biophys Res Commun 1118 Aug 28i241(3) :515-b00 15137313:

Uick MJi Ann DKi Lee NMi Loh HH-i Isolation of a cDNA encoding a novel zinc-finger protein from neuroblastoma x glioma NG106-15 cells- Gene 1115 Jan 23il52(2) :227-32

Peptide information for frame 1

ORF from 127 bp to 2352 bpi peptide length: 742

Category: similarity to known protein Classification: Nucleic acid management

Prosite motifs: RGD (14b-148)

ATP_GTP_A (115-202)

ZINC_FINGER_C2H2 (11b-21b)

ZINC_FINGER_C2H2 (224-244) ZINC_FINGER_C2H2 (252-272)

ZINC_FINGER_C2H2 (280-300)

ZINC_FINGER_C2H2 (306-328)

ZINC_FINGER_C2H2 (3b4-384)

ZINC_FINGER_C2H2 (312-412) ZINC_FINGER_C2H2 (420-440)

ZINC_FINGER_C2H2 (448-4b8)

ZINC_FINGER_C2H2 (510-530)

ZINC_FINGER__C2H2 (536-558)

ZINC_FINGER_C2H2 (Sbb-58b) ZINC_FINGER_C2H2 (514-bl4)

ZINC_FINGER_C2H2 (b22-b42)

ZINC_FINGER_C2H2 (b50-b70)

ZINC_FINGER_C2H2 (b78-b16) ZINC_FINGER_C2H2 (70b-72b) ZINC FINGER C2H2 (47b-418)

1 MPCCSHRSCR EDPGTSESRE MDPVAFEDVA VNFTiQEEUTL LDISlQKNLFR

51 EVMLETFRNL TSIGKKUSDiQ NIEYEYlQNPR RSFRSLIEEK VNEIKEDSHC

101 GETFTiQVPDD RLNFlQEKKAS PEVKSCDSFV CAEVGIGNSS FNMSIRGDTG

151 HKAYEYlQEYG PKPYKCiQlQPK NKKAFRYRPS IRTlQERDHTG EKPYACKVCG

201 KTFIFHSSIR RHMVMHSGDG TYKCKFCGKA FHSFSLYLIH ERTHTGEKPY 251 ECKiQCGKSFT YSATLiQIHER THTGEKPYEC SKCDKAFHSS SSYHRHERSH

301 MGEKPYQCKE CGKAFAYTSS LRRHERTHSG KKPYECKiQYG EGLSYLISFlQ

351 THIRMNSGER PYKCKICGKG FYSAKSFlQTH EKTHTGEKRY KCKlQCGKAFN

401 LSSSFRYHER IHTGEKPYEC KiQCGKAFRSA SiQLRVHGGTH TGEKPYECKE

451 CGKAFRSTSH LRVHGRTHTG EKPYECKECG KAFRYVKHLiQ IHERTEKHIR 501 MPSGERPYKC SICEKGFYSA KSFlQTHEKTH TGEKPYECNiQ CGKAFRCCNS

551 LRYHERTHTG EKPYECKlQCG KAFRSASHLR MHERTHTGEK PYECKiQCGKA bOl FSCASNLRKH GRTHTGEKPY ECKlQCGKAFR SASNLiQMHER THTGEKPYEC b51 KECEKAFCKF SSFiQIHERKH RGEKPYECKH CGNGFTSAKI LiQIHARTHIG

701 EKHYECKECG KAFNYFSSLH IHARTHMGEK PYECKDCGKA FS

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_10ilbι frame 1 No Alert BLASTP hits found

Peptide information for frame 2

ORF from 1703 bp to 2584 bpi peptide length-" 214 Category: questionable ORF Classification: no clue

1 MKKLTLERNP MNATNVVKPS DVAIPFDIMK GLTLERNPMS VSNVGKPSDL 51 PHTFECMKGL TLERNPMSVS NVGKPSVVPiQ TFESMVGLTL ERNPMSVSNV

101 GKPSDLPiQTF RCMKGLTLER NPMNVRNAKK HSVNSLLFKY MKGSTEERSP

151 MNVSIVGMDS HLPRFFKYMlQ EHTLERNTMN VRNAEKHSII FLPCIYTiQGL

201 IUERSHMNVR IVGKHSASLV PFMDMNRLTL EGSTMNASNV AKLSHFPVLF

251 DIMKGLTLGR NPINVSSVGK PSFLLLLFNV MKGLTRERNP MSVF

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_10ilbι frame 2

TREMBL:AF153201_1 product: "zinc finger protein dp"i Homo sapiens zinc finger protein dp mRNAi complete cds-i N = li Score = 225ι P 4-le-lβ >TREMBL:AF153201_1 product: "zinc finger protein dp"i Homo sapiens zinc finger protein dp mRNAi complete eds- Length = 423

HSPs:

Score = 225 (33-6 bits)ι Expect = 4-le-lβι P = 4-le-lβ Identities = 84/24b (34*)ι Positives = 122/24b (41*)

(Query: lb VVKPSDVA- IPFDIMKGLTLERNPMSVSNVGKPSDLPHTFECMKGLTLERNPMSVSNVGK 74

V KPS A I F I + + L RN + V +V K S T ++G TLERNP++V +VGK

Sb jct : 3 VGKPSVRAlQILFCIRESI-

LGRNHIHVISVAKVSVRIiQTLLNIEGSTLERNPINVMSVGK bl

(Query : 75 PSVVPlQTFESMVGLTLERNPMSVSNVGKPSDLPiQTFRCMKGLTLERNPMNVRNAKKHSVN 134

+ (Q+ + G LERNP+ V NV KPS Q + TLER+ +V

+ A K V

Sbj ct : b2

LLIRAiQSLFYIRGFILERNPIPVINVAKPSVGFfQILLIINEFTLERSLTHVISAIKCLVE 121

(Query: 135 SLLFKYMKGSTEERSPMNVSIVGMDS-

HLPRFFKYMiQEHTLERNTMNVRNAEKHSIIFLP 113

+ + + R+PMNV VG P F +++E TLERN M+V

K + Sbjct: 122 DEILLNITEFIiQVRNPMNVMNVGKPLVRAPTLF-

FIRESTLERNLMHVVIVLKALVAVlQI 180

(Query: 114

CIYTiQGLIUERSHMNVRIVGKHSASLVPFMDMNRLTLEGSTMNASNVAKLSHFPVLFDIM 253 + + ER+HM+V V K +++ TL S + A V K S

+ +

Sbjct: 181 LLSIKEYTLERNHMHVISVIKVLVKAlQTSLNIREYTLVKSLIIAIVVRKPSVRVLTLFFI 240 (Query: 254 KGLTLGRN 2bl

+ TL +N Sbjct: 241 REFTLEKN 248

Score = 215 (32-3 bits)ι Expect = 1-le-lbι P = 1-le-lb Identities = 82/24b (33*)ι Positives = 124/24b (50*)

(Query : 44

VGKPSDLPHTFECMKGLTLERNPMSVSNVGKPSVVPlQTFESMVGLTLERNPMSVSNVGKP 103 VGKPS C + + L RN + V +V K SV (QT ++^' G TLERNP++V +VGK Sbj ct : 3

VGKPSVRAiQILFCIRESILGRNHIHVISVAKVSVRIlQTLLNIEGSTLERNPINVMSVGKL b2

(Query : 104 SDLPlQTFRCMKGLTLERNPMNVRNAKKHSVNSLLFKYMKGSTEERSPMNV- SIVGM D 151

(Q+ + + G LERNP+ V N K SV + + T ERS +V S + D Sbjct: b3 LIRAiQSLFYIRGFILERNPIPVINVAKPSVGFiQILLIINEFTLERSLTHVISAIKCLVED 122

(Query: ibO SHLPRFFKYMlQEHTLERNTMNVRNAEKHSIIFLPCIY- TtQGLIUERSHMNVRIVGKHSAS 218

L +++(Q RN MNV N K ++ P ++ + ER+ M+V IV K +

Sbjct: 123 EILLNITEFIlQV RNPMNVMNVGK-

PLVRAPTLFFIRESTLERNLMHVVIVLKALVA 177

(Query: 211 LVPFMDMNRLTLEGSTMNASNVAK- LSHFPVLFDIMKGLTLGRNPINVSSVGKPSFLLLL 277

+ + + TLE + M+ +V K L +1 + TL ++ I V KPS +L Sbjct: 178 V(QILLSIKEYTLERNHMHVISVIKVLVKA(QTSLNIRE- YTLVKSLIIAIVVRKPSVRVLT 23b

(Query: 276 FNVMKGLTRERN 261

++ T E+N Sbjct: 237 LFFIREFTLEKN 246

Score = 207 (31-1 bits)ι Expect = 5-2e-15ι P = 5-2e-15 Identities = 80/270 (21*)ι Positives = 121/270 (47*) (Query: 1 MKKLTLERNPMNATNVVKPSDVAIPFDI-

MKGLTLERNPMSVSNVGKPSDLPHTFECMKG 51

+++ L RN ++ +V K S V I + ++G TLERNP++V +VGK

+ ++G

Sb j ct : lb IRESILGRNHIHVISVAKVS- VRI(QTLLNIEGSTLERNPINVMSVGKLLIRA(QSLFYIRG 74

(Query: bO

LTLERNPMSVSNVGKPSVVP(QTFESMVGLTLERNPMSVSNVGKPSDLP(QTFRCMKGLTLE 111

LERNP+ V NV KPSV Q + TLER+ V + K + +

Sbjct: 75 FILERNPIPVINVAKPSVGFlQILLIINEFTLERSLTHVISAIKCLVEDEILLNITEFIiQV 134

(Query: 120 RNPMNVRNAKKHSVNSLLFKYMKGSTEERSPMNVSIVGMDSHLPRFFKYMiQEHTLERNTM 171

RNPMNV N K V + +++ ST ER+ M+V IV +

++E+TLERN M

Sbjct: 135

RNPMNVMNVGKPLVRAPTLFFIRESTLERNLMHVVIVLKALVAViQILLSIKEYTLERNHM 114

(Query: 160

NVRNAEKHSIIFLPCIYTiQGLIUERSHMNVRIVGKHSASLVPFMDMNRLTLEGSTMNASN 231 +V + K + + + +S + +V K S ++ + TLE

+ + Sbjct: 115

HVISVIKVLVKAiQTSLNIREYTLVKSLIIAIVVRKPSVRVLTLFFIREFTLEKNYYLCTiQ 254

(Query : 240 VAKLSHFPVLFDIMKGLTL--GRNPINVSSVGK 270 + K F + D + + K + G P S K Sbjct : 255 CSK--SFS(QISDLIKH(3RIHTGEKPYKCSECRK 285

Score = 181 ( 27 - 2 bi ts ) ι Expect = l - 4e-ll ι P = l - 4e-ll Ident i t i es = 74 /2b1 ( 27* ⁾ ι Posit i ves = llb/2b1 ( 43* ) fluery: 5

TLERNPMNATNVVKPSDVAIPFDIMKGLTLERNPMSVSNVGKPSDLPHTFECMKGLTLER b4 TLERNP+N +V K A ++G LERNP+ V NV KPS + TLER

Sbjct: 48 TLERNPINVMSVGKLLIRAlQSLFYIRGFILERNPIPVINVAKPSVGFiQILLIINEFTLER 107

(Query: b5 NPMSVSNVGKPSVVPiQTFESMVGLTLERNPMSVSNVGKPSDLPiQTFRCMKGLTLERNPMN 124

+ V + K V + ++ RNPM+V NVGKP T ++

TLERN M+

Sbjct: 108

SLTHVISAIKCLVEDEILLNITEFIώVRNPMNVMNVGKPLVRAPTLFFIRESTLERNLMH lb7

(Query: 125 VRNAKKHSVNSLLFKYMKGSTEERSPMNV-

SIVGMDSHLPRFFKYMiQEHTLERNTMNVRN 183

V K V + +K T ER+ M+V S++ + ++E+TL

++ + Sbjct: Ibβ VVIVLKALVAViQILLSIKEYTLERNHMHVISVIKVLVKAiQTSLN- IREYTLVKSLIIAIV 22b

(Query: 164

AEKHSIIFLPCIYTi^QGLIUERSHMNVRIVGKHSASLVPFMDMNRLTLEGSTMNASNVAKL 243 K S+ L + + E + + + K + + + R +

S K

Sbjct: 227 VRKPSVRVLTLFFIREFTLEKNYYLCT(QCSKSFS(QISDLIKH(QRIHTGEKPYKCSECRKA 2δb (Query: 244 SHFPVLFDIMKGLTLGRNPINVSSVGKPSF 273

L + + + G+ P GK SF

Sbjct: 287 FS(QCSLLALH(QRIHTGKKPNPCDECGK-SF 315

Score = Ibb (24-1 bits)ι Expect = 8-4e-10ι P = 8-4e-10 Identities = b3/114 (32*)ι Positives = 61/114 (45*)

(Query: 100

VGKPSDLPώTFRCMKGLTLERNPMNVRNAKKHSVNSLLFKYMKGSTEERSPMNVSIVGMD 151 VGKPS Q C++ L RN ++V + K SV ++GST ER+P+NV VG Sbjct: 3

VGKPSVRA(^QILFCIRESILGRNHIHVISVAKVSVRI(QTLLNIEGSTLERNPINVMSVGKL b2

(Query: IbO SHLPRFFKYM(2EHTLERNTMNVRNAEKHSIIFLPCIYT(QGLIUERSHMNVRIVGKHSASL 211

+ Y++ LERN + V N K S+ F + ERS +V

K

Sbjct: b3

LIRA(^QSLFYIRGFILERNPIPVINVAKPSVGF(^QILLIINEFTLERSLTHVISAIKCLVED 122

(Query: 220 VPFMDMNRLTLEGSTMNASNVAK-

LSHFPVLFDIMKGLTLGRNPINVSSVGKPSFLLLLF 276

+++ + MN NV K L P LF I + TL RN ++V V K

+ + Sbjct: 123 EILLNITEFIiQVRNPMNVMNVGKPLVRAPTLFFIRES-

TLERNLMH VIVLKALVAViQIL 161

(Query: 271 NVMKGLTRERNPMSV 213 +K T ERN M V Sbjct: 162 LSIKEYTLERNHMHV lib

Pedant information for DKFZphtes3_10ilbι frame 1

Report for DKFZphtes3__10ilb-l

[LENGTH! 784 [MU! 10657-05

[pi! 1-24

[HOMOL! TREMBL:AB011414_1 gene: "ZKl"i product: "Kruppel- type zinc finger protein"i Homo sapiens ZK1 mRNA for Kruppel-type zinc finger proteini complete eds- 0-0

[FUNCAT! 30-10 nuclear organization [S- cerevisiaei YJL05bc! be-33

[FUNCAT! 04- 05- DI- 04 transcriptional control [S- cerevisiaei YJL05bc! be-33

[FUNCAT! 04-11 other transcription activities [S- cerevisiaei

Y0R113w! 5e-24

[FUNCAT! 04-01-01 rrna synthesis CS. cerevisiaei YPRlδbc PZFl -

TFIIIA! le-20 EFUNCAT! 04-03.01 trna synthesis ES- cerevisiaei YPRlβbc PZFl -

TFIIIA! le-20

[FUNCAT! 13-04 homeostasis of other ions [S- cerevisiaei

YNL027w! le-13

[FUNCAT! 11-07 detoxif icaton CS. cerevisiaei YGL254w! Se-IE [FUNCAT! 01-02-04 regulation of nitrogen and sulphur utilization CS- cerevisiaei YGL254w! 2e-12

[FUNCAT! 01.05-04 regulation of carbohydrate utilization [S- cerevisiaei YGL201w! 2e-ll

[FUNCAT! 04-05-11 other mrna-transcription activities [S- cerevisiaei YER028c! 3e-lD

[FUNCAT! 11-01 stress response [S- cerevisiaei YKLDb2w! le-01

[FUNCAT! 01-01-04 regulation of amino-acid metabolism [S- cerevisiaei YDR253c! 5e-01

[FUNCAT! 11 unclassified proteins CS- cerevisiaei YBRObbc! 3e-08

[FUNCAT! 03-07 pheromone responsei mating-type determinationi sex-specific proteins [S- cerevisiaei YDR14bc! le-D7

[FUNCAT! 03-25 cytokinesis CS. cerevisiaei YLR131c! 2e-0b

CBL0CKS! BL004bb TFIIS zinc ribbon domain proteins [BLOCKS! BLD024SA Phytochrome chro ophore attachment site proteins

[BLOCKS! DMD1151B

[BLOCKS! PF013b3B

[BLOCKS! BL01D30 EBLOCKS! PFOOOIbB

[BLOCKS! BL00026 Zinc fingeri C2H2 typei domain proteins

[BLOCKS! BP04213E

[BLOCKS! BP04213C

EBLOCKS! BP04213B [SCOP! d2adr 7-31-1-1-4 ADR1 [synthetic based on yeast

(Saccharomyce 2e-05

[PIRKU! nucleus le-53

[PIRKU! RNA binding 2e-58 [PIRKU! duplication le-34

[PIRKU! tandem repeat le-171

[PIRKU! spermatogenesis 5e-b2

[PIRKU! zinc le-lbl [PIRKU! zinc finger 0-0

[PIRKU! DNA binding 0-0

[PIRKU! metal binding le-12D

[PIRKU! phosphoprotein 2e-5δ

[PIRKU! leucine zipper le-53 [PIRKU! alternative splicing 2e-58

[PIRKU! eye lens le-111

[PIRKU! oocyte. le-lOb

[PIRKU! transcription factor le-111

[PIRKU! embryo le-lOb [PIRKU! segmentation le-34

[PIRKU! transcription regulation le-152

[SUPFAM! POZ domain homology 7e-63

[SUPFAM! transcription factor Krueppel le-34

[SUPFAM! zinc finger protein ZFP-3b le-173 [SUPFAM! transcription factor IIIA δe-31

[PROSITE! ATP_GTP_A 1

[PROSITE! RGD 1

[PROSITE! ZINC_FINGER_C2H2 16

[PFAM! Zinc fingeri C2H2 type [PFAM! TNFR/NGFR cysteine-rich region

[KU! Irregular

[KU! 3D

[KU! LOU COMPLEXITY 3-57 *

SElQ RKURGSLSSPSSLRGRRLVTGiQTSPRGTUCLYPGFCRSVACAMPCCSHRSCREDPGTSES SEG ■ ■ -xxxxxxxxxxxxxxx

ImeyF

SElQ REMDPVAFEDVAVNFTlQEEUTLLDISiQKNLFREVMLETFRNLTSIGKKUSDlQNIEYEYiQN SEG

ImeyF

SElQ PRRSFRSLIEEKVNEIKEDSHCGETFTiQVPDDRLNFlQEKKASPEVKSCDSFVCAEVGIGN SEG

ImeyF

SElQ SSFNMSIRGDTGHKAYEYlQEYGPKPYKClQiQPKNKKAFRYRPSIRTlQERDHTGEKPYACKV SEG

ImeyF

SElQ CGKTFIFHSSIRRHMVMHSGDGTYKCKFCGKAFHSFSLYLIHERTHTGEKPYECKiQCGKS SEG

ImeyF

SElQ FTYSATLl^QIHERTHTGEKPYECSKCDKAFHSSSSYHRHERSHMGEKPYi^QCKECGKAFAYT SEG xxxxxxxxxxxxx ImeyF

SElQ SSLRRHERTHSGKKPYECKiQYGEGLSYLISFiQTHIRMNSGERPYKCKICGKGFYSAKSFiQ SEG

ImeyF

SElQ THEKTHTGEKRYKCK(QCGKAFNLSSSFRYHERIHTGEKPYECK(2CGKAFRSAS<QLRVHGG SEG

ImeyF

SElQ THTGEKPYECKECGKAFRSTSHLRVHGRTHTGEKPYECKECGKAFRYVKHLiQIHERTEKH SEG

ImeyF

SE(3 IRMPSGERPYKCSICEKGFYSAKSFlQTHEKTHTGEKPYECNlQCGKAFRCCNSLRYHERTH SEG

ImeyF

SElQ TGEKPYECKiQCGKAFRSASHLRMHERTHTGEKPYECKiQCGKAFSCASNLRKHGRTHTGEK SEG

ImeyF

- -TTTEETTTTTCEETTHHHHHHHHHHHHTTCCEEETTTTEEECCHHHHHHHHHHHHCCC

SElQ PYECKiQCGKAFRSASNLiQMHERTHTGEKPYECKECEKAFCKFSSFiQIHERKHRGEKPYEC SEG

ImeyF

CEEETTTTEEECCHHHHHHHHHHH

SElQ KHCGNGFTSAKILiQIHARTHIGEKHYECKECGKAFNYFSSLHIHARTHMGEKPYECKDCG SEG

ImeyF

SElQ KAFS SEG ....

ImeyF

Prosite for DKFZphtes3_10ilb ■ 1

PSOOOlb 188- ->111 RGD PDOCOOOlb

PS00017 237- ->245 ATP_GTP_A PD0C00017

PS0D028 236- ->2S1 ZINC. FINGER _C2H2 PD0C00028

PS00028 2bb- ->287 ZINC FINGER _C2H2 PD0C00028

PS00026 214- ->315 ZINC FINGER. C2H2 PD0C00028

PS00026 322- ->343 ZINC_ FINGER _C2H2 PD0C00026

PS00026 350- ->371 ZINC. FINGER _C2H2 PD0C00026

PS00028 40b- ->427 ZINC FINGER _C2H2 PD0C00028

PS00028 434- ->455 ZINC FINGER _C2H2 PD0C00028

PS00028 4b2- ->463 ZINC FINGER _C2H2 PD0C00028

PS00026 410- ->511 ZINC FINGER C2H2 PD0C00028

PS00028 552- ->573 ZINC .FINGER. C2H2 PD0CO0028 PS00026 56D->b01 ZINC_FINGER_C2H2 PD0C00026

PS00028 b06->b21 ZINC_FINGER_C2H2 PD0C00026

PS00026 b3b->b57 ZINC_FINGER_C2H2 PD0C00026

PS00028 bb4->b85 ZINC_FINGER_C2H2 PD0C00028

PS00026 b12->713 ZINC_FINGER_C2H2 PD0C00028

PS00026 72D->741 ZINC_FINGER_C2H2 PD0C00028

PS00028 746->7b1 ZINC_FINGER_C2H2 PD0C00026

PS00028 518->S41 ZINC FINGER C2H2 PD0C00028

Pfam for DKFZphtes3_10ilb- 1

HMM_NAME TNFR/NGFR cysteine-rich region

HMM *CpeGtYtD-UNHvpqClpC- - trCePEMG(QYMvqPCTwT(QNTVC*

C + +++ +++++C C ++C+++ G++++++ ++ V

(Query 30 CLYPGFCRSVACAMPC—CSHRSCREDPGTSESREMDP VA b7

HMM_NAME Zinc fingeri C2H2 type

HMM *CpwPDCgKtFrrwsNLrRHMRTH*

C++ CGKTF S+ RRHM +H (Query 238 CKV—CGKTFIFHSSIRRHMVMH 258 32-15 (bits) f: 2bb t: 28b Target: dkfzphtes3_lUilb - 1 similarity to ZKl (Homo sapiens)ι complete eds-

Alignment to HMM consensus: (Query *CpwPDCgKtFrrwsNLrRHMRTH*

C++ CGK+F + S + +H RTH dkfzphtes3 2bb CKF—CGKAFHSFSLYLIHERTH 26b

(Query f: 214 t: 314 Target: dkfzphtes3_10ilb ■ 1 similarity to ZKl (Homo sapiens)ι complete eds- Alignment to HMM consensus: HMM *CpwPDCgKtFrrwsNLrRHMRTH*

C+ CGK+F+++ +L++H RTH (Query 214 CK<2--CGKSFTYSATLiQIHERTH 314

34-22 (bits) f: 322 t: 342 Target: dkfzphtes3_lUilb - 1 similarity to ZKl (Homo sapiens)ι complete eds- Alignment to HMM consensus: (Query *CpwPDCgKtFrrwsNLrRHMRTH*

C++ C+K+F ++S++ RH R+H dkfzphtes3 322 CSK--CDKAFHSSSSYHRHERSH 342

(Query f: 350 t "- 370 Target: dkfzphtes3_10ilb ■ 1 similarity to ZKl (Homo sapiens)ι complete eds-

Alignment to HMM consensus: HMM *CpwPDCgKtFrrwsNLrRHMRTH* C++ CGK+F + S+LRRH RTH

(Query 350 CKE--CGKAFAYTSSLRRHERTH 370 32-01 (bits) f: 40b t: 42b Target: dkfzphtes3_10ilb • 1 similarity to ZKl (Homo sapiens)ι complete eds-

Alignment to HMM consensus: (Query *CpwPDCgKtFrrwsNLrRHMRTH* C++ CGK F ++ ++++H +TH dkfzphtes3 40b CKI--CGKGFYSAKSF(QTHEKTH 42b

(Query f: 434 t: 454 Target: dkfzphtes3_10ilb .1 similarity to ZKl (Homo sapiens)ι complete eds- Alignment to HMM consensus:

HMM *CpwPDCgKtFrrwsNLrRHMRTH*

C+ CGK+F+ +S++R H R+H (Query 434 CK(Q—CGKAFNLSSSFRYHERIH 454 32-14 (bits) f: 4b2 t: 462 Target: dkfzphtes3_10ilb -1 similarity to ZKl (Homo sapiens)ι complete eds-

Alignment to HMM consensus: (Query *CpwPDCgKtFrrwsNLrRHMRTH*

C+ CGK+FR++S+LR H TH dkfzphtes3 4b2 CKiQ—CGKAFRSASlQLRVHGGTH 482

(Query f: 410 t: 510 Target: dkfzphtes3_10ilb ■ 1 similarity to ZKl (Homo sapiens)ι complete eds- Alignment to HMM consensus: HMM *CpwPDCgKtFrrwsNLrRHMRTH*

C++ CGK+FR+ S+LR H RTH (Query 410 CKE--CGKAFRSTSHLRVHGRTH 510

30- bl (bits) f: 518 t: 540 Target"^, dkfzphtes3_10ilb ■ 1 similarity to ZKl (Homo sapiens)ι complete eds- Alignment to HMM consensus: (Query *CpwPDCgKtFrrwsNLrRHMR- -T-H*

C++ CGK+FR+ +L++H R H dkfzphtes3 518 CKE~CGKAFRYVKHL(QIHERTE-KH 540 ώuery f: 552 t: 572 Target: dkfzphtes3_10ilb ■ 1 similarity to ZKl (Homo sapiens)ι complete eds-

Alignment to HMM consensus: HMM *CpwPDCgKtFrrwsNLrRHMRTH* C++ C+K F ++ ++++H +TH

(Query 552 CSI--CEKGFYSAKSF(QTHEKTH 572

31-33 (bits) f: 580 t: bOO Target: dkfzphtes3_lUϋb- 1 similarity to ZKl (Homo sapiens)ι complete eds- Alignment to HMM consensus:

(Query *CpwPDCgKtFrrwsNLrRHMRTH*

C+ CGK+FR +LR H RTH dkfzphtes3 560 CN(Q—CGKAFRCCNSLRYHERTH bOO (Query f: b06 t: b28 Target: dkfzphtes3_10ilb -1 similarity to ZKl (Homo sapiens)ι complete eds-

Alignment to HMM consensus: HMM *CpwPDCgKtFrrwsNLrRHMRTH*

C+ CGK+FR++S+LR+H RTH (Query bOβ CK(Q--CGKAFRSASHLRMHERTH b28

35-30 (bits) f: b3b t: bSb Target: dkfzphtes3_10ilb - 1 similarity to ZKl (Homo sapiens)ι complete eds- Alignment to HMM consensus: (Query *CpwPDCgKtFrrwsNLrRHMRTH*

C+ CGK+F+ +SNLR+H RTH dkfzphtes3 b3b CK(Q--CGKAFSCASNLRKHGRTH b5b

(Query f : bb4 t: b84 Target: dkfzphtes3_lDϋb • 1 similarity to ZKl (Homo sapiens)ι complete eds-

Alignment to HMM consensus: HMM *CpwPDCgKtFrrwsNLrRHMRTH* C+ CGK+FR++SNL++H RTH

(Query bb4 CK(Q--CGKAFRSASNL(QMHERTH b84

31-74 (bits) f: b12 t: 712 Target: dkfzphtes3_10ilb - 1 similarity to ZKl (Homo sapiens)ι complete eds- Alignment to HMM consensus:

(Query *CpwPDCgKtFrrwsNLrRHMRTH*

C++ C+K+F+ S++++H R H dkfzphtes3 b12 CKE—CEKAFCKFSSFiQIHERKH 712 (Query f: 720 t: 740 Target: dkfzphtes3_10ilb - 1 similarity to ZKl (Homo sapiens)ι complete eds-

Alignment to HMM consensus: HMM *CpwPDCgKtFrrwsNLrRHMRTH*

C++ CG F+++ L++H RTH (Query 720 CKH--CGNGFTSAKIL(QIHARTH 740

34-86 (bits) f: 748 t: 7b8 Target: dkfzphtes3_10ilb - 1 similarity to ZKl (Homo sapiens)ι complete eds- Alignment to HMM consensus: (Query *CpwPDCgKtFrrwsNLrRHMRTH*

C++ CGK+F++ S+L +H RTH dkfzphtes3 748 CKE--CGKAFNYFSSLHIHARTH 7bβ

Pedant _. information for DKFZphtes3_10ilbι frame 2

Report for DKFZphtes3_lDilb-2

[LENGTH! 214

[MU! 33083-18

[pi! 1-17 [HOMOL! TREMBL : AF153201_1 product: "zinc finger protein dp"i Homo sapiens zinc finger protein dp mRNAi complete eds. 7e- 17

[KU! All_Alpha

SElQ MKKLTLERNPMNATNVVKPSDVAIPFDIMKGLTLERNPMSVSNVGKPSDLPHTFECMKGL PRD cccccccccccceeeeecccccchhhhhccccccccccccccccccccccccchhhhhee

SElQ TLERNPMSVSNVGKPSVVPi^QTFESMVGLTLERNPMSVSNVGKPSDLPl^QTFRCMKGLTLER PRD ecccccccccccccccchhhhhhhhhhhhhccccccccccccccccchhhhhhhhhhhcc

SElQ NPMNVRNAKKHSVNSLLFKYMKGSTEERSPMNVSIVGMDSHLPRFFKYMi^QEHTLERNTMN PRD cccccccccccccccccccccccccccccccceeeeecccchhhhhhhhhhhhhhhcccc SE(Q VRNAEKHSIIFLPCIYTlQGLIUERSHMNVRIVGKHSASLVPFMDMNRLTLEGSTMNASNV PRD chhhhhhheeeccceeechhhhhcccceeeeeccccceeeeccchhhhhhhccccccccc

SEl^Q AKLSHFPVLFDIMKGLTLGRNPINVSSVGKPSFLLLLFNVMKGLTRERNPMSVF PRD cccccccchhhhhhhhcccccccccccccccchhhhhhhhhccccccccccccc

(No Prosite data available for DKFZphtes3_10ilb .2) (No Pfam data available for DKFZphtes3_10ilb ■ 2)

DKFZphtes3_10nlO

group: testis derived

DKFZphtes3_10nlO encodes a novel 502 amino acid protein without similarity to known proteins. The mRNA is differentially polyadenylated and the novel protein is ubiquitously expressed-

No informative BLAST resultsi No predictive prositei pfam or SCOP motife- The new protein can find application in studying the expression profile of testis-specific genes-

unknown protein differentially polyadenylated

Sequenced by (Qiagen Locus: unknown

Insert length: 2551 bp

Poly A stretch at pos- 2531ι polyadenylation signal at pos- 2513

1 CTCAGCCTCC CAAGTGGCTG GGACTGCAGG TTCTAAATGG CTTCTAAGAA

51 GTTGGGTGCA GATTTTCATG GGACTTTCAG TTACCTTGAT GATGTCCCAT

101 TTAAGACAGG AGACAAATTC AAAACACCAG CTAAAGTTGG TCTACCTATT

151 GGCTTCTCCT TGCCTGATTG TTTGCAGGTT GTCAGAGAAG TACAGTATGA 201 CTTCTCTTTG GAAAAGAAAA CCATTGAGTG GGCTGAAGAG ATTAAGAAAA

251 TCGAAGAAGC CGAGCGGGAA GCAGAGTGCA AAATTGCGGA AGCAGAAGCT

301 AAAGTGAATT CTAAGAGTGG CCCAGAGGGC GATAGCAAAA TGAGCTTCTC

351 CAAGACTCAC AGTACAGCCA CAATGCCACC TCCTATTAAC CCCATCCTCG

401 CCAGCTTGCA GCACAACAGC ATCCTCACAC CAACTCGGGT CAGCAGTAGT 451 GCCACGAAAC AGAAAGTTCT CAGCCCACCT CACATAAAGG CGGATTTCAA

501 TCTTGCTGAC TTTGAGTGTG AAGAAGACCC ATTTGATAAT CTGGAGTTAA

551 AAACTATTGA TGAGAAGGAA GAGCTGAGAA ATATTCTGGT AGGAACCACT bOl GGACCCATTA TGGCTCAGTT ATTGGACAAT AACTTGCCCA GGGGAGGCTC bSl TGGGTCTGTG TTACAGGATG AGGAGGTCCT GGCATCCTTG GAACGGGCAA 701 CCCTAGATTT CAAGCCTCTT CATAAACCCA ATGGCTTTAT AACCTTACCA

751 CAGTTGGGCA ACTGTGAAAA GATGTCACTG TCTTCCAAAG TGTCCCTCCC

801 CCCTATACCT GCAGTAAGCA ATATCAAATC CCTGTCTTTC CCCAAACTTG

651 ACTCTGATGA CAGCAATCAG AAGACAGCCA AGCTGGCGAG CACTTTCCAT

101 AGCACATCCT GCCTCCGCAA TGGCACGTTC CAGAATTCCC TAAAGCCTTC 151 CACCCAAAGC AGTGCCAGTG AGCTCAATGG GCATCACACT CTTGGGCTTT

1001 CAGCTTTGAA CTTGGACAGT GGCACAGAGA TGCCAGCCCT GACATCCTCC

1051 CAGATGCCTT CCCTCTCTGT TTTGTCTGTG TGCACAGAGG AATCATCACC

1101 TCCAAATACT GGTCCCACGG TCACCCCTCC TAATTTCTCA GTGTCACAAG

1151 TGCCCAACAT GCCCAGCTGT CCCCAGGCCT ATTCTGAACT GCAGATGCTG 1201 TCCCCCAGCG AGCGGCAGTG TGTGGAGACG GTGGTCAACA TGGGCTACTC

1251 GTACGAGTGT GTCCTCAGAG CCATGAAGAA GAAAGGAGAG AATATTGAGC

1301 AGATTCTCGA CTATCTCTTT GCACATGGAC AGCTTTGTGA GAAGGGCTTC

1351 GACCCTCTTT TAGTGGAAGA GGCTCTGGAA ATGCACCAGT GTTCAGAAGA 1401 AAAGATGATG GAGTTTCTTC AGTTAATGAG CAAATTTAAG GAGATGGGCT

1451 TTGAGCTGAA AGACATTAAG GAAGTTTTGC TATTACACAA CAATGACCAG

1501 GACAATGCTT TGGAAGACCT CATGGCTCGG GCAGGAGCCA GCTGAGACCA

1551 GGCCCTGCCT AGGCCCTGCC GCAGAACCAC CATCCCTGGG AGGCCCTGCA

IbOl GAGCCCACCT GTGGGGAAAG kGk kGGGGCk GCTTCCGGAT TTTCTTTTGG lb51 GGGTTAGAAG GTCAGGTGTG GAGACTGCTC GCCAGTCTCT GTGAGCCTAG

1701 GCCCTGAGCT GGGGAGGTGG GGAAGATTCG GGCATGTGAG TGCCCCCAGA

1751 ACTGTCCTGG CTCCTTCCGT ATTAAACGCA TTTGCATTTT GAGAAGTGTC

IflDl CTTCCCACTT CAGCCCTCCG GAGAGACTAC CCTAGTCTTT CTGGGGTGTT

1851 TATGTCCTCA GCTGAAGCCT GGCCTAGTTG CTGAGAGGGG CTGGGGAGAT

1101 GGGGCGGGkG GGCCAGACTC AGTGCTGCTG TGGAGCTAGG TGCTTCCCCC

1151 TTCCCCTGAG ACTGGTTGAC TGAACTCCAG TCAAGTTGAG TTCAAGTGAA

2001 AGATTCTTCC AGGGTTTTAT TTTTTCCCCT CCTAACAAAG TCTCATAGTG

2051 TTAACACTGG TTCTGCAATA TCTCTGAGGT GCAAAGAATG CACTTTTCCC

2101 TATGGGGCCC AGAGTTTGCC TTTTCTGCCA GGCAGTCACC ACGCTTCCCT

2151 ACCCCAGCCT GTTTCTTTTG GCTTGGTTTG GACCACAGTC CTCTGCTACC

2201 CAGGGTTTTA GAGCCCCTGC TCTAGGAAAC AGTTTAAGAA ATCATTGGCC

2251 CCTTCCCAGC ACATTGAATG GGTAAGCAGA CAGGCCATGA TTTAGTTGGC

2301 CAGCACTAAC TCCACCTCTG TTCTCCTTGA ACAGCTTCCC CTCCAGCCCA

2351 CTGCTTTAGG ATGACACAAT GAATAACACC TAGTCATAGA AATCAGTCTC

2401 TCTGGTTTGT TTTGTATTAT GTTGTACATC ATTAAAGATC TAAATACAAA

2451 GGATATACAG TCTTGAATCT AAAATAATTT GCTAACTATT TTGATTCTTC

25D1 AGAGAGAACT ACTAATAAAA ATCTAAAAGG TAAAAAAAAA AAAAAAAAAA

2551 A

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 1

ORF from 37 bp to 1542 bpi peptide length: 502 Category: putative protein Classification: unclassified

1 MASKKLGADF HGTFSYLDDV PFKTGDKFKT PAKVGLPIGF SLPDCLlQ VR

51 EVlQYDFSLEK KTIEUAEEIK KIEEAEREAE CKIAEAEAKV NSKSGPEGDS

101 KMSFSKTHST ATMPPPINPI LASLiQHNSIL TPTRVSSSAT KiQKVLSPPHI 151 KADFNLADFE CEEDPFDNLE LKTIDEKEEL RNILVGTTGP IMAiQLLDNNL

201 PRGGSGSVLiQ DEEVLASLER ATLDFKPLHK PNGFITLPiQL GNCEKMSLSS

251 KVSLPPIPAV SNIKSLSFPK LDSDDSNiQKT AKLASTFHST SCLRNGTFώN

301 SLKPSTC3SSA SELNGHHTLG LSALNLDSGT EMPALTSSiQM PSLSVLSVCT

351 EESSPPNTGP TVTPPNFSVS (QVPNMPSCPώ AYSELiQMLSP SERlQCVET V 401 NMGYSYECVL RAMKKKGENI ElQILDYLFAH GώLCEKGFDP LLVEEALEMH

451 (QCSEEKMMEF LlQLMSKFKEM GFELKDIKEV LLLHNNDώDN ALEDLMARAG 501 AS BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_10nl0ι frame 1

No Alert BLASTP hits found

Pedant information for DKFZphtes3_10nl0ι frame 1

Report for DKFZphtes3_10nlO -1

[LENGTH! 502

[MU! 55063-76

[pi! 5-02 [BLOCKS! PR01083D

[BLOCKS! BL0130bB

[KU! All_Alpha

[KU! L0U_C0MPLEXITY 6-57 *

SElQ MASKKLGADFHGTFSYLDDVPFKTGDKFKTPAKVGLPIGFSLPDCLlQVVREVlQYDFSLEK

SEG xx

PRD cccccccccccccccccccccccccccccccccccccccccccchhhhhhhhhhcccchh SElQ KTIEUAEEIKKIEEAEREAECKIAEAEAKVNSKSGPEGDSKMSFSKTHSTATMPPPINPI SEG xxxxxxxxxxxxxxxxxxxxxxxxxxxxx

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhcccccccccccccccccccccccccchhh

SElQ LASLiQHNSILTPTRVSSSATKlQKVLSPPHIKADFNLADFECEEDPFDNLELKTIDEKEEL SEG

PRD hhhhcccccccccccccchhhhhcccccchhhhhcccccccccccccccccchhhhhhhh

SElQ RNILVGTTGPIMAiQLLDNNLPRGGSGSVLiQDEEVLASLERATLDFKPLHKPNGFITLPlQL SEG PRD hhhhccccchhhhhhhhcccccccccccchhhhhhhhhhhhhcccccccccccccccccc

SElQ GNCEKMSLSSKVSLPPIPAVSNIKSLSFPKLDSDDSNlQKTAKLASTFHSTSCLRNGTFlQN

SEG

PRD ccccccccccccccccccccccccccccccccccccchhhhhhhhhcccccccccccccc

SElQ SLKPSTtQSSASELNGHHTLGLSALNLDSGTEMPALTSSiQMPSLSVLSVCTEESSPPNTGP

SEG xxxxxx

PRD ccccccccccccccccccccceeecccccccccccccccccceeeeeeeccccccccccc SElQ TVTPPNFSVS(QVPNMPSCP(QAYSEL(QMLSPSER(QCVETVVNMGYSYECVLRAMKKKGENI SEG xxxxxx

PRD cccccccccccccccccccchhhhhhhcccccchhhhhhhccccchhhhhhhhhhccchh

SElQ ElQILDYLFAHGiQLCEKGFDPLLVEEALEMHlQCSEEKMMEFLiQLMSKFKEMGFELKDIKEV SEG

PRD hhhhhhhhhhhccccccccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh

SElQ LLLHNNDiQDNALEDLMARAGAS SEG

PRD hhcccccchhhhhhhhhhhccc

(No Prosite data available for DKFZphtes3_10nlO -1)

(No Pfam data available for DKFZphtes3_10nlO.1) DKFZphtes3_llal7

group: transmembrane protein

DKFZphtes3_llal7 encodes a novel 428 amino acid protein without similarity to known proteins-

The novel protein contains 2 transmembrane regions and one leucine zipper- The protein is ubiquitously expressed with higher abundance in stomachi brain and testis-

No informative BLAST resultsi No predictive prositei pfam or SCOP motife-

The new protein can find application in studying the expression profile of testis-specific genes and as a new marker for testicular cells-

unknown protein Pedant: TRANSMEMBRANE 2 perhaps differential polyadenylation

Sequenced by (Qiagen Locus: unknown

Insert length: 2511 bp

Poly A stretch at pos- 2570ι polyadenylation signal at pos- 2548

1 CTCTCCTGC6 CCCTCTGGAG GAAGTGAGAA GAGTCAGTCC CACCCAGCTG

51 CCGCCTGGTA TCTGGGCTCC AGGCCACCGA GTATTTGGCC CCCAGCCACG

101 GAGCCCTTAG CACACACCTC CCCCACAGGT CCTGGAGATG TGGCTGAGCT

151 ACCTGCAGCC GTGGCGGTAC GCGCCTGACA AGCAGGCTCC GGGCAGCGAC 201 TCCCAGCCCC GGTGTGTGTC GGAGAAATGG GCACCCTTTG TCCAGGAGAA

251 CCTGCTGATG TACACCAAGT TGTTTGTGGG CTTTCTGAAC CGCGCGCTCC

301 GCACAGACCT GGTCAGCCCC AAGCACGCGC TCATGGTGTT CCGAGTGGCC

351 AAAGTCTTTG CCCAGCCCAA CCTGGCTGAG ATGATTCAGA AAGGTGAGCA

401 GCTATTCCTG GAGCCAGAGC TGGTCATCCC CCACCGCCAG CACCGACTCT 451 TCACGGCCCC CACATTCACT GGGAGCTTCC TGTCACCCTG GCCACCAGCG

501 GTCACTGATG CCTCCTTCAA GGTGAAGAGC CACGTCTACA GCCTGGAGGG

551 CCAGGACTGC AAGTACACCC CGATGTTTGG GCCCGAGGCC CGCACCCTGG bOl TCCTGCGCCT CGCTCAGCTC ATCACACAGG CCAAACACAC AGCCAAGTCC b51 ATCTCCGACC AGTGTGCGGA GAGCCCGGCT GGCCACTCCT TCCTCTCATG 701 GCTGGGCTTT AGCTCCATGG ACACCAATGG CTCCTACACA GCCAACGACC

751 TGGACGAGAT GGGGCAAGAC AGTGTCCGGA AGACAGATGA ATACCTGGAG

801 AAGGCCCTGG AGTACCTGCG CCAGATATTC CGGCTCAGCG AAGCGCAGCT

851 CAGGCAGTTC ACACTCGCCT TGGGCACCAC CCAGGATGAG AATGGAAAAA 101 AGCAACTCCC CGACTGCATC GTGGGTGAGG ACGGACTCAT CCTTACGCCC

151 CTGGGGCGGT ACCAGATCAT CAATGGGCTG CGAAGGTTTG AAATTGAGTA

1001 CCAGGGGGAC CCGGAGCTGC AGCCCATCCG GAGCTATGAG ATCGCCAGCT

1051 TGGTCCGCAC ACTCTTTAGG CTGTCGTCTG CCATCAACCA CAGATTTGCA 1101 GGACAGATGG CGGCTCTGTG TTCCCGGGAT GACTTCCTCG GCAGCTTCTG

1151 TCGCTACCAC CTCACAGAAC CTGGGCTGGC CAGCAGGCAC CTGCTGAGCC

1201 CTGTGGGGCG GAGGCAGGTG GCCGGCCACA CCCGCGGCCC CAGGCTCAGC

1251 CTGCGCTTCC TGGGCAGTTA CCGGACGCTG GTCTCGCTGC TGCTGGCCTT

1301 CTTCGTGGCC TCTCTGTTCT GCGTCGGGCC CCTCCCATGC ACGCTGCTGC 1351 TCACCCTGGG CTATGTCCTC TACGCCTCTG CCATGACACT GCTGACCGAG

1401 CGGGGGAAGC TGCACCAGCC CTGAAGGTGT CAGCTGCCTT CAGAGCAGGC

1451 TGGAGGGATT TGCCACACAG CCCCACCCTT GGGCTGAGAG GACCTGGGAA

1501 GCCCCTCCAG GAGGGAACAC GGTCATCCTC GGGCTTCTGG AGCGGGGTTC

1551 CTGCAGCCGC AGAGGCATCT GGAGGAAACG CAACCAAGAA AGGAAGGCAG IbOl GTGGGCCCCA GCAAAGGAGT AGCTGCCAGG GCTCAACAGC TACGCTCTGT lb51 GACAGCGCAG AGCTCAGCGC CGGCCTTTCC CTCCCTCCGC CAAGGACTCA

1701 CGGCCAAGCC AGCTCTCGGG GCCTTTTTTC CAGTGCCCAT TTGGCTACTC

1751 TGCTGCACCA AGCTTGGGAG CCAGCCTGCC AACAGCCACC TGGGCCTGGC

1801 CTCCCCACTG GCTGGCCTTG AGGTTGGCAG AGTGGGTTGT GGCGCTTCCT 1651 CTCTCTGTGT GGGACCAGGA CAGTGGCTTA AGTCTCCACT CCAGGAAAGA

1101 ATCAAAGTTT CTAGAGTTGT GAGAAAACCA GAGAGTGGCT GTCCTGATTC

1151 TTCACTGTGA GGGGCGTTCT TCATGTTCTC CCAGCTGTTC CAAGACTGGG

2001 CCGTAGAATT CCATGTTTCA GGAGCCTAAG ACCCTCCCAG AGCCCAGGGG

2051 CTTCACCGCA GACCCCAAGC CATTGAGCAC ATCACCCAAA GCAGTGGCCA 2101 ACATCGCGGA CCCCTGTGCC TTGTCACAGA TGGGTGCTGG TCCTCAGGCG

2151 TTGGGGACAC TGCTGGGTCG ATGGGGTCGG ATTCTGCCAG TTTCTGCTCT

2201 GCAGCCAAAG ATGGTCAGAA GCATTGTCAC TTCAGTAACA TCAAGTGCTC

2251 AAAGACATGG CAACCGTTCA GTGGTACTTA AGTATTCAAA ATATACAACT

2301 ACAGATTCTC TGACAGAAAC CAGCACGGGG TCTTCACCTT CATTCACCCC 2351 ACAGGCGACA TGCGAGGGAG AACAGCATCT CAGTGGTGAT TTCCAAACCA

2401 AGCCTTTGTT TTCGGTGTGG GGTTTTGGGG GTTTGCTTTA ATGTTTTTGA

2451 AATTGTAAAT GTTGGGCTTT TTATTTTGAT GTAAACTGAG AATAATGGCA

2501 TTTTAGGGCC TGTGACCAAA AATGAAGCTT GTAACGACCA TGGATCTGAA

2551 TAAACATGTC CTTGCTTCTG AAAAAAAAAA AAAAAAAAAA A

BLAST Results

Entry AF0S2134 from database EMBLNEU: Homo sapiens clone 23565 mRNA sequence. Score = 57b5ι P = 2-1e-254ι identities = 115S/115b 3' UTR

Medline entries

No Medline entry

Peptide information for frame 3

ORF from 136 bp to 1421 bpi peptide length: 426 Category: putative protein Classification: Transmembrane proteins unclassified Prosite motifs: LEUCINE_ZIPPER (404-425)

1 MULSYLiQPUR YAPDKώAPGS DSlQPRCVSEK UAPFViQENLL MYTKLFVGFL 51 NRALRTDLVS PKHALMVFRV AKVFAlQPNLA EMI(QKGE(QLF LEPELVIPHR 101 (QHRLFTAPTF TGSFLSPUPP AVTDASFKVK SHVYSLEGiQD CKYTPMFGPE 151 ARTLVLRLAfi LITώAKHTAK SISDώCAESP AGHSFLSULG FSSMDTNGSY 201 TANDLDEMGiQ DSVRKTDEYL EKALEYLRlQI FRLSEAiQLRtQ FTLALGTTQD 251 ENGKKfQLPDC IVGEDGLILT PLGRYiQIING LRRFEIEYlQG DPELlQPIRSY 301 EIASLVRTLF RLSSAINHRF AGiQMAALCSR DDFLGSFCRY HLTEPGLASR 351 HLLSPVGRRiQ VAGHTRGPRL SLRFLGSYRT LVSLLLAFFV ASLFCVGPLP 401 CTLLLTLGYV LYASAMTLLT ERGKLHiQP

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_llal7ι frame 3 No Alert BLASTP hits found

Pedant information for DKFZphtes3__llal7ι frame 3

Report for DKFZphtes3_llal7- 3

[LENGTH! 426 [MU! 46274-13 [pi! 8-12 [PROSITE! LEUCINE_ZIPPER 1 [KU! TRANSMEMBRANE 2

[KU! LOU COMPLEXITY 7-48 *

SElQ MULSYLlQPURYAPDKiQAPGSDSiQPRCVSEKUAPFVdJENLLMYTKLFVGFLNRALRTDLVS SEG

PRD cccccccccccccccccccccccccccccccchhhhhhhhhhhhhhhhhhhhhhhhhccc

MEM

SElQ PKHALMVFRVAKVFAlQPNLAEMIiQKGEiQLFLEPELVIPHRlQHRLFTAPTFTGSFLSPUPP SEG

PRD cchhhhhhhhhhhhcccchhhhhhhccceeeccceeeccccccccccccccccccccccc

MEM

SElQ AVTDASFKVKSHVYSLEG(QDCKYTPMFGPEARTLVLRLAιQLIT(QAKHTAKSISD(2CAESP SEG

PRD cccccccccccceeeccccccccccccccchhhhhhhhhhhhhhhhcccccccccccccc

MEM - -

SElQ AGHSFLSULGFSSMDTNGSYTANDLDEMGl^QDSVRKTDEYLEKALEYLRi^QIFRLSEAiQLRiQ SEG

PRD ccceeecccccccccccccccccccccccccccccchhhhhhhhhhhhhhhhhhhhhhhh

MEM SElQ FTLALGTTIQDENGKKIQLPDCIVGEDGLILTPLGRYIQIINGLRRFEIEYIQGDPELIQPIRSY

SEG

PRD hhhhhhccccccccccccceeecccccccccccceeeecchhhhheeecccccccccchh

MEM

SElQ EIASLVRTLFRLSSAINHRFAGiQMAALCSRDDFLGSFCRYHLTEPGLASRHLLSPVGRRlQ

SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhcccccceeeeeeccccchhhhhcccccccc

MEM

SElQ VAGHTRGPRLSLRFLGSYRTLVSLLLAFFVASLFCVGPLPCTLLLTLGYVLYASAMTLLT

SEG xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

PRD cccccccccccccccccchhhhhhhhhhhhhhhccccccchhhhhhhhhhhhhhhhhhhh

MEM MMMMMMMMMMMMMMMMM MMMMMMMMMMMMMMMMM -

SElQ ERGKLHlQP

SEG

PRD hhhccccc

MEM

Prosite for DKFZphtes3_llal7- 3 PS00021 404->42b LEUCINE_ZIPPER PD0C00021

(No Pfam data available for DKFZphtes3_llal7- 3)

DKFZphtes3_llc22

group: signal transduction

DKFZphtes3_llc22 encodes a novel 462 amino acid protein with partial similarity to mouse PC32b- The novel protein contains UD-repeats- UD-repeat proteins are known as regulatory elements in a large variety of pathways- The repeats form a propeller like strcturei which serves as a platform for protein/protein interaction- The new protein is ubiquitously expressed! indicating that it takes an essential regulatory function in the cell-

The new protein can find application in modulating/blocking of regulatory pathways-

similarity to mouse PC32b perhaps complete eds- contains UD-Repeats: cf- BLASTX-S37b14 perhaps differential polyadenylation

Sequenced by (Qiagen

Locus: /map=ⁿlq23- 2-24-3"

Insert length: 1152 bp

Poly A stretch at pos- 1132ι polyadenylation signal at pos- 1112

1 GAAGCAAGTG AGGTTGCACA AAGCAATAGA GGACGAGGAA GATCTCGACC

51 CAGAGGTGGA ACAAGTCAAT CAGATATTTC AACTCTTCCT ACGGTCCCAT

101 CAAGTCCTGA TTTGGAAGTG AGTGAAACTG CAATGGAAGT AGATACTCCA

151 GCTGAACAAT TTCTTCAGCC TTCTACATCC TCTACAATGT CAGCTCAGGC

201 TCATTCGACA TCATCTCCCA CAGAAAGCCC TCATTCTACT CCTTTGCTAT 251 CTTCTCCAGA TAGTGAACAA AGGCAGTCTG TTGAGGCATC TGGACACCAC

301 ACACATCATC AGTCTGATTC TCCTTCTTCT GTGGTTAACA AACAGCTCGG

351 ATCCATGTCA CTTGACGAGC AACAGGATAA CAATAATGAA AAGCTGAGCC

401 CCAAACCAGG GACAGGTGAA CCAGTTTTAA GTTTGCACTA CAGCACAGAA

451 GGAACAACTA CAAGCACAAT AAAACTGAAC TTTACAGATG AATGGAGCAG 501 TATAGCATCA AGTTCTAGAG GAATTGGGAG CCATTGCAAA TCTGAGGGTC

551 AGGAGGAATC TTTCGTCCCA CAGAGCTCAG TGCAACCACC AGAAGGAGAC bOl AGTGAAACAA AAGCTCCTGA AGAATCATCA GAGGATGTGA CAAAATATCA b51 GGAAGGAGTA TCTGCAGAAA ACCCAGTTGA GAACCATATC AATATAACAC

701 AATCAGATAA GTTCACAGCC AAGCCATTGG ATTCCAACTC AGGAGAAAGA 751 AATGACCTCA ATCTTGATCG CTCTTGTGGG GTTCCAGAAG AATCTGCTTC

801 ATCTGAAAAA GCCAAGGAAC CAGAAACTTC AGATCAGACT AGCACTGAGA

851 GTGCTACCAA TGAAAATAAC ACCAATCCTG AGCCTCAGTT CCAAACAGAA

IDl GCCACTGGGC CTTCAGCTCA TGAAGAAACA TCCACCAGGG ACTCTGCTCT

151 TCAGGACACA GATGACAGTG ATGATGACCC AGTCCTGATC CCAGGTGCAA 10D1 GGTATCGAGC AGGACCTGGT GATAGACGCT CTGCTGTTGC CCGTATTCAG

1051 GAGTTCTTCA GACGGAGAAA AGAAAGGAAA GAAATGGAAG AATTGGATAC

1101 TTTGAACATT AGAAGGCCGC TAGTAAAAAT GGTTTATAAA GGCCATCGCA

1151 ACTCCAGGAC AATGATAAAA GAAGCCAATT TCTGGGGTGC TAACTTTGTA 12D1 ATGAGTGGTT CTGACTGTGG CCACATTTTC ATCTGGGATC GGCACACTGC

1251 TGAGCATTTG ATGCTTCTGG AAGCTGATAA TCATGTGGTA AACTGCCTGC

1301 AGCCACATCC GTTTGACCCA ATTTTAGCCT CATCTGGCAT AGATTATGAC

1351 ATAAAGATCT GGTCACCATT AGAAGAGTCA AGGATTTTTA ACCGAAAACT 14D1 TGCTGATGAA GTTATAACTC GAAACGAACT CATGCTGGAA GAAACTAGAA

1451 ACACCATTAC AGTTCCAGCC TCTTTCATGT TGAGGATGTT GGCTTCACTT

1501 AATCATATCC GAGCTGACCG GTTGGAGGGT GACAGATCAG AAGGCTCTGG

1551 TCAAGAGAAT GAAAATGAGG ATGAGGAATA ATAAACTCTT TTTGGCAAGC

IbOl ACTTAAATGT TCTGAAATTT GTATAAGACA TTTATTATAT _TTTTTTCTTT IbSl ACAGAGCTTT AGTGCAATTT TAAGGTTATG GTTTTTGGAG TTTTTCCCTT

1701 TTTTTGGGAT AACCTAACAT TGGTTTGGAA TGATTGTGTG CATGAATTTG

1751 GGAGATTGTA TAAAACAAAA CTAGCAGAAT GTTTTTAAAA CTTTTTGCCG

1801 TGTATGAGGA GTGCTAGAAA ATGCAAAGTG CAATATTTTC CCTAACCTTC

1651 AAATGTGGGA GCTTGGATCA ATGTTGAAGA ATAATTTTCA TCATAGTGAA 1101 AATGTTGGTT CAAATAAATT TCTACACTTG CCAAAAAAAA AAAAAAAAAA 1151 AA

BLAST Results

Entry HS7D2J11 from database EMBL".

Human DNA sequence *** SEQUENCING IN PROGRESS *** from clone 702J11 Score = 2043ι P = 5-8e-252ι identities = 425/445 ID exons matching Bp 31b-1132

Entry HS53bl48 from database EMBL: human STS UI-b347- Score = 1203ι P = l-5e-47ι identities = 247/252

Entry HS7D3H14 from database EMBLNEU:

Human DNA sequence from clone 7D3H14 on chromosome lq23-2-24-3 Score = 13D7ι P = l-le-51ι identities = 2b3/2bS 2 exons matching Bp l-31b

Medline entries

1302b383:

Bergsagel PLi Timblin CRi Eckhardt Li Laskov Ri Kuehl UM-i Sequence and expression of a murine cDNA encoding PC32bι a novel gene expressed in plasmacytomas but not normal plasma cells.

Oncogene

1112 0cti7(lD) :2051-b4

Peptide information for frame 1

ORF from 133 bp to 1576 bpi peptide length: 482 Category: similarity to known protein Classification: Protein management Prosite motifs: MYB_1 (410-418)

1 MEVDTPAElQF LlQPSTSSTMS AiQAHSTSSPT ESPHSTPLLS SPDSE(QR(QSV 51 EASGHHTHHiQ SDSPSSVVNK (QLGSMSLDElQ (QDNNNEKLSP KPGTGEPVLS

101 LHYSTEGTTT STIKLNFTDE USSIASSSRG IGSHCKSEGiQ EESFVPiQSSV

151 (QPPEGDSETK APEESSEDVT KYiQEGVSAEN PVENHINITiQ SDKFTAKPLD

201 SNSGERNDLN LDRSCGVPEE SASSEKAKEP ETSDlQTSTES ATNENNTNPE

251 PiQFiQTEATGP SAHEETSTRD SALiQDTDDSD DDPVLIPGAR YRAGPGDRRS 3D1 AVARIlQEFFR RRKERKEMEE LDTLNIRRPL VKMVYKGHRN SRTMIKEANF

351 UGANFVMSGS DCGHIFIUDR HTAEHLMLLE ADNHVVNCLώ PHPFDPILAS

401 SGIDYDIKIU SPLEESRIFN RKLADEVITR NELMLEETRN TITVPASFML

451 RMLASLNHIR ADRLEGDRSE GSGώENENED EE

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_llc22ι frame 1

TREMBLNEU:HS0bb31_l gene: "H32b"i Human (H32b) mRNAi complete eds- ι N = li Score = 278ι P = 4e-22

PIR:S37b14 gene PC32b protein - mousei N = li Score = 2b5ι P = 2. le-20 PIR:T05b7b hypothetical protein F2DM13-40 - Arabidopsis thalianai N = li Score = 24Dι P = b-3e-18

>TREMBLNEU:HS0bb31_l gene: "H32b"i Human (H32b) mRNAi complete eds •

Length = 517

HSPs:

Score = 278 (41-7 bits)ι Expect = 4-De-22ι P = 4-0e-22 Identities = b3/14δ (42*)ι Positives = 14/146 (b3*)

(Query: 335 YKGHRNSRTMIKEANFUG-- ANFVMSGSDCGHIFIUDRHTAEHLMLLEADNH-VVNCLlQP 311

YKGHRN+ T +K NF+G + FV+SGSDCGHIF+U++ + + + +E D

VVNCL+P

Sbjct: 426 YKGHRNNAT-

VKGVNFYGPKSEFVVSGSDCGHIFLUEKSSClQIIiQFMEGDKGGVVNCLEP 4δb

(^Query: 312 HPFDPILASSGIDYDIKIUSPLEESRIFNRKLADEVITRNELMLEE-

TRNTITVPASFML 4SD

HP P+LA+SG+D+D+KIU+P E+ L D VI +N+ +E + +

+ S ML Sbjct: 467 HPHLPVLATSGLDHDVKIUAPTAEASTELTGLKD-

VIKKNKRERDEDSLHlQTDLFDSHML 545

(Query: 451 RMLASLNHIRADRLEGD-RSEGSGiQENENEDE 461 L ++H+R R R G G + + DE Sbjct: 54b UFL—MHHLRiQRRHHRRUREPGVGATDADSDE 575

Pedant information for DKFZphtes3_llc22ι frame 1

Report for DKFZphtes3_llc2 ■ 1

[LENGTH! 462

[MU! 53470-12

[pi! 4-72

[HOMOL! PIR:T041bl hypothetical protein T12J5-1D - Arabidopsis thaliana 2e-22

[FUNCAT! 30- DI organization of intracellular transport vesicles CS- cerevisiaei YDL145c! 4e-D5

[FUNCAT! 0β-07 vesicular transport (golgi networki etc) CS. cerevisiaei YDL145c! 4e-0S CFUNCAT! 11 unclassified proteins CS- cerevisiaei YCLD31w!

2e-04

[SUPFAM! UD repeat homology 4e-21

[PROSITE! MYB_1 1

[KU! Alpha_Beta [KU! LOU COMPLEXITY 17. DI *

SElQ MEVDTPAEIQFLIQPSTSSTMSAIQAHSTSSPTESPHSTPLLSSPDSEIQRIQSVEASGHHTHHIQ

SEG xxxxxxxxxxxxxxxxxxxxx PRD cccccceeeeecccccceeeeeeccccccccccccceeecccccchhhhhhccccceeec

SElQ SDSPSSVVNKlQLGSMSLDEώiQDNNNEKLSPKPGTGEPVLSLHYSTEGTTTSTIKLNFTDE

SEG

PRD ccccceeeeecccccccccccccccccccccccccccceeeeccccccccccceeeeccc

SElQ USSIASSSRGIGSHCKSEGiQEESFVPiQSSVlQPPEGDSETKAPEESSEDVTKYlQEGVSAEN

SEG -xxxxxxxxxxxx

PRD cccccccccccccccccccceeeeeccccccccccccccccccccccccccccccccccc SElQ PVENHINITiQSDKFTAKPLDSNSGERNDLNLDRSCGVPEESASSEKAKEPETSDlQTSTES

SEG xxxxxxxxxxxxxx • ■ • .xxxxx

PRD ccceeeeeecccccccccccccccccccccccccccccchhhhhhhhccccccccccccc

SElQ ATNENNTNPEPiQFlQTEATGPSAHEETSTRDSALlQDTDDSDDDPVLIPGARYRAGPGDRRS SEG xxxxxxxx xxxxxxxx

PRD cccccccccccceeeeeccccccccccccccccccccccccccccccccccccccccchh

SElQ AVARIiQEFFRRRKERKEMEELDTLNIRRPLVKMVYKGHRNSRTMIKEANFUGANFVMSGS

SEG xxxxxxxxxxxxxx PRD hhhhhhhhhhhhhhhhhhhhhhhhccccceeeeeeccccccceeeeccccccceeeeccc

SElQ DCGHIFIUDRHTAEHLMLLEADNHVVNCLi^QPHPFDPILASSGIDYDIKIUSPLEESRIFN

SEG

PRD ccceeeeeecchhhhhhhhhcccceeeecccccccceeecccccceeeecccchhhhhhh

SElQ RKLADEVITRNELMLEETRNTITVPASFMLRMLASLNHIRADRLEGDRSEGSGiQENENED SEG

PRD hhchhhhhhhhhhhhhhhhcceeecchhhhhhhhhhchhhhhhccccccccccccccccc SElQ EE SEG . . PRD cc

Prosite for DKFZphtes3_Hc22- 1 PS0D037 41D->411 MYB 1 PD0C0D037

(No Pfam data available for DKFZphtes3_llc22 - 1)

DKFZphtes3_lld21

group: signal transduction

DKFZphtes3_lld21 encodes a novel 122 acid protein and contains the full coding sequence of the human Nedd-4-like ubiquitin- protein ligase-

The novel protein contains four UU domains- The UU/rsp5/UUP domain has been shown to bind proteins with particular proline- motifsi and thus resembles somewhat SH3 domains- It is frequently associated with other domains typical for proteins in signal transduction processes- There is also a ubiquitin-protein ligase activity reported- The protein is believed to play an important role in protein-degradation pathways-

The new protein can find application in diagnosis of diseases due to unnormal protein degradation like muscular dystrophy or multiple sclerosis as well as in modulating the half life of specific proteins and in expression profiling-

similarity to Nedd-4-like ubiquitin-protein ligase (Homo sapiens) Sequenced by fliagen Locus: unknown

Insert length: 3382 bp

Poly A stretch at pos- 33b2ι polyadenylation signal at pos- 3345

1 ATTTTGGGAC ATGGCCACTG CTTCACCAAG GTCTGATACT AGTAATAACC

51 ACAGTGGAAG GTTGCAGTTA CAGGTAACTG TTTCTAGTGC CAAACTTAAA

IDl AGAAAAAAGA ACTGGTTCGG AACAGCAATA TATACAGAAG TAGTTGTAGA

151 TGGAGAAATT ACGAAAACAG CAAAATCCAG TAGTTCTTCT AATCCAAAAT

2D1 GGGATGAACA GCTAACTGTA AATGTTACGC CACAGACTAC ATTGGAATTT 251 CAAGTTTGGA GCCATCGCAC TTTAAAAGCA GATGCTTTAT TAGGAAAAGC

301 AACGATAGAT TTGAAACAAG CTCTGTTGAT ACACAATAGA AAATTGGAAA

351 GAGTGAAAGA ACAATTAAAA CTTTCCTTGG AAAACAAGAA TGGCATAGCA

4D1 CAAACTGGTG AATTGACAGT TGTGCTTGAT GGATTGGTGA TTGAGCAAGA

451 AAATATAACA AACTGCAGCT CATCTCCAAC CATAGAAATA CAGGAAAATG 501 GTGATGCCTT ACATGAAAAT GGAGAGCCTT CAGCAAGGAC AACTGCCAGG

551 TTGGCTGTTG AAGGCACGAA TGGAATAGAT AATCATGTAC CTACAAGCAC bOl TCTAGTCCAA AACTCATGCT GCTCGTATGT AGTTAATGGA GACAACACAC b51 CTTCATCTCC GTCTCAGGTT GCTGCCAGAC CCAAAAATAC ACCAGCTCCA

7D1 AAACCACTCG CATCTGAGCC TGCCGATGAC ACTGTTAATG GAGAATCATC 751 CTCATTTGCA CCAACTGATA ATGCGTCTGT CACGGGTACT CCAGTAGTGT

601 CTGAAGAAAA TGCCTTGTCT CCAAATTGCA CTAGTACTAC TGTTGAAGAT

851 CCTCCAGTTC AAGAAATACT GACTTCCTCA GAAAACAATG AATGTATTCC

IDl TTCTACCAGT GCAGAATTGG AATCTGAAGC TAGAAGTATA TTAGAGCCTG

151 ACACCTCTAA TTCTAGAAGT AGTTCTGCTT TTGAAGCAGC CAAATCAAGA 1001 CAGCCAGATG GGTGTATGGA TCCTGTACGG CAGCAGTCTG GGAATGCCAA

1051 CACAGAAACC TTGCCATCAG GGTGGGAACA AAGAAAAGAT CCTCATGGTA

1101 GAACCTATTA TGTGGATCAT AATACTCGAA CTACCACATG GGAGAGACCA

1151 CAACCTTTAC CTCCAGGTTG GGAAAGAAGA GTTGATGATC GTAGAAGAGT 12D1 TTATTATGTG GATCATAACA CCAGAACAAC AACGTGGCAG CGGCCTACCA

1251 TGGAATCTGT CCGAAATTTT GAACAGTGGC AATCTCAGCG GAACCAATTG

1301 CAGGGAGCTA TGCAACAGTT TAACCAACGA TACCTCTATT CGGCTTCAAT

1351 GTTAGCTGCA GAAAATGACC CTTATGGACC TTTGCCACCA GGCTGGGAAA 1401 AAAGAGTGGA TTCAACAGAC AGGGTTTACT TTGTGAATCA TAACACAAAA

1451 ACAACCCAGT GGGAAGATCC AAGAACTCAA GGCTTACAGA ATGAAGAACC

15D1 CCTGCCAGAA GGCTGGGAAA TTAGATATAC TCGTGAAGGT GTAAGGTACT

1551 TTGTTGATCA TAACACAAGA ACAACAACAT TCAAAGATCC TCGCAATGGG

IbOl AAGTCATCTG TAACTAAAGG TGGTCCACAA ATTGCTTATG AACGCGGCTT lb51 TAGGTGGAAG CTTGCTCACT TCCGTTATTT GTGCCAGTCT AATGCACTAC

17D1 CTAGTCATGT AAAGATCAAT GTGTCCCGGC AGACATTGTT TGAAGATTCC

1751 TTCCAACAGA TTATGGCATT AAAACCCTAT GACTTGAGGA GGCGCTTATA

1801 TGTAATATTT AGAGGAGAAG AAGGACTTGA TTATGGTGGC CTAGCGAGAG

1651 AATGGTTTTT CTTGCTTTCA CATGAAGTTT TGAACCCAAT GTATTGCTTA 1101 TTTGAGTATG CGGGCAAGAA CAACTATTGT CTGCAGATAA ATCCAGCATC

1151 AACCATTAAT CCAGACCATC TTTCATACTT CTGTTTCATT GGTCGTTTTA

20D1 TTGCCATGGC ACTATTTCAT GGAAAGTTTA TCGATACTGG TTTCTCTTTA

2051 CCATTCTACA AGCGTATGTT AAGTAAAAAA CTTACTATTA AGGATTTGGA

21D1 ATCTATTGAT ACTGAATTTT ATAACTCCCT TATCTGGATA AGAGATAACA 2151 ACATTGAAGA ATGTGGCTTA GAAATGTACT TTTCTGTTGA CATGGAGATT

2201 TTGGGAAAAG TTACTTCACA TGACCTGAAG TTGGGAGGTT CCAATATTCT

2251 GGTGACTGAG GAGAACAAAG ATGAATATAT TGGTTTAATG ACAGAATGGC

23D1 GTTTTTCTCG AGGAGTACAA GAACAGACCA AAGCTTTCCT TGATGGTTTT

2351 AATGAAGTTG TTCCTCTTCA GTGGCTACAG TACTTCGATG AAAAAGAATT 2401 AGAGGTTATG TTGTGTGGCA TGCAGGAGGT TGACTTGGCA GATTGGCAGA

2451 GAAATACTGT TTATCGACAT TATACAAGAA ACAGCAAGCA AATCATTTGG

25D1 TTTTGGCAGT TTGTGAAAGA GACAGACAAT GAAGTAAGAA TGCGACTATT

2551 GCAGTTCGTC ACTGGAACCT GCCGTTTACC TCTAGGAGGA TTTGCTGAGC

2b01 TCATGGGAAG TAATGGGCCT CAAAAGTTTT GCATTGAAAA AGTTGGCAAA 2b51 GACACTTGGT TACCAAGAAG CCATACATGT TTTAATCGCT TGGATCTACC

27D1 ACCATATAAG AGTTATGAAC AACTAAAGGA AAAACTTCTT TTTGCAATAG

2751 AAGAGACAGA GGGATTTGGA CAAGAATGAA TGTGGCTTCT TATTTTGGAG

2601 GAGCTCTTGC ATTTAAATAC CCCAGCCAAG AAAAATTGCA CAGATAGTGT

2851 ATATAAGCTG TTCATTCTGT ACAGTGAATT TTCCGAACCT CTCAAAGTAT 2101 GTTTTCCGTT CTTCCACAGA AATATGCAAA ACAGTTCATC CTTTTCTACT

2151 TTATTTATTG TTCCCTTGAA ATGACTGACC AGGAAAAAGA TCATCCTTAA

30D1 ATTTTGAAGC AAGTGAGAGA CTTTATTAAA AATACATATA TATCTATATA

3051 AACATATATG ATAGTGGCTC TAGTTTTATA GAGCTCCAAG TGTATTAAAC

31D1 ATGACAGCCA TTCATTCATA AAGATCTGGA TTTGCTTTAC CTTGTTAATA 3151 TTATCTAGGG GAAAAAGTGC AAATTGCTCC ATGTTCTTCT CTCCCTTATG

3201 TAACATCTCC TGAGGGTGTT TAGTTGCATG GCTGTTCAGA AAGGTATTAA

3251 GGGCTTAGGC CAAATCTTAC TTTGAGTATG TTAAAAAAAA AAAAATGCTG

3301 CTGGCTTTTC TGAAGACAGG TGCTTGAACT TGTCAGTTTG TTTTAAATAA

3351 ATACAATAGT TGAAAAAAAA AAAAAAAAAA AA

BLAST Results

No BLAST result

Medline entries

17313427:

Pirozzi Gi McConnell SJi Uveges AJi Carter JMi Sparks ABi Kay BKi

Fowlkes DM-i Identification of novel human UU domain-containing proteins by cloning of ligand targets-J Biol Chem 1117 Jun bi272(23) :14bll-b

Peptide information for frame 2

ORF from 11 bp to 277b bpi peptide length: 122

Category: known protein

Classification: Protein management

Prosite motifs: UU_D0MAIN_1 (355-380)

UU_D0MAIN_1 (367-412)

UU_D0MAIN_1 (4b2-487)

UU DOMAIN 1 (5D2-527)

1 MATASPRSDT SNNHSGRLlQL (QVTVSSAKLK RKKNUFGTAI YTEVVVDGEI

51 TKTAKSSSSS NPKUDElQLTV NVTPiQTTLEF (QVUSHRTLKA DALLGKATID

101 LKiQALLIHNR KLERVKElQLK LSLENKNGIA (QTGELTVVLD GLVIElQENIT

151 NCSSSPTIEI iQENGDALHEN GEPSARTTAR LAVEGTNGID NHVPTSTLViQ

2D1 NSCCSYVVNG DNTPSSPSiQV AARPKNTPAP KPLASEPADD TVNGESSSFA 251 PTDNASVTGT PVVSEENALS PNCTSTTVED PPVfQEILTSS ENNECIPSTS

301 AELESEARSI LEPDTSNSRS SSAFEAAKSR (QPDGCMDPVR (QiQSGNANTET

351 LPSGUEiQRKD PHGRTYYVDH NTRTTTUERP (QPLPPGUERR VDDRRRVYYV

401 DHNTRTTTUlQ RPTMESVRNF E1QU1QS1QRN1QL (QGAMlQlQFNlQR YLYSASMLAA

451 ENDPYGPLPP GUEKRVDSTD RVYFVNHNTK TTiQUEDPRTlQ GLώNEEPLPE 501 GUEIRYTREG VRYFVDHNTR TTTFKDPRNG KSSVTKGGPlQ lAYERGFRUK

551 LAHFRYLCiQS NALPSHVKIN VSRiQTLFEDS FIQIQIMALKPY DLRRRLYVIF bOl RGEEGLDYGG LAREUFFLLS HEVLNPMYCL FEYAGKNNYC LiQINPASTIN b51 PDHLSYFCFI GRFIAMALFH GKFIDTGFSL PFYKRMLSKK LTIKDLESID

7D1 TEFYNSLIUI RDNNIEECGL EMYFSVDMEI LGKVTSHDLK LGGSNILVTE 751 ENKDEYIGLM TEURFSRGVlQ ElQTKAFLDGF NEVVPLlQULlQ YFDEKELEVM

601 LCGMlQEVDLA DUiQRNTVYRH YTRNSKlQIIU FUiQFVKETDN EVRMRLLlQFV

651 TGTCRLPLGG FAELMGSNGP (QKFCIEKVGK DTULPRSHTC FNRLDLPPYK

101 SYEiQLKEKLL FAIEETEGFG iQE

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_lld21ι frame 2

No Alert BLASTP hits found Pedant information for DKFZphtes3_lld21ι frame 2

Report for DKFZphtes3_lld21- 2

[LENGTH! 125

[MU! 105b50.58

[pi! 5-bO [H0M0L! TREMBL:HSUlbll3_l product: "UUPl"i Homo sapiens

Nedd-4-like ubiquitin-protein ligase UUPl mRNAi partial eds- 0-D

[FUNCAT! 30-D2 organization of plasma membrane [S. cerevisiaei

YER125w! le-141 [FUNCAT! 11-01 stress response [S- cerevisiaei YER125w! le- 141

[FUNCAT! 0b-13.Dl cytoplasmic degradation [S- cerevisiaei

YER125w! le-141

[FUNCAT! D3-1D sporulation and germination [S. cerevisiaei YER125w! le-141

[FUNCAT! Ob-07 protein modification (glycolsylationi acylationi myristylationi palmitylationi farnesylation and processing)

[S- cerevisiaei YER125w! le-141

[FUNCAT! 03-22 cell cycle control and mitosis [S. cerevisiaei YDR457w! le-78

[FUNCAT! 11 unclassified proteins [S. cerevisiaei YJR03bc!

7e-31

[FUNCAT! 3D- 03 organization of cytoplasm [S- cerevisiaei

YKLDlOc! 6e-21 [FUNCAT! 30-10 nuclear organization [S- cerevisiaei YKL012w! be-05

[FUNCAT! 04.D5-D3 rna processing (splicing) [S. cerevisiaei

YKLD12w! be-05

[FUNCAT! 3D-01 organization of cell wall [S- cerevisiaei YIROllc! 3e-04

[FUNCAT! 30-1D extracellular/secretion proteins [S- cerevisiaei

YIRDllc! 3e-04

[FUNCAT! 01-D5.01 carbohydrate utilization [S- cerevisiaei

YIRDllc! 3e-04 [BLOCKS! BP0374bE

[BLOCKS! BP037blG

[BLOCKS! BLD0514E Fibrinogen beta and gamma chains C-terminal domain proteins

[BLOCKS! PR00731B [BLOCKS! BPOlSbbC

[BLOCKS! BL01151 UU/rsp5/UUP domain proteins

[BLOCKS! PR00403B

[BLOCKS! PR00403A

[BLOCKS! PF00b32B [BLOCKS! PF00b32A

[EC! b- 3-2.11 Ubiquitin—protein ligase le-151

[PIRKU! ligase le-151

[PIRKU! transmembrane protein 2e-37

[PIRKU! leucine zipper 2e-26 [SUPFAM! UU repeat homology le-151

[SUPFAM! UD repeat homology 2e-26

[SUPFAM! ubiquitin ligase homolog le-151

[PROSITE! UU_D0MAIN_1 4

CPFAM! UU/rsp5/UUP domain containing proteins [PFAM! C2 domain

[KU! Alpha_Beta

[KU! LOU COMPLEXITY 1 - 41 *

SElQ FUDMATASPRSDTSNNHSGRLlQLi^QVTVSSAKLKRKKNUFGTAIYTEVVVDGEITKTAKSS SEG

PRD ccccccccccccccccccceeeeeehhhhhhhhhhhhccccceeeeeeeccccceeeecc SElQ SSSNPKUDE(QLTVNVTP(QTTLEF(QVUSHRTLKADALLGKATIDLK(QALLIHNRKLERVKE

SEG

PRD ccccccccceeeeeccccceeeeeeecchhhhhhhhhhhhhhhhhhhhhhhchhhhhhhh SElQ (QLKLSLENKNGIAlQTGELTVVLDGLVIElQENITNCSSSPTIEIiQENGDALHENGEPSART

SEG

PRD hhhhhhcccccccccceeeeeecceeeeeeeccccccccceeeecccccccccccccchh

SElQ TARLAVEGTNGIDNHVPTSTLVlQNSCCSYVVNGDNTPSSPSlQVAARPKNTPAPKPLASEP SEG

PRD hhhhhhcccccccccccccccccccccccccccccccccccccccccccccccccccccc

SElQ ADDTVNGESSSFAPTDNASVTGTPVVSEENALSPNCTSTTVEDPPViQEILTSSENNECIP

SEG PRD cccccccccccccccccceeeccccccccccccccccccccccccccccccccccccccc

SElQ STSAELESEARSILEPDTSNSRSSSAFEAAKSRlQPDGCMDPVRiQlQSGNANTETLPSGUEiQ

SEG

PRD ccccccccceeeeccccccccccccccccccccccccccccccccccccccccccccccc

SElQ RKDPHGRTYYVDHNTRTTTUERPiQPLPPGUERRVDDRRRVYYVDHNTRTTTUlQRPTMESV

SEG xxxxxxxxxxxxx

PRD ccccccceeeecccccccccccccccccccccccccccceeeeecccccccccccccccc SElQ RNFEIQUIQSIQRNIQLIQGAMIQIQFNIQRYLYSASMLAAENDPYGPLPPGUEKRVDSTDRVYFVNH

SEG

PRD hhhhhhhhhhhhhhhhhhhcccccccccccccccccccccccccceeeeccccceeeeec

SElQ NTKTTiQUEDPRTiQGLlQNEEPLPEGUEIRYTREGVRYFVDHNTRTTTFKDPRNGKSSVTKG SEG

PRD ccceeeecccccccccccccccccceeeeecccceeeeeccceeeeeccccccccccccc

SElQ GPIQIAYERGFRUKLAHFRYLCIQSNALPSHVKINVSRIQTLFEDSFIQIQIMALKPYDLRRRLY

SEG PRD cccccchhhhhhhhhhhhhhhhhcccccceeeeehhhhhhhhhhhhhhhhcchhhhhhhh ElQ VIFRGEEGLDYGGLAREUFFLLSHEVLNPMYCLFEYAGKNNYCLlQINPASTINPDHLSYF

SEG

PRD hhhccccccccccchhhhhhhhhhhccccccceeeeecccceeeeecccccccccceeee

SElQ CFIGRFIAMALFHGKFIDTGFSLPFYKRMLSKKLTIKDLESIDTEFYNSLIUIRDNNIEE

SEG

PRD hhhhhhhhhhhhhhhccccccchhhhhhhhhhhhhhcccccccchhhhhheeeeeccccc SElQ CGLEMYFSVDMEILGKVTSHDLKLGGSNILVTEENKDEYIGLMTEURFSRGVIQEIQTKAFL

SEG

PRD chhhhhhhhhccccceeeeeeeccccceeeeeeccchhhhhhhhhhhhhhhhhhhhhhhh

SElQ DGFNEVVPLiQULiQYFDEKELEVMLCGMiQEVDLADUiQRNTVYRHYTRNSKiQIIUFUiQFVKE SEG

PRD hhhhhcccccchhhhhhhhhhhhhhcccccccccccccccccccccchhhhhhhhhhhhh

SEώ TDNEVRMRLLlQFVTGTCRLPLGGFAELMGSNGPiQKFCIEKVGKDTULPRSHTCFNRLDLP

SEG PRD hchhhhhhhhhhhccccccccccceeeecccccceeeeeecccccccccccccccccccc

SElQ PYKSYElQLKEKLLFAIEETEGFGiQE

SEG PRD cccchhhhhhhhhhhhhhccccccc

Prosite for DKFZphtes3_lld21 ■ 2

PSD1151 356->384 UU_D0MAIN_1 PD0C5D02D PS01151 31D->41b UU_D0MAIN_1 PD0C50D20 PSD1151 4b5->411 UU_D0MAIN_1 PD0C5D02D PS01151 505->531 UU_D0MAIN_1 PD0C50D20

Pf am f or DKFZphtes3_lld2L 2

HMM NAME C2 doma i n

HMM *LtVrIIeARNLUkMDMnGf SDPYVKVdMdPdpkDtkKUKTkTi UNN - GL

L V++ +A+ +K++++G+ Y +V +D++ TKT

+++ +

(Query 23 LiQVTVSSAKLKRKKNUFGTA-IYTEVVVDGE

ITKTAKSSSSS b3

HMM NPVUNEEeFvFedlPyPd l qrkMLRFaVUDUDRFSRBDFIGHCi *

NP U+ E+++ + + + L+F+VU + ++ + ++G ++

(Query b4 NPKUD-EiQLTVN VTPiQTT — LEFώVUSHRTLKADALLGKAT

IDl

HMM_NAME UU/rsp5/UUP domain containing proteins HMM *LPsGUEeHUDpsGRpUYYUNHETkTT(QUEpP*

LPSGUE+++DP GR+ YY++H+T+TT+UE+P (Query 354 LPSGUEiQRKDPHGRT-YYVDHNTRTTTUERP 383

50-01 36b 415 1 31 dkfzphtes3_lld21 - 2 similarity to Nedd-4-like ubiquitin-protein ligase (Homo sapiens) Alignment to HMM consensus: (Query *LPsGUEeHUDpsGRpUYYUNHETkTT<QUEpP*

LP+GUE++ D+ R YY++H+T+TT+U++P dkfzphtes3 38b LPPGUERRVDDRRRV-YYVDHNTRTTTUiQRP 415

(Query 410 1 31 dkfzphtes3_lld21 ■ 2 similarity to

Nedd-4-like ubiquitin-protein ligase (Homo sapiens)

Alignment to HMM consensus: HMM *LPsGUEeHUDpsGRpUYYUNHETkTT(QUEpP* LP+GUE++ D + R Y++NH+TKTT(QUE+P

(Query 4bl LPPGUEKRVDSTDRV-YFVNHNTKTTώUEDP 41D

38-b2 SD1 53D 1 31 dkfzphtes3_lld21 - 2 similarity to Nedd-4-like ubiquitin-protein ligase (Homo sapiens) Alignment to HMM consensus:

(Query *LPsGUEeHUDpsGRpUYYUNHETkTT(QUEpP*

LP GUE +++ +G + Y+++H+T+TT+ ++P dkfzphtes3 501 LPEGUEIRYTREGVR-YFVDHNTRTTTFKDP 530 PAGE INTENTIONALLY LEFT BLANK

DKFZphtes3_llel7

group: testis derived

DKFZphtes3_llel7 encodes a novel 573 amino acid protein without similarity to known proteins- No informative BLAST resultsi No predictive prositei pfam or SCOP motife •

The new protein can find application in studying the expression profile of testis-specific genes-

unknown protein

Sequenced by (Qiagen

Locus: unknown

Insert length: 2102 bp

Poly A stretch at pos. 208Dι polyadenylation signal at pos- 2051

1 GGCCTGGGGG GCTTCCCTGG GGGGCTTGTC GCCGGGGCCG CCTGGGCTTT

51 CAGGTCTTCC GAGGCTGACA TTCACGTTTC ATTCTGCCAC ACTCGGGAAC

IDl GGTGATCGGG GAAGCATGGG GATCCGGGAG AAGCACCCAC AAAACTAGCA 151 TCCTCCTGGA GGAGCTC6GG AATAGGATGA GTGATAATCC ACCCAGAATG

201 GAAGTGTGTC CTTACTGTAA GAAGCCATTT AAACGATTAA AATCCCACTT

251 GCCATACTGT AAGATGATAG GATCAACCAT ACCTACTGAT CAAAAAGTTT

301 ATCAGTCCAA GCCAGCTACA CTCCCACGTG CTAAAAAGAT GAAAGGACCA

351 ATCAAAGATT TAATTAAAGC TAAAGGGAAA GAGTTAGAGA CAGAGAATGA 401 AGAAAGAAAT TCTAAGTTGG TGGTGGACAA ACCAGAACAG ACAGTGAAGA

451 CCTTTCCACT GCCAGCTGTT GGTTTGGAAA GAGCAGCTAC TACAAAGGCA

501 GATAAAGACA TCAAGAATCC AATCCAACCA TCCTTCAAAA TGTTAAAAAA

551 TACTAAACCA ATGACTACTT TCCAAGAAGA AACCAAGGCT CAGTTTTACG bOl CATCAGAGAA AACCTCTCCT AAAAGAGAAC TTGCCAAAGA TTTGCCTAAA b51 TCAGGAGAAA GTCGATGTAA TCCTTCAGAA GCTGGAGCGT CTTTACTGGT

701 TGGCTCAATA GAACCTTCTT TGTCAAATCA AGATAGAAAA TATTCCTCAA

751 CTCTACCTAA TGATGTACAA ACTACCTCTG GTGATCTCAA ATTGGACAAA

601 ATTGATCCCC AAAGACAGGA ACTTCTAGTA AAATTACTAG ATGTGCCTAC

651 TGGTGATTGT CATATTTCTC CAAAGAATGT CAGTGATGGG GTTAAAAGGG 101 TAAGAACATT ATTAAGCAAT GAGAGAGATT CCAAAGGCAG GGATCACCTC

151 TCAGGAGTCC CTACTGATGT TACAGTTACT GAGACTCCAG AAAAGAACAC

1001 AGAATCCCTC ATTTTAAGCC TTAAAATGAG CTCATTAGGT AAAATCCAAG

1051 TCATGGAGAA ACAAGAGAAA GGACTTACCC TGGGAGTAGA GACGTGTGGG

1101 AGCAAAGGAA ATGCAGAGAA AAGTATGTCT GCAACAGAAA AGCAGGAACG 1151 GACTGTCATG AGCCATGGCT GTGAGAACTT CAACACCAGG GATTCAGTCA

1201 CAGGAAAGGA GTCTCAAGGG GAAAGACCAC ATTTAAGTTT GTTCATTCCG

1251 AGGGAGACGA CTTACCAGTT TCATTCTGTA TCGCAGTCAA GTAGTCAAAG

13D1 TCTTGCCTCT CTAGCTACAA CATTTCTTCA AGAAAAGAAA GCAGAAGCCC

1351 AGAATCATAA TTGTGTCCCT GATGTAAAGG CATTAATGGA GAGTCCCGAG 14D1 GGACAGTTAT CTCTGGAGCC CAAATCTGAT AGTCAGTTCC AAGCATCACA

1451 CACTGGGTGC CAGAGCCCTT TATGTTCAGC CCAGCGTCAC ACTCCTCAGA

1501 GCCCCTTCAC CAATCATGCT GCAGCTGCTG GCAGGAAGAC TCTTCGCAGC

1551 TGCATGGGGC TGGAGTGGTT TCCAGAGCTC TATCCTGGTT ACCTTGGACT IbOl AGGGGTGTTG CCAGGGAAGC CTCAGTGTTG GAATGCAATG ACCCAGAAGC

IbSl CACAACTTAT CAGTCCCCAG GGGGkkkGkC TCTCACAAGG CTGGATCAGG

1701 TGCAACACCA CCATAAGGAA GAGTGGATTC GGTGGCATCA CTATGCTCTT

1751 CACAGGATAC TTCGTCCTGT GTTGTAGCTG GAGTTTCAGA CGTCTGAAAA

1601 AATTGTGCCG ACCCCTGCCC TGGAAGAGCA CAGTACCTCC ATGCATTGGT

1851 GTGGCGAAGA CGACTGGGGA TTGCCGCTCT AAAACATGTT TGGATTAGGA

1101 AGCACGTTTA AGTAGGAGAA GCCTTCGTGA CTTCTCTCTA GTGCCTTCGT

1151 GCCCTGTGTT GCCCACTGAA TTGCCCTGTA ACACCTAAGT GTAGTGGTAG

20D1 CATTAAGGGA TAGCTTTTCA GCCCTCAAGG TTATCAGGAG CATTTGTATC

2051 ACTGCTATAA ATAAAGTAGT ATCACTTGTC ATAAAAAAAA AAAAAAAAAA

2101 AA

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 3

ORF from 177 bp to 1815 bpi peptide length: 573 Category: putative protein Classification: no clue

1 MSDNPPRMEV CPYCKKPFKR LKSHLPYCKM IGSTIPTDlQK VYiQSKPATLP 51 RAKKMKGPIK DLIKAKGKEL ETENEERNSK LVVDKPElQTV KTFPLPAVGL IDl ERAATTKADK DIKNPIiQPSF KMLKNTKPMT TFiQEETKAiQF YASEKTSPKR 151 ELAKDLPKSG ESRCNPSEAG ASLLVGSIEP SLSNlQDRKYS STLPNDVlQTT 2D1 SGDLKLDKID PIQRIQELLVKL LDVPTGDCHI SPKNVSDGVK RVRTLLSNER 251 DSKGRDHLSG VPTDVTVTET PEKNTESLIL SLKMSSLGKI (QVMEKiQEKGL 301 TLGVETCGSK GNAEKSMSAT EKiQERTVMSH GCENFNTRDS VTGKESiQGER 351 PHLSLFIPRE TTYiQFHSVSlQ SSSlQSLASLA TTFLiQEKKAE AiQNHNCVPDV 401 KALMESPEGiQ LSLEPKSDSώ FiQASHTGClQS PLCSAiQRHTP (QSPFTNHAAA 451 AGRKTLRSCM GLEUFPELYP GYLGLGVLPG KP(QCUNAMT(Q KPώLISPώGE 5D1 RLSiQGUIRCN TTIRKSGFGG ITMLFTGYFV LCCSUSFRRL KKLCRPLPUK 551 STVPPCIGVA KTTGDCRSKT CLD

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_llel7ι frame 3 No Alert BLASTP hits found

Pedant information for DKFZphtes3_llel7ι frame 3 Report for DKFZphtes3_Hel7 -3

[LENGTH! 573

[MU! b3381.66

[pi! 1-24

[BLOCKS! BL00D28 Zinc fingeri C2H2 typei domain proteins

[KU! Alpha_Beta [KU! LOU COMPLEXITY 7-50 *

SElQ MSDNPPRMEVCPYCKKPFKRLKSHLPYCKMIGSTIPTDIQKVYIQSKPATLPRAKKMKGPIK

SEG PRD ccccccceeecccccchhhhhhhcccceeeeccccccceeeeeccccchhhhhhhcccch

SElQ DLIKAKGKELETENEERNSKLVVDKPEiQTVKTFPLPAVGLERAATTKADKDIKNPKQPSF

SEG

PRD hhhhhhcccchhhhhhhhheeeeccccceeecccccchhhhhhhhhhhcccccccccchh

SElQ KMLKNTKPMTTFlQEETKAiQFYASEKTSPKRELAKDLPKSGESRCNPSEAGASLLVGSIEP

SEG

PRD hhhhcccccchhhhhhhhhhhhhcccccchhhhhccccccccccccccchhhhhhhcccc SElQ SLSNlQDRKYSSTLPNDViQTTSGDLKLDKIDPlQRiQELLVKLLDVPTGDCHISPKNVSDGVK

SEG

PRD ccccccceeecccccccccccccccccccccchhhhhhhhhccccccccccccccccchh

SEώ RVRTLLSNERDSKGRDHLSGVPTDVTVTETPEKNTESLILSLKMSSLGKIiQVMEKiQEKGL SEG xxxxxxxxxxxx

PRD hhhhhhhhcccccccccccccccceeeeeccccchhhhhhhhhhccccchhhhhhhhccc

SEl^Q TLGVETCGSKGNAEKSMSATEKiQERTVMSHGCENFNTRDSVTGKESiQGERPHLSLFIPRE

SEG PRD eeeeecccccccchhhhhhhhhhhhhhhcccccccccccccccccccccccceeeeeccc

SE(Q TTY(QFHSVS(QSSS(QSLASLATTFL<QEKKAEA<QNHNCVPDVKALMESPEG<QLSLEPKSDS(Q

SEG xxxxxxxxxxxxxx

PRD eeeeeeccccccchhhhhhhhhhhhhhhhhhhccccccchhhhhcccccccccccccccc

SEl^Q F(QASHTGC(QSPLCSAf^QRHTP(QSPFTNHAAAAGRKTLRSCMGLEUFPELYPGYLGLGVLPG

SEG xxxxxxxxxxxxxxx

PRD cccccccccccccccccccccccccchhhhhcchhhhhhccccccccccccccceeeccc SEl^Q KP(2CUNAMT(QKP(QLISP(QGERLS(QGUIRCNTTIRKSGFGGITMLFTGYFVLCCSUSFRRL

SEG xx

PRD ccccccccccccccccccccchhhhhccccceeeecccccceeeecceeeeeecchhhhh

SElQ KKLCRPLPUKSTVPPCIGVAKTTGDCRSKTCLD SEG

PRD hhhccccccccccccceeeeecccccccccccc

⁽No Prosite data available for DKFZphtes3_llel7.3) ⁽No Pfam data available for DKFZphtes3_llel7 -3) DKFZphtes3_12dl6

group: testis derived

DKFZphtes3_12dl8 encodes a novel 1170 amino acid protein without similarity to known proteins- The EST-distribution signifies an ubiquitous expression pattern- No informative BLAST resultsi No predictive prositei pfam or SCOP motife-

The new protein can find application in studying the expression profile of testis-specific genes-

unknown protein perhaps complete eds- Sequenced by (Qiagen Locus: /map="13b-1 cR from top of Chrl3 linkage group"

Insert length: 54b1 bp

Poly A stretch at pos- 5441ι polyadenylation signal at pos 5420

1 AAGGACAGAG GACGAGATTT TGAACGACAA AGAGAAAAGA GAGACAAGCC

51 AAGGTCTACT TCCCCAGCAG GACAGCATCA TTCTCCTATA TCTTCTAGAC

IDl ATCACTCATC TTCCTCACAA TCAGGATCAT CTATTCAAAG ACATTCTCCT

151 TCTCCTCGTC GAAAAAGAAC TCCTTCACCA TCTTATCAGC GGACACTAAC

2D1 TCCACCTTTA CGACGCTCTG CCTCTCCTTA TCCTTCACAT TCTTTGTCGT 251 CTCCCCAGAG AAAGCAGAGT CCTCCAAGAC ATCGCTCTCC AATGCGAGAG

301 AAAGGGAGAC ATGATCATGA ACGAACTTCA CAGTCTCATG ATCGACGCCA

351 CGAAAGGAGG GAAGATACTA GGGGCAAACG AGACAGAGAA AAGGACTCAA

401 GAGAAGAACG AGAATATGAA CAGGATCAGA GCTCTTCTAG AGACCACAGA

451 GATGACAGAG AACCTCGAGA TGGTCGGGAT CGGAGAGATG CCAGAGATAC 5D1 TAGGGACCGA AGGGAACTAA GAGACTCCAG AGACATGCGG GACTCAAGGG

551 AGATGAGAGA TTATAGCAGA GATACCAAAG AGAGCCGTGA TCCCAGAGAT bOl TCTCGGTCCA CTCGTGATGC CCATGACTAC AGGGACCGTG AAGGTCGAGA b51 TACTCATCGA AAGGAGGATA CATATCCAGA AGAATCCCGG AGTTATGGCC

701 GAAACCATTT GAGAGAAGAA AGTTCTCGTA CGGAAATAAG GAATGAGTCC 751 AGAAATGAGT CTCGAAGTGA AATTAGAAAT GACCGAATGG GCCGAAGTAG

6D1 GGGGAGGGTT CCTGAGTTAC CTGAAAAGGG AAGTCGAGGC TCAAGAGGTT

851 CTCAAATTGA TAGTCACAGT AGTAATAGCA ACTATCATGA CAGCTGGGAA

101 ACTCGAAGTA GCTATCCTGA AAGAGATAGA TATCCTGAAA GAGACAACAG

151 AGATCAAGCA AGGGATTCTT CCTTTGAGAG AAGACATGGA GAGCGAGACC 10D1 GTCGTGACAA CAGAGAGAGA GATCAAAGAC CAAGCTCACC AATTCGACAT

1051 CAGGGAAGGA ATGACGAGCT TGAGCGTGAT GAAAGAAGAG AGGAACGAAG

1101 AGTAGACAGA GTGGATGATA GGAGAGATGA AAGGGCTAGA GAGAGAGATC

1151 GGGAACGAGA ACGAGACAGG GAGCGGGAGA GAGAGAGGGA ACGTGAACGG

1201 GATCGGGAAA GAGAAAAAGA GAGAGAACTA GAAAGAGAGC GTGCTAGGGA 1251 ACGGGAGAGA GAAAGAGAAA AAGAGAGAGA TCGTGAAAGG GATAGAGACC

1301 GAGACCACGA TCGAGAGCGG GAAAGAGAGA GGGAACGAGA CAGGGAAAAA

1351 GAACGGGAAC GAGAAAGAGA AGAGAGAGAG AGGGAGAGAG AGCGAGAACG

14D1 GGAGAGAGAG CGAGAGCGAG AACGGGAACG AGAAAGAGCG AGAGAAAGGG 1451 ATAAAGAACG AGAACGCCAA AGGGATTGGG AAGACAAAGA CAAAGGACGA

1501 GATGACCGCA GAGAAAAGCG AGAAGAGATC CGAGAAGATA GGAATCCAAG

1551 AGATGGACAT GATGAAAGAA AATCAAAGAA GCGCTATAGA AATGAAGGGA

IbOl GTCCCAGCCC TAGACAGTCC CCGAAGCGCC GGCGTGAACA TTCTCCGGAC 1L.51 AGTGATGCCT ACAACAGTGG AGATGATAAA AATGAAAAAC ACAGACTCTT

17D1 GAGCCAAGTT GTACGACCTC AAGAATCTCG TTCTCTTAGT CCCTCGCACC

1751 TCACAGAAGA CAGACAGGGT AGATGGAAAG AGGAGGATCG TAAACCAGAA

1601 AGGAAAGAGA GTTCAAGGCG CTACGAAGAA CAGGAACTCA AGGAGAAAGT

1651 TTCTTCTGTA GATAAACAGA GAGAACAGAC AGAAATCCTG GAAAGCTCAA 1101 GAATGCGTGC ACAGGACATT ATAGGACACC ACCAGTCTGA AGATCGAGAG

1151 ACATCTGATC GAGCTCATGA TGAAAACAAG AAGAAAGCAA AAATTCAAAA

2001 GAAACCAATT AAGAAAAAGA AAGAGGATGA TGTTGGAATA GAGAGGGGTA

2D51 ACATAGAGAC AACATCTGAA GATGGTCAAG TATTTTCACC AAAAAAAGGA

21D1 CAGAAAAAGA AAAGCATTGA AAAAAAACGT AAAAAATCCA AAGGTGATTC 2151 TGATATTTCT GATGAAGAAG CAGCCCAGCA AAGTAAGAAG AAAAGAGGCC

2201 CACGGACTCC CCCTATAACA ACTAAAGAGG AATTGGTTGA AATGTGCAAT

2251 GGTAAGAATG GTATTCTAGA GGACTCCCAG AAAAAAGAAG ATACAGCATT

2301 CAGTGACTGG TCTGATGAGG ATGTCCCTGA CCGTACAGAG GTGACAGAAG

2351 CAGAGCATAC TGCCACCGCC ACGACTCCTG GTAGTACCCC TTCTCCTCTA 2401 TCTTCTCTTC TTCCTCCTCC ACCGCCTGTG GCTACTGCCA CTGCTACAAC

2451 TGTGCCTGCA ACTCTTGCTG CCACTACTGC TGCTGCCGCC ACCTCTTTCA

2501 GCACATCTGC CATCACTATT TCCACCTCTG CCACCCCCAC CAATACCACC

2551 AATAATACTT TTGCCAATGA AGACTCACAC AGAAAATGCC ACAGAACACG

2b01 AGTAGAAAAA GTAGAGACGC CTCACGTGAC TATAGAAGAT GCACAGCATC 2b51 GCAAGCCTAT GGATCAAAAG AGGAGCAGCA GCCTCGGGAG CAATCGGAGT

27D1 AACCGTAGTC ATACGTCTGG TCGTCTTCGC TCCCCATCCA ATGATTCAGC

2751 CCATCGAAGT GGAGATGACC AAAGTGGTCG AAAGAGAGTA CTGCACAGTG

2601 GCTCAAGAGA TA6AGAAAAA ACAAAAAGCC TGGAAATCAC AGGAGAGAGA

2851 AAATCTAGGA TTGATCAGTT AAAGCGTGGA GAACCCAGTC GAAGTACTTC 2101 TTCAGATCGC CAGGATTCAA GAAGCCATAG TTCAAGAAGA AGTTCTCCAG

2151 AGTCAGATCG ACAGGTCCAT TCAAGATCTG GGTCATTTGA TAGCAGAGAC

30D1 AGGCTTCAAG AACGAGATCG ATATGAACAC GACAGAGAGC GCGAGAGAGA

3051 GAGGAGAGAT ACGAGGCAGA GAGAATGGGA CCGAGATGCT GATAAAGATT

3101 GGCCACGCAA CAGGGATCGA GATAGATTGC GAGAACGAGA ACGAGAGAGA 3151 GAACGAGACA AAAGGAGAGA CTTGGATAGG GAAAGAGAGA GACTAATTTC

3201 TGATTCTGTT GAAAGGGACA GGGACAGAGA CAGAGACAGA ACTTTTGAGA

3251 GTTCTCAAAT AGAGTCTGTG AAACGCTGTG AAGCAAAACT GGAAGGTGAA

3301 CATGAAAGGG ATCTAGAAAG CACTTCCCGA GACTCTCTAG CCTTGGATAA

3351 AGAGAGAATG GATAAAGATC TGGGATCTGT GCAGGGATTT GAAGATACAA 3401 ATAAATCCGA GAGAACTGAG AGTCTGGAAG CAGGAGATGA CGAGTCCAAG

3451 TTAGATGATG CACATTCATT AGGCTCTGGT GCTGGAGAAG GATACGAGCC

3501 AATCAGTGAT GACGAACTAG ATGAAATTCT GGCAGGTGAT GCAGAAAAGA

3551 GGGAGGACCA ACAGGATGAG GAGAAGATGC CAGATCCCTT AGATGTGATA

3b01 GATGTGGATT GGTCTGGTCT TATGCCAAAG CATCCAAAAG AACCACGAGA 3b51 GCCTGGGGCT GCACTCTTAA AATTCACACC TGGAGCTGTT ATGCTAAGAG

3701 TTGGGATTTC TAAAAAGTTG GCAGGTTCTG AACTCTTTGC CAAAGTCAAA

3751 GAAACATGTC AGAGACTTTT AGAAAAACCC AAAGGTAGTT TCATTTTACT

3601 TTAACTATAT AATGTCTGTT AACCATTTAA GATGCCATCT GAAGGGGATT

3651 CTGATCTGTT CTTATGTAGC ACTTAACACT GTGTAGAAAC TATTTTTTGA 3101 GAAATCATTT TATAATCATT ATTTAACCCT CATGGTCAAA GTTTCTCTTT

3151 AAAATTTATT TTGAGAAGAA GAGTTATCCC ACAGAAAAGT TGGGAAAAGA

4D01 GTACAATGAC CTTTTTGTAT GAAAATTACT TATTAACAGG CCAGGCGTGG

4D51 TGTTGCATGT CTGTAGTCAC AGCTACTCA6 GGAGGTTGAG GCAGCAGGAT

41D1 TGCTGGAGCC CAGGAAATTG AGGCTGCAGT GAGCCATGAT TGAGCCACCA 4151 CACTCCAACC TAGGTGACAG AGCAAGACCC TGTCTCAAAA AAAAAAAAAC

42D1 AAATTAACCA ATAAGTTCTA ATATCAAAGT GCTCAGTGGT TTGCCCTTGG

4251 CTAAATGAAG CAGAGCCAGG AAAAACAGAC TACATATTTT TCATGTCTAA

4301 AGAAATTGGG TATTTTGGCA GCCCTTTCCC CTAGACATCT ACCCAAATGC 4351 AGGTGTGTAG GTTGAGTCTT TAACAAAGTG ATTAAGAGCT TGGTCTGTAA

4401 GGCCGGATGA TCTGGATTTC AGTAGGCACA CCACTTACTG GCTATTACTT

4451 AATCTGTGTG TTAGTGTCAT CATCTGTAAG TCAGGAATAA TCATACCACC

4501 AACTTCCTAT GGTAATTAGG AGCAAATGAG TTATTACAGG CAAAACACTT

4551 AGAACAGTTC CTGGCATATA GTAATACCCA ATAAATATTA ACTGCTACTT

4b01 TGAAAATATC CTATCACGCT GATTTTTGAC CTCACTGCAG CAATTTTCAG

4b51 TTATTCCAGA TTATCTAGCT TATGGATTCT GGTGGTAGGG GTTGTTTGGT

4701 TTTGGTTTTC ACTGTCTCTG TCTCATCTAG TACCTACCTT AGTTTATTTT

4751 GCAACTTACT AATACTTTAT TAATGGGGAG GGACGAGTAG ATGGTAAAAA

4801 GAAGGAAAAG GAGGTAAAAG GTGAAAGGAA CAACATTAAT TAACAATTTT

4851 ACGTCATGTC CCTGGACATA AAAGTTTAGT TAGTATTAAA TTTTTCACTA

41D1 ATACAAAATA AAAAAATATT GTTTTATGAG TTTTATGAAT TCATGCCCTT

4151 CCTTTACTCT ATTAGCATAA GCAGTAAATT TTTTTATTTT AATATAGCCC

50D1 AATAAACCTA GAGTATACAT GTACAAAATA CATATAATTG TTAACGTGTA

5051 TTAACCGAAA AATGACCCAA GACTTAGTTC TTGCCCTACT GTATCTGCCT

5101 TGTTTGGTTG GTTCTGTGAC CTTAAGCAAA TAACTCCTGT GAGCCTCAAT

5151 TTTATTTGTA AAGTGATGGA ATAAAACCCC TAAAATCTTA CCCACCTCTA

5201 AAGATATTTG TTTCTGTGAC CTTTTGCTAG TAGCATTTCA AGTTAAAATC

5251 TGGTTTGATT TTGCTACCCA TGAAATACAG TTCGGCCCTT ACTTATTGAT

5301 GACTTAACCT AAACAGTGAA AATATGCACT GTAAAGGGTG GGGTGATGTG

5351 GCTTAACAAT CAGACTTCTT CTATTTTTGC TGCTATGGTG GTTGTATTAG

5401 AGAACTGATG TATTATCTTG AATAAAGACT TTGTCTTGTT TACTGCCCTA

5451 AAAAAAAAAA AAAAAAAAA

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 1

ORF from 212 bp to 3801 bpi peptide length: 1170 Category: similarity to unknown protein Classification: no clue

1 MREKGRHDHE RTSlQSHDRRH ERREDTRGKR DREKDSREER EYEiQDlQSSSR

51 DHRDDREPRD GRDRRDARDT RDRRELRDSR DMRDSREMRD YSRDTKESRD

IDl PRDSRSTRDA HDYRDREGRD THRKEDTYPE ESRSYGRNHL REESSRTEIR

151 NESRNESRSE IRNDRMGRSR GRVPELPEKG SRGSRGSiQID SHSSNSNYHD 2D1 SUETRSSYPE RDRYPERDNR DiQARDSSFER RHGERDRRDN RERDώRPSSP

251 IRHiQGRNDEL ERDERREERR VDRVDDRRDE RARERDRERE RDRERERERE

301 RERDREREKE RELERERARE REREREKERD RERDRDRDHD RERERERERD

351 REKERERERE ERERERERER ERERERERER ERARERDKER ERiQRDUEDKD

401 KGRDDRREKR EEIREDRNPR DGHDERKSKK RYRNEGSPSP RfQSPKRRREH 451 SPDSDAYNSG DDKNEKHRLL SlQVVRPlQESR SLSPSHLTED RiQGRUKEEDR

501 KPERKESSRR YEEiQELKEKV SSVDKlQREiQT EILESSRMRA (QDIIGHHiQSE

551 DRETSDRAHD ENKKKAKIiQK KPIKKKKEDD VGIERGNIET TSEDGώVFSP bOl KKGiQKKKSIE KKRKKSKGDS DISDEEAAIQIQ SKKKRGPRTP PITTKEELVE b51 MCNGKNGILE DSώKKEDTAF SDUSDEDVPD RTEVTEAEHT ATATTPGSTP

701 SPLSSLLPPP PPVATATATT VPATLAATTA AAATSFSTSA ITISTSATPT

751 NTTNNTFANE DSHRKCHRTR VEKVETPHVT IEDAlQHRKPM DlQKRSSSLGS

801 NRSNRSHTSG RLRSPSNDSA HRSGDDlQSGR KRVLHSGSRD REKTKSLEIT

851 GERKSRIDlQL KRGEPSRSTS SDRiQDSRSHS SRRSSPESDR iQVHSRSGSFD

101 SRDRLiQERDR YEHDRERERE RRDTRiQREUD RDADKDUPRN RDRDRLRERE

151 RERERDKRRD LDRERERLIS DSVERDRDRD RDRTFESSiQI ESVKRCEAKL

1D01 EGEHERDLES TSRDSLALDK ERMDKDLGSV iQGFEDTNKSE RTESLEAGDD

1D51 ESKLDDAHSL GSGAGEGYEP ISDDELDEIL AGDAEKREDiQ (QDEEKMPDPL

11D1 DVIDVDUSGL MPKHPKEPRE PGAALLKFTP GAVMLRVGIS KKLAGSELFA

1151 KVKETCiQRLL EKPKGSFILL

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_12dl8ι frame 1 No Alert BLASTP hits found

Pedant information for DKFZphtes3_12dl8ι frame 1

Report for DKFZphtes3_12dl8-l

[LENGTH! 12b7 [MU! 150513-45 [pi! 1-22 [HOMOL! TREMBL:AB020bbO_l gene^; "KIAAD853"i product

"KIAAD653 protein i Homo sapiens mRNA for KIAA0653 proteini partial eds- 0-0

[BLOCKS! BL0D422C Granins proteins

[BLOCKS! BL0D803F

[BLOCKS! PR0D306C

[BLOCKS! PRD1081B

[BLOCKS! PRDDD41D

[BLOCKS! PR01D63A

[BLOCKS! PR00545A

[BLOCKS! BL00048 Protamine PI proteins

[BLOCKS! PF0114DD

[BLOCKS! PR0D833H

[KU! All_Alpha

[KU! LOU COMPLEXITY 44-12 *

SElQ KDRGRDFERiQREKRDKPRSTSPAGlQHHSPISSRHHSSSSiQSGSSIiQRHSPSPRRKRTPSP SEG xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

PRD ccccchhhhhhhhccccccccccccccccccccccccccccccceeeccccccccccccc

SElQ SYlQRTLTPPLRRSASPYPSHSLSSPl^QRKiQSPPRHRSPMREKGRHDHERTSiQSHDRRHERR

SEG x xxxxxxxxxxxxx xxxxxxxx PRD ccccccccccccccccccccccccccccccccccccccccccccccccccccchhhhhhc

SElQ EDTRGKRDREKDSREEREYEl^QDi^QSSSRDHRDDREPRDGRDRRDARDTRDRRELRDSRDMR

SEG xx-xxxxxxxxxxxxxxxxx-xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx PRD cccccccccccchhhhhhhhhhccccccccccccccccccchhhhhhhhhhhhhhhcccc

SElQ DSREMRDYSRDTKESRDPRDSRSTRDAHDYRDREGRDTHRKEDTYPEESRSYGRNHLREE

SEG xxxxxxxxxxx- • ■ xxxxxxxxxxxx

PRD hhhhhhhccccccccccccccccccccccccccccccccccccccccccccccccccccc

SElQ SSRTEIRNESRNESRSEIRNDRMGRSRGRVPELPEKGSRGSRGSlQIDSHSSNSNYHDSUE

SEG xxxxxxxxxxxx- •

PRD hhhhhhhccccccccccccccccccccccccccccccccccccccccccccccccccccc

SElQ TRSSYPERDRYPERDNRD1QARDSSFERRHGERDRRDNRERD1QRPSSPIRH1QGRNDELERD

SEG xxxxxxxxxxxxxxxxxx xxxxxx

PRD cccccccccccccccccccccccccccccccccccccccccccccccccccccchhhhhh SElQ ERREERRVDRVDDRRDERARERDRERERDRERERERERERDREREKERELERERARERER

SEG xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

PRD hhhhhhhhhcchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh

SElQ EREKERDRERDRDRDHDRERERERERDREKEREREREERERERERERERERERERERERA SEG xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

PRD hhhhhhhhhcccccccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh

SElQ RERDKERERiQRDUEDKDKGRDDRREKREEIREDRNPRDGHDERKSKKRYRNEGSPSPRlQS

SEG xxxxxxxxx- xxxxxxxxxxxxxxxxxxxxxxxx xxxxxxx PRD hhhhhhhhhhhhhhhccccccchhhhhhhhhhccccccccccchhhhhhccccccccccc

SElQ PKRRREHSPDSDAYNSGDDKNEKHRLLSIQVVRPIQESRSLSPSHLTEDRIQGRUKEEDRKPE

SEG xxxxx

PRD ccccccccccccccccccccchhhhhhhhhcccccccccccccccchhhhhhhhhhccch

SElQ RKESSRRYEE(QELKEKVSSVDK<QRE(QTEILESSRMRA(QDIIGHH(QSEDRETSDRAHDENK

SEG x

PRD hhhhhhhhhhhhhhhhhhccchhhhhhhhhhhhhhhhhheeeecccccccccccccccch SElQ KKAKIiQKKPIKKKKEDDVGIERGNIETTSEDGlQVFSPKKGiQKKKSIEKKRKKSKGDSDIS

SEG xxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxx

PRD hhhhhhhhccccccccccccccccceeecccceeecccccchhhhhhhhhhccccccccc

SElQ DEEAAlQiQSKKKRGPRTPPITTKEELVEMCNGKNGILEDSlQKKEDTAFSDUSDEDVPDRTE SEG xxx xx

PRD hhhhhhhhhhcccccccccccchhhhhhcccccceeecccccccccccccccccccceee

SElQ VTEAEHTATATTPGSTPSPLSSLLPPPPPVATATATTVPATLAATTAAAATSFSTSAITI

SEG xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx PRD hhhhhhhhccccccccccceeeccccccceeeeeeecccchhhhhhhhhhhhccccceee

SEA STSATPTNTTNNTFANEDSHRKCHRTRVEKVETPHVTIEDAiQHRKPMDiQKRSSSLGSNRS

SEG xxxxxxxxxxxxxxxx xxxxxxxxxx

PRD eccccccccccccccccccccchhhhheeeeccceeeecccccccccccccccccccccc

SElQ NRSHTSGRLRSPSNDSAHRSGDDlQSGRKRVLHSGSRDREKTKSLEITGERKSRIDlQLKRG

SEG xxx

PRD ccccccccccccccccccccecccccceeeeeccccccccceeeeehhhhhhhhhhhhcc SElQ EPSRSTSSDRiQDSRSHSSRRSSPESDRlQVHSRSGSFDSRDRLiQERDRYEHDRERERERRD

SEG - - xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxx

PRD ccccccccccccccccccccccccccceeeecccccccchhhhhhhhhhchhhhhhhhhh SElQ TRiQREUDRDADKDUPRNRDRDRLRERERERERDKRRDLDRERERLISDSVERDRDRDRDR

SEG xxxxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxx

PRD hhhhhhhhccccccccccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhccccccccccce SElQ TFESSlQIESVKRCEAKLEGEHERDLESTSRDSLALDKERMDKDLGSVtQGFEDTNKSERTE

SEG

PRD eechhhhhhhhhhhhhhhhhhccccccccccchhhhhhhhhhcccccccccccccccccc

SElQ SLEAGDDESKLDDAHSLGSGAGEGYEPISDDELDEILAGDAEKREDiQlQDEEKMPDPLDVI SEG

PRD cccccccccccccccccccccccccccccccccceeeecchhhhhhhhhhhcccccceee

SElQ DVDUSGLMPKHPKEPREPGAALLKFTPGAVMLRVGISKKLAGSELFAKVKETCiQRLLEKP

SEG PRD eccccccccccccccccccceeeeeccceeeeeecccccccchhhhhhhhhhhhhhhl-.ee

SEfQ KGSFILL

SEG

PRD ccccccc

( No Prosi te data avai lable for DKFZphtes3_12dlβ - 1 ) ( No Pf am data avai l abl e f or DKFZphtes3_12dlδ - 1 )

DKFZphtes3_1417

group: testis derived

DKFZphtes3_1417 encodes a novel 615 amino acid protein without similarity to known proteins- The mRNA is transcribed ubiquitously -

No informative BLAST resultsi No predictive prositei pfam or SCOP motife.

The new protein can find application in studying the expression profile of testis-specific genes-

similarity to C-elegans B0412-3 see also DKFZphtes3_17n3 perhaps complete eds-

Sequenced by BMFZ Locus: unknown

Insert length: 3522 bp

Poly A stretch at pos- 345bι polyadenylation signal at pos- 3437

1 AACACATCGA CTTGTGTAAG AAAAAGATTG GAAGTGCGGA GCTGTCTTTT

51 GAGCATGATG CATGGATGTC TAAACAATTC CAGGCCTTTG GAGATTTATT

IDl TGATGAAGCT ATTAAGTTAG GGTTAACAGC TATTCAAACT CAGAATCCTG

151 GTTTCTATTA CCAGCAGGCA GCATACTATG CCCAGGAGCG GAAACAGCTT 201 GCAAAAACCC TCTGTAA CCA CGAAGCTTCT GTAATGTATC CCAATCCTGA

251 TCCCTTAGAA ACACAAACAG GCGTTCTTGA CTTTTATGGA CAAAGATCAT

301 GGCGACAAGG AATACTAAGT TTTGATCTTT CTGATCCTGA AAAAGAAAAG

351 GTGGGAATTC TTGCCATTCA GCTGAAGGAG AGAAATGTTG TTCACTCTGA

401 GATAATCATA ACTCTTCTGA GCAATGCTGT TGCACAGTTC AAGAAGTATA 451 AGTGCCCGCG AATGAAAAGT CACCTAATGG TTCAGATGGG AGAGGAATAT

501 TATTACGCAA AGGATTATAC CAAAGCTTTG AAGTTGCTGG ATTATGTGAT

551 GTGTGATTAT CGGAGTGAAG GATGGTGGAC TCTGCTCACT TCTGTATTAA bOl CTACAGCTCT GAAGTGCTCC TACCTCATGG CCCAATTAAA GGATTACATT b51 ACTTACTCCC TAGAACTCCT TGGTAGAGCT TCAACTCTGA AAGATGACCA 701 GAAGTCTCGG ATAGAAAAGA ACCTCATAAA TGTTTTAATG AATGAAAGTC

751 CTGATCCAGA ACCCGACTGT GATATCTTAG CTGTGAAAAC TGCTCAGAAG

801 CTGTGGGCAG ACCGAATTTC TCTGGCTGGC AGCAATATTT TCACAATAGG

651 AGTACAGGAC TTTGTGCCAT TTGTGCAGTG CAAAGCCAAG TTTCATGCCC

IDl CAAGTTTTCA TGTTGATGTT CCTGTTCAGT TTGATATTTA TCTGAAGGCT 151 GATTGTCCAC ATCCCATTAG GTTTTCCAAG CTCTGTGTCA GCTTTAATAA

1D01 TCAGGAATAC AACCAGTTCT GTGTAATAGA AGAAGCATCC AAAGCAAATG

1D51 AAGTTTTAGA AAATCTGACT CAAGGAAAGA TGTGCCTAGT TCCTGGCAAA

1101 ACAAGAAAAC TGTTATTTAA GTTTGTTGCA AAAACTGAAG ATGTGGGAAA

1151 GAAAATTGAG ATTACTTCAG TGGATCTTGC TCTGGGCAAT GAGACGGGAA 12D1 GATGTGTGGT TTTAAATTGG CAGGGAGGAG GAGGAGATGC TGCTTCCTCC

1251 CAAGAAGCCT TACAGGCAGC TCGGTCTTTC AAAAGGCGAC CTAAGCTACC

1301 TGACAATGAA GTTCACTGGG ACAGCATTAT AATTCAGGCA AGCACAATGA

1351 TCATATCCAG AGTCCCAAAC ATTTCTGTAC ATCTGCTACA TGAACCCCCT 14D1 GCACTGACTA ATGAAATGTA TTGTTTGGTT GTGACTGTTC AGTCCCATGA

1451 AAAGACCCAA ATCAGAGATG TGAAGCTCAC TGCTGGCTTA AAACCAGGAC

1501 AGGATGCCAA TTTAACTCAG AAGACTCACG TGACTCTTCA TGGACCAGAA

1551 CTGTGTGATG AATCCTACCC GGCTTTACTC ACTGACATTC CTGTTGGAGA IbOl CTTACATCCA GGGGkkCkGC TGGAAAAAAT GTTGTATGTT CGCTGTGGAA lb51 CAGTGGGTTC CAGAATGTTT CTTGTATATG TTTCTTACCT GATAAATACA

17D1 ACCGTTGAAG AAAAAGAAAT TGTTTGCAAG TGTCACAAGG ATGAAACTGT

1751 AACAATTGAA ACAGTCTTTC CATTTGATGT TGC6GTTAAA TTTGTTTCTA

1801 CCAAGTTTGA GCACCTGGAA AGGGTTTATG CTGACATCCC CTTTCTGTTG 1851 ATGACGGACC TCTTAAGTGC CTCACCCTGG GCCCTCACTA TTGTTTCCAG

1101 TGAGCTCCAG CTTGCTCCAT CCATGACCAC AGTGGACCAG CTCGAGTCTC

1151 AAGTGGACAA TGTTATCTTA CAGACTGGAG AGAGTGCTAG TGAATGCTTT

20D1 TGTCTTCAAT GCCCATCTCT TGGAAATATT GAAGGTGGAG TAGCAACCGG

2051 GCATTATATT ATCTCTTGGA AAAGGACCTC AGCAATGGAG AATATCCCCA 2101 TCATCACAAC TGTCATCACT CTGCCGCACG TGATTGTGGA GAATATCCCT

2151 CTCCATGTGA ATGCAGATCT GCCGTCATTT GGGCGTGTCA GAGAGTCGTT

2201 ACCTGTCAAG TATCACCTAC AGAATAAGAC CGACTTAGTT CAAGATGTAG

2251 AAATTTCTGT GGAGCCCAGT GATGCCTTCA TGTTCTCAGG TCTCAAACAG

23D1 ATTCGATTAC GTATCCTCCC TGGCACGGAG CAGGAAATGC TATATAATTT 2351 CTATCCTCTG ATGGCTGGAT ACCAGCAGCT GCCATCTCTC AACATCAACT

2401 TGCTTAGATT TCCTAACTTC ACAAATCAGC TGCTCAGGCG TTTTATACCT

2451 ACCAGTATTT TTGTCAAGCC ACAGGGTCGA CTCATGGATG ATACCTCTAT

25D1 TGCTGCTGCA TGATGTTCAA GACCGGCCCT TGGCTGTTGT TACAGAGATG

2551 TTGGGCAGAG CTATGCAGGT GTTTCATTGT GAACTCTAGC TTTGATCATG 2b01 GTAAAAAGTT AACCTTTTCT ATTTTTTAAT GGATGTTATA CCAACTATTC

2b51 AGAGGAACTC ATACTTCAAA AATATTAGGA AAATCTGTCT TATAGTTTCT

27D1 CTAATAAATA TCTGAAATCT CAGTACGACA TGAAAGAATG TCAGACCATT

2751 GTTATTGTTG AAAGTCATTT GATGAATGGT AAATTCTATG AAAAGTAAGT

2801 GATTTGCATG TATAATATCA GGAAAATTAA GCATCCCAAG TGTGACTGGA 2651 CAAAGAGAGC AGATGCACCA GTGCCTGTGC CATAAAGTTC CGAATCCCCC

21D1 ATGTGTCTCT TTCAGAGCTG GCCAGACCGG AAATAAATCA TTCTCATAAA

2151 TTCAGTGTGT ACTCAGAACA CATACACAAC AACATAGGGA GTTGTATGAC

30D1 TGATACGGAA AACTTCCAGA AAGTTTTAAT CAAAGCAGTT TAATTAAGGT

3051 ATCAAAAATA TCTTTGCTTA CTATCAAGAA GTGTCAAATA GGTTCAGCTT 31D1 GCTGCCAAAA TATGGATCAT TTATGAAGCA GGTTCATATT TTAGAGGTGT

3151 TAATAAAATC CTCATCGGAA AAGATCCAAA GTGCAAGGAT TTGATTATAA

3201 ACATAATTTC CTAGACTGAA AGTTTTTGGA AAAGATGCAG GGTCTGAGTC

3251 AGGCCTTCTG GTTATATTGT GCAGTTTCAA AAGAACTATT TAAAACTCTT

3301 GAAAACTCAT GTAAATAAAA ATCATAGGGT GAAAATTGTA TTTGTTAAAA 3351 TACCTTAATA ATTTAAAATG ACCTGATTTC CTGGAAAATT TTATTATTCA

34D1 AAAGGTGGAG GCATTGTAAA AAGGAAATAG TGATGTAAAT AAACATGTTC

3451 TCTTTCAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA

3501 AAAAAAAAAA AAAAAAAAAA AA

BLAST Results

o BLAST result

Medline entries

o Medline entry Peptide information for frame 3

ORF from bb bp to 2510 bpi peptide length: 615 Category: similarity to unknown protein Classification-" no clue

1 MSKiQFlQAFGD LFDEAIKLGL TAIlQTiQNPGF YYlQiQAAYYAiQ ERKώLAKTLC

51 NHEASVMYPN PDPLETlQTGV LDFYGiQRSUR (QGILSFDLSD PEKEKVGILA 101 IiQLKERNVVH SEIIITLLSN AVAlQFKKYKC PRMKSHLMViQ MGEEYYYAKD

151 YTKALKLLDY VMCDYRSEGU UTLLTSVLTT ALKCSYLMAfQ LKDYITYSLE

201 LLGRASTLKD DiQKSRIEKNL INVLMNESPD PEPDCDILAV KTAlQKLUADR

251 ISLAGSNIFT IGVlQDFVPFV (QCKAKFHAPS FHVDVPVlQFD IYLKADCPHP

3D1 IRFSKLCVSF NNiQEYNiQFCV IEEASKANEV LENLTiQGKMC LVPGKTRKLL 351 FKFVAKTEDV GKKIEITSVD LALGNETGRC VVLNUUGGG6 DAASSlQEALfl

401 AARSFKRRPK LPDNEVHUDS IIIiQASTMII SRVPNISVHL LHEPPALTNE

451 MYCLVVTViQS HEKTlQIRDVK LTAGLKPGiQD ANLTiQKTHVT LHGPELCDES

5D1 YPALLTDIPV GDLHPGEώLE KMLYVRCGTV GSRMFLVYVS YLINTTVEEK

551 EIVCKCHKDE TVTIETVFPF DVAVKFVSTK FEHLERVYAD IPFLLMTDLL bOl SASPUALTIV SSELlQLAPSM TTVDiQLESlQV DNVILiQTGES ASECFCLUCP b51 SLGNIEGGVA TGHYIISUKR TSAMENIPII TTVITLPHVI VENIPLHVNA

7D1 DLPSFGRVRE SLPVKYHLώN KTDLVlQDVEI SVEPSDAFMF SGLKiQIRLRI

751 LPGTEώEMLY NFYPLMAGYlQ (QLPSLNINLL RFPNFTNiQLL RRFIPTSIFV

801 KPiQGRLMDDT SIAAA

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_1417ι frame 3 No Alert BLASTP hits found

Pedant information for DKFZphtes3_1417ι frame 3

Report for DKFZphtes3_1417- 3

[LENGTH! 63b

[MU! 14241-30

[pi! 5-64 [HOMOL! TREMBL : CEUB0412_2 gene: "B0412-3"i Caenorhabditis elegans cosmid BD412- be-30

[KU! ^< Alpha_Beta

CKU! L U_COMPLEXITY 1-20 *

SElQ HIDLCKKKIGSAELSFEHDAUMSK(QF(QAFGDLFDEAIKLGLTAI(3T(QNPGFYY(Q(QAAYYA

SEG xxxxxxxxx

PRD ccceeeeeehhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhccceeeccccchhhhhhhhh SE(Q (QERKiQLAKTLCNHEASVMYPNPDPLETi^QTGVLDFYGiQRSURiQGILSFDLSDPEKEKVGIL SEG x

PRD hhhhhhhhhhhhhcceeeccccccccceeeeeeeeccccceeeceeeeeccchhhhhhhh SEA AIi^QLKERNVVHSEIIITLLSNAVAlQFKKYKCPRMKSHLMViQMGEEYYYAKDYTKALKLLD

SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhccceeehhhhhhhhhhhh SElQ YVMCDYRSEGUUTLLTSVLTTALKCSYLMAlQLKDYITYSLELLGRASTLKDDiQKSRIEKN

SEG

PRD hhhhccccccceeehhhhhhhhhhhhhhhhhhhhhhhhhhhhhhchhhhhccccchhhhh

SElQ LINVLMNESPDPEPDCDILAVKTAlQKLUADRISLAGSNIFTIGVlQDFVPFViQCKAKFHAP SEG

PRD hheeeeccccccccccchhhhhhhhhhhhhhhhhhcccceeeeeeehhhhhhhhhhcccc

SElQ SFHVDVPViQFDIYLKADCPHPIRFSKLCVSFNNiQEYNiQFCVIEEASKANEVLENLTlQGKM

SEG PRD eeeeeeecceeeeeecccccceeeeeeeeecccccccceeeeeccccchhhhhccccccc

SElQ CLVPGKTRKLLFKFVAKTEDVGKKIEITSVDLALGNETGRCVVLNUlQGGGGDAASSiQEAL

SEG

PRD cccccccccchhhhhhhhhccceeeeeeeecccccccccceeeeeecccccccchhhhhh

SElQ (QAARSFKRRPKLPDNEVHUDSIIIlQASTMIISRVPNISVHLLHEPPALTNEMYCLVVTViQ

SEG

PRD hhhhhhhhcccccccccccceeeeeeeceeeeccccceeeeeccccccccceeeeeeeee SElQ SHEKTiQIRDVKLTAGLKPGiQDANLTiQKTHVTLHGPELCDESYPALLTDIPVGDLHPGEiQL

SEG

PRD cccccceeeeeccccccccchhhhhheeeeecccccccccceeeeecccccccccccchh

SElQ EKMLYVRCGTVGSRMFLVYVSYLINTTVEEKEIVCKCHKDETVTIETVFPFDVAVKFVST SEG

PRD hhhhhhcccccchhhhhcchhhhhccccceeeeeeecccccceeeeeeccceeeeeeeeh

SElQ KFEHLERVYADIPFLLMTDLLSASPUALTIVSSELlQLAPSMTTVDlQLESlQVDNVILlQTGE

SEG PRD hhhhhhhhhhccceeeehhhhhccccceeehhhhhhhhccceeeccccccccceeeeccc

SElQ SASECFCLiQCPSLGNIEGGVATGHYIISUKRTSAMENIPIITTVITLPHVIVENIPLHVN

SEG

PRD cceeeeeeeecccccccccccceeeeeeeeccccccccceeeeeeeeeeeeeeecccccc

SElQ ADLPSFGRVRESLPVKYHLlQNKTDLVlQDVEISVEPSDAFMFSGLKi^QIRLRILPGTEiQEML

SEG

PRD cccccccceeeccceeeeeecccccceeeeeecccccceeeccccccceeeccccccccc SElQ YNFYPLMAGYlQiQLPSLNINLLRFPNFTNiQLLRRFIPTSIFVKPiQGRLMDDTSIAAA

SEG

PRD cccccccccccccccccccccccccccchhhhhcccceeeeecccccccccccccc

( No Prosite data ava i l ab le f or DKFZphtes3_lM 17 - 3 ) ( No Pf am data avai l able f or DKFZphtes3_1417 - 3 ) DKFZphtes3_15nl4

group: testis derived

DKFZphtes3_15nl4 encodes a novel 713 amino acid protein with weak similarity to the neurofilament triplet M protein of the ratNeurofilaments are the intermediate filaments specific to nervous tissue- They are probably essential to the tensile strength of the neuroni as well as to transport of molecules and organelles within the axon- Until nowi ESTs of the novel mRNA could only be isolated from testesi germ cells and uterus- No informative BLAST resultsi No predictive prositei pfam or SCOP motife.

The new protein can find application in studying the expression profile of testis-specific genes.

similarity to neurofilament triplet M protein - rat few EST hits (b of 1 hits from testis) perhaps complete eds-

Sequenced by GBF

Locus: unknown

Insert length: 2381 bp

Poly A stretch at pos. 2328ι polyadenylation signal at pos- 230b

1 TGGGCCCCAC CTCCTCAGCA CAACTTTCTG AAAAACTGGC AGCGTAACAC

51 AGCCCTGCGG AAGAAGCAGC AGGAAGCCCT CAGCGAACAC CTAAAGAAGC

101 CAGTGAGTGA GCTGCTCATG CACACCGGGG AGACCTACAG ACGGATCCAG

151 GAGGAGCGGG AGCTCATTGA CTGCACACTT CCAACCCGGC GTGATAGGAA

201 AAGCTGGGAG AACAGTGGGT TCTGGAGTCG ACTGGAATAC TTGGGAGATG 251 AGATGACAGG TCTGGTCATG ACCAAGACAA AAACTCAGCG TGGCCTCATG

301 GAGCCCATCA CTCATATCAG GAAGCCCCAC TCCATCCGGG TGGAGACAGG

351 ATTACCAGCC CAGAGGGACG CTTCATACCG CTACACCTGG GATCGGAGTC

401 TGTTTCTGAT CTACCGACGC AAGGAGCTGC AGAGAATCAT GGAAGAGCTG

451 GATTTCAGCC AGCAGGATAT TGATGGCCTG GAGGTGGTGG GCAAAGGGTG 5D1 GCCCTTCTCG GCTGTTACTG TGGAAGACTA CACAGTGTTT GAAAGAAGTC

551 AGGGAAGCTC CTCTGAAGAC ACAACATACT TAGGCACATT GGCCAGTTCC bOl TCTGATGTCT CCATGCCTAT TCTCGGCCCT TCTCTGCTGT TCTGTGGGAA b51 GCCAGCTTGC TGGATCAGAG GCAGTAATCC ACAGGACAAG AGGCAGGTTG

701 GGATTGCTGC TCACTTGACC TTTGAAACCC TAGAAGGCGA GAAAACCTCC 751 TCAGAACTGA CTGTGGTCAA TAATGGCACC GTGGCCATTT GGTATGACTG

8D1 GCGACGGCAG CACCAGCCGG ACACTTTCCA AGACCTTAAG AAAAACAGGA

851 TGCAGCGATT TTACTTTGAC AACCGGGAAG GTGTGATTCT GCCTGGAGAA

101 ATTAAAACAT TTACCTTCTT CTTCAAGTCT TTGACTGCTG GGGTCTTCAG

151 GGAATTTTGG GAGTTTCGAA CCCATCCTAC TCTATTAGGA GGTGCTATAC 1001 TGCAGGTCAA TCTCCACGCG GTCTCCCTGA CCCAGGACGT TTTTGAGGAT

1051 GAGAGGAAAG TACTGGAGAG CAAGCTGACT GCCCATGAGG CAGTCACCGT

1101 CGTTCGCGAA GTGCTGCAGG AGCTGCTGAT GGGGGTCTTG ACCCCGGAGC

1151 GCACACCATC ACCTGTGGAT GCCTATCTCA CCGAGGAAGA CTTGTTCCGG 1201 CACAGAAATC CTCCGCTGCA TTATGAGCAC CAAGTGGTGC AAAGCCTGCA

1251 CCAACTGTGG CGCCAGTACA TGACCCTGCC CGCCAAGGCT GAGGAGGCCA

1301 GGCCAGGGGA CAAGGAGCAC GTCAGCCCCA TAGCCACAGA GAAGGCCTCT

1351 GTGAATGCTG AGCTGTTACC ACGCTTTAGG AGCCCCATCT CCGAAACTCA 1401 AGTGCCCCGG CCTGAGAACG AGGCCCTCAG GGAATCCGGG TCCCAGAAGG

1451 CCAGAGTGGG GACCAAGAGT CCTCAGCGGA AGAGCATCAT GGAGGAGATC

1501 CTGGTGGAGG AAAGCCCAGA TGTGGACAGC ACCAAGAGCC CCTGGGAGCC

1551 GGATGGCCTT CCCCTGCTGG AGTGGAACCT CTGCTTGGAG GACTTCAGAA

IbOl AGGCAGTGAT GGTGCTCCCT GATGAGAACC ACAGAGAGGA TGCGTTGATG lb51 AGGCTCAACA AAGCAGCCCT GGAGCTGTGC CAGAAGCCAA GGCCATTGCA

17D1 GTCCAACCTC CTGCACCAGA TGTGTTTGCA GCTGTGGCGA GATGTGATTG

1751 ACAGCCTGGT GGGCCATTCC ATGTGGCTGA GGTCTGTGCT GGGCCTGCCT

1801 GAGAAGGAGA CCATCTATTT GAATGTGCCT GAAGAGCAAG ATCAAAAATC

1851 ACCTCCTATC ATGGAAGTGA AGGTACCTGT GGGGAAAGCT GGGAAGGAGG 1101 AGCGGAAAGG AGCAGCCCAG GAAAAGAAGC AACTGGGGAT CAAAGACAAA

1151 GAAGACAAGA AAGGAGCCAA GCTGCTCGGG AAAGAGGACC GTCCCAACAG

20D1 CAAGAAGCAC AAGGCAAAGG ATGACAAGAA AGTCATAAAA TCTGCAAGTC

2051 AGGACAGGTT TTCTTTGGAA GACCCTACCC CTGACATCAT CCTCTCTTCT

2101 CAAGAACCCA TAGACCCCCT GGTCATGGGG AAATACACCC AGAGGCTGCA 2151 CAGTGAGGTC CGTGGGCTGC TGGACACCCT GGTGACCGAC CTGATGGTCC

2201 TGGCTGATGA GCTCAGCCCC ATAAAGAATG TCGAGGAGGC TTTGCGCCTC

2251 TGCAGGTGAC TCTCGGGCCC AAGCAACCTT CTGGAAAACG GGTTAATAAA

2301 TAAATCAATA AAGAACCTTC AAGTTTCTAC TAAAAAAAAA AAAAAAAAAA

2351 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA GGGCGGCCG

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 1

ORF from 118 bp to 225b bpi peptide length: 713 Category: putative protein Classification: Cell structure/motility

1 MHTGETYRRI (QEERELIDCT LPTRRDRKSU ENSGFUSRLE YLGDEMTGLV

51 MTKTKTώRGL MEPITHIRKP HSIRVETGLP AiQRDASYRYT UDRSLFLIYR

101 RKELiQRIMEE LDFSώiQDIDG LEVVGKGUPF SAVTVEDYTV FERSlQGSSSE 151 DTTYLGTLAS SSDVSMPILG PSLLFCGKPA CUIRGSNPώD KRlQVGIAAHL

201 TFETLEGEKT SSELTVVNNG TVAIUYDURR (QHiQPDTFlQDL KKNRMiQRFYF

251 DNREGVILPG EIKTFTFFFK SLTAGVFREF UEFRTHPTLL GGAILiQVNLH

301 AVSLTiQDVFE DERKVLESKL TAHEAVTVVR EVLlQELLMGV LTPERTPSPV

351 DAYLTEEDLF RHRNPPLHYE HiQVViQSLHlQL URiQYMTLPAK AEEARPGDKE 401 HVSPIATEKA SVNAELLPRF RSPISETiQVP RPENEALRES GSώKARVGTK

451 SPiQRKSIMEE ILVEESPDVD STKSPUEPDG LPLLEUNLCL EDFRKAVMVL

501 PDENHREDAL MRLNKAALEL C(QKPRPL(QSN LLHIQMCLIQLU RDVIDSLVGH

551 SMULRSVLGL PEKETIYLNV PEEIQDI^QKSPP IMEVKVPVGK AGKEERKGAA bOl (QEKKώLGIKD KEDKKGAKLL GKEDRPNSKK HKAKDDKKVI KSAStQDRFSL b51 EDPTPDIILS SiQEPIDPLVM GKYTiQRLHSE VRGLLDTLVT DLMVLADELS

7D1 PIKNVEEALR LCR

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_15nl4ι frame 1 No Alert BLASTP hits found Pedant information for DKFZphtes3_15nl4ι frame 1

Report for DKFZphtes3_15nl .1

[LENGTH! 713

[MU! 81760.53

[pi! b-DO

[BLOCKS! PF0D878C [BLOCKS! BLOOblOC DEAH-box subfamily ATP-dependent helicases proteins

[KU! Alpha_Beta

[KU! L0U_C0MPLEXITY 4-07 *

SE(Q MHTGETYRRIIQEERELIDCTLPTRRDRKSUENSGFUSRLEYLGDEMTGLVMTKTKTIQRGL

SEG

PRD ccchhhhhhhhhhhhhhhhccccchhhhhhccccccceeeeccccceeeeeecccccccc SElQ MEPITHIRKPHSIRVETGLPAIQRDASYRYTUDRSLFLIYRRKELIQRIMEELDFSIQIQDIDG SEG

PRD cccccccccccceeeeeccccchhhhhhhcccchhhhhhhhhhhhhhhhhhcccccccce

SElQ LEVVGKGUPFSAVTVEDYTVFERSiQGSSSEDTTYLGTLASSSDVSMPILGPSLLFCGKPA SEG

PRD eeeeeccccceeeeecceeeeeecccccccceeecccccccccccccccccceeeecccc

SElQ CUIRGSNPiQDKRiQVGIAAHLTFETLEGEKTSSELTVVNNGTVAIUYDURRiQHiQPDTFlQDL SEG PRD eeeeccccccchhhhhhhhhheeecccccccceeeeecccceeeeehhhhhccccchhhh

SElQ KKNRMlQRFYFDNREGVILPGEIKTFTFFFKSLTAGVFREFUEFRTHPTLLGGAILlQVNLH

SEG

PRD hhhhhhhhhcccccccccccceeeeeeeehhhhhhhhhhhhhhhcccccccchhhhhhhh

SElQ AVSLTIQDVFEDERKVLESKLTAHEAVTVVREVLIQELLMGVLTPERTPSPVDAYLTEEDLF

SEG

PRD hhhhhhhccchhhhhhhhhhhhhhhhhhhhhhhhhhhhccccccccccccceeeeccccc SElQ RHRNPPLHYEHlQVViQSLHiQLURlQYMTLPAKAEEARPGDKEHVSPIATEKASVNAELLPRF SEG

PRD cccccccccccchhhhhhhhhhhhhhhhhhhhhccccccccccccchhhhhhhhhccccc SElQ RSPISET(QVPRPENEALRESGS(QKARVGTKSP(QRKSIMEEILVEESPDVDSTKSPUEPDG

SEG

PRD cccccccccccccchhhhhcccccccccccccchhhhhhhhhhhcccccccccccccccc SElQ LPLLEUNLCLEDFRKAVMVLPDENHREDALMRLNKAALELCiQKPRPLiQSNLLHlQMCLiQLU

SEG

PRD ccccchhhhhhhhhhhhccccccchhhhhhhhhhhhhhhhhhcccccchhhhhhhhhhhh

SElQ RDVIDSLVGHSMULRSVLGLPEKETIYLNVPEElQDlQKSPPIMEVKVPVGKAGKEERKGAA SEG

PRD hhhhhhhhccchhhhhhccccccceeeeecccccccccccceeeeeccccchhhhhhhhh

SElQ (QEKKiQLGIKDKEDKKGAKLLGKEDRPNSKKHKAKDDKKVIKSASiQDRFSLEDPTPDIILS

SEG xxxxxxxxxxxxxxxxx PRD hhhhhhccccccccchhhhhccccccccccccccccceeeeecccccccccccccceeee

SElQ SiQEPIDPLVMGKYTlQRLHSEVRGLLDTLVTDLMVLADELSPIKNVEEALRLCR

SEG xxxxxxxxxxxx

PRD ccccccceeechhhhhhhhhhhhhhhhhhhhhhhhhhhccccchhhhhhhccc

(No Prosite data available for DKFZphtes3_15nl4 -1) (No Pfam data available for DKFZphtes3_15nl4 - 1)

DKFZphtes3_lbb5

group: cell structure and motility

DKFZphtes3_lbb5 encodes a novel 2b8 amino acid protein with similarity to various tropomyosins- Tropomyosins play regulatory roles in cellular structure and transport-

The new protein can find application in modulating cell structure and motility as well as modulationg cellular transport-

weak similarity to KIAA0774 perhaps complete eds- Sequenced by BMFZ Locus-" unknown Insert length: 131b bp

Poly A stretch at pos- 1247ι polyadenylation signal at pos. 1232

1 TGCTAAAATG GAATTAGAGA GAAGCATAGA CATCAGCAGA AGACAGAGTA 51 AGGAGCACAT ATGTAGAATT ACAGATCTAC AAGAGGAATT AAGACACAGA

IDl GAGCATCACA TCTCTGAATT GGATAAGGAG GTTCAGCACC TTCATGAGAA

151 TATAAGTGCC CTAACCAAAG AACTGGAATT TAAGGGGAAA GAAATTCTCA

201 GAATACGAAG TGAATCTAAC CAACAGATAA GGTTGCATGA ACAAGATTTA

251 AACAAGAGAC TTGAAAAAGA GTTGGATGTC ATGACAGCAG ACCACCTCAG 301 AGAGAAAAAT ATCATGCGGG CAGATTTTAA TAAGACTAAC GAGCTACTCA

351 AGGAAATAAA TGCCGCTTTA CAAGTGTCAT TAGAAGAAAT GGAAGAAAAA

401 TATCTAATGA GAGAATCAAA ACCAGAAGAT ATACAGATGA TTACAGAATT

451 AAAAGCCATG CTTACAGAAA GAGACCAGAT CATAAAGAAA CTAATTGAGG

501 ATAATAAGTT TTATCAGCTG GAATTAGTCA ATCGAGAAAC TAACTTCAAC 551 AAAGTGTTTA ACTCAAGTCC TACTGTTGGT GTTATTAATC CATTGGCTAA bOl GCAAAAGAAG AAGAATGATA AATCACCAAC AAACAGGTTT GTGAGTGTTC b51 CCAATCTAAG TGCTCTGGAA TCTGGTGGAG TGGGCAATGG ACATCCTAAC

7D1 CGCCTGGATC CCATTCCTAA TTCTCCAGTC CACGATATTG AGTTCAACAG

751 CAGCAAACCA CTTCCACAGC CAGTGCCACC TAAAGGGCCC AAGACATTTT 601 TGAGGTATCA GTAAGATGCA TGTGCATGAG CTCAAGGAAC ATGACTACTG

851 GAGTTTCCAT TACACATTGT TGCGTGCCTT GTAATTTTCC CCAAAGACGT

101 CCTGCTCAGA GTGAAGCTTC TCCAGTGGCT TCTCCAGATC CCCAGCGCCA

151 GGAGTGGTTT GCCCGGTACT TCACATTCTG AAAGAATTGT GTTGGCACAG

10D1 CTCTGTATAG ACTGTTACTA AGAGCATGAC TTTATACAGA TTGTTATGTA 1051 AATAGGCTTT CCTATGTCAA ACACTGTGAA TGAGAAAGTA TTTGTCTCTC

1101 CAACTTGAAA ATGCACTGTA TTTCCTGTGA TATTTATTGG AATCATTCTA

1151 TAAGGTACTA TATTATGTGT GTAATTATAA CTGTTATTTT TATTTGAGAT

1201 GGAAGAGTCT TTAACCTTTG TAATTACTGC ATAATAAATT TTGTTAGAAT

1251 CAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 1301 AAAAAAAAAA AAAAAA

BLAST Results No BLAST result

Medline entries

No Medline entry

Peptide information for frame 2

ORF from 8 bp to 611 bpi peptide length: 2bβ Category: similarity to known protein Classification: Cellular transport and traffic 1 MELERSIDIS RRlQSKEHICR ITDLiQEELRH REHHISELDK EViQHLHENIS

51 ALTKELEFKG KEILRIRSES NIQIQIRLHEIQD LNKRLEKELD VMTADHLREK

101 NIMRADFNKT NELLKEINAA LlQVSLEEMEE KYLMRESKPE DIiQMITELKA

151 MLTERDiQIIK KLIEDNKFYiQ LELVNRETNF NKVFNSSPTV GVINPLAKiQK

2D1 KKNDKSPTNR FVSVPNLSAL ESGGVGNGHP NRLDPIPNSP VHDIEFNSSK 251 PLPiQPVPPKG PKTFLRYiQ

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_lbb5ι frame 2 No Alert BLASTP hits found

Pedant information for DKFZphtes3_lbb5ι frame 2

Report for DKFZphtes3_lbb5- 2

[LENGTH! 270

[MU! 31413- DI [pi! b-10

[HOMOL! PIR:A57013 early endosome antigen 1 - human le-05

[FUNCAT! 03-11 recombination and dna repair [S- cerevisiaei

Y0L034w! le-D5

[FUNCAT! D3-22 cell cycle control and mitosis [S- cerevisiaei YFR031c! 2e-05

[FUNCAT! 30- ID nuclear organization [S- cerevisiaei YFR031c!

2e-D5

[FUNCAT! 11-04 dna repair (direct repairi base excision repair and nucleotide excision repair) [S- cerevisiaei YKRDISw! 5e-05 [FUNCAT! 30-04 organization of cytoskeleton [S- cerevisiaei

YDR35bw! 7e-05

[FUNCAT! 01-10 nuclear biogenesis [S- cerevisiaei YDR35bw!

7e-05 [FUNCAT! 06-07 vesicular transport (golgi networki etc) [S- cerevisiaei YDLOSβw! le-04

[FUNCAT! 3D-03 organization of cytoplasm [S- cerevisiaei

YDLOSδw! le-D4 [FUNCAT! 1 genome replication! transcriptioni recombination and repair [M- jannaschiii MJlb43! 2e-D4

[FUNCAT! 11 unclassified proteins [S- cerevisiaei YLR301c!

3e-04

[FUNCAT! 06-lb extracellular transport [S- cerevisiaei YNL272c! 5e-04

[FUNCAT! 30-D1 organization of intracellular transport vesicles

[S. cerevisiaei YNL272c! 5e-04

[KU! All_Alpha

[KU! L0LJ_C0MPLEXITY 4 - 81 * [KU! COILED COIL 10 - 74 *

SElQ AKMELERSIDISRRiQSKEHICRITDLlQEELRHREHHISELDKEViQHLHENISALTKELEF

SEG PRD ccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS CCCCCCCCCCCCCCCCCCCCCCCC

SElQ KGKEILRIRSESNiQiQIRLHElQDLNKRLEKELDVMTADHLREKNIMRADFNKTNELLKEIN SEG

PRD hhhhhhhhhhcchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS ccccc SElQ AALIQVSLEEMEEKYLMRESKPEDIIQMITELKAMLTERDIQIIKKLIEDNKFYIQLELVNRET SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS

SElQ NFNKVFNSSPTVGVINPLAKiQKKKNDKSPTNRFVSVPNLSALESGGVGNGHPNRLDPIPN SEG

PRD hhhhhhhcccceeeehhhhhhhhhhccccccceeeccccccccccccccccccccccccc COILS

SElQ SPVHDIEFNSSKPLPIQPVPPKGPKTFLRYIQ

SEG xxxxxxxxxxxxx

PRD ccceeeeecccccccccccccccceeeccc COILS

(No Prosite data available for DKFZphtes3_lbbS - 2) (No Pfam data available for DKFZphtes3_lbb5- 2) DKFZphtes3_lbp3

group: testis derived DKFZphtes3_lbp3 encodes a novel lbb3 amino acid protein without similarity to known proteins-

The novel protein is glutamine rich and contains a cell attachment RGD motif- According to the low number of ESTs and their origin the protein seems to be expressed ubiquitously at low levels- No informative BLAST resultsi No predictive prositei pfam or SCOP motife ■

The new protein can find application in studying the expression profile of testis-specific genes-

putative protein perhaps complete eds. Sequenced by BMFZ Locus: unknown

Insert length: 5411 bp Poly A stretch at pos- 5354ι polyadenylation signal at pos- 5340

1 GGCGGCCAGG TGGAGGACCT GAGCAAGCAG CTCAAGCGTG TGGACGGCCA

51 GGTGCAGGGC ATCGCCACGC ACGTGCAGCA CTTCTCCCAG GCCAGCGGGC

101 TTGACCTGGC CGCGCTAGAG TGGCCGGAGG AGCAGGAGGT GGGCGTGCGG 151 GCGTTCGATA GGGTGCGGAC TGGGAGTATC ATGAAGGACG CCGCCGAGGA

2D1 GCTCAGCTTT GCCAGGGTAC TTTTACAGCG GGTTGATGAA CTAGAGAAGC

251 TATTCAAAGA TCGGGAGCAA TTCCTGGAAC TAGTCAGCCG GAAGCTGAGT

301 TTGGTTCCTG GTGCAGAAGA AGTCACCATG GTCACCTGGG AAGAGCTGGA

351 GCAGGCGATT ACGGACGGCT GGAGAGCCTC ACAAGCGGGC TCAGAAACAC 401 TTATGGGATT TTCTAAGCAC GGAGGGTTCA CTTCCTTAAC ATCACCTGAA

451 GGGACTCTAA GCGGAGACTC TACCAAGCAA CCAAGTATTG AGCAGGCTCT

501 GGATTCTGCC AGTGGTCTTG GCCCGGATCG GACTGCATCA GGATCTGGTG

551 GCACAGCACA CCCCTCTGAT GGGGTTTCCA GTAGGGAACA AAGCAAGGTC bOl CCCTCTGGTA CTGGGAGACA GCAGCAGCCG AGGGCCCGTG ATGAAGCTGG b51 CGTGCCACGA CTCCATCAGT CTTCTACATT CCAATTCAAA TCAGACTCAG

7D1 ATCGTCACAG GAGTAGAGAG AAGCTTACCT CGACACAACC AAGAAGAAAT

751 GCACGTCCTG GTCCAGTTCA ACAGGACTTA CCCTTGGCCA GAGACCAGCC

ΘD1 CAGTAGTGTG CCCGCTAGCC AGAGTCAGGT CCATCTAAGG CCAGATCGTC

851 GTGGGTTAGA ACCAACTGGC ATGAATCAGC CTGGATTAGT GCCTGCTAGC 101 ACTTACCCAC ATGGTGTGGT ACCCCTCAGC ATGGGTCAGC TTGGTGTGCC

151 ACCACCTGAA ATGGATGATC GGGAATTGAT ACCATTTGTC GTGGATGAGC

10D1 AACGTATGTT GCCACCATCA GTACCTGGCA GAGACCAGCA AGGATTGGAA

1051 CTACCTAGCA CAGACCAACA TGGTCTGGTT TCAGTCAGTG CATATCAGCA

1101 TGGTATGACA TTTCCTGGCA CAGACCAACG CAGTATGGAA CCACTTGGCA 1151 TGGATCAGCG TGGATGTGTA ATATCAGGCA TGGGTCAGCA AGGACTAGTA

12D1 CCCCCTGGTA TAGACCAGCA AGGATTGACA TTGCCTGTCG TCGATCAACA

1251 TGGCCTGGTT CTACCTTTTA CAGACCAGCA TGGTTTGGTA TCACCTGGTT

13D1 TGATGCCAAT TAGTGCAGAT CAGCAAGGTT TTGTGCAGCC CAGTTTGGAA

1351 GCAACTGGCT TCATACAACC TGGCACAGAG CAGCATGATT TGATCCAGTC 1401 TGGCAGATTT CAGCGTGCTT TGGTGCAGCG TGGTGCATAT CAGCCTGGCT

1451 TGGTCCAACC TGGTGCAGAT CAGCGTGGTT TGGTCCGGCC TGGAATGGAT

1501 CAGTCTGGTT TGGCCCAACC TGGTGCAGAT CAGCGTGGTT TGGTCTGGCC

1551 TGGAATGGAT CAGTCTGGTT TGGCCCAACC TGGTAGAGAT CAGCATGGTT IbOl TGATCCAGCC TGGCACAGGT CAGCATGATT TGGTCCAATC TGGCACAGGT lb51 CAGGGTGTCT TGGTACAGCC TGGTGTAGAT CAGCCTGGCA TGGTCCAACC

17D1 TGGCAGATTT CAGCGTGCTT TGGTGCAGCC TGGTGCATAT CAGCCTGGCT

1751 TGGTCCAACC TGGTGCAGAT CAGATTGATG TGGTGCAACC TGGTGCAGAT 1801 CAGCATGGTT TGGTACAATC TGGTGCAGAT CAGAGTGATT TGGCTCAACC

1651 TGGTGCAGTT CAGCATGGTT TGGTCCAACC TGGAGTAGAT CAGCGTGGTT

1101 TGGCACAACC TCGTGCAGAT CATCAGCGTG GTTTGGTCCC ACCTGGTGCA

1151 GATCAGCGTG GTTTGGTCCA ACCTGGTGCA GATCAGCATG GTTTGGTCCA

2001 ACCTGGAGTG GATCAGCATG GTTTGGCACA ACCTGGTGAA GTTCAGCGTA 2051 GTTTGGTGCA ACCTGGTATA GTTCAGCGTG GTTTGGTGCA ACCTGGTGCA

2101 GTTCAGCGTG GTTTGGTGCA ACCTGGTGCA GTTCAGCGTG GTTTGGTCCA

2151 ACCTGGAGTG GATCAGCGTG GTTTGGTTCA ACCTGGTGCA GTTCAGCGTG

2201 GTTTGGTCCA ACCTGGTGCA GTTCAGCATG GTTTGGTCCA ACCTGGTGCA

2251 GATCAGCGTG GTTTGGTCCA ACCTGGAGTG GATCAGCGTG GTTTGGTGCA 2301 ACCTGGAGTG GATCAGCGTG GTTTGGTCCA ACCTGGAATG GACCAGCGTG

2351 GTTTGATCCA ACCTGGTGCA GATCAGCCT6 GTTTGGTCCA GCCTGGTGCA

2401 GGTCAGCTGG GTATGGTGCA GCCTGGAATA GGTCAGCAAG GTATGGTGCA

2451 ACCTCAGGCA GATCCACATG GCCTGGTACA ACCTGGTGCC TATCCTCTTG

2501 GTTTGGTACA ACCTGGTGCA TATTTGCATG ATTTATCTCA ATCTGGGACA 2551 TATCCACGTG GTCTGGTGCA GCCAGGAATG GATCAGTATG 6TTTGAGACA

2b01 ACCTGGTGCA TATCAGCCAG GCTTGATAGC ACCAGGCACA AAGCTTCGTG

2b51 GCTCTTCAAC ATTCCAGGCA GATTCTACAG GTTTTATATC AGTACGTCCA

27D1 TATCAACATG GTATGGTACC TCCTGGCAGA GAACAATACG GCCAGGTGTC

2751 ACCACTCCTA GCCAGTCAAG GTTTGGCATC ACCTGGTATA GATCGAAGGA 2801 GTTTGGTACC ACCAGAAACT TATCAGCAAG GTTTGATGCA TCCTGGCACA

2851 GACCAGCACA GCCCAATACC ACTGAGTACA GGTTTGGGAT CTACACACCC

2101 AGATCAACAG CATGTGGCAT CACCTGGCCC AGGTGAGCAT GACCAGGTAT

2151 ACCCAGATGC AGCTCAGCAT GGCCATGCTT TCTCTCTCTT TGACAGTCAT

30D1 GATTCAATGT ATCCTGGTTA TCGTGGCCCA GGGTATCTAA GTGCTGATCA 3051 GCATGGCCAG GAAGGTTTGG ATCCAAATAG AACACGAGCC TCGGACCGAC

3101 ATGGAATTCC TGCCCAGAAG GCCCCAGGCC AAGATGTCAC TCTTTTCA6G

3151 AGTCCAGACT CCGTCGACCG AGTCTTATCA GAAGGGAGCG AAGTCTCGAG

3201 TGAAGTCCTG AGTGAGCGAC GCAATTCACT GCGTAGAATG AGTTCTAGTT

3251 TCCCCACGGC AGTGGAGACA TTTCATCTGA TGGGAGAGCT CAGTAGCCTC 3301 TATGTGGGGC TAAAGGAGAG TATGAAGGAT CTGGATGAGG AGCAGGCCGG

3351 CCAAACCGAC TTGGAGAAGA TCCAGTTCCT GCTGGCACAG ATGGTCAAAA

3401 GGACCATACC TCCTGAACTG CAGGAGCAGC TGAAGACCGT AAAGACGCTA

3451 GCCAAAGAAG TTTGGCAGGA GAAAGCAAAA GTGGAAAGGC TGCAGAGGAT

3501 CCTGGAAGGG GAAGGGAATC AAGAAGCAGG GAAGGAACTG AAAGCTGGAG 3551 AGCTGAGATT GCAGCTGGGT GTCCTCAGAG TCACCGTGGC TGACATAGAA

3b01 AAGGAGCTGG CCGAGTTGAG GGAGAGCCAA GACAGGGGCA AGGCTGCCAT

3b51 GGAAAATTCT GTCTCTGAAG CCTCCCTTTA CCTGCAGGAC CAGTTGGACA

3701 AGCTCAGGAT GATCATTGAG AGCATGCTGA CCTCCTCCTC CACGCTCCTG

3751 TCCATGAGCA TGGCCCCGCA CAAGGCCCAC ACCTTGGCTC CTGGCCAGAT 3801 CGACCCTGAG GCCACCTGTC CAGCCTGCAG CCTGGATGTG AGCCATCAGG

3851 TCAGCACGCT GGTGCGGCGC TATGAGCAAC TCCAAGACAT GGTCAACAGC

3101 CTGGCCGTCT CCCGACCCTC CAAGAAGGCC AAGCTCCAGA GACAGGACGA

3151 GGAGCTGCTG GGCCGTGTGC AGAGTGCCAT CCTGCAGGTG CAGGGTGACT

40D1 GCGAGAAGCT CAACATCACC ACCAGCAACC TCATCGAGGA CCATCGGCAG 4051 AAACAGAAGG ACATTGCTAT GCTGTACCAG GGTCTGGAGA AGCTCGAAAA

41D1 GGAAAAGGCC AACAGGGAGC ACCTGGAGAT GGAGATCGAT GTGAAAGCCG

4151 ACAAGAGTGC TCTGGCCACC AAAGTGAGCC GTGTCCAGTT TGATGCCACC

4201 ACGGAGCAGC TGAACCACAT GATGCAGGAG CTGGTGGCCA AGATGAGCGG

4251 GCAGGAGCAG GACTGGCAGA AGATGCTGGA CAGGCTGCTC ACAGAGATGG 4301 ACAACAAGCT GGACCGCCTG GAGCTGGACC CAGTGAAGCA GTTGCTGGAG

4351 GATCGGTGGA AATCGCTGCG ACAGCAGCTC AGGGAGCGCC CCCCACTCTA

4401 CCAGGCAGAC GAGGCGGCTG CCATGCGGAG GCAGCTCCTG GCACATTTCC

4451 ACTGCCTCTC ATGTGACCGG CCCTTGGAGA CACCTGTGAC TGGACATGCC 4501 ATCCCCGTGA CCCCCGCGGG TCCAGGCCTA CCTGGGCACC ATTCCATCCG

4551 CCCCTACACG GTGTTTGAAC TGGAGCAGGT CCGGCAGCAT AGCCGCAACC

4b01 TCAAGCTGGG CAGCGCCTTC CCTCGGGGTG ACCTGGCGCA GATGGAGCAG

4bSl AGCGTGGGGC GCCTGCGCTC CATGCACTCC AAGATGCTGA TGAACATTGA

4701 GAAGGTGCAG ATCCACTTCG GGGGCTCCAC CAAGGCCAGC AGCCAGATAA

4751 TCCGCGAGCT GCTGCACGCC CAGTGCCTGG GCTCCCCCTG CTACAAACGG

4601 GTGACAGATA TGGCTGATTA CACCTACTCA ACTGTGCCCC GGCGCTGCGG

4851 GGGCAGCCAC ACCCTCACCT ACCCCTACCA CCGCAGCCGC CCGCAGCACC

4101 TTCCCCGGGG CCTGTATCCT ACTGAAGAGA TCCAGATTGC CATGAAGCAT

4151 GATGAGGTGG ACATCTTGGG CCTGGATGGC CACATTTACA AGGGACGGAT

5001 GGACACAAGG CTGCCAGGCA TCCTCCGAAA AGACAGCTCA GGGACCTCAA

5051 AGCGCAAGTC CCAGCAGCCC AGGCCCCACG TGCACAGGCC GCCATCCCTC

5101 AGCAGCAATG GCCAGCTGCC CTCTCGGCCA CAGAGCGCCC AGATTTCGGC

5151 TGGCAACACC TCAGAAAGAT AGACCTTCCT CCGAGGGCCG TCTCTCCCAG

5201 CCGAACACAG CCCACCCGCC CAGCTCCGCC TCGGTGGCAA ACAGGGGGCT

5251 GGAGAGGCAC GTGGACATGC CTCCTGGGGA GGGGCTCGAG GAGCCCACGC

5301 GGGGGCCGCG GTCCAGCACC GCTCAGTGAG CGGAGGTGTA AATAAACATT

5351 CAGGAGGAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA

5401 AAAAAAAAAA A

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 1

ORF from 181 bp to 51b1 bpi peptide length lbb3 Category: putative protein Classification: no clue Prosite motifs: RGD (1462-1484)

1 MKDAAEELSF ARVLLiQRVDE LEKLFKDREύ FLELVSRKLS LVPGAEEVTM 51 VTUEELEiQAI TDGURASlQAG SETLMGFSKH GGFTSLTSPE GTLSGDSTKiQ

101 PSIEiQALDSA SGLGPDRTAS GSGGTAHPSD GVSSREUSKV PSGTGRiQlQlQP

151 RARDEAGVPR LHiQSSTFiQFK SDSDRHRSRE KLTSTiQPRRN ARPGPVlQiQDL

2D1 PLARDiQPSSV PASIQSIQVHLR PDRRGLEPTG MNώPGLVPAS TYPHGVVPLS

251 MGώLGVPPPE MDDRELIPFV VDElQRMLPPS VPGRDlQiQGLE LPSTDύHGLV 301 SVSAYiQHGMT FPGTDiQRSME PLGMDiQRGCV ISGMGώlQGLV PPGIDiQlQGLT

351 LPVVDώHGLV LPFTDiQHGLV SPGLMPISAD (QlQGFVlQPSLE ATGFIiQPGTE

4D1 (QHDLKQSGRF (QRALVIQRGAY (QPGLViQPGAD (QRGLVRPGMD (QSGLAiQPGAD

451 (QRGLVUPGMD iQSGLAlQPGRD (QHGLIlQPGTG (QHDLViQSGTG (QGVLViQPGVD

501 (QPGMVlQPGRF (QRALViQPGAY (QPGLViQPGAD iQIDVVtQPGAD (QHGLViQSGAD 551 (QSDLAiQPGAV (QHGLViQPGVD (QRGLAlQPRAD HiQRGLVPPGA DiQRGLVlQPGA bOl DiQHGLVlQPGV DiQHGLAlQPGE ViQRSLViQPGI ViQRGLViQPGA VIQRGLVIQPGA b51 ViQRGLViQPGV DiQRGLVlQPGA VIQRGLVIQPGA VIQHGLVIQPGA DIQRGLVIQPGV

7D1 DIQRGLVIQPGV DiQRGLVώPGM DiQRGLIiQPGA DlQPGLVlQPGA GiQLGMVlQPGI 751 GIQ IQGM V IQ P IQ A DPHGLVlQPGA YPLGLViQPGA YLHDLSiQSGT YPRGLVlQPGM

801 D IQY GL R IQ P G A YlQPGLIAPGT KLRGSSTFlQA DSTGFISVRP YiQHGMVPPGR

651 ElQYGiQVSPLL ASiQGLASPGI DRRSLVPPET YiQlQGLMHPGT DlQHSPIPLST

101 G L GST H PD IQIQ HVASPGPGEH DlQVYPDAAiQH GHAFSLFDSH DSMYPGYRGP 151 GYLSADiQHGlQ EGLDPNRTRA SDRHGIPAiQK APGiQDVTLFR SPDSVDRVLS

10D1 EGSEVSSEVL SERRNSLRRM SSSFPTAVET FHLMGELSSL YVGLKESMKD

1051 LDEElQAGlQTD LEKIlQFLLAiQ MVKRTIPPEL iQElQLKTVKTL AKEVUlQEKAK

11D1 VERLiQRILEG EGNOEAGKEL KAGELRLiQLG VLRVTVADIE KELAELRESώ

1151 DRGKAAMENS VSEASLYLώD (QLDKLRMIIE SMLTSSSTLL SMSMAPHKAH 1201 TLAPGiQIDPE ATCPACSLDV SHiQVSTLVRR YEIQLIQDMVNS LAVSRPSKKA

1251 KL IQRIQD EE LL GRV IQS A ILIQV (QGDCEKLNIT TSNLIEDHRβ KώKDIAMLYiQ

1301 GLEKLEKEKA NREHLEMEID VKADKSALAT KVSRVlQFDAT TElQLNHMMlQE

1351 L V A KM SG IQ E IQ DUlQKMLDRLL TEMDNKLDRL ELDPVKiQLLE DRUKSLRiQlQL

1401 RERPPLYlQAD EAAAMRRiQLL AHFHCLSCDR PLETPVTGHA IPVTPAGPGL 1451 PGHHSIRPYT VFE LE IQVR IQ H SRNLKLGSAF PRGDLAlQMEiQ SVGRLRSMHS

1501 KMLMNIEKVώ IHFGGSTKAS SiQIIRELLHA (QCLGSPCYKR VTDMADYTYS

1551 TVPRRCGGSH TLTYPYHRSR PiQHLPRGLYP TEEIlQIAMKH DEVDILGLDG

IbOl HIYKGRMDTR LPGILRKDSS GT S KRKS IQ IQ P RPHVHRPPSL SSNGlQLPSRP

IbSl (QSAiQISAGNT SER

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_lbp3ι frame 1 No Alert BLASTP hits found

Pedant information for DKFZphtes3_lbp3ι frame 1

Report for DKFZphtes3_lbp3 -1

[LENGTH! 1723

[MU! 167354-16

[pi! b-11 [HOMOL! TREMBL-"AF0254bl_4 gene-" "M01D1.5"i Caenorhabditis elegans cosmid MD1D1- le-47

[FUNCAT! 30-D3 organization of cytoplasm [S- cerevisiaei

YDL056w! 6e-D7

[FUNCAT! 08-07 vesicular transport (golgi networki etc-) [S- cerevisiaei YDL058w! 8e-D7

[FUNCAT! 11 unclassified proteins [S- cerevisiaei Y0R21bc!

2e-04

[FUNCAT! 11-04 dna repair (direct repairi base excision repair and nucleotide excision repair) [S- cerevisiaei YKR015w! D-0D1 [FUNCAT! 30-10 nuclear organization [S- cerevisiaei YKROISw!

D-DD1

[BLOCKS! PR01D16C

[BLOCKS! BP023D8D

[BLOCKS! PR00543H [BLOCKS! PR0D210G

[BLOCKS! PRD021DE

[BLOCKS! BP0423bA

[PIRKU! RNA binding 3e-0b [PIRKU! hydroxylysine 2e-10

[PIRKU! endoplasmic reticulum 7e-18

[PIRKU! ATP 2e-0b

[PIRKU! phosphoprotein 3e-0b [PIRKU! seed 4e-34

[PIRKU! saliva 2e-lD

[PIRKU! glycoprotein 2e-10

[PIRKU! heterotrimer 3e-Db

[PIRKU! alternative splicing 2e-10 [PIRKU! P-loop 2e-0b

[PIRKU! storage protein 4e-34

[PIRKU! extracellular matrix 2e-10

[PIRKU! membrane protein 7e-18

[PIRKU! protein biosynthesis 7e-16 [SUPFAM! myosin motor domain homology 2e-0b

[SUPFAM! elastin 2e-lD

[SUPFAM! glutenin 2e-37

[SUPFAM! myosin heavy chain 2e-0b

[SUPFAM! unassigned ribonucleoprotein repeat-containing proteins 3e-0b

[SUPFAM! proline-rich protein 2e-10

[SUPFAM! ribonucleoprotein repeat homology 3e-0b

[PROSITE! RGD 1

[KU! All_Alpha [KU! L0U_C0MPLEXITY 2-84 *

CKU! C0ILED_C0IL 1-80 *

SElQ GGiQVEDLSK(QLKRVDGiQViQGIATHV(QHFS(QASGLDLAALEUPEE(^QEVGVRAFDRVRTGSI SEG

PRD cccchhhhhhhhhhhhheeeeeeeeeeccccccchhhhhhhhccceeeeeeeeeeecccc COILS

SElQ MKDAAEELSFARVLLi^QRVDELEKLFKDRElQFLELVSRKLSLVPGAEEVTMVTUEELEiQAI SEG

PRD chhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhccccccchhhhhhhhhhhhh COILS

SElQ TDGURASiQAGSETLMGFSKHGGFTSLTSPEGTLSGDSTKlQPSIEl^QALDSASGLGPDRTAS SEG

PRD hhhhccccccceeeeeccccccccccccccccccccccchhhhhhhhhhccccccceeec COILS

SElQ GSGGTAHPSDGVSSREi^QSKVPSGTGRl^Ql^QlQPRARDEAGVPRLHiQSSTFlQFKSDSDRHRSRE SEG

PRD cccccccccceeeccccccccccccccchhhhhhhhccchhhhhcccccccccccccccc COILS

SElQ KLTST(QPRRNARPGPV(Q(^QDLPLARD(QPSSVPAS<QS(QVHLRPDRRGLEPTGMN(QPGLVPAS SEG xxxxxxxxxxxx PRD cccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc COILS SElQ TYPHGVVPLSMGlQLGVPPPEMDDRELIPFVVDElQRMLPPSVPGRDlQiQGLELPSTDiQHGLV

SEG

PRD cccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc COILS

SElQ SVSAYlQHGMTFPGTDiQRSMEPLGMDiQRGCVISGMGiQiQGLVPPGIDlQlQGLTLPVVDiQHGLV SEG

PRD cccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc COILS

SElQ LPFTD(QHGLVSPGLMPISAD(Q(QGFV<QPSLEATGFI(QPGTEιQHDLI<QSGRF<QRALV(QRGAY SEG PRD cccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc COILS

SElQ (QPGLViQPGADiQRGLVRPGMDiQSGLAiQPGADiQRGLVUPGMDlQSGLAlQPGRDiQHGLIiQPGTG SEG

PRD cccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc COILS

SElQ (QHDLViQSGTGiQGVLViQPGVDiQPGMVlQPGRFlQRALVlQPGAYiQPGLViQPGADiQIDVViQPGAD SEG

PRD cccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc COILS

SElQ (QHGLVιQSGADιQSDLA<QPGAV<QHGLV(2PGVD(QRGLA(2PRADH<QRGLVPPGADιQRGLVι2PGA

SEG

PRD cccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc

COILS

SElQ D(QHGLVιQPGVD(QHGLAlQPGEV<QRSLV(QPGIV(QRGLV<QPGAV(QRGLVlQPGAV(QRGLV(QPGV SEG

PRD cccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc COILS

SElQ D(QRGLV<QPGAV(QRGLVιQPGAV<QHGLV(QPGAD (QRGLV(QPGVD<QRGLVιQPGVD(QRGLVιQPGM SEG PRD cccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc COILS

SElQ D(QRGLI(QPGAD (QPGLV<QPGAG<QLGMV<QPGIG(QlQGMV(QP<QADPHGLV(QPGAYPLGLV(QPGA SEG

PRD cccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc COILS

SElQ YLHDLSflSGTYPRGLVt^QPGMDl^QYGLRi^QPGAYi^QPGLIAPGTKLRGSSTFiQADSTGFISVRP SEG

PRD cccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc COILS

SElQ YιQHGMVPPGRE(QYG!2VSPLLAS<QGLASPGIDRRSLVPPETY(Q<QGLMHPGTD(QHSPIPLST SEG

PRD cccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc COILS

SElQ GLGSTHPDIQIQHVASPGPGEHDIQVYPDAAIQHGHAFSLFDSHDSMYPGYRGPGYLSADIQHGIQ SEG

PRD cccccccccccccccccccccccccccccccccccccccccccccccccccccccccccc COILS

SElQ EGLDPNRTRASDRHGIPAιQKAPG(3DVTLFRSPDSVDRVLSEGSEVSSEVLSERRNSLRRM

SEG xxxxxxxxxxxxxxxxxxxxxxx-

PRD ccccccccccccccccccccccccceeeeeccccccccccccchhhhhhhhhhhcccccc COILS

SElQ SSSFPTAVETFHLMGELSSLYVGLKESMKDLDEE(QAG(QTDLEKI(QFLLA(QMVKRTIPPEL SEG

PRD cccccceeeeeeeeeccceeehhhhhhhhhhhhhcccchhhhhhhhhhhhhhhhhcchhh COILS

SElQ (QEiQLKTVKTLAKEVUlQEKAKVERLlQRILEGEGNiQEAGKELKAGELRLiQLGVLRVTVADIE

SEG PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhccchhhhhhhhhhhhhhhhhhhhhhhhhhh COILS CCCCCCCCCCCCCCCCCCCCCC

SElQ KELAELRESiQDRGKAAMENSVSEASLYLiQDiQLDKLRMIIESMLTSSSTLLSMSMAPHKAH SEG xxxxxxxxxxxxxx

PRD hhhhhhhhhhhchhhhhcccchhhhhhhhhhhhhhhhhhhhhhccccceeeehhhhhhhh COILS ccccccccc SElQ TLAPG(QIDPEATCPACSLDVSH(QVSTLVRRYE(QL(QDMVNSLAVSRPSKKAKL(QRιQDEELL SEG

PRD hhcccccccccccccccccchhhhhhhhhhhhhhhhhhhhhhccccchhhhhhhhhhhhh COILS

SElQ GRVlQSAILiQViQGDCEKLNITTSNLIEDHRiQKiQKDIAMLYlQGLEKLEKEKANREHLEMEID SEG

PRD hhhhhhhhhhhhhhhcchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS

SElQ VKADKSALATKVSRVi^QFDATTElQLNHMMl^QELVAKMSGlQEiQDUi^QKMLDRLLTEMDNKLDRL SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhcccchhhhhhhhhhhhhhhhhhhhh COILS

SElQ ELDPVKIQLLEDRUKSLRIQIQLRERPPLYIQADEAAAMRRIQLLAHFHCLSCDRPLETPVTGHA SEG

PRD hhhhhhhhhhhhhhhhhhhhhhcccchhhhhhhhhhhhhhhhhhhcccccccccccccee COILS

SEl^Q IPVTPAGPGLPGHHSIRPYTVFELE(QVR<QHSRNLKLGSAFPRGDLA(QME<QSVGRLRSMHS SEG

PRD eeeecccccccccccccccchhhhhhhhhhhhhhcccccccccchhhhhhhhhhhhhhhh COILS

SEl^Q KMLMNIEKV(QIHFGGSTKASS(QIIRELLHA(QCLGSPCYKRVTDMADYTYSTVPRRCGGSH SEG

PRD hhhhhheeeeeecccccchhhhhhhhhhhhhhcccccceeeccccccceeeccccccccc COILS

SEl^Q TLTYPYHRSRP(QHLPRGLYPTEEI(QIAMKHDEVDILGLDGHIYKGRMDTRLPGILRKDSS SEG PRD ccccccccccccccccccccchhhhhhhhhcceeeeccccceeeecccccccceeecccc COILS

SElQ GTSKRKSIQIQPRPHVHRPPSLSSNGIQLPSRPIQSAUISAGNTSER SEG

PRD cccccccccccccccccccccccccccccccceeeeecccccc COILS

Prosite for DKFZphtes3_lbp3-l

PSODOlb 1542->1545 RGD PDOCDOOlb

(No Pfam data available for DKFZphtes3_lbp3.1)

DKFZphtes3_17i21

group: transmembrane protein

DKFZphtes3_17i21 encodes a novel 224 amino acid protein without similarity to known proteins- The novel protein contains 2 transmembrane regions- ESTs can be found in testisi retina and brain- No informative BLAST resultsi No predictive prositei pfam or SCOP motife- The new protein can find application in studying the expression profile of testis-specific genes and as a new marker for testicular cells-

unknown protein

Pedant: contains signal peptide (frame 1) and TRANSMEMBRANE 2 (frame 2) perhaps complete eds-

Sequenced by GBF

Locus: unknown

Insert length: 1518 bp

Poly A stretch at pos- 1480ι polyadenylation signal at pos 1454

1 GCCAGACAGC TAGGTGTCAT TCAGGGCTGG TGTCCTCTGT CCAGGCCATC

51 ATGGCCTCCA CTGCCGGCTA CATCGTCTCC ACCTCCTGCA AGCACATCAT

101 TGATGACCAA CACTGGCTGT CCTCTGCCTA CACGCAATTT GCTGTGCCCT

151 ACTTCATCTA CGACATCTAC GCCATGTTCC TCTGTCACTG GCACAAGCAC

2D1 CAGGTCAAAG GGCATGGAGG GGACGACGGA GCGGCCAGAG CCCCGGGCAG 251 CACGTGGGCC ATAGCGCGTG GCTACCTGCA CAAGGAGTTC CTCATGGTGC

301 TCCACCATGC CGCCATGGTG CTGGTGTGCT TCCCACTCTC AGTGGTGTGG

351 CGACAGGGTA AGGGAGACTT CTTTCTGGGT TGCATGTTGA TGGCACAGGT

401 CAGCACGCCC TTCGTCTGCC TTGGCAAGAT CCTCATCCAG TACAAGCAGC

451 AGCACACACT GCTGCACAAG GTGAACGGGG CCCTGATGCT GCTCAGCTTC 501 CTCTGCTGCC GGGTGCTGCT CTTTCCCTAC CTGTACTGGG CCTACGGGCG

551 CCATGCCGGC CTGCCCCTGC TGGCCGTGCC CCTGGCCATC CCTGCCCACG bOl TCAACCTGGG CGCTGCGCTG CTCCTGGCCC CTCAGCTCTA CTGGTTCTTC b51 CTCATCTGCC GTGGGGCCTG CCGCCTCTTC TGGCCCCGCT CCCGGCCGCC

701 CCCGGCCTGC CAGGCCCAGG ACTGAGGCCG GGGGCCGGGA CCCTCCCCCT 751 CCCCACCCCC ACCCCCGTGG AGACAGGGCT CTGGGGCTGA TGGCTGGGGT

601 TGGGAGCCAG GGTCCTCTTG CCCGGACAAC CCCAGGACTG ACGATGACCC

651 CGAAAGGGAA GAGGCCCCAT CTCTCGGGGA CTGAGGGGGT GGAGAGAGGG

101 GACCTCTTCC CCCTACTCTG CCCCCTTCCT GCACACCCTT GCGCTGGAGG

151 kGGGGkGGGG GCACCGCCTC CCACCCACTG AGGGCAGGAG GGCTTGTGGG 1D01 GAGGGACACC AACAGGGTTT CAAGGGGACC AGGAGTCAGA ATGTGGGGAG

1D51 ACGCCTCTGC CAAGGCCATC CCAGCCCCTA TGCTGCCATC CCCCAGGGCT

1101 CCCCATCACC CGAGAGGAGA GGACGCCCCA ACTAACCCCC GCTGGCCCTC

1151 GGGCCTCCCG AGTGGCCGGC TGCAACCACG GCTCCTCTCC AGGGTAGGCC 1201 AGCTTGAGGA ATCTTATTTA TTTTATTTAT TTACCCAAAT TTGAACTAGT

1251 CTGTTGGGTT GGGGGAAGGA GGTGGCTGCT ACCCCCAAGC CTTCCCAGTG

13D1 CTGACAACCC CGGGGGCAGG CGAGGGCGCC CAGTCCCTCA CCATCGGCTG

1351 CACATCGCGC CCTCGGGCCC TGCCATGTCC CTGGTGCTAC TGACCTCTCA

14D1 AGGCTTCCTC CAATCTGGGG TCGGGGGACC CTGGGAGGTG CTTTACAGAC

1451 CGCTAATAAA AGACGATCTG CGTGAACGCC AAAAAAAAAA AAAAAAAAAA

1501 AAAAAAAAAA AAAAAAAA

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 3

ORF from 51 bp to 722 bpi peptide length: 224

Category: putative protein

Classification: Transmembrane proteins unclassified 1 MASTAGYIVS TSCKHIIDDlQ HULSSAYTiQF AVPYFIYDIY AMFLCHUHKH

51 (QVKGHGGDDG AARAPGSTUA IARGYLHKEF LMVLHHAAMV LVCFPLSVVU

IDl RiQGKGDFFLG CMLMAEVSTP FVCLGKILIlQ YKlQQHTLLHK VNGALMLLSF

151 LCCRVLLFPY LYUAYGRHAG LPLLAVPLAI PAHVNLGAAL LLAPlQLYUFF

2D1 LICRGACRLF UPRSRPPPAC (QAlQD

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_17i21ι frame 3 No Alert BLASTP hits found

Pedant information for DKFZphtes3_17i21ι frame 3

Report for DKFZphtes3_17i21-3

[LENGTH! 224 [MU! 25224-11 [pi! 1-03 [HOMOL! TREMBLNEU : AF181b4b_l gene: "BcDNA - GH1232b"i product: "BcDNA - GH1232b"i Drosophila melanogaster BcDNA- GHD2340 (BcDNA-GHD2340) mRNAi complete eds- le-20 [BLOCKS! PR00b32H [BLOCKS! PR00104A [BLOCKS! BL01243C [KU! TRANSMEMBRANE 2 [KU! LOU COMPLEXITY b-25 *

SE(2 MASTAGYIVSTSCKHIIDDlQHULSSAYTiQFAVPYFIYDIYAMFLCHUHKHiQVKGHGGDDG

SEG

PRD cccceeeeeccccceeecchhhhhhhhhhheeehhhhhhhhhhhhhhhhhhccccccccc MEM

SElQ AARAPGSTUAIARGYLHKEFLMVLHHAAMVLVCFPLSVVURiQGKGDFFLGCMLMAEVSTP

SEG

PRD ccccccceeeeecccchhhhhhhhhhhhhhhhcccceeeeecccccchhhhhhhhhhccc MEM MMMMMMMMMMMMMMMMM

SElQ FVCLGKILIiQYKlQiQHTLLHKVNGALMLLSFLCCRVLLFPYLYUAYGRHAGLPLLAVPLAI

SEG xxxxxxxxxxxx

PRD ccchhhhhhhhhhhhhhhhccchhhhhhhhhhhhheeecceeeeccccccccceeeeccc MEM MMMMMMMMMMMMMMMMM

SElQ PAHVNLGAALLLAPlQLYUFFLICRGACRLFUPRSRPPPACiQAiQD

SEG xx

PRD cchhhhhhhhhhhccceeeeeecccccccccccccccccccccc MEM

(No Prosite data available for DKFZphtes3_17i21 -3) (No Pfam data available for DKFZphtes3_17i21. )

DKFZphtes3_18nl4

group: transcription factors

DKFZphtes3_18nl4 encodes a novel 377 amino acid protein with similarity to human giantin- Giantin is discussed as an autoantigen in rheumatoid arthritis- The novel protein contains a leucine zipper and a putative Helix- loop-helix DNA-binding domain- Therefore it might be a novel transkription factor- Most EST hits are from testis and germ cells-

The new protein can find application in modulation of gene expression and in expression profiling-

unknown protein see DKFZphtes3_30i23 wrong orientation perhaps complete cds-

Sequenced by MediGeno ix

Locus: /chromosome="lb" Insert length-" 5262 bp

Poly A stretch at pos- 5242ι polyadenylation signal at pos- 5227

1 CCGGCACCCG GAGCTCCTGG GCACACGGCA TTGGCAGGGG CCGCTTCGGC 51 AGAGTGATGA CTGATGATGA GTCCGAGAGC GTCCTCTCCG ACTCCCATGA

IDl AGGGTCGGAG CTGGAGCTGC CTGTTATCCA GCTGTGCGGG CTGGTGGAGG

151 AGCTCAGCTA TGTAAACTCT GCTCTCAAAA CTGAGACTGA GATGTTTGAG

201 AAATATTACG CTAAACTGGA GCCCAGGGAT CAGCGACCTC CACGATTATC

251 AGAAATTAAA ATATCAGCAG CAGATTATGC ACAGTTTCGA GGCAGGCGTA 3D1 GATCCAAATC CCGGACAGGT ATGGACCGTG GGGTAGGCCT GACTGCCGAC

351 CAAAAACTTG AGCTGGTACA AAAAGAGGTT GCGGACATGA AGGATGACTT

401 ACGACACACA AGGGCAAATG CGGAACGCGA CCTGCAGCAT CACGAGGCGA

451 TCATTGAGGA GGCTGAAATT CGATGGAGTG AAGTTTCGAG AGAAGTGCAT

5D1 GAGTTTGAAA AAGATATTCT AAAAGCCATA TCCAAGAAGA AAGGGAGTAT 551 TTTGGCCACT CAGAAAGTGA TGAAATACAT TGAGGACATG AACCGCCGGA bOl GGGATAATAT GAAGGAGAAA TTACGTTTGA AAAATGTTTC TCTCAAAGTT bSl CAGAGGAAAA AAATGCTTTT ACAATTGAGG CAGAAGGAAG AGGTGAGTGA

701 GGCCCTTCAC GATGTTGATT TTCAGCAGTT GAAGATAGAG AACGCTCAAT

751 TTCTTGAGAC AATTGAAGCA AGGAATCAAG AACTGACCCA GCTAAAGCTG 801 TCATCTGGAA ACACTCTGCA GGTTCTCAAT GCCTACAAAA GCAAGCTTCA

851 CAAGGCAATG GAAATATACC TCAATCTGGA CAAGGAGATC TTGCTGAGAA

101 AAGAGCTACT TGAAAAAATT GAAAAAGAAA CACTACAAGT AGAGGAGGAC

151 CGGGCCAAAG CCGAGGCAGT GAATAAGAGG CTCCGGAAGC AGCTGGCCGA

1001 GTTCCGGGCA CCACAGGTGA TGACTTACGT CCGGGAGAAG ATCTTAAATG 1051 CGGACCTGGA GAAGAGCATC AGGATGTGGG AAAGGAAAGT GGAGATAGCA

1101 GAGATGTCCT TAAAAGGCCA TCGTAAGGCT TGGAATCGAA TGAAAATAAC

1151 CAATGAGCAG TTGCAGGCAG ATTACCTTGC TGGGAAGTAG CCAGAGGCAG

1201 GCCACGGCTT ACAGACCACT ACATGACCTA TAAAAGTAAT CAGCTCCTTT 1251 CTAGTCACGG GCTCCTCTCA CTGTTCCCTG TCTGCCTGGT GTTCCCAACC

1301 CCCCACCCAG GCTGAGTATC ATCTCCTGGG CCACATCTGC CCATGGGGAG

1351 TGTTTTCACA GCCTGGCCCC TGGAACTGTT ACCACTGAAA GAACCACAGG

1401 GCACTCTAAT GGTTTGACAC TTGTTAGCCA GCATTTAGTT CACAAGCATA 1451 GTGAAAGTGA CCTTCCCACA CCTGGGAGAG GGATAGAGGA GGGAGAGCCA

1501 GCCCAGTGTA TGCCATGGGC TTATCCGTGG CAGCCCCAGT GTGCAACTAT

1551 CAAAAACAGA CATCAAAACA GCATGGTGAA TGCCTGGCAC TCAGCATTCT

IbOl CAGTTTACTC TTCAGTTTGG TGGGGTAGCT CCTGGACTAG ATACTGCTGC lb51 AAAAGAAAAC AAGCACGAAG GAAACCAAGA TGATTTCTTC GGGCTGATAC 17D1 AACCTGTTCT GACCTGCAAA AATCCTACCT TCCCCCACCT CCCCACCGTA

1751 ATAGTCATAG TATAAGGGTT GTACAGACGC CTCAGGAGAC CTGCCTGATT

1801 CCTTTACATC CTTCTCCCTA ACATCTAGAC TATCTCTAGA GCTGTTTCCT

1851 AGTCGTGAAT GCGTGATGGT CCTTCTTTGT CCCTGCAAGT ATGATCCAAC

1101 ATGGCCCAGT TCAGAATCAG AATATGTCTT CTGTGTCATG GTGGCATTTG 1151 GTCCATGGTG GGAGAAAGAA ATCAACTTTT CCCAGTGGTG GAGTGAGGAC

2001 AGGGGAGGGC CGGCCCTCTC AGCCTTGGAT GTGATCCATT TGCTGTAGTC

2051 TTCCACCTTG GTGTACAGAA ACAGGCCAGG GCACGTCTCA CCACCGAAGT

2101 TCAGGACTCC TCTCAGAACC CACAGATCGA ACTGCTGTAG CTGGCACATC

2151 ATTGGGCTTC CTGGGTCCCC CTGTGATAAA AGACAGAAGG CTTCAAGTCT 22D1 TAGAAAAACT AGTTTTTGTT GTAAATCTAT CCTTGTGCAA TATACTGTTT

2251 GTTCTAGAAA TGTTTTACGC TGGTTCTCAC TGGAAATGGG GCAAATTATA

23D1 GGATACAATT TCAAATCTAG GCAGCCACCA CCACAAATTC CAACAA6ATG

2351 ACTTTTCCTT TTATTATGCA AATTAGCTGT GGACTTCTGC TGATTGCCTA

2401 TAGCTTCCT6 GTTCATATTT CATTTTCTTG CCCCTTTCCA GTCCTTTGGC 2451 CAAACCTTCC CTCTCTTCTG GCTTCTCATT CCTGAAATGT TGGTGTTTGT

2501 TTCTGTTTTG TCCTGAAATG CTCACATTTT CCCTTCTCTG CCTTGCTTCA

2551 ACCCTTAGTG TAAGCCACTT CCTGCCACCT GGCAACTGCT TACCAGCCTG

2b01 GCTGGCCGTG CTCTGGGTCT TCCCTACTCC CAATGGAGCA GTCCTCTGGG

2b51 ACTTGGGAAT TCTGCCACAT ACACTTTATC TAACTTAAAG TGACGGAGTA 2701 GAAGCTTGGC ATCATTAGCT AGATATGGGA CCCTGGCAAG TGACCAAATC

2751 CTCTCTGAGC CAAGGTGGGA ACACAGTTAA TGCCTGTAAC ACGTGCTGAG

2601 CACAGCACAG TGCCTGGCAC ACAGCAAACA CTCAATAGAA TATTAGCTAC

2651 CATCATCCTG ATGTCGCTAT AAAGGCCAGC ATTTTTCTGA AAAGTTGGGG

2101 AAAATGGGAA AAGCAACAAG GCAACTAGTA GGTATCACTT ACCTTACCTG 2151 CCCAGACCCC ACACCCCTAG GTCTCCTCTC AAAGGAATTC CTGCCCCTCC

3D01 CATGGCCCAT CTTGGTCCGA GAAGGGGGTG GTCATCCCCA GGCTAGCCAG

3D51 CCACTTCTGA CCTGTGTGGC CTGCCTGGCT GGAAGGCCCA GGCAATGACA

3101 TGTTGCTCTC GCAGTTTGGA CTGAGACATG GAATGGGGCC GCAATTAACA

3151 ACAGGAAACA ATCTGAACAG ACTGAACCAC GAGCAGCAGA AAGGCAGAAG 3201 AGCAGCCGCT TCAGCCCCTT ACCATCCGAG ACCTGGGTGT GTGGTCTGTC

3251 TTGGTCACTC TCTCTGTCTC TCTTTCTCTC TTTCTTTCTC TGTCCCCAAG

3301 GCTGGAGTGC AGTGGTGCAA TCTTGGCTCA CTGCAACCTC CACCTCTGGG

3351 ATTCAAGCAA TTCTCCCACC TCAGCCTCTC GAGTAGCTGG GGCTACAGCT

3401 ATGCGCCACC ATGCCCAGCT AATTTTTTTT _TTTTTTTTTT GAGATGGAGT 3451 CTTGCTCTGT CCCCCATGCT GGAGTGCAGT GGCATGATCT CGGCTCGCTG

35D1 CAACCTCCTC CTCCTGGGTT CAAGCGATTC TCCTACCTCA GCCTCCCCAG

3551 TAGCTGGGAT TACAGGCGCC CACCACCACA CCTGGCTAAT TTTTATTTTT

3b01 AGTAGAGATG GGGTTTCACC ATGTTGGCCA GGCTGGTCTC GAACTCCTGA

3b51 CCTCATGATC CACCCGCCTC GGCCTCCCCA AGTGTTGGGA TTACAGGCGT 3701 GAGCCACTGC ACCCGGCCTA ATTTCTGTAT TTTTAGTAGA GATGGGGTTT

3751 CACGATGTTG GCCAGGCTGG TCTTAATCTA ACTTCAAGTG ATCTGCCCGC

3601 CTCGCCCTCT CAAAGTGCTG GGATTAGGCA TGAACTACCA TGCCCAGTGG

3851 GGTATTCTCT TTCAATAAAG CTCCTCTTTT CCAAGGAAGC CACACCAGAA

3101 CAGAGATGAA GACCAGTGGG AAAACATGGG AGCAACTCCG TGGGCAGGCC 3151 AGCGGGGAGG CCATGCTGCA AAGCTGCCGT GATTCCCTGG TGATCTCTCA

40D1 GCAGGCCAAG GCCAGACATG TGAGGAAGGC CTTGAGGACT TCATTCTGTG

4051 CCTCTCCTTG GATGGAAGGG GGTGCTTTAG TGTGGCACTC CTGACTTTTC

4101 AATTGACTGG TGAAGAGGCC CTTGTGTGCA CCTCACTATG TCTGCCTAGG 4151 TCATGGGGGC TCCCTGGCCA AGAATGACGT GGTTCCCCCT TTCATCAGTC

4201 CGATTCGCAG TTTGTCTTAA CTGTAGTGGT ATAGCCAGAG CAAGAAAAAG

4251 AATGTGATTT AGGACAAATG ATTGGATGAG TGATTGGTAG ATGTCCTCAG

43D1 CTATGGCGTG GTTTTGCAGG TCACTGTTCC ACCCACCTGG GCACAGCATA 4351 TACGCTTTTT CTCTTCCCCA TAATCCCGTA GGGGCTGCGA CTTCTGAAGC

4401 ACAAGAGGCA GAGGCGAACA GCTCCAGGTG CCCCTCTGGA GCTACCCTAC

4451 CTCATCTCCC AAGGGAGCGG CCACAGCCCA GAGTGGGGTC TTTCATTTTG

4501 TGATCTTTTC CCTTGACATT CAGCAAAAGC CCTGACAGTG GTAGAATAAA

4551 GGCAGGATGG GTGAGTGCAG AGTGATTCTG CTTTTGTTGG GTTTCAGGGA 4b01 AACCCATAGG CAGATTCTGA ACCTGGTGGT TGATTCTACA TGTGGGAATT

4b51 GTGGCTTTGA AGACCTCTGG ACATGAGAAC ATATTTCCAA GACAGAGGAT

47D1 TCTATGGGGA CGGGTCACCA TTAAATGGTG TGCAAGCATA ATTCTGTTCA

4751 AAAATGAAGG CATGTTTAGA GGTGTGTCAC AGTTAAAAAC CAACCTGAAC

4801 TTTGCAGTTA GATTTTAAAA GATGGTCAGT TAGAGTAGAA ATAGCTTAGA 4851 ATATTCCATT GAGTCTAAGA TACAGTTAGA AATCAACATC TTTGAAATTA

4101 GGGTGTGTCT TTTAATCAGT TGATGTCAGA GTTTAACGGG CAGCATTTTT

4151 TTCTTTCTTG GGATTACAAA AAATGATGGT GCATTCTATA ATTGGCAGCA

5001 TCTTAGATCT GAGGAAGTAT GATACTTGTT TGACGGAATG GTTGACGGCA

5051 GAATTTTGTT AAAAAGCTAT ATCTTCACTG TATTTTAACA CATTATCTAA 51D1 TTTAAGAAAT TGTTAAGATC CCCCACCTGG CAGAGGACCC AGTACAAAAT

5151 AGGCACTCAA TAGATGTTAC ACCAACTTTG GAAGGGCAAA CATATTTCTT

5201 AATGAGAGGC AGTCCTTCAT GTTTTGCAAT AAAATGACTT TTAAAAAAAA

5251 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AA

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 3

ORF from 57 bp to 1187 bpi peptide length: 377 Category: putative protein Classification: no clue Prosite motifs: LEUCINE_ZIPPER (11-40)

1 MTDDESESVL SDSHEGSELE LPVIlQLCGLV EELSYVNSAL KTETEMFEKY

51 YAKLEPRDiQR PPRLSEIKIS AADYAώFRGR RRSKSRTGMD RGVGLTADώK IDl LELViQKEVAD MKDDLRHTRA NAERDLiQHHE AIIEEAEIRU SEVSREVHEF

151 EKDILKAISK KKGSILATlQK VMKYIEDMNR RRDNMKEKLR LKNVSLKViQR

201 KKMLLlQLRiQK EEVSEALHDV DFiQULKIENA (QFLETIEARN (QELT(QLKLSS

251 GNTLiQVLNAY KSKLHKAMEI YLNLDKEILL RKELLEKIEK ETLlQVEEDRA

3D1 KAEAVNKRLR K(QLAEFRAP(Q VMTYVREKIL NADLEKSIRM UERKVEIAEM 351 SLKGHRKAUN RMKITNE(QL(Q ADYLAGK BLASTP hits No BLASTP hits available Alert BLASTP hits for DKFZphtes3_18nl4ι frame 3

No Alert BLASTP hits found

Pedant information for DKFZphtes3_18nl4ι frame 3

Report for DKFZphtes3_18nl4 -3

[LENGTH! 315

[MU! 4bl51-lb

[pi! 1-17

[H0M0L! TREMBL:AF13b711_l product: "myosin heavy chain"i

Amoeba proteus myosin heavy chain mRNAi complete eds- 5e-0b [FUNCAT! 11 unclassified proteins [S- cerevisiaei Y0R21bc!

7e-D4

[BLOCKS! BL005b3B Stathmin family proteins

[BLOCKS! PRD0115D

[PROSITE! LEUCINE_ZIPPER 1 [PFAM! Helix-loop-helix DNA-binding domain

[KU! All_Alpha

[KU! L0U_C0MPLEXITY b-33 *

[KU! COILED COIL 14- bδ *

SElQ GTRSSUAHGIGRGRFGRVMTDDESESVLSDSHEGSELELPVIlQLCGLVEELSYVNSALKT SEG

PRD cccccccccccccceeeeeccccceeeeeccccccceeeeeeeeccchhhhhhhhhhhhh COILS

SEώ ETEMFEKYYAKLEPRDORPPRLSEIKISAADYA(QFRGRRRSKSRTGMDRGVGLTAD(QKLE SEG

PRD hhhhhhhhhhhhcccccchhhhhhhhhhhhhhhhhhccchhhhhccccccccchhhhhhh COILS

SE(Q LV(QKEVADMKDDLRHTRANAERDL(QHHEAIIEEAEIRUSEVSREVHEFEKDILKAISKKK SEG xxxxxxxxx PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhc COILS CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC

SElQ GSILAT(QKVMKYIEDMNRRRDNMKEKLRLKNVSLKV(QRKKMLL(QLR(QKEEVSEALHDVDF SEG

PRD ccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS

SElQ (Q(QLKIENA(QFLETIEARN(QELTtQLKLSSGNTLιQVLNAYKSKLHKAMEIYLNLDKEILLRK SEG xxxxxxx

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhcccccccchhhhhhhhhhhhhhhhhhhhhhhhhh COILS

SElQ ELLEKIEKETLlQVEEDRAKAEAVNKRLRKlQLAEFRAPiQVMTYVREKILNADLEKSIRMUE SEG xxxxxxxxx

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS

CCCCCCCCCCCCCCCCCCCCCCCCCCC SElQ RKVEIAEMSLKGHRKAUNRMKITNElQLiQADYLAGK

SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhccc COILS

Prosite for DKFZphtes3_lβnl4 ■ 3 PSD0D21 37->51 LEUCINE_ZIPPER PD0C00D21

Pfam for DKFZphtes3_18nl4 -3

HMM_NAME Helix-loop-helix DNA-binding domain

HMM

*RRRNHNMRERRRRndINNUFeaLRDHIPHhnV- .. PNEKPLSKVEILRM RRR NM E+ R++++ + + ++++ +E L V+

++

(Query 116 RRR-DNMKEKLRLKNVSLKV(QRKKMLL(QL-R(QKEEVSEA-

LHDVDFύiQL 243

HMM AIEYIrsLiQ*

IE ++L+

(Query 244 KIENAiQFLE 252

DKFZphtes3_11pl2

group: testis derived

DKFZphtes3_11pl2 encodes a novel bb4 amino acid protein without similarity to known proteins- No informative BLAST resultsi No predictive prositei pfam or SCOP motife ■

The new protein can find application in studying the expression profile of testis-specific genes-

unknown protein

Sequenced by MediGenomix

Locus: unknown

Insert length: 21bl bp

Poly A stretch at pos- 206bι no polyadenylation signal found

1 CCCGAGCCAG CAACCCTGAG GGGCGGCCGG GCAGCGCCGC CACCATGTTC

51 CTGGGCACCG GGGAGCCGGC CTTGGACACG AGTCACCTTA TCTCTCTAAG

101 CCGAGCGTCC CTGACCCCGC AGAAGCTGTG GCTGGGAACC GCAAAGCCAG 151 GAAGTCTGAC CCAGGCCCTG AACTCACCCC TCACCTGGGA GCATGCGTGG

201 ACTGGCGTCC CCGGCGGCAC TCCTGACTGT CTGACAGACA CCTTCAGAGT

251 GAAGAGGCCA CATCTCAGGC GCTCTGCCAG CAACGGTCAT GTCCCTGGGA

301 CTCCTGTCTA CAGAGAAAAA GAAGATATGT ATGACGAGAT TATTGAGTTA

351 AAGAAGTCAT TGCACGTGCA GAAGAGCGAC GTGGACCTGA TGAGAACGAA 401 GCTCCGGCGC CTGGAGGAGG AAAACAGCAG GAAGGACCGG CAGATAGAGC

451 AGCTCCTGGA TCCCAGCCGC GGCACGGATT TTGTTCGGAC TCTGGCAGAG

501 AAAAGGCCCG ATGCCAGTTG GGTCATTAAC GGGCTGAAGC AGAGGATCCT

551 GAAGCTGGAA CAGCAGTGCA AGGAGAAGGA CGGCACCATC AGCAAACTCC bOl AGACCGATAT GAAGACTACC AACCTGGAAG AGATGCGGAT CGCCATGGAG faSl ACATACTACG AGGAGGTGCA TCGTCTCCAG ACCCTCTTGG CAAGTTCTGA

701 AACCACCGGA AAGAAGCCCC TGGGGGAGAA GAAGACGGGC GCCAAAAGGC

751 AGAAGAAGAT GGGCAGTGCC CTCCTGAGCT TGTCCCGGAG TGTCCAGGAG

601 CTCACGGAAG AGAACCAGAG CCTGAAGGAG GACCTGGACC GCGTGCTGAG

651 CACCTCCCCA ACCATCTCCA AGACACAGGG TTATGTGGAG TGGAGCAAGC 101 CCCGGCTGCT GAGGCGCATT GTGGAGCTGG AGAAGAAACT AAGTGTGATG

151 GAGAGCTCAA AATCACACGC CGCAGAGCCA GTCAGATCAC ACCCGCCAGC

1001 CTGCCTTGCA TCCAGCTCTG CGCTGCACAG ACAGCCACGA GGGGACCGCA

1051 ACAAGGACCA CGAGCGTCTC CGAGGGGCTG TGAGAGACCT GAAGGAAGAG

1101 CGGACCGCGC TGCAGGAGCA GCTGCTGCAG AGAGATTTGG AGGTGAAGCA 1151 GCTCCTGCAG GCGAAGGCCG ACCTGGAGAA GGAGCTGGAG TGCGCGAGGG

1201 AGGGCGAGGA GGAGAGGAGA GAGCGAGAGG AGGTTTTGAG AGAGGAGATT

1251 CAGACACTTA CCAGCAAGCT CCAAGAATTG CAAGAAATGA AGAAAGAAGA

1301 GAAAGAGGAT TGCCCGGAAG TTCCTCATAA GGCCCAAGAG CTCCCAGCTC

1351 CCACTCCCAG CAGCAGGCAC TGCGAGCAAG ACTGGCCGCC GGATTCCAGC 1401 GAGGAGGGGC TCCCGCGGCC CCGCTCCCCC TGCTCTGATG GGAGAAGAGA

1451 CGCCGCGGCC AGAGTCCTGC AGGCCCAGTG GAAGGTGTAC AAGCACAAGA

1501 AAAAAAAGGC TGTTCTGGAT GAGGCGGCTG TGGTGCTTCA GGCAGCTTTC

1551 AGGGGACATC TCACGCGGAC AAAGCTCTTA GCAAGCAAAG CACATGGCTC IbOl AGAGCCACCC AGCGTGCCAG GCCTCCCAGA CCAGAGCTCT CCTGTGCCCC lb51 GCGTTCCGAG CCCCATCGCC CAGGCCACGG GCAGCCCTGT GCAGGAGGAG

1701 GCCATCGTCA TCATCCAGTC CGCTCTGCGG GCACACCTGG CCCGGGCCAG

1751 GCACAGTGCT ACCGGTAAAA GAACCACCAC CGCAGCTTCT ACCAGGAGGA

1801 GATCGGCTTC AGCCACACAC GGGGACGCCT CCTCCCCACC CTTCCTCGCA

1851 GCTCTTCCTG ACCCCTCTCC CTCAGGGCCA CAGGCCTTGG CACCTCTACC

1101 TGGGGATGAC GTCAACTCCG ATGATTCCGA CGATATTGTC ATTGCACCGT

1151 CTCTGCCCAC GAAGAACTTT CCAGTTTAGG TCCCCGTCAC TGTCTCCACG

2001 CCGTGATGGC AGCGCTGCCG AGGACATAGG AACCACGACT GGAAAGATAA

2051 TTTATCGTGT TAGGAGAAGA ACGATGATAC CTACTTAAAA AAAAAAAAAA

2101 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA

2151 AAAAAAAAAA A

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 3

ORF from 45 bp to 117b bpi peptide length-" b44 Category: similarity to unknown protein Classification: unclassified Prosite motifs: RGD (332-334)

1 MFLGTGEPAL DTSHLISLSR ASLTPiQKLUL GTAKPGSLTiQ ALNSPLTUEH 51 AUTGVPGGTP DCLTDTFRVK RPHLRRSASN GHVPGTPVYR EKEDMYDEII 101 ELKKSLHVύK SDVDLMRTKL RRLEEENSRK DRIQIEIQLLDP SRGTDFVRTL 151 AEKRPDASUV INGLKlQRILK LElQiQCKEKDG TISKLlQTDMK TTNLEEMRIA 201 METYYEEVHR LiQTLLASSET TGKKPLGEKK TGAKRiQKKMG SALLSLSRSV 251 (QELTEENiQSL KEDLDRVLST SPTISKTiQGY VEUSKPRLLR RIVELEKKLS 301 VMESSKSHAA EPVRSHPPAC LASSSALHRiQ PRGDRNKDHE RLRGAVRDLK 351 EERTALlQElQL LIQRDLEVKIQL LlQAKADLEKE LECAREGEEE RREREEVLRE 401 EIlQTLTSKLiQ ELiQEMKKEEK EDCPEVPHKA (QELPAPTPSS RHCElQDUPPD 451 SSEEGLPRPR SPCSDGRRDA AARVLlQAiQUK VYKHKKKKAV LDEAAVVLiQA 501 AFRGHLTRTK LLASKAHGSE PPSVPGLPDiQ SSPVPRVPSP IAIQATGSPVIQ 551 EEAIVIIlQSA LRAHLARARH SATGKRTTTA ASTRRRSASA THGDASSPPF bOl LAALPDPSPS GPiQALAPLPG DDVNSDDSDD IVIAPSLPTK NFPV

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_11pl2ι frame 3 No Alert BLASTP hits found

Pedant information for DKFZphtes3_11pl2ι frame 3

Report for DKFZphtes3_11pl2- 3

[LENGTH! b44 [MU! 71810-41

[pi! 6-80

[H0M0L! TREMBL:AB02814b_l gene: "KIAA1023"i product:

"KIAA1023 protein"i Homo sapiens mRNA for KIAA1D23 proteini partial eds- 0-D [FUNCAT! 3D-03 organization of cytoplasm [S- cerevisiaei

YDLOS&w! 2e-07

[FUNCAT! 08-D7 vesicular transport (golgi networki etc) [S- cerevisiaei YDL056w! 2e-D7

[FUNCAT! 11 unclassified proteins CS- cerevisiaei YLR301c! 3e-0b

[FUNCAT! 3D-04 organization of cytoskeleton [S- cerevisiaei

YDR35bw! 2e-D5

[FUNCAT! 01-10 nuclear biogenesis CS- cerevisiaei YDR35bw!

2e-05 [FUNCAT! D3-22 cell cycle control and mitosis CS- cerevisiaei

YDR35bw! 2e-05

[FUNCAT! 16 classification not yet clear-cut [S- cerevisiaei

YJR134c! 4e-D5

[BLOCKS! DM01354I [BLOCKS! BL00b27B GHMP kinases ATP-binding domain proteins

[BLOCKS! BL0032bC Tropomyosins proteins

[BLOCKS! BLOllbOB Kinesin light chain repeat proteins

[BLOCKS! BL00620D Glucoamylase proteins region proteins

[BLOCKS! BP04417C [BLOCKS! BLD0412B Neuromodulin (GAP-43) proteins

[EC! 3. fa.1.35 Myosin ATPase 3e-06

[PIRKU! tandem repeat 3e-0θ

[PIRKU! transmembrane protein 2e-D7

[PIRKU! muscle contraction 3e-08 [PIRKU! actin binding 3e-D8

[PIRKU! ATP 3e-08

[PIRKU! thick filament 3e-D8

[PIRKU! alternative splicing 7e-07

[PIRKU! coiled coil 3e-D8 [PIRKU! P-loop 3e-0β

[PIRKU! heptad repeat 2e-D7

[PIRKU! methylated amino acid 3e-06

[PIRKU! hydrolase 3e-08

[PIRKU! Golgi apparatus 2e-07 [SUPFAM! myosin heavy chain 3e-0δ

[SUPFAM! myosin motor domain homology 3e-08

[SUPFAM! alpha-actinin actin-binding domain homology 8e-Db

[SUPFAM! plectin βe-Ob

[SUPFAM! ribosomal protein SID homology βe-Ob [SUPFAM! giantin 2e-07

[PROSITE! RGD 1

[KU! All_Alpha

[KU! L0U_C0MPLEXITY 14-bD * [KU! COILED COIL 15 - 22 *

SElQ MFLGTGEPALDTSHLISLSRASLTPiQKLULGTAKPGSLTiQALNSPLTUEHAUTGVPGGTP SEG

PRD cccccccccccceeeeeeeecccccceeeeecccccceeeeccccccccccccccccccc COILS

SElQ DCLTDTFRVKRPHLRRSASNGHVPGTPVYREKEDMYDEIIELKKSLHViQKSDVDLMRTKL

SEG

PRD cccccchhhhhhhhhhhhhhccccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh

COILS CCCCCCCCCCCCCCCCCCCCCCC

SElQ RRLEEENSRKDR(QIE(QLLDPSRGTDFVRTLAEKRPDASUVINGLK(QRILKLE(Q(QCKEKDG

SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh

COILS CCCCCC

SElQ TISKLlQTDMKTTNLEEMRIAMETYYEEVHRLiQTLLASSETTGKKPLGEKKTGAKRiQKKMG SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS cccc

SElQ SALLSLSRSVlQELTEENlQSLKEDLDRVLSTSPTISKTiQGYVEUSKPRLLRRIVELEKKLS SEG PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS

CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC

SElQ VMESSKSHAAEPVRSHPPACLASSSALHRiQPRGDRNKDHERLRGAVRDLKEERTALlQEiQL SEG

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS

SElQ LiQRDLEVKiQLLiQAKADLEKELECAREGEEERREREEVLREEIlQTLTSKLiQELlQEMKKEEK

SEG xxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxx

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS CCCCCCCCCCCCCCCCCCCCCCCCCCCCC

SElQ EDCPEVPHKAQELPAPTPSSRHCEiQDUPPDSSEEGLPRPRSPCSDGRRDAAARVLiQAlQUK

SEG x x

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS CCCCCC

SElQ VYKHKKKKAVLDEAAVVLiQAAFRGHLTRTKLLASKAHGSEPPSVPGLPDiQSSPVPRVPSP SEG xxxxxxxx

PRD hhhhhhhhhhhhhhhhhhhhhhhcchhhhhhhhhhhcccccccccccccccccccccccc COILS

SElQ IAlQATGSPVlQEEAIVIIi^QSALRAHLARARHSATGKRTTTAASTRRRSASATHGDASSPPF SEG xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

PRD ccccccccccceeeehhhhhhhhhhhhhhhhccccceeehhhhhhhhhccccccccccce COILS

SEl^Q LAALPDPSPSGPiQALAPLPGDDVNSDDSDDIVIAPSLPTKNFPV

SEG xxxxxxxxxxxxx

PRD eeecccccccccccccccccccccccccceeeeecccccccccc COILS

Prosite for DKFZphtes3_11pl2- 3 PSODOlb 332->335 RGD PDOCOODlb

⁽No Pfam data available for DKFZphtes3_11pl2-3)

DKFZphtes3_20hl2

group: transmembrane protein

DKFZphtes3_2Dhl2 encodes a novel 1204 amino acid protein without similarity to known proteins- The novel protein contains 1 transmembrane region and two leucine zippers.

No informative BLAST resultsi No predictive prositei pfam or SCOP motife- The new protein can find application in studying the expression profile of testis-specific genes and as a new marker for testicular cells-

putative protein perhaps complete eds- Pedant: TRANSMEMBRANE 1 Sequenced by MediGenomix

Locus: unknown

Insert length: 5614 bp Poly A stretch at pos. 5674ι no polyadenylation signal found

1 CTCTGCCTTT CCTCTCGCAG CCACCCTTCC TCTCAGACCA GTACGGTGGC

51 CGACGGGAGT CAGACGCTGG GGATGAATGA AGGATCAACA AACAGTAATA 101 ATGACTGAAT GTACAAGTCT TCAGTTTGTC AGCCCTTTTG CTTTTGAGGC

151 AATGCAGAAG GTGGATGTTG TTTGCCTGGC ATCTTTAAGT GATCCAGAAT

201 TAAGACTTCT TCTGCCCTGT TTGGTACGGA TG6CACTTTG TGCACCTGCT

251 GACCAGAGCC AAAGCTGGGC TCAGGATAAG AAACTCATCC TTCGCCTTCT

301 TTCTGGAGTG GAAGCTGTCA ACTCCATTGT TGCATTGTTG TCCGTGGACT 351 TTCATGCTTT AGAACAAGAT GCCAGCAAAG AACAGCAGCT TAGGCATAAA

401 CTTGGAGGAG GCAGTGGAGA GAGCATCCTG GTATCACAGC TTCAGCATGG

451 ACTGACGTTA GAGTTTGAAC ACAGTGATTC ACCTCGTCGA TTGCGTCTTG

501 TGCTTAGTGA ACTGTTGGCA ATTATGAACA AGGTGTCTGA GTCCAACGGA

551 GAATTTTTTT TCAAGTCTTC TGAACTTTTT GAGAGTCCAG TATATTTGGA bOl GGAAGCTGCA GATGTACTTT GTATTTTACA AGCAGAGCTC CCTTCCTTGC b51 TCCCTATAGT TGATGTAGCT GAAGCTTTGC TACATGTTAG AAATGGTGCC

701 TGGTTCTTGT GTCTCTTGGT GGCCAATGTT CCTGATAGTT TTAATGAAGT

751 TTGTAGGGGC CTGATAAAAA ATGGAGAACG ACAAGATGAA GAAAGTCTTG

6D1 GAGGAAGGCG CAGGACAGAT GCCTTACGCT TCTTGTGTAA AATGAATCCT 651 TCTCAGGCCC TCAAGGTCCG AGGCATGGTG GTGGAAGAAT GTCACTTGCC

101 AGGCCTTGGT GTGGCTTTGA CATTGGATCA TACTAAAAAT GAAGCTTGTG

151 AGGATGGAGT GAGTGACTTG GTTTGTTTTG TAAGTGGTTT GCTTCTTGGA

1001 ACAAATGCGA AAGTCCGGAC TTGGTTTGGA ACTTTTATCC GAAATGGACA

1051 GCAGAGAAAA AGAGAGACCA GCAGTTCTGT CCTTTGGCAG ATGAGAAGGC 1101 AGCTTCTTCT GGAGTTGATG GGCATTCTTC CCACAGTAAG AAGCACCCGA

1151 ATTGTGGAAG AAGCTGATGT GGATATGGAG CCCAATGTGT CTGTGTATTC

1201 GGGGCTGAAA GAAGAGCATG TTGTGAAAGC CAGTGCACTC TTACGTCTGT

1251 ACTGTGCTTT GATGGGGATC GCTGGACTCA AACCAACTGA AGAAGAAGCT 1301 GAGCAATTAC TGCAGTTGAT GACGAGCCGT CCTCCTGCTA CGCCAGCTGG

1351 GGTTCGCTTT GTTTCACTTT CCTTTTGTAT GCTACTGGCC TTTTCTACAC

14D1 TTGTCAGTAC ACCTGAACAG GAGCAGCTGA TGGTGGTGTG GCTAAGTTGG

1451 ATGATAAAAG AAGAAGCGTA TTTTGAGAGT ACTTCAGGCG TCTCTGCTTC 1501 TTTTGGGGAG ATGTTATTAT TGGTGGCTAT GTACTTTCAC AGCAACCAGC

1551 TTAGTGCTAT CATTGACTTG GTCTGTTCCA CTTTGGGGAT GAAGATTGTA

IbOl ATTAAGCCAA GCTCCTTGAG CAGGATGAAG ACAATCTTCA CACAGGAAAT

IfaSl TTTTACTGAG CAGGTTGTCA CAGCTCATGC AGTTCGGGTC CCTGTCACCA

1701 GCAACCTGAG TGCCAACATT ACTGGATTTT TGCCTATTCA TTGTATTTAC 1751 CAGCTTCTCA GGAGCCGTTC CTTTACCAAG CACAAAGTGT CAATAAAAGA

1601 TTGGATTTAT AGACAGCTGT GTGAAACCTC TACTCCACTT CATCCTCAAT

1A51 TACTTCCTTT GATTGATGTG TACATAAATT CTATACTTAC TCCTGCGTCG

1101 AAATCTAATC CAGAAGCCAC AAATCAGCCA GTCACAGAAC AGGAGATACT

1151 CAATATTTTC CAAGGAGTCA TTGGGGGTGA CAACATCCGC CTTAATCAGC 2001 GTTTCAGTAT CACAGCACAG CTTTTGGTGC TCTACTATAT ACTGTCTTAT

2051 GAAGAGGCTC TTCTAGCAAA CACGAAGACT TTAGCTGCCA TGCAAAGAAA

21D1 GCCCAAATCA TATTCTTCTT CTTTAATGGA TCAGATTCCT ATCAAATTCC

2151 TTATTCGACA GGCTCAAGGG CTGCAGCAGG AGTTGGGAGG GTTGCATTCA

2201 GCTTTACTAC GTCTCCTTGC TACTAACTAC CCACATTTAT GTATTGTGGA 2251 TGACTGGATT TGTGAAGAAG AAATCACAGG GACTGATGCC CTGCTACGGC

23D1 GAATGCTCCT GACTAATAAT GCTAAAAATC ATTCTCCCAA ACAACTCCAA

2351 GAAGCATTTT CAGCTGTCCC AGTAAATCAC ACACAAGTGA TGCAGATTAT

2401 AGAACACTTG ACTCTACTCT CTGCCAGTGA ACTTATACCA TATGCGGAAG

2451 TGTTAACATC CAATATGAGC CAGCTATTGA ATTCAGGGGT TCCACGGAGA 2501 ATTCTGCAAA CAGTCAATAA ACTATGGATG GTTCTTAATA CTGTGATGCC

2551 TAGAAGGCTA TGGGTAATGA CGGTTAATGC ACTTCAGCCT TCAATAAAGT

2b01 TTGTACGACA ACAAAAGTAT ACTCAGAATG ACCTGATGAT AGATCCTCTC

2b51 ATTGTCCTAA GGTGTGATCA GAGGGTTCAC AGATGCCCCC CACTGATGGA

27D1 TATTACCCTA CACATGTTGA ATGGATATCT TCTTGCATCT AAAGCCTACC 2751 TTAGTGCTCA TCTGAAGGAA ACAGAGCAAG ATAGGCCTTC CCAGAATAAT

2601 ACAATTGGTT TAGTTGGACA AACTGATGCT CCGGAAGTTA CCAGGGAAGA

2651 ATTGAAAAAT GCATTACTGG CCGCTCAGGA TAGTGCAGCT GTCCAGATTC

2101 TCTTAGAGAT TTGCCTACCT ACTGAAGAGG AGAAAGCAAA TGGTGTCAAT

2151 CCAGATAGCT TGTTAAGAAA TGTTCAAAGT GTTATTACCA CCAGCGCTCC 30D1 AAATAAGGGA ATGGAGGAAG GAGAAGACAA TTTGCTCTGT AACCTTCGAG

3D51 AAGTTCAGTG CCTTATCTGT TGTCTCTTGC ACCAAATGTA CATTGCAGAT

31D1 CCCAACATTG CTAAGCTTGT TCACTTTCAG GGTTATCCAT GTGAACTTTT

3151 GCCTCTGACG GTCGCAGGTA TTCCATCTAT GCACATCTGT CTAGATTTCA

3201 TACCTGAGCT TATTGCACAG CCAGAACTTG AGAAACAGAT ATTTGCTATC 3251 CAGTTGCTTT CTCACTTGTG TATACAATAT GCATTACCAA AGTCACTTAG

3301 TGTGGCTCGT TTAGCTGTCA ATGTCATGGG AACTTTGTTA ACAGTTTTAA

3351 CACAGGCTAA GCGGTATGCT TTTTTTATGC CAACTCTGCC AAGTTTGGTC

3401 TCTTTTTGTC GAGCATTTCC TCCATTGTAT 6AGGATATTA TGTCTTTGCT

3451 GATCCAAATA GGGCAAGTTT GTGCCTCTGA TGTTGCCACT CAGACAAGAG 3501 ACATTGATCC AATTATTACA CGTCTTCAAC AAATAAAGGA GAAACCAAGT

3551 GGATGGTCTC AAATCTGTAA AGATTCATCT TATAAAAATG GATCCAGGGA

3b01 CACTGGAAGC ATGGATCCTG ATGTACAGCT CTGTCACTGT ATTGAAAGAA

3b51 CAGTAATTGA AATAATAAAT ATGAGTGTTA GTGGAATTTA AAACAAAATT

3701 TAAAACAACA AAAAGTTGTT TGCTGCATAT ACCCAACATG AATCTGCATA 3751 TTAGTAACAA CTCTAAACTG AATGGGAACA GTAAAGTATT GTCTTGGAAT

3601 CACTAAAACA ATTCAATTCA ACATGAGTAT AGTTTAGAAC TTTATGAGAA

3651 TTATGCTTGC TTGTTTCTGA TTGGCACATC TTTGGATCTA CTTTGCTGAT

31D1 ATGTTTCTAT TGTAGCAGCT GAGCTTTTTT TTTTTCCACT GGGAACACAT

3151 GTAAGAAACT CATTATTGGA AAGGGAATTT GGCCTTGTAT TTAGCTTTTG 40D1 AAGTGAAGAC TGCCATGCCT TTAATTTCTT ATAAAAATGA GTCTGTGGGT

4051 AGCCCTAGTG TTTATTTTAA CTGTGAGCTT GTAACAGAAT GTGACAAAGA

4101 TGCAAAGATG GGAGAGGAAA AAAGGGTAAA GGGAAAGGAG AATTAAGGAA

4151 ATAATAGGAG TTAAAAACAC AAGTAGAAAT CTCAAAGATT TGCAGTGCAA 4201 GTAATAGTAA TGCAAGTTGG AATTCTAGTT CTCAAGAAAG AGTATTGAGA

4251 AGACTTTTAA AAAGGCAAGT AGCTTTTGTA AATGATTTCT GTGGAAATAC

4301 AGATGAGGAT TTAAAGATTT CACATATTTG CTTCAATTTT TATTAATATA

4351 TGAAGCCATA TGTTTAAAGA GATACTTGAA TAATTTGGAA TTTTAAGATA 4401 CTGGTGTAAA AGTGTTTACA GAAACATCTT TGTTCAAAGA AGAACCTGAG

4451 AGATCTCATT TAGTTTTATG TTTTAAATTT ATTTTTATAA TGCTTTATTA

45D1 ACTTACCTAA TGCTCAGAGG GGGGAAATAT GTATCAAATT AAATGAAGGT

4551 AGAGCAATAA AACCCACTGG ATTAAAGAGC TCTTGGTTTG TCATCAGGAT

4b01 TATAATTCAT ATCTTACTTT GAGAAGATCT TTGAGTAAGA AAATGCAGTG 4b51 TTTGAACCTG AGGAAAAGTT AAAGTGTAGA AAATATTGTC TTGCCGAAGG

47D1 ATTTTGCAGT CCTCTGTCAG TAACTTCCAT TGATTAGGCA GACATATTCA

4751 GGTAAACCCT AATCATTAAA AAAAAATTAT CAATGTAGAA AGTAATTCCC

4601 TTTTTTCTCT CTGAGATATA CCTCAATCAC ACACTTCCCC ACCCCCACTT

4651 GAAACAGACC TCTTCACTTG TGTTTTTTTT TTTTTTTTCC TGAGGTGGAG 41D1 TCTTCCCCTG TTGCCCAGGC TGGAGTGCAG TGGGATGATC TTGGCTCACT

4151 GCAACTTCTG CCACCTGGGT TCAAGGGATT CTCGTGCCTC AACCTCCTGA

5001 GTAGCTGGGA CTGCAGGCAC GCGCCACCTG TATTTTTGTA TTTTTAGTAG

5051 AGACGGGGGT TTGCCATGTT GCCCAGACTG GTTTTGAACT CCTGGCCTCA

51D1 GGTGATCTGC CCACCTTGGC CTCCCAAAGT GCTGGGATTA CAGGTGTGAG 5151 CCACCGCACC TGGCCAGACC GCTTCACTTG TAAAAGAAAT TAGGCTAATA

5201 AGAAGGTGTA GTTTTTGAGA AATGAAATTT AACTTTAGCC TTTTCACTAG

5251 TAAATAGTCA CATCTCATTT TCTTCCTTTG TAAAATGGGG TTACTACTGG

53D1 CCCTACCTCA TATTCTATGA GAATGAGTTT GTAGCTGTTT CAAATCATGA

5351 AGTGCATAGT ATCACATGTG ATAGAATATT TATAACTTTT TATTAGATGC 5401 TTAATGTTCA ATTAAGTAAT TTTGATGTGA AAAATAAAAG TAATAAAAGT

5451 ATCTTAAAAA TAGCATAAGA ATTTTCATAT TTTTAAACAA GGCAGTTTTG

5501 TAGTCCCTTA AGATTAAATA CAACTGCTCC _TTTTTTTTTT AAACTGAGGC

5551 CTTGCGATAT TTTGTGTGAA TAGATATGCC CTAGGAGTTC AGAAAAAGTT

5b01 AAAAGTATGT TTTCTAATTA AATGCAGTGC ACATTCCTGG ATCAATATTC 5b51 AAAGACTGGT CATAACCTGC TGTGTTAAAA TAATCACATA TGCTCTTTTT

5701 CATCAGATTT GTTGATGATG TAAATAAAAT GTGTAAATAT ATTAGTAAAT

5751 GTTAATATTC ATGTATTTTA AGTTAAGGTT ATAAAATTTG TCACAATGTG

5601 TTTTTTTATT CAAGTGAAAA CAGATGTGTG CAGCTATTTT GAATATTGGT

5651 TTATAAACAT TCATATTCTT TATCAAACAA AAAAAAAAAA AAAA

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 2

ORF from 77 bp to 3bβδ bpi peptide length: 1204 Category: putative protein Classification: unclassified

Prosite motifs: LEUCINE_ZIPPER (lb7-184) LEUCINE ZIPPER (b12-701) 1 MKDIQIQTVIMT ECTSLiQFVSP FAFEAMiQKVD VVCLASLSDP ELRLLLPCLV

51 RMALCAPADlQ SiQSUAlQDKKL ILRLLSGVEA VNSIVALLSV DFHALEiQDAS

101 KEIQIQLRHKLG GGSGESILVS (QLlQHGLTLEF EHSDSPRRLR LVLSELLAIM 151 NKVSESNGEF FFKSSELFES PVYLEEAADV LCILlQAELPS LLPIVDVAEA

2D1 LLHVRNGAUF LCLLVANVPD SFNEVCRGLI KNGERlQDEES LGGRRRTDAL

251 RFLCKMNPSiQ ALKVRGMVVE ECHLPGLGVA LTLDHTKNEA CEDGVSDLVC

301 FVSGLLLGTN AKVRTUFGTF IRNGIQIQRKRE TSSSVLUiQMR RiQLLLELMGI

351 LPTVRSTRIV EEADVDMEPN VSVYSGLKEE HVVKASALLR LYCALMGIAG 4D1 LKPTEEEAEiQ LLlQLMTSRPP ATPAGVRFVS LSFCMLLAFS TLVSTPE(QE(Q

451 LMVVULSUMI KEEAYFESTS GVSASFGEML LLVAMYFHSN (QLSAIIDLVC

501 STLGMKIVIK PSSLSRMKTI FTIQEIFTEIQV VTAHAVRVPV TSNLSANITG

551 FLPIHCIYlQL LRSRSFTKHK VSIKDUIYRώ LCETSTPLHP (QLLPLIDVYI bOl NSILTPASKS NPEATNώPVT EIQEILNIFIQG VIGGDNIRLN (QRFSITAiQLL b51 VLYYILSYEE ALLANTKTLA AMiQRKPKSYS SSLMDiQIPIK FLIRlQAiQGLlQ

701 (QELGGLHSAL LRLLATNYPH LCIVDDUICE EEITGTDALL RRMLLTNNAK

751 NHSPKlQL(3EA FSAVPVNHTύ VMiQIIEHLTL LSASELIPYA EVLTSNMSlQL

801 LNSGVPRRIL (QTVNKLUMVL NTVMPRRLUV MTVNALiQPSI KFVRiQiQKYTlQ

651 NDLMIDPLIV LRCDiQRVHRC PPLMDITLHM LNGYLLASKA YLSAHLKETE 101 (QDRPSiQNNTI GLVGtQTDAPE VTREELKNAL LAAlQDSAAVlQ ILLEICLPTE

151 EEKANGVNPD SLLRNVtQSVI TTSAPNKGME EGEDNLLCNL REVlQCLICCL

10D1 LHlQMYIADPN lAKLVHFlQGY PCELLPLTVA GIPSMHICLD FIPELIAiQPE

1051 LEKlQIFAIiQL LSHLCIlQYAL PKSLSVARLA VNVMGTLLTV LTiQAKRYAFF

1101 MPTLPSLVSF CRAFPPLYED IMSLLIiQIGώ VCASDVATiQT RDIDPIITRL 1151 (QiQIKEKPSGU SlQICKDSSYK NGSRDTGSMD PDVlQLCHCIE RTVIEIINMS

1201 VSGI

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_20hl2ι frame 2 No Alert BLASTP hits found

Pedant information for DKFZphtes3_20hl2ι frame 2

Report for DKFZphtes3_2Dhl2-2

[LENGTH! 1204 [MU! 134347-53

[pi! 5-75

[HOMOL! TREMBL :CEZC37b_3 gene-" "ZC37b-b"i Caenorhabditis elegans cosmid ZC37b 2e-22

[PROSITE! LEUCINE_ZIPPER 2 [KU! TRANSMEMBRANE 1

[KU! L U_C MPLEXITY 2-57 *

[KU! COILED COIL 2-33 *

SElQ MKDiQiQTVIMTECTSLlQFVSPFAFEAMi^QKVDVVCLASLSDPELRLLLPCLVRMALCAPADlQ SEG

PRD cccceeeeeeeccceeecchhhhhhhhheeeeeeecccchhhhhhhchhhhhhhhccccc COILS

MEM

SElQ S(QSUA(QDKKLILRLLSGVEAVNSIVALLSVDFHALE(QDASKE(Q(QLRHKLGGGSGESILVS SEG

PRD hhhhhhhhhhhhhhhccccccccccccccccchhhhhhhhhhhhhhhhhcccccceeeec COILS MEM

SElQ (QLlQHGLTLEFEHSDSPRRLRLVLSELLAIMNKVSESNGEFFFKSSELFESPVYLEEAADV SEG xxxxxxxxxxxx

PRD ccccccceeeecccccchhhhhhhhhhhhhhhhhhcccccccccccccccchhhhhhhhh COILS

MEM

SElQ LCILlQAELPSLLPIVDVAEALLHVRNGAUFLCLLVANVPDSFNEVCRGLIKNGERiQDEES SEG

PRD hhhhhhcccccchhhhhhhhhhhhhccchhhhhheeeccccccchhhhhccccccccccc COILS

MEM

SElQ LGGRRRTDALRFLCKMNPSiQALKVRGMVVEECHLPGLGVALTLDHTKNEACEDGVSDLVC

SEG

PRD ccccchhhhhhhhhhcccceeeeeeeeeeeeeccccccceeeecccccccccccccceee

COILS

MEM

SElQ FVSGLLLGTNAKVRTUFGTFIRNGIQIQRKRETSSSVLUIQMRRIQLLLELMGILPTVRSTRIV SEG PRD eeeccccccceeeeeeeeeeeecchhhhhcccchhhhhhhhhhhhhhhhccccceeeeee COILS

MEM SElQ EEADVDMEPNVSVYSGLKEEH VKASALLRLYCALMGIAGLKPTEEEAEiQLLiQLMTSRPP SEG

PRD eeeccccccceeeeccccchhhhhhhhhhhhhhhhhhhhccchhhhhhhhhhhhhhcccc COILS MEM

SElQ ATPAGVRFVSLSFCMLLAFSTLVSTPEIQEIQLMVVULSUMIKEEAYFESTSGVSASFGEML SEG

PRD cccceeeeeehhhhhhhhhhccccccchhhhhhhhhhhhhhhhhhhcccccccchhhhhh COILS

MEM MMMMMMMMMMMMMMMMM

SElQ LLVAMYFHSNlQLSAIIDLVCSTLGMKIVIKPSSLSRMKTIFTiQEIFTEiQVVTAHAVRVPV SEG

PRD hhhhhhhccchhhhhhhhhhhhccceeeeeccccchhhhhhhhhhhhhhhhhhhhheeec COILS MEM

SElQ TSNLSANITGFLPIHCIYlQLLRSRSFTKHKVSIKDUIYRlQLCETSTPLHPiQLLPLIDVYI SEG

PRD cccccceeeeeehhhhhhhhhhhhhcccccccchhhhhhhhhcccccccccccccceeee COILS

MEM SElQ NSILTPASKSNPEATNlQPVTEiQEILNIFiQGVIGGDNIRLNiQRFSITAlQLLVLYYILSYEE SEG

PRD eeccccccccccccccccchhhhhhhhhhhccccccceeeehhhhhhhhhhhhhhhhhhh COILS MEM

SElQ ALLANTKTLAAMlQRKPKSYSSSLMDlQIPIKFLIRiQAiQGLiQlQELGGLHSALLRLLATNYPH

SEG xxxxxxxxxxxxxxxxxxx

PRD hhhhhhhhhhhhhhcccccccccccchhhhhhhhhhhhhhhhhcccchhhhhhhhhcccc COILS CCCCCCCCCCCCCCCCCCCCCCCCCCCC

MEM

SElQ LCIVDDUICEEEITGTDALLRRMLLTNNAKNHSPKiQLiQEAFSAVPVNHTiQVMlQIIEHLTL SEG

PRD eeeecceeeeechhhhhhhhhhhhhhccccccccchhhhhhhhhhcccchhhhhhhhhhh COILS

MEM

SElQ LSASELIPYAEVLTSNMSlQLLNSGVPRRILiQTVNKLUMVLNTVMPRRLUVMTVNALiQPSI SEG

PRD hhhhhhhhhhcccccchhhhhccccchhhhhhhhhhhhhhhhccccchhhhhhcccccch COILS

MEM

SElQ KFVRiQtQKYTiQNDLMIDPLIVLRCDiQRVHRCPPLMDITLHMLNGYLLASKAYLSAHLKETE SEG PRD hhhhhhhcccccccccceeeeecccccccccccceeeccccccchhhhhhhhhhhhhhhh COILS

MEM SElQ (QDRPSiQNNTIGLVGlQTDAPEVTREELKNALLAAlQDSAAViQILLEICLPTEEEKANGVNPD SEG

PRD ccccccccccccccccccchhhhhhhhhhhhhhhhhhhhhhhhhhhcccccccccccccc COILS MEM

SElQ SLLRNVIQSVITTSAPNKGMEEGEDNLLCNLREVIQCLICCLLHIQMYIADPNIAKLVHFIQGY SEG

PRD cceeeeeeeeeecccccccccccchhhhhhhhhhhhhhhhhhhhhhhccccceeeecccc COILS

MEM SElQ PCELLPLTVAGIPSMHICLDFIPELIAiQPELEKiQIFAIlQLLSHLCIi^QYALPKSLSVARLA

SEG

PRD ccceeeeeeeecccceeeeehhhhhhhhhhhhhhhhhhhhhhhhhhhhhccchhhhhhhh COILS

MEM

SElQ VNVMGTLLTVLTiQAKRYAFFMPTLPSLVSFCRAFPPLYEDIMSLLIlQIGlQVCASDVATlQT SEG PRD hhhhhhhhhhhhhhhhhhhhccccccceeeccccccchhhhhhhhhhhhcchhhhhcccc COILS

MEM SElQ RDIDPIITRLiQl^QIKEKPSGUSl^QICKDSSYKNGSRDTGSMDPDVlQLCHCIERTVIEIINMS SEG

PRD cccchhhhhhhhhhhccccceeeeeccccccccccccccccceeeeeeeehhhhhhheee COILS MEM

SElQ VSGI SEG - - • • PRD eccc COILS

MEM

Prosite for DKFZphtes3_20hl • 2

PS0D021 lb7->161 LEUCINE_ZIPPER PD0CD0D21

PS0D021 b12->714 LEUCINE_ZIPPER PD0CD0021

(No Pfam data available for DKFZphtes3_20hl2 ■ 2)

DKFZphtes3_21kl4

group: testis derived

DKFZphtes3_21kl4 encodes a novel 556 amino acid protein without similarity to known proteins. No informative BLAST resultsi No predictive prositei pfam or SCOP motife-

The new protein can find application in studying the expression profile of testis-specific genes-

unknown protein perhaps complete eds-

Sequenced by LMU

Locus-" unknown Insert length: 2547 bp

Poly A stretch at pos- 25Dbι polyadenylation signal at pos- 2471

1 GGCCACGTTC AGCGGACACG GGAGCAAGAT GGCGATTCCG GGCAGGCAGT 51 ATGGGCTTAT TTTGCCAAAG AAAACACAGC AGTTGCACCC TGTTTTGCAA

101 AAACCATCAG TGTTTGGGAA TGATTCTGAT GATGATGATG AGACCTCTGT

151 GAGTGAAAGC CTTCAGAGGG AAGCTGCTAA GAAGCAGGCC ATGAAACAGA

201 CCAAACTGGA AATCCAGAAG GCCCTTGCAG AAGATGCTAC TGTGTATGAA

251 TATGACAGTA TTTATGATGA AATGCAGAAA AAAAAGGAGG AAAATAATCC 301 CAAATTGCTT TTGGGGAAAG ACA6AAA6CC CAAGTATATT CACAACTTGC

351 TAAAAGCAGT TGAGATCAGA AAAAAGGAAC AGGAAAAAAG AATGGAAAAG

401 AAAATACAGA GAGAACGAGA AATGGAAAAG GGGGAGTTTG ATGATAAAGA

451 AGCATTTGTG ACATCTGCAT ATAAGAAAAA ACTGCAAGAG AGAGCTGAAG

501 AAGAAGAAAG AGAAAAGAGG GCTGCTGCAC TGGAAGCATG TTTGGATGTA 551 ACCAAGCAGA AAGATCTCAG TGGATTTTAT AGGCACCTAT TAAATCAAGC bOl AGTTGGTGAA GAGGAAGTAC CTAAATGCAG CTTTCGTGAA GCCAGATCTG b51 GTATAAAGGA AGAAAAATCA AGGGGCTTCT CCAATGAAGT AAGTTCAAAA

7D1 AACAGAATAC CACAAGAGAA ATGCATTCTT CAAACTGATG TGAAAGTAGA

751 GGAAAACCCA GATGCAGACA GTGACTTCGA TGCTAAGAGC AGTGCGGATG 801 ATGAAATAGA AGAAACTAGA GTGAACTGCA GAAGGGAAAA GGTCATAGAG

651 ACCCCTGAGA ATGACTTCAA GCACCACAGG AGTCAAAACC ACTCTCGGTC

101 ACCTAGTGAA GAAAGAGGGC ACAGTACCAG GCACCACACG AAAGGATCAC

151 GAACGTCGAG AGGACATGAG AAAAGGGAAG ATCAGCACCA GCAGAAGCAA

1D01 TCCAGAGACC AAGAGAACCA TTACACTGAC CGTGATTACC GGAAAGAAAG 1D51 GGATTCTCAT AGGCACAGAG AGGCCAGTCA TAGAGATTCC CATTGGAAGA

1101 GGCATGAACA GGAAGATAAA CCAAGGGCGA GGGACCAAAG AGAAAGAAGT

1151 GACAGAGTAT GGkkkkGGGk GAAAGATAGG GAGAAATATT CCCAAAGAGA

1201 ACAAGAAAGA GATAGACAAC AAAATGATCA GAACCGACCC AGTGAGAAAG

1251 GAGAGAAGGA AGAGAAAAGC AAAGCAAAGG AAGAGCATAT GAAAGTAAGG 13D1 AAGGAAAGAT ATGAAAATAA TGATAAATAC AGAGATAGAG AAAAACGAGA

1351 GGTAGGTGTT CAGTCTTCAG AAAGAAATCA AGACAGAAAG GAAAGCAGCC

1401 CAAATTCTAG GGCAAAGGAT AAATTTCTTG ACCAAGAAAG ATCCAACAAA

1451 ATGAGAAACA TGGCAAAGGA CAAAGAAAGA AACCAAGAGA AACCCTCTAA 1501 TTCTGAATCA TCACTGGGAG CAAAACACAG ACTCACAGAG GAAGGGCAAG

1551 AGAAGGGTAA AGAACAAGAG AGACCACCTG AGGCAGTGAG CAAGTTTGCA

IbOl AAGCGGAACA ATGAAGAAAC TGTAATGTCA GCTAGAGACA GGTACTTGGC

IbSl CAGGCAGATG GCGCGGGTTA ATGCAAAGAC CTATATTGAG AAAGAAGATG 17D1 ATTGATGGCT ACCCCAAGAG AAAGATTTAA GGAAGCACAG AAAACTGTAA

1751 TTCCTGGAAC CTGCTGCGTA AAACCATAAA GGAGTGTGTT ACCAGTAGTT

1801 TGGAGGGCAT TTTTAAATTT ATTTTCAAAA TTTTAAGTTA AAAGTCAGTC

1851 TTACAGCTTG GATGTTTGGA TGTGGATGTT TGGCTGAATT TATATATAGT

1101 GTGTACTCAT CAATACCACA TTCTTTGTTG TATTCAAGAA CCGTTAAGAG 1151 TGTGCTAATT CCCTGTAGGT ACATAATGAG GAAAATTTGC TCCACTACAA

2001 CCATTAAAAA ATAATTTTGG CCAGATACGG TAGCTCGTGC CTGTAATACC

2051 AACATTTTGG GAGGCCAAGG CAGAAGGATA TTGAGGCTAG GCATTCAAGA

2101 CCAGCCTAGG CAGGATAATA AGACCTTGTC TCTATTTAAA AAACAAAAAG

2151 CCTAGCATGG TAGTCCATGC CTGTAGTCCC AGCTGTTCGA GAGGCTGAGG 22D1 CAAGAAGATC ACTTGAGCCT AGGAATTTGA TGTTACAGTG AGGTATGATC

2251 ATGCCACTGC ACTCCAACCT GGGCAACAGA ATGAGACCCT GTCTCTAAAA

2301 AATTTTTTTT AAATAAATAA TTTAACTCTT CTAATAATGT TTTGTTGCAG

2351 GAAATGTATT TCAGATAAAA TATGGATTTG AAAAACAGAA AATATACTTT

2401 ATGTTCTGAA ATTTGTATTT AAGTATAAAA TGTGAATCAT CTTGTCTAAA 2451 TAGCTTACAG CATAGTTGGC TTAAATGAAA ATAAAATGAT ATGCTTATAC

2501 ATTTGGAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAG

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 2

ORF from 21 bp to 1702 bpi peptide length: 558 Category: similarity to unknown protein Classification: Nucleic acid management

1 MAIPGRiQYGL ILPKKT(Q(QLH PVLlQKPSVFG NDSDDDDETS VSESLiQREAA 51 KK(QAMK(QTKL EIiQKALAEDA TVYEYDSIYD EMiQKKKEENN PKLLLGKDRK

101 PKYIHNLLKA VEIRKKElQEK RMEKKIiQRER EMEKGEFDDK EAFVTSAYKK

151 KLώERAEEEE REKRAAALEA CLDVTKlQKDL SGFYRHLLNO AVGEEEVPKC

201 SFREARSGIK EEKSRGFSNE VSSKNRIPlQE KCILlQTDVKV EENPDADSDF

251 DAKSSADDEI EETRVNCRRE KVIETPENDF KHHRSlQNHSR SPSEERGHST 301 RHHTKGSRTS RGHEKREDiQH (QιQK(QSRDι2EN HYTDRDYRKE RDSHRHREAS

351 HRDSHUKRHE (QEDKPRARDiQ RERSDRVUKR EKDREKYSiQR E(QERDR(Q(QND

401 (QNRPSEKGEK EEKSKAKEEH MKVRKERYEN NDKYRDREKR EVGVlQSSERN

451 (QDRKESSPNS RAKDKFLDlQE RSNKMRNMAK DKERNiQEKPS NSESSLGAKH

5D1 RLTEEGiQEKG KEiQERPPEAV SKFAKRNNEE TVMSARDRYL ARlQMARVNAK 551 TYIEKEDD BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_21kl4ι frame 2 No Alert BLASTP hits found

Pedant information for DKFZphtes3_21kl4ι frame 2

Report for DKFZphtes3_21kl4 -2

[LENGTH! 5b7 [MU! b72b2-61 [pi! δ-1b [H0M0L! TREMBL:AC00b233_14 gene: "F12K2.14"i Arabidopsis thaliana chromosome II BAC F12K2 genomic sequencei complete sequence 3e-ll [FUNCAT! 04-11 other transcription activities [S- cerevisiaei YKR012c! le-05 [FUNCAT! 30-1D nuclear organization [S- cerevisiaei YKR012c! le-05 [FUNCAT! Ob-07 protein modification (glycolsylationi acylationi myristylationi palmitylationi farnesylation and processing) [S. cerevisiaei YKL201c! le-04 [BLOCKS! PF00748F [BLOCKS! BL01182E Glycosyl hydrolases family 35 proteins [EC! 2-7.1.37 Protein kinase 7e-0b [EC! 5.11.1-2 DNA topoisomerase 4e-Dfa [PIRKU! phosphotransferase 7e-0b [PIRKU! pre-mRNA splicing le-Db [PIRKU! citrulline 3e-0b [PIRKU! tandem repeat 3e-0b [PIRKU! DNA binding 4e-0fa [PIRKU! DNA replication 4e-0b [PIRKU! isomerase 4e-Db [PIRKU! ATP 3e-0b [PIRKU! phosphoprotein le-Db [PIRKU! calcium binding 3e-Db [PIRKU! alternative splicing 7e-0fa [PIRKU! P-loop 3e-Db [PIRKU! EF hand 3e-0b [PIRKU! hair 3e-0b [SUPFAM! DEAD/H box helicase homology 3e-0b [SUPFAM! unassigned Ser/Thr or Tyr-specific protein kinases 4e- Ob

[SUPFAM! cal odulin repeat homology 3e-Db [SUPFAM! unassigned ribonucleoprotein repeat-containing proteins le-Ob [SUPFAM! unassigned DEAD/H box helicases 3e-0b [SUPFAM! trichohyalin 3e-Db CSUPFAM! protein kinase homology 4e-0b [SUPFAM! eukaryotic type I DNA topoisomerase 4e-0b [SUPFAM! ribonucleoprotein repeat homology le-Db [KU! All_Alpha [KU! LOU COMPLEXITY 22-75 * SElQ ATFSGHGSKMAIPGRiQYGLILPKKTiQlQLHPVLiQKPSVFGNDSDDDDETSVSESLiQREAAK

SEG xxxxxxxxxxxxx PRD ccccccccccccccccceeeeccccccccccccccccccccccccccccchhhhhhhhhh

SElQ KiQAMKlQTKLEIiQKALAEDATVYEYDSIYDEMiQKKKEENNPKLLLGKDRKPKYIHNLLKAV

SEG xxxxxxxxxxxxxx

PRD hhhhhhhhhhhhhhhhhhcccccccccchhhhhhhhhhchhhhhhccccchhhhhhhhhh

SE(Q EIRKKEiQEKRMEKKIiQREREMEKGEFDDKEAFVTSAYKKKLiQERAEEEEREKRAAALEAC

SEG xxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxxxxxx -

PRD hhhhhhhhhhhhhhhhhhhhhhccccccccchhhhhhhhhhhhhhhhhhhhhhhhhhhhh SElQ LDVTKlQKDLSGFYRHLLNiQAVGEEEVPKCSFREARSGIKEEKSRGFSNEVSSKNRIPiQEK

SEG

PRD hhhhhhhccchhhhhhhhhhhhccccccccccccchhhhhhhhhhhhhhhhhhhhhhhhh

SElQ CILlQTDVKVEENPDADSDFDAKSSADDEIEETRVNCRREKVIETPENDFKHHRSlQNHSRS SEG xxxxxxxxxxxxxx

PRD hhhhhhhhhhhcccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhcccc

SElQ PSEERGHSTRHHTKGSRTSRGHEKREDlQHiQiQKiQSRDlQENHYTDRDYRKERDSHRHREASH

SEG PRD ccccchhhhhhhhhhhhcccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhchh

SElQ RDSHUKRHEiQEDKPRARDlQRERSDRVUKREKDREKYSlQREiQERDRiQiQNDlQNRPSEKGEKE

SEG xxxxxxxxxxxxxxx . - xxxxxx

PRD hhhhhhhhccccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhccccccccccccchhh

SElQ EKSKAKEEHMKVRKERYENNDKYRDREKREVGVlQSSERNiQDRKESSPNSRAKDKFLDlQER

SEG xxxxxxxxxxx

PRD hhhhhhhhhhhhhhhhhhhccchhhhhhhhhhhhhhhhchhhhhhhhhhhhhhhhhhhhh SEA SNKMRNMAKDKERNlQEKPSNSESSLGAKHRLTEEGlQEKGKEiQERPPEAVSKFAKRNNEET

SEG xxxxxxxxxxx

PRD hhhhhhhhhhhhhhhhccchhhhhccchhhhhhhhhhhhhhhccccchhhhhhhccccch

SElQ VMSARDRYLARiQMARVNAKTYIEKEDD SEG

PRD hhhhhhhhhhhhhhhhhchhhhhcccc

(No Prosite data available for DKFZphtes3_21kl4 -2) (No Pfam data available for DKFZphtes3_21kl4 - 2) DKFZphtes3_22ill

group: testis derived

DKFZphtes3_22ill encodes a novel 580 amino acid protein with similarity to RCCl-like G exchanging factor RLGi UVR8 (UVB- resistance protein) of Arabidopsis thaliana and to the murine retinitis pigmentosa GTPase regulator- No informative BLAST resultsi No predictive prositei pfam or SCOP motife- The new protein can find application in studying the expression profile of testis-specific genes-

Homo sapiens chromosome 7q22 sequencei 0RF4ι extension differences to genmodel of 0RF4ι differential splicing

Sequenced by LMU

Locus: /map="?q22"

Insert length: 223b bp

Poly A stretch at pos- 2117ι polyadenylation signal at pos- 2160

1 ACAATGCTCA GATCGGGAGG TGGAGCCAAT CAGGTCCAAC CAAGAGGAGG

51 GGACACCGGC ACTCCACTAG CAGGAAAACG GGCCGAGGGA CCGCAAGCAG

101 GGGGTGCCTA GTCCTCGTCC CCCAAAGACC AATCGTAAGC CAGATACAGG 151 CGAGTGACTG TCAAGAAGGC CAATTAGAGC CTCCGAAGGG AATCTGGACC

201 TGCCTCTTCT CTGAGGGACG GCTCTACCTA CCAATAGCAT GGGCGAGAAG

251 GCGGTCCCTT TGCTAAGGAG GAGGCGGGTG AAGAGAA6CT GCCCTTCTTG

3D1 TGGCTCGGAG CTTGGGGTTG AAGAGAAGAG GGGGAAAGGA AATCCGATTT

351 CCATCCAGTT GTTCCCCCCA GAGCTGGTGG AGCATATCAT CTCATTCCTC 401 CCAGTCAGAG ACCTTGTTGC CCTCGGCCAG ACCTGCCGCT ACTTCCACGA

451 AGTGTGCGAT GGGGAAGGCG TGTGGAGACG CATCTGTCGC AGACTCAGTC

501 CGCGCCTCCA AGATCAGGGT TCTGGAGTCC GGCCCTGGAA GAGAGCTGCC

551 ATTCTGAACT ACACGAAGGG CCTGTATTTC CAGGCATTTG GAGGCCGCCG bOl CCGATGTCTC AGCAAGAGCG TGGCCCCCTT GCTAGCCCAC GGCTACCGCC b51 GCTTCTTGCC CACCAAGGAT CACGTCTTCA TTCTTGACTA CGTGGGGACC

7D1 CTCTTCTTCC TCAAAAATGC CCTGGTCTCC ACCCTCGGCC AGATGCAGTG

751 GAAGCGGGCC TGTCGCTATG TTGTGTTGTG TCGTGGAGCC AAGGATTTTG

801 CCTCGGACCC AAGGTGTGAC ACAGTTTACC GTAAATACCT CTACGTCTTG

851 GCCACTCGGG AGCCGCAGGA AGTGGTGGGT ACCACCAGCA GCCGGGCCTG 101 TGACTGTGTT GAGGTCTATC TGCAGTCTAG TGGGCAGCGG GTCTTCAAGA

151 TGACATTCCA CCACTCAATG ACCTTCAAGC AGATCGTGCT GGTTGGTCAG

10D1 GAGACCCAGC GGGCTCTACT GCTCCTCACA GAGGAAGGAA AGATCTACTC

1051 TTTGGTAGTG AATGAGACCC AGCTTGACCA GCCACGCTCC TACACGGTTC

11D1 AGCTGGCCCT GAGGAAGGTG TCCCACTACC TGCCTCACCT GCGCGTGGCC 1151 TGCATGACTT CCAACCAGAG CAGCACCCTC TACGTCACAG ACCAGGGGGG

12D1 AGTGTATTTT GAGGTGCATA CCCCAGGGGT GTATCGCGAT CTCTTTGGGA

1251 CCCTTCAAGC CTTTGACCCC CTGGACCAGC AGATGCCGCT TGCTCTCTCA

1301 CTGCCTGCCA AGATCCTATT CTGTGCTCTT GGCTACAACC ACCTTGGCCT 1351 GGTGGATGAA TTTGGCCGAA TCTTCATGCA AGGAAATAAC AGATACGGGC

14D1 AGCTAGGAAC AGGGGACAAA ATGGACCGAG GGGAACCCAC ACAGGTTTGT

1451 TACCTGCAGC GGCCCATCAC CCTGTGGTGC GGCCTCAACC ACTCCCTGGT

1501 GCTGAGCCAG AGCTCAGAGT TCAGCAAGGA GCTGCTGGGC TGCGGCTGTG

1551 GGGCIGGGGG CCGCCTCCCA GGCTGGCCCA AGGGGAGTGC CTCCTTCGTC

IbOl AAGCTCCAAG TCAAGGTCCC TCTGTGTGCC TGTGCCCTCT GTGCCACCAG lb51 GGAGTGCCTA TACATCCTGT CCAGCCACGA CATTGAGCAG CACGCCCCCT

1701 ATCGCCACCT GCCAGCCAGC AGGGTGGTGG GGACTCCTGA GCCCAGCCTG

1751 GGGGCCAGAG CACCCCAGGA CCCCGGGGGG ATGGCCCAGG CCTGCGAGGA

1601 GTACCTCAGC CAGATCCACA GTTGCCAAAC GTTGCAGGAC CGCACGGAGA

1851 AGATGAAGGA GATCGTAGGG TGGATGCCCC TGATGGCCGC ACAGAAGGAC

1101 TTCTTCTGGG AGGCCCTGGA CATGCTGCAG AGGGCTGAAG GAGGCGGGGG

1151 TGGTGTAGGG CCCCCAGCCC CTGAGACCTA ATCCCCCTCA TGCTAGCCTA

2001 GTCCCTGGAG GAGGGAGTCC GGCCCCAGGC CAGGGACTAA GGAGCAATGA

2051 CCATTGTGCA CATGCGTGTG GGAAGGGGTT GCTAGGGGGT GGGGACGGCT

2101 AACCAGGGTA AGAATGTTCA GGGGGCTGCC CAGGAGGGGC CCCCAACCTG

2151 ACTATCATGG ACAAGAGATT TGATGGATAG AATAAAAGGC TGCAGCGAAA

22D1 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAG

BLAST Results

Entry AFD5335b from database EMBL: Homo sapiens chromosome 7q22 sequence! complete sequence. Score = 2152ι P = O-De+OOi identities = bbb/721 ID exons

Medline entries

No Medline entry

Peptide information for frame 2

ORF from 231 bp to 1178 bpi peptide length: 580 Category: similarity to unknown protein Classification: no clue 1 MGEKAVPLLR RRRVKRSCPS CGSELGVEEK RGKGNPISIiQ LFPPELVEHI

51 ISFLPVRDLV ALGlQTCRYFH EVCDGEGVUR RICRRLSPRL (QDώGSGVRPU

101 KRAAILNYTK GLYFtQAFGGR RRCLSKSVAP LLAHGYRRFL PTKDHVFILD

151 YVGTLFFLKN ALVSTLG(QM(Q UKRACRYVVL CRGAKDFASD PRCDTVYRKY

2D1 LYVLATREPώ EVVGTTSSRA CDCVEVYLtQS SGiQRVFKMTF HHSMTFKlQIV 251 LVGOETlQRAL LLLTEEGKIY SL VNETiQLD (QPRSYTVlQLA LRKVSHYLPH

301 LRVACMTSNώ SSTLYVTDώG GVYFEVHTPG VYRDLFGTLlQ AFDPLD(Q(3MP

351 LALSLPAKIL FCALGYNHLG LVDEFGRIFM (QGNNRYGiQLG TGDKMDRGEP

401 TiQVCYLiQRPI TLUCGLNHSL VLSlQSSEFSK ELLGCGCGAG GRLPGUPKGS

451 ASFVKLώVKV PLCACALCAT RECLYILSSH DIEiQHAPYRH LPASRVVGTP 501 EPSLGARAPiQ DPGGMAώACE EYLSiQIHSCtQ TLiQDRTEKMK EIVGUMPLMA 551 AfiKDFFUEAL DMLiQRAEGGG GGVGPPAPET BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_22illι frame 2

TREMBL:AF05335b_ll product: "0RF4"i Homo sapiens chromosome 7q22 sequence! complete sequence-i N = li Score = 1554ι P = l-fae-151

TREMBL:AF130441_1 gene: "UVR8"i product: "UVB-resistance protein UVR8"i

Arabidopsis thaliana UVB-resistance protein UVR8 (UVRβ) mRNAi complete cds-i N = li Score = IDIi P = 0-D062

TREMBL:AF044b77_l gene: "Rpgr"i product: "retinitis pigmentosa GTPase regulator"i Mus musculus retinitis pigmentosa GTPase regulator (Rpgr) mRNAi complete cds-i N = li Score = 10bι P = 0-035

>TREMBL:AF05335b_ll product: "0RF4"i Homo sapiens chromosome 7q22 sequence! complete sequence- Length = 318

HSPs

Score = 1554 (233-2 bits)ι Expect = 1-be-lSlι P = l-be-151 Identities = 303/31S (15*)ι Positives = 303/316 (IS*)

(Query: 1 MGEKAVPLLRRRRVKRSCPSCGSELGVEEKRGKGNPISIiQLFPPELVEHIISFLPVRDLV bO

MGEKAVPLLRRRRVKRSCPSCGSELGVEEKRGKGNPISIώLFPPELVEHIISFLPVRDLV

Sbjct: 1

MGEKAVPLLRRRRVKRSCPSCGSELGVEEKRGKGNPISIiQLFPPELVEHIISFLPVRDLV bO βuery: bl

ALG(QTCRYFHEVCDGEGVURRICRRLSPRL(QD(QGSGVRPUKRAAILNYTKGLYF(QAFGGR 12D ALGlQTCRYFHEVCDGEGVURRICRRLSPRLiQDlQ

TKGLYFiQAFGGR Sbjct: bl ALGIQTCRYFHEVCDGEGVURRICRRLSPRLIQDIQD

TKGLYFiQAFGGR 10b

(Query: 121

RRCLSKSVAPLLAHGYRRFLPTKDHVFILDYVGTLFFLKNALVSTLG(QM(QUKRACRYVVL 180

RRCLSKSVAPLLAHGYRRFLPTKDHVFILDYVGTLFFLKNALVSTLG(QM(QUKRACRYVVL Sbjct: 107 RRCLSKSVAPLLAHGYRRFLPTKDHVFILDYVGTLFFLKNALVSTLG(QM(QUKRACRYVVL Ibb (Query: 181

CRGAKDFASDPRCDTVYRKYLYVLATREP(^QEVVGTTSSRACDCVEVYL(QSSG(QRVFKMTF 240

CRGAKDFASDPRCDTVYRKYLYVLATREP^(QEVVGTTSSRACDCVEVYL(^QSSG(QRVFKMTF Sbjct"- Ib7 CRGAKDFASDPRCDTVYRKYLYVLATREP(QEVVGTTSSRACDCVEVYL(QSSG(QRVFKMTF 22b

(Query: 241 HHSMTFKIQIVLVGIQETIQRALLLLTEEGKIYSLVVNETIQLDIQPRSYTVIQLALRKVSHYLPH 300

HHSMTFKiQIVLVGlQETlQRALLLLTEEGKIYSLVVNETlQLDlQPRSYTViQLALRKVSHYLPH Sbjct: 22? HHSMTFKlQIVLVGlQETlQRALLLLTEEGKIYSLVVNETiQLDiQPRSYTViQLALRKVSHYLPH 26b

(Query: 301 LRVACMTSNiQSSTLYVTD 318

LRVACMTSNtQSSTLYVTD Sbjct: 267 LRVACMTSNiQSSTLYVTD 304

Pedant information for DKFZphtes3_22illι frame 2

Report for DKFZphtes3_22ill- 2

[LENGTH! 560

[MU! b4881.41

[pi! 1-01 [HOMOL! TREMBL : AF0S335b_H product: "0RF4"i Homo sapiens chromosome 7q22 sequence! complete sequence- le-174

[BLOCKS! BLO0b25B Regulator of chromosome condensation (RCC1) proteins

[BLOCKS! BL00b25A Regulator of chromosome condensation (RCC1) proteins

[KU! Alpha_Beta

[KU! LOU COMPLEXITY 3-b2 *

SElQ MGEKAVPLLRRRRVKRSCPSCGSELGVEEKRGKGNPISIiQLFPPELVEHIISFLPVRDLV

SEG

PRD ccccchhhhhhhhhcccccccccccccccccccccceeeeccccchhhhhhheeeeeeee

SElQ ALGiQTCRYFHEVCDGEGVURRICRRLSPRLiQDlQGSGVRPUKRAAILNYTKGLYFiQAFGGR SEG

PRD ecccceeeeeeeecceeeeeeeeeecccccccccccccccccchhhhhhccceeeecccc

SElQ RRCLSKSVAPLLAHGYRRFLPTKDHVFILDYVGTLFFLKNALVSTLGlQMiQUKRACRYVVL

SEG PRD eeeeccchhhhhhhheeeeccccceeeeeeeeeeecccceeeeeeccchhhhhhhhheee

SElQ CRGAKDFASDPRCDTVYRKYLYVLATREPi^QEVVGTTSSRACDCVEVYLiQSSGlQRVFKMTF

SEG

PRD ecccccccccccceeeeeehhhhhhhhccceeeeeccccceeeeeeeeecccceeeeeec

SElQ HHSMTFKlQIVLVGlQETiQRALLLLTEEGKIYSLVVNETlQLDlQPRSYTViQLALRKVSHYLPH

SEG

PRD ccccceeeeeeeehhhhhhhhhhhhhcceeeeeeeccccccccceeeehhhhhhhhccce SElQ LRVACMTSNIQSSTLYVTDIQGGVYFEVHTPGVYRDLFGTLIQAFDPLDIQIQMPLALSLPAKIL

SEG

PRD eeeeeeccccccceeeecccceeeeeccccccccccceeeecccccccceeeeeccceee SElQ FCALGYNHLGLVDEFGRIFMiQGNNRYGlQLGTGDKMDRGEPTiQVCYLlQRPITLUCGLNHSL

SEG

PRD eeeeccccceeeeeceeeeeecccccccccccccccccccceeeeeccceeeecccccee SElQ VLSlQSSEFSKELLGCGCGAGGRLPGUPKGSASFVKLlQVKVPLCACALCATRECLYILSSH

SEG xxxxxxxxxxxxxx - - ■

PRD eeeeccccceeeeccccccccccccccccceeeeeeeeeeeeeeeeeeeecccceeeecc

SElQ DIE(QHAPYRHLPASRVVGTPEPSLGARAP(QDPGGMAιQACEEYLS(QIHSC(QTLtQDRTEKMK SEG

PRD cccccccccccccceeeecccccccccccccccchhhhhhhhhhhhhcchhhhhhhhhhh

SElQ EIVGUMPLMAAIQKDFFUEALDMLIQRAEGGGGGVGPPAPET

SEG xxxxxxx PRD hhhhcchhhhhhhhhhhhhhhhhhhhccccceeecccccc

(No Prosite data available for DKFZphtes3_22ill ■ 2) (No Pfam data available for DKFZphtes3_22ill - 2)

DKFZphtes3_22124

group: testis derived

DKFZphtes3_22124 encodes a novel 451 amino acid protein with similarity to the F-box protein FBL2 of the rat- No informative BLAST resultsi No predictive prositei pfam or SCOP motife-

The new protein can find application in studying the expression profile of testis-specif ic genes-

similarity to p37NB (Homo sapiens)

Sequenced by LMU

Locus". /map="7q22-q31-l"

Insert length: 1537 bp

Poly A stretch at pos- 1451ι no polyadenylation signal found

1 CAACAGGACG ATGCGACTCC TGCCGAGGCA CTTCCACAAC TTACAGAATC

51 TTAGTTTGGC TTATTGCAGA CGGTTCACAG ACAAAGGCTT ACAGTACCTG

101 AACTTGGGGA ATGGATGCCA CAAGCTCATC TATCTGGACC TCTCTGGCTG 151 CACCCAGATT TCAGTCCAAG GCTTCAGGTA CATTGCAAAC AGCTGCACTG

2D1 GAATTATGCA TCTTACCATT AATGACATGC CAACTCTGAC GGACAACTGT

251 GTAAAAGCTT TAGTTGAAAA ATGCTCTCGT ATTACATCGC TGGTTTTCAC

301 TGGTGCACCG CATATCTCCG ATTGTACTTT CAGAGCTCTT TCTGCTTGTA

351 AACTCAGAAA GATCCGATTT GAAGGAAATA AAAGGGTTAC TGATGCATCC 401 TTCAAATTTA TAGACAAGAA TTATCCAAAT CTCAGTCACA TTTATATGGC

451 TGACTGCAAG GGAATAACAG ACAGCAGCCT CAGATCCCTT TCACCTTTGA

501 AGCAACTGAC TGTGTTGAAT TTGGCAAATT GTGTAAGAAT TGGTGATATG

551 GGACTAAAGC AATTTCTTGA TGGTCCTGCA AGCATGAGGA TAAGAGAGCT bOl AAATTTAAGC AACTGTGTGC GGCTAAGTGA TGCCTTTGTT ATGAAACTAT bSl CTGAGCGCTG CCCTAATTTA AACTACTTGA GTTTACGAAA TTGTGAACAT

7D1 TTGACTGCCC AAGGAATTGG ATATATTGTA AACATCTTTT CCTTGGTATC

751 AATAGATCTC TCTGGAACAG ACATCTCTAA TGAGGGTTTG AATGTGCTTT

801 CCAGACATAA AAAATTGAAG GAACTTTCTG TATCTGAATG TTATAGAATC

851 ACTGATGAT6 GAATTCAGGC ATTCTGCAAA AGCTCACTGA TCTTGGAACA 101 TTTGGATGTC TCTTATTGCT CCCAGCTGTC AGATATGATT ATCAAAGCAC

151 TGGCCATTTA CTGCATTAAC CTCACATCTC TCAGCATTGC TGGCTGTCCA

1001 AAGATTACTG ACTCAGCAAT GGAGATGTTA TCGGCAAAAT GCCATTACCT

1051 GCACATTTTG GATATCTCTG GTTGTGTCTT GCTTACTGAC CAAATCCTTG

1101 AGGACCTTCA GATAGGCTGC AAACAACTCC GGATCCTTAA GATGCAATAC 1151 TGCACAAATA TTTCCAAGAA GGCAGCTCAA AGAATGTCAT CTAAAGTTCA

1201 GCAGCAGGAA TACAACACTA ATGACCCTCC ACGTTGGTTT GGCTATGATA

1251 GGGAAGGAAA CCCTGTTACA GAGCTTGACA ACATAACATC ATCTAAAGGA

13D1 GCCTTAGAAT TAACAGTGAA AAAGTCAACA TACAGCAGTG AAGACCAAGC

1351 AGCGTGACCT TCAGCCTCAA GCAGGAAGAA CAAAAAATCA AGAACTTGGC 1401 AAGTTTTCTC CATTTGTTGC AAGTATGTTT ACTAGCTGAA TCTCAATAAC

1451 AATGTAAACA AGCAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA

15D1 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAG BLAST Results

Entry AC00525D from database EMBL:

Homo sapiens BAC clone RG318M05 from 7q22-q31.1ι complete sequence.

Score = 630ι P = l-δe-124ι identities = 160/113 Entry HS321D7 from database EMBL: Human p37NB mRNAi complete eds- Score = 318ι P = 4.be-04ι identities = 70/78

Medline entries

1713bβ75: Kim i Laώuaglia MPi Yang SY- i A cDNA encoding a putative 37 kDa leeuucciinriee--rπicchπ rreeppeeaatt

(LRR) proteini p37NBι isolated from S-type neuroblastoma cell has a differential tissue distribution- Biochim Biojjphys Acta

111b Dec llil301(3):183-δ

Peptide information for frame 2

ORF from 11 bp to 1354 bpi peptide length: 446 Category: similarity to known protein Classification: unclassified

1 MRLLPRHFHN LώNLSLAYCR RFTDKGLiQYL NLGNGCHKLI YLDLSGCTiQI

51 SViQGFRYIAN SCTGIMHLTI NDMPTLTDNC VKALVEKCSR ITSLVFTGAP

101 HISDCTFRAL SACKLRKIRF EGNKRVTDAS FKFIDKNYPN LSHIYMADCK 151 GITDSSLRSL SPLKlQLTVLN LANCVRIGDM GLKlQFLDGPA SMRIRELNLS

201 NCVRLSDAFV MKLSERCPNL NYLSLRNCEH LTAlQGIGYIV NIFSLVSIDL

251 S6TDISNEGL NVLSRHKKLK ELSVSECYRI TDDGIiQAFCK SSLILEHLDV

301 SYCSiQLSDMI IKALAIYCIN LTSLSIAGCP KITDSAMEML SAKCHYLHIL

351 DISGCVLLTD (QILEDLiQIGC KlQLRILKMiQY CTNISKKAAlQ RMSSKVlQlQiQE 4D1 YNTNDPPRUF GYDREGNPVT ELDNITSSKG ALELTVKKST YSSEDlQAA

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_22124ι frame 2 No Alert BLASTP hits found

Pedant information for DKFZphtes3_22124ι frame 2 Report for DKFZphtes3_22154.2

[LENGTH! 451

[MU! 50545-15

[pi! δ-bβ

[HOMOL! TREMBLNEU:AF18b273_l product: "leucine-rich repeats containing F-box protein FBL3"i Homo sapiens leucine-rich repeats containing F-box protein FBL3 mRNAi complete eds- βe-31

[FUNCAT! 11- DI stress response CS- cerevisiaei YJRDIOc! 8e-20

[FUNCAT! 03-01 cell growth CS- cerevisiaei YJRO Oc! 8e-20

[FUNCAT! 08-11 cellular import CS- cerevisiaei YJROIOc! 8e-20

[FUNCAT! D3-22 cell cycle control and mitosis CS- cerevisiaei YJROIOc! δe-20

[FUNCAT! 03-04 buddingi cell polarity and filament formation [S- cerevisiaei YJROIOc! βe-2D

[FUNCAT! 01-05-04 regulation of carbohydrate utilization [S- cerevisiaei YJROIOc! βe-20 [FUNCAT! 11-04 dna repair (direct repairi base excision repair and nucleotide excision repair) [S- cerevisiaei YJR052w! 3e-07

[FUNCAT! 30-10 nuclear organization [S- cerevisiaei YJR052w!

3e-D7

[BLOCKS! PR00D11B [BLOCKS! PR003b4D

[BLOCKS! BP01121A

[BLOCKS! BP03743B

[PIRKU! tandem repeat 2e-lδ

[PIRKU! zinc finger le-07 [PIRKU! DNA binding le-07

[SUPFAM! leucine-rich alpha-2-glycoprotein repeat homology 2e-16

[SUPFAM! regulatory protein ESAG6c le-07 [KU! Alpha_Beta

SElQ NRTMRLLPRHFHNLiQNLSLAYCRRFTDKGLlQYLNLGNGCHKLIYLDLSGCTlQISVlQGFRY PRD ccccccccccccccccceeeeeecccccccceeeecccccceeecccccccccccccccc SElQ IANSCTGIMHLTINDMPTLTDNCVKALVEKCSRITSLVFTGAPHISDCTFRALSACKLRK PRD ccccccceeeeeccccccccchhhhhhhhhhhccccccccccccccccccccccccceee

SElQ IRFEGNKRVTDASFKFIDKNYPNLSHIYMADCKGITDSSLRSLSPLKlQLTVLNLANCVRI

PRD eeecccccccccccccccccccceeeeeeeccccccchhhhhhhhcccccccceeeeeec

SElQ GDMGLKIQFLDGPASMRIRELNLSNCVRLSDAFVMKLSERCPNLNYLSLRNCEHLTAIQGIG

PRD cccccccccccccccccceeeeccccccccccchhhhhhcccccccccccccccccccee

SElQ YIVNIFSLVSIDLSGTDISNEGLNVLSRHKKLKELSVSECYRITDDGIIQAFCKSSLILEH PRD eeccccceeeeeecccccccccchhhhhhcccccccccccccccchhhhhcccccccccc

SElQ LDVSYCSIQLSDMIIKALAIYCINLTSLSIAGCPKITDSAMEMLSAKCHYLHILDISGCVL

PRD cceeecccccchhhhhhhhccccceeeeeecccccchhhhhhhhhhccceeeeecccccc SElQ LTD(QILEDL(QIGCK(^QLRILKM(QYCTNISKKAA(QRMSSKVlQ(Q(QEYNTNDPPRUFGYDREGN

PRD chhhhhhhhhhcchhhhhhcceeeeechhhhhhhhhhhhheeeccccccccccccccccc

SElQ PVTELDNITSSKGALELTVKKSTYSSEDiQAA PRD ccccccccccccceeeeeccccccccccccc

(No Prosite data available for DKFZphtes3_22124 -2)

(No Pfam data available for DKFZphtes3_2212 - 2)

DKFZphtes3_2bg3

group: testis derived

DKFZphtes3_2fag3 encodes a novel 101D amino acid protein without similarity to known proteins- No informative BLAST resultsi No predictive prositei pfam or SCOP motife-

The new protein can find application in studying the expression profile of testis-specific genes-

similarity to C-elegans C01D4-4 on genomic level encoded by HSDJ116I1 perhaps complete eds-

Sequenced by EMBL

Locus: /map="b"

Insert length: 45b2 bp Poly A stretch at pos- 4550ι polyadenylation signal at pos- 4515

1 GATTCAGTTA CTGAAGACTT AGATGCACCC TGGATGGGAA TTCAGAATCT

51 TCAGAGATCA GAGTCCAGTA AAATGGATAA ATATGAGACT GAAGAAAGCT

IDl CTGTAGCAGG ACTTTCTAGC CCAGAGTTGA AAGTCAGACC TGCTGGTGCC

151 TCCAGTATTT GGTATACAGA AGGTGAAAAG CAGCTAACAA AATCTCTAAA

201 AGGAAAGAAT GAAGAATCAA ATAAATCCAA AGTTAAGGTT ACTAAGCTTA 251 TGAAAACAAT GAAATCTGAA AACACAAAAA AATTAATAAA ACAGAACTCT

3D1 AAGGATTCTG TGGTTTTGGT AGGCTACAAA TGTTTGAAAA GTACAGCATC

351 AAATGATCTC.ATTAAATGCT TTGAAGGCAA TCCTTCACAT AGTCAGAAGG

401 AAGGTCTGGA TCCCACAATA TGTGGATATA ATTTTGACCC AAAGACCTAC

451 ATGAGACAGA CAAGTCAAAA GGAAGCTAGC TGTTTGCCAA CTAATACAGA SD1 GAGAACTGAA CAAAAGTCTC CAGATATTGA AAATGTTCAA CCAGACCAGT

551 TTGATCCTTT GAACTCTGGC AACCTAAATC TTTGTGCAAA TTTGTCCATT bOl TCAGGTAAAC TTGATATCTC CCAGGAC6AT AGTGAAATTA CACAAATGGA b51 ACACAATCTG GCATCCAGAA GGTCATCAGA CGATTGCCAT GATCATCAAA

7D1 CAACCCCATC TTTGGGAGTT AGAACAATTG AAATAAAGCC CAGTAATAAA 751 GATCCTTTCA GTGGAGAGAA TATAACTGTC AAACTAGGAC CTTGGACAGA

601 GCTTCGACAA GAGGAAATAC TTGTGGATAA TTTACTACCC AACTTTGAGT

551 CCTTAGAATC TAATGGTAAA TCTAAATCTA TAGAAATAAC ATTTGAAAAG

101 GAAGCTTTGC AAGAAGCAAA GTGTCTTTCT ATTGGAGAAT CATTAACTAA

151 ATTACGAAGT AATCTACCTG CCCCTTCTAC AAAAGAATAT CATGTTGTAG 10D1 TAAGTGGAGA TACAATTAAG TTACCAGATA TTAGTGCCAC ATATGCCTCA

1051 TCTAGATTTT CAGATTCAGG TGTTGAAAGT GAACCGAGTT CTTTTGCGAC

1101 ACATCCAAAC ACTGATTTAG TCTTTGAAAC TGTGCAAGGG CAAGGTCCTT'

1151 GCAATAGTGA AAGATTATTT CCTCAGCTTT TGATGAAACC TGATTATAAT

12D1 GTAAAATTTT CATTAGGAAA TCATTGTACT GAGAGTACAA GTGCTATAAG 1251 TGAAATACAG TCATCTTTGA CATCCATAAA CTCTCTACCC TCCGATGATG

1301 AACTGTCACC TGATGAAAAT TCTAAGAAAT CTGTTGTACC TGAATGCCAT

1351 CTAAATGATA GCAAAACTGT ATTAAATCTA GGAACGACTG ATTTGCCAAA

14D1 ATGTGATGAT ACTAAAAAGT CAAGTATCAC TTTGCAACAG CAGAGTGTTG 1451 TATTTTCAGG GAACTTGGAC AATGAAACTG TAGCAATACA TTCCTTAAAT

1501 TCAAGCATTA AAGACCCTTT ACAATTTGTT TTTTCAGATG AAGAGACTTC

1551 CAGTGATGTG AAAAGTAGTT GCAGCTCCAA ACCTAACTTG GATACTATGT

IbOl GTAAAGGCTT CCAGAGTCCT GATAAATCTA ATAACTCTAC AGGGACAGCA IbSl ATTACATTAA ATTCAAAACT GATTTGTTTA GGCACTCCTT GTGTCATTTC

17D1 AGGTTCCATT TCTAGTAATA CAGATGTTAG TGAAGATAGA ACTATGAAAA

1751 AAAATAGTGA TGTATTAAAT CTCACACAGA TGTATTCAGA AATCCCTACA lδOl GTTGAAAGTG AAACTCATCT GGGTACAAGT GATCCTTTTT CAGCCAGTAC

1651 TGATATAGTA AAGCAAGGGC TTGTGGAAAA TTATTTTGGT TCTCAAAGCA 1101 GTACGGATAT TTCTGACACA TGTGCTGTTA GCTACAGCAA TGCACTTAGC

1151 CCTCAGAAGG AAACTTCTGA AAAAGAAATT AGTAATCTTC AGCAGGAACA

2D01 GGkJkkkGkG GATGAGGAGG kkGkGCkGGk TCAACAAATG GTTCAAAATG

2051 GGTACTATGA AGAAACAGAT TATTCAGCTT TGGATGGAAC AATAAATGCT

21D1 CACTATACAA GCAGAGATGA ACTAATGGAA GAAAGACTTA CAAAATCTGA 2151 AAAAATAAAC AGTGACTATC TGAGAGATGG TATAAACATG CCTACTGTCT

2201 GTACTTCTGG TTGTTTGTCC TTCCCGTCTG CACCACGAGA GTCTCCTTGT

2251 AATGTTAAAT ATTCTTCCAA AAGTAAATTT GATGCCATTA CAAAGCAGCC

23D1 AAGCAGTACT TCTTACAACT TCACTTCTTC GATTTCCTGG TATGAAAGTT

2351 CACCAAAACC TCAAATACAA GCCTTCCTTC AGGCAAAAGA AGAACTGAAG 2401 CTACTAAAAC TTCCTGGGTT CATGTACAGT GAAGTTCCTC TGCTGGCATC

2451 CTCAGTACCT TATTTTAGTG TAGAAGAAGA GGGTGGTTCT GAAGATGGAG

2501 TACATCTGAT TGTCTGTGTG CACGGTTTAG ATGGAAACAG TGCAGATCTC

2551 CGATTAGTAA AAACTTACAT TGAACTTGGA TTGCCTGGGG GAAGAATTGA

2b01 TTTTCTTATG TCTGAGAGAA ATCAGAATGA TACTTTTGCT GATTTTGATA 2b51 GCATGACTGA TCGTCTTTTG GATGAGATAA TACAGTATAT TCAGATATAT

27D1 AGTCTAACAG TCTCAAAAAT AAGCTTTATT GGACATTCGT TGGGCAATTT

2751 AATAATTCGT TCAGTGCTTA CAAGGCCAAG GTTTAAATAT TACCTCAACA

2601 AACTTCATAC CTTTCTGTCT CTTTCTGGAC CTCACCTTGG TACACTCTAC

2651 AACAGCAGTG CTCTTGTTAA TACAGGTCTC TGGTTTATGC AGAAATGGAA 2101 AAAATCAGGT TCGCTTTTGC AGCTGACATG TCGAGATCAC TCAGACCCTC

2151 GCCAAACTTT TTTATATAAG CTTAGTAACA AAGCAGGGCT TCATTATTTC

3001 AAAAATGTTG TGCTAGTGGG ATCCCTACAG GATCGCTATG TTCCTTATCA

3051 CTCTGCCCGC ATTGAAATGT GTAAAACAGC TTTAAAGGAC AAACAGTCAG

31D1 GACAGATCTA TTCAGAAATG ATCCACAACT TGCTTCGACC CGTTCTGCAA 3151 AGCAAGGACT GTAATTTGGT TCGCTATAAT GTCATCAATG CATTGCCCAA

3201 TACAGCTGAT TCACTCATTG GGAGAGCTGC ACATATAGCT GTTCTTGATT

3251 CGGAAATATT TTTAGAGAAA TTCTTTCTGG TTGCTGCCCT CAAATATTTC

3301 CAATAGTATA AAAGCATTGT TAGCGACTGG ACAATTACCT CATTCAACAA

3351 TGTTTCAAAT AATGTATTAT ATTAAAATGT AGATGCTGAT AAGTTCTAAG 34D1 AAATATTTAT ACCTTTTTAT ATGGAAGATA ATTTATATCA TCCATGTTTA

3451 GTGCTTTTTA AACATCAACT TTACTTTCTA GGTAATGTGG CTGTGCAATA

3501 TTTTTTTAAT TTTATCTTTT TACTTTTCTA TTACTTTTTC ATATATTTTG

3551 CTACCTAAGT ATTTCAGTGA AACTTTAAGC CCATACCTGT GTCTGATTGT

3b01 TTATTATTGG CTTTCCACAA TTCTTACATC AGACTACATT ATATTAGAGA 3b51 CCATTATTGC TAGAATAGCA TGGGATTTAA AATTTCTAAT ACTG6GGGTA

37D1 TTATTTAGTT AATTATAAAT TTTTCTTTTC ACATTTTACT GTGTTTTAAC

3751 TGGAAATAAA ATTATGGCTG CTACAATATA TTTTTTGAAA TCAACTTCTG

3601 TAGTTCTAAA ATACAACTTT ATCATACAAT CAAACCAGGT AGTTCATATA

3651 AAACAGTGTA ATACAAGTTT TCTATAAAGT CATTACTGTT GCTTAAACAT 3101 ATTTCATGCC TATTAAAATA TATTTTCTAC TGGTGATTTC AACATTATTT

3151 CTCATACTGA CTTTTATTAC TGGAAATGTT CCTGTACATG TTGGCAGCAG

4001 ATAAAGATTT TTGAATGTTT GAATGCCCTC TGCCTTGATT TGGTTGGATT

4051 TTGCTAATTG GTATGTTGCT TGAACTTTAT GACTACATTT TCTTTTAACT

4101 TTTTTCATGG ACTTCCTTAT ATGTACATAA TAATTAAATG TTGAAATTTA 4151 TGAAATACTT TTATGAATTT AGATAATTTT TAAATATTGT TAAAATTTAT

4201 TGAACTAAAA AGTAATGTAA ATAAAATAAT TCATGTTAAA GATGGAACAA

4251 AATAATTAAC TTTACATGTT TGGTGATACA GATGCAAATG TTTTTGATAT

4301 ATGGAGATGT TGAGTCTTTT GACTTTACTA AAGGTGCTGA ATAGCATTAA 4351 ATTCACTATT TTCCTTTTCT GTTTTACTTG TGAAAATAAA AATGCACTAA

4401 GGTTGGGTAG AAGTTCTGTT TGCACTCACT AATTGTGACA GACAGAGGTT

4451 TTTGTAAGTA TTTATTGTAC AATTGATGCA TGTT-TATTTT TAGCGTTGTT

4501 ATTGCCTCTG GTGTTAATAA ATGAACAAAT GGCTATCTGG AGGAACAGCT

4551 AAAAAAAAAA AA

BLAST Results

Entry HSDJ116I1 from database EMBLNEU:

Human DNA sequence *** SEQUENCING IN PROGRESS *** from clone

DJllδll

Score = 7221ι P = D-Oe+ODi identities = 1455/14bl

Medline entries

No Medline entry

Peptide information for frame 1

ORF from 34 bp to 3303 bpi peptide length: 1010 Category: similarity to unknown protein Classification: no clue

1 MGIiQNLlQRSE SSKMDKYETE ESSVAGLSSP ELKVRPAGAS SIUYTEGEKiQ

51 LTKSLKGKNE ESNKSKVKVT KLMKTMKSEN TKKLIKiQNSK DSVVLVGYKC

101 LKSTASNDLI KCFEGNPSHS (QKEGLDPTIC GYNFDPKTYM RiQTSiQKEASC 151 LPTNTERTEiQ KSPDIENVlQP DiQFDPLNSGN LNLCANLSIS GKLDISiQDDS

201 EITiQMEHNLA SRRSSDDCHD HlQTTPSLGVR TIEIKPSNKD PFSGENITVK

251 LGPUTELRlQE EILVDNLLPN FESLESNGKS KSIEITFEKE ALiQEAKCLSI

301 GESLTKLRSN LPAPSTKEYH VVVSGDTIKL PDISATYASS RFSDSGVESE

351 PSSFATHPNT DLVFETVlQGiQ GPCNSERLFP (QLLMKPDYNV KFSLGNHCTE 401 STSAISEIiQS SLTSINSLPS DDELSPDENS KKSVVPECHL NDSKTVLNLG

451 TTDLPKCDDT KKSSITLlQlQlQ SVVFSGNLDN ETVAIHSLNS SIKDPLiQFVF

5D1 SDEETSSDVK SSCSSKPNLD TMCKGFiQSPD KSNNSTGTAI TLNSKLICLG

551 TPCVISGSIS SNTDVSEDRT MKKNSDVLNL TlQMYSEIPTV ESETHLGTSD faOl PFSASTDIVK (QGLVENYFGS (QSSTDISDTC AVSYSNALSP (QKETSEKEIS b51 NLlQiQElQDKED EEEEIQDIQIQMV (QNGYYEETDY SALDGTINAH YTSRDELMEE

701 RLTKSEKINS DYLRDGINMP TVCTSGCLSF PSAPRESPCN VKYSSKSKFD

751 AITKiQPSSTS YNFTSSISUY ESSPKPlQIiQA FLlQAKEELKL LKLPGFMYSE

601 VPLLASSVPY FSVEEEGGSE DGVHLIVCVH GLDGNSADLR LVKTYIELGL

651 PGGRIDFLMS ERNiQNDTFAD FDSMTDRLLD EIIiQYIiQIYS LTVSKISFIG IDl HSLGNLIIRS VLTRPRFKYY LNKLHTFLSL SGPHLGTLYN SSALVNTGLU

151 FMiQKUKKSGS LLiQLTCRDHS DPRiQTFLYKL SNKAGLHYFK NVVLVGSLώD

10D1 RYVPYHSARI EMCKTALKDK (QSGiQIYSEMI HNLLRPVLiQS KDCNLVRYNV

1051 INALPNTADS LIGRAAHIAV LDSEIFLEKF FLVAALKYFiQ

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_2bg3ι frame 1 No Alert BLASTP hits found

Pedant information for DKFZphtes3_2bg3ι frame 1

Report for DKFZphtes3_2bg3- 1

[LENGTH! 1101

[MU! 122245-22 [pi! 5-12

[H0M0L! TREMBL:CEAF211b_l gene: "C01D4-4"i Caenorhabditis elegans cosmid C01D4- 2e-3δ

[FUNCAT! 11 unclassified proteins [S- cerevisiaei Y0R051c!

2e-0b [BLOCKS! BL0D120B

[KU! Alpha_Beta

[KU! LOU COMPLEXITY b-72 *

SElQ DSVTEDLDAPUMGIlQNLiQRSESSKMDKYETEESSVAGLSSPELKVRPAGASSIUYTEGEK

SEG

PRD ccccccccccceeeeechhhhhhhhhhccccccccccccccceeeeccccceeeccccch

SElQ iQLTKSLKGKNEESNKSKVKVTKLMKTMKSENTKKLIKiQNSKDSVVLVGYKCLKSTASNDL SEG xxxxxxxxxxxxxxx

PRD hhhhhhccccccccceeeehhhhhhhhhcccccceeecccccceeeeeeeeccccccccc

SElQ IKCFEGNPSHSiQKEGLDPTICGYNFDPKTYMRlQTSiQKEASCLPTNTERTEiQKSPDIENViQ

SEG PRD eeeecccccccccccccccccccccccccccccccccccccccccccccccccccccccc

SElQ PDIQFDPLNSGNLNLCANLSISGKLDISIQDDSEITIQMEHNLASRRSSDDCHDHIQTTPSLGV

SEG

PRD ccccccccccceeecccccccccccccccccccchhhhhhhcccccccccccccccccee

SElQ RTIEIKPSNKDPFSGENITVKLGPUTELRiQEEILVDNLLPNFESLESNGKSKSIEITFEK

SEG

PRD eeeeecccccccccccceeeccccchhhhhhhhhhhccccccccccccccceeeehhhhh SElQ EALlQEAKCLSIGESLTKLRSNLPAPSTKEYHVVVSGDTIKLPDISATYASSRFSDSGVES

SEG

PRD hhhhhhhhhhhhhhhhhhhhccccccccceeeeecccccccccccccccccccccccccc

SElQ EPSSFATHPNTDLVFETVlQGlQGPCNSERLFPiQLLMKPDYNVKFSLGNHCTESTSAISEIlQ SEG

PRD ccccccccccceeeeeeeccccccccccccccccccccceeeeecccccccccchhhhhh

SElQ SSLTSINSLPSDDELSPDENSKKSVVPECHLNDSKTVLNLGTTDLPKCDDTKKSSITLiQiQ

SEG PRD cccccccccccccccccccccccccccccccccccceeecccccccccccccccceeecc

SElQ (QSVVFSGNLDNETVAIHSLNSSIKDPLi^QFVFSDEETSSDVKSSCSSKPNLDTMCKGFlQSP

SEG xxxxxxxxxx PRD eeeeeecccccceeeeeeeccccccceeeeeccccccceeeccccccccccccccccccc

SElQ DKSNNSTGTAITLNSKLICLGTPCVISGSISSNTDVSEDRTMKKNSDVLNLTώMYSEIPT

SEG

PRD cccccccccccccceeeeeeeccceeeeecccccccccccccccccchhhhhhheeeeec

SElQ VESETHLGTSDPFSASTDIVKώGLVENYFGSiQSSTDISDTCAVSYSNALSPlQKETSEKEI

SEG

PRD cccccccccccccccceeeeeeeeeeeecccccccccceeeeeecccccccccccccccc

SE(2 SNLlQlQEiQDKEDEEEElQDiQlQMViQNGYYEETDYSALDGTINAHYTSRDELMEERLTKSEKIN

SEG ■ ■ - xxxxxxxxxxxxxxxx

PRD cchhhhhcccchhhhhhhhhhcccccccccccccccceeeeccchhhhhhhhhhhhhccc SElQ SDYLRDGINMPTVCTSGCLSFPSAPRESPCNVKYSSKSKFDAITKiQPSSTSYNFTSSISU

SEG xxxxxxxxxxxx.

PRD ccccccccccccccccceeecccccccccceeeecccccceeeeeccccccceeecceee

SElQ YESSPKPlQIiQAFLiQAKEELKLLKLPGFMYSEVPLLASSVPYFSVEEEGGSEDGVHLIVCV SEG xxxxxxxxx xxxxxxxxxxxx

PRD ccccccccchhhhhhhhhhhhhccccceeeeeeeeeecccceeeeeccccccceeeeeee

SElQ HGLDGNSADLRLVKTYIELGLPGGRIDFLMSERNiQNDTFADFDSMTDRLLDEIIlQYIiQIY

SEG PRD eccccccchhhhhhhhhhhccccccchhhhhccccccccccccchhhhhhhhhhhhhhhh

SElQ SLTVSKISFIGHSLGNLIIRSVLTRPRFKYYLNKLHTFLSLSGPHLGTLYNSSALVNTGL

SEG

PRD hccccccccccccceeeeeeeeccccchhhhhhhhhhccccccccceeeeccccccccch

SElQ UFMiQKUKKSGSLLlQLTCRDHSDPRlQTFLYKLSNKAGLHYFKNVVLVGSLiQDRYVPYHSAR

SEG

PRD hhhhhhhhhheeeeeecccccccceeeeeeccccceeeeeeeeeeeccccccceeehhhh SElQ IEMCKTALKDKlQSGiQIYSEMIHNLLRPVLlQSKDCNLVRYNVINALPNTADSLIGRAAHIA

SEG

PRD hhhhhhhccccccchhhhhhhhhhhccccccccceeeeeeecccccccccchhhhhhhhh

SElQ VLDSEIFLEKFFLVAALKYFiQ SEG

PRD hhhhhhhhhhhhhhhhhhccc

(No Prosite data available for DKFZphtes3_2bg3.1) (No Pfam data available for DKFZphtes3_2bg3-l) DKFZphtes3_21f24

group: signal transduction

DKFZphtes3_21f24 encodes a novel 52b amino acid protein with similarity to murine netla- The closely related mNETl activates signalling pathways in addition to those directly controlled by activated RhoA- The novel protein is expressed ubiquitously-

The new protein can find application in modulation/blocking signalling pathways-

similarity to netla (Mus musculus) perhaps complete eds- Sequenced by BMFZ Locus: /map="72-4D cR from top of Chr3 linkage group'

Insert length: 3551 bp

Poly A stretch at pos- 3534ι polyadenylation signal at pos- 3513

1 CGCCGCCGCC CGGCATCGTG GAGCTGGGGC CCCCTTTTGC CTGGGAGTTT

51 TGTAGTCGCC TAGGGTCAGC GGTGACATCC CAAAGGGCAG GCCCGGCAGC

101 CGCCATGGTG GCCAAGGATT ACCCCTTCTA CCTCACGGTC AAGAGAGCGA

151 ACTGCAGCCT GGAGCTACCC CCGGCCAGCG GTCCGGCCAA GGACGCTGAG

201 GAGCCTAGTA ATAAACGGGT CAAACCCCTT TCCCGAGTCA CGTCGCTAGC 251 AAACCTCATC CCGCCCGTGA AGGCCACGCC ATTAAAGCGC TTCAGTCAAA

301 CCCTGCAGCG CTCCATTAGC TTCCGCAGTG AGAGCCGCCC TGACATCCTC

351 GCCCCCCGAC CCTGGTCCAG AAATGCCGCC CCCTCGAGCA CGAAACGGAG

4D1 AGATAGCAAG CTGTGGAGTG AGACCTTCGA TGTGTGCGTC AATCAGATGC

451 TTACATCCAA GGAAATCAAA CGTCAGGAGG CGATCTTTGA GCTTTCCCAA 501 GGAGAAGAAG ACTTGATAGA AGACTTGAAA TTAGCAAAAA AGGCCTATCA

551 TGACCCCATG CTGAAACTCT CCATAATGAC AGAACAAGAG TTGAATCAAA bOl TTTTTGGAAC ACTGGACTCT CTAATTCCTC TACATGAAGA GCTCCTTAGT bSl CAGCTTCGAG ATGTTAGGAA GCCTGATGGC TCGACTGAAC ATGTTGGTCC

701 CATCCTCGTG GGCTGGCTCC CTTGCCTCAG CTCCTATGAT AGCTACTGCA 751 GCAATCAAGT AGCCGCCAAA GCTCTGCTGG ACCACAAAAA GCAAGATCAC

601 CGAGTCCAGG ATTTCCTACA GCGATGTTTA GAATCCCCCT TTAGCCGCAA

651 ACTAGATCTC TGGAATTTCC TCGATATTCC AAGAAGCCGC CTGGTAAAAT

101 ACCCTCTGCT TCTCCGAGAA ATCTTGAGGC ACACACCAAA TGATAATCCA

151 GATCAGCAGC ACTTGGAAGA AGCTATAAAT ATCATTCAGG GAATTGTGGC 10D1 AGAAATCAAC ACCAAGACTG GTGAATCTGA ATGCCGCTAT TATAAAGAGC

1051 GGCTTCTTTA CTTGGAAGAA GGCCAGAAAG ACTCCCTGAT CGACAGCTCT

1101 CGAGTCTTGT GTTGTCATGG TGAACTGAAG AACAATCGGG GCGTGAAACT

1151 GCATGTTTTC CTGTTCCAAG AAGTGCTTGT GATCACTCGA GCCGTCACCC

12D1 ACAATGAGCA GCTTTGCTAC CAGCTGTACC GTCAGCCAAT CCCCGTGAAA 1251 GACCTCCTGC TGGAAGACCT CCAGGATGGA GAAGTGAGGC TGGGTGGCTC

1301 CCTGCGAGGG GCATTCAGCA ACAATGAGAG AATTAAAAAC TTCTTCAGAG

1351 TCAGTTTCAA AAATGGATCC CAAAGTCAGA CCCACTCGCT ACAAGCCAAT

14D1 GACACTTTCA ACAAACAGCA GTGGCTTAAC TGTATTCGTC AAGCCAAAGA 1451 AACAGTTTTG TGTGCTGCCG GGCAAGCTGG GGTGCTTGAC TCCGAGGGAT

1501 CGTTCCTAAA TCCCACCACC GGGkGCkGkG AGCTACAGGG AGAAACAAAA

1551 CTTGAGCAGA TGGACCAATC GGACAGTGAG TCAGACTGTA GTATGGACAC

IbOl GAGTGAGGTC AGCCTCGACT GTGAGCGCAT GGAACAGACA GACTCTTCCT lb51 GTGGAAACAG CAGGCACGGT GAAAGTAACG TCTGACAGAA GCATGTGCAC

17D1 TTCGGGAAGC AGGCCTGCAT CTTACCTGTA CAGTATTTGC ATTCCACAGA

1751 TGGAACGGTT TGGAGAAGCA CTTTTTCATA CTTTTGTGAA AGTATACATG

1601 TTGGCCCAGT CTCTCGTATC TGTACCTTTG TCCCTAGTAC TGTAACTGCC

1651 AATCTGTCTG TGTAAGCTGG AATCTGTGGC AACTATTACC CTGTGTTGTA

1101 TTTCCCAAGT GTCTGGATGG ATGGAGAGGT ACTCAAACAA GTTACTTTCA

1151 GTTGTCCTGC TGGATTTTAA AAAAATAGAA AAAGAATCTC AAAACTACTG

20D1 TTTTACATAG ATTGTTTGAA GAGTCCTTCC TCTTGTGCTT CTGTACCACT

2051 TTCCCAGCTC TTAGATGTGG TAGCTAAAGG CACGGAATTT AGACGGCCTT

2101 GTAAATAGGG CATGAGGAAC TCATCTGTGT ATTGGGATGG TATTAGAGAG

2151 AGAATCAGGA AAGACCAACT CATGAAGTGA ACTTGGTTTG ATCTTACTCA

2201 ACTAGAAAGC TTGAAAACAT CCCTGGGGAT TCTGAAGGCT TAATTTTGCA

2251 AAGGAGGATG CATTGTCTGA ACTTTGCAAC TTCATCCAGT GCAAGTTTGA

23D1 TGCAAGAATG TATTAGGACA TAAAATAGAG GCTGACCTTA AAAGGGCCAG

2351 GACAGAAGCG GCTGCCAGCT CTGAATCTTT AACTGAAATG CACATGGCAC

2401 CAGGAGGTGT CTCTCATAGT TGGTTGCTAG CCTAAAACAT CAGAATAGAA

2451 CCCAAAGGGC TTAGGAAGGC CTGCCAGGAT AACAAGAAGG CCCTGTATTC

25D1 ATTGTGTTTC ATCTGCCTAG GCCTACTCAT TATTTTAGAG AATGAATGAA

2551 GCAACAAGGA AGAGAGACCA TGACTCTATC GATGACACTG TTTATAGAAA

2b01 CACAGGAGAG GAAGAATTTG GAATGAAAAG CACTTCGTCA GAACCTTCTG

2b51 TGGGAGCCAT TGAGAGAAAA GCATGGTCCA GTGCCTTCTG AGAAAGGCCA

27D1 GAGCTTTGGG CTTTCCTGCT CTGCTTTTGG GTCGTCAATT GCCATCTCT

2751 GGTTCTGTGC TATAATCAGA ATTGTAATTA TGTTCTCCAG AGGCCAATTT

26D1 CATTAACTCT GATTAATTAG AATCAGCTAG CCAGATTAGT AACCTCTTTG

2651 TCCAGCCTTG ATTTACAGTG CAGGGTAAAG TGCAGACCTT AAAAACAGCT

21D1 AAGTACCTAG AAGAGCTCCC TGCAAGTGTA AATATTAAGG ATGACCTGTG

2151 CAAAATTATA CCCACACCAG CACTAGTGGT AATTATTCTA AATTATTGCC

30D1 AAAAAGTTTT TTTTAATCTG TCTTTCAAGT TTACAGAAAA GAAAGCAGTA

3051 AATGCATTGA TGTCATTTTA TTATGTACAT ATATCATGTG CATTCAAGCT

3101 GTGTGACAAG ATATATCAAT ATAAAAACAA GGTATATACT TTATTATTTT

3151 TTGAAAACAA GGATATTGTG ATCAATTTTA CCCTGTAAAA CATATTTCTG

3201 TATTTATAGG TCTTAAACAT GATGAATTTT TTCTATTACA AGTTTATTTA

3251 AAACTGCTTT CTCAAGTCGT TATTGATACA GCAAGTGAAC CTGCTGCAGA

3301 CAGAAGCAGA GGAAAGCCAA GAACAGCCTT TATTGGTGAA GAAAAGAATG

3351 AATGATTCTT TGTAGGCGCC ATCAGCCACT TTTAGAAGCC ATCAGCCAGT

3401 GTGTTGGGAA AAGAGGTTTG TCAAGTGTTG GCCTATGGGA AGGTGGTCAA

3451 TGAATGTTTT GATGAAATGA ATGTTTTTGT ATAATGGCCT TAAACTTTTC

35D1 TGGAAGTATT TCAAATAAAT TACATTATTA AGTCAAAAAA AAAAAAAAAA

3551 AAAAAAAAA

BLAST Results

No BLAST result

Medline entries

1633bl1fa:

Alberts ASi Treisman R-i Activation of RhoA and SAPK/JNK signalling pathways by the RhoA-specif ic exchange factor mNETl- EMBO J 1116 Jul 15il7(14):4075-85

Peptide information for frame 3

ORF from 105 bp to lbδ2 bpi peptide length: 52b

Category: strong similarity to known protein Classification: Cell signaling/communication

1 MVAKDYPFYL TVKRANCSLE LPPASGPAKD AEEPSNKRVK PLSRVTSLAN 51 LIPPVKATPL KRFSιQTL(QRS ISFRSESRPD ILAPRPUSRN AAPSSTKRRD

101 SKLUSETFDV CVNiQMLTSKE IKRlQEAIFEL SlQGEEDLIED LKLAKKAYHD

151 PMLKLSIMTE IQELNIQIFGTL DSLIPLHEEL LSlQLRDVRKP DGSTEHVGPI

201 LVGULPCLSS YDSYCSNiQVA AKALLDHKKώ DHRVlQDFLlQR CLESPFSRKL

251 DLUNFLDIPR SRLVKYPLLL REILRHTPND NPDiQiQHLEEA INIIiQGIVAE 3D1 INTKTGESEC RYYKERLLYL EEGiQKDSLID SSRVLCCHGE LKNNRGVKLH

351 VFLFiQEVLVI TRAVTHNEiQL CYiQLYRlQPIP VKDLLLEDLlQ DGEVRLGGSL

401 RGAFSNNERI KNFFRVSFKN GSIQSIQTHSLIQ ANDTFNKlQiQU LNCIRiQAKET

451 VLCAAGlQAGV LDSEGSFLNP TTGSRELlQGE TKLElQMDlQSD SESDCSMDTS

5D1 EVSLDCERME (QTDSSCGNSR HGESNV

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_21f24 i frame 3 No Alert BLASTP hits found

Pedant information for DKFZphtes3_21f24ι frame 3

Report for DKFZphtes3_21f24 - 3

[LENGTH! 5b0

[MU! b32D2-65

[pi! fa.04 [HOMOL! TREMBL : AFD14520_1 gene: "Netl"i product: "NET1 homolog"i Mus musculus NET1 homolog (Netl) mRNAi complete eds- le-lb2

[FUNCAT! 01-01 biogenesis of cell wall [S- cerevisiaei

YLR371w! 3e-lb [FUNCAT! 03-D7 pheromone responsei mating-type determination! sex-specific proteins [S- cerevisiaei YLR371w! 3e-lb

[FUNCAT! 10-02-01 regulation of g-protein activity CS. cerevisiaei YLR371w! 3e-lfa

[FUNCAT! 01- 04 biogenesis of cytoskeleton [S- cerevisiaei YLR371w! 3e-lb

[FUNCAT! D3-D4 buddingi cell polarity and filament formation CS- cerevisiaei YLR371w! 3e-lb [FUNCAT! 01-05.04 regulation of carbohydrate utilization [S- cerevisiaei YLR371w! 3e-lfa

[FUNCAT! 3D-D3 organization of cytoplasm [S. cerevisiaei

YALD41w! 3e-ll [FUNCAT! 03-22 cell cycle control and mitosis [S- cerevisiaei

YAL041w! 3e-ll

[FUNCAT! 1D-05.01 regulation of g-protein activity [S- cerevisiaei YALD41w! 3e-ll

[BLOCKS! PR0051DE [BLOCKS! PR0D041E

[BLOCKS! BL00741B

[PIRKU! breakpoint cluster region le-Ob

[PIRKU! transmembrane protein 5e-13

[PIRKU! brain 3e-0b [PIRKU! signal transduction 5e-13

[PIRKU! alternative splicing le-Db

[SUPFAM! CDC24 homology le-15

[SUPFAM! SH2 homology le-11

[SUPFAM! CDC25-type guanine nucleotide exchange activator homology 2e-0δ

[SUPFAM! dbl transforming protein le-06

[SUPFAM! protein kinase C zinc-binding repeat homology le-11

[SUPFAM! SH3 homology le-11

[SUPFAM! bcr protein le-Db [SUPFAM! pleckstrin repeat homology 2e-ll

[SUPFAM! vav transforming protein le-11

[KU! All_Alpha

SElQ PPPGIVELGPPFAUEFCSRLGSAVTSlQRAGPAAAMVAKDYPFYLTVKRANCSLELPPASG

PRD cccceeeeccccccchhhhhhhhhhhhhcccccccccccccceeeecccccccccccccc

SElQ PAKDAEEPSNKRVKPLSRVTSLANLIPPVKATPLKRFSiQTLiQRSISFRSESRPDILAPRP

PRD cccccccccccccccccccccccccccccccccccchhhhhhcccccccccccccccccc

SElQ USRNAAPSSTKRRDSKLUSETFDVCVNlQMLTSKEIKRiQEAIFELSiQGEEDLIEDLKLAKK

PRD cccccccccchhhhhhhhhhhcccccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh

SElQ AYHDPMLKLSIMTEiQELNiQIFGTLDSLIPLHEELLSlQLRDVRKPDGSTEHVGPILVGULP

PRD hhhchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhccccccccccceeeeeccc

SElQ CLSSYDSYCSNiQVAAKALLDHKKlQDHRVlQDFLiQRCLESPFSRKLDLUNFLDIPRSRLVKY

PRD cccceeecccchhhhhhhhhhhhcchhhhhhhhhhhcccccccccccceeeccccccchh

SElQ PLLLREILRHTPNDNPDiQlQHLEEAINIIiQGIVAEINTKTGESECRYYKERLLYLEEGiQKD

PRD hhhhhhhhhhccccccchhhhhhhhhhhhhhhhhhhhcccchhhhhhhhhhhhhhhcccc SElQ SLIDSSRVLCCHGELKNNRGVKLHVFLFIQEVLVITRAVTHNEIQLCYIQLYRIQPIPVKDLLL

PRD hhhhhhheeecccccccccccceeeeehhhhhhhhhhhchhhhhhhhhhhhccccccccc

SElQ EDLιQDGEVRLGGSLRGAFSNNERIKNFFRVSFKNGS<QS(QTHSL(QANDTFNKιQ(QULNCIR(Q

PRD ccccccccccccccchhhhhhhhhhhhheeeeccccchhhhhhhhcccchhhhhhhhhhh

SElQ AKETVLCAAGIQAGVLDSEGSFLNPTTGSRELIQGETKLEIQMDIQSDSESDCSMDTSEVSLDC

PRD hhhhhhhhhccceeeeccccccccccccchhhhhhhhhhhhhhccccccccccccccccc

SElQ ERMEiQTDSSCGNSRHGESNV

PRD cccccccccccccccccccc (No Prosite data available for DKFZphtes3_21f24 -3) (No Pfam data available for DKFZphtes3_21f2 ■ 3)

DKFZphtes3_3Dpb

group: testis derived

DKFZphtes3_3Dpfa encodes a novel 4bl amino acid protein without similarity to known proteins- No informative BLAST resultsi No predictive prositei pfam or SCOP motife ■

The new protein can find application in studying the expression profile of testis-specific genes-

similarity to C-elegans F41H1D-4 perhaps complete eds-

Sequenced by LMU

Locus: unknown

Insert length: 1144 bp

Poly A stretch at pos- lllli no polyadenylation signal found

1 GGAACAGACC ACTGGGCTGG CAGCTGAGTT GCAGCAGCAG CAGGCTGAGT 51 ACGAGGACCT TATGGGACAG AAAGATGACC TCAACTCCCA GCTCCAGGAG

101 TCATTACGGG CCAATAGTCG ACTGCTGGAA CAACTTCAAG AAATAGGGCA

151 GGAGAAGGAG CAGTTGACCC AGGAATTACA GGAGGCTCGG AAGAGTGCGG

2D1 AGAAGCGGAA GGCCATGCTG GATGAGCTAG CAATGGAAAC GCTGCAAGAG

251 AAGTCCCAGC ACAAGGAAGA GCTGGGAGCA GTTCGTCTAC GGCATGAGAA 301 GGAGGTGCTG GGGGTGCGTG CCCGCTATGA GCGTGAGCTC CGAGAGCTGC

351 ATGAAGACAA GAAGCGTCAG GAGGAGGAGC TCCGTGGGCA GATCCGGGAG

4D1 GAGAAGGCCC GGACACGGGA GCTGGAGACT CTCCAGCAGA CAGTGGAAGA

451 ACTTCAAGCT CAGGTACATT CCATGGATGG AGCCAAGGGC TGGTTTGAAC

501 GGCGCTTGAA GGAAGCCGAG GAATCCCTGC AGCAGCAGCA GCAGGAACAA 551 GAGGAAGCCC TCAAGCAGTG TCGGGAGCAG CACGCTGCCG AGCTGAAGGG bOl CAAGGAGGAG GAGCTACAGG ATGTACGGGA TCAGCTCGAG CAGGCCCAGG fa51 AGGAGCGGGA CTGCCACCTG AAGACCATTA GCAGCCTGAA GCAGGAGGTG

701 AAGGACACAG TGGATGGGCA GAGGATCCTG GAGAAGAAGG GCAGTGCTGC

751 GCTCAAGGAC CTCAAGCGGC AGCTGCATTT GGAGCGGAAA CGGGCAGATA 601 AGCTGCAGGA GCGACTGCAG GACATCCTCA CTAACAGCAA GAGCCGCTCA

651 GGCCTTGAGG AGCTGGTTCT CTCAGAGATG AACTCACCAA GCCGGACCCA

101 GACAGGGGAC AGCAGTAGCA TCTCCTCCTT CAGCTACCGG GAGATCTTGC

151 GGGkkkkGGk GAGCTCGGCT GTTCCAGCCA GGTCCTTATC CAGCAGCCCT

1001 CAAGCCCAGC CCCCTCGGCC AGCAGAGCTG TCAGATGAGG AAGTGGCTGA 1051 GCTCTTTCAG CGGCTGGCAG AGACACAGCA GGAGAAATGG ATGCTGGAGG

1101 AGAAGGTGAA GCACCTGGAA GTGAGCAGTG CTTCCATGGC AGAGGACCTC

1151 TGCCGGAAGA GCGCCATCAT TGAGACCTAC GTCATGGACA GCCGGATCGA

1201 TGTGTCTGTG GCAGCAGGCC ACACAGACCG CAGCGGGCTG GGCAGCGTCC

1251 TGAGAGACCT AGTGAAGCCA GGCGACGAGA ACCTTCGGGA GATGAACAAG 1301 AAGCTGCAGA ACATGCTGGA GGAGCAGCTC ACCAAGAATA TGCACTTGCA

1351 CAAGGATATG GAAGTTCTGT CCCAGGAAAT TGTGCGGCTC AGCAAGGAGT

14D1 GCGTGGGGCC TCCTGACCCA GACCTAGAGC CAGGAGAAAC CAGCTAAAGA

1451 CCTGCAGGCT GCACCCACCT CCTCCCCTTC CTACCCCCTA GGATGCTATT 1501 CCCTTGGGCT GTGGTGGAAA AATGAGGGCT GGAGCCAAAA TCAAATAGCT

1551 TGGGAGACTG GACATTAAAG GGGCTAGAGG CCTGATGGTT AGTGTTAATG

IfaOl ATCCTGTCTT AGGGCAGAGG CCACCAGGGA GTGGGGATCC TGAGGGAAGG

^•IfaSl GGCAGGGATT TCTCCTTCTT CTTGGTCCTG GCTCCCAAGG GCTTCTGTCT

1701 TCATCTCTGC ATGAGCTCTC CTTCCCAGAG ACCAACTCTT TTTTATTTTA

1751 TTTTATTTTT TAATTTATGT CTGGAGCCTG GCTACTCTGC ATTTGGGATT

1601 GGGGATGCTG GGTGGGTGTG TGGTCCATGT TCAGCGTTCT AGCAACACGT

1651 GTGTGTGTGT GTGTGTAAAG GCTATGCAGC CAAAATACCA TCTGGCCAGA

1101 CGGGCCCACC CACAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAG

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 2

ORF from b2 bp to 1444 bpi peptide length: 4bl Category: similarity to unknown protein Classification: no clue

1 MGiQKDDLNSiQ LώESLRANSR LLEώLiQEIGώ EKE(QLT<QEL<2 EARKSAEKRK

51 AMLDELAMET LlQEKSiQHKEE LGAVRLRHEK EVLGVRARYE RELRELHEDK

101 KRiQEEELRGlQ IREEKARTRE LETLlQiQTVEE LlQAiQVHSMDG AKGUFERRLK 151 EAEESLiQlQlQlQ iQElQEEALKiQC RElQHAAELKG KEEELlQDVRD (QLElQAiQEERD

201 CHLKTISSLK (QEVKDTVDGiQ RILEKKGSAA LKDLKRiQLHL ERKRADKLlQE

251 RLiQDILTNSK SRSGLEELVL SEMNSPSRTiQ TGDSSSISSF SYREILREKE

301 SSAVPARSLS SSPiQAlQPPRP AELSDEEVAE LFIQRLAETIQIQ EKUMLEEKVK

351 HLEVSSASMA EDLCRKSAII ETYVMDSRID VSVAAGHTDR SGLGSVLRDL 401 VKPGDENLRE MNKKLiQNMLE ElQLTKNMHLH KDMEVLSiQEI VRLSKECVGP 451 PDPDLEPGET S

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_3Dpbι frame 2 No Alert BLASTP hits found

Pedant information for DKFZphtes3_3Dpbι frame 2

Report for DKFZphtes3_30pb -2 [LENGTH! 461

[MU! 55316-10

[pi! 5-07

[HOMOL! TREMBL:CEF41H1D_4 gene: "F41H10-4"i Caenorhabditis elegans cosmid F41H1D- 2e-12

[FUNCAT! 30-03 organization of cytoplasm [S- cerevisiaei

YDL056w! 5e-D4

[FUNCAT! 06-D7 vesicular transport (golgi networki etc-) [S- cerevisiaei YDL05δw! 5e-04 [BLOCKS! BLD110DD NNMT/PNMT/TEMT family of methyltransferases proteins

[KU! All_Alpha

[KU! L0U_C0MPLEXITY 11-13 *

[KU! C0ILED_C0IL 40-lb *

SElQ E(QTTGLAAELιQιQ(Q(QAEYEDLMG(QKDDLNS(QL(QESLRANSRLLEιQL(QEIG(QEKEιQLT(QEL(Q SEG xxxxxxxxxxxxxxx xxxxxxxxxxx

PRD ccchhhhhhhhhhhhhhhhhhhhhcchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS

- - -ccccccccccccccccccccccccccccccccccccccccccccccccccccccccc

SElQ EARKSAEKRKAMLDELAMETLiQEKSiQHKEELGAVRLRHEKEVLGVRARYERELRELHEDK SEG x PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh COILS cccccccc

SElQ KROEEELRG(QIREEKARTRELETL(Q<QTVEEL(QA(QVHSMDGAKGUFERRLKEAEESL(Q(Q<Q(Q SEG xxxxxxxxxxxxxxxx xxxxxxxxxxx

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhcccchhhhhhhhhhhhhhhhhh COILS CCCCCCCCCCCCCCCC SElQ IQ E IQ EEA LK IQ C RE IQ H A A E L KGKE EELIQDVR D IQ L E IQ A IQ E E RD CH L K T IS SLKIQ EVK D T V DG IQ

SEG xxxxxxxxx

PRD hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhcccc

COILS

CCCCCCCCCCCCC CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC

SElQ RILEKKGSAALKDLKRiQLHLERKRADKLlQERLlQDiLTNSKSRSGLEELVLSEMNSPSRTiQ

SEG

PRD cccccccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhccccchhhhhhhhhhhccccccc

COILS CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC

SElQ TGDSSSISSFSYREILREKESSAVPARSLSSSPlQAlQPPRPAELSDEEVAELFiQRLAETiQiQ SEG ---xxxxxxxx xxxxxxxxxxxxxxxxxxxxx

PRD cccccccchhhhhhhhhhhcccccccccccccccccccccchhhhhhhhhhhhhhhhhhh COILS

SElQ EKUMLEEKVKHLEVSSASMAEDLCRKSAIIETYVMDSRIDVSVAAGHTDRSGLGSVLRDL SEG PRD hhhhhhhhhhhhhhchhhhhhhhhhhhhhhcccccchhhhhhhccccccccccccccccc COILS SEl^Q VKPGDENLREMNKKLl^QNMLEEiQLTKNMHLHKDMEVLSiQEIVRLSKECVGPPDPDLEPGET SEG

PRD ccccchhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhcccccccccccccccc COILS CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC

SElQ S SEG . PRD c COILS

⁽No Prosite data available for DKFZphtes3_3Dpfa -2) ⁽No Pfam data available for DKFZphtes3_30pfa -2)

DKFZphtes3_31alD

group: nucleic acid management

DKFZphtes3_31alO encodes a novel 542 amino acid protein with similarity to histone HI of Drosophila hydei. Histone HI variants are known to act as specific regulators of genes via the differential condensation of DNA-

The new protein can find application in modulating/blocking the transcriptional activity and in expression profiling.

weak similarity to Drosophila histone HI perhaps complete eds-

Sequenced by LMU

Locus: /map="13" Insert length: 2667 bp

Poly A stretch at pos- 2855ι polyadenylation signal at pos- 2831

1 AGATGATCCC CAAAGTCAAC ATATGACATT AAGCCAGGCA TTTCACCTTA 51 AAAACAATAG TAAAAAGAAA CAAATGACTA CAGAAAAACA AAAGCAAGAT

IDl GCTAACATGC CCAAGAAACC TGTGCTTGGA TCTTATCGTG GCCAGATTGT

151 TCAGTCTAAG ATTAATTCAT TTAGAAAACC TCTACAAGTC AAAGATGAGA

201 GTTCTGCAGC AACAAAGAAA CTTTCAGCCA CTATACCTAA AGCCACAAAA

251 CCTCAGCCTG TAAACACCAG CAGTGTAACA GTGAAAAGTA ATAGATCCTC 3D1 CAATATGACT GCCACTACTA AATTTGTGAG CACTACATCT CAGAACACAC

351 AACTTGTGCG ACCTCCTATT AGAAGTCATC ACAGTAATAC CCGGGACACT

401 GTGAAACAAG GCATCAGTAG AACCTCTGCC AATGTTACAA TCCGGAAAGG

451 GCCTCATGAA AAAGAACTAT TACAATCAAA AACAGCTTTA TCTAGTGTCA

5D1 AAACCAGTTC TTCTCAAGGT ATAATAAGAA ATAAGACTCT ATCAAGATCC 551 ATAGCATCTG AAGTTGTAGC CAGGCCTGCT TCATTGTCTA ATGATAAACT bOl GATGGAAAAG TCAGAGCCCG TTGACCAGCG AAGACATACT GCAGGAAAAG b51 CAATTGTTGA TAGTAGATCA GCTCAGCCCA AAGAAACCTC GGAAGAGAGA

701 AAAGCTCGTC TGAGTGAGTG GAAAGCTGGC AAAGGAAGAG TGCTAAAAAG

751 GCCCCCTAAT TCAGTAGTTA CTCAGCATGA GCCTGCAGGA CAAAATGAAA 601 AACTAGTTGG GTCTTTTTGG ACTACCATGG CAGAAGAAGA TGAACAAAGA

651 TTATTTACTG AAAAAGTAAA CAACACATTT TCTGAATGCC TGAACTTGAT

IDl TAATGAGGGA TGTCCAAAAG AAGATATACT GGTCACACTG AATGACCTGA

151 TTAAAAATAT TCCAGATGCC AAAAAGCTTG TTAAGTATTG GATATGTCTT

1D01 GCACTTATTG AACCAATCAC AAGTCCTATT GAAAATATTA TTGCAATCTA 1D51 TGAGAAAGCC ATTCTGGCAG GGGCTCAGCC TATTGAAGAG ATGCGACACA

1101 CGATTGTAGA TATTCTAACA ATGAAGAGTC AAGAAAAAGC TAATTTAGGA

1151 GAAAATATGG AGAAGTCTTG TGCAAGCAAG GAAGAAGTCA AAGAAGTCAG

1201 TATTGAAGAT ACAGGTGTTG ATGTAGATCC AGAAAAACTG GAAATGGAGA

1251 GTAAACTTCA TAGAAATTTG CTATTTCAAG ATTGTGAAAA AGAGCAAGAC 13D1 AACAAAACAA AAGATCCAAC CCATGATGTT AAAACCCCCA ATACAGAAAC

1351 GAGGACAAGT TGCTTAATTA AATATAATGT GTCTACTACG CCATACTTGC

1401 AAAGTGTGAA AAAAAAGGTG CAGTTTGATG GAACAAATTC CGCATTTAAA

1451 GAGCTGAAGT TTTTAACACC AGTGAGACGT TCTCGACGTC TTCAAGAGAA 1501 AACTTCTAAA TTGCCAGATA TGTTAAAAGA TCATTATCCT TGTGTGTCTT 1551 CATTGGAACA GCTAACGGAG TTGGGAAGAG AAACTGATGC TTTTGTATGC IbOl CGCCCTAATG CAGCACTGTG CCGGGTGTAC TATGAGGCTG ATACAACATA IbSl AGAGAAATAA AGCTCTGTTA GGGAATGGGG TTTTTATTAT TTGTGGGGTG 17D1 TTTTGTTTTG AGTAGCTTTA TATTGCTCTT AGGTCTGGAG TTGGCCATGT 1751 ACCTATGTAT CCTAAGCATT CACGGCAGTG AGCTCCTTTA CTAACATTCA 1601 TGTTATGGCA AGAGTTGTCC TCTACATTGG AAAGCTAATC CTACCTTGTC 1851 AGTTTCAACC AACTGAGTTT TTTCTTTAAG AAAGGTAAAT TTTGTCAGCT 1101 AGTTTACTAT GTTCCTTGAA TATAAACAGG TTATAATACT ACCCTGTTCA 1151 CTTTACTAAA TATAAGTACA GTAATGATGC ATAATTAGAA AATGAGGTAT 20D1 TCTAGGTAAA ATGTATGTTT GCCTTGACAT GTTTTTAAAA GTTATGATGT 2051 ACCTCCCTGC CTTTAAACAG AATACTTTTT GGCCTTTCTC 21D1 AGATTAGTCA AAAATTCTAT AGAATGACTC ACTTCGAATA CTAAGACACA 2151 GGAGGTTTAG CCTGCTTTCT TACCAAATTC ATGTTACCCA GACTTGTGTT 2201 CTCTTGCGTC CCTTGGACTG CCTGTTGATT GATGGAAAGT GTCTGCACTG 2251 ACACTTTTCG TCAGTAGTCT GTAGTTTCGT GGCCTCTTTT GATTATAACT 23D1 GGGGTCACCA AGAAGGTTTA CTTAATTAAA TACCGCATTT CTAAGAGAAG 2351 ATACTTTGTG TAAGAAAAGA TGCCACATTT AGTGGTTTAA CTTTTGTAAC 2401 TTCACTTGAT AGTTTTTAAG CAATTAGAAT GGAGTTAGGG AAAGAACATA 2451 TCATACTGAA CAAATGTCAT TCTAGTTTAG ATAGCATTTC TAAGATAACT 25D1 GATACTAATA CTTGTTTTCT TCCCTATAAC ATAAAAAACT TCACTGTTAA 2551 GTCATGTCCC TTGAAACATG ATAGTTACAT ACACAGTTTT CTCTCCACAC 2b01 ATAAATAACA CCACTAAAGT TGTTTTGTAA GGTTCCAAAC TAATATGGCA 2b51 TATATCAACT CTACAGTTTC AAATAAATGA CTTTTTAATT GTAAAAGATT 27D1 AGTTGAAAAA CTGTATGAAT GTGAAGATCA CATGCTTAGT CATTTTTATG 2751 TTCATTCCAC TTTGTATATC TTTTCTATTT ATTGACTTCT CATGTTCTAG 2801 AGAGTAGGAC TTTTATTCCG TGTACCTGAT ATATATACAA TTAAAATATC 2851 TGTATAATTA AAAAAAAAAA AAAAAAAAAA AAAAAAG

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 2

ORF from 23 bp to lb48 bpi peptide length: 542 Category: similarity to known protein Classification: unclassified

1 MTLSlQAFHLK NNSKKKiQMTT EK(QK(QDANMP KKPVLGSYRG (QIViQSKINSF

51 RKPLiQVKDES SAATKKLSAT IPKATKPlQPV NTSSVTVKSN RSSNMTATTK

101 FVSTTS(QNT(Q LVRPPIRSHH SNTRDTVKtQG ISRTSANVTI RKGPHEKELL

151 (QSKTALSSVK TSSSiQGIIRN KTLSRSIASE VVARPASLSN DKLMEKSEPV 201 DiQRRHTAGKA IVDSRSAώPK ETSEERKARL SEUKAGKGRV LKRPPNSVVT

251 (QHEPAGlQNEK LVGSFUTTMA EEDEiQRLFTE KVNNTFSECL NLINEGCPKE

301 DILVTLNDLI KNIPDAKKLV KYUICLALIE PITSPIENII AIYEKAILAG

351 AiQPIEEMRHT IVDILTMKStQ EKANLGENME KSCASKEEVK EVSIEDTGVD 4D1 VDPEKLEMES KLHRNLLFiQD CEKElQDNKTK DPTHDVKTPN TETRTSCLIK

451 YNVSTTPYLlQ SVKKKViQFDG TNSAFKELKF LTPVRRSRRL iQEKTSKLPDM

501 LKDHYPCVSS LElQLTELGRE TDAFVCRPNA ALCRVYYEAD TT

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_31alDι frame 2 No Alert BLASTP hits found Pedant information for DKFZphtes3_31al0ι frame 2

Report for DKFZphtes3_31alO - 2

[LENGTH! 541

£MU! blfa77-3b

[pi! 1.33

[KU! Alpha_Beta

[[KKUU!! L LOOUU CCOOMMPPLLEEXXIITTYY 2-11 *

SElQ DDP(QS(QHMTLS(QAFHLKNNSKKK(QMTTEK<QKιQDANMPKKPVLGSYRG(QIV(QSKINSFRKP

SEG xxxxxxxxxxxx PRD ccccccchhhhheeeeccccccchhhhhhhhhccccccccccccccceeeeccccccccc

SElQ LIQVKDESSAATKKLSATIPKATKPIQPVNTSSVTVKSNRSSNMTATTKFVSTTSIQNTIQLVR

SEG

PRD cccccchhhhhhhhhhccccccccccccceeeeeccccccccccceeeeeccccceeeec

SElQ PPIRSHHSNTRDTVKiQGISRTSANVTIRKGPHEKELLlQSKTALSSVKTSSSlQGIIRNKTL

SEG

PRD cccccccccccccccccccccceeeeeccccchhhhhhhhhhcccccccccceeecccch SElQ SRSIASEVVARPASLSNDKLMEKSEPVDiQRRHTAGKAIVDSRSAiQPKETSEERKARLSEU

SEG

PRD hhhhhheeeecccccchhhhhhhcccchhhhhhcceeecccccccccchhhhhhhhhhhh

SElQ KAGKGRVLKRPPNSVVTiQHEPAGi^QNEKLVGSFUTTMAEEDEl^QRLFTEKVNNTFSECLNLI SEG

PRD hcccceeeeccccceeeeccccccceeeeeecchhhhhhhhhhhhhhhhccccccceeec

SElQ NEGCPKEDILVTLNDLIKNIPDAKKLVKYUICLALIEPITSPIENIIAIYEKAILAGAiQP

SEG PRD ccccccceeeeecccceeecccchhhhhhhhhhhhcccccccchhhhhhhhhhhhhcchh

SElQ IEEMRHTIVDILTMKSiQEKANLGENMEKSCASKEEVKEVSIEDTGVDVDPEKLEMESKLH

SEG

PRD hhhhhhhhhhhhhhhhhhhhhccchhhhhcccccceeeeeecccccccccchhhhhhhhh

SElQ RNLLFi^QDCEKEi^QDNKTKDPTHDVKTPNTETRTSCLIKYNVSTTPYLi^QSVKKKVlQFDGTNS SEG

PRD cccccccccccccccccccccccccccccccceeeeeeecccccchhhhhhheeecccch SElQ AFKELKFLTPVRRSRRLiQEKTSKLPDMLKDHYPCVSSLElQLTELGRETDAFVCRPNAALC

SEG

PRD hhhhhhhchhhhhhhhhhhhhhccccccccccccchhhhhhhhhccccceeeecccceee

SElQ RVYYEADTT

PRD eeeeccccc

(No Prosite data available for DKFZphtes3_31alD-2) (No Pfam data available for DKFZphtes3_31alO .2)

DKFZphtes3_31j2D

group: signal transduction

DKFZphtes3_31j2D encodes a novel 312 amino acid protein that contains a Protein phosphatase 2C motif. The novel protein shares 15* identity withthe rat protein phosphatase 2C and is expressed ubiquitously. PP2C is a structurally diversified protein phosphatase family with a wide range of functions in cellular signal transduction. The transcription of the PP2Cdelta gene was activated in response to stressi like alcohol or UV irridation- PP2C plays a role in cell cycle control-

The new protein can find application in and the diagnosis/therapy of stress related diseases and canceri as well as a for modulation of cell cycle and signal transduction.

strong similarity to protein phosphatase 2C (Rattus norvegicus) Sequenced by LMU

Locus: unknown

Insert length: 143b bp Poly A stretch at pos- 13b7ι polyadenylation signal at pos- 1341

1 CGCTGCTCGC GGGCTGAGTG TCTGTCGCTG CTGCCGCCTC CACCCAGCCT

51 CCGCCATGGA CCTCTTCGGG GACCTGCCGG AGCCCGAGCG CTCGCCGCGC 101 CCGGCTGCCG GGAAAGAAGC TCAGAAAGGA CCCCTGCTCT TTGATGACCT

151 CCCTCCGGCC AGCAGTACTG ACTCAGGATC AGGGGGACCT TTGCTTTTTG

2D1 ATGATCTCCC ACCCGCTAGC AGTGGCGATT CAGGTTCTCT TGCCACATCA

251 ATATCCCAGA TGGTAAAGAC TGAAGGGAAA GGAGCAAAGA GAAAAACCTC

301 CGAGGAAGAG AAGAATGGCA GTGAAGAGCT TGTGGAAAAG AAAGTTTGTA 351 AAGCCTCTTC GGTGATCTTT GGTCTGAAGG GCTATGTGGC TGAGCGGAAG

401 GGTGAGAGGG AGGAGATGCA GGATGCCCAC GTCATCCTGA ACGACATCAC

451 CGAGGAGTGT AGGCCCCCAT CGTCCCTCAT TACTCGGGTT TCATATTTTG

501 CTGTTTTTGA TGGACATGGA GGAATTCGAG CCTCAAAATT TGCTGCACAG

551 AATTTGCATC AAAACTTAAT CAGAAAATTT CCTAAAGGAG ATGTAATCAG bOl TGTAGAGAAA ACCGTGAAGA GATGCCTTTT GGACACTTTC AAGCATACTG b51 ATGAAGAGTT CCTTAAACAA GCTTCCAGCC AGAAGCCTGC CTGGAAAGAT

7D1 GGGTCCACTG CCACGTGTGT TCTGGCTGTA GACAACATTC TTTATATTGC

751 CAACCTCGGA GATAGTCGGG CAATCTTGTG TCGTTATAAT GAGGAGAGTC

601 AAAAACATGC AGCCTTAAGC CTCAGCAAAG AGCATAATCC AACTCAGTAT 851 GAAGAGCGGA TGAGGATACA GAAGGCTGGA GGAAACGTCA GGGATGGGCG

IDl TGTTTTGGGC GTGCTAGAGG TGTCACGCTC CATTGGGGAC GGGCAGTACA

151 AGCGCTGCGG TGTCACCTCT GTGCCCGACA TCAGACGCTG CCAGCTGACC

10D1 CCCAATGACA GGTTCATTTT GTTGGCCTGT GATGGGCTCT TCAAGGTCTT

1051 TACCCCAGAA GAAGCCGTGA ACTTCATCTT GTCCTGTCTC GAGGATGAAA 1101 AGATCCAGAC CCGGGAAGGG AAGTCCGCAG CCGACGCCCG CTACGAAGCA

1151 GCCTGCAACA GGCTGGCCAA CAAGGCGGTG CAGCGGGGCT CGGCCGACAA

1201 CGTCACTGTG ATGGTGGTGC GGATAGGGCA CTGAGGGGTG GCGCGCGGCC

1251 AGGAGCACGC ATGGTATTGA CTTAAAAGGT TCATTTTGTG TGTGTGCACA 1301 TTGTGTGTTT TGTGTACTCC TGTGGGACTC CCATGGTTGT AAATAAAGGT

1351 TTCTCTTTTT TTTTCCTAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA

1401 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAG

BLAST Results

No BLAST result

Medline entries

11074314:

Tong Yi (Quirion Ri Shen SH-i Cloning and characterization of a novel mammalian PP2C isozyme. J Biol Chem 1118 Dec 25i273 (52) : 35282-10

Peptide information for frame 2

ORF from 5b bp to 1231 bpi peptide length: 312 Category: strong similarity to known protein Classification: Protein management Prosite motifs: PP (147-155)

1 MDLFGDLPEP ERSPRPAAGK EAlQKGPLLFD DLPPASSTDS GSGGPLLFDD

51 LPPASSGDSG SLATSISiQMV KTEGKGAKRK TSEEEKNGSE ELVEKKVCKA 101 SSVIFGLKGY VAERKGEREE MlQDAHVILND ITEECRPPSS LITRVSYFAV

151 FDGHGGIRAS KFAAiQNLHiQN LIRKFPKGDV ISVEKTVKRC LLDTFKHTDE

2D1 EFLKlQASSlQK PAUKDGSTAT CVLAVDNILY IANLGDSRAI LCRYNEESiQK

251 HAALSLSKEH NPTiQYEERMR IlQKAGGNVRD GRVLGVLEVS RSIGDGlQYKR

301 CGVTSVPDIR RClQLTPNDRF ILLACDGLFK VFTPEEAVNF ILSCLEDEKI 351 (QTREGKSAAD ARYEAACNRL ANKAViQRGSA DNVTVMVVRI GH

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_31j20ι frame 2 No Alert BLASTP hits found

Pedant information for DKFZphtes3_31j20ι frame 2

Report for DKFZphtes3_31J20-2

[LENGTH! 410 [MU! 44751 - 85

[pi! 7 - 15

[HOMOL! TREMBL:AFD15127_1 product: "protein phosphatase

2C"i Rattus norvegicus protein phosphatase 2C mRNAi complete eds- 0-D

[FUNCAT! 03-01 cell growth CS- cerevisiaei YDLOObw! fae-2S

[FUNCAT! 10-03-13 key phosphatases CS. cerevisiaei YDLOObw! be-25

[FUNCAT! 01- lb mitochondrial biogenesis [S. cerevisiaei YDLOObw! be-25

[FUNCAT! 11-01 stress response CS- cerevisiaei YDLOObw! be-25

[FUNCAT! D3-D4 buddingi cell polarity and filament formation

CS. cerevisiaei YDLOOfaw! be-25

[FUNCAT! 01.05-04 regulation of carbohydrate utilization CS. cerevisiaei YDLOObw! be-25

[FUNCAT! 18 classification not yet clear-cut CS- cerevisiaei

YEROβlc! le-23

[FUNCAT! 11 unclassified proteins CS- cerevisiaei YORDIOc! le-12 [FUNCAT! 03-22 cell cycle control and mitosis CS- cerevisiaei

YJLODSw! 3e-10

[FUNCAT! D3-10 sporulation and germination CS. cerevisiaei

YJLDOSw! 3e-lD

[FUNCAT! 30-D2 organization of plasma membrane [S- cerevisiaei YJL0D5w! 3e-10

[FUNCAT! 01-03-10 metabolism of cyclic and unusual nucleotides

CS- cerevisiaei YJLODSw! 3e-10

[FUNCAT! 1D.04-D3 second messenger formation [S- cerevisiaei

YJL005w! 3e-lD [BLOCKS! PR01023F

[BLOCKS! PR00fa77D

[BLOCKS! BL01D32I

[BLOCKS! BL01D32H

[BLOCKS! BL01D32G [BLOCKS! BL01D32C Protein phosphatase 2C proteins

[BLOCKS! BL01032B Protein phosphatase 2C proteins

[SCOP! dlabq 4.16.1.1-1 Protein serine/threonine phosphatase 2C [Huma le-107

[EC! 3-1-3-43 [Pyruvate dehydrogenase ( lipoamide) !- phosphatase 3e-D1

[EC! 3-1-3-lb Phosphoprotein phosphatase 7e-35

[EC! 4-fa-l-l Adenylate cyclase Se-11

[PIRKU! duplication Se-11

[PIRKU! tandem repeat 8e-01 [PIRKU! serine/threonine-specific phosphatase 2e-27

[PIRKU! magnesium fae-2b

[PIRKU! cAMP biosynthesis 5e-ll

[PIRKU! liver 2e-27

[PIRKU! leucine zipper le-08 [PIRKU! mitochondrion 3e-01

[PIRKU! phosphoric monoester hydrolase 7e-35

[PIRKU! phosphorus-oxygen lyase 2e-ll

[SUPFAM! leucine-rich alpha-2-glycoprotein repeat homology 2e-ll [SUPFAM! yeast adenylate cyclase catalytic domain homology 2e-ll

[SUPFAM! kinase interaction domain homology 3e-ll [SUPFAM! yeast adenylate cyclase Se-11 [PROSITE! PP2C 1

[PFAM! Protein phosphatase 2C

[KU! Alpha_Beta

SE(Q AARGLSVCRCCRLHPASAMDLFGDLPEPERSPRPAAGKEAiQKGPLLFDDLPPASSTDSGS PRD ccceeeeeeeeccccccceeeecccccccccccccccccccccccccccccccccccccc

SElQ GGPLLFDDLPPASSGDSGSLATSISOMVKTEGKGAKRKTSEEEKNGSEELVEKKVCKASS PRD ccceeeccccccccccccccccccccccccccccccccccccccccccccccccccccce

SE(Q VIFGLKGYVAERKGEREEMlQDAHVILNDITEECRPPSSLITRVSYFAVFDGHGGIRASKF PRD eeeceeeecchhhhhhhhhhhhheeeeccccccccccccccceeeeeeeccccchhhhhh SElQ AAIQNLHIQNLIRKFPKGDVISVEKTVKRCLLDTFKHTDEEFLKIQASSIQKPAUKDGSTATCV PRD hhhhhhhhhhhcccccccchhhhhhhhhhhhhhhhhhhhhhhhhhhcccccccccceeee

SElQ LAVDNILYIANLGDSRAILCRYNEESiQKHAALSLSKEHNPTlQYEERMRIlQKAGGNVRDGR

PRD eeccceeeeeccccceeeeeeccccccccceeeeecccccccchhhhhhhhcccceeeee

SElQ VLGVLEVSRSIGDGlQYKRCGVTSVPDIRRCiQLTPNDRFILLACDGLFKVFTPEEAVNFIL

PRD ccccceeeeccccccccccccccccccccccccccceeeeeecccccccccchhhhhhhh

SElQ SCLEDEKIiQTREGKSAADARYEAACNRLANKAVlQRGSADNVTVMVVRIGH PRD hhhhhhhhhhhhcchhhhhhhhhhhhhhhhhhhhccccccceeeeeeccc

Prosite for DKFZphtes3_31 j20 - 2

PS01D32 lbS->174 PP2C PD0C0D712

Pfam for DKFZphtes3_31j20.2

HMM_NAME Protein phosphatase 2C HMM

*Gl CcM(QGPRURMsMEDaH i aylNF pcn l DUUh i MFFGVFDGHg

+++ +G R++M+DAH+ + ++ P++L ++

+++F+VFDGHG

(Query 128 YVAERKG--EREEM(QDAHVILNDITEECRPPSSLITR- VSYFAVFDGHG 173

HMM GDiQCSiQUCgeHUHdII*

G+++S++ +++H+ + (Query 174 GIRASKFAAiQNLHiQNL 161 DKFZphtes3_5k22

5. group: signal transduction

DKFZphtes3_5k22 encodes a novel 455 amino acid protein with similarity to human paraneoplastic neuronal antigen MAI- 0 Antibodies against MAI where found in patients with paraneoplastic neurological disorders- The protein is predominantly expressed in testis and braini but ESTs are also found in liveri lung uterus and kidney. 5 The new protein can find application in studying/therapy of paraneoplastic neurological disorders-

strong similarity to paraneoplastic neuronal antigen MAI 0

Sequenced by (Qiagen

Locus: unknown 5 Insert length: 3534 bp

Poly A stretch at pos- 3S14ι polyadenylation signal at pos- 3414

1 GAACGTCCGC GCTGGGAGCC AGGGGTGCCC GACCCCCGTC CGCCGCCGCC 0 51 GCCGCCGCCG CGCATAGCCC CCGGAGAGCC CTCTGGGGAC CCCGACCAGA

101 AGGGACCTTG CCCTGGGAGA AGGCTGTGGA GACCTGGGCC TTCTGCGATC

151 ACCCTAGGAG TTGATCCAGA TATGTGCCTC ACGCCCTGAT CACTCCCCCC

2D1 AAATTAGTAT CCGCAGAGAT TCGAGGACAT GCCGTTGACC TTGTTACAGG

251 ACTGGTGTCG GGGGGAACAC CTGAACACCC GGAGGTGCAT GCTCATCCTG 5 301 GGGATCCCCG AGGACTGTGG CGAGGATGAG TTTGAGGAGA CACTCCAGGA

3S1 GGCTTGCAGG CACCTGGGCA GATACAGGGT GATTGGCAGG ATGTTTAGGA

4D1 GGGAGGAGAA CGCCCAGGCG ATTCTACTGG AGCTGGCACA AGATATCGAC

451 TATGCTTTGC TCCCAAGGGA AATACCAGGA AAGGGGGGGC CCTGGGAAGT

501 GATTGTAAAA CCCCGTAACT CAGATGGGGA ATTTCTCAAC AGACTGAACC 0 SSI GCTTCTTAGA GGAGGAGAGG CGGACCGTGT CAGATATGAA CCGAGTCCTC faOl GGGTCGGACA CCAATTGTTC GGCTCCAAGA GTGACTATAT CACCAGAGTT faSl CTGGACCTGG GCCCAGACTC TGGGGGCAGC AGTGCAGCCT CTGCTAGAAC

7D1 AAATGTTGTA CCGAGAACTA AGAGTGTTTT CTGGGAACAC CATATCCATC

751 CCAGGTGCAC TGGCCTTTGA TGCCTGGCTT GAGCACACCA CTGAGATGCT 5 801 ACAGATGTGG CAGGTGCCCG AGGGGGAAAA GAGGCGGAGG CTGATGGAAT

8S1 GCTTACGGGG CCCTGCTCTC CAGGTGGTCA GTGGGCTCCG GGCCAGCAAT

101 GCTTCCATAA CTGTGGAGGA GTGCCTGGCT GCCTTGCAGC AGGTGTTCGG

151 ACCTGTGGAG AGCCATAAAA TTGCCCAGGT GAAGTTGTGT AAAGCCTATC

1D01 AGGAGGCAGG AGAGAAAGTA TCTAGCTTTG TGTTACGTTT GGAACCCCTG 0 1DS1 CTCCAAAGAG CTGTAGAAAA CAATGTGGTA TCACGTAGAA ACGTGAATCA

1101 GACTCGCCTG AAACGAGTCT TAAGTGGGGC CACCCTTCCT GACAAACTCC

1151 GAGATAAGCT TAAGCTGATG AAACAGCGAA GGAAGCCTCC TGGTTTCCTG

1201 GCCCTGGTGA AGCTCCTGCG TGAGGAGGAG GAATGGGAGG CCACTTTAGG

1251 TCCAGATAGG GAGAGTCTGG AGGGGCTGGA AGTAGCCCCA AGGCCACCTG 5 13D1 CCAGGATCAC TGGGGTTGGG GCAGTACCTC TCCCTGCCTC TGGCAACAGT

1351 TTTGATGCGA GGCCTTCCCA GGGCTACCGG CGCCGGAGGG GCAGAGGCCA

1401 ACACCGAAGG GGTGGTGTGG CAAGGGCTGG CTCTCGAGGC TCAAGAAAAC

1451 GGAAACGCCA CACATTCTGC TATAGCTGTG GGGAAGACGG CCACATCAGG 1501 GTACAGTGCA TCAACCCCTC CAACCTGCTC TTGGCCAAGG AGACAAAAGA

1551 GATATTGGAA GGkGGGGkkk GAGAAGCCCA GACAAACAGC AGATGAGTTG lfaOl AGTGGGGCAG AGGGACAGGG CAGCCAGACC AAGGCCAAGC CTTCTCACCC lfa51 TTGGCCAGCT GGAAGGGACT TCAGCAACCA AGACCACCTG GCAACAGGCT 1701 CAGTGGGGGT CAGGTCCAGG TCCCCGAAGA GGTGCTGGAG AGGAAAGCAG

17S1 GGAGCCACTG CATCCAGCAC ATGGGGTGCC TGGGCCTCAG ATGGGGACCC

16D1 CAAAGAAGCA GAAGCTGAAG AAGGTACGGC TGGGGGTTCT GTCCTGCTCA

1651 TCCAACCACC CCTAAATACC CACCCTGTGG ACTTTGAGCT GAACATGCCC

1101 ACTGGCCCCC AGGCCACATG GGACCTGGAG GAGCCTACCT GGGGCCTGCC 1151 CCTGCCAGCA GGTGCCAGGG CTGGTGAGGA AGAGCTGGGG GGCAGAGGTA

2D01 AAGCCCTGCA GGGGAGGCCA CAGGGTCCAT CCCGTCTTCA GGATCATCTA

2D51 CACTGCACTA GGGGAGCCCC AGGAAGGCAG CACCCTGGAG GCCCTGTGCC

21D1 AGTGAGGACA GGAGACCCTA AGGCCCCGGG AGCCCAGTGC CAGCCAGAGG

2151 TTGTGCAGGC AAGGAGACCA AAGATTGATG AGAAGACCCC CAGCAGGGGT 22D1 ACTGGGTACC CGGCAGGCCA GTGCCCTCAC AGTTGACTTG GACCAGGGTG

2251 GCTGTGAAGG GAAGTCTTTG TTGCAAAGGA GGAGGAGGAA AAGGGAGGAC

2301 TTGGTAGGGT TTTGTTTCTT CTGCTTGTTT CTGTACAGGG CCACCAGACT

2351 CCTGGAGAGA TCAAGCAAGG AGAACCTGGG GCTGCCATGG CCAAAGCAAC

2401 TCAACAGATG CCAATGCCAA TTCCAAGGCC AGCCACAACC CTGCCACCTT 2451 GGGGAATCCA GCCTGGAGGC ATCCCCTAAG CAGCCAGCCA TGGCCTGGGT

25D1 GGAGGCACCT GAAGACGTCT GTCCCAAACT CCCCCAGCCC TGAGCTGGGA

2551 GATGACAGGG GGAAAGAGGC CCTCTCAAGG GTGCCAGATG CCTGGGTCTC

2b01 CCAAGAGGGG TCCCCCAACT CACCGTTCCC GGGACAGGCT GCCCCCTGTT

2b51 CCAGGAAGCT CATCCTCACC TGTGTAGGCC CCTGTAGTGA CCCACGCGTC 2701 CAGCAGACGC CCACCCACCG CTAGCCGTTG TTCCTGTGCA AAGTAGTGTG

2751 CTATGCACCC ACCCAGGTGG CCGCCTCTGG GCCCAAGGCA CATGCTGTGA

28D1 GCTTCCTGTG AGCCCAGGCT CTGCTCACTG CTGTCCCGCG TCATGAGCAC

2851 CACCTCTGCT TTCCCTGTGT AGATCTAGGC CAGTGGCTGC TTGTTCTTGT

2101 GGAGCTGTGT GTGTTCTTCT CTGAGCAGCT CCTCCCCGGA GTCCCCCAGC 2151 ACAGTCCCAG GAGATGACAG GAAGGAAGCA CCAGGGCAAG GCGGACGCTC

3D01 ACCCTGTGAC CACGATGGTG ACCGTGGCTG TGGGAGGAAG AACTGGACCC

3D51 AGGACGGAGC GGGGCTGCCC TGCCTGAGGC TCCCGAGGAG CTTTGTGCTT

3101 TGGTGTTCCA CCCCTGTTGT TACTCATGAC TCAGTTTCCT TGACCTGGTA

3151 GGGTGTTCCC TGCTGTGTTT TCCAGTGTCC TGTGACTGTC CTGTGCGGGC 3201 CATAGGGCAG GGCCCTGCCC CAGCAGATGG GCTTGGGAGG GGGCTCCCTA

3251 AAGCCAGTGG ACACTGCCAG AGTCTACCTT CCTGGCAAGA GGCAGACCCC

33D1 GGGGCCCTCA GGAAGGAGGG AGTTGGCAGC GGGGGCTGCA GCAGGAGTAG

3351 GAGCAGATGA GGCGTCTTGC CAGGAACCTC AGGAGGAGGG GGCCCGGGAC

3401 CTGTGTGGGA CCTGTGTCCT GTGGTGGCCG TTTGCAGTTT CTCTCTGTGT 3451 TGTGATTCCC TTCTCTTCAA TGGTTTCAGT ACGTGTTTCT CTTCAATAAA

3501 CTTCATTCAG TGTTAAAAAA AAAAAAAAAA AAAA

BLAST Results

No BLAST result

Medline entries

11156171:

Mali a novel neuron- and testis-specific proteini is recognized by the serum of patients with paraneoplastic neurological disorders Peptide information for frame 1

ORF from 221 bp to 1513 bpi peptide length: 455

Category: strong similarity to known protein Classification: unclassified 1 MPLTLLiQDUC RGEHLNTRRC MLILGIPEDC GEDEFEETLlQ EACRHLGRYR

51 VIGRMFRREE NAώAILLELA (QDIDYALLPR EIPGKGGPUE VIVKPRNSDG

IDl EFLNRLNRFL EEERRTVSDM NRVLGSDTNC SAPRVTISPE FUTUAiQTLGA

151 AVlQPLLEiQML YRELRVFSGN TISIPGALAF DAULEHTTEM LIQMUIQVPEGE

201 KRRRLMECLR GPALlQVVSGL RASNASITVE ECLAALlQiQVF GPVESHKIAiQ 251 VKLCKAYlQEA GEKVSSFVLR LEPLLiQRAVE NNVVSRRNVN (QTRLKRVLSG

301 ATLPDKLRDK LKLMKfQRRKP PGFLALVKLL REEEEUEATL GPDRESLEGL

351 EVAPRPPARI TGVGAVPLPA SGNSFDARPS (QGYRRRRGRG (QHRRGGVARA

401 GSRGSRKRKR HTFCYSCGED GHIRVlQCINP SNLLLAKETK EILEGGEREA 451 (QTNSR

BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_Sk22ι frame 1

TREMBLNEU:AB020b1D_l gene: "KIAA0863"i product: "KIAAD663 protein"i

Homo sapiens mRNA for KIAA0883 proteini complete cds-i N = li

Score =

TREMBL:AF0373b4_l gene: "MAl"i product: "paraneoplastic neuronal antigen MAl"i Homo sapiens paraneoplastic neuronal antigen MAI (MAI) mRNAi complete cds-i N = li Score = bfa5ι P = 2-fae-faS

>TREMBLNEU:ABD20b1D_l gene: "KIAA0663"i product: "KIAAD683 protein"i Homo sapiens mRNA for KIAA0883 proteini complete eds- Length = 3b4

HSPs:

Score = 722 ( 106 - 3 b its ) ι Expect = 2 - 4e-71 ι P = 2 - 4e-71 Ident it i es = 15fa/348 ( 44* ) ι Posit i ves = 215/348 ( bl* )

(Query : l

MPLTLL(QDUCRGEHLNTRRCMLILGIPEDCGEDEFEETL(QEACRHLGRYRVIGRMFRREE bO

M L LL + DUCR ++ ++ + + + GIP D E E +E L(QE + LGRYR++G++FR++E Sb jct : 1

MALALLEDUCRIMSVDE(QKSLMVTGIPADFEEAEI^(QEVL(QETLKSLGRYRLLGKIFRK(QE faD (Query: bl

NAiQAILLELAlQDIDYALLPREIPGKGGPUEVIVKPRNSDGXXXXXXXXXXXXXXXTVSDM 120

NA A+LLEL +D D + +P E+ GKGG U+VI K N D TVS M Sbjct: bl

NANAVLLELLEDTDVSAIPSEV(QGKGGVUKVIFKTPN(QDTEFLERLNLFLEKEG(QTVSGM 12D

(Query: 121 NRVLGSDTNCSAPRVTISPEFUTU-- AlQTLGAAViQPLLEiQMLYRELRVFSGNTISIPGAL 178 R LG + A ISPE <Q + A iQPLL M YR + LRVFSG +

+ P

Sbjct: 121 FRALGlQEGVSPATVPCISPELLAHLLGlQAMAHAPlQPLLP- MRYRKLRVFSGSAVPAPEEE 171 (Query: 171

AFDAULEHTTEML(QMUιQVPEGEKRRRLMECLRGPAL(QVVSGLRASNASITVEECLAAL(Q(Q 236 +F+ ULE TE+++ U V E EK+R L E LRGPAL ++ ++A N

SI+VEECL A +__

Sbjct: 160 SFEVULEIQATEIVKEUPVTEAEKKRULAESLRGPALDLMHIVIQADNPSISVEECLEAFKIQ 231

(Query: 231

VFGPVESHKIAIQVKLCKAYIQEAGEKVSSFVLRLEPLLIQXXXXXXXXXXXXXXXXXLKRVL 216 VFG +ES + AιQV+ K YiQE GEKVS + + VLRLE LL + L++V+

Sbjct: 240 VFGSLESRRTAiQVRYLKTYiQEEGEKVSAYVLRLETLLRRAVEKRAIPRRIADiQVRLElQVM 211

(Query: 211 SGATLPDKLRDKLKLMKlQRRKPPGFLALVKLLREEEEUEATLGPDRESLE 346

+GATL L +L+ +K + PP FL L+K++REEEE EA+ + ES+E Sbjct: 30D AGATLNiQMLUCRLRELKDlQGPPPSFLELMKVIREEEEEEASF — ENESIE

347

Pedant information for DKFZphtes3_5k22ι frame 1

Report for DKFZphtes3_Sk22-l

[LENGTH! 455

[MU! 51514-34

[pi! 1-27 [HOMOL! TREMBLNE : ABD20b10_l gene: "KIAA0863"i product

"KIAAD883 protein"i Homo sapiens mRNA for KIAA0883 proteini complete eds- 3e-75

[BLOCKS! BLDD87bB Indoleamine 2ι3-dioxygenase proteins

[PFAM! Zinc fingeri CCHC class [KU! Alpha_Beta

[KU! LOU COMPLEXITY 13-41 *

SElQ MPLTLLiQDUCRGEHLNTRRCMLILGIPEDCGEDEFEETLiQEACRHLGRYRVIGRMFRREE SEG

PRD ccchhhhhccccccccccceeeeeecccccchhhhhhhhhhhhhhccceeehhhhhhhhh

SElQ NAiQAILLELAlQDIDYALLPREIPGKGGPUEVIVKPRNSDGEFLNRLNRFLEEERRTVSDM SEG xxxxxxxxxxxxxxx

PRD hhhhhhhhhhhcccccccccccccccceeeeeeecccccchhhhhhhhhhhhhhchhhhh

SEl^Q NRVLGSDTNCSAPRVTISPEFUTUAiQTLGAAVlQPLLEiQMLYRELRVFSGNTISIPGALAF SEG

PRD hhhhcccccccccccccccchhhhhhhhhhhhhhhhhhhhhhhheeeccccccccchhhh

SEl^Q DAULEHTTEMLiQMUiQVPEGEKRRRLMECLRGPALiQVVSGLRASNASITVEECLAALlQiQVF

SEG PRD hhhhhhhhhhhhhhhccchhhhhhhhhhhhccccccccccccccceeehhhhhhhhhhhh

SEl^Q GPVESHKIAIQVKLCKAYIQEAGEKVSSFVLRLEPLLIQRAVENNVVSRRNVNIQTRLKRVLSG

SEG ■ ■ -xxxxxxxxxxxxxxxxx

PRD hccchhhhhhhhhhhhhhhcccccceeeeehhhhhhhhhhhhcchhhhhhhhhhhhhhhc

SElQ ATLPDKLRDKLKLMKlQRRKPPGFLALVKLLREEEEUEATLGPDRESLEGLEVAPRPPARI

SEG

PRD ccccchhhhhhhhhhhhccccchhhhhhhhhhhhhhhhhcccchhhhheeeecccccccc SElQ TGVGAVPLPASGNSFDARPSlQGYRRRRGRGiQHRRGGVARAGSRGSRKRKRHTFCYSCGED

SEG XXXXXXXXXXXXXXXXXXXXXXXXXXXXX

PRD eeeeeeccccccccccccccccccccccccccceeeeeeccccccccccceeeeeccccc

SElQ GHIRVlQCINPSNLLLAKETKEILEGGEREAiQTNSR SEG

PRD ceeeeeeccccchhhhhhhhhhhcccccccccccc

(No Prosite data available for DKFZphtes3_5k22 -1)

Pfam for DKFZphtes3_5k22 ■ 1

HMM_NAME Zinc fingeri CCHC class

HMM *(QkCUNCGKPGHMMRDCPE*

C++CG+ GH+ +C + (Query 412 TFCYSCGEDGHIRViQCIN 421

DKFZphtes3_7nl2

group: transmembrane protein

DKFZphtes3_7nl2 encodes a novel 7D3 amino acid protein without similarity to known proteins- The novel protein contains 1 transmembrane domain

No informative BLAST resultsi No predictive prositei pfam or SCOP motife ■

The new protein can find application in studying the expression profile of testis-specific genes and as a new marker for testicular cells-

putative protein contains transmembrane domain perhaps complete eds-

Sequenced by BMFZ

Locus: unknown

Insert length: 2347 bp

Poly A stretch at pos- 2271ι polyadenylation signal at pos- 2253

1 CGGCTGCAGT CTGGGCCGGG GCCCTGTGCC GCTGAAGACA TGGAGTTTGT

51 GTCTGGATAC CGGGATGAGT TCCTTGATTT CACTGCCCTT CTCTTCGGCT

101 GGTTCCGAAA GTTTGTGGCA GAGCGTGGAG CTGTAGGGAC TAGCCTTGAG 151 GGCCGCTGCC GGCAGCTGGA GGCCCAGATC AGAAGGCTAC CCCAGGACCC

201 TGCCCTTTGG GTGCTCCATG TCCTGCCCAA CCATAGTGTG GGCATCAGCC

251 TGGGGCAAGG GGCAGAACCA GGTCCTGGAC CAGGCCTGGG GACTGCCTGG

301 CTCCTGGGAG ACAACCCTCC ACTCCACCTG CGAGACCTGA GCCCCTACAT

351 CAGCTTTGTC AGCCTAGAGG ATGGGGAGGA AGGGGAGGAG GAAGAGGAGG 401 AAGATGAAGA AGAAGAGAAG AGAGAGGACG GGGGTGCAGG CAGCACAGAG

451 AAGGTGGAAC CAGAGGAGGA CCGGGAGCTA GCCCCTACCA GCAGGGAGTC

501 CCCCCAGGAA ACAAACCCTC CAGGAGAGTC AGAGGAGGCT GCCCGGGAGG

551 CAGGAGGTGG CAAGGATGGC TGCCGAGAGG ACAGGGTGGA GAACGAAACA bOl AGACCCCAGA AGAGGAAGGG ACAGAGGAGT GAGGCTGCCC CCCTGCACGT b51 TTCCTGTCTC TTACTTGTGA CGGATGAGCA TGGCACCATC TTGGGCATTG

7D1 ATCTGCTAGT GGATGGAGCC CAGGGAACCG CAAGCTGGGG CTCAGGGACC

751 AAGGACCTGG CTCCTTGGGC CTATGCTCTC CTCTGTCACA GCATGGCCTG

801 TCCCATGGGC TCTGGGGATC CCCGAAAGCC CCGACAGCTT ACTGTGGGAG

851 ATGCCCGGCT GCATCGAGAG CTGGAGAGCT TGGTCCCAAG GCTAGGTGTG 101 AAGTTAGCCA AAACCCCAAT GCGGACATGG GGTCCCCGGC CAGGCTTCAC

151 CTTTGCTTCC CTTCGTGCTC GAACCTGCCA TGTGTGTCAC AGGCACAGCT

1001 TTGAAGCGAA GCTGACACCT TGCCCCCAGT GTAGTGCTGT CTTGTATTGT

1051 GGAGAGGCTT GTCTCCGGGC TGACTGGCAG CGGTGCCCAG ATGATGTGAG

1101 TCACCGATTT TGGTGCCCAA GGCTTGCAGC CTTCATGGAG CGGGCAGGAG 1151 AACTGGCAAC CCTACCTTTT ACCTACACCG CAGAGGTGAC CAGTGAAACC

1201 TTCAACAAAG AGGCCTTCCT GGCCTCTCGG GGCCTCACTC GTGGCTATTG

1251 GACCCAGCTC AGCATGCTGA TTCCAGGCCC GGGCTTCTCC AGACACCCCC

1301 GAGGCAACAC GCCATCCCTC AGCCTTCTTC GCGGTGGAGA CCCCTACCAG 1351 CTTCTCCAGG GAGACGGGAC TGCCCTGATG CCTCCTGTGC CCCCACATCC

14D1 ACCCCGGGGT GTTTTTGTCC CTGAGCTCAA CATCCAAAAC AAACAGTCAC

1451 TGAAGATCCA CGTGGTGGAG GCCGGGkkGG AGTTT6ACCT TGTCATGGTG

1501 TTTTGGGAGC TTTTGGTCCT GCTCCCCCAT GTGGCCCTGG AGCTGCAGTT 1551 TGTAGGTGAT GGCCTGCCCC CCGAAAGCGA CGAGCAGCAT TTTACCCTGC

IbOl AGAGGGACAG CCTGGAGGTG TCTGTCCGGC CTGGTTCCGG CATATCAGCA lb51 CGGCCCAGCT CTGGCACTAA GGAGAAAGGG GGCCGCAGGG ACCTGCAGAT

1701 CAAGGTGTCA GCAAGGCCCT ACCACCTGTT CCAGGGGCCC AAGCCTGACC

1751 TGGTTATTGG ATTTAACTCC GGGTTTGCTC TCAAGGATAC GTGGCTGAGG 1601 TCTCTGCCCC GGTTACAGTC CCTCCGAGTG CCAGCCTTCT TCACCGAGAG

1651 CAGCGAGTAC AGCTGTGTGA TGGACGGCCA GACCATGGCG GTGGCCACTG

1101 GAGGGGGCAC CAGCCCTCCC CAGCCCAACC CCTTCCGCTC CCCCTTTCGC

1151 CTCAGAGCGG CCGACAACTG CATGTCCTGG TACTGCAATG CCTTCATCTT

20D1 CCACCTGGTT TACAAGCCTG CTCAAGGGAG CGGGGCCCGC CCGGCGCCCG 2051 GGCCCCCACC CCCATCCCCA ACTCCCTCTG CTCCTCCTGC CCCCACCCGA

2101 AGGCGCCGAG GAGAAAAGAA ACCTGGGCGG GGGGCCCGCC GGCGGAAATG

2151 AATGCTGATA CCCTAGTAGT CCCCAGCTCC CAAACACTGA AAGGAAAACG

2201 TGAAAACACT CAAGGCCTAG GGGGAGGACA GGTTGGTAAA ACATGAAAAG

2251 GTAAATAAAA TTACTTGTTT GAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 2301 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAA

BLAST Results

No BLAST result

Medline entries

No Medline entry

Peptide information for frame 1

ORF from 40 bp to 2148 bpi peptide length: 703 Category: putative protein

Classification: Transmembrane proteins unclassified

1 MEFVSGYRDE FLDFTALLFG UFRKFVAERG AVGTSLEGRC R(QLEA(QIRRL

51 PlQDPALUVLH VLPNHSVGIS LGlQGAEPGPG PGLGTAULLG DNPPLHLRDL IDl SPYISFVSLE DGEEGEEEEE EDEEEEKRED GGAGSTEKVE PEEDRELAPT

151 SRESPώETNP PGESEEAARE AGGGKDGCRE DRVENETRPiQ KRKGlQRSEAA

2D1 PLHVSCLLLV TDEHGTILGI DLLVDGAiQGT ASUGSGTKDL APUAYALLCH

251 SMACPMGSGD PRKPRlQLTVG DARLHRELES LVPRLGVKLA KTPMRTUGPR

301 PGFTFASLRA RTCHVCHRHS FEAKLTPCPώ CSAVLYCGEA CLRADUiQRCP 351 DDVSHRFUCP RLAAFMERAG ELATLPFTYT AEVTSETFNK EAFLASRGLT

401 RGYUTiQLSML IPGPGFSRHP RGNTPSLSLL RGGDPY(QLL(Q GDGTALMPPV

451 PPHPPRGVFV PELNIiQNKdS LKIHVVEAGK EFDLVMVFUE LLVLLPHVAL

501 ELώFVGDGLP PESDElQHFTL ORDSLEVSVR PGSGISARPS SGTKEKGGRR

551 DLlQIKVSARP YHLFiQGPKPD LVIGFNSGFA LKDTULRSLP RLiQSLRVPAF bOl FTESSEYSCV MDGiQTMAVAT GGGTSPPiQPN PFRSPFRLRA ADNCMSUYCN b51 AFIFHLVYKP AiQGSGARPAP GPPPPSPTPS APPAPTRRRR GEKKPGRGAR 701 RRK BLASTP hits No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_7nl2ι frame 1

No Alert BLASTP hits found

Pedant information for DKFZphtes3_7nl2ι frame 1

Report for DKFZphtes3_7nl2-l

[LENGTH! 7D3

[MU! 77312 - 72

[pi! b - 45

CKU! TRANSMEMBRANE 1

[KU! LOU COMPLEXITY 15 - 22 *

SE lQ MEFVSGYRDEFLDFTALLFGUFRKFVAERGAVGTSLEGRCR(QLEA(QIRRLP(QDPALUVLH

SEG

PRD ccceeeccchhhhhhhhhhhhhhhhhhhhccccccchhhhhhhhhhhhhccccccccccc

MEM

SE lQ VLPNHSVGISLGiQGAEPGPGPGLGTAULLGDNPPLHLRDLSPYISFVSLEDGEEGEEEEE

SEG xxxxxxxxxxx

PRD cccccccccccccccccccccceeeeeecccccccccccccceeeeeeccccchhhhhhh

MEM

SE lQ EDEEEEKREDGGAGSTEKVEPEEDRELAPTSRESPiQETNPPGESEEAAREAGGGKDGCRE

SEG xxxxxxxxxxxx xxxxxxxxxxxxx

PRD hhhhhhhhcccccccccccccccccccccccccccccccccchhhhhhhhccccccccce

MEM

SElQ DRVENETRP(QKRKG(QRSEAAPLHVSCLLLVTDEHGTILGIDLLVDGA(QGTASUGSGTKDL

SEG

PRD eeccccccccccccccccccchhhhhheeeecccccccchhhhhhccccccccccccccc

MEM

S ElQ APUAYALLCHSMACPMGSGDPRKPRiQLTVGDARLHRELESLVPRLGVKLAKTPMRTUGPR

SEG

PRD hhhhhhhhhhhhccccccccccccceeeecchhhhhhhhhhhcccccccccccccccccc

MEM

SE(Q PGFTFASLRARTCHVCHRHSFEAKLTPCP(^QCSAVLYCGEACLRADU(QRCPDDVSHRFUCP

SEG

PRD ccccchhhhhhhhcccccccccccccccccceeeeccchhhhhhhhccccccccccccch

MEM

SEώ RLAAFMERAGELATLPFTYTAEVTSETFNKEAFLASRGLTRGYUTiQLSMLIPGPGFSRHP

SEG

PRD hhhhhhhhhhhhhccccccccchhhhhhhhhhhhhhhhcccccchhhhhccccccccccc

MEM SElQ RGNTPSLSLLRGGDPYtQLL(QGD6TALMPPVPPHPPRGVFVPELNI(QNK(QSLKIHVVEAGK

SEG xxxxxxxxxxxxxx

PRD cccccceeeeeccccceeeccccccccccccccccceeeeccccchhhhhheeeeeeccc

MEM

SElQ EFDLVMVFUELLVLLPHVALELiQFVGDGLPPESDEiQHFTLlQRDSLEVSVRPGSGISARPS

SEG xxxxxxxxxxxxx

PRD cccchhhhhhhhhchhhhhhhhhhhcccccccchhhhhhhccccceeeeccccccccccc

MEM - - - MMMMMMMMMMMMMMMMM

SElQ SGTKEKGGRRDLiQIKVSARPYHLFlQGPKPDLVIGFNSGFALKDTULRSLPRLlQSLRVPAF

SEG

PRD ccccccccccceeeeeeccccccccccccceeeecccccccccccccccccccccccccc

MEM

SElQ FTESSEYSCVMDGiQTMAVATGGGTSPPi^QPNPFRSPFRLRAADNCMSUYCNAFIFHLVYKP

SEG x

PRD cccccceeeecccceeeeeecccccccccccccccchhhhhcchhhhhhhhhhhhhhccc

MEM

SElQ AiQGSGARPAPGPPPPSPTPSAPPAPTRRRRGEKKPGRGARRRK

SEG xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

PRD ccccccccccccccccccccccccchhhhhccccccccccccc

MEM

(No Prosite data available for DKFZphtes3_7nl2 - 1) (No Pfam data available for DKFZphtes3_7nl2- 1) DKFZphtes3_1elb

group: transmembrane protein

DKFZphtes3_1elb encodes a novel 531 amino acid protein without similarity to known proteins- The novel protein contains 1 transmembrane region. The only EST described so far is from testis-

No informative BLAST resultsi No predictive prositei pfam or SCOP motife ■ The new protein can find application in studying the expression profile of testis-specif ic genes and as a new marker for testicular cells-

putative protein

1 EST hit perhaps complete eds- Sequenced by DKFZ

Locus: unknown Insert length: 2011 bp

Poly A stretch at pos- 116bι no polyadenylation signal found

1 CATGGCAACA TGAGCAGTGC TGAGATAATT GGTTCTACAA ATCTTATAAT

51 TCTGCTAGAG GATGAAGTCT TTGCCGATTT TTTCAACACA TTTCTTTCCC

101 TCCCGGTTTT TGGTCAGACA CCATTTTATA CTGTTGAAAA TTCACAGTGG

151 AGCTTGTGGC CAGAAATACC TTGTAACTTG ATTGCCAAAT ACAAAGGGTT

201 ATTGACCTGG TTGGAAAAAT GCCGATTACC TTTCTTCTGT AAAACAAACT 251 TGTGTTTCCA TTACATTCTC TGTCAGGAGT TCATCAGTTT CATTAAGTCC

3D1 CCAGAAGGAG CCAAGATGAT GAGATGGAAA AAGGCAGACC AGTGGCTACT

351 CCAGAAATGC ATTGGCGGGG TCAGAGGGAT GTGGCGCTTC TATTCCTACC

4D1 TCACAGGCAG TGCAGGTGAA GAATTGGTGG ATTTCTGGAT CCTTGCTGAG

451 AACATCCTGA GCATAGATGA GATGGACCTG GAAGTGAGAG ACTACTACCT 501 GTCCCTCCTC CTCATGCTGA GGGCCACTCA TCTGCAGGAG GGCTCCAGGG

551 TGGTAACCCT CTGTAACATG AACATCAAGT CCCTCCTGAA CCTCTCCATC bOl TGGCATCCCA ACCAATCAAC CACTAGGAGG GAGATCCTGA GCCACATGCA bSl GAAAGTGGCT CTGTTCAAAC TCCAGAGCTA TTGGCTTCCC AACTTTTACA

701 CCCACACCAA GATGACCATG GCCAAGGAGG AAGCATGCCA TGGTCTGATG 751 CAAGAGTACG AGACTCGCTT ATACAGCGTT TGCTACACCC ACATAGGAGG

801 GCTCCCTCTG AACATGAGCA TCAAGAAGTG CCACCACTTT CAGAAACGGT

651 ACTCAAGCAG GAAAGCCAAG AGGAAGATGT GGCAATTGGT AGATCCTGAC

101 TCTTGGTCTC TGGAAATGGA TCTCAAGCCA GATGCTATTG GTATGCCCCT

151 ACAGGAGACA TGTCCTCAAG AGAAGGTGGT TATACAAATG CCTTCCCTGA 1001 AAATGGCTTC TTCAAAGGAA ACAAGAATCA GTTCCCTGGA AAAGGATATG

1051 CATTATGCAA AAATATCCAG CATGGAGAAT AAAGCCAAGA GCCACCTCCA

1101 CATGGAAGCC CCCTTTGAGA CAAAGGTCTC TACCCACCTG AGGACTGTCA

1151 TCCCCATTGT CAATCACTCC TCCAAGATGA CAATTCAGAA GGCCATCAAG

1201 CAAAGCTTCT CCTTAGGATA CATCCACTTG GCCTTGTGTG CTGATGCCTG 1251 TGCAGGGAAC CCTTTCCGGG ACCACCTGAA GAAGCTGAAT TTGAAAGTGG

13D1 AGATCCAACT TCTTGACCTC TGGCAGGACT TGCAGCATTT CCTCAGTGTC

1351 CTTCTGAATA ACAAAAAGAA TGGGAATGCA ATCTTTCGTC ACTTGCTGGG

1401 TGACAGAATC TGCGAGCTCT ACCTGAATGA GCAGATTGGT CCGTGCTTAC

1451 CACTCAAATC CCAAACCATT CAGGGCCTGA AGGAACTATT GCCCTCTGGG 1501 GATGTGATCC CCTGGATTCC CAAAGCCCAG AAGGAGATTT GCAAGATGCT

1551 CAGTCCCTGG TATGATGAGT TTCTAGATGA AGAGGACTAC TGGTTTCTCC

IfaOl TTTTTACGGT AGGAAGGACT TTGGGTTAGG AAGGAATCAT GAGGATGAGG lfa51 GAAGAAGAAA GAGTAATTAC TGTTTTAAAA GGGTTATGTG TTAAAGTAAA

17D1 TGAAATTGTT ATTTTTCCTA GAGTCAACCA AAGATCAGCA TGGTCCCTGT 1751 TGTTCTAAAG CTAAACCTCT CAAGGAAAAG GACTCAGTGC ATAAGATGAC

1801 TTTGGTGAAA CCCCGTCTCT ACTAAAAATA CAAAAAATTA GCCGGGCGTA

1851 GTGGCGGGCG CCTGTAGTCC CAGCTACTTG GGAGGCTGAG GCAGGAGAAT

1101 GGTGTGAACC CGGGAGGCGG AGCTTGCAGT GAGCCGAGAT CCCGCCACTG

1151 CACGCCAGCC TGGGCGACAG AGCGAGACTC CGTCTCAAAA AAAAAAAAAA 20D1 AAAAAAAAAA G

BLAST Results

No BLAST result

Medline entries

No Medline entry Peptide information for frame 1

ORF from 10 bp to lb2b bpi peptide length: 531 Category: putative protein Classification: no clue 1 MSSAEIIGST NLIILLEDEV FADFFNTFLS LPVFGiQTPFY TVENSiQUSLU

51 PEIPCNLIAK YKGLLTULEK CRLPFFCKTN LCFHYILCiQE FISFIKSPEG

IDl AKMMRUKKAD (QULLiQKCIGG VRGMURFYSY LTGSAGEELV DFUILAENIL

151 SIDEMDLEVR DYYLSLLLML RATHLύEGSR VVTLCNMNIK SLLNLSIUHP

2D1 NlQSTTRREIL SHMiQKVALFK LiQSYULPNFY THTKMTMAKE EACHGLMOEY 251 ETRLYSVCYT HIGGLPLNMS IKKCHHFtQKR YSSRKAKRKM UiQLVDPDSUS

301 LEMDLKPDAI GMPLiQETCPlQ EKVVIiQMPSL KMASSKETRI SSLEKDMHYA

351 KISSMENKAK SHLHMEAPFE TKVSTHLRTV IPIVNHSSKM TIIQKAIKIQSF

4D1 SLGYIHLALC ADACAGNPFR DHLKKLNLKV EIlQLLDLUlQD LiQHFLSVLLN

451 NKKNGNAIFR HLLGDRICEL YLNElQIGPCL PLKSiQTIlQGL KELLPSGDVI 501 PUIPKAώKEI CKMLSPUYDE FLDEEDYUFL LFTVGRTLG

BLASTP hits

No BLASTP hits available

Alert BLASTP hits for DKFZphtes3_1elbι frame 1 No Alert BLASTP hits found

Pedant information for DKFZphtes3_1elfaι frame 1

Report for DKFZphtes3_1elb - 1

[LENGTH! 542

[MU! b210b-0b [pi! 8-35

[KU! Alpha_Beta

SElQ HGNMSSAEIIGSTNLIILLEDEVFADFFNTFLSLPVFGiQTPFYTVENSlQUSLUPEIPCNL PRD cccccceeeeccccceeehhhhhhhhhccccccccccccccccccccccccccccccchh

SElQ IAKYKGLLTULEKCRLPFFCKTNLCFHYILClQEFISFIKSPEGAKMMRUKKADiQULLiQKC PRD hhhhccceeecccccccccccccceeehhhhhhhhhhhccccchhhhhhhcchhhhhhhh SElQ IGGVRGMURFYSYLTGSAGEELVDFUILAENILSIDEMDLEVRDYYLSLLLMLRATHLlQE PRD ccccccceeeeeecccccccchhhhhhhhhhhhcccchhhhhhhhhhhhhhhhhhhhccc

SElQ GSR VTLCNMNIKSLLNLSIUHPNiQSTTRREILSHMiQKVALFKLiQSYULPNFYTHTKMTM

PRD cceeeeecccchhhhhhhhhccccccchhhhhhhhhhhhhhhhhhhccccccchhhhhhh

SElQ AKEEACHGLMlQEYETRLYSVCYTHIGGLPLNMSIKKCHHFiQKRYSSRKAKRKMUiQLVDPD

PRD hhhhhhhhhhhhhhhhheeeeeeccccccccccccccccchhhhhhhhhhhhhheeeccc SElQ SUSLEMDLKPDAIGMPLIQETCPIQEKVVIIQMPSLKMASSKETRISSLEKDMHYAKISSMEN

PRD cccccccccccccccccccccccceeeeeccccccccccccccchhhhhccccchhhhhh

SElQ KAKSHLHMEAPFETKVSTHLRTVIPIVNHSSKMTIlQKAIKlQSFSLGYlHLALCADACAGN PRD hhhhhhhccccccccccccceeeeeeeccccchhhhhhhhhhcccccccchhhhhhcccc

SElQ PFRDHLKKLNLKVEIlQLLDLUlQDLiQHFLSVLLNNKKNGNAIFRHLLGDRICELYLNEiQIG

PRD ccccchhhhhhhhhhhhhhhhhhhhhhhhhhhhccccccceeeecccchhhhhhhhhhcc SElQ PCLPLKSlQTIiQGLKELLPSGDVIPUIPKAiQKEICKMLSPUYDEFLDEEDYUFLLFTVGRT

PRD ccccccchhhhhhhhccccccceeecccchhhhhhhcccchhhhhccccceeeccccccc

SElQ LG PRD cc

(No Prosite data available for DKFZphtes3_1elfa - 1) (No Pfam data available for DKFZphtes3_1elfa ■ 1)

The PROSITE is a database of protein families and domains- It consists of biologically significant sitesi patterns and profiles that help to reliably identify to which known protein family (if any) a new sequence belongs- Uorld Uide Ueb URL http://www-expasy.ch/prosite/ is the entry point to the database. A description of the prosite consensus patterns follows-

NAME: N-glycosylation site CONSENSUS: N--CP>-[ST!--CP> -

NAME: Glycosaminoglycan attachment site- CONSENSUS: S-G-x-G-

NAME: Tyrosine sulfation site-

NAME: cAMP- and cGMP-dependent protein kinase phosphorylation site-

CONSENSUS: CRK! (2 ) -x-CST! .

NAME: Protein kinase C phosphorylation site. CONSENSUS: CST!-x-[RK!-

NAME: Casein kinase II phosphorylation site CONSENSUS: CSTJ-x (2 ) -[DE! .

NAME: Tyrosine kinase phosphorylation site- CONSENSUS: [RK!-x (2ι3) -CDE!-x (2ι3) -Y .

NAME: N-myristoylation site-

CONSENSUS: G--CEDRKHPFYU>-x (2) -CSTAGCN!--CP • NAME: Amidation site.

CONSENSUS: x-G-[RK!-[RK! -

NAME: Aspartic acid and asparagine hydroxylation site. CONSENSUS : C-x-CDN!-x ( 4 ) -CFY!-x-C-x-C -

NAME: Vitamin K-dependent carboxylation domain- CONSENSUS: x (12) -E-x (3) -E-x-C-x (fa) -CDEN!-x-[LIVMFY!-x (1) - [FYU!-

NAME: Phosphopantetheine attachment site- CONSENSUS: [DEtQGSTALMKRH!-[LIVMFYSTAC!-[GN(Q!-[LIVMFYAG!- [DNEKHS!-S-[LIVMST!- CONSENSUS: -CPCFY3--[STAGCP<QLIVMF!-[LIVMATN!-[DEN(QGTAKRHLM!- CLIVMUSTA!-[LIVGSTACR!- CONSENSUS: x (2) -CLIVMFA! ■

NAME: Acyl carrier protein phosphopantetheine domain profile-

NAME: Prokaryotic membrane lipoprotein lipid attachment site-

CONSENSUS: ERK3- (fa) -[LIVMFUSTAG! (2) -[LIVMFYSTAGC(Q!-[AGS!-C .

NAME: Prokaryotic N-terminal methylation site- CONSENSUS: [KRHE(QSTAG!-G-[FYLIVM!-[ST!-[LT!-[LIVP!-E- [LIVMFUSTAG!(14) - NAME: Prenyl group binding site (CAAX box). CONSENSUS: C--CDEN(Q}-[LIVM!-x>.

NAME: Protein splicing signature.

CONSENSUS: [DNEG!-x-CLIVFA!-[LIVMY!-[LVAST!-H-N-[STC! •

NAME: Endoplasmic reticulum targeting sequence CONSENSUS: [KRH(QSA!-[DEN(Q!-E-L> •

NAME: Microbodies C-terminal targeting signal- CONSENSUS: [STAGCN!-[RKH!-[LIVMAFY!> -

NAME: Gram-positive cocci surface proteins 'anchoring' hexapeptide-

CONSENSUS: L-P-x-T-G-[STGAVDE! .

NAME Bipartite nuclear targeting sequence

NAME: Cell attachment sequence CONSENSUS: R-G-D-

NAME: ATP/GTP-binding site motif A (P-loop) CONSENSUS: _ [AG!-x ( 4 ) -G-K-[ST! ■

NAME: Cyclic nucleotide-binding domain signature 1. CONSENSUS: [LIVM!-[VIC!-x (2) -G-[DEN(QTA!-x-CGAC!-x (2 ) - [LIVMFY!(4)-x(2)-G.

NAME: Cyclic nucleotide-binding domain signature 2- CONSENSUS: [LIVMF!-G-E-x-[GAS!-[LIVM!-x (Sill) -R-^[STA(Q!-A-x- [LIVMA!-x-[STACV!-

NAME: cAMP/cGMP binding motif. NAME: EF-hand calcium-binding domain-

CONSENSUS: D-x-[DNS!-€ILVFYU}-[DENSTG!-[DN(QGHRK!--CGP}- [LIVMCJ-[DEN(QSTAGC!-x(2)- CONSENSUS: [DE!-[LIVMFYU! -

NAME: Actinin-type actin-binding domain signature 1- CONSENSUS: [E(Q!-x (2) -CATV!-[FY!-x (2) -U-x-N -

NAME: Actinin-type actin-binding domain signature 2- CONSENSUS: CLIVM!-x-[SGN!-[LIVM!-[DAGHE!-[SAG!-x- NEAG!- [LIVM!-x-[DEAG!-x(4)- CONSENSUS: [LIVM!-x-[LM!-[SAG!-[LIVM!-[LIVMT!-U-x-[LIVM! (2 ) -

NAME: Anaphylatoxin domain signature- CONSENSUS: [CSH!-C-x (2) -[GAPl-x (7ι8) -[GASTDE(QR!-C-[GASTDE(QL!- x(3ι1)-[GASTDE(QN!-x(2)- CONSENSUS: ECE!-x (faι7) -C-C .

NAME: Anaphylatoxin domain profile.

NAME: Apple domain-

CONSENSUS: C-x (3) -[LIVMFY!-x (5) -[LIVMFY!-x (3) -CDENiQ!- CLIVMFY!-x(10)-C-x(3)-C-T-

CONSENSUS: x ( ) -C-x-CLIVMFY!-F-x-CFY!-x (13ιl4) -C-x-[LIVMFY!- [RK!-x-[ST!-x(14ιl5)-

CONSENSUS: S-G-x-[ST!-[LIVMFY!-x (2) -C -

NAME: Band 4-1 family domain signature 1- CONSENSUS: U-CLIV!-x (3 ) -CKR(Q!-x-[LIVM!-x (2) -[(QH!-x (0 ι2 ) - [LIVMF!-x(faι6)-[LIVMF!-

CONSENSUS: x (3ι 5) -F-[FY!-x (2) -[DENS! -

NAME: Band 4-1 family domain signature 2-

CONSENSUS: [HYU!-x (1) - EN(QSTV!-[SA!-x (3 ) -[FY!-[LIVM!-x ( 2) - [ACV!-x(2)-[LM!-x(2)-

CONSENSUS-" [FY!-G-x-CDEN(QST!-[LIVMFYS!-

NAME: Band 4-1 family domain profile. NAME: Clq domain signature-

CONSENSUS: F-x ( 5) -CND!-x (4 ) -[FYUL!-x (b) -F- (5) -G-x-Y-x-F-x- [FY!-

NAME: C-terminal cystine knot signature- CONSENSUS: C-C-X (13) -C-x (2) -CGN!-x (12) -C-x-C-x (2ι4 )-C -

NAME: C-terminal cystine knot profile-

NAME: CUB domain profile-

NAME: Death domain profile-

NAME-" EGF-like domain signature 1- CONSENSUS: C-x-C-x (5) -G-x (2 ) -C •

NAME: EGF-like domain signature 2- CONSENSUS: C-x-C-x (2) -CGP!-CFYU!-x ( 4 iβ) -C . NAME: Calcium-binding EGF-like domain pattern signature- CONSENSUS: CDE(QN!-x-CDE(QN! (2) -C-x (3ιl4 ) -C-x (3ι7 ) -C-x-[DN!- x(4)-CFY!-x-C NAME: Laminin-type EGF-like (LE) domain signature-

CONSENSUS: C-x (lι2) -C- ( 5) -G-x (2) -C-x (2) -C-x (3ι4 ) -CFYU!-

NAME: Coagulation factors 5/6 type C domain (FA58C) signature 1-

CONSENSUS: CGAS!-U-x (7ιl5) -CFYU!-[LIV!-x-[LIVFA!-[GSTDEN!- x(fa)-[LIVF!-x(2)-[IV!-x-

CONSENSUS: CLIVT!-[(QKM!-G - NAME: Coagulation factors 5/8 type C domain (FA58C) signature 2. CONSENSUS: P-x (8 ilO) -[LM!-R-x-[GE!-[LIVP!-x-G-C •

NAME: Forkhead-associated (FHA) domain profile-

NAME: Fibrinogen beta and gamma chains C-terminal domain signature.

CONSENSUS: U-U-CLIVMFYU!-x (2) -C-x (2) -[GSA!-x (2) -N-G - NAME: Type I fibronectin domain-

CONSENSUS: C-x (fa iS ) -CLFY!-x (5) -[FYU!-x-[RK!-x (8ιl0) -C-x-C- x(bι1)-C

NAME: Type II fibronectin collagen-binding domain- CONSENSUS: C-x (2 ) -P-F-x-CFYUI!-x (7 ) -C-x (8ιlD ) -U-C-x ( 4 ) - [DNSR!-[FYU!-x(3ι5)-[FYU!-x- CONSENSUS: [FYUO-O

NAME: Hemopexin domain signature- CONSENSUS: [LIFAT!-x (3) -U-x (2ι3) -[PE!-x (2 ) -[LIVMFY!- EN(QS!- [STA!-[AV!-[LIVMFY!-

NAME: Kringle domain signature. CONSENSUS: [FY!-C-R-N-P- NR! -

NAME: Kringle domain profile-

NAME: LDL-receptor class A (LDLRA) domain signature- CONSENSUS: C-[VILMA!-x (5) -C- NH!-x (3) - EN(QHT!-C-x (3ι 4 ) - [STADE!-[DEH!-[DE!-x(lι5)~ CONSENSUS: C

NAME: LDL-receptor class A (LDLRA) domain profile- NAME: C-type lectin domain signature-

CONSENSUS: C-[LIVMFYATG!-x (5ιl2) -[UL!-x-[DNSR!-x (2) -C-x ( 5ιb ) -

[FYULIVSTA!-[LIVMSTA!-

CONSENSUS: C NAME: C-type lectin domain profile-

NAME: Link domain signature-

CONSENSUS: C-x (15) -A-x (3ι4 ) -G-x ⁽3) -C-x ⁽2⁾ -G-x ^(βil) -P-χ (7 ) -C - NAME: Osteonectin domain signature 1-

CONSENSUS: C-x-[DN!-x (2) -C-x (2) -G-CKRH!-x-C-x (faι7) -P-x-C-x-C- x(3ι5)-C-P.

NAME: Osteonectin domain signature 2- CONSENSUS: F-P-x-R-[IM!-x-D-U-L-x-[N(Q! .

NAME: Somatomedin B domain signature-

CONSENSUS: C-x-C-x (3) -C-x (5) -C-C-x-CDN!-[FY!-x (3) -C .

NAME: Thyroglobulin type-1 repeat signature-

CONSENSUS: [FYUHP!-x-P-x-C-x (3ι 4 ) -G-x-[FYU!-x (3) -iQ-C-x (4 ilO)

C-[FYU!-C-V-x(3ι4)- CONSENSUS: CSG!

NAME: P-type 'Trefoil' domain signature-

CONSENSUS: R-x(2)-C-x-[FYPST!-x(3ι4)-[ST!-x(3)-C-x(4)-C-C-

[FYUH!-

NAME-" Cellulose-binding domaini bacterial type-

CONSENSUS: U-N-[STAGR!-[STDN!-[LIVM!-x(2)-[GST!-x-[GST!-x(2)'

CLIVMFT!-CGA! NAME: Cellulose-binding domaini fungal type-

CONSENSUS: C-G-G-x (4 ι7) -G-x (3) -C-x ( 5) -C-x (3ι 5) -CNHG!-x- [FYUM!-x(2)-(Q-C

NAME: Chitin recognition or binding domain signature. CONSENSUS: C-x (4 i 5 ) -C-C-S-x (2) -G-x-C-G-x ( 4 ) -CFYU!-C -

NAME: Barwin domain signature 1- CONSENSUS: C-G-[KR!-C-L-x-V-x-N ■ NAME: Barwin domain signature 2-

CONSENSUS: V- N!-Y-[E(Q!-F-V-[DN!-C ■

NAME: BIR repeat-

CONSENSUS: [HKEPILVY!-x (2 ) -R-x (3ι7) -[FYU!-x (11 ιl4 ) -[STAN!-G- [LMF!-X-[FYHDA!-X(4)-

C NSENSUS-" [DESL!-X(2ι 3) -C-X (2) -C-X (b) -CUA!-X (D-H-X (4 ) - CPRSD!-X-C-X(2)-CLIVMA!-

NAME: UAP-type ' four-disulfide core' domain signature. CONSENSUS: C-x-CO-CDN!-x (2) -C-x (5) -C-C

NAME: Phorbol esters / diacylglycerol binding domain- CONSENSUS: H-x-CLIVMFYU!-x (δill) -C-x (2) -C-x (3) -[LIVMFC!- x(5ιlO)-C-x(2)-C-x(4)-[HD!- CONSENSUS: x (2) -C-x (5ι1 ) -C -

NAME: C2 domain signature-

CONSENSUS: [ACG!-x (2) -L-x (2ι3> -D-x (li 2) -[NGSTLIF!-[GTMR!-x-

[STAP!-D-[PA!-[FY!-

NAME". C2-domain profile- NAME-" CAP-Gly domain signature CONSENSUS: G-x (βilO ) -[FYU!-x-G-^[LIVM!-x-[LIVMFY!-x ( 4 ) -G-K-

CNH!-x-G-[STAR!-x(2)-G-

CONSENSUS: x(2)-[LY!-F- NAME: Ly-b / u-PAR domain signature-

CONSENSUS: CE(QR!-C-[LIVMFYAH!-x-C-x ( 5ιδ) -C-x ^^-[EDNOSTVI- C-CO-x ( 5) -C- CONSENSUS". x(12ι24)-C NAME: MAM domain signature-

CONSENSUS: G-x-CLIVMFY! (2) -x (3) -CSTAJ-x (10 ill ) -CLV!-x (4 ) -

[LIVMF!-x(bι7)-C-CLIVM!-x-

CONSENSUS: F-x-[LIVMFY!-x (3) -[GSC! - NAME: MAM domain profile-

NAME: PH domain profile-

NAME: Phosphotyrosine interaction domain (PID) profile-

NAME: Src homology 2 (SH2) domain profile-

NAME-" Src homology 3 (SH3) domain profile- NAME: VUFC domain signature-

CONSENSUS: C-x (2ι3 ) -C-x-C-x (bιl4 ) -C-x (3 ι4 ) -C-x (2ι 10) -C- x(1ιlfa)-C-C-x(2ι4)-C-

NAME: UU/rsp5/UUP domain signature- CONSENSUS: U-x dill ) -CVFY!-[FYU!-x (bι7) -[GSTNE!-[GSTιQCR!- [FYU!-x(2)-P-

NAME: UU/rsp5/UUP domain profile- NAME: ZP domain signature-

CONSENSUS: CLIVMFYU!-x (7) -[STAPDNL!-x (3) -[LIVMFYU!-x-

[LIVMFYU!-x-[LIVMFYU!-x(2)-C-

CONSENSUS: [LIVMFYU!-x-[ST!-[PSL!-x (2ι4 ) - ENS!-x-[STADN(QLF!- x(fa)-[LIVM!(2)-x(3ι4)- CONSENSUS: C

NAME: S-layer homology domain signature-

CONSENSUS: CLVFYT!-x-[DA!-x (2ι 5) -[DN6SATPHY!-[UYFPDA!-x ( ) - [LIV!-x(2)-[GTALV!- CONSENSUS: x ( ifa )-[LIVFYC!-x (2) -G-x-[PGSTA!-x (2ι3)-[MFYA!-x- [PGAV!-x(3ιlO)-[LIVMA!- CONSENSUS: [STKR!-[RY!-x-[EιQ!-x-[STALIVM! -

NAME: 'Homeobox' domain signature- CONSENSUS: ^[LIVMFYG!-^[ASLVR!-x ⁽2 ) -[LIVMSTACN!-x-[LIVM!-x (4 ) - [LIV!-[RKN<QESTAIY!- CONSENSUS: [LIVFSTNKH!-U-^[FYVC!-x-[NDιQTAH!-x ⁽5⁾ -[RKNAIMU! -

NAME: 'Homeobox' domain profile.

NAME." 'Homeobox' antennapedia-type protein signature. CONSENSUS: [LIVMFE!-[FY!-P-U-M-[KR(QTA! . NAME: 'Homeobox' engrailed-type protein signature- CONSENSUS: L-M-A-(Q-G-L-Y-N -

NAME: 'Paired box' domain signature- CONSENSUS: R-P-C-x (11) -C-V-S -

NAME: 'POU' domain signature 1-

CONSENSUS: CRK(Q!-R-[LIM!-x-[LF!-G-[LIVMFY!-x-(Q-x-[DN(Q!-V-G - NAME-" 'POU' domain signature 2-

CONSENSUS: S-(Q-[ST!-[TA!-I-[SC!-R-F-E-x-ELS(Q!-x-[LI!-[ST! -

NAME: Zinc fingeri C2H2 typei domain- CONSENSUS: C-x(2ι4)-C-x(3)-[LIVMFYUC!-x(δ)-H-x(3ι5)-H

NAME: Zinc fingeri C3HC4 type (RING finger)ι signature CONSENSUS: C-x-H-x-[LIVMFY!-C-x (2) -C-[LIVMYA! -

NAME: Nuclear hormones receptors DNA-binding region signature-

CONSENSUS: C-x (2)-C-x-CDE!-x (5) -[HN!-[FY!-x (4 ) -C-x (2) -C-x (2) ^■ F-F-x-R.

NAME: GATA-type zinc finger domain- CONSENSUS: C-x-CDN!-C-x ( 4 ι5) -[ST!-x (2) -U-[HR!-[RK!-x (3) -[GN!- x(3ι4)-C-N-CAS!-C

NAME: Poly ( ADP-ribose) polymerase zinc finger domain signature. CONSENSUS: C-CKR!-x-C-x (3) -I-x-K-x (3) -[RG!-x (Ifailβ ) -U-[FYH!- H-x(2)-C

NAME-" Poly (ADP-ribose) polymerase zinc finger domain profile ■

NAME: Fungal Zn(2)-Cys(fa) binuclear cluster domain signature .

CONSENSUS: CGASTPV!-C-x (2) -C-CRKHSTACU!-x (2) -[RKH(Q!-x (2) -C- x(5ιl2)-C-x(2)-C-x(faιβ)- CONSENSUS: C

NAME: Fungal Zn(2)-Cys(fa) binuclear cluster domain profile-

NAME-" Prokaryotic dksA/traR C4-type zinc finger- CONSENSUS: C-[DES!-x-C-x (3) -I-x (3) -R-x (4 ) -P-x ( ) -C-x (2) -C -

NAME: Copper-fist domain signature-

CONSENSUS: M-CLIVMF! (3) -x (3 ) -K-CMY!-A-C-x (2) -C-I-CKR!-x-H- CKR!-x(3)-C-x-H-x(β)- CONSENSUS: CKR!-x-[KR!-G-R-P -

NAME: Copper fist DNA binding domain profile-

NAME: Leucine zipper pattern- CONSENSUS-" L-x (fa ) -L-x (fa )-L-x (fa )-L -

NAME: bZIP transcription factors basic domain signature- CONSENSUS : [KR!- x ( l ι 3 ) -[RKSAιQ!-N- x ( 2 ) -CSAlQ! ( 2 ) -χ-[RKTAEN<Q!-x-

R- x-[RK! -

NAME: Myb DNA-binding domain repeat signature 1- CONSENSUS: U-CST!-x (2 ) -E-[DE!-x (2) -[LIV! .

NAME: Myb DNA-binding domain repeat signature 2-

CONSENSUS: U-x (2) -[LI!-[SAG!-x ( 4 i 5) -R-x (8) -[YU!-x (3) -[LIVM! - NAME: Myc-typei 'helix-loop-helix' dimerization domain signature-

CONSENSUS: [DEMSTAP!-K-[LIVMUAGSN!--CFYUCPHKR>-[LIVT!-[LIV!- x(2)-[STAV!-[LIVMSTAC!-x- CONSENSUS: [VMFYH!-[LIVMTA!--CP>--CP>-[LIVMSR! -

NAME: p53 tumor antigen signature- CONSENSUS: π-C-N-S-S-C-M-G-G-M-N-R-R

NAME: CBF-A/NF-YB subunit signature- CONSENSUS: C-V-S-E-x-I-S-F-[LIVM!-T-[SG!-E-A-[SC!- E!-[KRιQ!- C

NAME: CBF-B/NF-YA subunit signature-

CONSENSUS: γ__V-N-A-K-(Q-Y-x-R-I-L-K-R-R-x-A-R-A-K-L-E -

NAME: 'Cold-shock' DNA-binding domain signature- CONSENSUS: [FY!-G-F-I-x (bι7) - ER!-[LIVM!-F-x-H-x-[STKR!-x- [LIVMFY!- NAME: CTF/NF-I signature-

CONSENSUS: _R__κ__R_κ-γ__F_<_<---._H-E-K-R -

NAME: Ets-domain signature 1-

CONSENSUS: L-[FYU!-[<QEDH!-F-[LI!-[LVt2K!-x-[LI!-L -

NAME: Ets-domain signature 2.

CONSENSUS: [RKH!-x (2 ) -M-x-Y-[DEN(Q!-x-[LIVM!-[STAG!-R-[STAG!-

[LO-R-x-Y. NAME: Ets-domain profile-

NAME: Fork head domain signature 1-

CONSENSUS: [KR!-P-[PT(Q!-[FYLVιQH!-S-[FY!-x (2) -[LIVM!-x (3ι 4 ) -

[AC!-[LIM!.

NAME: Fork head domain signature 2- CONSENSUS: U-[(QKR!-[NS!-S-[LIV!-R-H -

NAME: Fork head domain profile-

NAME: HSF-type DNA-binding domain signature-

CONSENSUS: L-x (3) -[FY!-K-H-x-N-x-[STAN!-S-F-CLIVM!-R-ιQ-L-

[NH!-x-Y-x-[FYU!-[RKH!-K-

CONSENSUS: [LIVM!-

NAME: Tryptophan pentad repeat (IRF family) signature- CONSENSUS: U-x- NH!-x (5) -[LIVF!-x-[IV!-P-U-x-H-x (lilO ) -[DE!- x(2)-[LIVF!-F-[KR(Q!-x- CONSENSUS : [UR!-A -

NAME: LIM domain signature-

CONSENSUS: C-x (2 ) -C-x (15-ιΞl) -CFYUH!-H-x (2) -[CH!-x (2) -C-x (2) - C-x(3)-CLIVMF!-

NAME: LIM domain profile-

NAME: NF-kappa-B/Rel/dorsal domain signature- CONSENSUS: F-R-Y-x-C-E-G -

NAME: MADS-box domain signature-

CONSENSUS: R-x-CRK!-x ( 5) -I-x- N!-x (3) -[KR!-x (2) -T-[FY!-x- [RK!(3)-x(2)-[LIVM!-x- CONSENSUS: K (2 ) -A-x-E-CLIVM!-CST!-x-L-x ( 4 ) -CLIVM!-x- CLIVM!(3)-x(fa)-[LIVMF!-x(2)- CONSENSUS: CFY!-

NAME: MADS-box domain profile-

NAME: T-box domain signature 1-

CONSENSUS: L-U-x (2) -CFC!-x (3ι ) -[NT!-E-M-[LIV! (2) -T-x (2 ) -G-

[RG!-[KR(Q!- NAME: T-box domain signature 2-

CONSENSUS: [LIVMYU!-H-[PADH!- EN!-[GS!-x (3) -G-x (2) -U-M-x (3) - [IVA!-x-F-

NAME: TEA domain signature- CONSENSUS: G-R-N-E-L-I-x (2) -Y-I-x (3) -CTC!-x (3) -R-T-[RK! (2 ) -(Q- [LIVM!-S-S-H-[LIVM!- CONSENSUS: (Q-V-

NAME: Transcription factor TFIIB repeat signature- CONSENSUS: G-[KR!-x (3) -[STAGN!-x-[LIVMYA!-[GSTA! (2 ) -[CSAV!- [LIVM!-[LIVMFY!-[LIVMA!- CONSENSUS: [GSA!-[STAC! -

NAME: Transcription factor TFIID repeat signature- CONSENSUS: Y-x-P-x (2) -CIF!-x (2 ) -CLIVM! (2) -x-[KRH!-x ( 3) -P- [RK(Q!-x(3)-L-[LIVM!-F-x-

CONSENSUS: [STN!-G-[KR!-[LIVM!-x (3) -G-[TAGL!-[KR!-x ( 7 ) -[AGC!- x(7)-CLIVM!- NAME: TFIIS zinc ribbon domain signature-

CONSENSUS: C-x (2 ) -C-x (1 ) -CLIVM(QSAR!-[(QH!-[STιQL!-[RA!-[SACR!- x-[DE!-[DET!-[PGSEA!-

CONSENSUS: x (fa ) -C-x (2ι5) -C-x (3) -CFU! - NAME: TSC-22 / dip / bun family signature-

CONSENSUS: M-D-L-V-K-x-H-L-x (2) -A-V-R-E-E-V-E -

NAME: Prokaryotic transcription elongation factors signature 1- CONSENSUS: CST!-x ( 2) -[GS!-x (3) -[LI!-x (2) -E-L-x (2) -L-x (3ι 4 ) -R- x(2)-CIV!-x(3)-[LIV!- CONSENSUS: x (fa ) -G-D-x (2) -E-N-CGSA!-x-Y - NAME: Prokaryotic transcription elongation factors signature

2-

CONSENSUS: S-x (2) -S-P-^[LIVM!-[AG!-x-[SAG!-^[LIVM!-[LIVMY!- x(4)-[DG!-[DE!-

NAME: DEAD-box subfamily ATP-dependent helicases signature- CONSENSUS: [LIVMF!(2)-D-E-A-D-[RKEN!-x-[LIVMFYGSTN!-

NAME: DEAH-box subfamily ATP-dependent helicases signature- CONSENSUS: [GSAH!-x-[LIVMF!(3)-D-E-[ALIV!-H-[NECR!-

NAME: Eukaryotic putative RNA-binding region RNP-1 signature.

CONSENSUS: [RK!-G--CEDRKHPCG>-[AGSCI!-[FY!-[LIVA!-x-[FYLM!.

NAME: Fibrillarin signature-

CONSENSUS: [GST!-[LIVMAP!-V-Y-A-[IV!-E-[FY!-[SA!-x-R-x(2)-R-

CDE!.

NAME: MCM family signature- CONSENSUS: G-CIVT!-[LVAC!(2)-[IVT!-D-[DE!-[FL!-[DNST!.

NAME: MCM family domain-

NAME: XPA protein signature 1-

CONSENSUS: C-x-CDE!-C-x (3) -CLIVMF!-x (lι2) -D-x (2) -L-x (3) -F- x(4)-C-x(2)-C

NAME: XPA protein signature 2-

CONSENSUS: [LIVM!(2)-T-[KR!-T-E-x-K-x-[DE!-Y-[LIVMF!(2)-x-D- x-[DE!-

NAME: XPG protein signature 1-

CONSENSUS: CVI!-[KRE!-P-x-[FYIL!-V-F-D-G-x(2)-[PIL!-x-[LVC!-

K.

NAME: XPG protein signature 2- CONSENSUS: [GS!-[LIVM!-[PER!-[FYS!-[LIVM!-x-A-P-x-E-A-[DE!-

[PAS!-[(QS!-[CLM!-

NAME: Bacterial regulatory proteinsi araC family signature

CONSENSUS: [KR(Q!-[LIVMA!-x (2) -[GSTALIV!--CFYUPGDN>-x (2) -

[LIVMSA!-x( ι1)-[LIVMF!-

CONSENSUS: x (2) -[LIVMSTA!-[GSTACIL!-x (3) -[GAN(QRF!-[LIVMFY!-

CONSENSUS: CFYIVAI--CFYUHCMJ-X (3) -[GSADEN(QKR!-x-[NSTAPKL!-

[PARL!.

NAME: Bacterial regulatory proteinsi araC family DNA-binding domain profile-

NAME: Bacterial regulatory proteinsi arsR family signature. CONSENSUS: C-x ⁽2) -D-[LIVM!-x (fa ⁾ -[ST!-x (4 ) -S-[HYR!-[H(Q! ■ NAME: Bacterial regulatory proteinsi asnC family signature. CONSENSUS: [GSTAP!-x (2) - NEA!-[LIVM!-[GSA!-x (2) -[LIVMFY!- [GN!-[LIVMST!-[ST!-x(b)-R- CONSENSUS: [LVT!- (2)-[LIVM!-x (3) -G. NAME: Bacterial regulatory proteinsi crp family signature- CONSENSUS: [LIVM!-[STAG!-[RHNU!-x (2) -[LIM!-[GA!-x-[LIVMFYA!- [LIVSC!-[GA!-x-[STACN!- CONSENSUS: x (2) -[MST!-x-[GSTN!-R-x-[LIVMF!-x (2) -[LIVMF! -

NAME: Bacterial regulatory proteinsi deoR family signature. CONSENSUS: R-x (3) -CLIVM!-x (3) -[LIVM!-x (lbιl7) -CSTA!-x (2) -T- [LIVMA!-[RH!-[KRNA!-D- CONSENSUS: [LIVMF!-

NAME: Bacterial regulatory proteinsi gntR family signature. CONSENSUS: [LIVAPKR!-[PILV!-x-[E(QTIVMR!-x (Ξ) -[LIVM!-x (3) - [LIVMFYK!-x-[LIVFT!- CONSENSUS: NGSTK!-[RGTLV!-x-[STAIVP!-[LIVA!-x (2) -[STAGV!- [LIVMFYH!-x(2)-[LMA!>

NAME: Bacterial regulatory proteinsi iclR family signature CONSENSUS: [GA!-x (3) - S!-x ⁽2) -E-x ⁽fa) -[CSA!-[LIVM!-[GSA!- x(2)-[LIVM!-[FYH!-[DN!-

NAME: Bacterial regulatory proteinsi lad family signature CONSENSUS: [LIVM!-x-[DE!-[LIVM!-A-x (2⁾ -[STAGV!-x-V-[GSTP!- x(2)-CSTAG!-[LIVMA!-x(2)- CONSENSUS: [LIVMFYAN!-[LIVMC! .

NAME: Bacterial regulatory proteinsi luxR family signature. CONSENSUS: [GDC!-x (2⁾ -[NSTAVY!-x (2)- V!-[GSTA!-x (2) - [LIVMFYUCT!-x-[LIVMFYUCR!-x(3)- CONSENSUS: [NST!-[LIVM!-x (5) -CNRHSA!-[LIVMSTA!-x (2) -[KR! .

NAME: Bacterial regulatory proteinsi lysR family signature. CONSENSUS: [N<QKRHSTAG!-[LIVMFYTA!-x (2) -[STAGLV!-CSTAG!-x ( 4 ) - [LIVMYCT(QR!-[PSTANLVER!- CONSENSUS: x-[PSTAG(QV!-[PSTAGNVMF!-[LIVMFA!-[STAGH!-x (2) - [LIVMF!-x(2)-[LIVMFU!- CONSENSUS: [RKEAV!-x (2) -[LIVMFYNTAE!-x (3) -[LIMVT! .

NAME-" Bacterial regulatory proteinsi marR family signature. CONSENSUS: [STNA!-[LIA!-x-[RNGS!-x (4 ) -[LM!-[EIV!-x (2) -[GES!- [LFYU!-[LIVC!-x(7)- CONSENSUS: [DN!-[RK(QG!-[RK!-x (fa) -T-x (2) -[GA! ■

NAME: Bacterial regulatory proteinsi merR family signature. CONSENSUS: [GSA!-x-[LIVMFA!-[ASM!-x (2) -[STACLIV!-[GSDEN(QR!- [LIVC!-[STANHK!-x(3)-

CONSENSUS: [LIVM!-[RHF!-x-[YU!- EtQ!-x (2ι3) -[GHDNlQ!- [LIVMF!(2) . NAME-" Bacterial regulatory proteinsi tetR family signature- CONSENSUS: G-[LIVMFYS!-x (2ι3) -[TS!-CLIVMT!-x (2) -[LIVM!-x (5) - [LIV(QS!-[STAGEN(QH!-x-

CONSENSUS: [GPAR!-x-[LIVMF!-[FYST!-x-[HFY!-[FV!-x- NST!-K- x(2)-[LIVM!>

NAME: Transcriptional antiterminators bglG family signature CONSENSUS: [ST!-x-H-x (2) -[FA! (2) -[LIVM!-[E(QK!-R-x (2 ) -[(QNK! . NAME: Sigma-54 factors family signature 1-

CONSENSUS: P-CLIVM!-x-CLIVM!-x ( ) -[LIVM!-A-x (2) -CLIVMF!-x (2 ) -

[HS!-x-S-T-[LIVM!-S-R. NAME: Sigma-54 factors family signature 2- CONSENSUS: R-R-T-[IV!-[AT!-K-Y-R •

NAME: Sigma-54 factors family profile- NAME: Sigma-70 factors family signature 1-

CONSENSUS: [DE!-[LIVMF! (2) -[HE(QS!-x-G-x-[LIVMFA!-G-L- [LIVMFYE!-x-[GSAM!-[LIVMAP!-

NAME: Sigma-70 factors family signature 2- CONSENSUS: [STN!-x (2) -[DE(Q!-[LIVM!-CGAS!-x ( 4 ) -[LIVMF!-[PSTG!- x(3)-[LIVMA!-x-[N(QR!- CONSENSUS: CLIVMA!-[E(QH!-x (3) -[LIVMFU!-x (2) -[LIVM! •

NAME: Sigma-7D factors ECF subfamily signature- CONSENSUS: [STAIV!-[P(QDEL!- E!-[LIV!-[LIVTA!-(Q-x-[STAV!- [LIVMFYC!-[LIVMAK!-x-

CONSENSUS: [GSTAIV!-[LIMFYU(Q!-x (12ιl4 ) -[STAP!-[FYU!-[LIF!- x(2)-[IV!- NAME: Sigma-54 interaction domain ATP-binding region A signature-

CONSENSUS: CLIVMFY! (3) -x-G-CDE(Q!-[STE!-G-[STAV!-G-K-x (2) - [LIVMFY!- NAME: Sigma-54 interaction domain ATP-binding region B signature.

CONSENSUS: [GS!-x-[LIVMF!-x (2 ) -A-[DNE(QASH!-[GNEK!-G-[STIM!-

CLIVMFY!(3)-[DE!-[E -

CONSENSUS: [LIVM!-

NAME: Sigma-54 interaction domain C-terminal part signature.

CONSENSUS: [FYU!-P-[GS!-N-[LIVM!-R-[E(Q!-L-x-[NHAT! ■

NAME: Sigma-54 interaction domain profile-

NAME: Single-strand binding protein family signature 1- CONSENSUS: [LIVMF!-[NST!-[KRT!-[LIVM!-x-[LIVMF! (2) -G- HR - [LIVM!-[GST!-x-[DET!. NAME: Single-strand binding protein family signature 2- CONSENSUS: T-x-U-[HY!-[RNS!-[LIVM!-x-[LIVMF!-[FY!-[NGKR! .

NAME: Bacterial histone-like DNA-binding proteins signature. CONSENSUS: [GS -F-x (2 ) -[LIVMF!-x ( 4 ) -[RKEιQA!-x (2) -[RST!-x- [GA!-x-[KN!-P-x-T.

NAME: Dps protein family signature 1-

CONSENSUS: H-CFU!-x-CLIVM!-x-G-x (5) -[LV!-H-x (3) -OE! - NAME: Dps protein family signature 2-

CONSENSUS: [LIVMFY!-[DH!-x-[LIVM!-[GA!-E-R-x (3) -[LIF!-[GDN!- x(2)-[PA!. NAME: DNA repair protein radC family signature- CONSENSUS: H-N-H-P-S-G-

NAME: recA signature-

CONSENSUS: A-L-[KR!-[IF!-[FY!-[STA!-[STAD!-[LIVM(Q!-R

NAME: RecF protein signature 1-

CONSENSUS: P-[ED!-x (3) -[LIVM! ( ) -x-G-[GSAD!-P-x (2) -R-R-x-

[FY!-[LIVM!-D-

NAME: RecF protein signature 2-

CONSENSUS: [LIVMFY!(2)-x-D-x(2ι3)-[SA!-[EH!-L-D-x(2)-[KRH!- x(3)-L- NAME: RecR protein signature-

CONSENSUS: C-x (2) -C-x (3) -CST!-x ( 4 ) -C-x-I-C-x ( 4 ) -R .

NAME: Histone H2A signature- CONSENSUS: CA -G-L-x-F-P-V -

NAME: Histone H2B signature-

CONSENSUS: CKR!-E-CLIVM!-[E(Q!-T-x (2) -[KR!-x-[LIVM! (2 ) -x-

[PAG!-[DE!-L-x-[KR!-H-A-

CONSENSUS: [LIVM!-[STA!-E-G -

NAME: Histone H3 signature 1- CONSENSUS: K-A-P-R-K-(Q-L -

NAME: Histone H3 signature 2-

CONSENSUS: P-F-x-[RA!-L-[VA!-[KR<Q!-CDEG!-[IV! .

NAME: Histone H4 signature- CONSENSUS: G-A-K-R-H- NAME: HMG1/2 signature-

CONSENSUS: [FI!-S-[KR!-K-C-S-[EK!-R-U-K-T-M

NAME: HMG-I and HMG-Y DNA-binding domain (A+T-hook) CONSENSUS: [AT!-x (1 ι2 ) -[RK! (2 ) -[GP!-R-G-R-P-[RK!-x -

NAME: HMG14 and HMG17 signature- CONSENSUS: R-R-S-A-R-L-S-A-[RK!-P .

NAME: Bromodomain signature- CONSENSUS: [STANVF!-x (2)-F-x (4 )-[DNS!-x (5ι 7) - EN(QTF!-Y- CHFY!-x(2)-[LIVMFY!-x(3)-

CONSENSUS: CLIVM!-x (4 ) -[LIVM!-x (faiδ) -Y-x (12ιl3 ) -[LIVM!-x (2) ^■ N-[SACF!-x(2)-[FY!. NAME: Bromodomain profile

NAME: Chromo domain signature-

CONSENSUS: CFYL!-x-CLIVMC!-[KR!-U-x-[GDNR!-[FYULE!-x (5ιfa) ^■

CST!-U-[ES!-CPSTDN!-x(3)-

CONSENSUS: [LIVMC!-

NAME: Chromo and chromo shadow domain profile NAME: Regulator of chromosome condensation (RCCl) signature

1-

CONSENSUS: G-x-N-D-x (2 ) -[AV!-L-G-R-x-T - NAME: Regulator of chromosome condensation (RCCl) signature 2-

CONSENSUS: CLIVMFA!-[STAGC! (2) -G-x (2)-H-[STAGLI!-[LIVMFA!-x- [LIVM!- NAME: Protamine PI signature-

CONSENSUS: [AV!-R-CNFY!-R-x (2ι3) -[ST!-x-S-x-S-

NAME: Nuclear transition protein 1 signature CONSENSUS: S-K-R-K-Y-R-K -

NAME: Nuclear transition protein 2 signature 1 CONSENSUS: H-x (3) -H-S-[NS!-S-x-P-(Q-S -

NAME: Nuclear transition protein 2 signature 2- CONSENSUS: K-x-R-K-x (2) -E-G-K-x (2) -K-[KR!-K -

NAME: Ribosomal protein LI signature-

CONSENSUS: [IM!-x (2)-[LIVA!-x (2ι3) -[LIVM!-G-x (2 ) -[LMS!- [GSNH!-[PTKR!-[KRAV!-G-x- CONSENSUS: [LMF!-P-[DENSTK! -

NAME: Ribosomal protein L2 signature-

CONSENSUS: P-x (2 ) -R-G-[STAIV! (2 ) -x-N-[APK!-x-[DE! - NAME: Ribosomal protein L3 signature-

CONSENSUS: CFL!-x (fa) - N!-x (2) -[AGS!-x-[ST!-x-G-[KRH!-G-x (2) - G-x(3)-R-

NAME: Ribosomal protein L5 signature- CONSENSUS: [LIVM!-x (2) -[LIVM!-[STAC!-[GE!-[(QV!-x (2) -[LIVMA!- x-[STC!-x-[STAG!-[KR!- CONSENSUS: x-[STA!-

NAME: Ribosomal protein Lfa signature 1- CONSENSUS: [PS!-[DENS!-x-Y-K-[GA!-K-G-[LIVM! .

NAME: Ribosomal protein Lfa signature 2-

CONSENSUS: (Q-x (3 ) -CLIVM!-x (2) -[KR!-x (2 ) -R-x-F-x-D-G-[LIVM!-Y- CLIVM!-x(2)-[KR!.

NAME: Ribosomal protein LI signature-

CONSENSUS: G-x (2) -CGN!-x ( 4 ) -V-x (2) -G-CFY!-x (2) -N-CFY!-L-x (5) -

[GA!-x(3)-[STN!- NAME: Ribosomal protein LID signature-

CONSENSUS: CDEH!-x (2 ) -CGS!-[LIVMF!-[STN!-[VA!-x-[DEιQK!- [LIVMA!-x(2)-[LIM!-R-

NAME: Ribosomal protein Lll signature- CONSENSUS: [RKN!-x-[LIVM!-x-G-[ST!-x (2 ) -[SNιQ!-[LIVM!-G-x (2) - [LIVM!-x(Oιl)-[DENG!-

NAME: Ribosomal protein L13 signature- CONSENSUS: [LIVM!-[KRV!-[GK!-M-CLIV!-[PS!-x (4 -, 5) -C6S3-

[N(QEKRA!-x(5)-[LIVM!-x-[AIV!-

CONSENSUS: [LFY!-x-[GDN! - NAME: Ribosomal protein L14 signature-

CONSENSUS: CGA!-[LIV!(3 ) -x (lilO ) -CDNS!-G-x (4 ) -CFY!-x (2) -[NT!- x(2)-V-CLIV!-

NAME: Ribosomal protein L15 signature- CONSENSUS: K-CLIVM! (2) -[GAL!-x-[GT!-x-[LIVMA!-x (2ι5) -[LIVM!- x-CLIVMF!-x(3ι4)- CONSENSUS: CLIVMFC!-CST!-x (2) -A-x (3) -CLIVM!- (3) -G -

NAME-" Ribosomal protein Lib signature 1- CONSENSUS: [KR!-R-x-[GSAC!-[KιQVA!-[LIVM!-U-[LIVM!-[KR!- [LIVM!-[LFY!-[AP!-

NAME: Ribosomal protein Lib signature 2. CONSENSUS: R-M-G-x-[GR!-K-G-x ( 4 ) -[FUKR! •

NAME: Ribosomal protein L17 signature-

CONSENSUS: I-x-[ST!-[GT!-x (2) -[KR!-x-K-x (fa) - E!-x-[LIMV!-

[LIVMT!-T-x-[STAG!-[KR!- NAME: Ribosomal protein L11 signature-

CONSENSUS: [RT!-[KRSVY!-[GSA!-x-V-[RS!-[KR!-[SA!-K-L-Y-Y-L-R .

NAME: Ribosomal protein L2D signature-

CONSENSUS: K-x (3) -[KRC!-x-[LIVM!-U-[IV!-[STNALV!-R-[LIVM!-N- x(3)-[RKH!-

NAME: Ribosomal protein L21 signature-

CONSENSUS: [IVT!-x (3) -[KR!-x (3) -[KR(Q!-K-x (fa ) -G-[HF!-R-[RιQ!- x(2)-T-

NAME: Ribosomal protein L22 signature-

CONSENSUS: [RK(QN!-x ( 4 ) -[RH!-[GAS!-x-G-[KR(QS!-x (1)-[HDN!-

[LIVM!-x-[LIVMS!-x-[LIVM!- NAME: Ribosomal protein L23 signature-

CONSENSUS: [RK! (2 ) -[AM!-[IVFYT!-[IV!-[RKT!-L-[STAN(QK!-x (7) - [LIVMFT!-

NAME: Ribosomal protein L24 signature- CONSENSUS: [GDEN!-D-x-V-x-[IV!-[LIVMA!-x-G-x (2 ) -[KA!-[GN!-

NAME: Ribosomal protein L27 signature- CONSENSUS: G-x-CLIVM! (2) -x-R-(Q-R-G-x ( 5) -G -

NAME-" Ribosomal protein L21 signature-

CONSENSUS: CKN(QS!-CPSTL!-x (2) -[LIMFA!-[KRGSAN!-x-[LIVYSTA!-

[KR!-[KRH!-[DESTANRL!-

CONSENSUS: [LIV!-A-[KRC(QVT!-[LIVMA! -

NAME: Ribosomal protein L30 signature-

CONSENSUS: [IVT!-[LIVM!-x (2) -[LF!-x-[LI!-x-[KRH(QEG!-x (2) -

CSTN(QH!-x-[IVT!- CONSENSUS : x ( 10 ) -CLMS!-[LIV!-x ( 2 ) -[LIVA!-x ( 2 ) -CLMFY!-[IVT! •

NAME: Ribosomal protein L31 signature- CONSENSUS: H-P-F-[FY!-[TI!-x (1 ) -G-R-[AV!-x-[KR! -

NAME: Ribosomal protein L33 signature-

CONSENSUS: Y-x-[ST!-x-[KR!-[NS!-x ( ) -[PAT!-x (Iι2)-[LIVM!-

[EA!-x(2)-K-[FY!-[CSD!- NAME: Ribosomal protein L34 signature-

CONSENSUS: K-[RG!-T-[FYUL!-[EιQS!-x (5) -[KRHS!-x ( 4 ι5) -G-F-x (2) - R-

NAME: Ribosomal protein L35 signature- CONSENSUS: [LIVM!-K-[TV!-x (2) -[GSA!-[SAIL!-x-K-R-[LIVMFY!- [KRL!-

NAME: Ribosomal protein L3b signature-

CONSENSUS: C-x (2 ) -C-x (2) -[LIVM!-x-R-x (3) -[LIVMN!-x-[LIVM!-x- C-x(3ι4)-[KR!-H-x-(Q-x-(Q-

NAME: Ribosomal protein Lie signature-

CONSENSUS: N-x (3) -[KR!-x (2) -A-[LIVT!-x-S-A-[LIV!-x-A-CST!-

[SGA!-x(7)-[RK!-G-H.

NAME: Ribosomal protein Lbe signature- CONSENSUS: N-x (2) -P-L-R-R-x ( ) -[FY!-V-I-A-T-S-x-K .

NAME: Ribosomal protein L7Ae signature- CONSENSUS: CCAl-x ( 4 ) -CIV!-P-[FY!-x (2 ) -CLIVM!-x-[GSιQ!-[KR(Q!- x(2)-L-G-

NAME: Ribosomal protein LlOe signature- CONSENSUS: R-x-A-CFYU!-G-K-[PA!-x-G-x (2 ) -A-R-V -

NAME: Ribosomal protein L13e signature-

CONSENSUS: CKR!-Y-x (2) -K-[LIVM!-R-[STA!-G-[KR!-G-F-[ST!-L-x-

E- NAME: Ribosomal protein L15e signature-

CONSENSUS: [DE!-[KR!-A-R-x-L-G-[FY!-x-[SAP!-x (2) -G- [LIVMFY!(4)-R-x-R-V-x-R-G-

NAME: Ribosomal protein L18e signature- CONSENSUS: [KRE!-x-L-x (2) -[PS!-[KR!-x (2) -[RH!-[PSA!-x-[LIVM!- [NS!-[LIVM!-x-[RK!- CONSENSUS: [LIVM!-

NAME: Ribosomal protein Llle signature- CONSENSUS: R-x-CKR!-x (5) -CKR!-x (3) -[KRH!-x (2) -G-x-G-x-R-x-G- x(3)-A-R-x(3)-CK(Q!- CONSENSUS: x (2) -U-x (7) -R-x (2) -L-x (3) -R -

NAME: Ribosomal protein L21e signature- CONSENSUS: G-CDE!-x-V-x (10) -[GV!-x (2) -[FYH!-x (2) -[FY!-x-G-x- T-G-

NAME: Ribosomal protein L24e signature- CONSENSUS : CFY!-x-[GS!-x ( 2 ) -CIV!-x-P-G-x-G-x ( 2 ) -CFYV!-x-

[KRHE!-x-D -

NAME: Ribosomal protein L27e signature. CONSENSUS:

.

NAME: Ribosomal protein L3De signature 1-

CONSENSUS: CSTA!-x ( 5) -G-x-[(QKR!-x (2 ) -[LIVM!-[K(QT!-x (2) -[KR!- x-G-x(2)-K-x-CLIVM!(3) •

NAME: Ribosomal protein L30e signature 2-

CONSENSUS: CDE!-L-G-[STA!-x (2) -G-[KR!-x (fa ) -[LIVM!-x-[LIVM!-x-

[DEN!-x-G. NAME: Ribosomal protein L31e signature-

CONSENSUS: V-[KR!-[LIVM!-x (3) -[LIVM!-N-x-[AK!-x-U-x-[KR!-G -

NAME: Ribosomal protein L32e signature-

CONSENSUS: F-x-R-x (4 ) -[KR!-x (2 ) -[KR!-[LIVM!-x (3)-U-R-[KR!- x(2)-G-

NAME: Ribosomal protein L34e signature- CONSENSUS: Y-x-[ST!-x-S-[NY!-x (5) -[KR!-T-P-G - NAME: Ribosomal protein L35Ae signature-

CONSENSUS: G-K-[LIVM!-x-R-x-H-G-x (2) -G-x-V-x-A-x-F-x (3 ) -[LI!- P-

NAME: Ribosomal protein L3fae signature- CONSENSUS: P-Y-E-[KR!-R-x-[LIVM!-[DE!-[LIVM! (2) -[KR! -

NAME: Ribosomal protein L37e signature-

CONSENSUS: G-T-x-[SA!-x-G-x-[KR!-x (3) -[ST!-x (Oιl)-H-x (2 ) -C-x- R-C-G-

NAME-" Ribosomal protein L31e signature-

CONSENSUS: [KRA!-T-x (3) -[LIVM!-[KRιQF!-x-[NHS!-x (3) -R-[NHY!-U-

R-R. NAME: Ribosomal protein L44e signature-

CONSENSUS: K-x-[TV!-K-K-x (2) -L-[KR!-x (2) -C -

NAME: Ribosomal protein S2 signature 1-

CONSENSUS: [LIVMFA!-x (2) -[LIVMFYC! (2) -x-[STAC!-[GSTAN(QEKR!- [STALV!-[HY!-[LIVMF!-G.

NAME: Ribosomal protein S2 signature 2-

CONSENSUS: P-x (2) -[LIVMF! (2) -[LIVMS!-x-[GDN!-x (3)-[DENL!- x(3)-CLIVM!-x-E-x(4)- CONSENSUS: CGN(QKRH!-[LIVM!-[AP! •

NAME: Ribosomal protein S3 signature-

CONSENSUS: CGSTA!-[KR!-x (fa) -G-x-[LIVMT!-x (2) -[N<QSCH!-x (lι3 ) - [LIVFCA!-x(3)-[LIV!- CONSENSUS: CDENιQ!-x (7 ) -[LMT!-x (2) -G-x (2) -G -

NAME: Ribosomal protein S4 signature- CONSENSUS: [LIVM!-[DE!-x-R-L-x (3) -CLIVMC!-[VMFYH(Q!-[KRT!- x(3)-[STAGCF!-x-[ST!-x(3)-

CONSENSUS". [SAI!-[KR!-x-[LIVMF!(2) .

NAME: Ribosomal protein S5 signature-

CONSENSUS: G-[KR(Q!-x (3) -[FY!-x-[ACV!-x (2) -[LIVMA!-[LIVM!-

[AG!-[DN!-x(2)-G-x-

CONSENSUS: [LIVM!-G-x-[SAG!-x ( 5ιb) -[DE(Q!-[LIVM!-x (2) -A-

[LIVMF!-

NAME: Ribosomal protein Sb signature-

CONSENSUS: G-x-[KRC!-[DEN(QRH!-L-[SA!-Y-x-I-[KRNSA! -

NAME: Ribosomal protein S7 signature- CONSENSUS: [DENSK!-x-[LIVMET!-x (3) -[LIVMFT! (2 ) -x (fa ) -G-K-[KR!- x(5)-[LIVMF!-[LIVMFC!- CONSENSUS: x(2)-[STA!.

NAME: Ribosomal protein S8 signature- CONSENSUS: [GE!-x (2) -[LIV! (2) -[STY!-T-x (2 ) -G-[LIVM! (2) -x (4 ) - [AG!-[KRHAYI!-

NAME: Ribosomal protein SI signature-

CONSENSUS: G-G-G-x (2 ) -CGSA!-(Q-x (2) -CSA!-x (3) -[GSA!-x-[GSTAV!- [KR!-[GSAL!-[LIF!-

NAME: Ribosomal protein SID signature-

CONSENSUS: [AV!-x (3) -[GDNSR!-[LIVMSTA!-x (3) -G-P-[LIVM!-x-

[LIVM!-P-T-

NAME: Ribosomal protein Sll signature-

CONSENSUS: [LIVMF!-x-[GSTAC!-[LIVMF!-x (2) -[GSTAL!-x (Oil)

[GSN!-[LIVMF!-x-[LIVM!-

CONSENSUS: x ( 4 ) -[DEN!-x-T-P-x-[PA!-[STCH!-[DN! -

NAME: Ribosomal protein S12 signature- CONSENSUS: [RK!-x-P-N-S-[AR!-x-R -

NAME: Ribosomal protein S13 signature- CONSENSUS: [KR(QS!-G-x-R-H-x (2) -[GSNH!-x (2) -[LIVMC!-R-G-(Q

NAME: Ribosomal protein S14 signature-

CONSENSUS: [RP!-x (Oil) -C-x (Hi 12 ) -[LIVMF!-x-[LIVMF!-[SC!-

[RG!-x(3)-[RN!-

NAME: Ribosomal protein S15 signature-

CONSENSUS: CLIVM!-x (2 ) -H-[LIVMFY!-x (5) -D-x (2) -[SAGN!-x (3 ) -

[LF!-x(1)-[LIVM!-x(2)~

CONSENSUS: CFY!-

NAME: Ribosomal protein Sib signature-

CONSENSUS: CLIVMT!-x-[LIVM!-[KR!-L-[STAK!-R-x-G-[AKR! .

NAME: Ribosomal protein S17 signature- CONSENSUS: G-D-x-[LIV!-x-[LIVA!-x-[(QEK!-x-[RK!-P-[LIV!-S

NAME: Ribosomal protein Slβ signature- CONSENSUS: CIV!-[DY!-Y-x (2⁾ -CLIVMT!-x (2 ) -CLIVM!-x (2) -[FYT!-

[LIVM!-[ST!-[DERP!-x-

CONSENSUS: [GY!-K-[LIVM!-x (3) -R-[LIVMAS! - NAME: Ribosomal protein S11 signature-

CONSENSUS: [STDNιQ!-G-[KR(QM!-χ (fa) -[LIVM!-x ( 4 ) -[LIVM!-[GSD!- x(2)-[LF!-[GAS!-[DE!-F-

CONSENSUS: x(2)-[ST!- NAME: Ribosomal protein S21 signature-

CONSENSUS: CDE!-x-A-[LY!-[KR!-R-F-K-[KR!-x (3) -[KR! -

NAME: Ribosomal protein S3Ae signature- CONSENSUS: [LIV!-x-[GH!-R-[IV!-x-E-x-[SC!-L-x-D-L .

NAME: Ribosomal protein S4e signature-

CONSENSUS: H-x-K-R-[LIVM!-[SAN!-x-P-x (2) -U-x-[LIVM!-x-[KR!

NAME: Ribosomal protein Sbe signature- CONSENSUS: [LIVM!-[STAMR!-G-G-x-D-x (2 ) -G-x-P-M -

NAME: Ribosomal protein S7e signature- CONSENSUS: [KR!-L-x-R-E-L-E-K-K-F-[SAP!-x-[KR!-H • NAME: Ribosomal protein S8e signature-

CONSENSUS: R-x (2) -T-G-[GA!-x (5) -[HR!-K-[KR!-x-K-x-E-[LM!-C

NAME: Ribosomal protein S12e signature-

CONSENSUS: A-L-CKRιQP!-x-V-L-x (2 ) -[SA!-x (3) -[DN!-G-L .

NAME: Ribosomal protein S17e signature-

CONSENSUS: A-x-I-x-[ST!-K-x-L-R-N-[KR!-I-A-G-[FY!-x-T-H

NAME: Ribosomal protein Slle signature-

CONSENSUS: P-x⁽b)-[SAN!-x(2)-[LIVMA!-x-R-x-[ALIV!-[LV!-(Q-x-L-

[E(Q!-

NAME: Ribosomal protein S21e signature-

CONSENSUS: -Y-V-P-R-K-C-S-[SA! •

NAME: Ribosomal protein S24e signature.

CONSENSUS: [FA!-G-x (2) -[KR!-[STA!-x-G-[FY!-[GA!-x-[LIVM!-Y-

[DN!-[SN!. NAME: Ribosomal protein S2be signature-

CONSENSUS: [YH!-C-V-S-C-A-I-H -

NAME: Ribosomal protein S27e signature-

CONSENSUS: C<QK!-C-x (2) -C-x (fa ) -F-CGS!-x-CPSA!-x ( 5) -C-x (2 ) -C- [GS!-x(2)-L-x(2)-P-x-G-

NAME: Ribosomal protein S2βe signature.

CONSENSUS: E-CST!-E-R-E-A-R-x-L • NAME: DNA mismatch repair proteins mutL / hexB / PMS1 signature-

CONSENSUS: ^• G-F-R-G-E-A-L - NAME: DNA mismatch repair proteins mutS family signature- CONSENSUS: [ST!-[LIVM!-x-[LIVM!-x-D-E-[LIVMY!-[GC!-[RKH!-G- [GST!-x(4)-G- NAME: mutT domain signature-

CONSENSUS: G-x (5) -E-x ( 4 ) -CSTAGC!-[LIVMAC!-x-R-E-[LIVMFT!-x-E- E-

NAME: DnaA protein signature- CONSENSUS: I-[GA!-x (2) -[LIVMF!-[SGDNK!-x (Oil) -[KR!-x-H-[STP!- [STV!-[LIVM!(2)-x- CONSENSUS: [SA!-x (2 ) -[KRE!-CLIVM! -

NAME: Smalli acid-soluble spore proteinsi alpha/beta typei signature 1-

CONSENSUS: K-x-E-[LIV!-A-x-[DE!-[LIVMF!-G-[LIVMF! .

NAME: Smalli acid-soluble spore proteinsi alpha/beta typei signature 2. CONSENSUS: [KR!-CSA<Q!-x-G-x-V-G-G-x-[LIVM!-x-[KR!(2) - [LIVM!(2).

NAME: Zinc-containing alcohol dehydrogenases signature- CONSENSUS: G-H-E-x (2) -G-x (5) -CGA!-x (2) -[IVSAC! -

NAME: (Quinone oxidoreductase / zeta-crystallin signature. CONSENSUS: CGSD!-CDE<QH!-x (2) -L-x (3) -[SA! (2) -G-G-x-G-x ( 4 ) -Q- x(2)-[KR!- NAME: Iron-containing alcohol dehydrogenases signature 1- CONSENSUS: CSTALIV!-[LIVF!-x-[DE!-x (faι7 ) -P-x (4 ) -[ALIV!-x- [GST!-x(2)-D-[TAIVM!- CONSENSUS: CLIVMF!-x ( 4 ) -E • NAME: Iron-containing alcohol dehydrogenases signature 2- CONSENSUS: CGSU!-x-[LIVTSACD!-[GH!-x (2) -[GSAE!-[GSHY(Q!-x- [LIVTP!-[GAST!-[GAS!-x(3)~ CONSENSUS: [LIVMT!-x-[HNS!-[GA!-x-[GTAC! • NAME: Short-chain dehydrogenases/reductases family signature-

CONSENSUS: [LIVSPADNK!-x (12) -Y-[PSTAGNCV!-[STAGNιQCIVM!-

[STAGC!-K--CPO-[SAGFR!-

CONSENSUS: [LIVMSTAGD!-x (2) -[LIVMFYU!-x (3) -[LIVMFYUGAPTHlQ!- [GSACiQRHM!-

NAME: Aldo/keto reductase family signature 1- CONSENSUS: G-[FY!-R-[HSAL!-[LIVMF!-D-[STAGC!-[AS!-x ( 5) -E- x(2)-CLIVM!-G-

NAME: Aldo/keto reductase family signature 2-

CONSENSUS: CLIVMFY!-x (1) -CKRE(Q!-x-[LIVM!-G-[LIVM!-[SC!-N-

[FY!- NAME: Aldo/keto reductase family putative active site signature-

CONSENSUS: [LIVM!-[PAIV!-[KR!-[ST!-x ( 4 ) -R-x (2) -[GSTAElQK!- [NSL!-x(2)-[LIVMFA!- NAME: Homoserine dehydrogenase signature-

CONSENSUS: A-x (3) -G-[LIVMFY!-[STAG!-x (2ι3) -CDNSl-P-x (2) -D- [LIVM!-x-G-x-D-x(3)-K-

NAME: NAD-dependent glycerol-3-phosphate dehydrogenase signature.

CONSENSUS: G-CAT!-[LIVM!-K-[DN!-[LIVM! (2) -A-x-CGA!-x-G- CLIVMF!-x-CDE!-G-[LIVM!-x- CONSENSUS: [LIVMFYU!-G-x-N ■

NAME: FAD-dependent glycerol-3-phosphate dehydrogenase signature 1-

CONSENSUS: [IV!-G-G-G-x (2) -G-[STACV!-G-x-A-x-D-x (3) -R-G.

NAME: FAD-dependent glycerol-3-phosphate dehydrogenase signature 2-

CONSENSUS: G-G-K-x (2) -[GSTE!-Y-R-x (2 ) -A - NAME: Mannitol dehydrogenases signature-

CONSENSUS: [LIVMY!-x-[FS!-x (2) -[STAGCV!-x-V-D-R-[IV!-x-[PS! -

NAME: Histidinol dehydrogenase signature-

CONSENSUS: I-D-x (2 ) -A-G-P-[ST!-E-[LIVS!-[LIVMA! (3) -[AC!-x (3) • A-x(4)-[LIVM!-[AV!-

CONSENSUS: [SACL!-[DE!-[LIVMFC!-[LIVM!-[SA!-x (2 ) -E-H -

NAME: L-lactate dehydrogenase active site CONSENSUS: [LIVMA!-G-[E(Q!-H-G-[DN!-[ST! -

NAME: D-isomer specific 2-hydroxyacid dehydrogenases NAD- binding signature-

CONSENSUS: [LIVMA!-[AG!-[IVT!-[LIVMFY!-[AG!-x-G-[NHKR(QGSAC!- [LIV!-G-x(13ιl4)- CONSENSUS: [LIVfMT!-x (2 ) -[FYwCTH!-[DNSTK! -

NAME: D-isomer specific 2-hydroxyacid dehydrogenases signature 2-

CONSENSUS: [LIVMFYUA!-[LIVFYUC!-x (2) -[SAC!-[DN(QHR!-[IVFA!- [LIVF!-x-[LIVF!-[HNI!-x-

CONSENSUS: P-x ( 4 ) -[STN!-x (2 ) -[LIVMF!-x-[GSDN! -

NAME: D-isomer specific 2-hydroxyacid dehydrogenases signature 3- CONSENSUS: [LMFATC!-[KP(Q!-x-[GSTDN!-x-[LIVMFYUR!- [LIVMFYU!(2)-N-x-[STAGC!-R-[GP!-x- CONSENSUS: [LIVH!-[LIVMC!-[DNV! -

NAME". 3-hydroxyisobutyrate dehydrogenase signature- CONSENSUS: [LIVMFY! (2) -G-L-G-x-[M(Q!-G-x-[PGS!-[MA!-[SA! -

NAME: Hydroxymethylglutaryl-coenzyme A reductases signature

1-

CONSENSUS: [RKH!-x (fa ) -D-x-M-G-x-N-x-[LIVMA! -

NAME: Hydroxymethylglutaryl-coenzyme A reductases signature

2-

CONSENSUS: [LIVM!-G-x-[LIVM!-G-G-[AG!-T - NAME: Hydroxymethylglutaryl-coenzyme A reductases signature 3-

CONSENSUS: A-[LIVM!-x-[STAN!-x (2) -[LI!-x-[KRN(Q!-[GSA!-H-[LM!- x-CFYLH!-

NAME: Hydroxymethylglutaryl-coenzyme A reductases profile-

NAME: 3-hydroxyacyl-CoA dehydrogenase signature- CONSENSUS: [DNE!-x (2) -[GA!-F-[LIVMFY!-x-[NT!-R-x (3 ) -CPA!- CLIVMFY!(2)-x(S)- CONSENSUS: CLIVMFYCT!-[LIVMFY!-x (2 ) -[GV! -

NAME: Malate dehydrogenase active site signature- CONSENSUS: [LIVM!-T-[TRKMN!-L-D-x (2) -R-[STA!-x (3)-[LIVMFY! -

NAME: Malic enzymes signature-

CONSENSUS: F-x-CDV!-D-x (2) -G-T-CGSA!-x-[IV!-x-[LIVMA!-

CGAST!(2)-CLIVMF!(2) ■

NAME-" Isocitrate and isopropylmalate dehydrogenases signature-

CONSENSUS: CNS!-[LIMYT!-[FYDN!-G-[DNT!-[IMVY!-x-[STGDN!-[DN!- x(2)-[SGAP!-x(3ι4)-G- CONSENSUS: [STG!-[LIVMPA!-G-[LIVMF! -

NAME: fa-phosphogluconate dehydrogenase signature- CONSENSUS: [LIVM!-x-D-x (2 ) -[GA!-[N(QS!-K-G-T-G-x-U- NAME: Glucose-fa-phosphate dehydrogenase active site- CONSENSUS: D-H-Y-L-G-K-[E(QK! -

NAME: IMP dehydrogenase / GMP reductase signature- CONSENSUS: [LIVM!-[RK!-[LIVM!-G-[LIVM!-G-x-G-S-[LIVM!-C-x-T -

NAME: Bacterial quinoprotein dehydrogenases signature 1- CONSENSUS: CDEN!-U-x (3) -G-CR -x (fa) -[FYU!-S-x ( 4 ) -CLIVM!-N- x(2)-N-V-x(2)-L-[RK!- NAME: Bacterial quinoprotein dehydrogenases signature 2- CONSENSUS: U-x ( 4 ) -Y-D-x (3 ) -CDN!-[LIVMFY! ( 4 ) -x (2) -G-x (2) - [STA!-P-

NAME: FMN-dependent alpha-hydroxy acid dehydrogenases active site-

CONSENSUS: S-N-H-G-[AG!-R-(Q -

NAME: GMC oxidoreductases signature 1-

CONSENSUS: [GA!-[RKN!-x-[LIV!-G (2) -[GST! (2) -x-[LIVM!-N-x (3 ) - CFYUA!-x(2)-CPAG!-x(5)- CONSENSUS: ONESH!-

NAME: GMC oxidoreductases signature 2-

CONSENSUS: [GS!-[PSTA!-x (2) -[ST!-P-x-[LIVM! (2) -x (2) -S-G- [LIVM!-G-

NAME: Eukaryotic molybdopterin oxidoreductases signature- CONSENSUS-" [GA!-x(3)-[KRN(QHT!-x(llιl4)-[LIVMFYUS!-x(8)-

CLIVMF!-x-C-x(2)-[DEN!-R-

CONSENSUS: x(2)-[DE!- NAME: Prokaryotic molybdopterin oxidoreductases signature 1. CONSENSUS: CSTAN!-x-[CH!-x (2ι3) -C-[STAG!-[GSTVMF!-x-C-x- [LIVMFYU!-x-CLIVMA!-x(3ι4)- CONSENSUS: [DENiQKHT!- NAME: Prokaryotic molybdopterin oxidoreductases signature 2. CONSENSUS: [STA!-x-[STAC! (2) -x (2) -[STA!-D-[LIVMY! (2) -L-P-x- CSTAC!(2)-x(2)-E-

NAME: Prokaryotic molybdopterin oxidoreductases signature 3. CONSENSUS: A-x (3) -CGDT!-I-x-[DN(QTK!-x-[DEA!-x-[LIVM!-x- [LIVMC!-x-[NS!-x(2)-[GS!- CONSENSUS: x ( 5) -A-x-[LIVM!-[ST! ■

NAME: Aldehyde dehydrogenases glutamic acid active site- CONSENSUS: [LIVMFGA!-E-[LIMSTAC!-CGS!-G-CKNLM!-[SADN!- [TAPFV!.

NAME: Aldehyde dehydrogenases cysteine active site- CONSENSUS: [FYLVA!-x (3) -G-[(QE!-x-C-[LIVMGSTANC!-[AGCN!-x- [GSTADNEKR!.

NAME: Aspartate-semialdehyde dehydrogenase signature- CONSENSUS: [LIVM!-[SADN!-x (2) -C-x-R-[LIVM!-x ( 4 ) -[GSC!-H- [STA!-

NAME: Glyceraldehyde 3-phosphate dehydrogenase active site- CONSENSUS: [ASV!-S-C-[NT!-T-x (2 ) -[LIM! -

NAME-" N-acetyl-gamma-glutamyl-phosphate reductase active site-

CONSENSUS: [LIVM!-[GSA!-x-P-G-C-[FY!-[AVP!-T-[GA!-x (3) - [GTAC!-[LIVM!-x-P-

NAME: Gamma-glutamyl phosphate reductase signature- CONSENSUS: V- (5) -A-[LIV!-x-H-I-x (2) -[HY!-[GS!-[ST!-x-H-CST!- [DE!-x-I-

NAME: Dihydrodipicolinate reductase signature- CONSENSUS: E-[IV!-x-E-x-H-x (3) -K-x-D-x-P-S-G-T-A -

NAME: Dihydroorotate dehydrogenase signature 1-

CONSENSUS: [GS!-x ( 4 ) -[GK!-[STA!-[IVSTA!-[GT!-x (3) -[N(QR!-x-G-

[NH!-x(2)-P-CRT!- NAME: Dihydroorotate dehydrogenase signature 2-

CONSENSUS: [LIV! (2) -[GSA!-x-G-G-[IV!-x-[STGN!-x (3) -CACVJ- x(b)-G-A.

NAME: Coproporphyrinogen III oxidase signature- CONSENSUS: K-x-U-C-x (2 ) -[FYH! (3) -[LIVM!-x-H-R-x-E-x-R-G- [LIVM!-G-G-[LIVM!-F-F-D- NAME: Fumarate reductase / succinate dehydrogenase FAD- binding site-

CONSENSUS: R-[ST!-H-[ST!-x (2) -A-x-G-G - NAME: Acyl-CoA dehydrogenases signature 1.

CONSENSUS: CGAC!-CLIVM!-[ST!-E-x (2) -[GSAN!-G-[ST!-D-x (2) - [GSA!-

NAME: Acyl-CoA dehydrogenases signature 2- CONSENSUS: [(QDE!-x (2)-G-[GS!-x-G-[LIVMFY!-x (2) - EN!-x ( 4 ) - [KR!-x(3)-[DEN!>

NAME: Alanine dehydrogenase & pyridine nucleotide transhydrogenase signature 1- CONSENSUS: G-[LIVM!-P-x-E-x (3) -N-E-x (lι3) -R-V-A-x-[ST!-P-x- [GST!-V-x(2)-L-x-[KRH!- CONSENSUS: x-G-

NAME: Alanine dehydrogenase & pyridine nucleotide transhydrogenase signature 2-

CONSENSUS: [LIVM! (2) -G-[GA!-G-x-A-G-x (2) -[SA!-x (3) -[GA!-x-

[SG!-[LIVM!-G-A-x-V-

CONSENSUS: x(3)-D- NAME: Glu / Leu / Phe / Val dehydrogenases active site-

CONSENSUS: [LIV!-x (2) -G-G-[SAG!-K-x-[GV!-x (3) - NST!-[PL! .

NAME: D-amino acid oxidases signature-

CONSENSUS: CLIVM! (2 ) -H-[NHA!-Y-G-x-[GSA! (2) -x-G-x ( 5) -G-x-A

NAME: Pyridoxamine 5'-phosphate oxidase signature- CONSENSUS: [LIVF!-E-F-U-[<QHG!-x ( 4 ) -R-[LIVM!-H-[DNE!-R -

NAME: Copper amine oxidase topaquinone signature- CONSENSUS: [LIVM!-[LIVMA!-[LIVM!-x ( 4 ) -T-x (2) -N-Y-[DE!-[YN! -

NAME: Copper amine oxidase copper-binding site signature- CONSENSUS: T-x-G-x (2) -H-[LIVMF!-x (3 ) -E- E!-x-P - NAME: Lysyl oxidase putative copper-binding region signature- CONSENSUS: U-E-U-H-S-C-H-(Q-H-Y-H -

NAME: Delta l-pyrroline-5-carboxylate reductase signature- CONSENSUS: [PALF!-x (2ι3) -[LIV!-x (3 ) -[LIVM!-[STAC!-[STV!-x- [GAN!-G-x-T-x(2)-[AG!- CONSENSUS: [LIV!-x (2) -CLMF!-[DEN(QK! -

NAME: Dihydrofolate reductase signature. CONSENSUS: [LVAGC!-[LIF!-G-x (4 ) -[LIVMF!-P-U-x ( 4ι 5) -[DE!-x (3) - [FYIV!-x(3)-[STI(Q!-

NAME: Tetrahydrofolate dehydrogenase/cyclohydrolase signature 1- CONSENSUS: CE(Q!-x-[E(QK!-[LIVM! (2) -x (2) -[LIVM!-x (2) -CLIVMY!-N- x-[DN!-x(5)-[LIVMF!(3)- CONSENSUS: (Q-L-P-CLV!- NAME: Tetrahydrofolate dehydrogenase/cyclohydrolase signature 2-

CONSENSUS: P-G-G-V-G-P-CMF!-T-[IV! - NAME: Oxygen oxidoreductases covalent FAD-binding site-

CONSENSUS: P-x (10) -CDE!-[LIVM!-x (3) -CLIVM!-x (1 ) -[LIVM!-x (3) - [GSA!-CGST!-G-H-

NAME: Pyridine nucleotide-disulphide oxidoreductases class-I active site-

CONSENSUS: G-G-x-C-[LIVA!-x (2) -G-C-[LIVM!-P .

NAME: Pyridine nucleotide-disulphide oxidoreductases class- II active site- CONSENSUS: C-x (2) -C-D-CGA!-x (2ι 4 ) -CFY!-x ( 4 ) -CLIVM!-x- [LΪVM!(2)-G(3)-ON!.

NAME: Respiratory-chain NADH dehydrogenase subunit 1 signature 1- CONSENSUS: G-CLIVMFYKRS!-[LIVMAGP!-(Q-x-[LIVMFY!-x-D-[AGIM!- [LIVMFTA!-K-CLVMYST!- CONSENSUS: [LIVMFYG!-x-[KR!-[EιQG! -

NAME: Respiratory-chain NADH dehydrogenase subunit 1 signature 2-

CONSENSUS: P-F-D-[LIVMFY(Q!-[STAGPVM!-E-[GAC!-E-x-[E(Q!- [LIVMS!-x(2)-G-

NAME: Respiratory-chain NADH dehydrogenase 2D Kd subunit signature-

CONSENSUS: [GN!-x-D-[KRST!-[LIVMF! (2) -P-[IV!-D-[LIVMFYU! (2) - x-P-x-C-P-[PT!-

NAME: Respiratory-chain NADH dehydrogenase 24 Kd subunit signature.

CONSENSUS: D-x (2 ) -F-CST!-x (5) -C-L-G-x-C-x (2) -CGA!-P .

NAME: Respiratory chain NADH dehydrogenase 30 Kd subunit signature- CONSENSUS: E-R-E-x (2) -CDE!-[LIVMF! (2) -x (b ) -[HK!-x(3) -[KRP!-x- [LIVM!-[LIVMS!-

NAME: Respiratory chain NADH dehydrogenase 41 Kd subunit signature. CONSENSUS: [LIVMH!-H-[RT!-[GA!-x-E-K-[LIVMT!-x-E-x-[KR(Q! •

NAME: Respiratory-chain NADH dehydrogenase 51 Kd subunit signature 1-

CONSENSUS: G-[AM!-G-[AR!-Y-[LIVM!-C-G- E! (2) -[STA! (2) - [LIM!(2)-[EN!-S-

NAME: Respiratory-chain NADH dehydrogenase 51 Kd subunit signature 2-

CONSENSUS: E-S-C-G-x-C-x-P-C-R-x-G ■

NAME: Respiratory-chain NADH dehydrogenase 75 Kd subunit signature 1-

CONSENSUS: P-x ( ) -C-[YUS!-x (7) -G-x-C-R-x-C - NAME: Respiratory-chain NADH dehydrogenase 75 Kd subunit signature 2-

CONSENSUS: C-P-x-C-CDE!-x-[GS! (2) -x-C-x-L-(Q •

NAME: Respiratory-chain NADH dehydrogenase 75 Kd subunit signature 3.

CONSENSUS: R-C-CLIVM!-x-C-x-R-C-[LIVM!-x-CFY! - NAME: Nitrite and sulfite reductases iron-sulfur/siroheme- binding site- CONSENSUS: [STV!-G-C-x (3) -C-x (fa ) - E!-[LIVMF!-[GAT!-[LIVMF!

NAME: Uricase signature. CONSENSUS: L-x-[LV!-L-K-[ST!-T-x-S-x-F-x (2) -[FY!-x ( 4 ) -[FY! .

NAME-" He e-copper oxidase catalytic subuniti copper B binding region signature.

CONSENSUS: [YUG!-[LIVFYUTA! (2) -[VGS!-H-[LNP!-x-V-x ( 44 i 47 ) -H- H.

NAME: CO II and nitrous oxide reductase dinuclear copper centers signature-

CONSENSUS: V-x-H-x (33ι 40 ) -C-x (3) -C-x (3) -H-x (2) -M -

NAME: Cytochrome c oxidase subunit Vbi zinc binding region signature-

CONSENSUS: CLIVM! (2) -[FYU!-x (10) -C-x (2) -C-G-x (2) -[FY!-K-L - NAME: Multicopper oxidases signature 1-

CONSENSUS: G-x-[FYU!-x-[LIVMFYU!-x-[CST!- (8) -G-[LM!-x (3) - [LIVMFYU!.

NAME: Multicopper oxidases signature 2- CONSENSUS: H-C-H-x (3) -H-x (3) -CAG!-CLM! ■

NAME: Peroxidases proximal heme-ligand signature- CONSENSUS: CDET!-[LIVMTA!-x (2) -[LIVM!-[LIVMSTAG!-[SAG!- [LIVMSTAG!-H-[STA!-CLIVMFY!-

NAME: Peroxidases active site signature-

CONSENSUS: [SGATV!- (3 ) -[LIVMA!-R-[LIVMA!-x-[FU!-H-x-[SAC! .

NAME: Catalase proximal heme-ligand signature- CONSENSUS: R-[LIVMFSTAN!-F-[GASTNP!-Y-x-D-[AST!-[(QEH! -

NAME: Catalase proximal active site signature- CONSENSUS: [IF!-x-[RH!-x ( 4 ) -[E(Q!-R-x (2 ) -H-x (2) -[GAS!-[GASTF!- [GAST!-

NAME: Glutathione peroxidases selenocysteine active site. CONSENSUS: [GN!-[RKHNFYC!-x-[LIVMFC!-[LIVMF! (2) -x-N-[VT!-x- [STC!-x-C-[GA!-x-T. NAME: Glutathione peroxidases signature Ξ« CONSENSUS: [LIV!-[AGD!-F-P-[CS!-[NG!-ι3- .

NAME: Lipoxygenases iron-binding region signature 1. CONSENSUS : H-CEflJ-x ( 3 ) -H-x-CLM!-[NιQRC!-[GST!-H-[LIVMSTAC! ( 3 )

E -

NAME: Lipoxygenases iron-binding region signature 2- CONSENSUS: CLIVMA!-H-P-[LIVM!-x-[KR(Q!-[LIVMF! (2) -x-[AP!-H -

NAME: Extradiol ring-cleavage dioxygenases signature- CONSENSUS: [GNTIV!-x-H-x ( 5ι7) -[LIVMF!-Y-x (2) -CDENTA!-P-x- [GP!-x(2ι3)-E-

NAME: Intradiol ring-cleavage dioxygenases signature- CONSENSUS: CLIVM!-x-G-x-[LIVM!-x (4 ) -[GS!-x (2) -[LIVM!-x (4 ) - [LIVM!-[DE!-[LIVMFY!- CONSENSUS: x (fa ) -G-x-CFY! .

NAME-" Indoleamine 2ι3-dioxygenase signature 1- CONSENSUS: G-G-S-CAN!-CGA!-(Q-S-S-x (2) -(Q •

NAME: Indoleamine 2ι3-dioxygenase signature 2- CONSENSUS: CFY!-L-[D(Q!-[DE!-[LIVM!-x (2) -Y-M-x (3) -H-[KR! •

NAME: Bacterial ring hydroxylating dioxygenases alpha- subunit signature-

CONSENSUS: C-x-H-R-[GA!-x (6 ) -G-N-x ( 5) -C-x-[FY!-H -

NAME: Bacterial luciferase subunits signature- CONSENSUS: [GA!-[LIVM!-P-[LIVM!-x-[LIVMFY!-x-U-x (fa ) -[RK!- x(b)-Y-x(3)-[AR!- NAME: ubiH/COiQb monooxygenase family signature- CONSENSUS: H-P-[LIV!-[AG!-G-(Q-G-x-N-x-G-x (2) -D -

NAME: Biopterin-dependent aromatic amino acid hydroxylases signature ■ CONSENSUS: P-D-x ( ) -H- E!-[LI!-[LIVMF!-G-H-[LIVMC!-P -

NAME: Copper type Hi ascorbate-dependent monooxygenases signature 1-

CONSENSUS: H-H-M-x (2) -F-x-C -

NAME: Copper type Hi ascorbate-dependent monooxygenases signature 2-

CONSENSUS: H-x-F-x ( 4 ) -H-T-H-x (2 ) -G ■ NAME: Tyrosinase CuA-binding region signature-

CONSENSUS: H-x (4 i 5) -F-[LIVMFTP!-x-[FU!-H-R-x (2 ) -[LM!-x (3) -E .

NAME: Tyrosinase and hemocyanins CuB-binding region signature- CONSENSUS: D-P-x-F-CLIVMFYU!-x (2) -H-x (3) -D -

NAME: Fatty acid desaturases family 1 signature- CONSENSUS: G-E-x-[FY!-H-N-[FY!-H-H-x-F-P-x-D-Y - NAME: Fatty acid desaturases family 2 signature-

CONSENSUS: [ST!-[SA!-x (3) -[(QR!-[LI!-x (5ιfa ) -D-Y-x (2) - [LIVMFYU!-[LIVM!-[DE!- NAME: Cytochrome P450 cysteine heme-iron ligand signature- CONSENSUS: . [FU!-[SGNH!-x-[GD!-x-[RHPT!-x-C-[LIVMFAP!-[GAD! -

NAME: Heme oxygenase signature- CONSENSUS: L-L-V-A-H-A-Y-T-R -

NAME: Copper/Zinc superoxide dismutase signature 1- CONSENSUS: [GA!-[IFAT!-H-[LIVF!-H-x (2 ) -CGP!-CSDG!-x-[STAGD! ■ NAME: Copper/Zinc superoxide dismutase signature 2- CONSENSUS: G-[GN!-[SGA!-G-x-R-x-[SGA!-C-x (2) -[IV! .

NAME: Manganese and iron superoxide dismutases signature- CONSENSUS: D-x-U-E-H-[STA!-[FY! ( 2 ) -

NAME-" Ribonucleotide reductase large subunit signature- CONSENSUS: U-x (2)-CLF!-x (faι7) -G-[LIVM!-[FYRA!-[NH!-x (3) - [STA(QLIVM!-[ASC!-x(2)- CONSENSUS: [PA!-

NAME: Ribonucleotide reductase small subunit signature-

CONSENSUS: [IVMSE(Q!-E-x (lι2 ) -[LIVTA!-[HY!-[GSA!-x-[STAVM!-Y- x(2)-[LIVM(Q!-x(3)-

CONSENSUS: CLIFY!-[IVFYCSA! -

NAME: Nitrogenases component 1 alpha and beta subunits signature 1-

CONSENSUS: [LIVMFYH!-[LIVMFST!-H-[AG!-[AGSP!-[LIVMN(QA!-[AG!-

C

NAME: Nitrogenases component 1 alpha and beta subunits signature 2-

CONSENSUS: [STAN(Q!-[ET!-C-x ( 5) -G-D-[DN!-[LIVMT!-x-[STAGR!-

[LIVMFYST!-

NAME: NifH/frxC family signature 1- CONSENSUS: E-x-G-G-P-x (2) -[GA!-x-G-C-[AG!-G-

NAME: NifH/frxC family signature 2- CONSENSUS: D-x-L-G-D-V-V-C-G-G-F-[AG!-x-P -

NAME: Nickel-dependent hydrogenases large subunit signature 1-

CONSENSUS: R-G-[LIVMF!-E-x ( 15) -[(QESM!-R-x-C-G-[LIVM!-C -

NAME: Nickel-dependent hydrogenases large subunit signature

2-

CONSENSUS: [FY!-D-P-C-[LIM!-[ASG!-C-x (2ι3) -H - NAME: Glutamyl-tRNA reductase signature-

CONSENSUS: H-[LIVM!-x (2) -[LIVM!-[GSTAC! (3) -[LIVM!-[DE(Q!-S-

[LIVMA!-[LIVM!(2)-[GF!-E-

CONSENSUS: x-[(QR!-[IV!-[LIT!-[STAG!-(Q-[LIVM!-[KR! - NAME: Bacterial-type phytoene dehydrogenase signature-

CONSENSUS: [NG!-x-[FYUV!-[LIVMF!-x-G-[AGC!-[GS!-[TA!-[H(QT!-P-

G-[STAV!-G-[LIVM!-

CONSENSUS: x(5)-[GS!- NAME: Glycine radical signature-

CONSENSUS: [STIV!-x-R-[IVT!-[CSA!-G-Y-x-[GACV! .

NAME: Ergosterol biosynthesis ERG4/ERG24 family signature 1 CONSENSUS: G-x (2 ) -CLIVM!-Y-D-x-[FY!-x-G-x (2) -L-N-P-R -

NAME: Ergosterol biosynthesis ERG4/ERG24 family signature 2 CONSENSUS: CLIVM! (2) -H-R-x (2 ) -R-D-x (3) -C-x (2) -K-Y-G -

NAME: NNMT/PNMT/TEMT family of methyltransferases signature CONSENSUS: ---_I---.])-._I-_G__s__G_p_'_r---.fl;iV!-Y-(Q-L-L-S-A-C .

NAME: RNA methyltransferase trmA family signature 1. CONSENSUS: [DN!-P-[PA!-R-x-G-x (14 ilfa ) -[LIVM! (2 ) -Y-x-S-C-N- x(2)-T-

NAME: RNA methyltransferase trmA family signature 2- CONSENSUS: [LIVMF!-D-x-F-P-[(QHY!-[ST!-x-H-[LIVMFY!-E-.

NAME: Thymidylate synthase active site-

CONSENSUS: R-x (2) -[LIVM!-x (3) -[FU!-[(QN!-x (βil ) -[LV!-x-P-C-

[HAVM!-x(3)-[(QMT!-[FYU!-

CONSENSUS." x-[LV!.

NAME: Ribosomal RNA adenine dimethylases signature-

CONSENSUS: [LIVM!-[LIVMFY!-[DE!-x-G-[STAPV!-G-x-[GA!-x-

[LIVMF!-[ST!-x(2)-[LIVM!-

CONSENSUS: x (fa) -[LIVMY!-x-[STAGV!-[LIVMFYHC!-E-x-D •

NAME: Methylated-DNA--protein-cysteine methyltransferase active site-

CONSENSUS: [LIVMF!-P-C-H-R-[LIVMF! (2) . NAME: N-fa Adenine-specific DNA methylases signature- CONSENSUS: [LIVMAC!-[LIVFYUA!-x-[DN!-P-P-[FYU! -

NAME: N-4 cytosine-specific DNA methylases signature- CONSENSUS: [LIVMF!-T-S-P-P-[FY! -

NAME: C-5 cytosine-specific DNA methylases active site- CONSENSUS: [DENKS!-x-[FLIV!-x (2) -[GSTC!-x-P-C-x (2) -[FYULIM!- S- NAME: C-5 cytosine-specific DNA methylases C-terminal signature -

CONSENSUS: [RK(QGTF!-x (2) -G-N-[STAG!-[LIVMF!-x (3) -[LIVMT!- x(3)-CLIVM!-x(3)-[LIVM!- NAME: Protein-L-isoaspartate ( D-aspartate) 0- methyltransferase signature- CONSENSUS: [GSA!-D-G-x (2) -G-[FYUV!-x (3) -[AS!-P-[FY!-[DN!-x-I .

NAME: Uroporphyrin-III C-methyltransferase signature 1- CONSENSUS: [LIVM!-[GS!-[STAL!-G-P-G-x (3) -[LIVMFY!-[LIVM!-T- [LIVM!-[KRH(QG!-[AG!.

NAME: Uroporphyrin-III C-methyltransferase signature 2- CONSENSUS: V-x (2) -ELIJ- (2) -G-D-x (3) -[FYU!-[GS!-x (6) -CLIVF!- x(5ιfa)-[LIVMFYUPAC!-

CONSENSUS: x-CLIVMY!-x-P-G .

NAME: ubiE/C0(Q5 methyltransferase family signature 1- CONSENSUS: Y-D-x-M-N-x (2) -CLIVM!-S-x (3) -H-x (2) -U-

NAME: ubiE/COiQS methyltransferase family signature 2. CONSENSUS: R-V-CLIVM!-K-[PV!-G-G-x-[LIVMF!-x (2 ) -CLIVM!-E-x-S .

NAME: Serine hydroxymethyltransferase pyridoxal-phosphate attachment site-

CONSENSUS: [DEH!-[LIVMFY!-x-[STMV!-[GST!-[ST! (2) -H-K-[ST!- [LF!-x-G-[PAC!-[R(Q!- CONSENSUS: [GSA!-[GA!-

NAME: Phosphoribosylglycinamide formyltransferase active site-

CONSENSUS: G-x-[STM!-[IVT!-x-[FYUV(Q!-[VMAT!-x-[DEVM!-x- [LIVMY!-D-x-G-x(2)-[LIVT!- CONSENSUS: x(fa)-[LIVM!-

NAME: Aspartate and ornithine carbamoyltransferases signature. CONSENSUS: F-x-CEK!-x-S-CGT!-R-T ■

NAME: Transketolase signature 1-

CONSENSUS: R-x (3) -CLIVMTA!- EN(QSTHKF!-x (Sifa) -[GSN!-G-H- [PLIVMF!-[GSTA!-x(2)- CONSENSUS: [LIMC!-[GS!-

NAME: Transketolase signature 2-

CONSENSUS: G-[DE(QGSA!-[DN!-G-[PAE(Q!-[ST!-[H(Q!-x-[PAGM!- [LIVMYAC!-[DEFYU!-x(2)- CONSENSUS: [STAP!-x (2) -[RGA! .

NAME: Transaldolase signature 1-

CONSENSUS: [DG!-[IVSA!-T-[ST!-N-P-[STA!-[LIVMF! (2) ■ NAME: Transaldolase active site.

CONSENSUS: [LIVM!-x-[LIVM!-K-CLIVM!-[PAS!-x-[ST!-x-[DEN(QPAS!-

G-[LIVM!-x-[AGV!-x-

CONSENSUS: [(QEKRST!-x-[LIVM! . NAME: Acyltransferases ChoActase / COT / CPT family signature 1-

CONSENSUS: [LI!-P-x-[LVP!-P-[IVTA!-P-x-[LIVM!-x-[DEN(QAS!- [ST!-[LIVM!-x(2)-[LY!- NAME: Acyltransferases ChoActase / COT / CPT family signature 2-

CONSENSUS: R-[FYU!-x-[DA!-[KA!-x (Oil) -[LIVMFY!-x-[LIVMFY! (2 ) - x(3)-[DNS!-[GSA!-x(fa)- CONSENSUS: CDE!-CHS!-x (3) -[DE!-[GA! -

NAME: Thiolases acyl-enzyme intermediate signature- CONSENSUS: [LIVM!-CNST!-x (2)-C-[SAGLI!-[ST!-[SAG!-[LIVMFYNS!- x-[STAG!-[LIVM!-x(fa)- CONSENSUS : [LIVM! -

NAME: Thiolases signature 2-

CONSENSUS: N-x (2) -G-G-x-CLIVM!-[SA!-x-G-H-P-x-G-x-[ST!-G -

NAME: Thiolases active site-

CONSENSUS: CAG!-CLIVMA!-[STAGLIVM!-[STAG!-[LIVMA!-C-x-[AG!-x-

[AG!-x-[AG!-x-[SAG!- NAME: Chloramphenicol acetyltransferase active site- CONSENSUS: ώ-[LIV!-H-H-[SA!-x (2) -D-G-[FY!-H -

NAME: Hexapeptide-repeat containing-transferases signature- CONSENSUS: [LIV!-[GAED!-x (2) -[STAV!-x-[LIV!-x (3) -CLIVAC!-x- [LIV!-[GAED!-x(2)-

CONSENSUS: [STAVR!-x-[LIV!-[GAED!-x (2) -[STAV!-x-[LIV!-x (3) - [LIV!-

NAME: Beta-ketoacyl synthases active site- CONSENSUS: G-x (4 ) -[LIVMFAP!-x (2 ) -[AGC!-C-[STA! (2)-[STAG!- x(3)-[LIVMF!-

NAME: Chalcone and stilbene synthases active site- CONSENSUS: R-[LIVMFYS!-x-[LIVM!-x-[ιQHG!-x-G-C-[FYNA!-[GA!-G- [GA!-[STAV!-x-[LIVMF!- CONSENSUS: [RA!-

NAME: Myristoyl-CoA: protein N-myristoyltransferase signature 1- CONSENSUS: E-I-N-F-L-C-x-H-K -

NAME: Myristoyl-CoA:protein N-myristoyltransferase signature

2-

CONSENSUS: K-F-G-x-G-D-G -

NAME: Gamma-glutamyltranspeptidase signature-

CONSENSUS: T-[STA!-H-x-[ST!-[LIVMA!-x ( 4 ) -G-[SN!-x-V-[STA!-x-

T-x-T-[LIVM!-[NE!-

CONSENSUS: x ( lι2 ) -CFY!-G -

NAME: Transglutaminases active site-

CONSENSUS: [GT!-(Q-[CA!-U-V-x-[SA!-[GA!- VT!-x (2)-T-x-[LMSC!-

R-[CSA!-[LV!-G- NAME: Phosphorylase pyridoxal-phosphate attachment site- CONSENSUS: E-A-[SC!-G-x-[GS!-x-M-K-x (2 ) -[LM!-N -

NAME: UDP-glycosyltransferases signature-

CONSENSUS: [FU!-x (2) -<Q-x (2 ) -[LIVMYA!-[LIMV!-x ( 4ιb) -[LVGAC!- [LVFYA!-[LIVMF!-[STAGCM!-

CONSENSUS: CHN<Q!-CSTAGC!-G-x (2) -[STAG!-x (3) -[STAGL!-[LIVMFA!- x(4)-[P(QR!-[LIVMT!-

CONSENSUS: x (3) -CPA!-x (3) -[DES!-[<QEHN! - NAME: Purine/pyri idine phosphoribosyl transferases signature-

CONSENSUS: [LIVMFYUCTA!-[LIVM!-[LIVMA!-[LIVMFC!-[DE!-D- [LIVMS!-[LIVM!-[STAVD!- CONSENSUS : ^[STAR!-^[GAC!-x-^[STAR! -

NAME: Glutamine amidotransferases class-I active site-

CONSENSUS: [PAS!-[LIVMFYT!-[LIVMFY!-G-[LIVMFY!-C-[LIVMFYN!-G- x-[(QEH!-x-[LIVMFA!-

NAME: Glutamine amidotransferases class-II active site- CONSENSUS: <x (Dill) -C-[GS!-[IV!-CLIVMFYU!-[AG! •

NAME: Purine and other phosphorylases family 1 signature- CONSENSUS: CGST!-x-G-[LIVM!-G-x-[PA!-S-x-CGSTA!-I-x (3) -E-L

NAME: Purine and other phosphorylases family 2 signature-

CONSENSUS: CLIVJ-x (3) -G-x (2) -H-x-[LIVMFY!-x (4 ) -[LIVMF!-x (3) -

CATV!-x(lι2)-[LIVM!-x-

CONSENSUS: CATV!-x ( 4) -CGN!-x (3ι4 -CLIVMF! (2) -x (2)-CSTN!-[SA!- x-G-[GS!-[LIVM!-

NAME: Thymidine and pyrimidine-nucleoside phosphorylases signature. CONSENSUS: S-[GS!-R-[GA!-[LIV!-x(2)-[TA!-[GA!-G-T-x-D-x- [LIV!-E-

NAME: ATP phosphoribosyltransferase signature-

CONSENSUS: E-x(5)-G-x-[SAG!-x(2)-[IV!-x-D-[LIV!-x(2)-[ST!-G- x-T-[LM!-

NAME: NAD:arginine ADP-ribosyltransferases signature. CONSENSUS: [FY!-x-[FY!-K-x(2)-H-[FY!-x-L-[ST!-x-A-

NAME: Prolipoprotein diacylglyceryl transferase signature CONSENSUS: G-R-x-[GA!-N-F-CLIVMF!-N-x-E-x(2)-G-

NAME: S-adenosylmethionine synthetase signature 1- CONSENSUS: G-A-G-D-(Q-G-x (3) -G-Y -

NAME: S-adenosylmethionine synthetase signature 2 CONSENSUS: G-[GA!-G-CASC!-F-S-x-K-[DE! -

NAME-" Polyprenyl synthetases signature 1- CONSENSUS [LIVM!(2)-x-D-D-x(2ι4)-D-x(4)-R-R-[GH!-

NAME: Polyprenyl synthetases signature 2-

CONSENSUS CLIVMFY!-G-x(2)-[FYL!-ιQ-[LIVM!-x-D-D-[LIVMFY!-x-

[DNG!-

NAME: Squalene and phytoene synthases signature 1. CONSENSUS: Y-[CSAM!-x(2)-[VSG!-A-[GSA!-[LIVAT!-[IV!-G-x(2)-

[LMSC!-x(2)-[LIV!-

NAME: Squalene and phytoene synthases signature 2- CONSENSUS: [LIVM!-G-x (3⁾ -ι^Q-x ⁽2ι3⁾ -N-[IF!-x-R-D-^[LIVMFY!-x (2) [DE!-x(4ι7)-R-x-[FY!- CONSENSUS: x-P-

NAME: Protein prenyltransferases alpha subunit repeat signature- CONSENSUS : ^[PSIAV!-x-[NDFV!-[NEιQIY!-x-[LIVMAGP!-U-[N(QSTHF!-

[FYH(Q!-[LIVMR! -

NAME: Riboflavin synthase alpha chain family signature- CONSENSUS: [LIVMF!-x ( 5) -G-[STADN<Q!-[KRE(QIYU!-V-N-[LIVM!-E -

NAME: Dihydropteroate synthase signature 1-

CONSENSUS: CLIVM!-x-[AG!-[LIVMF! (2) -N-x-T-x-D-S-F-x-D-x-[SG! - NAME: Dihydropteroate synthase signature 2-

CONSENSUS: [GE!-[SA!-x-[LIVM! (2) -D-[LIVM!-G-[GP!-x (2) -[STA!- x-P-

NAME-" EPSP synthase signature 1- CONSENSUS: [LIVM!-x (2 ) -CGN!-N-[SA!-G-T-[STA!-x-R-x-[LIVMY!-x- [GSTA!-

NAME-" EPSP synthase signature 2-

CONSENSUS: [KR!-x-[KH!-E-[CST!-[DNE!-R-[LIVM!-x-[STA!- [LIVMC!-x(2)-[EN!-[LIVMF!-x-

CONSENSUS: [KRA!-[LIVMF!-6 -

NAME: FLAP/GST2/LTC4S family signature- CONSENSUS: G-x (3) -F-E-R-V-[FY!-x-A-[NιQ!-x-N-C .

NAME: Aminotransferases class-I pyridoxal-phosphate attachment site-

CONSENSUS: [GS!-[LIVMFYTAC!-[GSTA!-K-x (2 ) -[GSALVN!-[LIVMFA!- x-[GNAR!-x-R-[LIVMA!- CONSENSUS: [GA!-

NAME: Aminotransferases class-II pyridoxal-phosphate attachment site-

CONSENSUS: T-[LIVMFYU!-[STAG!-K-[SAG!-[LIVMFYUR!-[SAG!-x (2 ) - [SAG!-

NAME: Aminotransferases class-Ill pyridoxal-phosphate attachment site-

CONSENSUS: [LIVMFYUC! (2) -x-D-E-[LIVMA!-x (2) -CGP!-x (Oil ) - CLIVMFYUAG!-x(Dιl)-[SACR!-x-

CONSENSUS: [GSAD!-x (IΞ-ilb ) -D-[LIVMFYUC!-x (2ι3) -[GSA!-K-x (3) - CGSTADN!-[GSA!-

NAME: Aminotransferases class-IV signature- CONSENSUS: E-x-[STAGCI!-x (2) -N-[LIVMFAC!-[FY!-x (bιl2) - [LIVMF!-x-T-x(faι6)-[LIVM!-x- CONSENSUS: CGS!-CLIVM!-x-[KR! ■

NAME: Aminotransferases class-V pyridoxal-phosphate attachment site-

CONSENSUS: CLIVFYCHT!-[DGH!-[LIVMFYAC!-[LIVMFYA!-x (2) -

[GSTAC!-[GSTA!-[H<QR!-K-

CONSENSUS: x ( 4ιfa) -G-x-[GSAT!-x-[LIVMFYSAC! - NAME: Hexokinases signature-

CONSENSUS: [LIVM!-G-F-[TN!-F-S-[FY!-P-x ( 5) -CLIVM!-[DNST!- x(3)-ELIVM!-x(2)-U-T-K-x-

CONSENSUS: CLF!- NAME: Galactokinase signature- CONSENSUS: G-R-x-N-CLIV!-I-G-E-H-x-D-Y - NAME: GHMP kinases putative ATP-binding domain-

CONSENSUS: [LIVM!-[PK!-x-[GSTA!-x (Oil) -G-L-CGS!-S-S-[GSA!- [GSTAC!-

NAME"- Phosphofructokinase signature- CONSENSUS: [RK!-x ( 4 ) -G-H-x-<Q-[(QR!-G-G-x (5) -D-R -

NAME: pfkB family of carbohydrate kinases signature 1- CONSENSUS: CAG!-G-x (0 il) -[GAP!-x-N-x-[STA!-x (fa ) -[GS!-x (1 ) -G • NAME: pfkB family of carbohydrate kinases signature 2-

CONSENSUS: [DNSK!-[PSTV!-x-[SAG! (2 ) -[GD!-D-x (3 ) -[SAGV!-[AG!- [LIVMFY!-[LIVMSTAP!-

NAME: ROK family signature. CONSENSUS: [LIVM!-x (2) -G-[LIVMFCT!-G-x-[GA!-[LIVMFA!-x (8 ) -G- x(3ι5)-CGATP!-x(2)- CONSENSUS: G-CRKH!-

NAME: Phosphoribulokinase signature- CONSENSUS: K-[LIVM!-x-R-D-x (3) -R-G-x-[ST!-x-E -

NAME: Thymidine kinase cellular-type signature- CONSENSUS: [GA!-x (lι2) -CDE!-x-Y-x-[STAP!-x-C-[NKR!-x-[CH!- [LIVMFYUH!-

NAME: FGGY family of carbohydrate kinases signature 1- CONSENSUS: [MFYGS!-x-[PST!-x ( 2 ) -K-[LIVMFYU!-x-U-[LIVMF!-x- [DEN(QTKR!-[EN<QH!. NAME: FGGY family of carbohydrate kinases signature 2- CONSENSUS: [GSA!-x-[LIVMFYU!-x-G-[LIVM!-x ( 7ιβ) -[HDENlQ!- [LIVMF!-x(2)-[AS!-[STAIVM!- CONSENSUS: [LIVMFY!-[DEιQ! • NAME: Protein kinases ATP-binding region signature.

CONSENSUS: [LIV!-G--CP3--G--CP}-[FYUMGSTNH!-[SGA!--CPU}-[LIVCAT!-

^■CPD>-x-[GSTACLIVMFY!-

CONSENSUS". x(5ιl8)-[LIVMFYUCSTAR!-[AIVP!-[LIVMFAGCKR!-K- NAME: Serine/Threonine protein kinases active-site signature-

CONSENSUS: [LIVMFYC!-x-[HY!-x-D-[LIVMFY!-K-x (2 ) -N- CLIVMFYCT!(3)- NAME: Tyrosine protein kinases specific active-site signature-

CONSENSUS: [LIVMFYC!-x-[HY!-x-D-[LIVMFY!-[RSTAC!-x (2 ) -N- [LIVMFYC!(3) - NAME: Protein kinase domain profile-

NAME: Casein kinase II regulatory subunit signature- CONSENSUS : C-P-x-CLIVMY!-x-C-x ( 5 ) -L-P-CLIVMC!-G-x ⁽ 1 ) -V-CKR!- x ( 2 ) -C-P-x-C -

NAME: Pyruvate kinase active site signature- CONSENSUS: CLIVAC!-x-CLIVM! (2) -[SAPCV!-K-[LIV!-E-[NKRST!-x- [DE(QH!-[GSTA!-[LIVM!-

NAME"- Shikimate kinase signature-

CONSENSUS: CKR!-x (2) -E-x (3) -[LIVMF!-x (6ιl2) -[LIVMF! (2) -[SA!- x-G(3)-x-CLIVMF!-

NAME: Prokaryotic diacylglycerol kinase signature- CONSENSUS: E-x-[LIVM!-N-[ST!-[SA!-[LIV!-E-x (2) -V-D - NAME: Phosphatidylinositol 3- and 4-kinases signature 1- CONSENSUS: [LIVMFAC!-K-x (lι3) - EA!-[DE!-[LIVMC!-R-(Q-[DE!- x(4)-(Q.

NAME: Phosphatidylinositol 3- and 4-kinases signature 2- CONSENSUS: [GS!-x-[AV!-x (3) -[LIVM!-x (2) -[FYH!-[LIVM! (2 ) -x- [LIVMF!-x-D-R-H-x(2)-N-

NAME: Acetate and butyrate kinases family signature 1 CONSENSUS: [LIVM! (2) -x-[LIVM!-N-x-G-S-[ST!-S-x-[KE! .

NAME: Acetate and butyrate kinases family signature 2-

CONSENSUS: [LIVMA!(2)-x(2)-H-x-G-x-G-x-[ST!-[LIVM!-x-[AV!- x(3)-6. NAME". Phosphoglycerate kinase signature.

CONSENSUS: [KRHGTCV!-[VT!-[LIVMF!-[LIVMC!-R-x-D-x-N-[SACV!-P .

NAME: Aspartokinase signature-

CONSENSUS: [LIVM!-x-K-[FY!-G-G-[ST!-[SC!-[LIVM! -

NAME: Glutamate 5-kinase signature-

CONSENSUS: [GSTN!-x (2) -G-x-G-[GC!- M!-x-[STA!-K-[LIVM!-x-

[SA!-[TCA!-x(2)-[GALV!-

CONSENSUS: x(3)-G-

NAME: ATP:guanido phosphotransferases active site- CONSENSUS: C-P-x (Oil) -[ST!-N-[IL!-G-T -

NAME-" PTS HPR component histidine phosphorylation site signature.

CONSENSUS: G-[LIVM!-H-[STA!-R-[PA!-[GSTA!-[STAM! •

NAME: PTS HPR component serine phosphorylation site signature. CONSENSUS: [GSADE!-[KRE(QTV!-x ( 4 ) -[KRN!-S-[LIVMF! (2 ) -x-[LIVM!- x(2)-[LIVM!-[GAD!.

NAME: PTS EIIA domains phosphorylation site signature 1- CONSENSUS: G-x (2) -[LIVMF! (3) -H-[LIVMF!-G-[LIVMF!-x-T-[ALV! .

NAME: PTS EIIA domains phosphorylation site signature 2. CONSENSUS: ENlQ!-x (b) -[LIVMF!-[GA!-x (2) -[LIVM!-A-[LIVM!-P-H- [GAC!. NAME: PTS EIIB domains cysteine phosphorylation site signature.

CONSENSUS: N-[LIVMFY!-x ( 5) -C-x-T-R-[LIVMF!-x-[LIVMF!-x-

[LIVM!-x-[D(Q!.

NAME: Adenylate kinase signature- CONSENSUS: [LIVMFYU!(3)-D-G-[FYI!-P-R-x(3)-[N(Q!-

NAME: Nucleoside diphosphate kinases active site- CONSENSUS: N-x(2)-H-[GA!-S-D-[SA!-[LIVMPKNE!-

NAME: Guanylate kinase signature-

CONSENSUS: T-[ST!-R-x(2)-[KR!-x(2)-[DE!-x(2)-G-x(2)-Y-x-[FY!- CLIVM .

NAME: Guanylate kinase domain profile-

NAME: Phosphoribosyl pyrophosphate synthetase signature CONSENSUS: D-CLI!-H-[SA!-x-(Q-[IMST!-[(QM!-G-[FY!-F-x(2)-P- CLIVMF -D

NAME: 7ι8-dihydro-b-hydroxymethylpterin-pyrophosphokinase signature. CONSENSUS: G-[PE!-R-x(2)-D-L-D-[LIVM!(2) -

NAME: Bacteriophage-type RNA polymerase family active site signature 1 CONSENSUS: P-[LIVM!-x(2)-D-[GA!-[ST!-[AC!-[SN!-[GA!-[LIVMFY!- Q -

NAME: Bacteriophage-type RNA polymerase family active site signature 2-

CONSENSUS: [LIVMF!-x-R-x(3)-K-x(2)-[LIVMF!-M-[PT!-x(2)-Y-

NAME: Eukaryotic RNA polymerase II heptapeptide repeat- CONSENSUS: Y-[ST!-P-[ST!-S-P-[STANK!-

NAME: RNA polymerases beta chain signature.

CONSENSUS: G-x-K-[LIVMFA!-[STAC!-[GSTN!-x-[HSTA!-[GS!-[(QNH!-

K-G-[IVT!.

NAME: RNA polymerases M / 15 Kd subunits signature. CONSENSUS: F-C-x-[DEKST!-C-[GNK!- NSA!-[LIVMH!-[LIVM!-

NAME: RNA polymerases D / 3D to 4D Kd subunits signature CONSENSUS: N-[SGA!-[LIVMF!-R-R-x ( 1) -[SA!-x (3) -V-x( ) -N-x- [STA!-x(3)-[DN!-E-x-[LI!- CONSENSUS: CGA!-x-R-[LI!-[GA!-[LIVM!(2)-P.

NAME: RNA polymerases H / 23 Kd subunits signature- CONSENSUS: H-[NEI!-[LIVM!-V-P-x-H-x(2)-[LIVM!-x(2)-[DE!-

NAME: RNA polymerases K / 14 to 18 Kd subunits signature-

CONSENSUS: [ST!-x-[FY!-E-x-[AT!-R-x-[LIVM!-[GSA!-x-R-[SA!-x-

(Q. NAME: RNA polymerases L / 13 to lfa Kd subunits signature- CONSENSUS: CDE! (2) -H-CST!-[LIVM!-[GAP!-N-x (11) -V-x-CFM!-x (2) - Y-x(3)-H-P- NAME: RNA polymerases N / 8 Kd subunits signature- CONSENSUS: CLIVMF! (2) -P-CLIVM!-x-C-F-[ST!-C-G -

NAME: DNA polymerase family A signature.

CONSENSUS: R-x (2) -CGSAV!-K-x (3 ) -[LIVMFY!-[AG(Q!-x (2) -Y-x ( 2) - [GS!-x(3)-[LIVMA!.

NAME: DNA polymerase family B signature-

CONSENSUS: [YA!-[GLIVMSTAC!-D-T-D-[SG!-[LIVMFTC!-x- [LIVMSTAC!-

NAME: DNA polymerase family X signature-

CONSENSUS: G-[SG!-[LFY!-x-R-[GE!-x (3) -[SGCL!-x-D-[LIVM!-D-

[LIVMFY!(3)-x(2)-[SAP!- NAME: Galactose-1-phosphate uridyl transferase family 1 active site signature- CONSENSUS: F-E-N-CRK!-G-x (3) -G-x ( 4 ) -H-P-H-x-(Q -

NAME: Galactose-1-phosphate uridyl transferase family 2 signature-

CONSENSUS: D-L-P-I-V-G-G-[ST!-[LIVM! (2) -[SA!-H- EN!-H-[FY!- Q-G-G -

NAME: ADP-glucose pyrophosphorylase signature 1- CONSENSUS: [AG!-G-G-x-G-[STK!-x-L-x (2 ) -L-[TA!-x (3) -A-x-P-A- [LV!.

NAME: ADP-glucose pyrophosphorylase signature 2- CONSENSUS: U-[FY!-x-G-[ST!-A-[DNSH!-[AS!-[LIVMFYU! -

NAME: ADP-glucose pyrophosphorylase signature 3- CONSENSUS: [APV!-[GS!-M-G-[LIVMN!-Y-[IVC!-[LIVMFY!-x (2 ) - [DENPHK!. NAME: Phosphatidate cytidylyltransferase signature-

CONSENSUS: S-x-[LIVMF!-K-R-x ( 4 ) -K-D-x-[GSA!-x (2) -[LI!-CPG!-x-

H-G-G-[LIVM!-x-D-R-

CONSENSUS". [LIVMFT!-D- NAME". Ribonuclease PH signature-

CONSENSUS: C-[DE!-[LIVM! (2 ) -(Q-[GTA!-D-G-[SG!-x (2)-[TA!-A -

NAME: 2'-5'-oligoadenylate synthetases signature 1- CONSENSUS: G-G-S-x-[AG!-[KR!-x-T-x-L-CKR!-[GST!-x-S-D-[AG! ■

NAME: 2'-5'-oligoadenylate synthetases signature 2 CONSENSUS: R-P-V-I-L-D-P-x-[DE!-P-T -

NAME: CDP-alcohol phosphatidyltransferases signature- CONSENSUS: D-G-x (2) -A-R- (8) -G-x (3) -D-x (3) -D -

NAME: PEP-utilizing enzymes phosphorylation site signature CONSENSUS: G-[GA!-x-[TN!-x-H-[STA!-[STAV!-[LIVM! (2 ) -[STAVING!.

NAME: PEP-utilizing enzymes signature 2- CONSENSUS: E(QS!-x-[LIVMF!-S-[LIVMF!-G-[ST!-N-D-[LIVM!-x-(Q- [LIVMFYGT!-[STALIV!- CONSENSUS: CLIVMF!-[GAS!-x (2) -R .

NAME". Rhodanese signature 1- CONSENSUS: CFY!-x (3) -H-CLIVΪ-P-G-A- (2) -CLIVF! ■

NAME: Rhodanese C-terminal signature-

CONSENSUS: [AV!-x (2) -CFY!-[DEAP!-G-[GSA!-[UF!-x-E-[FYU! - NAME: CoA transferases signature 1-

CONSENSUS: [DN!-[GN!-x (2) -[LIVMFA! (3) -G-G-F-x (3) -G-x-P -

NAME: CoA transferases signature 2- CONSENSUS: [LF!-[H(Q!-S-E-N-G-[LIVF! (2) -[GA! .

NAME: - Phospholipase A2 histidine active site CONSENSUS: C-C-x (2 ) -H-x (2) -C ■

NAME: Phospholipase A2 aspartic acid active site. CONSENSUS: [LIVMA!-C--CLIVMFYUPCSTΪ-C-D-x (5) -C •

NAME: Lipasesi serine active site.

CONSENSUS: [LIV!-x-[LIVFY!-[LIVMST!-G-[HYUV!-S-x-G-[GSTAC! ■ NAME: Colipase signature-

CONSENSUS: γ__{x (Ξ)} -γ_γ__x_c-_x-C .

NAME: Lipolytic enzymes "G-D-S-L" familyi serine active site- CONSENSUS: [LIVMFYAG! ( 4 ) -G-D-S-[LIVM!-x (lι2) -[TAG!-G -

NAME: Lipolytic enzymes "G-D-X-G" familyi putative histidine active site-

CONSENSUS: [LIVMF! (2)-x-[LIVMF!-H-G-G-[SAG!-[FY!-x (3)-[STDN!- x(2)-[ST!-H-

NAME: Lipolytic enzymes "G-D-X-G" familyi putative serine active site-

CONSENSUS: CLIVM!-x-[LIVMF!-[SA!-G-D-S-[CA!-G-[GA!-x-L-[CA! -

NAME: Carboxylesterases type-B serine active site- CONSENSUS: F-[GR!-G-x ( 4 ) -[LIVM!-x-[LIV!-x-G-x-S-[STAG!-G •

NAME: Carboxylesterases type-B signature 2- CONSENSUS: [ED!-D-C-L-[YT!-[LIV!-[DNS!-[LIV!-[LIVFYU!-x- IPQR1 -

NAME: Pectinesterase signature 1-

CONSENSUS: [GSTN!-x (5) -[LIVM!-x-[LIVM!-x (2) -G-x-Y-[DNK!-E-x- [LIVM!-x-[LIVM!>

NAME: Pectinesterase signature 2- CONSENSUS: G-[STAD!-[LIVMT!-D-F-I-F-G . NAME." Peptidyl-tRNA hydrolase signature 1-

CONSENSUS: CFY!-x(2)-T-R-H-N-x-G-x(2)-[LIVMFA!(2)-[DE!-

NAME: Peptidyl-tRNA hydrolase signature 2-

CONSENSUS: [GS!-x(3)-H-N-G-[LIVM!-[KR!-[DNS!-[LIVMT!-

NAME: Alkaline phosphatase active site-

CONSENSUS: [IV!-x-D-S-[GAS!-[GASC!-[GAST!-[GA!-T.

NAME: Histidine acid phosphatases phosphohistidine signature.

CONSENSUS: [LIVM!-x(2)-[LIVMA!-x(2)-[LIVM!-x-R-H-[GN!-x-R-x-

[PAS!.

NAME: Histidine acid phosphatases active site signature.

CONSENSUS: [LIVMF!-x-[LIVMFAG!-x(2)-[STAGI!-H-D-[STAN(3!-x-

[LIVM!-x(2) -[LIVMFY!-x(2)~

CONSENSUS: [STA!.

NAME: Class A bacterial acid phosphatases signature-

CONSENSUS: G-S-Y-P-S-G-H-T-

NAME: 5 ' -nucleotidase signature 1- C COONNSSEENNSSUUSS:: CLIVM!-x-[LIVM! (2) -[HEA!-[TI!-x-D-x-H-[GSA!-x-

[LIVMF!.

NAME: 5 ' -nucleotidase signature 2-

CONSENSUS: [FYP!-x(4)-[LIVM!-G-N-H-E-F-[DN!

NAME: Fructose-1-fa-bisphosphatase active site-

CONSENSUS: [AG!-[RK!-L-x(lι2)-[LIV!-[FY!-E-x(2)-P-[LIVM!-

[GSA!.

NNAAMMEE:: Serine/threonine specific protein phosphatases signature.

CONSENSUS: [LIVM!-R-G-N-H-E-

NAME: Protein phosphatase 2A regulatory subunit PR55 signature 1

CONSENSUS: E-F-D-Y-L-K-S-L-E-I-E-E-K-I-N.

NAME: Protein phosphatase 2A regulatory subunit PR55 signature 2

CCOONNSSEENNSSUUSS:: N-[AG!-H-[TA!-Y-H-I-N-S-I-S-[LIVM!-N-S-D .

NAME: Protein phosphatase 2C signature-

CONSENSUS: [LIVMFY!-[LIVMFYA!-[GSAC!-[LIVM!-[FYC!-D-G-H-

[GAV!.

NAME: Tyrosine specific protein phosphatases active site-

CONSENSUS: [LIVMF!-H-C-x⁽2⁾-G-x(3)-CSTC!-[STAGP!-x-[LIVMFY!

NAME: Tyrosine specific protein phosphatases profile-

NAME: Dual specificity protein phosphatase profile-

NAME: PTP type protein phosphatase profile- NAME: Inositol monophosphatase family signature 1- CONSENSUS: CFUV!-x (Oil ) -[LIVM!-D-P-[LIVM!-D-[SG!-[ST!-x (2) - [FY!-x-[HKRNSTY!-

NAME: Inositol monophosphatase family signature 2- CONSENSUS: [UV!-D-x-[AC!-[GSA!-[GSAPV!-x-[LIVACP!-[LIV!-. [LIVAC!-x(3)-[GH!-[GA!. NAME: Prokaryotic zinc-dependent phospholipase C signature. CONSENSUS: H-Y-x-[GT!-D-[LIVM!-[DNS!-x-P-x-H-[PA!-x-N •

NAME: Phosphatidylinositol-specific phospholipase X-box domain profile-

NAME: Phosphatidylinositol-specific phospholipase Y-box domain profile-

NAME: 3'5'-cyclic nucleotide phosphodiesterases signature- CONSENSUS: H-D-[LIVMFY!-x-H-x-[AG!-x (2) -[N(Q!-x-[LIVMFY! -

NAME: cAMP phosphodiesterases class-II signature- CONSENSUS: H-x-H-L-D-H-[LIVM!-x-[GS!-[LIVMA!-[LIVM! (2) -x-S- [AP!-

NAME: Sulfatases signature 1-

CONSENSUS: [SAP!-[LIVMST!-[CS!-[STAC!-P-[STA!-R-x (2)-

[LIVMFU!(2)-[TR!-G- NAME: Sulfatases signature 2-

CONSENSUS: G-CYV!-x-[ST!-x (2) -[IVA!-G-K-x (Oil ) -[FYUK!-[HL! -

NAME: AP endonucleases family 1 signature 1- CONSENSUS: [APF!-D-[LIVMF! (2) -x-[LIVM!-(Q-E-x-K .

NAME: AP endonucleases family 1 signature 2. CONSENSUS: D-[ST!-[FY!-R-[KH!-x (7ι8) -[FYU!-[ST!-[FYU! (2 )

NAME: AP endonucleases family 1 signature 3- CONSENSUS: N-x-G-x-R-[LIVM!-D-[LIVMFYH!-x-[LV!-x-S

NAME: AP endonucleases family 2 signature 1- CONSENSUS: H-x (2) -Y-[LIVMF!-[IM!-N-[LIVMCA!-[AG! . NAME: AP endonucleases family 2 signature 2- CONSENSUS: [GR!-[LIVMF!-C-[LIVM!-D-T-C-H •

NAME: AP endonucleases family 2 signature 3- CONSENSUS: [LIVMU!-H-x-N- E!-[SA!-K-x (3) -G-[SA!-x (2) -D •

NAME: Deoxyribonuclease I signature 1.

CONSENSUS: [LIVM! (2 ) -[AP!-L-H-[STA! (2) -P-x (5) -E-[LIVM!-[DN!- x-L-x-[DE!-V- NAME: Deoxyribonuclease I signature 2- CONSENSUS: G-D-F-N-A-x-C-[SA! .

NAME: Endonuclease III iron-sulfur binding region signature CONSENSUS : C-x ( 3 ) -[KRS!-P-[KRAGL!-C-x ( 2 ) -C-x ( 5 ) -C .

NAME: Endonuclease III family signature-

CONSENSUS: [GST!-x-[LIVMF!-P-χ (5) -[LIVMU!-x (2ι3) -CLI!-[PAS!- G-V-CGA!-x(3)-[GAC!-

CONSENSUS: x (3) -[LIVM!-x (2) -[SALV!-[LIVMFYU!-[GANK! -

NAME: Ribonuclease II family signature- CONSENSUS: [HI!-[FYE!-[GSTAM!-[LIVM!-x (4ιS) -Y-[STAL!-x- [FUVAC!-[TV!-[SA!-P-[LIVMA!-

CONSENSUS: [R(Q!-[KR!-[FY!-x-D-x (3) -[H(Q! -

NAME: Ribonuclease III family signature- CONSENSUS: [DE(Q!-[R(Q!-[LM!-E-[FYU!-[LV!-G-D-[SAR! -

NAME: Bacterial Ribonuclease P protein component signature- CONSENSUS: [LIVMFYS!-x (2 ) -A-x (2) -R-[NH!-[KR(QL!-[LIVM!-[KRA!- R-x-[LIVMTA!-[KR!- NAME: Ribonuclease T2 family histidine active site 1- CONSENSUS: [FYUL!-x-[LIVM!-H-G-L-U-P •

NAME: Ribonuclease T2 family histidine active site 2- CONSENSUS: [LIVMF!-x (2) -[HDGTY!-[E(Q!-[FYU!-x-[KR!-H-G-x-C .

NAME: Pancreatic ribonuclease family signature CONSENSUS: C-K-x (2 ) -N-T-F •

NAME: DNA/RNA non-specific endonucleases active site- CONSENSUS: D-R-G-H-[(QIL!-x (3) -A •

NAME: Thermonuclease family signature 1.

CONSENSUS: D-G-D-T-[LIVM!-x-[LIVMC!-x (lilD ) -R-[LIVM!-x (2 )

[LIVM!-D-x-P-E-

NAME: Thermonuclease family signature 2- CONSENSUS: D-[KR!-Y-[G(Q!-R-x-[LV!-[GA!-x-[IV!-[FYU! .

NAME: Beta-amylase active site 1. CONSENSUS: H-x-C-G-G-N-V-G-D .

NAME: Beta-amylase active site 2- CONSENSUS: G-x-[SA!-G-E-[LIVM!-R-Y-P-S-Y ■ NAME: Glucoamylase active site region signature.

CONSENSUS: [STN!-[GP!-x (lι2) - E!-x-U-E-E-x (2 ) -[GS! •

NAME: Polygalacturonase active site-

CONSENSUS." [GSDENKRH!-x(2)-[VMFC!-x(2)-[GS!-H-G-CLIVMAG!- x(lι2)-[LIVM!-G-S.

NAME: Clostridium cellulosome enzymes repeated domain signature-

CONSENSUS: D-CLIVMFY!-[DNV!-x-[DNS!-x (2 ) -[LIVM!-[DN!-[SALM!- x-D-x(3)-[LIVMF!-x-

CONSENSUS: [RKS!-x-[LIVMF! -

NAME: Chitinases family 16 active site- CONSENSUS : ^[LIVMFY!-^[DN!-G-[LIVMF!-[DN!-^[LIVMF!-^[DN!-x-E -

NAME-" Chitinases family 11 signature 1-

CONSENSUS: C-x (4 -, 5) -F-Y-CSTJ-x (3) -[FY!-[LIVMF!-x-A-x (3) -CYF!- x(2)-F-CGSA!.

NAME: Chitinases family 11 signature 2-

CONSENSUS: CLIVM!-[GSA!-F-x-[STAG!(2)-[LIVMFY!-U-[FY!-U-

[LIVM!-

NAME: Alpha-lactalbumin / lysozyme C signature. CONSENSUS: C-x(3)-C-x(2)-[LMF!-x(3)-[DEN!-[LI!-x(S)-C-

NAME: Alpha-galactosidase signature.

CONSENSUS: G-CLIVMFY!-x(2)-CLIVMFY!-x-[LIVM!-D-D-x-U-x(3ι4)

R- NSF!-

NAME: Trehalase signature 1- CONSENSUS: P-G-G-R-F-x-E-x-Y-x-U-D-x-Y

NAME: Trehalase signature 2- CONSENSUS: <Q-U-D-x-P-x-[GA!-U-[PA!-P

NAME: Alpha-L-fucosidase putative active site. CONSENSUS: P-x (2) -L-x (3) -K-U-E-x-C ■

NAME: Glycosyl hydrolases family 1 active site- CONSENSUS: [LIVMFSTC!-[LIVFYS!-[LIV!-[LIVMST!-E-N-G- [LIVMFAR!-[CSAGN!-

NAME: Glycosyl hydrolases family 1 N-terminal signature CONSENSUS: F-x-[FYUM!-[GSTA!-x-[GSTA!-x-[GSTA! (2)-[FYNH!- [N(Q!-x-E-x-[GSTA!. NAME-" Glycosyl hydrolases family 2 signature 1-

CONSENSUS: N-x-[LIVMFYUD!-R-[STACN! (2 ) -H-Y-P-x (4 ) -

[LIVMFYU!(2)-x(3)-[DN!-x(2)-

CONSENSUS: G-CLIVMFYU! ( 4 ) • NAME: Glycosyl hydrolases family 2 acid/base catalyst-

CONSENSUS: CDEN(QF!-CKRVU!-N-H-[AP!-[SAC!-[LIVMF! (3 ) -U-[GS!- x(2ι3)-N-E-

NAME: Glycosyl hydrolases family 3 active site- CONSENSUS: CLIVM! (2 ) -CKR!-x-[E(QK!-x ( 4 ) -G-[LIVMFT!-[LIVT!- [LIVMF!-[ST!-D-x(2)~ CONSENSUS: [SGADNI!-

NAME: Glycosyl hydrolases family 5 signature- CONSENSUS: [LIV!-[LIVMFYUGA! (2) - NE(QG!-[LIVMGST!-x-N-E-[PV!- [RHDNSTLIVFY!.

NAME: Glycosyl hydrolases family fa signature 1- CONSENSUS: V-x-Y-x(2)-P-x-R-D-C-[GSAF!-x(2)-[GSA!(2)-x-G

NAME: Glycosyl hydrolases family fa signature 2-

CONSENSUS: [LIVMYA!-[LIVA!-[LIVT!-[LIV!-E-P-D-[SAL!-[LI!-

[PSAG!. NAME: Glycosyl hydrolases family 6 signature- CONSENSUS: A-CST!-D-[AG!-D-x (2 ) -CIM!-A-x-[SA!-[LIVM!-[LIVMG!- x-A-x(3)-CFU!-

NAME: Glycosyl hydrolases family 1 active sites signature 1. CONSENSUS: CSTV!-x-[LIVMFY!-[STV!-x (2) -6-x-[NKR!-x ( )- [PLIVM!-H-x-R- NAME-" Glycosyl hydrolases family 1 active sites signature 2. CONSENSUS: [FYU!-x-D-x (4 ) -[FYU!-x (3) -E-x-[STA!-x (3) -N-[STA! -

NAME: Glycosyl hydrolases family ID active site- CONSENSUS: [GTA!-x (2) -[LIVN!-x-[IVMF!-[ST!-E-[LIY!- N!- [LIVMF!-

NAME"- Glycosyl hydrolases family 11 active site signature 1. CONSENSUS: [PSA!-[L(Q!-x-E-Y-Y-[LIVM! (2 ) -[DE!-x-[FYUHN! - NAME: Glycosyl hydrolases family 11 active site signature 2. CONSENSUS: [LIVMF!-x (2 ) -E-[AG!-[YUG!-[(QRFGS!-[SG!-[STAN!-G-x- [SAF!-

NAME: Glycosyl hydrolases family lb active sites- CONSENSUS: E-[LIV!-D-[LIV!-x (Oil) -E-x (2) -[G(Q!-[KRNF!-x- [PSTA!-

NAME: Glycosyl hydrolases family 17 signature- CONSENSUS: [LIVM!-x-[LIVMFYUA! (3) -[STAG!-E-[STA!-G-U-P-[STN!- x-[SAG(Q!-

NAME: Glycosyl hydrolases family 25 active sites signature- CONSENSUS: D-CLIVM!-x (3) -CN(Q!-[PG!-x (lilO) -G-x ( 4 )- [LIVMFY!(2)-K-x-[ST!-E-[GS!-x(2)- CONSENSUS: Y-x- N!-

NAME: Glycosyl hydrolases family 31 active site- CONSENSUS: [GF!-[LIVMF!-U-x-D-M-CNSA!-E - NAME: Glycosyl hydrolases family 31 signature 2-

CONSENSUS: G-[AV!-D-[LIVMT!-C-G-[FY!-x (3) -[ST!-x (3) -L-C-x-R-

U-x(2)-[LV!-[GS!-[SA!-

CONSENSUS: F-x-P-F-x-R- N! - NAME: Glycosyl hydrolases family 32 active site- CONSENSUS: H-x (2) -P-x ( 4 ) -[LIVM!-N-D-P-N-G -

NAME: Glycosyl hydrolases family 35 putative active site. CONSENSUS: G-G-P-[LIVM! (2)-x (2) -ιQ-x-E-N-E-[FY! -

NAME: Glycosyl hydrolases family 31 active site- CONSENSUS: U-x-F-E-x-U-N-E-P- N! -

NAME: Glycosyl hydrolases family 45 active site CONSENSUS: [STA!-T-R-Y-[FYU!-D-x ( 5) -[CA! •

NAME: Prokaryotic transglycosylases signature CONSENSUS: CLIVM!-x (3) -E-S-x (3) -CAP!-x (3) -S-x (5) -G-CLIVM!-

[LIVMFYU!-x-[LIVMFYU!-

CONSENSUS: x(4)-[SAG!- NAME: Inosine-uridine preferring nucleoside hydrolase family signature- CONSENSUS: D-x-D-CPT!-[GA!-x-D-D-[TAV!-[VI!-A .

NAME: Alkylbase DNA glycosidases alkA family signature- CONSENSUS: G-I-G-x-U-CST!-CAV!-x-[LIVMFY! (2) -x-[LIVM!-x (6) - [MF!-x(2)-[ED!-D-

NAME: Formamidopyrimidine-DNA glycosylase signature- CONSENSUS: C-x (2ι 4 ) -C-x-CGTAιQ!-x-[IV!-x ( 7 ) -R-[GSTAN!-[STA!-x- [FYI!-C-x(2)-C-(Q-

NAME: Uracil-DNA glycosylase signature- CONSENSUS: [KR!-[LIV!-[LIVC!-[LIVM!-x-G-[(QI!-D-P-Y - NAME: S-adenosyl-L-homocysteine hydrolase signature 1-

CONSENSUS: [CS!-N-x-[FYL!-S-[ST!-[(QA!-[DEN!-x-[AV! (2) -A-A- [LIV!-[SAV!.

NAME: S-adenosyl-L-homocysteine hydrolase signature 2- CONSENSUS: G-K-x (3) -[LIV!-x-G-Y-G-x-V-G-[KR!-G-x-A .

NAME: Cytosol aminopeptidase signature- CONSENSUS: _N__T_D__A-E-G-R-L - NAME: Aminopeptidase P and proline dipeptidase signature- CONSENSUS: [HA!-[GSYR!-[LIVMT!-[SG!-H-x-[LIV!-G-[LIVM!-x- [IV!-H-[DE!-

NAME: Methionine aminopeptidase subfamily 1 signature- CONSENSUS: [MFY!-x-G-H-G-[LIVMC!-[GSH!-x (3 ) -H-x (4) -[LIVM!-x- [HN!-[YUV!.

NAME: Methionine aminopeptidase subfamily 2 signature- CONSENSUS: [DA!-[LIVMY!-x-K-[LIVM!-D-x-G-x-CH(Q!-[LIVM!-[DNS!- G-x(3)-[DN!-

NAME: Renal dipeptidase active site-

CONSENSUS: CLIVM!-E-G-[GA!-x (2 ) -[LIVMF!-x ( fa ) -L-x (3) -Y-x (2) -G-

[LIVM!-R-

NAME: Serine carboxypeptidasesi serine active site CONSENSUS: [LIVM!-x-[GTA!-E-S-Y-[AG!-[GS! .

NAME: Serine carboxypeptidasesi histidine active site- CONSENSUS: [LIVF!-x (2) -[LIVSTA!-x-[IVPST!-x-[GSDN(QL!-[SAGV!- [SG!-H-x-[IVA(Q!-P-x(3)- CONSENSUS: [PSA!-

NAME: Zinc carboxypeptidasesi zinc-binding region 1 signature-

CONSENSUS: [PK!-x-[LIVMFY!-x-[LIVMFY!-x ( 4 ) -H-[STAG!-x-E-x-

[LIVM!-[STAG!-x(fa)-

CONSENSUS: [LIVMFYTA!- NAME: Zinc carboxypeptidasesi zinc-binding region 2 signature.

CONSENSUS: H-[STAG!-x(3)-[LIVME!-x(2)-[LIVMFYU!-P-[FYU!.

NAME: Serine proteasesi trypsin familyi histidine active site- CONSENSUS: [LIVM!-[ST!-A-CSTAG!-H-C. NAME: Serine proteasesi trypsin familyi serine active site CONSENSUS: [DNSTAGC!-[GSTAPIMV(QH!-x (2) -G-[DE!-S-G-CGS!- [SAPHV!-[LIVMFYUH!- CONSENSUS: [LIVMFYSTANiQH! . NAME: Serine proteasesi subtilase familyi aspartic acid active site.

CONSENSUS: [STAIV!-x-[LIVMF!-[LIVM!-D- STA!-G-[LIVMFC!-

NAME: Serine proteasesi subtilase familyi histidine active site-

CONSENSUS: H-G-CSTM!-x-[VIC!-[STAGC!-[GS!-x-[LIVMA!- [STAGCLV!-[SAGM!-

NAME: Serine proteasesi subtilase familyi serine active site. CONSENSUS: G-T-S-x-[SA!-x-P-x(2)-[STAVC!-[AG!-

NAME: Serine proteasesi V8 familyi histidine active site- CONSENSUS: [ST!-G-[LIVMFYU!(3)-[GN!-x(2)-T-[LIVM!-x-T-x(2)-H.

NAME: Serine proteasesi V8 familyi serine active site- CONSENSUS: T-x(2)-CGC!-[N(Q!-S-G-S-x-[LIVM!-[FY!.

NAME: Serine proteasesi omptin family signature 1- CONSENSUS: U-T-D-x-S-x-H-P-x-T.

NAME: Serine proteasesi omptin family signature 2-

CONSENSUS: A-G-Y-(Q-E-[ST!-R-[FYU!-S-[FYU!-[TN!-A-x-G-G-EST!-

Y.

NAME: Prolyl endopeptidase family serine active site

CONSENSUS: D-x(3)-A-x(3)-[LIVMFYU!-x(14)-G-x-S-x-G-G-

[LIVMFYU!(2)

NAME-" Endopeptidase Clp serine active site-

CONSENSUS: T-x (2) -[LIVMF!-G-x-A-[SAC!-S-[MSA!-[PAG!-[STA! -

NAME-" Endopeptidase Clp histidine active site- CONSENSUS: R-x (3) -[EAP!-x (3) -[LIVMFYT!-M-[LIVM!-H-ιQ-P -

NAME: ATP-dependent serine proteasesi lon familyi serine active site-

CONSENSUS: D-G-[PD!-S-A-[GS!-[LIVMCA!-[TA!-[LIVM! -

NAME: Eukaryotic thiol (cysteine) proteases cysteine active site.

CONSENSUS: (Q-x (3) -[GE!-x-C-CYU!-x (2) -[STAGC!-^[STAGCV!- NAME: Eukaryotic thiol (cysteine) proteases histidine active site.

CONSENSUS: [LIVMGSTAN!-x-H-EGSACE!-[LIVM!-x-[LIVMAT! (2) -G-x- [GSADNH!-

NAME: Eukaryotic thiol (cysteine) proteases asparagine active site-

CONSENSUS: [FYCH!-[UI!-[LIVT!-x-[KR(QAG!-N-[ST!-U-x (3) -CFYϋlJ- G-x(2)-G-[LFYU!-

CONSENSUS: [LIVMFYG!-x-[LIVMF! ■

NAME: Ubiquitin carboxyl-terminal hydrolase family 1 cysteine active-site- CONSENSUS: (Q-x (3) -N-CSA!-C-G-x (3) -CLIVM! (2 ) -H-CSA!-CLIVM!- [SA!-

NAME: Ubiquitin carboxyl-terminal hydrolases family 2 signature 1- CONSENSUS: G-CLIVMFY!-x (lι3) -CAGC!-CNASM!-x-C-CFYU!-[LIVMC!- [NST!-[SACV!-x-[LIVMS!- CONSENSUS: Q -

NAME-" Ubiquitin carboxyl-terminal hydrolases family 2 signature 2 ■

CONSENSUS: Y-x-L-x-[SAG!-[LIVMFT!-x (2) -H-x-G-x (4ι5) -G-H-Y -

NAME: Caspase family histidine active site- CONSENSUS: H-x (2ι4 ) -CSC!-x ( 4 ) -[LIVMF! (2) -[ST!-H-C

NAME: Caspase family cysteine active site CONSENSUS: K-P-K-[LIVMF! ( 4 ) -ιQ-A-C-[RιQG!-G .

NAME: Eukaryotic and viral aspartyl proteases active site- CONSENSUS: ELIVMFGAC!-[LIVMTADN!-[LIVFSA!-D-[ST!-G-[STAV!- [STAPDEN(Q!-x-[LIVMFSTNC!- CONSENSUS: x-[LIVMFGTA! ■

NAME: Neutral zinc metallopeptidasesi zinc-binding region signature.

CONSENSUS: [GSTALIVN!-x (2 ) -H-E-[LIVMFYU!--CDEHRKP}-H-x- [LIVMFYUGSPiQ!.

NAME: Matrixins cysteine switch- CONSENSUS: P-R-C-[GN!-x-P-[DR!-[LIVSAPKιQ! -

NAME: Insulinase familyi zinc-binding region signature. CONSENSUS: G-x (βil ) -G-x-[STA!-H-[LIVMFY!-[LIVMC!- ERN!- [HRKL!-[LMFAT!-x-[LFSTH!-x- CONSENSUS: [GSTAN!-[GST! ■

//

AC PSDIOlfai DE Glycoprotease family signature-

CONSENSUS: [KR!-[GSAT!-x (4 ) -[FYUHL!-[D(QNGK!-x-P-x-[LIVMFY!- x(3)-H-x(2)-[AG!-H-

CONSENSUS: CLIVM!- NAME: Proteasome A-type subunits signature-

CONSENSUS: [FY!-x ( 4 ) -CSTNV!-x-[FYU!-S-P-x-G-[RKH!-x (2) -ύ-

[LIVM!-[DE!-Y-[SAD!-x(2)-

CONSENSUS: [SAG!-

NAME: Proteasome B-type subunits signature-

CONSENSUS: CLIVMA!-[GSA!-[LIVMF!-x-[FYLVGAC!-x (2) -[GSACFY!-

[LIVMSTAC!(3)-[GAC!-

CONSENSUS: [GSTACV!-[DES!-x (15) -CRK!-x (12ιl3) -G-x (2 ) -[GSTA!-

D-

NAME: Signal peptidases I serine active site- CONSENSUS: [GS!-x-S-M-x-[PS!-[AT!-[LF!-

NAME: Signal peptidases I lysine active site-

CONSENSUS: K-R-[LIVMSTA!(2)-G-x-[PG!-G-[DE!-x-[LIVM!-x-

[LIVMFY!- NAME: Signal peptidases I signature 3-

CONSENSUS: [LIVMFYU! (2) -x (2) -G-D-[NH!-x (3) -[SND!-x (2) -[SG! .

NAME: Signal peptidases II signature-

CONSENSUS: [GAF!-[GA!-[GAS!-CLIVM!-[GAS!-N-[LVMFG!-[LIVMFY!-

D-R-[LIMFA!

NAME: Peptidase family U32 signature-

CONSENSUS: E-x-F-x (2) -G-CSA!-[LIVM!-C-x (4 ) -G-x-C-x-CLIVM!-S - NAME: Amidases signature.

CONSENSUS: G-CGA!-S-S-[GS!-G-x-[GSA!-[GSAVY!-x-[LIVM!-[GSA!- x(fa)-[GSA!-x-[GA!-x-D-

CONSENSUS: x-[GA!-x-S-[LIVM!-R-x-P-[GSAC! • NAME: Asparaginase / glutaminase active site signature 1- CONSENSUS: [LIVM!-x (2) -T-G-G-T-[IV!-[AGS! .

NAME: Asparaginase / glutaminase active site signature 2- CONSENSUS: G-x-[LIVM!-x (2 ) -H-G-T-D-T-[LIVM! -

NAME: Urease nickel ligands signature-

CONSENSUS: T-EAY!-[GA!-[GAT!-[LIVM!-D-x-H-[LIVM!-H-x (3) -P ^,

NAME: Urease active site-

CONSENSUS ^[LIVM!⁽2)-[CT!-H-[HN!-L-x(3)-[LIVM!-x(2)-D-ELIVM!- x-F-A-

NAME: ArgE / dapE / ACYl / CPG2 / yscS family signature 1. CONSENSUS: ELIV!-^[GALMY!-[LIVMF!-x-[GSA!-H-x-D-[TV!-[STAV! .

NAME: ArgE / dapE / ACYl / CPG2 / yscS family signature 2. CONSENSUS: [GSTAI!-[SAN(Q!-D-x-K-[GSACN!-x (2) -[LIVMA!-x (2 ) - CLIVMFY!-x(1 ιl7)-[LIVM!-

CONSENSUS: x-CLIVMF!-CLIVMSTAG!-[LIVMFA!-x (2⁾ - NG!-E-E-x- CGSTN!.

NAME: Dihydroorotase signature 1-

CONSENSUS: D-[LIVMFYUSAP!-H-^[LIVA!-H-[LIVF!-^[RN!-x-[PGN! . NAME: Dihydroorotase signature 2- CONSENSUS: CGA!-[ST!-D-x-A-P-H-x ( ) -K . NAME: Beta-lactamase class-A active site-

CONSENSUS: CFY!-x-[LIVMFY!-x-S-[TV!-x-K-x (4 ) -[AGLM!-x (2) - CLC!.

NAME: Beta-lactamase class-C active site. CONSENSUS: F-E-[LIVM!-G-S-[LIVMG!-[SA!-K •

NAME: Beta-lactamase class-D active site-

CONSENSUS: [PA!-x-S-[ST!-F-K-[LIV!-[PAL!-x-[STA!-[LI! • NAME: Beta-lactamases class B signature 1-

CONSENSUS: [LI!-x-[STN!-[HN!-x-H-[GSTA!-D-x (2) -G-[GP!-x (7ιδ ) • [GS!.

NAME: Beta-lactamases class B signature 2 - CONSENSUS: P-x (3) -CLIVM! (2) -x-G-x-C-[LIVMF! (2) -K-

NAME: Arginase family signature 1.

CONSENSUS: [LIVMF!-G-G-x-H-x-[LIVMT!-[STAV!-x-[PAG!-x (3) -

[GSTA!

NAME: Arginase family signature 2- CONSENSUS: [LIVM! (2 ) -x-[LIVMFY!-D-[AS!-H-x-D

NAME: Arginase family signature 3- CONSENSUS: [ST!-[LIVMFY!-D-[LIVM!-D-x (3) -[PA(Q!-x (3) -P-[GSA!- x(7)-G-

NAME: Adenosine and AMP deaminase signature-

CONSENSUS: [SA!-[LIVM!-[NGS!-[STA!-D-D-P -

NAME: Cytidine and deoxycytidylate deaminases zinc-binding region signature-

CONSENSUS: [CH!-[AGV!-E-x (2) -[LIVMFGAT!-[LIVM!-x (17ι33) -P-C- x(2ι8)-C-x(3)-CLIVM!-

NAME: GTP cyclohydrolase I signature 1-

CONSENSUS: CEN!-[LIVM! (2 ) -x (2) -[KR(QN!-[DN!-[LIVM!-x (3) -[ST!- x-C-E-H-H- NAME: GTP cyclohydrolase I signature 2-

CONSENSUS: [SA!-x-[RK!-x-(Q-[LIVM!-(Q-E-[RN!-[LI!-[TSN! -

NAME: Nitrilases / cyanide hydratase signature 1- CONSENSUS: G-x (2) -[LIVMFY! (2 ) -x-[IF!-x-E-x (2) -[LIVM!-x-G-Y-P .

NAME-" Nitrilases / cyanide hydratase active site signature- CONSENSUS: G-[GA(Q!-x (2) -C-[UA!-E-[NH!-x (2) -[PST!-[LIVMFYS!-x- [KR!- NAME: Inorganic pyrophosphatase signature-

CONSENSUS: D-[SGDN!-D-[PE!-[LIVMF!-D-[LIVMGAC! ■

NAME: Acylphosphatase signature 1. CONSENSUS : [LIV!-x-G-x-V-(Q-G-V-x-[FM!-R .

NAME: Acylphosphatase signature 2- CONSENSUS: G-CFYU!-[AVC!-[KR(QAM!-N-x(3⁾-G-x-V-x(5)-G.

NAME: ATP synthase alpha and beta subunits signature- CONSENSUS: P-[SAP!-[LIV!-[DNH!-x(3)-S-x-S-

NAME: ATP synthase gamma subunit signature- CONSENSUS: [IV!-T-x-E-x(2)-[DE!-x(3)-G-A-x-[SAKR!-

NAME: ATP synthase delta (OSCP) subunit signature- CONSENSUS: [LIVM!-x-[LIVMFYT!-x(3)-[LIVMT!-[DEN(QK!-x(2)-

[LIVM!-x-[GSA!-G-[LIVMFYGA!- CONSENSUS: x-[LIVM!-[KRHEN(Q!-x-[GSEN!-

NAME: ATP synthase a subunit signature- CONSENSU [STAGN!-x-[STAG!-[LIVMF!-R-L-x-[SAGV!-N-[LIVMT!-

NAME: ATP synthase c subunit signature-

CONSENSUS: [GSTA!-R-[N(Q!-P-x(10)-[LIVMFYU!(2)-x(3)-[LIVMFYU!- x-CDE!.

NAME: E1-E2 ATPases phosphorylation site- CONSENSUS: D-K-T-G-T-[LI!-[TI!-

NAME: Sodium and potassium ATPases beta subunits signature

1-

CONSENSUS: [FYU!-x(2)-[FYU!-x-[FYU!-[DN!-x(b)-[LIVM!-G-R-T- x(3)-U-

NAME: Sodium and potassium ATPases beta subunits signature

2.

CONSENSUS: [RK!-x(2)-C-[RK(QUI!-x(5)-L-x(2)-C-[SA!-G-

NAME: GDA1/CD31 family of nucleoside phosphatases signature

CONSENSUS: CLIVM!-x-G-x(2)-E-G-x-[FY!-x-[FU!-[LIVA!-[TAG!-x-

N-[HY!-

NAME". Iodothyronine deiodinases active site- CONSENSUS: R-P-L-V-x-N-F-G-S-[CA!-T-C-P-x-F-

NAME: Cutinasei serine active site- CONSENSUS: P-x-[STA!-x-[LIV!-[IVT!-x-[GS!-G-Y-S-[(QL!-G-

NAME: Cutinasei aspartate and histidine active sites. CONSENSUS: C-x(3)-D-x-[IV!-C-x-G-[GST!-x(2)-[LIVM!-x(2i3)-H-

NAME: DDC / GAD / HDC / TyrDC pyridoxal-phosphate attachment site-

CONSENSUS: S-[LIVMFYU!-x ( 5) -K-[LIVMFYUG! (2 ) -x (3) -[LIVMFYU!-x-

[CA!-x(2)-[LIVMFYU(Q!-

CONSENSUS: x(2)-[RK!-

NAME: Orn/Lys/Arg decarboxylases family 1 pyridoxal-P attachment site-

CONSENSUS: [STAV!-x-S-x-H-K-x (2) -[GSTAN! (2) -x-[STA!-(Q- [STA!(2) . NAME: Orn/DAP/Arg decarboxylases family 2 pyridoxal-P attachment site-

CONSENSUS: [FY!-[PA!-x-K-[SACV!-[NHCLFU!-x ( 4 ) -[LIVMF!- CLIVMTA!-x(2)-[LIVMA!-x(3)- CONSENSUS: [GTE!-

NAME: Orn/DAP/Arg decarboxylases family 2 signature 2- CONSENSUS: [GS!-x (Sit ) -CLIVMSCP!-x (2) -ELIVMF!-CDNS!-CLIVMCA!- G-G-G-ELIVMFY!-

CONSENSUS: CGSTPCElQ!-

NAME: Orotidine 5'-phosphate decarboxylase active site- CONSENSUS: CLIVMFTA!-[LIVMF!-x-D-x-K-x (2) -D-I-[GP!-x-T- CLIVMTA!.

NAME: Phosphoenolpyruvate carboxylase active site 1- CONSENSUS: CVT!-x-T-A-H-P-T-[E(Q!-x (2) -R-CKRH! . NAME: Phosphoenolpyruvate carboxylase active site 2. CONSENSUS: [IV!-M-[LIVM!-G-Y-S-D-S-x-K-D-[STAG!-G ■

NAME: Phosphoenolpyruvate carboxykinase (GTP) signature CONSENSUS: F-P-S-A-C-G-K-T-N •

NAME: Phosphoenolpyruvate carboxykinase (ATP) signature CONSENSUS: L-I-G-D-D-E-H-x-U-x- E!-x-G-[IV!-x-N .

NAME: Uroporphyrinogen decarboxylase signature 1- CONSENSUS: P-x-U-x-M-R-ύ-A-G- .

NAME: Uroporphyrinogen decarboxylase signature 2. CONSENSUS: G-F-[STAGCV!-[STAGC!-x-P-[FYU!-T-[LV!-x (2 ) -Y-x (2) ■ [AE!-[GK!.

NAME: Indole-3-glycerol phosphate synthase signature- CONSENSUS: [LIVMFY!-[LIVMC!-x-E-[LIVMFYC!-K-[KRSP!-[STAK!-S- P-[ST!-x(3)-[LIVMFYST!- NAME: Ribulose bisphosphate carboxylase large chain active site- CONSENSUS: G-x-[DN!-F-x-K-x-D-E -

NAME: Fructose-bisphosphate aldolase class-I active site- CONSENSUS: [LIVM!-x-[LIVMFYU!-E-G-x-[LS!-L-K-P-[SN! -

NAME: Fructose-bisphosphate aldolase class-II signature 1- CONSENSUS: [FYVM!-x (lι3) -[LIVMH!-[APN!-[LIVM!- (lι2) -ELIVM!- H-x-D-H-[GACH!-

NAME: Fructose-bisphosphate aldolase class-II signature 2 CONSENSUS: [LIVM!-E-x-E-[LIVM!-G-x (2) -[GM!-[GSTA!-χ-E ■

NAME." Malate synthase signature- CONSENSUS: [KR!- EN(Q!-H-x (2) -G-L-N-x-G-x-U-D-Y-[LIVM!-F -

NAME: Hydroxymethylglutaryl-coenzyme A lyase active site CONSENSUS: S-V-A-G-L-G-G-C-P-Y - NAME: Hydroxymethylglutaryl-coenzyme A synthase active site CONSENSUS: N-x-CDN!-[IV!-E-G-[IV!-D-x (2) -N-A-C-CFY!-χ-G - NAME: Citrate synthase signature-

CONSENSUS: G-[FYA!-[GA!-H-x-[IV!-x (lι2)-ERKT!-x (2) -D-EPS!-R-

NAME"- Alpha-isopropylmalate and homocitrate synthases signature 1- CONSENSUS: L-R-[DE!-G-x-(Q-x (10) -K -

NAME: Alpha-isopropylmalate and homocitrate synthases signature 2-

CONSENSUS: CLIVMFU!-x (2) -H-x-H-[DN!-D-x-G-x-[GAS!-x-[GASLI! ■

NAME". KDPG and KHG aldolases active site CONSENSUS: G-[LIVM!-x (3)-E-[LIV!-T-[LF!- .

NAME: KDPG and KHG aldolases Schiff-base forming residue- CONSENSUS: G-x (3) -[LIVMF!-K-[LF!-F-P-[SA!-x (3) -G -

NAME: Isocitrate lyase signature- CONSENSUS: K-[KR!-C-G-H-[LM(Q! - NAME: Beta-eliminating lyases pyridoxal-phosphate attachment site -

CONSENSUS: Y-x-D-x (3) -M-S-[GA!-K-K-D-x-[LIVM! (2) -x-[LIVM!-G- G- NAME: DNA photolyases class 1 signature 1-

CONSENSUS: T-G-x-P-[LIVM! (2 ) -D-A-x-M-[RA!-x-[LIVM! -

NAME: DNA photolyases class 1 signature 2-

CONSENSUS: [DN!-R-x-R-[LIVM! (2) -x-[STA! (2) -F-[LIVMFA!-x-K-x- L-x(2ι3)-U-[KR(Q!.

NAME: DNA photolyases class 2 signature 1- CONSENSUS: F-x-E-E-x-CLIVM! (2) -R-R-E-L-x (2 ) -N-F . NAME: DNA photolyases class 2 signature 2.

CONSENSUS: G-x-H-D-x (2) -U-x-E-R-x-[LIVM!-F-G-K-[LIVM!-R-[FY!- M-N.

NAME: Eukaryotic-type carbonic anhydrases signature- CONSENSUS: S-E-H-x-[LIVM!-x ( 4 ) -[FYH!-x (2 ) -E-[LIVM!-H- [LIVMFA!(2) ■

NAME: Prokaryotic-type carbonic anhydrases signature 1- CONSENSUS: C-[SA!-D-S-R-[LIVM!-x-[AP! -

NAME: Prokaryotic-type carbonic anhydrases signature 2- CONSENSUS: CE(J!-Y-A-[LIVM!-x (2) -[LIVM!-x (4 ) -[LIVMF! (3) -x-G-H- x(2)-C-G- NAME: Fumarate lyases signature- CONSENSUS: G-S-x (2) -M-x (2) -K-x-N -

NAME: Aconitase family signature 1- CONSENSUS: CLIVMJ-x ⁽2) -[GSACIVM!-x-[LIV!-^[GTIV!-[STP!-C- x(0ιl)-T-N-[GSTANI!-x(4)-

CONSENSUS: [LIVMA!- NAME: Aconitase family signature 2-

CONSENSUS: G-x (2) -CLIVUP(Q!-x (3) -[GAC!-C-[GSTAM!-[LIMPTA!-C- [LIMV!-[GA!-

NAME : D i hydroxy-acid and fa-phosphog luconate dehydratases s i gnature 1 .

CONSENSUS : C-D-K-x ( 2 ) -P-CGA!-x ( 3 ) -CGA! ■

NAME: Dihydroxy-acid and fa-phosphogluconate dehydratases signature 2- CONSENSUS: [SA!-L-[LIVM!-T-D-[GA!-R-[LIVMF!-S-[GA!-[GAV!- CST3.

NAME: Dehydroquinase class I active site-

CONSENSUS: D-CLIVM!-EDE!-CLIVN!-x (18ι20) -[LIVM! (2) -x-CSC!- [NHY!-H-[DN!.

NAME: Dehydroquinase class II signature.

CONSENSUS: [LIVM!-[N(Q!-G-P-N-[LV!-x (2 ) -L-G-x-R-[(QED!-P-x (2) -

[FY!-G-

NAME: Enolase signature-

CONSENSUS: [LIV! (3) -K-x-N-(Q-I-G-[ST!-[LIV!-[ST!-[DE!-[STA!

NAME: Serine/threonine dehydratases pyridoxal-phosphate attachment site-

CONSENSUS: [DESH!-x ( 4 ι5) -[STVG!-x-[AS!-[FYI!-K-[DLIFSA!- [RVMF!-[GA!-[LIVMGA!-

NAME: Enoyl-CoA hydratase/isomerase signature- CONSENSUS: [LIVM!-[STA!-x-[LIVM!-[DEN(QRHSTA!-G-x (3) -[AG! (3) - x(4)-[LIVMST!-x-[CSTA!- CONSENSUS: [D(QHP!-[LIVMFY! •

NAME: Imidazoleglycerol-phosphate dehydratase signature 1- CONSENSUS: [LIVMY!-[DE!-x-H-H-x (2) -E-x (2) -[GCA!-ELIVM!- [STAC!-[LIVM!>

NAME: Imidazoleglycerol-phosphate dehydratase signature 2- CONSENSUS: G-x-[DN!-x-H-H-x (2) -E-[STAGC!-x-[FY!-K ■

NAME: Tryptophan synthase alpha chain signature- CONSENSUS: [LIVM!-E-[LIVM!-G-x (2) -[FYC!-[ST!- E!-[PA!- [LIVMY!-[AGLI!-[DE!-G. NAME: Tryptophan synthase beta chain pyridoxal-phosphate attachment site. CONSENSUS: [LIVM!-x-H-x-G-[STA!-H-K-x-N •

NAME: Delta-aminolevulinic acid dehydratase active site- CONSENSUS: G-x-D-x-ELIVM! (2) -[IV!-K-P-[GSA!-x (2) -Y -

NAME-" Urocanase active site- CONSENSUS: F-(Q-G-L-P-x-R-I-C-U . NAME". Prephenate dehydratase signature !•

CONSENSUS: CFY!-x-[LIVM!-x (2) -[LIVM!-x (5) - N!-x (5) -T-R-F- [LIVMU!-x-[LIVM!>

NAME: Prephenate dehydratase signature 2. CONSENSUS: [LIVM!-[ST!-[KR!-[LIVM!-E-[ST!-R-P ■

NAME: Dihydrodipicolinate synthetase signature !■ CONSENSUS: [GSA!-[LIVM!-[LIVMFY!-x (2) -G-[ST!-[TG!-G-E- [GASNF!-x(fa)-[E(Q!-

NAME: Dihydrodipicolinate synthetase signature 2- CONSENSUS: Y-[DNS!-[LIVMF!-P-x (2) -[ST!- (3) -[LIVM!-x (13ιl [LIVM!-x-[SGA!-[LIVMF!-

CONSENSUS: K-[DE(QAF!-[STAC! •

NAME: RsuA family of pseudouridine synthase signature. CONSENSUS: G-R-L-D-x (2) -[ST!-x-G-[LIVMF! ( 4 ) -[ST!-[DNT! .

NAME: Cysteine synthase/cystathionine beta-synthase P- phosphate attachment site-

CONSENSUS: K-x-E-x (3⁾ -[PA!-[STAGC!-x-S-EIVAP!-K-x-R-x-[STAG!- x(2)-[LIVM!.

NAME: Phenylalanine and histidine ammonia-lyases signature- CONSENSUS: G-CSTG!-[LIVM!-[STG!-[AC!-S-G-EDH!-L-x-P-L-[SA!- x(2)-[SA!- NAME: Porphobilinogen deaminase cofactor-binding site-

CONSENSUS: E-R-x-CLIVMFA!-x (3) -[LIVMF!-x-G-[GSA!-C-x-[IVT!-P- [LIVMF!-[GSA!-

NAME-" Cys/Met metabolism enzymes pyridoxal-phosphate attachment site-

CONSENSUS: [DιQ!-[LIVMF!-x (3) -[STAGC!-[STAGCI!-T-K-[FYUtQ!- [LIVMF!-x-G-[HtQ!-[SGNH!.

NAME: Glyoxalase I signature 1- CONSENSUS: [H<Q!-[IVT!-x-[LIVFY!-x-[IV!-x ( 5) -[STA!-x (2) -F- [YM!-x(2i3)-[LMF!-G-[LMF!-

NAME". Glyoxalase I signature 2-

CONSENSUS: G-CNTKιQ!-x (Dι5⁾ -[GA!-[LVFY!-[GH!-H-[IVF!-[CGA!-x- [STAGL!-x(2)-[DNC!-

NAME: Cytochrome c and cl heme lyases signature 1. CONSENSUS: H-N-x (2) -N-E-x (2) -U-CN(QKR!-x (4 ) -U-E - NAME: Cytochrome c and cl heme lyases signature 2- CONSENSUS: P-F-D-R-H-D-U •

NAME: Adenylate cyclases class-I signature 1- CONSENSUS: E-Y-F-G-[SA! (2) -L-U-x-L-Y-K ■

NAME-" Adenylate cyclases class-I signature 2- CONSENSUS: Y-R-N-x-U-[NS!-E-[LIVM!-R-T-L-H-F-x-G . NAME: Guanylate cyclases signature.

CONSENSUS: G-V-CLIVM!-x (Oil) -G-x ( 5) -CFY!-x-[LIVM!-[FYU!-[GS!- CDNTHKU!-[DNT!-[IV!- CONSENSUS: [DNTA!-x (5) -[DE! .

NAME: Chorismate synthase signature 1-

CONSENSUS: G-E-S-H-[GC!-x (2) -[LIVM!-[GTV!-x-[LIVM! (2) - E!-G- x-[PV!- NAME : Chor i smate synthase signature 2 -

CONSENSUS : [GE!-R-[SA! ( 2 ) -[SAG!-R-[EV!-[ST!-x ( 2 ) -[RH!-V-x ( 2 ) -

G .

NAME : Chor i smate synthase signature 3 - CONSENSUS : R-[SH!-D-[PSV!-[CSAV!-x ( 4 ) -[GAI!-x-[IVGSP!-[LIVM!- x-E-[STAH!-[LIVM! -

NAME: b-pyruvoyl tetrahydropterin synthase signature 1. CONSENSUS: C-N-N-x (2) -G-H-G-H-N-Y ■

NAME: fa-pyruvoyl tetrahydropterin synthase signature 2. CONSENSUS: D-H-K-N-L-D-x-D -

NAME: Ferrochelatase signature- CONSENSUS: [LIVMF! (2 ) -x-S-x-H-[GS!-[LIVM!-P-x (4 ι5) -[DENiQKR!- x-G-D-x-Y-

NAME: Alanine racemase pyridoxal-phosphate attachment site- CONSENSUS: V-x-K-A-[DN!-[GA!-Y-G-H-G -

NAME: Aspartate and glutamate racemases signature 1- CONSENSUS: [IVA!-[LIVM!-x-C-x (Dil ) -N-[ST!-[MSA!-[STH!- [LIVFYSTANK!- NAME: Aspartate and glutamate racemases signature 2.

CONSENSUS: [LIVM! (2) -x-[AG!-C-T-[DEH!-[LIVMFY!-[PNGRS!-x- [LIVM!.

NAME: Mandelate racemase / muconate lactonizing enzyme family signature 1-

CONSENSUS: A-x-[SAG! (2) -[LIVM!-[DE!-x-A-x (2) -D-x (2) -[GA!- [KR!-

NAME: Mandelate racemase / muconate lactonizing enzyme family signature 2-

CONSENSUS: G-x (7 ) -D-x (1 ) -A-x (14 ) -CLIVM!-E-[DENιQ!-P-x ( 4 ) - [DENlQ!.

NAME: Ribulose-phosphate 3-epimerase family signature 1- CONSENSUS: [LIVMF!-H-[LIVMFY!-D-[LIVM!-x-D-x (lι2) -[FY!- [LIVM!-x-N-x-[STAV!.

NAME". Ribulose-phosphate 3-epimerase family signature 2- CONSENSUS: [LIVMA!-x-[LIVM!-M-[ST!-[VS!-x-P-x (3) -G-lQ-x-F- x(b)-[NK!-[LIVMC!-

NAME: Aldose 1-epimerase putative active site- CONSENSUS: [NS!-x-T-N-H-x-Y-^[FU!-N-[LI! - NAME: Cyclophilin-type peptidyl-prolyl cis-trans isomerase signature-

CONSENSUS: [FY!-x ⁽2⁾ -CSTCNLV!-x-F-H-[RH!-[LIVMN!-[LIVM!-x (2) - F-[LIVM!-x-(Q-[AG!-G-

NAME: Cyclophilin-type peptidyl-prolyl cis-trans isomerase profile- NAME: FKBP-type peptidyl-prolyl cis-trans isomerase signature 1-

CONSENSUS: CLIVMC!-x-[YF!-x-[GVL!-x (lι2) -CLFT!-x (2) -G-x (3) - [DE!-[STAE(Q -[STAN!- NAME: FKBP-type peptidyl-prolyl cis-trans isomerase signature 2-

CONSENSUS: [LIVMFY!-x (2) -[GA!-x (3ι 4 ) -[LIVMF!-x (2) -[LIVMFHK!- x⁽2)-G-x(4)-CLIVMF!- CONSENSUS: x (3) -[PSGA(Q!-x (2) -[AG!-[FY!-G -

NAME: FKBP-type peptidyl-prolyl cis-trans isomerase domain profile -

NAME: PpiC-type peptidyl-prolyl cis-trans isomerase signature-

CONSENSUS: F-[GSADEI!-x-[LVA(Q!-A-x (3) -[ST!-x (3ι4 )-[ST(Q!- x⁽3ι5)-[GER!-G-x-[LIVM!-

CONSENSUS: [GS!- NAME: Triosephosphate isomerase active site-

CONSENSUS: [AV!-Y-E-P-[LIVM!-U-[SA!-I-G-T-[GK! -

NAME-" Xylose isomerase signature 1- CONSENSUS: [LO-E-P-K-P-x (2) -P .

NAME: Xylose isomerase signature 2- CONSENSUS: [FL!-H-D-x-D-[LIV!-x-[PD!-x-[GDE! .

NAME: Phosphomannose isomerase type I signature 1- CONSENSUS: γ__x-D-χ-N-H-K-P-E -

NAME: Phosphomannose isomerase type I signature 2- CONSENSUS: H-A-Y-[LIVM!-x-G-x ⁽2⁾ -[LIVM!-E-x-M-A-x-S-D-N-x- ELIVM!-R-A-G-x-T-P-K-

NAME: Phosphoglucose isomerase signature 1-

CONSENSUS: [DENS!-x-[LIVM!-G-G-R-[FY!-S-[LIVMT!-x-[STA!-

[PSAC!-[LIVMA!-G- NAME-" Phosphoglucose isomerase signature 2.

CONSENSUS: [GS!-x-[LIVM!-[LIVMFYU!-x (4 ) -[FY!- N!-(Q-x-G-V-E- x(2)-K-

NAME: Glucosamine/galactosamine-fa-phosphate iso erases signature-

CONSENSUS: [LIVM!-x (3⁾ -G-x-[LIT!-x-[LIV!-x-[LIVM!-x-G-[LIVM!- G-x-[DEN!-G-H- NAME: Phosphoglycerate mutase family phosphohistidine signature-

CONSENSUS: CLIVM!-x-R-H-G-CEιQ!-x (3) -N - NAME: Phosphogluco utase and phosphomannomutase phosphoserine signature-

CONSENSUS: [GSA!-[LIVM!-x-[LIVM!-[ST!-[PGA!-S-H-x-P-x ( 4 ) - [GNHE!- NAME: Methylmalonyl-CoA mutase signature-

CONSENSUS: R-I-A-R-N-CTflJ-x (2) -[LIVMFY! (2⁾ -x-EE(Q!-E-x ( 4 ⁾ -

CKRN!-x(2)-D-P-x-[GSA!-

CONSENSUS: G-S- NAME: Terpene synthases signature-

CONSENSUS: CDE!-G-S-U-x-G-x-U-[GA!-[LIVM!-x-[FY!-x-Y-[GA! -

NAME-" Eukaryotic DNA topoisomerase I active site- CONSENSUS: CDEN!-x (fa) -[GS!-[IT!-S-K-x (2 ) -Y-[LIVM!-x (3) - [LIVM!.

NAME: Prokaryotic DNA topoisomerase I active site- CONSENSUS: [E(Q!-x-L-Y- E(QT!-x (3ιl2) -[LI!-[ST!-Y-x-R-[ST!-

[DE(QS!

NAME: DNA topoisomerase II signature- CONSENSUS: [LIVMA!-x-E-G-[DN!-S-A-x-[STAG!

NAME: Aminoacyl-transfer RNA synthetases class-I signature- CONSENSUS: P-x (Dι2) -[GSTAN!-[DEN(QGAPK!-x-[LIVMFP!-EHT!- [LIVMYAC!-G-[HNTG!- CONSENSUS: [LIVMFYSTAGPC! -

NAME: Aminoacyl-transfer RNA synthetases class-II signature 1-

CONSENSUS: CFYH!-R-x- E!-x (4 ιl2) -[RH!-x (3) -F-x (3) -[DE! .

NAME: Aminoacyl-transfer RNA synthetases class-II signature 2- CONSENSUS: [GSTALVF!--CDEN(QHRKP}-[GSTA!-[LIVMF!-[DE!-R- [LIVMF!-x-[LIVMSTAG!-[LIVMFY!-

NAME: UHEP-TRS domain signature-

CONSENSUS: [<QY!-G-[DNEA!-x-[LIV!-[KR!-x (2) -K-x (2)-[KRNG!- [AS!-x(4)-[LIV!-[DEN -

CONSENSUS: x (2) -CIV!-x (2) -L-x (3) -K -

NAME: ATP-citrate lyase / succinyl-CoA ligases family signature 1- CONSENSUS: S-CKR!-S-G-CGT!-[LIVM!-[GST!-x-^[E(Q!-x ⁽8ιlD) -G- x(4)-[LIVM!-[GA!-[LIVM!-G- CONSENSUS: G-D-

NAME: ATP-citrate lyase / succinyl-CoA ligases family active site-

CONSENSUS: G-x (2⁾ -A-x ⁽ 4ι7⁾ -[R(QT!-[LIVMF!-G-H-^[AS!-[GH! - NAME: ATP-citrate lyase / succinyl-CoA ligases family signature 3-

CONSENSUS: G-x-CIV!-x (2) -CLIVMF!-x-[NA!-G-[GA!-G-[LA!-[STAV!- x(4)-D-x-[LIVM!-x(3)-

CONSENSUS: G-CGRE!-

NAME: Glutamine synthetase signature 1-

CONSENSUS: [FYUL!-D-G-S-S-x (faiδ) - EN(QSTAK!-[SA!-[DE!-x (2) -

[LIVMFY!-

NAME: Glutamine synthetase putative ATP-binding region signature.

CONSENSUS: K-P-CLIVMFYA!-x (3ι 5) -[NPAT!-G-[GSTAN!-G-x-H-x (3) -

S-

NAME: Glutamine synthetase class-I adenylation site- CONSENSUS: K-[LIVM!-x (5) -[LIVMA!-D-[RK!- N!-[LI!-Y .

NAME: D-alanine--D-alanine ligase signature 1- CONSENSUS: H-G-x (2) -G-E-D-G-x-[LIVMA!-[(QSA!-[GSA! .

NAME: D-alanine— -alanine ligase signature 2. CONSENSUS: [LIV!-x (3) -[GA!-x-[GSAIV!-R-[LIVCA!-D-[LIVMF! (2 ) - x(7ι1)-[LI!-x-E- CONSENSUS: [LIVA!-N-[STP!-x-P-[GA! ■

NAME: SAICAR synthetase signature !•

CONSENSUS: [LIVMF! (2) -P-[LIVM!-E-x-[LIVM!-[LIVMCA!-R-x (3) -

[TA!-G-S-

NAME: SAICAR synthetase signature 2- CONSENSUS: [LIVM!-[LIVMA!-D-x-K-[LIVMFY!-E-F-G .

NAME: Folylpolyglutamate synthase signature 1- CONSENSUS: [LIVMFY!-x-[LIVM!-[STAG!-G-T-[NK!-G-K-x-[ST!-x (7) - [LIVM!(2)-x(3)-[GSK!.

NAME: Folylpolyglutamate synthase signature 2- CONSENSUS: CLIVMFY! (2 ) -E-x-G-[LIVM!-[GA!-G-x (2 ) -D-x-[GST!-x- [LIVM!(2)-

NAME: Ubiquitin-activating enzyme signature 1- CONSENSUS: K-A-C-S-G-K-F-x-P ■ NAME: Ubiquitin-activating enzyme active site. CONSENSUS: P-[LIVM!-C-T-[LIVM!-[KRH!-x-[FT!-P .

NAME: Ubiquitin-conjugating enzymes active site. CONSENSUS: [FYULSP!-H-[PC!-[NH!-[LIV!-x (3ι 4 ) -G-x-[LIV!-C- [LIV!-x-[LIV!-

NAME: Formate—tetrahydrofolate ligase signature 1- CONSENSUS: G-[LIVM!-K-G-G-A-A-G-G-G-Y ■ NAME: Formate--tetrahydrofolate ligase signature 2- CONSENSUS: V-A-T- V!-R-A-L-K-x-[HN!-G-G -

NAME: Adenylosuccinate synthetase GTP-binding site- CONSENSUS : (Q-U-G-D-E-G-K-G .

NAME: Adenylosuccinate synthetase active site- CONSENSUS: G-I-CGR!-P-x-Y-x (2) -K-x (2) -R •

NAME: Argininosuccinate synthase signature 1. CONSENSUS: A-CFY!-S-G-G-L-D-T-S ■

NAME: Argininosuccinate synthase signature 2- CONSENSUS: G-x-T-x-K-G-N-D-x (2) -R-F •

NAME: Phosphoribosylglycinamide synthetase signature- CONSENSUS: R-F-G-D-P-E-x-C(QM! - NAME: Carbamoyl-phosphate synthase subdomain signature 1 CONSENSUS: CFYV!-[PS!-[LIVMC!-[LIVMA!-[LIVM!-[KR!-[PSA!- [STA!-x(3)-[SG!-G-x-[AG!-

NAME: Carbamoyl-phosphate synthase subdomain signature 2 CONSENSUS: [LIVMF!-[LIMN!-E-[LIVMCA!-N-[PATLIVM!-[KR!- [LIVMSTAC!-

NAME: ATP-dependent DNA ligase AMP-binding site- CONSENSUS: [EDιQH!-x-K-x-[DN!-G-x-R-[GACIVM! -

NAME: ATP-dependent DNA ligase signature 2-

CONSENSUS: E-G-[LIVMA!-[LIVM! (2 ) -[KR!-x ( 5ι β) -CYU!-[(QNEK!- x(2ιb)-[KRH!-x(3ι5)-K-

CONSENSUS: CLIVMFY3-K-

NAME: NAD-dependent DNA ligase signature 1-

CONSENSUS: K-CLIVM!-D-G-[LIVM!-[SA!-x ( 4 ) -Y-x (2) -G-x-L-x ( 4 ) -

[ST!-R-G-[DN!-G-x(2)-G-

CONSENSUS: [DE!-[DENL!-

NAME: NAD-dependent DNA ligase signature 2.

CONSENSUS: [IV!-G-[KR!-[ST!-G-x-[LIVM!-[STNK!-x-[VT!-x (2 ) -L- x-[PS!-V- NAME: RNA 3'-terminal phosphate cyclase signature- CONSENSUS: [RH!-G-x (2) -P-x-G (3) -x-[LIV! -

NAME: Lipoate-protein ligase B signature-

CONSENSUS: R-G-G-x (2) -T-[FYU!-H-x (2 ) -[GH!-(Q-x-[LIV!-x-Y .

NAME: Isopenicillin N synthetase signature 1- CONSENSUS: [RK!-x-[STA!-x (2) -S-x-C-Y-[SL! ■

NAME: Isopenicillin N synthetase signature 2- CONSENSUS: [LIVM! (2) -x-C-G-[STA!- (2) -[STAG!-x (2)-T-x-[DNG! .

NAME: Site-specific recombinases active site- CONSENSUS: Y-[LIVAC!-R-[VA!-S-[ST!-x (2) -(Q . NAME: Site-specific recombinases signature 2-

CONSENSUS: G-[DE!-x (2) -[LIVM!-x (3) -[LIVM!- T!-R-[LIVM!- [GSA!. NAME: Transposasesi Mutator familyi signature- CONSENSUS: D-x (3) -G-[LIVMF!-x (fa) -CSTAV!-[LIVMFYU!-[PT!-x- [STAV!-x(2)-[(QR!-x-C-x(2)- CONSENSUS: H-

NAME: Transposasesi IS3D familyi signature-

CONSENSUS: R-G-x (2) -E-N-x-N-G-CLIVM! (2) -R-[(QE!-[LIVMFY! (2) -P-

K- NAME: Autoinducers synthetases family signature-

CONSENSUS: CLMFY!-R-x (3) -F-x (2) -[KR!-x (2) -U-x-[LIVM!-x (fa il) - E-x-D-x-[FY!-D-

NAME: Thiamine pyrophosphate enzymes signature- CONSENSUS: [LIVMF!-[GSA!-x ( 5) -P-x ( 4 ) -[LIVMFYU!-x-[LIVMF!-x-G- D-[GSA!-[GSAC!-

NAME: Biotin-requiring enzymes attachment site- CONSENSUS: [GN!-[DEtQTR!-x-[LIVMFY!-x (2) -[LIVM!-x-[AIV!-M-K- [LMAT!-x(3)-[LIVM!-x- CONSENSUS: [SAV!-

NAME: 2-oxo acid dehydrogenases acyltransferase component lipoyl binding site- CONSENSUS: CGN!-x (2) -[LIVF!-x (5) -[LIVFC!-x (2) -[LIVFA!-x (3) -K- CSTAIV!-[STAV(QDN!- CONSENSUS: x (2 ) -[LIVMFS!-x (5) -[GCN!-x-[LIVMFY! -

NAME: Putative AMP-binding domain signature- CONSENSUS: [LIVMFY!-x (2) -[STG!-[STAG!-G-[ST!-[STEI!-[SG!-x- [PASLIVM!-[KR!-

NAME: Molybdenum cofactor biosynthesis proteins signature 1. CONSENSUS: [LIVM! (3) -[LIT! (2 ) -G-G-T-G-x (4 ) -D -

NAME-" Molybdenum cofactor biosynthesis proteins signature 2. CONSENSUS: S-x-[GS!-x (2 ) -D-x (5) -[LIVU!-x (10ιl2) -[LIV!-x (2 ) - CKR!-P-G-[KRL!-P-x(2)- CONSENSUS: [LIVMF!-[GA! ■

NAME: moaA / nifB / pqqE family signature-

CONSENSUS: [LIV!-x (3) -C-[NP!-[LIVMF!-[(QRS!-C-x-[FYM!-C -

NAME: Radical activating enzymes signature- CONSENSUS: [GV!-x-G-x-[KR!-x (3) -F-x (2)-G-x (Oil )-C- (3) -C- x(2)-C-x-[NL!-

NAME: Tpx family signature-

CONSENSUS: S-x-D-L-P-F-A-x (2) -CKR!-CFU!-C -

NAME: Cytochrome c family heme-binding site signature CONSENSUS: C--CCPUHF}--CCPUR>-C-H--CCFYU -

NAME: Cytochrome b5 familyi heme-binding domain signature. CONSENSUS: [FY!-[LIVMK!-x (2)-H-P-CGA!-G-

NAME: Cytochrome b/bfa heme-ligand signature- CONSENSUS: [DEN(Q!-x (3) -G-[FYUM(Q!-x-[LIVMF!-R-x (2)-H - NAME: Cytochrome b/bfa 1Q0 site signature- CONSENSUS: P-CDE!-U-[FY!-JLLFY! (2) . NAME: Cytochrome bSSI subunits heme-binding site signature- CONSENSUS: ELIV!-x-CST!-CLIVF!-R-[FYU!-x (2) -[IV!-H-[STGA!- [LIV!-[STGA!-[IV!-P-

NAME: Nickel-dependent hydrogenases b-type cytochrome subunit signature 1-

CONSENSUS: R-[LIVMFYU!-x-H-U-[LIVM!-x (2) -[LIVMF!-[STAC!- [LIVM!-x(2)-L-x-[LIVM!-T-G-

NAME: Nickel-dependent hydrogenases b-type cytochrome subunit signature 2-

CONSENSUS: ERH!-[STA!-[LIVMFYU!-H-[RH!-[LIVM!-x (2) -U-x- [LIVMF!-x(2)-F-x(3)-H-

NAME: Succinate dehydrogenase cytochrome b subunit signature 1.

CONSENSUS: R-P-[LIVMT!-x (3) -[LIVM!-x (fa) -[LIVMUPK!-x ( 4 ) -S- x(2)-H-R-x-CST!.

NAME: Succinate dehydrogenase cytochrome b subunit signature 2.

CONSENSUS: H-x (3) -CGA!-CLIVMT!-R-CHF!-[LIVMF!-x-[FYUM!-D-x- [GVA!-

NAME: Thioredoxin family active site- CONSENSUS: ELIVMF!-[LIVMSTA!-x-[LIVMFYC!-[FYUSTHE!-x (2) - EFYUGTN!-C-[GATPLVE!- CONSENSUS: [PHYUSTA!-C-x (fa) -[LIVMFYUT! •

NAME: Glutaredoxin active site. CONSENSUS: [LIVD!-[FYSA!-x ( 4 ) -C-[PV!-[FYU!-C-x (2) -CTAV1-

NAME: Type-1 copper (blue) proteins signature- CONSENSUS: EGA!-x (Dι2) -CYSA!-x (0 il) -[VFY!-x-C-x (lι2) -[PG!- x(Dιl)-H-x(2ι4)-[M(Q!-

NAME: 2Fe-2S ferredoxinsi iron-sulfur binding region signature-

CONSENSUS: C--CC}--CC}-[GA!--CC>-C-[GAST!--CCPDEKRHFYU>-C -

NAME: Adrenodoxin familyi iron-sulfur binding region signature.

CONSENSUS: C-x (2) -ESTA(Q!-x-[STAMV!-C-[STA!-T-C-[HR! ■ NAME: 4Fe-4S ferredoxinsi iron-sulfur binding region signature. CONSENSUS: C-x (2) -C-x (2) -C-x (3) -C-CPEG! ■

NAME: High potential iron-sulfur proteins signature- CONSENSUS: C-x (fail) -CLIVMI-x (3) -G-[YU!-C-x (2) -CFYU! -

NAME: Rieske iron-sulfur protein signature 1- CONSENSUS: C-[TK!-H-L-G-C-[LIVT! . NAME: Rieske iron-sulfur protein signature 2- CONSENSUS: C-P-C-H-x-CGSA! - NAME: Flavodoxin signature.

CONSENSUS: [LIV!-[LIVFY!-[FY!-x-[ST!-x (2) -CAG -x-T-x ( 3) -A- x(2)-CLIV!.

NAME: Rubredoxin signature- CONSENSUS: CLIVM!-x (3) -U-x-C-P-x-C-[AGD! -

NAME: Electron transfer flavoprotein alpha-subunit signature.

CONSENSUS: [LI!-Y-[LIVM!-[AT!-x-G- V!-[SD!-G-x-[IV!-(Q-H- x(2)-G-x(b)-CIV!-x-A- CONSENSUS: CIV!-N-

NAME: Electron transfer flavoprotein beta-subunit signature CONSENSUS: CIVA!-x-CKR!-x (2) - E!-[GD!-[GDE!-x (lι2 ) -[E(Q!-x- [LIV!-x(4)-P-x-[LIVM!(2)- CONSENSUS: [TAC!-

NAME: Vertebrate metallothioneins signature-

CONSENSUS: C-x-C-[GSTAP!-x (2) -C-x-C-x (2) -C-x-C-x (2) -C-x-K -

NAME: Ferritin iron-binding regions signature 1-

CONSENSUS: E-x-[KR!-E-x (2) -E-[KR!-[LF!-[LIVMA!-x (2) -ώ-N-x-R- x-G-R. NAME: Ferritin iron-binding regions signature 2-

CONSENSUS: D-x (2) -[LIVMF!-[STAC!-EDH!-F-[LI!-EEN!-x (2 ) -[FY!- L-x(b)-[LIVM!-[KN!-

NAME: Bacterioferritin signature- CONSENSUS: <M-x-G-x (3) -V-CLIV!-x (2) -[LM!-x (3) -L-x (3) -L .

NAME: Transferrins signature 1-

CONSENSUS: Y-x (Oil ) -[VAS!-V-[IVAC!-[IVA!-[IVA!-[RKH!-[RKS!- [GDENSA!.

NAME: Transferrins signature 2-

CONSENSUS: Y-x-G-A-[FL!-[KRHN(Q!-C-L-x (3ι 4 ) -G- EN(Q!-V-[GA!-

[FYU!- NAME: Transferrins signature 3-

CONSENSUS: ENιQ!-[YF!-x-ELY!-L-C-x-[DN!-x (5ιβ) -[LIV!-x ( 4ιS) ^■

C-x(2)-A-x(4)-[H(QR!-x-

CONSENSUS: [LIVMFYU!-[LIVM! • NAME: Globins profile-

NAME: Protozoan/cyanobacterial globins signature- CONSENSUS: F-CLF!-x (5) -G-[PA!-x ( 4 ) -G-[KRA!-x-[LIVM!-x (3) -H - NAME: Plant hemoglobins signature-

CONSENSUS: [SN!-P-x-L-x (2) -H-A-x (3) -F -

NAME: Hemerythrins signature- CONSENSUS : U-L-x-^[NιQ!-H-I-x ( 3 ) -D-F .

NAME: Arthropod hemocyanins / insect LSPs signature 1 CONSENSUS: Y-CFYU!-x-E-D-[LIVM!-x(2)-N-x(b)-H-x(3)-P-

NAME: Arthropod hemocyanins / insect LSPs signature 2 CONSENSUS: T-x(2)-R-D-P-x-CFY!-[FYU!-

NAME: Heavy-metal-associated domain- CONSENSUS: [LIVN!-x (2) -[LIVMFA!-x-C-x-[STAGCDNH!-C-x (3) - [LIVFG!-x(3)-[LIV!-x(1ιlD- CONSENSUS: [IVA!-x-[LVFYS! -

NAME-" ABC transporters family signature- CONSENSUS: [LIVMFYC!-[SA!-[SAPGLVFYK(QH!-G-[DEN(QMU!-

[KR(QASPCLIMFU!-[KRN(QSTAVM!-

CONSENSUS: [KRACLVM!-[LIVMFYPAN!--CPHY>-[LIVMFU!-CSAGCLIVP!-

^•CFYUHP --KRHP>-

CONSENSUS: [LIVMFYUSTA! -

NAME: Binding-protein-dependent transport systems inner membrane comp- sign-

CONSENSUS: [LIVMFY!-x (6 ) -[E(QR!-[STAGV!-[STAG!-x (3) -G-

[LIVMFYSTAC!-x(5)-[LIVMFYSTA!- CONSENSUS: x ( )-[LIVMFY!-[PKR! -

NAME"- ABC-2 type transport system integral membrane proteins signature-

CONSENSUS: [LIMST!-x (2) -[LIMU!-x (2) -[LIMCA!-[GSTC!-x-[GSAIV!- x(fa)-[LIMGA!-[PGSN(Q!-

CONSENSUS: x (1 ιl2) -P-CLIMFT!-x-[HRSY!-x (5) -[R(Q! -

NAME: Bacterial extracellular solute-binding proteinsi family 1 signature- CONSENSUS: [GAP!-[LIVMFA!-[STAVDN!-x ( 4 ) -[GSAV!-[LIVMFY! ( 2 ) -Y- [ND!-x(3)-[LIVMF!-x- CONSENSUS: [KNDE!-

NAME: Bacterial extracellular solute-binding proteinsi family 3 signature-

CONSENSUS: G-[FYIL!- E!-[LIVMT!-[DE!-[LIVMF!-x (3) -[LIVMA!- [VAGC!-x(2)-[LIVMAGN!-

NAME: Bacterial extracellular solute-binding proteinsi family 5 signature-

CONSENSUS: [AG!-x ( bι7) - NEG!-x (2 ) -[STAVE!-[LIVMFYUA!-x-

[LIVMFY!-x-[LIVM!-[KR!-

CONSENSUS: [KRHDE!-[GDN!-[LIVMA!-[KNGSP!-[FU! - NAME: Serum albumin family signature-

CONSENSUS: [FY!-x (fa )-C-C-x (7) -C-CLFYJ-x (fa) -[LIVMFYU! -

NAME: Transthyretin signature 1- CONSENSUS: S-K-C-P-L-M-V-K-V-L-D-[AS!-V-R-G

NAME: Transthyretin signature 2>

CONSENSUS: S-P-[FY!-S-[FY!-S-T-T-A-[LIVM!-V-[ST!-x-P NAME: Avidin / Streptavidin family signature-

CONSENSUS: [DEN!-x(2⁾-[KR!-[STA!-x(2)-V-G-x- N!-x-[FU!-T-

[KR!-

NAME: Eukaryotic cobalamin-binding proteins signature- CONSENSUS: CSN!-V-D-T-[GA!-A-[LIVM!-A-x-L-A-[LIVMF!-T-C.

NAME: Lipocalin signature-

CONSENSUS: [DENG!-x-[DEN(QGSTARK!-x (0ι2) -CDEN(QARK!-[LIVFY!- -CCPD-G--tO-U-[FYULRH!-x- CONSENSUS: [LIVMTA!-

NAME: Cytosolic fatty-acid binding proteins signature- CONSENSUS: [GSAIVK!-x-[FYU!-x-[LIVMF!-x ( 4 ) -[NHG!-[FY!-[DE!-x- [LIVMFY!-[LIVM!-x(2)-

CONSENSUS: [LIVMAKR!-

NAME: Acyl-CoA-binding protein signature-

CONSENSUS: P-[STA!-x-[DEN!-x-[LIVMF!-x (2) -[LIVMFY!-Y-CGSTA!- x-[FY!-K-(Q-[STA!(2)-x-G-

NAME: LBP / BPI / CETP family signature-

CONSENSUS: CPA!-[GA!-[LIVMC!-x (2) -R-[IV!-[ST!-x (3) -L-x (5) -

[E(Q!-x(4)-[LIVM!-[EιQK!- CONSENSUS: x(β)-P-

NAME: Phosphatidylethanolamine-binding protein family signature.

CONSENSUS: [FY!-x-[LIVMF!(3)-x-[DC!-P-D-x-P-[SN!-x(lD)-H-

NAME: Plant lipid transfer proteins signature-

CONSENSUS [LIVM!-[PA!-x(2)-C-x-[LIVM!-x-[LIVM!-x-[LIVMFY!-x-

[LIVM!-[ST!-x(3)-

CONSENSUS: [DN!-C-x(2)-[LIVM!-

NAME: Uteroglobin family signature 1-

CONSENSUS: [GA!-x(3)-I-C-P-x-[LIVMF!-x(3)-[LIVM!-[DE!-x-

[LIVMF!(2)

NAME: Uteroglobin family signature 2-

CONSENSUS: [DE(Q!-x(4)-[SN!-x(5)-[DEιQ!-x-I-x(2)-S-[PSE!-[LS!-

C

NAME: Mitochondrial energy transfer proteins signature- CONSENSUS: P-x-[DE!-x-[LIVAT!-[RK!-x-[LRH!-[LIVMFY!-[ιQMAIGV! .

NAME: Sugar transport proteins signature 1- CONSENSUS: [LIVMSTAG!-[LIVMFSAG!-x (2) -[LIVMSA!- E!-x- [LIVMFYUA!-G-R-[RK!-x(4ιfa)~ CONSENSUS: [GSTA!.

NAME: Sugar transport proteins signature 2-

CONSENSUS: [LIVMF!-x-G-[LIVMFA!-x(2)-G-x(δ)-[LIFY!-x(2)-[E(Q!- x(fa)-[RK!.

NAME: LacY family proton/sugar symporters signature 1- CONSENSUS: G-[LIVM!(2)-x-D-ERK!-L-G-L-[RK!(2)-x-ELIVM!(2)-U. NAME: LacY family proton/sugar symporters signature 2- CONSENSUS: P-x-CLIVMF! (2) -N-R-ELIVM!-G-x-K-N-[STA!-[LIVM! (3) -

NAME: PTR2 family proton/oligopeptide symporters signature 1.

CONSENSUS: CGA!-[GAS!-[LIVMFYUA!-[LIVM!-[GAS!-D-x-[LIVMFYUT!-

[LIVMFYU!-G-x(3)-[TAV!-

CONSENSUS: CIV!-x (3) -CGSTAV!-x-[LIVMF!-x (3) -[GA!- NAME: PTR2 family proton/oligopeptide symporters signature 2-

CONSENSUS." [FYT!-x(2)-CLMFY!-[FYV!-ELIVMFYUA!-x-[IVG!-N- [LIVMAG!-G-[GSA!-[LIMF!- NAME: Amiloride-sensitive sodium channels signature-

CONSENSUS: Y-x (2) -[E(QTF!-x-C-x (2) -[GSTDNL!-C-x-E(QT!-x (2) - [LIVMT!-[LIVMS!-x(2)-C-x-C

NAME: Sodium:alanine symporter family signature- CONSENSUS: G-G-x-CGA! (2) -[LIVM!-F-U-M-U-[LIVM!-x-[STAV!- CLIVMFA!(2)-G-

NAME: Sodium: dicarboxylate symporter family signature 1- CONSENSUS: P-x (Oil) -G-CDE!-x-CLIVMF! (2 ) -x-CLIVM! (2 ) -[KRElQ!- [LIVM!(3)-x-P-

NAME: Sodium:dicarboxylate symporter family signature 2- CONSENSUS: P-x-G-x-CSTA!-x-[NT!-[LIVMC!-D-G-[STAN!-x-[LIVM!- [FY!-x(2)-[LIVM!-x(2)- CONSENSUS: CLIVM!-[FY!-[LI!-[SA!-(Q -

NAME: Sodium:galactoside symporter family signature- CONSENSUS: D-x (3) -G-x (3) -[DN!-x (biδ ) -G-CKH!-F-[KR!-P-[FYU!- [LIVM!(2)-x-CGSTA!(2).

NAME: Sodium:neurotransmitter symporter family signature 1 CONSENSUS: U-R-F-[GP!-Y-x ( 4 ) -N-G-G-G-x-[FY! -

NAME: Sodium:neurotransmitter symporter family signature 2. CONSENSUS: Y-[LIVMFY!-x (2) -[SC!-[LIVMFY!-[STιQ!-x (2 ) -L-P-U- x(2)-C-x(4)-N-CGST!-

NAME: Sodium:solute symporter family signature 1- CONSENSUS: CGS!-x (2) -[LIY!-x (3) -[LIVMFYUSTAG! (10)-[LIY!- [TAV!-x(2)-G-G-[LMF!-x- CONSENSUS: [SAP!-

NAME: Sodium:solute symporter family signature 2- CONSENSUS: [GAST!-[LIVM!-x (3) -[KR!-x ( 4 ) -G-A-x ( ) -[GAS!- [LIVMGS!-[LIVMU!-[LIVMGAT!-G- CONSENSUS: x-[LIVMG!-

NAME: Sodium:sulfate symporter family signature- CONSENSUS: [STACP!-S-x (2) -F-x ⁽2⁾ -P-[LIVM!-[GSA!-x (3) -N-x- [LIVM!-V.

NAME: lpT family of transporters signature- CONSENSUS: R-G-x ( 5) -U-N-x (2) -H-N-x-G-G- NAME: Ammonium transporters signature-

CONSENSUS: D-CFYUS!-A-G-[GSC!-x (2) -EIV!-x (3) -CSAG! (2) -x (2) -

ESAG!-CLIVMF!-x(3)-

CONSENSUS: [LIVMFYUA!⁽2⁾-x-[GK!-x-R

NAME: BCCT family of transporters signature- CONSENSUS: [GSDN!-U-T-[LIVM!-x-[FY!-U-x-U-U - NAME-" Flagellar motor protein motA family signature-

CONSENSUS: A-[LMF!-x-[GAT!-T-[LIVF!-x-G-x-[LIVMF!-x (7) -P

NAME: Formate and nitrite transporters signature 1- CONSENSUS: [LIVMA!-CLIVMY!-x-G-[GSTA!-[DES!-L-[FI!-[TN!-[GS!

NAME: Formate and nitrite transporters signature 2- CONSENSUS: [GA!-x (2) -[CA!-N-ELIVMFYU! (2) -V-C-[LV!-A -

NAME: Prokaryotic sulfate-binding proteins signature 1. CONSENSUS: K-x-[N(QEK!-[GT!-G-[D<Q!-x-[LIVM!-x (3) -iQ-S -

NAME: Prokaryotic sulfate-binding proteins signature 2- CONSENSUS: N-P-K-[ST!-S-G-x-A-R - NAME: Sulfate transporters signature.

CONSENSUS: P-x-Y-CGS!-L-Y-[STAG! (2) -x (4 ) -ELIVMFY! (3) -x (3 ) - [GSTA!(2)-S-[KR!-

NAME: Amino acid permeases signature- CONSENSUS: [STAGC!-G-[PAG!-x (2ι3) -[LIVMFYUA! ⁽2 ) -x-[LIVMFYU!- x-[LIVMFUSTAGC!(2)-

CONSENSUS: [STAGC!- (3) -[LIVMFYU!-x-[LIVMST!-x (3)-[LIMCTA!- EGA!-E-x(S)-[PSAL!- NAME: Aromatic amino acids permeases signature-

CONSENSUS: I-G-[GA!-G-M-[LF!-[SA!-x-P-x (3 ) -[SA!-G-x (2) -F -

NAME: Xanthine/uracil permeases family signature- CONSENSUS: [LIVM!-P-x-[PASIF!-V-[LIVM!-G-G-x ( 4 ) -[LIVM!-[FY!- [GSA!-x-[LIVM!-x(3)-G-

NAME: Anion exchangers family signature 1- CONSENSUS: F-G-G-[LIVM! (2) -[KR!-D-[LIVM!-[RK!-R-R-Y. NAME: Anion exchangers family signature 2- CONSENSUS: EFO-L-I-S-L-I-F-I-Y-E-T-F-X-K-L -

NAME: MIP family signature- CONSENSUS: [HN(3A!-x-N-P-[STA!-[LIVMF!-[ST!-[LIVMF!-[GSTAFY!.

NAME: General diffusion Gram-negative porins signature-

CONSENSUS: [LIVMFY!-x⁽2⁾-G-x⁽2)-Y-x-F-x-K-x⁽2⁾-[SN!-[STAV!-

[LIVMFYU!-V NAME: OmpA-like domain-

CONSENSUS: [LIVMA!-x-[GT!-x-[TA!-EDA!-x (2 ) - G!-[GSTP!-x (2) - [LFYDE!-[N(QS!-x(2)~ CONSENSUS: CLI!-CSG!-[(QE!-[KR(QE!-R-A-x (2⁾ -CLVJ-x (3) -CLIVMF!- x(4ι5)-CLIVM!-x(4)-

CONSENSUS: CLIVM!-x (3) -CSG!-x-G •

NAME: Eukaryotic mitochondrial porin signature.

CONSENSUS: CYH!-x (2)-D-[SPA!-x-[STA!-x (3)-CTAG!-[KR!-CLIVMF!-

[DNSTA!-[DNS!-x(4)-

CONSENSUS [GSTAN!-[LIVMA!-x-[LIVMY!. NAME: Insulin-like growth factor binding proteins signature. CONSENSUS: G-C-[GS!-C-C-x (2) -C-A-x (fa) -C •

NAME: GPRl/FUN34/yaaH family signature- CONSENSUS: N-P-[AV!-P-[LF!-G-L-x-[GSA!-F

NAME: GNS1/SUR4 family signature- CONSENSUS: L-x-F-L-H-x-Y-H-H -

NAME: 43 Kd postsynaptic protein signature. CONSENSUS: _G-(Q-D-ιQ-T-K-(Q-(Q-I -

NAME: Actins signature 1-

CONSENSUS: [FY!-[LIV!-G- E!-E-A-lQ-x-[RK(Q! (2) -G . NAME: Actins signature 2-

CONSENSUS: U-[IV!-[STA!-[RK!-x-[DE!-Y-[DNE!-[DE! .

NAME-" Actins and actin-related proteins signature- CONSENSUS: [LM!-[LIVM!-T-E-[GAP<Q!-x-[LIVMFYUH(Q!-N-[PSTAιQ!- x(2)-N-[KR!-

NAME: Annexins repeated domain signature-

CONSENSUS: CTG!-[STV!-x (6) -[LIVMF!-x (2) -R-x (3) - E(QNH!-x (7) -

[IFY!-x(7)-[LIVMF!- CONSENSUS: x(3)-[LIVMF!-x(ll)-[LIVMFA!-x(2)-[LIVMF!

NAME: Caveolins signature- CONSENSUS: F-E-D-V-I-A-E-P - NAME: Clathrin light chain signature 1 CONSENSUS: F-L-A-(Q-(Q-E-S -

NAME: Clathrin light chain signature 2-

CONSENSUS: [KR!-D-x-S-[KR!-[LIVM!-[KR!-x-[LIVM! (3) -x-L-K

NAME: Clusterin signature 1- CONSENSUS: C-K-P-C-L-K-x-T-C -

NAME: Clusterin signature 2-

CONSENSUS: C-L-[RK!-M-[RK!-x-[E<Q!-C-[ED!-K-C

NAME"- Connexins signature 1-

CONSENSUS: C-[DN!-T-x-ιQ-P-G-C-x (2) -V-C-Y-

NAME: Connexins signature 2-

CONSENSUS: C-x⁽3ι4⁾-P-C-x⁽3⁾-^[LIVM!-^[DEN!-C-^[FY!-[LIVM!-[SA!-

[KR!-P- NAME: Crystallins beta and gamma 'Greek key' motif signature-

CONSENSUS: ^[LIVMFYUA!-x--CDEHRKSTP>-[FY!-^[DElQHKY!-x (3⁾ ~[FY!-x- G-x(4)-[LIVMFCST!-

NAME: Dynamin family signature-

CONSENSUS: L-P-[RK!-G-[STN!-[GN!-[LIVM!-V-T-R -

NAME: Dynein light chain type 1 signature- CONSENSUS: H-x-I-x-G-[KR!-x-F-[GA!-S-x-V-[ST!-[HY!-E -

NAME: FtsZ protein signature 1-

CONSENSUS: N-CST!-D-x-(Q-x-L-x (Ifailβ) -G-x-G-CATV!-G-CGSAN!-x-

P-x(2)-G-

NAME: FtsZ protein signature 2-

CONSENSUS." [DNHKR!-[LIVMF!-x-[LIVMF!(2)-[VSTAC!-[STAC!-G-x-G-

[GK!-G-T-G-[ST!-G-

CONSENSUS: [GSAR!-[STA!-P-[LIVMFT!-[LIVMF!-[SGAV! -

NAME: Fungal hydrophobins signature-

CONSENSUS: [GN!-[DN(QPSA!-x-C-[GSTANK!-[GSTADN(Q!-[STN(QI!-

[PTIV!-x-C-C-[DEN(QKPST!- NAME: Intermediate filaments signature-

CONSENSUS: [IV!-x-[TACI!-Y-[RKH!-x-[LM!-L-[DE! -

NAME-" Involucrin signature-

CONSENSUS: <M-S-[ιQH!-ιQ-x-T-[LV!-P-V-T-[LV! -

NAME: Kinesin motor domain signature-

CONSENSUS: [GSA!-[KRHPST(QVM!-[LIVMF!-x-[LIVMF!-[IVC!-D-L-

[AH!-G-[SAN!-E- NAME: Kinesin motor domain profile-

NAME: Kinesin light chain repeat-

CONSENSUS: [DE(QR!-A-L-x (3) -IGEQl-x (3) -G-x-[DNS!-x-P-x-V-A- x(3)-N-x-L-[AS!- CONSENSUS: x ( 5) -[(QR!-x-[KR!-[FY!-x (2) -[AV!-x ( 4 ) -[HKNiQ! .

NAME: Myelin basic protein signature- CONSENSUS: V-V-H-F-F-K-N - NAME: Myelin PO protein signature-

CONSENSUS: S-[KR!-S-x-K-[AG!-x-[SA!-E-K-K-[STA!-K -

NAME: Myelin proteolipid protein signature 1- CONSENSUS: G-[MV!-A-L-F-C-G-C-G-H -

NAME: Myelin proteolipid protein signature 2-

CONSENSUS: C-x-[ST!-x-[DE!-x (3) -[ST!-[FY!-x-L-[FY!-I-x (4 ) -G-

A- NAME: Neuromodulin (GAP-43) signature 1- CONSENSUS: <M-L-C-C-[LIVM!-R-R -

NAME". Neuromodulin (GAP-43) signature 2. CONSENSUS : S-F-R-G-H-I-x-R-K-K-CLIVM! •

NAME: Osteopontin signature- CONSENSUS: CKιQ!-x-[TA!-x (2) -CGA!-S-S-E-E-K -

NAME: Peripherin / rom-1 signature-

CONSENSUS: D-[GS!-V-P-F-[ST!-C-C-N-P-x-S-P-R-P-C -

NAME-" Profilin signature- CONSENSUS: <x (Oil ) -[STA!-x (Oil) -U-[DEN(QH!-x-[YI!-x-CDE<Q! -

NAME: Surfactant associated polypeptide SP-C palmitoylation sites-

CONSENSUS: I-P-C-C-P-V-

NAME: Synapsins signature 1. CONSENSUS: |___R__R__R__L__S_D-S .

NAME"- Synapsins signature 2- CONSENSUS: G-H-A-H-S-G-M-G-K-V-K -

NAME: Synaptobrevin signature-

CONSENSUS: N-[LIVM!-[DENS!-[KL!-V-x-[DEιQ!-R-x (2) -[KR!-[LIVM!- [STDE!-x-[LIVM!-x-[DE!- CONSENSUS: [KR!-[TA!-[DE! .

NAME: Synaptophysin / synaptoporin signature- CONSENSUS: L-S-V-[DE!-C-x-N-K-T - NAME: Tropomyosins signature- CONSENSUS: L-K-E-A-E-x-R-A-E -

NAME: Tubulin subunits alphai betai and gamma signature- CONSENSUS: [SAG!-G-G-T-G-[SA!-G -

NAME: Tubulin-beta mRNA autoregulation signal CONSENSUS: <M-R-[DE!-[IL! -

NAME: Tau and MAP proteins tubulin-binding domain signature. CONSENSUS: G-S-x (2) -N-x (2) -H-x-[PA!-[AG!-G (2) -

NAME: Neuraxin and MAPIB proteins repeated region signature. CONSENSUS: [STAGDN!-Y-x-Y-E-x (2 ) - E!-[KR!-[STAGCI! ■ NAME: F-actin capping protein alpha subunit signature 1- CONSENSUS: V-H-[FY! (2) -E-D-G-N-V -

NAME: F-actin capping protein alpha subunit signature 2- CONSENSUS: F-K-[AE!-L-R-R-x-L-P -

NAME: F-actin capping protein beta subunit signature. CONSENSUS: c-D-Y-N-R-D-

NAME: Vinculin family talin-binding region signature- CONSENSUS: [KR!-x-[LIVMF!-x ⁽3⁾ -^[LIVMA!-x ⁽2 ⁾-^[LIVM!-x (fa) -R-ιQ- iQ-E-L-

NAME-" Vinculin repeated domain signature- CONSENSUS : CLIVM!-x-[<QA!-A-x ( 2 ) -U-CIL!-x- N!-P -

NAME: Amyloidogenic glycoprotein extracellular domain signature-

CONSENSUS: G-CVT!-E-CFY!-V-C-C-P -

NAME: Amyloidogenic glycoprotein intracellular domain signature-

CONSENSUS: G-Y-E-N-P-T-Y-[KR! -

NAME: Cadherins extracellular repeated domain signature- CONSENSUS: [LIV!-x-[LIV!-x-D-x-N-D-[NH!-x-P •

NAME: Insect cuticle proteins signature. CONSENSUS: G-x ( 7) - EN!-G-x (fa) -Y-x-A- NG!-x (2 ι3) -G-[FY!-x- [AP!.

NAME: Gas vesicles protein GVPa signature 1- CONSENSUS: [LIVM!-x-[DE!-[LIVMFYT!-[LIVM!- E!-x-[LIVM! (2) - CDKR!(2)-G-x-[LIVM!(2) ■

NAME: Gas vesicles protein GVPa signature 2- CONSENSUS: R-[LIVA! (3) -A-CGS!-[LIVMFY!-x-T-x (3) -Y-CAG! • NAME: Gas vesicles protein GVPc repeated domain signature- CONSENSUS: F-L-x (2 ) -T-x (3) -R-x (3) -A-x (2) -iQ-x (3) -L-x (2) -F -

NAME: Bacterial microcompartiments proteins signature- CONSENSUS: D-x (Oil ) -M-x-K-[SAG! (2 ) -x-[IV!-x-[LIVM!-[LIVMA!- [GCS!-x(4)-[GD!-[SGPD!- CONSENSUS: [GA!-

NAME: Flagella basal body rod proteins signature- CONSENSUS: [GTARY(Q!-x (1)-[LIVMYSTA! (2 ) -[GSTA!-[STADEN!-N- [LIVM!-[SAN!-N-x-[SADNFR!- CONSENSUS: [STV!-

NAME: Flagella transport protein fliP family signature 1- CONSENSUS." [PA!-A-[FY!-x-CLIVT!-[STHJ-[E(Q!-[LI!-x(2)-[GA!-F- [KRE<Q!-[IM!-G-[LIF!.

NAME: Flagella transport protein fliP family signature 2- CONSENSUS: P-[LIVMF!-K-CLIVMF! (5) -x-[LIVMA!- NGS!-G- . NAME: Plant viruses icosahedral capsid proteins 'S' region signature-

CONSENSUS: [FYU!-x-[PSTA!-x (7 ) -G-x-[LIVM!-x-[LIVM!-x-[FYUI!- x(2)-D-x(5)-P- NAME: Potexviruses and carlaviruses coat protein signature. CONSENSUS: [RK!-[FYU!-A-[GAP!-F-D-x-F-x (2) -[LV!-x (3) - CGASTKS).

NAME: Neurotransmitter-gated ion-channels signature- CONSENSUS: C-x-[LIVMFιQ!-x-[LIVMF!-x (2) -[FY!-P-x-D-x (3) -C -

NAME: ATP P2X receptors signature- CONSENSUS : G-G-x-[LIVM!-G-[LIVM!-x- V!-x-U-x-C-[DN!-L-D- x ( 5 ) -C-x-P-x-Y-x-F -

NAME-" G-protein coupled receptors signature- CONSENSUS: [GSTALIVMFYUC!-[GSTANCPDE!-CEDPKRH]--x (2 ) -

[LIVMN(QGA!-x(2)-[LIVMFT!- CONSENSUS: [GSTANC!-CLIVMFYUSTAC!- ENH!-R-[FYUCSH!-x(2) -

[LIVM!- NAME-" G-protein coupled receptors family 2 signature 1- CONSENSUS: C-x (3) -[FYULIV!-D-x (3ι 4 ) -C-[FU!-x(2 ) -CSTAGV!-

NAME: G-protein coupled receptors family 2 signature 2- CONSENSUS: (Q-G-[LMFCA!-[LIVMFT!-[LIV!-x-[LIVFST!-[LIF!- [VFYH!-C-[LFY!-x-N-x(2)-V-

NAME: G-protein coupled receptors family 3 signature 1- CONSENSUS: [LV!-x-N-[LIVM! (2) -x-L-F-x-I-[PA!-ιQ-[LIVM!-[STA!- x-[STA!(3)-[STAN!-

NAME: G-protein coupled receptors family 3 signature 2- CONSENSUS: C-C-CFYU!-x-C-x (2) -C-x ( 4 ) -[FYU!-x (2ι4) - N!-x (2) - [STAH!-C-x(2)-C

NAME: G-protein coupled receptors family 3 signature 3. CONSENSUS: F-N-E-[STA!-K-x-I-[STAG!-F-[ST!-M.-

NAME: Visual pigments (opsins) retinal binding site- CONSENSUS: [LIVMUAC!-[PGAC!-x (3) -[SAC!-K-[STALIMR!-[GSACPNV!- [STACP!-x(2)-[DENF!- CONSENSUS: CAP!-x (2) -[IY! •

NAME: Bacterial rhodopsins signature 1- CONSENSUS: R-Y-x-[DT!-U-x-[LIVMF!-[ST!-T-P-[LIVM! ( 3) •

NAME: Bacterial rhodopsins retinal binding site- CONSENSUS: [FYIV!-x-[FYVG!-[LIVM!-D-[LIVMF!-x-[STA!-K-x (2) -

[FY!.

NAME: Receptor tyrosine kinase class II signature CONSENSUS: [DN!-[LIV!-Y-x (3) -Y-Y-R .

NAME: Receptor tyrosine kinase class III signature- CONSENSUS: G-x-H-x-N-[LIVM!-V-N-L-L-G-A-C-T -

NAME: Receptor tyrosine kinase class V signature 1- CONSENSUS: F-x-[DN!-x-[GAU!-[GA!-C-[LIVM!-[SA!-[LIVM! (2) - [SA!-[LV!-[KRH(Q!-[LIVA!- CONSENSUS: x (3) -[KR!-C-[PSAU! -

NAME: Receptor tyrosine kinase class V signature 2- CONSENSUS: C-x (2) -[DE!-G- E(Q!-U-x (2ι3) -[PA(Q!-[LIVMT!-[GT!-x- C-x-C-x(2)-G-[HFY!- CONSENSUS: [E(Q!-

NAME: Growth factor and cytokines receptors family signature 1- CONSENSUS : C-[LVFYR!-x ( 7 ι β ) -[STIVDN!-C-x-U -

NAME: Growth factor and cytokines receptors family signature

2-

CONSENSUS: [STGL!-x-U-[SG!-x-U-S-

NAME: TNFR/NGFR family cysteine-rich region signature- CONSENSUS: C-x(4ιfa)-[FYH!-x(5ιlD)-C-x(0ι2)-C-x(2ι3)-C- x(7ιll)-C-x(4ιfa)-CDNE(QSKP!-

CONSENSUS: x(2)-C

NAME: TNFR/NGFR family cysteine-rich region domain-

NAME: Integrins alpha chain signature. CONSENSUS: [FYUS!-[RK!-x-G-F-F-x-R.

NAME-" Integrins beta chain cysteine-rich domain signature. CONSENSUS: C-x-[GN(Q!-x(lι3)-G-x-C-x-C-x(2)-C-x-C

NAME: Natriuretic peptides receptors signature- CONSENSUS: G-P-x-C-x-Y-x-A-A-x-V-x-R-x(3)-H-U-

NAME: Photosynthetic reaction center proteins signature-

CONSENSUS: [NH!-x(4)-P-x-H-x(2)-[SAG!-x(ll)-[SAGC!-x-H-

CSAG!(2).

NAME: Antenna complexes alpha subunits signature- CONSENSUS: [LIVFAG!-x-[GASV!-[LIVFA!-x-[IV!-H-x (3) -[LIVM!- CGSTAE!-[STANH!-x(lι3)- CONSENSUS: [STN!-U-[LIVMFYU! -

NAME: Antenna complexes beta subunits signature-

CONSENSUS: CE(Q!-x (4 )-H-x ( 5) -CGSTA!-x (3) -[FY!-x (3)-[AG!-x (2) -

[AV!-H-x(7)-P-

NAME-" Photosyste I psaA and psaB proteins signature- CONSENSUS: c-D-G-P-G-R-G-G-T-C -

NAME: Photosystem I psaG and psaK proteins signature- CONSENSUS: G-F-x-[LIVM!-x-[DEA!-x (2)-[GA!-x-CGTA!-[SA!-x-G-H- x-[LIVM!-[GA!-

NAME: Phytochrome chromophore attachment site signature CONSENSUS: [RGS!-[GSA!-[PV!-H-x-C-H-x(2)-Y-

NAME: Phytochrome chromophore attachment site domain profile-

NAME: Speract receptor repeated domain signature-

CONSENSUS: G-x(5⁾-G-x(2⁾-E-x⁽fa⁾-U-G-x(2)-C-x⁽3)-[FYU!-x(δ)-C- x(3)-G-

NAME: TonB-dependent receptor proteins signature 1- CONSENSUS: <x(10ιll5)-^[DENF!-^[ST!-[LIVMF!-[LIVSTE(Q!-V-x-

CAGP!-[STANE(QPK!-

NAME: TonB-dependent receptor proteins signature 2 CONSENSUS: [LYGSTANE!-χ (3) -[GSTAEN(Q!-x-[PGE!-R-x-[LIVFYUA!-x-

[LIVMFTA!-[STAGNιQ!-

CONSENSUS: [LIVMFYGTA!-χ-[LIVMFYUGTAD(Q!-x-F> - NAME-" Transmembrane 4 family signature-

CONSENSUS: G-x (3) -CLIVMF!-x (2) -CGSA!-[LIVMF! (2) -G-C-x-[GA!-

CSTA!-x(2)-CEG!-x(2)-

CONSENSUS: [CUN!-[LIVM! (2) - NAME: Bacterial chemotaxis sensory transducers signature-

CONSENSUS: R-T-E-[EιQ!-(Q-x (2) -CSA!-[LIVM!-x-[E(Q!-T-A-A-S-M-E- (Q-L-T-A-T-V-

NAME: ER lumen protein retaining receptor signature 1- CONSENSUS: G-I-S-x-[KR!-x-(Q-x-L-[FY!-x-[LIV! (2 ) -F-x (2) -R-Y .

NAME: ER lumen protein retaining receptor signature 2- CONSENSUS: L-E-[SA!-V-A-I-[LM!-P-(Q-L ■ NAME: Ephrins signature-

CONSENSUS: CKR(Q!-CLF!-[CST!-x-K-[IF!-(Q-x-[FY!-[ST!-[PA!-x (3) -

G-x-E-F-x(5)-[FY!(2)-

CONSENSUS: x(2)-[SA!- NAME: Granulins signature-

CONSENSUS: C-x-D-x (2) -H-C-C-P-x ( 4 ) -C .

NAME". HBGF/FGF family signature.

CONSENSUS: G-x-L-x-[STAGP!-x (bι7 ) -[DE!-C-x-[FM!-x-E-x (b ) -Y •

NAME: PTN/MK heparin-binding protein family signature 1- CONSENSUS: S- E!-C-x- E!-U-x-U-x (2) -C-x-P-x-[SN!-x-D-C-G- [LIVMA!-G-x-R-E-G. NAME: PTN/MK heparin-binding protein family signature 2-

CONSENSUS: C-[KR!-[LIVM!-P-C-N-U-K-K-x-F-G-A-[DE!-C-K-Y-x-F- [EιQ!-x-U-G-x-C

NAME: Nerve growth factor family signature- CONSENSUS: G-C-[KR!-G-[LIV!-[DE!-x (3) -[YU!-x-S-x-C -

NAME: Platelet-derived growth factor (PDGF) family signature ■

CONSENSUS: P-[PS!-C-V-x (3) -R-C-[GSTA!-G-C- .

NAME: Small cytokines (intercrine/chemokine) C-x-C subfamily signature ■

CONSENSUS: C-x-C-[LIVM!-x (Sifa ) -[LIVMFY!-x (2) -[RKSE(Q!-x-

[LIVM!-x(2)-[LIVM!-x(5)~ CONSENSUS: CSAG!-x (2) -C-x (3) -CE(Q!-[LIVM! (2 ) -x (lilO) -C-L-[DN! •

NAME: Small cytokines (intercrine/chemokine) C-C subfamily signature.

CONSENSUS: C-C-[LIFYT!-x ( Sifa) -[LI!-x ( 4 ) -[LIVMF!-x (2 ) -CFYU!- x(bιβ)-C-x(3ι4)-[SAG!-

CONSENSUS: CLIVM! (2) -[FL!-x (6 ) -C-[STA! -

NAME: TGF-beta family signature- CONSENSUS : [LIVM!-x ( 2 ) -P-x ( 2 ) -[FY!-x ( 4 ) -C-x-G-x-C

NAME-" TNF family signature-

CONSENSUS: CLV!-x-[LIVM!-x (3) -G-[LIVMF!-Y-[LIVMFY! (2) -x (2) - [<QEKHL!-[LIVMGT!-x-

CONSENSUS: [LIVMFY!-

NAME: TNF family profile- NAME: Unt-1 family signature-

CONSENSUS: C-K-C-H-G-CLIVMT!-S-G-x-C -

NAME: Interferon alphai beta and delta family signature- CONSENSUS: CFYH!-[FY!-x-[GNRC!-[LIVM!-x (2 ) -[FY!-L-x (7 ) -[CY!- A-U-

NAME: Granulocyte- acrophage colony-stimulating factor signature-

CONSENSUS: C-P-[LP!-T-x-E-[ST!-x-C -

NAME: Interleukin-1 signature-

CONSENSUS: CFC!-x-S-[ASLV!-x (2) -P-x (2) -CFYLIV!-[LI!-[SCA!-T- x(7)-[LIVM!- NAME: Interleukin-2 signature-

CONSENSUS: T-E-CLF!-x (2) -L-x-C-L-x (2) -E-L .

NAME: Interleukins -4 and -13 signature-

CONSENSUS: L-x-E-CLIVM! (2 ) -x (4 i 5) -[LIVM!-[TL!-x (5ι7) -C-x ( 4 ) - [IVA!-x-[DNS!-[LIVMA!-

NAME: Interleukin-b / G-CSF / MGF signature- CONSENSUS: C-x (1 ) -C-x (fa ) -G-L-x (2 ) -CFY!-x (3 ) -L - NAME: Interleukin-7 and -1 signature- CONSENSUS: N-x-[LAP!-[SCT!-F-L-K-x-L-L -

NAME: Interleukin-ID family signature-

CONSENSUS: [GS!-C-x (2 ) -CLV!-x (2 ) -[LIVM! (2) -x-F-Y-L-x (2) -V -

NAME: LIF / OSM family signature.

CONSENSUS: CPST!-x ( 4 ) -F-[NιQ!-x-K-x (3) -C-x-[LF!-L-x (2) -Y-[HK! .

NAME: Macrophage migration inhibitory factor family signature-

CONSENSUS: E!-P-C-A-x (3) -[LIVM!-x-S-I-G-x-[LIVM!-G ■

NAME: Adipokinetic hormone family signature- CONSENSUS: ιQ-[LV!-[NT!-[FY!-[ST!-x (2) -U -

NAME: Bombesin-like peptides family signature CONSENSUS: U-A-x-G-[SH!-[LF!-M -

NAME: Calcitonin / CGRP / IAPP family signature. CONSENSUS: C-[SAGDN!-[STN!-x (Oil) -[SA!-T-C-[VMA!-χ (3) -CLYF3- x(3)-[LYF!-

NAME Corticotropin-releasing factor family signature CONSENSUS : CP(Q!-x-[LIVM!-S-[LIVM!-x ( 2 ) -CPST!-CLIVMF!-χ-

[LIVM!-L-R-x ( 2 ) -[LIVM! -

NAME: Crustacean CHH/MIH/GIH neurohormones family signature CONSENSUS: C-CDENK!-D-C-x-N-[LIV!-[FY!-R-x (7) -C-[KR!-x (2 ) -C -

NAME: Erythropoietin / thrombopoeitin signature- CONSENSUS: P-x (4 ) -C-D-x-R-CLIVM! (2) -x-[KR!-x (14 ) -C - NAME: Granins signature 1-

CONSENSUS: E!-CSN!-L-[SAN!-x (2) -[DE!-x-E-L -

NAME: Granins signature 2-

CONSENSUS: C-[LIVM! (2) -E-[LIVM! (2) -S-[DN!-[STA!-L-x-K-x-S- x(3)-[LIVM!-CSTA!-x-E-C-

NAME: Galanin signature-

CONSENSUS: G-U-T-L-N-S-A-G-Y-L-L-G-P-H - NAME: Gastrin / cholecystokinin family signature- CONSENSUS: Y-x (Oil) -[GD!-[UH!-M-[DR!-F -

NAME: Glucagon / GIP / secretin / VIP family signature- CONSENSUS: [YH!-[STAIVGD!- EιQ!-[AGF!-[LIVMSTE!-[FYLR!-x- [DENSTAK!-[DENSTA!-

CONSENSUS: [LIVMFYG!-x (1) -[KRE(QL!-[KRDEN(QL!-[LVFYUG!-[LIV(Q! -

NAME: Glycoprotein hormones alpha chain signature 1 CONSENSUS: C-x-G-C-C-[FY!-S-R-A-[FY!-P-T-P •

NAME: Glycoprotein hormones alpha chain signature 2 CONSENSUS: N-H-T-x-C-x-C-x-T-C-x (2 ) -H-K .

NAME: Glycoprotein hormones beta chain signature 1- CONSENSUS: C-[STAGM!-G-[HFYL!-C-x-[ST! -

NAME: Glycoprotein hormones beta chain signature 2- CONSENSUS: CPA!-V-A-x (2) -C-x-C-x (2) -C-x ( 4 ) -[STD!-[DEY!-C- x(faιβ)-[PGSTAVM!-x(2)-C

NAME: Gonadotropin-releasing hormones signature CONSENSUS: <Q-H-CFYU!-S-x(4)-P-G.

NAME: Insulin family signature- CONSENSUS: C-C--CP>-x (2) -C-[STDNEKPI!-x (3) -CLIVMFS!-x (3) -C .

NAME: Natriuretic peptides signature- CONSENSUS: C-F-G-x (3) -D-R-I-x (3) -S-x (2) -G-C - NAME: Neurohypophysial hormones signature- CONSENSUS: C-[LIFY! (2) -x-N-[CS!-P-x-G -

NAME: Neuromedin U signature- CONSENSUS: F-[LIVMF!-F-R-P-R-N -

NAME: Endogenous opioids neuropeptides precursors signature- CONSENSUS: C-x (3) -C-x (2) -C-x (2) -CKRH!-x (bι7⁾ -[LIF!- N!-x (3) - C-x-[LIVM!-[E(Q!-C- CONSENSUS : CE(Q!-x ⁽ δ ) -U-x ( 2 ) -C

NAME : Pancreatic hormone family signature-

CONSENSUS : [FY!-x(3)-[LIVM!-x(2)-Y-x(3)-[LIVMFY!-x-R-x-R-

[YF! -

NAME: Parathyroid hormone family signature. CONSENSUS: V-S-E-x-(Q-x(2)-H-x(2)-G- NAME: Pyrokinins signature-

CONSENSUS: F-CGSTV!-P-R-L-CG>!-

NAME: Somatotropini prolactin and related hormones signature 1- CONSENSUS: C-x-[ST!-x (2) -[LIVMFY!-x-[LIVMSTA!-P-x ( 5) -CTALIV!- x(7)-CLIVMFY!-x(b)- CONSENSUS: CLIVMFY!-x (2) -CSTA!-U -

NAME: Somatotropini prolactin and related hormones signature 2-

CONSENSUS: C-CLIVMFY!-x (2) -D-CLIVMFYSTA!-x (5) -[LIVMFY!-x (2) - [LIVMFYT!-x(2)-C

NAME: Tachykinin family signature- CONSENSUS: F-[IVFY!-G-[LM!-M-[G>! -

NAME: Thymosin beta-4 family signature. CONSENSUS: K-L-K-K-T-E-T-(Q-E-K-N -

NAME: Urotensin II signature- CONSENSUS: c-F-U-K-Y-C

NAME: Cecropin family signature-

CONSENSUS: U-x (Dι2 ) -[KDN!-x (2) -K-[KRE!-[LI!-E-[RKN!

NAME: Mammalian defensins signature- CONSENSUS: C-x-C-x (3ι5) -C-x (7) -G-x-C-x (1) -C-C -

NAME: Arthropod defensins signature-

CONSENSUS: C-x(2ι3)-[HN!-C-x(3ι4)-[GR!-x(2)-G-G-x-C-x(4ι7)-C- x-C

NAME: Cathelicidins signature 1-

CONSENSUS: Y-x-[ED!-x-V-x-[R(Q!-A-[LIVMA!- £2G!-x-[LIVMFY!-N-

CE(Q!-

NAME: Cathelicidins signature 2- CONSENSUS: F-x-[LIVM!-K-E-T-x-C-x(lD)-C-x-F-[KR!-[KE!

NAME: Endothelin family signature- CONSENSUS: C-x-C-x(4)-D-x(2)-C-x(2)-[FY!-C-

NAME: Plant thionins signature- CONSENSUS C-C-x(5)-R-x(2)-[FY!-x(2)-C-

NAME: Gamma-thionins family signature-

CONSENSUS: [KR!-x-C-x(3)-[SV!-x(2)-[FYUH!-x-[GF!-x-C-x(5)-C- x(3)-C- NAME: Snake toxins signature-

CONSENSUS: G-C-x (lι3⁾ -C-P-x (βilO) -C-C-x (2) -[PDEN! - NAME: Myotoxins signature-

CONSENSUS: K-x-C-H-x-K-x (2) -H-C-x (2) -K-x (3 ⁾ -C-x (6) -K-x (2 ) -C- x⁽2)-[RK!-x-K-C-C-K-K-

NAME: Scorpion short toxins signature- CONSENSUS: C-x (3) -C-x (fail) -CGAS!-K-C-[IM(QT!-x (3) -C-x-C -

NAME: Heat-stable enterotoxins signature- CONSENSUS: C-C-x ( 2) -C-C-x-P-A-C-x-G-C - NAME: Aerolysin type toxins signature- CONSENSUS: CKT!-x (2) -N-U-x (2) -T-[DN!-T -

NAME: Shiga/ricin ribosomal inactivating toxins active site signature. CONSENSUS: [LIVMA!-x-[LIVMSTA! (2) -x-E-[SAGV!-[STAL!-R-[FY!- [RKN(QS!-x-[LIVM!-[E(QS!- CONSENSUS: x (2 ) -CLIVMF! .

NAME: Channel forming colicins signature- CONSENSUS: T-x (2) -U-x-P-CLIVMFY! (3) -x (2) -E •

NAME: Hok/gef family cell toxic proteins signature- CONSENSUS: [LIVMA! ( 4 ) -C-[LIVMFA!-T-[LIVMA! (2) -x (4) -[LIVM!-x- [RG!-x(2)-L-[CY!-

NAME: Staphylococcal enterotoxin/Streptococcal pyrogenic exotoxin signature 1-

CONSENSUS: Y-G-G-[LIV!-T-x (4 ) -N - NAME : Staphy l occocal enterotox i n/Streptococca l pyrogen i c exotoxin si gnature 2 -

CONSENSUS : K-x ( 2 ) -CLIV!-x ( 4 ) -[LIV!-D-x ( 3 ) -R-x ( 2 ) -L-x ( 5 ) -

[LIV!-Y - NAME: Thiol-activated cytolysins signature- CONSENSUS: [RK!-E-C-T-G-L-x-U-E-U-U-[RK! -

NAME: Membrane attack complex components / perforin signature. CONSENSUS: Y-x (b) -[FY!-G-T-H-[FY! .

NAME: Pancreatic trypsin inhibitor (Kunitz) family signature-

CONSENSUS: F-x (3) -G-C-x (fa) -CFY!-x (5) -C -

NAME: Bowman-Birk serine protease inhibitors family signature.

CONSENSUS: C-x (5ιb ) -[DEN(QKRHSTA!-C-[PASTDH!-[PASTDK!-[ASTDV!-

C-[NDKS!-[DEKRHSTA!-C

NAME: Kazal serine protease inhibitors family signature- CONSENSUS: C-x (7 ) -C-x (fa) -Y-x (3) -C-x (2ι3) - • NAME: Soybean trypsin inhibitor (Kunitz) protease inhibitors family signature-

CONSENSUS : [LIVM!-x-D-x-[EDNTY!-[DG!-[RKHDEN(Q!-x-[LIVM!-x ( 5 ) -

Y-x-CLIVM! -

NAME: Serpins signature.

CONSENSUS: [LIVMFY!-x-[LIVMFYAC!-[DN(Q!-[RKH(QS!-[PST!-F-

[LIVMFY!-[LIVMFYC!-x-

CONSENSUS: [LIVMFAH!-

NAME: Potato inhibitor I family signature- CONSENSUS: [FYU!-P-[E(QH!-[LIV!(2)-G-x(2)-[STAGV!-x(2)-A-

NAME: Squash family of serine protease inhibitors signature. CONSENSUS: C-P-x(5)-C-x(2)-D-x-D-C-x(3)-C-x-C

NAME: Streptomyces subtilisin-type inhibitors signature- CONSENSUS: C-x-P-x(2ι3)-G-x-H-P-x(4)-A-C-[ATD!-x-L-

NAME: Cysteine proteases inhibitors signature-

CONSENSUS: [GSTE(QKRV!-(Q-[LIVT!-[VAF!-[SAG(Q!-G-x-[LIVMNK!- x(2)-[LIVMFY!-x-[LIVMFYA!-

CONSENSUS: [DENiQKRHSIV!-

NAME: Tissue inhibitors of metalloproteinases signature CONSENSUS: C-x-C-x-P-x-H-P-(Q-x-A-F-C

NAME: Cereal trypsin/alpha-amylase inhibitors family signature.

CONSENSUS: C-x(4)-[SAGD!-x(4)-[SPAL!-CLF!-x(2)-C-CRH!-x-

[LIVMFY!(2)-x(3ι4)-C

NAME: Alpha-2-macroglobulin family thiolester region signature

CONSENSUS CPG!-x-CGS!-C-CGA!-E-[E(Q!-x-[LIVM!-

NAME: Disintegrins signature- CONSENSUS: C-x(2)-G-x-C-C-x-[N(QRS!-C-x-[FM!-x(fa)-C-[RK!-

NAME: Lambdoid phages regulatory protein CIII signature-

CONSENSUS: E-S-x-L-x-R-x(2)-[KR!-x-L-x(4)-[KR!(2)-x(2)-[DE!- x-L-

NAME: Chape onins cpnfaD signature- CONSENSUS: A-[AS!-x-[DE(Q!-E-x(4)-G-G-[GA!-

NAME: Chaperonins cpnlO signature-

CONSENSUS: CLIVMFY!-x-P-[ILT!-x-[DEN!-[KR!-[LIVMFA! (3) -

[KRE(Q!-x(δι1)-CSG!-x-

CONSENSUS: [LIVMFY!(3)-

NAME: Chaperonins TCP-1 signature 1-

CONSENSUS: [RKEL!-[ST!-x-[LMFY!-G-P-x-[GSA!-x-x-K-[LIVMF! (2) NAME: Chaperonins TCP-1 signature 2-

CONSENSUS: [LIVM!-[TS!-[NK!-D-[GA!-[AVNHK!-[TAV!-[LIVM! (2) - x(2)-[LIVM!-x-[LIVM!-x-

CONSENSUS: [SNH!-[P(QH! - NAME: Chaperonins TCP-1 signature 3- CONSENSUS: (Q-[DEK!-x-x-[LIVMGTA!-[GA!-D-G-T - NAME: Heat shock hsp2D proteins family profile-

NAME: Heat shock hsp7D proteins family signature 1- CONSENSUS: CIV!-D-L-G-T-[ST!-x-[SC! - NAME: Heat shock hsp7D proteins family signature 2-

CONSENSUS: CLIVMF!-[LIVMFY!-[DN!-[LIVMFS!-G-[GSH!-[GS!-[AST!- x(3)-[ST!-[LIVM!-

CONSENSUS: [LIVMFC!- NAME: Heat shock hsp70 proteins family signature 3-

CONSENSUS: [LIVMY!-x-[LIVMF!-x-G-G-x-[ST!-x-[LIVM!-P-x- [LIVM!-x-[DE(QKRSTA!-

NAME: Heat shock hsplD proteins family signature- CONSENSUS: Y-x-[N<QH!-K- E!-[IVA!-F-L-R-[ED! -

NAME: Chaperonins clpA/B signature 1-

CONSENSUS: D-[AI!-[SGA!-N-[LIVMF! (2) -K-[PT!-x-L-x (2) -G - NAME: Chaperonins clpA/B signature 2-

CONSENSUS: R-[LIVMFY!-D-x-S-E-[LIVMFY!-x-E-[KR(Q!-x-[STA!-x-

[STA!-[KR!-[LIVM!-x-G-

CONSENSUS: [STA!- NAME: Nt-dnaJ domain signature-

CONSENSUS: [FY!-x (2) -[LIVMA!-x (3) -[FYUHNT!-[DEN<QSA!-x-L-x- [DN!-x(3)-[KR!-x(2)-[FYI!-

NAME: dnaJ domain profile-

NAME: CXXCXGXG dnaJ domain signature-

CONSENSUS: C-[DEGSTHKR!-x-C-x-G-x-[GK!-[AGSDM!-x (2 ) -[GSNKR!- x(4ιb)-C-x(2ι3)-C-x-G-x-G- NAME: grpE protein signature-

CONSENSUS: [FL!-CDN!-[PHEA!-x (2) -[HM!-x-A-CLIVMTN!-x (lbι2D) -

G-[FY!-x(3)-CDEG!-x(2)-

CONSENSUS: CLIVM!-CRI!-x-[SA!-x-V-x-[IV! - NAME: Bacterial type II secretion system protein C signature-

CONSENSUS: p-χ (fa ) -F-x ( 4 ) -L-x (3) -D-[LIVM!-A-[LIVM!-x-[LIVM!-N- x-[LIVM!-x-L- NAME: Bacterial type II secretion system protein D signature-

CONSENSUS: [GR!-[DE(QKG!-[STVM!-[LIVMA! (3) -CGA!-G-[LIVMFY!- x(ll)-[LIVM!-P-

CONSENSUS: [LIVMFYUGS!-[LIVMF!-[GSAE!-x-[LIVM!-P- CLIVMFYU!(2)-x(2)-[LV!-F-

NAME: Bacterial type II secretion system protein E signature- CONSENSUS : CLIVM!-R-x ( 2 ) -P-D-x-[LIVM! ( 3 ) -G-E-CLIVM!-R-D .

NAME: Bacterial type II secretion system protein F signature . CONSENSUS: CKRιQ!-[LIVMA!-x (2) -[SAIV!-[LIVM!-x-[TY!-P-x (2) - [LIVM!-x(3)-[STAGV!-x(fa)~ CONSENSUS: CLMY!-x (3) -CLIVMF! (2 ) -P -

NAME: Bacterial type II secretion system protein N signature.

CONSENSUS: G-T-L-U-x-G-x (11 ) -L-x ( 4 ) -U ■

NAME: Bacterial export FHIPEP family signature- CONSENSUS: R-CLIVM!-[GSA!-E-V-[GSA!-A-R-F-[STV!-L-D-[GSA!-M- P-G-K-<Q-M-[GSA!-I-D-

CONSENSUS: [GSA!-D-

NAME: Protein secA signatures-

CONSENSUS: [IV!-x-[IV!-[SA!-T-[N(Q!-M-A-G-R-G-x-D-I-x-L -

NAME: Protein secY signature 1-

CONSENSUS: [GST!-[LIVMF! (2) -x-[LIVM!-G-[LIVM!-x-P-

[LIVMFY!(2)-x-[AS!-[GST(Q!-

CONSENSUS: [LIVMFAT! (3) -(Q-[LIVMFA! (2) -

NAME: Protein secY signature 2-

CONSENSUS: [LIVMFYU! (2) -x-[DE!-x-[LIVMF!-[STN!-x (2)-G-

[LIVMF!-[GST!-[NST!-G-x-[GST!-

CONSENSUS: [LIVMF!(3).

NAME: Protein secE/secfal-gamma signature-

CONSENSUS: [LIVMFY!-x (2) - EN(QGA!-x ( 4 ) -[LIVMTA!-x-[KRV!-x (2) -

[KU!-P-x(3)-[SE(Q!-x(7)-

CONSENSUS: CLIVT!-CLIVGA!-[LIVFGAST! -

NAME: Gram-negative pili assembly chaperone signature-

CONSENSUS: CLIVMFY!-[APN!-x-[DNS!-[KRE(Q!-E-[STR!-[LIVMΛR!-x-

[FYUT!-x-[NC!-[LIVM!-

CONSENSUS: x (2) -[LIVM!-P-[PAS! -

NAME: Fimbrial biogenesis outer membrane usher protein signature.

CONSENSUS: [VL!-[PAS(Q!-[PAS!-G-[PAD!-[FY!-x-[LI!-[DN(QSTAP!-

[DNH!-[LIVMFY!-

NAME: SRP54-type proteins GTP-binding domain signature- CONSENSUS: P-[LIVM!-x-[FYL!-[LIVMAT!-[GS!-x-[GS!-[E(Q!-x ( 4 ) - [LIVMF!- NAME: Cytochrome c oxidase assembly factor COXlO/ctaB/cyoE signature- CONSENSUS: CED!-x-D-x (2)-M-x-R-T-x (2) -R-x ( 4 )-G -

NAME: Cyclin-dependent kinases regulatory subunits signature 1-

CONSENSUS: Y-S-x-CKR!-Y-x-CDE! ⁽2) -x-[FY!-E-Y-R-H-V-x-[LV!- [PT!-[KRP!- NAME: Cyclin-dependent kinases regulatory subunits signature

2.

CONSENSUS: H-x-P-E-x-H-[IV!-L-L-F-CKR! - NAME: Pentaxin family signature- CONSENSUS: H-x-C-x-CST!-U-x-[ST! -

NAME"- Immunoglobulins and major histocompatibility complex proteins signature- CONSENSUS: CFY!-x-C-x-CVA!-x-H -

NAME: Prion protein signature 1- CONSENSUS: A-G-A-A-A-A-G-A-V-V-G-G-L-G-G-Y • NAME." Prion protein signature 2.

CONSENSUS: E-x-CED!-x-K-[LIVM! (2) -x-[KR!-[LIVM! (2) -x-[<QE!-M- C-x(2)-(Q-Y.

NAME: Cyclins signature- CONSENSUS: R-x (2) -CLIVMSA!-x (2) -[FYUS!-[LIVM!-x (δ) -[LIVMFC!- x(4)-[LIVMFYA!-x(2)-

CONSENSUS: CSTAGC!-[LIVMFY(Q!-x-[LIVMFYC!-[LIVMFY!-D-[RKH!- [LIVMFYU!- NAME: Proliferating cell nuclear antigen signature 1.

CONSENSUS: [GA!-[LIVMF!-x-[LIVMA!-x-[SAV!-[LIVM!-D-x-[NSAE!-

[HKR!-[VI!-x-[LY!-

CONSENSUS: [VGA!-x-CLIVM!-x-[LIVM!-x ( ) -F ■ NAME: Proliferating cell nuclear antigen signature 2-

CONSENSUS: [RKA!-C-[DE!-[RH!-x (3) -[LIVMF!-x (3) -[LIVM!-x-

[SGAN!-[LIVMF!-x-K-

CONSENSUS: [LIVMF!(2). NAME: Actin-depolymerizing proteins signature-

CONSENSUS: P- E!-x-[SA!-x-[LIVMT!-[KR!-x-[KR!-M-[LIVM!-[YA!-

CSTA!(3)-x(3)-CLIVMF!-

CONSENSUS: CKR!- NAME: BCL2-like apoptosis inhibitors (spans part of BH3ι BHI and BH2) -

NAME: Apoptosis regulator! Bcl-2 family BHI domain signature- CONSENSUS: CLVME!-[FT!-x-[GSD!-[GL!-x (lι2 ) -[NS!-[YU!-G-R- [LIV!-[LIVC!-[GAT!- CONSENSUS: CLIVMF! (2)-x-F-[GSAE!-[GSARY! -

NAME: Apoptosis regulator! Bcl-2 family BH2 domain signature-

CONSENSUS: U-[LIM!-x (3 ) -[GR!-G-[UιQ!-[DENSAV!-x-[FLGA!- [LIVFTC!-

NAME: Apoptosis regulator! Bcl-2 family BH3 domain signature-

CONSENSUS: [LIVAT!-x ⁽3⁾ -L-^[KAR<^Q!-x-[IVAL!-G-D-^[DESG!-[LIMFV!-

[DENSH(Q!-[LVSHR(Q!-

CONSENSUS: [NSR!- NAME: Apoptosis regulator! Bcl-2 family BH4 domain signature-

CONSENSUS: EDS!-[NT!-R-[AE!-CLI!-V-x-[KD!-^[FY!-[LIV!-[GHS!-Y- K-L-CSR!-(Q-[RK!-G-

CONSENSUS: CHY!-x-CCU!-

NAME: Apoptosis regulator! Bcl-2 family BH4 domain profile- NAME: Arrestins signature-

CONSENSUS: [FY!-R-Y-G-x-[DE! (2) -x-[DE!-[LIVM! (2 ) -G-CLIVM!-x- F-x-[RK!-CDE(Q!-[LIVM!-

NAME: AAA-protein family signature- CONSENSUS: CLIVMT!-x-[LIVMT!-[LIVMF!-x-[GATMC!-[ST!-[NS!- x(4)-[LIVM!-D-x-A-[LIFA!- CONSENSUS: x-R-

NAME: Ubiquitin domain signature- CONSENSUS: K-x (2) -[LIVM!-x- ESAK!- (3) -[LIVM!-CPA!-x (3) -ώ-x- [LIVM!-[LIVMC!- CONSENSUS: [LIVMFY!-x-G-x ( 4 ) -[DE! -

NAME: Ubiquitin domain profile-

NAME: ADP-ribosylation factors family signature- CONSENSUS: CHR(QT!-x-[FYUI!-x-[LIVM!-x (4 ) -A-x (2 ) -G-x (2) [LIVM!-x(2)-[GSA!-[LIVMF!-x- CONSENSUS: [UK!-[LIVM!-

NAME: GTP-binding nuclear protein ran signature- CONSENSUS: D-T-A-G-<Q-E-K-[LF!-G-G-L-R-[DE!-G-Y-Y -

NAME-" SARI family signature- CONSENSUS: R-x-[LIVM!-E-V-F-M-C-S-[LIVM! (2) -x-[KR(Q!-x-G-Y-x- E-[AG!-[FI!-x-U-[LIVM!- CONSENSUS: x-(Q-Y.

NAME: Band 7 protein family signature- CONSENSUS: R-x (2) -CLIV!-[SAN!-x (fa ) -[LIV!-D-x (2) -T-x (2) -U-G- [LIV!-[KRH!-[LIV!-x- CONSENSUS: [KR!-[LIV!-E-[LIV!-[KR! -

NAME: Trp-Asp (UD) repeats signature- CONSENSUS: [LIVMSTAC!-[LIVMFYUSTAGC!-[LIMSTAG!-[LIVMSTAGC!- x(2)-[DN!-x(2)- CONSENSUS: CLIVMUSTAC!-x-[LIVMFSTAG!-U-[DEN!-[LIVMFSTAGCN! -

NAME: G-protein gamma subunit profile-

NAME: Ras GTPase-activating proteins signature- CONSENSUS: [GSN!-x-[LIVMF!-[FY!-[LIVMFY!-R-[LIVMFY! (2) - [GACN!-P-[AV!-[LIV!(2)- CONSENSUS: [SGAN!-P-

NAME: Ras GTPase-activating proteins profile- NAME: Guanine-nucleotide dissociation stimulators CDC24 family signature-

CONSENSUS: L-x (2) -CLIVMFYU!-L-x (2) -P-[LIVM!-x (2 ) -CLIVfO-x-

[KRS!-x(2)-L-x-[LIVM!-x-

CONSENSUS: CDE(Q!-[LIVM!-x (3) -CST! ■

NAME: Guanine-nucleotide dissociation stimulators CDC25 family signature-

CONSENSUS: [GAP!-[CT!-V-P-[FY!-x ( 4 ) -[LIVMFY!-x- N!-[LIVM! .

NAME: MARCKS family signature 1- CONSENSUS: G-lQ-E-N-G-H-V-CKR! -

NAME: MARCKS family phosphorylation site domain- CONSENSUS: E-T-P-K ( 5) -x (Oil) -F-S-F-K-K-x-F-K-L-S-G-x-S-F-K- [KR!-[NS!-[KR!-K-E-

NAME: Stathmin family signature 1- CONSENSUS: P-[K<Q!-[KR! (2) -[DE!-x-S-L-[EG!-E .

NAME: Stathmin family signature 2- CONSENSUS: A-E-K-R-E-H-E-[KR!-E-V .

NAME: GTP-binding elongation factors signature. CONSENSUS: D-[KRSTGANlQFYU!-x (3) -E-CKRA(Q!-x-[RK(QD!-[GC!- [IVMK!-[ST!-[IV!-x(2)- CONSENSUS: CGSTACKRNiQ! ■

NAME: Elongation factor 1 beta/beta ' /delta chain signature I-

CONSENSUS: [DE!-[DEG!-[DE! (2) -[LIVMF!-D-L-F-G •

NAME: Elongation factor 1 beta/beta ' /delta chain signature 2- CONSENSUS: V-ιQ-S-x-D-[LIVM!-x-A-[FUM!-[N<Q!-K-[LIVM! .

NAME: Elongation factor 1 gamma chain profile-

NAME: Elongation factor Ts signature 1- CONSENSUS: L-R-x (2) -T-[GD(Q!-x-[GS!-[LIVMF!-x (Oιl)-[DENKAC!-x- K-[KRNEιQS!-[AV!-L.

NAME: Elongation factor Ts signature 2-

CONSENSUS: E-[LIVM!-N-[SCV!-[ιQE!-T-D-F-V-[SA!-[KRN! .

NAME: Elongation factor P signature-

CONSENSUS: K-x-A-x ( 4 ) -G-x (2) -CLIV!-x-V-P-x (2) -[LIV!-x (2) -G .

NAME: Eukaryotic initiation factor 1A signature- CONSENSUS: [IM!-x-G-x-[GS!-[KRH!-x (4 ) -[CL!-x-D-G-x (2) -R-x (2) - [RH!-I-x-G-

NAME: Eukaryotic initiation factor 4E signature- CONSENSUS: CDE!-[IFY!-x (2) -F-[KR!-x (2) -[LIVM!-x-P-x-U-E- V!- x(S)-G-G-[KR!-U-

NAME: Eukaryotic initiation factor 5A hypusine signature- CONSENSUS: CPT!-G-K-H-G-x-A-K - NAME: Initiation factor 2 signature-

CONSENSUS: G-x-CLIVIU-x (2) -L-[KR!-[KRHNS!-x-K-x (5) -CLIVM!- x(2)-G-x-CDEN!-C-G.

NAME: Initiation factor 3 signature-

CONSENSUS: CKR!-CLIVM! ⁽2) -CDN!-CFY!-CGSN!-CKR!-[LIVMFYS!-x-

[FY!-[DE(QT!-x(2)-[KR!- NAME Translation initiation factor SUI1 signature- CONSENSUS: CLIVM!-[E(Q!-[LIVM!-(Q-G-[DEN!-[KH(Q!-[KRV! -

NAME: Prokaryotic-type class I peptide chain release factors signature. CONSENSUS: [AR!-[STA!-x-G-x-G-G-(Q-[HNGCS!-V-N-x(3)-[ST!-A- CIV!-

NAME: Transcription termination factor nusG signature- CONSENSUS: [LIVM!-F-G-[KRU!-x-T-P-[IV!-x-[LIVM!-

NAME: Calponin family repeat- CONSENSUS: [LIVM!-x-[LS!-(Q-[MAS!-G-[STY!-[NT!-[KR(Q!-x(2)

CSTN!-(Q-x-G-x(3ι4)-G-

NAME: CAP protein signature 1-

CONSENSUS: CLIVM! (2⁾ -x-R-L-[DE!-x ⁽ 4 ) -R-L-E -

NAME: CAP protein signature 2-

CONSENSUS: D-[LIVMFY!-x-E-x-[PA!-x-P-E-(Q-[LIVMFY!-K -

NAME: Calreticulin family signature 1-

CONSENSUS: [KRHN!-x- E(QN!-[DE<QNK!-x (3) -C-G-G-[AG!-[FY!-

[LIVM!-[KN!-CLIVMFY!(2) - NAME: Calreticulin family signature 2 CONSENSUS: [LIVM! ( 2⁾ -F-G-P-D-x-C-[AG! -

NAME: Calreticulin family repeated motif signature- CONSENSUS: [IV!-x-D-x-[DENST!-x (2 ) -K-P- EH!-D-U-[DEN! ,

NAME: Calsequestrin signature 1-

CONSENSUS: CE(Q!-CDE!-G-L-[DN!-F-P-x-Y-D-G-x-D-R-V .

NAME: Calsequestrin signature 2-

CONSENSUS: CDE!-L-E-D-U-CLIVM!-E-D-V-L-x-G-x-CLIVM!-N-T-E-D-

D-D-

NAME: S-lOD/ICaBP type calcium binding protein signature. CONSENSUS: CLIVMFYU! ⁽2) -x (2 ⁾ -CL -D-x (3) -CDN!-x (3) -CDNSG!- CFY!-x-[ES!-CFYVC!-x(2)- CONSENSUS: CLIVMFS!-[LIVMF! ■

NAME: Hemolysin-type calcium-binding region signature- CONSENSUS: D-x-[LI!-x ( 4 ) -G-x-D-x-[LI!-x-G-G-x (3) -D -

NAME: HlyD family secretion proteins signature- CONSENSUS: CLIVM!-x ⁽2⁾ -G-CLM!-x ⁽3⁾ -CSTGAV!-x-^[LIVMT!-x- [LIVMT!-[GE!-x-[KR!-x- CONSENSUS: [LIVMFYU! ⁽2⁾ -x-^[LIVMFYU! (3) ■

NAME: P-II protein urydylation site- CONSENSUS: Y-CKR!-G-CAS!-[AE!-Y .

NAME: P-II protein C-terminal region signature- CONSENSUS: CST!-x (3) -G-[DY!-G-CKR!-[IV!-[FU!-[LIVM!-x (2 ) - CLIVM!- NAME: 14-3-3 proteins signature 1-

CONSENSUS: R-N-L-CLIV!-S-CVG!-[GA!-Y-[KN!-N-CIVA! •

NAME: 14-3-3 proteins signature 2-

CONSENSUS: Y-K-[DE!-S-T-L-I- M!-ιQ-L-[LF!-[RHC!-D-N-[LF!-T- [LS!-U-[TAN!-[SAD!-

NAME: ATP1G1 / PLM / MAT6 family signature-

CONSENSUS: [DNS!-x-F-x-Y-D-x (2) -[ST!-[LIVM!-[R(Q!-x (2) -G - NAME: BTG1 family signature 1-

CONSENSUS: Y-x (2) -[HP!-U-[FY!-[AP!-E-x-P-x-K-G-x-[GA!-[FY!-R- C-[IV!-[RH!-[IV!-

NAME: BTG1 family signature 2- CONSENSUS: [LV!-P-x-[DE!-[LM!-[ST!-[LIVM!-U-[IV!-D-P-x-E-V- [SC!-x-[R(Q!-x-G-E.

NAME: Cullin family signature-

CONSENSUS: CLIV!-K-x (2) -[LIV!-x (2) -L-I-[DE(Q!-[KRHN(Q!-x-Y- [LIVM!-x-R-x(faι7)-[FY!-x- CONSENSUS: Y-x-[SA!>-

NAME: Cullin family profile. NAME: Enhancer of rudimentary signature-

CONSENSUS: Y-D-I-[SA!-x-L-[FY!-x-F-[IV!-D-x (3) -D-[LIV!-S -

NAME: G10 protein signature 1-

CONSENSUS: L-C-C-x-[KR!-C-x ( 4 ) - E!-x-N-x ( 4 ) -C-x-C-R-V-P

NAME: G1D protein signature 2- CONSENSUS: C-x-H-C-G-C-[KRH!-G-C-[SA! -

NAME: Glucokinase regulatory protein family signature. CONSENSUS: G-[PA!-E-x-[LIV!-[STA!-G-S-[ST!-R-[LIVM!-K- CSTGA!(3)-x(2)-K-

NAME: GTP1/0BG family signature-

CONSENSUS: D-CLIVM!-P-G-CLIVM! (2 ) -[DEY!-[GN!-A-x (2) -G-x-G -

NAME: HIT family signature-

CONSENSUS: [N(^QA!-x ⁽4 ⁾ -^[GAV!-x-^[(^QF!-x-[LIVM!-x-H-[LIVMFYT!-H-

[LIVMFT!-H-[LIVMF!(2)-

CONSENSUS: [PSGA!-

NAME: Caseins alpha/beta signature- CONSENSUS: C-L-[LV!-A-x-A-[LVF!-A - NAME: Clathrin adaptor complexes medium chain signature 1- CONSENSUS: CIVT!-[GSP!-U-R-χ (2ι3) -CGAD!-x (2 ) -CHY!-x (2 ) -N-x- [LIVMAFY!(3)-D-[LIVM!-

CONSENSUS: [LIVMT!-E-

NAME: Clathrin adaptor complexes medium chain signature 2 CONSENSUS: CLIV!-x-F-I-P-P-x-G-x-[LIVMFY!-x-L-x (2) -Y -

NAME: Clathrin adaptor complexes small chain signature. CONSENSUS: CLIVM! (2) -Y-[KR!-x ( 4 ) -L-Y-F -

NAME: Ependymins signature 1-

CONSENSUS: F-E-E-G-x-CLIVMF!-Y-CED!-I-D-x(2)-N-C(QE!-S-C-

[RKH!(2).

NAME: Ependymins signature 2-

CONSENSUS: [(QE!-[LIVMA!-F-x(2)-P-[STA!-[FY!-C-[DE!-[GA!-

CLIVM!-x(2)-CDE3(2). NAME: Syntaxin / epimorphin family signature-

CONSENSUS: CR(Q!-x ⁽3) -CLIVMA!-x ⁽2) -CLIVM!-[ESH!-x (2) -[LIVMT!- x-[DEVM!-[LIVM!-x(2)-

CONSENSUS: [LIVM!-[FS!-x (2 ) -[LIVM!-x (3) -[LIVT!-x (2) -<Q-

[GADE(Q!-x(2)-[LIVM!-[DN(QT!-x- CONSENSUS: CLIVMF!-[DESV!-x (2) -CLIVM! -

NAME: Extracellular proteins SCP/Tpx-l/Ag5/PR-l/Sc7 signature 1-

CONSENSUS: [GDER!-H-[FYUH!-T-(Q-[LIVM! (2) -U-x (2 ) -[STN! -

NAME: Extracellular proteins SCP/Tpx-l/Ag5/PR-l/Sc7 signature 2-

CONSENSUS: [LIVMFYH!-[LIVMFY!-x-C-[N(QRHS!-Y-x-[PARH!-x-[GL!-

N-[LIVMFYUDN!-

NAME: Fetuin family signature 1-

CONSENSUS: C-x ⁽5b⁾ -C-x ⁽10 ) -C-x ⁽13⁾ -C-x (17ιlβ) -C-x (13) -C-x (2 ) ^■

C-x(5δ)-C-x(lDιlD-

CONSENSUS: C-x (10 i 12) -C-x (lb i 22) -C -

NAME: Fetuin family signature 2- CONSENSUS: L-E-T-x-C-H-x-L-D-P-T-P .

NAME". Legume lectins beta-chain signature. CONSENSUS: [LIV!-[STAG!-V-[DEιQV!-[FLI!-D-[ST!

NAME: Legume lectins alpha-chain signature. CONSENSUS: CLIV!-x-[ED(Q!-[FYUKR!-V-x-[LIV!-G-[LF!-[ST! . NAME: Vertebrate galactoside-binding lectin signature. CONSENSUS: U-[GEK!-x-CE(Q!-x-[KRE!-x (3ιfa) -CPCTF!-[LIVMF!- [N(QEGSKV!-x-[GH!-x(3)~ CONSENSUS: [DENKHS!-[LIVMFC! • NAME: Lysosome-associated membrane glycoproteins duplicated domain signature-

CONSENSUS: [STA!-C-[LIVM!-^[LIVMFYU!-A-x-[LIVMFYU!-x (3) - CLIVMFYU!-x(3)-Y- NAME: LAMP glycoproteins transmembrane and cytoplasmic domain signature-

CONSENSUS: C-x (2) -D-x (3ι4 ) -CLIVM! (2) -P-[LIVM!-x-[LIVM!-G- x(2)-CLIVM!-x-G-CLIVM!(2)-

CONSENSUS: x-CLIVM! ( 4 ) -A-[FY!-x-[LIVM!-x (2) -[KR!-[RH!-x (lι2) - [STAG!(2)-Y-[EiQ!-

NAME: Glycophorin A signature. CONSENSUS: I-I-x-[GAC!-V-M-A-G-[LIVM! (2) ■

NAME: PMP-22 / EMP / MP2D family signature 1-

CONSENSUS: [LIVMF! (4 ) -[SA!-T-x (2) -[DNKS!-x-U-x (1ιl3) -[LIV!-U- x(2)-C

NAME: PMP-22 / EMP / MP20 family signature 2-

CONSENSUS: CR(Q!-CAV!-x-M-CIV!-L-S-x-CLI!-x ( 4 ) -CGSA!- CLIVMF!(3). NAME: Oxysterol-binding protein family signature- CONSENSUS: E-CK(Q!-x-S-H-CHR!-P-P-x-CSTACF!-A -

NAME-" Yeast PIR proteins repeats signature- CONSENSUS: S-ιQ-CIV!-CSTGNH!-D-G-(Q-CLIV!-(Q-CAIV!-CSTA! -

NAME: Seminal vesicle protein I repeats signature- CONSENSUS: CIVM!-x-G-(Q-D-x-V-K-x ( 5) -CKN!-G-x (3) -CSTLV!

NAME: Seminal vesicle protein II repeats signature- CONSENSUS: [GSA!-(Q-x-K-S-[FY!-x-ιQ-x-K-[SA! .

NAME". Serum amyloid A proteins signature- CONSENSUS: A-R-G-N-Y-[ED!-A-x-[ιQKR!-R-G-x-G-G-x-U-A - NAME: Spermadhesins family signature 1-

CONSENSUS: C-G-x (2) -CLO-x ( 4) -G-x-I-x (1) -C-x-U-T .

NAME: Spermadhesins family signature 2-

CONSENSUS: C-x-K-E-x-CLIVM!-E-CLIVM!-x-CDE!-x (3) -CGS!-x (5) -K- x-C

NAME: Stress-induced proteins SRPl/TIPl family signature. CONSENSUS: P-U-Y-CST! (2) -R-L ■ NAME: Glypicans signature-

CONSENSUS: C-x (2) -C-x-G-CLIVM!-x (4 ) -P-C-x (2) -CFY!-C-x (2) - CLIVM!-x(2)-G-C

NAME: Syndecans signature- CONSENSUS: CFY!-R-CIM!-CKR!-K (2) -D-E-G-S-Y -

NAME: Tissue factor signature-

CONSENSUS: U-K-x-K-C-x ⁽2⁾ -T-x-^[DEN!-T-E-C-D-^[LIVM!-T-D-E - NAME: Translationally controlled tumor protein signature 1- CONSENSUS: CIA!-G-[GAS!-N-^[PA!-S-A-E-CGDE!-^[PAGE!-x (Oil ) - [DEG!-x-[DEN!-x(2)-[DE!- NAME: Translationally controlled tumor protein signature 2. CONSENSUS: CFL!-CFY!-[IVT!-G-E-x-[MA!-x (2ι5) - EN!-[GAS!-x- CLV!-CAV!-x(3)-CFY!-CKR!- CONSENSUS: CDE!-

NAME: Tub family signature 1-

CONSENSUS: F-CKHlQ!-G-R-V-[ST!-x-A-S-V-K-N-F-(Q .

NAME: Tub family signature 2- CONSENSUS: A-F-CAG!-I-CSAC!-[LIVM!-[ST!-S-F-x-[GST!-K-x-A-C- E.

NAME: HCP repeats signature- CONSENSUS: H-R-H-R-G-H-x (2) -[DE! (7) .

NAME: Bacterial ice-nucleation proteins octamer repeat. CONSENSUS: A-G-Y-G-S-T-x-T ■

NAME: Cell cycle proteins ftsU / rodA / spoVE signature- CONSENSUS: [NV!-x ( 5) -[GTR!-[LIVMA!-x-P-[PTLIVM!-x-G-[LIVM!- x(3)-[LIVMFU!(2)-S-[YSA!- CONSENSUS: G-G-[STN!-[SA! -

NAME: Enterobacterial virulence outer membrane protein signature 1-

CONSENSUS: G-[LIVMFY!-N-[LIVM!-K-Y-R-Y-E •

NAME: Enterobacterial virulence outer membrane protein signature 2- CONSENSUS: [FYU!-x (2) -G-x-G-Y-[KR!-F> .

NAME: Hydrogenases expression/synthesis hypA family signature ■

CONSENSUS: F-[CSA!-[FY!-CDE!-[LIVA! (2) -x (3 ) -[ST!-[LIVM!- x(lfa)-C-x(2)-C-x(12!lS)- CONSENSUS: C-P-x-C-

NAME: Hydrogenases expression/synthesis hupF/hypC family signature ■ CONSENSUS: <M-C-[LIV!-[GA!-CLIV!-P-x-[(QKR!-[LIV! .

NAME: Staphylocoagulase repeat signature-

CONSENSUS: _A-R-P-x (3) -K-x-S-x-T-N-A-Y-N-V-T-T-x (2) -CDN!-G- x(3)-Y-G-

NAME: 11-S plant seed storage proteins signature- CONSENSUS: N-G-x-CDE! (2 ) -x-CLIVMF!-C-[ST!-x (llιl2) -[PAG!-D .

NAME: Dehydrins signature 1- CONSENSUS: S (5) -CDE!-x-CDE!-G-x (lι2) -G-x (Oτl ) -[KR! ( )

NAME: Dehydrins signature 2-

CONSENSUS: [KR!-[LIM!-K-[DE!-K-[LIM!-P-G ■ NAME: Germin family signature-

CONSENSUS: G-x ( 4 ) -H-x-H-P-x-A-x-E-[LIVM! -

NAME: Oleosins signature- CONSENSUS: CAG!-CST!-χ (2) -CAG!-x (2 ) -CLIVM!-[SAD!-T-P-

CLIVMF!⁽4⁾-F-S-P-^[LIVM!⁽3)-

CONSENSUS: P-A-

NAME: Small hydrophilic plant seed proteins signature- CONSENSUS: G-[E<Q!-T-V-V-P-G-G-T •

NAME: Pathogenesis-related proteins Betvl family signature- CONSENSUS: G-x (2 ) -CLIVMF!-x (4 ) -E-x (2) -CCSTAEN!-x (δil) -CGND!- G-CGS!-[CS!-x(2)-K-x(4)-

CONSENSUS: CFY!-

NAME: Pollen proteins Ole e I family signature- CONSENSUS: CE(Q!-G-x-V-Y-C-D-T-C-R-

NAME: Thaumatin family signature- CONSENSUS: G-x-CGF!-x-C-x-T-CGA!-D-C-x(lι2)-G-x(2ι3)-C-

NAME: Mrp family signature- CONSENSUS: U-x(2)-[LIVM!-D-[LIVMY!(4)-D-x-P-P-G-T-[GS!-D-

NAME: Glucose inhibited division protein A family signature

1-

CONSENSUS: [GS!-P-x-Y-C-P-S-[LIVM!-E-x-K-[LIVM!-x-[KR!-F-

NAME: Glucose inhibited division protein A family signature

2-

CONSENSUS: A-G-(Q-x-[NT!-G-x(2)-G-Y-x-E-[SAG!(3)-[(2S!-G-

[LIVM!(2)-A-G-[LIVMT!-N-A

NAME: N0Ll/N0P2/sun family signature-

CONSENSUS: [FV!-D-[KRA!-[LIVMA!-L-x-D-[AV!-P-C-[ST!-[GA!

NAME: PET112 family signature-

CONSENSUS: [DN!-x- N!-R-x (3) -P-L-[LIV!-E-[LIV!-x-[ST!-x-P .

NAME: Protein smpB signature-

CONSENSUS: [TA!-G-[LIVM!-x-L-x-G-x-E-[LIVM!-[K(Q!-[SA!-[LIVM! . NAME: Hypothetical cof family signature 1-

CONSENSUS: [LIVFYAN!-[LIVMFA!-x (2) -D-[LIVMF!-[ND!-G-T-[LIV!- [LVY!-[STANLM!-

NAME: Hypothetical cof family signature 2- CONSENSUS: [LIVMFC!-G-D-[GSAN(Q!-x-N-D-x (3) -[LIMFY!-x (2) -CAV3- x(2)-CGSCP!-x(2)- CONSENSUS: CLMP!-x (2) -CGAS! -

NAME." RI01/ZKfa32-3/MJ0444 family signature- CONSENSUS: CLIVM!-V-H-CGA!-D-L-S-E-CFY!-N-x-CLIVM! -

NAME: SUA5/yciO/yrdC family signature-

CONSENSUS: [LIVMTA! (3) -CLIVMFYC!-CPG!-T-CDE!-[STA!-x-[FY!-

[GA!-[LIVM!-[GS!-

NAME: Uncharacterized protein family UPF00D1 signature- CONSENSUS: [FU!-H-[FM!-[IV!-G-x-[LIV!-ιQ-x-[NKR!-K-x (3 ) -[LIV! . NAME: Uncharacterized protein family UPF0D03 signature- CONSENSUS: G-x-V-x (2) -CLIV!-x (3) -CSA!-x (b) -D-x (3)-CLIVT! (3) - P-N-x(2)-CLIVMF!(2)- CONSENSUS: x(5)-N-

NAME: Uncharacterized protein family UPFD0D4 signature- CONSENSUS: [LIVM!-x-[LIVMT!-x (2) -G-C-x (3) -C-[STAN!-[FY!-C-x- [LIVM!-x(4)-G- NAME: Uncharacterized protein family UPF0D05 signature- CONSENSUS: G-CLIVM! (2 ) -[SA!-x (5ιβ) -G-x (2) -[LIVM!-G-P-x-L-

CONSENSUS: CLIVM! (2) -x (2) -A-x (3) -T-A-CLIVM! (2 ) -F - NAME: Uncharacterized protein family UPFDOOfa signature 1- CONSENSUS: CLIVMFY! (2 ) -D-CSTA!-H-x-H-CLIVMF!-CDN! -

NAME: Uncharacterized protein family UPFDODb signature 2. CONSENSUS: P-[LIVM!-x-[LIVM!-H-x-R-x-[TA!-x-[DE! -

NAME"- Uncharacterized protein family UPFODOb signature 3. CONSENSUS: CLVSA!-CLIVA!-x (2) -CLIVM!-CPS!-x (3) -L-CLIVM!- [LIVMS!-E-T-D-x-P- NAME: Uncharacterized protein family UPFDDD7 signature- CONSENSUS: V-L-[IV!-H-D-[GA!-A-R -

NAME-" Uncharacterized protein family UPF0011 signature- CONSENSUS: S-D-A-G-x-P-x-[LIV!-[SN!-D-P-G -

NAME: Uncharacterized protein family UPFDD12 signature- CONSENSUS: [GTA!-x (2) -CIVT!-C-Y-D-[LIVM!-x-F-P-x (1) -G -

NAME: Uncharacterized protein family UPF0D15 signature- CONSENSUS: [DE!-[LIVMF! (3) -R-T-[SG!-G-x (2 ) -R-x-S-x-[FY!- [LIVM!(2)-U-(Q-

NAME: Uncharacterized protein family UPFODlfa signature- CONSENSUS: E-[LIVM!-G-D-K-T-F-[LIVMF! (2 ) -A -

NAME: Uncharacterized protein family UPF0D17 signature-

CONSENSUS: D-x (δ ) -CGN!-CLFY!-x ( 4 ) -CDET!-CLY!-Y-x (3) -CST!- x(7)-[IV!-x(2)-[PS!-x-

CONSENSUS: CLIVM!-x-CLIVM!-x (3) -[DN!-D -

NAME: Uncharacterized protein family UPF0D11 signature- CONSENSUS: L-P-V-CVT!-CN(QL!-F-CAT!-A-G-G-[LIV!-A-T-P-A-D-A-A- [LM!- NAME: Uncharacterized protein family UPF0D20 signature- CONSENSUS: D-P-[LIVMF!-C-G-[ST!-G-x (3 ) -[LI!-E -

NAME: Uncharacterized protein family UPFD021 signature. CONSENSUS: C-K-x(2)-F-x(4)-E-x(22ι23)-S-G-G-K-D-

NAME: Uncharacterized protein family UPFD023 signature CONSENSUS: D-x-D-E-[LIV!-L-x ( 4 ) -V-F-x (3) -S-K-G - NAME: Uncharacterized protein family UPF0024 signature- CONSENSUS: G-x-K-D-CKR!-x-A-[LV!-T-x-<Q-x-[LIVF!-[SGC! -

NAME: Uncharacterized protein family UPFD025 signature- CONSENSUS: D-V-CLIV!-x (2) -G-H-CST!-H-x (12) -[LIVMF!-N-P-G -

NAME: Uncharacterized protein family UPFD027 signature- CONSENSUS: (Q-[LIVM!-x-N-x-A-x-[LIVM!-P-x-I-x (fa ) -CLIVM!-P-D-x- H-x-G-x-G-x(2)-[IV!-G-

NAME: Uncharacterized protein family UPFD026 signature- CONSENSUS: [GA!-[GS!-G-[GA!-A-R-G-x-[SA!-H-x-G-x (1) -[IV!-x- [IV!-D-x(2)-CGA!-G-x-S- CONSENSUS: x-G-

NAME". Uncharacterized protein family UPFD021 signature. CONSENSUS: G-x (2) -CLIVM! (2 ) -x (2 ) -CLIVM!-x (4 ) -CLIVM!-x (5) - CLIVM!(2)-x-R-CFYU!(2)-G- CONSENSUS: G-x (2) -CLIVM!-G .

NAME: Uncharacterized protein family UPFD03D signature- CONSENSUS: [GA!-L-I-[LIV!-P-G-G-E-S-T-[STA! -

NAME: Uncharacterized protein family UPF0D31 signature 1- CONSENSUS: [SAV!- VU!-[LVA!-[LIV!-G-[PNS!-G-L-[GP!-x- [DENiQT!-

NAME: Uncharacterized protein family UPF0031 signature 2- CONSENSUS: [GA!-G-x-G-D-[TV!-[LT!-[STA!-G-x-[LIVM! -

NAME: Uncharacterized protein family UPF0032 signature- CONSENSUS: Y-x (2) -F-CLIVMA! (2) -x-L-x ( 4 ) -G-x (2 ) -F-CEiQ!- [LIVMF!-P-[LIVM!. NAME: Uncharacterized protein family UPF0D33 signature- CONSENSUS: L-[DN!-x (2) -[TAG!-x (2) -C-P-x-P-x-[LIVM! -

NAME: Uncharacterized protein family UPF0034 signature- CONSENSUS: [LIVM!-[DNG!-[LIVM!-N-x-G-C-P-x (3) -[LIVMASιQ!-x (5) G-[SAC!-

NAME: Uncharacterized protein family UPF0D35 signature- CONSENSUS: L-L-T-x-R-CSA!-x (3) -R-x (3) -G-x (3) -F-P-G-G - NAME: Uncharacterized protein family UPF003fa signature-

CONSENSUS: H-x-S-G-H-CGA!-x (3) - E!-x (3) -[LM!-x (5) -P-x (3) - [LIVM!-P-x-H-G-[DE!-

NAME: Uncharacterized protein family UPFD036 signature- CONSENSUS: G-x-CLI!-x-R-x (2) -L-x ( 4 ) -F-x (6 ) -CLIV!-x ( 5) -P-x- CLIV!-

NAME: Uncharacterized protein family UPF0044 signature- CONSENSUS: L-CST!-x ⁽3) -K-x ⁽3⁾ -CKR!-[SGA!-x-[GA!-H-x-L-x-P- [LIV!-x(2)-[LIV!-[GA!- CONSENSUS: x(2)-G-

NAME: Uncharacterized protein family UPF0047 signature- CONSENSUS : S-X ⁽ 2 ⁾ -CLIV!-x-[LIV!-x ( 2 ) -G-x ( 4 ⁾ -G-T-U-iQ-x-CLIV! -

NAME: Uncharacterized protein family UPF0054 signature- CONSENSUS: H-CGS!-x-L-H-L-CLI!-G-CFYU!-D-H -

NAME-" Uncharacterized protein family UPF0057 signature- CONSENSUS: CLIV!-x-CSTA!-CLIVF! (3) -P-P-CLIVA!-[GA!-[IV!-x (4 ) - [GKN!- NAME: Hypothetical YER0S7c/yjjV family signature-

CONSENSUS: P-[AT!-R-[SA!-x-[LIVMY!-x (2) -[AK!-x-L-P-x ( 4 ) - [LIVM!-E-

NAME: Hypothetical hesB/yadR/yfhF family signature- CONSENSUS: F-x-[LIVMFY!-x-N-[PG!-[NSK!-x ( 4 ) -C-x-C-[GS!-x-S-F -

NAME: Hypothetical yabO/yceC/sfhB family signature- CONSENSUS: [NHY!-R-[LI!-D-x (2) -T-[ST!-G-[LIVMA!-[LIVMF! (2) - [LIVMFG!-[SGAC!-

Deposit of Clones Each clone has been transfected into separate bacterial cells (E- coli) in the composite deposit-

The clones are located and publically available from the Resource Center of the German Human Genome Project (Heubner Ueg bi 14D51 Berlini GERMANY)ι from which each clone comprising a particular polynucleotide is obtainable- The Resource Center library numbers are slightly different that those presented herei but may be readily obtained by the following key or with the assistance of Resource Center personnel.

The library name becomes a number: brain (hfbr2) becomes 5fa4i kidney (hfkd2) becomes 5bbi mammary carcinoma (hmcfl) becomes 727i testis (htes3) becomes 434i amygdala (hamy2) becomes 7blι melanoma (hmel2) becomes 7b2 and uterus (hutel) becomes 56fa- Nexti the plate number is converted to two digits (e.g-i ^Ll2" becomes "02") and is moved behind the plate coordinate! and the underscore is dropped. The following examples are helpful:

Listed Number Resource Center Number

DKFZphamy2_lDhl7 DKFZp7falH1710

DKFZphfbr2_7δi21 DKFZpSfa4I217δ DKFZphfkd2_3kl DKFZp5fabK013

DKFZphmcfl_lc23 DKFZp727C231

DKFZhmel2_12jl DKFZp7b2JD112

DKFZphtes3_lfab5 DKFZp434BD51fa

DKFZphutel_17k7 DKFZp5βfaK0717 The libraries were constructed using two commercially available vectors- The brain (hfbr2 designations) and kidney (hfkd2 designations) libraries utilize pAMP 1 from Life Technologies and are maintained in XL-2Blue (Strategene) i the amygdala (hamy2)ι testes (htes3) and melanoma (hmel2) libraries are constructed in pSPORTli also from Life Technologies! and are maintained in DH10B (LifeTechnologies) ■ In addition to the following techniques! consultation with the commercial literature available on these clones will make evident all of the housekeeping techniques needed to propagate and isolate the individual constructs- All inserts may be excised with a Notl/Sall digestion. Alternatively! universal pri ersi flanking the cloning regioni may be used to amplify the inserts using PCR methods- Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:

An oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone- This sequence can be derived from the sequences provided hereini or from a combination of those sequences- Methods of probe design are presented below-

Oligonucleotide probes may be labeled with -^3ΞP ATP (specific activity faOOO Ci/mmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides. Otheri non-radioactive labeling techniques can also be used- Unincorporated label typically is removed by gel filtration chromatography or other established methods- The amount of radioactivity incorporated into the probe can be quantified by measurement in a scintillation counter- Preferably! specific activity of the resulting probe generally should be approximately 4XlD^b dmp/p ole-

The bacterial culture containing the pool of full-length clones should preferably be thawed and 100 1 of the stock used to inoculate a sterile culture flask containing 25 ml of sterile L-broth containing ampicillin at 50 - 1DD g/ml (for XL-2Blue strains 25 g/ml tetracycline should also be used)- The culture should preferably be grown to saturation at 37°C-ι and the saturated culture should preferably be diluted in fresh L-broth- Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5D00 distinct and well-separated colonies on solid bacteriological media containing L-broth containing ampicillin at 10D g/ml (for XL-2Blue strains 25 g/ml tetracycline should also be used)and agar at 1-5 in a 150 mm petri dish when grown overnight at 37°C- Other known methods of obtaining distincti well-separated colonies can also be employed-

Standard colony hybridization procedures should then be used to transfer the colonies to nitrocellulose filters and lysei denature and bake them- The filter is then preferably incubated at fa5°C- for 1 hour with gentle agitation in fa x SSC (2D x stock is 175-3 g NaCl/literi δβ-2 g Na citrate/liter i adjusted to pH 7-0 with NaOH) containing 0-5C SDSi 1D0 g/ml of yeast RNAi and 10 mM EDTA (approximately 10 mL per 150 mm filter)- Preferably! the probe is then added to the hybridization mix at a concentration greater than or equal to 1X10*-* dpm/mL- The filter is then preferably incubated at fa5°C- with gentle agitation overnight. The filter is then preferably washed in 500 mL of 2 x SSC/D-5 SDS at room temperature without agitationi preferably followed by 5D0 mL of 2 x SSC/0-1 SDS at room temperature with gentle shaking for 15 minutes. A third wash with 0-1 x SSC/D-5 SDS at b5°C- for 30 minutes to 1 hour is optional- The filter is then preferably dried and subjected to autoradiography for sufficient time to visualize the positives on the X-ray film- Other known hybridization methods can also be employed.

The positive colonies are pickedi grown in culturei and plasmid DNA isolated using standard procedures. The clones can then be verified by restriction analysisi hybridization analysis! or DNA sequencing-

Alternatively! clones may be grown as described abovei and PCR used to isolate the insert DNAs- Methods of PCR are described below and are otherwise well known ■

ERROR SCREENING

The DNA sequences found herein derive from individual clonesi which are publicly availablei as noted above- Thusi the skilled artisan will recognize that any specific sequence disclosed herein readily can be screened for errors by resequencing a particular fragment! in both directions (.i . e. -, by sequencing both strands)- Alternatively! error screening can be performed by amplifying and/or cloning any of the inventive DNAsi using for example RT- PCRi and sequencing the resulting amplified product- In the event that there is a sequencing errori reference should be made to the deposited clone as the correct sequence-

USES AND BIOLOGICAL ACTIVITIES OF THE INVENTIVE MOLECULES

The inventive molecules and their derivatives are susceptible to a wide variety of usesi based on functional and/or structural properties. The skilled worker will appreciate! based on the biological activities detailed belowi and discussed with regard to the individual sequences hereini that the inventive molecules will find usefulness in numerous therapeutic and diagnostic applications.

The DNA moleculesi especially the potassium salts thereofi can be used as fertilizer supplements due to their high nitrogen and phosphorus contents- Since the DNAs are of defined lengthi they are also useful in gel electrophoresis as molecular weight markers. Due to their similarity with known moleculesi certain of the DNA molecules and their variants and derivatives may be used in any number of different diagnostic procedures and therapeutic applications- They may also be used to make the encoded proteins-

The proteins themselves have many possible uses- They may be used as a nutritional supplement for humansi animals and even for laboratory use asi for examplei medium for bacterial cultures- Moreoveri since the proteins are of definedi known sizesi they may be used as molecular weight markers for gel electrophoresis and gel filtration. Because they are of defined sequences! they also have use in microsequencing and protein fingerprinting applications.

Expression Profiling Applications

Given their known tissue expression and functional associations! assemblages of the inventive proteins (or corresponding antibodies) and nucleic acids are particularly suited to expression profiling applications- Expression profiling generally entails constructing an array of indicators that signal the presence of a particular RNA or protein expression product. Such arrays can be used to evaluate! for examplei pharmacological effectiveness and toxicity. In particulari expression profiles from such arrays can be generated from cells treated with known compounds! having known properties! and these profiles can be compared to profiles of unknowns to evaluate similarities and differences! which can be correlated with efficacy or toxicity.

Additional uses of profiling include diagnosis! tracking development! and ascertaining signaling and metabolic pathways- For examples of references describing profiling and its usesi see Farr et al . -, U-S- Patent 5ιδllι231 (111δ)i Seilhamer et al . -, U-S- Patent 5ιβ40ι464 (111δ)i Rine et al - -, U-S- Patent No- Sι777ιβδδ (1116) i UO 17/27317i UO 11/05323i UO 11/0121βi and UO 11/143b1. For a device for implementing such techniques! see Lipshutz et al . -, U-S- Patent No- 5ιδ5bιl74 (1111) and Anderson et al.-i U-S- Patent No- 5ι122ι511 (1111).

In one embodimenti a subset of the inventive DNAs will be arrayed on a substratei like a gene chipi a filter or a lb-well plate- Test samples containing cells are maintained in the presence of a label capable of incorporation into nascent mRNA- Samples are treated with test and control compoundsi which will induce mRNA expression in the samplei resulting in incorporation of label- Uhole mRNA is isolated and applied to the array such that it hybridizes with the DNAs contained therein- After washingi the amount of hybridization is quantified and a profile is generated. These steps are repeated with various control and test compoundsi thereby generating a library of profiles! which can be used to ascertain the relationships relevant to pharmacological efficacy or toxicity- The matrices used in such profiling! howeveri need not be limited to those utilizing DNAs- Ratheri other nucleic acidsi like RNAs and protein nucleic acids (PNAs)ι as well as the inventive proteins and antibodies corresponding to the inventive proteins may also be employed- Hencei for examplei antibodies could form the array and the samples could be treated in order to label nascent proteins- Uhole proteins then would be isolated and applied to the antibody matrix- Developing the resulting signal would result in a protein expression profile! which is useful in essentially the same manner as the nucleic acid profile- A protein matrix could be usedi for examplei in evaluating antibody responses to pharmaceutical agents in order to eliminate possible cross-reactivity- Moreover! where nucleic acids are used in the matrixi it is often beneficial to use variants (as defined below) of the molecules described hereinin- This can be used to account for genetic variations that are of little or no consequence to the function of the resultant gene product- Hencei they can account for wobble or conservative amino acid variations that do not perturb function! like variations in some of the protein motifs elucidated below- Thusi each position in the matrix can employ multiple nucleic acid probes that account for a series of variants - Expression profiling may also be donei in another embodiment! using two-dimensional protein gels in which the inventive proteins are detected- The resultant profiles can be used in the same way as described- Matrices useful for profiling may be constructed based on different criteria- Of coursei the more relevant profiles will take into account expression of most human genesi preferably all of them- In certain situationsi howeveri it is advantageous to look at a smaller subset- For examplei if one were concerned about fetal neural toxicityi a fetal brain-specific matrix might be chosen- On the other handi if one were interested in targeting mammary carcinoma tissuei a corresponding matrix could be used- Thusi matrices may be constructed using all of the sequences available from a tissue-specific library-

* * * The following discussion relates to some of the various functional and structural groupings that would be of interest to the artisan wishing to construct profiling matrices- Of coursei the artisan will also recognized that these functional descriptions may find additional applicability in the therapeutic and diagnostic applications discussed below-

Cell Cycle

A proliferating cell must coordinate replication and chromosomal separation to ensure that the genome is replicated completelyi and that a single copy is correctly inherited by each daughter cell- The cell cycle is the coordinated series of events that achieves these aims- Many of the key events are initiated by a family of conserved Seiren/threonine protein kinasesi the cyclin-dependent kinases (CDKs)ι that are activated by the cyclin family of proteins (cyclins A-H)- In turni the cyclin-CDK complexes are modulated by other protein kinases or phosphatasesi and by binding specific inhibitor proteins- The enormous variety of ways in which CDK activity can be regulated allows the cell to respond to internal signals generated by preceding events in the cell cycle and to external growth signals-

The somatic cell cycle is divided into four phases: DNA replication (S phase) and chromosome separation (M phase) are separated by gap phases (GI and G2)- At specific control points the decision to begin the next stage (DNA synthesis or mitosis) is carefully regulated-

Cdc2ι the primary kinasei is especially required for the Gl- S transition and S phase- Cdc4 and Cdcfa are involved at the restriction pointi where the cell can decide to proliferate or arrest (GK->GD) and Cdc7 is a CDK activating kinase (CAK) as well as a subunit of TFIIH-

The Cyclin-CDK complexes are regulated in various ways- One is through phosphorylation by CDK activating kinases (CAK)ι like the Y15 kinase (Ueel) and dephosphorylation by CDK associated phosphatases (CAP)ι like Cdc25A a member of the Cdc25 family

An other way of regulation occurs through two classes of CDK inhibitors (CKI)ι the INK4 proteins pl5ι plfai plδi and plli who negatively regulates the cyclin D CDK complexes and second the p21 family with p21ι p27ι and p57-

The cell cycle is also regulated through ubiquitin-mediated proteolysis involving the destruction of both cyclins and CDK inhibitors by the 2faS proteasomei that requires an ubiquitin conjugating enzyme (UBC) and an ubiquitin ligase- The instability is conferred by PEST regions (cyclin D and E) or a ten amino acid region in the amino terminus (degradation box) in the A- and B- type cyclins-

All these modifications play an important role for the cellular localizationi because only the nuclear CDK-cyclin complexes are functional for cell cycle- During GI phase of the cell cyclei cyclines Ai E and D are synthesized and bind to their cyclin-dependent kinase (CDK) partners- CDK complexes containing cyclins Ai E and DI are then imported into and concentrated within nuclei- Cdkfa- cyclin D3 has been localized to both cytoplasmic and nuclear compartmentsi although only the nuclear complex is active- As cells enter S phasei cyclin A and cyclin E complexes remain within the nucleusi whereas cyclin DI relocalizes to the cytoplasm for proteolysis at the onset of S phase- Like Cdk2-cyclin Ai Cdc2-cyclin A is nuclear and remains so until it is degraded during mitosis- By contrasti as a result of ongoing nuclear import and more rapid re-exporti cyclin Bli which binds to Cdc2 upon synthesis during S phasei is predominantly cytoplasmic. Cdc2-cyclin B2 is also cytoplasmici although this might occur through anchoring of the complex to some cytoplasmic constituent- At prophasei phosphorylation of cyclin Bl promotes accumulation of Cdc2-cyclin Bl in the nucleusi whereas cyclin B2 remains in the cytoplasm until nuclear envelope breakdown.

Two crucial regulators of Cdc2-cyclin B-Ueel and Cdc25C exist and are responsible for the G2 to M control point- Ueel is a nuclear protein throughout the cell cyclei whereas Cdc25C binds to 14-3-3 proteins during interphase and remains predominantly cytoplasmic. In some systems Cdc25Cι like cyclin Bli rushes precipitously into the nucleus just before entry into mitosis-

The 110-kDa retinoblastoma (tumor suppressor) protein (RB)ι a pRB-family member is an important regulator of cell-cycle progression and differentiation- Like the E2F family (E2F1-5) or DP family (DP1-3) of transcription activatorsi RB suppresses inappropriate proliferation by arresting cells in GI by repressing the transcription of genes required for the transition into S phase- Before the cell proceeds into S phasei RB becomes phosphorylated at multiple sites by the cyclin dependent protein kinases (CDKs) and loses its transcriptional repressing activity- Phosphorylation of RB during late GI phase results in the dissociation of the E2F-RB repressor complex which allows S-phase specific genes to be transcribed- Cyclin E is the evolutionary conserved target for E2F and interacts together with CDC2 in late GI-

For a proliferating cell it is vital that only undamaged DNA is replicated because if DNA damage is substantial! its replication can lead to chromosome loss or rearrangement. Thusi we find a GK->S checkpoint in late GI that requires tumor suppressor p53- A p53-dependent GI arrest is effected by the cyclin dependent kinase inhibitor p21 through higher expression levels that inhibits almost all cyclin CDK complexes.

The kinase responsible for phosphorylating the unidentified kinetochore component in metaphase may be a member of the MAP kinase family and appears to be the proto oηcogene c-M0Sι a cytostatic factor (CSF) in meiosis.

Several categories of proteins are coded for by clones of the invention within the overall group of Cell cycle"and includei among othersi the following:

PA2fa-T2 protein: PA2fa-T2 is a p53 responsive gene- The protein is predominantly expressed in braini breast and kidney and represents a novel regulator of cellular growth- Isoforms are differentially induced by genotoxic stress (UVi gamma-irradiation and cytotoxic drugs)in a p53-dependent manner- The p53 tumor antigen is found in increased amounts in a wide variety of transformed cells- The protein is also detectable in many actively proliferating! nontransformed cellsi but it is undetectable or present at low levels in resting cells- P53 is postulated to bind as a tetramer to a p53-binding site (PBS) and to activate the expression of adjacent genes that inhibit growth and/or invasion- Deletion or inactivation of one or both p53 alleles reduces the expression of tetra ersi resulting in decreased expression of the growth inhibitory genes- This mechanism is found in tumors of several types- (OMIN *111170) Clones in this category include: amy2_121m2 Cell structure and motility

One of the major differences between prokaryotes and eukaryotes is the ability of the eukaryotic cell to adopt very different shapes dependent on its function during the differentiation process- Animal cells vary from being round to extended cylindric forms like motorneurons or muscle cells- In humansi more than 1D0 different cell types can be distinguished! each having a characteristic shape- The form of a cell often is closely related to its capacity to move- Some completely differentiated cells like fibroblasts can still change their form actively! thereby migrating. Other cell types serve as motor elements - "macroscopically¹¹ like muscle cells or "microscopically" like ciliated epithelia. Such tasks are fulfilled by a big class of proteinsi on the one hand responsible for maintenance of cell structure and contacting neighbor cells or the intercellular matrix and on the other hand for cell motility. These topics cannot be regarded separately: The motility apparatus e-g- must be fixed in the cytoskeleton ■ Three different types of filaments can be distinguished: Actin filamentsi tubulin filaments and intermediate filamentsi each present in almost all types of cells.

Actin filaments (F-actin) are built up of monomers (G-

Actin). In muscle cellsi actini myosini for both of which several paralogous genes are knowni as well as many more proteins are constituents of the contractile apparatus-

The "thin" and "thick filaments¹¹ in a muscle cell consist mainly of actin and myosini respectively-

Several different proteins are responsible for the anchoring of the actin filaments in the Z-disks (e-g- alpha-actinin and desmin) or at the end of the myofibers in the cell membrane-

Troponin Ii -Ci -T and Tropomyosin - associated with actin - confer the Ca++- dependent triggering of contraction. Length of the sarcomere is controlled by the giant protein titin-

In smooth musclei there is no troponin- Contraction activity is controlled by phosphorylation / dephosphorylation of myosin by a specialized kinase instead. Contractile fibers are not organized in sarcomeres-

Apart from contributing to muscle contraction! the actomyosin system is responsible for many other motions at cellular leveli e-g- the amoeboid movement of pseudopodia or the fission of cells at the end of mitosis by a contractile ring.

Besides thisi actin fibers fulfill structural tasks like maintenance of the shape of stereocilia or microvilli- Herei actin filaments are connected by proteins like fimbrin- But not only specialized structures like the mentioned ones contain actin fibers- There is a network covering the complete cell volume with F-actin as a major constituent. Uhereas the actin filaments in the structures mentioned above are relatively stablei this F- actin is highly dynamic- Management of the network structure and turnover is achieved by connecting proteins like alpha-actinini fimbrin or fill-ini turnover is regulated by gelsolini villini and different capping- and fragmentation-proteins-

Microtubules are built up of alpha-beta tubulin heterodi ers- Turnover of filaments is achieved by building-in and releasing of monomers with different time constant rates at both ends- The resulting cycle is called "treadmilling" ■ Thirteen strings of tubulin duplets build up one subfiberi whereas one fiber contains two or three of those- A complete axoneme consists of 1 radial and 2 central fibers- This "1+2" - structure is the basis both of flagellai their basal bodies and centrioles- In flagellai several additional structures like radial elements exist- Nexin connects the fibers and dyneine is the motor ATPase which shifts the fibers relative to each other- Several genetic diseases like the Cartageneric syndrome are caused by deficiencies of distinct proteins in cilia-

Besides thisi microtubules are abundant in all types of cells- They are part of a delivery system for organellesi e-g- in the golgi apparatus- A further very important system based on microtubules is the mitotic spindlei it is organized by the centrosomes- Besides many other components! the major part of a centrosome are two centrioles which are built up of nine microtubule-triplets- Most remarkablyi new centrioles are not synthesized de novo but generated by duplication of old ones-

Cytoplasmic microtubules are associated with many different proteins- Two major classes are known: The MAPs ("microtubule- associated proteins¹¹! with molecular masses between 20D and 300 kD) and the much smaller tau-Proteins with a MU between bO and 70 kD- These proteins regulate the treadmill-process and the interaction with other structures in the cell-

Besides actin and myosin the so-called intermediate filaments constitute a third class of filaments- In contrast to the former two groupsi they do not participate in motilityi nor are they dynamic structures subject to a vivid turnover- The most important ones are neurofilaments (in neurons)ι keratin filaments (mainly in epithelial cells)ι and vimentin filaments (in many sorts different cell types)-

The biological function of both the cytoskeleton as well as contractile apparatus of a cell does not end at the cell membrane. Cells must be embedded in the extracellular matrixi all cells of a muscle must act as one single mechanical unit and epithelia must resist macroscopic mechanical forces- Hencei cell adhesion and the extracellular matrix are closely connected to the cytoskeleton- Vincullin is one of the proteins which serve as an anchor for intracellular fibers (actin)- Different types of desmosomes and tight junctions connect neighbor cells with intercellular fibers- On the insidei cytoplasmic plaques connect them to the cytoskeleton- These structures! on the one handi serve as mechanical elements whereas gap junctionsi on the other handi connect cells metabolically -

The extracellular matrix consists of a network of proteinsi glycoproteins and polysaccharides- Different proteins are present in relation to different mechanical demands:- Elastin is found in tissues with high elasticity (lungsi heart) whereas collageni a more hard-wearing proteini is found in tendons and ligaments- Fibronectin is an extracellular protein highly important for cell adhesion-

Reference: Murray J et al (1112): Cell Motil Cytoskeleton 22"- 211-223-

Uithin the overall group of Cell Structure and Motility several categories of proteins are coded for by clones of the invention:

Ankyrins: Ankyrins are peripheral membrane proteins which interconnect integral proteins with the spectrin-based membrane skeleton. Thus these proteins are involved in coupling of cyto skeleton and cell membrane. OMIN reports that Ankyrins have associations (as potentially diagnostic! therapeutic! causativei and/or relatedi etc..) with the following diseases: 1) Heriditary Spherocytosis (OMIN *162100)i 2) Hemolytic Poikilocytic Anemia due to reduced ankyrin binding sites (OMIN 14170D)i 3) Atypical Elliptocytosis (OMIN 225450)i 4) Autosomal recessive spherocystosis (OMIN #270170)i 5) Uerner Syndrome (OMIN *277700)i and b) Rhesus-unlinked type Elliptocytosis (OMIN #130b00). Ankyrin bindung glycoprotein proteins mediate Ankyrin effectsi especially in neuronal adhesion and prostate tumour vcell transformation: Clones in this category include: amy2_121fl1.

Tropomyosins are ubiquitous proteins of 35 to 45 kD associated with the actin filaments of myofibrils and stress fibers. They are involved in cardiomyopathies (OMIN *111030ι *11101Dι *11011Dι *fa00317)- Clones in this category include: tes3_lbb5-

Differentiation/Development

Almost every multicellular organism originates from meiotic cell divisions and the recombination of a paternal and a maternal set of chromosomes- After fertilization of the eggi all cells of a body originate from this one cell- Thus the cells of the developing body are initially genetically alike- But phenotypically they become very different- They are specialized to a certain cell type and arranged in an organized pattern to a certain type of tissue and the whole structure has the well- defined shape of an organ. All these features are determined by the DNA sequence of the genomei which is reproduced in every cell- Each cell acts on the genetic instructions given to a certain time and at a certain place of development and plays its individual part in the multicellular organism- Cell differentiation may be divided into three general steps: cell cycle exiti apoptosis protection and tissue specific gene expression- These processes are coordinated to provide the final and unique tissue characteristics-

An animal cell that has achieved a certain level of development is said to be determined- This differentiation of a cell may be irreversible and in that case the cell may be renewed only by simple duplication- Other cells are renewed by means of stem cells which are immortal ( e-g- stem cells of the bone marrowi epidermal stem cells). The genetic control of development is extensively studied in non-vertebrates and vertebrates- The classical animal model is the fruit fly Drosophilia and the modern model is the transgenic mouse. Animal transgenesis has proven to be useful for physiological as well as physiopathological studies- Besides the approach based on the random integration of a DNA construct in the mouse genomei gene targeting can be achieved using totipotent embryonic stem cells for targeted transgenesis. Transgenic mice are than derived from the embryonic stem cells- This allows the introduction of null mutations in the genome (so-called knock-out) or the control of the transgene expression by the endogeneous regulatory sequence of the gene of interest (so-called knock-in). Mice can be created that express wild-type genesi mutant genesi marker genes or cell lethal genes in a tissue specific manner- These animal models allow to follow changes in tissue and organ development and lead to a better understanding of the cellular function of many genes or to the generation of animal models for human diseases- Fundamental problems in immunology! onset and development of canceri regulation in fatty acid metabolismi aspects of cardiovascular function! control of the central nervous system development! analysis of reproductive development and function are only some examples of research interests. The final stage of cell differentiation is growth arrest- In animal tissues with rapid cell turnover terminally differentiated cells undergo programmed cell death- The cells have the ability to kill themselves by activating an intrinsic cell suicide program when they are no longer needed or have become seriously damaged- The execution of this program is termed apoptosis- Apoptosis is of importance for development and homeostasis of animals- The key components of this program have been conserved in evolution from worms (C- elegans) to insects (Drosophilia) to humans- The roles of apoptosis include the sculpting of structures during development! deletion of unneeded cells and tissuesi regulation of growth and cell numberi and the elimination of abnormal and potentially dangerous cells- In this way apoptosis provides "quality control mechanism" that limits the accumulation of harmful cellsi such as virus-infected cells and tumor cells- On the other hand inappropriate apoptosis is associated with a wide variety of diseases! including AIDSi neuro-degenerative disorders and ischemic stroke. Because it is now clear that apoptosis is a result of an activei gene-directed processi it should be eventually possible to manipulate this form of cell death by developing drugs that interact with its recently identified mechanisms of action. Inducers of cell differentiation! cell cycle arrest and apoptosis might be the novel molecular targets for new anticancer agents in addition to the signaling pathways for growth factors and cytokines-

Proteinsi factorsi receptors and genes of importance in apoptosis:

Proteases :

- Calpaini an intracellular cysteine proteasei exact role unknown-

- Caspase-1 to Caspase-lli a family of proteases synthesized as an inactive proenzyme- Targets of the activated enzymes include: poly (ADP-ribose) polymerasei DNA-dependent protein kinasei Ul ribonucleoprotein! nuclear la inins and cytoskeleton components (actin)- - Granzyme Bi a serine protease released by cytotoxic T- cells-

Receptors :

- CD 15 (synonyms: Fasi AP0-l)ι a receptor protein of the TNF-receptor family which includes TNF-Rl and TNF-R2 with the common characteristic of a 70 amino acid cytoplasmic domain-

- FADD (synonym: MORT-Di a cytoplasmic protein

- DR-3 (synonym: APO-3) a member of the TNF-receptor-family

- DR-4 and DR-5

Genes:

- ced-3ι ced-4 and ced-1 encode the general apoptotic and antiapoptotic program in Caenorhabditis elegans- Apaf-3 is the mammalian homologue of ced-3-

- Bcl-2 / Bcl-xL / Bax / Bcl-xS / Bak: a large gene family that can either inhibit or promote apoptosis-

- Cytokine response modifier Ai a cowpox virus gene whose gene product inhibits caspases-

Others:

- Caspase-activated DNase (CAD) and its inhibitor (ICAD)ι causes DNA fragmentation in the nucleus

- Ceramidei a complex lipid that acts as a second messenger-

- c-Jun N-terminal kinase (JNK) is a proline-directed kinase

- p53 proteini is essential for the induction of apoptosis as a response to chromosomal damage-

- RAIDDi a death signal-transducing protein-

- Receptor interacting protein (RIP) is an accessory protein with a death domain and a serine/threonine kinase activity- - Sphingo yelinasei an enzyme that hydrolyzes the complex lipid sphingomyelin to ceramide-

- Tumor necrosis factor (TNF) is a type -II membrane protein

- TNF-receptor associated factor (TRAF2)ι is an accessory protein that can bind to both TNF-Rl and TNF-R2-

Uithin the overall group of Differentiation/Develop ent i several categories of proteins are coded for by clones of the invention:

Notch family proteins: Notch family molecules are negative regulators of neuronal differentiation in early brain development- Clones in this category include: amy2_li24-

Testis-specific Y-encoded proteins: The TSPY genes are arranged in clusters on the Y chromosome of many mammalian species. TSPY is believed to function in early spermatogenesis and is a candidate for GBYi the putative gonadoblastoma-inducing gene on the Y. These proteins are involved in early spermatogenesis. Clones in this category include: amy2_7j5-

Inflammation-mediating proteins: Inflammation is a basic mechanism responsible for recruiting and activation of im un- competent cells- By various mediators! cells are activated and triggered to differentiate- Hyperactivation of these pathways leads to various disease states: In neuronal tissuesi in inflammatory diseases such as experimental autoimmune encephalomyelitis (EAE)ι neuritis (EAN) and uveitis (EAU) allograft inflammatory factor-1 is produced by macrophages and microglia cells- Clones in this category include: amy2_2bl1-

Intracellular transport and trafficking Eukaryotic cells rely for their viability on the partitioning of many basic cellular processes into membrane- bounded organelles. These are the nucleusi endoplasmic reticulum (ER)ι Golgi apparatus! endosomesi lysosomal compartments! mitochondria and peroxisomes- Most molecules destined for the lysosomei cell surface and outside the cell are routed through the ER and Golgii which together with the vesicular intermediates between themi comprise the secretory pathway (Palade 1175). In the ER and Golgi compartments proteins are sortedi modified and often assembled into complexes en route to their final destination- Incorrectly assembled proteins are retained in the ER until they fold correctly or are targeted for degradation- Additional proteins are translocated into and function within the lumenal spaces of organelles or are secreted- Thus a large proportion of proteins synthesized require targeting to membranes either for insertion into or transport across them- A major purpose of this is growth- The secretory pathway is dependent on an intact cytoskeleton and also closely linked to general metabolism by affecting ribosome biogenesis (Mizuta and Uarneri 1114). A huge number of proteins is required for targeting! translocation and sorting of newly synthesized proteins-

The first step in sorting is the recognition of cis-acting targeting or signal sequences that organelle-targeted proteins contain. This is carried out by cytosolic targeting factors and/or receptors on the membrane to which the protein is targeted- In some cases the primary sequences are extremely degenerate! with only the overall character being conserved (hydrophobicity for an ER signal sequencei helical amphiphilicity for mitochondrial targeting sequence (Kaiser et al - -, 1187i Lemire et al - -, 1161)- Following the targeting stepi proteins are either inserted into or transported across the membrane (translocated) through a proteinaceous apparatus (termed the translocon). The translocon include or recruit motors to drive the translocation process in the correct direction (Schatz and Dobbersteini 111b). Defined intracellular protein transport steps: ■ ER

- targeting to the ER

- translocation into the lumen of the ERi andi depending on the presence of certain signals in the peptide sequence transport through the golgi complex ■ Mitochondria

- targeting

- translocation ■ Peroxiso es ■ The general secretory pathway

- protein modification! assembly and quality control in the ER

- vesicle-mediated trafficking - vesicle docking and fusion

- transport through the golgi apparatus and sorting at the trans-golgi

- transport to the cell surface

- transport routes to the lysosome ■ Endocytosis

■ Specialized protein transport routes

■ Protein export from the cytoplasm

References: Paladei G (1175) Science lδ1:347-35δi Mizuta et al. (1114) Mol Cell Biol 14: 2413-2502i Kaiser et al - (1167) Science 235: 312-317i Lemire et al - (1161) J Biol Chem 2b4: 2D20b-2D215i Schatz et al. (111b) Science 271: 1511-152b.

Rab proteins

In eukaryotic cells the compartmentalisation of processes is a prerequisite for a tight regulation of processes and activities- The cells contain a highly dynamic set of membrane compartments that are responsible for packaging! sortingi secretingi and recycling proteins and other molecules- Trafficking between organelles within the secretory pathway occurs as vesicles derived from a donor compartment fuse with specific acceptor membranesi resulting in the directional transfer of cargo molecules- This process is tightly controlled by the Rab/Ypt family of proteins (reviewed by Novick and Zeriali 1117) i a branch of the superfamily of small GTPases- Rab proteins regulate a variety of functions! including vesicle translocation and docking at specific fusion sites- Rabs may also play critical roles in higher order processes such as modulating the levels of neurotransmitter release in neuronsi a likely mechanism in synaptic plasticity that underlies learning and memory (Geppert and SUdhofi 1116)- Small GTPases share a common three-dimensional fold thati in the GTP bound statei can bind a variety of downstream effector proteins- GTP hydrolysis leads to a conformational change in the "switch" regions that renders the GTPase unrecognizable to its effectors- In this wayi by localizing and activating a select set of effectorsi a common structural motif is used to control a wide array of distinct cellular processes-

The final steps in membrane fusion are likely to be driven by a set of proteins known as SNAREs- After a vesicle becomes dockedi the cytoplasmic domains of VAMP (also termed synaptobrevin) and syntaxin on opposing membranesi in combination with a SNAP-25 moleculei coalesce into an elongated -helical bundle (Poirier et al-i lllβi Sutton et al-i 111β)ι which may lead to fusion- Because numerous SNARE isoforms have been identified that localize to distinct membrane compartments! it was originally proposed that the specificity of interaction between the SNARE proteins accounted for the specificity in membrane trafficking- Recent resultsi howeveri suggest that SNAREs are not specific in their ability to form complexes in vitroi suggesting that trafficking specificity requires additional factors (Yang et al-i 1111)- In this regardi Rab proteins are strong candidates for governing the specificity of vesicle trafficking. Like the SNAREsi many isoforms (40) of the Rab family have been identified that localize to specific membrane compartments (reviewed by Novick and Zeriali 1117).

Concomitant with the SNARE cyclei Rab proteins undergo a intricate cycle of membrane and protein interactions. Rabs are posttranslationally modified at C-terminal cysteines by the addition of two geranylgeranyl groupsi which mediate membrane association when the Rab is in the GTP-bound state- After guanine nucleotide hydrolysis occursi the Rab is extracted from the membrane upon forming a complex with a cytosolic GDP-dissociation inhibitor (GDI)- This cytosolic intermediate is then recycled onto a newly forming vesiclei most likely through a secondary factor termed a GDI dissociation factor (GDF)ι which displaces GDI- After the Rab becomes membrane boundi a guanidine nucleotide exchange factor (GEF) promotes release of GDP and the subsequent loading of GTP- In its GTP-bound conformation! the Rab is then free to associate with its specific set of effectorsi which can in turn trigger events leading to the eventual fusion of the vesicle with a target membrane- To complete the cyclei perhaps after or concurrent with membrane fusioni a GTPase activating protein (GAP) accelerates nucleotide hydrolysis! switching off the GTPase. The remaining GDP-bound Rab can then participate in a new round of fusion-

Rab interactions with effectors are likely to regulate vesicle targeting and membrane fusion in three ways- Firsti a Rab may specifically facilitate vectorial vesicle transport- Vesicles are transported from their site of origin to acceptor compartments likely through associations with cytoskeletal elements and transport motors- A protein has been identified with a domain structure that suggests a connection between the cytoskeleton and the Rabs- This proteini called Rabkinesin-fai contains a kinesin-like ATPase motor domain followed by a coiled- coil stalk region and a RBD that specifically binds Rabfa (Echard et al-i 1116 )• An additional link with the cytoskeleton is provided by the Rab effectori Rabphilin-3A ■ Rabphilin-3A has been shown in vitro to interact with -actinini an actin-bundling proteini but only when not bound to Rab3A (Kato et al-i lllfa )■ These results raise the intriguing possibility that Rab proteins regulate vesicle interactions with the cytoskeleton and thereby play an active role in targeting vesicles to their appropriate destinations-

Secondi Rab proteins may regulate membrane trafficking at the vesicle docking step- A number of Rab effectorsi including Rabaptin-5ι EEAli Rabphilin-3Aι and Rimi may serve as molecular tethers- Each effector protein contains a RBDi followed by a linker region (some having the potential to form elongated coiled-coil structures)! and a domain capable of interacting with a second Rab or the target membrane- Rabaptin-5ι for examplei contains two RBDsi one near the N terminus that specifically recognizes Rab4 and a second near the C terminus that binds Rab5 (Vitale et al-i lllδ )- Both Rimi which is localized to the target membranei and Rabphilin-3Aι which is localized to the vesiclei contain N-terminal RBDs and C-terminal Ca2+-binding C2 domainsi implicating these effectors in synaptic vesicle localization or docking in response to Ca2+ influx (Uang et al-i 1117 ) ■ Tethering effectors may also recognize protein complexes on the acceptor membrane- Sec4pι a yeast Rab3A ho ologi interacts with the exocyst (Guo et al-i 1111 )ι a complex of seven or more subunits that is assembled at sites of vesicle fusion along the plasma membrane- The exocyst complex may therefore function as a landmark for Rab/effectoi—mediated vesicle docking-

Thirdi once a vesicle has become tethered to its fusion sitei Rab proteins may selectively activate the SNARE fusion machinery. The mechanism of this activation is unknown but may involve direct interactions of Rabs ori more likelyi their effectors with SNAREs- For examplei Hrs-2 is a protein that binds to SNAP-25 and contains a Zn2+-finger motif characteristic of Rab-binding proteins such as Rabphilin-3Aι Rimi EEAli and Noc2ι suggesting that Hrs-2 may form a physical link between Rabs and SNAREs (Bean et al-i 1117)- In addition! certain mutations in the syntaxin-binding protein Slylpi the Seclp homolog utilized in ER to Golgi trafficking! eliminate the requirement for Yptlpi a Rab protein that functions at this trafficking step (Dascher et al-i 1111 ) • Rabs may therefore regulate SNARE associations through Seel family members. In support of this ideai a Rab effector was recently found to interact with a vacuole Rabi a Seclp homologi and a SNARE protein (Peterson et al-i 1111 )ι which suggests that this effector serves to connect Rab and SNARE function- In this wayi Rabs and their effectors may facilitate the correct pairing of SNAREs.

References: Dascher et al. (1111) Mol- Cell- Biol- 11-, 672- 665i Echard et al- (lllδ). Science- 271ι 5δ0-565i Geppert et al- (1116) Annu- Rev. Neurosci- Ξl-i 75-1Si Guo et al. (1111). EMBO J. lδi 1071-lOδOi Kato et al. (lllfa) J- Biol- Chem- 271ι 31775- 3177βi Novick et al. (1117) Curr- Opin. Cell Biol- li 41fa-5D4i Peterson (1111) Curr. Biol- li 151-lb2i Poirier et al. (1116) Nat- Struct- Biol- 5ι 7b5-7fa1i Vitale et al- (1116) EMBO J- 17ι 1141-115U Uang et al. (1117) Nature- 3δδι 513-51βi Yang et al- (1111) J- Biol- Chem- 274ι 5fa41-Sfa53-

Uithin the overall group of Intracellular Transport and Trafficking several categories of proteins are coded for by clones of the invention-

Vesicular trafficing: Various proteins are involved in trafficing of vesicles inside the cell and for the exocytotic pathway- For examplei See? of Saccharomyees cerevisiae takes function in vesicular traficking. Synaptotagmins are essential for Ca (2+)-regulated exocytosis of neurosecretory vesicles. Other proteins such as Dynamin are microtubule-associated force- producing proteinsi which are involved in the production of microtubule bundles.^" By binding and subsequent hydrolysation of GTP such proteins provide the motor for vesicular transport during endocytosis- Clones in this category include: amy2_14b5ι amy_2ol3 and fkd2_3kl-

Protein sorting: Protein sorting is a process essential for the maintenance of a cells functionality and structural integrity. Most proteins perform their biological function in special compartments in the cell-The process of sorting is complex and highlky regulated. Clones in this category include: mel2_7gl4.

Metabolism

This group includes proteins which are involved in the uptake and consumption of nutrientsi and enzymes which are part of the biochemical pathways for energy metabolism or which are involved in the supply of building blocks of nucleic acidsi proteins (NTPsi dNTPsi amino acids) for DNA/RNA and protein synthesis! and fatty acids (membranes)ι to allow for the generation of higher order structures- This group constitutes the most important and largest group in prokaryotes and lower eukaryotes- The higher the evolutionary level of an organism isi however! the more other protein classes like "-signal transduction^"11 ^Lcell cycle¹ and differentiation and development^"1 increase in importance and number of representatives.

Proteins involved in the metabolism of energy and compounds (here: other than nucleic acids or proteins) are usually the products of house keeping genesi they are often constitutively and/or ubiquitously expressed- Several categories of proteins are coded for by clones of the invention within the overall group of Metabolism:

Fatty acid metabolism: OMIN lists more than 50 diseases caused by pathologic altered fatty acid metabolism- 1-acyl- glycerol-3-phosphate acyltransferase is involved in fatty acid metabolism and is ubiqitous expressed! with a slight predominance in uterusi placenta and foreskin- Clones in this category include: amy2_2c22 Repair and surveillance nf protein damage: Several classes of protein are involved in reapair and surveilance of protein damage. L-isoaspartyl methyltransferase (Pimt)ι as an examplei is a highly conserved enzyme utilising S-adenosylmethionine (AdoMet) to methylate aspartate residues of proteins damaged by age- related isomerisation and deamidation- Clones in this categroy include: fbr2_7βi21-

Nucleic acid management

The genetic information is stored in the form of nucleic acids in all organisms- Two kinds of nucleic acids existi DNA and RNA- Uhereas the more stable DNA in most organisms constitutes the storage form of the genetic information! the labile RNA and in particular mRNA is an intermediate used for the temporal expression of specific genes- In eukaryotesi DNA is usually a double stranded linear molecule consisting of two antiparallel strands and made up of a deoxyribosei a phosphorus backbone and the four bases Ai Ci Gi and T- The DNA of some organisms has a ring structure- The structure of DNA was unraveled years ago by Uatson and Crick- DNA is directional molecule determined by the C-atoms of the sugar-

The most important processes dealing with nucleic acids are :

• replication (e-g- DNA poly erasesi Telomerase)

• transcription (RNA polymerases)

• RNA processing (maturation - splicing and degradation) • in addition! enzymes and proteins exist which require a nucleic acid (mostly RNA) in the active center to be functional (ribozymes - e-g- RNasei Ribosomal proteins)

The DNA of a cell is replicated in the S-phase of the cell cycle- Several enzymes carry out the task of doubling this nucleic acid- As all steps of the cell cyclei also the process of replication is tightly regulated- The enzyme DNA polymerase and several other proteins are involved in this process. Uhereas many prokaryotes do have only one origin of replication (i-e-i the starting point of the replication cycle)ι in eukaryotic DNAs (chromosomes) multiple such start points exist- The switch from the synthesis (S) phase to the subsequent G2 or M phases of the cell cycle are dependent on the completion of the replication. This makes cleari that a number of proteins are involved in the replication itself as well as in the control of the process. Since most eukaryotic chromosomes are linear structures! additional proteins and enzymes are necessary to make sure that the structure is maintained through successive generations. This includes those proteins necessary to build the three dimensional structure of chromosomes (e-g- histones) and the structural network of the nucleus and nucleolus (including the defined localization of transcriptionally active genes in the vicinity of nucleoli) but also such enzymes as telo erase which guarantees the integrity of the chromosomal ends.

The expression of genes is usually performed in two steps. First a messenger RNA (mRNA) is produced (transcribed) in one to many copies and second this mRNA is translated into the protein product- The regulation of transcription is discussed under the separate heading "-transcription factors^πι but also the classes "-signal transduction^"11 '-development^'' i ^Lcell cycle¹ and others are affected as the expression of certain genes determines the fate of a cell or organism- The primary transcript (hnRNA - heterogeneous nuclear RNA) is a single stranded one-to-one copy of the gene as it is located on the chromosome- Before a protein can be translated! already during transcription the process of maturation is initiated- Firstlyi a 5^"" cap structure is enzymatically and covalently added to the RNAi blocking the 5^"1 end of the RNA- Secondi when the RNA polymerase has terminated polymerizationi the enzyme poly A polymerase adds varying numbers of adenine residues to the 3¹ end of the transcript. This enzyme recognizes the sequence AAUAAA or AUUAAA (+ some minor variations)! cuts the RNA 10 - 30 nucleotides downstream and adds the A residues- The size of the poly A sequence affects the stability of the RNA- Finallyi in the process of splicingi the introns present on the genomic level and also present in the hnRNA are spliced out by a multi-protein complex consisting of several proteins and RNAs- The finally maturated mRNA is exported to the cytoplasm where it is translated with help of the ribozymes.

The half life of RNA is usually much shorter than that of DNA- Usuallyi the mRNA is degraded shortly after synthesis! to guarantee a very defined window of expression of a given gene- This regulation is necessary to specifically maintain or change the set of proteins present at any time in a cell- Specific regions in the 3^""UTR (untranslated region) determine the stability of the mRNA in the cytoplasm before it is degraded by RNasesi enzymes consisting both of protein and RNA-

References: Uatson and Crick (1153) Nature 171". 737-736- Several categories of proteins are coded for by clones of the invention within the overall group of "Nucleic acid management"and includei among othersi the following:

Proteins induced by DNA-Damage: There are several distinct pathways responsible for repair of DNA- Nucleotide excision repair is the most versatile DNA repair pathway and isthe main defense of mammalian cells against UV-induced DNA damage- Defects in proteins involved in this pathway can lead to inherited disorders (such as xeroderma pigmentosu OMIN *276700ι *276720ι *27δ740 and *114400i Cockayne's syndrome OMIN *21b400 and trichothiodystrophy OMIN #b01b75). Study of UV-sensitive yeast RAD mutants has greatly aided this process and has revealed strong conservation of the components of nucleotide excision repair in eukaryotes- Clones in this category include: amy2_lln4 and tes3_10ilb-

Proteins involved in Loading of transferRNAs : transfer RNAs must be coupled to an aminoacidi which then is transported to the peptideyl-transferase centre of the ribosome. Clones in this category include: fbr2_7δcl2-

Cytosolic ribosomal proteins: Several proteins are part of the eukaryotic ribosomal peptidyl transferase center or modulate the activity of this centre- Such proteins can find application in modulation of ribosome assembly! maintenance and activity. Clones in this category include: amy21il

Histones: Histones are DNA-binding protein responsible not only for DNA structure and folding and packingi but also are discussed to be involved in activation and silencing of large chromosomal regions- Clones in this category include: tes3_31al0-

mRNA-binding proteins: mRNA-binding are involved in regulation of mRNA foldingi translation and stability- For examplei the VILIP protein binds specifically to the 3'untranslated region of the neurotropin receptor mRNA- Clones in this group include amy2_2gl2-

Signal transduction

Cells in higher order organisms need to continuously communicate with its environment especially with other cells of the same organism in order to maintain the function and specialization of the whole system these cells are part of- This important task of communication is performed with help of cell- surface receptors which receive and transmit signals from outside into the cell- G-proteins

The largest known family of cell-surface receptors is that of the G-protein-coupled receptorsi which mediate the transmission of diverse stimuli such as neurotransmittersi glycopeptidesi hormonesi peptidesi odorant moleculesi and photons- The functional unit of these receptors is composed of the receptor molecule itself (GPCR) which is anchored in the cytoplasma membrane with seven membrane spanning domainsi the heterotrimeric G-protein which is composed of and -subunits (G and G )ι and the effectors that interact with G and / or G - In particular! the dissociated G and G can regulate the activities of a number of effector molecules such as adenylate cyclasesi phopholipase C isoformsi ion channels! and tyrosine kinasesi resulting in a variety of cellular functions- The process of signal transduction must be tightly regulated and reversible in order to avoid overstimulationi to achieve signal termination! and render the receptor responsive to subsequent stimuli [Iacovelly L- et al.-i (1111) FASEB J. 13ι 1-βι Hammi H-E- (1116) J. Biol . Chem- 273ι bb1-fa723. G-proteins are GTPases thati upon binding of GTP change their conformation which in return unmasks structural motivesi in particular the so called effector loopi which can mediate the interactions to target proteinsi or effectorsi for the GTPases- This ability enables the GTPases to cycle between activei GTP- bound and inactivei GDP bound conformations and in the process to function as molecular traffic lights in a multitude of signal transduction pathways- The most important of these signal transduction pathways that are regulated with help of G-proteins are that of the phospholipase C / protein kinase C and that of the adenylate cyclase / protein kinase A-

The cycling of GTPases is tightly regulated by three main classes of proteins: The exchange of hydrolyzed GDP for a fresh GTP is facilitated by guanosine nucleotide exchange factors (GEFs)ι the hydrolysis of GTP to GDP is sped up by GTPase- activating proteins (GAPs)ι and the dissociation of GDP from the GTPases is inhibited by GDP dissociation inhibitors (GDIs) [Tapon and Hall (1117) Curr. Opin. Cell . Biol . 9 -, 6b-12ι Van Aelst and D- Souza-Schorey (1117) Genes Dev. Hi 2215-23223-

SOC-family

A conserved motif that was originally identified in proteins that negatively regulate the signaling action of cytokines was termed SOCS boxi the Suppressor Of Cytokine Signaling- Based on ho ologyi five distinct structural protein classes have been identified since that carry this motif- The function of most of these proteins is presently not known- Common to the proteins is only the SOCS box which is located near the C-terminus of the respective peptides- Recently! the SOCS box has been demonstrated to induce binding of proteins to elongins B and C which could target the proteins (and bound substrates) to the proteasomal protein degradation pathway (Kamurai T- et al . (1116) Genes Dev. 12ι 3672-3δδli Zhangi J--G- et al . (1111) Proc. Natl . Acad. Sci . USA 96ι 2071-207b) - The class where the SOCS box was originally described contains several members (S0CS-1-S0CS-7 and CIS)- In addition to the SOCS boxi these proteins also contain a SH2 (Src-homology 2) domain and a variable N-terminus- These SOCS proteins appear to form part of a classical negative feedback loop that regulates cytokine signal transduction- Upon cytokine stimulation! expression of SOCS proteins is rapidly induced and the proteins inhibit further cytokine action- The mode of action of the SOCS proteins is variable- Uhile SOCS-1 binds and inhibits the JAK (Janus kinases) family of cytoplasmic protein kinases [Narahzaki II. et al. (1116) Proc . Natl . Acad . Sci . USA 951 13130-1313 1

Nicholsoni S-E- et al - (1111) EMBO. J- 18ι 375-3653ι CIS appears to act by competing with signaling molecules such as the STATs ⁽Transducers and Activators of Transcription) family for binding to phosphorylated receptor cytoplasmic domains [Yoshimurai A- et al . (1115) EMBO J. 14ι 2δlfa-2δ2fai MatsumotOi A- et al - (1117) Blood 89ι 3146-31541-

A second class of SOCS box protein contains additionally UD- 40 repeats which were initially identified in the mouse USB-1 and -2 proteins. The functions of UD-40 proteins are not completely understood but seem to be rather divergent- In Cdc4p the UD-4D repeats probably are necessary for binding the substrate for Cdc34p [Mathiasi N- et al . (1111) Mol . Cell Biol . 19 -, 17S1-17fa73. Cdc4p is a component of a ubiquitin ligase that tethers the ubiquitin-conjugating enzyme Cdc34p to its substrates. The posttranslational modification of a protein by ubiquitin usually results in rapid degradation of the ubiquitinated protein by the proteasome. The transfer of ubiquitin to substrate is a multistep process where UD-40 repeats might play an important function- Other UD-40 containing proteins (e-g- the retino blastoma binding protein RbAp46) have been shown to bind metal ions (Zinc) and that this metal binding might mediate and/or regulate protein-protein interactions which are functionally important in chromatin metabolism [Kenziori A-L- and Folki U-R- (1116) FEBS Lett. 440ι 425-4213- These proteins are involved in the RAS-cAMP pathway that regulates cellular growth [Ach R-A- et al - (1117) Plant Cell 9 -, 1515-lbObJ-

The SPRY domain has been identified in pyrin or marenostrini a protein which is mutated in patients with Mediterranean fever and which is similar to the butyrophilin family- Uhile butyrophilins seem to be involved in the lactation process in mammalsi the function pyrin is unknown- Three proteins (SSB-1 to -3) have been identified to contain both SPRY and SOCS box motifs- The function of these proteins is also not known- Ankyrin repeat containing proteins share a 33-residue repeating motifi an L-shaped structure with protruding -hairpin tips which mediate specific macromolecular interactions with cytoskeletal i me branei and regulatory proteins- These proteins play fundamental roles in diverse biological activities including growth and development! intracellular protein trafficking! the establishment and maintenance of cellular polarityi cell adhesion signal transductioni and mRNA transcription- Three proteins that contain ankyrin repeats (ASB-1 to -3) have been identified to contain a C-terminal SOCS box additionally to the ankyrin repeats- The function of these proteins or the individual domains remains to be discovered [Hiltoni D-J- et al - (1116) Proc. Natl . Acad . Sci . USA 95ι 114-1113-

A few small GTPases (RAR and RAR like) do also contain a SOCS box- GTPases are involved in signal transduction during cellular communication. The function of the SOCS box in this type of proteins is currently unclear [Hiltoni D-J. et al - (lllδ) Proc. Natl . Acad. Sci . USA 95 i 114-1113-

Ca ⁵⁺ as second messenger

The bivalent cation Ca^Ξ+ isi besides cAMPi one of the two major second messengers in eukaryotic cells- Its intracellular concentration is tightly regulated and usually kept very low compared to the cell¹s environment- Ca^Ξ+ binding proteins and transporters (Gap junction! Voltage-gatedi second messenger- gated) help to sequester huge amounts of the ion in various organelles from where Ca^Ξ+ can be released upon extracellular stimuli- E-g- the contraction of the muscle is dependent on the presence of Ca^Ξ+ ions which are readily transported back into the organelles in order for the muscle to relax. In signal transductioni Ca^Ξ+ functions as a second messenger that activates Ca^Ξ+ dependent processes through the activation of Ca^B+/calmodulin dependent protein kinases (CaM kinases) which are the major effector molecules of Ca⁵⁺- In the signaling cascades! the CaM dependent kinases activate phospholipases (e-g. phospholipase C) that in return activate other protein kinases such as protein kinase C cAMP The cyclic AMP is produced by the enzyme adenylate cyclase in response to extracellular signals. Certain G-proteins stimulate the activity of adenylate cyclase which converts ATP to cAMP and PPi- Two molecules of cAMP bind to each of two regulatory subunits of cAMP dependent protein kinase which in turn dissociate from the two catalytic subunits of the heterotetramer RaCa- Upon release of the C-subunitSi they become active and phosphorylate substrate proteins at Ser and Thr residues. The process leading from binding of extracellular molecules to their receptorsi the transmission of the stimuli into the celli the activation of adenylate cyclase and the subsequent activation of cAMP dependent protein kinase is one of two major signal transduction pathways in eukaryotic cells. Since the phosphorylation of proteins is a posttranslational modification of proteinsi the kinases are described in the class "signal transduction-"

SARA

Members of the transforming growth factor β (TGFβ) superfamily signal through a family of cell-surface transmembrane serine/threonine kinasesi known as type I and type II receptors (Heldin et al-i 1117 i Attisano and Uranai 1116 i Kretzschmar and Massaguei 1116). Ligand induces formation of heteromeric complexes of these receptorsi and signaling is initiated when receptor I is phosphorylated and activated by the constitutively active kinase of receptor II (Urana et al-i 1114 ). The activated type I receptor kinase then propagates the signal to a family of intracellular signaling mediators known as Smads (contraction of the C-elegans S a and Drosophila Mad genes which were the first identified members of this class of signaling effectors).

Three classes of Smads with distinct functions have been defined: the receptor-regulated Smadsi which include Smadli 2ι 3ι 5ι and 6i the common mediator S adi Smad4i and the antagonistic Smadsi which include Smadfa and 7 (Heldin et al-i 1117i Attisano and Uranai lllδ i Kretzschmar and Massaguei lllδ )■ Receptor- regulated Smads (R-Smads) act as direct substrates of specific type I receptorsi and the proteins are phosphorylated on the last two serines at the carboxyl terminus within a highly conserved SSXS motif (Macϊas-Silva et al-i lllfa i Abdollah et al-i 1117 i Kretzschmar et al-i 1117 i Liu et al.-i 1117b i Souchelnytskyi et al-i 1117 )■ Regulation of R-Smads by the receptor kinase provides an important level of specificity in this system- Thusi Smad2 and Smad3 are substrates of TGFβ or activin receptors and mediate signaling by these ligands (Macϊas-Silva et al-i lllfa i Liu et al-i 1117b i Nakao et al-i 1117 )ι whereas Smadi! 5ι and 6 are targets of BMP receptors and propagate BMP signals (Hoodless et al-i 111b i Chen et al-i 1117b i Kretzschmar et al-i 1117 i Nishimura et al-i 1116 )■ Once phosphorylatedi R-Smads associate with the common Smadi Smad4 (Lagna et al-i 111b i Zhang et al-i 1117 )ι and mediate nuclear translocation of the heteromeric complex. In the nucleusi Smad complexes then activate specific genes through cooperative interactions with DNA and other DNA- binding proteins such as FASTli FAST2ι and Fos/Jun (Chen et al-i lllfa i Chen et al-i 1117a i Liu et al-i 1117a i Labbe et al-i 1116 i Zhang et al-i lllδ i Zhou et al-i 1116 ). In contrast to R-Smads and Smad4ι the antagonistic Smadsi Smadfa and 7ι appear to function by blocking ligand-dependent signaling (reviewed in Heldin et al-i 1117 ) • Phosphorylation of R-Smads by the type I receptor is essential for activating the TGFβ signaling pathway (Heldin et al-i 1117 i Attisano and Uranai 1116 i Kretzschmar and Massaguei 1116 )■ Howeveri little is known of how Smad interaction with receptors is controlled- A novel Smad2/Smad3 interacting protein has been described (Tsukazaki T- et al-i 1116 ) that contains a double zinc fingeri or FYVE domaini and which has been called SARA (Smad anchor for receptor activation)- The SARA motif recruits Smad2 into distinct subcellular domains and co-localizes and interacts with TGFβ receptors- TGFβ signaling induces dissociation of Smad2 from SARA with concomitant formation of Smad2/Smad4 complexes and nuclear translocation- Moreover! deletion of the FYVE domain in SARA causes mislocalization of Smad2 and inhibits TGFβ-dependent transcriptional responses. Thusi SARA defines a component of TGFβ signaling that functions to recruit Smad2 to the receptor by controlling the subcellular localization of Smad-

References: Abdollah et al- (1117) J- Biol- Chem- 272ι 27fa7δ-27faδ5i Attisano et al- (1116) Curr- Opin- Cell Biol- lDi 16δ-114i Chen et al. (lllfa) Nature 363ι fall-falfai Chen et al. (1117a) Nature 361ι δS-61i Chen et al- (1117b) Proc Natl. Acad- Sci- USA 14ι 1213δ-12143i Heldin et al. (1117) Nature 31Dι 4b5-471i Hoodless et al. (111b) Cell 65ι 461-SDOi Kretzschmar et al- (1116) Curr- Opin- Genet. Dev. δi 103-llli Kretzschmar et al- (1117) Genes Dev- Hi 1δ4-115i Labbe et al- (1116) Mol- Cell 2ι 101-120i Lagna et al- (111b) Nature 363ι 632-63bi Liu et al- (1117a) Genes Dev. Hi 3157-31fa7i Liu et al- (1117b) Proc Natl- Acad- Sci. USA 14ι 10fab1-107b4i Macϊas- Silva et al- (lllfa) Cell δ7ι 1215-1224i Nakao et al- (1117) EMBO J- Ibi 5353-53fa2i Nishimura et al. (1116) J. Biol- Chem. 273ι 1672-1671i Souchelnytskyi et al- (1117) J. Biol- Chem- 272ι 26107-2βllSi Tsukazaki et al- (1116) Cell 15ι 771-71U Urana et al. (1114) Nature 37Dι 341-347i Zhang et al- (1117) Curr- Biol- 7ι 270-27fai Zhang et al- (1116) Nature 314ι 101- 113i Zhou et al. (lllδ) Mol- Cell Si 121-127-

Calcium

The bivalent cation Ca²⁺ isi along with cAMPi one of the two major second messengers in eukaryotic cells- Its intracellular concentration is tightly regulated and usually kept very low compared to the cell^os environment- Ca^Ξ+ binding proteins and transporters (Gap junction! Voltage-gatedi second messenger- gated) help to sequester huge amounts of the ion in various organelles from where Ca^H+ can be released upon extracellular stimuli- E-g- the contraction of the muscle is dependent on the presence of Ca^Ξ+ ions which are readily transported back into the organelles in order for the muscle to relax- In signal transductioni Ca⁵⁺ functions as a second messenger that activates Ca^Ξ+ dependent processes through the activation of Ca^Ξ+/calmodulin dependent protein kinases (CaM kinases) which are the major effector molecules of Ca^Ξ+- In the signaling cascadesi the CaM dependent kinases activate phospholipases (e-g- phospholipase C) that in return activate other protein kinases such as protein kinase C- Rab proteins

In eukaryotic cells the compartmentalization of processes is a prerequisite for a tight regulation of processes and activities. The cells contain a highly dynamic set of membrane compartments that are responsible for packaging! sortingi secretingi and recycling proteins and other molecules- Trafficking between organelles within the secretory pathway occurs as vesicles derived from a donor compartment fuse with specific acceptor membranesi resulting in the directional transfer of cargo molecules- This process is tightly controlled by the Rab/Ypt family of proteins (reviewed by Novick and Zeriali 1117 )ι a branch of the superfamily of small GTPases- Rab proteins regulate a variety of functions! including vesicle translocation and docking at specific fusion sites- Rabs may also play critical roles in higher order processes such as modulating the levels of neurotransmitter release in neuronsi a likely mechanism in synaptic plasticity that underlies learning and memory (Geppert and Sϋdhofi lllδ )■

Small GTPases share a common three-dimensional fold thati in the GTP bound statei can bind a variety of downstream effector proteins- GTP hydrolysis leads to a conformational change in the "switch" regions that renders the GTPase unrecognizable to its effectors- In this wayi by localizing and activating a select set of effectorsi a common structural motif is used to control a wide array of distinct cellular processes-

The final steps in membrane fusion are likely to be driven by a set of proteins known as SNAREs- After a vesicle becomes dockedi the cytoplasmic domains of VAMP (also termed synaptobrevin) and syntaxin on opposing membranesi in combination with a SNAP-25 moleculei coalesce into an elongated -helical bundle (Poirier et al-i 1116 i Sutton et al-i 1116 )ι which may lead to fusion. Because numerous SNARE isoforms have been identified that localize to distinct membrane compartments! it was originally proposed that the specificity of interaction between the SNARE proteins accounted for the specificity in membrane trafficking- Recent resultsi howeveri suggest that SNAREs are not specific in their ability to form complexes in vitroi suggesting that trafficking specificity requires additional factors (Yang et al-i 1111 )■ In this regardi Rab proteins are strong candidates for governing the specificity of vesicle trafficking- Like the SNAREsi many isoforms (40) of the Rab family have been identified that localize to specific membrane compartments (reviewed by Novick and Zeriali 1117 )■

Concomitant with the SNARE cyclei Rab proteins undergo a intricate cycle of membrane and protein interactions- Rabs are posttranslationally modified at C-terminal cysteines by the addition of- two geranylgeranyl groupsi which mediate membrane association when the Rab is in the GTP-bound state- After guanine nucleotide hydrolysis occursi the Rab is extracted from the membrane upon forming a complex with a cytosolic GDP-dissociation inhibitor (GDI)- This cytosolic intermediate is then recycled onto a newly forming vesiclei most likely through a secondary factor termed a GDI dissociation factor (GDF)ι which displaces GDI- After the Rab becomes membrane boundi a guanidine nucleotide exchange factor (GEF) promotes release of GDP and the subsequent loading of GTP- In its GTP-bound conformation! the Rab is then free to associate with its specific set of effectorsi which can in turn trigger events leading to the eventual fusion of the vesicle with a target membrane- To complete the cyclei perhaps after or concurrent with membrane fusioni a GTPase activating protein (GAP) accelerates nucleotide hydrolysis! switching off the GTPase- The remaining GDP-bound Rab can then participate in a new round of fusion- Rab interactions with effectors are likely to regulate vesicle targeting and membrane fusion in three ways- Firsti a Rab may specifically facilitate vectorial vesicle transport. Vesicles are transported from their site of origin to acceptor compartments likely through associations with cytoskeletal elements and transport motors- A protein has been identified with a domain structure that suggests a connection between the cytoskeleton and the Rabs- This proteini called Rabkinesin-fai contains a kinesin-like ATPase motor domain followed by a coiled- coil stalk region and a RBD that specifically binds Rabfa (Echard et al-i 1116 )■ An additional link with the cytoskeleton is provided by the Rab effectori Rabphilin-3A ■ Rabphilin-3A has been shown in vitro to interact with -actinini an actin-bundling proteini but only when not bound to Rab3A (Kato et al-i 111b )■ These results raise the intriguing possibility that Rab proteins regulate vesicle interactions with the cytoskeleton and thereby play an active role in targeting vesicles to their appropriate destinations.

Secondi Rab proteins may regulate membrane trafficking at the vesicle docking step. A number of Rab effectorsi including Rabaptin-5ι EEAli Rabphilin-3Aι and Rimi may serve as molecular tethers. Each effector protein contains a RBDi followed by a linker region (some having the potential to form elongated coiled-coil structures)! and a domain capable of interacting with a second Rab or the target membrane- Rabaptin-5ι for examplei contains two RBDsi one near the N terminus that specifically recognizes Rab4 and a second near the C terminus that binds Rab5 (Vitale et al-i 1116 )■ Both Rimi which is localized to the target membranei and Rabphilin-3Aι which is localized to the vesiclei contain N-terminal RBDs and C-terminal Ca2+-binding C2 domainsi implicating these effectors in synaptic vesicle localization or docking in response to Ca2+ influx ⁽Uang et al-i 1117 ) - Tethering effectors may also recognize protein complexes on the acceptor membrane- Sec4pι a yeast Rab3A homologi interacts with the exocyst (Guo et al-i 1111 )ι a complex of seven or more subunits that is assembled at sites of vesicle fusion along the plasma membrane- The exocyst complex may therefore function as a landmark for Rab/ef fector-mediated vesicle docking-

Thirdi once a vesicle has become tethered to its fusion sitei Rab proteins may selectively activate the SNARE fusion machinery- The mechanism of this activation is unknown but may involve direct interactions of Rabs ori more likelyi their effectors with SNAREs- For examplei Hrs-2 is a protein that binds to SNAP-25 and contains a Zn2+-finger motif characteristic of Rab-binding proteins such as Rabphilin-3Aι Rimi EEAli and Noc2ι suggesting that Hrs-2 may form a physical link between Rabs and SNAREs (Bean et al-i 1117). In addition! certain mutations in the syntaxin-binding protein Slylpi the Seclp homolog utilized in ER to Golgi trafficking! eliminate the requirement for Yptlpi a Rab protein that functions at this trafficking step (Dascher et al-i 1111 ) ■ Rabs may therefore regulate SNARE associations through Seel family members- In support of this ideai a Rab effector was recently found to interact with a vacuole Rabi a Seclp homologi and a SNARE protein (Peterson et al-i 1111 )ι which suggests that this effector serves to connect Rab and SNARE function. In this wayi Rabs and their effectors may facilitate the correct pairing of SNAREs-

References: Dascher et al. ⁽1111). Mol- Cell- Biol- Hi δ72- 665i Echard et al- (1116). Science- 271ι 5δ0-5δ5i Geppert et al. (1116). Annu- Rev- Neurosci- 21ι 75-15i Guoet al- (1111). EMBO J. Iδi 1071-lOδOi Kato et al- (111b). J. Biol. Chem- 271ι 31775- 3177δi Novick et al- (1117). Curr. Opin- Cell Biol- li 41b-5D4i Peterson et al- (1111). Curr- Biol- li 151-lfa2i Poirier et al- (1116). Nat. Struct- Biol- 5ι 7b5-7fa1i Vitale et al- (1116). EMBO J- 17ι 1141-HSli Uang et al- ⁽1117). Nature- 36δι 513-51δi Yang et al- (1111)- J- Biol- Chem- 274ι 5b41-Sb53.

Kinases Reversible posttranslational modifications of proteins are major means of regulating cellular activities- Among the various modifications that are carried out by the cellsi the addition of phosphoryl groups to Ser/Thr or Tyr residues is the most important and widely used- The phosphorylation of proteins is accomplished by protein kinasesi while the reverse reaction! the removal of phosphoryl groupsi is carried out by phosphatases- Kinases / Phosphatases regulate key positions e-g- in the processes of cell proliferation! differentiation and communication/signaling- These processes must be tightly regulated in order to maintain a steady state level of cellular fate- Mis-regulation of kinase activities (or that of phosphatases) is made responsible for a multitude of disease processes such as oncogenesisi inflammatory processes! arteriosclerosis! and psoriasis-

Protein kinases constitute the largest protein family that is currently known- Several hundred kinases have been identified already. Classically! kinases are subdivided into two classes based on the amino acid residues in their substrates that are phosphorylated by the particular enzymes- The kinases specifically add phosphoryl groups from adenosine triphosphate (ATP) ori less frequently! guanosine triphosphate (GTP)ι either to serine and/or threonine or to tyrosine residues of substrate proteins- An estimated liODO to lOiDOO proteins present in a typical mammalian cell are believed to be regulated also by the action of protein kinases.

Protein kinases are frequently integral parts of signaling cascades that transmit extracellular stimuli (e-g- hormonesi neurotransmittersi growth- or differentiation factors) into the cell and result in various responses by the cells- The kinases play key roles in these cascades as they constitute a sort of "-molecular switches^"1 turning on or off the activities of other enzymes and proteinsi e-g- metabolic regulatoryi channels and pumpsi receptorsi cytoskeletal ι transcription factors- The regulation of kinase activities is accomplished by various means-"

The best characterized example for the regulation via regulatory subunits is the cAMP-dependent protein kinase (PKA) which is also a prototype for second messenger activated protein kinases- This enzyme consists of a heterotetramer of two catalytic (C) and two regulatory (R) subunits- Upon binding of two molecules of second messenger (cAMP) in each R subuniti the catalytic subunits are released and active- Both of the catalytic and the regulatory subunits several isoforms exist- The combination of catalytic and regulatory subunits determines the localization of the holoenzyme and also the substrate spectrum that is available for phosphorylation- The consensus pattern necessary to be present in the substrate for PKA action is RRXS/T where X can be any amino acid-

The casein kinase II comprises another examples for holoenzymes that consist of catalytic and regulatory subunits- Other kinases that are activated by second messengers are cGMP- dependent protein kinase and Protein kinase C (PKC) which is activated by diacylglycerol i which in turn is produced by phospholipases by cleavage of phosphatidylcholine-

Receptor kinases usually consists of an extracellular domain which can bind effector molecules (e.g. growth factors and hormones) and transfer the stimulus to the intracellular domain of these proteins which usually is a protein tyrosine kinase- Other tyrosine kinases lack an extracellular domain but are associated with receptors which transfer the signal after effector binding by activating the associated protein kinase enzyme (e-g- Src kinase familyi Src Blki Fgri Fyni Lck Lyni Yes and Janus kinase familyi Jakl-3ι Tyk2)-

Dysfunction of kinasesi e-g- caused by non-functioning regulation! can be the cause of inflammatory diseases and uncontrolled proliferation- v-Src which is a truncated version of the C-Src protooncogene tyrosine kinase is a classical example for this process as v-Src does not contain the regulatory domain of the cellular gene and is thus constitutively active-

Several categories of proteins are coded for by clones of the invention within the overall group of "Signal transduction"and includei among othersi the following:

Discs-large family: In Drosophila more than 50 genes are discribed ιin which mutation leads to loss of cell proliferation control indicating that they are tumor suppressor genes- Most of these genes have mammalian homologs- The Drosophila 'discs large' tumor suppressor proteini Dlgi is the prototype of a family of proteins termed MAGUKs (membrane-associated guanylate kinase homologs). MAGUKs are localized at the membrane-cytoskeleton interface! usually at cell-cell junctioni where they appear to have both structural and signaling roles- They contain several distinct domainsi including a modified guanylate kinase domaini an SH3 motifi and 1 or 3 copies of the DHR (GLGF/PDZ) domain- Recessive lethal mutations in the 'discs large' tumor suppressor gene interfere with the formation of septate junctions (thought to be the arthropod equivalent of tight junctions) between epithelial cellsi and they also cause neoplastic overgrowth of imaginal discsi suggesting a role for cell junctions in proliferation control- These proteins can f ind application in modulating/blocking the guanylate cyclase-pathway ■ Clones in this category include: amy2_12d7-

Proteins with a UU Domain: Proteins that contain a UU domain which has been originally described as a short conserved region in a number of unrelated proteinsi among them dystrophini the gene responsible for Duchenne muscular dystrophy- The domaini which spans about 35 residues! is repeated up to 4 times in some proteins- It has been shown to bind proteins with particular proline-motifsi [AP3-P-P-[AP3-Yι and thus resembles somewhat SH3 domains- This domain is frequently associated with other domains typical for proteins in signal transduction processes- Examples of proteins containing the UU domain are Dystrophini Utrophini vertebrate YAP protein (binds the SH3 domain of the Yes oncoprotein) i murine NEDD-4 (embryonic development and differentiation of the central nervous system) i IQGkP (human GTPase activating protein acting on ras). Therefore these proteins should be involved in intracellular signal transduction- Diseases associated (as potentially diagnostic therapeutic causativei and/or relatedi etc..) with these proteins include as reported by OMIN 1) Muscular Dystrophyi Pseudohypertrophic

Progressive Duchenne and Becker Types (OMIN *31Q20D). Clones in this category include: tes3_lld21- Ion-Transporters: For signalling stringent control od ion fluxes over biological membranes is of the essence- Several trans-membrane ion-chennel-proteins key elements of signal transduction pathways- Clones in this category include: amy2_10p7 and amy2_2fl6-

RING-finger proteins: A Zinc finger motif of the C3HC4 type (the so-called RING finger domain) is involved in mediating protein-protein interactions- Proteins containing a RING-finger are '- mammalian V(D)J recombination activating protein (RAGl)ι mouse rpt-li human rfpi human 52 Kd Ro/SS-A protein and others- The family of RING finger proteins contains a number of oncogenes- For example PMLi a probable transcription factori BRCAli the mammalian cbl- and bmi-1 proto-oncogenes- Clones in this category include: amy2_10hl7-

Phosphatases : Proper targeting of PTPs is essential for many cellular signalling events including antigen induced proliferative responses of B and T cells- The physiological significance of PTPs is further unveiled through mice gene knockout studies and human genome sequencing and mapping projects- Several PTPs are shown to be critical in the pathogenesis of human diseases! as shown by over 210 entries in OMIN- Clones in this category include: tes3_31j20.

Phosphoproteins: Some paraneoplastic syndromes affecting the nervous system are associated with antibodies that react with neuronal proteins and the causal tumor (onconeuronal antigens). Several of these antibodies are markers of specific neurologic syndromes associated with distinct types of cancer- One of the antigenes recognised by such antibodies is Ma-li the neuron- and testis-specific protein 1- The expression of Mai mRNA is highly restricted to the brain and testis- Subsequent analysis suggested that Mai is likely to be a phosphoprotein (see OMIN *fa04010). Clones in this category include: tes3_5k22.

Transmembrane proteins

Membrane region prediction was effected using the AL0M2 software (Klein et al-i llδSi version 2 by K- Nakai). Similar to many other methodsi the Kyte & Doolitle (1162) amino acid hydrophobicity scale is used in AL0M2 as the primary variable for classifying sequences in terms of their localization- High prediction accuracy is achieved through the system of intelligent decision rules and the utilization of a carefully selected training data set- The method also generates reliability estimates which makes it possible to distinguish between membrane-spanning proteins (Ii intrinsic) and globular proteins with regions of high hydrophobicity buried in the core-

For a protein of length Li the block of length 1 with maximum hydrophobicity is found:

where H± represents the hydrophobicity of an individual residue ■

Let P(I/maxΗ) and P(E/maxH) be the conditional probabilities that a protein is integral or peripheral! respectively! given its value of maximal hydrophobicity maxHi and let P(I) and P(E) be the prior probabilities of intrinsic and extrinsic membrane proteins estimated from the training set- Then a sequence is assigned to E if

P(E/maxH) > P(I/maxH)

ori after applying the Bayes rulei

P(E)P(maxH/E) > P (DP (maxH/I) i

where the conditional probabilities P(maxH/E) and P(maxH/I) can be determined based on the estimates of probability distributions of maxH in both groups-

Discriminant analysis allows to simplify this task by calculating the odds P(E/MaxH) :P⁽I/maxH) as e^h-, where b is the left-hand side of a linear or quadratic inequality. For examplei for the window of length 17ι the protein is allocated to the peripheral category E based on the empirically derived quadratic inequality:

1.05(maxH)^Ξ+12.30maxH+17.41 >0ι

whereas the optimal inequality for assigning membrane proteins (category I) is linear:

-1-02maxH + 14.27 > 0

The odds parameter can be made more or less stringent- For examplei one can require odds at least 1:10 for a protein to be classified as integral- This leads to higher selectivity but less sensitivity-

The boundaries of membrane-spanning regions in putative membrane proteins are detected by means of an iterative procedure whereby the most hydrophobic region corresponding to the value maxH is considered to be membrane and removed from the sequence- The classification procedure is then repeated again for the remaining sequence! andi if such a protein is again classified as integrali the next most hydrophobic region is considered-

Reference: Kleini P-i Kanehisai M-i DeLisii C- (1165) The detection and classification of membrane-spanning proteins- Biochem Biophys Acta 815: 4fa6-47fa

Transcription factors

Purified eukaryotic RNA polymerase II is unable to initiate promoter-specific transcription. A family of factors that collectively confer RNAPII promoter specificity is known as the general transcription factors (GTFs). They include the TATA- binding Protein (TBP) TFIIBi TFIIEi TFIIF and TFI IH- These factors are conserved among all eukaryotes-

RNAPII complexes containing the entire set of GTFs or a subset of GTFs together with other proteins have been isolated from mammalian and yeast cells- Although purified RNAPII and GTFs are sufficient for promoter-specific initiation! this system fails to respond to activators- This is mediated by a further complex termed mediator complex which associates with the carboxy-terminal heptapeptide domain (CTD) of the largest subunit of RNAPII.

Purification of human RNAPII complexes resulted in two distinct forms of human RNAPII after analysis of functional properties. One complex contained chromatin remodeling activities but was devoid of GTFs. The other complex did not contain factors that modify chromatin but contained a subset of SRB/mediator subunits and GTFs and other polypeptides that mediate transcriptional activation! a scenario similar to that reported for yeast-

A complex designated NAT (-20 SU) for negative regulator of transcription contains RNAPIIi Cdkδi homologs of the yeast mediator complex as well as Rgrl and SrblO/11 known as negative regulators of transcription-

A complex with striking similar structural and functional properties to NAT has been identified designated SMCC (-15 SU) (SRB/mediator coactivator complex) i that can also mediate transcriptional activation-

The SMCC complex includes all reported NAT subunits including subunits of the TRAP complex- TRAP is a coactivator complex isolated on the basis of its interaction with the thyroid hormone receptor- Another coactivator complex DRIPi isolated on the basis of its ability to interact with the vitamin D3 receptori contains novel subunits as well as subunits of NAT/SMCC and TRAP complexes-

The effects of each of these coactivator complexes is dependent on the TFIID complex- It is not known if the T AF subunits of TFIID are required- It is likely that new coactivator complexes will be uncovered containing both novel and previously defined components.

Beside the huge amount of transcription factors which can be part of the RNAIIP holoenzyme or the coactivator complexes there is an even larger quantity of specific transcription factors binding to promoter elements within the DNA sequences of a given gene leading to activation or repression of transcription. A broad range of cellular responses like differentiation! proliferation! cell death and others are elicited through activating or repressing the transcription of target genes-

There are at least five superclasses of transcription factors:

1- Superclass contains members with characteristic basic domains:

Members are '-

Leucine zipper factorsi where the basic domain is followed by a leucine zipper of repeated leucine residues at every seventh position- The zipper mediates protein dimerization as a prerequisite for DNA-binding-

Helix-loop-helix factors (bHLH) contain a DNA-binding basic region followed by a motif of two potential amphipathic alpha- helices connected by a loop of variable length also mediating dimerization ■

Factors with a combination of Helix-loop-helix and leucine zipper.

Further members of this superclass are NF-li RF-Xi and bHSH like proteins-

2- Superclass comprises factors containing zinc-coordinating DNA-binding domains.

Members are '-

Proteins with Cys4 zinc finger of nuclear receptor typei where two such motifs differing in sizei composition and function are present in each receptor molecule- Each finger comprises 4 cysteine residues coordinating one zinc ion- The second half including the second cysteine pair has alpha-helix conformation and the helix of the first finger binds to the DNA through the major groove- The sequence between the first two cysteines of the second finger mediates dimerization upon DNA-binding- This class includes the steroid hormone receptors and the thyroid hormone receptor-like factors- Other diverse cys4 zinc fingers have a motif of GATA-type-

Proteins with Cys2His2 zinc finger domain(s). Each finger comprises 2 cysteine and 2 histidine residues coordinating one zinc ioni and in some cases one histidine is replaced by another cysteine. The zinc ion is essential for DNA-binding-

Proteins with Cysb cysteine-zinc cluster(s)- Six cysteine residues coordinate two zinc ionsi i- e- two of the thiol groups are coordinating two zinc ions each- Present in many fungal regulators-

Zinc fingers of alternating composition.

3. Superclass contains factors of helix-turn-helix type-

Members are '-

Proteins with homeo domains- Homeo domains are three consecutive alpha-helix structures- Helix 3 contacts mainly the major groove of the DNAi some contacts at the minor groove are observed as well- Helix 2 and 3 resemble the helix-turn-helix structure of prokaryotic regulators-

Proteins with Paired box domain(s). This is a DNA-binding domain of approximately 130 amino acid residues- Its N-terminal half is basic its C-terminal half is highly charged in general- It probably comprises 3 alpha-helices-

Proteins with Fork head / winged helix domain(s)- This domain was identified by homology between HNF-3A and fkh- The domain comprises approx- 110 AA- Analysis of the crystal structure has revealed a compact structure of three alpha- helicesi the third alpha-helix being exposed towards the major groove of the DNA- The domain also exerts minor groove contacts. Upon binding to DNAi it induces a bend of 13 degree-

Heat shock factors

Proteins with Tryptophan clusters- The tryptophan clusters comprise several tryptophan residues with a spacing of 12-21 amino acid residuesi the subclass of myb-type DNA-binding domains typically exhibit a spacing of 11-21 amino acid residues-

Proteins with TEA domain(s)- The TEA domain has been identified as a region which is conserved among the transcription factors TEF-li TEC1 and abaA- This domain in TEF-1 has been shown to interact with DNAi although two additional regions may also contribute to DNA-binding- It is predicted to fold into three alpha-helicesi with a randomly coiled region of lb-16 amino acid residues between helices 1 and 2ι and a short stretch between helices 2 and 3 of 3-6 residues-

4- Superclass contains beta-Scaffold Factors with Minor Groove Contacts

Members are :

Proteins with RHR (Rel homology) region-

The structure of the Rel-type DBD exhibits a bipartite subdomain structurei each subdomain comprising a beta-barrel with five loops that form an extensive contact surface to the major groove of the DNA- Particularly! the first loop of the N-terminal subdomain (the highly conserved recognition loop) performs contacts with the recognition element on the DNAi but other loops are involved- The fact that the main DNA-contacts are made through loops has been suggested to provide a high degree of flexibility in binding to a range of different target sequences- Augmenting interactions are achieved by two alpha-helices within the N-terminal Part that form strong minor groove contacts to the A/T-rich center of the B-element- In pfaSi the sequence between both alpha-helices is much shorter and even helix 2 is truncated- The secondi C-terminal domain is necessary mainly for protein dimerization •

p53 proteins

MADS (MCMl-agamous-deficiens-SRF) box proteins- Proteins of this class comprise a region of homology- The DNA-binding domain also comprises the dimerization capability- In the DNA-bound dimer (shown for SRF)ι two antiparallel amphipathic alpha-helices (alpha-I)ι form a coiled coil and are oriented approximately parallel on the minor groove- These helices make minor and major groove contacts! the N-terminal extensions form minor groove contacts- The bound DNA is bent and wrapped around the protein- It exhibits a compressed minor groove in the center and widened minor groove in the flanks.

Beta-Barrel alpha-helix transcription factors-

TATA-binding proteins

HMG proteins

Proteins of this class comprise a region of homology with the chromosomal non-histone HMG proteins such as HMG1- This region comprises the DNA-binding domain which in some instances such as HMG1 mediates sequence-unspecific in other cases such LEF-1 sequence-specific binding to DNA- This domain exhibits a typical L-shaped conformation made up of 3 alpha-helices and an extended N-terminal extension of the first helix- The latter together with helix li which contains a kinki form the long arm of the Li whereas helices 1 and 2 form the short arm- Binding to the minor groove induces a sharp bending of the DNA by more than 10 degreei away from the bound protein- The overall topology of the DNA-protein complexes resembles somewhat that of the TBP-TATA box complex.

Heteromeric CCAAT factors

Proteins with Grainyhead domain(s)

Cold-shock domain factors. Cold-shock domain proteins are characterized by a highly conserved region first found in prokaryotic cold-shock proteins- This domain is a single-stranded nucleic acid-binding structure interacting with DNA or RNA- It consists of an antiparallel five-stranded beta-barreli the strands of which are connected by turns and loops- Uithin this structure! a three-stranded beta-strand contains a conserved RNA- binding motifi RNP1- Not all CSD proteins are transcription factors- Those which specifically bind to a certain sequence are termed Y-box proteins- Proteins of this class were previously called protamine-like domain proteins because of having a highly positively charged domain with interspersed proline residues-

Proteins with Runt homology domain

The members of this transcription factor class have been identified on the basis of their homology to a defined region within the Drosophilia protein Runt- The runt domain is part of the DNA-binding domain of these factors- It consists mainly of beta-strandsi does not contain alpha-helical regions and seems to be most similar to the palm domain found in DNA polymerase beta (rat)-

5- Superclass contains other transcription factors like Copper fist proteinsi HMGI(Y)ι STATi Pocket domain proteins and Ap2/EREBP-related factors-

The classification of transcription factors originates from TRANSFAC database:

http: //transfa gbf.de/TRANSFAC/

Reference: Heinemeyer

Several categories of proteins are coded for by clones of the invention within the overall group of "Transcription Factors" and includei among othersi the following:

Homeobox-proteins: Homeodomain-containing transcription factors are essential for a variety of processes in vertebrate development! including organogenesis. They have been shown to regulate cell proliferation! pattern segmental identity anddetermine cell fate decisions during embryogenesis- For examplei In zebrafish emx2 mRNAs are found in the dorsal telencephaloni parts of the diencephalon and the otocyst- The human homologue Emx2 appears to be already expressed in 6-5 day embryos- It is also expressed in the presumptive cerebral cortexi olfactory bulbsi in some neuroectodermal areas in embryonic head including olfactory placodes in earlier stages and olfactory epithelia later in development. Mutants of the D- melanogaster gene "mempty spiracles" display spiracles devoid of filzkorperi no antenna and an open head- Clones in this category include: amy2_14mlfa-

Proteins with myc-tvpei helix-loop-helix dimerization domain signature (s) . This helix-loop-helix domain mediates protein dimerization has been found in various multimeric transcrpition factors. Clones in this category include: tes3_lδnl4-

Transcriptional silencers: In addition to transcription factorsi other proteinsi such as YDL153c of Saccharomyees cerevisia are responsible for silencing of genes. Clones in this category include: amy2_2f22-

Proteins regulating transcription factors: The activity of several transcription factor is regulated by the binding or dissociation of other proteins or by phosphorylation or dephosphorylation of the transcription factor- For exampleil- kappa-B-related protein interacts with the transcription factor NF-κB- I-kappa-B-alpha mutations contribute to constitutive NF- kappaB activity in cultured and primary HRS (Hodgkin/Reed- Sternberg) cells and are therefore involved in the pathogenesis of Hodgkin's disease (HD) patients- Clones in this category include: amy2_lcl2-

Signal transducing proteins: Beta-transducin subunits of G- proteins contain UD-40 repeats- The beta subunits seem to be required for the replacement of GDP by GTP as well as for membrane anchoring and receptor recognition- Due to the zinc finger the novel protein seems to be a new molecule involved in signal transduction and transcription- These proteins have been reported by OMIN to be associated (as potentially diagnostic therapeutic causativei and/or relatedi etc..) with the following diseases: 1) essential hypertension (OMIN *131130)- Clones in this category include: tes3_llc22-

* * * The invention! therefore! specifically contemplates the following assemblages of materials! which track the above- identified fourteen functional groupings! that are useful in practicing the profiling aspects of the invention- One type of assemblage is nucleic acid-based and can include the following groupings of sequences and their derivatives: all sequencesi human fetal brain sequencesi brain derived sequencesi human fetal kidney library sequencesi kidney derived sequencesi human mammary carcinoma library sequencesi mammary carcinoma derived sequencesi human testis library sequencesi testes derived sequencesi cell cycle genesi cell structure and motility genesi differentiation and development genesi intracellular transport and trafficking genesi metabolism genesi nucleic acid management genesi signal transduction genesi transmembrane protein genesi and transcription factor genes- Other assemblages contain proteins or their corresponding antibodies or antibody fragments! divided along the same groupings-

Database Applications

Because they are human genes and gene productsi the inventive molecules are useful as members of a database- Such a database may be usedi for examplei in drug discovery and rationale drug design or in testing the novelty and non- obviousness of newly sequenced materials- In additioni they are particularly suited in designing variants for the profiling (and other) applications described herein- Hencei the following discussion of electronic embodiments applies equally to such variants! whichi naturallyi will be generated and stored using a computer using known methodologies-

Accordingly! one aspect of the invention contemplates a database of at least one of the inventive sequences stored on computer readable media- Againi the individual sequences may be grouped with regard to the individual functional and structural groups mentioned above- Uhile the individual sequences of a database may exist in printed formi they are preferably in electronic formi as in an ascii or a text file- They may also exist as word processing files or they may be stored in database applications like DB2ι Sybasei Oraclei GCG and GenBank- One skilled in the art will understand the range of applications suitable for using and storing the electronic embodiments of the invention-

"Computer readable media" refers to any medium which can be read and accessed by a computer- These include: magnetic storage mediai like floppy discsi hard drives and magnetic tapei optical storage mediai like CD-ROMi electrical storage mediai like RAM and ROMi and hybrids of these categoriesi like magnetic/optical storage media- One skilled in the art will readily understand the scope of computer readable media and how to implement them-

Biological Activities and Assays for Implementing Therapeutic and Diagnostic Applications This section provides assays for biological activity that are useful in characterizing and quantifying the biological activity of the inventive molecules and their derivatives! which is relevant to the pharmacological effects of the inventive molecules. As used in this sectioni it will be understood that "protein" may also refer to the inventive antibodies (including fragments) ■

Cytokine and Cell Proliferation/Differentiation Activity

A protein of the present invention may exhibit cytokinei cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations- Many protein factors discovered to datei including all known cytokinesi have exhibited activity in one or more factor dependent cell proliferation assaysi and hence the assays

as a convenient confirmation of cytokine activity. The activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines includingi without limitation! 32Dι DA2ι DAlGi TlDi Bli Bl/lli BaF3ι MCI/Gi M + (preB M + )ι 2Eβι RB5ι DAli 123ι TllfaSi HT2ι CTLL2ι TF-li Mo7e and CMK-

The activity of a protein of the invention mayi among other eansi be measured by the following methods:

Assays for T-cell or thymocyte proliferation include without limitation those described in: Current Protocols in Immunologyi. Ed by J. E- Coligani A- M- Kruisbeeki D- H. Marguliesi E- M.

Shevachi U- Stroberi Pub- Greene Publishing Associates and Uiley- Interscience (Chapter 3ι In Vitro assays for Mouse Lymphocyte Function 3.1-3-lli Chapter 7ι Immunologic studies in Humans)i Takai et al-i J. Immunol- 137 : 3414-3500! llβfai Bertagnolli et al-i J- Immunol. 145: 170fa-1712ι HlOi Bertagnolli et al-i

Cellular Immunology 133:327-341ι lllli Bertagnollii et al.-, I- Immunol. 141 : 377δ-3763ι 1112i Bowman et al.-i I- Immunol.

Assays for cytokine production and/or proliferation of spleen cellsi lymph node cells or thymocytes includei without limitation! those described in: Polyclonal T cell stimulation! Kruisbeeki A- M- and Shevachi E- M- In Current Protocols in Immunology- J. E- e - a - Coligan eds- Vol 1 pp- 3-12 ■ l-3.12-14ι

John Uiley and Sonsi Toronto- 1114i and Measurement of mouse and human interleukin gamma i Schreiberi R- D- In Current Protocols in Immunology. J. E- e - a - Coligan eds- Vol 1 pp. b-δ.l-b.β.δi John Uiley and Sonsi Toronto. 1114- Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells includei without limitation! those described in: Measurement of Human and Murine Interleukin 2 and Interleukin 4ι Botto lyi K-i Davisi L- S. and Lipskyi P- E- In Current Protocols in Immunology. J. E- e - a - Coligan eds. Vol 1 pp. fa.3-l-b .3-12ι John Uiley and Sonsi

Toronto- lllli deVries et al-i J. Exp- Med- 173: 12D5-1211ι lllli Moreau et al-i Nature 33b:fa1D-b12ι llδβi Greenberger et al-i Proc Natl- Acad- Sci- U-S-A- 60 :2131-213βι 11δ3i Measurement of mouse and human interleukin b-Nordani R- In Current Protocols in Immunology- J- E- e - a - Coligan eds. Vol 1 pp. fa-fa. l-b.fa.5i John Uiley and Sonsi Toronto, lllli Smith et al-i Proc- Natl- Aced- Sci- U-S-A- 63:lδ57-lβblι llδbi Measurement of human Interleukin 11-Bennettι F-i Giannottii J-i Clarki S- C. and Turneri K- J. In Current Protocols in Immunology. J. E- e - a - Coligan eds- Vol 1 pp. fa.15-1 John Uiley and Sonsi Toronto- lllli Measurement of mouse and human Interleukin 1-Ciarlettaι A-i Giannottii J-i Clarki S- C- and Turneri K- J- In Current Protocols in Immunology- J- E- e - a - Coligan eds- Vol 1 pp- fa-13-lι John Uiley and Sonsi Toronto- 1111. Assays for T-cell clone responses to antigens (which will identify! among othersi proteins that affect APC-T cell interactions as well as direct T-cell effects by measuring proliferation and cytokine production) includei without limitation! those described in: Current Protocols in Immunology! Ed by J- E- Coligani A. M- Kruisbeeki D- H- Marguliesi E- M-

Shevachi U Stroberi Pub- Greene Publishing Associates and Uiley- Interscience (Chapter 3ι In Vitro assays for Mouse Lymphocyte Functioni Chapter bi Cytokines and their cellular receptorsi Chapter 7ι Immunologic studies in Humans)i Ueinberger et al-i Proc Natl- Acad- Sci- USA 77 : fa011-fa015ι HδOi Ueinberger et al-i Eur- J- Immun- 11:405-411! llδli Takai et al-i J- Immunol. 137:3414-350Dι llδbi Takai et al-i J- Immunol- 140:50δ-512ι llδβ-

Immune Stimulating or Suppressing Activity A protein of the present invention may also exhibit immune stimulating or immune suppressing activityi including without limitation the activities for which assays are described herein- A protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SCID))ι e-g-i in regulating (up or down) growth and proliferation of T and/or B lymphocytes! as well as effecting the cytolytic activity of NK cells and other cell populations- These immune deficiencies may be genetic or be caused by vital (e-g-i HIV) as well as bacterial or fungal infections! or may result from autoimmune disorders- More specifically! infectious diseases causes by virali bacteriali fungal or other infection may be treatable using a protein of the present inventioni including infections by HIVi hepatitis virusesi herpesvirusesi mycobacteriai Leishmania spp-i malaria spp- and various fungal infections such as candidiasis- Of coursei in this regardi a protein of the present invention may also be useful where a boost to the immune system generally may be desirablei i-e-i in the treatment of cancer- Autoimmune disorders which may be treated using a protein of the present invention includei for examplei connective tissue diseasei multiple sclerosisi systemic lupus erythematosusi rheumatoid arthritisi autoimmune pulmonary inflammation! Guillain-Barre syndromei autoimmune thyroiditisi insulin dependent diabetes mellitisi myasthenia gravisi graft-versus-host disease and autoimmune inflammatory eye disease- Such a protein of the present invention may also to be useful in the treatment of allergic reactions and conditions! such as asthma (particularly allergic asthma) or other respiratory problems- Other conditions! in which immune suppression is desired (including! for examplei organ transplantation)! may also be treatable using a protein of the present invention- Using the proteins of the invention it may also be possible to modify immune responsesi in a number of ways- Down regulation may be in the form of inhibiting or blocking an immune response already in progress or may involve preventing the induction of an immune response- The functions of activated T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cellsi or both- Immunosuppression of T cell responses is generally an activei non-antigen-specific process which requires continuous exposure of the T cells to the suppressive agent- Tolerancei which involves inducing non- responsiveness or anergy in T cellsi is distinguishable from immunosuppression in that it is generally antigen-specific and persists after exposure to the tolerizing agent has ceased- Operationally! tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolerizing agent- Down regulating or preventing one or more antigen functions (including without limitation B lymphocyte antigen functions (such asi for examplei B7))ι e-g-i preventing high level lymphokine synthesis by activated T cellsi will be useful in situations of tissuei skin and organ transplantation and in graft-versus-host disease (GVHD). For examplei blockage of T cell function should result in reduced tissue destruction in tissue transplantation. Typicallyi in tissue transplants! rejection of the transplant is initiated through its recognition as foreign by T cellsi followed by an immune reaction that destroys the transplant. The administration of a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural ligand(s) on immune cells (such as a solublei monomeric form of a peptide having B7-2 activity alone or in conjunction with a monomeric form of a peptide having an activity of another B lymphocyte antigen (e-g.i B7-lι B7-3) or blocking antibody)ι prior to transplantation can lead to the binding of the molecule to the natural ligand(s) on the immune cells without transmitting the corresponding costimulatory signal- Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cellsi such as T cellsi and thus acts as an immunosuppressant- Moreover! the lack of costimulation may also be sufficient to anergize the T cellsi thereby inducing tolerance in a subject. Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents- To achieve sufficient immunosuppression or tolerance in a subjecti it may also be necessary to block the function of a combination of B lymphocyte antigens ■ The efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans- Examples of appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in micei both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as described in Lenschow et al-i Science 257:761-712 (1112) and Turka et al-i Proc Natl- Acad- Sci USAi δl : 11102-11105 (1112)- In addition! murine models of GVHD (see Paul ed-i Fundamental Immunology! Raven Pressi New Yorki llδli pp. 64b-647) can be used to determine the effect of blocking B lymphocyte antigen function in vivo on the development of that disease- Blocking antigen function may also be therapeutically useful for treating autoimmune diseases- Many autoimmune disorders are the result of inappropriate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoantibodies involved in the pathology of the diseases- Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms- Administration of reagents which block costimulation of T cells by disrupting receptor : ligand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoantibodies or T cell-derived cytokines which may be involved in the disease process- Additionally! blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease- The efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well-characterized animal models of human autoimmune diseases- Examples include murine experimental autoimmune encephalitis! systemic lupus erythmatosis in MRL/lpr/lpr mice or NZB hybrid micei murine autoimmune collagen arthritisi diabetes mellitus in NOD mice and BB ratsi and murine experimental myasthenia gravis (see Paul ed-i Fundamental Immunologyi Raven Pressi New Yorki llβli pp. 640- 65b).

Upregulation of an antigen function (preferably a B lymphocyte antigen function)! as a means of up regulating immune responses! may also be useful in therapy- Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response- For examplei enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection- In addition! systemic viral diseases such as influenzai the common coldi and encephalitis might be alleviated by the administration of stimulatory forms of B lymphocyte antigens systemically -

Alternatively! anti-vital immune responses may be enhanced in an infected patient by removing T cells from the patienti costimulating the T cells in vitro with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into the patient. Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patienti transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surfacei and reintroduce the transfected cells into the patient- The infected cells would now be capable of delivering a costimulatory signal toi and thereby activate! T cells in vivo-

In another application! up regulation or enhancement of antigen function (preferably B lymphocyte antigen function) may be useful in the induction of tumor immunity. Tumor cells (e-g-i sarcomai melanomai lymphomai leukemiai neuroblastomai carcinoma) transfected with a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject- If desiredi the tumor cell can be transfected to express a combination of peptides- For examplei tumor cells obtained from a patient can be transfected ex vivo with an expression vector directing the expression of a peptide having B7-2-like activity alonei or in conjunction with a peptide having B7-l-like activity and/or B7-3- like activity- The transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell- Alternatively! gene therapy techniques can be used to target a tumor cell for transfection in vivo-

The presence of the peptide of the present invention having the activity of a B lymphocyte antigen(s) on the surface of the tumor cell provides the necessary costimulation signal to T cells to induce a T cell mediated immune response against the transfected tumor cells- In addition! tumor cells which lack MHC class I or MHC class II moleculesi or which fail to reexpress sufficient mounts of MHC class I or MHC class II moleculesi can be transfected with nucleic acid encoding all or a portion of (e-g-i a cytoplasmic-domain truncated portion) of an MHC class I alpha chain protein and beta 2 microglobulin protein or an MHC class II alpha chain protein and an MHC class II beta chain protein to thereby express MHC class I or MHC class II proteins on the cell surface- Expression of the appropriate class I or class II MHC in conjunction with a peptide having the activity of a B lymphocyte antigen (e-g-i B7-lι B7-2ι B7-3) induces a T cell mediated immune response against the transfected tumor cell- Optionallyi a gene encoding an antisense construct which blocks expression of an MHC class II associated proteini such as the invariant chaini can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity- Thusi the induction of a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject-

The activity of a protein of the invention ayi among other meansi be measured by the following methods: Suitable assays for thymocyte or splenocyte cytotoxicity includei without limitation! those described in: Current Protocols in Immunology! Ed by J- E- Coligani A- M- Kruisbeeki D. H- Marguliesi E- M- Shevachi U- Stroberi Pub. Greene Publishing Associates and Uiley-Interscience (Chapter 3ι In Vitro assays for Mouse Lymphocyte Function 3-1-3. Hi Chapter 7ι Immunologic studies in Humans)i Herrmann et al-i Proc- Natl- Acad- Sci- USA 7δ:246δ-2412ι llδli Herrmann et al-i J. Immunol- 12δ :11bδ-1174ι 1162i Handa et al-i J- Immunol- 135"-15fa4-1572ι 1165i Takai et al-! I- Im unol- 137."3414-3500ι Hδbi Takai et al-i J. Immunol- 140:5D6-512ι Hβδi Herrmann et al-i Proc- Natl- Acad- Sci- USA 7δ:2466-2412ι llδli Herrmann et al-i J- Immunol- 126 :11bβ-1174ι 1162i Handa et al.-i J- Immunol- 135 : 15b4-1572ι 1165i Takai et al-i J- Immunol. 137 : 3414-3500ι llδfai Bowmanet al-i J. Virology fal:1112-111βi Takai et al-i J. Immunol- 140:5D6-512ι Hδβi

Bertagnolli et al-i Cellular Immunology 133:327-341ι lllli Brown et al-i J- Immunol. 153: 3071-3D12ι H14-

Assays for T-cell-dependent immunoglobulin responses and isotype switching (which will identify! among othersi proteins that modulate T-cell dependent antibody responses and that affect Thl/Th2 profiles) includei without limitation! those described in: Maliszewskii J- Immunol- 144 :3026-3033ι HlOi and Assays for B cell function: In vitro antibody production! Mondi J- J- and Brunswicki M- In Current Protocols in Immunology. J. E. e - a - Coligan eds- Vol 1 pp. 3-6.l-3.fi.lbi John Uiley and Sonsi Toronto. 1114-

Mixed lymphocyte reaction (MLR) assays (which will identify! among othersi proteins that generate predominantly Thl and CTL responses) includei without limitation! those described in: Current Protocols in Immunology! Ed by J- E- Coligani A- M- Kruisbeeki D- H- Marguliesi E. M- Shevachi U- Stroberi Pub- Greene Publishing Associates and Uiley-Interscience (Chapter 3ι In Vitro assays for Mouse Lymphocyte Function 3-l-3-11i Chapter 7ι Immunologic studies in Humans)i Takai et al-i J. Immunol- 137:3414-350Dι Hfibi Takai et al-i J- Immunol- 140:5Dβ-512ι Hβδi Bertagnolli et al-i J- Immunol- 141 : 377δ-3763ι 1112-

Dendritic cell-dependent assays (which will identify! among othersi proteins expressed by dendritic cells that activate naive T-cells) includei without limitation! those described in: Guery et al-i J- Immunol- 134:53fa-544ι 1115i Inaba et al-i Journal of Experimental Medicine 173:541-551ι lllli Macatonia et al-i Journal of Immunology 154 :S071-5071ι HlSi Porgador et al-i Journal of Experimental Medicine 162:255-2b0ι 1115i Nair et al-i Journal of Virology b7:40b2-40b ! 1113i Huang et al.-, Science 2fa4:1fal-1fa5ι 1114i Macatonia et al-i Journal of Experimental Medicine Ibl :1255-12b4ι llδli Bhardwaj et al-i Journal of Clinical Investigation 14:717-607ι 1114i and Inaba et al-i Journal of Experimental Medicine 172:b31-fa40ι HID. Assays for lymphocyte survival/apoptosis (which will identifyi among othersi proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) includei without limitation! those described in: Darzynkiewicz et al-i Cytometry 13:715-606ι 1112i Gorczyca et al-i Leukemia 7 : b51-fa70ι 1113i Gorczyca et al-i Cancer Research 53:1145-1151ι 1113i Itoh et al.-i Cell fafa:233-243ι lllli Zacharchuki Journal of Immunology 145 : 4D37-4045ι HlOi Zamai et al- Cytometry 14:611-617i 1113i Gorczyca et al-i International Journal of Oncology I:fa31-fa4δι 1112-

Assays for proteins that influence early steps of T-cell commitment and development includei without limitation! those described in: Antica et al-i Blood δ4:lll-117ι 1114i Fine et al- Cellular Immunology 155".lll-122ι 1114i Galy et al-i Blood 6S:2770-277βι 1115i Toki et al-i Proc Nat. Acad Sci- USA

Hematopoiesis Regulating Activity

A protein of the present invention may be useful in regulation of hematopoiesis andi consequentlyi in the treatment of myeloid or lymphoid cell deficiencies- Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesisi e-g- in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokinesi thereby indicating utilityi for examplei in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cellsi in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i-e-i traditional CSF activity) usefuli for examplei in conjunction with chemotherapy to prevent or treat consequent myelo-suppressioni in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopeniai and generally for use in place of or complimentary to platelet transfusionsi and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above- mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders (such as those usually treated with transplantationi includingi without limitation! aplastic anemia and paroxysmal nocturnal hemoglobinuria) i as well as in repopulating the stem cell compartment post irradiation/chemotherapyi either in-vivo or ex-vivo (i-e-i in conjunction with bone marrow transplantation or with peripheral progenitor cell transplantation (homologous or heterologous)) as normal cells or genetically manipulated for gene therapy-

The activity of a protein of the invention ayi among other meansi be measured by the following methods:

Suitable assays for proliferation and differentiation of various hematopoietic lines are cited above-

Assays for embryonic stem cell differentiation (which will identify! among othersi proteins that influence embryonic differentiation hematopoiesis) includei without limitation! those described in: Johansson et al- Cellular Biology 15:l41-151ι 1115i Keller et al-i Molecular and Cellular Biology 13:473-4βbι 1113i McClanahan et al-i Blood 61 :2103-2115ι 1113-

Assays for stem cell survival and differentiation (which will identify! among othersi proteins that regulate lympho- hematopoiesis) includei without limitation! those described in: Methylcellulose colony forming assaysi Freshneyi M- G- In Culture of Hematopoietic Cells- R- I- Freshneyi et al- eds- Vol pp- 2fa5- 2faδι Uiley-Lissi Inc-i New Yorki N-Y- 1114i Hiraya a et al.-. Proc Natl- Acad- Sci- USA δl : 5107-5111ι 1112i Primitive hematopoietic colony forming cells with high proliferative potential! McNiecei I- K- and Briddelli R- A- In Culture of Hematopoietic Cells. R- I- Freshneyi et al. eds- Vol pp. 23-31ι Uiley-Lissi Inc-i New Yorki N-Y- 1114i Neben et al-i Experimental Hematology 22-"353-351ι 1114i Cobblestone area forming cell assayi Ploemacheri R- E- In Culture of Hematopoietic Cells- R- I-

Freshneyi et al- eds- Vol pp. l-21ι Uiley-Lissi Inc-i New Yorki N-Y- 1114i Long term bone marrow cultures in the presence of stromal cellsi Spoonceri E-i Dexteri M- and Alleni T- In Culture of Hematopoietic Cells- R- I- Freshneyi et al- eds- Vol pp- lfa3- 171ι Uiley-Lissi Inc-i New Yorki N-Y- 1114i Long term culture initiating cell assayi Sutherland! H- J- In Culture of Hematopoietic Cells- R- I- Freshneyi et al- eds- Vol pp. 131-lfa2ι Uiley-Lissi Inc-i New Yorki N-Y- 1114-

Tissue Growth Activity A protein of the present invention also may have utility in compositions used for bonei cartilagei tendoni ligament and/or nerve tissue growth or regeneration! as well as for wound healing and tissue repair and replacement! and in the treatment of burnsi incisions and ulcers- A protein of the present invention! which induces cartilage and/or bone growth in circumstances where bone is not normally for edi has application in the healing of bone fractures and cartilage damage or defects in humans and other animals- Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints. De novo bone formation induced by an osteogenic agent contributes to the repair of congenital! trauma inducedi or oncologic resection induced craniofacial defectsi and also is useful in cosmetic plastic surgery-

A protein of this invention may also be used in the treatment of periodontal diseasei and in other tooth repair processes- Such agents may provide an environment to attract bone-forming cellsi stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells- A protein of the invention may also be useful in the treatment of osteoporosis or osteoarthritisi such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (collagenase activity! osteoclast activity! etc-) mediated by inflammatory processes-

Another category of tissue regeneration activity that may be attributable to the protein of the present invention is tendon/ligament formation- A protein of the present invention! which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formedi has application in the healing of tendon or ligament tearsi deformities and other tendon or ligament defects in humans and other animals- Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissuei as well as use in the improved fixation of tendon or ligament to bone or other tissuesi and in repairing defects to tendon or ligament tissue- De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenitali trauma inducedi or other tendon or ligament defects of other origini and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments- The compositions of the present invention may provide environment to attract tendon- or ligament-forming cellsi stimulate growth of tendon- or ligament-forming cellsi induce differentiation of progenitors of tendon- or ligament-forming cellsi or induce growth of tendon/ligament cells or progenitors ex vivo for return in vivo to effect tissue repair- The compositions of the invention may also be useful in the treatment of tendonitisi carpal tunnel syndrome and other tendon or ligament defects- The compositions may also include an appropriate matrix and/or sequestering agent as a carrier as is well known in the art-

The protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissuei i-e- for the treatment of central and peripheral nervous system diseases and neuropathiesi as well as mechanical and traumatic disorders! which involve degeneration! death or trauma to neural cells or nerve tissue. More specifically! a protein may be used in the treatment of diseases of the peripheral nervous systemi such as peripheral nerve injuries! peripheral neuropathy and localized neuropathiesi and central nervous system diseases! such as Alzheimer's! Parkinson's diseasei Huntington's diseasei amyotrophic lateral sclerosisi and Shy-Drager syndrome- Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders! such as spinal cord disordersi head trauma and cerebrovascular diseases such as stroke- Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention- Proteins of the invention may also be useful to promote better or faster closure of non-healing woundsi including without limitation pressure ulcersi ulcers associated with vascular insufficiency! surgical and traumatic woundsi and the like- It is expected that a protein of the present invention may also exhibit activity for generation or regeneration of other tissuesi such as organs (including! for examplei pancreas i liveri intestinei kidneyi skini endothelium) i muscle (smoothi skeletal or cardiac) and vascular (including vascular endothelium) tissuei or for promoting the growth of cells comprising such tissues- Part of the desired effects may be by inhibition or modulation of fibrotic scarring to allow normal tissue to regenerate- A protein of the invention may also exhibit angiogenic activity-

A protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosisi reperfusion injury in various tissuesi and conditions resulting from systemic cytokine damage-

A protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cellsi or for inhibiting the growth of tissues described above-

The activity of a protein of the invention mayi among other meansi be measured by the following methods: Assays for tissue generation activity includei without limitation! those described in: International Patent Publication No. U015/lfaD35 (bonei cartilagei tendon)i International Patent Publication No- U015/0564b (nervei neuronaDi International - Patent Publication No- U011/D7411 (skini endothelium). Assays for wound healing activity includei without limitation! those described in: Uinteri Epidermal Uound Healingi pps- 71-112 (Maibachi H- I. and Roveei D- T-i eds-)ι Year Book Medical Publishers! Inc-i Chicagoi as modified by Eaglstein and Mertzi J- Invest- Dermatol 71:362-64 (1176)-

Activin/Inhibin Activity

A protein of the present invention may also exhibit activin- or inhibin-related activities- Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH)ι while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thusi a protein of the present invention! alone or in heterodimers with a member of the inhibin alpha familyi may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals. Alternatively! the protein of the invention! as a homodimer or as a heterodimer with other protein subunits of the inhibin- beta groupi may be useful as a fertility inducing therapeutic based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. Seei for examplei U«S- Pat- No- 4ι716ιδδ5- A protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammalsi so as to increase the lifetime reproductive performance of domestic animals such as cowsi sheep and pigs-

The activity of a protein of the invention mayi among other meansi be measured by the following methods: Assays for activin/inhibin activity includei without limitation! those described in: Vale et al-i Endocrinology 11:5b2-572ι 1172i Ling et al--. Nature 321:771-7δ2ι Hδfai Vale et al-i Nature 321:77b-771ι Hδbi Mason et al.-. Nature 31β:b51-bfa3ι HβSi Forage et al-i Proc Natl- Acad- Sci- USA 63:3011-3015!

Chemotactic/Che okinetic Activity

A protein of the present invention may have chemotactic or ^•■ chemokinetic activity (e-g-i act as a chemokine) for mammalian cellsi including! for examplei monocytesi fibroblastsi neutrophilsi T-cellsi mast cellsi eosinophilsi epithelial and/or endothelial cells- Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action- Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissuesi as well as in treatment of localized infections- For examplei attraction of lymphocytes! monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent- A protein or peptide has chemotactic activity for a particular cell population if it can stimulate! directly or indirectly! the directed orientation or movement of such cell population- Preferably! the protein or peptide has the ability to directly stimulate directed movement of cells- Uhether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis-

The activity of a protein of the invention mayi among other meansi be measured by the following methods: Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population- Suitable assays for movement and adhesion includei without limitation! those described in: Current Protocols in Immunology! Ed by J- E- Coligani A- M- Kruisbeeki D- H- Marguilesi E- M- Shevachi U- Stroberi Pub- Greene Publishing Associates and Uiley-Interscience (Chapter fa-12ι Measurement of alpha and beta Chemokines fa -12-1-fa .12 ■ βi Taub et al- J- Clin- Invest- 1S:1370-137bι HlSi Lind et al. APMIS 103:140-14bι 1115i Muller et al Eur- J- Immunol- 25 : 1744-174δi Gruber et al- J- of Immunol. 152 : 56fa0-5δfa7ι 1114i Johnston et al- J. of Immunol.

153:17fa2-17faβι 1114-

Hemostatic and Thrombolytic Activity

A protein of the invention may also exhibit hemostatic or thrombolytic activity. As a resulti such a protein is expected to be useful in treatment of various coagulation disorders

(including hereditary disorders! such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from traumai surgery or other causes- A protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such asi for examplei infarction of cardiac and central nervous system vessels (e-g-i stroke)-

The activity of a protein of the invention mayi among other meansi be measured by the following methods: Assay for hemostatic and thrombolytic activity includei without li itationi those described in". Linet et al-i J. Clin- Pharmacol. 2b:131-14Dι Hδbi Burdick et al.-. Thrombosis Res- 45:413-411ι 1167i Humphrey et al.-. Fibrinolysis 5:71-71 (Hll)i Schaubi Prostaglandins 35:4b7-474ι 1166-

Receptor/Ligand Activity

A protein of the present invention may also demonstrate activity as receptorsi receptor ligands or inhibitors or agonists of receptor/ligand interactions- Examples of such receptors and ligands includei without limitationi cytokine receptors and their ligandsi receptor kinases and their ligandsi receptor phosphatases and their ligandsi receptors involved in cell-cell interactions and their ligands (including without limitation! cellular adhesion molecules (such as selectinsi integrins and their ligands) and receptor/ligand pairs involved in antigen presentation! antigen recognition and development of cellular and humoral immune responses). Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction- A protein of the present invention ⁽including! without limitation! fragments of receptors and ligands) may themselves be useful as inhibitors of receptor/ligand interactions- The activity of a protein of the invention mayi among other meansi be measured by the following methods'.

Suitable assays for receptor-ligand activity include without limitation those described in:Current Protocols in Immunology! Ed by J. E- Coligani A- M- Kruisbeeki D- H- Marguliesi E- M- Shevachi U- Stroberi Pub. Greene Publishing Associates and Uiley- Interscience (Chapter 7-26ι Measurement of Cellular Adhesion under static conditions 7 -26 -l-7.26-22) i Takai et al-i Proc Natl- Acad. Sci- USA 64 : faβb4-bβbδι 1187i Bierer et al-i J. Exp. Med. lbδ:1145-115fa! Hββi Rosenstein et al-i J. Exp. Med- Ifa1:141-lb0 Hβli Stoltenborg et al--. J- Immunol- Methods 175:51- bδi 1114i Stitt et al-i Cell δ0:bbl-fa70ι 1115-

Anti-Inf lammatorv Activity

Proteins of the present invention may also exhibit anti- inflammatory activity. The anti-inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory responsei by inhibiting or promoting cell-cell interactions (such asi for examplei cell adhesion)ι by inhibiting or promoting chemotaxis of cells involved in the inflammatory processi inhibiting or promoting cell extravasationi or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response- Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions)! including without limitation intimation associated with infection (such as septic shocki sepsis or systemic inflammatory response syndrome (SIRS))ι ischemia-reperfusion injuryi endotoxin lethalityi arthritisi complement-mediated hyperacute rejection! nephritisi cytokine or che okine-induced lung injuryi inflammatory bowel diseasei Crohn's disease or resulting from over production of cytokines such as TNF or IL-1- Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material- Tumor Inhibition Activity

In addition to the activities described above for immunological treatment or prevention of tu orsi a protein of the invention may exhibit other anti-tumor activities- A protein may inhibit tumor growth directly or indirectly (such asi for examplei via ADCO- A protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissuei by inhibiting formation of tissues necessary to support tumor growth (such asi for examplei by inhibiting angiogenesis) i by causing production of other factorsi agents or cell types which inhibit tumor growthi or by suppressing! eliminating or inhibiting factorsi agents or cell types which promote tumor growth-

Other Activities

A protein of the invention may also exhibit one or more of the following additional activities or effects: inhibiting the growthi infection or function ofi or killingi infectious agentsi including! without limitationi bacterial virusesi fungi and other parasitesi effecting (suppressing or enhancing) bodily characteristics! including! without limitation! heighti weighti hair colori eye colori skini fat to lean ratio or other tissue pigmentation! or organ or body part size or shape (such asi for examplei breast augmentation or diminutioni change in bone form or shape)i effecting biorhythms or caricadic cycles or rhythmsi effecting the fertility of male or female subjectsi effecting the metabolismi catabolismi anabolismi processing! utilization! storage or elimination of dietary fati lipidi proteini carbohydratei vitaminsi mineralsi cofactors or other nutritional factors or component (s) i effecting behavioral characteristics! including! without limitation! appetitei libidoi stressi cognition (including cognitive disorders)! depression (including depressive disorders) and violent behaviorsi providing analgesic effects or other pain reducing effectsi promoting differentiation and growth of embryonic stem cells in lineages other than hematopoietic lineages hormonal or endocrine activityi in the case of enzymesi correcting deficiencies of the enzyme and treating deficiency-related diseasesi treatment of hyperproliferative disorders (such asi for examplei psoriasis)i immunoglobulin-like activity (such asi for examplei the ability to bind antigens or complements and the ability to act as an antigen in a vaccine composition to raise an immune response against such protein or another material or entity which is cross-reactive with such protein-

Particular Applications for Certain Clones

The following sets out a non-exclusive list of applications for certain embodiments of the invention- In the interest of economyi applications relevant to multiple embodiments are not duplicated in this list- Other embodiments described herein have similar characteristics! as described there- The artisan is directedi therefore! to the Description of the Sequences for similar descriptions of the functions of other embodiment-

Testes htes3_lDilfa: The new protein can find application in diagnosis/therapy in leukemia predisposition/disease in the modulation of DNA repair-

htes3_10nlD: The new protein can find application in studying the expression profile of testis-specif ic genes-

htes3_llal7: The new protein can find application in studying the expression profile of testis-specif ic genes and as a new marker for testicular cells-

htes3_llc22: The new protein can find application in modulating/blocking of regulatory pathways-

htes3_lld21: The new protein can find application in diagnosis of diseases due to unnormal protein degradation like muscular dystrophy or multiple sclerosis as well as in modulating the half life of specific proteins and in expression profiling-

Kidney hfkd2_3kl The new protein can find application in modulation of endocytosis ■ strong similarity to testicular dynamin (Rattus norvegicus)- Amygdala; hamy2_10hl7: The new protein can find application in modulating protein-protein-interaction and in studying the expression profile of amygdala-specific genes-

hamy2_10p7: The new protein can find application in modulation of NA+/Ca2+-exchange and voltage-dependend processes.

hamy2_lld2: The new protein can find application in studying the expression profile of amygdala-specific genes and as a new marker for amygdala cells-

hamy2_lln4: The new protein can find application in modulation of DNA-repair and a as a new tool for manipulation of nucleic acids-

hamy2_121f11-" The new protein can find application modulation of cyto skeleton-membrane interactions.

Fetal Brain: hfbr2_7δcl2: The new protein can find application in the modulation of translational pathways- hfbr2_7βdlβ: The new protein can find application in studying the expression profile of brain-specific genes- hfbr2_7fid4: The new protein can find application in studying the expression profile of brain-specific genes and as a new marker for amygdala cells- hfbr2_78elδ: The new protein can find application in studying the expression profile of brain-specific genes- hfbr2_7fii21: The new protein can find application in diagnosis/modulation of protein damage and age-related degenerative processes-

Melanoma: hmel2_12jl: The new protein can find application in studying the expression profile of melanoma-specific genes-

hmel2_7gl4: The new protein can find application in modulation of the sorting of proteins into different compartments.

hmel2_7kl1: The new protein can find application in studying the expression profile of melanoma-specific genes-

VARIANTS OF THE INVENTIVE DNA MOLECULES

Variants in General

"Variantsi" according to the invention! include DNA and/or protein molecules that resemblei structurally and/or functionally! those set forth herein- Variants may be isolated from natural sources ("homologs") i may be entirely synthetic or may be based in part o-n both natural and synthetic approaches-

The section set forth below presents various structural and functional characteristics of molecules within the invention- Preferred molecules are characterized by a combination of one or more of these characteristics- For instance! some preferred molecules are described with reference to at least two structural characteristics! while others may be described with reference to at least one structural and at least one functional characteristic- It will be recognized by the skilled artisan that structure ultimately defines function! i.e. the functions of the molecules described herein derives from the structures of those molecules- Accordingly! the structural variants described below that bear the closest structural relationship (as variously defined below) to the inventive molecules are the variants that most likely will preserve biological function- This relationship between structure and function will guide the skilled artisan in identifying the preferred embodiments of the invention- Splicing Variants

It is well-known that eukaryotic structural genes are comprised of both protein coding and non-coding portions. Uhen the messenger RNA is transcribed from the DNA template! it contains intronsi which are non-codingi and exonsi which are coding. In order to form a translation competent mRNAi the introns must be "spliced" out of this initial pre mRNA-

Specific sequences within the pre mRNA represent "splice junctions" that direct the cellular splicing machinery to the appropriate position- The splice junctions are loosely conserved sequence regions of the pre mRNAi which almost invariably begin with GT and end with AG (DNA perspective). The 5' end of the splice junction typically contains about nine somewhat conserved residuesi for examplei C/AAGTA/GAGT ■ The 3' end usually contains a pyrimidine rich stretch of at least about 11 nucleotidesi followed by NC/TAGG- Splicing occurs before the GT and after the AG. Mounti Nucleic Acids Res. 10:451-72 (1162).

Interestingly! exons often correspond to discrete functional domains of the protein product- The intron/exon arrangement thus creates a linear array of nucleotides which can be correlated to discrete! and often interchangeable! functional protein fragments- GOT Nature 211:10-12 (1161) i Branden et al.i EMBO J. 3:1307-10 (1164)- This linear arrangement creates the possibility of generating multiple different full length proteins by rearranging the order of the different functional portions in the array - For examplei if a set of exons are arranged l-2-3-4ι where (-) represents the introns separating the exonsi a splicing event need not simply produce 1234ι but may produce 123ι 134ι 124 and so on- Production of different mRNA products in this way is commonly called "alternative splicing-" Andreadis et al . -, Ann. Rev. Cell Biol . 3:2D7-42 (1167)-

Some of the present DNA molecules can be represented in modular fashion in terms of their coding regions- Essentially! these modules are exons (though each "exon" may in fact be made up of several exons) i which may be combined in different ways to form a variety of different DNA moleculesi each encoding a different functional protein- Splicing variants are indicated in the Description of the Sequences- Degenerate Variants

One aspect of the present invention provides "degenerate variants" of the nucleic acid fragments of the present invention- A "degenerate variant" is a nucleotide fragment which differs from those of inventive molecules by nucleotide sequence! but due to the degeneracy of the genetic codei encodes an identical polypeptide sequence- Given the known relationship between DNA sequences and the proteins they encodei degenerate variants typically are described by reference to this relationship- It is well known that the degeneracy of the genetic code results in many possible DNA sequences which encode a particular protein- Indeedi of the three bases which comprise an amino acid-encoding tripleti the third position! and often the secondi almost always may vary- This fact alone allows for a class of variant DNA molecules which encode protein sequences identical to those disclosed hereini yet have about 3D sequence variation- In other wordsi the variant DNA molecules are about 70* identical to the inventive DNAsi having no additional or deleted sequences- Thusi one aspect of the invention provides degenerate variant DNA molecules encoding the inventive protein sequences-

In one embodiment! these variants have at least about 70* sequence identity with the DNA molecules described herein- In a preferred embodimenti these variants have at least about 60* sequence identity to the inventive molecules- In a more preferred embodiment these variants have at least about 10* sequence identity with the inventive molecules-

Conservative Amino Acid Variants

Variants according to the invention also may be made that conserve the overall molecular structure of the encoded proteins- Given the properties of the individual amino acids comprising the disclosed protein products! some rational substitutions will be recognized by the skilled worker. Amino acid substitutions! i.e. "conservative substitutions!" may be madei for instance! on the basis of similarity in polarityi chargei solubilityi hydrophobicityi hydrophilicityi and/or the amphipathic nature of the residues involved- For example: (a) nonpolar (hydrophobic) amino acids include alaninei leucinei isoleucinei valinei prolinei phenylalaninei tryptophani and methioninei (b) polar neutral amino acids include glycinei serinei threoninei cysteinei tyrosinei asparaginei and glutaminei (c) positively charged (basic) amino acids include argininei lysinei and histidinei and (d) negatively charged (acidic) amino acids include aspartic acid and glutamic acid- Substitutions typically may be made within groups (a)-(d)- In additioni glycine and proline may be substituted for one another based on their ability to disrupt α-helices- Similarly! certain amino acidsi such as alaninei cysteinei leucinei methioninei glutamic acidi glutaminei histidine and lysine are more commonly found in α-helicesi while valinei isoleucinei phenylalaninei tyrosinei tryptophan and threonine are more commonly found in β- pleated sheets- Glycinei serinei aspartic acidi asparaginei and proline are commonly found in turns- Some preferred substitutions may be made among the following groups: (i) S and Ti (ii) P and Gi and (iii) Ai Vi L and I- Given the known genetic codei and recombinant and synthetic DNA techniquesi the skilled scientist readily can construct DNAs encoding the conservative amino acid variants-

As used hereini "sequence identity" between two polypeptide sequences indicates the percentage of amino acids that are identical between the sequences- "Sequence similarity" indicates the percentage of amino acids that either are identical or that represent conservative amino acid substitutions-

Functionally Equivalent Variants

Yet another class of DNA variants within the scope of the invention may be described with reference to the product they encode- As shown in the Description of the Sequences! some of the inventive DNA molecules encode a protein having a degree of homology with known proteinsi or protein domains- It is expectedi thereforei that they will have some or all of the requisite functional features of such molecules- These "functionally equivalent variants" products are characterized by the fact that they are functionally equivalent! with respect to biological activity! to certain known molecules- Also provided herein is information on common structural motifsi including consensus sequences that will guide the artisan in constructing functionally equivalent variants- It will be understood that the motifsi identified in the Description of the Sequences for each inventive proteini may be modified within the identified consensus sequences- Thusi the invention contemplates the proteins in the Description of the Sequences that contain variability in the consensus sequences identified! and the invention further contemplates the full range of nucleic acids encoding themi and the complements of those nucleic acids-

Hybridizing Variants

DNA variants within the invention also may be described by reference to their physical properties in hybridization- One skilled in the field will recognize that DNA can be used to identify its complement andi since DNA is double strandedi its equivalent or homologi using nucleic acid hybridization techniques. It will also be recognized that hybridization can occur with less than 10D* complementarity- Howeveri given appropriate choice of conditions! hybridization techniques can be used to differentiate among DNA sequences based on their structural relatedness to a particular probe- For guidance regarding such conditions seei for examplei Sambrook et al . i llδli MOLECULAR CLONINGi A LABORATORY MANUALi Cold Spring Harbor Pressi N-Y-i and Ausubel et al . -, 11^β1τ CURRENT PROTOCOLS IN MOLECULAR BIOLOGYi Green Publishing Associates and Uiley Intersciencei N-Y-

Structural relatedness between two polynucleotide sequences can be expressed as a function of "stringency" of the conditions under which the two sequences will hybridize with one another- As used hereini the term "stringency" refers to the extent that the conditions disfavor hybridization- Stringent conditions strongly disfavor hybridization! and only the most structurally related molecules will hybridize to one another under such conditions. Converselyi non-stringent conditions favor hybridization of molecules displaying a lesser degree of structural relatedness. Hybridization stringency! therefore! directly correlates with the structural relationships of two nucleic acid sequences- The following relationships are useful in correlating hybridization and relatedness (where T_m is the melting temperature of a nucleic acid duplex) :

a- T_m = bl-3 + 0.4KG+O* b- The Tm of a duplex DNA decreases by 1°C with every increase of 1* in the number of mismatched base pairs. c (T_ra)_μS - ⁽Tm μi = 16-5 logι_Dμ2/μl where μl and μ2 are the ionic strengths of two solutions-

Hybridization stringency is a function of many factorsi including overall DNA concentration! ionic strengthi temperaturei probe size and the presence of agents which disrupt hydrogen bonding. Factors promoting hybridization include high DNA concentrations! high ionic strengths! low temperatures! longer probe size and the absence of agents that disrupt hydrogen bonding- Hybridization usually is done in two stages- Firsti in the "binding" stagei the probe is bound to the target under conditions favoring hybridization- Stringency is usually controlled at this stage by altering the temperature- For high stringency! the temperature is usually between b5°C and 7D°Cι unless short (<20 nt) oligonucleotide probes are used- A representative hybridization solution comprises faX SSCi D-5* SDSi 5X Denhardt's solution and lODμg of non-specific carrier DNA- See Ausubel et al . -, supra-, section 2-1ι supplement 27 (1114)- Of course many different! yet functionally equivalent! buffer conditions are known- Uhere the degree of relatedness is loweri a lower temperature may be chosen- Low stringency binding temperatures are between about 25°C and 40°C- Medium stringency is between at least about 40°C to less than about fa5°C- High stringency is at least about fa5°C- Secondi the excess probe is removed by washing- It is at this stage that more stringent conditions usually are applied- Hencei it is this "washing" stage that is most important in determining relatedness via hybridization. Uashing solutions typically contain lower salt concentrations. One exemplary medium stringency solution contains 2X SSC and 0-1* SDS- A high stringency wash solution contains the equivalent (in ionic strength) of less than about 0-2X SSCi with a preferred stringent solution containing about D-1X SSC The temperatures associated with various stringencies are the same as discussed above for "binding." The washing solution also typically is replaced a number of times during washing- For example! typical high stringency washing conditions comprise washing twice for 30 minutes at 55° C- and three times for 15 minutes at b0° C-

The present invention includes nucleic acid molecules that hybridize to the inventive molecules under high stringency binding and washing conditions- More preferred molecules (from an mRNA perspective) are those that are at least 50 * of the length of any one of those depicted in the Description of the Sequences- Particularly preferred molecules are at least 75 * of the length of those molecules-

Substi utions, Insertions , Additions and Deletions

In a general sensei the preferred DNA variants of the invention are those that retain the closest relationship! as described by "sequence identity" to the inventive DNA molecules- According to another aspect of the invention! thereforei substitutions! insertions! additions and deletions of defined properties are contemplated- It will be recognized that sequence identity between two polynucleotide sequences! as defined hereini generally is determined with reference to the protein coding region of the sequences- Thusi this definition does not at all limit the amount of DNAi such as vector DNAi that may be attached to the molecules described herein- Preferred DNA sequence variants include molecules encoding proteins sharing some or all of any relevant biological activity of the native molecule-

In creating these variants! the skilled worker will be guided by reference to the protein structure- Firsti insertions and deletions in any recognized functional domain above generally should be avoidedi except as noted below in the section entitled "Proteinsi" where this domain is discussed in detail- Alterations in such domains usually will be limited to conservative amino acid substitutions. In addition! where insertions and deletions are desiredi this may be accomplished at the N- and/or C-terminus of the protein molecule (or the corresponding coding regions of the DNA). If insertions or deletions are made within the proteini deletions of major structural features usually should be avoided- Thusi a preferred place to make insertion or deletion variants is in non-structural regionsi such as linker regions between two alpha helices- "Substitutions" generally refer to alterations in the DNA sequence which do not change its overall lengthi but only alter one or more nucleotide positions! substituting one for another in the common sense of the word- One class of preferred substitutions! "degenerate substitutions!" are those that do not alter the encoded amino acid sequence. Some subsitutions retains 50*ι 55*! bD* or faS* identity. Preferred substitutions retain at least about 70* identity! more preferably at least 70* or 75* identity! with the inventive DNAs- Some more preferred molecules have at least about 60* identity! more preferably at least 60* or 65* identity. Particularly preferred DNAs share at least about 10* identity! more preferably at least ID* or 15* identity.

"Insertions!" unlike substitutions! alter the overall length of the DNA moleculei and thus sometimes the encoded protein. Insertions add extra nucleotides to the interior (not the 5' or 3' ends) of the subject DNAs. Preferred insertions are made with reference to the protein sequence encoded by the DNA- Thusi it is most preferred to provide an insertion in the DNA at a location that corresponds to an area of the encoded protein which lacks structure- For instance! it typically would not be beneficiali if the preservation of biological activity is desiredi to provide an insertion within an alpha-helical region or a beta-pleated sheet- Accordingly! non-structural areasi such as those containing helix- breaking glycines and proline residuesi are most preferred sites of insertion. Other preferred sites of insertion are the splice sitesi which are indicated above in the description of the inventive DNA molecules-

Uhile the optimal size of insertions will vary depending upon the site of insertion and its effect on the overall conformation of the encoded proteini some general guides are useful- Generally! the total insertions (irrespective of their number) should not add more than about 3D* (or preferably not more than 30*) to the overall size of the encoded protein- More preferablyi the insertion adds less than about 1D-2D* (yet more preferably 10- 20*) in sizei with less than about 10* being most preferred. The number of insertions is limited only by the number of suitable insertions sitesi and secondarily by the foregoing size preferences-

"Additions!" like insertions! also add to the overall size of the DNA oleculei and usually the encoded protein- Howeveri instead of being made within the moleculei they are made on the 5' or 3' endi usually corresponding to the N- or C- terminus of the encoded protein- Unlike deletions! additions are not very size- dependent- Indeedi additions may be of virtually any size- Preferred additions! howeveri do not exceed about 1D0* of the size of the native molecule- More preferably! they add less than about bD to 30* to the overall sizei with less than about 30* being most preferred-

"Deletions" diminish the overall size of the DNA andi therefore! also reduce the size of the protein encoded by that DNA- Deletions may be made from either end of the molecule or internal to it- Typical preferred deletions remove discrete structural features of the encoded protein- For examplei some deletions will comprise the deletion of one or more exons which may define a structural feature- Preferred deletions remove less than about 30* of the size of the subject molecule- More preferred deletions remove less than about 20* and most preferred deletions remove less than about ID*-

Computer -De fined Variants and Definition of "Sequence Identity" In generali both the DNA and protein molecules of the invention can be defined with reference to "sequence identity-" As used hereini "sequence identity" refers to a comparison made between two molecules usingi for examplei the standard Smith- Uaterman algorithm that is well known in the art- Some molecules have at lease about 50*ι 55* or bO* identity- Preferred molecules are those having at least about b5* sequence identity! more preferably at least fa5* or 70* sequence identity. Other preferred molecules have at least about 6D*ι more preferably at least δO* or 65*ι sequence identity. Particularly preferred molecules have at least about 10* sequence identity! more preferably at least 10* sequence identity- Most preferred molecules have at least about 15*ι more preferably at least 15*ι sequence identity- As used hereini two nucleic acid molecules or proteins are said to "share significant sequence identity" if the two contain regions which possess greater than 65* sequence (amino acid or nucleic acid) identity-

"Sequence identity" is defined herein with reference the Blast 2 algorithm! which is available at the NCBI

(http://www.ncbi -nlm.nih.gov/BLAST) i using default parameters- References pertaining to this algorithm include: those found at http: //www- ncbi ■ nlm-nih-gov/BLAST/blast_references • htmli Altschuli S-F-i Gishi U-i Milleri U-i Myersi E-U- & Lipmani D-J- (1110) "Basic local alignment search tool-" J- Mol- Biol-

215:403-410i Gishi hi. & Statesi D-J. (1113) "Identification of protein coding regions by database similarity search." Nature Genet- 3:2bb-272i Maddeni T-L-i Tatusovi R.L- & Zhangi J. (111b) "Applications of network BLAST server" Meth- Enzymol. 2bb:131- 141i Altschuli S-F-i Maddeni T-L-i Schafferi A-A-i Zhangi J-i Zhangi Z-i Milleri U- & Lipmani D-J. (1117) "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs-" Nucleic Acids Res- 25 : 3361-3402i and Zhangi J- & Maddeni T-L- (1117) "PowerBLAST: A new network BLAST application for interactive or automated sequence analysis and annotation-" Genome Res- 7:fa41-b5fa-

METHODS OF MAKING VARIANTS

It will be recognized that variants of the inventive molecules can be constructed in several different ways- For examplei they may be constructed as completely synthetic DNAs- Methods of efficiently synthesizing oligonucleotides in the range of 20 to about 150 nucleotides are widely available- See Ausubel et al . -, supra-, section 2-llι Supplement 21 (1113)- Overlapping oligonucleotides may be synthesized and assembled in a fashion first reported by Khorana et al.-. J- Mol- Biol- 72:201-217 (1171)i see also Ausubel et all Section 6-2. The synthetic DNAs are designed with convenient restriction sites engineered at the 5' and 3' ends of the gene to facilitate cloning into an appropriate vector- An alternative method of generating variants is to start with one of the inventive DNAs and then to conduct site-directed mutagenesis- See Ausubel et al.i supra-, chapter 6ι Supplement 37 (1117)- In a typical methodi a target DNA is cloned into a single-stranded DNA bacteriophage vehicle- Single-stranded DNA is isolated and hybridized with a oligonucleotide containing the desired nucleotide alteration (s) ■ The complementary strand is synthesized and the double stranded phage is introduced into a host- Some of the resulting progeny will contain the desired mutanti which can be confirmed using DNA sequencing. In addition! various methods are available that increase the probability that the progeny phage will be the desired mutant. These methods are well known to those in the field and kits are commercially available for generating such mutants-

ISOLATING HOMOLOGS

Methods

By using the sequences disclosed herein as probes or .as primersi and techniques such as PCR cloning and colony/plaque hybridization! one skilled in the art can obtain homologs- "Homologs" are essentially naturally-occurring variants and include allelic species-specific and tissue-specific variants-

Region-specific primers or probes derived from the nucleotide sequence(s) provided can be used to prime DNA synthesis and PCR amplification! as well as to identify colonies containing cloned DNA encoding a homolog using known methods (Innis et aϊ . , PCR Protocols, Academic Pressi San Diegoi CA (1110))- Such an application is useful in diagnostic methodsi as described in more detail belowi as well as in preparing full-length DNAs from various sources- The PCR primers are preferably at least 15 basesi and more preferably at least 16 bases in length- Uhen selecting a primer sequence! it is preferred that the primer pairs have approximately the same G/C ratioi so that melting temperatures are approximately the same- As a general guidei the formula 3(G+C) + 2(A+T) = °Cι is useful.

Uhen using primers derived from the inventive sequences! one skilled in the art will recognize that by employing high stringency conditions ( e. g. -, annealing at 50-faO°C)ι only sequences with greater than 75* sequence identity to the primer will be amplified- By employing lower stringency conditions (e-g-i annealing at 35-37°C)ι sequences which have greater than 4D-50* sequence identity to the primer also will be amplified-

The PCR product may be subcloned and sequenced to confirm that it indeed displays the expected sequence identity. The PCR fragment may then be used to isolate a full length cDNA clone by a variety of methods- For examplei the amplified fragment may be labeled and used to screen a bacteriophage cDNA library. Alternatively! the labeled fragment may be used to screen a genomic library. PCR technology may also be utilized to isolate full length cDNA sequences- For examplei RNA may be isolatedi following standard procedures! from an appropriate cellular or tissue source- A reverse transcription reaction may be performed on the RNA using an oligonucleotide primer specific for the most 5' end of the amplified fragment for the priming of first strand synthesis. The resulting RNA/DNA hybrid may then be "tailed" with guanines using a standard terminal transferase reaction! the hybrid may be digested with RNAase Hi and second strand synthesis may then be primed with a poly-C primer- Thusi cDNA sequences upstream of the amplified fragment may easily be isolated- For a review of cloning strategies which may be usedi see e-g-i Sambrook et al-i 1161 i supra .

Uhen using DNA probes derived from the inventive sequences for colony/plaque hybridizationi one skilled in the art will recognize that by employing medium to high stringency conditions (e-g-i hybridizing at 50-b5°C in 5X SSPC and 50* formamidei and washing at 5D-b5°C in D-5X SSPOi sequences having regions with greater than ID* sequence identity to the probe can be obtained! and that by employing lower stringency conditions (e-g-i hybridizing at 35-37°C in 5X SSPC and 4D-45* formamidei and washing at 42°C in SSPOi sequences having regions with greater than 35-45* sequence identity to the probe will be obtained.

Suitably! genomic or cDNA libraries can be constructed and screened in accord with the previous paragraph- The libraries should be derived from a tissue or organism that is known to express the gene of interest! or that is suspected of expressing the gene- The clone containing the homolog may then be purified through methods routinely practiced in the arti and subjected to sequence analysis-

Additionally! an expression library can be constructed utilizing DNA isolated from or cDNA synthesized from a tissue or organism that is known to express the gene of interesti or that is suspected of expressing the gene- In this manneri clones may be induced and screened using standard antibody screening techniques in conjunction with antibodies raised against the normal gene producti as described herein- (For screening techniquesi seei for examplei Harlowi E- and Lanei eds-i l βδi ANTIBODIES: A LABORATORY MANUALi Cold Spring Harbor Pressi Cold Spring Harbor Press ■ )

Human Homologs

Any organism or tissue can be used as the source for homologs of the present invention so long as the organism or tissue naturally expresses such a protein or contains genes encoding the same- The most preferred organism for isolating homologs is human ■

PROTEINS OF THE INVENTION One class of proteins included within the invention is encoded by the inventive DNA molecules presented- Other proteins according to the invention are those encoded by the DNA variants described above- As notedi these variants are designed with the encoded proteins in mind- A preferred class of protein fragments includes those fragments which retain any biological activity- These molecules share functional features common the family of proteinsi although these characteristics may vary in degree-

According to one aspect of the invention fragments of the inventive proteins are contemplated- Some preferred fragments are those which are capable of eliciting an immune response- Generally these "antigenic" fragments will be from about five amino acids in length to about fifty amino acids in length- Some preferred antigenic fragments are from five to about twenty amino acids long- "Antigenic" response may refer to a T cell responsei a B cell response or a response by cells of the macrophage/monocyte lineages- In most casesi howeveri it will refer to the immune response involved in the generation of antibodies- In other wordsi the relevant immune response is that of helper T cells and/or B cells- These preferred molecules comprise one or more T cell and /or B cell epitopes-

ANTIBODIES OF THE INVENTION

Antibodies raised against the proteins and protein fragments of the invention also are contemplated by the invention- Described below are antibody products and methods for producing antibodies capable of specifically recognizing one or more epitopes of the presently described proteins and their derivatives- Antibodies includei but are not limited to polyclonal antibodies! monoclonal antibodies (mAbs)ι humanized or chimeric antibodies! single chain antibodies including single chain Fv (scFv) fragments! Fab fragments! F(ab')s fragments! fragments produced by a Fab expression libraryi anti-idiotypic (anti-Id) antibodiesi epitope-binding fragments! and humanized forms of any of the above- As known to one in the arti these antibodies may be usedi for examplei in the detection of a target protein in a biological sample- They also may be utilized as part of treatment methodsi and/or may be used as part of diagnostic techniques whereby patients may be tested for abnormal levels or for the presence of abnormal forms of the such proteins. In generali techniques for preparing polyclonal and monoclonal antibodies as well as hybridomas capable of producing the desired antibody are well known in the art (Campbelli A-M-i Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology-, Elsevier Science Publishers! Amsterdam! The Netherlands (1164) i St- Groth et al-i J. Immunol . Methods 35:1-21 (1160) i Kohler and Milsteini Nature 25fa:41S-417 (1175))ι the trioma technique! the human B-cell hybridoma technique (Kozbor et al-i Immunology Today 4:72 (1163) i Cole et al-i in Monoclonal Antibodies and Cancer Therapy-, Alan R- Lissi Inc. (1165) i pp. 77-1b). Antibodies may also be generated by the known techniques of phage display and in vitro immunization. Polyclonal Antibodies

Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of animals immunized with an antigeni such as an inventive protein or an antigenic derivative thereof-

Polyclonal antiserumi containing antibodies to heterogeneous epitopes of a single proteini can be prepared by immunizing suitable animals with the expressed protein described abovei which can be unmodified or modifiedi as known in the arti to enhance immunogenicity- Immunization methods include subcutaneous or intraperitoneal injection of the polypeptide-

Effective polyclonal antibody production is affected by many factors related both to the antigen and to the host species- For examplei small molecules tend to be less immunogenic than other and may require the use of carriers and/or adjuvant- In addition! host animal response may vary with site of inoculation- Both inadequate or excessive doses of antigen may result in low titer antisera- In generali howeveri small doses (high ng to low μg levels) of antigen administered at multiple intradermal sites appears to be most reliable- Host animals may include but are not limited to rabbitsi micei chickens and ratsi to name but a few- An effective immunization protocol for rabbits can be found in Vaitukaitisi J- et al., J. Clin. Endocrinol . Metab. 33:166-111 (1171) - The protein immunogen may be modified or administered in an adjuvant in order to increase the protein's antigenicity- Methods of increasing the antigenicity of a protein are well known in the art and includei but are not limited to coupling the antigen with a heterologous protein (such as globulin β-galactosidase) or through the inclusion of an adjuvant during immunization- Adjuvants include Freund's (complete and incomplete)! mineral gels such as aluminum hydroxidei surface active substances such as lysolecithini pluronic polyolsi polyanionsi peptidesi oil emulsionsi keyhole limpet he ocyanini dinitrophenoli and potentially useful human adjuvants such as BCG ⁽bacille Calmette- Guerin) and Corynebacterium parvum .

Booster injections can be given at regular intervals! with at least one usually being required for optimal antibody production. The antiserum may be harvested when the antibody titer begins to fall- Titer may be determined semi-quantitativelyi for examplei by double immunodiffusion in agar against known concentrations of the antigen- Seei for examplei Ouchterlony et al . , Chap. 11 in: Handbook of Experimental Immunology, Uieri edi Blackwell (1173)- Plateau concentration of antibody is usually in the range of D-l to D-2 mg/ml of serum (about 12 μM). The antiserum may be purified by affinity chromatography using the immobilized immunogen carried on a solid support. Such methods of affinity chromatography are well known in the art- Affinity of the antisera for the antigen may be determined by preparing competitive binding curvesi as described! for examplei by Fisher i Chap- 42 in: Manual of Clinical Immunology, second editioni Rose and Fried ani eds-i Amer- Soc- For Microbiology! Uashingtoni D-C (1160).

In addition to using protein an the immunogeni DNA molecules may be used directly- In this manneri a DNA encoding the protein immunogen is administered- Boosting and harvesting is done in a manner analogous to that detailed above- Yet another method of producing antibodies entails immunizing chickens and harvesting the antibodies from their eggs-

Monoclonal Antibodies

Monoclonal antibodies (MAbs)ι are homogeneous populations of antibodies to a particular antigen- They may be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture or in vivo- MAbs may be produced by making hybridomas which are immortalized cells capable of secreting a specific monoclonal antibody-

Monoclonal antibodies to any of the proteinsi peptides and epitopes thereof described herein can be prepared from murine hybridomas according to the classical method of Kohleri G- and Milsteini d Nature 25b:415-417 (1175) (and U-S- Patent No- 4ι37bιll0) or modifications of the methods thereofi such as the human B-cell hybridoma technique (Kosbor et al.i 1163ι Immunology Today 4:72i Cole et al . ^■> 11δ3ι Proc. Natl . Acad. Sci . USA δ0: 2D2b-2030)! and the EBV-hybridoma technique (Cole et al . -, 11δ5ι MONOCLONAL ANTIBODIES AND CANCER THERAPYi Alan R- Lissi Inc-i pp. 77-1b).

In one method a mouse is repetitively inoculated with a few micrograms of the selected protein over a period of a few weeks- The mouse is then sacrificed! and the antibody producing cells of the spleen are isolated- The spleen cells are fusedi typically using polyethylene glycoli with mouse myeloma cellsi such as SP2/0-Agl4 myeloma cells- The excessi unfused cells are destroyed by growth of the system on selective media comprising aminopterin (HAT media)- The successfully fused cells are dilutedi and aliquots are plated to microliter plates where growth is continued- Antibody— producing clones (hybridomas) are identified by detection of antibody in the supernatant fluid of the wells by immunoassay procedures- These include ELISAi as originally described by Engvalli Meth. Enzymol . 70:411 (11δ0)ι western blot analysis! radioimmunoassay (Lutz et al . -, Exp. Cell Res. 175:101-124 (1166)) and modified methods thereof- Selected positive clones can be expanded and their monoclonal antibody product harvested for use- Detailed procedures for monoclonal antibody production are described in Davisi L- et al . BASIC METHODS IN MOLECULAR BIOLOGYi Elsevieri New York- Section 21-2 (1161). The hybridoma clones may be cultivated in vitro or in vivo-, for instance as ascites- Production of high titers of mAbs in vivo makes this the presently preferred method of production- Alternatively! hybridoma culture in hollow fiber bioreactors provides a continuous high yield source of monoclonal antibodies-

The antibody class and subclass may be determined using procedures known in the art ⁽Ca pbelli A-M-i Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology-, Elsevier Science Publishers! Amsterdami The Netherlands (11δ4))- MAbs may be of any immunoglobulin class including IgGi IgMi IgEi IgAi IgD and any subclass thereof- Methods of purifying monoclonal antibodies are well known in the art-

Antibody Derivatives and Fragments

Fragments or derivatives of antibodies include any portion of the antibody which is capable of binding the target antigeni or a specific portion thereof. Antibody derivatives include poly- specific ( e. g. , bi-specific) antibodies! which contain binding sites specific for two or more different epitopes- These epitopes may be from the same or different inventive molecules or one or more epitope may be from a molecule not specifically disclosed here- Antibody fragments specifically include F(ab')gι Fabi Fab' and Fv fragments- These can be generated from any class of antibodyi but typically are made from IgG or IgM- They may be made by conventional recombinant DNA techniques ori using the classical methodi by proteolytic digestion with papain or pepsin- See CURRENT PROTOCOLS IN IMMUNOLOGYi chapter 2ι Coligan et al . -, eds-i (John Uiley & Sons 1111-12)-

F(ab')s fragments are typically about 110 kDa (IgG) or about 15D kDa (IgM) and contain two antigen-binding regionsi joined at the hinge by disulfide bond(s). Virtually alii if not alii of the Fc is absent in these fragments- Fab' fragments are typically about 55 kDa (IgG) or about 75 kDa (IgM) and can be formedi for examplei by reducing the disulfide bond(s) of an F(ab')e fragment- The resulting free sulfhydryl group(s) may be used to conveniently conjugate Fab' fragments to other moleculesi such as detection reagents ( e . g. -, enzymes).

Fab fragments are onovalent and usually are about 50 kDa (from any source). Fab fragments include the light (L) and heavy (H) chaini variable (VL and VHI respectively) and constant (CL C_HI respectively) regions of the antigen-binding portion of the antibody. The H and L portions are linked by an intramolecular disulfide bridge-

Fv fragments are typically about 25 kDa (regardless of source) and contain the variable regions of both the light and heavy chains (VL and VHI respectively)- Usuallyi the VL and VH chains are held together only by non-covalent interacts andi thusi they readily dissociate. They doi howeveri have the advantage of small size and they retain the same binding properties of the larger Fab fragments- Accordingly! methods have been developed to crosslink the VL and VH chainsi usingi for examplei glutaraldehyde (or other chemical crosslinkers) i intermolecular disulfide bonds (by incorporation of cysteines) and peptide linkers- The resulting Fv is now a single chain (i.e.i SCFv). Other antibody derivatives include single chain antibodies (U-S- Patent 4ι14bι776i Birdi Science 242:423-42fa (11βδ)i Huston et al.i Proc- Natl- Acad- Sci- USA δ5:5671-56δ3 (11δδ)i and Uard et al . -, Nature 334:544-54b (1161))- Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridgei resulting in a single chain FV (SCFv) -

One preferred method involves the generation of scFvs by recombinant methodsi which allows the generation of Fvs with new specificities by mixing and matching variable chains from different antibody sources- In a typical methodi a recombinant vector would be provided which comprises the appropriate regulatory elements driving expression of a cassette region- The cassette region would contain a DNA encoding a peptide linkeri with convenient sites at both the 5' and 3' ends of the linker for generating fusion proteins- The DNA encoding a variable region(s) of interest may be cloned in the vector to form fusion proteins with the linkeri thus generating an scFv-

In an exemplary alternative approachi DNAs encoding two Fvs may be ligated to the DNA encoding the linkeri and the resulting tripartite fusion may be ligated directly into a conventional expression vector. The scFv DNAs generated any of these methods may be expressed in prokaryotic or eukaryotic cellsi depending on the vector chosen-

Antibody fragments which recognize specific epitopes may be generated by known techniques. For examplei such fragments include but are not limited to: the F(ab')Ξ fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab)2 fragments. Alternatively! Fab expression libraries may be constructed (Huse et al-i llδli Science-, 24b:1275-l261) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity- Derivatives also include "chimeric antibodies" (Morrison et al.i Proc. Natl . Acad. Sci . -, δl:faβSl-faδ55 (1164) i Neuberger et al . -, Nature-, 312:fa04-b0δ (11δ4)i Takeda et al . -, Nature-, 314:452- 454 (1165))- These chimeras are made by splicing the DNA encoding a mouse antibody molecule of appropriate specificity withi for instance! DNA encoding a human antibody molecule of appropriate specificity- Thusi a chimeric antibody is a molecule in which different portions are derived from different animal speciesi such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. These are also known sometimes as "humanized" antibodies and they offer the added advantage of at least partial shielding from the human immune system. They arei therefore! particularly useful in therapeutic in vivo applications-

Labeled Antibodies The present invention further provides the above-described antibodies in detectably labeled form- Antibodies can be detectably labelled through the use of radioisotopesi affinity labels (such as biotini avidini etc-)ι enzymatic labels (such as horseradish peroxidasei alkaline phosphatasei etc) fluorescent labels (such as FITC or rhodaminei etc)ι paramagnetic atomsi etc Procedures for accomplishing such labeling are well-known in the arti for example see (Sternberger et al-i J^". Histochem. Cytochem- 16:315 (1170) i Bayer et al-i Meth. Enzym- b2:306 (1171) i Engval et al-i Immunol . 101:121 (1172) i Godingi J. Immunol . Meth- 13:215 (117fa)). The labeled antibodies of the present invention can be used for in vitro, in vivo-, and in situ diagnostic assays-

Immobilized Antibodies

The foregoing antibodies also may be immobilized on a solid support- Examples of such solid supports include plastics such as polycarbonate! complex carbohydrates such as agarose and sepharosei^' acrylic resins and such as polyacryla ide and latex beads- Techniques for coupling antibodies to such solid supports are well known in the art (Ueir et al-i "Handbook of Experimental Immunology" 4th Ed-i Blackwell Scientific Publications! Oxfordi Englandi Chapter 10 (116b) i Jacoby et al . , Meth. Enzym- 34 Academic Pressi N-Y. (1174))- The immobilized antibodies of the present invention can be used for in vitro, in vivo-, and in situ assays as well as for immunoaffinity purification of the proteins of the present invention-

THERAPEUTIC AND DIAGNOSTIC COMPOSITIONS

The proteinsi antibodies and polynucleotides of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions! whereby these materialsi or their functional derivatives! are combined in admixture with a pharmaceutically acceptable carrier vehicle- Suitable vehicles and their formulation! inclusive of other human proteinsi e-g-i human serum albumini are described! for examplei in Remington ' s Pharmaceutical Sciences (Ifath ed-i Osoli A-i Ed-i Macki Easton PA (116D))- In order to form a pharmaceutically acceptable composition suitable for effective administration! such compositions will contain an effective amount of one or more of the agents of the present invention! together with a suitable amount of carrier vehicle-

Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using¹ one or more physiologically acceptable carriers or excipients. Thusi the compounds and their physiologically acceptable salts and solvate may be formulated for administration by inhalation or insufflation (either through the mouth or the nose) or orali buccali parenteral or rectal administration-

For oral administrationi the pharmaceutical compositions may take the form ofi for examplei tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. -, pregelatinised maize starchi polyvinylpyrrolidone or hydroxypropyl methylcellulose) i fillers (e.gr.i lactosei microcrystalline cellulose or calcium hydrogen phosphate)i lubricants (e.g. -, magnesium stearatei talc or silica)i disintegrants ( e.g. -, potato starch or sodium starch glycolate)i or wetting agents (e.gr.i sodium lauryl sulphate). The tablets may be coated by methods well known in the art- Liquid preparations for oral administration may take the form ofi for examplei solutions! syrups or suspensions! or they maybe presented as a dry product for constitution with water or other suitable vehicle before use- Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.gr.i sorbitol syrupi cellulose derivatives or hydrogenated edible fats)i emulsifying agents ( e.g. -, lecithin or acacia) i non-aqueous vehicles ( e.g. -, almond oili oily estersi ethyl alcohol or fractionated vegetable oils)i and preservatives ( e.g. -, methyl or propyl-p-hydroxybenzoates or sorbic acid)- The preparations may also contain buffer saltsi flavoring! coloring and sweetening agents as appropriate- Preparations for oral administration may be suitably formulated to give controlled release of the active compound- For buccal administration the composition may take the form of tablets or lozenges formulated in conventional manner-

For administration by inhalationi the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliseri with the use of a suitable propellanti e . g. -, dichlorodifluoromethanei trichlorofluoromethanei dichlorotetraf luoroethanei carbon dioxide or other suitable gas- In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount- Capsules and cartridges ofi e. g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch- The compounds may be formulated for parenteral administration by injection! e.gr.i by bolus injection or continuous infusion- Formulations for injection may be presented in unit dosage formi e.gr.i in ampules or in multi-dose containersi with an added preservative. The compositions may take such forms as suspensions! solutions or emulsions in oily or aqueous vehicles! and may contain formulatory agents such as suspending! stabilizing and/or dispersing agents- Alternatively! the active ingredient may be in powder form for constitution with a suitable vehiclei e.gr.i sterile pyrogen-free wateri before use-

The compounds may also be formulated in rectal compositions such as suppositories or retention enemasi e. g. -, containing conventional suppository bases such as cocoa butter or other glycerides-

In addition to the formulations described previously! the compounds may also be formulated as a depot preparation- Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection- Thusi for examplei the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resinsi or as sparingly soluble derivatives! for examplei as a sparingly soluble salt-

The compositions mayi if desiredi be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient- The pack may for example comprise metal or plastic foili such as a blister pack- The pack or dispenser device may be accompanied by instructions for administration.

RECOMBINANT CONSTRUCTS AND EXPRESSION

The present invention further provides recombinant DNA constructs comprising one or more of the nucleotide sequences of the present invention. The recombinant constructs of the present invention comprise a vectori such as a plasmid or viral vectori into which a DNA or DNA fragment! typically bearing an open reading framei is insertedi in either orientation. The gene products encoded by the subject DNAs may be produced by recombinant DNA technology using techniques well known in the art- Seei for examplei the techniques described in Sambrook et al-i llθli supra-, and Ausubel et al-i llδli supra- Alternatively! the DNA sequences may be chemically synthesized usingi for examplei synthesizers. Seei for examplei the techniques described in OLIGONUCLEOTIDE SYNTHESIS! 1164ι Gaiti ed-i IRL Pressi Oxfordi which is incorporated by reference herein in its entirety- They may be assembled from fragments and short oligonucleotide linkersi or from a series of oligonucleotides- The are preferably made by RT-PCR methods. The resulting synthetic gene is capable of being expressed in a recombinant vector- In some cases the recombinant constructs will be expression vectorsi which are capable of expressing the RNA and/or protein products of the encoded DNA(s)- Thusi the vector may further comprise regulatory sequences! including for examplei a promoteri operably linked to the open reading frame (ORF)- The vector may further comprise a selectable marker sequence. Specific initiation signals may also be required for efficient translation of inserted target gene coding sequences- These signals include the ATG initiation codon and adjacent sequences- In cases where a target DNA includes its own initiation codon and adjacent sequences is inserted into the appropriate expression vectori no additional translation control signals may be needed- Howeveri in cases where only a portion of an ORF is usedi exogenous translational control signalsi including! perhapsi the ATG initiation codoni must be provided- Furthermore! the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire target- These exogenous translational control signals and initiation codons can be of a variety of originsi both natural and synthetic The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements! transcription terminators! etc- (see Bittner et al . -, Methods in Enzymol . 153:51b-544 (11δ7))- Some appropriate cloning and expression vectors for use with prokaryotic and eukaryotic hosts are described by Sambrooki et al . , in Molecular Cloning: A Laboratory Manual -, Second Edition! Cold Spring Harbori New York (1161) i the disclosure of which is hereby incorporated by reference-

If desiredi to enhance expression and facilitate proper protein foldingi the codon context and codon pairing of the sequence may be optimized for the particular expression organismi as explained by Hatfield et al . , U-S- Patent No. 5i062i7b7-

The present invention further provides host cells containing at least one of the DNAs of the present invention. The host cell can be virtually any cell for which expression vectors are available- It may bei for examplei a higher eukaryotic host celli such as a mammalian celli a lower eukaryotic host celli such as a yeast celli or the host cell can be a prokaryotic celli such as a bacterial cell- Introduction of the recombinant construct into the host cell can be effected by calcium phosphate transfectioni DEAEi dextran mediated transfectioni or electroporation (Davis et al . , Basic Methods in Molecular Biology (116b))-

A wide variety of expression systems are available! such as: yeast ( e.g. Saccharomyees, Pichia) transformed with recombinant yeast expression vectors containing the target DNAi insect cell systems infected with recombinant virus expression vectors (e.gr.i baculovirus) containing the target DNA sequencesi plant cell systems infected with recombinant virus expression vectors (e.gr.i cauliflower mosaic virusi CaMVi tobacco mosaic virusi TMV) or transformed with recombinant plasmid expression vectors ( e. g. Ti plasmid) containing target DNA coding sequencesi or mammalian cell systems ( e. g. COSi CHOi BHKi 213ι 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells ( e. g. -, metallothionein promoter) or from mammalian viruses (e.gr.i the adenovirus late promoteri the vaccinia virus 7-5K promoter).

Depending on the system choseni the resulting product may differ- For examplei proteins expressed in most bacterial cultures! e.gr.i E. coli , will be free of glycosylation modificationsi polypeptides or proteins expressed in yeast will have a glycosylation pattern different from that expressed in mammalian cells-

Vectors

Generally! recombinant expression vectors will include origins of replication and selectable markers permitting selection of the host celli e.gr.i the ampicillin resistance gene of E. coli and S. cerevisiae TRP1 genei and a promoter derived from a highly- expressed gene to direct transcription of a downstream structural sequence. Such promoters can be derived from operons encoding glycolytic enzymes such as 3-phosphoglycerate kinase (PGK)ι -factori acid phosphatasei or heat shock proteinsi among others- The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequence! and in one aspect of the invention! a leader sequence capable of directing secretion of translated protein into the periplasmic space or extracellular medium- Optionallyi the heterologous sequence can encode a fusion protein including an N-terminal or C- terminal identification peptide imparting desired characteristics! e.gr.i stabilization or simplified purification of expressed recombinant product-

Bacterial Expression Useful expression vectors for bacterial use are constructed by inserting a structural DNA sequence encoding a desired protein together with suitable translation initiation and termination signals in operable reading phase with a functional promoter- The vector will comprise one or more phenotypic selectable markers and an origin of replication to ensure maintenance of the vector andi if desirablei to provide amplification within the host- Suitable prokaryotic hosts for transformation include E. coli, Bacillus subtilis, Salmonella typhimurium and various species within the genera Pseudomonasi Strepto ycesi and Staphylococcus! although others mayi also be employed as a matter of choice-

Bacterial vectors may bei for examplei bacteriophage-i plasmid- or cosmid-based- These vectors can comprise a selectable marker and bacterial origin of replication derived from commercially available plasmids typically containing elements of the well known cloning vector pBR322 (ATCC 37017)- Such commercial vectors includei for examplei GEM 1 (Promega Biotec Madisoni UIi USA)ι pBsi phagescripti PsiX174ι pBluescript SKi pBs KSi pNHβai pNHlfaai pNHlβai pNH4faa (Stratagene) i pTrcl Ai pKK223-3ι pKK233-3ι pKK232-βι pDRS40ι and pRIT5 (Pharmacia). These "backbone" sections are combined with an appropriate promoter and the structural sequence to be expressed. Bacterial promoters include lac T3ι T7ι lambda PR or PLI trpi and ara -

Following transformation of a suitable host strain and growth of the host strain to an appropriate cell densityi the selected promoter is derepressed/induced by appropriate means (e.g-i temperature shift or chemical induction) and cells are cultured for an additional period- Cells are typically harvested by centrifugation! disrupted by physical or chemical meansi and the resulting crude extract retained for further purification-

In bacterial systemsi a number of expression vectors may be advantageously selected depending upon the use intended for the protein being expressed- For examplei when a large quantity of such a protein is to be producedi for the generation of antibodies or to screen peptide libraries! for examplei vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable- Such vectors includei but are not limitedi to the E. coli expression vector pUR276 (Ruther et al.-. 11δ3ι EMBO J. 2:1711) i in which the coding sequence may be ligated into the vector in frame with the lac Z coding region so that a fusion protein is producedi pIN vectors (Inouye et al . 1165ι Nucleic Acids Res. 13 : 3101-31D1i Van Heeke et al . -, llβli J. Biol . Chem. 2b4 : 5503-55D1) i pET vectors! Studier et al . -, Methods in Enzymology 165: bO-61 (Academic Press 111D)i and the like-

Moreover! pGEX vectors may be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In generali such fusion proteins are soluble and easily can be purified from lysed cells by adsorption to glutathione- agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene protein can be released from the GST moiety. In a one embodiment! full length cDNA sequences are appended with in-frame BamHl sites at the amino terminus and EcoRI sites at the carboxyl terminus using standard PCR methodologies (Innis et al-i lllOi supra) and ligated into the pGEX-2TK vector (Pharmaciai Uppsalai Sweden). The resulting cDNA construct contains a kinase recognition site at the amino terminus for radioactive labeling and glutathione S-transferase sequences at the carboxyl terminus for affinity purification (Nilssoni et al . 1165ι EMBO J. 4: lD75i Zabeau and Stanleyi 1162ι EMBO J^". 1:1217-

Eukaryotic Expression Various mammalian cell culture systems can also be employed to express recombinant protein- Examples of mammalian expression systems include the COS-7 lines of monkey kidney fibroblastsi described by Gluzmani Cell 23:175 (11δl)ι and other cell lines capable of expressing a compatible vectori for examplei the C127ι 3T3ι CHOi HeLa and BHK cell lines- Mammalian expression vectors will comprise an origin of replication! a suitable promoter and enhanceri and also any necessary ribosome binding sitesi polyadenylation sitei splice donor and acceptor sitesi transcriptional termination sequences! and 5' flanking nontranscribed sequences- DNA sequences derived from the SV4D viral genomei for examplei SV4D origini early promoter! enhanceri splicei and polyadenylation sites may be used to provide the required nontranscribed genetic elements-

Mammalian promoters include CMV immediate earlyi HSV thymidine kinasei early and late SV40ι LTRs from retrovirusi and mouse metallothionein-I- Exemplary mammalian vectors include pULneoi pSV2catι pOG44ι pXTli pSG (Stratagene) pSVK3ι pBPVi pMSGi and pSVL (Pharmacia)- Selectable markers include CAT (chloramphenicol transferase)-

In mammalian host cellsi a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vectori the coding sequence of interest may be ligated to an adenovirus transcription/translation control complexi e. g. i the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non- essential region of the viral genome (e.gr. i region El or E3) will result in a recombinant virus that is viable and capable of expressing a target protein in infected hosts- (E.g. -, See Logan et al.-. 11β41 Proc. Natl . Acad. Sci . USA 61 "■ 3b55-3b51) -

In one embodiment! cDNA sequences encoding the full-length open reading frames are ligated into pCMVIS replacing the 13- galactosidase gene such that cDNA expression is driven by the CMV promoter (Alami lllDi Anal . Biochem. 166: 245-254i MacGregor et al.i llδli Nucl . Acids Res . 17: 23b5i Norton et al . 1165ι Mol . Cell . Biol . 5 : 261). In addition! a host cell strain may be chosen which modulates the expression of the inserted sequences! or modifies and processes the gene product in the specific fashion desired- Such modifications (e.gr.i glycosylation) and processing (e.gr.i cleavage) of protein products may be important for the function of the protein- Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins- Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed- To this endi eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcripti glycosylation! and phosphorylation of the gene product may be used- Such mammalian host cells include but are not limited to CHOi VEROi BHKi HeLai COSi MDCKi 213ι 3T3ι UI3δι etc-

For long-termi high-yield production of recombinant proteins in eukaryotic cellsi stable expression is preferred- Rather than using expression vectors which contain viral origins of replication! host- cells can be transformed with DNA controlled by appropriate expression control elements (e.gr.i promoter! enhanceri sequences! transcription terminators! polyadenylation sitesi etc.)ι and a selectable marker- Following the introduction of the foreign DNAi engineered cells may be allowed to grow for 1-2 days in an enriched mediai and then are switched to a selective media- The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines- This method may advantageously be used to engineer cell lines which express the target protein- Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the protein-

A number of selection systems may be usedi including but not limited to the herpes simplex virus thymidine kinase (Uigleri et al.i Cell 11:223 (1177))ι hypoxanthine-guanine phosphoribosyltransferase (Szybalska et al . -, Proc. Natl . Acad. Sci . USA 46:2D2b (11b2))ι and adenine phosphoribosyltransferase (Lowyi et al . -, Cell 22:617 (118D)) genes can be employed in tk"ι hgprt" or aprt" cellsi respectively. Alsoi antimetabolite resistance can be used as the basis of selection for dhfri which confers resistance to methotrexate (Uigleri et al . -, Proc. Natl . Acad, Sci . USA 77:3Sb7 (1160) )i O'Harθi et al . -, 11611 Proc. Natl . Acad. Sci . USA 76:1527) gpti which confers resistance to mycophenolic acid (Mulligan et al.i Proc. Natl . Acad. Sci . USA 76:2072 (11βl))i neoi which confers resistance to the aminoglycoside G-41δ (Colberre-Garapini et al.i llδli J^". Mol . Biol . 150:1) i and hydroi which confers resistance to hygromycin (Santerrei et al.i 1164ι Gene 30:147) genes.

An alternative fusion protein system allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknechti et al.i Proc. Natl . Acad. Sci . USA 68: 6172-617fa (1111)). In this systemi the gene of interest is subcloned into a vaccinia-based plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues- Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni²⁺ nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers-

In an insect systemi Autographa californica nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes- The virus grows in Spodoptera frugiperda cells- The target coding sequence may be cloned individually into non- essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of a target gene coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i-e-i virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect Spodoptera frugiperda cells in which the inserted gene is expressed- (E. g. -, see Smith et al-i 1163ι J. Virol . 4b: 564i Smithi U-S- Patent No- 4ι21SιOSl).

Uhile the present proteins can be expressed in recombinant systemsi as described abovei cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA constructs of the present invention- Purification of Recombinant Proteins

Recombinant proteins produced may be isolated by host cell lysis- This may be followed by one or more salting-outi aqueous ion exchange or size exclusion chromatography steps- Finallyi high performance liquid chromatography (HPLC) can be employed for final purification steps- Microbial cells employed in expression of proteins can be disrupted by any convenient methodi including freeze-thaw cyclingi sonicationi mechanical disruption! or use of cell lysing agentsi like lysozyme and chelators- If inclusion bodies are formed in bacterial systemsi they may be extracted from cell pellets usingi for examplei detergents! reducing agentsi saltsi ureai guanidinium chloride and extremes of pH (e.g. <4 or >1D)- If denaturation occursi protein refolding steps (e.gr.i dialysis) can be usedi as necessaryi in completing configuration of the mature protein- If disulfide bridges are present in the native proteini they may be reoxidized using known methods.

By way of specific non-limiting examplei the recombinant bacterial cellsi for example E. coli , are grown in any of a number of suitable mediai for example LBi and the expression of the recombinant protein induced by adding IPTG (e.gr.i lac operator- promoter) to the media or switching incubation to a higher temperature (e.gr.i λ cl^a57) ■ After culturing the bacteria for a further period of between 2 and 24 hoursi the cells are collected by centrifugation and washed to remove residual media- The bacterial cells are then lysedi for examplei by disruption in a cell homogenizer and centrifuged to separate the cell membranes from the soluble cell components. If the protein aggregates into inclusion bodiesi this centrifugation can be performed under conditions whereby the dense inclusion bodies are selectively enriched by incorporation of sugars such as sucrose into the buffer and centrifugation at a selective speed- The inclusion bodies can then be washed in any of several solutions to remove some of the contaminating host proteinsi then solubilized in solutions containing high concentrations of urea (e.gr. 6M) or chaotropic agents such as guanidinium hydrochloride in the presence of reducing agents such as β-mercaptoethanol or DTT (dithiothreitol) ■ At this stage it may be advantageous to incubate the protein for several hours under conditions suitable for the protein to undergo a refolding process into a conformation which more closely resembles that of the native protein- Such conditions generally include low protein concentrations less than 500 μg/ml) i low levels of reducing agenti concentrations of urea less than 2 M and often the presence of reagents such as a mixture of reduced and oxidized glutathione which facilitate the interchange of disulphide bonds within the protein molecule- The refolding process can be monitoredi for examplei by SDS-PAGE or with antibodies which are specific for the native molecule- Following refolding! the protein can then be purified further and separated from the refolding mixture by chromatography on any of several supports including ion exchange resinsi gel permeation resins or on a variety of affinity columns-

Labeling Proteins

Uhen used as a component in assay systems such as those described! belowi the target protein may be labeledi either directly or indirectlyi to facilitate detection of the present res-like molecules either in vitro or in vivo- Any of a variety of suitable labeling systems may be used including but not limited to radioisotopes such as ^1S5Ii enzyme labeling systems that generate a detectable colorimetric signal or light when exposed to substratei and fluorescent labels- Uhere recombinant DNA technology is used for protein production thei it may be advantageous to engineer fusion proteins that can facilitate labeling! immobilization and/or detection- These fusion proteins mayi for examplei add amino acids which facilitate further chemical modification- They also may add a functional moietyi such as an enzymei which directly facilitates detection. TRANSGENIC ANIMALS

The invention further contemplates animal models for studying the function of the present molecules and for overproducing the protein products. The disclosed DNA sequences may be used in conjunction with techniques for producing transgenic animals that are well known to those of skill in the art.

To prepare transgenic animalsi target gene sequences may for example be introduced intoi and overexpressed ini the genome of the animal of interesti ori if endogenous target gene sequences are presenti they may either be overexpressed ori alternatively! be disrupted in order to underexpress or inactivate target gene expression! such as described for the disruption of apoE in mice (Plum et al.i Cell 71: 343-353 (1112)).

In order to overexpress a target gene sequence! the coding portion of the target gene sequence may be ligated to a regulatory sequence which is capable of driving gene expression in the animal and cell type of interest- Such regulatory regions will be well known to those of skill in the arti and may be utilized in the absence of undue experi entation- For underexpression of an endogenous target gene sequence! such a sequence may be isolated and engineered such that when reintroduced into the genome of the animal of interesti the endogenous target gene alleles will be inactivated- Preferably! the engineered target gene sequence is introduced via gene targeting such that the endogenous target sequence is disrupted upon integration of the engineered target gene sequence into the animal's genome- Animals of any speciesi including! but not limited toi icei ratSi rabbitsi guinea pigsi pigsi micro-pigsi goatsi and non-human primatesi e.gr.i baboonsi monkeysi and chimpanzees may be used to generate cardiovascular disease animal models- Goatsi cows and sheep are particularly preferred for producing protein in vivo-

Any technique known in the art may be used to introduce a target gene transgene into animals to produce the founder lines of transgenic animals- Such techniques includei but are not limited to pronuclear microinjection (Hoppe et al.i U-S- Pat- No- 4ι673ιl11 (1161))i retrovirus mediated gene transfer into germ lines (Van der Putten et al.i Proc. Natl . Acad. Sci . , USA 62:fal48- bl52 (1165) )i gene targeting in embryonic stem cells (Thompson et al.i Cell 5fa:313-321 (1181) )i electroporation of embryos (Loi Mol . Cell . Biol . 3:1603-1814 (1183) )i and sperm-mediated gene transfer (Lavitrano et al . -, Cell 57:717-723 (1181) )i etc. For a review of such techniques! see Gordoni Transgenic Animalsi Intl . Rev. Cytol . 115:171-221 (1161)-

The present invention provides for transgenic animals that carry the transgene in all their cellsi as well as animals which carry the transgene in somei but not all their cellsi i.e.i mosaic animals. The transgene may be integrated as a single transgene or in concatamersi e.gr.i head-to-head tandems or head-to-tail tandems- The transgene may also be selectively introduced into and activated in a particular cell type by following! for examplei the teaching of Lasko et al- (Lasko et al.i Proc. Natl . Acad. Sci . USA 61:3232-fa23b (1112))- The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interesti and will be apparent to those of skill in the art- Uhen it is desired that the target gene be integrated into the chromosomal site of the endogenous target genei gene targeting is preferred- Brieflyi when such a technique is to be utilized! vectors containing some nucleotide sequences homologous to the endogenous target gene of interest are designed for the purpose of integrating! via homologous recombination with chromosomal sequences! into and disrupting the function of the nucleotide sequence of the endogenous target gene-

The transgene may also be selectively introduced into a particular cell typei thus inactivating the endogenous gene of interest in only that cell typei by followingi for examplei the teaching of Gu et al . Science 2b5: 103-lOb (1114))- The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interesti and will be apparent to those of skill in the art-

Once transgenic animals have been generated! the expression of the recombinant target gene and protein may be assayed utilizing standard techniques- Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to assay whether integration of the transgene has taken place- The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include but are not limited to Northern blot analysis of tissue samples obtained from the animali in situ hybridization analysis! and RT-PCR. Samples of target gene-expressing tissuei may also be evaluated immunocytochemically using antibodies specific for the target gene transgene gene product of interest.

The transgenic animals that express target gene mRNA or target gene transgene peptide (detected immunocytochemicallyi using antibodies directed against the target gene product's epitopes) at easily detectable levels should then be further evaluated to identify those animals which display characteristic increased susceptibility to carcinogenesis- Additionally! specific cell types within the transgenic animals may be analyzed and assayed in vi tro f or cellular phenotypes characteristic of mutant phenotype.

Once target gene transgenic founder animals are producedi they may be bredi inbredi outbredi or crossbred to produce colonies of the particular animal- Examples of such breeding strategies include but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate linesi inbreeding of separate lines in order to produce compound target gene transgenics that express the target gene transgene of interest at higher levels because of the effects of additive expression of each target gene transgenei crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order both to augment expression and eliminate the possible need for screening of animals by DNA analysisi crossing of separate homozygous lines to produce compound heterozygous or homozygous linesi breeding animals to different inbred genetic backgrounds so as to examine effects of modifying alleles on expression of the target gene transgene and the possible development of carcinogenesis. One such approach is to cross the target gene transgenic founder animals with a wild type strain to produce an FI generation that exhibits increased susceptibility to carcinogenesis. The FI generation may then be inbred in order to develop a homozygous linei if it is found that homozygous target gene transgenic animals are viable- Methods of generating "knockout" mice using homologous recombination in embryonic stem cells are well known in the art- Suitable methods are described! for examplei in Mansour et al.i Nature-, 33b:34δ (1166) i Zijlstra et al.i Nature-, 342:435 (1161) and 344:742 (1110) i and Hasty et al.i Nature! 350:243 (1111). This genomic DΝA can be obtained by conventional methods using the cDΝA sequence as a probe in a commercially-available genomic DΝA library.

Brieflyi a genomic fragment is cleaved with a restriction endonuclease and a heterologous cassette containing a neomycin- resistance gene is inserted at the cleavage site- A suitable cassette is the GTI-II neo cassette described by Lufkin et al.i Cell bfa:HD5 (1111). The modified genomic fragment is cloned into a suitable targeting vector that is introduced into murine embryonic stem cells by electroporation- Cells that have undergone homologous recombination (and hence disruption of the gene) are selected by resistance to G41βι and used to generate chimeric mice using well known methods- See Lufkin et al.i supra- Traditional breeding methods then can be used to generate mice that are homozygous for the disrupted gene-

The phenotype of mice that are homozygous for the mutation then can be studied to provide insights into the role of the protein ini for examplei carcinogenesis. These mice also can be used as models for developing new treatments for cancers- If this mutation is lethal in homozygous mice (for example during embryogenesis) heterozygous micei which express only half the amount of the protein can also be studied-

GENE THERAPY APPLICATIONS

Uhen mutations in the inventive proteini or in the elements controlling expression of that proteini are found to be associated with a malignant phenotypei control of cellular proliferation can be restored by gene therapy methods- For examplei overexpression of the protein can be counteracted by concurrent expression of an antisense molecule that binds to and inhibits expression of the mRNA encoding the protein- Alternatively! overexpression can be inhibited in an analogous manner using a ribozyme that cleaves the mRNA- In another embodiment! where expression of a mutated protein induces the malignant phenotypei concomitant expression of the non-mutated molecule via introduction of an exogenous gene may be used- Methods of using antisense and ribozyme technology to control gene expression! or of gene therapy methods for expression of an exogenous gene in this manner are well known in the art- Each of these methods requires a system for introducing a vector into the cells containing the mutated gene- The vector encodes either an antisense or ribozyme transcript of the inventive protein- The construction of a suitable vector can be achieved by any of the methods well-known in the art for the insertion of exogenous DNA into a vector- See, e.gr.i Sambrook et al.i Molecular Cloning (Cold Spring Harbor Press 2d ed- 1161) ι which is incorporated herein by reference- In addition! the prior art teaches various methods of introducing exogenous genes into cells in vivo- See Rosenberg et al.i Science 242:1575-1578 (1186) and Uolff et al.i PNAS δfa:1Dll-1014 (1161) i which are incorporated herein by reference- The routes of delivery include systemic administration and administration in situ- Uell-known techniques include systemic administration with cationic liposomesi and administration in situ with viral vectors. Any one of the gene delivery methodologies described in the prior art is suitable for the introduction of a recombinant vector containing an inventive gene according to the invention into a MTX-resistanti transport- deficient cancer cell- A listing of present-day vectors suitable for the purpose of this invention is set forth in Hodgsoni

Bio /Technology 13 '- 222 (1115) i which is incorporated by reference-

For examplei liposome-mediated gene transfer is a suitable method for the introduction of a recombinant vector containing an inventive gene according to the invention into a MTX-resistanti transport-deficient cancer cell- The use of a cationic liposomei such as DC-Chol/DOPE liposomei has been widely documented as an appropriate vehicle to deliver DNA to a wide range of tissues through intravenous injection of DNA/cationic liposome complexes- See Caplen et al.i Nature Med. l:31-4fa (1115) and Zhu et al.i Science 262:201-211 (1113) i which are herein incorporated by reference- Liposomes transfer genes to the target cells by fusing with the plasma membrane. The entry process is relatively efficient! but once inside the celli the liposome-DNA complex has no inherent mechanism to deliver the DNA to the nucleus- As suchi the most of the lipid and DNA gets shunted to cytoplasmic waste systems and destroyed- The obvious advantage of liposomes as a gene therapy vector is that liposomes contain no proteinsi which thus minimizes the potential of host immune responses.

As another examplei viral vector-mediated gene transfer is also a suitable method for the introduction of the vector into a target cell. Appropriate viral vectors include adenovirus vectors and adeno-associated virus vectorsi retrovirus vectors and herpesvirus vectors-

Adenoviruses are lineari double stranded DNA viruses complexed with core proteins and surrounded by capsid proteins. The common serotypes 2 and 5ι which are not associated with any human malignancies! are typically the base vectors- By deleting parts of the virus genome and inserting the desired gene under the control of a constitutive viral promoteri the virus becomes a replication deficient vector capable of transferring the exogenous DNA , to differentiated! non-proliferating cells- To enter cellsi the adenovirus fibre interacts with specific receptors on the cell surfacei and the adenovirus surface proteins interact with the cell surface integrins- The virus penton-cell integrin interaction provides the signal that brings the exogenous gene- containing virus into a cytoplasmic endosome- The adenovirus breaks out of the endosome and moves to the nucleusi the viral capsid falls aparti and the exogenous DNA enters the cell nucleus where it functions! in an epichromosomal fashioni to express the exogenous gene- Detailed discussions of the use of adenoviral vectors for gene therapy can be found in Berkneri Biotechniques £:falb-fa21 (1166) and Trapnell i Advanced Drug Delivery Rev. 12:165- 111 (1113) i which are herein incorporated by reference- Adenovirus-derived vectorsi particularly non-replicative adenovirus vectorsi are characterized by their ability to accommodate exogenous DNA of 7-5 kBi relative stability! wide host rangei low pathogenicity in raarii and high titers (ID⁴ to ID⁵ plaque forming units per cell). See Stratford-Perricaudet et al.i PNAS 89:2561 (1112) -

Adeno-associated virus (AAV) vectors also can be used for the present invention- AAV is a linear single-stranded DNA parvovirus that is endogenous to many mammalian species- AAV has a broad host range despite the limitation that AAV is a defective parvovirus which is dependent totally on either adenovirus or herpesvirus for its reproduction in vivo- The use of AAV as a vector for the introduction into target cells of exogenous DNA is well-known in the art- See, e.g. -, Lebkowski et al.i Mole. & Cell . Biol . 6:3166 (116β)ι which is incorporated herein by reference- In these vectorsi the capsid gene of AAV is replaced by a desired DNA fragmenti and transco plementation of the deleted capsid function is used to create a recombinant virus stock- Upon infection the recombinant virus uncoats in the nucleus and integrates into the host genome-

Another suitable virus-based gene delivery mechanism is retroviral vector-mediated gene transfer- In general! retroviral vectors are well-known in the art- See Breakfield et al.i Mole. Neuro. Biol . 1:331 (1167) and Shih et al.i in Vaccines 65: 177 (Cold Spring Harbor Press 1165)- A variety of retroviral vectors and retroviral vector-producing cell lines can be used for the present invention- Appropriate retroviral vectors include Moloney Murine Leukemia Virusi spleen necrosis virusi and vectors derived from retroviruses such as Rous Sarcoma Virusi Harvey Sarcoma Virusi avian leukosis virusi human immunodeficiency virusi yeloproliferative sarcoma virusi and mammary tumor virus- These vectors include replication-competent and replication-defective retroviral vectors- In addition! amphotropic and xenotropic retroviral vectors can be used- In carrying out the invention! retroviral vectors can be introduced to a tumor directly or in the form of free retroviral vector producing-cell lines- Suitable producer cells include fibroblastsi neuronsi glial cellsi keratinocytesi hepatocytesi connective tissue cellsi ependymal cells-, chromaffin cells- See Uolff et al.i PNAS 84:3344 (llδl).

Retroviral vectors generally are constructed such that the majority of its structural genes are deleted or replaced by exogenous DNA of interesti and such that the likelihood is reduced that viral proteins will be expressed- See Bender et al . -x J. Virol . bl:lb31 (1167) and Armento et al.-i J. Virol . 6i:lfa47 (1167)ι which are herein incorporated by reference- To facilitate expression of the antisense or ribozyme moleculei of the inventive proteini a retroviral vector employed in the present invention must integrate into the genome of the host cell genomei an event which occurs only in mitotically active cells- The necessity for host cell replication effectively limits retroviral gene expression to tumor cellsi which are highly replicativei and to a few normal tissues- The normal tissue cells theoretically most likely to be transduced by a retroviral vectori therefore! are the endothelial cells that line the blood vessels that supply blood to the tumor- In addition! it is also possible that a retroviral vector would integrate into white blood cells both in the tumor or in the blood circulating through the tumor-

The spread of retroviral vector to normal tissuesi howeveri is limited- The local administration to a tumor of a retroviral vector or retroviral vector producing cells will restrict vector propagation to the local region of the tumori minimizing transductioni integration! expression and subsequent cytotoxic effect on surrounding cells that are mitotically active-

Both replicatively deficient and replicatively competent retroviral vectors can be used in the invention! subject to their respective advantages and disadvantages- For instance! for tumors that have spread regionally! such as lung cancersi the direct injection of cell lines that produce replication-deficient vectors may not deliver the vector to a large enough area to completely eradicate the tumori since the vector will be released only form the original producer cells and their progenyi and diffusion is limited. Similar constraints apply to the application of replication deficient vectors to tumors that grow slowlyi such as human breast cancers which typically have doubling times of 30 days versus the 24 hours common among human gliomas. The much shortened survival-time of the producer cellsi probably no more than 7-14 days in the absence of immunosuppression! limits to only a portion of their replicative cycle the exposure of the tumor cells to the retroviral vector-

The use of replication-defective retroviruses for treating tumors requires producer cells and is limited because each replication-defective retrovirus particle can enter only a single cell and cannot productively infect others thereafter- Because these replication-defective retroviruses cannot spread to other tumor cellsi they would be unable to completely penetrate a deepi multilayered tumor in vivo- See Markert et al . , Neurosurg. 77: 510 (1112). The injection of replication-competent retroviral vector particles or a cell line that produces a replication- competent retroviral vector virus may prove to be a more effective therapeutic because a replication competent retroviral vector will establish a productive infection that will transduce cells as long as it persists. Moreover! replicatively competent retroviral vectors may follow the tumor as it metastasizesi carried along and propagated by transduced tumor cells- The risks for complications are greateri with replicatively competent vectorsi however- Such vectors may pose a greater risk then replicatively deficient vectors of transducing normal tissuesi for instance- The risks of undesired vector propagation for each type of cancer and affected body area can be weighed against the advantages in the situation of replicatively competent verses replicatively deficient retroviral vector to determine an optimum treatment-

Both amphotropic and xenotropic retroviral vectors may be used in the invention- Amphotropic viruses have a very broad host range that includes most or all mammalian cellsi as is well known to the art- Xenotropic viruses can infect all mammalian cell cells except mouse cells- Thusi amphotropic and xenotropic retroviruses from many speciesi including cowsi sheepi pigsi dogsi catsi ratsi and micei inter alia can be used to provide retroviral vectors in accordance with the invention! provided the vectors can transfer genes into proliferating human cells in vivo.

Clinical trials employing retroviral vector therapy treatment of cancer have been approved in the United States- See Culveri Clin . Chem. 40 - 510 (1114)- Retroviral vectoi—containing cells have been implanted into brain tumors growing in human patients- See Oldfield et al . , Hum. Gene Ther. 4 - 31 (1113). These retroviral vectors carried the HSV-1 thymidine kinase (HSV-tk) gene into the surrounding brain tumor cellsi which conferred sensitivity of the tumor cells to the antiviral drug ganciclovir- Some of the limitations of current retroviral based cancer therapyi as described by Oldfield are : (1) the low titer of virus producedi (2) virus spread is limited to the region surrounding the producer cell implanti (3) possible immune response to the producer cell linei (4⁾ possible insertional mutagenesis and transformation of retroviral infected cellsi (5) only a single treatment regimen of pro-drugi gancicloviri is possible because the "suicide" product kills retrovirally infected cells and producer cells and (fa) the bystander effect is limited to cells in direct contact with retrovirally transformed cells. See Bi et al.i Human Gene Therapy 4 -^m 725 (1113).

Yet another suitable virus-based gene delivery mechanism is herpesvirus vectoi—mediated gene transfer- Uhile much less is known about the use of herpesvirus vectorsi replication-competent HSV-1 viral vectors have been described in the context of antitumor therapy. See Martuza et al . , Science 252 '- 654 (1111) i which is incorporated herein by reference-

DIAGNOSTIC METHODS

The present invention also contemplates! for certain molecules described belowi methods for diagnosis of human disease- In particular! patients can be screened for the occurrence of cancersi or likelihood of occurrence of cancersi associated with mutations in the encoded protein. DNA from tumor tissue obtained from patients suffering from cancer can be isolated. and the gene encoding the protein can be sequenced- By examining a number of patients in this manneri mutations in the gene that are associated with a malignant cellular phenotype can be identified. In addition! correlation of the nature of the observed mutations with subsequent observed clinical outcomes allows development of prognostic model for the predicted outcome in a particular patient- Screening for mutations conveniently can be carried out at the DNA level by use of PCRi although the skilled artisan will be aware that many other well known methods are available for the screening. PCR primers can be selected that flank known mutation sitesi and the PCR products can be sequenced to detect the occurrence of the mutation- Alternatively! the 3' residue of one PCR primer can be selected to be a match only for the residue found in the unmutated gene- If the gene is mutatedi there will be a mismatch at the 3' end of the primeri and primer extension cannot occuri and no PCR product will be obtained- Alternatively! primer mixtures can be used where the 3' residue of one primer is any nucleotide other than the nonmutated residue- Observation of a PCR product then indicates that a mutation has occurred- Other methods of usingi for examplei oligonucleotide probes to screen for mutations are described! or examplei in U-S- Patent No- 4ιβ71ιβ36ι which is herein incorporated by reference in its entirety-

Alternatively! antibodies can be generated that selectively bind either mutated or non-mutated protein- The antibodies then can be used to screen tissue samples for occurrence of mutations in a manner analogous to the DNA-based methods described supra -

The diagnostic methods described above can be used not only for diagnosis and for prognosis of existing diseasei but may also be used to predict the likelihood of the future occurrence of disease- For examplei clinically healthy patients can be screened for mutations in the inventive molecule that correlate with later disease onset- Such mutations may be observed in the heterozygous state in healthy individuals- In such cases a single mutation event can effectively disable proper functioning of the gene and induce a transformed or malignant phenotype- This screening also may be carried out prenatally or neonatally-

DNA molecules according to the invention also are well suited for use in so-called "gene chip" diagnostic applications- Such applications have been developed byi inter alia-, Synteni and Affymetrix- Brieflyi all or part of the DNA molecules of the invention can be used either as a probe to screen a polynucleotide array on a "gene chipi" or they may be immobilized on the chip itself and used to identify other polynucleotides via hybridization to the surface of the chip- In this manneri for examplei related genes can be identified! or expression patterns of the gene in various tissues can be simultaneously studied- Such gene chips have particular application for diagnosis of diseasei or in forensic analysis to detect the presence or absence of an analyte- Suitable chip technology is described for examplei in Uodicka et al.i Nature Biotechnology-, 15:1351 (1117) which is hereby incorporated by reference in its entiretyi and references cited therein-

PROTEIN-PROTEIN INTERACTIONS Due to their similarity to certain known proteinsi it is anticipated that some of the inventive protein molecules will interact with another class of cellular proteins. This is particularly true of those molecule containing leucine zipper motifs-

Any method suitable for detecting protein-protein interactions can be employed for identifying interacting targets- Among the traditional methods which can be employed are co- immunoprecipitationi crosslinking and co-purification through gradients or chromatographic columns- Utilizing procedures such as these allows for the identification of GAP gene products- Once identified! a GAP protein can be usedi in conjunction with standard techniques! to identify its corresponding pathway gene- For examplei at least a portion of the amino acid sequence of the pathway gene product can be ascertained using techniques well known to those of skill in the arti such as via the Edman degradation technique (seei e-g-i Creightoni 1163ι PROTEINS: STRUCTURES AND MOLECULAR PRINCIPLES! Id • H • Freeman & Co.i N-Y-i pp.34-41). The amino acid sequence obtained can be used as a guide for the generation of oligonucleotide mixtures that can be used to screen for pathway gene sequences- Screening can be accomplished! for examplei by standard hybridization or PCR techniques- Techniques for the generation of oligonucleotide mixtures and for screening are well-known. (See e.g. -, Ausubeli supra^ and PCR PROTOCOLS: A GUIDE TO METHODS AND APPLICATIONS! l lOi Innis et al.i eds- Academic Pressi Inc-i New York).

Additionally! methods can be employed which result in the simultaneous identification of interacting target genes- One method which detects protein interactions in vivo-, the two-hybrid systemi is described in detail for illustration purposes only and not by way of limitation- One version of this system has been described (Chien et al.i Proc. Natl . Acad. Sci . USA-, δδ: 1576-1562 (1111)) and is commercially available from Clontech (Palo Altoi CA)- Briefly! utilizing such a systemi plasmids are constructed that encode two hybrid proteins: one consists of the DNA-binding domain of a transcription activator protein fused to a known proteini in this case an inventive proteini and the other contains the activator protein's activation domain fused to an unknown protein (a putative GAPi for instance) that is encoded by a cDNA which has been recombined into this plasmid as part of a cDNA library- The plasmids are transformed into a strain of the yeast Saccharomyees cerevisiae that contains a reporter gene ( e. g. , lacZ) whose regulatory region contains the transcription activator's binding sites- Either hybrid protein alone cannot activate transcription of the reporter genei the DNA-binding domain hybrid cannot because it does not provide activation function! and the activation domain hybrid cannot because it cannot localize to the activator's binding sites- Interaction of the two hybrid proteins reconstitutes the functional activator protein and results in expression of the reporter genei which is detected by an assay for the reporter gene product- The two-hybrid system or related methodology can be used to screen activation domain libraries for proteins that interact with a known "bait" gene product- By way of examplei and not by way of limitation! gene products known to be involved in TH cell subpopulation-related disorders and/or differentiation! maintenance! and/or effector function of the subpopulations can be used as the bait gene products- Total genomic or cDNA sequences are fused to the DNA encoding on activation domain- This library and a plasmid encoding a hybrid of the bait gene product fused to the DNA-binding domain are cotransformed into a yeast reporter straini and the resulting transformants are screened for those that express the reporter gene- For examplei and not by way of limitationi the bait gene can be cloned into a vector such that it is translationally fused to the DNA encoding the DNA-binding domain of the GAL4 protein- These colonies are purified and the library plasmids responsible for reporter gene expression are isolated. DNA sequencing is then used to identify the proteins encoded by the library plasmids-

The present invention! thus generally described! will be understood more readily by reference to the following examples! which are provided by way of illustration and are not intended to be limiting of the present invention- The examples below are provided to illustrate the subject invention- These examples are provided by way of illustration and are not included for the purpose of limiting the invention-

EXAMPLES

EXAMPLE I: cDNA Library Construction

cDNA library plates and clones originated from five cDNA libraries that were constructed by directional cloning- These are available through the Resource Center (http://www-rzpd.de) of the German Genome Project- In particular! the hfbr2 (human fetal braini RZPD number DKFZp5b4) and hfkd2 (human fetal kidneyi DKFZp5bfa) libraries were generated using the Smart kit (Clontech) i except that PCR was carried out with primers that contained uracil residues to permit directional cloning without restriction digestion and ligationi and were complementary with the pAMPl (LifeTechnologies) cloning sites for directional cloning- The htes3 (human testesi DKFZp434)ι hutel (human uterusi DKFZp56fa) and hmcfl (human mammary carcinomai DKFZp727) libraries are conventional (Gubleri U-i Hoffmani B-J-i (1163)ι A simple and very efficient method for generating cDNA libraries- Gene 25ι 2fa3-2fa1)ι size-selected cDNA libraries- They are cloned into pSPORTl (LifeTechnologies) via a Notl site which is introduced during reverse transcription downstream of the oligo dT primer and a Sail site that is introduced by the ligation of a adapters- The human mammary carcinoma library was constructed from MCF7 cells -

In a similar fashioni the hamy2 (human amygdala nucleus (inside the brain) RZPD number DKFZp7bl) and hmel2 (human melanomai RZPD number DKFZp7b2) libraries have been generated using conventional approaches! emplying a Notl -dT V primer for first strand synthesis (GAGCGGCCGC(T)HV) - After second strand synthesis! Sail adapters were ligated to the blunted cDNA- Then the cDNA was cut with Notl to generate Sall-Notl compatible ends at the 5¹ and 3^"1 ends of the cDNAi respectively! to allow directional cloning- The cDNAs were then size selected on agarose gels in two dimensions and cloned into the pSPORTl plasmid vector which had been pre-cut with Sail and Notl (LifeTechnologies) ■ The DNA was transformed into the DH1DB bacterial strain and single colonies were picked into 364well microtiter plates from the non- amplified library. The human melanoma library was constructed from MeUo cellsi published by Kerni M-A-i Helmbachi H-i Artuc M-i Karmanni D-i Jurgovskyi K. and Schadendorfi D- (1117) Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatini fotemustinei vindesine or etoposide: modulation of proto-oncogene expression- Anticancer Res- 17ι 4351-4370- The cDNA sequences of this application were first identified among the sequences comprising various libraries. Technology has advanced considerably since the first cDNA libraries were made- Many small variations in both chemicals and machinery have been instituted over timei and these have improved both the efficiency and safety of the process- Although the cDNAs could be obtained using an older procedure! the procedure presented in this application is exemplary of one currently being used by persons skilled in the art- For the purpose of providing an exemplary methodi the mRNA isolation and cDNA library construction described here is for the MCF-7 library (DKFZp727) from which the clones named DKFZphmcfl_xxyyxx were obtained-

The human cell line MCF-7 was grown in DMEM supplemented with 10* fetal calf serum until confluency- 3 X 10^s cells were harvested with a cell scraper in PBS- Cells were lysed in buffer containing D-5 * NP-4D to leave the nuclei intact- The debris was pelleted by centrifugation at 15 ODD x g for 10 minutes at 4 degrees Celsius- Proteins in the supernatant were degraded in presence of SDS and Proteinase K (30 minutes at 5fa degrees Celsius)- Precipitation of proteins was done in a Phenol/Chloroform extraction! RNA was precipitated from the aqueous phase with Na-acetate and Ethanol- Polyadenylated messages were isolated using ώiagen Oligotex (ώlAGENi Hilden Germany) -

First strand cDNA synthesis was accomplished using an oligo (dT) primer which also contained an Notl restriction site- Second strand synthesis was performed using a combination of DNA polymerase Ii E. coli ligase and RNase Hi followed by the addition of a Sail adaptor to the blunt ended cDNA- The Sail adaptedi double-stranded cDNA was then digested with Notl restriction enzymei and fractionated by size on an agarose gel- DNA of the appropriate size was cut from the gel and cast into a second gel in a 10° angle- After electrophoresis in the second dimension! cDNA of the appropriate size was cut from the gel- The agarose block was broken down with help of gelase- The cDNA was purified with help of two phenol extractions and an ethanol precipitation. The cDNA was ligated into Sall/Notl pre-digested pSportl vector (LifeTechnologies) and transformed into DH1DB bacteria .

The libraries were arrayed into 364-well microtiter plates and spotted on high density nylon membranes for hybridization analysis- All libraries have been arrayed into 364well microtiter plates and spotted on high density nylon membranes for hybridization analysis-

The hamy2 Library consists of 121 364well plates comprising 4b4fa4 clones. The hmel2 library consists of 72 364well plates comprising 27b4δ clones. Filters and clones are available through the Resource Center of German Genome Project

(http://www.RZPD.de). Uhole library plates were distributed to the sequencing partners of the consortium for systematic sequencing ■

EXAMPLE II: Sequencing of cDNA Clones

All clones in the 364-well microtiter plates were sequenced from the 5' end- Sequencing was done preferentially using dye terminator chemistry (ABD or Amersham) on ABI automated DNA sequencers (ABI 377ι Applied Biosystems) i one partner used EMBL prototype instruments (Arakis) mainly with dye primer chemistry.

The resulting expressed sequence tag (EST) sequences ("rl ESTs¹¹ = sequenced from 5'-end) were analysed for:

a) the lack of identical matches with known genes-

For thisi the EST-sequence was blasted against the cDNA consortiums own database and after that against public databases and (with BLASTn and BLASTx against EMBL/EMBLNEU and assembled ESTsi please refer to EXAMPLE III: Bioinformatics analysis of full length cDNAsi for description and parameter settings)- ESTs which were identical to known genes in more than 10D bpi with less than 2 mismatchesi were excluded from further analysis-

fa) the presence of an open reading frame

Open reading frames (ORFs) were detected with an tool developed by Munich Information Center for Protein Sequences (MIPS) called ORF-map- ORF- ap visualises potential start and stop-codons- If an ORF without a stop codon was detected in a rl-ESTi the sequence was processed further-

c) the presence of GC rich sequences

A script developed by MIPS computed the GC-content of the rl-sequencei which should be >4D*. Uriting similar scripts is within the ordinary skill of one in bioinformatics -

d) the lack of repeat structures

Repeats such as Alui Line or CA-repeats were detected by blasting (BLASTn and BLASTxi please refer to EXAMPLE III: Bioinformatics analysis of full length cDNAsi for description and parameter settings) against a repeat-database compiled by MIPS-

If a repeat was present within the rl-sequencei the sequence were not processed further-

Novel clones that met all criteria were identified to the sequencers! who then performed S^-end sequencing of these clones- The resulting 3¹ ESTs (^usl ESTs" = sequenced from 3'-end) were checked for

a) the lack of matches with known genes in public databases! and sequences already generated by us-

This was done by blasting against EMBL/EMBLNEU and assembled EST (BLASTn and BLASTxi please refer to EXAMPLE III:

Bioinformatics analysis of full length cDNAsi for description and parameter settings)- b) the presence of polyadenylation signals-

Again only clones matching the selection criteria were chosen to be sequenced completely by the sequencers. Clones were selected after the following criteria:

A very good ORF had at least one BLASTx match to other proteins. A "good ORF" should extend to the 3' end and be longer than ~4D codons- If the ORF started in the rl sequence! in front of the potential start codoni there should not exist too many competing start codons in frame with the ORF start codon and the start should match the Kozak consensus ATG- If the EST sequence was to short to decide according to the potential ORFi and there were only a few or no start codons in the sequence the GC content of the Sequence should be greater than 40*- The rl sequences needed not contain an polyA-tail at the 3' end- In addition! the results of the blasting against the assembled human ESTs could help in questionable cases to decide whether to stop or to continue- A hit against these ESTs was an indication to go further ■

Clones passing the above-described screening were sequenced in full- Sequencing was done preferentially using dye terminator chemistry (ABD or Amersham) on ABI automated DNA sequencers (ABI 377ι Applied Biosystems)ι one partner used EMBL prototype instruments (Arakis) mainly with dye primer chemistry- Primer walking (Strauss et al-i llδbi Specific-primer-directed DNA sequencing- Anal Biochem- 154ι 353-3bD) was the preferred sequencing strategy because of the lower redundancy possible compared to random shotgun (Messingi J-i Creai R-i Seeburgi H-P- (1161) A system for shotgun DNA sequencing- Nucleic Acids Res- li 32-31) methods- Ualking primers were generally designed using software (e-g- Haasi S-i Vingroni M-i Poustkai A-i Uiemanni S- (lllδ) Primer design in large-scale sequencing- Nucleic Acids Res- 2faι 300fa-3D12ι Schwageri d Uiemanni S-i Ansorgei U. (1115) GeneSkipper: integrated software environment for DNA sequence assembly and alignment- HUGO Genome Digest 2ι δ-1) that permitted complete automation of this usually time consuming process and helped in the parallel processing of large numbers of clones. EXAMPLE III: Bioinformatics analysis of full length cDNAs

Each sequence obtained was compared on nucleotide level in a stepwise manner to sequences in EMBL/EMBLNEUi EMBL-ESTi EMBL-STS using the BLASTn algorithm- Basic Local Alignment Search Tool (BLASTi Altschul S- F- (1113) J Mol Evol 3b-"210-300i Altschuli S- F- et al (HID) J Mol Biol 215:403-10) is used to search for local sequence alignments. BLAST produces alignments of both nucleotide (BLASTn) and amino acid sequences (BLASTp or BLASTx) to determine sequence similarity. BLAST is especially useful in determining exact matches or in identifying homologsi because of the local nature of the alignments. Uhile it is useful for matches which do not contain gapsi it is inappropriate for performing motif-style searching- The fundamental unit of BLAST algorithm output is the High-scoring Segment Pair (HSP).

An HSP consists of two sequence fragments of arbitrary but equal lengths whose alignment is locally maximal and for which the alignment BLAST approach is to look threshold or cut off score set by the user- BLAST looks for HSPs between a query sequence and a database sequence! to evaluate the statistical significance of any matches foundi and to report only those matches which satisfy the user-selected threshold of significance- The parameter E establishes the statistically significant threshold for reporting database sequence matches- E is interpreted as the upper bound of the expected frequency of chance occurrence of an HSP (or set of HSPs) within the context of the entire database search- Any database sequence whose match satisfies E is reported in the program output- Parameter settings for the BLAST-operations (BLASTN 2 - OallMP-UashU) described were: EMBL-EMBLNEU: H=0 V=5 B=S -filter segi EMBL-EST-" H=D E=le-10 B=5D0 V=500 -filter segi EMBL-STS: H=D V=5 B=S-

Search against EMBL/EMBLNEU was done to determine whether the cDNAs are already knowni and also to find out whether the cDNAs are encoded by genomic sequences already sequenced and published/submitted to these databases.

Search against EMBL-EST was performed to get a first impression how abundant a particular cDNA would be and to get information on tissue specificity (so-called "electronic Northern-Blot"ι e-g- some of the cDNAs derived of the testis library show only hits to ESTs also derived of testis libraries)-

The cDNA-sequences were blasted against EMBL-STS to determine STS-sequence-match to the cDNAi thus providing a mapping information to the new cDNA-

The potential protein-sequences were generated automatically by a script searching for the longest open reading frame (ORF) in each of the three forward frames with a minimum length of 10 codons. Nexti the automatically generated ORFs were translated into protein sequences- These protein sequences were searched against the non redundant protein data set of PIR/SwissProt/Trembel/Tre blnew (BLASTP 2- OallMP-UashUi parameter setting". V=7 B=7 H=0 -filter seg). If the script generated more than one ORFi one ORF was chosen manually by the annotater according to the degree of similarity to known proteinsi the location of the ORF in the cDNAi the lengthi the amino acid composition and the content of Prosite-Motifs ■

Additionally there was a BLASTx (BLASTX 2 -DallMP-UashU against non redundant protein database comprising PIR/SUISSPROT/TREMBL/TREMBLNEUi parameter-settings were: matrix/home/data/blast/matrix/aa/BL0SUMb2 H=D V=5 B=5 -filter seg) search to find potential frame shift in the complementary eds of the cDNAs and to identify unspliced or partly spliced cDNAs- The protein sequence was then transferred to the PEDANT systemi in order to generate additional information on the new proteins- PEDANT (Protein Extraction! Description! and ANalysis Tooli Frishmani D- & Mewesi H--U- (1117) PEDANTic genome analysis. Trends in Genetics i 13ι 415-41b) is a platform developed at the Munich Information Center for Protein Sequences (MIPSi Munichi Germany)! which incorporates practically all bioinformatics methods important for the functional and structural characterisation of protein sequences- Computational methods used by PEDANT are : FASTA

Very sensitive protein sequence database searches with estimates of statistical significance. Pearson U-R. (1110) Rapid and sensitive sequence comparison with FASTP and FASTA- Methods Enzymol- 183ι b3-16-

BLAST2

Very sensitive protein sequence database searches with estimates of statistical significance- Altschul S-F-i Gish U-i Miller U-i Myers E-U-i and Lipman D-J- Basic local alignment search tool- Journal of Molecular Biology 215ι 4D3-10-

PREDATOR

High-accuracy secondary structure prediction from single and multiple sequences- Frishmani D- and Argosi P- (1117) 75* accuracy in protein secondary structure prediction- Proteins! 27ι 321-335- Frishmani D. and Argosi P-(lllb) Incorporation of longdistance interactions in a secondary structure prediction algorithm. Prot- Eng- li 133-142-

STRIDE

Secondary structure assignment from atomic coordinates. Frishmani D- and Argosi P-(1115) Knowledge-based secondary structure assignment. Proteins 23ι Sbfa-571-

CLUSTALU

Multiple sequence alignment- Thompson! J-D-i Higginsi D-G- and Gibsoni T-J- (1114) CLUSTAL U: improving the sensitivity of progressive multiple sequence alignment through sequence weighting! positions-specific gap penalties and weight matrix choice- Nucleic Acids Research! 22: 4b73-4bδD-

TMAP

Transmembrane region prediction from multiply aligned sequences. Perssoni B- and Argosi P. (1114) Prediction of transmembrane segments in proteins utilising multiple sequence alignments. J- Mol- Biol- 237ι 182-112- AL0M2

Transmembrane region prediction from single sequences. Kleini P-i Kanehisai M-i and DeLisii C Prediction of protein function from sequence properties: A discriminant analysis of a database. Biochim- Biophys- Acta 767ι 221-22b (1184). Version 2 by Dr. K- Nakai-

SIGNALP

Signal peptide prediction Nielseni H-i Engelbrechti J.i Brunaki S-i and von Heijnei G (1117). Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites- Protein Engineering IDi 1-fa-

SEG

Detection of low complexity regions in protein sequences. Uoottoni J.C-i Federheni S- (1113) Statistics of local complexity in amino acid sequences and sequence databases- Computers & Chemistry 17-. 141-lfa3-

COILS

Detection of coiled coils- Lupasi A-i M- Van Dykei and J- Stocki "Predicting Coiled Coils from Protein Sequences-" Science (1111) 252ι Ilfa2-llfa4-

PROSEARCH

Detection of PROSITE protein sequence patterns- Kolakowski L-F- Jr-i Leunissen J-A-M-i Smith J-E- (1112) ProSearch: fast searching of protein sequences with regular expression patterns related to protein structure and function- Biotechniques 13ι 111- 121-

BLIMPS

Similarity searches against a database of ungapped blocks- J-C- Uallace and Henikoff S-i (1112) PATMAT: a searching and extraction program for sequence! pattern and block queries and databases! CABIOS δi 241-254- Uritten by Bill Alford. HMMER

Hidden Markov model software - Sonnhammer E-L-L-i Eddy S.R-i Durbin R. (1117) Pfam". A Comprehensive Database of Protein Families Based on Seed Alignments- Proteins 2δι 405-420-

pi

Perl script that returns the amino acid composition! molecular weighti theoretical pli and expected extinction coefficient of an amino acid sequence- By Fred Lindberg- The parameter-settings were as follows: known3d: score > lODi BLAST"- E-value < IDi SCOP: <= 50 Alignments! E-Value < 0-OOOli signalp: Y=D-7i untersucht vom N-Terminus her: 5D aai funcat: E-value < D-ODli BLOCKS: <= 10 hitsi BLIMPS: threshold 1100-Oi COILS: threshold D-15i SEG: threshold 20-Di BLAST in report: E-value < 0-DOli PIR-KUi superfa iliesi EC-Nummern in report: E-value < D-ODODli known3d in report: score > 120

The results of PEDANT analysis together with the results of the similarity searches constitute the basis for the structural and functional annotation of the cDNAs and the encoded proteinsi as specified herein-

Claims

Ue cl a im :

1- An assemblage! comprising at least one nucleic acid molecule having the sequence of a clone selected from the group consisting of: amy2_12g7i amy2_12ili amy2_13gl1i amy2_lfael4i amy2_24kl5i amy2_2al3i amy2_2il7i fbr2_7δdlδi fbr2_7δelβi amy2_121m2i amy2_24b4i amy2_121fl1i tes3_lfab5i amy2_li24i amy2_ljl1i amy2_2bl1i amy2_7j5i amy2_14b5i amy2_2ol3i fkd2_3kli mel2_7gl4i mel2_12jl i mel2_7kl1i amy2_2c22i fbr2_7δi21i amy2_lln4i amy2_lcl2i amy2_lili amy2_2f22i amy2_2gl2i fbr2_7βcl2i tes3_10ilfai tes3_31al0i amy2_10hl7i amy2_10p7i amy2_12d7i amy2_2flβi tes3_llc22i tes3_lld21i tes3_21f24i tes3_31j20i tes3_5k22i Tes3_lDnl0i Tes3_Hel7i Tes3_12dlβ i Tes3_141?i Tes3_15nl4i Tes3_lfap3i Tes3_Hpl2i Tes3_21kl4i Tes3_22illi Tes3_22124i- tes3_2bg3i tes3_30pbi amy2_lld2i amy2_121ol7i amy2_lil4i amy2_24cδi fbr2_7βd4i tes3_llal7i tes3_17i21i tes3_20hl2i tes3_7nl2i tes3_1elfai amy2_14mlbi tes3_lδnl4i their complementsi and variants thereof-

2- An assemblagei comprising at least one nucleic acid molecule having the sequence of a clone selected from the group consisting of: amy2_12g7i amy2_12ili amy2_13gl1i amy2_lbel4i amy2_24kl5i amy2_2al3i amy2_2il7i amy2_lΞlm2i amy2_24b4i amy2_121fl1i amy2_li24i amy2_ljl1i amy2_2bl1i amy2_7j5i amy2_14b5i amy2_2ol3i amy2_2c22i amy2_lln4i amy2_lcl2i amy2_lili amy2_2f22i amy2_2gl2i amy2_10hl7i amy2_10p7i amy2_12d7i amy2_2flβi amy2_lld2i amy2_121ol7i amy2_lil4i amy2_24cβi their complementsi and variants thereof-

3- An assemblagei comprising at least one nucleic acid molecule having the sequence of a clone selected from the group consisting of: fbr2_7βdlδi fbr2_7βelδi fbr2_76i21i fbr2_76cl2i fbr2_7δd4i their complementsi and variants thereof.

4- An assemblage! comprising at least one nucleic acid molecule having the sequence of a clone selected from the group consisting of: amy2_121m2i amy2_24b4i their complementsi and variants thereof.

5- An assemblage! comprising at least one nucleic acid molecule having the sequence of a clone selected from the group consisting of: amy2_121fl1i tes3_lbb5i their complementsi and variants thereof-

fa- An assemblage! comprising at least one nucleic acid molecule having the sequence of a clone selected from the group consisting of: amy2_li24i amy2_ljl1i amy2_2bl1i amy2_7j5i their complementsi and variants thereof.

7. An assemblagei comprising at least one nucleic acid molecule having the sequence of a clone selected from the group consisting of: amy2_14b5i amy2_2ol3i fkd2_3kli mel2_7gl4i their complementsi and variants thereof.

6. An assemblage! comprising at least one nucleic acid molecule having the sequence of a clone selected from the group consisting of mel2_7gl4i mel2_12jl i mel2_7kl1i their complementsi and variants thereof-

1- An assemblage! comprising at least one nucleic acid molecule having the sequence of a clone selected from the group consisting of: amy2_2c22i fbr2_7δi21ϊ their complementsi and variants thereof.

ID- An assemblage! comprising at least one nucleic acid molecule having the sequence of a clone selected from the group consisting of: amy2_lln4i amy2_lili amy2_2gl2i fbr2_7βcl2i tes3_10ilbi tes3_31al0i their complementsi and variants thereof-

11- An assemblagei comprising at least one nucleic acid molecule having the sequence of a clone selected from the group consisting of: amy2_10hl7i amy2_lDp7i amy2_12d7i amy2_2flβi tes3_llc22i tes3_lld21i tes3_21f24i tes3_31j20i tes3_5k22i their complementsi and variants thereof-

12- An assemblage! comprising at least one nucleic acid molecule having the sequence of a clone selected from the group consisting of: tes3_lbb5i tes3_10ilfai tes3_31al0i tes3_llc22i tes3_lld21i tes3_21f24i tes3_31j20i tes3_Sk22i Tes3_10nl0i Tes3_llel7i Tes3_12dl8 i Tes3_1417i Tes3_15nl4i Tes3_lfap3i Tes3_Hpl2i Tes3_21kl4i Tes3_22illi Tes3_22124i tes3_2bg3i tes3_30pbi tes3_llal7i tes3_17i21i tes3_2Dhl2i tes3_7nl2i tes3_1elfai their complementsi and variants thereof.

13- An assemblage! comprising at least one nucleic acid molecule having the sequence of a clone selected from the group consisting of: amy2_lld2i amy2_121ol?i amy2_lil4i amy2_24cδi fbr2_7δd4i tes3_llal7i tes3_l?iΞli tes3_20hl2i tes3_7nl2i tes3_1elfai their complementsi and variants thereof-

14- An assemblage! comprising at least one nucleic acid molecule having the sequence of a clone selected from the group consisting of: amy2_14mlfai tes3_lδnl4i amy2_lcl2i amy2_2f22i their complementsi and variants thereof.

15- A nucleic acid molecule comprising a nucleotide sequence of the clone fkd2_3kl-

lfa. A computer readable mediumi comprising in electronic form at least one nucleic acid or protein sequence of a clone selected from the group consisting of: amy2_12g7i amy2_12ili amy2_13gl1i amy2_lfael4i amy2_24kl5i amy2_2al3i amy2_2il7i fbr2_7βdlδi fbr2_7βelδi amy2_121m2i amy2_24b4i amy2_121fl1i tes3_lfab5i amy2_li24i amy2_ljl1i amy2_2bl1i amy2_7j5i amy2_14b5i amy2_2ol3i fkd2_3kli mel2_7gl4i mel2_12jl i mel2_7kl1i amy2_2c22i fbr2_7βi21i amy2_lln4i amy2_lcl2i amy2_lili amy2_2f22i amy2_2gl2i fbr2_78cl2i tes3_lDilbi tes3_31al0i amy2_lDhl7i amy2_10p7i amy2_12d7i amy2_2fl8i tes3_Hc22i tes3_lld21i tes3_21f24i tes3_31j2Di tes3_5k22i Tes3_10nl0i Tes3_llel7i Tes3_12dlβ i Tes3_1417i Tes3_15nl4i Tes3_lbp3i Tes3_11pl2i Tes3_21kl4i Tes3_22illi Tes3_22124i tes3_2bg3i tes3_30pfai amy2_lld2i amy2_121ol7i amy2_lil4i amy2_24c8i fbr2_78d4i tes3_llal7i tes3_17i21i tes3_20hl2i tes3_7nl2i tes3_1elfai amy2_14mlbi tes3_18nl4i their complementsi and variants thereof.

17- A computer readable mediumi comprising in electronic form at least one nucleic acid or protein sequence of a clone selected from the group consisting of: amy2_12g7i amy2_12ili amy2_13gl1i amy2_lbel4i amy2_24kl5i amy2_2al3i amy2_2il7i amy2_121m2i amy2_24b4i amy2_121fl1i amy2_li24i amy2_ljl1i amy2_2bl1i amy2_7j5i amy2_14b5i amy2_2ol3i amy2_2c22i amy2__lln4i amy2_lcl2i amy2_lili amy2_2f22i amy2_2gl2i amy2_10hl7i amy2_lDp7i amy2_12d7i amy2_2fl8i amy2_lld2i amy2_121ol7i amy2_lil4i amy2_24cδi their complementsi and variants thereof.

16- A computer readable mediumi comprising in electronic form at least one nucleic acid or protein sequence of a clone selected from the group consisting of: fbr2_7δdlδi fbr2_7βel6i fbr2_7βi21i fbr2_7βcl2i fbr2_7δd4i their complementsi and variants thereof-

11- A computer readable mediumi comprising in electronic form at least one nucleic acid or protein sequence of a clone selected from the group consisting of: amy2_121m2i amy2_24b4i their complementsi and variants thereof-

20- A computer readable mediumi comprising in electronic form at least one nucleic acid or protein sequence of a clone selected from the group consisting of: amy2_121fl1i tes3_lbb5i their complementsi and variants thereof.

21- A computer readable mediumi comprising in electronic form at least one nucleic acid or protein sequence of a clone selected from the group consisting of: amy2_li24i amy2_ljl1i amy2_2bl1i amy2_7j5i their complementsi and variants thereof-

22- A computer readable mediumi comprising in electronic form at least one nucleic acid or protein sequence of a clone selected from the group consisting of: amy2_14b5i amy2_2ol3i fkd2_3kli mel2_7gl4i their complementsi and variants thereof-

23- A computer readable mediumi comprising in electronic form at least one nucleic acid or protein sequence of a clone selected from the group consisting of: mel2_12jl i mel2_7kl1i their complementsi and variants thereof.

24- A computer readable mediumi comprising in electronic form at least one nucleic acid or protein sequence of a clone selected from the group consisting of: amy2_2c22i fbr2_7βi21i their complementsi and variants thereof. 25- A computer readable mediumi comprising in electronic form at least one nucleic acid or protein sequence of a clone selected from the group consisting of: amy2_lln4i amy2_lili amy2_2gl2i fbr2_78cl2i tes3_10ilbi tes3_31al0i their complementsi and variants thereof.

2fa- A computer readable mediumi comprising in electronic form at least one nucleic acid or protein sequence of a clone selected from the group consisting of: amy2_10hl7i amy2_10p7i amy2_lΞd7i amy2_2fl8i tes3_llc22i tes3_lldSli tes3_21f24i tes3_31j2Di tes3_5k22i their complementsi and variants thereof.

27- A computer readable mediumi comprising in electronic form at least one nucleic acid or protein sequence of a clone selected from the group consisting of: tes3_lfab5i tes3_10ilfai tes3_31al0i tes3_llc22i tes3_lld21i tes3_21f24i tes3_31j20i tes3_5k22i Tes3_lDnl0i Tes3_llel7i Tes3_lΞdlβ i Tes3_1417i Tes3_15nl4i Tes3_lbp3i Tes3_11pl2i Tes3_21kl4i Tes3_22illi Tes3_22124i tes3_2bg3i tes3_30pbi tes3_llal7i tes3_17i21i tes3_20hl2i tes3_7nl2i tes3_1elfai their complementsi and variants thereof-

28- A computer readable mediumi comprising in electronic form at least one nucleic acid or protein sequence of a clone selected from the group consisting of: amy2_lld2i amy2_121ol7i amy2_lil4i amy2_24c8i fbr2_78d4i tes3_llal7i tes3_17i21i tes3_20hl2i tes3_7nl2i tes3_1elbi their complementsi and variants thereof •

21- A computer readable mediumi comprising in electronic form at least one nucleic acid or protein sequence of a clone selected from the group consisting of: amy2_14mlbi tes3_18nl4i amy2_lcl2i amy2_2f22i their complementsi and variants thereof-

3D- A computer readable mediumi comprising in electronic form a nucleic acid or protein sequence of the clone fkd2_3kl-